<SEC-DOCUMENT>0001641172-25-001826.txt : 20250331
<SEC-HEADER>0001641172-25-001826.hdr.sgml : 20250331
<ACCEPTANCE-DATETIME>20250331170031
ACCESSION NUMBER:		0001641172-25-001826
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		92
CONFORMED PERIOD OF REPORT:	20241231
FILED AS OF DATE:		20250331
DATE AS OF CHANGE:		20250331

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Celcuity Inc.
		CENTRAL INDEX KEY:			0001603454
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MEDICAL LABORATORIES [8071]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38207
		FILM NUMBER:		25794636

	BUSINESS ADDRESS:	
		STREET 1:		16305 36TH AVENUE N
		STREET 2:		SUITE 100
		CITY:			MINNEAPOLIS
		STATE:			MN
		ZIP:			55446
		BUSINESS PHONE:		763-392-0767

	MAIL ADDRESS:	
		STREET 1:		16305 36TH AVENUE N
		STREET 2:		SUITE 100
		CITY:			MINNEAPOLIS
		STATE:			MN
		ZIP:			55446

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Celcuity LLC
		DATE OF NAME CHANGE:	20140324
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>form10-k.htm
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:CELC="http://celcuity.com/20241231">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_029_US%2DGAAP%2D2024%2D(with%2DECD%2Dand%2DCYD) -->
<!-- Field: Set; Name: xdx; ID: xdx_03F_CELC_celcuity.com_20241231 -->
<!-- Field: Set; Name: xdx; ID: xdx_04C_20240101_20241231 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_056_edei%2D%2DEntityCentralIndexKey_0001603454 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000004" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000005" name="dei:EntityCentralIndexKey">0001603454</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2024-12-31" id="xdx2ixbrl0118" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2023-12-31" id="xdx2ixbrl0119" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0204" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0205" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0237" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0239" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELC:StockIssuedDuringPeriodValueConversionOfPreferredToCommonStock" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0247" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELC:StockIssuedDuringPeriodValueConversionOfPreferredToCommonStock" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0248" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0255" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0257" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0263" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0265" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELC:ExerciseOfCommonStockWarrants" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0271" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELC:ExerciseOfCommonStockWarrants" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0273" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELC:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsIssuanceWithPrivatePlacementOffering" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0278" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELC:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsIssuanceWithPrivatePlacementOffering" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0279" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELC:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsIssuanceWithPrivatePlacementOffering" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0281" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0285" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0287" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0292" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0293" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0295" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELC:AdditionalPaidInCapitalPreFundedWarrantIssued" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0298" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELC:AdditionalPaidInCapitalPreFundedWarrantIssued" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0299" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELC:AdditionalPaidInCapitalPreFundedWarrantIssued" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0301" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELC:IssuanceCostsAssociatedWithPrefundedWarrants" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0304" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELC:IssuanceCostsAssociatedWithPrefundedWarrants" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0305" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELC:IssuanceCostsAssociatedWithPrefundedWarrants" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0307" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0310" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0311" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0337" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0339" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELC:StockIssuedDuringPeriodValueConversionOfPreferredToCommonStock" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0347" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELC:StockIssuedDuringPeriodValueConversionOfPreferredToCommonStock" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0348" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0355" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0357" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0363" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0365" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELC:StockIssuedDuringPeriodValueStockWarrantsExercised" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0371" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELC:StockIssuedDuringPeriodValueStockWarrantsExercised" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0373" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0379" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0381" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0386" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0387" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0389" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELC:StockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0393" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELC:StockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0395" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0400" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0401" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0403" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0406" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0407" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0408" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromOtherEquity" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0502" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0505" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0512" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsOfDebtIssuanceCosts" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0518" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FinanceLeasePrincipalPayments" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0521" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELC:CommonStockWarrantsIssuedWithNotePayableTransaction" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0555" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" contextRef="AsOf2024-12-31_us-gaap_USTreasurySecuritiesMember" id="xdx2ixbrl0659" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" contextRef="AsOf2024-12-31" id="xdx2ixbrl0663" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" contextRef="AsOf2023-12-31_us-gaap_USTreasurySecuritiesMember" id="xdx2ixbrl0667" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" contextRef="AsOf2023-12-31" id="xdx2ixbrl0671" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0776" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FinanceLeaseInterestExpense" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0779" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FinanceLeaseInterestPaymentOnLiability" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0796" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FinanceLeasePrincipalPayments" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0799" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELC:FinalFee" contextRef="AsOf2023-12-31" id="xdx2ixbrl1250" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl1293" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1294" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="AsOf2024-12-31" id="xdx2ixbrl1325" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="AsOf2023-12-31" id="xdx2ixbrl1326" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="celc-20241231.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2024-01-01to2024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-28">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-24">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_srt_MinimumMember_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_srt_MaximumMember_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_srt_MinimumMember_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_srt_MaximumMember_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_PreferredStockOnAnAsIfConvertedToCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELC:PreferredStockOnAnAsIfConvertedToCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_PreferredStockOnAnAsIfConvertedToCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELC:PreferredStockOnAnAsIfConvertedToCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_OptionsToPurchaseCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CELC:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_OptionsToPurchaseCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CELC:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_WarrantsToPurchaseCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CELC:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_WarrantsToPurchaseCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CELC:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_USTreasurySecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_USTreasurySecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CELC:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CELC:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-222024-04-22_custom_OpenMarketSaleAgreementMember_custom_JefferiesLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:OpenMarketSaleAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CELC:JefferiesLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-22</xbrli:startDate>
        <xbrli:endDate>2024-04-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-04-22_custom_OpenMarketSaleAgreementMember_custom_JefferiesLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:OpenMarketSaleAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CELC:JefferiesLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-04-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-082024-05-08_custom_OpenMarketSaleAgreementMember_custom_JefferiesLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:OpenMarketSaleAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CELC:JefferiesLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-08</xbrli:startDate>
        <xbrli:endDate>2024-05-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-05-08_custom_OpenMarketSaleAgreementMember_custom_JefferiesLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:OpenMarketSaleAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CELC:JefferiesLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-05-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-302024-04-30_custom_OpenMarketSaleAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:OpenMarketSaleAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-30</xbrli:startDate>
        <xbrli:endDate>2024-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-312024-05-31_custom_OpenMarketSaleAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:OpenMarketSaleAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-31</xbrli:startDate>
        <xbrli:endDate>2024-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-302024-05-30_custom_UnderwritingAgreementMember_custom_LeerinkPartnersLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:UnderwritingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:LeerinkPartnersLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-30</xbrli:startDate>
        <xbrli:endDate>2024-05-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-05-30_custom_UnderwritingAgreementMember_custom_LeerinkPartnersLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:UnderwritingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:LeerinkPartnersLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-05-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-312024-05-31_custom_UnderwritingAgreementMember_custom_LeerinkPartnersLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:UnderwritingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:LeerinkPartnersLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-31</xbrli:startDate>
        <xbrli:endDate>2024-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-182023-10-18_custom_SecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-18</xbrli:startDate>
        <xbrli:endDate>2023-10-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-10-18_custom_SecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-10-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-10-18_custom_SecuritiesPurchaseAgreementMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-10-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-202023-10-20_custom_InstitutionalAndOtherAccreditedInvestorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">CELC:InstitutionalAndOtherAccreditedInvestorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-20</xbrli:startDate>
        <xbrli:endDate>2023-10-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_WarrantOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_WarrantOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_WarrantTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_WarrantTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_WarrantThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_WarrantThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_WarrantFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_WarrantFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_WarrantFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_WarrantFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_WarrantSixMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantSixMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_WarrantSixMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantSixMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_WarrantSevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantSevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_WarrantSevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantSevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_WarrantEightMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantEightMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_WarrantEightMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantEightMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_WarrantNineMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantNineMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_WarrantNineMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantNineMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_WarrantTenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantTenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_WarrantTenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantTenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-08-10_custom_EquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELC:EquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-08-10</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-10-25_custom_StockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELC:StockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-10-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-01_custom_StockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELC:StockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-01_custom_StockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELC:StockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-05-12_custom_StockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELC:StockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-05-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-05-12_custom_StockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELC:StockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-05-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-05-11_custom_StockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELC:StockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-05-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-05-09_custom_StockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELC:StockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-05-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-05-31_custom_MayTwoThousandTwentyTwoExercisePriceModificationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:MayTwoThousandTwentyTwoExercisePriceModificationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_MayTwoThousandTwentyTwoExercisePriceModificationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:MayTwoThousandTwentyTwoExercisePriceModificationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_MayTwoThousandTwentyTwoExercisePriceModificationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:MayTwoThousandTwentyTwoExercisePriceModificationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_DecemberTwoThousandTwentyOneExercisePriceModificationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:DecemberTwoThousandTwentyOneExercisePriceModificationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_DecemberTwoThousandTwentyOneExercisePriceModificationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:DecemberTwoThousandTwentyOneExercisePriceModificationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_DecemberTwoThousandTwentyOneExercisePriceModificationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:DecemberTwoThousandTwentyOneExercisePriceModificationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-05-31_custom_MayTwoThousandTwentyExercisePriceModificationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:MayTwoThousandTwentyExercisePriceModificationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_MayTwoThousandTwentyExercisePriceModificationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:MayTwoThousandTwentyExercisePriceModificationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_MayTwoThousandTwentyExercisePriceModificationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:MayTwoThousandTwentyExercisePriceModificationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_RestrictedStockMember1617133937">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RestrictedStockMember1617133937">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_TwoThousandSeventeenPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:TwoThousandSeventeenPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-05-10_custom_EmployeeStockPurchasePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELC:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-05-10</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-01_custom_EmployeeStockPurchasePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELC:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-01_custom_EmployeeStockPurchasePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELC:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_EmployeeStockPurchasePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELC:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_EmployeeStockPurchasePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELC:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_StockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELC:StockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_StockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELC:StockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember1617134281">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember1617134281">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember1617134453">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:AmendedAndRestatedLoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-05-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:AmendedAndRestatedLoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-05-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermALoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:AmendedAndRestatedLoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELC:TermALoanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-05-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermBLoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:AmendedAndRestatedLoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELC:TermBLoanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-05-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermCLoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:AmendedAndRestatedLoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELC:TermCLoanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-05-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermDLoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:AmendedAndRestatedLoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELC:TermDLoanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-05-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermELoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:AmendedAndRestatedLoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELC:TermELoanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-05-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermFLoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:AmendedAndRestatedLoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELC:TermFLoanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-05-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-302024-05-30_custom_AmendedAndRestatedLoanAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:AmendedAndRestatedLoanAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-30</xbrli:startDate>
        <xbrli:endDate>2024-05-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-302024-05-30_custom_PriorLoanAgreementMember_custom_InnovatusLifeSciencesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:PriorLoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-30</xbrli:startDate>
        <xbrli:endDate>2024-05-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-05-30_custom_PriorLoanAgreementMember_custom_InnovatusLifeSciencesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:PriorLoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-05-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-302024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:AmendedAndRestatedLoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-30</xbrli:startDate>
        <xbrli:endDate>2024-05-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:AmendedAndRestatedLoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-05-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-302024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:AmendedAndRestatedLoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-30</xbrli:startDate>
        <xbrli:endDate>2024-05-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_DomesticCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_StateAndLocalJurisdictionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-022025-01-31_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-02</xbrli:startDate>
        <xbrli:endDate>2025-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-01-31_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-012024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 4pt solid; font-size: 1pt; border-bottom: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 18pt"><b>UNITED STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 18pt"><b>SECURITIES AND EXCHANGE&#160;COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 12pt"><b>Washington, D.C.
20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>FORM <span id="xdx_905_edei--DocumentType_c20240101__20241231_zNFMtQCBkYZb"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000011" name="dei:DocumentType">10-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">(Mark One)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 36px"><span style="font-family: Times New Roman, Times, Serif"><b><span id="xdx_908_edei--DocumentAnnualReport_c20240101__20241231_z8iuosBRicL1"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000012" name="dei:DocumentAnnualReport">&#9746;</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>ANNUAL REPORT PURSUANT
    TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT&#160;OF 1934</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>For the fiscal year ended <span id="xdx_90C_edei--DocumentPeriodEndDate_c20240101__20241231_zRmrlGlGIdYb"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:datemonthdayyearen" id="Fact000013" name="dei:DocumentPeriodEndDate"><span id="xdx_90A_edei--CurrentFiscalYearEndDate_c20240101__20241231_zEhsXmfzUcDj"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:datemonthdayen" id="Fact000014" name="dei:CurrentFiscalYearEndDate">December 31</ix:nonNumeric></span>, <span id="xdx_900_edei--DocumentFiscalYearFocus_c20240101__20241231_ztnI2kMPJACf"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000015" name="dei:DocumentFiscalYearFocus">2024</ix:nonNumeric></span></ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>or</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 36px"><span style="font-family: Times New Roman, Times, Serif"><b><span id="xdx_902_edei--DocumentTransitionReport_c20240101__20241231_zWG8PuD1noak"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000016" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>TRANSITION REPORT
    PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>For the transition period from _______________________ to ___________________</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Commission File Number: <span id="xdx_909_edei--EntityFileNumber_c20240101__20241231_zzha88hUAko7"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000017" name="dei:EntityFileNumber">001-38207</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>



<hr style="background-color: black; border-width: 0; height: 1px; width: 25%; color: black"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="xdx_90D_edei--EntityRegistrantName_c20240101__20241231_zg6rbbhiM18b"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000018" name="dei:EntityRegistrantName">Celcuity Inc.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Exact name of registrant as specified in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: center"><b><span id="xdx_905_edei--EntityIncorporationStateCountryCode_c20240101__20241231_zBypgnrSThdb"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:stateprovnameen" id="Fact000019" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: center"><b><span id="xdx_902_edei--EntityTaxIdentificationNumber_c20240101__20241231_zPtWSDFYRIsl"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000020" name="dei:EntityTaxIdentificationNumber">82-2863566</ix:nonNumeric></span></b></td></tr>
  <tr style="vertical-align: top">
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(State or Other Jurisdiction of</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Incorporation or Organization)</p></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(I.R.S. Employer</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Identification No.)</p></td></tr>
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_907_edei--EntityAddressAddressLine1_c20240101__20241231_zXoctnqKIIph"><b><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000021" name="dei:EntityAddressAddressLine1">16305
    36<sup>th</sup></ix:nonNumeric></b></span><b> <span id="xdx_907_edei--EntityAddressAddressLine2_c20240101__20241231_zOw3taMq9hKg"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000022" name="dei:EntityAddressAddressLine2">Avenue North</ix:nonNumeric></span></b><b>,
    <span id="xdx_90C_edei--EntityAddressAddressLine3_c20240101__20241231_zfFmUBiOx4Z8"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000023" name="dei:EntityAddressAddressLine3">Suite 100</ix:nonNumeric></span></b><b><br/>
    <span id="xdx_90F_edei--EntityAddressCityOrTown_c20240101__20241231_zF7tVegLCfq3"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000024" name="dei:EntityAddressCityOrTown">Minneapolis</ix:nonNumeric></span></b><b>, <span id="xdx_908_edei--EntityAddressStateOrProvince_c20240101__20241231_zuyIwke4MRPb"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000025" name="dei:EntityAddressStateOrProvince">MN</ix:nonNumeric></span></b></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><b><span id="xdx_902_edei--EntityAddressPostalZipCode_c20240101__20241231_zPlMQ1H2j3f3"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000026" name="dei:EntityAddressPostalZipCode">55446</ix:nonNumeric></span></b></td></tr>
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">(Address of principal executive offices)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">(Zip Code)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Registrant&#8217;s telephone number, including area
code:&#160;<span id="xdx_90F_edei--CityAreaCode_c20240101__20241231_z0yLJRfV6UK"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000027" name="dei:CityAreaCode">(763)</ix:nonNumeric></span> <span id="xdx_903_edei--LocalPhoneNumber_c20240101__20241231_zbwMFXcy0loh"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000028" name="dei:LocalPhoneNumber">392-0767</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">_________________________________________</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Securities registered pursuant to Section 12(b)
of the Act:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 36%; padding-right: 3pt; padding-left: 3pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;Title of each class</p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 28%; padding-right: 3pt; padding-left: 3pt; text-align: center">Trading Symbol(s)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 36%; padding-right: 3pt; padding-left: 3pt; text-align: center">Name of each exchange on which registered</td></tr>
  <tr>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 3pt; padding-left: 3pt; text-align: center"><span id="xdx_90D_edei--Security12bTitle_c20240101__20241231_zJ9vbpO8x2z9"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000029" name="dei:Security12bTitle">Common Stock, $0.001 par value per share</ix:nonNumeric></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 3pt; padding-left: 3pt; text-align: center"><span id="xdx_905_edei--TradingSymbol_c20240101__20241231_zVqncWRaBNN7"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000030" name="dei:TradingSymbol">CELC</ix:nonNumeric></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 3pt; padding-left: 3pt; text-align: center">The <span id="xdx_904_edei--SecurityExchangeName_c20240101__20241231_zSjF6g5VQEF3"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:exchnameen" id="Fact000031" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Stock Market LLC</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Securities registered pursuant to Section 12(g)
of the Act:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">None</p>



<hr style="background-color: black; border-width: 0; height: 1px; width: 25%; color: black"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">Indicate by check mark if the registrant is a well-known seasoned issuer,
as defined in Rule 405 of the Securities Act. <span style="font-family: Times New Roman, Times, Serif">&#9744;</span>&#160;Yes&#160;&#160;&#160;&#9746;&#160;<span id="xdx_909_edei--EntityWellKnownSeasonedIssuer_c20240101__20241231_zxZJVaq7Ldw5"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000032" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">Indicate by check mark if the registrant is not required to file reports
pursuant to Section&#160;13 or Section 15(d) of the Act. <span style="font-family: Times New Roman, Times, Serif">&#9744;</span>&#160;Yes&#160;&#160;&#160;&#9746;&#160;<span id="xdx_90E_edei--EntityVoluntaryFilers_c20240101__20241231_zxHvAJ9rqYG6"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000033" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter
period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
&#9746; <span id="xdx_906_edei--EntityCurrentReportingStatus_c20240101__20241231_z9jFPJJexNWl"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000034" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span>&#160;&#160;&#160;<span style="font-family: Times New Roman, Times, Serif">&#9744;</span> No</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">Indicate by check mark whether the registrant has submitted electronically
every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the
preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160; &#9746;
<span id="xdx_907_edei--EntityInteractiveDataCurrent_c20240101__20241231_zjdceK4DHvrh"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000035" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span>&#160;&#160;&#160;<span style="font-family: Times New Roman, Times, Serif">&#9744;</span> No</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">Indicate by check mark whether the registrant is a large accelerated filer,
an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.&#160;See the definitions of
&#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth
company&#8221; in Rule 12b-2 of the Exchange Act.:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; font-size: 10pt; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Large
    accelerated filer &#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt">Accelerated filer <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_906_edei--EntityFilerCategory_c20240101__20241231_zxVbS3BNpqel"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:entityfilercategoryen" id="Fact000036" name="dei:EntityFilerCategory">Non-accelerated
    filer</ix:nonNumeric></span> &#9746;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt">Smaller reporting company <span id="xdx_908_edei--EntitySmallBusiness_c20240101__20241231_z2lHajvI8Wda"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000037" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt">Emerging growth company <span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_edei--EntityEmergingGrowthCompany_c20240101__20241231_zswKeYUYR5d3"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000038" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act&#160;&#160;&#160;<span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">Indicate by check mark whether the registrant has filed a report on and
attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b)
of the Sarbanes-Oxley Act (15 U.S.C. 262(b)) by the registered public accounting firm that prepared or issued its audit report. <span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_edei--IcfrAuditorAttestationFlag_c20240101__20241231_zv5zsOyCaOQ"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000039" name="dei:IcfrAuditorAttestationFlag">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">If securities are registered pursuant to Section 12(b) of the Act, indicate
by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously
issued financial statements. <span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_edei--DocumentFinStmtErrorCorrectionFlag_c20240101__20241231_zVCcFNmKfqI4"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000040" name="dei:DocumentFinStmtErrorCorrectionFlag">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">Indicate by check mark whether any of those error corrections are restatements
that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during
the relevant recovery period pursuant to &#167;240.10D-1(b). <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">Indicate by check mark whether the registrant is a shell company (as defined
in Rule 12b-2 of the Act).&#160;&#160;&#160;<span style="font-family: Times New Roman, Times, Serif">&#9744;</span> Yes&#160;&#160;&#160;<span id="xdx_90D_edei--EntityShellCompany_dbF_c20240101__20241231_zuJtfoJiJZEc"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000041" name="dei:EntityShellCompany">&#9746;</ix:nonNumeric></span>
No</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">The aggregate market value of the voting and non-voting common equity held
by non-affiliates of the registrant, based on $16.38, the closing price of the shares of common stock on June 28, 2024 (the last business
day of the registrant&#8217;s most recently completed second fiscal quarter) as reported by The Nasdaq Capital Market on such date, was
approximately $<span id="xdx_90E_edei--EntityPublicFloat_iI_c20240628_z54Hibubv3g2"><ix:nonFraction name="dei:EntityPublicFloat" contextRef="AsOf2024-06-28" id="Fact000042" format="ixt:numdotdecimal" decimals="0" unitRef="USD">530,223,434</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">As of March 24, 2025, there were <span id="xdx_906_edei--EntityCommonStockSharesOutstanding_iI_pid_c20250324_zt53SqRjCZK2"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2025-03-24" id="Fact000043" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">37,839,392</ix:nonFraction> </span>shares
of the registrant&#8217;s common stock outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b>DOCUMENTS INCORPORATED IN PART BY REFERENCE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span id="xdx_90E_edei--DocumentsIncorporatedByReferenceTextBlock_c20240101__20241231_zZQBvy1RKhmi"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000044" name="dei:DocumentsIncorporatedByReferenceTextBlock">Portions of the registrant&#8217;s definitive proxy statement relating
to its 2025 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual Report on Form 10-K.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt; border-bottom: Black 4pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2024 Annual Report on Form 10-K</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Table of Contents</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 9%">&#160;</td>
    <td style="width: 84%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 7%; text-align: center"><b>Page</b></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><a href="#a_001"><b>PART I</b></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top">Item 1.</td>
    <td style="vertical-align: top"><a href="#a_002">Business</a></td>
    <td style="text-align: center; vertical-align: bottom">5<span style="font-size: 10pt"></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">Item 1A.</td>
    <td style="vertical-align: top"><a href="#a_003">Risk Factors</a></td>
    <td style="text-align: center; vertical-align: bottom"><span style="font-size: 10pt">21</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top">Item 1B.</td>
    <td style="vertical-align: top"><a href="#a_004">Unresolved Staff Comments</a></td>
    <td style="text-align: center; vertical-align: bottom"><span style="font-size: 10pt">37</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">Item 1C.</td>
    <td style="vertical-align: top"><a href="#a_004a">Cybersecurity</a></td>
    <td style="text-align: center; vertical-align: bottom">37</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top">Item 2.</td>
    <td style="vertical-align: top"><a href="#a_005">Properties</a></td>
    <td style="text-align: center; vertical-align: bottom">38</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">Item 3.</td>
    <td style="vertical-align: top"><a href="#a_006">Legal Proceedings</a></td>
    <td style="text-align: center; vertical-align: bottom">38</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top">Item 4.</td>
    <td style="vertical-align: top"><a href="#a_007">Mine Safety Disclosures</a></td>
    <td style="text-align: center; vertical-align: bottom">38</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><a href="#a_008"><b>PART II</b></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>Item 5.</td>
    <td><a href="#a_009">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of</a><a href="#a_009">
    Equity Securities</a></td>
    <td style="vertical-align: bottom; text-align: center">39</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top">Item 6.</td>
    <td style="vertical-align: top"><a href="#a_010">Reserved</a></td>
    <td style="text-align: center; vertical-align: bottom">40</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">Item 7.</td>
    <td style="vertical-align: top"><a href="#a_011">Management&#8217;s Discussion and Analysis of Financial Condition and Results
    of Operations</a></td>
    <td style="text-align: center; vertical-align: bottom">40</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top">Item 7A.</td>
    <td style="vertical-align: top"><a href="#a_012">Quantitative and Qualitative Disclosures About Market Risk</a></td>
    <td style="text-align: center; vertical-align: bottom">47</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">Item 8.</td>
    <td style="vertical-align: top"><a href="#a_013">Financial Statements and Supplementary Data</a></td>
    <td style="text-align: center; vertical-align: bottom">48</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top">Item 9.</td>
    <td style="vertical-align: top"><a href="#a_014">Changes in and Disagreements with Accountants on Accounting and Financial
    Disclosure</a><span style="text-decoration: underline">s</span></td>
    <td style="text-align: center; vertical-align: bottom">67</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">Item 9A.</td>
    <td style="vertical-align: top"><a href="#a_015">Controls and Procedures</a></td>
    <td style="text-align: center; vertical-align: bottom">67</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>Item 9B.</td>
    <td><a href="#a_016">Other Information</a></td>
    <td style="vertical-align: bottom; text-align: center">67</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>Item 9C.</td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><a href="#a_017">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></p></td>
    <td style="vertical-align: bottom; text-align: center">67</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><a href="#a_018"><b>PART III</b></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top">Item 10.</td>
    <td style="vertical-align: top"><a href="#a_019">Directors, Executive Officers and Corporate Governance</a></td>
    <td style="text-align: center; vertical-align: bottom">68</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">Item 11.</td>
    <td style="vertical-align: top"><a href="#a_020">Executive Compensation</a></td>
    <td style="text-align: center; vertical-align: bottom">70</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top">Item 12.</td>
    <td style="vertical-align: top"><a href="#a_021">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder&#160;Matters</a></td>
    <td style="text-align: center; vertical-align: bottom">70</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">Item 13.</td>
    <td style="vertical-align: top"><a href="#a_022">Certain Relationships and Related Transactions, and Director Independence</a></td>
    <td style="text-align: center; vertical-align: bottom">70</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top">Item 14.</td>
    <td style="vertical-align: top"><a href="#a_023">Principal Accountant Fees and Services</a></td>
    <td style="text-align: center; vertical-align: bottom">70</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><a href="#a_024"><b>PART IV</b></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">Item 15.</td>
    <td style="vertical-align: top"><a href="#a_025">Exhibits and Financial Statement Schedules</a></td>
    <td style="text-align: center; vertical-align: bottom">71</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top">Item 16.</td>
    <td style="vertical-align: top"><a href="#a_026">Form 10-K Summary</a></td>
    <td style="text-align: center; vertical-align: bottom">71</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="#a_027">Signatures</a></td>
    <td style="text-align: center; vertical-align: bottom">72</td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"><span style="background-color: white">The Private
Securities Litigation Reform Act of 1995 provides a &#8220;safe harbor&#8221; for forward-looking statements.&#160;</span>This Annual
Report on Form 10-K (this &#8220;Annual Report&#8221;) contains forward-looking statements regarding us, our business prospects and our
results of operations that are subject to certain risks and uncertainties that could cause our actual business, prospects and results
of operations to differ materially from those that may be anticipated by such forward-looking statements.&#160;Factors that could cause
or contribute to such differences include, but are not limited to, those described in Part I, Item 1A, &#8220;Risk Factors&#8221; and
elsewhere in this Annual Report. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only
as of the date of this Annual Report.&#160;We expressly disclaim any intent or obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.&#160;Readers are urged to carefully review and consider the various
disclosures made by us in this Annual Report and in our other reports filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;)
that advise interested parties of the risks and uncertainties that may affect our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">All statements, other than statements of historical
facts, contained in this Annual Report, including statements regarding our plans, objectives and expectations for our business, operations
and financial performance and condition, are forward-looking statements. In some cases, you can identify forward-looking statements by
the following words: &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221;
&#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;target,&#8221; &#8220;ongoing,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221;
&#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; or the negative of these terms or other
comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements involve known and
unknown risks, uncertainties and other factors that may cause our results, performance or achievements to be materially different from
the information expressed or implied by the forward-looking statements in this Annual Report. Additionally, our forward-looking statements
do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that we may make.
Forward-looking statements may include, among other things, statements relating to:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">our clinical trial plans and the estimated timelines and costs for such trials;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">our plans to develop and commercialize our products, and our expectations about the market opportunity for gedatolisib and our ability
to serve that market;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">our expectations with respect to our competitive advantages, including the potential efficacy of gedatolisib in various patient types
alone or in combination with other treatments;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">our expectations regarding the timeline of patient enrollment and results from clinical trials, including our existing Phase 3 VIKTORIA-1
clinical trial, upcoming Phase 3 VIKTORIA-2 clinical trial, and Phase 1b/2 clinical trial for gedatolisib;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">our expectations regarding our ability to obtain United States Food and Drug Administration (&#8220;FDA&#8221;) approval to commercialize
gedatolisib;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">our expectations regarding governmental laws and regulations affecting our operations, including, without limitation, developments
in laws and regulations or their interpretation, including, among others, changes in tax laws and regulations internationally and in the
U.S. and laws that affect our operations and our laboratory;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">our expectations with respect to the development, validation, required approvals, costs and
                                                                     timelines of our drug candidate gedatolisib;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">our beliefs related to the potential benefits resulting from Breakthrough Therapy designation for gedatolisib;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">our plans with respect to research and development and related expenses for the foreseeable future;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">our beliefs about our ability to capitalize on the exclusive global development and commercialization rights obtained from our license
agreement with Pfizer with respect to gedatolisib;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">our expectations regarding the future payments that may be owed to Pfizer under our license agreement with them; </td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">our beliefs with respect to the potential rate and degree of market acceptance, both in the United States and internationally, and
clinical utility of gedatolisib;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">our revenue expectations;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">our expectations regarding business development activities, including collaborations with pharmaceutical companies; </td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">our plans with respect to pricing in the United States and internationally, and our ability to obtain reimbursement for our drug candidate,
gedatolisib, including expectations as to our ability or the amount of time it will take to achieve successful reimbursement from third-party
payors, such as commercial insurance companies and health maintenance organizations, and from government insurance programs, such as Medicare
and Medicaid; </td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">our expectations as to the use of proceeds from our financing activities; </td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">our expectations with respect to availability of capital, including accessing our current debt facility or any other debt facility
or other capital sources in the future, and our assumption that we will have adequate authorized shares for future equity issuances; </td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">our beliefs regarding the adequacy of our cash on hand to fund our clinical trials, capital expenditures, working capital, and other
general corporate expenses, as well as the increased costs associated with being a public company; </td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">our plans with respect to potentially raising capital; and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, including
our gedatolisib drug candidate and our CELsignia platform and tests.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">These statements involve known and unknown risks, uncertainties and other
factors that may cause our results or our industry&#8217;s actual results, levels of activity, performance or achievements to be materially
different from the information expressed or implied by these forward-looking statements. Certain risks, uncertainties and other factors
include, but are not limited to, our limited operating history; our potential inability to develop, validate and commercialize gedatolisib
on a timely basis or at all; the uncertainties and costs associated with clinical studies and with developing and commercializing biopharmaceuticals;
the complexity and difficulty of demonstrating the safety and sufficient magnitude of benefit to support regulatory approval of gedatolisib
and other products we may develop; challenges we may face in developing and maintaining relationships with pharmaceutical company partners;  the uncertainty and costs associated with clinical trials; the uncertainty
regarding market acceptance by physicians, patients, third-party payors and others in the medical community, and with the size of market
opportunities available to us; <span style="background-color: white">difficulties we may face in managing growth, such as hiring and retaining
a qualified sales force and attracting and retaining key personnel; changes in government regulations; tightening credit markets and limitations
on access to capital; stock market volatility or other factors that may affect our ability to access capital on favorable terms or at
all; and obtaining and maintaining intellectual property protection for our technology and time and expense associated with defending
third-party claims of intellectual property infringement, investigations or litigation threatened or initiated against us.&#160;S</span>ee
&#8220;Risk Factors&#8221; in Part I, Item 1A of this Annual Report for additional risks, uncertainties and other factors applicable to
the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>SUMMARY OF RISK FACTORS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">Below is a summary of the material factors that make an investment in our
common stock speculative or risky. This summary does not address all of the risks that we face. Additional discussion of the risks summarized
in this risk factor summary, and other risks that we face, can be found in the &#8220;Risk Factors&#8221; section of Part I, Item 1A of
this Annual Report and should be carefully considered, together with other information in this Annual Report and our other filings with
the Securities and Exchange Commission before making investment decisions regarding our common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">We have a limited operating history and we may never generate revenue or profit;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Our inability to raise additional capital on acceptable terms in the future may limit our ability to develop and commercialize our
drug candidate, gedatolisib;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Future financing activities could dilute the percentage ownership of our stockholders and could cause our stock price to fall, or
could result in operating or other restrictions;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">We are currently conducting and will continue to conduct clinical trials. Clinical trials are expensive and complex with uncertain
outcomes, which may prevent or delay commercialization of our products;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Our near-term revenue prospects depend on the success of our initial drug product, gedatolisib. If we are unable to successfully complete
clinical development of, obtain regulatory approval for, or commercialize, gedatolisib, or if we experience delays in doing so, our business
will be materially and adversely impacted;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">The successful development and commercialization of our products is highly uncertain;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">We were not involved in the early development of gedatolisib, so we are dependent on third parties having accurately generated, collected,
interpreted and reported data from certain preclinical and clinical trials;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">We have not yet successfully completed any registrational clinical trials, and we may be unable to do so for any drug candidates we
may develop;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">For a new drug to be approved for marketing, the FDA in the United States and health authorities in other countries must determine
that the drug is safe and effective. Because all drugs can have adverse effects, the data from our Phase 3 clinical study must demonstrate
to the satisfaction of the FDA and other health authorities that the benefits of gedatolisib in combination with palbociclib and fulvestrant,
or gedatolisib in combination with fulvestrant, outweigh its risks. Failure to demonstrate sufficient magnitude of benefit, even if the
benefit is found to be statistically significant, may not support regulatory approval;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">We must navigate lengthy, uncertain, and expensive regulatory approval processes to be able to market our products in the U.S. and
other jurisdictions;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">If we encounter difficulties enrolling patients in any of our clinical trials, our clinical development activities could be delayed
or otherwise adversely affected;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">We depend on intellectual property licensed from third parties, including from Pfizer for our lead product candidate, gedatolisib,
and termination of this license could result in the loss of significant rights, which would materially and adversely impact our business;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">If we and our business partners are unable to obtain and maintain intellectual property protection for our products and technology,
or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize
drug candidates similar or identical to ours, and our ability to successfully commercialize our drug candidate may be impaired;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">If we fail to comply with our obligations under our patent license with Pfizer, we could lose certain license rights that are important
to our business;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">We rely on third parties to conduct certain aspects of our preclinical studies and clinical trials and to formulate and manufacture
our drug product. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or comply with
regulatory requirements, we may not be able to obtain regulatory approval for, or commercialize, any potential product candidates;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">We will be dependent on our ability to attract and retain key personnel;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">We may encounter difficulties in scaling production, commercializing, marketing and distributing our products, including in hiring
and retaining a qualified sales force;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">Our estimate of the market opportunity for our drug candidate may not prove to be accurate;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">We face significant competition from other pharmaceutical and diagnostic companies; and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">The price of our common stock may be volatile and fluctuate substantially.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b><span id="a_001"></span>PART I</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span id="a_002"></span><b>ITEM 1. Business </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>Overview</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"><i>Unless otherwise provided in this Annual Report,
references to the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; and similar references refer to Celcuity
Inc., a Delaware corporation. We own various unregistered trademarks and service marks, including our corporate logo. Solely for convenience,
the trademarks, trade names and service marks in this Annual Report, including those owned by third parties, may be referred to without
the&#160;<sup>&#174;</sup>,<sup>TM</sup> or <sup>SM</sup> symbols, but such references should not be construed as any indicator that the
owner of such trademarks, trade names and service marks will not assert, to the fullest extent under applicable law, their rights thereto.
We do not intend the use or display of other companies&#8217; trademarks, trade names and service marks to imply an endorsement or sponsorship
of us by any other companies.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">We are a clinical-stage biotechnology company focused
on the development of targeted therapies for the treatment of multiple solid tumor indications. Our lead therapeutic candidate is gedatolisib,
a potent, well-tolerated, small molecule reversible inhibitor, administered intravenously, that selectively targets all Class I isoforms
of phosphatidylinositol-3-kinase (&#8220;PI3K&#8221;) and the two mechanistic targets of rapamycin (&#8220;mTOR&#8221;) sub-complexes,
mTORC1 and mTORC2. Gedatolisib&#8217;s mechanism of action and pharmacokinetic properties are differentiated from other currently approved
and investigational therapies that target PI3K or mTOR alone or together. We believe there is significant potential for gedatolisib to
address breast and prostate cancer tumors, and it has the potential to be used in other tumor types where the PI3K/protein kinase B (&#8220;AKT&#8221;)/mTOR
(&#8220;PAM&#8221;) pathway is either: i) driving tumorigenesis directly; ii) cooperating with other dysregulated signaling pathways;
or iii) a mechanism of resistance to other drug therapies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Our initial clinical development programs for gedatolisib
are focusing on the treatment of patients with hormone receptor positive (&#8220;HR+&#8221;), human epidermal growth factor receptor 2
negative (&#8220;HER2-&#8221;), or HR+/HER2-, advanced or metastatic breast cancer (&#8220;ABC&#8221;), and patients with metastatic castration
resistant prostate cancer (&#8220;mCRPC&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">In January 2022, gedatolisib was granted Fast Track
designation for the treatment of patients with HR+/HER2- advanced breast cancer after progression on CDK4/6 therapy. Fast Track designation
is granted by the FDA for products that are intended for the treatment of serious or life-threatening diseases or conditions and which
demonstrate the potential to address an unmet medical need.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">In July 2022, gedatolisib was granted Breakthrough
Therapy Designation for HR+/HER2- advanced breast cancer after progression on CDK4/6 therapy. Breakthrough Therapy designation is granted
by the FDA to expedite the development and regulatory review of an investigational medicine that is intended to treat a serious or life-threatening
condition. The criteria for Breakthrough Therapy designation requires preliminary clinical evidence that demonstrates the drug may have
substantial improvement on one or more clinically significant endpoints over available therapy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">In December 2022, we dosed the first patient in our
Phase 3, open-label, randomized two-part clinical trial, VIKTORIA-1. This trial is evaluating the efficacy and safety of gedatolisib in
combination with fulvestrant with and without palbociclib in adults with HR+, HER2- advanced breast cancer who have received prior treatment
with a CDK4/6 inhibitor in combination with an aromatase inhibitor. Two studies based on PIK3CA mutation status are included in the trial.
According to confirmed PIK3CA mutation status, patients will be manually assigned to a cohort evaluating patients who have PIK3CA wild
type (&#8220;WT&#8221;) tumors or to a cohort evaluating patients who have PIK3CA mutant (&#8220;MT&#8221;) tumors. The two cohorts are
randomized separately. The cohort evaluating PIK3CA WT patients completed enrollment during the fourth quarter of 2024 while the cohort
evaluating patients with PIK3CA MT (as defined below) continues to enroll patients.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">In February 2024, we dosed our first patient in our
Phase 1b/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with mCRPC. Initial preliminary
data for the Phase 1 portion of the trial is expected to be available by the end of the second quarter of 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">During the third quarter of
2024, we commenced site selection and activation activities to support a Phase 3, open-label, randomized clinical trial, VIKTORIA-2.
This trial is expected to dose its first patient in Q2 2025. This trial will evaluate the efficacy and safety of gedatolisib plus a
CDK4/6 inhibitor and fulvestrant as first-line treatment for patients with HR+/HER2- endocrine treatment resistant advanced breast
cancer. For the CDK4/6 inhibitor, investigators may choose either ribociclib or palbociclib. Approximately 200 clinical sites in
North America, Europe, Latin America, and Asia-Pacific, including many sites included in the VIKTORIA-1 clinical
trial, will participate in the study.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>The PI3K/AKT/mTOR (PAM) Pathway</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Dysregulation of the PAM signaling pathway is observed
in many types of cancer, including breast and prostate cancer. The important role the PAM pathway plays in cancer has led to significant
investment in the development of many different PI3K and mTOR inhibitors for solid tumors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Activities associated with PI3K involve complex essential
cell regulatory mechanisms, including feedforward and feedback signaling loops. Overactivation of the pathway is frequently present in
human malignancies and plays a key role in cancer progression. Four catalytic isoforms of Class I PI3K preferentially mediate signal transduction
and tumor cell survival based on the type of malignancy and the genetic or epigenetic alterations an individual patient harbors. Due to
the multiple subcellular locations, activities, and importance of the different PI3K complexes in regulating many types of cancer cell
proliferation, control of PI3K activity is an important target in cancer therapy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">mTOR is a critical effector in cell-signaling pathways
commonly dysregulated in human cancers. The mTOR signaling pathway integrates both intracellular and extracellular signals and serves
as a central regulator of cell metabolism, growth, proliferation, and survival. mTOR is a serine/threonine protein kinase, a downstream
effector of PI3K, and regulated by hormones, growth factors, and nutrients, that are contained in two functionally distinct protein assemblies
&#8211; mTORC1 and mTORC2. In cancer, dysfunctional signaling leads to various constitutive activities of the mTOR complexes, making mTOR
a good therapeutic target.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Developing efficacious and well-tolerated therapies
that target this pathway has been challenging. This reflects the inherent adaptability and complexity of the PAM pathway, where numerous
feedforward and feedback loops, crosstalk with other pathways, and compensatory pathways enable resistance to PAM pathway inhibition.
Another major hurdle for the development of PAM pathway inhibitors has been the inability to achieve optimal drug-target blockade in tumors
while avoiding undue toxicities in patients.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>Gedatolisib</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">By targeting multiple nodes of the PAM pathway, gedatolisib
can overcome adaptive resistance mechanisms that inhibitors targeting single PI3K/AKT/mTOR nodes do not address. As a result, we believe
gedatolisib offers distinct advantages over currently approved and investigational therapies that target PI3K or mTOR alone or together.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify"><b>Overcomes limitations of therapies that only inhibit a single Class I PI3K isoform or only one mTOR kinase complex.</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in">Gedatolisib is a pan-class I isoform PI3K inhibitor with low
nanomolar potency for the p110&#945;, p110&#946;, p110&#947;, and p110&#948; isoforms. Because gedatolisib inhibits all four PI3K isoforms
and both the mTORC1 and mTORC2 complexes, it prevents the confounding effect of isoform interaction that may occur with isoform specific
PI3K inhibitors and the confounding interaction between PI3K isoforms, AKT, and mTOR. By contrast, node-specific inhibitors cross-activate
uninhibited sub-units due to numerous feedforward and feedback loops between the PI3K isoforms, AKT, and mTOR complexes, which in turn
induces compensatory resistance that reduces the efficacy of isoform specific PI3K, AKT, or mTORC1 inhibitors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in">To compare the functional effect of inhibiting single versus
multiple PAM pathway nodes, we evaluated gedatolisib, and node-selective inhibitors for PI3K&#945; (alpelisib), AKT (capivasertib) and
mTORC1 (everolimus) in a panel of breast cancer cell lines using a live cell proliferation rate dose response analysis. The results of
this analysis are presented in the table below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b>Breast Cancer Cell Line Proliferation
Rate Dose Response Analysis </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><i>Average values for 14 PIK3CA MT and 14
PIK3CA WT breast cancer cell lines</i></p>

<p style="font: 10pt Sans-Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b>&#160;<img src="image_001.jpg" alt=""/></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><b>&#160;&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in"><i>Note: Growth rate (&#8220;GR&#8221;) was assessed using 28
cell lines by measuring live cells reducing potential with Real Time-Glo MT luciferase assay before and after 72-hour drug treatment.
GR50 (concentration required to inhibit growth rate by 50%) is a measure of potency. Max cell growth inhibition (GR at highest drug concentration
tested) is a measure of efficacy.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in"><i>Source: Rossetti S. et.al., npj Breast Cancer, 2024</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in">On average, gedatolisib was 300-fold more potent than the single
node PAM inhibitors analyzed and only gedatolisib induced a significant cytotoxic effect. In addition, gedatolisib&#8217;s potency and
efficacy was comparable in cell lines with and without PIK3CA mutations, in contrast to the single node PAM inhibitors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify"><b>Better tolerated by patients than oral PI3K and mTOR drugs.</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in">Gedatolisib is administered intravenously (IV) on a four-week
cycle of three-weeks-on, one-week-off, in contrast to the orally administered pan-PI3K or dual PI3K/mTOR inhibitors that are no longer
being clinically developed. Oral pan-PI3K or PI3K/mTOR inhibitors have repeatably been found to induce significant side effects that were
not well tolerated by patients. This typically leads to a high proportion of patients requiring dose reductions or treatment discontinuation,
despite showing promising efficacy. By contrast, gedatolisib stabilizes at lower concentration levels in plasma compared to orally administered
PI3K inhibitors, resulting in less toxicity, while maintaining concentrations sufficient to inhibit PAM pathway signaling.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in">Isoform-specific PI3K or mTORC1 inhibitors administered orally
were developed to reduce toxicities in patients. While the range of toxicities associated with single-node PAM inhibitors is narrower
than oral pan-PI3K or PI3K/mTOR inhibitors, administering them orally on a continuous basis still leads to challenging toxicities. The
experience with the FDA approved oral PI3K-&#945; inhibitor, alpelisib, and mTORC1 inhibitor, everolimus, illustrates the challenge.
In their Phase 3 pivotal trials, alpelisib and everolimus were found to induce hyperglycemia in 79% and 69% of patients evaluated, respectively.
In addition, 26% and 24% of patients discontinued alpelisib and everolimus, respectively, due to treatment related adverse events. By
contrast, in the 103-patient dose expansion portion of the Phase 1b clinical trial with gedatolisib, only 25% of patients experienced
hyperglycemia and less than 9% discontinued treatment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>Clinical Development </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">As of December 31, 2024, 492 patients with solid tumors
have received gedatolisib in eight completed clinical trials. Gedatolisib&#8217;s safety, tolerability and pharmacokinetic profile were
determined in a Phase 1 First-in-Human clinical trial. Of the 492 patients, 129 were treated with gedatolisib as a single agent in three
clinical trials. The remaining 363 patients received gedatolisib in combination with other anti-cancer agents in five clinical trials.
Additional patients received gedatolisib in combination with other anti-cancer agents in nine investigator sponsored clinical trials.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><i>Breast Cancer Program</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Breast cancer is the most prevalent cancer in women,
accounting for 30% of all female cancers and 13% of cancer-related deaths in the United States. The National Cancer Institute estimated
that approximately 310,720 new cases of breast cancer would be diagnosed in the United States in 2024, and approximately 42,250 breast
cancer patients would die of the disease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Four different breast cancer subtypes are currently
identified using molecular tests that determine the level of HR and HER2 expression. The most common subtype of ABC is HR+/HER2-. Approximately
70% of all breast cancer tumors express the estrogen receptor (&#8220;ER&#8221;), which, upon activation, regulates the expression of
various genes involved in tumor proliferation. Despite progress in treatment strategies, metastatic HR+/HER2- breast cancer (&#8220;MBC&#8221;) remains
an incurable disease, with a median overall survival (OS) of three years and a five-year survival rate of 34%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Three different classes of targeted therapies are
currently used to treat HR+/HER2- tumors: endocrine-based therapies, CDK4/6 inhibitors, and PAM inhibitors. Each of the CDK4/6 inhibitors
and PAM inhibitors are generally used to respond to the related mechanisms of resistance to endocrine therapy, namely, activation of the
CDK4/6 and PAM pathways.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Over 70% of breast cancers have direct or indirect
activation of the PAM pathway. The upregulation of the PAM pathway promotes hormone-dependent and independent ER transcriptional activity,
which contributes to endocrine resistance, leading to tumor cell growth, survival, motility, and metabolism. Clinical studies have demonstrated
that PAM inhibition can restore sensitivity to estrogen therapy (ET).</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Additionally, the PAM pathway, like other mitogenic
pathways, can also promote the activities of cyclin D and CDK4/6 to drive proliferative cell cycling. The available evidence indicates
that resistance to CDK4/6 inhibition in patients with HR+/HER2- advanced breast cancer is a transient adaptive mechanism, most likely
involving the PAM pathway. This data indicates that CDK4/6 signaling may be restored in CDK4/6 resistant tumors when PAM inhibitors are
applied. Thus, continuing CDK4/6 inhibitor treatment in combination with a PAM inhibitor in patients who progressed on their prior CDK4/6
inhibitor, would both blockade the potentially reactivated CDK4/6 pathway and prevent adaptive activation of the PAM pathway. This suggests
the limited efficacy induced by current standard-of-care (SOC) therapies in patients who have progressed on a CDK4/6 therapy reflects
the mechanistic inadequacy of relying on partial PAM inhibition (e.g., alpelisib or everolimus) and no CDK4/6 inhibition to address this
complex disease mechanism.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">We believe the complex connection between the PAM
and CDK4/6 pathways can potentially enable gedatolisib to adaptively reactivate CDK4/6 signaling that reportedly occurs in CDK4/6 resistant
tumors when the PAM pathway is comprehensively blockaded. By re-activating CDK4/6 signaling, we believe gedatolisib can restore the therapeutic
effect of CDK4/6 inhibition when it is combined with a CDK4/6 inhibitor. The contributory effect of a CDK4/6 inhibitor when combined with
gedatolisib would thus largely reflect the interaction between the two therapies that gedatolisib initiates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Evidence of gedatolisib&#8217;s anti-tumor activity
in breast cancer cells was provided in a study evaluating the MCF7 xenograft model (ER+/HER2-/PIK3CA mutant), where the combination of
gedatolisib with palbociclib and fulvestrant caused 90% tumor regression with no tumor regrowth observed for more than 60 days after the
final dose.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><i></i><img src="form10-k_001.jpg" alt="" style="width: 800px"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><i></i>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.25in"><i>Source: Layman SABCS 2021</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><i>Clinical Experience with Gedatolisib in Breast Cancer</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">The favorability of preliminary results from our most
recently completed clinical trial, a Phase 1b clinical trial which evaluated 138 patients with HR+/HER2- ABC, led us to focus on our initial
clinical development program on advanced breast cancer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">On January 13, 2022, gedatolisib was granted Fast
Track designation for the treatment of patients with HR+/HER2- advanced breast cancer after progression on CDK4/6 therapy. Fast Track
designation is granted by the FDA for products that are intended for the treatment of serious or life-threatening diseases or conditions
and which demonstrate the potential to address an unmet medical need. The designation offers the opportunity for frequent interactions
with the FDA to discuss the drug&#8217;s development plan and to ensure collection of appropriate data needed to support drug approval,
as well as eligibility for rolling submission of a New Drug Application.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">On July 18, 2022, gedatolisib was granted Breakthrough
Therapy Designation for HR+/HER2- advanced breast cancer after progression on CDK4/6 therapy. Breakthrough Therapy designation is granted
by the FDA to expedite the development and regulatory review of an investigational medicine that is intended to treat a serious or life-threatening
condition. The criteria for Breakthrough Therapy designation require preliminary clinical evidence that demonstrates the drug may have
substantial improvement on one or more clinically significant endpoints over available therapies. The benefits of Breakthrough Therapy
Designation include more intensive guidance from the FDA on an efficient development program, access to a scientific liaison to help accelerate
review time, and potential eligibility for priority review if relevant criteria are met. Celcuity&#8217;s breakthrough application was
supported by data from a Phase 1b clinical trial that assessed the safety, tolerability and clinical activity of gedatolisib in combination
with palbociclib and fulvestrant in patients with HR+/HER2- advanced breast cancer whose disease progressed during treatment with a CDK4/6
therapy and an aromatase inhibitor.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"><span style="text-decoration: underline">Phase 1b HR+/HER2- ABC Clinical Trial Results </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">A Phase 1b dose-finding trial with an expansion portion
for safety and efficacy evaluated gedatolisib when added to either the standard doses of palbociclib plus letrozole or palbociclib plus
fulvestrant in patients with HR+/HER2- advanced breast cancer. PI3K mutation status was not used as an eligibility criterion. Patient
enrollment for the trial is complete.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">A total of 138 patients with HR+/HER2- advanced breast
cancer were dosed in the clinical trial. Four patients from this study continue to receive study treatment, as of December 31, 2024, each
of whom have received study treatment for more than five years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">35 patients were enrolled in two dose escalation arms to evaluate the safety and tolerability and determine the maximum tolerable
dose (&#8220;MTD&#8221;) of gedatolisib when used in combination with the standard doses of palbociclib and endocrine therapies. The MTD
was determined to be 180 mg administered intravenously once weekly.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">103 patients were enrolled in one of four expansion arms (A, B, C, D) to determine if the triplet combination of gedatolisib plus
palbociclib and letrozole or gedatolisib plus palbociclib and fulvestrant produced a superior objective response (OR), compared to historical
control data of the doublet combination (palbociclib plus endocrine therapy). All patients received gedatolisib in combination with standard
doses of palbociclib and endocrine therapy (either letrozole or fulvestrant). In Arms A, B, and C, patients received an intravenous dose
of 180 mg of gedatolisib once weekly. In Arm D, patients received an intravenous dose of 180 mg of gedatolisib on a four-week cycle of
three-weeks-on, one-week-off. Objective response was determined using Response Evaluation Criteria in Solid Tumors v1.0, or RECIST v1.0.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 1in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.75in"/><td style="text-align: justify; width: 0.25in"><span style="font-family: Courier New, Courier, Monospace">&#9675;</span></td><td style="text-align: justify"><b>Arm A</b>: ABC with progression and no prior endocrine-based systemic therapy or a CDK4/6 inhibitor in the metastatic setting.
First-line endocrine-based therapy for advanced disease (CDK4/6 treatment naive).</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 1in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.75in"/><td style="text-align: justify; width: 0.25in"><span style="font-family: Courier New, Courier, Monospace">&#9675;</span></td><td style="text-align: justify"><b>Arm B</b>: ABC with progression during one or two prior endocrine-based systemic therapies in the advanced setting, with no prior
therapy with any CDK inhibitor. Second- or third-line endocrine-based therapy for metastatic disease.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 1in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.75in"/><td style="text-align: justify; width: 0.25in"><span style="font-family: Courier New, Courier, Monospace">o</span></td><td style="text-align: justify"><b>Arm C</b>: ABC with progression during one or two prior endocrine-based systemic therapies in the advanced setting and following
prior therapy with a CDK inhibitor. Second- or third-line endocrine-based therapy for advanced disease.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 1in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.75in"/><td style="text-align: justify; width: 0.25in"><span style="font-family: Courier New, Courier, Monospace">o</span></td><td style="text-align: justify"><b>Arm D</b>: ABC with progression during one or two prior endocrine-based systemic therapies in the advanced setting and following
prior therapy with a CDK inhibitor. Second- or third-line endocrine-based therapy for advanced disease.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">For the 103 patients enrolled in the expansion portion of the Phase 1b clinical trial, the objective response rate (&#8220;ORR&#8221;)
in aggregate among patients with evaluable tumors was 63%.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">Best responses, as measured by RECIST v1.0, are shown in the following chart for Arm A (1<sup>st</sup> line patients) and Arm D (2<sup>nd</sup>/3<sup>rd</sup>
line patients who received Phase 3 dosing regimen). The dotted line represents the cutoff for partial response (PR), defined as a 30%
reduction from the baseline tumor assessment.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><img src="form10-k_002.jpg" alt="" style="width: 800px"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"><i>Source: Layman SABCS 2021</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">Safety analysis:</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 1in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.75in"/><td style="text-align: justify; width: 0.25in">&#9675;</td><td style="text-align: justify">For all arms in aggregate, all patients experienced at least one Grade 1 or Grade 2 treatment-emergent adverse event. The Grade 3
and 4 treatment-emergent adverse events occurring in at least 20% of patients were neutropenia (63%), stomatitis (27%) and rash (20%).
Neutropenia is a known class effect of CDK4/6 inhibitors. Stomatitis was reversible in most patients with a steroidal mouth rinse. All
grades of treatment-related adverse events related to hyperglycemia were reported in 22% of patients; Grade 3 or 4 hyperglycemia was reported
in 7% of patients. Gedatolisib was discontinued in less than 9% of patients.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 1in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.75in"/><td style="text-align: justify; width: 0.25in">&#9675;</td><td style="text-align: justify">For the patients in Arm D, who received the Phase 3 dosing schedule, Grade 3 and 4 treatment-emergent adverse events occurring in
at least 20% of patients were neutropenia (67%), leukopenia (22%), and stomatitis (22%). All grades of treatment-related adverse events
related to hyperglycemia were reported in 26% of patients; Grade 3 or 4 hyperglycemia were reported in 7% of patients. Gedatolisib was
discontinued in 4% of patients.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 1in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">Best overall response data for each arm is presented in the table below:</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 92%; border-collapse: collapse; margin-left: 0.25in">
  <tr style="vertical-align: top">
    <td colspan="9" style="border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Total Expansion Arms</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 7.7pt"><b>(N=103)</b></p>

</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: left; padding-bottom: 1pt; width: 36%; vertical-align: middle">&#160;</td>
    <td style="padding-bottom: 1pt; width: 1%; text-align: justify">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 15%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Arm A</b></span></td>
    <td style="padding-bottom: 1pt; width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 15%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Arm B</b></span></td>
    <td style="padding-bottom: 1pt; width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 15%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Arm C</b></span></td>
    <td style="padding-bottom: 1pt; width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 15%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Arm D</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="vertical-align: middle; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Prior Therapy</b></span></td>
    <td style="text-align: justify">&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">1L</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">CDKi-naive</p></td>
    <td style="text-align: center">&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">2L+</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">CDKi-naive</p></td>
    <td style="text-align: center">&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">2L/3L</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">CDKi-pretreated</p></td>
    <td style="text-align: center">&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">2L/3L</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">CDKi-pretreated</p></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="vertical-align: middle; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>n (Full, response evaluable)</b></span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31, 27</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13,13</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32, 28</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">27, 27</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="vertical-align: middle; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Study Treatment</b></span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">P + L + G</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">P + F + G</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">P + F + G</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">P + F + G</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="vertical-align: middle; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Gedatolisib schedule</b></span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">weekly</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">weekly</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">weekly</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3 wks on/1 wk off</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="vertical-align: middle; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ORR <sup>1&#160;</sup>(evaluable)</b></span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">85%</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">77%</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">36%</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">63%</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="vertical-align: middle; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>mPFS&#160;<sup>2&#160;</sup>, mos (range)</b></span></td>
    <td style="text-align: justify">&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">48.4</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(16.9, NR)</p></td>
    <td style="text-align: center">&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">12.9</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(7.6, 38.3)</p></td>
    <td style="text-align: center">&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">5.1</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(3.3, 7.5)</p></td>
    <td style="text-align: center">&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">12.9</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(7.4, 16.7)</p></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="vertical-align: middle; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PFS % at 12 mos&#160;<sup>2</sup></b></span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">72.1%</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54.5%</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.6%</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">53.2%</span></td></tr>
  </table>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 8pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 92%; margin-left: 0.25in">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">WT</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">MT</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">WT</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">MT</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">WT</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">MT</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">WT</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">MT</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; font-weight: bold">PIK3CA status</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">81</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">16</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">69</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">31</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">75</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">25</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">56</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">41</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify">ORR (evaluable)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">81</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">78</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">75</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">63</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">60</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">73</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">PFS at 12 months</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">74</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">60</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">67</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">49</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">60</td><td style="text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">(1) ORR represents PR, except in Arm A, which had 1 CR = Complete
response. Responses per RECIST 1.1; (2) Includes 2 unconfirmed PR</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">Abbreviations: 1L= first line, 2L= second line; mos= months;
NR = not reached; ORR, objective response rate; PFS, progression free survival</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.25in; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0in; text-align: justify; text-indent: 0.25in">Source: Layman R. et. al, Lancet Oncol.,
2024</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"><span style="text-decoration: underline">Phase 3 HR+/HER2- ABC Clinical Trial (VIKTORIA-1)
</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">In 2022, we initiated VIKTORIA-1, a Phase 3, open-label,
randomized clinical trial to evaluate the efficacy and safety of gedatolisib in combination with fulvestrant with or without palbociclib
in adults with HR+/HER2- advanced breast cancer whose disease has progressed after prior CDK4/6 therapy in combination with an aromatase
inhibitor. This multi-center, international trial is expected to enroll approximately 701 total subjects at more than 200 clinical sites
across North America, Europe, Latin America, and Asia-Pacific. The first patient was dosed in December 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">The clinical trial enables separate evaluation of
subjects according to their <i>PIK3CA</i> status.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.75in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.5in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">Subjects who meet eligibility criteria and do not have confirmed <i>PIK3CA</i> mutations (i.e., WT) are randomly assigned (1:1:1)
to receive a regimen of either gedatolisib, palbociclib, and fulvestrant (Arm A), gedatolisib and fulvestrant (Arm B), or fulvestrant
(Arm C). During the fourth quarter of 2024, we achieved our enrollment goal of 351 subjects who are PIK3CA WT. We expect topline data
for this group to be available in Q2 2025.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.75in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.5in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">Subjects who meet eligibility criteria and have <i>PIK3CA</i> mutations (i.e., MT) are randomly assigned (3:3:1) to receive a regimen
of either gedatolisib, palbociclib, and fulvestrant (Arm D), alpelisib and fulvestrant (Arm E), or gedatolisib and fulvestrant (Arm F).
Enrollment of up to 350 subjects who are PIK3CA MT is ongoing. We expect topline data for this group to be available in the fourth quarter
of 2025.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.75in; text-indent: -0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">The clinical trial primary endpoints are progression
free survival (&#8220;PFS&#8221;), per RECIST 1.1 criteria, as assessed by blinded independent central review (&#8220;BICR&#8221;). Two
primary endpoints will be evaluated in subjects who are PI3KCA WT, and one primary endpoint will be evaluated in subjects who are PI3KCA
MT. In subjects who are PI3KCA WT, the PFS of gedatolisib in combination with palbociclib and fulvestrant (Arm A) will be compared to
fulvestrant monotherapy (Arm C), and the PFS in gedatolisib in combination with fulvestrant (Arm B) will be compared to fulvestrant monotherapy
(Arm C). In subjects who are PI3KCA MT, the PFS of gedatolisib in combination with palbociclib and fulvestrant (Arm D) will be compared
to alpelisib combined with fulvestrant (Arm E).</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">All subjects will receive treatment according to the
assigned study arm until objective progressive disease, unacceptable toxicity, death, or withdrawal of consent, whichever occurs first.
Subjects in Arm C will have the option to receive the treatment regimen provided in Arm A or Arm B upon radiographically confirmed disease
progression. Subjects will be followed for adverse events, safety laboratory testing, tumor assessment by RECIST v1.1, quality of life,
and overall survival.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"><span style="text-decoration: underline">Phase 3 HR+/HER2- ABC Clinical Trial (VIKTORIA-2)
</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">During the third quarter of 2024, we initiated site
selection and activation activities to support a Phase 3, open-label, randomized clinical trial to evaluate the efficacy and safety of
gedatolisib plus a CDK4/6 inhibitor and fulvestrant as first-line treatment for patients with HR+/HER2- advanced breast cancer that is
endocrine treatment resistant (VIKTORIA-2). For the CDK4/6 inhibitor, investigators may choose either ribociclib or palbociclib. This
multi-center, international trial is expected to enroll approximately 12&#8211;36 evaluable subjects in the safety run-in portion of the
study to evaluate the safety of gedatolisib when combined with ribociclib and fulvestrant. In the Phase 3 portion of the study, approximately
638 subjects will be randomized and assigned to Cohort 1 (&#8220;PIK3CA WT&#8221;) or Cohort 2 (&#8220;PIK3CA MT&#8221;) based on their PIK3CA status.
Subjects in each cohort will be randomized on a 1:1 basis to either Arm A (gedatolisib with fulvestrant and ribociclib or palbociclib)
or Arm B (fulvestrant and ribociclib or palbociclib). It is expected that approximately 200 clinical sites across North America, Europe,
Latin America, and Asia-Pacific will participate. The first patient is expected to be dosed in the second quarter of 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">The clinical trial primary endpoints for this study
are PFS, per RECIST 1.1 criteria, as assessed by BICR. The statistical analyses of Cohort 1 and 2 are independent of the other. For each
cohort, the PFS of gedatolisib in combination with fulvestrant and either palbociclib or ribociclib (Arm A) will be compared to fulvestrant
combined with either palbociclib or ribociclib (Arm B).</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><i>Prostate Cancer Program </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">In the United States, prostate cancer is the second
leading cause of cancer death in men. Current estimates predict that one in eight men will be diagnosed with prostate cancer in his lifetime.
The National Cancer Institute estimates that in 2024 there will be over 299,000 new cases of prostate cancer in the United States and
approximately 35,250 deaths from the disease. Although approximately 69% of patients are diagnosed with localized prostate cancer, about
8% of patients present with metastatic disease with a 5-year survival rate of 37%. Androgen deprivation therapy (&#8220;ADT&#8221;) via
medical or surgical castration has been the mainstay treatment for metastatic prostate cancer. However, prostate cancer cells develop
resistance to ADT and progress to castration resistance, leading to poor prognosis and a median overall survival of about three to five years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Men with mCRPC have a poor prognosis and a predicted
survival rate of fewer than two years from the initial time of progression. Treatment options for prostate cancer depend on many different
factors, including the stage of the cancer. Castration-resistant prostate cancer is defined by disease progression despite ADT and is
often indicated by rising levels of PSA. Current standard of care for men with castration-resistant prostate cancer provides that patients
should initially receive a combination of ADT and either abiraterone, which works by decreasing androgen levels, or enzalutamide, which
works by blocking androgen binding to androgen receptors (&#8220;AR&#8221;). If the disease progresses despite these second-generation
hormonal therapies, chemotherapy is considered the next treatment option. Treatment with chemotherapy is generally postponed for as long
as possible due to the potential for severe side effects including neuropathies, nausea, diarrhea, decreased mental capacity and increased
risk of infections.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Preclinical studies have demonstrated a potential
association between the PAM pathway and AR signaling in prostate cancer cells developing resistance to ADT. In these studies, the AR and
PAM pathways were shown to cross-regulate each other. This is similar to the relationship demonstrated in breast cancer with the estrogen
receptor pathway and the PAM pathway. Additionally, 70% - 100% of mCRPC tumors have PAM related pathway alterations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Several clinical studies have shown promising results
by inhibiting the PAM pathway in combination with an AR inhibitor. In separate Phase 2 and Phase 3 trials, the AKT inhibitor, ipatasertib,
showed improvement in radiographic PFS (&#8220;rPFS&#8221;) in patients with mCRPC and tumors with phosphatase and tensin homolog (&#8220;PTEN&#8221;)
loss when ipatasertib was combined with the AR inhibitor, abiraterone, versus abiraterone alone. In a Phase 2 trial, the pan-PI3K inhibitor,
samotolisib, reported median rPFS of 10.2 when combined with enzalutamide versus 5.5 months for enzalutamide alone.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Evidence of gedatolisib&#8217;s in vivo activity in
prostate cancer was provided in a study evaluating the 22RV-1, PC3, and C4-2 prostate cancer xenograft models. As seen in the figures
below, gedatolisib induced greater than 80% tumor growth inhibition, regardless of the xenograft model&#8217;s sensitivity to the AR inhibitor,
enzalutamide and the cell lines&#8217; PTEN or AR status. In addition, gedatolisib combined with enzalutamide induced significantly greater
tumor growth inhibition than enzalutamide alone in the enzalutamide sensitive model (&#8220;C4-2&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><img src="form10-k_003.jpg" alt="" style="width: 800px"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 24.55pt"><i>S</i>ource: Sen, ASCO-GU, 2023</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"><span style="text-decoration: underline">Phase 1b/2 mCRPC Clinical Trial (CELC-G-201) </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">We received approval from the FDA in mid-2023 to proceed
with the clinical development of gedatolisib in combination with Nubeqa&#174; (darolutamide), an approved androgen receptor inhibitor,
for the treatment of patients with mCRPC. We have since initiated a Phase 1b/2 clinical trial (CELC-G-201) that will enroll up to 54 participants
with mCRPC who progressed after treatment with an AR inhibitor. We dosed our first patient in this trial in February 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">In the Phase 1b portion of the clinical trial, we
enrolled 36 participants randomly assigned to receive 600 mg darolutamide combined with either 120 mg gedatolisib in Arm 1 or 180 mg gedatolisib
in Arm 2. An additional 12 participants will then be enrolled in the Phase 2 portion of the study at the recommended phase 2 dose (&#8220;RP2D&#8221;)
level to enable evaluation of 30 participants treated with the RP2D of gedatolisib.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">The primary objectives of the Phase 1b portion of
the trial include assessment of the safety and tolerability of gedatolisib in combination with darolutamide and determination of the recommended
Phase 2 dose of gedatolisib. The primary objective of the Phase 2 portion of the trial is to assess the rPFS at six months of patients
who received the RP2D.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><i>Pfizer License Agreement</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">In April 2021, we entered into a license agreement
(&#8220;the Gedatolisib License Agreement&#8221;) with Pfizer pursuant to which we acquired exclusive (including as to Pfizer) worldwide
sublicensable rights to research, develop, manufacture, and commercialize gedatolisib for the treatment, diagnosis and prevention of all
diseases. Pursuant to the Gedatolisib License Agreement, we are obligated to use commercially reasonable efforts to develop and seek regulatory
approval for at least one product in the U.S. and if regulatory approval is obtained, to commercialize such product in the U.S. and at
least one international major market.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">We paid Pfizer a $5.0 million upfront fee upon execution
of the Gedatolisib License Agreement and issued to Pfizer $5.0 million of our common stock. We are also required to make milestone payments
to Pfizer upon achievement of certain development and commercial milestone events, up to an aggregate of $335.0 million. We will pay Pfizer
tiered royalties on sales of gedatolisib at percentages ranging from the low to mid-teens, that may be subject to deductions for expiration
of valid claims, amounts due under third-party licenses and generic competition. Unless earlier terminated, the Gedatolisib License Agreement
will expire upon the expiration of all royalty obligations. The royalty period will expire on a country-by-country basis upon the later
of (a) 12 years following the date of First Commercial Sale of such Product in such country, (b) the expiration of all regulatory or data
exclusivity in such country for such Product, or (c) the date upon which the manufacture, use, sale, offer for sale or importation of
such Product in such country would no longer infringe, but for the license granted herein, a Valid Claim of a Licensed Patent Right. Capitalized
terms in this paragraph have the meanings set forth in the Gedatolisib License Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">We have the right to terminate the Gedatolisib License
Agreement for convenience upon 90 days&#8217; prior written notice. Pfizer may not terminate the agreement for convenience. Either we
or Pfizer may terminate the Gedatolisib License Agreement if the other party is in material breach and such breach is not cured within
the specified cure period. In addition, either we or Pfizer may terminate the Gedatolisib License Agreement in the event of specified
insolvency events involving the other party.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><i>Manufacturing </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">We rely on third parties to manufacture gedatolisib.
We have entered into agreements with contract manufacturing organizations (&#8220;CMOs&#8221;), to produce the drug substance gedatolisib,
and produce, package and distribute finished drug product for clinical supply. We require all of our CMOs to conduct manufacturing activities
in compliance with applicable laws including current good manufacturing practice (&#8220;cGMP&#8221;), requirements. We anticipate that
these CMOs will have the capacity to support both clinical supply and commercial-scale production, and we have started negotiating agreements
at this time to cover commercial production. We may also elect to enter into agreements with other CMOs to manufacture supplies of drug
substance and finished drug product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><i>Sales and Marketing</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">If any of our product candidates are approved, we
intend to market and commercialize them in the U.S. and select international markets, either alone or in partnership with others. Cancer
patients are primarily treated by medical, surgical, or radiation oncologists, and we believe they can be reached with a targeted sales
force.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><i>Competition for Gedatolisib</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">The pharmaceutical industry is characterized by rapid
evolution of technologies and intense competition. While we believe that our product candidates, technology, knowledge, experience, intellectual
property, and scientific resources provide us with competitive advantages, we face competition from major pharmaceutical and biotechnology
companies, academic institutions, governmental agencies and public and private research institutions, among others. Any product candidates
that we successfully develop and commercialize will compete with approved treatment options, including off-label therapies, and new therapies
that may become available in the future. Key considerations that would impact our ability to effectively compete with other therapies
include the efficacy, safety, method of administration, cost, level of promotional activity and intellectual property protection of our
products. Many of the companies against which we may compete have significantly greater financial resources and expertise than we do in
research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing
approved products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">There are several PI3K, AKT, and mTOR inhibitors approved
by the FDA, including PIQRAY and AFINITOR from Novartis AG, TRUQAP from AstraZeneca plc, Itovebi from F. Hoffmann-La Roche Ltd, COPIKTRA
from Verastem, Inc., and ZYDELIG from Gilead Sciences, Inc. We are aware that other companies are, or may be, developing products for
this indication, including BridgeBio Pharma Inc., Eli Lilly and Company, Kazia Therapeutics Limited, Relay Therapeutics, Inc., Revolution
Medicines Inc., and Takeda Pharmaceutical Company Limited. There may be additional companies with programs suitable for addressing these
patient populations that could be competitive with our efforts but that have not yet disclosed specific clinical development plans. Smaller
or early-stage companies, including oncology-focused therapeutics companies, may also prove to be significant competitors, particularly
through collaborative arrangements with large and established companies. These companies may also compete with us in recruiting and retaining
qualified scientific and management personnel, establishing clinical trial sites, enrolling patients in clinical trials and acquiring
technologies complementary to, or necessary for, our programs. The availability of reimbursement from government and private payors will
also significantly impact the pricing and competitiveness of our products. Our competitors may obtain FDA or other regulatory approvals
for their products more rapidly than we may obtain approvals for our product candidates, which could result in our competitors establishing
a strong market position before we are able to commercialize our product candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>CELsignia </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">We founded our company to develop our proprietary
CELsignia diagnostic platform and relied on the capability of this technology to identify our lead drug candidate, gedatolisib. CELsignia
characterizes the specific activity of various oncogenic signaling pathways, including the PAM pathway, in living patient tumor cells.
As previously disclosed, we made the decision to focus on the clinical development of gedatolisib and minimize our activities to support
development of CELsignia.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>Intellectual Property </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 22.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 22.5pt">Our success depends in part on our ability to obtain
and maintain proprietary protection for our product candidates, manufacturing and process discoveries and other know-how, to operate without
infringing the proprietary rights of others, and to prevent others from infringing our proprietary rights. We plan to protect our proprietary
positions using a variety of methods, which include protecting current U.S. and foreign patents related to proprietary technology, inventions
and improvements and prosecuting additional U.S. and foreign patents that we determine are important to the development and implementation
of our business. For example, we, our licensors, or our collaborators currently have, or are pursuing, patents covering the composition
of matter for our drug product candidates and we plan to generally pursue patent protection covering methods-of-use for one or more clinical
programs. We also rely on trade secrets, trademarks, know-how, continuing technological innovation and potential in-licensing opportunities
to develop and maintain our proprietary position.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><i>Gedatolisib Patents</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">We entered into the Gedatolisib License Agreement
with Pfizer in April 2021, pursuant to which we acquired exclusive worldwide rights under Pfizer patents and know-how to develop, manufacture
and commercialize gedatolisib. We have exclusive licenses under the Gedatolisib License Agreement to patent rights in the U.S. and numerous
foreign jurisdictions relating to gedatolisib. The patent rights in-licensed under the Gedatolisib License Agreement include 12 granted
patents in the U.S. and more than 290 patents granted in foreign jurisdictions including Australia, Canada, China, France, Germany, Spain,
United Kingdom and Japan. A U.S. patent covering gedatolisib as a composition of matter has a statutory expiration date in December 2029
(including 209 days of Patent Term Adjustment) and a U.S. patent that covers the cyclodextrin formulation of gedatolisib that is currently
in clinical development expires in January 2041 (including 578 days of Patent Term Adjustment), not including any patent term extension
that may be awarded by the FDA, and relevant foreign counterparts.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><i>CELsignia Patents</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">With respect to CELsignia, we have six issued U.S.
patents and 30 issued international patents covering our diagnostic approach using cell signaling analysis in living patient cells to
guide treatment of patients with targeted therapies and cell sample preparation methods. The earliest expiration date of the patents is
2033. In addition, we have developed significant proprietary know-how and trade secrets for the various cell sample preparation and cellular
analysis methods we have developed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><i>Product Trademark</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">We have applied for trademark protection for our preferred
commercial product tradename. While we expect the trademark to issue, the FDA ultimately will determine whether we can use the trademark
with our product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><i>Trade Secrets</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">In addition to patents, we rely on trade secrets and
know-how to develop and maintain our competitive position. We typically rely on trade secrets to protect aspects of our business that
are not amenable to, or that we do not consider appropriate for, patent protection. We protect trade secrets and know-how by establishing
confidentiality agreements and invention assignment agreements with our employees, consultants, scientific advisors, contractors and partners.
These agreements generally provide that all confidential information developed or made known during the course of an individual or entity&#8217;s
relationship with us must be kept confidential during and after the relationship. These agreements also generally provide that all inventions
resulting from work performed for us or relating to our business and conceived or completed during the period of employment or assignment,
as applicable, shall be our exclusive property. In addition, we take other appropriate precautions, such as physical and technological
security measures, to guard against misappropriation of our proprietary information by third parties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>Government Regulation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>Approval of Gedatolisib and Other Drug Products</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Government authorities in the U.S. at the federal,
state and local level and in other countries and jurisdictions, including the EU, extensively regulate, among other things, the research,
development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution,
post-approval monitoring and reporting, marketing and export and import of drug products, such as gedatolisib and other drugs that may
be used in combination with or compete with gedatolisib. Generally, before a new drug can be marketed, considerable data demonstrating
its quality, safety and efficacy must be obtained, organized into a format specific for each regulatory authority and submitted for review
and approved by the regulatory authority. The regulatory approval process is time-consuming and requires significant capital expenditures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><i>U.S. Approval Process</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"><span style="text-decoration: underline">Overview of FDA Approval Process</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">In the U.S., pharmaceutical products are subject to
extensive regulation by the FDA. The Federal Food, Drug, and Cosmetic Act (the &#8220;FDC Act&#8221;), and other federal and state statutes
and regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling,
promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of pharmaceutical products.
Failure to comply with applicable U.S. requirements may subject a company to a variety of administrative or judicial sanctions, such as
FDA refusal to approve pending New Drug Applications (&#8220;NDAs&#8221;), warning or untitled letters, product recalls, product seizures,
total or partial suspension of production or distribution, injunctions, fines, civil penalties and criminal prosecution. The process required
by the FDA before a drug may be marketed in the United States generally involves the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">completion of nonclinical laboratory tests, animal studies and formulation studies according to good laboratory
practices (GLP), or other applicable regulations;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">submission to the FDA of an application for an investigational new drug application (&#8220;IND&#8221;),
which must become effective before human clinical trials may begin;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">performance of adequate and well-controlled human clinical trials according to the FDA&#8217;s regulations
commonly referred to as current good clinical practices (&#8220;GCPs&#8221;), to establish the safety and efficacy of the proposed drug
for its intended use;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">submission to the FDA of an NDA for a new drug;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">satisfactory completion of an FDA inspection of the manufacturing facility or facilities where the drug
is produced to assess compliance with the FDA cGMPs, to assure that the facilities, methods and controls are adequate to preserve the
drug&#8217;s identity, strength, quality and purity;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">potential FDA inspection of the nonclinical and clinical trial sites that generated the data in support
of the NDA; and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">FDA review of the NDA.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; background-color: white">The
lengthy process of seeking required approvals and the continuing need for compliance with applicable statutes and regulations require
the expenditure of substantial resources and approvals are inherently uncertain.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"><span style="text-decoration: underline">Preclinical and Clinical Stages</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Preclinical tests include laboratory evaluation of
product chemistry, formulation and toxicity, as well as animal trials to assess the characteristics and potential safety and efficacy
of the product. The conduct of the preclinical tests must comply with federal regulations and requirements, including good laboratory
practices. The results of preclinical testing are submitted to the FDA as part of an IND along with other information, including information
about product chemistry, manufacturing and controls and a proposed clinical trial protocol. Long term preclinical tests, such as animal
tests of reproductive toxicity and carcinogenicity, may continue after the IND is submitted. A 30-day waiting period after the submission
of each IND is required prior to the commencement of clinical testing in humans. If the FDA has neither commented on nor questioned the
IND within this 30-day period, the clinical trial proposed in the IND may begin.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">The clinical stage of development involves the administration
of the investigational product to healthy volunteers or disease-affected patients under the supervision of qualified investigators, generally
physicians not employed by, or under control of, the trial sponsor, in accordance with GCPs. Clinical trials are conducted under protocols
detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria and the
parameters to be used to monitor subject safety and assess efficacy. Each protocol, and any subsequent amendments to the protocol, must
be submitted to the FDA as part of an IND. Furthermore, each clinical trial must be reviewed and approved by an Institutional Review Board
(&#8220;IRB&#8221;), for each institution at which the clinical trial will be conducted to ensure that the risks to individuals participating
in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also monitors the clinical trial
until completed. Human clinical trials are typically conducted in three sequential phases, which may overlap or be combined:</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">Phase 1 clinical trials generally involve a small number of healthy volunteers or disease-affected patients who are initially exposed
to a single dose and then multiple doses of the product candidate. The primary purpose of these clinical trials is to assess the metabolism,
pharmacologic action, side effect tolerability and safety of the drug.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">Phase 2 clinical trials involve studies in disease-affected patients to determine the dose required to produce the desired benefits.
At the same time, safety and further pharmacokinetic and pharmacodynamic information is collected, possible adverse effects and safety
risks are identified, and a preliminary evaluation of efficacy is conducted.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">Phase 3 clinical trials generally involve a larger number of patients at multiple sites and are designed to provide the data necessary
to demonstrate the effectiveness of the product for its intended use, its safety in use and to establish the overall benefit/risk relationship
of the product and provide an adequate basis for product approval. These trials may include comparisons with placebo and/or other comparator
treatments. The duration of treatment is often extended to mimic the actual use of a product during marketing.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">A registrational trial is a clinical trial that adequately
meets regulatory agency requirements for the evaluation of a drug candidate&#8217;s efficacy and safety such that it can be used to justify
the approval of the drug. Generally, registrational trials are Phase 3 trials but may be Phase 2 trials if the trial design provides a
reliable assessment of clinical benefit, particularly in situations where there is an unmet medical need.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Post-approval trials, sometimes referred to as Phase
4 clinical trials, may be conducted after initial marketing approval. These trials are used to gain additional experience from the treatment
of patients in the intended therapeutic indication, particularly for long-term safety follow up.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Progress reports detailing the results of the clinical
trials must be submitted at least annually to the FDA and more frequently if serious adverse events occur. The FDA or the sponsor may
suspend or terminate a clinical trial at any time, or the FDA may impose other sanctions on various grounds, including a finding that
the research patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical
trial at its institution if the clinical trial is not being conducted in accordance with the requirements of the IRB or if the drug has
been associated with unexpected serious harm to patients.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">There also are requirements governing the reporting
of ongoing clinical trials and completed clinical trial results to public registries. Information about most clinical trials must be submitted
within specific timeframes for publication on the www.clinicaltrials.gov website. Information related to the product, patient population,
phase of investigation, trial sites and investigators and other aspects of the clinical trial is made public as part of the registration
of the clinical trial. Sponsors are also obligated to discuss the results of their clinical trials after completion. Disclosure of the
results of these trials can be delayed in some cases for up to two years after the date of completion of the trial. Competitors may use
this publicly available information to gain knowledge regarding the progress of development programs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"><span style="text-decoration: underline">FDA Review and Approval Process</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">After completion of the required clinical testing,
an NDA is prepared and submitted to the FDA. Prior to granting approval of the NDA, which is required before marketing of the product
may begin in the U.S., the FDA must determine whether to accept the submission and, thereafter, conduct an in-depth review. This process
may take a year or more. The NDA must include the results of all preclinical, clinical and other testing and a compilation of data relating
to the product&#8217;s pharmacology, chemistry, manufacture and controls. The cost of preparing and submitting an NDA is substantial.
The submission of an NDA to FDA, absent an applicable fee waiver, is subject to a substantial application user fee, currently $4,310,002
for Fiscal Year 2025, and the manufacturer and/or sponsor under an approved NDA are also subject to annual program fees for eligible products,
which are currently $403,889 for Fiscal Year 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">The FDA may also refer applications for novel drug
products, or drug products that present difficult questions of safety or efficacy, to an advisory committee&#8212;typically a panel that
includes clinicians and other experts&#8212;for review, evaluation and a recommendation as to whether the application should be approved.
The FDA is not bound by the recommendation of an advisory committee, but it generally follows such recommendations. Before approving an
NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. Additionally, the FDA will inspect the facility
or the facilities at which the drug is manufactured. The FDA will not approve the product unless compliance with cGMP is satisfactory
and the NDA contains data that provide substantial evidence that the drug is safe and effective in the indication studied.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">After the FDA evaluates the NDA and the manufacturing
facilities, it issues either an approval letter or a complete response letter. A complete response letter generally outlines the deficiencies
in the submission and may require substantial additional testing, or information, in order for the FDA to reconsider the application.
If, or when, those deficiencies have been addressed to the FDA&#8217;s satisfaction in a resubmission of the NDA, the FDA will issue an
approval letter. The FDA has committed to reviewing such resubmissions in two to six months depending on the type of information included.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">An approval letter authorizes commercial marketing
of the drug with specific prescribing information for specific indications. As a condition of NDA approval, the FDA may require a risk
evaluation and mitigation strategy (&#8220;REMS&#8221;), to help ensure that the benefits of the drug outweigh the potential risks. REMS
can include medication guides, communication plans for healthcare professionals and elements to assure safe use (&#8220;ETASU&#8221;).
ETASU can include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain
circumstances, special monitoring and the use of patient registries. The requirement for a REMS can materially affect the potential market
and profitability of the drug. Moreover, product approval may require substantial post-approval testing and surveillance to monitor the
drug&#8217;s safety or efficacy. Once granted, product approvals may be withdrawn if compliance with regulatory standards is not maintained
or problems are identified following initial marketing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Changes to some of the conditions established in an
approved application, including changes in indications, labeling or manufacturing processes or facilities, require submission and FDA
approval of a new NDA or NDA supplement before the change can be implemented. An NDA supplement for a new indication typically requires
clinical data similar to that in the original application, and the FDA uses the same procedures and actions in reviewing NDA supplements
as it does in reviewing NDAs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"><span style="text-decoration: underline">U.S. Marketing Exclusivity</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Upon NDA approval of a new chemical entity (&#8220;NCE&#8221;),
which is a drug (i.e., gedatolisib) that contains no active moiety that has been approved by the FDA in any other NDA, that drug receives
five years of marketing exclusivity during which the FDA cannot accept any Abbreviated New Drug Application (&#8220;ANDA&#8221;), seeking
approval of a generic version of that drug. Certain changes to a drug, such as the addition of a new indication to the package insert,
are associated with a three-year period of exclusivity during which the FDA cannot approve an ANDA for a generic drug that includes the
change. An ANDA may be submitted one year before NCE exclusivity expires if a Paragraph IV certification is filed. If there is no listed
patent in the Orange Book, there is no Paragraph IV certification, and, thus, no ANDA may be filed before the expiration of the exclusivity
period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"><span style="text-decoration: underline">Patent Term Extension</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">After NDA approval, owners of relevant drug patents
may apply for up to a five-year patent extension for one patent. The allowable patent term extension is calculated as half of the drug&#8217;s
testing phase&#8212;the time between IND and NDA submission&#8212;and all of the review phase&#8212;the time between NDA submission and
approval up to a maximum of five years. The time can be shortened if the FDA determines that the applicant did not pursue approval with
due diligence. The total patent term after the extension may not exceed 14 years from approval.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">For patents that might expire during the application
phase, the patent owner may request an interim patent extension. An interim patent extension increases the patent term by one year and
may be renewed up to four times. For each interim patent extension granted, the post-approval patent extension is reduced by one year.
The director of the U.S. Patent and Trademark Office must determine that approval of the drug covered by the patent for which a patent
extension is being sought is likely. Interim patent extensions are not available for a drug for which an NDA has not been submitted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"><span style="text-decoration: underline">Fast Track Designation </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">The FDA is required to facilitate the development,
and expedite the review, of drugs that are intended for the treatment of a serious or life-threatening disease or condition for which
there is no effective treatment, and which demonstrate the potential to address unmet medical needs for the condition. Under the Fast
Track program, the sponsor of a new drug candidate may request that the FDA designate the drug candidate for a specific indication as
a Fast Track drug concurrent with, or after, the filing of the IND for the drug candidate. The FDA must determine if the drug candidate
qualifies for Fast Track Designation within 60 days of receipt of the sponsor&#8217;s request.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Under the Fast Track program and the FDA&#8217;s accelerated
approval regulations, the FDA may approve a drug for a serious or life-threatening illness that provides meaningful therapeutic benefit
to patients over existing treatments based upon a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical
endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible
morbidity or mortality or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and the availability
or lack of alternative treatments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">In clinical trials, a surrogate endpoint is a measurement
of laboratory or clinical signs of a disease or condition that substitutes for a direct measurement of how a patient feels, functions
or survives. Surrogate endpoints can often be measured more easily or more rapidly than clinical endpoints. A drug candidate approved
on this basis is subject to rigorous post-marketing compliance requirements, including the completion of Phase 4 or post-approval clinical
trials to confirm the effect on the clinical endpoint. Failure to conduct required post-approval studies, or confirm a clinical benefit
during post-marketing studies, will allow the FDA to withdraw the drug from the market on an expedited basis. All promotional materials
for product candidates approved under accelerated regulations are subject to prior review by the FDA.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">In addition to other benefits such as the ability
to use surrogate endpoints and engage in more frequent interactions with the FDA, the FDA may initiate review of sections of a Fast Track
drug&#8217;s NDA before the application is complete. This rolling review is available if the applicant provides, and the FDA approves,
a schedule for the submission of the remaining information and the applicant pays applicable user fees. However, the FDA&#8217;s time
period goal for reviewing an application does not begin until the last section of the NDA is submitted. Additionally, the Fast Track Designation
may be withdrawn by the FDA if the FDA believes that the designation is no longer supported by data emerging in the clinical trial process.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"><span style="text-decoration: underline">Breakthrough Therapy Designation</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Breakthrough Therapy Designation by the FDA provides
more extensive development consultation opportunities with FDA senior staff, allows for the rolling review of the drug&#8217;s application
for approval and indicates that the product could be eligible for priority review if supported by clinical data at the time of application
submission for drugs that are intended to treat a serious or life-threatening disease or condition where preliminary clinical evidence
indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints.
Under the breakthrough therapy program, the sponsor of a new drug candidate may request that the FDA designate the drug candidate for
a specific indication as a breakthrough therapy concurrent with, or after, the filing of the IND for the drug candidate. The FDA must
determine if the drug candidate qualifies for Breakthrough Therapy Designation within 60 days of receipt of the sponsor&#8217;s request.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"><span style="text-decoration: underline">Disclosure of Clinical Trial Information</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Sponsors of clinical trials of FDA regulated products,
including drugs, are required to register and disclose certain clinical trial information. Information related to the product, patient
population, phase of investigation, trial sites and investigators and other aspects of the clinical trial is then made public as part
of the registration. Sponsors are also obligated to discuss the results of their clinical trials after completion. Disclosure of the results
of these trials can be delayed in certain circumstances for up to two years after the date of completion of the trial. Competitors may
use this publicly available information to gain knowledge regarding the progress of development programs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><i>European Union Approval Process</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"><span style="text-decoration: underline">Overview</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">In the EU, our product candidates may also be subject
to extensive regulatory requirements. As in the U.S., medicinal products can be marketed only if a marketing authorization from the competent
regulatory agencies has been obtained. Similar to the U.S., the various phases of preclinical and clinical research in the EU are subject
to significant regulatory controls.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">The Clinical Trials Regulation
(EU) No 536/2014 came into effect in 2022. The Clinical Trials Regulation is directly applicable in all the EU Member States, and repealed
the Clinical Trials Directive 2001/20/EC. The Clinical Trials Regulation aims to simplify and streamline the approval of clinical trials
in the EU. The main characteristics of the regulation include: a streamlined application procedure via a single-entry point, the Clinical
Trial Information System (&#8220;CTIS&#8221;); a single set of documents to be prepared and submitted for the application
as well as simplified reporting procedures for clinical trial sponsors; and a harmonized procedure for the assessment of applications
for clinical trials, which is divided in two parts. Part I is assessed by the competent authorities of all EU Member States in which
an application for authorization of a clinical trial has been submitted (Member States concerned). Part II is assessed separately by
each Member State concerned. Strict deadlines have been established for the assessment of clinical trial applications. The role of the
relevant ethics committees in the assessment procedure will continue to be governed by the national law of the concerned EU Member State.
However, overall related timelines will be defined by the Clinical Trials Regulation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">To obtain a marketing authorization of a drug in the
EU, we may submit Marketing Authorisation Applications (&#8220;MAA&#8221;), either under the so-called centralized or national authorization
procedures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"><span style="text-decoration: underline">Centralized Procedure</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">The centralized procedure provides for the grant of
a single marketing authorization following a favorable opinion by the European Medicines Agency (&#8220;EMA&#8221;), that is valid in
all EU Member States, as well as Iceland, Liechtenstein and Norway. The centralized procedure is compulsory for medicines produced by
specified biotechnological processes, products designated as orphan medicinal products, advanced therapy medicines (such as gene-therapy,
somatic cell-therapy or tissue-engineered medicines) and products with a new active substance indicated for the treatment of specified
diseases, such as HIV/AIDS, cancer, diabetes, neurodegenerative disorders or autoimmune diseases and other immune dysfunctions and viral
diseases. The centralized procedure is optional for products that represent a significant therapeutic, scientific or technical innovation,
or whose authorization would be in the interest of public health. Under the centralized procedure, the maximum timeframe for the evaluation
of an MAA by the EMA is 210 days, excluding clock stops, when additional written or oral information is to be provided by the applicant
in response to questions asked by the Committee of Medicinal Products for Human Use (the &#8220;CHMP&#8221;). Accelerated assessment might
be granted by the CHMP in exceptional cases when a medicinal product is expected to be of a major public health interest, particularly
from the point of view of therapeutic innovation. The timeframe for the evaluation of an MAA under the accelerated assessment procedure
is 150 days, excluding stop-clocks.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"><span style="text-decoration: underline">National Authorization Procedures</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">There are also two other possible routes to authorize
medicinal products in several EU countries, which are available for investigational medicinal products that fall outside the scope of
the centralized procedure:</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">Decentralized procedure. Using the decentralized procedure, an applicant may apply for simultaneous authorization in more than one
EU country of medicinal products that have not yet been authorized in any EU country and that do not fall within the mandatory scope of
the centralized procedure.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">Mutual recognition procedure. In the mutual recognition procedure, a medicine is first authorized in one EU Member State, in accordance
with the national procedures of that country. Following this, further marketing authorizations can be sought from other EU countries in
a procedure whereby the countries concerned agree to recognize the validity of the original, national marketing authorization.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Under the above-described procedures, before granting
an MAA, the EMA or the competent authorities of the Member States of the European Economic Area (&#8220;EEA&#8221;), assess the risk-benefit
balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"><span style="text-decoration: underline">EU Regulatory Exclusivity</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">In the EU, new products authorized for marketing (i.e.,
reference products) qualify for eight years of data exclusivity and an additional two years of market exclusivity upon marketing authorization.
The data exclusivity period prevents generic applicants from relying on the preclinical and clinical trial data contained in the dossier
of the reference product when applying for a generic marketing authorization in the EU during a period of eight years from the date on
which the reference product was first authorized in the EU. The market exclusivity period prevents a successful generic applicant from
commercializing its product in the EU until ten years have elapsed from the initial authorization of the reference product in the EU.
The ten-year market exclusivity period can be extended to a maximum of eleven years if, during the first eight years of those ten years,
the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation
prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><i>Drug Approval-Related Regulations &#8211; Rest of the World</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">For other countries outside of the EU and the U.S.,
such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials, product licensing,
pricing and reimbursement vary from jurisdiction to jurisdiction. Additionally, the clinical trials must be conducted in accordance with
cGCP requirements and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.
If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal
of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>Regulations of CELsignia Tests</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.25in"><span style="text-decoration: underline">CLIA and CMS for Diagnostic </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Our CELsignia tests are laboratory developed tests
(&#8220;LDTs&#8221;), and subject to regulation under the Clinical Laboratory Improvement Amendments (&#8220;CLIA&#8221;).&#160;The Centers
for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;), an agency within the U.S. Department of Health and Human Services (&#8220;HHS&#8221;),
regulates all clinical laboratory testing (except research) performed on humans in the United States through CLIA. All clinical laboratories
that perform clinical lab services on human specimens for the purpose of providing information on the diagnosis, prevention or treatment
of disease must receive CLIA certification. We received our CLIA certification in 2016. We also had our laboratory certified by the College
of American Pathologists (&#8220;CAP&#8221;), in 2016, an organization recognized by CMS as a third-party reviewer of clinical laboratories.
Several states, including, among others, New York and California, require licensure of out-of-state labs that receive specimens from the
state and compliance with the state&#8217;s individual laboratory regulations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"><span style="text-decoration: underline">FDA for Diagnostics</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">FDA approval or clearance is not currently required
for CELsignia tests offered as a stand-alone LDT test. If we are partnered with a drug company to launch a CELsignia test as a companion
diagnostic for a new drug indication, we would be required to obtain premarket approval (PMA), in conjunction with the pharmaceutical
company seeking a new drug approval for the matching therapy. Historically, the FDA has exercised enforcement discretion with respect
to tests performed solely in a central laboratory, like the CELsignia tests or LDTs. The FDA has not required laboratories that furnish
only LDTs to comply with the agency&#8217;s requirements for medical devices (e.g., establishment registration, device listing, quality
systems regulations, premarket clearance or premarket approval, and post-market controls). However, the FDA has discussed potential regulation
of LDTs and may regulate LDTs in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>Pricing and Reimbursement of our Product Candidates</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Significant uncertainty exists as to the coverage
and reimbursement status of any products we sell or may sell. Sales of our drug products will depend, in part, on the extent to which
the costs of the products will be covered by third-party payors, including government health programs such as VA, Tricare, Medicare and
Medicaid, commercial health insurers, and other managed care organizations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">In order to obtain coverage and reimbursement for
our drug product, we will conduct extensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness
of our product. Whether or not we conduct such studies, our products may not be considered medically necessary or cost-effective. A third-party
payor&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Further,
one payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage, and adequate
reimbursement, for the product. Third-party reimbursement may not be sufficient to enable us to maintain price levels high enough to realize
an appropriate return on our investment in product development.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">The containment of healthcare costs has become a priority
of federal, state and foreign governments, and the prices of drugs have been a focus in this effort. Third-party payors are increasingly
challenging the prices charged for medical products, examining the medical necessity and reviewing the cost-effectiveness of drug products
and questioning product safety and efficacy. If these third-party payors do not consider our product to be cost-effective compared to
other available products, they may not cover our product or, if they do, the level of reimbursement may not be sufficient to allow us
to realize a profit on the use of our product. The U.S. government, state legislatures and foreign governments have shown significant
interest in implementing cost-containment programs to limit the growth of government-paid healthcare costs, including price controls and
restrictions on reimbursement. Adoption of such controls and measures, and tightening of restrictive policies in jurisdictions with existing
controls and measures, could limit payments for our product and could adversely affect our net revenue and results.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">In August 2022, the Inflation Reduction Act (&#8220;IRA&#8221;)
was signed into law, which, among other things, requires manufacturers of certain drugs to engage in price negotiations with Medicare
(beginning in 2026), imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation, and
replaces the Part D coverage gap discount program with a new discounting program. We will evaluate the impact of the IRA on our business,
operations and financial condition and results as the full effect of the IRA on our business strategy and the pharmaceutical industry
remains uncertain. In addition, changes to the Medicaid program or the federal 340B drug pricing program, which imposes ceilings on prices
that drug manufacturers can charge for medications sold to certain health care facilities, could have a material impact on our business
following commercialization. We expect to see continued focus by Congress and the Trump Administration on regulating pricing, which could
result in legislative and regulatory changes designed to control costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Pricing and reimbursement schemes vary widely from
country to country. Some countries may require the completion of additional studies that compare the cost-effectiveness of a particular
drug product to currently available drugs. The downward pressure on healthcare costs in general, particularly prescription drugs, has
become intense. As a result, increasingly high barriers are being erected to the entry of new drug products. In addition, in some countries,
cross-border imports from low-priced markets exert competitive pressure that may reduce pricing within a country. Any country that has
price controls or reimbursement limitations for drug products may not allow favorable reimbursement and pricing arrangements for our product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Coverage policies, third-party reimbursement rates
and pricing regulation may change at any time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><i>Other Healthcare Laws</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Manufacturing, sales, promotion and other activities
following product approval are also subject to regulation by numerous regulatory authorities in the U.S. in addition to the FDA, including
CMS, the HHS Office of Inspector General and HHS Office for Civil Rights, other divisions of the HHS, the Department of Justice and state
regulatory bodies including Boards of Pharmacy and Price Transparency Boards.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Healthcare systems, physicians, pharmacists, and third-party
payors will play a primary role in the recommendation and prescription of any products for which we obtain marketing approval. Our current
and future arrangements with third-party payors, healthcare systems, physicians and pharmacists may expose us to broadly applicable fraud
and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through
which we market, sell and distribute our drug product. In the U.S., these laws include, without limitation, state and federal anti-kickback,
false claims, physician payment transparency, and patient data privacy and security laws and regulations, including but not limited to
those described below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">The U.S. federal Anti-Kickback Statute (&#8220;AKS&#8221;)
prohibits, among other things, any person or entity from knowingly and willfully offering, paying, soliciting, receiving or providing
any remuneration, directly or indirectly, overtly or covertly, to induce or in return for purchasing, leasing, ordering or arranging for
or recommending the purchase, lease or order of any good, facility, item or service reimbursable, in whole or in part, under Medicare,
Medicaid or other federal healthcare programs. The term &#8220;remuneration&#8221; has been broadly interpreted to include anything of
value. The AKS has been interpreted to apply to arrangements between pharmaceutical and medical device manufacturers on the one hand and
prescribers, purchasers, formulary managers and beneficiaries on the other hand. A person does not need to have actual knowledge of the
statute or specific intent to violate it in order to have committed a violation of the AKS.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Moreover, a claim including items or services resulting
from a violation of the AKS constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act, which imposes
civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities (including manufacturers) for,
among other things, knowingly presenting, or causing to be presented to federal programs (including Medicare and Medicaid) claims for
items or services that are false or fraudulent, claims for items or services not provided as claimed, or claims for medically unnecessary
items or services. This could apply even if we are not submitting claims directly to payors as would be the case with drug products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">In addition, under a federal law directed at &#8220;self-referral,&#8221;
commonly known as the &#8220;Stark Law,&#8221; there are prohibitions, with certain exceptions, on referrals for certain designated health
services, including laboratory services, that are covered by the Medicare and Medicaid programs by physicians who personally, or through
a family member, have an investment or ownership interest in, or a compensation arrangement with, an entity performing the tests. The
prohibition also extends to payment for any testing referred in violation of the Stark Law. Bills submitted in violation of the Stark
Law may not be paid by Medicare or Medicaid, and there may be significant penalties for violations. Many states have comparable laws that
are not limited to Medicare and Medicaid referrals.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">These regulations present compliance and litigation
risks for our business and others in our industry. We incur compliance-related expenses and expect to incur additional expenses if and
when our products are commercialized. We may be subject to penalties or limitations on government program participation if we are found
to have violated these regulations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">The federal Health Insurance Portability and Accountability
Act of 1996 (&#8220;HIPAA&#8221;) created additional federal criminal statutes that prohibit, among other actions, knowingly and willfully
executing, or attempting to execute, a scheme to defraud or to obtain, by means of false or fraudulent pretenses, representations or promises,
any money or property owned by, or under the control or custody of, any healthcare benefit program, including private third-party payors,
knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a
healthcare offense and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious
or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the AKS,
a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a
violation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">In addition, there has been a recent trend of increased
federal and state regulation of payments made to physicians and certain other healthcare providers, and their ownership and investment
interests. The Affordable Care Act (the &#8220;ACA&#8221;), imposed, among other things, annual reporting requirements through the Physician
Payments Sunshine Act for covered manufacturers for certain payments and &#8220;transfers of value&#8221; to these providers. Failure
to submit timely, accurately and completely the required information for all payments, transfers of value and ownership or investment
interests may result in civil monetary penalties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">We may also be subject to data privacy and security
regulation by both the federal government and the states in which we conduct our business. HIPAA, as amended by the Health Information
Technology for Economic and Clinical Health Act (&#8220;HITECH&#8221;), and their respective implementing regulations, impose specified
requirements relating to the privacy, security and transmission of individually identifiable health information held by covered entities
and their business associates. Among other things, HITECH made HIPAA&#8217;s security standards directly applicable to &#8220;business
associates,&#8221; defined as independent contractors or agents of covered entities that create, receive, maintain or transmit protected
health information in connection with providing a service for or on behalf of a covered entity, although it is unclear that we would be
considered a &#8220;business associate&#8221; in the normal course of our business. HITECH also increased the civil and criminal penalties
that may be imposed against covered entities, business associates and possibly other persons, and gave state attorneys general new authority
to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney&#8217;s fees and
costs associated with pursuing federal civil actions. In addition, state laws govern the privacy and security of health information in
certain circumstances, many of which differ from each other in significant ways and may not have the same requirements, thus complicating
compliance efforts. See &#8220;European Data Collection&#8221; below for a discussion of data privacy and security enactments of the EU.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">At the state level, the California Consumer Privacy
Act (the &#8220;CCPA&#8221;), as amended and expanded by the California Privacy Rights Act (the &#8220;CPRA&#8221;), impose data protection
obligations on certain businesses. While we believe that certain limited exceptions under the CPRA for clinical trial data and other health
data would apply to us, these regulations exemplify the vulnerability of our business to the evolving regulatory environment related to
personal data and protected health information, which causes us to incur compliance costs. Privacy legislation similar to the CCPA has
been adopted in other U.S. states, including Colorado, Connecticut, Kentucky, Maryland, Minnesota, Montana, New Jersey, New Hampshire,
Nevada, Oregon, Rhode Island, Tennessee, Texas, Utah, and Virginia.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">States and foreign jurisdictions also have fraud and
abuse laws and regulations, such as state anti-kickback and false claims laws, which may apply to sales or marketing arrangements and
claims involving healthcare items or services. Some state laws also require pharmaceutical companies to comply with the pharmaceutical
industry&#8217;s voluntary compliance guidelines and the relevant federal government compliance guidance, and require drug manufacturers
to report information related to payments and other transfers of value to physicians and other healthcare providers, marketing expenditures
or drug pricing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">In order to sell products, we will need to comply
with state laws, including those that require the registration of manufacturers and wholesale distributors of drug and biological products.
Several states have enacted legislation requiring pharmaceutical and biotechnology companies to establish marketing compliance programs,
file periodic reports with the state, make periodic public disclosures on sales, marketing, pricing, clinical trials and other activities,
and/or register their sales representatives, as well as to prohibit pharmacies and other healthcare entities from providing certain physician
prescribing data to pharmaceutical and biotechnology companies for use in sales and marketing, and to prohibit certain other sales and
marketing practices. If and when we commercialize our products, all of our activities are potentially subject to federal and state consumer
protection and unfair competition laws.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">The scope and enforcement of each of these laws is
uncertain and subject to rapid change in the current environment, especially in light of the lack of applicable precedent and regulations.
If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may
be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, contractual damages, reputational
harm, diminished profits and future earnings, imprisonment, exclusion of drugs from government funded healthcare programs, such as Medicare
and Medicaid, and the curtailment or restructuring of our business strategy operations, as well as additional reporting obligations and
oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these
laws, any of which could adversely affect our ability to operate our business and our financial results. If any of the physicians or other
healthcare providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be
subject to significant criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. Ensuring
business arrangements comply with applicable healthcare laws, as well as responding to possible investigations by government authorities,
can be time- and resource consuming and can divert a company&#8217;s attention from the business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><i>European Data Collection</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">We are subject to the General Data Protection Regulation
(the &#8220;GDPR&#8221;), and associated Data Protection Legislation, which govern the collection and use of personal data as it pertains
to the EU/EEA/UK. This legislation imposes several requirements, including, but not limited to: determining the lawful bases of the processing
of personal data, providing transparency information to the affected individuals, <span style="background-color: white">managing contractual
relationships with relevant vendors and other third parties, </span>notifying the appointment of a data protection officer to the relevant
EU/EEA/UK competent national data protection authorities, and ensuring the security and confidentiality of personal data. The GDPR also
imposes strict rules on the transfer of personal data outside of the EU/EEA/UK to the U.S. Failure to comply with the requirements of
the GDPR and the related national data protection laws of the EU/EEA Member States and the UK may result in administrative penalties and
other enforcement actions. We have incurred, and expect to continue to incur, compliance expenses in connection with the GDPR. If we are
found to be in violation of the GDPR, our product development timeline may be affected, which would potentially affect our ability to
generate revenue and might impact our competitive position.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><i>Current and Future Legislation</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">In the U.S. and other jurisdictions, continued healthcare
reform measures may result in more rigorous coverage criteria and additional downward pressure on the price that we, or any collaborators,
may receive. Individual states in the U.S. have also been increasingly passing legislation and implementing regulations designed to control
pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain
product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other
countries and bulk purchasing. Regulations may also prevent or delay marketing approval of our product candidates, restrict or regulate
post-approval activities and affect our ability to profitably sell any product candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><i>Other Regulatory Requirements</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Our operations use small amounts of hazardous materials
in research and development and generate regulated medical waste in the normal course of performing our CELsignia tests. This subjects
us to a variety of federal, state and local environmental and safety laws and regulations. Some of the regulations under the current regulatory
structure provide for strict liability, holding a party potentially liable without regard to fault or negligence. We could be held liable
for damages and fines as a result of our, or others&#8217;, business operations should contamination of the environment or individual
exposure to hazardous substances occur. We cannot predict how changes in laws or development of new regulations will affect our business
operations or the cost of compliance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>Impact of Public Health Matters on our Business</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">As witnessed during the COVID-19 pandemic, future
outbreaks or variants of the virus or other public health disruptions may cause additional delays in our clinical trial work or impact
our ability to access health care practitioners who might utilize our product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>Corporate History</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">We were organized as a Minnesota limited liability
company in 2011 and commenced operations in 2012. On September&#160;15, 2017, we converted from a Minnesota limited liability company
into a Delaware corporation and changed our name from Celcuity LLC to Celcuity Inc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>Employees and Labor Relations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">As of December&#160;31, 2024, we had 87 full-time
employees, most of which were engaged in research and development activities, though hiring employees in preparation for anticipated commercial
launch has begun. None of our employees are currently represented by a labor union or covered by a collective bargaining agreement and
we believe that our relations with our employees are good. During 2024, our voluntary turnover rate was approximately 5%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;<b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><span id="a_003"></span>ITEM 1A. Risk Factors</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"><i>Risk factors that could cause actual results to
differ from our expectations and that could negatively impact our financial condition and results of operations are discussed below and
elsewhere in this Annual Report.&#160;Additional risks and uncertainties not presently known to us or that are currently not believed
to be significant to our business may also affect our actual results and could harm our business, financial condition and results of operations.&#160;If
any of the risks or uncertainties described below or any additional risks and uncertainties actually occur, our business, results of operations
and financial condition could be materially and adversely affected. </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>Risks Relating to Our Business</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>We have a limited operating history and we may never generate revenue
or profit.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">We are a clinical-stage biotechnology company that
commenced activities in January 2012. We have a limited operating history, and our business plan has not been tested. Since inception,
we have had no revenue and have incurred significant operating losses. We have financed our operations primarily through equity and debt
offerings. To generate revenue and become and remain profitable, we need to successfully complete our existing clinical trials, cultivate
partnerships with pharmaceutical companies, and develop and commercialize gedatolisib pursuant to our license agreement with Pfizer. We
must also build operational and financial infrastructure to support commercial operations, train and manage employees, and market and
sell our anticipated drug product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">We may never succeed in any of these activities and,
even if we do, we may never generate revenue that is sufficient to achieve profitability. We expect to continue to incur significant expenses
and operating losses for the foreseeable future, and the net losses we incur may fluctuate significantly from quarter to quarter. Our
failure to become and remain profitable would decrease our value and could impair our ability to raise capital, maintain or expand our
research and development efforts, expand our business, or continue our operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>Our inability to raise additional capital on acceptable terms in
the future may limit our ability to develop and commercialize our drug candidate, gedatolisib.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">We will require additional capital to finance operating
expenses and capital expenditures over the next several years if we launch gedatolisib and expand our infrastructure, commercial operations
and research and development activities. If we are not able to secure additional funding when needed, we may have to delay, reduce the
scope of or eliminate one or more research and development programs or selling and marketing initiatives. In addition, we may have to
work with a partner on one or more of our products or market development programs, which could lower the economic value of those programs
to our company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>Future financing activities could dilute the percentage ownership
of our stockholders and could cause our stock price to fall or could result in operating or other restrictions.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">We may seek to raise additional capital through equity
offerings, debt financings, collaborations or licensing arrangements. Additional funding may not be available to us on acceptable terms,
or at all. If we raise funds by issuing equity securities, it will result in dilution to current stockholders. Any equity securities issued
may also provide for rights, preferences or privileges senior to those of holders of our existing securities. The incurrence of additional
indebtedness or the issuance of certain equity securities could result in increased fixed payment obligations and could also include restrictive
covenants, such as limitations on our ability to incur additional debt or issue additional equity, limitations on our ability to acquire
or license intellectual property rights, and other operating restrictions that could adversely affect our ability to conduct our business.
In the event that we enter into collaborations or licensing arrangements to raise capital, we may be required to accept unfavorable terms.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>We are dependent on our ability to attract and retain key personnel.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Our operations are materially dependent upon the services
of our officers and key employees, including Brian F. Sullivan, our Chief Executive Officer, and Dr. Lance G. Laing, our Chief Science
Officer. Successful implementation of our business plan will also require the services of other consultants and additional personnel.
We cannot assure you that we will be able to attract and retain such persons as employees, independent contractors, consultants or otherwise.
If we are not able to attract individuals with the skills required for our business, or if we lose the services of either Mr. Sullivan
or Dr. Laing, we may be unable to successfully implement our business plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>Product liability claims may damage our reputation and, if insurance
proves inadequate, these claims may harm our business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">We may be exposed to the risk of product liability
claims that is inherent in the biopharmaceutical industry. A product liability claim may damage our reputation by raising questions about
our product&#8217;s safety and efficacy and could limit our ability to sell one or more products by preventing or interfering with commercialization
of our drug candidate. In addition, product liability insurance for the biopharmaceutical industry is generally expensive to the extent
it is available at all. There can be no assurance that we will be able to obtain or maintain such insurance on acceptable terms for any
product we bring to market. Further, our product liability insurance coverage may not provide coverage or may be insufficient to reimburse
us for any or all expenses or losses we may suffer. A successful claim against us with respect to uninsured liabilities or in excess of
insurance coverage could have a material adverse effect on our business, financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>We expect to expand our development and regulatory capabilities and
potentially implement sales, marketing and distribution capabilities, and as a result, we may encounter difficulties in managing our growth,
which could disrupt our operations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">We expect to experience significant growth in the
number of our employees and the scope of our operations, particularly in the areas of drug development, regulatory affairs and, if our
product candidate receives marketing approval, sales, marketing and distribution. To manage our anticipated future growth, we must continue
to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional
qualified personnel. Due to our limited financial and human resources, we may not be able to effectively manage the expansion of our operations
or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our
management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt
our operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>Risks Related to Our Product Strategy </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>Our near-term revenue prospects depend on the success of our initial
drug product, gedatolisib. If we are unable to successfully complete clinical development of, obtain regulatory approval for or commercialize
gedatolisib, or if we experience delays in doing so, our business will be materially harmed.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">To date, we have not yet completed any registrational
clinical trials or the development of our initial drug candidate, gedatolisib. Our future success and ability to generate revenue, which
we do not expect until 2026 or later, if ever, is dependent on our ability to successfully develop, obtain regulatory approval for and
commercialize gedatolisib for one or more intended uses. We may not have the financial resources to continue development of, or to modify
existing or enter into new collaborations for, our current or future product candidates if we experience any issues that delay or prevent
regulatory approval of, or our ability to commercialize, gedatolisib, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">our inability to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that gedatolisib is safe
and effective;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">insufficiency of our financial and other resources to complete the necessary preclinical studies and clinical trials;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">negative or inconclusive results from our clinical trials or the clinical trials of others for drug products similar to ours, leading
to a decision or requirement to conduct additional preclinical studies or clinical trials or abandon a program;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">product-related adverse events experienced by subjects in our clinical trials or by individuals using drugs or therapeutic biologics
similar to gedatolisib;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">delays in submitting applications, delays or failure in obtaining the necessary approvals from regulators to commence a clinical trial,
or a suspension or termination of a clinical trial once commenced;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">conditions imposed by the FDA or comparable foreign regulatory authorities regarding the scope or design of our clinical trials;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">poor effectiveness of gedatolisib or companion therapeutics during clinical trials;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">better than expected performance of control arms, such as placebo groups, which could lead to negative or inconclusive results from
our clinical trials;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">delays in enrolling subjects in clinical trials;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">high drop-out rates of subjects from clinical trials;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">inadequate supply or quality of drug products or other materials necessary for the conduct of our clinical trials;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">greater than anticipated clinical trial or manufacturing costs;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">unfavorable FDA or comparable regulatory authority inspection and review of a clinical trial site;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">failure of our third-party contractors or investigators to comply with regulatory requirements or otherwise meet their contractual
obligations in a timely manner, or at all;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">delays and changes in regulatory requirements, policy and guidelines, including the imposition of additional regulatory oversight
around clinical testing generally or with respect to our therapies in particular; or</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">varying interpretations of data by the FDA and comparable foreign regulatory authorities.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>We were not involved in the early development of gedatolisib; therefore,
we are dependent on third parties having accurately generated, collected, interpreted and reported data from certain preclinical and clinical
trials of gedatolisib.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">We had no involvement with or control over the initial
preclinical and clinical development of gedatolisib. We are dependent on third parties having conducted their research and development
in accordance with the applicable protocols and legal, regulatory and scientific standards; having accurately reported the results of
all preclinical studies and clinical trials conducted with respect to such drug product; and having correctly collected and interpreted
the data from these trials. If these activities were not compliant, accurate or correct, the clinical development, regulatory approval
or commercialization of our drug product will be delayed and may be adversely affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>We have not yet successfully completed any registrational clinical
trials, and we may be unable to do so for any drug candidates we may develop.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">We will need to successfully complete registrational
clinical trials in order to obtain the approval of the FDA or comparable foreign regulatory authorities to market our drug product. Carrying
out clinical trials, including later-stage registrational clinical trials, is a complicated process. As an organization, we have not previously
completed any registrational clinical trials. In order to do so, we are building and expanding our clinical development and regulatory
capabilities, and there is risk that we may be unable to recruit and train qualified personnel. We also expect to continue to rely on
third parties to conduct our clinical trials. If these third parties do not successfully carry out their contractual duties, meet expected
deadlines or comply with regulatory requirements, we may not be able to obtain regulatory approval of or commercialize any product candidates.
Consequently, we may be unable to successfully and efficiently execute and complete necessary clinical trials in a way that leads to submission
and approval of our drug product. We may require more time and incur greater costs than our competitors and may not succeed in obtaining
regulatory approval of any drug products that we develop. Failure to commence or complete, or delays in, our planned clinical trials,
could prevent us from or delay us in commercializing our drug products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>The successful development of our products is highly uncertain.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Our business depends on the successful development
of biopharmaceuticals, which is highly uncertain and is dependent on numerous factors, many of which are beyond our control. Product candidates
that appear promising in the early phases of development may fail to reach the market for several reasons including, among other things,
that clinical trial results may show the product candidates to be less effective than expected or to have unacceptable side effects or
toxicities; we may fail to receive the necessary regulatory approvals or there may be a delay in receiving such approvals; or the proprietary
rights of others and their competing products and technologies may prevent our product candidates from being commercialized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">The length of time necessary to complete clinical
trials and to submit an application for marketing approval for a final decision by a regulatory authority varies significantly from one
drug product to the next and from one country to the next and may be difficult to predict. We will incur significant research and development
expenses before knowing whether our products are commercially viable, and may abandon development of a specific trial, or a product candidate,
at any time for a variety of reasons. If we expend resources on products that are ultimately not commercially viable, our timing for becoming
profitable and our ability to invest in other products in our pipeline would be adversely affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">In addition, if <span style="background-color: white">gedatolisib</span>
receives marketing approval for the intended uses that we are pursuing, we will continue to be subject to significant post-approval regulatory
obligations. Compliance with these requirements is costly, and any failure to comply or other issues with our drug products post-approval
could adversely affect our business, financial condition and results of operations. In addition, there is always the risk that we, a regulatory
authority or a third party might identify previously unknown problems with a product post-approval, such as adverse events of unanticipated
severity or frequency.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>If we encounter difficulties enrolling patients in any of our clinical
trials, our clinical development activities could be delayed or otherwise adversely affected.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">The timely completion of clinical trials in accordance
with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the trial until
its conclusion. We may experience difficulties in patient enrollment in our clinical trials for a variety of reasons, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">the patient eligibility and exclusion criteria defined in the protocol;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">the size of the patient population required for analysis of the clinical trial&#8217;s primary endpoints;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">the proximity of patients to clinical trial sites;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">the design of the clinical trial;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">our ability to recruit clinical trial investigators with the appropriate competencies and experience, and the ability of these investigators
to identify and enroll suitable patients;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">perception of the safety profile of our drug products;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">our ability to obtain and maintain patient consents; and</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">the risk that patients enrolled in clinical trials will drop out of the trials before completion.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Delays in patient enrollment may result in increased
costs or may affect the timing or outcome of our clinical trials, which could prevent completion of these trials and adversely affect
our ability to advance the development of our product candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>Interim, topline and preliminary data from our clinical studies that
we announce or publish from time to time may change as more data becomes available and are subject to audit and verification procedures
that could result in material changes in the final data.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">From time to time, we may publicly disclose preliminary
or topline data from our clinical studies, which is based on a preliminary analysis of then-available data, and the results and related
findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study. We also
make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity
to fully and carefully evaluate all data. As a result, the topline results that we report may differ from future results of the same studies,
or different conclusions or considerations may qualify such results once additional data have been received and fully evaluated. Topline
data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary
data we previously published. As a result, topline data should be viewed with caution until the final data are available. From time to
time, we may also disclose interim data from our clinical studies. Interim data from clinical studies that we may complete are subject
to the risk that one or more of the clinical outcomes may materially change as more patient data becomes available. Adverse differences
between preliminary or interim data and final data could significantly harm our reputation and marketing efforts.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Further, others, including healthcare providers or
payors, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance
of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular
product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular
study is based on what is typically extensive information, and you or others may not agree with what we determine is the material or otherwise
appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant
with respect to future decisions, conclusions, views, activities or otherwise regarding our business. If the topline or interim data that
we report differ from actual results, or if others, including healthcare providers or payors, disagree with the conclusions reached, our
ability to commercialize our product candidate may be harmed, which could harm our business, operating results, prospects or financial
condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>Clinical development involves a lengthy and expensive process, with
an uncertain outcome. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development
and commercialization of our product candidates.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">To obtain the requisite regulatory approvals to commercialize
any drug products, we must demonstrate through extensive preclinical studies and clinical trials that such drug product is safe and effective
in humans. Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. We may be unable
to establish clinical endpoints that applicable regulatory authorities would consider clinically meaningful, and a clinical trial can
fail at any stage of testing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Differences in trial design between early-stage clinical
trials and later-stage clinical trials, which involve a greater number of patients and take years to complete, make it difficult to extrapolate
the results of earlier clinical trials to later clinical trials. Moreover, clinical data are often susceptible to varying interpretations
and analyses, and many companies that have believed their product candidates performed satisfactorily in clinical trials have nonetheless
failed to obtain marketing approval of their products. Additionally, we are conducting and plan to conduct some open-label clinical trials,
where both the patient and investigator know whether the patient is receiving the investigational product candidate or either an existing
approved drug or placebo. Most typically, open-label clinical trials test only the investigational product candidate and sometimes may
do so at different dose levels. Open-label clinical trials are subject to various limitations that may exaggerate any therapeutic effect
as patients in those trials are aware when they are receiving treatment. Open-label clinical trials may be subject to a &#8220;patient
bias&#8221; where patients perceive their symptoms to have improved merely due to their awareness of receiving an experimental treatment.
In addition, open-label clinical trials may be subject to an &#8220;investigator bias&#8221; where those assessing and reviewing the outcomes
of the clinical trials are aware of which patients have received treatment and may interpret the information of the treated group more
favorably given this knowledge. Where a randomized, placebo-controlled clinical trial is designed to allow enrolled subjects to cross-over
to the treatment arm, there may be a risk of inadvertent unblinding of subjects prior to cross-over, which may limit the clinical meaningfulness
of those data and may require the conduct of additional clinical trials. As such, the results from an open-label clinical trial may not
be predictive of future clinical trial results with any of our product candidates for which we include an open-label clinical trial when
studied in a controlled environment with a placebo or active control.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Successful completion of clinical trials is a prerequisite
to submitting a new drug application, or NDA, to the FDA and similar marketing applications to comparable foreign regulatory authorities
for each drug product and, consequently, the ultimate approval and commercial marketing of any drug products. We may experience delays
in initiating or completing clinical trials, including if it takes longer than expected to activate the targeted number of clinical sites,
if the enrollment of patients is slower than anticipated or negatively affected by staffing shortages at clinical sites, or by other unanticipated
factors, or if the FDA or other regulatory authorities require us to pause one or more of our clinical trials due to unexpected safety
issues. We also may experience numerous unforeseen events during, or as a result of, any future clinical trials that we could conduct
that could delay or prevent our ability to receive marketing approval or commercialize our current product candidates or any future product
candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Our costs will increase if we experience delays in
clinical testing or marketing approvals. We do not know whether our clinical trials will begin or continue as planned, will need to be
reassigned or will be completed on schedule, or at all. Significant clinical trial delays also could shorten any periods during which
we may have the exclusive right to commercialize our product candidates and may allow our competitors to bring products to market before
we do, potentially impairing our ability to successfully commercialize our product candidates and harming our business and results of
operations. Any delays in our clinical development programs may harm our business, financial condition and results of operations significantly.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>We face significant competition, and our operating results will suffer
if we fail to compete effectively.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Our industry is characterized by intense competition
and rapid innovation. Our competitors may be able to develop other compounds or drugs that are able to achieve similar or better results
than our lead product candidate, gedatolisib. Our potential competitors include major multinational pharmaceutical companies, established
biotechnology companies, specialty pharmaceutical and diagnostic companies, and universities and other research institutions. Many of
our competitors have substantially greater financial, technical and other resources, such as larger research and development staff and
experienced marketing and manufacturing organizations and well-established sales forces.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Smaller or early-stage companies may also prove to
be significant competitors, particularly as they develop novel approaches to treating disease indications that gedatolisib is also focused
on treating. Established pharmaceutical companies may also invest heavily to accelerate discovery and development of novel therapeutics
or to in-license novel therapeutics that could make the product candidates that we develop obsolete. Mergers and acquisitions in the biotechnology
and pharmaceutical industries may result in even more resources being concentrated in our competitors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Competition may increase further as a result of advances
in the commercial applicability of technologies and greater availability of capital for investment in these industries. Our competitors,
either alone or with collaboration partners, may succeed in developing, acquiring or licensing on an exclusive basis products that are
more effective, safer, more easily commercialized or less costly than our product candidates or may develop proprietary technologies or
secure patent protection that we may need for the development of our technologies and products. We believe the key competitive factors
that will affect the development and commercial success of our product candidates are efficacy, safety, tolerability, reliability, convenience
of use, price, and reimbursement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Even if we obtain regulatory approval of drug products,
the availability and price of our competitors&#8217; products could limit the demand and the price we are able to charge for our product
candidates. We may not be able to implement our business plan if the acceptance of our product candidates is inhibited by price competition
or the reluctance of physicians to switch from existing methods of treatment to our product candidates, or if physicians switch to other
new drug or biologic products or choose to reserve our product candidates for use in limited circumstances.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>If our information technology systems or data, or those of third
parties upon which we rely, are or were compromised, we could face clinical trial delays; regulatory investigations or actions; litigation;
fines and penalties; disruptions of our business operations; reputational harm; and other adverse consequences.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Cyberattacks, malicious internet-based activity, online
and offline fraud, and other similar activities threaten the confidentiality, integrity, and availability of our sensitive information
and information technology systems, and those of the third parties upon which we rely. We rely on contract research organizations, contract
manufacturing organizations, distributors, supply chain resources, and other third-party service providers and technologies to operate
critical business systems to process sensitive information in a variety of contexts, including, without limitation, on-site systems and
cloud-based data centers, systems handling human resources, financial reporting and controls, customer relationship management, regulatory
compliance, and other infrastructure operations. We also communicate sensitive data, including patient data, electronically, and through
relationships with multiple third-party vendors and their subcontractors. These applications and data encompass a wide variety of sensitive
information, including research and development information, patient data, commercial information, and business and financial information.
Our ability to monitor these third parties&#8217; security practices is limited, and these third parties may not have adequate security
measures in place. If we or any of our third-party service providers experience a security incident or other interruption, we could experience
adverse consequences. We cannot guarantee that third parties and infrastructure in our supply chain or our third-party partners&#8217;
supply chains have not been compromised or that they do not contain exploitable defects or bugs that could result in a breach of or disruption
to our information technology systems or the third-party information technology systems that support us and our services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Cybersecurity threats are becoming increasingly difficult
to detect, and come from a variety of sources, including without limitation, nation-state actors and activists that create disruption
for geopolitical reasons and in conjunction with military conflicts and defense activities. This risk is heightened during times of war
and other major conflicts, including the war between Russia and Ukraine, the conflict between Israel and Hamas and the risk of a larger
regional conflict. In addition, we and the third parties upon which we rely face an evolving cybersecurity threat landscape, which includes
social-engineering attacks (including through deep fakes, which may be increasingly more difficult to identify as fake, and phishing attacks),
malicious code (such as viruses and worms), malware (including as a result of advanced persistent threat intrusions), denial-of-service
attacks, credential stuffing, credential harvesting, personnel misconduct or error, ransomware attacks, supply-chain attacks, software
bugs, server malfunctions, attacks enhanced or facilitated by artificial intelligence (&#8220;AI&#8221;), software or hardware failures,
loss of data or other information technology assets, adware, telecommunications failures, natural disasters, terrorism, and other similar
threats.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">The majority of our employees and contractors work
remotely. Remote work involves risks to our information technology systems and data, as individuals utilize network connections, computers
and devices outside our premises or network, including working at home, while in transit and in public locations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Ransomware attacks also continue to increase in prevalence
and severity and can lead to significant interruptions in our operations, ability to provide our services, loss of data and income, reputational
harm, and diversion of funds. Extortion payments may alleviate the negative impact of a ransomware attack, but we may be unwilling or
unable to make such payments due to, for example, applicable laws or regulations prohibiting such payments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">While we take steps designed to identify, prevent,
assess and mitigate vulnerabilities in our information systems and to mitigate related third-party risks, there can be no assurance that
we will be able to detect and remediate all such vulnerabilities, including on a timely basis. The threats and techniques used to exploit
vulnerabilities change frequently and are often sophisticated in nature. Therefore, we (or third parties on whom we rely) may be unable
to detect a vulnerability until after a security incident has occurred. Further, we or third parties on which we rely may face downtime
as a result of adopting new information technology systems that are designed to enhance compliance or reduce vulnerabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">A security incident or other interruption could result
in unauthorized, unlawful, or accidental acquisition, modification, destruction, loss, alteration, encryption, disclosure of, or access
to our sensitive information or our information technology systems, or those of the third parties upon whom we rely. This could disrupt
our clinical trials, damage our reputation, and negatively affect our ability to conduct our business in the ordinary course, including
our ability to collect, process, and prepare company financial information, provide information and educational materials through our
website, and manage the administrative aspects of our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">We may expend significant resources or modify our
business activities (including our clinical trial activities) to try to protect against security incidents. Additionally, certain data
privacy and security obligations may require us to implement and maintain certain measures to protect our information technology systems
and sensitive information and to notify relevant stakeholders, including affected individuals, regulatory authorities and our stockholders,
of certain security incidents. The disclosure decisions are complex, may take time to determine, and may be subject to change as an investigation
progresses. Providing disclosure may be costly, and the failure to comply with such requirements could also lead to adverse consequences.
If we (or a third party upon whom we rely) experience a security incident or are perceived to have experienced a security incident, we
may face government enforcement actions (for example, investigations, fines, penalties, audits, and inspections); additional reporting
requirements and/or oversight; restrictions on processing sensitive information (including personal information); litigation (including
class claims) and mass arbitration; indemnification obligations; negative publicity; reputational harm; monetary fund diversions; interruptions
in our operations (including availability of data); financial loss; and other similar harms. Accordingly, security incidents and attendant
consequences may damage our financial position and negatively impact our ability to grow and operate our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Further, if the information technology systems of
the third parties upon which we rely become subject to security incidents, we may have insufficient recourse against such third parties,
and we may have to expend significant resources to mitigate the impact of such an event, and to develop and implement protections to prevent
future events of this nature from occurring. There can be no assurance that limitations of liability in our third-party contracts are
sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations. We cannot be sure
that our insurance coverage will be adequate or sufficient to protect us from or to mitigate liabilities arising out of our data privacy
and security practices. Additionally, we cannot be sure that such coverage will continue to be available on commercially reasonable terms
or at all, or that such coverage will pay future claims.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">In addition to experiencing a security incident, third
parties may gather, collect, or infer sensitive information about us from public sources, data brokers, or other means that reveals competitively
sensitive details about our organization and could be used to undermine our competitive advantage or market position. Additionally, our
sensitive information could be leaked, disclosed, or revealed as a result of or in connection with our employees&#8217;, personnel&#8217;s,
or vendors&#8217; use of generative AI technologies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; background-color: white"><b><i>Public health matters may materially and
adversely impact our business, including ongoing clinical trials.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in; background-color: white">The outbreak of COVID-19
and government measures taken in response demonstrated that public health matters have a significant impact on the global economy, with
healthcare systems particularly affected. Future outbreaks or variants of COVID-19, or the emergence of other pandemics or public health
disruptions, could materially and adversely impact our clinical trials, business, financial condition and results of operations. Potential
disruptions include but are not limited to:</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in; text-indent: -0.25in; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">delays or difficulties in enrolling patients in clinical trials and obtaining the results of completed clinical trials;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">increased rates of patients withdrawing from clinical trials following enrollment as a result of quarantine or public health concerns;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">diversion of healthcare resources away from the conduct of clinical trials;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">delays in prospective clinical trial collaborations with pharmaceutical companies and sponsors;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">interruption or delays in the operations of the FDA or other regulatory authorities, which may impact review and approval timelines;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">limitations on our ability to recruit and hire key personnel due to our inability to meet with candidates because of travel restrictions;
and</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">limitations on employee resources that would otherwise be focused on the conduct of clinical trials and research as a result of focus
on health matters and loss of productivity from remote work.&#160;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>Artificial intelligence presents risks and challenges that can impact
our business including by posing security risks to our confidential information, proprietary information and personal data.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Issues in the use of artificial intelligence, combined
with an uncertain regulatory environment, may result in reputational harm, liability or other adverse consequences to our business operations.
As with many technological innovations, artificial intelligence presents risks and challenges that could impact our business. Our vendors
may incorporate generative artificial intelligence tools into their offerings without disclosing this use to us, and the providers of
these generative artificial intelligence tools may not meet existing or rapidly evolving regulatory or industry standards with respect
to privacy and data protection and may inhibit our or our vendors&#8217; ability to maintain an adequate level of service and experience.
If any of our vendors experiences an actual or perceived breach or privacy or security incident because of the use of generative artificial
intelligence, we may lose valuable intellectual property and confidential information and our reputation and the public perception of
the effectiveness of our security measures could be harmed. Further, bad actors around the world use increasingly sophisticated methods,
including the use of artificial intelligence, to engage in illegal activities involving the theft and misuse of personal information,
confidential information and intellectual property. Any of these outcomes could damage our reputation, result in the loss of valuable
property and information, and adversely impact our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>Risks Related to Product Development and Product Regulation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>If we are unable to obtain approval from the FDA or comparable foreign
regulatory authorities to market our products for their intended use, we will not be able to generate revenue. For a new drug to be approved
for marketing, the FDA and other regulatory authorities must determine that the drug is safe and effective. Because all drugs can have
adverse effects, the data from our Phase 3 clinical study must demonstrate to the satisfaction of the FDA and other health authorities
that the benefits of gedatolisib in combination with palbociclib and fulvestrant, gedatolisib in combination with fulvestrant, or gedatolisib
in combination with fulvestrant plus a CDK4/6 inhibitor, outweigh its risks. Failure to demonstrate sufficient magnitude of benefit, even
if the benefit is found to be statistically significant, may not support regulatory approval.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">The marketability of our products, particularly gedatolisib,
depends on securing approval from the FDA and equivalent foreign regulatory bodies. This requires rigorous pre-clinical and clinical studies,
including Phase 3 clinical trials for each intended use, that the benefits of the therapy outweigh its risks. Failure to demonstrate sufficient
magnitude of benefit, even if the benefit is found to be statistically significant, may not support regulatory approval. Satisfaction
of the FDA&#8217;s regulatory requirements typically takes many years and requires substantial resources for research, development and
testing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"><span style="background-color: white">If
a drug meets its primary efficacy endpoint objective in a Phase 3 clinical trial, and the drug sponsor has additional nonclinical
and clinical data required by the FDA or other regulatory authorities, the drug sponsor may submit an NDA seeking marketing
approval. Upon submission of an NDA, these health authorities perform a benefit-risk assessment that considers the strength and
quality of evidence available and takes remaining uncertainties into account. These considerations include an assessment of the
strengths and limitations of clinical trials, including design, and potential implications for assessing drug efficacy, the
magnitude of benefit and interpretation of clinical importance, the benefit attributed to the drug when studied in combination with
other therapies, and the clinical relevance of the study endpoints. We are currently conducting a Phase 3 clinical trial,
VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib, in patients with </span>HR+/HER2-
advanced breast cancer after progression on CDK4/6 therapy<span style="background-color: white">, </span>conducting a Phase 3
clinical trial, VIKTORIA-2, evaluating gedatolisib in combination with a CDK4/6 inhibitor and fulvestrant as first-line treatment
for patients with endocrine treatment resistant HR+/HER2- advanced breast cancer, <span style="background-color: white">and
conducting a Phase 1b/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with
metastatic castration resistant prostate cancer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"><span style="background-color: white">We have sought
feedback from the FDA and other regulatory authorities on the design of gedatolisib clinical trials, with the goal of addressing these
considerations in the clinical trials&#8217; design. However, due to the complexity of clinical trials, the uncertainty of outcomes, and
the uncertainty of how the FDA and other regulatory authorities may balance benefits and risks in their review of an NDA, it may not be
practical or possible to address all benefit-risk assessment considerations in a clinical trial so that sufficient evidence is generated
to support a marketing approval, even if the primary endpoint objective is achieved in the Phase 3 stage of the trial. The FDA or other
regulatory authorities may require us to redesign or conduct additional unplanned clinical trials before granting any approval and we
may not get approval at all. Regulatory approval </span>may also be delayed by changes in government regulation, future legislation or
administrative action or changes in FDA policy that occur prior to or during our regulatory review. We cannot predict whether our research
and clinical approaches will result in a drug that the FDA considers safe for humans and effective for indicated uses. In light of these
uncertainties, t<span style="background-color: white">he results from clinical trials that we conduct may not support approval of gedatolisib.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"><span style="background-color: white">If regulatory
approvals are delayed or not obtained, especially with respect to gedatolisib, it will negatively impact our ability to commercialize
our products and generate revenue and may </span>diminish any competitive advantages that we may otherwise enjoy<span style="background-color: white">.
If we are required to conduct additional clinical trials or other testing of gedatolisib beyond those that we currently contemplate, if
we are unable to successfully complete clinical trials or other testing of gedatolisib, or if the results of these trials or tests are
not positive or are only modestly positive or if there are safety concerns, we may:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">be delayed in obtaining marketing approval or not obtain marketing approval at all;</td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">obtain approval for indications or patient populations that are not as broad as intended or desired;</td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings, including boxed warnings;</td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">be subject to changes in the way our products are administered;</td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">be required to perform additional clinical trials to support approval or be subject to additional post-marketing testing requirements;</td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">have regulatory authorities withdraw, or suspend, their approval of the product or impose restrictions on its distribution in the
form of the FDA&#8217;s Risk Evaluation and Mitigation Strategies program (&#8220;REMS&#8221;) or through modification to an existing
REMS;</td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">be sued; or</td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">experience damage to our reputation.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Additionally, if the size of the FDA group dedicated
to reviewing oncology-related submissions is reduced, further delays of any regulatory submission by Celcuity may be encountered.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>Breakthrough Therapy Designation or Fast Track Designation from the
FDA may not actually lead to a faster development or regulatory review or approval process.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">If a drug is intended for the treatment of a serious
or life-threatening condition and the product demonstrates the potential to address unmet medical needs for this condition, the product
sponsor may apply for Fast Track Designation. The designation offers the opportunity for frequent interactions with the FDA to discuss
the drug&#8217;s development plan and to ensure collection of appropriate data needed to support drug approval, as well as eligibility
for submission of a New Drug Application.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">In addition, a drug may receive Breakthrough Therapy
Designation if it is intended, alone or in combination with one or more other products, to treat a serious or life-threatening disease
or condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies
on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The benefits
of Breakthrough Therapy Designation include more intensive guidance from the FDA on an efficient development program, access to a scientific
liaison to help accelerate review time, and potential eligibility for priority review if relevant criteria are met. This designation can
expedite the development and regulatory review of an investigational medicine that is intended to treat a serious or life-threatening
condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Both Fast Track and Breakthrough Therapy Designations
are within the discretion of the FDA. While the FDA has granted both designations to our lead drug candidate, gedatolisib, such designations
may not result in a faster development process, review or approval compared to products considered for approval under conventional FDA
procedures, and neither designation assures ultimate approval by the FDA. In addition, the FDA may later decide that the product no longer
meets the qualification conditions and may rescind either or both such designations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>Obtaining and maintaining regulatory approval of our product candidates
in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Obtaining and maintaining regulatory approval of our
product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other
jurisdiction, while a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory
approval process in others. For example, even if the FDA grants marketing approval of a product candidate, a comparable foreign regulatory
authority must also approve the manufacturing, marketing and promotion of the product candidate in those countries.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Approval procedures vary among jurisdictions and can
involve requirements and administrative review periods different from, and greater than, those in the U.S., including additional preclinical
studies or clinical trials, as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions.
In many jurisdictions outside the U.S., a product candidate must be approved for reimbursement before it can be approved for sale in that
jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Obtaining foreign regulatory approvals and compliance
with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the
introduction of our products in certain countries. If we fail to comply with the regulatory requirements in international markets and/or
receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our
product candidates will be harmed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>Even if we receive initial regulatory approvals, we will be subject
to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense, and we may be subject
to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">If any of our product candidates are approved, they
will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling,
record-keeping, conduct of post-marketing studies and submission of safety, efficacy and other post-marketing information, including both
federal and state requirements in the U.S. and requirements of comparable foreign regulatory authorities. In addition, we will be subject
to continued compliance with requirements for any clinical trials that we conduct post-approval.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Manufacturers and manufacturers&#8217; facilities
are required to comply with extensive FDA and comparable foreign regulatory authority requirements. Accordingly, we and others with whom
we work must continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production and
quality control.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Any regulatory approvals that we receive for our product
candidates may be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of
approval, or contain requirements for potentially costly post-marketing testing, including Phase 4 clinical trials and surveillance to
monitor the safety and efficacy of the product candidate. Certain endpoint data we hope to include in any approved product labeling also
may not make it into such labeling, including exploratory or secondary endpoint data such as patient-reported outcome measures. The FDA
may impose consent decrees or withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems
occur after the product reaches the market. Later discovery of previously unknown problems with our product candidates, including adverse
events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply
with regulatory requirements, may result in revisions to the approved labeling to add new safety information, imposition of post-marketing
studies or clinical trials to assess new safety risks or imposition of distribution restrictions or other restrictions under a REMS program.
Other potential consequences include, among other things:</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">restrictions on the marketing or manufacturing of our products, withdrawal of the product from the market or voluntary or mandatory
product recalls;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">fines, warning letters or holds on clinical trials;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or revocation
of license approvals;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">product seizure or detention or refusal to permit the import or export of our product candidates; and</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">injunctions or the imposition of civil or criminal penalties.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">The FDA strictly regulates marketing, labeling, advertising
and promotion of products that are placed on the market. Products may be promoted only for the approved indications and in accordance
with the provisions of the approved label. If we are slow or unable to adapt to changes in existing requirements or adopt new requirements
or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and
we may not achieve or sustain profitability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>Our focus on the clinical development of gedatolisib has led us to
minimize the Company&#8217;s activities to support development of CELsignia, which will significantly delay, or potentially forestall,
further advancement of clinical development of CELsignia tests or finding appropriate pharmaceutical company partners.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">The success of our CELsignia tests depends on our
ability to attract pharmaceutical company partnerships that provide revenue from the sale of CELsignia tests during clinical trials, from
milestone payments during clinical trials, from sales of our CELsignia tests as companion diagnostics or stand-alone tests thereafter,
and, potentially, from royalties on the incremental drug revenues our tests enable. Our ability to obtain such partnerships and generate
such revenue depends in part on the ability of our first CELsignia tests to demonstrate the potential incremental opportunity available
for pharmaceutical companies, as well as our ability to establish strategic partnerships or other arrangements with suitable pharmaceutical
companies. Since these activities are no longer a priority for the Company, further advancement of the clinical development of the CELsignia
platform will be substantially delayed or forestalled.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>Risks Related to Intellectual Property </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>We depend on intellectual property licensed from third parties, including
from Pfizer for our lead product candidate, and termination of this license could result in the loss of significant rights, which would
harm our business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">We are dependent on patents, know-how and proprietary
technology, both our own and licensed from others. All patents covering gedatolisib and any combination therapies using our product candidates
are licensed from third parties. Any termination of a product license could result in the loss of significant rights and would cause material
adverse harm to our ability to commercialize our product candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Disputes may also arise between us and our licensors
regarding intellectual property subject to a license agreement, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">the scope of rights granted under the license agreement and other interpretation-related issues;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject
to the licensing agreement;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">our right to sublicense patent and other rights to third parties under collaborative development relationships;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">our diligence obligations with respect to the use of licensed technology in relation to our development and commercialization of our
product candidates and what activities satisfy those diligence obligations; and</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us
and our partners.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">If disputes over intellectual property that we have
licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully
develop and commercialize the affected product candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">We are generally also subject to all of the same risks
with respect to protection of intellectual property that we own, as we are for intellectual property that we license. If we or our licensors
fail to adequately protect this intellectual property, our ability to commercialize products could materially suffer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>If we fail to comply with our obligations under our patent license
with Pfizer, we could lose license rights that are important to our business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">We are a party to a license agreement with Pfizer
pursuant to which we in-license key patents for gedatolisib. This license imposes various diligence, milestone payment, royalty, insurance
and other obligations on us. If we fail to comply with these obligations, Pfizer may have the right to terminate the license, in which
event we would not be able to develop or market the products covered by such licensed intellectual property. Further, we cannot be certain
that the activities by these licensors were conducted in compliance with applicable laws and regulations or will result in additional
valid and enforceable patents and other intellectual property rights.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>We may not be successful in obtaining or maintaining necessary rights
to develop any future product candidates on acceptable terms.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Our clinical trials and other programs currently,
and may in the future, involve additional product candidates that require the use of, or reliance on, proprietary rights held by third
parties. Accordingly, the growth of our business depends in part on our ability to acquire, in-license or use these proprietary rights.
We may be unable to acquire or in-license any compositions, methods of use, processes or other third-party intellectual property rights
from third parties that we identify as necessary or important to our business operations. We may fail to obtain any of these licenses
at a reasonable cost or on reasonable terms, if at all, which could harm our business. We may need to cease use of the compositions or
methods covered by such third-party intellectual property rights, and may need to seek to develop alternative approaches that do not infringe
on such intellectual property rights which may entail additional costs and development delays, even if we were able to develop such alternatives,
which may not be feasible. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to
the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license
replacement technology.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">The licensing and acquisition of third-party intellectual
property rights is a competitive area, and companies that may be more established or have greater resources than we do may also be pursuing
strategies to license or acquire third-party intellectual property rights that we may consider necessary or attractive in order to commercialize
our product candidates. More established companies may have a competitive advantage over us due to their size, cash resources and greater
clinical development and commercialization capabilities. There can be no assurance that we will be able to successfully complete such
negotiations and ultimately acquire the rights to the intellectual property surrounding the additional product candidates that we may
seek to acquire.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>If we are not able to prevent disclosure of our trade secrets and
other proprietary information, the value of our products could be significantly diminished.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">We rely on trade secret protection to protect our
interests in proprietary know-how and in processes for which patents are difficult to obtain or enforce. We may not be able to protect
our trade secrets adequately. We have a policy of requiring our consultants, advisors and strategic partners to enter into confidentiality
agreements and our employees to enter into invention, non-disclosure and non-compete agreements. However, no assurance can be given that
we have entered into appropriate agreements with all parties that have had access to our trade secrets, know-how or other proprietary
information. There is also no assurance that such agreements will provide meaningful protection of our trade secrets, know-how or other
proprietary information in the event of any unauthorized use or disclosure of information. Furthermore, we cannot provide assurance that
any of our employees, consultants, contract personnel, or strategic partners, either accidentally or through willful misconduct, will
not cause serious damage to our programs and/or our strategy, for example by disclosing important trade secrets, know-how or proprietary
information to our competitors. It is also possible that our trade secrets, know-how or other proprietary information could be obtained
by third parties as a result of breaches of our physical or electronic security systems. Any disclosure of confidential data into the
public domain or to third parties could allow our competitors to learn our trade secrets and use the information in competition against
us. In addition, others may independently discover our trade secrets and proprietary information. Any action to enforce our rights is
likely to be time consuming and expensive, and may ultimately be unsuccessful, or may result in a remedy that is not commercially valuable.
These risks are accentuated in foreign countries where laws or law enforcement practices may not protect proprietary rights as fully as
in the United States. Any unauthorized disclosure of our trade secrets or proprietary information could harm our competitive position.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>We may be subject to claims by employees claiming ownership of what
we regard as our own intellectual property.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">While it is our policy to require our employees and
contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property
to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard
as our own. Our and their assignment agreements may not be self-executing or may be breached, and we may be forced to bring claims against
third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property.
If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property
rights or personnel. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial
costs and be a distraction to management.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>If we are unable to obtain and maintain intellectual property protection
for our product candidates, or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors
could develop and commercialize product candidates similar or identical to ours, and our ability to successfully commercialize our product
candidates may be impaired.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">We have applied for patents that protect our product
candidates, and our patent portfolio currently includes, for CELsignia, six issued U.S. patents and 30 issued international patents, and,
for our drug candidate gedatolisib, 12 granted patents in the U.S. and more than 290 patents granted in foreign jurisdictions including
Australia, Canada, China, France, Germany, Spain, United Kingdom and Japan. We cannot ensure that our intellectual property position will
not be challenged or that all patents for which we have applied will be granted. We cannot know with certainty whether we were the first
to make the inventions claimed in our owned or licensed patents or pending patent applications, or that we were the first to file for
patent protection of such inventions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">The patent prosecution
process is expensive and time-consuming, and we may not be able to file, prosecute, maintain, enforce or license all necessary or desirable
patent applications at a reasonable cost or in a timely manner, or in all jurisdictions. We may choose not to seek patent protection for
certain innovations and may choose not to pursue patent protection in certain jurisdictions, and under the laws of certain jurisdictions,
patents or other intellectual property rights may be unavailable or limited in scope. Additionally, the laws and regulations governing
patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and
patents that we might obtain in the future. There also may be patent reforms in foreign jurisdictions that could increase the uncertainties
and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents in those jurisdictions.
It is also possible that we will fail to identify patentable aspects of our discovery and nonclinical development output before it is
too late to obtain patent protection.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">As a result of these factors, the issuance, scope,
validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may
not result in patents being issued that protect our product candidates, in whole or in part, or which effectively prevent others from
commercializing competitive product candidates. Moreover, given the amount of time required for the development, testing and regulatory
review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized.
As a result, our owned patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar
or identical to ours.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>Third parties may initiate legal proceedings alleging that we are
infringing their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the
success of our business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">The commercial success of our products depends upon
our ability to use proprietary technologies without infringing the proprietary rights of third parties. There is considerable intellectual
property litigation in the medical technology, biotechnology and pharmaceutical industries. We may become party to, or threatened with,
future adversarial proceedings or litigation regarding intellectual property rights with respect to our products. Additionally, because
current and future employees may have been previously employed at universities or other biotechnology, diagnostic technology or pharmaceutical
companies, including our competitors or potential competitors and strategic partners, third parties may assert infringement claims against
us based on existing patents or patents that may be granted in the future, or they may allege that our employees or we have used or disclosed
intellectual property, including trade secrets or other proprietary information, of any such employee&#8217;s former employer. Litigation
may be necessary to defend against these claims.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Patent litigation could result in loss of exclusivity
or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our
ability to stop others from using or commercializing similar or identical technology and product candidates, or limit the duration of
the patent protection of our technology and potential diagnostic tests. If we are found to infringe a third party&#8217;s intellectual
property rights, we could be required to obtain additional licenses from such third party to continue developing and marketing our applicable
products. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able
to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. We could
be forced, including by court order, to cease commercializing the infringing technology or product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">In addition, we could be found liable for monetary
damages, including treble damages and attorneys&#8217; fees if we are found to have willfully infringed a patent. A finding of infringement
could prevent us from commercializing our products or force us to cease some of our business operations, which could materially harm our
business. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative
impact on our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>Any lawsuits relating to infringement of intellectual property rights
necessary to defend ourselves or enforce our rights will be costly and time consuming and could be unsuccessful.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Because competition in our industry is intense, competitors
may infringe or otherwise violate our issued patents, patents of our licensors or other intellectual property. To counter infringement
or unauthorized use, we may be required to file infringement claims, which can be expensive and time consuming, and could distract our
technical and management personnel from their normal responsibilities. Any claims we assert against perceived infringers could provoke
these parties to assert counterclaims against us alleging that we infringe their patents. In addition, in a patent infringement proceeding,
a court may decide that a patent of ours is invalid or unenforceable, in whole or in part, construe the patent&#8217;s claims narrowly
or refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question.
An adverse result in any litigation proceeding could put one or more of our patents at risk of being invalidated or interpreted narrowly.
We may also elect to enter into license agreements in order to settle patent infringement claims or to resolve disputes prior to litigation,
and any such license agreements may require us to pay royalties and other fees that could be significant. Furthermore, because of the
substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential
information could be compromised by disclosure.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 30; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>Risks Related to Our Reliance on Third Parties</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>We rely on third parties to conduct certain aspects of our preclinical
studies and clinical trials. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or
comply with regulatory requirements, we may not be able to obtain regulatory approval for, or commercialize, any potential product candidates.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">We depend upon third parties to execute our operational
plans and to conduct certain aspects of our preclinical studies. Additionally, we depend on third parties, including independent investigators,
to conduct our clinical trials, under agreements with universities, medical institutions, contract research organizations, or CROs, strategic
partners and others. Our reliance on third parties may affect our development timelines and increase our costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">We have limited control over third-party clinical
investigators and limited visibility into their day-to-day activities, including with respect to their compliance with the approved clinical
protocol. Nevertheless, we are responsible for ensuring that each of our clinical trials is conducted in accordance with the applicable
protocol, legal and regulatory requirements and scientific standards. We and these third parties are required to comply with GCP requirements,
which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for product candidates in clinical
development. Regulatory authorities enforce these GCP requirements through periodic inspections of clinical trial sponsors, clinical investigators
and clinical trial sites. If we or any of these third parties fail to comply with applicable GCP requirements, the clinical data generated
in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to suspend or
terminate these trials or perform additional preclinical studies or clinical trials before approving our marketing applications. Moreover,
our business may be adversely affected if any of these third parties violates federal or state fraud and abuse or false claims laws and
regulations or healthcare privacy and security laws.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Any third parties conducting aspects of our preclinical
studies or our clinical trials will not be our employees and, except for remedies that may be available to us under our agreements with
such third parties, we cannot control whether or not they devote sufficient time and resources to our preclinical studies and clinical
programs. These third parties may also have relationships with other commercial entities, including our competitors, for whom they may
also be conducting clinical trials or other product development activities, which could affect their performance on our behalf. If these
third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced
or if the quality or accuracy of the preclinical or clinical data they obtain is compromised due to the failure to adhere to our protocols
or regulatory requirements or for other reasons, our development timelines, including clinical development timelines, may be extended,
delayed or terminated and we may not be able to complete development of, obtain regulatory approval of or successfully commercialize our
product candidates. As a result, our financial results and the commercial prospects for our product candidates would be harmed, our costs
could increase and our ability to generate revenue could be delayed or precluded entirely.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>Our reliance on third parties to formulate and manufacture our drug
product will expose us to risks that may delay the development, regulatory approval and commercialization of our drug product or result
in higher product costs.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">We do not directly formulate or manufacture our drug
product candidate and do not intend to establish our own manufacturing facilities. We will contract with one or more manufacturers to
manufacture and supply our drug product, and we will use other third parties to package, store and distribute drug supplies for our clinical
trials. If our drug product receives FDA approval, we will rely on one or more third-party contractors to manufacture and distribute our
drug product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Our reliance on a limited number of third-party manufacturers,
including one primary manufacturer of the active ingredient gedatolisib, exposes us to risks that, among other things, we may be unable
to identify manufacturers on acceptable terms or at all because the number of potential manufacturers is limited and the FDA must approve
any replacement or additional manufacturer; our third-party manufacturers might be unable to formulate and manufacture our drugs in the
volume and of the quality required to meet our clinical and/or commercial needs, if any; our contract manufacturers may not perform as
agreed or may not remain in the contract manufacturing business for the time required to supply our clinical trials, or to successfully
produce, store and distribute our products commercially; and our contract manufacturers may fail to comply with good manufacturing practice
and other government regulations and corresponding foreign standards. Each of these risks could delay our clinical trials, the approval,
if any, of our product candidates by the FDA, or the commercialization of our product candidates or result in higher costs or deprive
us of potential product revenues.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>The pharmaceutical companies that we partner with for our CELsignia
tests may not be successful in receiving regulatory approval for drug indications or may not commercialize their companion therapies for
our expected companion diagnostic programs.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">There can be no assurances that our pharmaceutical
partners for our CELsignia tests will be able to obtain regulatory approval for new indications to treat applicable patient populations
or otherwise be successful in commercializing their therapies. Among other risks, our pharmaceutical company partners may not meet clinical
trial endpoint targets, may encounter regulatory or production delays, may not pursue commercialization of companion therapeutics, or
may terminate their relationship with us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 31; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>Performance issues or price increases by our shipping carriers could
adversely affect our business, results of operations and financial condition, and harm our reputation and ability to provide our products
on a timely basis.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Expedited, reliable shipping is essential to our operations.
Should our shipping carriers encounter delivery performance issues such as loss, damage or destruction of a sample, such occurrences may
damage our reputation and lead to decreased demand for our services and increased cost and expense to our business. In addition, any significant
increase in shipping rates could adversely affect our operating margins and results of operations. Similarly, strikes, severe weather,
natural disasters or other service interruptions by delivery services we use would adversely affect our ability to receive and process
patient samples on a timely basis. There are only a few providers of overnight nationwide transport services, and there can be no assurance
that we will be able to maintain arrangements with providers on acceptable terms, if at all.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>Risks Related to Commercializing Our Products</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>Even if our products achieve positive clinical trial results and
requisite approvals, they may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in
the medical community necessary for commercial success.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">If any product we develop achieves positive clinical
trial results and receives marketing approval, whether on a standalone basis or in combination with other therapies, it may nonetheless
fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. For example,
existing drug therapies may be viewed as more reliable than gedatolisib. If the product candidates we develop do not achieve an adequate
level of acceptance, we may not generate significant product revenues and we may not become profitable. The degree of market acceptance
of any product candidate, if approved for commercial sale, will depend on a number of factors, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">efficacy and potential advantages compared to alternatives;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">the ability to offer our products, if approved, for sale at competitive prices;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">convenience and ease of administration compared to other treatments;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">the willingness of the target patient population to try new therapies or diagnostics and of physicians to prescribe or initiate these
therapies;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">the strength of marketing and distribution support;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">the ability to obtain sufficient third-party coverage, market access and adequate reimbursement; and</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">the prevalence and severity of any side effects.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">If our products do
not achieve an adequate level of acceptance, we may never generate significant product revenues and we may not become profitable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>If we commercialize any product candidates, we will be subject to
U.S. and foreign governmental regulations as well as private payor policies that mandate price controls or limitations on patient access
to our products or establish prices paid by government entities or programs for our products. Our business and our future results could
be adversely affected by changes in such regulations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Even if we or our partners are successful in obtaining
marketing approval, commercial success of any approved products will also depend in large part on the availability of insurance coverage
and adequate reimbursement from third-party payors, including government payors such as the VA, Medicare and Medicaid programs, 340B,
and managed care organizations in the U.S. or country specific governmental organizations in foreign countries. Government and private
payors routinely seek to manage utilization and control costs, and there is considerable public and government scrutiny of pharmaceutical
and diagnostic pricing. Efforts by states and the federal government to regulate prices or payment for pharmaceutical products, including
proposed actions to facilitate drug importation, limit reimbursement to lower international reference prices, require deep discounts,
and require manufacturers to report and make public price increases and sometimes provide a written justification for such price increases,
could adversely affect our business if implemented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Availability of reimbursement may be affected by existing
and future healthcare reform measures designed to reduce the cost of healthcare, including the Inflation Reduction Act, which requires
manufacturers of certain drugs to engage in price negotiations with Medicare, imposes rebates under Medicare Part B and Medicare Part
D to penalize price increases that outpace inflation, and replaces the Part D coverage gap discount program with a new discounting program.
Some states have implemented, and others are considering implementing, patient access constraints or cost cutting under the Medicaid program,
and some are considering measures that would apply to broader segments of their populations that are not Medicaid-eligible. State legislatures
also have continued to focus on addressing drug costs, generally by increasing price transparency or limiting drug price increases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 32; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Third-party payors also could require us to conduct
additional studies, including post-marketing studies related to the cost effectiveness of a product and appropriateness for specific patient
populations, to qualify for reimbursement, which could be costly and divert our resources. If government and other healthcare payors do
not provide coverage and adequate reimbursement for our products once approved, market acceptance and commercial success would be reduced.
Even if coverage is provided, the approved reimbursement amount may not be high enough to support pricing that results in a sufficient
return on our research and development investment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">We expect pricing pressures will continue globally.
U.S. and foreign governmental regulations that mandate price controls or limitations on patient access to our products or establish prices
paid by government entities or programs for our products could impact our business, and our future results could be adversely affected
by changes in such regulations or policies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>We may encounter difficulties in scaling production of, commercializing,
marketing and distributing our products, including in hiring and retaining a qualified sales force.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">In order to commercialize any of our products, we
must build production, marketing, sales, managerial and other non-technical capabilities or make arrangements with third parties to perform
these services, and we may not be successful in doing so. Our beliefs that our products will be commercially viable have not been tested.
These activities will be expensive and time-consuming and will require significant attention of our executive officers to manage. There
are risks involved in establishing our own sales and marketing capabilities, as well as with entering into arrangements with third parties
to perform these services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">In particular, there is intense competition for qualified
sales personnel and our inability to hire or retain an adequate number of sales representatives could limit our ability to maintain or
expand our business and increase sales. Furthermore, there is no guarantee that the market opportunity for gedatolisib will be as significant
as we expect or exist at all. If we are unable to
successfully commercialize our products, or if we are delayed in doing so, including if we are unable to develop our marketing and sales
networks or if our sales personnel do not perform as expected, we may never generate any revenue and our business may fail.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>Our business, operational and financial goals may not be attainable
if the market opportunities for our products are smaller than we expect. Our internal research and third party estimates may not accurately
reflect the market opportunities for gedatolisib today or in the future. </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">The total market opportunities that we believe exist
are based on a variety of assumptions and estimates, including the size of the addressable patient population in applicable jurisdictions,
the penetration of other drugs in these markets, the number of potential companion diagnostic programs we will be able to successfully
pursue, the amount of potential milestone payments that we could receive in companion diagnostic programs, the number of patients we will
test in clinical trials, the price we will be able to charge for our products and the total annual number of cancer patients with undiagnosed
abnormal cell signaling. In addition, we have relied on third-party publications, research, surveys and studies for information related
to determining market opportunities, including without limitation, information on the number of cancer patients and those receiving various
forms of treatment, the cost of drug therapy, the amount of revenue generated from various types of drug therapy, the objective response
rates of drug therapies, the number of deaths caused by cancer and the expected growth in cancer drug therapy and diagnostic markets.
Our internal research and estimates on market opportunities have been verified by independent sources, but any or all of our assumptions
and/or estimates may prove to be incorrect for several reasons, such as inaccurate reports or information that we have relied on, potential
patients or providers not being amenable to using our products or such patients becoming difficult to identify and access, limited reimbursement
for our products, pricing pressure due to availability of alternative drugs or an inability to obtain the necessary regulatory approvals
for new indications. If any or all of our assumptions and estimates prove inaccurate, we may not attain our business, operational and
financial goals.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 33; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>Other Risks Related to Government Regulation for Our Business</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>Failure to comply with the HIPAA security and privacy regulations
may increase our operational costs.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">A portion of the data that we obtain and handle for
or on behalf of our clients is considered protected health information, or PHI, subject to HIPAA. Under HIPAA and our contractual agreements
with our HIPAA-covered entity health plan customers, we may be considered a &#8220;business associate&#8221; to those customers and are
required to maintain the privacy and security of PHI in accordance with HIPAA and the terms of our business associate agreements with
our clients, including by implementing HIPAA-required administrative, technical and physical safeguards. We are also required to maintain
similar business associate agreements with our subcontractors that have access to PHI of our customers in rendering services to us or
on our behalf. We will incur significant costs to establish and maintain these safeguards and, if additional safeguards are required to
comply with HIPAA regulations or our clients&#8217; requirements, our costs could increase further, which would negatively affect our
operating results. Furthermore, we cannot guarantee that such safeguards have been and will continue to be adequate under applicable laws.
If we have failed, or fail in the future, to maintain adequate safeguards, or we or our agents or subcontractors use or disclose PHI in
a manner prohibited or not permitted by HIPAA, our subcontractor business associate agreements, or our business associate agreements with
our customers, or if the privacy or security of PHI that we obtain and handle is otherwise compromised, we could be subject to significant
liabilities and consequences.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>Compliance with global privacy and data security requirements could
result in additional costs and liabilities to us or inhibit our ability to collect and process data globally, and the failure to comply
with such requirements could subject us to significant fines and penalties, which may have a material adverse effect on our business,
financial condition or results of operations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">In addition to PHI, we collect, receive, store, process,
use, generate, transfer, disclose, make accessible, protect, secure, dispose of, transmit and share (collectively, process) personal data
and other sensitive information. Accordingly, we are, or may become, subject to numerous federal, state, local and foreign privacy and
security laws regulating the collection, use, safeguarding, transfer and other processing of information.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Globally, virtually every jurisdiction in which we
operate has established its own data security and privacy frameworks with which we must comply. For example, the collection, use, disclosure,
transfer, or other processing of personal data regarding individuals in the UK, and the European Economic Area (the &#8220;EEA&#8221;),
including personal health data, is subject to the UK/EU General Data Protection Regulation (the &#8220;GDPR&#8221;), which is wide-ranging
in scope and imposes numerous requirements on companies that process personal data, including requirements relating to the processing
of health and other sensitive data, obtaining consent of the individuals to whom the personal data relates, providing information to individuals
regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, providing
notification of data breaches, and taking certain measures when engaging third-party processors. In addition, the GDPR also imposes strict
rules on the transfer of personal data to countries outside the UK/European Union, including the United States, and, as a result, increases
the scrutiny that clinical trial sites located in the EEA should apply to transfers of personal data from such sites to countries that
are considered to lack an adequate level of data protection, such as the United States. The GDPR also permits data protection authorities
to require destruction of improperly gathered or used personal information and/or impose substantial fines for violations of the GDPR,
which can be up to 4% of global revenue or &#8364;20 million, whichever is greater, and it also confers a private right of action on data
subjects and consumer associates to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for
damages resulting from violations of the GDPR. In addition, the GDPR provides that UK/EU member states may make their own further laws
and regulations limiting the processing of personal data, including genetic, biometric or health data. Given the breadth and depth of
changes in data protection obligations, preparing for and complying with these requirements is rigorous and time intensive and requires
significant resources and a review of our technologies, systems and practices, as well as those of any third-party collaborators, service
providers, contractors or consultants that process or transfer personal data collected in the European Union.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Similar actions are either in place or underway in
the United States. For example, the California Consumer Privacy Act of 2018 (the &#8220;CCPA&#8221;), as amended and expanded by the California
Privacy Rights Act (the &#8220;CPRA&#8221;), applies to personal information of consumers, business representatives, and employees, and
requires covered businesses to provide specific disclosures related to a business&#8217;s processing of personal data, new operational
practices, and requirements to respond to certain requests from California residents related to their personal data. There is uncertainty
about how the CPRA and other similar laws may be implemented and applied, and inconsistencies across jurisdictions complicate our compliance
efforts. Accordingly, the CPRA and other similar laws may impact our business activities and increase our compliance costs, as well as
our legal risks. The regulatory framework for the collection, use, safeguarding, transfer and other processing of information is rapidly
evolving and is likely to remain uncertain for the foreseeable future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Evolving data privacy regulations may interrupt or
delay our development, regulatory and commercialization activities and increase our cost of doing business, and could lead to government
enforcement actions, private litigation and significant fines and penalties against us and could have a material adverse effect on our
business, financial condition or results of operations. Even if we are not determined to have violated these laws, government investigations
into these issues typically require the expenditure of significant resources and generate negative publicity, which could harm our reputation
and our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>We will also need to expend a considerable amount of resources complying
with other federal, state and foreign laws and regulations. If we are unable to comply or have not complied with such laws, we could face
substantial penalties or other adverse actions.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Our operations are subject, directly or indirectly,
to other federal, state and foreign laws and regulations that are complex and their application to our specific products, services and
relationships may not be clear and may be applied to our business in ways that we do not anticipate. Compliance with laws and regulations
will require us to expend considerable resources implementing internal policies and procedures for compliance and ongoing monitoring and
will require significant attention of our management team. This will be challenging as an early-stage company with limited financial resources
and human capital. These laws include, for example:</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">Title XI of the Social Security Act, commonly referred to as the federal Anti-Kickback Statute, which prohibits the knowing and willful
offer, payment, solicitation or receipt of remuneration, directly or indirectly, in cash or in kind, in return for or to reward the referral
of patients or arranging for the referral of patients, or in return for the recommendation, arrangement, purchase, lease or order of items
or services that are covered, in whole or in part, by a federal healthcare program such as Medicare or Medicaid;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">The civil False Claims Act, which forbids the knowing submission or &#8220;causing the submission&#8221; of false or fraudulent information
or the failure to disclose information in connection with the submission and payment of claims for reimbursement to Medicare, Medicaid,
federal healthcare programs or private health plans;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 34; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">The federal Physician Self-referral Law, commonly known as the Stark Law, which prohibits physicians from referring Medicare or Medicaid
patients to providers of&#8201;&#8220;designated health services&#8221; with whom the physician or a member of the physician&#8217;s immediate
family has an ownership interest or compensation arrangement, unless a statutory or regulatory exception applies, and similar state equivalents
that may apply regardless of payor; and</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">The U.S. Foreign Corrupt Practices Act of 1977, as amended, or FCPA, the U.S. domestic bribery statute contained in 18 U.S.C. &#167;
201, the U.S. Travel Act, and the USA PATRIOT Act, which among other things, prohibit companies and their employees, agents, third-party
intermediaries, joint venture partners and collaborators from authorizing, promising, offering, or providing, directly or indirectly,
improper payments or benefits to recipients in the public or private sector.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Many states and foreign
governments have adopted similar laws and regulations. Violations of law could subject us to civil or criminal penalties, monetary fines,
disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits and future earnings and curtailment
of our operations. We could also be required to change or terminate some portions of operations or business or could be disqualified from
providing services to healthcare providers doing business with government programs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>Risks Relating to Our Common Stock </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>Provisions in our corporate charter
documents and under Delaware law could make an acquisition of our company, which may be beneficial to our stockholders, more difficult
and may prevent attempts by our stockholders to replace or remove our current management.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Provisions in our certificate of incorporation and
our bylaws may discourage, delay or prevent a merger, acquisition or other change in control of our company that stockholders may consider
favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions could also limit the
price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our
common stock. In addition, because our board of directors will be responsible for appointing the members of our management team, these
provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult
for stockholders to replace members of our board of directors. Among other things, these provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">allow the authorized number of our directors to be changed only by resolution of our board of directors;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">limit the manner in which stockholders can remove directors from our board of directors;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and nominations to our
board of directors;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by
written consent;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">limit who may call stockholder meetings;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">authorize our board of directors to issue preferred stock without stockholder approval, which could be used to institute a &#8220;poison
pill&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have
not been approved by our board of directors; and</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">require the approval of the holders of at least two-thirds of the votes that all our stockholders would be entitled to cast to amend
or repeal specified provisions of our certificate of incorporation or bylaws.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Moreover, we are governed
by the provisions of Section 203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding
voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired
in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Any of these provisions of our charter documents or
Delaware law could, under certain circumstances, depress the market price of our common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>The price of our common stock may be volatile and fluctuate substantially,
which could result in substantial losses for purchasers of our common stock or could subject us to securities litigation.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Our stock price may be extremely volatile. The stock
market in general and the market for smaller medical technology companies in particular have experienced extreme volatility that has often
been unrelated to the operating performance of particular companies. As a result of this volatility, investors may not be able to sell
our common stock at or above the price they paid for such stock. The market price for our common stock may be influenced by many factors,
including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">the success of competitive products or technologies;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">results of existing or future clinical trials;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">regulatory or legal developments in the United States and other countries;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">developments or disputes concerning patent applications, issued patents or other proprietary rights;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">the recruitment or departure of key personnel;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">the level of expenses related to any of our products or clinical development programs;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">operating results that fail to meet expectations of securities analysts that cover our company;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">variations in our financial results or those of companies that are perceived to be similar to us;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 35; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">changes in the structure of healthcare payment systems;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">market conditions in the pharmaceutical, biotechnology and medical technology sectors;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">sales of our stock by us, our insiders and our other stockholders;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">general economic and market conditions; and</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">the other factors described in this &#8220;Risk Factors&#8221; section.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Additionally, companies that have experienced volatility
in the market price of their stock have been subject to an increased incidence of securities class action litigation. We may be the target
of this type of litigation in the future. Securities litigation against us could result in substantial costs and divert our management&#8217;s
attention from other business concerns, which could seriously harm our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>Future sales of shares of our common stock, including by us and significant
stockholders, could negatively affect our stock price. </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Sales of a substantial number of shares of our common
stock in the public market could occur at any time. Since December 2022, we have issued 5,340,914 shares of common stock pursuant to equity
financing arrangements, including pursuant to our Open Market Sale Agreement<sup>SM</sup> with Jefferies LLC, as agent, pursuant to which
we may offer and sell, from time to time, through Jefferies, shares of our common stock having an aggregate offering price of up to $125.0
million. At December 31, 2024, $125.0 million of common stock remains available for sale under the Jefferies agreement. We may enter into
additional equity financing arrangements in the future. The shares of common stock that we have issued pursuant to equity financings,
or may issue in the future, may be resold at any time in the discretion of the investors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, an aggregate of 14,444,709 shares of
common stock are issuable upon conversion or exercise of currently outstanding preferred stock and financing warrants, subject to certain
beneficial ownership limitations, which the investors may subsequently resell into the market, and 4,306,977 shares of common stock are
issuable upon exercise of awards granted under our 2017 Stock Incentive Plan and 2012 Equity Incentive Plan. Under our Amended and Restated
Loan and Security Agreement, Innovatus has the right, at its election and until August 9, 2025, to convert up to 20% of the outstanding
principal of the Term A Loan into shares of the Company&#8217;s common stock at a price per share of $10.00 (the &#8220;Conversion Right&#8221;).
Innovatus will continue to have the right to exercise a previously disclosed warrant granted to it under the Prior Loan Agreement to purchase
26,042 shares of common stock at a price per share of $14.40 through April 8, 2031. In connection with the funding of each of the Term
C Loan, the Term D Loan, the Term E Loan and the Term F Loan, the Company agreed to issue to Innovatus and Oxford warrants to purchase
that number of shares of the Company&#8217;s common stock equal to 2.5% of the principal amount of the applicable Term Loan divided by
the exercise price, which shall, with respect to the Term C Loan, be equal to the lower of (i) the volume weighted average closing price
of the Company&#8217;s common stock for the five-trading day period ending on the last trading day immediately preceding the execution
of the A&amp;R Loan Agreement or (ii) the closing price on the last trading day immediately preceding the execution of the A&amp;R Loan
Agreement. Accordingly, on May 30, 2024, the Company issued 103,876 warrants with an exercise price of $14.84 per share. The relative
fair value of the warrants was approximately $1.2 million. For the additional Term Loans, the exercise price will be based on the lower
of (i) the exercise price for the Warrants issued pursuant to the Term C Loan or (ii) the volume weighted average closing price of the
Company&#8217;s common stock for the five-trading day period ending on the last trading day immediately preceding the applicable Term
Loan funding. The Warrants may be exercised on a cashless basis and are exercisable through the tenth anniversary of the applicable funding
date. The number of shares of common stock for which each Warrant is exercisable and the associated exercise price are subject to certain
proportional adjustments as set forth in such Warrant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Sales of substantial amounts of shares of our common
stock or other securities by these investors or our other stockholders or by us under the Open Market Sale Agreement<sup>SM</sup>, or
the perception in the market that the holders of a large number of shares of our common stock intend to sell their shares, could reduce
the trading price of our common stock, make it more difficult for you to sell your shares at a price that you desire and impair our ability
to raise capital through the sale of equity or equity-related securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>Our Series A Preferred Stock has rights, preferences, and privileges
that are not held by, and are preferential to, the rights of holders of our common stock.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">We issued 1,120,873 shares of Series A Preferred Stock
in a financing transaction in December 2022, and 317,577 shares of Series A Preferred Stock were outstanding as of December 31, 2024.
The Certificate of Designations of Preferences, Rights and Limitations of Series A Convertible Preferred Stock provides that, in the event
of any voluntary or involuntary liquidation, dissolution or winding up of the Company, or in the event of a Deemed Liquidation Event (as
defined in the Certificate of Designations of Preferences, Rights and Limitations of Series A Convertible Preferred Stock), the holders
of Series A Preferred Stock are entitled to be paid from assets of the Company available for distribution to its stockholders, before
any payment is made to the holders of common stock by reason of their ownership thereof, an amount per share equal to the greater of (i)
the original issue price ($5.75 on an as-converted-to-common stock basis), plus all accrued and unpaid dividends and (ii) the amount that
the holder would have been entitled to receive at such time if the Series A Preferred Stock were converted into common stock. The Company
may not, without the consent of holders of a majority of the outstanding shares of Series A Preferred Stock, amend its charter in a manner
that adversely affects the powers, preferences or rights of the Series A Preferred Stock or issue or obligate itself to issue shares of
any additional class or series of capital stock unless the same ranks junior to the Series A Preferred Stock with respect to the distribution
of assets on the liquidation, dissolution or winding up of the Company and the payment of dividends.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>If securities or industry analysts do not publish research or reports
about our business, or publish negative reports about our business, our stock price and trading volume could decline.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">The trading market for our common stock depends in
part on the research and reports that securities or industry analysts publish about us or our business. We do not have any control over
these analysts. There can be no assurance that analysts will cover us or provide favorable coverage. If one or more of the analysts who
cover us downgrade our stock or change their opinion of our stock, our stock price would likely decline. If one or more of these analysts
cease coverage of our company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which could
cause our stock price or trading volume to decline.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 36; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>We incur increased costs as a result of operating as a public company,
and our management devotes substantial time to new compliance initiatives and corporate governance practices.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">As a public company, we incur significant legal, accounting
and other expenses that we did not incur as a private company and that private company competitors do not incur. The Sarbanes-Oxley Act,
the Dodd-Frank Wall Street Reform and Consumer Protection Act, the continued listing requirements of The Nasdaq Stock Market and other
applicable securities rules and regulations impose various requirements on public companies, including establishment and maintenance of
effective disclosure and financial controls and corporate governance practices. Our management and other personnel devote a substantial
amount of time to these compliance initiatives. Moreover, these rules and regulations have increased our ongoing legal and financial compliance
costs and make some activities more time-consuming and costly.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Pursuant to Section 404 of the Sarbanes-Oxley Act,
or Section 404, we are required to furnish a report by our management on our internal control over financial reporting. Depending upon
our filer status, we could also be required to include an attestation report on internal control over financial reporting issued by our
independent registered public accounting firm as required by Section 404(b). While we, as of December 31, 2024, concluded that our internal
control over financial reporting was effective, we may need to dedicate additional internal resources and engage outside consultants to
maintain compliance with Section 404 in the future. Any material weaknesses that we may identify in the future could result in an adverse
reaction in the financial markets due to a loss of confidence in the reliability of our financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>We do not currently intend to pay dividends on our common stock,
and, consequently, our stockholders&#8217; ability to achieve a return on their investment will depend on appreciation in the price of
our common stock.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">We currently intend to invest our future earnings,
if any, to fund our growth. We do not currently intend to pay dividends on our common stock for the foreseeable future, and, consequently,
our stockholders&#8217; ability to achieve a return on their investment will depend on appreciation in the price of our common stock.
There is no guarantee that our common stock will appreciate or even maintain the price at which our holders have purchased it.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><span id="a_004"></span>ITEM 1B. Unresolved Staff Comments</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.25in">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>

<p id="xdx_988_ecyd--CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_iB_c20240101__20241231_gBFCRMPFAIAMT-YNSTIA_z6Nl7oU7ZhI5" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" continuedAt="ConU000049-01" escape="true" id="Fact000049" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"><b><span id="a_004a"></span>ITEM 1C. Cybersecurity</b></ix:nonNumeric></p>

<div id="xdx_C02_gBFCRMPFAIAMT-YNSTIA_znRv4XBhwRG9"><ix:continuation continuedAt="ConU000049-02" id="ConU000049-01"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Risk Management &amp; Strategy</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"><span><span><span>Our cybersecurity risk management process is a component
of our overall approach to managing material risks that could impact our operations, including cybersecurity threats. In general, we seek
to manage material internal and third-party cybersecurity risks through an approach that focuses on: (i) protecting information systems
and the information residing therein; (ii) identifying, preventing, and mitigating cybersecurity threats; and (iii) assessing and responding
to cybersecurity incidents when they occur. Maintaining, monitoring, and updating our information security program&#8212;in an effort
to ensure that it remains reasonable and appropriate in light of changes in the security threat landscape, available technology, and applicable
legal and contractual requirements&#8212;is an ongoing effort.</span></span></span></p>

<div><div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"><span><span><span id="xdx_900_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20240101__20241231_zEEWnsACXBQg" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000050" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag">We have implemented and maintain various processes,
procedures, and measures to support our overall risk management strategy and to manage and mitigate the material risks posed by cybersecurity
threats to our systems and data.</ix:nonNumeric></span> With respect to cybersecurity, these measures include conducting risk assessments of our operations and
using a risk register to assess identified risks; developing business continuity, disaster recovery and incident response plans; implementing
technical safeguards and tools; conducting ongoing cybersecurity awareness training; and using contractual protections where appropriate.
Our incident response plan outlines the procedures for reporting, investigating, and remediating cybersecurity incidents, including a
framework to facilitate the escalation to our management team and board of cybersecurity incidents, so that our management team is alerted
in a timely manner to material information that would be required to be disclosed or reported.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"><span><span>Our IT department maintains policies and procedures
regarding network security, data protection and incident response. Pursuant to those policies, IT engages with the Chief Financial Officer,
General Counsel and other experts when assessing cybersecurity threats, incident response, and making disclosure determinations following
a data or network breach. The Vice President, IT is accountable at the management level for our overall IT risk management program. Additionally,
our Chief Executive Officer and Audit Committee receives regular updates from the Chief Financial Officer, General Counsel and the Vice
President, IT about significant threats and incidents involving cybersecurity and data protection, as well as security enhancements made
to our IT infrastructure.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"><span><span>We use <span id="xdx_90E_ecyd--CybersecurityRiskManagementThirdPartyEngagedFlag_dbT_c20240101__20241231_zWJmelwkbqj" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000051" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag">third-party</ix:nonNumeric></span> service providers for a variety
of services throughout our business, ranging from infrastructure support and maintenance, cybersecurity incident response, data protection
and privacy compliance. In addition, we engage with contract research organizations, contract manufacturing organizations, distributors,
and other supply chain resources.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"><span><span>We believe that the use of external service providers
improves our operational capabilities, and we have implemented a vendor qualification and management program that applies to our service
providers, including those that handle protected health information, personal information, or other information subject to protection
under applicable privacy and data protection regulations. This program is designed to identify, address and seek to mitigate potential
cybersecurity and data protection risks that arise from our use of external service providers. While we do not have full visibility into
the cybersecurity risk management processes of our vendors, we require new service providers to complete a vendor questionnaire that identifies
the vendor&#8217;s network and user protections, such as the use of multi-factor authentication, and other cybersecurity risk management
processes. Vendors that store or access our confidential information are required to certify that their information systems comply with
applicable industry guidelines for cybersecurity, backup, and system recovery. We rely on our third-party service providers to provide
notification of, and remediate, significant cybersecurity threats and cybersecurity incidents that jeopardize the confidentiality, integrity,
or availability of our information.</span></span></p>

</div></div></ix:continuation></div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span id="xdx_C0D_gBFCRMPFAIAMT-YNSTIA_zWUu63uEJoni"><ix:continuation continuedAt="ConU000049-03" id="ConU000049-02">&#160;</ix:continuation></span></p>


<!-- Field: Page; Sequence: 37; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;&#160;</p>

<div id="xdx_C0F_gBFCRMPFAIAMT-YNSTIA_zROp45TMrsBa"><ix:continuation continuedAt="ConU000049-04" id="ConU000049-03"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"><span><span>We periodically evaluate, test, and update our policies,
standards, and processes to mitigate cybersecurity threats and manage incidents effectively. These efforts include risk assessments, vulnerability
assessments and remediations, phishing tests and employee education, and external scans. Additionally, to enhance our capabilities, we
periodically engage third-party service providers, including cybersecurity consultants, to incorporate threat intelligence into our processes.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"><span>As of the date of this Form 10-K, we are <span id="xdx_902_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbF_c20240101__20241231_z07C1xRxsPki" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000052" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">no</ix:nonNumeric></span>t aware
of any risks from cybersecurity threats, including those resulting from any previous cybersecurity incidents experienced by us or, to
our knowledge, by any of our third-party service providers, that have materially affected, or are reasonably likely to materially affect,
our business strategy, results of operations, or financial condition. For further discussion of cybersecurity and data privacy risks that
may materially affect the Company and how they may do so, see &#8220;Risk Factors&#8212;If our information technology systems or data,
or those of third parties upon which we rely, are or were compromised, we could face clinical trial delays; regulatory investigations
or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; and other adverse consequences,&#8221;
included in Item 1A of this Annual Report on Form 10-K.</span></p>

</ix:continuation></div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span id="xdx_C00_gBFCRMPFAIAMT-YNSTIA_zEMNTDUvq5fh"><ix:continuation id="ConU000049-04"><span><b>&#160;</b></span></ix:continuation></span></p>

<p id="xdx_981_ecyd--CybersecurityRiskBoardOfDirectorsOversightTextBlock_c20240101__20241231_gBFCRBODOTB-FDIA_zHVhkhQP3OZk" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" continuedAt="ConU000055-01" escape="true" id="Fact000055" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock"><b>Governance</b></ix:nonNumeric></p>

<div id="xdx_C06_gBFCRBODOTB-FDIA_z7P0kh4z53ea"><ix:continuation continuedAt="ConU000055-02" id="ConU000055-01"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"><span><span><span id="xdx_90D_ecyd--CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_c20240101__20241231_z8aaMZ4bqBpa" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000056" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">Our Audit Committee oversees Celcuity&#8217;s management
of risks arising from cybersecurity threats. <span id="xdx_901_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_c20240101__20241231_zLJMLFtcwxz5" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000057" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">Our CEO delivers periodic briefings to the Board and Audit Committee on material cybersecurity
risks that are pertinent to our business operations.</ix:nonNumeric></span> Additionally, we have processes to promptly notify the Audit Committee and Board
of a significant cybersecurity incident and to inform the Audit Committee and Board of remediation progress, as appropriate.</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"><span><span>The Vice President, IT has overall responsibility
for our information security program, with support from our management team and specialized partners in cybersecurity incident response
and privacy. <span id="xdx_90F_ecyd--CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_c20240101__20241231_zQDUHaxm1Nzl" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000058" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">The process includes managing our incident response strategy. If a cybersecurity incident meets certain criteria, however,
our CEO, CFO and General Counsel will become involved with the response strategy, including decisions about public disclosure and reporting.
Our Vice President, IT also coordinates with our CEO, CFO and General Counsel to determine strategic cybersecurity priorities and to establish
compliance procedures.</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"><span><span>We believe our business leaders have the appropriate
expertise, background and depth of experience to manage risks arising from cybersecurity threats. Our Vice President, IT has served in
various roles in information technology and information security for over three decades, which includes experience in the biotech, pharmaceutical
and healthcare industries and experience in cybersecurity risk management and data privacy compliance.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"><span>In the ordinary course of our business, we, and the
third parties upon which we rely, collect, process, receive, generate, use, transfer, disclose, make accessible, protect, secure, dispose
of, transmit, share and store (collectively, &#8220;process&#8221;) proprietary, confidential, and sensitive information, including protected
health information, personal information, credit card and other financial information, or other sensitive information owned or controlled
by ourselves or our customers, payors, and other parties.</span></p>

</ix:continuation></div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span id="xdx_C0B_gBFCRBODOTB-FDIA_z9C0S5Ddqdhi"><ix:continuation id="ConU000055-02"><span><b>&#160;</b></span></ix:continuation></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><span id="a_005"></span>ITEM 2. Properties</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">We currently lease and occupy approximately 16,000
square feet in Minneapolis, Minnesota, which includes our clinical laboratory and offices. On March 13, 2023, we signed the fourth amendment
to our lease agreement, which expires April 30, 2026. We anticipate leasing new office and lab space in advance of the end date of our
lease. The lease provides for monthly rent, real estate taxes and operating expenses. We believe that this leased space is adequate to
meet current and anticipated future requirements and that additional or substitute space will be available as needed to accommodate any
expansions that our operations require.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><span id="a_006"></span>ITEM 3. Legal Proceedings</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">From time to time we may be involved in disputes or
litigation relating to claims arising out of our operations. We are not currently a party to any legal proceedings that could reasonably
be expected to have a material adverse effect on our business, financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><span id="a_007"></span>ITEM 4. Mine Safety Disclosures</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 22.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 22.5pt">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 38; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b><span id="a_008"></span>PART II</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; background-color: white"><b><span id="a_009"></span>ITEM 5. Market For Registrant&#8217;s Common
Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; background-color: white"><b>Market Price Information</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Our common stock has been listed on The Nasdaq Capital
Market under the symbol &#8220;CELC&#8221; since September 20, 2017.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">As of March 17,
2025, there were approximately 107 holders of record of our common stock. The actual number of holders of common stock is
greater than this number of record holders and includes stockholders who are beneficial owners, but whose shares are held in street
name by brokers and nominees. The number of holders of record also does not include stockholders whose shares may be held in trust
by other entities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>Dividends</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">We have never declared or paid any cash dividends
on our common stock. We currently intend to retain our future earnings, if any, to finance the operation and expansion of our business.
We do not expect to pay cash dividends on our common stock in the foreseeable future. Payment of future cash dividends, if any, will be
at the discretion of our board of directors after taking into account various factors, including our financial condition, operating results,
current and anticipated cash needs, outstanding indebtedness and plans for expansion and restrictions imposed by lenders, if any.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>Recent Sales of Unregistered Securities</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>Issuer Purchases of Equity Securities</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>Equity Compensation Plan Information</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">The information required by this Item concerning equity
compensation plans is incorporated herein by reference from Part III, Item&#160;11 of this Annual Report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>


<!-- Field: Page; Sequence: 39; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><span id="a_010"></span>ITEM 6. Reserved.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><span id="a_011"></span>ITEM&#160;7. Management&#8217;s Discussion and Analysis of Financial
Condition and Results of Operations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">You should read the following discussion and analysis
of our financial condition and results of operations together in conjunction with our financial statements and the related notes included
elsewhere in this Annual Report. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual
Report, including information with respect to our plans and strategy for our business and expected financial results, includes forward-looking
statements that involve risks and uncertainties. You should review the &#8220;Risk Factors&#8221; discussed in Item 1A of Part I of this
Annual Report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>OVERVIEW </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Celcuity is a
clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid tumor
indications. The Company&#8217;s lead therapeutic candidate is gedatolisib, a potent, well-tolerated, small molecule reversible
inhibitor, administered intravenously, that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase
(&#8220;PI3K&#8221;) and the two mechanistic targets of rapamycin (&#8220;mTOR&#8221;) sub-complexes, mTORC1 and mTORC2. Its
mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies
that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with
fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients. Site
selection activities are completed and activation activities for a Phase 3 clinical trial, VIKTORIA-2, evaluating gedatolisib in
combination with a CDK4/6 inhibitor and fulvestrant as first-line treatment for patients with endocrine treatment resistant
HR+/HER2- advanced breast cancer has commenced, and the first patient is expected to be dosed in the second quarter of 2025. A Phase
1b/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with mCRPC, is currently
underway.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">In April 2021, we obtained exclusive global development
and commercialization rights to gedatolisib under a license agreement with Pfizer Inc. We believe gedatolisib&#8217;s unique mechanism
of action, differentiated chemical structure, favorable pharmacokinetic properties, and intravenous route of administration offer distinct
advantages over currently approved and investigational therapies that target PI3K, AKT, or mTOR alone or together.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify"><b>Overcomes limitations of therapies that only inhibit a single Class I PI3K isoform or only one mTOR kinase complex.</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in">Gedatolisib is a pan-class I isoform PI3K inhibitor with low
nanomolar potency for the p110&#945;, p110&#946;, p110&#947;, and p110&#948; isoforms and mTORC1 and mTORC2 complexes. Each PI3K isoform
and mTOR complex is known to preferentially affect different signal transduction events that involve tumor cell survival, depending upon
the aberrations associated with the linked pathway. When a therapy only inhibits a single Class I isoform (e.g., alpelisib, a PI3K-&#945;
inhibitor) or only one mTOR kinase complex (e.g., everolimus, an mTORC1 inhibitor), numerous feedforward and feedback loops between the
PI3K isoforms and mTOR complexes cross-activate the uninhibited sub-units. This, in turn, induces compensatory resistance that reduces
the efficacy of isoform specific PI3K or single mTOR kinase complex inhibitors. Inhibiting all four PI3K isoforms and both mTOR complexes,
as gedatolisib does, thus prevents the confounding effect of isoform interaction that may occur with isoform-specific PI3K inhibitors
and the confounding interaction between PI3K isoforms and mTOR.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify"><b>Better tolerated by patients than oral PI3K and mTOR drugs.</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in">Gedatolisib is administered intravenously on a four-week cycle
of three weeks-on, one week-off, in contrast to the orally administered pan-PI3K or dual PI3K/mTOR inhibitors that are no longer being
clinically developed. Oral pan-PI3K or PI3K/mTOR inhibitors have repeatably been found to induce significant side effects that were not
well tolerated by patients. This typically leads to a high proportion of patients requiring dose reductions or treatment discontinuation.
The challenging toxicity profile of these drug candidates ultimately played a significant role in the decisions to halt their development,
despite showing promising efficacy. By contrast, gedatolisib stabilizes at lower concentration levels in plasma compared to orally administered
PI3K inhibitors, resulting in less toxicity, while maintaining concentrations sufficient to inhibit PI3K/mTOR signaling.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in">Isoform-specific PI3K inhibitors administered orally were developed
to reduce toxicities in patients. While the range of toxicities associated with isoform-specific inhibitors is narrower than oral pan-PI3K
or PI3K/mTOR inhibitors, administering them orally on a continuous basis still leads to challenging toxicities. The experience with an
FDA approved oral p110-&#945; specific inhibitor, PIQRAY, illustrates the challenge. In its Phase 3 pivotal trial, PIQRAY was found to
induce a Grade 3 or 4 adverse event (&#8220;AE&#8221;) related to hyperglycemia in 39% of patients evaluated. In addition, 26% of patients
discontinued alpelisib due to treatment related AEs. By contrast, in the 103-patient dose expansion portion of the Phase 1b clinical trial
with gedatolisib, only 7% of patients experienced Grade 3 or 4 hyperglycemia and less than 9% discontinued treatment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">As of December 31, 2024, 492 patients with solid tumors
have received gedatolisib in eight clinical trials sponsored by Pfizer. Of the 492 patients, 129 were treated with gedatolisib as a single
agent in three clinical trials. The remaining 363 patients received gedatolisib in combination with other anti-cancer agents in five clinical
trials. Additional patients received gedatolisib in combination with other anti-cancer agents in nine investigator sponsored clinical
trials.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">A Phase 1b trial (B2151009) evaluating patients with
HR+/HER2- metastatic breast cancer was initiated in 2016 and subsequently enrolled 138 patients. Four patients from this study continue
to receive study treatment, as of December 31, 2024, each of whom have received study treatment for more than five years. The B2151009
clinical trial was an open label, multiple arm Phase 1b clinical trial that evaluated gedatolisib in combination with palbociclib (CDK4/6
inhibitor) and fulvestrant or letrozole in patients with HR+/HER2- advanced breast cancer. Thirty-five patients were enrolled in two dose
escalation arms to evaluate the safety and tolerability and to determine the maximum tolerated dose (&#8220;MTD&#8221;) of gedatolisib
when used in combination with the standard doses of palbociclib and endocrine therapy (letrozole or fulvestrant). The MTD was determined
to be 180 mg administered intravenously once weekly. A total of 103 patients were subsequently enrolled in one of four expansion arms
(A, B, C, and D).</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 40; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in; background-color: white">High objective overall response
rates (&#8220;ORR&#8221;) were observed in all four expansion arms and were comparable in each arm for PIK3CA wild type (&#8220;WT&#8221;)
and PIK3CA mutant (&#8220;MT&#8221;) patients. In patients who received prior hormonal therapy alone or in combination with a CDK4/6 inhibitor
(Arms B, C, and D), the ORR (including unconfirmed partial responses) ranged from 36% to 77%. In patients who were treatment na&#239;ve
in the advanced setting (Arm A), the ORR was 85%. Each arm achieved its primary endpoint target, which was reporting higher ORR in the
study arm than the ORR from either the PALOMA-2 study (ORR=55%) that evaluated palbociclib plus letrozole for Arm A or the PALOMA-3 study
(ORR=25%) that evaluated palbociclib plus fulvestrant for Arms B, C, and D. For all patients enrolled in the expansion portion of the
study who had evaluable tumors, the ORR observed was 63%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in; background-color: white">Median progression-free survival
(PFS) was 12.9 months for patients who received a prior CDK4/6 inhibitor and were treated in the study with the Phase 3 dosing schedule
(Arm D). For all treatment na&#239;ve patients who received gedatolisib combined with palbociclib plus letrozole in Expansion Arm A and
Escalation Arm A (N=41), median PFS was 48.6 months and ORR was 79%. These results compare favorably to published data for current first-line
standard-of-care treatments for patients with HR+/HER2-advanced breast cancer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Gedatolisib combined with palbociclib and endocrine
therapy demonstrated a favorable safety profile with manageable toxicity. The majority of treatment emergent adverse events were Grade
1 and 2. The most frequently observed adverse events included stomatitis/mucosal inflammation, the majority of which were Grade 1 and
2. The most common Grade 4 AEs were neutropenia and neutrophil count decrease, which were assessed as related to treatment with palbociclib.
No Grade 5 events were reported in this study.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">We are currently enrolling patients in a Phase 3,
open-label, randomized clinical trial,VIKTORIA-1, to evaluate the efficacy and safety of two regimens in adults with HR+/HER2- advanced
breast cancer whose disease has progressed after prior CDK4/6 therapy in combination with an aromatase inhibitor: 1) gedatolisib in combination
with palbociclib and fulvestrant; and 2) gedatolisib in combination with fulvestrant. Over two hundred clinical sites in North America,
Europe, Latin America, and Asia-Pacific are participating in the study. The first patient was dosed in this trial in December 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">The VIKTORA-1 Phase 3 clinical trial will enable separate
evaluation of subjects according to their PIK3CA status. Subjects who meet eligibility criteria and are PIK3CA WT will be randomly assigned
(1:1:1) to receive a regimen of either gedatolisib, palbociclib, and fulvestrant (Arm A), gedatolisib and fulvestrant (Arm B), or fulvestrant
(Arm C). The WT enrollment target was achieved in the fourth quarter of 2024. Subjects who meet eligibility criteria and are PIK3CA MT
will be randomly assigned (3:3:1) to receive a regimen of either gedatolisib, palbociclib, and fulvestrant (Arm D), alpelisib and fulvestrant
(Arm E), or gedatolisib and fulvestrant (Arm F). Topline data from Arms A, B and C of this clinical trial are expected in Q2 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">We received approval from the FDA in mid-2023 to proceed
with the clinical development of gedatolisib in combination with Nubeqa&#174; (darolutamide), an approved androgen receptor inhibitor,
for the treatment of patients with metastatic castration resistant prostate cancer (&#8220;mCRPC&#8221;). We have since initiated a Phase
1b/2 study, CELC-G-201, that is enrolling patients with mCRPC who progressed after treatment with an androgen receptor inhibitor. The
first patient was dosed in this trial in February 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">In the Phase 1b portion of the clinical trial, Celcuity
expects approximately 36 participants will be randomly assigned to receive 600 mg darolutamide combined with either 120 mg gedatolisib
in Arm 1 or 180 mg gedatolisib in Arm 2. An additional 12 participants will then be enrolled in the Phase 2 portion of the study at the
recommended phase 2 dose (&#8220;RP2D&#8221;) level to enable evaluation of 30 participants treated with the RP2D of gedatolisib.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">The primary objectives of the Phase 1b portion of
the trial include assessment of the safety and tolerability of gedatolisib in combination with darolutamide and determination of the recommended
Phase 2 dose of gedatolisib. The primary objective of the Phase 2 portion of the trial is to assess the radiographic progression-free
survival at six months of patients who received the RP2D. Initial preliminary data for the Phase 1b dose escalation portion of the trial
is expected to be available by the end of the second quarter of 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">A Phase 3, open-label, randomized clinical trial to
evaluate the efficacy and safety of gedatolisib plus a CDK4/6 inhibitor and fulvestrant as first-line treatment for patients with HR+/HER2-
advanced breast cancer that is endocrine treatment resistant (&#8220;VIKTORIA-2&#8221;) is currently activating clinical trial sites.
For the CDK4/6 inhibitor, investigators may choose either ribociclib or palbociclib. This multi-center, international trial is expected
to enroll approximately 12&#8211;36 evaluable subjects in the safety run-in portion of the study to evaluate the safety of gedatolisib
when combined with ribociclib and fulvestrant. In the Phase 3 portion of the study, approximately 638 subjects will be randomized and
assigned to Cohort 1 (PIK3CA WT) or Cohort 2 (PIK3CA MT) based on their PIK3CA status. Subjects in each cohort will be randomized on
a 1:1 basis to either Arm A (gedatolisib with fulvestrant and ribociclib or palbociclib) or Arm B (fulvestrant and ribociclib or palbociclib).
It is expected that approximately 200 clinical sites across North America, Europe, Latin America, and Asia-Pacific will participate. The first
patient is expected to be dosed in the second quarter of 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>Recent Developments</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The VIKTORIA-1 Phase 3 clinical trial evaluating
gedatolisib in combination with fulvestrant with and without palbociclib in adults with HR+, HER2- advanced breast cancer who have received
prior treatment with a CDK4/6 inhibitor is 100% enrolled for the <i>PIK3CA</i> wild-type cohort. We expect to provide topline data in
Q2 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
VIKTORIA-2 Phase 3 open-label randomized study evaluating the efficacy and safety of gedatolisib in combination with fulvestrant plus
a CDK4/6 inhibitor, either ribociclib or palbociclib, in comparison to fulvestrant plus a CDK4/6 inhibitor as a first-line treatment
for patients with HR+/HER2- advanced breast cancer who are endocrine therapy resistant remains on track to enroll its first patient in
Q2 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2024, Celcuity presented overall survival data from a Phase 1b trial, which evaluated gedatolisib in combination with palbociclib
and either letrozole or fulvestrant, in patients with HR+, HER2- advanced or metastatic breast cancer during a poster session at the
2024 San Antonio Breast Cancer Symposium (SABCS). Median overall survival was 77.3 months among patients with HR+, HER2- advanced breast
cancer who were treatment-na&#239;ve in the advanced setting and 33.9 months among patients previously treated with a CDK4/6 inhibitor.</span></p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-indent: 18pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">We have not generated any revenue from sales to date,
and we continue to incur significant research and development and other expenses related to our ongoing operations. As a result, we are
not and have never been profitable and have incurred losses in each period since we began operations in 2012. For the years ended December
31, 2024 and 2023, we reported a net loss of approximately&#8201;$111.8 million and $63.8 million, respectively. As of December&#160;31,
2024, our cash and cash equivalents and short-term investments were approximately $235.1 million, and we had an accumulated deficit of&#8201;approximately
$271.9 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 41; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>RESULTS OF OPERATIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>Components of Operating Results</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><i>Revenue</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">To date, we have not generated any revenue. With the
execution of the Pfizer license agreement in April 2021, whereby we acquired exclusive world-wide licensing rights to develop and commercialize
gedatolisib, we initiated a Phase 3 clinical trial, VIKTORIA-1, in 2022 to support potential regulatory approval to market gedatolisib.
In August 2023, we initiated a Phase 1b/2 clinical trial, CELC-G-201, and we have initiated a second Phase 3 clinical trial, VIKTORIA-2,
with dosing of the first patient planned in Q2 2025 to support submission to the FDA seeking approval for this indication for gedatolisib.
If we obtain regulatory approvals to market gedatolisib, we expect to generate revenue from sales of the drug for the treatment of breast
cancer patients.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><i>Research and Development</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Since our inception, we have primarily focused on
research and development of gedatolisib, a PI3K/mTOR targeted therapy, and our CELsignia platform and corresponding tests. Research and
development expenses primarily include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">employee-related expenses related to our research and development activities, including salaries, benefits, recruiting, travel and
stock-based compensation expenses;</td></tr>
<tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">laboratory supplies;</td>
</tr>
<tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">consulting fees paid to third parties;</td>
</tr>
<tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">clinical trial costs;</td>
</tr>
<tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">validation costs for gedatolisib;</td>
</tr>
<tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">facilities expenses; and</td>
</tr>
<tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">legal costs associated with patent applications.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.25in; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Internal and external research and development costs
are expensed as they are incurred. As we continue development of gedatolisib and manage studies and clinical trials, including the VIKTORIA-1
Phase 3 clinical trial, the CELC-G-201 Phase 1b/2 clinical trial, and the VIKTORIA-2 Phase 3 clinical trial, the proportion of research
and development expenses allocated to external spending will grow at a faster rate than expenses allocated to internal expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><i>General and Administrative</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">General and administrative expenses consist primarily
of salaries, benefits and stock-based compensation related to our executive, finance and support functions. Other general and administrative
expenses include professional fees for auditing, tax, and legal services associated with being a public company, director and officer
insurance, investor relations and travel expenses for our general and administrative personnel.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><i>Sales and Marketing</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Expenses and costs related to the initiation and operation
of our medical and marketing teams, supply chain and distribution network are being incurred in anticipation of the commercialization
of our first drug candidate, gedatolisib. <span style="background-color: white">These expenses consist primarily of employee-related expenses,
professional and consulting fees related to these functions and operations, software costs,</span> and the acquisition of data required
to support our market analysis for our drug product. <span style="background-color: white">We would expect to begin to incur sales </span>force,
sales support staff <span style="background-color: white">and marketing expenses closer to a potential FDA approval date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><i>Interest Expense</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Interest expense is primarily due to a Loan Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><i>Interest Income</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Interest income consists of interest income earned
on our cash, cash equivalents and investment balances.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>&#160;</i></b></p>


<!-- Field: Page; Sequence: 42; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>&#160;&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>Results of Operations </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>Comparison of the Years Ended December 31, 2024 and 2023</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 92%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Years Ended</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Increase (Decrease)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2024</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2023</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">$</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Percent Change</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Statements of Operations Data:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; text-align: justify; text-indent: 10pt">Research and development</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">104,203,230</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">60,594,005</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">43,609,225</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">72</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt; text-indent: 10pt">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">9,063,721</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5,636,326</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,427,395</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">61</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Total operating expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">113,266,951</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">66,230,331</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">47,036,620</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">71</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Loss from operations</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(113,266,951</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(66,230,331</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(47,036,620</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">71</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Other (expense) income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: 10pt">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(10,280,445</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,326,387</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,954,058</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">93</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt; text-indent: 10pt">Interest income</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">11,768,291</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">7,777,602</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,990,689</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">51</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Other income, net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,487,846</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,451,215</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(963,369</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(39</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1pt">Net loss before income taxes</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(111,779,105</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(63,779,116</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(47,999,989</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">75</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Income tax benefits</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Net loss</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(111,779,105</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(63,779,116</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(47,999,989</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">75</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>&#160;&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><i>Research and Development</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 16.2pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 16.2pt">For the year ended December 31, 2024, our research
and development expenses were approximately $104.2 million, representing an increase of approximately $43.6 million, or 72%, compared
to 2023. Of the $43.6 million increase in research and development expense, $30.7 million was primarily related to costs supporting ongoing
activities for the VIKTORIA-1 and CELC-G-201 trials and the commencement of the VIKTORIA-2 Phase 3 pivotal trial. The remaining $12.9
million was related to increased employee and consulting expenses, of which $0.1 million was in the form of non-cash stock-based compensation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 16.2pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 16.2pt">Conducting a significant amount of research and development
is central to our business model. We plan to increase our research and development expenses for the foreseeable future as we seek to develop
gedatolisib and manage the VIKTORIA-1 Phase 3 clinical trial, the CELC-G-201 Phase 1b/2 clinical trial, and the VIKTORIA-2 Phase 3 clinical
trial.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><i>General and Administrative</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">For the year ended December 31, 2024, our total general
and administrative expenses were $9.1 million, representing an increase of approximately $3.4 million, or 61%, compared to 2023. Employee
related expenses accounted for $2.6 million of the $3.4 million increase. The remaining $0.8 million of the increase resulted from professional
fees, expanding infrastructure and other administrative expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 16.2pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 16.2pt">We anticipate that our general
and administrative expenses will increase in future periods, reflecting both increased costs in connection with the potential future commercialization
of gedatolisib, an expanding infrastructure, and increased professional fees associated with public company regulatory developments and
requirements, and other compliance matters.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><i>Interest Expense</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">For the year ended December 31, 2024, interest expense
was $10.3 million and represents an increase of $5.0 million compared to 2023. The increase is due primarily to the increased debt balance
in 2024 compared to 2023 due to the incremental $61.7 million funding of Term Loan C in May 2024. The $10.3 million of interest expense
includes $2.7 million of non-cash interest expense.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><i>Interest Income</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 16.2pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 16.2pt">For the year ended December 31,
2024, interest income was $11.8 million and represents an increase of $4.0 million compared to 2023. The increase was primarily the result
of closing on additional equity and debt financing activities in May 2024, leading to higher cash, cash equivalents and short-term investment
balances.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>LIQUIDITY AND CAPITAL RESOURCES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Since our inception, we have incurred losses and cumulative
negative cash flows from operations. Through December 31, 2024, we have funded our operations primarily through private placements and
registered offerings of our equity securities and unsecured convertible notes, and borrowings under loan agreements. From inception through
December 31, 2024, we raised an aggregate of approximately $369.0 million of net proceeds through sales of our securities, and as of December
31, 2024 had $100.0 million of borrowings under loan agreements, not including payable-in-kind interest. In March 2024, an investor exercised
1,739,080 warrants at an exercise price of $8.05, which generated approximately $14 million in cash. In March 2025, an investor exercised 695,650 warrants at an exercise price of $8.05, which generated approximately $5.6 million in cash.
<span style="letter-spacing: -0.1pt">The warrants exercised in </span> March 2024 and 2025 were issued pursuant
to a private placement that closed on December 9, 2022. As of December&#160;31, 2024, our cash and cash equivalents and short-term investments
were approximately $22.5 million and $212.6 million, respectively, and we had an accumulated deficit of&#8201;approximately $271.9 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 16.2pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 16.2pt"><i>Open Market Sale Agreement&#8480;.</i> On February
4, 2022, we entered into an Open Market Sale Agreement<sup>SM</sup> with Jefferies LLC, as agent, pursuant to which we may offer and sell,
from time to time, through Jefferies, shares of our common stock having an aggregate offering price of up to $50.0 million, which amount
was subsequently increased to $125.0 million on December 6, 2024. On October 12, 2022, pursuant to this agreement, the Company sold 500,000
shares of common stock in a single transaction at a price of $10.35 per share generating gross proceeds of $5.2 million ($4.8 million
net of commissions and offering expenses). On December 1, 2023, pursuant to this agreement, the Company sold 1,034,500 shares of common
stock in a single transaction at a price of $14.50 per share, generating gross proceeds of $15.0 million ($14.4 million net of commissions
and offering expenses). In April 2024 and May 2024, pursuant to this agreement, the Company sold 285,714 and 149,700 shares of common
stock, respectively, at an average selling price of $17.55 per share, generating gross proceeds of $7.6 million before deducting commissions
and other offering expenses of $0.3 million. At December 31, 2024, $125.0 million of common stock remains available for sale under the
Jefferies agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 16.2pt">&#160;</p>


<!-- Field: Page; Sequence: 43; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;<i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"><i>Private Placement. </i>On December 9, 2022, we
issued 6,182,574 shares of common stock, 1,120,873 shares of Series A Preferred Stock and warrants exercisable for 6,956,450 shares of
common stock to certain institutional and other accredited investors pursuant to a securities purchase agreement entered into on May 15,
2022. Pursuant to the securities purchase agreement, the closing (funding) of the private placement occurred following dosage of the first
patient in the Company&#8217;s Phase 3 study, VIKTORIA-1. Investors purchased shares of common stock and Series A Preferred Stock at a
price of $5.75 per share (on an as converted to common stock basis), with forty percent (40%) warrant coverage (on an as converted to
common stock basis) and customary resale registration rights. The warrants have an exercise price of $8.05 per share. The private placement
generated gross proceeds of approximately $100.0 million before deducting placement agent fees and other offering expenses of $4.3 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in; background-color: white"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in; background-color: white"><i>Pre-funded Warrants.</i>
On October 18, 2023, the Company entered into a securities purchase agreement to sell pre-funded warrants at a price of $8.70 per warrant,
to purchase up to 5,747,787 shares of the Company&#8217;s common stock in a private placement. The closing of the private placement occurred
on October 20, 2023, and resulted in gross proceeds of approximately $50.0 million, before deducting offering expenses of approximately
$0.1 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 16.2pt"><i>Equity Offering</i>. On May 30, 2024, the Company
entered into an underwriting agreement with Leerink Partners LLC, TD Securities (USA) LLC and Stifel, Nicolaus &amp; Company, Incorporated
as representatives of the several underwriters relating to the issuance and sale of 3,871,000 shares of common stock, at a price to the
public of $15.50, generating gross proceeds of approximately $60.0 million. The offering closed on May 31, 2024 and resulted in net proceeds
to the Company of approximately $56.3 million after deducting underwriting discounts and other offering expenses payable by the Company.
The Company intends to use the net proceeds from the offering for working capital and general corporate purposes, which may include research
and development expenditures, clinical trial expenditures, expansion of business development activities and other general corporate purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 16.2pt"><i>Loan Agreement. </i>On May 30, 2024, the Company
entered into an Amended and Restated Loan and Security Agreement (the &#8220;A&amp;R Loan Agreement&#8221;) with Innovatus Life Sciences
Lending Fund I, LP, a Delaware limited partnership (&#8220;Innovatus&#8221;), as collateral agent, and the Lenders including Innovatus
in its capacity as a Lender and Oxford Finance LLC (&#8220;Oxford&#8221;), pursuant to which Innovatus and Oxford, as Lenders, have agreed
to make certain term loans (&#8220;Term Loans&#8221;) to the Company in the aggregate principal amount of up to $180 million. The A&amp;R
Loan Agreement amends and restates, in its entirety, that certain Loan and Security Agreement, dated April 8, 2021, as amended, between
the Company and Innovatus, as collateral agent, and the Lenders named therein (the &#8220;Prior Loan Agreement&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 20.25pt">Funding of the first $100 million under the A&amp;R
Loan Agreement occurred on May 30, 2024, including tranche payments of $16.8 million (the &#8220;Term A Loan&#8221;) and $21.5 million
(the &#8220;Term B Loan&#8221;) reflecting repayment of the principal amount of loans under the Prior Loan Agreement plus accrued payment-in-kind
interest, in addition to $61.7 million of new borrowings (the &#8220;Term C Loan&#8221;). The Company will be eligible to draw on a fourth
tranche of $30 million (the &#8220;Term D Loan&#8221;) and fifth tranche of $50 million (the &#8220;Term E Loan&#8221;), in each case
upon achievement of certain clinical trial milestones and satisfaction of certain financial covenants determined on a pro forma as-funded
basis. The Lenders may, in their sole discretion upon the Company&#8217;s request, make additional term loans to the Company of $45 million
(the &#8220;Term F Loan&#8221;). Funding of these additional tranches is also subject to other customary conditions and limits on when
the Company can request funding for such tranches. Costs associated with the new borrowings were approximately $2.4 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 16.2pt">Pursuant to the A&amp;R Loan Agreement, the Company
is entitled to make interest-only payments for thirty-six months, or up to forty-eight months if certain conditions are met. The Term
Loans will mature on May 1, 2029 and will bear interest at a rate equal to the sum of (a) the greater of (i) the Prime Rate (as defined
in the A&amp;R Loan Agreement) or (ii) 7.75%, plus (b) 2.85%, provided that 1.0% of such interest will be payable in-kind by adding an
amount equal to such 1.0% of the outstanding principal amount to the then outstanding principal balance on a monthly basis through May
31, 2027. The A&amp;R Loan Agreement is secured by all assets of the Company. Proceeds will be used for working capital purposes and to
fund the Company&#8217;s general business requirements, including the Phase 3 VIKTORIA-2 clinical trial. The A&amp;R Loan Agreement contains
customary representations and warranties and covenants, subject to customary carve-outs, and includes financial covenants related to liquidity
and other financial measures. Innovatus has the right, at its election and until August 9, 2025, to convert up to 20% of the outstanding
principal of the Term A Loan into shares of the Company&#8217;s common stock at a price per share of $10.00 (the &#8220;Conversion Right&#8221;).
Innovatus will continue to have the right to exercise a previously disclosed warrant granted to it under the Prior Loan Agreement to purchase
26,042 shares of common stock at a price per share of $14.40 through April 8, 2031.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 16.2pt">The A&amp;R Loan Agreement contains a Final Fee, which
is equal to 4.5% of the initial funding of the agreement and is due on the earliest to occur of (a) the Maturity Date, (b) the acceleration
of any Term Loan, and (c) the prepayment of the Term Loans. There is also a contingent non-utilization fee for both the Term D and Term
E loans. If the Company achieves the Term D Milestone and (i) fails to draw the full amount of the Term D Loan during the Term D Draw
Period and (ii) fails to notify Collateral Agent, at any time before the date that is four weeks after the Company&#8217;s achievement
of the Term D Milestone, of the Company&#8217;s intent not to draw the full amount of the Term D Loan, a non-utilization fee of $900,000,
with respect to the Term D Loan shall become due and payable on the earliest of (i) the termination of the Term D Draw Period, (ii) the
Maturity Date, (iii) the acceleration of any Term Loan, and (iv) the prepayment in whole of the Term Loans. If the Company achieves the
Term E Milestone and (i) fails to draw the full amount of the Term E Loan during the Term E Draw Period and (ii) fails to notify Collateral
Agent, at any time before the date that is four weeks after the Company&#8217;s achievement of the Term E Milestone, of the Company&#8217;s
intent not to draw the full amount of the Term E Loan, a non-utilization fee of $1,500,000, with respect to the Term E Loan shall become
due and payable on the earliest of (i) the termination of the Term E Draw Period, (ii) the Maturity Date, (iii) the acceleration of any
Term Loan, and (iv) the prepayment in whole of the Term Loans. After the 18-month anniversary of the Effective Date, the Company shall
have the option to prepay all, but not less than all, of the Term Loans advanced by the Lenders under the A&amp;R Loan Agreement, provided
the Company (i) provides written notice to Collateral Agent of its election to prepay the Term Loans at least seven Business Days prior
to such prepayment, and (ii) pays to Lenders on the date of such prepayment, payable to each Lender in accordance with its respective
Pro Rata Share, an amount equal to the sum of (A) all outstanding principal of the Term Loans plus accrued and unpaid interest thereon
through the prepayment date, (B) the Final Fee, (C) the Prepayment Fee, plus (D) all other outstanding Obligations that are due and payable,
including, without limitation, Lenders&#8217; Expenses and interest at the Default Rate with respect to any past due amounts. At May 30,
2024, the Company recognized the Final Fee of $4.5 million as additional debt principal and a corresponding debt discount to be amortized
over the life of the loan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 16.2pt">&#160;</p>


<!-- Field: Page; Sequence: 44; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 16.2pt">In connection with the funding of each of the Term
C Loan, the Term D Loan, the Term E Loan and the Term F Loan, the Company agreed to issue to Innovatus and Oxford warrants to purchase
that number of shares of the Company&#8217;s common stock equal to 2.5% of the principal amount of the applicable Term Loan divided by
the exercise price, which shall, with respect to the Term C Loan, be equal to the lower of (i) the volume weighted average closing price
of the Company&#8217;s common stock for the five-trading day period ending on the last trading day immediately preceding the execution
of the A&amp;R Loan Agreement or (ii) the closing price on the last trading day immediately preceding the execution of the A&amp;R Loan
Agreement. Accordingly, on May 30, 2024, the Company issued 103,876 warrants with an exercise price of $14.84 per share. The relative
fair value of the warrants was approximately $1.2 million. For the additional Term Loans, the exercise price will be based on the lower
of (i) the exercise price for the Warrants issued pursuant to the Term C Loan or (ii) the volume weighted average closing price of the
Company&#8217;s common stock for the five-trading day period ending on the last trading day immediately preceding the applicable Term
Loan funding. The Warrants may be exercised on a cashless basis and are exercisable through the tenth anniversary of the applicable funding
date. The number of shares of common stock for which each Warrant is exercisable and the associated exercise price are subject to certain
proportional adjustments as set forth in such Warrant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 16.2pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 16.2pt">We expect that our research and development and general
and administrative expenses will increase as we continue to develop gedatolisib, manage the VIKTORIA-1 Phase 3 clinical trial, the CELC-G-201
Phase 1b/2 trial, and the VIKTORIA-2 Phase 3 trial, conduct other studies and clinical trials, and pursue other business development activities.
We would also expect to incur sales and marketing expenses as we commercialize gedatolisib. We expect to use cash on hand, together with
the funds to be received under the debt and equity financings described above, to fund our research and development expenses, clinical
trial costs, capital expenditures, working capital, sales and marketing expenses, and general corporate expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 16.2pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Based on our current business plan, we believe that
our current cash, cash equivalents and short-term investments together with available borrowings under the Innovatus Loan Agreement will
provide sufficient cash to finance our clinical development program activities through 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Our expectations as to how long our current capital
resources will be sufficient to fund our operations are based on assumptions that may not be accurate, and we could use our current capital
resources sooner than we currently expect. In addition, we may seek to raise additional capital to finance capital expenditures and operating
expenses over the next several years as we launch our integrated therapeutic and companion diagnostic strategy and expand our infrastructure,
commercial operations and research and development activities, and to take advantage of financing or other opportunities that we believe
to be in the best interests of the Company and our stockholders. Additional capital may be raised through the sale of common or preferred
equity or convertible debt securities, entry into debt facilities or other third-party funding arrangements. The sale of equity and convertible
debt securities may result in dilution to our stockholders and those securities may have rights senior to those of our common shares.
Agreements entered into in connection with such capital raising activities could contain covenants that would restrict our operations
or require us to relinquish certain rights. Additional capital may not be available on reasonable terms, or at all.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>Cash Flows</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">The following table sets forth the primary sources
and uses of cash for the years ended December 31:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 84%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="6" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Net cash (used in) provided by:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 70%; text-align: justify; text-indent: 10pt">Operating activities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(83,466,743</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(53,812,253</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: 10pt">Investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(63,069,283</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,008,207</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt; text-indent: 10pt">Financing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">138,388,075</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">64,911,677</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Net (decrease) increase in cash and cash equivalents</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(8,147,951</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,091,217</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><i>&#160;</i></p>


<!-- Field: Page; Sequence: 45; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><i>&#160;&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><i>Operating Activities </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Net cash used in operating activities was approximately
$83.5 million for the year ended December 31, 2024 and consisted primarily of a net loss of&#8201;approximately $111.8 million, partially
offset by working capital changes of $18.3 million and non-cash expense items of approximately $10.0 million. Non-cash expense items of
approximately $10.0 million primarily consisting of $7.0 million of stock-based compensation expense, net non-cash interest income and
expense of $2.8 million, and depreciation expense of $0.1 million. The approximately $18.3 million of working capital changes was primarily
due to increases in accrued expenses and accounts payable, and a decrease in other current assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 16.2pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 16.2pt">Net cash used in operating activities
was approximately $53.8 million for the year ended December 31, 2023 and consisted primarily of a net loss of approximately $63.8 million,
partially offset by working capital changes of $3.9 million and non-cash expense items of approximately $6.1 million. Non-cash expense
items of approximately $6.1 million primarily consisted of $4.9 million of stock-based compensation expense, non-cash interest expense
of $2.1 million and depreciation expense of $0.1 million, partially offset by $1.0 million of accrued interest income. The approximately
$3.9 million of working capital changes was primarily due to increases in accounts payable and accrued expenses, offset by an increase
in other current assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><i>Investing Activities</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Net cash used in investing activities for the year
ended December 31, 2024 was approximately $63.1 million and consisted of approximately $62.8 million of net purchases of short-term investments
in government securities (U.S. Treasury Bills and U.S. government securities) and approximately $0.3 million in purchases of property
and equipment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Net cash used in investing activities for the year
ended December 31, 2023 was approximately $5.0 million and consisted of approximately $4.9 million of net purchases of short-term investments
in government securities (U.S. Treasury Bills and U.S. government securities) and approximately $0.1 million in purchases of property
and equipment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><i>Financing Activities</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 16.2pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 16.2pt">Net cash provided by financing
activities for the year ended December 31, 2024 was approximately $138.4 million and primarily consisted of net proceeds of approximately
$59.2 million from incremental debt financing, $56.3 million from an equity offering and $7.3 million from an at-the market offering.
The remaining $15.6 million consisted of proceeds from the exercise of common stock warrants, the exercise of employee stock options and
employee stock purchases, slightly offset by payments for a secondary registration statement costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Net cash provided by financing activities for the
year ended December 31, 2023 was approximately $64.9 million and primarily consisted of net proceeds from a pre-funded warrant offering
and at-the-market offering, collectively totaling $64.4 million. The remaining $0.5 million was the result of proceeds from the exercise
of employee stock options, the exercise of warrants, and proceeds from employee stock purchases, slightly offset by payments for secondary
registration statement and debt issuance costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>RECENT ACCOUNTING PRONOUNCEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">From time-to-time new accounting pronouncements are
issued by the Financial Accounting Standards Board or other standard setting bodies and adopted by us as of the specified effective date.
Unless otherwise discussed in Note 2 to our financial statements included elsewhere in this Annual Report, we believe that the impact
of recently issued standards that are not yet effective will not have a material impact on our financial position or results of operations
upon adoption.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Our management&#8217;s discussion and analysis of
financial condition and results of operations is based on our financial statements, which have been prepared in accordance with accounting
principles generally accepted in the United States, or Generally Accepted Accounted Principles (&#8220;U.S. GAAP&#8221;). The preparation
of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities
and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported expenses during
the reporting periods. These items are monitored and analyzed by us for changes in facts and circumstances, and material changes in these
estimates could occur in the future. We base our estimates on historical experience and on various other factors that we believe are reasonable
under the circumstances; the results of which form the basis for making judgments about the carrying value of assets and liabilities that
are not readily apparent from other sources. Changes in estimates are reflected in reported results for the period in which they become
known. Actual results may differ materially from these estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 46; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Our significant accounting policies are more fully
described in Note 2 to our financial statements included elsewhere in this Annual Report. Of our significant accounting policies, we believe
that the following are the most critical:</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>Stock-Based Compensation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 2.15pt 0 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 2.15pt 0 0; text-align: justify; text-indent: 0.25in">Our stock-based compensation
consists of common stock options and restricted stock issued to certain employees and non-employees and our Employee Stock Purchase Plan
(&#8220;ESPP&#8221;). We recognize compensation expense based on an estimated grant date fair value using the Black-Scholes option-pricing
method for equity-based awards and the Monte Carlo simulation model for the performance-based awards. We have elected to account for forfeitures
as they occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">The inputs for the Black-Scholes valuation model require
management&#8217;s significant assumptions. Prior to our IPO, the price per share of common stock was determined by our board based on
recent prices of common stock sold in private offerings. Subsequent to the IPO, the price per share of common stock is determined by using
the closing market price on the Nasdaq Capital Market on the grant date. The risk-free interest rates are based on the rate for U.S. Treasury
securities at the date of grant with maturity dates approximately equal to the expected life at the grant date. The expected life was
based on the simplified method in accordance with SEC Staff Accounting Bulletin Nos. 107 and 110. The expected volatility was estimated
based on historical volatility information of peer companies that are publicly available in combination with our calculated volatility
since being publicly traded.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">All assumptions used to calculate the grant date fair
value of non-employee options are generally consistent with the assumptions used for options granted to employees. In the event we terminate
any of our consulting agreements, the unvested options issued in connection with such agreements would also be cancelled.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">For grants of restricted stock, we record compensation
expense based on the quoted fair value of the shares on the grant date over the requisite service period. Compensation expense for ESPP
rights is recorded in line with each respective offering period<span style="font-family: inherit,serif">. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>Clinical Trial Costs</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 16.2pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 16.2pt">The Company records prepaid assets or accrued expenses
for prepaid or estimated clinical trial costs conducted by third-party service providers, which includes the conduct of preclinical studies
and clinical trials.&#160;These costs can be a significant component of the Company&#8217;s research and development expenses.&#160;The
Company primarily relies on a compilation of progress reports from third-party service providers, including the respective invoicing,
to record actual expenses, along with determining changes to prepaid assets and accrued liabilities. To date, the Company believes utilization
of third-party reports most accurately reflects expenses incurred. With the ongoing VIKTORIA-1 Phase 3 trial and the CELC-G-201 Phase
1b/2 trial, and the commencement of the VIKTORIA-2 Phase 3 trial site activation and patient enrollment<span style="font-size: 10pt">,
</span>the Company&#8217;s estimated expenses in future periods and the actual services performed may vary from these estimates, and these
estimates may become more significant. Changes in these estimates that result in material changes to the Company&#8217;s prepaid assets
or accrued expenses could materially affect the Company&#8217;s results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0"/><td style="text-align: justify; width: 1in"><b><span id="a_012"></span>ITEM&#160;7A.</b></td><td style="text-align: justify"><b>Quantitative and Qualitative Disclosures About Market Risk</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">As a smaller reporting company, we are not required
to provide disclosure pursuant to this item.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>


<!-- Field: Page; Sequence: 47; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><span id="a_013"></span>ITEM&#160;8. Financial Statements and Supplementary Data</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span id="fin_01"></span>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Board of Directors and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholders of Celcuity Inc.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-align: left">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion
on the Financial Statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.75pt 0pt 5.95pt; text-align: justify">&#160;</p>

<p id="xdx_986_edei--AuditorOpinionTextBlock_c20240101__20241231_z71zRcAyqCw1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000059" name="dei:AuditorOpinionTextBlock"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying balance sheets of Celcuity Inc. (the Company) as of December 31, 2024 and 2023, and the related statements
of operations, changes in stockholders&#8217; equity, and cash flows for each of the years in the two-year period ended December 31,
2024, and the related notes (collectively referred to as the financial statements). In our opinion, the financial statements present
fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations
and its cash flows for each of the years in the two-year period ended December 31, 2024, in conformity with accounting principles generally
accepted in the United States of America.</span></ix:nonNumeric></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.95pt; text-align: justify">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basis
for Opinion</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.75pt 0pt 5.95pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s
financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent
with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities
and Exchange Commission and the PCAOB.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.7pt 0pt 5.95pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company
is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits,
we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion
on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.7pt 0pt 6pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error
or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits
provide a reasonable basis for our opinion.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-align: justify">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Critical
Audit Matters</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.8pt 0pt 6pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Critical
audit matters are matters arising from the current period audit of the consolidated financial statements that were communicated or required
to be communicated to the audit committee and that (1) relate to accounts or disclosures that are material to the financial statements
and (2) involved our especially challenging, subjective, or complex judgments. We determined that there were no critical audit matters.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>/s/ <span id="xdx_909_edei--AuditorName_c20240101__20241231_zxYbS938HHt8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000060" name="dei:AuditorName">Boulay
LLP</ix:nonNumeric></span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have served as the Company&#8217;s auditor since 2017.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span id="xdx_908_edei--AuditorLocation_c20240101__20241231_zOgiyfNadFs4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000061" name="dei:AuditorLocation">Minneapolis,
Minnesota</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2025</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCAOB
ID: <span id="xdx_904_edei--AuditorFirmId_c20240101__20241231_z4wBtnDYlsBd"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000062" name="dei:AuditorFirmId">542</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 48; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b>Celcuity Inc.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b><span id="fin_02"></span>Balance Sheets</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_30E_111_zpx1b4XmaZ62" summary="xdx: Statement - Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20241231_z0z0BMNqLLXa" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31, 2024</td><td style="white-space: nowrap; text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20231231_zOZPsD8UNVdc" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31, 2023</td><td style="white-space: nowrap; text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AssetsAbstract_iB_zpRLRd1WA79h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AssetsCurrentAbstract_i01B_zTx2mVaMlyl1" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify">Current Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maACzcOu_zuvrvamygE7e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; text-align: justify; text-indent: 10pt">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2024-12-31" id="Fact000070" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,514,823</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2023-12-31" id="Fact000071" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,662,774</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ShortTermInvestments_i02I_maACzcOu_zjQr8DKtoUWa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: 10pt">Investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShortTermInvestments" contextRef="AsOf2024-12-31" id="Fact000073" format="ixt:numdotdecimal" decimals="0" unitRef="USD">212,588,960</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShortTermInvestments" contextRef="AsOf2023-12-31" id="Fact000074" format="ixt:numdotdecimal" decimals="0" unitRef="USD">149,919,974</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OtherAssetsCurrent_i02I_maACzcOu_zW9ybF3hwPr2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt; text-indent: 10pt">Other current assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="AsOf2024-12-31" id="Fact000076" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,467,247</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="AsOf2023-12-31" id="Fact000077" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,007,849</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AssetsCurrent_i02TI_mtACzcOu_maAzrcF_zcZRGJ4Fk7nd" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify">Total current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2024-12-31" id="Fact000079" format="ixt:numdotdecimal" decimals="0" unitRef="USD">244,571,030</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2023-12-31" id="Fact000080" format="ixt:numdotdecimal" decimals="0" unitRef="USD">190,590,597</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentNet_i01I_maAzrcF_zEjJtvz8bcc3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Property and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2024-12-31" id="Fact000082" format="ixt:numdotdecimal" decimals="0" unitRef="USD">336,515</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-12-31" id="Fact000083" format="ixt:numdotdecimal" decimals="0" unitRef="USD">228,782</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_maAzrcF_zpaSRk2cDuR5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Operating lease right-of-use assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2024-12-31" id="Fact000085" format="ixt:numdotdecimal" decimals="0" unitRef="USD">215,502</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2023-12-31" id="Fact000086" format="ixt:numdotdecimal" decimals="0" unitRef="USD">400,019</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--Assets_i01TI_mtAzrcF_zsdPBsRIWrFe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Total Assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2024-12-31" id="Fact000088" format="ixt:numdotdecimal" decimals="0" unitRef="USD">245,123,047</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-12-31" id="Fact000089" format="ixt:numdotdecimal" decimals="0" unitRef="USD">191,219,398</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zvkb4uivjOIi" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify">Liabilities and Stockholders&#8217; Equity:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--LiabilitiesCurrentAbstract_i01B_zsdHghMFfGrh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Current Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AccountsPayableCurrent_i02I_maLCzhJn_zeFR0uHz9wei" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: 10pt">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2024-12-31" id="Fact000097" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,366,007</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2023-12-31" id="Fact000098" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,076,699</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_maLCzhJn_zsRRnkmfXeJ3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: 10pt">Operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2024-12-31" id="Fact000100" format="ixt:numdotdecimal" decimals="0" unitRef="USD">171,952</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2023-12-31" id="Fact000101" format="ixt:numdotdecimal" decimals="0" unitRef="USD">184,950</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AccruedLiabilitiesCurrent_i02I_maLCzhJn_zNYEszIBvQK3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt; text-indent: 10pt">Accrued expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000103" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,184,948</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000104" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,927,094</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LiabilitiesCurrent_i02TI_mtLCzhJn_maLzHFK_znixfRaV5wFj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Total current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000106" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,722,907</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000107" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,188,743</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OperatingLeaseLiabilityNoncurrent_i02I_maLzHFK_zNsDU1l3ykSb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2024-12-31" id="Fact000109" format="ixt:numdotdecimal" decimals="0" unitRef="USD">53,969</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2023-12-31" id="Fact000110" format="ixt:numdotdecimal" decimals="0" unitRef="USD">225,922</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LongTermNotesPayable_i01I_maLzHFK_zmsTEIzEddra" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Note payable, non-current</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LongTermNotesPayable" contextRef="AsOf2024-12-31" id="Fact000112" format="ixt:numdotdecimal" decimals="0" unitRef="USD">97,727,136</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LongTermNotesPayable" contextRef="AsOf2023-12-31" id="Fact000113" format="ixt:numdotdecimal" decimals="0" unitRef="USD">37,035,411</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--Liabilities_i01TI_mtLzHFK_maLASEzbfR_zikSu0e1h7n2" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1pt">Total Liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2024-12-31" id="Fact000115" format="ixt:numdotdecimal" decimals="0" unitRef="USD">129,504,012</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2023-12-31" id="Fact000116" format="ixt:numdotdecimal" decimals="0" unitRef="USD">51,450,076</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--CommitmentsAndContingencies_i01I_maLASEzbfR_z1UkT6FguRL8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Commitments and Contingencies (Note 9)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0118">-</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0119">-</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--StockholdersEquityAbstract_i01B_zX3FAXlOkMM8" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify">Stockholders&#8217; Equity:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--PreferredStockValue_i02I_maSEzxE9_zGiUSeoS0n13" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Preferred stock, $<span id="xdx_908_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20241231_zoQXPBH1azL8" title="Preferred stock, par value"><span id="xdx_906_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20231231_z5oNgZLunslb" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31" id="Fact000127" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31" id="Fact000129" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span> par value: <span id="xdx_90B_eus-gaap--PreferredStockSharesAuthorized_iI_c20241231_zGh1fshTn1jc" title="Preferred stock, shares authorized"><span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_c20231231_pdd" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact000131" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-12-31" id="Fact000133" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,500,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized; <span id="xdx_90E_eus-gaap--PreferredStockSharesIssued_iI_c20241231_z8vuqCspbPOc" title="Preferred stock, shares issued"><span id="xdx_90E_eus-gaap--PreferredStockSharesOutstanding_iI_c20241231_ziRGwLoUHEw3" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2024-12-31" id="Fact000135" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-12-31" id="Fact000137" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">317,577</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_905_eus-gaap--PreferredStockSharesIssued_iI_c20231231_z1dvKQHPclL6" title="Preferred stock, shares issued"><span id="xdx_909_eus-gaap--PreferredStockSharesOutstanding_iI_c20231231_zJYbBQyo3Or2" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2023-12-31" id="Fact000139" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-12-31" id="Fact000141" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">854,134</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2024-12-31" id="Fact000124" format="ixt:numdotdecimal" decimals="0" unitRef="USD">318</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-12-31" id="Fact000125" format="ixt:numdotdecimal" decimals="0" unitRef="USD">854</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--CommonStockValue_i02I_maSEzxE9_zkUR818hWLU5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Common stock, $<span id="xdx_90E_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20241231_zZxqwmCRti8j" title="Common stock, par value"><span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20231231_zwaMmBqCpgaj" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31" id="Fact000146" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31" id="Fact000148" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span> </span>par
    value: <span id="xdx_907_eus-gaap--CommonStockSharesAuthorized_iI_c20241231_zJKzDm4RUmx8" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact000150" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">95,000,000</ix:nonFraction></span> and <span id="xdx_90D_eus-gaap--CommonStockSharesAuthorized_iI_c20231231_zeQo4vBmx3me" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-12-31" id="Fact000152" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">65,000,000</ix:nonFraction></span> shares
    authorized as of December 31, 2024 and December 31, 2023, respectively; <span id="xdx_90F_eus-gaap--CommonStockSharesIssued_iI_c20241231_zvRb4Q6T4RF" title="Common stock, shares issued"><span id="xdx_905_eus-gaap--CommonStockSharesOutstanding_iI_c20241231_zaIrHsYs91y7" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-12-31" id="Fact000154" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-12-31" id="Fact000156" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">37,143,242</ix:nonFraction></ix:nonFraction></span> </span>and <span id="xdx_90A_eus-gaap--CommonStockSharesIssued_iI_c20231231_zzmzj29SXXSe" title="Common stock, shares issued"><span id="xdx_90A_eus-gaap--CommonStockSharesOutstanding_iI_c20231231_zp5UeXav3c0b" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-12-31" id="Fact000158" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-12-31" id="Fact000160" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,506,012</ix:nonFraction></ix:nonFraction></span></span>
    shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2024-12-31" id="Fact000143" format="ixt:numdotdecimal" decimals="0" unitRef="USD">37,143</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-12-31" id="Fact000144" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,506</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AdditionalPaidInCapital_i02I_maSEzxE9_zQ0pMM3I9b9f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2024-12-31" id="Fact000162" format="ixt:numdotdecimal" decimals="0" unitRef="USD">387,436,682</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2023-12-31" id="Fact000163" format="ixt:numdotdecimal" decimals="0" unitRef="USD">299,818,965</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_maSEzxE9_ziMcQMmGdXVi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Accumulated deficit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2024-12-31" id="Fact000165" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">271,855,108</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-12-31" id="Fact000166" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">160,076,003</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--StockholdersEquity_i02TI_pp0p0_maLASEzbfR_mtSEzxE9_zlGkHxF6iWpb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1pt">Total Stockholders&#8217; Equity</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000168" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">115,619,035</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000169" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">139,769,322</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_pp0p0_mtLASEzbfR_zmjnUlinaH36" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Total Liabilities and Stockholders&#8217; Equity</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000171" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">245,123,047</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000172" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">191,219,398</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><i>See accompanying notes to the financial statements</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>


<!-- Field: Page; Sequence: 49; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b>Celcuity Inc.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b><span id="fin_03"></span>Statements of Operations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_30D_113_zU3lr92vQXHl" summary="xdx: Statement - Statements of Operations" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20240101__20241231_zkigVm92How2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20230101__20231231_zPAovDyFXMEg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Twelve Months Ended December 31,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingExpensesAbstract_iB_zwQeh7tYnm1k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ResearchAndDevelopmentExpense_i01_maCzRup_zT3qBDhdne16" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; text-align: justify; text-indent: 10pt">Research and development</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000177" format="ixt:numdotdecimal" decimals="0" unitRef="USD">104,203,230</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31" id="Fact000178" format="ixt:numdotdecimal" decimals="0" unitRef="USD">60,594,005</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--GeneralAndAdministrativeExpense_i01_maCzRup_zbrGozwJsVEb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt; text-indent: 10pt">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000180" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,063,721</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-01-012023-12-31" id="Fact000181" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,636,326</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingExpenses_i01T_mtCzRup_msCzvE6_zRjc0EN1my24" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Total operating expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2024-01-01to2024-12-31" id="Fact000183" format="ixt:numdotdecimal" decimals="0" unitRef="USD">113,266,951</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2023-01-012023-12-31" id="Fact000184" format="ixt:numdotdecimal" decimals="0" unitRef="USD">66,230,331</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingIncomeLoss_iT_mtCzvE6_maCzj6U_zWVBVKZai8cj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Loss from operations</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000186" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">113,266,951</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000187" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">66,230,331</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_z6LGPrE0xi84" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Other (expense) income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--InterestExpenseNonoperating_i01N_di_msCz7wH_zuQ58dk5fd1b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: 10pt">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="From2024-01-01to2024-12-31" id="Fact000192" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,280,445</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="From2023-01-012023-12-31" id="Fact000193" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,326,387</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--InvestmentIncomeInterest_i01_maCz7wH_zXEq54Mb6F84" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt; text-indent: 10pt">Interest income</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="From2024-01-01to2024-12-31" id="Fact000195" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,768,291</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="From2023-01-012023-12-31" id="Fact000196" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,777,602</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--NonoperatingIncomeExpense_i01T_mtCz7wH_maCzj6U_zOHdgTrGFBRe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Other income, net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000198" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,487,846</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2023-01-012023-12-31" id="Fact000199" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,451,215</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_mtCzj6U_maCzn5E_zAKuD5psRrhk" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1pt">Net loss before income taxes</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2024-01-01to2024-12-31" id="Fact000201" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">111,779,105</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2023-01-012023-12-31" id="Fact000202" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">63,779,116</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--IncomeTaxExpenseBenefit_msCzn5E_zqI0T5LzFcic" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Income tax benefits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0204">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0205">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetIncomeLoss_iT_mtCzn5E_zdgRXHPww2K4" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Net loss</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000207" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">111,779,105</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000208" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">63,779,116</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Net loss per share, basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_907_eus-gaap--EarningsPerShareBasic_pid_c20240101__20241231_zsOVLARM4Wjk" title="Net loss per share, basic" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zAA__"><span id="xdx_90C_eus-gaap--EarningsPerShareDiluted_pid_c20240101__20241231_zOocH9aNr7Bh" title="Net loss per share, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zAA__">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-01-01to2024-12-31" id="Fact000210" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-01-01to2024-12-31" id="Fact000212" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">2.83</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_903_eus-gaap--EarningsPerShareBasic_pid_c20230101__20231231_zbtQAo7nKbJk" title="Net loss per share, basic" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zAA__"><span id="xdx_909_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20231231_zFIajJRpcWd4" title="Net loss per share, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zAA__">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-01-012023-12-31" id="Fact000214" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-01-012023-12-31" id="Fact000216" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">2.69</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Weighted average common shares outstanding, basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240101__20241231_zsstoPrmTHlh" title="Weighted average common shares outstanding, basic" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zAA__"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240101__20241231_zIRdzGhwNBu" title="Weighted average common shares outstanding, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zAA__"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-01-01to2024-12-31" id="Fact000218" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-01-01to2024-12-31" id="Fact000220" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">39,449,393</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230101__20231231_zLAQGQ1IUQU4" title="Weighted average common shares outstanding, basic" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zAA__"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230101__20231231_z6DfDidQcIT4" title="Weighted average common shares outstanding, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zAA__"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-012023-12-31" id="Fact000222" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-012023-12-31" id="Fact000224" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">23,679,472</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><i>See accompanying notes to the financial statements</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>


<!-- Field: Page; Sequence: 50; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b>Celcuity Inc.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b><span id="fin_04"></span>Statements of Changes in Stockholders&#8217; Equity</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b>&#160;&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b></b></p>

<table cellpadding="0" cellspacing="0" id="xdx_30D_114_zvffmGj5YYt3" summary="xdx: Statement - Statements of Changes in Stockholders' Equity" style="font: 8pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">Shares</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B9_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zgTxgEanEZA" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">Amount</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">Shares</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B8_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_z1CwqrqNqns3" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">Amount</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B8_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zEuAHFej0YHc" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"> Capital</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4BB_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zzf1ImzEk7t1" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">Deficit</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B7_zmmeDUsLPNX7" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">Total</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">Common Stock</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">Preferred Stock</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; padding-bottom: 1pt; text-align: center">Additional <br/>
Paid-In</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; padding-bottom: 1pt; text-align: center">Accumulated</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">Shares</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">Amount</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">Shares</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">Amount</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"> Capital</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">Deficit</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">Total</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_433_c20230101__20231231_eus-gaap--StockholdersEquity_iS_zX0GoHfASZgd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 30%; font-weight: bold">Balance at December 31, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z4koEW85RvAb" title="Balance, shares" style="width: 7%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000232" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">21,667,250</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000226" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,667</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zNd8ZRExu9Qc" title="Balance, shares" style="width: 7%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember" id="Fact000234" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,120,873</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember" id="Fact000227" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,121</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000228" format="ixt:numdotdecimal" decimals="0" unitRef="USD">230,045,566</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" id="Fact000229" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">96,296,887</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" id="Fact000230" format="ixt:numdotdecimal" decimals="0" unitRef="USD">133,771,467</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensationGross_z3FRA4vZ07g9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationGross_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5QaAHxY1ZPa" title="Stock-based compensation, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000242" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,958</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000236" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0237">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000238" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,901,432</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0239">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="From2023-01-012023-12-31" id="Fact000240" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,901,434</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--StockIssuedDuringPeriodValueConversionOfPreferredToCommonStock_z8yJR2vfivPb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Conversion of preferred to common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--StockIssuedDuringPeriodSharesConversionOfPreferredToCommonStock_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zs44gpSRxT5i" title="Conversion of preferred to common stock, shares" style="text-align: right"><ix:nonFraction name="CELC:StockIssuedDuringPeriodSharesConversionOfPreferredToCommonStock" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000250" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,667,390</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:StockIssuedDuringPeriodValueConversionOfPreferredToCommonStock" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000244" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,668</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--StockIssuedDuringPeriodSharesConversionOfPreferredToCommonStock_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zbwUlWnqe5p5" title="Conversion of preferred to common stock, shares" style="text-align: right">(<ix:nonFraction name="CELC:StockIssuedDuringPeriodSharesConversionOfPreferredToCommonStock" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember" id="Fact000252" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">266,739</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="CELC:StockIssuedDuringPeriodValueConversionOfPreferredToCommonStock" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember" id="Fact000245" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">267</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="CELC:StockIssuedDuringPeriodValueConversionOfPreferredToCommonStock" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000246" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,401</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0247">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0248">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_zDdWIJNVkus9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Employee stock purchases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zo6O0m7h7rYb" title="Employee stock purchases, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000260" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">33,850</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000254" format="ixt:numdotdecimal" decimals="0" unitRef="USD">33</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0255">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000256" format="ixt:numdotdecimal" decimals="0" unitRef="USD">202,812</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0257">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="From2023-01-012023-12-31" id="Fact000258" format="ixt:numdotdecimal" decimals="0" unitRef="USD">202,845</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_zfKLXTxgHcEg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise of common stock options, net of shares withheld for exercise price</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zGJyDOt5RYg8" title="Exercise of common stock options, net of shares withheld for exercise price, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000268" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">98,695</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000262" format="ixt:numdotdecimal" decimals="0" unitRef="USD">99</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0263">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000264" format="ixt:numdotdecimal" decimals="0" unitRef="USD">388,423</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0265">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2023-01-012023-12-31" id="Fact000266" format="ixt:numdotdecimal" decimals="0" unitRef="USD">388,522</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--ExerciseOfCommonStockWarrants_iN_di_zk2UIIfD8iK6" style="vertical-align: bottom; background-color: White">
    <td>Exercise of common stock warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--ExerciseOfCommonStockSharesWarrants_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zsHAMTcKuBcf" title="Exercise of common stock warrants, shares" style="text-align: right"><ix:nonFraction name="CELC:ExerciseOfCommonStockSharesWarrants" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000276" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,369</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:ExerciseOfCommonStockWarrants" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000270" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0271">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:ExerciseOfCommonStockWarrants" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000272" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">22,503</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0273">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:ExerciseOfCommonStockWarrants" contextRef="From2023-01-012023-12-31" id="Fact000274" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">22,505</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsIssuanceWithPrivatePlacementOffering_iN_di_zvM3A3pY1AO9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance costs associated with private placement offering</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0278">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0279">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="CELC:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsIssuanceWithPrivatePlacementOffering" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000280" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,486</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0281">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="CELC:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsIssuanceWithPrivatePlacementOffering" contextRef="From2023-01-012023-12-31" id="Fact000282" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,486</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zxN86sxBaeGi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Issuance of common stock in an ATM offering</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zIf811GdV8bj" title="Issuance of common stock in an ATM offering, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000290" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,034,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000284" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,035</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0285">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000286" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,999,216</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0287">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31" id="Fact000288" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,000,251</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_iN_di_zPDTtmVLF784" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance costs associated with an ATM offering</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0292">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0293">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000294" format="ixt:numdotdecimal" decimals="0" unitRef="USD">614,205</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0295">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2023-01-012023-12-31" id="Fact000296" format="ixt:numdotdecimal" decimals="0" unitRef="USD">614,205</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_ecustom--AdditionalPaidInCapitalPreFundedWarrantIssued_z8WCa7FKEOvf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Issuance of pre-funded warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0298">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0299">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:AdditionalPaidInCapitalPreFundedWarrantIssued" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000300" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0301">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:AdditionalPaidInCapitalPreFundedWarrantIssued" contextRef="From2023-01-012023-12-31" id="Fact000302" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--IssuanceCostsAssociatedWithPrefundedWarrants_zYTTkG2JvMyf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance costs associated with pre-funded warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0304">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0305">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="CELC:IssuanceCostsAssociatedWithPrefundedWarrants" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000306" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">116,895</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0307">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="CELC:IssuanceCostsAssociatedWithPrefundedWarrants" contextRef="From2023-01-012023-12-31" id="Fact000308" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">116,895</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--NetIncomeLoss_z4YIOqrHT56g" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0310">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0311">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="Fact000313" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">63,779,116</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000314" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">63,779,116</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_43D_c20240101__20241231_eus-gaap--StockholdersEquity_iS_zV2RahdL9tG7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance at December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharesOutstanding_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zOeFOpy6jmYl" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000322" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,506,012</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000316" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,506</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharesOutstanding_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zDIOvBQwGKla" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember" id="Fact000324" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">854,134</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember" id="Fact000317" format="ixt:numdotdecimal" decimals="0" unitRef="USD">854</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000318" format="ixt:numdotdecimal" decimals="0" unitRef="USD">299,818,965</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact000319" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">160,076,003</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000320" format="ixt:numdotdecimal" decimals="0" unitRef="USD">139,769,322</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_437_c20240101__20241231_eus-gaap--StockholdersEquity_iS_zmfzpbxFtSQf" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharesOutstanding_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zOGyud3UoVw7" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000332" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,506,012</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000326" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,506</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharesOutstanding_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zypTgGJeXGhg" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember" id="Fact000334" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">854,134</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember" id="Fact000327" format="ixt:numdotdecimal" decimals="0" unitRef="USD">854</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000328" format="ixt:numdotdecimal" decimals="0" unitRef="USD">299,818,965</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact000329" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">160,076,003</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000330" format="ixt:numdotdecimal" decimals="0" unitRef="USD">139,769,322</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensationGross_zOTjNFGLhpL8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationGross_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxcybyMfT8Tk" title="Stock-based compensation, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000342" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,429</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000336" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0337">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000338" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,988,340</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0339">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="From2024-01-01to2024-12-31" id="Fact000340" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,988,341</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--StockIssuedDuringPeriodValueConversionOfPreferredToCommonStock_zLRpMMLLLExa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Conversion of preferred to common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--StockIssuedDuringPeriodSharesConversionOfPreferredToCommonStock_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2EZfaHhb4gf" title="Conversion of preferred to common stock, shares" style="text-align: right"><ix:nonFraction name="CELC:StockIssuedDuringPeriodSharesConversionOfPreferredToCommonStock" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000350" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,365,570</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:StockIssuedDuringPeriodValueConversionOfPreferredToCommonStock" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000344" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,367</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--StockIssuedDuringPeriodSharesConversionOfPreferredToCommonStock_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zhN3gaupJCi4" title="Conversion of preferred to common stock, shares" style="text-align: right">(<ix:nonFraction name="CELC:StockIssuedDuringPeriodSharesConversionOfPreferredToCommonStock" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember" id="Fact000352" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">536,557</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="CELC:StockIssuedDuringPeriodValueConversionOfPreferredToCommonStock" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember" id="Fact000345" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">536</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="CELC:StockIssuedDuringPeriodValueConversionOfPreferredToCommonStock" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000346" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,831</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0347">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0348">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_z28VD9X4vkw7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Employee stock purchases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ziduJ16LieL3" title="Employee stock purchases, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000360" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">33,215</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000354" format="ixt:numdotdecimal" decimals="0" unitRef="USD">33</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0355">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000356" format="ixt:numdotdecimal" decimals="0" unitRef="USD">275,568</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0357">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="From2024-01-01to2024-12-31" id="Fact000358" format="ixt:numdotdecimal" decimals="0" unitRef="USD">275,601</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_zOVzhsa1pxUf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise of common stock options, net of shares withheld for exercise price</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zbH0Ypvg7SOh" title="Exercise of common stock options, net of shares withheld for exercise price, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000368" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">103,245</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000362" format="ixt:numdotdecimal" decimals="0" unitRef="USD">104</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0363">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000364" format="ixt:numdotdecimal" decimals="0" unitRef="USD">769,463</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0365">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2024-01-01to2024-12-31" id="Fact000366" format="ixt:numdotdecimal" decimals="0" unitRef="USD">769,567</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--StockIssuedDuringPeriodValueStockWarrantsExercised_zFIRGRZmlnsh" style="vertical-align: bottom; background-color: White">
    <td>Exercise of common stock warrants, net of shares withheld for exercise price</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--StockIssuedDuringPeriodSharesStockWarrantsExercised_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zYsg8d1M2P66" title="Exercise of common stock warrants, net of shares withheld for exercise price, shares" style="text-align: right"><ix:nonFraction name="CELC:StockIssuedDuringPeriodSharesStockWarrantsExercised" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000376" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,827,357</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:StockIssuedDuringPeriodValueStockWarrantsExercised" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000370" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,826</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0371">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:StockIssuedDuringPeriodValueStockWarrantsExercised" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000372" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,733,991</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0373">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:StockIssuedDuringPeriodValueStockWarrantsExercised" contextRef="From2024-01-01to2024-12-31" id="Fact000374" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,735,817</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--StockIssuedDuringPeriodValueNewIssues_z2hYXmZtALUl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of common stock in an ATM offering</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zrpLePaqMMH2" title="Issuance of common stock in an ATM offering, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000384" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">435,414</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000378" format="ixt:numdotdecimal" decimals="0" unitRef="USD">435</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0379">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000380" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,641,765</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0381">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-01to2024-12-31" id="Fact000382" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,642,200</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_iN_di_zEPiiGOJj3Ja" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Issuance costs associated with an ATM offering</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0386">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0387">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000388" format="ixt:numdotdecimal" decimals="0" unitRef="USD">263,727</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0389">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2024-01-01to2024-12-31" id="Fact000390" format="ixt:numdotdecimal" decimals="0" unitRef="USD">263,727</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_ecustom--StockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts_zoaxPqCbdO72" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of common stock upon closing of follow-on offering, net of underwriting discounts and offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--StockIssuedDuringPeriodSharesIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zKarBxNtyLE7" title="Issuance of common stock upon closing of follow-on offering, net of underwriting discounts and offering costs, shares" style="text-align: right"><ix:nonFraction name="CELC:StockIssuedDuringPeriodSharesIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000398" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,871,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:StockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000392" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,871</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0393">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:StockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000394" format="ixt:numdotdecimal" decimals="0" unitRef="USD">56,248,237</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0395">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:StockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts" contextRef="From2024-01-01to2024-12-31" id="Fact000396" format="ixt:numdotdecimal" decimals="0" unitRef="USD">56,252,108</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AdjustmentsToAdditionalPaidInCapitalWarrantIssued_zjSuuARW2Swh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Issuance of common stock warrants, note payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0400">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0401">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000402" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,228,911</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0403">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2024-01-01to2024-12-31" id="Fact000404" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,228,911</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetIncomeLoss_zhvbIbjmihe1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0406">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0407">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0408">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="Fact000409" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">111,779,105</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000410" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">111,779,105</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_437_c20240101__20241231_eus-gaap--StockholdersEquity_iE_zzI1nVi8loQl" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharesOutstanding_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmQ6aHy36X25" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000418" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">37,143,242</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000412" format="ixt:numdotdecimal" decimals="0" unitRef="USD">37,143</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharesOutstanding_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_znFRGjrCNFZ7" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember" id="Fact000420" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">317,577</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember" id="Fact000413" format="ixt:numdotdecimal" decimals="0" unitRef="USD">318</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000414" format="ixt:numdotdecimal" decimals="0" unitRef="USD">387,436,682</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember" id="Fact000415" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">271,855,108</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000416" format="ixt:numdotdecimal" decimals="0" unitRef="USD">115,619,035</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_438_c20240101__20241231_eus-gaap--StockholdersEquity_iE_zcvu2eGOgNvh" style="display: none; vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharesOutstanding_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zn3AfhXvrf83" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000428" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">37,143,242</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000422" format="ixt:numdotdecimal" decimals="0" unitRef="USD">37,143</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharesOutstanding_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zf5vKh6W6HY9" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember" id="Fact000430" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">317,577</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember" id="Fact000423" format="ixt:numdotdecimal" decimals="0" unitRef="USD">318</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000424" format="ixt:numdotdecimal" decimals="0" unitRef="USD">387,436,682</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember" id="Fact000425" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">271,855,108</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000426" format="ixt:numdotdecimal" decimals="0" unitRef="USD">115,619,035</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><i>See accompanying notes to the financial statements</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>


<!-- Field: Page; Sequence: 51; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b>Celcuity Inc.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b><span id="fin_05"></span>Statements of Cash Flows</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;&#160;</b></p>

<table cellpadding="0" cellspacing="0" id="xdx_304_112_z4RO45EoALA6" summary="xdx: Statement - Statements of Cash Flows" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: center; text-indent: 0pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20240101__20241231_zvfdaVDhSJ96" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20230101__20231231_zgSjnMvqskAc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; padding-left: 0pt; text-align: center; text-indent: 0pt">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Twelve Months Ended December 31,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: center; text-indent: 0pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_z0yo34kXFuXd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; font-weight: bold; text-align: justify; text-indent: 0pt">Cash flows from operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--NetIncomeLoss_i01_maNCPBUzA3U_zSDn4Pv3mRgd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; width: 70%; text-align: justify; text-indent: 0pt">Net loss</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000435" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">111,779,105</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000436" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">63,779,116</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zAOz6sFI5hk9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: justify; text-indent: 0pt">Adjustments to reconcile net loss to net cash used for operations:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--Depreciation_i02_maNCPBUzA3U_zOYgQDRMTrR2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-align: justify; text-indent: 0pt">Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2024-01-01to2024-12-31" id="Fact000441" format="ixt:numdotdecimal" decimals="0" unitRef="USD">129,947</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2023-01-012023-12-31" id="Fact000442" format="ixt:numdotdecimal" decimals="0" unitRef="USD">142,772</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ShareBasedCompensation_i02_maNCPBUzA3U_zMg072iK5lci" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: justify; text-indent: 0pt">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-01to2024-12-31" id="Fact000444" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,988,341</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-12-31" id="Fact000445" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,901,434</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_i02_maNCPBUzA3U_zDLR9kNHNNB1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-align: justify; text-indent: 0pt">Amortization of debt issuance costs and discount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="From2024-01-01to2024-12-31" id="Fact000447" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,330,652</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="From2023-01-012023-12-31" id="Fact000448" format="ixt:numdotdecimal" decimals="0" unitRef="USD">241,752</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PaidInKindInterest_i02_maNCPBUzA3U_zq4AvKpQwj04" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: justify; text-indent: 0pt">Payment-in-Kind interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PaidInKindInterest" contextRef="From2024-01-01to2024-12-31" id="Fact000450" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,363,708</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PaidInKindInterest" contextRef="From2023-01-012023-12-31" id="Fact000451" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,810,584</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--NoncashOperatingLeaseExpenseNet_i02_maNCPBUzA3U_zbMK495t03e2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-align: justify; text-indent: 0pt">Non-cash operating lease, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="CELC:NoncashOperatingLeaseExpenseNet" contextRef="From2024-01-01to2024-12-31" id="Fact000453" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">434</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:NoncashOperatingLeaseExpenseNet" contextRef="From2023-01-012023-12-31" id="Fact000454" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,368</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--ChangeInAccruedInterestIncome_i02N_di_msNCPBUzA3U_zBU2TCNB3K97" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: justify; text-indent: 0pt">Change in accrued interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:ChangeInAccruedInterestIncome" contextRef="From2024-01-01to2024-12-31" id="Fact000456" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">150,421</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="CELC:ChangeInAccruedInterestIncome" contextRef="From2023-01-012023-12-31" id="Fact000457" format="ixt:numdotdecimal" decimals="0" unitRef="USD">993,457</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B_ztrWJF6d5N77" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; text-align: justify; text-indent: 0pt">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--IncreaseDecreaseInOtherCurrentAssets_i03N_di_msNCPBUzA3U_zAiwrQx8Gt07" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: justify; text-indent: 0pt">Other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" contextRef="From2024-01-01to2024-12-31" id="Fact000462" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">775,981</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" contextRef="From2023-01-012023-12-31" id="Fact000463" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,438,018</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--IncreaseDecreaseInAccountsPayable_i03_maNCPBUzA3U_z0qAbuQAi74f" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-align: justify; text-indent: 0pt">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2024-01-01to2024-12-31" id="Fact000465" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,315,892</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2023-01-012023-12-31" id="Fact000466" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,430,614</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--IncreaseDecreaseInAccruedLiabilities_i03_maNCPBUzA3U_zOChBxtn2rqa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: justify; padding-bottom: 1pt; text-indent: 0pt">Accrued expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2024-01-01to2024-12-31" id="Fact000468" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,257,854</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2023-01-012023-12-31" id="Fact000469" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,866,814</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_mtNCPBUzA3U_maCCERCzxA5_zqkBV5JKH7Bh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.375in; text-align: justify; padding-bottom: 1pt; text-indent: 0pt">Net cash used for operating activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-01-01to2024-12-31" id="Fact000471" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">83,466,743</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-01-012023-12-31" id="Fact000472" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">53,812,253</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zv1BTP8rPFGb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; font-weight: bold; text-align: justify; text-indent: 0pt">Cash flows from investing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ProceedsFromSaleAndMaturityOfOtherInvestments_i01_maNCPBUztw7_z1XhAYJd2hd5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; text-align: justify; text-indent: 0pt">Proceeds from maturities of investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments" contextRef="From2024-01-01to2024-12-31" id="Fact000477" format="ixt:numdotdecimal" decimals="0" unitRef="USD">642,345,545</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments" contextRef="From2023-01-012023-12-31" id="Fact000478" format="ixt:numdotdecimal" decimals="0" unitRef="USD">309,614,521</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PaymentsToAcquireInvestments_i01N_di_msNCPBUztw7_zoUAYAzctHY9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: justify; text-indent: 0pt">Purchases of investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireInvestments" contextRef="From2024-01-01to2024-12-31" id="Fact000480" format="ixt:numdotdecimal" decimals="0" unitRef="USD">705,164,950</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireInvestments" contextRef="From2023-01-012023-12-31" id="Fact000481" format="ixt:numdotdecimal" decimals="0" unitRef="USD">314,525,084</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_di_msNCPBUztw7_zD40xBO9spN1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; text-align: justify; padding-bottom: 1pt; text-indent: 0pt">Purchases of property and equipment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2024-01-01to2024-12-31" id="Fact000483" format="ixt:numdotdecimal" decimals="0" unitRef="USD">249,878</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2023-01-012023-12-31" id="Fact000484" format="ixt:numdotdecimal" decimals="0" unitRef="USD">97,644</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_mtNCPBUztw7_maCCERCzxA5_zBWMC8lPEqDi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.375in; text-align: justify; padding-bottom: 1pt; text-indent: 0pt">Net cash used for investing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2024-01-01to2024-12-31" id="Fact000486" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">63,069,283</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2023-01-012023-12-31" id="Fact000487" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,008,207</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_z8fSclKhNVxk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; font-weight: bold; text-align: justify; text-indent: 0pt">Cash flows from financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--ProceedsFromWarrantExercises_i01_maNCPBUzW8h_zFmkUtBvRhy2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: justify; text-indent: 0pt">Proceeds from exercise of common stock warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2024-01-01to2024-12-31" id="Fact000492" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,735,817</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2023-01-012023-12-31" id="Fact000493" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,505</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ProceedsFromStockOptionsExercised_i01_maNCPBUzW8h_zJAiHhUo9Xc8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; text-align: justify; text-indent: 0pt">Proceeds from exercise of employee stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2024-01-01to2024-12-31" id="Fact000495" format="ixt:numdotdecimal" decimals="0" unitRef="USD">769,571</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2023-01-012023-12-31" id="Fact000496" format="ixt:numdotdecimal" decimals="0" unitRef="USD">388,522</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ProceedsFromStockPlans_i01_maNCPBUzW8h_zyTRbjF5tFC" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: justify; text-indent: 0pt">Proceeds from employee stock purchases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromStockPlans" contextRef="From2024-01-01to2024-12-31" id="Fact000498" format="ixt:numdotdecimal" decimals="0" unitRef="USD">275,601</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromStockPlans" contextRef="From2023-01-012023-12-31" id="Fact000499" format="ixt:numdotdecimal" decimals="0" unitRef="USD">202,845</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ProceedsFromOtherEquity_i01_maNCPBUzW8h_zkL9Ubt73v7k" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; text-align: justify; text-indent: 0pt">Proceeds from follow-on offering, net of underwriting discounts and offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromOtherEquity" contextRef="From2024-01-01to2024-12-31" id="Fact000501" format="ixt:numdotdecimal" decimals="0" unitRef="USD">56,252,108</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0502">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ProceedsFromDebtNetOfIssuanceCosts_i01_maNCPBUzW8h_z5Jmc5BngwAd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: justify; text-indent: 0pt">Proceeds from note payable, net of debt issuance costs and discount of $<span id="xdx_908_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumNet_iI_c20241231_z17zjuM3hojl" title="Debt issuance costs and discount"><ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet" contextRef="AsOf2024-12-31" id="Fact000507" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,437,644</ix:nonFraction></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" contextRef="From2024-01-01to2024-12-31" id="Fact000504" format="ixt:numdotdecimal" decimals="0" unitRef="USD">59,226,276</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0505">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--ProceedsFromAtmOfferingNetOfIssuanceCosts_i01_maNCPBUzW8h_zJUBStL0SzZh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; text-align: justify; text-indent: 0pt">Proceeds from an ATM offering, net of issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:ProceedsFromAtmOfferingNetOfIssuanceCosts" contextRef="From2024-01-01to2024-12-31" id="Fact000509" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,356,107</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:ProceedsFromAtmOfferingNetOfIssuanceCosts" contextRef="From2023-01-012023-12-31" id="Fact000510" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,431,186</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--ProceedsFromIssuanceOfWarrants_i01_pp0p0_maNCPBUzW8h_zEO7n2RmkYv4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: justify; text-indent: 0pt">Proceeds from pre-funded warrants, net of offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0512">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="From2023-01-012023-12-31" id="Fact000513" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">49,917,589</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--PaymentsForSecondaryRegistrationStatementCosts_i01N_di_msNCPBUzW8h_zpgJLjnXKn78" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; text-align: justify; text-indent: 0pt">Payments for secondary registration statement costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="CELC:PaymentsForSecondaryRegistrationStatementCosts" contextRef="From2024-01-01to2024-12-31" id="Fact000515" format="ixt:numdotdecimal" decimals="0" unitRef="USD">227,405</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="CELC:PaymentsForSecondaryRegistrationStatementCosts" contextRef="From2023-01-012023-12-31" id="Fact000516" format="ixt:numdotdecimal" decimals="0" unitRef="USD">45,805</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--PaymentsOfDebtIssuanceCosts_i01N_di_msNCPBUzW8h_zJTjREfAyKE3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: justify; text-indent: 0pt">Payments for debt issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0518">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsOfDebtIssuanceCosts" contextRef="From2023-01-012023-12-31" id="Fact000519" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,716</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--FinanceLeasePrincipalPayments_i01N_di_msNCPBUzW8h_zHFl0seNZTnf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; text-align: justify; padding-bottom: 1pt; text-indent: 0pt">Payments for finance leases</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0521">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FinanceLeasePrincipalPayments" contextRef="From2023-01-012023-12-31" id="Fact000522" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,449</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_mtNCPBUzW8h_maCCERCzxA5_zvHRwBYPIuc8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.375in; text-align: justify; padding-bottom: 1pt; text-indent: 0pt">Net cash provided by financing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2024-01-01to2024-12-31" id="Fact000524" format="ixt:numdotdecimal" decimals="0" unitRef="USD">138,388,075</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2023-01-012023-12-31" id="Fact000525" format="ixt:numdotdecimal" decimals="0" unitRef="USD">64,911,677</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_iT_mtCCERCzxA5_zxWQ0S1Pt5a8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; text-align: justify; text-indent: 0pt">Net change in cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2024-01-01to2024-12-31" id="Fact000527" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,147,951</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2023-01-012023-12-31" id="Fact000528" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,091,217</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--CashAndCashEquivalentsAbstract_iB_z1mz7Z3IbJWk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; font-weight: bold; text-align: justify; text-indent: 0pt">Cash and cash equivalents:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_i01S_zPCd0jBUPkh2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; text-align: justify; padding-bottom: 1pt; text-indent: 0pt">Beginning of period</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2023-12-31" id="Fact000533" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,662,774</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-12-31" id="Fact000534" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,571,557</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_i01E_zM7fGGXltTWj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: justify; padding-bottom: 2.5pt; text-indent: 0pt">End of period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2024-12-31" id="Fact000536" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,514,823</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2023-12-31" id="Fact000537" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,662,774</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; text-align: justify; text-indent: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>

<tr id="xdx_40E_eus-gaap--SupplementalCashFlowInformationAbstract_iB_z8UtRYLZpT07" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Supplemental disclosure of cash flow information:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--InterestPaidNet_i01_z2pTuNx0vrS3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Interest paid</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2024-01-01to2024-12-31" id="Fact000542" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,586,084</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2023-01-012023-12-31" id="Fact000543" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,274,051</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_iB_z7VtT0Qktaw7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Supplemental disclosures of non-cash investing and financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--DeferredFinancingCostsAndOfferingAndRegistrationStatementCostsIncludedInAccountsPayable_i01_zQIVCCdLkNd1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Deferred financing costs and offering and registration statement costs included in accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="CELC:DeferredFinancingCostsAndOfferingAndRegistrationStatementCostsIncludedInAccountsPayable" contextRef="From2024-01-01to2024-12-31" id="Fact000548" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,028</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="CELC:DeferredFinancingCostsAndOfferingAndRegistrationStatementCostsIncludedInAccountsPayable" contextRef="From2023-01-012023-12-31" id="Fact000549" format="ixt:numdotdecimal" decimals="0" unitRef="USD">56,414</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--PropertyAndEquipmentIncludedInAccountsPayable_i01_z8FSnf9EMcek" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Property and equipment included in accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="CELC:PropertyAndEquipmentIncludedInAccountsPayable" contextRef="From2024-01-01to2024-12-31" id="Fact000551" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,417</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="CELC:PropertyAndEquipmentIncludedInAccountsPayable" contextRef="From2023-01-012023-12-31" id="Fact000552" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,615</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--CommonStockWarrantsIssuedWithNotePayableTransaction_i01_zFtWu9hVDxJ9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Common stock warrants issued with the note payable transaction</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="CELC:CommonStockWarrantsIssuedWithNotePayableTransaction" contextRef="From2024-01-01to2024-12-31" id="Fact000554" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,228,911</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0555">-</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><i>See accompanying notes to the financial statements</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>


<!-- Field: Page; Sequence: 52; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;<b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b>CELCUITY INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b><span id="fin_06"></span>NOTES TO FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000557" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><p id="xdx_80C_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zkK9dFmkB548" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"> <b>1.</b> <b><span id="xdx_829_znHvbdCz6Xc6">Organization</span></b></p>



<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><span style="text-decoration: underline">Nature of Business</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">Celcuity Inc., a Delaware corporation (the &#8220;Company&#8221;) is a
clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid tumor indications.
The Company&#8217;s lead therapeutic candidate is gedatolisib, a potent, well-tolerated, small molecule reversible inhibitor, administered
intravenously, that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (&#8220;PI3K&#8221;) and the two mechanistic
targets of rapamycin (&#8220;mTOR&#8221;) sub-complexes, mTORC1 and mTORC2. Gedatolisib&#8217;s mechanism of action and pharmacokinetic
properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together.
A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with
HR+/HER2- advanced breast cancer is currently enrolling patients. Site selection and activation activities for a Phase 3 clinical trial,
VIKTORIA-2, evaluating gedatolisib in combination with a CDK4/6 inhibitor and fulvestrant as first-line treatment for patients with HR+/HER2-
advanced breast cancer has commenced. The first patient is expected to be dosed in the second quarter of 2025. A Phase 1b/2 clinical trial,
CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer,
is currently underway. The Company was co-founded in 2012 by Brian F. Sullivan and Dr. Lance G. Laing and is based in Minnesota. The Company
has not generated any revenues to date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000559" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"><p id="xdx_800_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zlI0nJT6ysn7" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"> <b>2.</b> <b><span id="xdx_826_zryuu22buLa6">Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements</span></b></p>



<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000561" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_846_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zqle3EpLCqti" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><span style="text-decoration: underline"><span id="xdx_86F_zfvrrS2Urjua">Basis of Presentation</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="background-color: white">The accompanying financial statements
have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;) and pursuant
to the rules and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;). Operating results for the year ended December
31, 2024 are not necessarily indicative of results to be expected for any future year.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000563" name="us-gaap:UseOfEstimates"><p id="xdx_842_eus-gaap--UseOfEstimates_zqYd2kAzJWZ7" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_86E_zTnkypDHItge">Accounting Estimates</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 2.15pt 0 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 2.15pt 0 0">Management uses estimates and assumptions in preparing these
financial statements in accordance with U.S. GAAP. Those estimates and assumptions affect the reported amounts of assets and liabilities,
the disclosure of contingent assets and liabilities, and the reported revenues and expenses. Actual results could differ from those estimates
and the difference could be material. Significant items subject to such estimates and assumptions include the valuation of stock-based
compensation and prepaid or accrued clinical trial costs.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000565" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_84F_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zs41NFVAgjWa" style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="text-decoration: underline"><span id="xdx_862_zBSE7imawy8h">Cash and Cash Equivalents</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 2.15pt 0 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 2.15pt 0 0">The Company maintains its accounts at two financial institutions.
At times throughout the year, the Company&#8217;s cash balances may exceed amounts insured by the Federal Deposit Insurance Corporation.
At December 31, 2024 and December 31, 2023, the Company had $<span id="xdx_90D_eus-gaap--CashFDICInsuredAmount_iI_c20241231_zKYFJ5FLHDC3" title="Cash equivalents FDIC insured, amount"><ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="AsOf2024-12-31" id="Fact000567" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,514,823</ix:nonFraction></span> and $<span id="xdx_909_eus-gaap--CashFDICInsuredAmount_iI_c20231231_zdbbCz0ZDuN3" title="Cash equivalents FDIC insured, amount"><ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="AsOf2023-12-31" id="Fact000569" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,662,774</ix:nonFraction></span>, respectively, in business checking accounts and
money market funds that are considered cash equivalents and not insured by the Federal Deposit Insurance Corporation.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000571" name="us-gaap:InvestmentPolicyTextBlock"><p id="xdx_84F_eus-gaap--InvestmentPolicyTextBlock_zZcCsrawuJQe" style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="text-decoration: underline"><span id="xdx_86C_zVP5ib2lPBri">Investments</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 2.15pt 0 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 2.15pt 0 0">The Company maintains its investments in U.S. governmental agency
securities and U.S. treasury bills and has classified them as held-to-maturity at the time of purchase. Held-to-maturity purchases are
those securities in which the Company has the ability and intent to hold until maturity. Held-to-maturity securities are recorded at amortized
cost, adjusted for the amortization or accretion of premiums and discounts. Premiums and discounts are amortized or accreted over the
life of the related held-to-maturity security using a straight-line method. The difference between the carrying value, which is based
on cost, and the aggregate fair value of the held-to-maturity securities, was immaterial as of December 31, 2024. At December 31, 2024
and December 31, 2023, the Company had $<span id="xdx_902_eus-gaap--ShortTermInvestments_iI_c20241231_zeScxzKuWOu3" title="Short-term investments"><ix:nonFraction name="us-gaap:ShortTermInvestments" contextRef="AsOf2024-12-31" id="Fact000573" format="ixt:numdotdecimal" decimals="0" unitRef="USD">212,588,960</ix:nonFraction></span> and $<span id="xdx_904_eus-gaap--ShortTermInvestments_iI_c20231231_zqV7aaEms22i" title="Short-term investments"><ix:nonFraction name="us-gaap:ShortTermInvestments" contextRef="AsOf2023-12-31" id="Fact000575" format="ixt:numdotdecimal" decimals="0" unitRef="USD">149,919,974</ix:nonFraction></span>, respectively, of short-term investments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 53; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000577" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p id="xdx_84A_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zErkpyNvmfA4" style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="text-decoration: underline"><span id="xdx_869_zcPUi34VFRg">Property and Equipment</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 2.15pt 0 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Property and equipment are stated at cost. Depreciation is provided
over estimated useful lives using the straight-line method. Maintenance and repairs are expensed as incurred; major improvements and betterments
are capitalized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000579" name="CELC:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock"><p id="xdx_89B_ecustom--ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock_zbXmEHbRuoxi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Estimated useful lives of property and equipment are as follows for the
major classes of assets:</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.6in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B2_zvVaDreWGHl2" style="display: none">Schedule of Estimated Useful Lives of Property and Equipment</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 84%; margin-right: auto">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">Estimated</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; width: 85%; font-weight: bold; text-align: justify">Asset Description</td><td style="padding-bottom: 1pt; width: 1%; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 14%; font-weight: bold; text-align: center">Lives</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Furniture and Equipment</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_za2Cizkodqzb" title="Estimated useful lives"><ix:nonNumeric contextRef="AsOf2024-12-31_srt_MinimumMember_us-gaap_FurnitureAndFixturesMember" format="ixt-sec:duryear" id="Fact000581" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">4</ix:nonNumeric></span>-<span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zoToZonzLH2l" title="Estimated useful lives"><ix:nonNumeric contextRef="AsOf2024-12-31_srt_MaximumMember_us-gaap_FurnitureAndFixturesMember" format="ixt-sec:duryear" id="Fact000583" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Leasehold Improvements</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zwNRQRUPKqkj" title="Estimated useful lives"><ix:nonNumeric contextRef="AsOf2024-12-31_srt_MinimumMember_us-gaap_LeaseholdImprovementsMember" format="ixt-sec:duryear" id="Fact000585" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">2</ix:nonNumeric></span>-<span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zjy5QdetKmE2" title="Estimated useful lives"><ix:nonNumeric contextRef="AsOf2024-12-31_srt_MaximumMember_us-gaap_LeaseholdImprovementsMember" format="ixt-sec:duryear" id="Fact000587" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">3</ix:nonNumeric></span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_ziLDoGxeSjz5" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.6in">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000589" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"><p id="xdx_846_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zUrX149Fdpnj" style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="text-decoration: underline"><span id="xdx_862_zXjBiAbWKt3e">Long-Lived Assets</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">Long-lived assets, such as property and equipment, are reviewed for impairment
whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require
a long-lived asset or asset group be tested for possible impairment, the Company first compares undiscounted cash flows expected to be
generated by that asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group is not recoverable
on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying value exceeds its fair value. Fair value
is determined through various valuation techniques including discounted cash flow models, quoted market values, and third-party independent
appraisals, as considered necessary.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000591" name="us-gaap:DeferredChargesPolicyTextBlock"><p id="xdx_845_eus-gaap--DeferredChargesPolicyTextBlock_zLw1ZX7RHbof" style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="text-decoration: underline"><span id="xdx_861_zc3C9lJETGe7">Deferred Transaction Costs</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">Deferred transaction costs primarily consist of legal fees that are capitalized
as incurred and will be offset against the proceeds from future equity financing arrangements. The deferred transaction costs will be
reviewed periodically to assess the probability that future securities will be offered. In the event that no future offering will occur,
any deferred transaction costs will be expensed. Total costs incurred, but not accounted for as a reduction in equity, were $<span id="xdx_902_eus-gaap--DeferredCostsCurrent_iI_c20241231_znLH97VNiqpa" title="Deferred transaction costs"><ix:nonFraction name="us-gaap:DeferredCostsCurrent" contextRef="AsOf2024-12-31" id="Fact000593" format="ixt:numdotdecimal" decimals="0" unitRef="USD">235,379</ix:nonFraction></span> and
$<span id="xdx_900_eus-gaap--DeferredCostsCurrent_iI_c20231231_zSoIRAfiqV2" title="Deferred transaction costs"><ix:nonFraction name="us-gaap:DeferredCostsCurrent" contextRef="AsOf2023-12-31" id="Fact000595" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> as of December 31, 2024 and 2023, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000597" name="us-gaap:DebtPolicyTextBlock"><p id="xdx_845_eus-gaap--DebtPolicyTextBlock_zIQrsrmEItuc" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><span style="text-decoration: underline"><span id="xdx_862_zWjiikqHPfM1">Debt Issuance Costs</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">The Company recognizes debt issuance costs as deferred costs, which are
capitalized and amortized over the term of the related debt using the effective interest method. These costs primarily consist of fees,
commissions, legal, and other costs directly attributable to securing debt financing. Debt issuance costs are reported as a direct reduction
of the carrying amount of the related debt on the balance sheets. Amortization of these costs is recorded as interest expense in the statements
of operations over the life of the debt instrument.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000599" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock"><p id="xdx_840_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zFOlTBRBCjeh" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><span style="text-decoration: underline"><span id="xdx_865_zapig2q36X4b">Comprehensive Loss</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">Comprehensive loss includes net loss as well as other changes in stockholders&#8217;
equity that result from transactions and economic events other than those with stockholders. For all periods presented, there was no difference
between net loss and comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000601" name="us-gaap:ConcentrationRiskCreditRisk"><p id="xdx_846_eus-gaap--ConcentrationRiskCreditRisk_zoGHHydaSJ1g" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><span style="text-decoration: underline"><span id="xdx_860_zimzFr8eXqGb">Risks and Uncertainties</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">The Company is subject to risks common to companies in the development
stage including, but not limited to, dependency on the clinical and commercial success of its initial drug product, gedatolisib, the ability
to obtain regulatory approval for gedatolisib, the need for substantial additional financing to achieve its goals, uncertainty of broad
adoption of its approved products, if any, by physicians and consumers, and significant competition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000603" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_840_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zzWZPOiyddAl" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><span style="text-decoration: underline"><span id="xdx_860_zVnMYaSQNEed">Fair Value of Financial Instruments</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 5.75pt 0 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The Company&#8217;s accounting for fair value measurements of
assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring or nonrecurring basis
adheres to the Financial Accounting Standards Board (&#8220;FASB&#8221;) fair value hierarchy that prioritizes the inputs to valuation
techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical
assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level
3 measurements). The three levels of the fair value hierarchy are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 5.85pt 0 41pt; text-indent: -0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.5in; text-align: left">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Level
1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the Company at the measurement
date.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 5.95pt 0 41pt; text-indent: -0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.5in; text-align: left">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Level
2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly,
for substantially the full term of the asset or liability.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 5.8pt 0 41pt; text-indent: -0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.5in; text-align: left">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Level
3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available,
thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date.</span></td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 54; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The level in the fair value hierarchy within which a fair value
measurement in its entirety falls, is based on the lowest level input that is significant to the fair value measurement in its entirety.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 5.95pt 0 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The carrying values of cash equivalents, accounts payable, accrued
expenses and other financial working capital items approximate fair value at December 31, 2024 and December 31, 2023, due to the short
maturity nature of these items.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000605" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_845_eus-gaap--IncomeTaxPolicyTextBlock_z8vEUxHWNSgh" style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="text-decoration: underline"><span id="xdx_866_zgynWj3fZcYb">Income Taxes</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">The Company accounts for income taxes using the asset and liability method,
as required by the accounting standard for income taxes. Under this method, deferred tax assets and liabilities are recognized for the
future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities
and their respective tax bases, as well as net operating loss and tax credit carryforwards. Deferred taxes are measured using enacted
tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.
The effect on deferred taxes of a change in tax rates is recognized in results of operations in the period that includes the enactment
date. The effects of any future changes in tax laws or rates have not been considered. The Company regularly reviews deferred tax assets
to assess their potential realization and establish a valuation allowance for portions of such assets to reduce the carrying value if
the Company does not consider it to be more likely than not that the deferred tax assets will be realized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">The Company recognizes the impact of an uncertain tax position in its financial
statements if, in management&#8217;s judgment, the position is more-likely-than-not sustainable upon audit based on the position&#8217;s
technical merits. This involves the identification of potential uncertain tax positions, the evaluation of applicable tax laws and an
assessment of whether a liability for an uncertain tax position is necessary.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000607" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy"><p id="xdx_847_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zeKwV8b1dP64" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><span style="text-decoration: underline"><span id="xdx_866_zBXECk6Wy7Bj">Stock-Based Compensation</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 2.15pt 0 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 2.15pt 0 0">The Company&#8217;s stock-based compensation consists of stock
options and restricted stock issued to certain employees and non-employees of the Company and the Company&#8217;s 2017 Employee Stock
Purchase Plan. The Company recognizes compensation expense based on an estimated grant date fair value using the Black-Scholes option-pricing
method for equity-based awards and the Monte Carlo simulation model for performance-based awards. If the factors change and different
assumptions are used, the Company&#8217;s stock-based compensation expense could be materially different in the future. The Company recognizes
stock-based compensation expense for these options on a straight-line basis over the requisite service period. The Company has elected
to account for forfeitures as they occur.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000609" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_843_eus-gaap--ResearchAndDevelopmentExpensePolicy_zvGCg70bmtpj" style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="text-decoration: underline"><span id="xdx_864_z3XHAIp3vYBc">Research and Development</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">Research and development costs are expensed as incurred. Research and development
costs amounted to $<span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20241231_zxOzlJ7CAvLe" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000611" format="ixt:numdotdecimal" decimals="0" unitRef="USD">104,203,230</ix:nonFraction></span> for the year ended December 31, 2024 and $<span id="xdx_900_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231_zck4ehiBYfJ" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31" id="Fact000613" format="ixt:numdotdecimal" decimals="0" unitRef="USD">60,594,005</ix:nonFraction></span> for the year ended December 31, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000615" name="us-gaap:InProcessResearchAndDevelopmentPolicy"><p id="xdx_84E_eus-gaap--InProcessResearchAndDevelopmentPolicy_zKtIk5RQdI77" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><span style="text-decoration: underline"><span id="xdx_862_zcho2GdqM904">Clinical Trial Costs</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">The Company relies on third parties to conduct
certain aspects of clinical studies and to formulate and manufacture our drug product. While there are alternative vendors that can
perform these functions, any disruption or delay by the Company&#8217;s current third parties in carrying out their contractual
duties could delay the clinical trials. The Company records prepaid assets or accrued expenses for prepaid or estimated clinical
trial costs conducted by third-party service providers, which includes the conduct of preclinical studies and clinical trials. These
costs can be a significant component of the Company&#8217;s research and development expenses. The Company primarily relies on a
compilation of progress reports from third-party service providers, including the respective invoicing, to record actual expenses,
along with determining changes to prepaid assets and accrued liabilities. To date, the Company believes utilization of third-party
reports most accurately reflects expenses incurred. With the ongoing VIKTORIA-1 Phase 3 trial and the CELC-G-201 Phase 1b/2 trial,
and the commencement of the VIKTORIA-2 Phase 3 clinical trial site activation and patient enrollment anticipated in Q2 2025<span style="font-size: 10pt">,</span>
the Company&#8217;s estimated expenses in future periods and actual services performed may vary from these estimates, and these
estimates may become more significant. Changes in these estimates that result in material changes to the Company&#8217;s prepaid
assets or accrued expenses could materially affect the Company&#8217;s results of operations and financial position.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000617" name="us-gaap:SegmentReportingPolicyPolicyTextBlock"><p id="xdx_841_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zASjcBnZart7" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><span style="text-decoration: underline"><span id="xdx_867_zAWp6ew8cnbi">Segment Data</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">In November 2023, the FASB issued ASU 2023-07: Improvements to Reportable
Segment Disclosures. This ASU, which amends Topic 280: <i>Segment Reporting,</i> improves disclosure requirements for reportable segments
and enhances disclosures for companies with single reportable segments. The Company has a single reportable segment based on the nature
of its operations. The nature of business and the accounting policies of the segment are the same as described throughout Notes 1 and
2. The Company&#8217;s Chief Operating Decision Maker (&#8220;CODM&#8221;) is its executive team. The CODM assesses the reportable segment&#8217;s performance
and allocates resources for the reportable segment based on net income and total assets, which are the same amounts in all material respects
as those reported on the statements of operations and balance sheets. The Company adopted the standard on January 1, 2024. The adoption
did not have a material impact on the Company&#8217;s financial statements.</p>

</ix:nonNumeric><p id="xdx_856_z4iFfU2SxhT3" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 55; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000619" name="us-gaap:SubstantialDoubtAboutGoingConcernTextBlock"><p id="xdx_80C_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_z0ZFGxAR4GLj" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"> <b>3.</b> <b><span id="xdx_822_zLpUqUXslu48">Liquidity</span></b></p>



<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">Based on the Company&#8217;s cash and cash equivalents and short-term investments
on hand at December 31, 2024 of $<span id="xdx_900_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20241231_zRw1Bj5a73Aj" title="Cash and cash equivalents"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2024-12-31" id="Fact000621" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,514,823</ix:nonFraction></span> and $<span id="xdx_902_eus-gaap--ShortTermInvestments_iI_c20241231_zf8nTGzmfy1d" title="Short-term investments"><ix:nonFraction name="us-gaap:ShortTermInvestments" contextRef="AsOf2024-12-31" id="Fact000623" format="ixt:numdotdecimal" decimals="0" unitRef="USD">212,588,960</ix:nonFraction></span>, respectively, the Company believes that its cash and short-term investments
will be sufficient to fund the Company&#8217;s current operating plan through at least the next 12 months from the issuance date of this
Annual Report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000625" name="us-gaap:EarningsPerShareTextBlock"><p id="xdx_808_eus-gaap--EarningsPerShareTextBlock_ztLssPXQLrA5" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"> <b>4.</b> <b><span id="xdx_82C_zPsfjWKgtLxh">Net Loss Per Common Share</span></b></p>



<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">Basic and diluted net loss per common share is determined by dividing net
loss attributable to common stockholders by the weighted-average common shares outstanding during the period. For all periods presented,
the common shares underlying the preferred stock, options, warrants, and restricted stock have been excluded from the calculation because
their effect would be anti-dilutive. Therefore, the weighted-average shares outstanding used to calculate both basic and diluted loss
per common share are the same.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000627" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"><p id="xdx_895_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zCuI9maWij26" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes the potentially-dilutive shares excluded
from the diluted weighted-average shares outstanding:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B2_zsg6iauW7oD" style="display: none">Schedule of Potentially-Dilutive Shares Excluded from the Diluted Weighted-Average Shares Outstanding</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20240101__20241231_zofYC9DpIg31" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20230101__20231231_zPlGbIJe3Srk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--EarningsPerShareDilutedOtherDisclosuresAbstract_iB_zK5U31WUGCoh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Potentially-dilutive shares excluded from diluted weighted-average shares outstanding:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--StatementEquityComponentsAxis__custom--PreferredStockOnAnAsIfConvertedToCommonStockMember_zfg4f3aaJtE8" style="vertical-align: bottom; background-color: White">
    <td style="width: 68%; text-align: justify; text-indent: 0pt; padding-left: 20pt">Preferred stock on an as-if-converted to common stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_custom_PreferredStockOnAnAsIfConvertedToCommonStockMember" id="Fact000632" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,175,770</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_custom_PreferredStockOnAnAsIfConvertedToCommonStockMember" id="Fact000633" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,541,340</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsToPurchaseCommonStockMember_zvdpJd90xmai" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: 0pt; padding-left: 20pt">Options to purchase common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_custom_OptionsToPurchaseCommonStockMember" id="Fact000635" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,306,977</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_custom_OptionsToPurchaseCommonStockMember" id="Fact000636" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,815,392</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseCommonStockMember_zJErXOX8mBe3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: 0pt; padding-left: 20pt">Warrants to purchase common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_custom_WarrantsToPurchaseCommonStockMember" id="Fact000638" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,521,152</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_custom_WarrantsToPurchaseCommonStockMember" id="Fact000639" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,263,733</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_zQ1WuGg1Brne" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 0pt; text-indent: 0pt; padding-left: 20pt">Restricted common stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockMember" id="Fact000641" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,079</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockMember" id="Fact000642" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,958</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zxL8MHByRdU7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 0pt; text-indent: 0pt; padding-left: 10pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-01to2024-12-31" id="Fact000644" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,004,978</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31" id="Fact000645" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">18,622,423</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_z2UeiMuqyUJd" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 0pt; text-indent: 0pt; padding-left: 10pt">Anti-dilutive securities excluded from
    diluted weighted- average shares outstanding</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-01to2024-12-31" id="Fact000647" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,004,978</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31" id="Fact000648" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">18,622,423</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


</ix:nonNumeric><p id="xdx_8AC_zZQ7HsPeDVT2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">Pre-funded warrant shares of <span id="xdx_90C_ecustom--PrefundedWarrantShares_iI_c20241231_zJYxKIAPfTj6" title="Pre-funded warrant shares"><span id="xdx_907_ecustom--PrefundedWarrantShares_iI_c20231231_zpkA2iVop4qg" title="Pre-funded warrant shares"><ix:nonFraction name="CELC:PrefundedWarrantShares" contextRef="AsOf2024-12-31" id="Fact000650" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="CELC:PrefundedWarrantShares" contextRef="AsOf2023-12-31" id="Fact000652" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,747,787</ix:nonFraction></ix:nonFraction></span></span> are included in the computation
of basic and diluted net loss per share for the years ended December 31, 2024 and 2023, as the pre-funded warrants are issuable for nominal
consideration.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000654" name="us-gaap:InvestmentTextBlock"><p id="xdx_80F_eus-gaap--InvestmentTextBlock_zfn6QW5wgbd1" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"> <b>5.</b> <b><span id="xdx_822_zFpVbHn6lS2">Investments</span></b></p>



<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000656" name="us-gaap:InvestmentTableTextBlock"><p id="xdx_89F_eus-gaap--InvestmentTableTextBlock_zCCqsRWlGsz4" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">The following table summarizes the Company&#8217;s held-to-maturity investment
securities at amortized cost as of December 31, 2024 and 2023:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B1_zjh6YZbQciIj" style="display: none">Schedule of Investment</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_48F_eus-gaap--HeldToMaturitySecurities_iI_zY95Wjuj9ZT9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amortized Cost, as Adjusted</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_489_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_iI_zDtVvdKS6E7j" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Gross Unrealized Holding Gains</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_48C_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_iI_zzFiqM32a51g" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Gross Unrealized Holding Losses</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_482_eus-gaap--HeldToMaturitySecuritiesFairValue_iI_zzI3b8XK0XTj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Estimated Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amortized Cost, as Adjusted</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Gross Unrealized Holding Gains</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Gross Unrealized Holding Losses</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Estimated Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_412_20241231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zLcyrLP42a6c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: justify; padding-bottom: 1pt; text-indent: 0pt">U.S. Treasury Bills</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><ix:nonFraction name="us-gaap:HeldToMaturitySecurities" contextRef="AsOf2024-12-31_us-gaap_USTreasurySecuritiesMember" id="Fact000657" format="ixt:numdotdecimal" decimals="0" unitRef="USD">212,588,960</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><ix:nonFraction name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" contextRef="AsOf2024-12-31_us-gaap_USTreasurySecuritiesMember" id="Fact000658" format="ixt:numdotdecimal" decimals="0" unitRef="USD">82,251</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0659">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><ix:nonFraction name="us-gaap:HeldToMaturitySecuritiesFairValue" contextRef="AsOf2024-12-31_us-gaap_USTreasurySecuritiesMember" id="Fact000660" format="ixt:numdotdecimal" decimals="0" unitRef="USD">212,671,211</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_41D_20241231_zYVPzrbFP6sh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: 0pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:HeldToMaturitySecurities" contextRef="AsOf2024-12-31" id="Fact000661" format="ixt:numdotdecimal" decimals="0" unitRef="USD">212,588,960</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" contextRef="AsOf2024-12-31" id="Fact000662" format="ixt:numdotdecimal" decimals="0" unitRef="USD">82,251</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0663">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:HeldToMaturitySecuritiesFairValue" contextRef="AsOf2024-12-31" id="Fact000664" format="ixt:numdotdecimal" decimals="0" unitRef="USD">212,671,211</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_48F_eus-gaap--HeldToMaturitySecurities_iI_zQN0gpxq8gjk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amortized Cost, as Adjusted</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_48D_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_iI_zmcNOsJuEX0d" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Gross Unrealized Holding Gains</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_489_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_iI_zoua8HzmLeGd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Gross Unrealized Holding Losses</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_487_eus-gaap--HeldToMaturitySecuritiesFairValue_iI_zeXoWJsBIjm6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Estimated Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amortized Cost, as Adjusted</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Gross Unrealized Holding Gains</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Gross Unrealized Holding Losses</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Estimated Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_41D_20231231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zSaeWsAUrXNe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: justify; padding-bottom: 1pt; text-indent: 0pt">U.S. Treasury Bills</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><ix:nonFraction name="us-gaap:HeldToMaturitySecurities" contextRef="AsOf2023-12-31_us-gaap_USTreasurySecuritiesMember" id="Fact000665" format="ixt:numdotdecimal" decimals="0" unitRef="USD">149,919,974</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><ix:nonFraction name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" contextRef="AsOf2023-12-31_us-gaap_USTreasurySecuritiesMember" id="Fact000666" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,995</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0667">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><ix:nonFraction name="us-gaap:HeldToMaturitySecuritiesFairValue" contextRef="AsOf2023-12-31_us-gaap_USTreasurySecuritiesMember" id="Fact000668" format="ixt:numdotdecimal" decimals="0" unitRef="USD">149,950,969</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_419_20231231_zbU8GJk04tyf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: 0pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:HeldToMaturitySecurities" contextRef="AsOf2023-12-31" id="Fact000669" format="ixt:numdotdecimal" decimals="0" unitRef="USD">149,919,974</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" contextRef="AsOf2023-12-31" id="Fact000670" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,995</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0671">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:HeldToMaturitySecuritiesFairValue" contextRef="AsOf2023-12-31" id="Fact000672" format="ixt:numdotdecimal" decimals="0" unitRef="USD">149,950,969</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_zwHyF3yoQHrc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">The fair value of the Company&#8217;s held-to-maturity debt securities
is determined based upon inputs, other than the quoted prices in active markets, that are observable either directly or indirectly, and
are classified as Level 2 fair value instruments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 56; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000674" name="us-gaap:OtherCurrentAssetsTextBlock"><p id="xdx_802_eus-gaap--OtherCurrentAssetsTextBlock_z90pEKHcg1m2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"> <b>6.</b> <b><span id="xdx_823_z5Xy4NBhlHo">Other Current Assets</span></b></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000676" name="us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock"><p id="xdx_894_eus-gaap--ScheduleOfOtherCurrentAssetsTableTextBlock_zL9Ky7RnXgpg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other current assets consisted of the following at
December 31:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B4_z25EpmOVAL45" style="display: none">Schedule of Other Current Assets</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20241231_zVoI33oyf2Qc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20231231_zzvMBVr3J0x9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PrepaidExpenseAndOtherAssetsCurrentAbstract_iB_zLjAY6e2KQIa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Current:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--PrepaidClinicalTrialCosts_iI_maOACz5EC_maOACzcDD_zrZR1MIwztZ7" style="vertical-align: bottom; background-color: White">
    <td style="width: 70%; text-align: justify">Prepaid clinical trial costs</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="CELC:PrepaidClinicalTrialCosts" contextRef="AsOf2024-12-31" id="Fact000681" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,768,668</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="CELC:PrepaidClinicalTrialCosts" contextRef="AsOf2023-12-31" id="Fact000682" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,763,150</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--MiscellaneousReceivable_iI_maOACz5EC_maOACzcDD_zgMqnqJOdguc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Miscellaneous receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:MiscellaneousReceivable" contextRef="AsOf2024-12-31" id="Fact000684" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,600,621</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:MiscellaneousReceivable" contextRef="AsOf2023-12-31" id="Fact000685" format="ixt:numdotdecimal" decimals="0" unitRef="USD">805,882</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--PrepaidInsurance_iI_maOACz5EC_maOACzcDD_ziST3dg7Mh91" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Directors &amp; officers&#8217; insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidInsurance" contextRef="AsOf2024-12-31" id="Fact000687" format="ixt:numdotdecimal" decimals="0" unitRef="USD">256,629</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidInsurance" contextRef="AsOf2023-12-31" id="Fact000688" format="ixt:numdotdecimal" decimals="0" unitRef="USD">157,453</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OtherPrepaidExpenseCurrent_iI_maOACz5EC_maOACzcDD_zCAHir9ln44e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="AsOf2024-12-31" id="Fact000690" format="ixt:numdotdecimal" decimals="0" unitRef="USD">841,329</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="AsOf2023-12-31" id="Fact000691" format="ixt:numdotdecimal" decimals="0" unitRef="USD">281,364</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OtherAssetsCurrent_iTI_mtOACz5EC_mtOACzcDD_zg52Bfkt2t9a" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: 10pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="AsOf2024-12-31" id="Fact000693" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,467,247</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="AsOf2023-12-31" id="Fact000694" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,007,849</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AA_zkFuD3XDj5sa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000696" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock"><p id="xdx_802_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zM8LlpPMpLIi" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"> <b>7.</b> <b><span id="xdx_822_zwIPC0KzkEof">Property and Equipment</span></b></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000698" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><p id="xdx_895_eus-gaap--PropertyPlantAndEquipmentTextBlock_zjOntXtkfmah" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Property and equipment consisted of the following
at December 31:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B2_zbRUXA1exdqi" style="display: none">Summary of Property and Equipment</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20241231_zWj4eYpg8fQg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20231231_zrJj7qrX1pE3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zQPkm78BcDr" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; text-align: justify">Furniture and equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-12-31_us-gaap_FurnitureAndFixturesMember" id="Fact000700" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,025,875</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31_us-gaap_FurnitureAndFixturesMember" id="Fact000701" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,788,195</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zfceKsZ0katd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Leasehold improvements</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember" id="Fact000703" format="ixt:numdotdecimal" decimals="0" unitRef="USD">302,577</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31_us-gaap_LeaseholdImprovementsMember" id="Fact000704" format="ixt:numdotdecimal" decimals="0" unitRef="USD">302,577</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzGp4_zUcwYof0nbwg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment, Gross</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-12-31" id="Fact000706" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,328,452</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31" id="Fact000707" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,090,772</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzGp4_zxNtpWD73oi5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Less: Accumulated depreciation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2024-12-31" id="Fact000709" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,991,937</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2023-12-31" id="Fact000710" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,861,990</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzGp4_zSksBfWIeGEh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: 10pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2024-12-31" id="Fact000712" format="ixt:numdotdecimal" decimals="0" unitRef="USD">336,515</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-12-31" id="Fact000713" format="ixt:numdotdecimal" decimals="0" unitRef="USD">228,782</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_zeJmzC3fp6o5" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0in"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0in"><span style="font-weight: normal">Depreciation expense
was $<span id="xdx_901_eus-gaap--Depreciation_c20240101__20241231_zQhBxC99Wyy1" title="Depreciation expense"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2024-01-01to2024-12-31" id="Fact000715" format="ixt:numdotdecimal" decimals="0" unitRef="USD">129,947</ix:nonFraction></span> and $<span id="xdx_90F_eus-gaap--Depreciation_c20230101__20231231_zYqgbosfs3d5" title="Depreciation expense"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2023-01-012023-12-31" id="Fact000717" format="ixt:numdotdecimal" decimals="0" unitRef="USD">142,772</ix:nonFraction></span> for the years ended December 31, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0in"><span style="font-weight: normal">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000719" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"><p id="xdx_80A_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_ziPJdj5s7qcg" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"> <b>8.</b> <b><span id="xdx_821_zucYWNR76scc">Accrued Expenses</span></b></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000721" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock"><p id="xdx_896_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zErn4kMaNMrd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Accrued expenses consisted of the following at December
31:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B9_zyjmZEJcNGpa" style="display: none">Schedule of Accrued Expenses</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20241231_zl2ZIfBfvp8h" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20231231_zh5dZYKsqVf3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--AccruedClinicalTrialExpense_iI_maALCzp59_z7oRfzlBSGBa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; text-align: justify">Clinical trial costs</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="CELC:AccruedClinicalTrialExpense" contextRef="AsOf2024-12-31" id="Fact000723" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,708,499</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="CELC:AccruedClinicalTrialExpense" contextRef="AsOf2023-12-31" id="Fact000724" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,464,772</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--WorkersCompensationLiabilityCurrent_iI_maALCzp59_zkOBO8hhZ2P4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Accrued compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:WorkersCompensationLiabilityCurrent" contextRef="AsOf2024-12-31" id="Fact000726" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,987,786</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:WorkersCompensationLiabilityCurrent" contextRef="AsOf2023-12-31" id="Fact000727" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,763,316</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OtherAccruedLiabilitiesCurrentAndNoncurrent_iI_maALCzp59_z0cp9ECn6pQ2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent" contextRef="AsOf2024-12-31" id="Fact000729" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,384,803</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent" contextRef="AsOf2023-12-31" id="Fact000730" format="ixt:numdotdecimal" decimals="0" unitRef="USD">641,512</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AccruedEmployeeBenefitsCurrent_iI_maALCzp59_zb9wHpWbxTpj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Employee stock purchase plan</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccruedEmployeeBenefitsCurrent" contextRef="AsOf2024-12-31" id="Fact000732" format="ixt:numdotdecimal" decimals="0" unitRef="USD">103,860</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccruedEmployeeBenefitsCurrent" contextRef="AsOf2023-12-31" id="Fact000733" format="ixt:numdotdecimal" decimals="0" unitRef="USD">57,494</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCzp59_zHV3x8o5H9pg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: 10pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000735" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,184,948</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000736" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,927,094</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_zsNaltowHbTk" style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0in">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 57; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;&#160;</b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000738" name="us-gaap:CommitmentsDisclosureTextBlock"><p id="xdx_80A_eus-gaap--CommitmentsDisclosureTextBlock_zqHIgLYt2X65" style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"> 9. <span id="xdx_829_zwaUruN7uOv2">Commitments</span></p>



<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 19.8pt; text-indent: -19.8pt">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 19.8pt; text-indent: -19.8pt"><span style="text-decoration: underline">Operating and Finance Leases</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company leases its corporate space in Minneapolis,
Minnesota, with an operating lease in place through April 30, 2026. The lease provides for monthly rent, real estate taxes, and operating
expenses. Rent expense is recorded on a straight-line basis over the lease term. In March 2023, the Company signed the fourth amendment
to extend this lease through April 30, 2026. This amendment provides for monthly rent, real estate taxes and operating expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 2.15pt 0 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 2.15pt 0 0">In May 2018, the Company entered into a non-cancelable finance
lease agreement for office equipment with a five-year term. The underlying assets are included in furniture and equipment. The lease contains
a bargain purchase option at the end of the lease. The finance lease expired in May 2023 and the equipment was acquired for the bargain
purchase option price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 2.15pt 0 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 2.15pt 0 0">When an implicit rate is not provided, the Company uses its
incremental borrowing rate based on the information available at the lease commencement date in determining the present value of the lease
payments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000740" name="srt:ScheduleOfCondensedBalanceSheetTableTextBlock"><p id="xdx_895_esrt--ScheduleOfCondensedBalanceSheetTableTextBlock_zuQPu1QXBhwi" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">Supplemental balance sheet information consisted of the following at December
31, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BE_zw3HBbzqg8w2" style="display: none">Schedule of Supplemental Balance Sheet Information Related to Leases</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" id="xdx_494_20241231_zT5RGc8NWm4i" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseDescriptionAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Operating Lease</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_zYQVceoYWCU9" style="vertical-align: bottom; background-color: White">
    <td style="width: 85%; text-align: justify; text-indent: 10pt">Right-of-use assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2024-12-31" id="Fact000744" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">215,502</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLeaseLiability_iI_pp0p0_zqUIZyHNsvma" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Operating lease liability</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2024-12-31" id="Fact000746" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">225,921</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_pp0p0_di_z5q7RAlD6Jv6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt; text-indent: 10pt">Less: short term portion</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2024-12-31" id="Fact000748" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">171,952</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: 10pt">Long term portion</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2024-12-31" id="Fact000750" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">53,969</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AF_zIoqi1yE0MD" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000752" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><p id="xdx_890_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zzBGTQLd23i6" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">Maturity analysis under lease agreements consisted of the following as
of December 31, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B6_zXuYNHI4W3Af" style="display: none">Schedule of Maturity Analysis Under Lease Agreements</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20241231_zDYLnRejo5O3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Operating Leases</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzXrd_zrlJrxLp6Y" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 85%; text-align: justify">2025</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2024-12-31" id="Fact000754" format="ixt:numdotdecimal" decimals="0" unitRef="USD">220,389</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzXrd_zVnagI2JM905" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">2026</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2024-12-31" id="Fact000756" format="ixt:numdotdecimal" decimals="0" unitRef="USD">74,170</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzXrd_zobhmhwBJj9g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt; text-indent: 10pt">Total minimum lease payments</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2024-12-31" id="Fact000758" format="ixt:numdotdecimal" decimals="0" unitRef="USD">294,559</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zuqyqXxybD88" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt; text-indent: 10pt">Less: Present value discount</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2024-12-31" id="Fact000760" format="ixt:numdotdecimal" decimals="0" unitRef="USD">68,638</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingLeaseLiability_iI_zEXjJaN3t6Nh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: 10pt">Present value of net minimum lease payments</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2024-12-31" id="Fact000762" format="ixt:numdotdecimal" decimals="0" unitRef="USD">225,921</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: left">Weighted Average</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Remaining Lease Term</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Discount Rate</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 70%; text-align: justify">Operating lease</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;<span id="xdx_903_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20241231_zXNR8NJKHJM2" title="Operating leases, remaining lease term"><ix:nonNumeric contextRef="AsOf2024-12-31" format="ixt-sec:duryear" id="Fact000764" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">1.3</ix:nonNumeric></span> years</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20241231_zYOM30IiwEf6" title="Operating leases, discount rate"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2024-12-31" id="Fact000766" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10.5</ix:nonFraction></span></td><td style="width: 1%; text-align: left">%</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8AE_zAQnpZs3RsI9" style="margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000768" name="us-gaap:LeaseCostTableTextBlock"><p id="xdx_89C_eus-gaap--LeaseCostTableTextBlock_zQqx8BBfFLxi" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Lease costs for the period ended December 31:</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>



<p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BE_ztIUpipt8P0d" style="display: none">Schedule of Lease Costs</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt; width: 70%">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left; width: 1%">&#160;</td><td id="xdx_498_20240101__20241231_z69Lp53vEyD4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; width: 12%">2024</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left; width: 1%">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left; width: 1%">&#160;</td><td id="xdx_49A_20230101__20231231_zXZfNMCMdLtg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; width: 12%">2023</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left; width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeaseCost_maLCzXSJ_maLCzphc_zWFKr6cRbmY7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: 10pt">Operating lease cost</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2024-01-01to2024-12-31" id="Fact000770" format="ixt:numdotdecimal" decimals="0" unitRef="USD">213,104</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2023-01-012023-12-31" id="Fact000771" format="ixt:numdotdecimal" decimals="0" unitRef="USD">212,238</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--FinanceLeaseCostAbstract_iB_zAH1tDujDzwa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: 10pt">Finance lease cost:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_i01_pp0p0_maLCzXSJ_maLCzphc_z20xoyVtRiyd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify; text-indent: 10pt">Amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0776">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" contextRef="From2023-01-012023-12-31" id="Fact000777" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,411</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--FinanceLeaseInterestExpense_i01_pp0p0_maLCzXSJ_maLCzphc_zmNVG91Je0i9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: justify; text-indent: 10pt">Interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0779">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseInterestExpense" contextRef="From2023-01-012023-12-31" id="Fact000780" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--VariableLeaseCost_pp0p0_maLCzXSJ_maLCzphc_zPL8DHsVukc2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt; text-indent: 10pt">Variable lease cost</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:VariableLeaseCost" contextRef="From2024-01-01to2024-12-31" id="Fact000782" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">111,246</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:VariableLeaseCost" contextRef="From2023-01-012023-12-31" id="Fact000783" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">101,957</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--LeaseCost_iT_pp0p0_mtLCzphc_z3QzfXkEUPq4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif">Lease costs</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="From2024-01-01to2024-12-31" id="Fact000785" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">324,350</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="From2023-01-012023-12-31" id="Fact000786" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">316,610</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A9_zEDcf5xIIusl" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000788" name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"><p id="xdx_89B_eus-gaap--ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_zB9UJmmc6PJc" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Supplemental cash flow information related to leases for the period ended December 31:</p>



<p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B8_zV76IQ6kDx15" style="display: none">Schedule of Supplemental Cash Flow Information Related to Leases</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20240101__20241231_zacNrvbFYyT" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20230101__20231231_zxZ1MztQsrH5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--CashPaidForOperatingAndFinanceLeasesAbstract_iB_z3T0lMG9DfWk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Cash paid for amounts included in operating and finance leases:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeasePayments_i01_pp0p0_maCPFOAzLxF_zT8id1pwmdac" style="vertical-align: bottom; background-color: White">
    <td style="width: 70%; text-align: justify; text-indent: 10pt">Operating cash outflow from operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2024-01-01to2024-12-31" id="Fact000793" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">324,783</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2023-01-012023-12-31" id="Fact000794" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">308,914</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--FinanceLeaseInterestPaymentOnLiability_i01_pp0p0_maCPFOAzLxF_zDLaW6oH5lYg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: 10pt">Operating cash outflow from finance leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0796">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseInterestPaymentOnLiability" contextRef="From2023-01-012023-12-31" id="Fact000797" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--FinanceLeasePrincipalPayments_i01_pp0p0_maCPFOAzLxF_zhJwihAQWkdi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt; text-indent: 10pt">Financing cash outflow from finance leases</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0799">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeasePrincipalPayments" contextRef="From2023-01-012023-12-31" id="Fact000800" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,449</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--CashPaidForOperatingAndFinanceLeases_i01T_pp0p0_mtCPFOAzLxF_zodVNHNWeyx3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total cash paid for amounts
    included in operating and finance leases</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="CELC:CashPaidForOperatingAndFinanceLeases" contextRef="From2024-01-01to2024-12-31" id="Fact000802" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">324,783</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="CELC:CashPaidForOperatingAndFinanceLeases" contextRef="From2023-01-012023-12-31" id="Fact000803" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">311,367</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A9_zqcdOdtzXxkj" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>


<ix:exclude><!-- Field: Page; Sequence: 58; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><span style="text-decoration: underline">Clinical Research Studies</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">The Company enters into contracts in the normal course of business to conduct
research and development programs internally and through third parties that include, among others, arrangements with vendors, consultants,
CMOs, and CROs. The Company has a license agreement in place with Pfizer to research, develop, manufacture and commercialize gedatolisib.
In conjunction with the license agreement, the Company completed a Phase 1b clinical trial &#8211; B2151009 related to gedatolisib. These
patients subsequently transitioned to an Expanded Access study &#8211; CELC-G-001. Contracts related to the Expanded Access study are
generally based on time and material. In addition, contracts related to the Company&#8217;s Phase 3 clinical studies (VIKTORIA-1 and VIKTORIA-2)
and the Phase 1b/2 clinical trial (CELC-G-201) are generally cancelable with reasonable notice within 120 days and the Company&#8217;s
obligations under these contracts are primarily based on services performed through termination dates plus certain cancelation charges,
if any, as defined in each of the respective agreements. In addition, these agreements may, from time to time, be subjected to amendments
as a result of any change orders executed by the parties. As of December 31, 2024, the Company had five material non-cancelable contractual
commitments with respect to these arrangements, which totaled approximately $<span id="xdx_90F_eus-gaap--ContractualObligation_iI_pn5n6_c20241231_zShRqHtvWBG8" title="Non-cancelable contractual commitment"><ix:nonFraction name="us-gaap:ContractualObligation" contextRef="AsOf2024-12-31" id="Fact000805" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">9.7</ix:nonFraction></span> million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000807" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_807_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zoZ49RQScqt" style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"> 10. <span id="xdx_82C_zwjOQJ2kzy5i">Stockholders&#8217; Equity</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><span style="text-decoration: underline">Capital Stock</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At December 31, 2023, the Company&#8217;s authorized
capital stock consisted of <span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20231231_z58AORwDfBs2" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-12-31" id="Fact000809" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">65,000,000</ix:nonFraction></span> shares of $<span id="xdx_90F_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20231231_zJgTYDzfpAjg" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31" id="Fact000811" decimals="INF" unitRef="USDPShares">.001</ix:nonFraction></span> par value common stock, of which <span id="xdx_908_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20231231_zuH94DHujqf8" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-12-31" id="Fact000813" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,506,012</ix:nonFraction></span> shares were outstanding, and <span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20231231_zNohAz6s1cH6" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-12-31" id="Fact000815" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,500,000</ix:nonFraction></span>
shares of $<span id="xdx_90B_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20231231_z4m7C5nD0oQb" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31" id="Fact000817" decimals="INF" unitRef="USDPShares">.001</ix:nonFraction></span> par value preferred stock, of which <span id="xdx_903_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20231231_zC5Hjt6xmnYb" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-12-31" id="Fact000819" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">854,134</ix:nonFraction></span> shares were outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In 2024, several of the Company&#8217;s preferred
shareholders elected to convert <span id="xdx_900_eus-gaap--ConversionOfStockSharesConverted1_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zxGrOsknkA46" title="Number of shares converted"><ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="From2024-01-012024-12-31_custom_SeriesAConvertiblePreferredStockMember" id="Fact000821" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">536,557</ix:nonFraction></span> shares of Series A Convertible Preferred Stock into <span id="xdx_906_eus-gaap--ConversionOfStockSharesIssued1_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zfGlI0y7O6ge" title="Number of shares issued in conversion"><ix:nonFraction name="us-gaap:ConversionOfStockSharesIssued1" contextRef="From2024-01-012024-12-31_custom_SeriesAConvertiblePreferredStockMember" id="Fact000823" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,365,570</ix:nonFraction></span> shares of common stock, in accordance
with the Securities Purchase Agreement dated May 15, 2022. The cost basis of the shares transferred is $<span id="xdx_906_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zaMIf0ZK13X4" title="Cost basis of shares transferred"><ix:nonFraction name="us-gaap:PreferredStockConvertibleConversionPrice" contextRef="AsOf2024-12-31_custom_SeriesAConvertiblePreferredStockMember" id="Fact000825" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.75</ix:nonFraction></span> per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In 2024, several of the Company&#8217;s investors
exercised <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20241231_zHADFndXnH52" title="Additional warrants exercised"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-12-31" id="Fact000827" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,827,357</ix:nonFraction></span> common stock warrants at exercise prices ranging between $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__srt--RangeAxis__srt--MinimumMember_zcaYVo5rE405" title="Class of warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_srt_MinimumMember" id="Fact000829" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.05</ix:nonFraction></span> and $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__srt--RangeAxis__srt--MaximumMember_z1c6oiZLr7F8" title="Class of warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_srt_MaximumMember" id="Fact000831" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.50</ix:nonFraction></span> per share, which generated approximately
$<span id="xdx_904_eus-gaap--ProceedsFromWarrantExercises_pn5n6_c20240101__20241231_zB5yUMl1KEBa" title="Proceeds from warant exercise"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2024-01-01to2024-12-31" id="Fact000833" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">14.7</ix:nonFraction></span> million in cash. The <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20241231_zfuggXWgi9Bj" title="Additional warrants exercised"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-12-31" id="Fact000835" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,827,357</ix:nonFraction></span> common stock warrants were net of shares withheld for exercise price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify">At December 31, 2024, the Company&#8217;s
authorized capital stock consisted of <span id="xdx_903_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20241231_zwohx9jQHp8a" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact000837" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">95,000,000</ix:nonFraction></span> shares of common stock, of which <span id="xdx_908_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20241231_zbgW50KgkuCj" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-12-31" id="Fact000839" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">37,143,242</ix:nonFraction></span> shares were outstanding, and <span id="xdx_90E_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20241231_z1wnbw5zl0Tc" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact000841" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,500,000</ix:nonFraction></span> shares
of preferred stock, including <span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z1ANVoyml8F5" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember" id="Fact000843" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,850,000</ix:nonFraction></span> shares designated as Series A Preferred Stock, of which <span id="xdx_900_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20241231_zoFdcoiNvWJc" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-12-31" id="Fact000845" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">317,577</ix:nonFraction></span> shares were outstanding. As of
December 31, 2024, no dividends have been declared on the Company&#8217;s capital stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><i>Sale and Issuance of Stock</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 22, 2024, pursuant to an Open Market Sale
Agreement<sup>SM</sup> with Jefferies LLC, as agent, the Company sold <span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240422__20240422__us-gaap--TypeOfArrangementAxis__custom--OpenMarketSaleAgreementMember__dei--LegalEntityAxis__custom--JefferiesLLCMember_zB8F5dHpHsJ4" title="Sale of stock"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2024-04-222024-04-22_custom_OpenMarketSaleAgreementMember_custom_JefferiesLLCMember" id="Fact000847" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">285,714</ix:nonFraction></span> shares of common stock in a single transaction at a price
of $<span id="xdx_90F_eus-gaap--SaleOfStockPricePerShare_iI_c20240422__us-gaap--TypeOfArrangementAxis__custom--OpenMarketSaleAgreementMember__dei--LegalEntityAxis__custom--JefferiesLLCMember_zMSLcCZSIj85" title="Share price"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2024-04-22_custom_OpenMarketSaleAgreementMember_custom_JefferiesLLCMember" id="Fact000849" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">17.50</ix:nonFraction></span> per share, generating gross proceeds of $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20240422__20240422__us-gaap--TypeOfArrangementAxis__custom--OpenMarketSaleAgreementMember__dei--LegalEntityAxis__custom--JefferiesLLCMember_zVZfRImdr93h" title="Gross proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2024-04-222024-04-22_custom_OpenMarketSaleAgreementMember_custom_JefferiesLLCMember" id="Fact000851" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.0</ix:nonFraction></span> million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify">On May 8, 2024, pursuant to an Open Market
Sale Agreement with Jefferies LLC, as agent, the Company sold <span id="xdx_90B_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240508__20240508__us-gaap--TypeOfArrangementAxis__custom--OpenMarketSaleAgreementMember__dei--LegalEntityAxis__custom--JefferiesLLCMember_zFgMBNFaayBa" title="Sale of stock number of shares issued in transaction"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2024-05-082024-05-08_custom_OpenMarketSaleAgreementMember_custom_JefferiesLLCMember" id="Fact000853" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">149,700</ix:nonFraction></span> shares of common stock in a single transaction at a price of $<span id="xdx_90A_eus-gaap--SaleOfStockPricePerShare_iI_c20240508__us-gaap--TypeOfArrangementAxis__custom--OpenMarketSaleAgreementMember__dei--LegalEntityAxis__custom--JefferiesLLCMember_ziybsioOdUcl" title="Issuance of public offering price per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2024-05-08_custom_OpenMarketSaleAgreementMember_custom_JefferiesLLCMember" id="Fact000855" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">17.65</ix:nonFraction></span>
per share, generating gross proceeds of $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20240508__20240508__us-gaap--TypeOfArrangementAxis__custom--OpenMarketSaleAgreementMember__dei--LegalEntityAxis__custom--JefferiesLLCMember_zQMxRGkCOtN8" title="Gross proceeds from public offering"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2024-05-082024-05-08_custom_OpenMarketSaleAgreementMember_custom_JefferiesLLCMember" id="Fact000857" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.6</ix:nonFraction></span> million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">Commissions and other offering expenses related to the Open Market Sale
Agreement transactions in April and May 2024 were $<span id="xdx_902_eus-gaap--PaymentsOfStockIssuanceCosts_pn5n6_c20240430__20240430__us-gaap--TypeOfArrangementAxis__custom--OpenMarketSaleAgreementMember_zWIGxvNR9XP3" title="Commissions and other offering expenses"><span id="xdx_90D_eus-gaap--PaymentsOfStockIssuanceCosts_pn5n6_c20240531__20240531__us-gaap--TypeOfArrangementAxis__custom--OpenMarketSaleAgreementMember_zqlqF4DntbM9" title="Commissions and other offering expenses"><ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2024-04-302024-04-30_custom_OpenMarketSaleAgreementMember" id="Fact000859" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD"><ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2024-05-312024-05-31_custom_OpenMarketSaleAgreementMember" id="Fact000861" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.3</ix:nonFraction></ix:nonFraction></span></span> million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 59; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 30, 2024, the Company entered into an underwriting
agreement with Leerink Partners LLC, TD Securities (USA) LLC and Stifel, Nicolaus &amp; Company, Incorporated as representatives of the
several underwriters relating to the issuance and sale of <span id="xdx_903_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240530__20240530__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LeerinkPartnersLLCMember_zgi2coic5Ai3" title="Sale of stock number of shares issued in transaction"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2024-05-302024-05-30_custom_UnderwritingAgreementMember_custom_LeerinkPartnersLLCMember" id="Fact000863" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,871,000</ix:nonFraction></span> shares of common stock, at a price to the public of $<span id="xdx_901_eus-gaap--SaleOfStockPricePerShare_iI_c20240530__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LeerinkPartnersLLCMember_zhSUJT3GX9q2" title="Issuance of public offering price per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2024-05-30_custom_UnderwritingAgreementMember_custom_LeerinkPartnersLLCMember" id="Fact000865" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">15.50</ix:nonFraction></span>, generating
gross proceeds of approximately $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20240530__20240530__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LeerinkPartnersLLCMember_zHKpZqZCKbF7" title="Gross proceeds from public offering"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2024-05-302024-05-30_custom_UnderwritingAgreementMember_custom_LeerinkPartnersLLCMember" id="Fact000867" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">60.0</ix:nonFraction></span> million. The offering closed on May 31, 2024 and resulted in net proceeds to the Company of approximately
$<span id="xdx_909_ecustom--ProceedsFromIssuanceOfCommonStockNet_pn5n6_c20240531__20240531__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LeerinkPartnersLLCMember_zeh8eaXyABs9" title="Net proceeds from public offering"><ix:nonFraction name="CELC:ProceedsFromIssuanceOfCommonStockNet" contextRef="From2024-05-312024-05-31_custom_UnderwritingAgreementMember_custom_LeerinkPartnersLLCMember" id="Fact000869" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">56.3</ix:nonFraction></span> million after deducting underwriting discounts and other offering expenses payable by the Company. The Company intends to use the
net proceeds from the offering for working capital and general corporate purposes, which may include capital expenditures, research and
development expenditures, clinical trial expenditures, expansion of business development activities and other general corporate purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline">Pre-Funded Warrants</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On October 18, 2023, the
Company entered into a securities purchase agreement (the &#8220;Securities Purchase Agreement&#8221;) with certain investors (the &#8220;Investors&#8221;)
pursuant to which the Company agreed to sell to the Investors in a private placement pre-funded warrants to purchase up to <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20231018__20231018__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zKSMTxN8oQMl" title="Pre-funded warrants sold to investors"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-10-182023-10-18_custom_SecuritiesPurchaseAgreementMember" id="Fact000871" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,747,787</ix:nonFraction></span> shares
of the Company&#8217;s common stock, par value $<span id="xdx_902_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20231018__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z97C4UWFVdbh" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-10-18_custom_SecuritiesPurchaseAgreementMember" id="Fact000873" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span> per share. Each Warrant to purchase one share had a purchase price of $<span id="xdx_90F_eus-gaap--SharePrice_iI_pid_c20231018__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zeccBRVy2gef" title="Warrant purchase price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-10-18_custom_SecuritiesPurchaseAgreementMember_us-gaap_WarrantMember" id="Fact000875" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.699</ix:nonFraction></span> per
share, and an exercise price of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231018__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTLu4QIKk9Q8" title="Exercise price of common stock warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-10-18_custom_SecuritiesPurchaseAgreementMember_us-gaap_WarrantMember" id="Fact000877" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span> per share for the common stock issuable upon exercise of the Warrant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The closing of the Private
Placement occurred on October 20, 2023, and resulted in gross proceeds to the Company of approximately $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn5n6_c20231020__20231020__srt--TitleOfIndividualAxis__custom--InstitutionalAndOtherAccreditedInvestorsMember_zkxYRPpeIkJj" title="Proceeds from issuance of private placement"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="From2023-10-202023-10-20_custom_InstitutionalAndOtherAccreditedInvestorsMember" id="Fact000879" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">50.0</ix:nonFraction></span> million, before deducting
offering expenses of approximately $<span id="xdx_90F_ecustom--OfferingExpenses_pn5n6_c20231020__20231020__srt--TitleOfIndividualAxis__custom--InstitutionalAndOtherAccreditedInvestorsMember_znvLnnmM5k9d" title="Offering expenses"><ix:nonFraction name="CELC:OfferingExpenses" contextRef="From2023-10-202023-10-20_custom_InstitutionalAndOtherAccreditedInvestorsMember" id="Fact000881" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction></span> million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Each Warrant is immediately
exercisable and will not expire. Under the terms of the Warrants, the Company may not effect the exercise of any such Warrant, and a holder
will not be entitled to exercise any portion of any Warrant, if, upon giving effect to such exercise, the aggregate number of shares of
common stock beneficially owned by the holder (together with its affiliates, other persons acting or who could be deemed to be acting
as a group together with the holder or any of the holder&#8217;s affiliates, and any other persons whose beneficial ownership of common
stock would or could be aggregated with the holder&#8217;s or any of the holder&#8217;s affiliates for purposes of Section 13(d) or Section
16 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)) would exceed 4.99% of the number of shares of
common stock outstanding immediately after giving effect to the exercise, as such percentage ownership is calculated in accordance with
Section 13(d) of the Exchange Act and the applicable regulations of the SEC (the &#8220;Maximum Percentage&#8221;). A holder may reset
the Maximum Percentage to a higher percentage (not to exceed 19.99%), effective 61 days after written notice to the Company, or a lower
percentage, effective immediately upon written notice to the Company. Any such increase or decrease will apply only to that holder and
not to any other holder of Warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Securities Purchase Agreement
contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations
of the Company, other obligations of the parties and termination provisions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><span style="text-decoration: underline">Warrants</span></b></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000883" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><p id="xdx_89E_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zsto21sRl4t3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BE_z2rn7RsYGXm4" style="display: none">Schedule of Warrants</span></span></b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>At December 31, 2024:</b></p></td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Issue Date</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Expiration <br/>
Date</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"># of Warrants <br/>
Outstanding</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise <br/>
Price</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Offering</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 14%; text-align: justify"><span id="xdx_90F_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantOneMember_zzy3QVehUMPk" title="Issue Date"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_WarrantOneMember" format="ixt:datemonthdayyear" id="Fact000885" name="CELC:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue">1/21/2016</ix:nonNumeric></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 12%; text-align: justify"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantOneMember_zm3MP6vzpn65" title="Expiration Date"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_WarrantOneMember" format="ixt:datemonthdayyear" id="Fact000887" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">1/14/2026</ix:nonNumeric></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantOneMember_zbQLB19xUdXe" title="Number of Warrants Outstanding" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_custom_WarrantOneMember" id="Fact000889" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">33,719</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantOneMember_zRbGEXr1AZl4" title="Exercise Price" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_WarrantOneMember" id="Fact000891" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.56</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 42%; text-align: justify"><span id="xdx_905_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantOneMember_zUP5W0NkT54d" title="Offering"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_WarrantOneMember" id="Fact000893" name="us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees">private placement offering - issued to placement agent</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span id="xdx_909_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTwoMember_z1ejCN8TQZCl" title="Issue Date"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_WarrantTwoMember" format="ixt:datemonthdayyear" id="Fact000895" name="CELC:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue">5/2/2016</ix:nonNumeric></span></td><td>&#160;</td>
    <td style="text-align: justify"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTwoMember_zK2dMnFBPlWe" title="Expiration Date"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_WarrantTwoMember" format="ixt:datemonthdayyear" id="Fact000897" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">5/2/2026</ix:nonNumeric></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTwoMember_zcrZXcNI65sg" title="Number of Warrants Outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_custom_WarrantTwoMember" id="Fact000899" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">21,530</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTwoMember_zbZhsymVAKHh" title="Exercise Price" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_WarrantTwoMember" id="Fact000901" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.56</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTwoMember_zaMNtZcQeDf7" title="Offering"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_WarrantTwoMember" id="Fact000903" name="us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees">private placement offering - issued to placement agent</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span id="xdx_902_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantThreeMember_zpzw3gFg5DZd" title="Issue Date"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_WarrantThreeMember" format="ixt:datemonthdayyear" id="Fact000905" name="CELC:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue">4/28/2017</ix:nonNumeric></span></td><td>&#160;</td>
    <td style="text-align: justify"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantThreeMember_zNzbIHPWCVg7" title="Expiration Date"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_WarrantThreeMember" format="ixt:datemonthdayyear" id="Fact000907" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">4/28/2027</ix:nonNumeric></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantThreeMember_zLssEEQmrMab" title="Number of Warrants Outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_custom_WarrantThreeMember" id="Fact000909" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">33,250</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantThreeMember_zMkDOC743szj" title="Exercise Price" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_WarrantThreeMember" id="Fact000911" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.42</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify"><span id="xdx_901_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantThreeMember_zpmhmG59Rpw" title="Offering"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_WarrantThreeMember" id="Fact000913" name="us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees">private placement offering - issued to placement agent</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span id="xdx_909_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFourMember_zalzNQqwbrFg" title="Issue Date"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_WarrantFourMember" format="ixt:datemonthdayyear" id="Fact000915" name="CELC:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue">5/17/2017</ix:nonNumeric></span></td><td>&#160;</td>
    <td style="text-align: justify"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFourMember_zAC3xvDT3uBh" title="Expiration Date"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_WarrantFourMember" format="ixt:datemonthdayyear" id="Fact000917" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">5/17/2027</ix:nonNumeric></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFourMember_zEOCCLNsGUaj" title="Number of Warrants Outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_custom_WarrantFourMember" id="Fact000919" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,365</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFourMember_zWOlYvSBfhO1" title="Exercise Price" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_WarrantFourMember" id="Fact000921" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.42</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify"><span id="xdx_906_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFourMember_zrnfbCEu7dgl" title="Offering"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_WarrantFourMember" id="Fact000923" name="us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees">private placement offering - issued to placement agent</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span id="xdx_90A_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFiveMember_zQhAPm6hIohg" title="Issue Date"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_WarrantFiveMember" format="ixt:datemonthdayyear" id="Fact000925" name="CELC:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue">9/22/2017</ix:nonNumeric></span></td><td>&#160;</td>
    <td style="text-align: justify"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFiveMember_zNI3eGRxNbO3" title="Expiration Date"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_WarrantFiveMember" format="ixt:datemonthdayyear" id="Fact000927" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">9/19/2025</ix:nonNumeric></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFiveMember_z5ZtsHEZfpGh" title="Number of Warrants Outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_custom_WarrantFiveMember" id="Fact000929" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">70,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFiveMember_zTABzIthnJkc" title="Exercise Price" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_WarrantFiveMember" id="Fact000931" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.45</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify"><span id="xdx_909_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFiveMember_zBu5zK2pk5v2" title="Offering"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_WarrantFiveMember" id="Fact000933" name="us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees">IPO - issued to underwriter</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span id="xdx_90F_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSixMember_zdKdLvwXNT5j" title="Issue Date"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_WarrantSixMember" format="ixt:datemonthdayyear" id="Fact000935" name="CELC:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue">4/8/2021</ix:nonNumeric></span></td><td>&#160;</td>
    <td style="text-align: justify"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSixMember_zNZWWRgIdd82" title="Expiration Date"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_WarrantSixMember" format="ixt:datemonthdayyear" id="Fact000937" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">4/8/2031</ix:nonNumeric></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSixMember_z3G9nwBSAyp3" title="Number of Warrants Outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_custom_WarrantSixMember" id="Fact000939" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">26,042</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSixMember_zGWjh2pO9xnc" title="Exercise Price" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_WarrantSixMember" id="Fact000941" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">14.40</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify"><span id="xdx_901_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSixMember_zZ1HBufNeQwg" title="Offering"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_WarrantSixMember" id="Fact000943" name="us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees">debt financing - issued to lender</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span id="xdx_90D_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSevenMember_zJK8FAIwIrY6" title="Issue Date"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_WarrantSevenMember" format="ixt:datemonthdayyear" id="Fact000945" name="CELC:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue">5/30/2024</ix:nonNumeric></span></td><td>&#160;</td>
    <td style="text-align: justify"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSevenMember_zbQ5vZeVB7Wf" title="Expiration Date"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_WarrantSevenMember" format="ixt:datemonthdayyear" id="Fact000947" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">5/30/2034</ix:nonNumeric></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSevenMember_z0LFPrsZBT1g" title="Number of Warrants Outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_custom_WarrantSevenMember" id="Fact000949" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">84,227</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSevenMember_zf0PaICGlbRj" title="Exercise Price" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_WarrantSevenMember" id="Fact000951" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">14.84</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSevenMember_zblij2Twobbj" title="Offering"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_WarrantSevenMember" id="Fact000953" name="us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees">debt financing &#8211; issued to lender</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span id="xdx_90A_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantEightMember_zic20g9rc1ql" title="Issue Date"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_WarrantEightMember" format="ixt:datemonthdayyear" id="Fact000955" name="CELC:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue">5/30/2024</ix:nonNumeric></span></td><td>&#160;</td>
    <td style="text-align: justify"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantEightMember_z7Sv8tviQRx6" title="Expiration Date"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_WarrantEightMember" format="ixt:datemonthdayyear" id="Fact000957" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">5/30/2034</ix:nonNumeric></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantEightMember_zFTIPLLSQhH" title="Number of Warrants Outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_custom_WarrantEightMember" id="Fact000959" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">19,649</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantEightMember_zZi0ytehV8Ya" title="Exercise Price" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_WarrantEightMember" id="Fact000961" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">14.84</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify"><span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantEightMember_zYLtdPeigg8j" title="Offering"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_WarrantEightMember" id="Fact000963" name="us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees">debt financing &#8211; issued to lender</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span id="xdx_90F_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantNineMember_zNmKUWPO56H8" title="Issue Date"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_WarrantNineMember" format="ixt:datemonthdayyear" id="Fact000965" name="CELC:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue">12/9/2022</ix:nonNumeric></span></td><td>&#160;</td>
    <td style="text-align: justify">see below</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantNineMember_zXGAEV0ZyuAf" title="Number of Warrants Outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_custom_WarrantNineMember" id="Fact000967" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,217,370</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantNineMember_zev3Pr9tOfF7" title="Exercise Price" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_WarrantNineMember" id="Fact000969" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.05</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantNineMember_zsYj2m7PJUt3" title="Offering"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_WarrantNineMember" id="Fact000971" name="us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees">securities purchase agreement - issued to institutional and other accredited investors</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt"><span id="xdx_905_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTenMember_zQ2aRRiyhzKh" title="Issue Date"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_WarrantTenMember" format="ixt:datemonthdayyear" id="Fact000973" name="CELC:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue">10/18/2023</ix:nonNumeric></span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: justify; padding-bottom: 1pt">see above</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTenMember_zIHxFG7oVpml" title="Number of Warrants Outstanding" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_custom_WarrantTenMember" id="Fact000975" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,747,787</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTenMember_z48GIU4yN60b" title="Exercise Price" style="padding-bottom: 1pt; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_WarrantTenMember" id="Fact000977" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: justify; padding-bottom: 1pt"><span id="xdx_908_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTenMember_zbmOZ3d2wQE2" title="Offering"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_WarrantTenMember" id="Fact000979" name="us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees">private placement offering - issued to investors</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Total Warrants Outstanding</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231_zOC3YLP8ubx8" title="Number of Warrants Outstanding" style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31" id="Fact000981" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,268,939</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_zxzmxtlf4sgd" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 60; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">At December 31, 2024 and 2023, the Company had warrants
to purchase <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4Jkj0ItTUN3"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2024-12-31_us-gaap_WarrantMember" id="Fact000982" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,268,939</ix:nonFraction>
</span>and <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zKQ3kFlcT3t"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2023-12-31_us-gaap_WarrantMember" id="Fact000983" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,011,520</ix:nonFraction>
</span>shares of common stock outstanding, at a weighted average exercise price of $<span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOfWarrants_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwqCFb5kt6e7"><ix:nonFraction name="CELC:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOfWarrants" contextRef="AsOf2024-12-31_us-gaap_WarrantMember" id="Fact000984" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.04</ix:nonFraction>
</span>and $<span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOfWarrants_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zO2YxejSqGT5"><ix:nonFraction name="CELC:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOfWarrants" contextRef="AsOf2023-12-31_us-gaap_WarrantMember" id="Fact000985" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.53</ix:nonFraction></span>,
respectively. A total of <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z7O3Q99RMm4a"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember" id="Fact000986" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,842,913</ix:nonFraction>
</span>and <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zT8cYO0TaCMl"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember" id="Fact000987" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,369</ix:nonFraction>
</span>warrants were exercised in the years ended December 31, 2024 and 2023, respectively. There were <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPsKJxVdYTxd"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember" id="Fact000988" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,544</ix:nonFraction>
</span>warrants that expired in 2024.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000990" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"><p id="xdx_80F_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zl77xoio4Lj7" style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"> 11. <span id="xdx_823_z4h8In7A7UFf">Stock-Based Compensation</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><span style="text-decoration: underline">2012 Equity Incentive Plan</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">The 2012 Equity Incentive Plan, as amended, was adopted by the Company&#8217;s
board and approved by the members of Celcuity LLC on August 10, 2012. The Company reserved a maximum of <span id="xdx_905_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20120810__us-gaap--AwardTypeAxis__custom--EquityIncentivePlanMember_zvYAhqdRedX2" title="Common stock, shares reserved for issuance"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2012-08-10_custom_EquityIncentivePlanMember" id="Fact000992" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">625,000</ix:nonFraction></span> shares of common stock
for issuance under the 2012 Equity Incentive Plan. The 2012 Equity Incentive Plan provides for options, restricted stock awards, performance
stock awards or stock bonuses. The exercise price of each option granted under the 2012 Equity Incentive Plan is not less than 100% of
the fair market value of one share on the date of grant. The maximum permitted term of options granted under the 2012 Equity Incentive
Plan is ten years. The Company&#8217;s board administers the 2012 Equity Incentive Plan and determines the provisions of incentive awards,
including eligible recipients, number of shares subject to an incentive award, exercise price, vesting schedule, duration of an incentive
award and other restrictions an incentive award may be subject to. The 2012 Equity Incentive Plan was frozen on September 6, 2017 and
new awards are issued under the terms of the 2017 Amended and Restated Stock Incentive Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><span style="text-decoration: underline">2017 Stock Incentive Plan</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">The 2017 Amended and Restated Stock Incentive Plan (the &#8220;2017 Plan&#8221;)
was adopted by the Company&#8217;s board on September 6, 2017, became effective following the corporate conversion on September 15, 2017,
and was approved by stockholders at the Company&#8217;s annual stockholder meeting on May 10, 2018. The 2017 Plan was amended and approved
by stockholders at the Company&#8217;s annual stockholder meeting on May 14, 2020. The Company initially reserved a maximum of <span id="xdx_90B_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20171025__us-gaap--AwardTypeAxis__custom--StockIncentivePlanMember_zy9mw031BNRd" title="Common stock, shares reserved for issuance"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2017-10-25_custom_StockIncentivePlanMember" id="Fact000994" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">750,000</ix:nonFraction></span>
shares of common stock for issuance under the 2017 Plan. The number of shares reserved for issuance was automatically increased by <span id="xdx_90F_ecustom--ChangeInCommonStockSharesReservedForIssuance_iI_pid_c20240101__us-gaap--AwardTypeAxis__custom--StockIncentivePlanMember_zj1lXpOBs0Sd" title="Change in common stock, shares reserved for issuance"><ix:nonFraction name="CELC:ChangeInCommonStockSharesReservedForIssuance" contextRef="AsOf2024-01-01_custom_StockIncentivePlanMember" id="Fact000996" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">255,060</ix:nonFraction></span>
and <span id="xdx_907_ecustom--ChangeInCommonStockSharesReservedForIssuance_iI_pid_c20230101__us-gaap--AwardTypeAxis__custom--StockIncentivePlanMember_zjcWnIEgzKP7" title="Change in common stock, shares reserved for issuance"><ix:nonFraction name="CELC:ChangeInCommonStockSharesReservedForIssuance" contextRef="AsOf2023-01-01_custom_StockIncentivePlanMember" id="Fact000998" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">216,673</ix:nonFraction></span> shares on January 1, 2024 and 2023, respectively, and will increase automatically on January 1 of each of 2025 through 2027
by the number of shares equal to 1.0% of the aggregate number of outstanding shares of Company common stock as of the immediately preceding
December 31. However, the Company&#8217;s board may reduce the amount of the increase in any particular year. At each of the Annual Meetings
held on May 12, 2021 and May 12, 2022, the stockholders approved a <span id="xdx_90A_ecustom--ChangeInCommonStockSharesReservedForIssuance_iI_pid_c20210512__us-gaap--AwardTypeAxis__custom--StockIncentivePlanMember_zdDMs0cGZwwi" title="Change in common stock, shares reserved for issuance"><span id="xdx_90D_ecustom--ChangeInCommonStockSharesReservedForIssuance_iI_pid_c20220512__us-gaap--AwardTypeAxis__custom--StockIncentivePlanMember_znRdBrTBdr27" title="Change in common stock, shares reserved for issuance"><ix:nonFraction name="CELC:ChangeInCommonStockSharesReservedForIssuance" contextRef="AsOf2021-05-12_custom_StockIncentivePlanMember" id="Fact001000" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="CELC:ChangeInCommonStockSharesReservedForIssuance" contextRef="AsOf2022-05-12_custom_StockIncentivePlanMember" id="Fact001002" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">500,000</ix:nonFraction></ix:nonFraction></span></span> increase for a total of <span id="xdx_906_ecustom--TotalCommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20210512__us-gaap--AwardTypeAxis__custom--StockIncentivePlanMember_ztQYTaUZcTtl" title="Total common stock, shares reserved for issuance"><span id="xdx_907_ecustom--TotalCommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20220512__us-gaap--AwardTypeAxis__custom--StockIncentivePlanMember_zow5jheWFTJ4" title="Total common stock, shares reserved for issuance"><ix:nonFraction name="CELC:TotalCommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2021-05-12_custom_StockIncentivePlanMember" id="Fact001004" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="CELC:TotalCommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2022-05-12_custom_StockIncentivePlanMember" id="Fact001006" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></ix:nonFraction></span></span> increase, to the number of
shares reserved for issuance under the 2017 Plan. At each of the Annual Meetings held on May 11, 2023 and May 9, 2024, the stockholders
approved <span id="xdx_90F_ecustom--TotalCommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20230511__us-gaap--AwardTypeAxis__custom--StockIncentivePlanMember_z6TU2PbwJaR3" title="Total common stock, shares reserved for issuance"><ix:nonFraction name="CELC:TotalCommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2023-05-11_custom_StockIncentivePlanMember" id="Fact001008" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,500,000</ix:nonFraction></span> increases for a total increase of <span id="xdx_90E_ecustom--TotalCommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20240509__us-gaap--AwardTypeAxis__custom--StockIncentivePlanMember_zCBabljzE0E" title="Total common stock, shares reserved for issuance"><ix:nonFraction name="CELC:TotalCommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2024-05-09_custom_StockIncentivePlanMember" id="Fact001010" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,000,000</ix:nonFraction></span> to the number of shares reserved for issuance under the 2017 Plan. The
2017 Plan provides for options, restricted stock awards, stock appreciation rights, restricted stock units, performance awards and stock
bonuses. The exercise price of each option granted under the 2017 Plan is not less than 100% of the fair market value of one share on
the date of grant. The maximum permitted term of options granted under the 2017 Plan is ten years. The 2017 Plan is generally administered
by the compensation committee of the Company&#8217;s board, which has the authority to interpret the 2017 Plan, grant awards and make
all other determinations necessary for the administration of the 2017 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001012" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zOSgvTIVLrI" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">The following table summarizes the activity for all stock options outstanding
for the years ended December 31:</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B6_zl6OpamZLCef" style="display: none">Schedule of Stock Options Activity</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: justify">Options outstanding at beginning of year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zSPYsmp3gBwc" title="Options outstanding at beginning of year" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember" id="Fact001014" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,815,392</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zmesmf88ipEf" title="Options outstanding, weighted average exercise price at beginning of year" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember" id="Fact001016" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.95</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zmfBnJOTCI6a" title="Options outstanding at beginning of year" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-12-31_us-gaap_EmployeeStockOptionMember" id="Fact001018" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,976,586</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zCBET0BdBjxa" title="Options outstanding, weighted average exercise price at beginning of year" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_us-gaap_EmployeeStockOptionMember" id="Fact001020" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.34</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: justify">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_z9St0zHMEwu1" title="Shares, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember1617134281" id="Fact001022" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,716,729</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zGD33vgHmzEg" title="Weighted Average Exercise Price, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember1617134281" id="Fact001024" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">16.14</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zfISnnkWBnl1" title="Shares, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember1617134281" id="Fact001026" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,003,298</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zjbip3FB4WRk" title="Weighted Average Exercise Price, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember1617134281" id="Fact001028" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.69</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zHJlvZJj8Zm5" title="Shares, Exercised" style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember1617134281" id="Fact001030" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">103,245</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zDuKZUDpU8J4" title="Weighted Average Exercise Price, Exercised" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember1617134281" id="Fact001032" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.45</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_ze5YikrvvFd2" title="Shares, Exercised" style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember1617134281" id="Fact001034" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">98,695</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zpugTMFU0Hn7" title="Weighted Average Exercise Price, Exercised" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember1617134281" id="Fact001036" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.94</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: justify; padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zBIb2UJGk9f3" title="Shares, Forfeited" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember1617134281" id="Fact001038" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">121,899</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zUV6nYVTuh13" title="Weighted Average Exercise, Forfeited" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember1617134281" id="Fact001040" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">11.57</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zSbSduUjp7d7" title="Shares, Forfeited" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember1617134281" id="Fact001042" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">65,797</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zxA7HOqB6AK4" title="Weighted Average Exercise, Forfeited" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember1617134281" id="Fact001044" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.45</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify; padding-bottom: 1pt">Balance at December 31:</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_z9AKSp0QPPxe" title="Options outstanding at end of year" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember" id="Fact001046" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,306,977</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zrGgSswWkEri" title="Options outstanding, weighted average exercise price at end of year" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember" id="Fact001048" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">11.13</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zruFBhv5jPE2" title="Options outstanding at end of year" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember" id="Fact001050" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,815,392</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zLTfuTkJ2kz9" title="Options outstanding, weighted average exercise price at end of year" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember" id="Fact001052" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.95</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Options exercisable at December 31:</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zPa7Q8m6DZj" title="Shares, options exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember" id="Fact001054" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,011,474</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zTG5EMBmFq7i" title="Weighted Average Exercise Price, Options exercisable" style="padding-bottom: 2.5pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember" id="Fact001056" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.35</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zOW35pU1Ftd1" title="Shares, options exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember" id="Fact001058" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,524,731</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_z3k2bDel1Ute" title="Weighted Average Exercise Price, Options exercisable" style="padding-bottom: 2.5pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember" id="Fact001060" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.44</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Weighted Average Grant Date Fair Value for options granted during the year:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zkqfx8wCiia5" title="Weighted Average Grant Date Fair Value for options granted during the period" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember1617134281" id="Fact001062" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">11.22</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zIgbZ80Sv321" title="Weighted Average Grant Date Fair Value for options granted during the period" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember1617134281" id="Fact001064" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.48</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_zulv7JG4heh4" style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt; text-align: justify">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 61; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001066" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock"><p id="xdx_89C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_z03Q5zIYvzg7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><span style="font-weight: normal">The
following table summarizes additional information about stock options outstanding and exercisable at December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><span style="font-weight: normal">&#160;&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BE_zbSIJPkNPEXi" style="display: none">Schedule
of Stock Options Outstanding and Exercisable</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options Outstanding</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options Exercisable</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options Outstanding</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options Exercisable</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zpuOPQ73lAua" title="Options outstanding" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember1617134453" id="Fact001068" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,306,977</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zlB135Ixbs0g" title="Options outstanding, weighted average remaining contractual life"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear" id="Fact001070" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">7.96</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z6s9z4Tfe23g" title="Options outstanding, weighted average exercise price" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember1617134453" id="Fact001072" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">11.13</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pp0p0_c20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zaI6V7rIDWik" title="Options outstanding, aggregate intrinsic value" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember1617134453" id="Fact001074" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">13,914,458</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zNs1vu03paZi" title="Options exercisable" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember1617134453" id="Fact001076" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,011,474</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zYO9GUIJqj6l" title="Options exercisable, weighted average exercise price" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember1617134453" id="Fact001078" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.35</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4NHWs1M5Klb" title="Options exercisable, aggregate intrinsic value" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember1617134453" id="Fact001080" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">11,781,660</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AD_zM2nNZh2BdGk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">The Company recognized stock-based compensation expense for stock options
of $<span id="xdx_901_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z2Ij1CKZiohc" title="Recognized stock-based compensation expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember" id="Fact001082" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,626,402</ix:nonFraction></span> and $<span id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zthctUGcW1x1" title="Recognized stock-based compensation expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember" id="Fact001084" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,716,475</ix:nonFraction></span> for the years ended December 31, 2024 and 2023, respectively. In May 2022, the Company modified the exercise
price on <span id="xdx_900_ecustom--StockOptionAwardsSharesModified_iI_c20220531__us-gaap--PlanNameAxis__custom--MayTwoThousandTwentyTwoExercisePriceModificationMember_zMu9IcaD1gei" title="Stock option awards shares modified"><ix:nonFraction name="CELC:StockOptionAwardsSharesModified" contextRef="AsOf2022-05-31_custom_MayTwoThousandTwentyTwoExercisePriceModificationMember" id="Fact001086" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">776,324</ix:nonFraction></span> stock option awards to $<span id="xdx_904_ecustom--ModifiedStockOptionExercisePrice_iI_c20220531__us-gaap--PlanNameAxis__custom--MayTwoThousandTwentyTwoExercisePriceModificationMember_zrI3NB8onBGd" title="Stock option exercise price per share"><ix:nonFraction name="CELC:ModifiedStockOptionExercisePrice" contextRef="AsOf2022-05-31_custom_MayTwoThousandTwentyTwoExercisePriceModificationMember" id="Fact001088" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.50</ix:nonFraction></span>, the closing market price on the Nasdaq Capital Market on May 17,2022. The effect of this
modification on stock-based compensation was $<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_pp0p0_c20240101__20241231__us-gaap--PlanNameAxis__custom--MayTwoThousandTwentyTwoExercisePriceModificationMember_zK8zr4ymllGb" title="Stock based compensation expense related to modification"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" contextRef="From2024-01-012024-12-31_custom_MayTwoThousandTwentyTwoExercisePriceModificationMember" id="Fact001090" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">106,000</ix:nonFraction></span> and $<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_pp0p0_c20230101__20231231__us-gaap--PlanNameAxis__custom--MayTwoThousandTwentyTwoExercisePriceModificationMember_z86b0ScheOb" title="Stock based compensation expense related to modification"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" contextRef="From2023-01-012023-12-31_custom_MayTwoThousandTwentyTwoExercisePriceModificationMember" id="Fact001092" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">134,000</ix:nonFraction></span> for the years ended December 31, 2024 and 2023, respectively. The effect
of this modification on stock-based compensation over the remaining service period will be approximately $<span id="xdx_902_ecustom--RemainingStockBasedCompensationExpenseRelatedToModification_pdp0_c20240101__20241231__us-gaap--PlanNameAxis__custom--MayTwoThousandTwentyTwoExercisePriceModificationMember_zhOlYVakGVQk" title="Remaining stock based compensation expense related to modification"><ix:nonFraction name="CELC:RemainingStockBasedCompensationExpenseRelatedToModification" contextRef="From2024-01-012024-12-31_custom_MayTwoThousandTwentyTwoExercisePriceModificationMember" id="Fact001094" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">57,000</ix:nonFraction></span>. In December 2021, the
Company modified the exercise price on <span id="xdx_903_ecustom--StockOptionAwardsSharesModified_iI_c20211231__us-gaap--PlanNameAxis__custom--DecemberTwoThousandTwentyOneExercisePriceModificationMember_zLWEK4WL3HE9" title="Stock option awards shares modified"><ix:nonFraction name="CELC:StockOptionAwardsSharesModified" contextRef="AsOf2021-12-31_custom_DecemberTwoThousandTwentyOneExercisePriceModificationMember" id="Fact001096" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">311,000</ix:nonFraction></span> stock option awards to $<span id="xdx_90C_ecustom--ModifiedStockOptionExercisePrice_iI_c20211231__us-gaap--PlanNameAxis__custom--DecemberTwoThousandTwentyOneExercisePriceModificationMember_zBR1hrTDyBL1" title="Stock option exercise price per share"><ix:nonFraction name="CELC:ModifiedStockOptionExercisePrice" contextRef="AsOf2021-12-31_custom_DecemberTwoThousandTwentyOneExercisePriceModificationMember" id="Fact001098" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">13.44</ix:nonFraction></span>, the closing market price on the Nasdaq Capital Market on
December 15, 2021. No director or officer awards were modified. The effect on stock-based compensation was $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_pp0p0_c20240101__20241231__us-gaap--PlanNameAxis__custom--DecemberTwoThousandTwentyOneExercisePriceModificationMember_zs7MfDLj4Je2" title="Stock based compensation expense related to modification"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" contextRef="From2024-01-012024-12-31_custom_DecemberTwoThousandTwentyOneExercisePriceModificationMember" id="Fact001100" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">63,000</ix:nonFraction></span> and $<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_pp0p0_c20230101__20231231__us-gaap--PlanNameAxis__custom--DecemberTwoThousandTwentyOneExercisePriceModificationMember_z9DvLiy1lnsh" title="Stock based compensation expense related to modification"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" contextRef="From2023-01-012023-12-31_custom_DecemberTwoThousandTwentyOneExercisePriceModificationMember" id="Fact001102" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">65,000</ix:nonFraction></span> for the
years ended December 31, 2024 and 2023, respectively. The effect on stock-based compensation over the remaining service period will be
approximately $<span id="xdx_903_ecustom--RemainingStockBasedCompensationExpenseRelatedToModification_c20240101__20241231__us-gaap--PlanNameAxis__custom--DecemberTwoThousandTwentyOneExercisePriceModificationMember_zHxFEnBStVxa" title="Remaining stock based compensation expense related to modification"><ix:nonFraction name="CELC:RemainingStockBasedCompensationExpenseRelatedToModification" contextRef="From2024-01-012024-12-31_custom_DecemberTwoThousandTwentyOneExercisePriceModificationMember" id="Fact001104" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,000</ix:nonFraction></span>. In May 2020, the Company modified the exercise price on <span id="xdx_909_ecustom--StockOptionAwardsSharesModified_iI_c20200531__us-gaap--PlanNameAxis__custom--MayTwoThousandTwentyExercisePriceModificationMember_zPmCcuOZAGuj" title="Stock option awards shares modified"><ix:nonFraction name="CELC:StockOptionAwardsSharesModified" contextRef="AsOf2020-05-31_custom_MayTwoThousandTwentyExercisePriceModificationMember" id="Fact001106" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">203,750</ix:nonFraction></span> stock option awards to $<span id="xdx_907_ecustom--ModifiedStockOptionExercisePrice_iI_c20200531__us-gaap--PlanNameAxis__custom--MayTwoThousandTwentyExercisePriceModificationMember_zEAhVaMiniV6" title="Stock option exercise price per share"><ix:nonFraction name="CELC:ModifiedStockOptionExercisePrice" contextRef="AsOf2020-05-31_custom_MayTwoThousandTwentyExercisePriceModificationMember" id="Fact001108" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.10</ix:nonFraction></span>, the closing market
price on the Nasdaq Capital Market on May 14, 2020. No director or officer awards were modified. The effect on stock-based compensation
was $<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_pp0p0_c20240101__20241231__us-gaap--PlanNameAxis__custom--MayTwoThousandTwentyExercisePriceModificationMember_zjCIyWfxx8kh" title="Stock based compensation expense related to modification"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" contextRef="From2024-01-012024-12-31_custom_MayTwoThousandTwentyExercisePriceModificationMember" id="Fact001110" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">696</ix:nonFraction></span> and $<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_pp0p0_c20230101__20231231__us-gaap--PlanNameAxis__custom--MayTwoThousandTwentyExercisePriceModificationMember_zIbRdVdy4F4k" title="Stock based compensation expense related to modification"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" contextRef="From2023-01-012023-12-31_custom_MayTwoThousandTwentyExercisePriceModificationMember" id="Fact001112" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">19,000</ix:nonFraction></span> for the years ended December 31, 2024 and 2023, respectively. There is no effect on stock-based compensation remaining.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 4.9pt 0 0">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001114" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><p id="xdx_894_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zi73cEuSmWcd" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 4.9pt 0 0">The Black-Scholes option-pricing model was used to estimate the
fair value of equity-based awards and the Monte Carlo simulation model was used to estimate the fair value of the performance-based awards,
with the following weighted-average assumptions for the years ended December 31:</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 4.9pt 0 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BD_zHcfdfNr9DFl" style="display: none">Schedule
of Assumptions for Fair Value of Equity-based Awards</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 84%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Risk-free interest rate</td><td>&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20240101__20241231_z1XNMJkdpoic" title="Risk-free interest rate, minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="From2024-01-01to2024-12-31" id="Fact001116" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.48</ix:nonFraction></span>% - <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20240101__20241231_zhikFLceRTj2" title="Risk-free interest rate, maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="From2024-01-01to2024-12-31" id="Fact001118" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.71</ix:nonFraction></span>%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20230101__20231231_zoSbEHdl2yq3" title="Risk-free interest rate, minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="From2023-01-012023-12-31" id="Fact001120" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.41</ix:nonFraction></span>% - <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20230101__20231231_zoIxufmX3D6j" title="Risk-free interest rate, maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="From2023-01-012023-12-31" id="Fact001122" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.86</ix:nonFraction></span>%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Expected volatility</td><td>&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right">&#160;<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20240101__20241231_zuYuGglRn2gd" title="Expected volatility, minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="From2024-01-01to2024-12-31" id="Fact001124" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">71.2</ix:nonFraction></span>% - <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20240101__20241231_zan1YJLKGjMl" title="Expected volatility, maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="From2024-01-01to2024-12-31" id="Fact001126" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">76.20</ix:nonFraction></span>%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20230101__20231231_zTjU6ctWXmQh" title="Expected volatility, minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="From2023-01-012023-12-31" id="Fact001128" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">77.1</ix:nonFraction></span>% - <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20230101__20231231_zNAdQkiZXBB2" title="Expected volatility, maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="From2023-01-012023-12-31" id="Fact001130" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">79.8</ix:nonFraction></span>%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Expected life (years)</td><td>&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_ztcUXQwc3aKf" title="Expected life (years)"><ix:nonNumeric contextRef="From2024-01-012024-12-31_srt_MinimumMember" format="ixt-sec:duryear" id="Fact001132" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.25</ix:nonNumeric></span> to <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_zLukX40oGYQi" title="Expected life (years)"><ix:nonNumeric contextRef="From2024-01-012024-12-31_srt_MaximumMember" format="ixt-sec:duryear" id="Fact001134" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">10.00</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_ztrk0FdUILQj" title="Expected life (years)"><ix:nonNumeric contextRef="From2023-01-012023-12-31_srt_MinimumMember" format="ixt-sec:duryear" id="Fact001136" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.25</ix:nonNumeric></span> to <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_zH5GuzyAtgvh" title="Expected life (years)"><ix:nonNumeric contextRef="From2023-01-012023-12-31_srt_MaximumMember" format="ixt-sec:duryear" id="Fact001138" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6.08</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 70%; text-align: justify">Expected dividend yield</td><td style="width: 1%">&#160;</td>
    <td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20241231_z6k1cfE1V3Ql" title="Expected dividend yield" style="white-space: nowrap; width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2024-01-01to2024-12-31" id="Fact001140" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20231231_ztVVj0EN6zzc" title="Expected dividend yield" style="white-space: nowrap; width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2023-01-012023-12-31" id="Fact001142" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A9_zJTc14J4s0Xa" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">The inputs for the Black-Scholes valuation model and the Monte Carlo simulation
model require management&#8217;s significant assumptions. Prior to the Company&#8217;s initial public offering, the price per share of
common stock was determined by the Company&#8217;s board based on recent prices of common stock sold in private offerings. Subsequent
to the initial public offering, the price per share of common stock is determined by using the closing market price on the Nasdaq Capital
Market on the grant date. The risk-free interest rates are based on the rate for U.S. Treasury securities at the date of grant with maturity
dates approximately equal to the expected life at the grant date. The expected life is based on the simplified method for the time-based
awards and the life of the option for the performance-based awards, in accordance with the SEC Staff Accounting Bulletin Nos. 107 and
110. The expected volatility is estimated based on historical volatility information of peer companies that are publicly available in
combination with the Company&#8217;s calculated volatility since being publicly traded for the time-based awards. For the performance-based
awards, the Company&#8217;s full historical volatility was used to value the options.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">All assumptions used to calculate the grant date fair value of non-employee
options are generally consistent with the assumptions used for options granted to employees. In the event the Company terminates any of
its consulting agreements, the unvested options issued in connection with the agreements would also be cancelled.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">The Company had <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_pid_c20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zyz9NJPipx76" title="Restricted stock awards outstanding"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2024-12-31_us-gaap_RestrictedStockMember" id="Fact001144" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,079</ix:nonFraction></span> and <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_pid_c20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zC846HM4wu1e" title="Restricted stock awards outstanding"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2023-12-31_us-gaap_RestrictedStockMember" id="Fact001146" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,958</ix:nonFraction></span> shares of restricted stock outstanding
at December 31, 2024 and 2023, respectively, and <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zhLZjZ9GRrL2" title="Restricted stock awards vested"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockMember1617133937" id="Fact001148" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,308</ix:nonFraction></span> and <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zYwuq1lotWr" title="Restricted stock awards vested"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockMember1617133937" id="Fact001150" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,273</ix:nonFraction></span> shares of restricted stock vested during the years ended December 31,
2024 and 2023, respectively. The Company recognized stock-based compensation expense for restricted stock of $<span id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zQClfC2rh6K6" title="Recognized stock-based compensation expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockMember1617133937" id="Fact001152" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">22,220</ix:nonFraction></span> and $<span id="xdx_908_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zHg1gQ7rcRhd" title="Recognized stock-based compensation expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockMember1617133937" id="Fact001154" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">18,499</ix:nonFraction></span> for the
years ended December 31, 2024 and 2023, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">The total remaining shares available for grant under the Company&#8217;s
2017 Plan as of December 31, 2024 was <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenPlanMember_zvVaB84mvc22" title="Shares available for grant under the 2017 Plan"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2024-12-31_custom_TwoThousandSeventeenPlanMember" id="Fact001156" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,177,450</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 62; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001158" name="us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock"><p id="xdx_89C_eus-gaap--ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_zFlXY2ZIJtIf" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">Total unrecognized compensation cost related to stock options and restricted
stock is estimated to be recognized at December 31:</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BF_zruehIE5AH0e" style="display: none">Schedule
of Unrecognized Compensation Cost</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_497_20241231_zDiqDKG6Yend" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td></tr>
<tr id="xdx_40D_ecustom--EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostToBeRecognizedNextTwelveMonths_iI_pp0p0_maESSBCzuFt_zL2GOdxD4VQ1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 85%; text-align: justify">2025</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="CELC:EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostToBeRecognizedNextTwelveMonths" contextRef="AsOf2024-12-31" id="Fact001160" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,776,307</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostToBeRecognizedWithinTwoYear_iI_pp0p0_maESSBCzuFt_zcDSPaQcZ7Vf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostToBeRecognizedWithinTwoYear" contextRef="AsOf2024-12-31" id="Fact001162" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,307,024</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostToBeRecognizedwithinThreeYears_iI_pp0p0_maESSBCzuFt_zUon9dbpcGAk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostToBeRecognizedwithinThreeYears" contextRef="AsOf2024-12-31" id="Fact001164" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,165,880</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostToBeRecognizedWithinFourYears_iI_pp0p0_maESSBCzuFt_zShnqUzpWSag" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">2028</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="CELC:EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostToBeRecognizedWithinFourYears" contextRef="AsOf2024-12-31" id="Fact001166" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,964,136</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostToBeRecognized_iTI_pp0p0_mtESSBCzuFt_zFTAbaTPyOAj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt; text-indent: 10.05pt">Total estimated compensation cost to be recognized</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="CELC:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostToBeRecognized" contextRef="AsOf2024-12-31" id="Fact001168" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">21,213,347</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A9_zcEaKapNqQVk" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><span style="text-decoration: underline">2017 Employee Stock Purchase Plan</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">The Company&#8217;s 2017 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;)
was adopted by the Company&#8217;s board on September 6, 2017 and approved by stockholders at the Company&#8217;s annual stockholder meeting
on May 10, 2018. The Company initially reserved a total of <span id="xdx_908_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20180510__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_zWkJLEboRYu8" title="Common stock, shares reserved for issuance"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2018-05-10_custom_EmployeeStockPurchasePlanMember" id="Fact001170" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000</ix:nonFraction></span> shares for issuance under the ESPP. The number of shares reserved for
issuance was automatically increased by <span id="xdx_90A_ecustom--ChangeInCommonStockSharesReservedForIssuance_iI_pid_c20240101__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_zplg5h83yCw1" title="Change in common stock, shares reserved for issuance"><ix:nonFraction name="CELC:ChangeInCommonStockSharesReservedForIssuance" contextRef="AsOf2024-01-01_custom_EmployeeStockPurchasePlanMember" id="Fact001172" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">127,530</ix:nonFraction></span> and <span id="xdx_90A_ecustom--ChangeInCommonStockSharesReservedForIssuance_iI_pid_c20230101__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_zgxHaixpYMVb" title="Change in common stock, shares reserved for issuance"><ix:nonFraction name="CELC:ChangeInCommonStockSharesReservedForIssuance" contextRef="AsOf2023-01-01_custom_EmployeeStockPurchasePlanMember" id="Fact001174" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">108,337</ix:nonFraction></span> shares on January 1, 2024 and 2023, respectively and will increase automatically
on each subsequent January 1 by <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_zjzjj9Oukk05" title="Annual employee stock purchase plan description"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_EmployeeStockPurchasePlanMember" id="Fact001176" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">the number of shares equal to 0.5% of the total outstanding number of shares of Company common stock as
of the immediately preceding December 31.</ix:nonNumeric></span> However, the Company&#8217;s board may reduce the amount of the increase in any particular year.
The total remaining shares available for issuance under the employee stock purchase plan as of December 31, 2024 is <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_zAoN60aqUax5" title="Shares available for grant under the 2017 Plan"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2024-12-31_custom_EmployeeStockPurchasePlanMember" id="Fact001178" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">360,950</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">The ESPP provides participating employees with an opportunity to purchase
shares of the Company&#8217;s common stock at a discount through payroll deductions. The ESPP is available to all employees unless they
are employed for less than 20 hours per week or own 5% or more of the total combined voting power or value of the Company&#8217;s common
stock. The ESPP is administered using overlapping 24 month offering periods, referred to as an Offering Period. Each Offering Period has
four six-month purchase periods. A new Offering Period and purchase period begin every six months on May 1 and November 1 of each year.
Participating employees may purchase common stock, on a voluntary after tax-basis, at a price equal to 85% of the fair market value of
a share of common stock on either the offering date or the purchase date, whichever is lower. If the purchase date has a lower price,
the employee will automatically be placed in the Offering Period beginning immediately after the purchase date. The Company recognized
stock-based compensation expense related to the ESPP of $<span id="xdx_908_eus-gaap--AllocatedShareBasedCompensationExpense_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockIncentivePlanMember_zPgOedyf822b" title="Recognized stock-based compensation expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-12-31_custom_StockIncentivePlanMember" id="Fact001180" format="ixt:numdotdecimal" decimals="0" unitRef="USD">339,719</ix:nonFraction></span> and $<span id="xdx_90A_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockIncentivePlanMember_zgmMNiIojL2h" title="Recognized stock-based compensation expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-12-31_custom_StockIncentivePlanMember" id="Fact001182" format="ixt:numdotdecimal" decimals="0" unitRef="USD">166,460</ix:nonFraction></span> for the years ended December 31, 2024 and 2023, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001184" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"><p id="xdx_89A_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zqjQEPVij6Hl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognized total stock-based compensation
expense as follows for the years ended December 31:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BC_zjAZERWI5os" style="display: none">Schedule
of Stock-based Compensation Expenses</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20240101__20241231_z4pmCOqoASr7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20230101__20231231_zIZEONn9stw4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Years Ended</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31:</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Stock-based compensation expense in operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zE5iyqF5CJ8l" style="vertical-align: bottom; background-color: White">
    <td style="width: 70%; text-align: justify; text-indent: 10pt">Research and development</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact001186" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,404,518</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact001187" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,700,318</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zGtGu59uNYjh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt; text-indent: 10pt">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact001189" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,583,823</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact001190" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,201,116</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ShareBasedCompensation_zQia2ur1xLX7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: 10pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-01to2024-12-31" id="Fact001192" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,988,341</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-12-31" id="Fact001193" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,901,434</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ShareBasedCompensation_zcZVzUBneNid" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: 10pt">Stock-based compensation expense</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-01to2024-12-31" id="Fact001195" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,988,341</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-12-31" id="Fact001196" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,901,434</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A1_zb28X9McXF7f" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001198" name="us-gaap:DebtDisclosureTextBlock"><p id="xdx_807_eus-gaap--DebtDisclosureTextBlock_zMNrH3n0QoW1" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"> <b>12.</b> <b><span id="xdx_824_zR4RVYUpgQR3">Debt</span></b></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 30, 2024, the Company entered into an Amended
and Restated Loan and Security Agreement (the &#8220;A&amp;R Loan Agreement&#8221;) with Innovatus Life Sciences Lending Fund I, LP, a
Delaware limited partnership (&#8220;Innovatus&#8221;), as collateral agent, and the Lenders including Innovatus in its capacity as a
Lender and Oxford Finance LLC (&#8220;Oxford&#8221;), pursuant to which Innovatus and Oxford, as Lenders, have agreed to make certain
term loans (&#8220;Term Loans&#8221;) to the Company in the aggregate principal amount of up to $<span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_pn6n6_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__srt--RangeAxis__srt--MaximumMember_ztfxGLKU9yUi" title="Funded contingent loan, outstanding"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_srt_MaximumMember" id="Fact001200" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">180</ix:nonFraction></span> million. The A&amp;R Loan Agreement
amends and restates, in its entirety, that certain Loan and Security Agreement, dated April 8, 2021, as amended, between the Company and
Innovatus, as collateral agent, and the Lenders named therein (the &#8220;Prior Loan Agreement&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 63; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Funding of the first $<span id="xdx_90A_eus-gaap--DebtInstrumentCarryingAmount_iI_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_zTSalFNX08oc" title="Funded loan amount"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember" id="Fact001202" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100</ix:nonFraction></span> million under the A&amp;R
Loan Agreement occurred on May 30, 2024, including tranche payments of $<span id="xdx_904_eus-gaap--DebtInstrumentCarryingAmount_iI_pn5n6_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermALoanMember_zi3GRpUmejQ" title="Funded loan amount"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermALoanMember" id="Fact001204" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">16.8</ix:nonFraction></span> million (the &#8220;Term A Loan&#8221;) and $<span id="xdx_90B_eus-gaap--DebtInstrumentCarryingAmount_iI_pn5n6_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermBLoanMember_zvbZPwsSfz59" title="Funded loan amount"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermBLoanMember" id="Fact001206" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">21.5</ix:nonFraction></span> million
(the &#8220;Term B Loan&#8221;) reflecting repayment of the principal amount of loans under the Prior Loan Agreement plus accrued payment-in-kind
interest, in addition to $<span id="xdx_90E_eus-gaap--DebtInstrumentCarryingAmount_iI_pn5n6_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermCLoanMember_zrqJkjMwWZa6" title="Funded loan amount"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermCLoanMember" id="Fact001208" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">61.7</ix:nonFraction></span> million of new borrowings (the &#8220;Term C Loan&#8221;). The Company will be eligible to draw on a fourth
tranche of $<span id="xdx_90D_eus-gaap--DebtInstrumentCarryingAmount_iI_pn6n6_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermDLoanMember_zc9qqqOg8Oje" title="Funded loan amount"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermDLoanMember" id="Fact001210" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">30</ix:nonFraction></span> million (the &#8220;Term D Loan&#8221;) and fifth tranche of $<span id="xdx_909_eus-gaap--DebtInstrumentCarryingAmount_iI_pn6n6_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermELoanMember_ztkNXOFDwlz5" title="Funded loan amount"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermELoanMember" id="Fact001212" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">50</ix:nonFraction></span> million (the &#8220;Term E Loan&#8221;), in each case
upon achievement of certain clinical trial milestones and satisfaction of certain financial covenants determined on a pro forma as-funded
basis. The Lenders may, in their sole discretion upon the Company&#8217;s request, make additional term loans to the Company of $<span id="xdx_904_eus-gaap--DebtInstrumentCarryingAmount_iI_pn6n6_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermFLoanMember_z5LlJXBabZYf" title="Funded loan amount"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermFLoanMember" id="Fact001214" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">45</ix:nonFraction></span> million
(the &#8220;Term F Loan&#8221;). Funding of these additional tranches is also subject to other customary conditions and limits on when
the Company can request funding for such tranches. Costs associated with the new borrowings was approximately $<span id="xdx_908_eus-gaap--OtherBorrowings_iI_pn5n6_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_z0VgYGhNj4qa" title="Costs associated with new borrowings"><ix:nonFraction name="us-gaap:OtherBorrowings" contextRef="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember" id="Fact001216" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.4</ix:nonFraction></span> million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the A&amp;R Loan Agreement, <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateTerms_pid_dp_c20240530__20240530__us-gaap--TypeOfArrangementAxis__custom--AmendedAndRestatedLoanAgreementMember_zUcTcz1HmJW8" title="Debt instrument interest rate description"><ix:nonNumeric contextRef="From2024-05-302024-05-30_custom_AmendedAndRestatedLoanAgreementMember" id="Fact001218" name="us-gaap:DebtInstrumentInterestRateTerms">the Company
is entitled to make interest-only payments for thirty-six months, or up to forty-eight months if certain conditions are met. The Term
Loans will mature on May 1, 2029 and will bear interest at a rate equal to the sum of (a) the greater of (i) the Prime Rate (as defined
in the A&amp;R Loan Agreement) or (ii) 7.75%, plus (b) 2.85%, provided that 1.0% of such interest will be payable in-kind by adding an
amount equal to such 1.0% of the outstanding principal amount to the then outstanding principal balance on a monthly basis through May
31, 2027.</ix:nonNumeric></span> The A&amp;R Loan Agreement is secured by all assets of the Company. Proceeds will be used for working capital purposes and to
fund the Company&#8217;s general business requirements, including the Phase 3 VIKTORIA-2 clinical trial. The A&amp;R Loan Agreement contains
customary representations and warranties and covenants, subject to customary carve-outs, and includes financial covenants related to liquidity
and other financial measures. Innovatus has the right, at its election and until August 9, 2025, to convert up to <span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermALoanMember_zn4oUIqq2pW4" title="Loan conversion percentage"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermALoanMember" id="Fact001220" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">20</ix:nonFraction></span>% of the outstanding
principal of the Term A Loan into shares of the Company&#8217;s common stock at a price per share of $<span id="xdx_904_eus-gaap--SaleOfStockPricePerShare_iI_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermALoanMember_zj7cWUAWnNya" title="Common stock price per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermALoanMember" id="Fact001222" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction></span> (the &#8220;Conversion Right&#8221;).
Innovatus will continue to have the right to exercise a previously disclosed warrant granted to it under the Prior Loan Agreement to purchase
<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240530__20240530__us-gaap--PlanNameAxis__custom--PriorLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_ziM1TP4R2dq1" title="Common stock issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-05-302024-05-30_custom_PriorLoanAgreementMember_custom_InnovatusLifeSciencesMember" id="Fact001224" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">26,042</ix:nonFraction></span> shares of common stock at a price per share of $<span id="xdx_90D_eus-gaap--SaleOfStockPricePerShare_iI_c20240530__us-gaap--PlanNameAxis__custom--PriorLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_zsPSU0AbrZni" title="Common stock price per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2024-05-30_custom_PriorLoanAgreementMember_custom_InnovatusLifeSciencesMember" id="Fact001226" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">14.40</ix:nonFraction></span> through April 8, 2031.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The A&amp;R Loan Agreement contains a Final Fee, which
is equal to <span id="xdx_90C_ecustom--FinalFeePercentage_dp_uPure_c20240530__20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_zCEAWTy4P444" title="Final fee percentage"><ix:nonFraction name="CELC:FinalFeePercentage" contextRef="From2024-05-302024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember" id="Fact001228" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.5</ix:nonFraction></span>% of the initial funding of the agreement and is due on the earliest to occur of (a) the Maturity Date, (b) the acceleration
of any Term Loan, and (c) the prepayment of the Term Loans. There is also a contingent non-utilization fee for both the Term D and Term
E loans. If the Company achieves the Term D Milestone and (i) fails to draw the full amount of the Term D Loan during the Term D Draw
Period and (ii) fails to notify Collateral Agent, at any time before the date that is four weeks after the Company&#8217;s achievement
of the Term D Milestone, of the Company&#8217;s intent not to draw the full amount of the Term D Loan, a non-utilization fee of $<span id="xdx_909_ecustom--NonUtilizationFee_iI_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermDLoanMember_ziF0ZP2kePig" title="Non utilization fee"><ix:nonFraction name="CELC:NonUtilizationFee" contextRef="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermDLoanMember" id="Fact001230" format="ixt:numdotdecimal" decimals="0" unitRef="USD">900,000</ix:nonFraction></span>,
with respect to the Term D Loan shall become due and payable on the earliest of (i) the termination of the Term D Draw Period, (ii) the
Maturity Date, (iii) the acceleration of any Term Loan, and (iv) the prepayment in whole of the Term Loans. If the Company achieves the
Term E Milestone and (i) fails to draw the full amount of the Term E Loan during the Term E Draw Period and (ii) fails to notify Collateral
Agent, at any time before the date that is four weeks after the Company&#8217;s achievement of the Term E Milestone, of the Company&#8217;s
intent not to draw the full amount of the Term E Loan, a non-utilization fee of $<span id="xdx_90D_ecustom--NonUtilizationFee_iI_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermELoanMember_z3jgeNPV2N8g" title="Non utilization fee"><ix:nonFraction name="CELC:NonUtilizationFee" contextRef="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermELoanMember" id="Fact001232" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,500,000</ix:nonFraction></span>, with respect to the Term E Loan shall become
due and payable on the earliest of (i) the termination of the Term E Draw Period, (ii) the Maturity Date, (iii) the acceleration of any
Term Loan, and (iv) the prepayment in whole of the Term Loans. After the 18-month anniversary of the Effective Date, the Company shall
have the option to prepay all, but not less than all, of the Term Loans advanced by the Lenders under the A&amp;R Loan Agreement, provided
the Company (i) provides written notice to Collateral Agent of its election to prepay the Term Loans at least seven Business Days prior
to such prepayment, and (ii) pays to Lenders on the date of such prepayment, payable to each Lender in accordance with its respective
Pro Rata Share, an amount equal to the sum of (A) all outstanding principal of the Term Loans plus accrued and unpaid interest thereon
through the prepayment date, (B) the Final Fee, (C) the Prepayment Fee, plus (D) all other outstanding Obligations that are due and payable,
including, without limitation, Lenders&#8217; Expenses and interest at the Default Rate with respect to any past due amounts. At May 30,
2024, the Company recognized the Final Fee of $<span id="xdx_90C_ecustom--FinalFee_iI_pn5n6_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_z1eqrYRN6cq7" title="Final fee"><ix:nonFraction name="CELC:FinalFee" contextRef="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember" id="Fact001234" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.5</ix:nonFraction></span> million as additional debt principal and a corresponding debt discount to be amortized
over the life of the loan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the funding of each of the Term
C Loan, the Term D Loan, the Term E Loan and the Term F Loan, the Company agreed to issue to Innovatus and Oxford warrants to purchase
that number of shares of the Company&#8217;s common stock equal to <span id="xdx_904_ecustom--WarrantOrRightToPurchasePercentage_iI_dp_uPure_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_zKnFu5iBraW4" title="Warrant or right, reason for issuance, description"><ix:nonFraction name="CELC:WarrantOrRightToPurchasePercentage" contextRef="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember" id="Fact001236" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.5</ix:nonFraction></span>% of the principal amount of the applicable Term Loan divided by
the exercise price, which shall, with respect to the Term C Loan, be equal to the lower of (i) the volume weighted average closing price
of the Company&#8217;s common stock for the five-trading day period ending on the last trading day immediately preceding the execution
of the A&amp;R Loan Agreement or (ii) the closing price on the last trading day immediately preceding the execution of the A&amp;R Loan
Agreement. Accordingly, on May 30, 2024, the Company issued <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zql8p3XMfkNb" title="Warrants issued"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_us-gaap_WarrantMember" id="Fact001238" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">103,876</ix:nonFraction></span> warrants with an exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zetOICOmbxl6" title="Warrants exercise price per share"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_us-gaap_WarrantMember" id="Fact001240" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">14.84</ix:nonFraction></span> per share. The relative
fair value of the warrants was approximately $<span id="xdx_909_eus-gaap--FairValueAdjustmentOfWarrants_pn5n6_c20240530__20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8m7nFWbi5Ol" title="Fair value of warrants"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2024-05-302024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_us-gaap_WarrantMember" id="Fact001242" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.2</ix:nonFraction></span> million. For the additional Term Loans, the exercise price will be based on the lower
of (i) the exercise price for the Warrants issued pursuant to the Term C Loan or (ii) the volume weighted average closing price of the
Company&#8217;s common stock for the five-trading day period ending on the last trading day immediately preceding the applicable Term
Loan funding. The Warrants may be exercised on a cashless basis and are exercisable through the tenth anniversary of the applicable funding
date. The number of shares of common stock for which each Warrant is exercisable and the associated exercise price are subject to certain
proportional adjustments as set forth in such Warrant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 64; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company evaluated the change of terms under ASC
470-50, &#8220;Debt &#8211; Modification and Extinguishment&#8221;, and concluded the change in terms did not result in significant and
consequential changes to the economic substance of the debt and thus resulted in a modification of the debt and not an extinguishment
of the debt.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001244" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock"><p id="xdx_893_eus-gaap--ScheduleOfDebtInstrumentsTextBlock_z4FIW90rHuC5" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">Long-term debt consisted of the following at December 31, 2024 and 2023:</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B0_z8dSaWmxp0n4" style="display: none">Schedule
of Long-term Debt</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 84%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20241231_zKix3ZlY60Vk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20231231_zyyPM9XP68Be" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_maLTNPzDBl_zXqzR6wOdP28" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; text-align: justify">Note payable</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ConvertibleNotesPayable" contextRef="AsOf2024-12-31" id="Fact001246" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">100,000,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ConvertibleNotesPayable" contextRef="AsOf2023-12-31" id="Fact001247" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">35,000,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--FinalFee_iI_pp0p0_maLTNPzDBl_zy5rhZjOi9Yc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: 10pt">Add: Final fee</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:FinalFee" contextRef="AsOf2024-12-31" id="Fact001249" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,500,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1250">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--PaymentInKindInterestDebt_iI_pp0p0_maLTNPzDBl_z4bMaU1j59nf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: 10pt">Add: PIK interest (added to principal)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:PaymentInKindInterestDebt" contextRef="AsOf2024-12-31" id="Fact001252" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">593,288</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:PaymentInKindInterestDebt" contextRef="AsOf2023-12-31" id="Fact001253" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,565,660</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_pp0p0_di_msLTNPzDBl_zFCkF9UCglm2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: 10pt">Less: unamortized debt issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" contextRef="AsOf2024-12-31" id="Fact001255" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,613,734</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" contextRef="AsOf2023-12-31" id="Fact001256" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">480,810</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_pp0p0_di_msLTNPzDBl_zXHN7LV8JQd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt; text-indent: 10pt">Less: unamortized debt discount</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="AsOf2024-12-31" id="Fact001258" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,752,418</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="AsOf2023-12-31" id="Fact001259" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">49,439</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--LongTermNotesPayable_iTI_pp0p0_mtLTNPzDBl_zaFsIYSIvzXj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total long-term debt</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LongTermNotesPayable" contextRef="AsOf2024-12-31" id="Fact001261" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">97,727,136</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LongTermNotesPayable" contextRef="AsOf2023-12-31" id="Fact001262" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">37,035,411</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AD_zZXKhh9oIsed" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001264" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"><p id="xdx_89A_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_zouddcjRuUoj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Future principal payments, including the incurred PIK interest and Final
Fee, are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B1_zAZvIQEIocXl" style="display: none">Schedule
of Long Term Debt Future Principal Payments</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20241231_zCLwHSzl0jza" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Years Ending December 31,</td><td style="white-space: nowrap; text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_pp0p0_maLTDz4sG_zqGYNr5TbYpi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 85%; text-align: justify">2027</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" contextRef="AsOf2024-12-31" id="Fact001266" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">30,615,349</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_pp0p0_maLTDz4sG_zEDf33kGEZCk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" contextRef="AsOf2024-12-31" id="Fact001268" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">52,483,455</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_iI_pp0p0_maLTDz4sG_z1hIXAWYJFK" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">2029</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" contextRef="AsOf2024-12-31" id="Fact001270" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">21,994,484</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LongTermDebt_iTI_pp0p0_mtLTDz4sG_zu2R6m7Uw7ol" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LongTermDebt" contextRef="AsOf2024-12-31" id="Fact001272" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">105,093,288</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_zvrM2ifobLvf" style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001274" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_807_eus-gaap--IncomeTaxDisclosureTextBlock_zVs5ZXjffgLk" style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"> 13. <span id="xdx_829_zCdWARHhC9p1">Income Taxes</span></p>



<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-weight: normal">Following the conversion of Celcuity
LLC to Celcuity Inc. on September 15, 2017, Celcuity Inc. began filing federal and state returns where required. No income tax benefit
was recorded for the years 2024 and 2023, due to net losses and recognition of a valuation allowance. The following table presents a reconciliation
of the tax expense computed at the statutory federal rate and the Company&#8217;s tax expense for the years ended December 31:</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001276" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"><p id="xdx_89B_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zB5UX1r18GWb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span><span id="xdx_8B5_zEiyrQ6Thjgj" style="display: none">Schedule of Effective Income Tax Rate Reconciliation</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20240101__20241231_zd3FMT1mNz5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20230101__20231231_z8BoF2S3Hl7i" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBzqmi_zXiOhWKs6Rtj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; text-align: justify">Tax benefit at statutory federal rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="From2024-01-01to2024-12-31" id="Fact001278" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">23,474,000</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="From2023-01-012023-12-31" id="Fact001279" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,394,000</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBzqmi_z6hbwe6AMNp6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">State income tax benefit, net of federal tax effect</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="From2024-01-01to2024-12-31" id="Fact001281" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">95,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="From2023-01-012023-12-31" id="Fact001282" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">82,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzqmi_zM6obevT0q2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Change in valuation allowance on deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2024-01-01to2024-12-31" id="Fact001284" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,081,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2023-01-012023-12-31" id="Fact001285" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,542,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_iN_di_msITEBzqmi_zww4MI5HDY4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Research &amp; Development Credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" contextRef="From2024-01-01to2024-12-31" id="Fact001287" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,236,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" contextRef="From2023-01-012023-12-31" id="Fact001288" format="ixt:numdotdecimal" decimals="0" unitRef="USD">550,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseOther_maITEBzqmi_zMmUTdfnRDg1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Other permanent items</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" contextRef="From2024-01-01to2024-12-31" id="Fact001290" format="ixt:numdotdecimal" decimals="0" unitRef="USD">724,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" contextRef="From2023-01-012023-12-31" id="Fact001291" format="ixt:numdotdecimal" decimals="0" unitRef="USD">484,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzqmi_zPQ1UHAjVfC2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: 10pt">Income tax benefits</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1293">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1294">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AC_zx3lRmetW93i" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 65; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">Deferred income taxes reflect the net effects of temporary differences
between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.
The Company&#8217;s deferred tax assets relate primarily to its net operating loss carryforwards and other balance sheet basis differences.
In accordance with ASC 740, &#8220;Income Taxes,&#8221; the Company recorded a valuation allowance to fully offset the net deferred tax
asset, because it is more likely than not that the Company will not realize future benefits associated with these deferred tax assets
at December 31, 2024. The tax effects of temporary differences and carryforwards that give rise to significant portions of the deferred
tax assets are at December 31:</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001296" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><p id="xdx_892_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zxB9MWb50gj5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B5_zbu4fytXjawc" style="display: none">Schedule of Deferred Tax Assets and Liabilities</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 84%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20241231_zvHguWFXE48f" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20231231_zdFXcPVIh0h7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Deferred tax assets (liabilities):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_iI_pp0p0_maDTALNzvdJ_zx0aXuA1qHg4" style="vertical-align: bottom; background-color: White">
    <td style="width: 70%; text-align: justify">Accrued expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" contextRef="AsOf2024-12-31" id="Fact001298" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">459,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" contextRef="AsOf2023-12-31" id="Fact001299" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">207,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pp0p0_maDTALNzvdJ_zVFZ3xyBdvE3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2024-12-31" id="Fact001301" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,861,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2023-12-31" id="Fact001302" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,141,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_pp0p0_maDTALNzvdJ_zTTjiupXCBl3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" contextRef="AsOf2024-12-31" id="Fact001304" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">420,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" contextRef="AsOf2023-12-31" id="Fact001305" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">393,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--DeferredTaxAssetsRightofuseAssets_iI_pp0p0_maDTALNzvdJ_zirTF1tRZYJl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="CELC:DeferredTaxAssetsRightofuseAssets" contextRef="AsOf2024-12-31" id="Fact001307" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">45,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="CELC:DeferredTaxAssetsRightofuseAssets" contextRef="AsOf2023-12-31" id="Fact001308" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">85,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_ecustom--DeferredTaxAssetsLeaseLiability_iNI_pp0p0_di_msDTALNzvdJ_zqCaJTda7Ey1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:DeferredTaxAssetsLeaseLiability" contextRef="AsOf2024-12-31" id="Fact001310" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">48,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:DeferredTaxAssetsLeaseLiability" contextRef="AsOf2023-12-31" id="Fact001311" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">87,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIRC174Expenditures_iI_pp0p0_maDTALNzvdJ_zgCv0dVYT3uc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">IRC 174 Expenditures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIRC174Expenditures" contextRef="AsOf2024-12-31" id="Fact001313" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">30,133,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIRC174Expenditures" contextRef="AsOf2023-12-31" id="Fact001314" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">13,900,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStartupExpenditures_iI_pp0p0_maDTALNzvdJ_zpUYiefYGzRg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Start-up expenditures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStartupExpenditures" contextRef="AsOf2024-12-31" id="Fact001316" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">12,998,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStartupExpenditures" contextRef="AsOf2023-12-31" id="Fact001317" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">11,029,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_maDTALNzvdJ_z4pNHArrA8fj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Net operating losses and tax credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2024-12-31" id="Fact001319" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">13,340,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2023-12-31" id="Fact001320" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,461,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_msDTALNzvdJ_zaxSpx68x7fh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2024-12-31" id="Fact001322" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">60,214,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2023-12-31" id="Fact001323" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">36,133,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pp0p0_mtDTALNzvdJ_zOBeSGoAa3xf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: 10pt">Net deferred tax assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1325">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1326">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A4_zFiEZ3lOBR6c" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At December 31, 2024, the Company had federal and
state net operating loss carryforwards of approximately $<span id="xdx_909_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_pn5n6_c20241231_zZBpufBRnsbe" title="Federal net operating loss carryforwards"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" contextRef="AsOf2024-12-31" id="Fact001328" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">43.2</ix:nonFraction></span> million and $<span id="xdx_907_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_pn5n6_c20241231_zzH4SSSOB6Tf" title="State net operating loss carryforwards"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" contextRef="AsOf2024-12-31" id="Fact001330" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.8</ix:nonFraction></span> million, respectively. The federal and state net operating
loss carryforwards for 2017 will begin to expire in the year ending December 31, 2037. The federal net operating loss carryforwards starting
in 2018 have no expiration. These deferred tax assets were subject to a full valuation allowance as of December 31, 2024 and December
31, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At December 31, 2024, the Company had federal and
state research and development tax credit carryforwards resulting in deferred tax assets of approximately $<span id="xdx_904_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pn5n6_c20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zd68bjXK0bbh" title="Tax credit carryforwards"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="AsOf2024-12-31_us-gaap_DomesticCountryMember" id="Fact001332" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.9</ix:nonFraction></span> million and $<span id="xdx_902_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pn5n6_c20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_z2KWtq0AfJC1" title="Tax credit carryforwards"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="AsOf2024-12-31_us-gaap_StateAndLocalJurisdictionMember" id="Fact001334" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.6</ix:nonFraction></span> million,
respectively. The federal and state credit carryforwards will begin to expire in the years ending December 31, 2038 and December 31, 2033,
respectively. These deferred tax assets were subject to a full valuation allowance as of December 31, 2024 and December 31, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under the provisions of Section&#160;382 of the Internal
Revenue Code of 1986, certain substantial changes in the Company&#8217;s ownership, including a sale of the Company, or significant changes
in ownership due to sales of equity, may limit in the future the amount of net operating loss carryforwards available to offset future
taxable income.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognizes uncertain tax positions in
accordance with ASC 740 on the basis of evaluating whether it is more-likely-than not that the tax positions will be sustained upon examination
by tax authorities. For those tax positions that meet the more-likely-than not recognition threshold, we recognize the largest amount
of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement. As of December 31, 2024, and 2023, the Company
has no significant uncertain tax positions. There are no unrecognized tax benefits included on the balance sheet that would, if recognized,
impact the effective tax rate. The Company does not anticipate there will be a significant change in unrecognized tax benefits within
the next 12 months.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Prior to the conversion, Celcuity was a limited liability
company and therefore was taxed as a partnership for income tax purposes. Accordingly, no benefit for income taxes was recorded prior
to the conversion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For years prior to 2021, the Company is no longer
subject to U.S. federal or state income tax examinations and remains open for the unutilized tax attributes as of December 31, 2024, carried
forward from these years. The Company&#8217;s policy is to recognize interest and penalties related to uncertain tax positions as a component
of general and administrative expenses.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001336" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_803_eus-gaap--SubsequentEventsTextBlock_z5nkbanmoN2c" style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">14.
<span id="xdx_82A_zdjZSpiV6W98">Subsequent Event</span></p>



<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2025, the Board of Directors approved a repricing of certain outstanding stock options previously granted to employees. As of
the repricing date, the exercise prices of these options were reduced to $<span id="xdx_90F_eus-gaap--StockOptionExercisePriceDecrease_c20250102__20250131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zEvaBNA3zmjk" title="Exercise price reduced"><ix:nonFraction name="us-gaap:StockOptionExercisePriceDecrease" contextRef="From2025-01-022025-01-31_us-gaap_SubsequentEventMember" id="Fact001338" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">11.92</ix:nonFraction></span> per share, from their previous exercise prices ranging
from $<span id="xdx_909_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20250102__20250131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zP91PGC6ViA5" title="Exercise price lower"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2025-01-022025-01-31_us-gaap_SubsequentEventMember" id="Fact001340" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.80</ix:nonFraction></span> to $<span id="xdx_900_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250102__20250131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z0vWZ92OjNY9" title="Exercise price upper"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2025-01-022025-01-31_us-gaap_SubsequentEventMember" id="Fact001342" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">18.73</ix:nonFraction></span> per share. This adjustment was made in response to the decline in the company&#8217;s stock price, with the intent
of retaining and motivating key employees. As a result of this repricing, approximately <span id="xdx_908_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zF9SiEaWKlWa" title="Stock options held"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2025-01-31_us-gaap_SubsequentEventMember" id="Fact001344" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">837,000</ix:nonFraction></span> stock options held by 44 employees were
affected. The repriced options will continue to vest according to their original schedule.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2025, an investor exercised <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20250131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zOjQRy4feQNd" title="Warrants exercised"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2025-01-31_us-gaap_SubsequentEventMember" id="Fact001346" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">695,650</ix:nonFraction></span> warrants at an exercise price of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zcWNGZfE8Jg6" title="Warrants exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-01-31_us-gaap_SubsequentEventMember" id="Fact001348" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.05</ix:nonFraction></span>, which generated approximately $<span id="xdx_909_eus-gaap--ProceedsFromWarrantExercises_pn5n6_c20250102__20250131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zv4arleANkt" title="Proceeds from warrants exercised"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2025-01-022025-01-31_us-gaap_SubsequentEventMember" id="Fact001350" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.6</ix:nonFraction></span> million in cash.
The warrants were issued pursuant to a private placement that closed and was funded on December 9, 2022.</span></p>

</ix:nonNumeric><p id="xdx_812_zaYNmmQjcLN4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 66; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><span id="a_014"></span>ITEM 9. Changes in and Disagreements With Accountants on Accounting
and Financial Disclosure</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><span id="a_015"></span>ITEM 9A. Controls and Procedures</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>Evaluation of Disclosure
Controls and Procedures</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in; background-color: white">Our management, with the
participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures
as of December 31, 2024. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under
the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), means controls and other procedures of a company that
are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange
Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms. Disclosure
controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed
by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management,
including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure.
Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance
of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible
controls and procedures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in; background-color: white">&#160;Based on the evaluation
of our disclosure controls and procedures as of December 31, 2024, our Chief Executive Officer and Chief Financial Officer concluded that,
as of such date, our disclosure controls and procedures were effective.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Management Report on Internal Control over Financial
Reporting</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"><b>&#160;</b>Our management is responsible for establishing
and maintaining adequate internal control over financial reporting as such term is defined in Rule 13a-15(f) under the Securities Exchange
Act of 1934. Management has assessed the effectiveness of our internal control over financial reporting as of December 31, 2024 based
on criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (&#8220;COSO &#8211; 2013&#8221;) in Internal
Control-Integrated Framework. Based on this assessment, our Chief Executive Officer and Chief Financial Officer concluded that our system
of internal control over financial reporting was effective as of such date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in; background-color: white">This Annual Report does not
include an attestation report of our registered public accounting firm regarding internal control over financial reporting. Management&#8217;s
report was not subject to attestation by our registered public accounting firm pursuant to our designation as a small reporting company
or SRC and Non-Accelerated filer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>Changes in Internal Control
over Financial Reporting</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in; background-color: white">There were no changes to
our system of internal control over financial reporting during the three months ended December 31, 2024 that have materially affected, or are reasonably likely to materially affect, our system
of internal controls over financial reporting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><span id="a_016"></span>ITEM 9B. Other Information</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">On November 19, 2024, Brightstone Venture Capital Fund, LP (&#8220;Brightstone&#8221;)
adopted a 10b5-1 plan that provided for the sale of up to 220,000 shares of Celcuity Inc. common stock through November 19, 2025. This
plan was terminated on December 12, 2024. On December 13, 2024,
Brightstone adopted a 10b5-1 plan that provides for the sale of up to 229,325 shares
of Celcuity Inc. common stock through December 13, 2025. David Dalvey is a General Partner at Brightstone.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">During the three months ended December 31, 2024, none
of our other directors or officers (as defined in Rule 16a-1(f) of the Exchange Act)&#160;<span id="xdx_905_eecd--Rule10b51ArrAdoptedFlag_dbF_c20241001__20241231_zmfdk6udAmJ" title="Rule 10b51 Arrangement Adopted" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><span id="xdx_90B_eecd--NonRule10b51ArrAdoptedFlag_dbF_c20241001__20241231_zG1CUZJrxbX6" title="Non-Rule 10b51 Arrangement Adopted" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><ix:nonNumeric contextRef="From2024-10-012024-12-31" format="ixt:booleanfalse" id="Fact001352" name="ecd:Rule10b51ArrAdoptedFlag"><ix:nonNumeric contextRef="From2024-10-012024-12-31" format="ixt:booleanfalse" id="Fact001354" name="ecd:NonRule10b51ArrAdoptedFlag">adopted</ix:nonNumeric></ix:nonNumeric></span></span>&#160;or&#160;<span id="xdx_900_eecd--Rule10b51ArrTrmntdFlag_dbF_c20241001__20241231_zf4K8nu6WAgf" title="Rule 10b51 Arrangement Terminated" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><span id="xdx_901_eecd--NonRule10b51ArrTrmntdFlag_dbF_c20241001__20241231_z4cWpFRFQ4Li" title="Non-Rule 10b51 Arrangement Terminated" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><ix:nonNumeric contextRef="From2024-10-012024-12-31" format="ixt:booleanfalse" id="Fact001356" name="ecd:Rule10b51ArrTrmntdFlag"><ix:nonNumeric contextRef="From2024-10-012024-12-31" format="ixt:booleanfalse" id="Fact001358" name="ecd:NonRule10b51ArrTrmntdFlag">terminated</ix:nonNumeric></ix:nonNumeric></span></span>&#160;a &#8220;Rule
10b5-1 trading arrangement&#8221; or &#8220;non-Rule 10b5-1 trading arrangement,&#8221; as each term is defined in Item 408 of Regulation
S-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 28, 2025, the Compensation Committee of the Board of Directors (the &#8220;Committee&#8221;) of the Company
adopted the Celcuity Inc. Change in Control and Severance Plan (the &#8220;Severance Plan&#8221;). The purpose of the Severance Plan
is to provide assurances to employees of the Company of specified benefits in the event of a Change in Control of the Company (as defined
in the Company&#8217;s equity plan) or certain terminations of employment following a Change in Control. The Severance Plan covers all
regular full or part-time employees of the Company, including each executive officer of the Company. The Committee is responsible for
administering the Severance Plan. <span style="background-color: white">The Severance Plan may be amended or terminated at any time prior
to a Change in Control.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In the event of a
participant&#8217;s involuntary termination of employment without cause or resignation for good reason (as such terms are defined in
the Severance Plan) within the twelve-month period following a Change in Control, the Severance Plan provides for: (i) a severance
payment in an amount ranging from three months to three years of the participant&#8217;s base salary and target cash bonus, plus
(ii) COBRA premiums for the participant and their enrolled dependents for the same time period, but no greater than eighteen months,
both payable in a lump sum.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The amount of severance provided under the Severance
Plan is: three years for the Company&#8217;s chief executive officer; two years for the Company&#8217;s other executive officers; one
year for the Company&#8217;s other executives that are not executive officers; six months for the Company&#8217;s vice presidents; and
for all other participants, the greater of (i) three months or (ii) two weeks per each full year of employment, with a maximum of six
months.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In addition, the Severance Plan provides that
in the event of a Change in Control, all outstanding equity awards held by any participant will fully vest (with performance awards vesting
at the greater of target or actual performance levels) immediately upon the effective date of such change in control.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The foregoing description of the Severance Plan
does not purport to be complete and is qualified in its entirety by reference to the full text of the Severance Plan, which is filed
as Exhibit 10.35 hereto and is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><span id="a_017"></span>ITEM 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 67; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white"><b><span id="a_018"></span>PART&#160;III</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><span id="a_019"></span>ITEM 10.&#160;&#160;Directors, Executive Officers and Corporate Governance</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>Directors</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"><i>Brian F. Sullivan</i>, age 63, is our co-Founder
and has served as Chairman of the Board and Chief Executive Officer since we commenced operations in 2012. Mr. Sullivan has over 30 years
of experience founding and building successful, high-growth technology companies. He was Chairman and CEO of SterilMed, a medical device
reprocessing company, from 2003, when he led an investment group to acquire a majority interest, until its sale to Ethicon Endo-Surgery
Inc., a Johnson &amp; Johnson company, for $330 million in 2011. Previously, he was co-founder and Chief Executive Officer of Recovery
Engineering, a filtration company, which he took public and subsequently sold to Procter &amp; Gamble for $265 million in 1999. Mr. Sullivan
previously served on the board of directors of two publicly-held companies, Entegris, Inc. and Virtual Radiologic Inc. Mr.&#160;Sullivan
has received nine U.S. patents and has several pending. He graduated <i>magna cum laude</i> with distinction from Harvard College with
an A.B. in economics. Among other attributes, skills, and qualifications, the board of directors believes Mr.&#160;Sullivan is uniquely
qualified to serve as a director based on his extensive operational and business development experience, and his knowledge in building
stockholder value, growing a company from inception and navigating significant corporate transactions and the public company process.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"><i>Lance G. Laing, Ph.D., </i>age 63, is our co-Founder
and has served as Chief Science Officer, Vice President, Secretary and Director since we commenced operations in 2012. Dr. Laing&#8217;s
career spans more than 20 years in drug discovery research and technology development. He received his doctorate in biophysics and biochemistry
from The Johns Hopkins University and completed a National Institutes of Health post-doctoral fellowship at Washington University Medical
School. He has received 24 U.S. patents and has several U.S. patents pending. His drug discovery research career began at Scriptgen/Anadys
Pharmaceuticals (purchased by Novartis), where he worked under Professor Peter Kim, who became President of Merck Research. He also was
Director of Chemistry and Bioapplications and Director of Detection Product Development for two companies that each developed instruments
similar to those Celcuity uses to perform the CELsignia tests. His work at these two instrument companies gave him unique expertise and
experience in developing a variety of patented applications for these instruments. Most recently, he served as an executive director for
an international drug discovery and development company. Among other attributes, skills, and qualifications, the board of directors believes
Dr. Laing is uniquely qualified to serve as a director based on his significant research, medical and scientific expertise.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"><i>Richard E. Buller, M.D., Ph.D., </i>age 75, was
appointed to Celcuity&#8217;s board of directors in December 2019. Dr. Buller has over 15 years of experience leading oncology clinical
development and translational medicine departments at major pharmaceutical companies. He has participated in the development of 15 drugs
and several companion diagnostics that received U.S. FDA approval. Dr. Buller most recently served as Head Oncology Clinical Development
and Vice President of Translational Oncology at Pfizer, Inc, one of the world&#8217;s largest pharmaceutical companies, until he retired
in 2016. He had previously served as Vice President of Translational Medicine at Exelixis, a leading biopharmaceutical company, where
he led efforts to study patients selected by molecular testing for inclusion in their phase 2 and phase 3 clinical trials. He began his
pharmaceutical company career at GlaxoSmithKline as Director of the Oncology Medicine Development Center. Prior to his leadership positions
in drug development, he was Professor of Gynecologic Oncology at the University of Iowa, where he led laboratory research focused on identifying
genomic variants involved in ovarian cancer. He received his M.D. from the Baylor College of Medicine, where he also received his Ph.D.
in cell biology. Among other attributes, skills, and qualifications, the board of directors believes Dr. Buller is uniquely qualified
to serve as a director based on his oncology drug and diagnostic development expertise.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 68; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"><i>David F. Dalvey</i>, age 66, has served as a member
of Celcuity&#8217;s board of directors since February&#160;2014. Mr.&#160;Dalvey has more than 30 years of experience in the fields of
corporate finance and venture capital, working primarily with growth-oriented technology and life-science businesses. He has over 10 years
of corporate finance advisory experience with two national investment banks, completing over 150 individual transactions. He has been
the General Partner of Brightstone Venture Capital, a venture capital management company, since September&#160;2000. Brightstone is a
25-year old venture capital management company that has raised and managed ten venture partnerships. Previously, he held management positions
with R.J. Steichen and Company, an investment bank, from 1995 to 2000, The Food Fund LP, a venture capital firm, from 1992 to 1995 and
Wessels, Arnold &amp; Henderson, an investment bank, from 1987 to 1992. Mr. Dalvey served on the board of directors for Navarre Corporation
(now Speed Commerce, Inc.) from 2009 until November&#160;2012, on the board of managers for Blue Rock Market Neutral Fund, a mutual fund
registered under the Investment Company Act of 1940 from 2000 to 2014 and on the board of directors for Digitiliti, Inc. from July&#160;2011
until October&#160;2012. Mr. Dalvey has significant operational exposure as a board director or advisor to many other public and privately
held growth businesses and has served on these companies&#8217; audit, strategic or governance committees, including companies such as
HomeSpotter, Definity Health, AppTec Laboratories, CHF Solutions, BiteSquad, Agiliti, and Nature Vision. Mr. Dalvey received a B.S. in
Business/Management Economics from University of Minnesota. Among other attributes, skills, and qualifications, the board of directors
believes Mr. Dalvey is uniquely qualified to serve as a director based on his leadership experience in operating both public and private
companies and his experience working in the investment community and with investment firms, which enable him to bring valuable insight
and knowledge to our board of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"><i>Leo T. Furcht, M.D., </i>age 78, was appointed
to Celcuity&#8217;s board of directors in May 2019. Dr. Furcht is currently Allen-Pardee Professor of Cancer Biology and Head of the Department
of Laboratory Medicine and Pathology at the University of Minnesota and a member of the Division of Molecular Pathology and Genomics.
He served as Chairman of the Board of Directors for University of Minnesota Physicians, the Medical School practice plan with approximately
700 physicians, from 2004-2014. He was also the founding Director of the Biomedical Engineering Center from 1990-2001, where he led efforts
to establish stem cell and molecular diagnostics expertise at the University of Minnesota. He has published more than 180 scientific papers
and holds more than 30 patents in the fields of polypeptides, biomaterials, and adult stem cells. His business experience includes co-founding
two medical technology companies, South Bay Medical, a medical device company that was acquired by Mentor Corporation, and Diascreen,
a diagnostics company, which was later acquired by Chronimed. Among other attributes, skills, and qualifications, the board of directors
believes Dr. Furcht is uniquely qualified to serve as a director based on his research in tumor cell behavior and extracellular matrix
proteins, Head of the University of Minnesota&#8217;s Department of Laboratory Medicine and Pathology, and his experience in several biotechnology
start-ups.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"><i>Polly A. Murphy, D.V.M., Ph.D., </i>age 60, was
appointed to Celcuity&#8217;s board of directors in September 2022. Dr. Murphy has served as Chief Business Officer at Avadel Pharmaceuticals
plc since May 2024. Prior to that, Dr. Murphy was Chief Business Officer at UroGen Pharma, Inc. from August 2020 through May 2024 and
served in various leadership roles at Pfizer Inc. from September 2008 to August 2020, including as Vice President and Head of Early Commercial
Development, Pfizer Oncology Business Unit from January 2019 to August 2020, Vice President and Head of Global Marketing and Commercial
Development, Pfizer Oncology Business Unit from June 2017 to December 2018, and Vice President and Head of Strategy and Business Development
for Pfizer China from November 2013 to May 2018. Since August 2020,
Dr. Murphy as served on the board of directors of Atea Pharmaceuticals, Inc., a publicly held company. Dr. Murphy received her D.V.M.
and Ph.D. from Iowa State University and her M.B.A. from Nova Southeastern University. Among other attributes, skills, and qualifications,
the board of directors believes Dr. Murphy is uniquely qualified to serve as a director based on her significant medical and scientific
expertise <span style="background-color: white">and experience in the pharmaceutical industry in business development and commercialization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"><i>Richard J. Nigon</i>, age 77, is currently Senior
Vice President of Cedar Point Capital, LLC., a private company that raises capital for early-stage companies, where he has served since
2007. Mr. Nigon has also been a board member for Northern Technologies International Corp. since February&#160;2010, including its non-executive
Chairman of the board of directors since November&#160;2012. Mr. Nigon also serves as a director of several private companies. Mr. Nigon
previously served as a board member for Tactile Systems Technology from September 2012 to May 2022, Vascular Solutions, Inc. from November&#160;2000
to February&#160;2017, when it was acquired by Teleflex, Incorporated and as a board member for Virtual Radiologic Corporation from May&#160;2007
until it was acquired in July&#160;2010. From February&#160;2001 until December&#160;2006, Mr. Nigon was a Director of Equity Corporate
Finance for Miller Johnson Steichen Kinnard, a privately held investment firm, which was acquired in December&#160;2006 by Stifel Nicolaus,
a brokerage and investment banking firm. After that acquisition, Mr. Nigon became a Managing Director of Private Placements of Stifel
Nicolaus until May&#160;2007. From February&#160;2000 to February&#160;2001, Mr. Nigon served as the Chief Financial Officer of Dantis,
Inc., a web hosting company. Prior to joining Dantis, Mr. Nigon was employed by Ernst &amp; Young LLP from 1970 to 2000, where he served
as a partner from 1981 to 2000. While at Ernst &amp; Young, Mr. Nigon served as the Director of Ernst &amp; Young&#8217;s Twin Cities
Entrepreneurial Services Group and was the coordinating partner on several publicly-traded companies in the consumer retailing and manufacturing
sectors. Among other attributes, skills, and qualifications, the board of directors believes Mr. Nigon is qualified to serve as a director
because of his extensive public accounting and auditing experience, including particular experience with emerging growth companies. The
board of directors also believes that Mr. Nigon will bring to the board of directors a strong background in financial controls and reporting,
financial management, financial analysis, SEC reporting requirements and mergers and acquisitions. His strategic planning expertise gained
through his management and leadership roles at private investment firms also makes him well-suited to serve as a member of the board of
directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>


<!-- Field: Page; Sequence: 69; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>Executive Officers</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Information regarding our Chief Executive Officer,
Brian F. Sullivan, and our Chief Science Officer, Lance G. Laing, PhD., is included above under the heading &#8220;Directors&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"><i>Vicky Hahne</i>, age 58, joined as our Chief Financial
Officer in July 2017. She has more than 25 years of financial leadership experience, including the most recent 15 years in the healthcare
industry. Prior to joining Celcuity, Ms. Hahne served as Controller of Respiratory Technologies Inc., a medical device manufacturer, from
2015 to 2017. While at Respiratory Technologies, she played a key role in the due diligence process to sell the company to Koninklijke
Philips. In 2014, she served as Controller for Ability Network Inc., a healthcare information technology company. From 2007 to 2012, Ms.
Hahne served as Controller of SterilMed Inc., a medical device reprocessing company, where she was significantly involved in the sale
of the company to Johnson &amp; Johnson. Prior to these roles, Ms. Hahne held several senior financial positions at SimonDelivers Inc.,
including Chief Financial Officer. Ms. Hahne has extensive experience in early stage, high growth companies with responsibilities including
financial controls and stewardship, financial analysis, mergers and acquisitions, building infrastructure and systems. She received a
B.S. degree in Finance and Accounting from Northern State University and received her CPA certificate in 1990.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>Corporate Governance</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">Our board of directors has adopted a Code of Ethical
Business Conduct that applies to our directors, officers and employees.&#160;&#160;In addition, our CEO, CFO and other senior financial
officers of the company are subject to a Code of Ethical Business Conduct for Senior Financial Officers. These Codes are available on
the corporate governance section of our website (which is a subsection of the investor relations section of our website) at the following
address: www.celcuity.com. We intend to disclose on our website any amendments or waivers to these codes that are required to be disclosed
by SEC or Nasdaq rules.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Additional information required
by this Item 10 will be contained in our definitive proxy statement for our 2025 Annual Meeting of Stockholders (the &#8220;Definitive
Proxy Statement&#8221;) under the captions &#8220;Corporate Governance,&#8221; and &#8220;Meetings and Committees of the Board of Directors&#8221;
and is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; background-color: white"><b><span id="a_020"></span>ITEM 11. Executive Compensation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">The information required by this Item 11 will be contained
in the Definitive Proxy Statement under the captions &#8220;Corporate Governance,&#8221; &#8220;Executive Compensation&#8221; and &#8220;Director
Compensation&#8221; and is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; background-color: white"><b><span id="a_021"></span>ITEM 12. Security Ownership of Certain Beneficial
Owners and Management and Related Stockholder Matters</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">The information required by this Item 12 will be contained
in the Definitive Proxy Statement under the captions &#8220;Beneficial Ownership of Common Stock&#8221; and &#8220;Securities Authorized
for Issuance under Equity Compensation Plans&#8221; and is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><span id="a_022"></span>ITEM 13. Certain Relationships and Related Transactions, and Director
Independence</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">The information required by this Item 13 will be contained
in the Definitive Proxy Statement under the captions and &#8220;Corporate Governance&#8221; and &#8220;Certain Relationships and Related
Transactions&#8221; and is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><span id="a_023"></span>ITEM 14. Principal Accountant Fees and Services</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">The information required by this Item 14 will be contained
in the Definitive Proxy Statement under the caption &#8220;Proposal No. 2, Ratification of Appointment of Independent Registered Public
Accounting Firm&#8221; and is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>


<!-- Field: Page; Sequence: 70; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b><span id="a_024"></span>PART IV</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><span id="a_025"></span>ITEM&#160;15. Exhibits and Financial Statement Schedules.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 96%; margin-left: 0.25in">
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid; text-align: justify">
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>Item</b></p></td>
    <td style="padding-bottom: 1pt; text-align: justify; width: 0.1in">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 0.5in; text-align: center"><b>Page</b></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><a href="#fin_01">Report of Independent Registered Public Accounting Firm</a></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">48</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify"><a href="#fin_02">Balance Sheets &#8211; December 31, 2024 and 2023</a></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">49</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><a href="#fin_03">Statements of Operations &#8211; Years ended December 31, 2024 and 2023</a></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">50</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify"><a href="#fin_04">Statements of Changes in Stockholders&#8217; Equity &#8211; Years ended December 31, 2024 and 2023</a></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">51</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><a href="#fin_05">Statements of Cash Flows &#8211; Years ended December 31, 2024 and 2023</a></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">52</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify"><a href="#fin_06">Notes to Consolidated Financial Statements</a></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">53</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>FINANCIAL STATEMENT SCHEDULES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>EXHIBITS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">See Exhibit Index immediately following the signature
page hereto, which is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><span id="a_026"></span>ITEM 16. Form 10-K Summary</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 71; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;<b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b><span id="a_027"></span>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="text-align: justify; vertical-align: top; width: 50%">Dated: March 31, 2025</td>
    <td style="text-align: justify; vertical-align: top; width: 3%">&#160;</td>
    <td style="text-align: justify; vertical-align: bottom; width: 1%">&#160;</td>
    <td style="text-align: justify; vertical-align: top; width: 46%">CELCUITY INC.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td></tr>
  <tr>
    <td style="text-align: justify; vertical-align: top">&#160;</td>
    <td style="text-align: justify; vertical-align: top">By</td>
    <td style="text-align: justify; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: justify; vertical-align: top"><i>/s/ Brian F. Sullivan</i></td></tr>
  <tr>
    <td style="text-align: justify; vertical-align: top">&#160;</td>
    <td style="text-align: justify; vertical-align: bottom">&#160;</td>
    <td style="text-align: justify; vertical-align: bottom">&#160;</td>
    <td style="text-align: justify; vertical-align: bottom">Brian F. Sullivan</td></tr>
  <tr>
    <td style="text-align: justify; vertical-align: top">&#160;</td>
    <td style="text-align: justify; vertical-align: bottom">&#160;</td>
    <td style="text-align: justify; vertical-align: bottom">&#160;</td>
    <td style="text-align: justify; vertical-align: bottom">Chairman and Chief Executive Officer</td></tr>
  <tr>
    <td style="text-align: justify; vertical-align: top">&#160;</td>
    <td style="text-align: justify; vertical-align: bottom">&#160;</td>
    <td style="text-align: justify; vertical-align: bottom">&#160;</td>
    <td style="text-align: justify; vertical-align: bottom">(Principal Executive Officer)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">Pursuant to the requirements of the Securities Exchange Act of 1934, this
report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">Each person whose signature appears below constitutes
and appoints Brian F. Sullivan and Vicky Hahne as the undersigned&#8217;s true and lawful attorneys-in fact and agents, each acting alone,
with full power of substitution and resubstitution, for the undersigned and in the undersigned&#8217;s name, place and stead, in any
and all amendments to this Annual Report on Form 10-K and to file the same, with all exhibits thereto, and other documents in connection
therewith, with the Securities and Exchange Commission, granted unto said attorneys-in-fact and agents, each acting alone, full power
and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to
all intents and purposes as the undersigned might or could do in person, hereby ratifying and confirming all said attorneys-in-fact and
agents, each acting alone, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue thereof.&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; width: 28%">
    <p style="border-bottom: black 0.75pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b>Signature</b></p></td>
    <td style="text-align: justify; width: 2%">&#160;</td>
    <td style="text-align: center; white-space: nowrap; width: 50%">
    <p style="border-bottom: black 0.75pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b>Title</b></p></td>
    <td style="text-align: justify; width: 2%">&#160;</td>
    <td style="text-align: center; white-space: nowrap; width: 18%">
    <p style="border-bottom: black 0.75pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b>Date</b></p></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center; white-space: nowrap">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center; white-space: nowrap">&#160;</td></tr>
  <tr>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Brian F. Sullivan</i></span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman and Chief Executive Officer</span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2025&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian F. Sullivan</span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive Officer)</span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Vicky Hahne</i></span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer </span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2025&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vicky Hahne</span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Financial and Accounting Officer)</span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Lance G. Laing</i></span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Science Officer, Vice President and Secretary, and </span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2025&#160;</span></td></tr>
  <tr>
    <td style="border-top: black 1pt solid; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lance G. Laing</span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: center">&#160;</td></tr>
  <tr>
    <td style="border-bottom: black 1pt solid; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Richard E. Buller</i></span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2025&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Richard E. Buller</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: center">&#160;</td></tr>
  <tr>
    <td style="border-bottom: black 1pt solid; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Dave F. Dalvey</i></span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2025&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dave F. Dalvey</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr>
    <td style="border-bottom: black 1pt solid; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Leo T. Furcht</i></span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2025&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leo T. Furcht</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: center">&#160;</td></tr>
  <tr>
    <td style="border-bottom: black 1pt solid; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Polly A. Murphy</i></span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2025&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Polly A. Murphy</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Richard J. Nigon</i></span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2025&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Richard J. Nigon</span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 72; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b>EXHIBIT INDEX</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b>CELCUITY INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b>FORM 10-K</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: justify; width: 0.75in; padding-right: 0pt; padding-left: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b>Exhibit</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b>No.</b></p></td>
    <td style="padding-right: 0pt; padding-bottom: 1pt; text-align: justify; width: 0.1in; padding-left: 0pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-size: 10pt"><b>Description</b></span></td></tr>

<tr style="vertical-align: bottom">
    <td style="text-align: justify; padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt">&#160;</td>
    <td style="padding-right: 0pt; padding-left: 0pt; text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt">2.1</td>
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt">&#160;</td>
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt"><a href="http://www.sec.gov/Archives/edgar/data/1603454/000157104917007846/t1702519_ex2-1.htm" style="-sec-extract: exhibit">Form of Plan of Conversion (incorporated by reference to Exhibit 2.1 to the Company&#8217;s Registration Statement on Form S-1/A filed with the SEC on September 12, 2017).</a></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt">&#160;</td>
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt">&#160;</td>
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt">3.1</td>
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt">&#160;</td>
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000149315224040594/ex3-1.htm" style="-sec-extract: exhibit">Certificate of Incorporation of the Company, as amended, including the Certificate of Designations of Preferences, Rights and Limitations of Series A Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on October 9, 2024).</a></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt">&#160;</td>
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt">&#160;</td>
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt">3.2</td>
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt">&#160;</td>
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt"><a href="http://www.sec.gov/Archives/edgar/data/1603454/000114420417058480/tv478251_ex3-2.htm" style="-sec-extract: exhibit">Bylaws of the Company (incorporated by reference to Exhibit 3.2 to the Company&#8217;s Quarterly Report on Form 10-Q filed with the SEC on November 13, 2017).</a></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt">&#160;</td>
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt">&#160;</td>
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt">4.1</td>
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt">&#160;</td>
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt"><a href="http://www.sec.gov/Archives/edgar/data/1603454/000157104917007846/t1702519_ex4-1.htm" style="-sec-extract: exhibit">Specimen Certificate representing shares of common stock of Celcuity Inc. (incorporated by reference to Exhibit 4.1 to the Company&#8217;s Registration Statement on Form S-1/A filed with the SEC on September 12, 2017).</a></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt">&#160;</td>
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt">&#160;</td>
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt">4.2*</td>
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt">&#160;</td>
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt"><a href="ex4-2.htm">Description of Registered Securities.</a></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt">&#160;</td>
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt">&#160;</td>
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt">4.3</td>
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt">&#160;</td>
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000157104917007662/t1702400_ex10-9.htm" style="-sec-extract: exhibit">Form of Warrant to Purchase Units of Membership Interest issued by Celcuity LLC to Cedar Point Capital, LLC, as placement agent of membership units and unsecured convertible promissory notes of Celcuity LLC (incorporated by reference to Exhibit 10.9 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on August 23, 2017).</a></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt">&#160;</td>
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt">&#160;</td>
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt">4.4</td>
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt">&#160;</td>
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000114420417049520/v475747_ex10-2.htm" style="-sec-extract: exhibit">Form of Warrant to Purchase Common Stock issued by Celcuity Inc. in connection with the conversion of 1.25% Unsecured Convertible Promissory Notes (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on September 25, 2017).</a></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt">&#160;</td>
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt">&#160;</td>
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt">4.5</td>
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt">&#160;</td>
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000114420417049520/v475747_ex10-1.htm" style="-sec-extract: exhibit">Representative&#8217;s Warrant to Purchase Common Stock (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on September 25, 2017).</a></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt">&#160;</td>
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt">&#160;</td>
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt">4.6</td>
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt">&#160;</td>
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000149315222025891/ex10-1.htm" style="-sec-extract: exhibit">First Amendment to Representative&#8217;s Warrant, dated September 13, 2022, between Celcuity Inc. and Craig-Hallum Capital Group LLC (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on September 14, 2022).</a></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt">&#160;</td>
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt">&#160;</td>
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt">4.7</td>
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt">&#160;</td>
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000165495421003990/celc_ex42.htm" style="-sec-extract: exhibit">Form of Warrant issued by Celcuity Inc. to Innovatus Life Sciences Lending Fund I, LP in connection with the Loan and Security Agreement dated April 8, 2021 (incorporated by reference to Exhibit 4.2 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on April 8, 2021).</a></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt">&#160;</td>
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt">&#160;</td>
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt">4.8</td>
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt">&#160;</td>
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000165495421003990/celc_ex41.htm" style="-sec-extract: exhibit">Equity Grant Agreement, dated April 8, 2021, between the Company and Pfizer Inc. (incorporated by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on April 8, 2021).</a></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt">&#160;</td>
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt">&#160;</td>
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt">4.9</td>
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt">&#160;</td>
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000149315222014348/ex4-1.htm" style="-sec-extract: exhibit">Form of Stock Purchase Warrant issued by Celcuity Inc. in connection with the Securities Purchase Agreement, dated May 15, 2022 (incorporated by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on May 18, 2022).</a></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt">&#160;</td>
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt">&#160;</td>
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt">4.10</td>
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt">&#160;</td>
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000149315223038005/ex4-1.htm" style="-sec-extract: exhibit">Form of Pre-Funded Warrant to Purchase Common Stock issued by Celcuity Inc. in connection with the Securities Purchase Agreement, dated October 18, 2023 (incorporated by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on October 23, 2023).</a></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt">&#160;</td>
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt">&#160;</td>
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt">4.11</td>
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt">&#160;</td>
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000149315224019974/ex4-3.htm" style="-sec-extract: exhibit">Form of Amendment to Placement Agent&#8217;s Warrants, dated February 13, 2024 (incorporated by reference to Exhibit 4.3 to the Company&#8217;s Quarterly Report on Form 10-Q filed with the SEC on May 15, 2024).</a></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt">&#160;</td>
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt">&#160;</td>
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt">4.12</td>
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt">&#160;</td>
    <td style="padding-right: 0pt; text-align: justify; padding-left: 0pt"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000149315224019974/ex4-5.htm" style="-sec-extract: exhibit">Form of Amendment to Warrants to Purchase Shares of Common Stock, dated February 13, 2024 (incorporated by reference to Exhibit 4.5 to the Company&#8217;s Quarterly Report on Form 10-Q filed with the SEC on May 15, 2024).</a></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 73; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.75in">4.13</td>
    <td style="text-align: justify; width: 0.1in">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000149315224021864/ex4-1.htm" style="-sec-extract: exhibit">Form of Warrant to Purchase Stock issued by Celcuity Inc. in connection with the Amended and Restated Loan Agreement, dated May 30, 2024 (incorporated by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on May 30, 2024).</a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">10.1+</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1603454/000157104917007846/t1702519_ex10-1.htm" style="-sec-extract: exhibit">Celcuity Inc. 2017 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Registration Statement on Form S-1/A filed with the SEC on September 12, 2017).</a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">10.2+</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000165495420005645/celc_ex101.htm" style="-sec-extract: exhibit">Celcuity Inc. Amended and Restated 2017 Stock Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on May 15, 2020).</a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">10.3+</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000149315223016627/ex10-1.htm" style="-sec-extract: exhibit">Amendment to the Celcuity Inc. Amended and Restated 2017 Stock Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on May 12, 2023).</a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">10.4+</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1603454/000157104917007846/t1702519_ex10-3.htm" style="-sec-extract: exhibit">Form of Stock Option Agreement pursuant to Celcuity Inc. 2017 Stock Incentive Plan (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Registration Statement on Form S-1/A filed with the SEC on September 12, 2017).</a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">10.5+</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1603454/000157104917007846/t1702519_ex10-4.htm" style="-sec-extract: exhibit">Form of Restricted Stock Agreement pursuant to Celcuity Inc. 2017 Stock Incentive Plan (incorporated by reference to Exhibit 10.4 to the Company&#8217;s Registration Statement on Form S-1/A filed with the SEC on September 12, 2017).</a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">10.6+</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1603454/000157104917007846/t1702519_ex10-5.htm" style="-sec-extract: exhibit">Form of Restricted Stock Unit Agreement pursuant to Celcuity Inc. 2017 Stock Incentive Plan (incorporated by reference to Exhibit 10.5 to the Company&#8217;s Registration Statement on Form S-1/A filed with the SEC on September 12, 2017).</a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">10.7+</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1603454/000157104917007846/t1702519_ex10-6.htm" style="-sec-extract: exhibit">Form of Stock Appreciation Rights Agreement pursuant to Celcuity Inc. 2017 Stock Incentive Plan (incorporated by reference to Exhibit 10.6 to the Company&#8217;s Registration Statement on Form S-1/A filed with the SEC on September 12, 2017).</a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">10.8+</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1603454/000157104917007662/t1702400_ex10-7.htm" style="-sec-extract: exhibit">Celcuity LLC 2012 Equity Incentive Plan, adopted August 10, 2012, as amended by First Amendment to the Celcuity LLC 2012 Equity Incentive Plan, adopted November 12, 2015 (incorporated by reference to Exhibit 10.7 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on August 23, 2017).</a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">10.9+</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1603454/000157104917007662/t1702400_ex10-8.htm" style="-sec-extract: exhibit">Form of Unit Option Agreement pursuant to the Celcuity LLC 2012 Equity Incentive Plan (incorporated by reference to Exhibit 10.8 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on August 23, 2017).</a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">10.10</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1603454/000114420417058480/tv478251_ex10-11.htm" style="-sec-extract: exhibit">Commercial Lease, dated September 28, 2017, between West Glen Development I, LLC and Celcuity, LLC (incorporated by reference to Exhibit 10.11 to the Company&#8217;s Quarterly Report on Form 10-Q filed with the SEC on November 13, 2017).</a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">10.11</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1603454/000165495420008729/celc_ex103.htm" style="-sec-extract: exhibit"><span style="background-color: white">Commercial Lease, First Amendment to Lease, dated July 28, 2020, between West Glen Development I, LLC and Celcuity Inc. (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Quarterly Report on Form 10-Q filed with the SEC on August 10, 2020).</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">10.12</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000165495421008769/celc_ex104.htm" style="-sec-extract: exhibit">Commercial Lease, Second Amendment to Lease, dated July 19, 2021, between West Glen Development I, LLC and Celcuity Inc. (incorporated by reference to Exhibit 10.4 to the Company&#8217;s Quarterly Report on Form 10-Q filed with the SEC on August 11, 2021).</a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">10.13</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000149315222020778/ex10-1.htm" style="-sec-extract: exhibit">Commercial Lease, Third Amendment to Lease, dated July 27, 2022, by and between Celcuity Inc. and West Glen Development I, LLC (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on July 29, 2022).</a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">10.14</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000149315223007785/ex10-1.htm" style="-sec-extract: exhibit">Commercial Lease, Fourth Amendment to Lease, dated March 13, 2023, by and between Celcuity Inc. and West Glen Development I, LLC (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on March 15, 2023).</a></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 74; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.75in">10.15</td>
    <td style="text-align: justify; width: 0.1in">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1603454/000157104917007662/t1702400_ex10-13.htm" style="-sec-extract: exhibit">Clinical Trial Agreement, dated May 8, 2017, by and between NSABP Foundation, Inc. and Celcuity LLC (incorporated by reference to Exhibit 10.13 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on August 23, 2017).</a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">10.16</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1603454/000165495421001743/celc_ex1015.htm" style="-sec-extract: exhibit">Amendment No. 1, Clinical Trial Agreement for FB-12 Phase II Study, by and between NSABP Foundation, Inc and Celcuity Inc., dated October 15, 2020 (incorporated by reference Exhibit 10.15 to the Company&#8217;s Annual Report on Form 10-K filed with the SEC on February 16, 2021).</a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">10.17+</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1603454/000157104917007662/t1702400_ex10-14.htm" style="-sec-extract: exhibit">Confidentiality, Assignment of Inventions and Non-Competition Agreement, dated November 15, 2011, between Celcuity LLC and Brian F. Sullivan (incorporated by reference to Exhibit 10.14 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on August 23, 2017).</a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">10.18+</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1603454/000157104917007662/t1702400_ex10-15.htm" style="-sec-extract: exhibit">Confidentiality, Assignment of Inventions and Non-Competition Agreement, dated November 15, 2011, between Celcuity LLC and Lance G. Laing (incorporated by reference to Exhibit 10.15 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on August 23, 2017).</a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">10.19+</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1603454/000157104917007662/t1702400_ex10-16.htm" style="-sec-extract: exhibit">Confidentiality, Non-Compete and Proprietary Rights Agreement, dated May 17, 2017, between Celcuity LLC and Vicky Hahne (incorporated by reference to Exhibit 10.16 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on August 23, 2017).</a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">10.20</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1603454/000157104917007846/t1702519_ex10-17.htm" style="-sec-extract: exhibit">Form of Indemnification Agreement between Celcuity Inc. and each of its officers and directors (incorporated by reference to Exhibit 10.17 to the Company&#8217;s Registration Statement on Form S-1/A filed with the SEC on September 12, 2017).</a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">10.21&#8224;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000165495421008769/celc_ex103.htm" style="-sec-extract: exhibit">License Agreement, dated April 8, 2021, by and between the Company and Pfizer, Inc (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Quarterly Report on Form 10-Q filed with the SEC on August 11, 2021).</a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">10.22&#8224;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000165495421008769/celc_ex105.htm" style="-sec-extract: exhibit">Amendment No. 1 to License Agreement, dated May 6, 2021, by and between the Company and Pfizer Inc. (incorporated by reference to Exhibit 10.5 to the Company&#8217;s Quarterly Report on Form 10-Q filed with the SEC on August 11, 2021).</a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">10.23</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000149315222003285/ex1-1.htm" style="-sec-extract: exhibit">Open Market Sale Agreement<sup>SM</sup>, dated February 4, 2022, by and between Celcuity Inc., and Jefferies LLC (incorporated by reference to Exhibit 1.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on February 4, 2022).</a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">10.24</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000149315222014348/ex10-1.htm" style="-sec-extract: exhibit">Securities Purchase Agreement, dated May 15, 2022, by and among the Registrant and the Investors named therein (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on May 18, 2022).</a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">10.25</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000149315222014348/ex10-2.htm" style="-sec-extract: exhibit">Registration Rights Agreement, dated May 15, 2022, by and among the Registrant and the Investors named therein (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on May 18, 2022).</a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">10.26</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000165495421008769/celc_ex102.htm" style="-sec-extract: exhibit">Loan and Security Agreement, dated as of April 8, 2021, by and between the Company and Innovatus Life Sciences Lending Fund I, LP. (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Quarterly Report on Form 10-Q filed with the SEC on August 11, 2021).</a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">10.27</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000149315222022062/ex10-1.htm" style="-sec-extract: exhibit">First Amendment to Loan and Security Agreement, dated August 9, 2022, by and among the Company and Innovatus Life Sciences Lending Fund I, LP (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on August 11, 2022).</a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">10.28</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000149315223038005/ex10-1.htm" style="-sec-extract: exhibit">Securities Purchase Agreement, dated October 18, 2023, by and among the Company and the Investors named therein (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on October 23, 2023).</a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">10.29</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000149315223038005/ex10-2.htm" style="-sec-extract: exhibit">Registration Rights Agreement, dated October 18, 2023, by and among the Company and the Investors named therein (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on October 23, 2023).</a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">10.30</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000149315224012030/ex10-1.htm" style="-sec-extract: exhibit">Second Amendment to Loan and Security Agreement, dated March 29, 2024, by and among the Company and Innovatus Life Sciences Lending Fund I, LP (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on March 29, 2024).</a></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 75; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.75in">10.31+</td>
    <td style="text-align: justify; width: 0.1in">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000149315224018943/ex10-1.htm" style="-sec-extract: exhibit">Amendment to the Celcuity Inc. Amended and Restated 2017 Stock Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on May 13, 2024).</a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">10.32+</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000149315224019974/ex10-1.htm" style="-sec-extract: exhibit">Amendment to Form of Stock Option Agreement pursuant to Celcuity Inc. Amended and Restated 2017 Stock Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q filed with the SEC on May 15, 2024).</a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">10.33+</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000149315224019974/ex10-2.htm" style="-sec-extract: exhibit">Form of Non-Qualified Stock Option Transfer Agreement pursuant to Celcuity Inc. Amended and Restated 2017 Stock Incentive Plan (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Quarterly Report on Form 10-Q filed with the SEC on May 15, 2024).</a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">10.34&#8224;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000149315224021864/ex10-1.htm" style="-sec-extract: exhibit">Amended and Restated Loan and Security Agreement, dated May 30, 2024, by and among the Company, Innovatus Life Sciences Lending Fund I, LP, as collateral agent, and the Lenders named therein (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on May 30, 2024).</a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">10.35+*</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="ex10-35.htm">Change in Control and Severance Plan and Summary Plan Description.</a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">19*</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="ex19.htm">Celcuity Inc. Policy to Prohibit Insider Trading.</a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">23.1*</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="ex23-1.htm" style="-sec-extract: exhibit">Consent of Boulay PLLP.</a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">24.1*</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="#a_027">Power of Attorney (included on the signature page).</a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">31.1*</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="ex31-1.htm" style="-sec-extract: exhibit">Certification of principal executive officer required by Rule 13a-14(a).</a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">31.2*</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="ex31-2.htm" style="-sec-extract: exhibit">Certification of principal financial officer required by Rule 13a-14(a).</a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">32.1**</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="ex32-1.htm" style="-sec-extract: exhibit">Section 1350 Certification of principal executive officer.</a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">32.2**</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="ex32-2.htm" style="-sec-extract: exhibit">Section 1350 Certification of principal financial officer.</a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">97</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000149315224011549/ex97.htm" style="-sec-extract: exhibit">Celcuity Inc. Policy for the Recoupment of Erroneously Awarded Compensation (incorporated by reference to Exhibit 97 to the Company&#8217;s Annual Report on Form 10-K filed with the SEC on March 27, 2024).</a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">101</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: inherit,serif">The following information from the Annual Report on Form 10-K of the Company for the year ended December 31, 2024, formatted, in Inline XBRL: (i) the Balance Sheets, (ii) the Statements of Operations, (iii) the Statements of Changes in Stockholders&#8217; Equity, (iv) the Statements of Cash Flows, (v) the Notes to Financial Statements, and (vi) the information under Part II, Item 9B &#8220;Other Information.&#8221;.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">104</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: inherit,serif">Cover Page Interactive Data File (embedded within the Inline XBRL document and included in Exhibit 101).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.5in; text-align: left">*</td><td style="text-align: justify">Filed herewith.</td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.5in; text-align: left">**</td><td style="text-align: justify">Furnished herewith.</td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.5in; text-align: left">+</td><td style="text-align: justify">Management contract or compensatory plan.</td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.5in; text-align: left">&#8224;</td><td style="text-align: justify">Certain portions have been omitted from this exhibit.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 76; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!--   -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>2
<FILENAME>ex4-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-right: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
4.2</B></FONT></P>

<P STYLE="margin-right: 0pt; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description
of Registrant&rsquo;s Securities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registered
Pursuant to Section 12 of the</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Securities
Exchange Act of 1934, as amended</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following summary of the terms of our capital stock is subject to and qualified in its entirety by reference to our certificate of incorporation,
as amended, and bylaws, copies of which are on file with the SEC as exhibits to previous SEC filings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, Celcuity Inc. (&ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our,&rdquo; and the &ldquo;Company&rdquo;) had one class
of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;): common
stock, par value $0.001 per share. In addition, we have certain equity interests outstanding that are convertible into common stock,
which are described in more detail below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, we were authorized to issue 95,000,000 shares of common stock and 2,500,000 shares of preferred stock, $0.001 par
value per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Fully
Paid and Nonassessable</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
outstanding shares of our common stock are fully paid and nonassessable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Voting
Rights</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
holder of common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Dividend
Rights</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of our common stock are entitled to receive ratably any dividends that our board of directors may declare out of funds legally available
for that purpose.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Rights
and Preferences</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of our common stock have no preemptive, conversion, subscription or other rights, and there are no redemption or sinking fund provisions
applicable to our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Right
to Liquidation Distributions</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
our liquidation, dissolution or winding-up, the assets legally available for distribution to our stockholders would be distributable
ratably among the holders of our common stock and any participating preferred stock outstanding at that time, subject to prior satisfaction
of all outstanding debt and liabilities and the preferential rights of and the payment of liquidation preferences, if any, on any outstanding
shares of preferred stock, including the liquidation preference of our Series A Preferred Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Transfer
Agent and Registrar</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
transfer agent and registrar for our common stock is Continental Stock Transfer &amp; Trust Company. The transfer agent and registrar&rsquo;s
address is One State Street Plaza, 30th Floor, New York, NY 10004.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
Nasdaq Capital Market</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is listed for quotation on The Nasdaq Capital Market under the symbol &ldquo;CELC&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Preferred
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors is authorized, without action by the stockholders, to designate and issue up to an aggregate of 2,500,000 shares of
preferred stock in one or more series. Our board of directors is authorized to designate the rights, preferences and privileges of the
shares of each series and any of its qualifications, limitations or restrictions. Our board of directors is able to authorize the issuance
of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of common
stock. The issuance of preferred stock, while providing flexibility in connection with possible future financings and acquisitions and
other corporate purposes, could, under certain circumstances, have the effect of restricting dividends on our common stock, diluting
the voting power of our common stock, impairing the liquidation rights of our common stock, or delaying, deferring or preventing a change
in control of the Company, which might harm the market price of our common stock. See also &ldquo;Anti-Takeover Effect of Delaware Law
and Certain Charter and Bylaw Provisions&rdquo; below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 16, 2022, in connection with a Securities Purchase Agreement, dated May 15, 2022, by and among the Company and the Investors named
therein (the &ldquo;2022 Investors,&rdquo; and such Securities Purchase Agreement, the &ldquo;2022 Securities Purchase Agreement&rdquo;),
the Company filed a Certificate of Designations (the &ldquo;Certificate of Designations&rdquo;) with the Secretary of State of the State
of Delaware, designating 1,850,000 shares out of the authorized but unissued shares of its preferred stock as Series A Convertible Preferred
Stock (&ldquo;Series A Preferred Stock&rdquo;). The following is a summary of the principal terms of the Series A Preferred Stock:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Dividend
Rights</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of Series A Preferred Stock shall be entitled to receive dividends or distributions on shares of Series A Preferred Stock equal (on an
as-if-converted-to-common stock basis) to and in the same form as dividends or distributions actually paid on shares of the common stock
when, as and if such dividends or distributions are paid on shares of the common stock. No other dividends or distributions shall be
paid on shares of Series A Preferred Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Right
to Liquidation Distributions</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, the holders of shares of Series A Preferred
Stock then outstanding shall be entitled to be paid out of the assets of the Company available for distribution to its stockholders,
and in the event of a Deemed Liquidation Event (as defined in the Certificate of Designations), the holders of shares of Series A Preferred
Stock then outstanding shall be entitled to be paid out of the consideration payable to stockholders in such Deemed Liquidation Event
or out of the Available Proceeds (as defined in the Certificate of Designations), as applicable, before any payment shall be made to
the holders of common stock by reason of their ownership thereof, an amount per share equal to the greater of (i) the Series A Original
Issue Price (as defined in the Certificate of Designations), plus any dividends declared but unpaid thereon, or (ii) such amount per
share as would have been payable had all shares of Series A Preferred Stock been converted into common stock pursuant to the Certificate
of Designations immediately prior to such liquidation, dissolution, winding up or Deemed Liquidation Event.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Voting
Rights</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series A Preferred Stock is non-voting stock and does not entitle the holder thereof to vote on any matter submitted to the stockholders
of the Company for their action or consideration, except as otherwise provided by the General Corporation Law of the State of Delaware
or the other provisions of the Certificate of Incorporation or the Certificate of Designations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
long as any shares of Series A Preferred Stock are outstanding, the Company may not, without the approval of the holders of a majority
of the outstanding shares of Series A Preferred Stock, take the following actions: (i) amend, alter or repeal any provision of the Certificate
of Incorporation, the Certificate of Designations or Bylaws of the Company in a manner that adversely affects the powers, preferences
or rights of the Series A Preferred Stock; (ii) create, or authorize the creation of, or issue or obligate itself to issue shares of,
any additional class or series of capital stock unless the same ranks junior to the Series A Preferred Stock with respect to the distribution
of assets on the liquidation, dissolution or winding up of the Company, the payment of dividends and rights of redemption, or increase
the authorized number of shares of Series A Preferred Stock or increase the authorized number of shares of any additional class or series
of capital stock of the Company unless the same ranks junior to the Series A Preferred Stock with respect to the distribution of assets
on the liquidation, dissolution or winding up of the Company, the payment of dividends and rights of redemption; (iii) (A) reclassify,
alter or amend any existing security of the Company that is pari passu with the Series A Preferred Stock in respect of the distribution
of assets on the liquidation, dissolution or winding up of the Company, the payment of dividends or rights of redemption, if such reclassification,
alteration or amendment would render such other security senior to the Series A Preferred Stock in respect of any such right, preference,
or privilege or (B) reclassify, alter or amend any existing security of the Company that is junior to the Series A Preferred Stock in
respect of the distribution of assets on the liquidation, dissolution or winding up of the Company, the payment of dividends or rights
of redemption, if such reclassification, alteration or amendment would render such other security senior to or pari passu with the Series
A Preferred Stock in respect of any such right, preference or privilege; or (iv) purchase or redeem (or permit any subsidiary to purchase
or redeem) or pay or declare any dividend or make any distribution on, any shares of capital stock of the Company (with exceptions for
(i) redemptions of or dividends or distributions on the Series A Preferred Stock as expressly authorized in the Certificate of Designations,
and (ii) dividends or other distributions payable on our common stock solely in the form of additional shares of common stock).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Conversion
Rights</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the Beneficial Ownership Limitation described below, each share of Series A Preferred Stock shall be convertible, at the option of
the holder thereof, at any time and from time to time, and without the payment of additional consideration by the holder thereof, into
such number of fully paid and non-assessable shares of common stock as is determined by multiplying one share of Series A Preferred Stock
by the Series A Conversion Rate in effect at the time of conversion. The &ldquo;Series A Conversion Rate&rdquo; shall initially be ten
(10) shares of Common Stock for each share of Series A Preferred Stock. The Series A Conversion Rate shall be subject to adjustment as
provided in the Certificate of Designations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the terms of the Certificate of Designations, the Company may not effect the conversion of Series A Preferred Stock into common stock,
and a holder will not be entitled to request the conversion of shares of Series A Preferred Stock, if, upon giving effect to such conversion,
the aggregate number of shares of common stock beneficially owned by the holder (together with its affiliates, any other persons acting
as a group together with the holder or any of the holder&rsquo;s affiliates, and any other persons whose beneficial ownership of common
stock would or could be aggregated with the holder&rsquo;s for purposes of Section 13(d) or Section 16 of the Exchange Act) would exceed
the Beneficial Ownership Limitation, which is 9.9% of the number of shares of common stock outstanding immediately after giving effect
to the conversion, as such percentage ownership is calculated in accordance with Section 13(d) of the Exchange Act and the applicable
regulations of the Securities and Exchange Commission. A holder may reset the Beneficial Ownership Limitation percentage to a higher
percentage (not to exceed 19.9%), effective 61 days after written notice to the Company, or a lower percentage, effective immediately
upon written notice to the Company. Any such increase or decrease will apply only to that holder and not to any other holder of Series
A Preferred Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series A Preferred Stock does not have, nor is subject to, any preemptive or similar rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>2024
Warrants</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Amended and Restated Loan and Security Agreement, dated as of May 30, 2024, by and among the Company, Innovatus Life Sciences Lending
Fund I, LP (&ldquo;Innovatus&rdquo;), as collateral agent, and the Lenders named therein, including Innovatus in its capacity as a Lender
and Oxford Finance LLC (&ldquo;Oxford&rdquo;) (the &ldquo;A&amp;R Loan Agreement&rdquo;), pursuant to which Innovatus and Oxford, as
Lenders, have agreed to make certain term loans, including the Term C Loan, the Term D Loan, the Term E Loan, and the Term F Loan (as
such terms are defined in the A&amp;R Loan Agreement and, each, a &ldquo;Term Loan&rdquo;) to the Company, the Company issued to Innovatus
and Oxford warrants (the &ldquo;2024 Warrants&rdquo;) to purchase that number of shares of common stock equal to <FONT STYLE="background-color: white">2.5%
of the principal amount of the applicable Term Loan divided by the exercise price, which was, with respect to the Term C Loan, be equal
to the lower of (i) the volume weighted average closing price of the Company&rsquo;s common stock for the five-trading day period ending
on the last trading day immediately preceding the execution of the A&amp;R Loan Agreement or (ii) the closing price on the last trading
day immediately preceding the execution of the A&amp;R Loan Agreement. Accordingly, on May 30, 2024, the Company issued 103,876 2024
Warrants with an exercise price of $14.84 per share. For the additional Term Loans, the exercise price will be based on the lower of
(i) the exercise price for the 2024 Warrants issued pursuant to the Term C Loan or (ii) the volume weighted average closing price of
the Company&rsquo;s common stock for the five-trading day period ending on the last trading day immediately preceding the applicable
Term Loan funding. The 2024 Warrants may be exercised on a cashless basis and are exercisable through the tenth anniversary of the applicable
funding date. The number of shares of common stock for which each 2024 Warrant is exercisable and the associated exercise price are subject
to certain proportional adjustments as set forth in such 2024 Warrant.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>2023
Pre-Funded Warrants</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Securities Purchase Agreement, dated October 18, 2023, by and among the Company and the Investors named therein (the &ldquo;2023
Investors,&rdquo; and such Securities Purchase Agreement, the &ldquo;2023 Securities Purchase Agreement&rdquo;), the Company issued pre-funded
warrants (the &ldquo;2023 Warrants&rdquo;) to purchase 5,747,787 shares of common stock. Each 2023 Warrant to purchase one share was
sold for a purchase price of $8.699 per Warrant and has an exercise price of $0.001 per share (for aggregate consideration equating to
$8.70 per share of common stock issuable upon exercise of the 2023 Warrants).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
2023 Warrant is immediately exercisable and will not expire. Under the terms of the 2023 Warrants, the Company may not effect the exercise
of any such 2023 Warrant, and a holder will not be entitled to exercise any portion of any 2023 Warrant, if, upon giving effect to such
exercise, the aggregate number of shares of common stock beneficially owned by the holder (together with its affiliates, other persons
acting or who could be deemed to be acting as a group together with the holder or any of the holder&rsquo;s affiliates, and any other
persons whose beneficial ownership of common stock would or could be aggregated with the holder&rsquo;s or any of the holder&rsquo;s
affiliates for purposes of Section 13(d) or Section 16 of the Exchange Act) would exceed 4.99% of the number of shares of common stock
outstanding immediately after giving effect to the exercise, as such percentage ownership is calculated in accordance with Section 13(d)
of the Exchange Act and the applicable regulations of the Securities and Exchange Commission (the &ldquo;Maximum Percentage&rdquo;).
A holder may reset the Maximum Percentage to a higher percentage (not to exceed 19.99%), effective 61 days after written notice to the
Company, or a lower percentage, effective immediately upon written notice to the Company. Any such increase or decrease will apply only
to that holder and not to any other holder of 2023 Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>2022
Warrants</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the 2022 Securities Purchase Agreement, the Company issued Warrants (the &ldquo;2022 Warrants&rdquo;) to purchase 695,645 shares of Series
A Preferred Stock, each 2022 Warrant having an exercise price of $85.50 per share. The exercise price of the 2022 Warrants is at a 40%
premium to the price (on an as converted to common stock basis) paid by the 2022 Investors for the initial shares of common stock purchased
under the 2022 Securities Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 1, 2022, the Company amended its Certificate of Incorporation to increase the aggregate authorized number of shares of capital
stock and the number of shares of common stock such that the Company has available, and has reserved, such number of its duly authorized
but unissued shares of common stock as shall be sufficient to effect the conversion of all shares of Series A Preferred Stock then outstanding
or available for issuance upon the exercise of the 2022 Warrants (the &ldquo;Authorized Share Increase&rdquo;). Following this Authorized
Share Increase, and notice to the 2022 Investors, the 2022 Warrants became exercisable for an aggregate 6,956,450 shares of common stock
with an exercise price per share adjusted of $8.05.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
2022 Warrant, when issued, is immediately exercisable and will remain exercisable until the earlier of (i) five years from the date of
issuance and (ii) seventy-five (75) days after the Company announces (x) whether the progression-free survival (&ldquo;PFS&rdquo;) of
gedatolisib in combination with Palbociclib and fulvestrant (Arm A) to fulvestrant (Arm C) in the Phase 3 study met its primary endpoint
target, (y) whether the PFS of gedatolisib in combination with fulvestrant (Arm B) to fulvestrant (Arm C) in the Phase 3 study met its
primary endpoint target, and (z) the associated hazard ratios and median PFS values for each of Arm A, Arm B, and Arm C.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the terms of the 2022 Warrants, the Company may not effect the exercise of any such 2022 Warrant, and a holder will not be entitled to
request the exercise any portion of any 2022 Warrant, if, upon giving effect to such exercise, the aggregate number of shares of common
stock beneficially owned by the holder (together with its affiliates, any other persons acting as a group together with the holder or
any of the holder&rsquo;s affiliates, and any other persons whose beneficial ownership of common stock would or could be aggregated with
the holder&rsquo;s for purposes of Section 13(d) or Section 16 of the Exchange Act) would exceed the Beneficial Ownership Limitation
as described in the &ldquo;Preferred Stock&mdash;Conversion Rights&rdquo; section above. A holder may reset the Beneficial Ownership
Limitation percentage to a higher percentage (not to exceed 19.9%), effective 61 days after written notice to the Company, or a lower
percentage, effective immediately upon written notice to the Company. Any such increase or decrease will apply only to that holder and
not to any other holder of 2022 Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registration
Rights Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>2023
Registration Rights Agreement</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the 2023 Securities Purchase Agreement, the Company entered into a Registration Rights Agreement (the &ldquo;2023 Registration
Rights Agreement&rdquo;) with the 2023 Investors, pursuant to which the Company agreed to register for resale the Registrable Securities
(the &ldquo;2023 Registrable Securities&rdquo;), which include: (i) the shares of common stock then issued or issuable upon exercise
of the 2023 Warrants (assuming the 2023 Warrants are exercisable in full without regard to any exercise limitation therein) (the &ldquo;2023
Warrant Shares&rdquo;), and (ii) any other securities issued or issuable with respect to, in exchange for or in replacement of, the 2023
Warrant Shares issued and sold pursuant to the 2023 Securities Purchase Agreement. Under the 2023 Registration Rights Agreement, the
Company agreed to file a registration statement covering the resale by the 2023 Investors of the 2023 Registrable Securities no later
than 30 days following the Closing Date (as defined in the 2023 Registration Rights Agreement). The Company agreed to use commercially
reasonable efforts to cause the registration statement to become effective and to keep such registration statement effective until such
time as there are no longer 2023 Registrable Securities held by the 2023 Investors. The Company agreed to be responsible for all fees
and expenses incurred in connection with the registration of the 2023 Registrable Securities. The Company filed a registration statement
on Form S-3 registering for resale the 2023 Registrable Securities, which was declared effective on November 28, 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company granted the 2023 Investors customary indemnification rights in connection with the registration statement, including for liabilities
arising under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;). The 2023 Investors also granted the Company
customary indemnification rights in connection with the registration statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>2022
Registration Rights Agreement</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the 2022 Securities Purchase Agreement, the Company entered into a Registration Rights Agreement (the &ldquo;2022 Registration
Rights Agreement&rdquo;) with the 2022 Investors, pursuant to which the Company agreed to register for resale the Registrable Securities
(the &ldquo;2022 Registrable Securities&rdquo;), which include: (i) the common stock, (ii) the shares of common stock then issued or
issuable upon conversion of the Series A Preferred Stock (assuming on such date the shares of Series A Preferred Stock are convertible
in full without regard to any conversion limitations in the Certificate of Designations), and (iii) the common stock then issued or issuable
upon exercise of the 2022 Warrants (assuming the 2022 Warrants are exercisable in full without regard to any exercise limitations therein).
Under the 2022 Registration Rights Agreement, the Company agreed to file a registration statement covering the resale by the 2022 Investors
of the 2022 Registrable Securities no later than 30 days following (i) the Closing Date (as defined in the 2022 Registration Rights Agreement)
and (ii) the date the Company obtained the necessary stockholder approval to effect the Authorized Share Increase. The Company agreed
to use commercially reasonable efforts to cause the registration statement to become effective and to keep such registration statement
effective until such time as there are no longer 2022 Registrable Securities held by the 2022 Investors. The Company agreed to be responsible
for all fees and expenses incurred in connection with the registration of the 2022 Registrable Securities. The Company filed a registration
statement on Form S-3 registering for resale the 2022 Registrable Securities, which was declared effective on January 11, 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company granted the 2022 Investors customary indemnification rights in connection with the registration statement, including for liabilities
arising under the Securities Act. The 2022 Investors also granted the Company customary indemnification rights in connection with the
registration statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
representations, warranties and covenants contained in each of the 2023 Warrants, the 2022 Warrants, the 2023 Securities Purchase Agreement,
the 2022 Securities Purchase Agreement, the 2023 Registration Rights Agreement and the 2022 Registration Rights Agreement were made solely
for the benefit of the parties thereto and may be subject to limitations agreed upon by the contracting parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Anti-Takeover
Effect of Delaware Law and Certain Charter and Bylaw Provisions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
certificate of incorporation, as amended, and bylaws contain provisions that could have the effect of discouraging potential acquisition
proposals or tender offers or delaying or preventing a change of control of our Company. A summary of these provisions is as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Board
                                            of directors vacancies. </I></B>Our bylaws authorize only our board of directors to fill
                                            vacant directorships, including newly created seats. In addition, the number of directors
                                            constituting our board of directors will be permitted to be set only by a resolution adopted
                                            by our board of directors. These provisions would prevent a stockholder from increasing the
                                            size of our board of directors and then gaining control of our board of directors by filling
                                            the resulting vacancies with its own nominees. This makes it more difficult to change the
                                            composition of our board of directors but promotes continuity of management.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Advance
                                            notice requirements for stockholder proposals and director nominations.</I></B> Our bylaws
                                            provide advance notice procedures for stockholders seeking to bring business before our annual
                                            meeting of stockholders or to nominate candidates for election as directors at our annual
                                            meeting of stockholders. Our bylaws also specify certain requirements regarding the form
                                            and content of a stockholder&rsquo;s notice. These provisions might preclude our stockholders
                                            from bringing matters before our annual meeting of stockholders or from making nominations
                                            for directors at our annual meeting of stockholders if the proper procedures are not followed.
                                            These provisions may also discourage or deter a potential acquirer from conducting a solicitation
                                            of proxies to elect the acquirer&rsquo;s own slate of directors or otherwise attempting to
                                            obtain control of the Company.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>No
                                            cumulative voting.</I></B> The Delaware General Corporation Law, or DGCL, provides that stockholders
                                            are not entitled to the right to cumulate votes in the election of directors unless a corporation&rsquo;s
                                            certificate of incorporation provides otherwise. Our certificate of incorporation, as amended,
                                            does not provide for cumulative voting.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Stockholder
                                            action; special meetings of stockholders.</I></B> Our certificate of incorporation, as amended,
                                            provides that our stockholders may not take action by written consent, but may only take
                                            action at annual or special meetings of our stockholders. As a result, a holder controlling
                                            a majority of our capital stock would not be able to amend our bylaws or remove directors
                                            without holding a meeting of our stockholders called in accordance with our bylaws. Further,
                                            our bylaws provide that special meetings of our stockholders may be called only by a majority
                                            of our board of directors, the chairperson of our board of directors, or our Chief Executive
                                            Officer, thus prohibiting a stockholder from calling a special meeting. These provisions
                                            might delay the ability of our stockholders to force consideration of a proposal or for stockholders
                                            controlling a majority of our capital stock to take any action, including the removal of
                                            directors.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Issuance
                                            of undesignated preferred stock.</I></B> We have 650,000 shares of undesignated preferred
                                            stock. Subject to certain limitations and approval requirements with respect to our Series
                                            A Preferred Stock as described in &ldquo;Preferred Stock&mdash;Voting Rights&rdquo; above,
                                            our board of directors has the authority, without further action by the stockholders, to
                                            issue this preferred stock with rights and preferences, including voting rights, designated
                                            from time to time by our board of directors. The existence of authorized but unissued shares
                                            of preferred stock would enable our board of directors to render more difficult or to discourage
                                            an attempt to obtain control of us by means of a merger, tender offer, proxy contest or other
                                            means.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Amendment
                                            of charter and bylaw provisions.</I></B> The affirmative vote of stockholders representing
                                            at least two-thirds of the voting power of all then-outstanding capital stock, and in certain
                                            instances, the vote of the holders of a majority of the then-outstanding Series A Preferred
                                            Stock, is required to amend, alter or repeal certain provisions of our certificate of incorporation,
                                            as amended, including the provision noted above regarding stockholders not being able to
                                            act by written consent. Subject to certain limitations and approval requirements with respect
                                            to our Series A Preferred Stock as described in &ldquo;Preferred Stock&mdash;Voting Rights&rdquo;
                                            above, a majority of our board of directors has authority to adopt, amend or repeal provisions
                                            of our bylaws. Stockholders also have the authority to adopt, amend or repeal provisions
                                            of our bylaws, but only with the affirmative vote of stockholders representing at least two-thirds
                                            of the voting power of all then-outstanding capital stock and in certain instances, the vote
                                            of the holders of a majority of the then-outstanding Series A Preferred Stock.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to the provisions of Section 203 of the DGCL, an anti-takeover law. In general, Section 203 prohibits a publicly held Delaware
corporation from engaging in a &ldquo;business combination&rdquo; with an &ldquo;interested stockholder&rdquo; for a period of three
years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved
in a prescribed manner. For purposes of Section 203, a &ldquo;business combination&rdquo; includes a merger, asset sale or other transaction
resulting in a financial benefit to the interested stockholder, and an &ldquo;interested stockholder&rdquo; is a person who owns 15%
or more of the voting stock of a corporation, or any affiliate or associate of a corporation who, within three years prior, did own 15%
or more of the voting stock of that corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 6; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.35
<SEQUENCE>3
<FILENAME>ex10-35.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.35</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CELCUITY
INC.<BR>
<BR>
CHANGE IN CONTROL AND SEVERANCE PLAN</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AND</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SUMMARY
PLAN DESCRIPTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">1. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Introduction</U>.
The purpose of this Celcuity Inc. Change in Control and Severance Plan is to provide assurances of specified benefits to employees of
the Company in the event of a Change in Control or certain terminations of employment following a Change in Control as described in this
Plan (as such terms are defined below). This Plan is governed by ERISA. With respect to Plan benefits provided to Eligible Employees
other than the Chief Executive Officer, the Plan is considered a &ldquo;welfare benefit plan&rdquo;, as defined in Section 3(1) of ERISA,
and with respect to Plan benefits provided to the Chief Executive Officer, this Plan is considered a &ldquo;pension plan&rdquo;, as defined
in Section 3(2) of ERISA, which is established solely for the purpose of providing severance benefits to a select group of management
or highly compensated employees (i.e., a &ldquo;top hat&rdquo; plan), and will be construed accordingly. This document constitutes both
the written instrument under which this Plan is maintained and the required summary plan description for this Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">2. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Definitions</U>.
As used herein, the following definitions will apply:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1 &ldquo;<U>Administrator</U>&rdquo;
means (a) the Compensation Committee of the Board or, (b) solely with respect to Participants who are not Executive Officers of the Company,
(i) the Chief Executive Officer of the Company; or (ii) any other officer of the Company to whom the Board has delegated any authority
or responsibility with respect to this Plan pursuant to Section 11, but only to the extent of such delegation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2 &ldquo;<U>Affiliate</U>&rdquo;
means any corporation or any other entity (including, but not limited to, partnerships and joint ventures) controlling, controlled by,
or under common control with the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3 &ldquo;<U>Annual
Base Salary</U>&rdquo; means the greater of Participant&rsquo;s annual base salary as in effect as of the date of the Participant&rsquo;s
Involuntary Termination or the Change in Control (without regard to any reduction that would constitute Good Reason). Annual Base Salary
does not include bonuses, commissions, overtime pay, incentive pay, performance awards, equity compensation, or any other additional
compensation, payments and/or benefits provided by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4 &ldquo;<U>Board</U>&rdquo;
means the board of directors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5 &ldquo;<U>Bonus
Payment Date</U>&rdquo; means the date when a Participant&rsquo;s actual bonus is paid to such Participant pursuant to the Company&rsquo;s
annual cash bonus program.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.6 &ldquo;<U>Cause</U>&rdquo;
has the meaning set forth in the Equity Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.7 &ldquo;<U>Change
in Control</U>&rdquo; has the meaning set forth in the Equity Plan. Notwithstanding this definition, no Change in Control shall be deemed
to have occurred for purposes of this Plan unless the event would also constitute a change in ownership or effective control of, or a
change in the ownership of a substantial portion of the assets of, the Company under Section 409A.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.8 &ldquo;<U>Change
in Control Period</U>&rdquo; means the time period beginning on the date of the Change in Control and ending on the date that is twelve
(12) months following a Change in Control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.9 &ldquo;<U>CIC
Severance Multiplier</U>&rdquo; means the following based on the Participant&rsquo;s position with the Company (if a Participant holds
more than one position, only the higher level CIC Severance Multiplier will apply):</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Participant&rsquo;s
    Position</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CIC
    Severance Multiplier</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive
    Officers</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    Other Executives (Chief Commercial Officer, Chief Medical Officer, VP Pharmaceutical Operations, VP Quality, General Counsel)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    Vice Presidents </FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6
    </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    Other Eligible Employees</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,
    or if greater, the lesser of (a) .5 months multiplied by full years of continuous employment and (b) 6</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.10
&ldquo;<U>COBRA</U>&rdquo; means the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.11 &ldquo;<U>Code</U>&rdquo;
means the U.S. Internal Revenue Code of 1986, as amended and in effect from time to time. For purposes of the Plan, references to sections
of the Code shall be deemed to include any applicable treasury regulations and guidance promulgated thereunder and any successor or similar
statutory provisions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.12 &ldquo;<U>Committee</U>&rdquo;
means the Compensation Committee of the Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.13 &ldquo;<U>Company</U>&rdquo;
means Celcuity Inc., a Delaware corporation, or any successor thereto, which, for the avoidance of doubt, includes any successor to the
Company of all or substantially all of the Company&rsquo;s business and/or assets (whether direct or indirect and whether by purchase,
merger, consolidation, liquidation or other transaction).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.14 &ldquo;<U>Disability</U>&rdquo;
has the meaning set forth in the Equity Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.15 &ldquo;<U>Eligible
Employee</U>&rdquo; means any regular full or part-time employee of the Company, excluding seasonal and temporary employees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.16 &ldquo;<U>Equity
Awards</U>&rdquo; means a Participant&rsquo;s outstanding stock options, stock appreciation rights, restricted stock, restricted stock
units, performance shares, performance stock units and other equity-based awards.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.17 &ldquo;<U>Equity
Plan</U>&rdquo; means the Celcuity Inc. Amended and Restated 2017 Stock Incentive Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.18 &ldquo;<U>ERISA</U>&rdquo;
means the Employee Retirement Income Security Act of 1974, as amended, including the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.19 &ldquo;<U>Exchange
Act</U>&rdquo; means the U.S. Securities Exchange Act of 1934, as amended, including the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.20 &ldquo;<U>Executive
Officer</U>&rdquo; means an &ldquo;officer&rdquo; of the Company within the meaning of Rule 16a-1(f) of the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.21 &ldquo;<U>Good
Reason</U>&rdquo; means, with respect to a Participant, the occurrence of one or more of the following (through a single action or series
of actions) without the Participant&rsquo;s written consent: (i) a material reduction in the Participant&rsquo;s duties, authority or
responsibilities; (ii) a material diminution in the authority, duties, or responsibilities of the supervisor to whom the Participant
is required to report, including, as applicable, a requirement that the Participant report to a corporate officer or employee instead
of reporting directly to the Chief Executive Officer or the Board; (iii) a material reduction in the Participant&rsquo;s Annual Base
Salary from the Participant&rsquo;s Annual Base Salary at the time of the Change in Control; or (iv) a change in the geographic location
of the Participant&rsquo;s primary work facility or location, including (A) a change from working remotely, if remote work is permitted
for such Participant, to requiring the Participant to work on-site or in a hybrid arrangement, or (B) by more than 25 miles from its
current primary location, other than travel reasonably required in the performance of the Participant&rsquo;s responsibilities. Notwithstanding
the foregoing, the Participant will not be entitled to resign for Good Reason without first providing the Company with written notice
of the acts or omissions constituting the grounds for &ldquo;Good Reason&rdquo; within 60 days of the initial existence of the grounds
for &ldquo;Good Reason&rdquo; and the Company fails to reasonably cure such grounds within a reasonable cure period of not less than
30 days following the date of such notice. In addition, the Participant&rsquo;s resignation will qualify as a resignation for &ldquo;Good
Reason&rdquo; only if (x) the grounds for &ldquo;Good Reason&rdquo; are not reasonably cured within the cure period specified in the
preceding sentence and (y) the Participant resigns within 60 days following the end of such cure period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.22 &ldquo;<U>Involuntary
Termination</U>&rdquo; means a termination of the Participant&rsquo;s employment with the Company and its Affiliates (a) by the Participant
for Good Reason, or (b) by the Company and its Affiliates for a reason other than Cause, death or Disability. For the avoidance of doubt,
a transfer of the Participant&rsquo;s employment or service from one business group, including corporate groups, or Affiliate of the
Company to another business group or Affiliate of the Company, shall not be considered an Involuntary Termination of the Participant&rsquo;s
employment with the Company and its Affiliates unless the circumstances of such transfer meet the definition of Good Reason.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.23 &ldquo;<U>Participant</U>&rdquo;
means any Eligible Employee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.24 &ldquo;<U>Plan</U>&rdquo;
means the Celcuity Inc. Change in Control and Severance Plan, as set forth in this document, and as hereafter amended from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.25 &ldquo;<U>Section
280G</U>&rdquo; means Section 280G of the Code, including the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.26 &ldquo;<U>Section
409A</U>&rdquo; means Section 409A of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.27 &ldquo;<U>Separation
from Service</U>&rdquo; means a &ldquo;separation from service&rdquo; as such term is defined for purposes of Section 409A.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.28 &ldquo;<U>Severance
Benefits</U>&rdquo; means the compensation and other benefits that the Participant will be eligible to receive under this Plan in the
event of an Involuntary Termination as provided in Section 5, subject to the terms and conditions of this Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.29 &ldquo;<U>Target
Annual Bonus</U>&rdquo; means the Participant&rsquo;s target annual cash bonus amount pursuant to the Company&rsquo;s annual cash bonus
program (without regard to any reduction that would constitute Good Reason).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">3. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Equity
Acceleration</U>. In the event of a Change in Control, all outstanding Equity Awards held by any Participant in the Plan will fully vest
(with performance awards vesting at the greater of target or actual performance levels) immediately upon the effective date of such Change
in Control (the &ldquo;<U>Equity Acceleration</U>&rdquo;). For the avoidance of doubt, the Equity Acceleration will occur immediately
upon the effective date of a Change in Control regardless of whether the Participant experiences an Involuntary Termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">4. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Eligibility
for Severance Benefits</U>. A Participant is eligible for Severance Benefits, as described in Section 5, only if the Participant experiences
an Involuntary Termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">5. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Involuntary
Termination during the Change in Control Period</U>. Subject to the Participant&rsquo;s compliance with Section 6, upon an Involuntary
Termination that is within the Change in Control Period, the Participant will be eligible to receive the following Severance Benefits,
subject to the terms and conditions of this Plan:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1 <U>Cash
Severance</U>. An amount in cash equal to the product of (a) the Participant&rsquo;s (i) Annual Base Salary plus (ii) Target Annual Bonus,
(b) divided by twelve (12), and (c) multiplied by the CIC Severance Multiplier, payable, subject to Section 6, in a single lump sum on
the 60<SUP>th</SUP> day after the Participant&rsquo;s Involuntary Termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2 <U>COBRA
Premiums</U>. If the Participant timely elects COBRA continuation coverage, a lump sum amount in cash equal to the monthly COBRA premiums
(on an after-tax basis) that the Participant would be required to pay to continue the group health and prescription drug (but not dental
or vision) coverage in effect on the date of the Participant&rsquo;s Involuntary Termination (which amount will be based on the premium
for the first month of COBRA coverage) for the Participant and any dependents of the Participant who are enrolled in Company benefits
at the time of termination, multiplied by the lesser of the CIC Severance Multiple or 18, payable, subject to Section 9, in a single
lump sum on the 75<SUP>th</SUP> day after the Participant&rsquo;s Involuntary Termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">6. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Conditions
to Receipt of Severance</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.1 <U>Release
Agreement</U>. As a condition to receiving the Severance Benefits, each Participant will be required to sign and not revoke a separation
and release of claims in favor of the Company in a form of agreement provided by the Company (the &ldquo;<U>Release</U>&rdquo;). In all
cases, the Release must become effective and irrevocable no later than the 55th day following the Participant&rsquo;s Involuntary Termination
(the &ldquo;<U>Release Deadline Date</U>&rdquo;). If the Release does not become effective and irrevocable by the Release Deadline Date,
the Participant will forfeit any right to the Severance Benefits. In no event will the Severance Benefits be paid or provided until the
Release becomes effective and irrevocable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.2 <U>Restrictive
Covenants</U>. A Participant&rsquo;s receipt of Severance Benefits will be subject to the Participant continuing to comply with the terms
of any enforceable non-compete, non-solicit, employee invention and confidentiality agreement or similar agreement or policy. Any unpaid
Severance Benefits under this Plan will be forfeited immediately if the Participant violates any such agreement and/or the provisions
of this Section 6.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">7. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Limitation
on Payments</U>. In the event that the Severance Benefits, Equity Acceleration, and any other severance or benefits otherwise payable
to a Participant (i) constitute &ldquo;parachute payments&rdquo; within the meaning of Section 280G (the &ldquo;<U>280G Payments</U>&rdquo;)
and (ii) but for this Section 7, would be subject to the excise tax imposed by Section 4999 of the Code (the &ldquo;<U>Excise Tax</U>&rdquo;),
then the 280G Payments will be either:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) delivered
in full; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) delivered
as to such lesser extent which would result in no portion of such benefits being subject to the Excise Tax, whichever of the foregoing
amounts, taking into account the applicable federal, state and local income taxes and the excise tax imposed by Section 4999 of the Code,
results in the receipt by the Participant on an after-tax basis, of the greatest amount of benefits, notwithstanding that all or some
portion of such benefits may be taxable under Section 4999 of the Code. If a reduction in the 280G Payments is necessary so that no portion
of such benefits is subject to the Excise Tax, such reduction will be first applied to reduce any cash payments and will thereafter be
applied to reduce noncash payments and benefits, in each case, in reverse order beginning with the payments or benefits that are to be
paid the furthest in time from the date of such determination; <U>provided</U>, <U>however</U>, that, in no event may the 280G Payments
be reduced in a manner that would result in subjecting the Participant to additional taxation or penalties under Section 409A.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
determination required under this Section 7 will be made in writing by the Company&rsquo;s independent public accountants immediately
prior to the Change in Control or such other independent accountant as determined in good faith by the Company (the &ldquo;<U>Accounting
Firm</U>&rdquo;), whose determination will be conclusive and binding upon the Participant and the Company. For purposes of making the
calculations required by this Section 7, the Accounting Firm may make reasonable assumptions and approximations concerning applicable
taxes and may rely on reasonable, good faith interpretations concerning the application of Sections 280G and 4999 of the Code. The Participant
and the Company will furnish to the Accounting Firm such information and documents as the Accounting Firm may reasonably request in order
to make a determination under this Section 7. The Company will bear all costs the Accounting Firm may incur in connection with any calculations
contemplated by this Section 7.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">8. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Other
Arrangements</U>. Except as otherwise provided by the Company in writing, (i) in the event that the Participant is eligible for any other
arrangement of the Company regarding severance or severance-type benefits in connection with a Change in Control (&ldquo;<U>Change in
Control Severance Benefits</U>&rdquo;), the Eligible Employee will be entitled to receive the better of the Change in Control Severance
Benefits and the benefits under this Plan; and (ii) the Plan shall not provide duplicative benefits with other Change in Control Severance
Benefits, provided, however, that this nonduplication provision will not apply to any Change in Control bonus or retention arrangement
which provides for benefits not in connection with an Involuntary Termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">9. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
409A</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.1 This
Plan and the Severance Benefits and Equity Acceleration are intended to comply with or be exempt from the requirements of Section 409A
and will be construed and interpreted in accordance with such intent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.2 Except
as permitted under Section 409A, any deferred compensation (within the meaning of Section 409A) payable to any Participant or for the
benefit of any Participant under this Plan may not be reduced by, or offset against, any amount owing by any such Participant to the
Company or any of its Affiliates to the extent such offset would result in taxes or penalties under Section 409A. Amounts reimbursable
to Participant under this Plan shall be paid to Participant on or before the last day of the year following the year in which the expense
was incurred and the amount of expenses eligible for reimbursement (and in-kind benefits provided to Participant) during one year may
not affect amounts reimbursable or provided in any subsequent year);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.3 To
the extent required to avoid accelerated taxation and/or tax penalties under Section 409A, amounts that would otherwise be payable and
benefits that would otherwise be provided pursuant to this Plan during the six (6) month period immediately following Participant&rsquo;s
Separation from Service shall instead be paid on the first business day after the date that is six (6) months following Participant&rsquo;s
Separation from Service (or, if earlier, Participant&rsquo;s date of death). Such amount will be paid without interest.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.4 Participant
will be solely responsible and liable for the satisfaction of all taxes and penalties that may be imposed on such Participant in connection
with any Severance Benefits or Equity Acceleration (including any taxes and penalties under Section 409A), and neither the Company nor
any of its Affiliates will have any obligation to indemnify or otherwise hold such Participant harmless from any or all of such taxes
or penalties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.5 Each
payment and benefit payable under this Plan is intended to constitute a separate payment for purposes of Section 409A. For purposes of
Section 409A, the right to receive payments in the form of installment payments shall be treated as a right to receive a series of separate
payments and, accordingly, each installment payment shall at all times be considered a separate and distinct payment. In addition, to
the extent necessary to comply with Section 409A of the Code, if the period during which a Release must be executed and become irrevocable
spans two calendar years, payment of the Severance Benefits will commence in the second calendar year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.6 For
purposes of any provision of this Plan providing for the payment of any amount or benefit upon or following a termination of employment
that constitutes &ldquo;nonqualified deferred compensation&rdquo; Section 409A, a termination of employment shall not be deemed to have
occurred unless such termination is also a Separation from Service and, for purposes of any such provision of this Plan, references to
a &ldquo;termination,&rdquo; &ldquo;termination of employment&rdquo; or like terms shall mean Separation from Service.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">10. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Withholdings</U><B>.
</B>The Company or any Affiliate will have the right and is hereby authorized to withhold from any Severance Benefits or Equity Acceleration
due under this Plan or from any compensation or other amount owing to a Participant, the amount (in cash, shares, other securities or
other property) of any applicable withholding taxes in respect of the amounts payable under this Plan and to take such other action as
may be necessary in the opinion of the Administrator or the Company to satisfy all obligations for the payment of such taxes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">11. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Administration</U><B>.
</B>This Plan will be administered and interpreted by the Administrator (in his or her sole discretion). The Administrator is the &ldquo;named
fiduciary&rdquo; of this Plan for purposes of ERISA and will be subject to the fiduciary standards of ERISA when acting in such capacity.
Any decision made or other action taken by the Administrator with respect to this Plan, and any interpretation by the Administrator of
any term or condition of this Plan, or any related document, will be conclusive and binding on all persons and be given the maximum possible
deference allowed by law. In accordance with Section 2.1, the Administrator (a) may, in its sole discretion and on such terms and conditions
as it may provide, delegate in writing to one or more officers of the Company all or any portion of its authority or responsibility with
respect to this Plan and (b) has the authority to act for the Company (in a non-fiduciary capacity) as to any matter pertaining to this
Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">12. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Eligibility
to Participate</U>. To the extent that the Administrator has delegated administrative authority or responsibility to one or more officers
of the Company in accordance with Sections 2.1 and 11, each such officer will not be excluded from participating in this Plan if otherwise
eligible, but he or she is not entitled to act upon or make determinations regarding any matters pertaining specifically to his or her
own benefit or eligibility under this Plan. The Committee will act upon and make determinations regarding any matters pertaining specifically
to the benefit or eligibility of each such officer under this Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">13. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Amendment
or Termination</U>. The Committee reserves the right to amend or terminate this Plan or the benefits provided hereunder at any time,
subject to the provisions of this Section 13. Any amendment or termination will be effective, with or without advance notice, as of the
date determined by the Committee. Notwithstanding the foregoing, beginning on the date that a Change in Control occurs, the Company may
not, without a Participant&rsquo;s written consent, amend or terminate this Plan in any way, nor take any other action under this Plan,
which (a) prevents the Participant from becoming eligible for Severance Benefits or Equity Acceleration or (b) reduces or alters to the
detriment of the Participant the Severance Benefits or Equity Acceleration payable, or potentially payable, to the Participant (including,
without limitation, imposing additional conditions). Unless and until a Change of Control occurs, the Participants&rsquo; rights under
this Plan are unvested and may be amended or revoked at any time. Any action of the Company in amending or terminating this Plan will
be taken in a non-fiduciary capacity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">14. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Claims
and Appeals</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.1 <U>Claims
Procedure</U>. Any employee or other person (or his or her authorized representative) who believes he or she is entitled to any Severance
Benefits or Equity Acceleration (&ldquo;<U>Claimant</U>&rdquo;) may submit a claim in writing to the Administrator within 90 days of
the earlier of (a) the date the Claimant learned the amount of his or her Severance Benefits or Equity Acceleration or (b) the date the
Claimant learned that he or she will not be entitled to any Severance Benefits or Equity Acceleration. If the claim is denied (in full
or in part), the Claimant will be provided a written notice explaining the specific reasons for the denial and referring to the provisions
of this Plan on which the denial is based. The notice also will describe any additional information needed to support the claim and this
Plan&rsquo;s procedures for appealing the denial. The denial notice will be provided within 90 days after the claim is received. If special
circumstances require an extension of time (up to 90 days), written notice of the extension will be given within the initial 90-day period.
This notice of extension will indicate the special circumstances requiring the extension of time and the date by which the Administrator
expects to render its decision on the claim.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.2 <U>Appeal
Procedure</U>. If the Claimant&rsquo;s claim is denied, the Claimant may apply in writing to the Administrator for a review of the decision
denying the claim. Review must be requested within 60 days following the date the Claimant received the written notice of their claim
denial or else the Claimant loses the right to review. The Claimant then has the right to review and obtain copies of all documents and
other information relevant to the claim, upon request and at no charge, and to submit issues and comments in writing. The Administrator
will provide written notice of its decision on review within 60 days after it receives a review request. If additional time (up to 60
days) is needed to review the request, the Claimant will be given written notice of the reason for the delay. This notice of extension
will indicate the special circumstances requiring the extension of time and the date by which the Administrator expects to render its
decision. If the claim is denied (in full or in part), the Claimant will be provided a written notice explaining the specific reasons
for the denial and referring to the provisions of this Plan on which the denial is based. The notice also will include a statement that
the Claimant will be provided, upon request and free of charge, reasonable access to, and copies of, all documents and other information
relevant to the claim and a statement regarding the Claimant&rsquo;s right to bring an action under Section 502(a) of ERISA. The decision
of the Administrator will be made in its sole discretion and is final and binding on all parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.3 <U>Limitations
Period</U>. The claims and appeals procedure above is mandatory. If a Claimant has completed the entire claims and appeals procedure
and still disagrees with the outcome of his or her claim, the Claimant may commence a civil action under ERISA. The Claimant must commence
such civil action within one year of the date of the final denial, or the Claimant will waive all rights to relief under ERISA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">15. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Source
of Payments</U>. All payments under this Plan will be paid from the general funds of the Company; no separate fund will be established
under this Plan, and this Plan will have no assets. No right of any person to receive any payment under this Plan will be any greater
than the right of any other general unsecured creditor of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">16. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Benefits
Nontransferable</U>. In no event may any current or former employee of the Company or any of its Affiliates sell, transfer, anticipate,
assign or otherwise dispose of any right or interest under this Plan. At no time will any such right or interest be subject to the claims
of creditors nor liable to attachment, execution or other legal process.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">17. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>No
Right to Continued Employment</U>. Neither the establishment or maintenance or amendment of this Plan, nor the making of any benefit
payment hereunder, will be construed to confer upon any individual any right to continue to be an employee of the Company. This Plan
in no way alters a Participant&rsquo;s at-will employment arrangement with the Company, and the Company expressly reserves the right
to discharge any of its employees, including the Participant, at any time, with or without cause. However, as described in this Plan,
a Participant may be eligible for Severance Benefits depending upon the circumstances of his or her termination of employment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">18. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Successors</U>.
Any successor to the Company of all or substantially all of the Company&rsquo;s business and/or assets (whether direct or indirect and
whether by purchase, merger, consolidation, liquidation or other transaction) will assume the obligations under this Plan and agree expressly
to perform the obligations under this Plan in the same manner and to the same extent as the Company would be required to perform such
obligations in the absence of a succession. For all purposes under this Plan, the term &ldquo;Company&rdquo; will include any successor
to the Company&rsquo;s business and/or assets which become bound by the terms of this Plan by operation of law, or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">19. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Applicable
Law</U>. This Plan will be governed by, and construed in accordance with, ERISA. For purposes of any action, lawsuit or other proceedings
brought to enforce this Plan, relating to it, or arising from it, the parties hereby submit to and consent to the sole and exclusive
jurisdiction of the federal courts for the United States for the District of Minnesota.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">20. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Severability</U>.
If any provision of this Plan is or becomes or is deemed to be invalid, illegal, or unenforceable for any reason in any jurisdiction
or as to any Participant, such invalidity, illegality or unenforceability will not affect the remaining parts of this Plan, and this
Plan will be construed and enforced as to such jurisdiction or Participant as if the invalid, illegal or unenforceable provision had
not been included.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">21. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Headings
and Construction</U>. Headings are given to the Sections and subsections of this Plan solely as a convenience to facilitate reference.
Such headings will not be deemed in any way material or relevant to the construction or interpretation of this Plan or any provision
thereof. Whenever the words &ldquo;include&rdquo;, &ldquo;includes&rdquo; or &ldquo;including&rdquo; are used in this Plan, they will
be deemed to be followed by the words &ldquo;but not limited to&rdquo;, and the word &ldquo;or&rdquo; will not be deemed to be exclusive.
Pronouns and other words of gender will be read as gender neutral. Words importing the plural will include the singular and the singular
will include the plural.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">22. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Indemnification</U>.
The Company hereby agrees to indemnify and hold harmless the officers and employees of the Company, and the members of its Board, from
all losses, claims, costs or other liabilities arising from their acts or omissions in connection with the administration, amendment
or termination of this Plan, to the maximum extent permitted by applicable law. This indemnity will cover all such liabilities, including
judgments, settlements and costs of defense. The Company will provide this indemnity from its own funds to the extent that insurance
does not cover such liabilities. This indemnity is in addition to and not in lieu of any other indemnity provided to such person by the
Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Appendix</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">STATEMENT
OF ERISA RIGHTS </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 6.95pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a participant in this Plan, you are entitled to certain rights and protections under the Employee Retirement Income Security Act of 1974
(ERISA). ERISA provides that all plan participants shall be entitled to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&#9632;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Receive
                                            Information About Your Plan and Benefits</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt .5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt .5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Examine,
without charge, at the Administrator&rsquo;s office and at other specified locations all documents governing the plan and a copy of the
latest annual report (Form 5500 Series) required to be filed by the plan with the U.S. Department of Labor and available at the Public
Disclosure Room of the Employee Benefits Security Administration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt .5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obtain,
upon written request to the Administrator, copies of documents governing the operation of the plan and copies of the latest annual report
(Form 5500 Series), if any required, and updated summary plan description. The administrator may make a reasonable charge for the copies.</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&#9632;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prudent
                                            Actions by Plan Fiduciaries</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt .5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt .5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to creating rights for plan participants ERISA imposes duties upon the people who are responsible for the operation of the employee
benefit plan. The people who operate your plan, called &ldquo;fiduciaries&rdquo; of the plan, have a duty to do so prudently and in the
interest of you and other plan participants and beneficiaries. No one, including your employer, or any other person, may fire you or
otherwise discriminate against you in any way to prevent you from obtaining a welfare benefit or exercising your rights under ERISA.</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&#9632;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enforce
                                            Your Rights</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt .5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt .5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
your claim for a severance benefit is denied or ignored, in whole or in part, you have a right to know why this was done, to obtain copies
of documents relating to the decision without charge, and to appeal any denial, all within certain time schedules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt .5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
ERISA, there are steps you can take to enforce the above rights. For instance, if you request a copy of plan documents or the latest
annual report from the plan and do not receive them within 30 days, you may file suit in a Federal court. In such a case, the court may
require the Administrator to provide the materials and pay you up to $110 a day until you receive the materials, unless the materials
were not sent because of reasons beyond the control of the administrator. If you have a claim for benefits which is denied or ignored,
in whole or in part, you may file suit in a state or Federal court. If it should happen that plan fiduciaries misuse the plan&rsquo;s
money, or if you are discriminated against for asserting your rights, you may seek assistance from the U.S. Department of Labor, or you
may file suit in a Federal court. The court will decide who should pay court costs and legal fees. If you are successful the court may
order the person you have sued to pay these costs and fees. If you lose, the court may order you to pay these costs and fees, for example,
if it finds your claim is frivolous.</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&#9632;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assistance
                                            with Your Questions</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt .5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt .5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you have any questions about your plan, you should contact the Administrator. If you have any questions about this statement or about
your rights under ERISA, or if you need assistance in obtaining documents from the Administrator, you should contact the nearest office
of the Employee Benefits Security Administration, U.S. Department of Labor, listed in your telephone directory or the Division of Technical
Assistance and Inquiries, Employee Benefits Security Administration, U.S. Department of Labor, 200 Constitution Avenue N.W., Washington,
D.C. 20210. You may also obtain certain publications about your rights and responsibilities under ERISA by calling the publications hotline
of the Employee Benefits Security Administration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt .5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 5.55pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ADDITIONAL
INFORMATION </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employer
    and Plan Sponsor:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 65%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Celcuity
    Inc.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16305
    36th Avenue North; Suite 100</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Minneapolis,
    Minnesota 55446</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employer
    Identification Number (EIN):</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">82-2863566</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;Plan
    Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Celcuity
    Inc. Change in Control and Severance Plan</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Type
    of Plan:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Welfare
    benefit plan - severance pay</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Plan
    Year:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Calendar
    year</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Plan
    Number:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">502</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Plan
    Administrator:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Administrator</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Celcuity
    Inc.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16305
    36th Avenue North; Suite 100</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Minneapolis,
    Minnesota 55446</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agent
    for Service of Legal Process:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    Counsel and Chief Compliance Officer</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Celcuity
    Inc.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16305
    36th Avenue North; Suite 100</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Minneapolis,
Minnesota 55446</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Service
    of legal process may be also made upon the Plan Administrator</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Funding</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unfunded;
    benefits are paid solely from the Employer&rsquo;s general assets</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 10; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19
<SEQUENCE>4
<FILENAME>ex19.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right; text-indent: 4.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
19</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CELCUITY
INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>POLICY
TO PROHIBIT INSIDER TRADING</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
Amended &amp; Restated February 13, 2025</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Executive
Summary</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Policy to Prohibit Insider Trading (the &ldquo;<B>Insider Trading Policy</B>&rdquo; or the &ldquo;<B>Policy</B>&rdquo;) provides guidelines
for directors, officers, employees, or other representatives of Celcuity Inc. (&ldquo;<B>Celcuity</B>&rdquo; or the &ldquo;<B>Company</B>&rdquo;)
who may have access to material non-public information about the Company or its customers, suppliers and other business partners.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Both
federal securities laws and Company policy prohibit transactions in Company Securities at a time when you may be in possession of material
information about the Company that has not been publicly disclosed. &ldquo;<B>Company Securities</B>&rdquo; means the Company&rsquo;s
common stock, options to purchase common stock, or any other type of securities that the Company may issue, including (but not limited
to) preferred stock, convertible debentures and warrants, as well as derivative securities that are not issued by the Company, such as
exchange-traded put or call options or swaps relating to the Company&rsquo;s Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
are similarly prohibited from buying or selling securities of Company customers, suppliers or other business partners when you have received,
through your employment or other relationship with the Company, material non-public information about such customers, suppliers or business
partners. These prohibitions also apply to members of your household as well as all others whose transactions may be attributable to
you. Anyone who violates these prohibitions can face severe civil and criminal penalties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Material
information</B>&rdquo; is any information that a reasonably prudent investor would consider to be important in making a decision to buy
or sell a security. It specifically includes any information that would affect the public market price for the Company&rsquo;s common
stock. Either positive or negative information may be material. Once a public announcement has been made of the material information,
you should wait at least 24 hours following the announcement before engaging in any market trade of Company stock (e.g., announcement
at 10:00 a.m. on Monday, trade after 10:00 a.m. on Tuesday; announcement at 2:00 p.m. on Friday, trade after 2:00 p.m. on Monday), assuming
at the time of the transaction you do not have other material information that has not been made public.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
laws and Company policy also prohibit disclosure of material non-public information except on a need-to-know basis. Even if you are not
engaging in any stock trading activity, you must not disclose material information to others, especially to those outside the Company.
This information is owned by the Company and must be protected as such. <B>Any questions from brokers, securities analysts or the media
regarding the Company should be directed to the Chief Executive Officer, the Chief Financial Officer, or the General Counsel.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
is only a summary. Please refer to the entire Insider Trading Policy set forth below for additional restrictions and requirements. If
you have any questions about this Policy or your ability to share information or engage in a transaction involving Company Securities,
please contact our General Counsel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Insider
Trading Policy</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
Need for an Insider Trading Policy</B>: The Company&rsquo;s stock is publicly-traded; therefore, the Company is required to take active
steps to prevent violations of insider trading laws by Company personnel, and members of the Board of Directors (each, a &ldquo;<B>Director</B>&rdquo;).
Although insider trading has long been illegal, over the years Congress has expanded the enforcement authority of the Securities and
Exchange Commission (the &ldquo;<B>SEC</B>&rdquo;) and the Justice Department, increased substantially the penalties for insider trading,
and created potential liability for companies and other &ldquo;controlling persons,&rdquo; such as directors and managers, for violations
by anyone under their supervision, influence or control. We are adopting this Insider Trading Policy to protect the Company and its Directors
and personnel from liability and reputational harm, and to avoid even the appearance of improper conduct on the part of anyone employed
by or associated with Celcuity (because anyone with material non-public information could be considered an &ldquo;insider&rdquo;). We
cannot afford to have our reputation for integrity and ethical conduct damaged.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
Consequences</B>: The consequences of insider trading violations can be severe. For individuals who trade on inside information (or tip
information to others), the consequences can include a civil penalty of up to three times the profit gained or loss avoided, a criminal
penalty (no matter how small the profit) of up to $5 million, and a prison sentence of up to 20 years. For a company (as well as possibly
any supervisory person) that fails to take appropriate steps to prevent illegal trading, the consequences can include a civil penalty
of the greater of $1 million or three times the profit gained or loss avoided as a result of the individual&rsquo;s violation, and a
criminal penalty of up to $25 million. In addition, any employee or consultant who violates this Policy faces discipline or even termination
of employment for cause.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of the above consequences, even an SEC investigation that does not result in prosecution, can tarnish one&rsquo;s reputation and irreparably
damage a career. Regulators use sophisticated surveillance techniques to identify transactions that may appear illegal, so you should
assume that any suspicious trading activity, even if it is through foreign accounts or family members or friends or relates to only a
small number of shares, will be detected and vigorously prosecuted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Administration
of the Policy</B>: Our General Counsel will administer the Policy, provided that with respect to the General Counsel, the Chief Financial
Officer will administer the Policy. All determinations by such individuals will be final and not subject to further review.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Policy</B>: It is the policy of the Company that no Director, employee or other Company personnel (including contractors) who is aware
of material non-public information relating to the Company (so-called &ldquo;inside&rdquo; information of a nature which could affect
the Company&rsquo;s stock price or affect an investor&rsquo;s decision to buy or sell the Company Securities) may, directly or indirectly
through family members or other persons or entities:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Engage
                                            in any transaction in Company Securities (including sales, purchases and bona fide gifts),
                                            unless this Policy provides a specific exception;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recommend
                                            that others engage in transactions in Company Securities;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclose
                                            material non-public information to persons within the Company whose jobs do not require them
                                            to have that information, or outside of the Company to anyone; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Engage
                                            in any other action to take advantage of material non-public information, including assisting
                                            anyone engaged in the above activities.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Small
transactions, and transactions that may be necessary or justifiable for independent reasons (such as the need to sell Company stock to
raise money for an emergency expenditure), are no exception. The securities laws do not recognize any mitigating circumstances, and even
the appearance of an improper transaction must be avoided to preserve our reputation for adhering to the highest standards of conduct.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Material
                                            Information</U>. Material information is any information that a reasonable investor would
                                            consider important in a decision to buy, hold or sell securities. In short, any information
                                            that could reasonably affect a company&#8217;s stock is deemed to be &#8220;material.&#8221;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Examples</U>.
                                            Common examples of information that will frequently be regarded as material are: projections
                                            of future earnings or losses; changes in projections; news of
                                            a pending or proposed merger, acquisition, or tender offer; news of a significant product
                                            development or clinical trial results; changes in dividend policies, the declaration of a
                                            stock split or the offering of additional securities; changes in management; impending bankruptcy
                                            or financial liquidity problems; significant licensing or collaboration agreements; significant
                                            cybersecurity incidents or other significant disruptions in our business, reputation or assets;
                                            and the gain or loss of a substantial customer, supplier or other business partner. This
                                            is not an exhaustive list. Either positive or negative information may be material.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>&#8220;Non-public&#8221;
                                            Information</U>. As you can appreciate, it is also improper for Company personnel to enter
                                            a trade immediately after Celcuity has made a public announcement of material information,
                                            including earnings releases. Because Company stockholders and the investing public should
                                            be afforded the time to receive the information and act upon it, as a general rule you should
                                            not engage in any transactions until at least 24 hours after the information has been released.
                                            Thus, if an announcement is made at 10:00 a.m. on Monday, after 10:00 a.m. on Tuesday generally
                                            would be the first time you should trade, assuming you do not have other material information
                                            that has not been made public. If an announcement is made at 2:00 p.m. on Friday, the first
                                            time trading would be permitted would generally be after 2:00 p.m. on the following Monday.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>20/20
                                            Hindsight</U>. Remember, if your securities transactions become the subject of scrutiny,
                                            they will be viewed after-the-fact with the benefit of hindsight. As a result, before engaging
                                            in any securities transaction, you should carefully consider how regulators and others might
                                            view your transaction in hindsight.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Transactions
                                            by Dependents &amp; Household Members</U>. This Policy also applies to anyone living in your
                                            household (other than an unrelated person who the applicable Administrator of this Policy
                                            determines should not be covered by this Policy) and anyone financially dependent upon you
                                            or whose transactions in Company Securities are directed by you or are subject to your influence
                                            or control, even if they do not live in your household (such as parents, siblings or adult
                                            children who consult with you before they trade in Company Securities). Company personnel
                                            are expected to be responsible for compliance by their dependents and personal household,
                                            and you should treat all transactions by such persons as if the transactions were for your
                                            own account.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Policy does not, however, apply to personal securities transactions of family members, financial dependents, or household members where
the purchase or sale decision is made by a third party not controlled by, influenced by, or related to you or your family members.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Transactions
                                            by Entities That You Influence or Control.</U> This Policy applies to any entities that you
                                            influence or control, including any corporations, partnerships or trusts (collectively referred
                                            to as &#8220;<B>Controlled Entities</B>&#8221;), and transactions by these Controlled Entities
                                            should be treated for the purposes of this Policy and applicable securities laws as if they
                                            were for your own account. However, nothing in this Policy is intended to limit the ability
                                            of a venture capital partnership or other similar entity with which a director is affiliated
                                            to distribute Company Securities to its partners, members or other similar persons. It is
                                            the responsibility of each affected Director and the affiliated entity, in consultation with
                                            their own counsel (as appropriate), to determine the timing of any distributions, based on
                                            all relevant facts and circumstances and applicable securities laws.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Disclosing
                                            Information to Others</U>. Whether the information is proprietary information about the Company
                                            or one of its customers, suppliers or other business partners, or information that could
                                            have an impact on the market price of the Company&#8217;s or its customer&#8217;s, supplier&#8217;s
                                            or other business partner&#8217;s stock, Company personnel must not pass the information
                                            on to others. The above penalties apply whether or not you derive any benefit from another&#8217;s
                                            actions. In order to prevent unintentional disclosure, all inquiries and requests for information
                                            regarding the Company or the Company&#8217;s customers, suppliers or other business partners
                                            (e.g., from the media, stockbrokers or securities analysts) should be referred to our General
                                            Counsel.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Policy also applies to information relating to any other organization, including our customers, suppliers, and other business partners,
and organizations that are involved in a potential transaction or business relationship with the Company, obtained in the course of your
employment or other relationship with Celcuity. For example, you must keep information about that other company confidential and cannot
engage in transactions in that other company&rsquo;s securities if you are aware of non-public information that is material to that company.
Note that what constitutes &ldquo;material non-public information&rdquo; differs by company. Information that is not material to Celcuity
may be material to another company. Please consult with our General Counsel if you have any questions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exceptions</B>:
This Policy does not apply to the following transactions, except as specifically noted:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            exercise of stock options, except this Policy <B>does apply</B> to both the cashless exercise
                                            of such options and open market sales of shares acquired through the exercise of any options.
                                            Furthermore, stock option exercises are subject to the terms of the Company&#8217;s governing
                                            stock option plans and any agreements entered into between the Company and the holders of
                                            such options.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            purchase of Company Securities under the Company&#8217;s employee stock purchase plan resulting
                                            from the periodic contribution of money to the plan pursuant to a payroll deduction election,
                                            including any decision to terminate contributions made during any pay period, except that
                                            this Policy <B>does apply</B> to the sale of Company Securities purchased pursuant to the
                                            employee stock purchase plan.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            initial election to participate in the employee stock purchase plan for any enrollment period
                                            or any modifications following such initial election (i.e., to increase or decrease the contributions
                                            made during any pay period), if such election or modification was made at a time when the
                                            Covered Person does not possess material non-public information.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            purchase of Company Securities in the Company&#8217;s 401(k) plan resulting from the periodic
                                            contribution of money to the plan pursuant to a payroll deduction election. This Policy <B>does
                                            apply</B>, however, to certain elections you may make under the 401(k) plan, including: (a)
                                            an election to increase or decrease the percentage of your periodic contributions that will
                                            be allocated to the Company Securities fund; (b) an election to make an intra-plan transfer
                                            of an existing account balance into or out of the Company Securities fund; (c) an election
                                            to borrow money against your 401(k) plan account if the loan will result in a liquidation
                                            of some or all of your Company Securities fund balance; and (d) an election to pre-pay a
                                            plan loan if the pre-payment will result in the allocation of loan proceeds to the Company
                                            stock fund. It should be noted that sales of Company Securities from a 401(k) account are
                                            also subject to Rule 144, and therefore &#8220;affiliates&#8221; of the Company (typically
                                            officers and Directors) should ensure that a Form 144 is filed when required.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
                                            other purchase of Company Securities from the Company or sales of Company Securities to the
                                            Company.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Additional
Prohibited Transactions: </B>Celcuity prohibits Company personnel from engaging in any of the following activities with respect to Company
Securities:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Trading
                                            in Company Securities on a short-term basis</U>. Any Company stock purchased in the open
                                            market must be held for a minimum of six months. Subject to the terms of the applicable awards,
                                            stock received from the Company as a compensatory equity award that is registered with the
                                            SEC on a Form S-8 need not be held for six months and can be sold at any time, assuming you
                                            do not have any material non-public information.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Margin
                                            accounts and pledged securities</U>. This Policy prohibits holding Company Securities in
                                            a margin account or otherwise pledging Company Securities as collateral for a loan. Securities
                                            held in a margin account as collateral for a margin loan may be sold by the broker without
                                            the customer&#8217;s consent if the customer fails to meet a margin call. Similarly, securities
                                            pledged (or hypothecated) as collateral for a loan may be sold in foreclosure if the borrower
                                            defaults on the loan.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Hedging
                                            Transactions.</U> This Policy prohibits engaging in any hedging transactions with respect
                                            to Company Securities. Hedging transactions include transactions for which the value of the
                                            trade is tied to the value of Company Securities. Examples are put options, call options,
                                            and other derivative and financial instruments such as prepaid variable forwards, equity
                                            swaps, collars and exchange funds. Such transactions may permit a director, officer or employee
                                            to continue to own Company Securities obtained through employee benefit plans or otherwise,
                                            but without the full risks and rewards of ownership. When that occurs, the director, officer
                                            or employee may no longer have the same objectives as the Company&#8217;s other shareholders.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Short
                                            Sales.</U> This Policy prohibits short sales of Company Securities. Short sales (i.e., the
                                            sale of a security that the seller does not own) may evidence an expectation on the part
                                            of the seller that the securities will decline in value, and therefore have the potential
                                            to signal to the market that the seller lacks confidence in the Company&#8217;s prospects.
                                            In addition, short sales may reduce a seller&#8217;s incentive to seek to improve the Company&#8217;s
                                            performance. Section 16(c) of the Securities Exchange Act of 1934, as amended (the &#8220;<B>Exchange
                                            Act</B>&#8221;), also prohibits officers and directors from engaging in short sales.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Standing
                                            and Limit Orders.</U> Standing and limit orders (except standing and limit orders under approved
                                            Rule 10b5-1 Plans, as described below) create heightened risks for insider trading violations
                                            similar to the use of margin accounts. There is no control over the timing of purchases or
                                            sales that result from standing instructions to a broker, and as a result the broker could
                                            execute a transaction when a director, officer or other employee is in possession of material
                                            non-public information. The Company therefore discourages placing standing or limit orders
                                            on Company Securities. If a person subject to this Policy determines that they must use a
                                            standing order or limit order, the order should be limited to short duration and should otherwise
                                            comply with the restrictions and procedures outlined below under the heading &#8220;Trading
                                            Windows and Advance Notice Procedure for Directors, Executive Officers and Certain Other
                                            Key Employees.&#8221; In addition, if you are a Covered Person under this Policy, you should
                                            inform any broker with whom you place a standing or limit order of that designation at the
                                            time the order is placed.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Trading
Windows and Advance Notice Procedure for Directors, Executive Officers and Certain Other Key Employees</B>: Because the Company&rsquo;s
directors, executive officers and certain other key employees listed below (the &ldquo;<B>Covered Persons</B>&rdquo;) have regular access
to material non-public information, this Policy requires that such persons comply with the trading window and advance notice procedures
described below for all transactions in Company Securities. A &ldquo;<B>Covered Person</B>&rdquo; is any of the following persons subject
to this Policy: (a) all executive officers and Directors of Celcuity Inc., (b) all administrative assistants supporting executive officers,
(c) all members of the senior management team of Celcuity, (d) those persons within Celcuity identified by the Company&rsquo;s General
Counsel as a Covered Person for purposes of this Insider Trading Policy, and (e) if they are otherwise subject to this Policy, the household
members, dependents and Controlled Entities of the individuals identified in (a), (b), (c), or (d) of this sentence. The Company may
amend the list from time to time as it deems necessary to add or subtract from the list of Covered Persons.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading window and advance notice procedures are not applicable to employees other than the Covered Persons. However, even if you are
not subject to these additional restrictions, you should exercise caution when engaging in transactions outside of the trading window
because of the heightened risk that those transactions will attract regulatory scrutiny and may expose you to accusations of improper
behavior.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Trading
Window</U>: Transactions in Company Securities by Covered Persons will be restricted to certain window periods following the end of each
quarter. The window during which trades generally will be permitted, provided such trades comply with advance notice procedures (see
below) and provided you possess no material non-public information, will begin 24 hours (not including weekends and other non-business
days) after the public release of all material information with respect to the financial results of the most recently completed quarter
and will end at the close of market on the 15th day of the third month following the end of the most recent fiscal quarter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Event-Specific
Restricted Periods</U>: From time to time, there may be a material event that is known only to certain Covered Persons. In such instances,
to avoid the appearance of impropriety, the General Counsel, together with the Chief Financial Officer, may not allow any Covered Persons
to engage in transactions in Company Securities, regardless of whether the trading window is open. The General Counsel also has discretion
to close the trading window early in any particular quarter. In either of these situations, the General Counsel may notify Covered Persons
that they should not trade in Company Securities, without disclosing the reason for the restriction. The existence of an event-specific
restricted period or shortening of the trading window will not be announced to the Company as a whole and should not be communicated
to any other person. Even if the General Counsel has not designated you as a person who should not trade due to an event-specific restriction,
you should not trade while aware of material non-public information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Pre-Clearance
of Transactions</U>: To provide assistance in avoiding even the appearance of an improper transaction (which could result, for example,
where a person engages in a trade while unaware of a pending major development), all transactions in Company Securities by &ldquo;Covered
Persons&rdquo; (as defined above) must notify the General Counsel of the proposed transaction by submitting the Transaction Pre-Clearance
Form set forth in <U>Attachment 1</U>, as updated from time to time by the Company, and await pre-clearance from the General Counsel.
The pre-clearance request should be submitted at least two business days in advance of the proposed transaction and must be effected
within five business days of receipt of pre-clearance, unless an exception is granted. Covered Persons should also notify the General
Counsel once the pre-cleared transaction is completed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
pre-clearance will serve only to confirm the status of the trading window. Even if you receive pre-clearance of an open trading window
from the General Counsel, you are still prohibited under this Policy from effecting the transaction if you possess material non-public
information or it would violate any other provision of this Policy or any applicable securities law or regulation. Pre-clearance is not
a defense to a claim of insider trading and does not excuse you from otherwise complying with securities laws or this Policy. You may
want to consult outside counsel regarding the proposed transaction. Transactions by the General Counsel must receive pre-clearance by
the Chief Financial Officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Rule
10b5-1 Plans and Exceptions</U>: The trading window restrictions and pre-clearance procedures set forth above do not apply to the transactions
to which this Policy does not apply, as described under the heading &ldquo;Exceptions.&rdquo; Further, the trading window restrictions,
event-specific restricted periods, and pre-clearance procedures do not apply to transactions conducted pursuant to a binding contract,
written plan or specific instruction that is adopted and operated in compliance with Rule 10b5-1(c) of the Exchange Act and is adopted
at a time when such Covered Person does not possess material non-public information, so long as the underlying contract, instruction
or plan also complies with the Company&rsquo;s Rule 10b5-1 Plan Guidelines set forth in <U>Attachment 2</U> (&ldquo;<B>Rule 10b5-1 Plan
Guidelines</B>&rdquo;). Any adoption, modification or termination of a Rule 10b5-1 Plan must be submitted to the General Counsel for
approval, at least five business days prior to entering into, modifying or terminating the Rule 10b5-1 Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, Covered Persons who enter into any written contract, plan, instruction or arrangement at a time that they are not aware of
material non-public, which (i) specifies the amount of Company Securities to be purchased or sold and the price at which and the date
on which they are to be purchased or sold, or (ii) includes a written formula or algorithm to determine those transactions, or (iii)
does not permit the Covered Person to exercise any subsequent influence over the transactions, must also submit a request for approval
at least five business days prior to entering into, modifying or terminating the contract, plan, instruction or arrangement, even if
it does not meet the specific criteria of Rule 10b5-1(c) or the Company&rsquo;s Rule 10b5-1 Plan Guidelines.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Post-Termination
Transactions:</B> This Policy continues to apply to transactions in Company Securities even after termination of service to the Company.
If an individual is in possession of material non-public information when his or her service terminates, that individual may not engage
in transactions in Company Securities until that information has become public or is no longer material.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Certification:
</B>Company personnel may be required from time to time to re-certify their understanding of and intent to comply with this Policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Company
Assistance: </B>Any person who has any general questions about this Policy or questions about specific transactions should contact the
General Counsel. Remember, however, the ultimate responsibility for adhering to this Policy and avoiding improper transactions rests
with <U>you</U>. In this regard, it is imperative that you use your best judgment and consult with your legal and financial advisors,
as needed. We advise you to seek assistance if you have any questions at all. The rules relating to insider trading can be complex, and
a violation can carry severe consequences.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ATTACHMENT
1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CELCUITY
INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TRANSACTION
PRE-CLEARANCE FORM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Covered Person: ________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date
of Notice: ________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anticipated
Date of Transaction: __________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Please
describe the proposed transaction, including the type of transaction (purchase, sale, option exercise, gift, etc.), the number of shares,
and any third parties involved in the transaction:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Please
list any transactions in the securities of Celcuity Inc. (&ldquo;Celcuity&rdquo;) in which you have engaged during the six months prior
to the date of this notice, including, but not limited to, purchases or sales in the open market, exercises of options or warrants, gifts,
or receipt of grants of restricted stock or other equity, <U>OR</U> if you have not had any such transactions in the preceding six months,
please so indicate by checking this box. &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Date</U></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 65%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Type
    of Transaction</U></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Please
check the following box to indicate that you are not in possession of material non-public information regarding Celcuity. &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature
of Covered Person</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>NOTICE:
This Form relates only to certain aspects of Celcuity&rsquo;s Policy to Prohibit Insider Trading. Pre-clearance by the Company only indicates
that a trading window is open. It does not indicate whether the transaction is allowable under applicable securities laws or Celcuity
policies. YOU are responsible for compliance with all applicable securities laws and Celcuity policies. You are encouraged to consult
outside counsel before engaging in the proposed transaction. Failure to receive pre-clearance at all or on a timely basis shall not give
rise to any claims against the General Counsel, Chief Financial Officer, Chief Executive Officer or Celcuity.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I></I></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
be completed by the Company:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-cleared this
  ____ day of ______________, 20___.</FONT></TD>
    <TD STYLE="width: 8%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature:</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 42%"></TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
  <TD STYLE="padding-bottom: 1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
  Counsel</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Attachment
2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Celcuity
Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Rule
10b5-1 Plan Guidelines</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rule
10b5-1 under the Securities Exchange Act of 1934, as amended (the &ldquo;<B>Exchange Act</B>&rdquo;), provides a defense from insider
trading liability if transactions occur pursuant to a plan that complies with the conditions set forth in Rule 10b5-1(c) of the Exchange
Act (a &ldquo;<B>Rule 10b5-1 Plan</B>&rdquo;). If the plan meets the requirements of Rule 10b5-1, transactions in Company Securities
may occur without regard to certain insider trading restrictions. In order to avoid a violation of securities laws and to comply with
the Celcuity Inc. Policy to Prohibit Insider Trading (the &ldquo;<B>Policy</B>&rdquo;), any person subject to the Policy that intends
to use a Rule 10b5-1 Plan must comply with these Rule 10b5-1 Guidelines. Please note that brokers may apply additional procedures, which
may be more stringent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, a Rule 10b5-1 Plan must be entered into at a time when the person entering into the plan is not aware of material non-public
information. Once the plan is adopted, the person must not exercise any influence over the amount of securities to be traded, the price
at which they are to be traded or the date of the trade. The Rule 10b5-1 Plan must either specify the amount, pricing and timing of transactions
in advance or delegate discretion on these matters to an independent third party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
specified in the Policy, a Rule 10b5-1 Plan must be approved by the General Counsel and meet the requirements of Rule 10b5-1 and these
Guidelines. Any Rule 10b5-1 Plan must be submitted for approval five business days prior to entering into, modifying or terminating the
Rule 10b5-1 Plan. Following approval of entry into the Rule 10b5-1 Plan, no further pre-approval of transactions conducted under the
Rule 10b5-1 Plan will be required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following guidelines apply to all Rule 10b5-1 Plans:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
                                            may enter into, modify or terminate a Rule 10b5-1 Plan only during a trading window. In addition,
                                            you may not enter into, modify or terminate a Rule 10b5-1 Plan during an event-specific restricted
                                            period or otherwise while you are aware of material non-public information.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
                                            otherwise determined by the General Counsel, all Rule 10b5-1 Plans must have a duration of
                                            at least 6 months and no more than 2 years.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
                                            officers and directors, no transaction may take place under a Rule 10b5-1 Plan until the
                                            later of (a) 90 days after adoption or modification (as specified in Rule 10b5-1) of the
                                            Rule 10b5-1 Plan or (b) two business days following the disclosure of the Company&#8217;s
                                            financial results in a Form 10-Q or Form 10-K for the fiscal quarter (the Company&#8217;s
                                            fourth fiscal quarter in the case of a Form 10-K) in which the Rule 10b5-1 Plan was adopted
                                            or modified (as specified in Rule 10b5-1). In any event, the cooling-off period is subject
                                            to a maximum of 120 days after adoption of the plan.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
                                            persons other than officers and directors, no transaction may take place under a Rule 10b5-1
                                            Plan until 30 days following the adoption or modification (as specified in Rule 10b5-1) of
                                            a Rule 10b5-1 Plan.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
                                            to certain limited exceptions specified in Rule 10b5-1, you may not enter into more than
                                            one Rule 10b5-1 Plan at the same time.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
                                            to certain limited exceptions specified in Rule 10b5-1, you are limited to only one &ldquo;single
                                            trade&rdquo; Rule 10b5-1 Plan during any 12-month period (i.e., a Rule 10b5-1 Plan designed
                                            to effect an open market purchase or sale of the total amount of securities subject to the
                                            Rule 10b5-1 Plan as a single transaction).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
                                            must act in good faith with respect to a Rule 10b5-1 Plan. A Rule 10b5-1 Plan cannot be entered
                                            into as part of a plan or scheme to evade the prohibition of Rule 10b-5. Therefore, although
                                            modifications to an existing Rule 10b5-1 Plan are not prohibited, a Rule 10b5-1 Plan should
                                            be adopted with the intention that it will not be amended or terminated prior to its expiration.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Officer
                                            and directors must include a representation in the Rule 10b5-1 Plan at the time of its adoption
                                            or modification that (i) the person is not aware of material non-public information about
                                            the Company or Company Securities and (ii) the person is adopting the plan in good faith
                                            and not as part of a plan or scheme to evade the prohibitions of Rule 10b-5.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company and the Company&rsquo;s officers and directors must make certain disclosures in SEC filings concerning Rule 10b5-1 Plans. Officers
and directors of the Company must undertake to provide any information requested by the Company regarding Rule 10b5-1 Plans for the purpose
of providing the required disclosures or any other disclosures that the Company deems to be appropriate under the circumstances. Each
director, officer and other Section 16 insider understands that the approval or adoption of a pre-planned selling program in no way reduces
or eliminates such person&rsquo;s obligations under Section 16 of the Exchange Act, including such person&rsquo;s disclosure and short-swing
trading liabilities thereunder. If any questions arise, such person should consult with their own counsel in implementing a Rule 10b5-1
Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CELCUITY
INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DIRECTOR
AND EXECUTIVE OFFICER ADDENDUM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>POLICY
TO PROHIBIT INSIDER TRADING</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the provisions of Celcuity Inc.&rsquo;s Policy to Prohibit Insider Trading (the &ldquo;<B>Policy</B>&rdquo;), all Celcuity
Inc. (&ldquo;<B>Celcuity</B>&rdquo; or the &ldquo;<B>Company</B>&rdquo;) directors and executive officers, and in some cases also significant
stockholders, are subject to additional legal restrictions, including under Sections 16 and 13 of the Securities Exchange Act of 1934
and the rules promulgated thereunder (the &ldquo;<B>Exchange Act</B>&rdquo;). This Addendum summarizes the regulations that directors
and executive officers are most likely to encounter. In addition, this Addendum serves as a reminder that you are required to comply
with the Policy&rsquo;s pre-clearance and trading window requirements. <B>In light of the Securities and Exchange Commission (the &ldquo;SEC&rdquo;)
regulations that apply to you, it is particularly important to comply with the pre-clearance procedures under the Policy.</B> Please
refer to the full Policy for additional details and exceptions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Trading
Window</B>: Under the Policy, you, as well as any of your household members, dependents and Controlled Entities who are subject to the
Policy, may engage in transactions in Company Securities only during the &ldquo;window periods&rdquo; following the end of each quarter.
The window during which trades generally will be permitted, provided the trades comply with advance notice procedures (see below) and
provided you possess no material non-public information, will begin 24 hours (not including weekends and other non-business days) after
the public release of all material information with respect to the financial results of the most recently completed quarter and will
end at the close of market on the 15th day of the third month following the end of the most recent fiscal quarter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Event-Specific
Restricted Periods</B>: From time to time, there may be a material event that is known only by a few of the Company&rsquo;s officers,
directors or employees. In those instances, to avoid the appearance of impropriety, you should not engage in transactions in Company
Securities, regardless of whether the trading window is open. The General Counsel also has discretion to close the trading window early
in any particular quarter. In these situations, the General Counsel may notify you that you should not trade in the Company&rsquo;s Securities,
without disclosing the reason for the restriction. The existence of an event-specific restricted period or shortening of the trading
window will not be announced to the Company as a whole and should not be communicated to any other person. Even if the General Counsel
has not designated you as a person who should not trade due to an event-specific restriction, you should not trade while aware of material
non-public information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pre-Clearance:
</B>The Policy prohibits you, as well as any of your household members, dependents and Controlled Entities who are subject to the Policy,
from engaging in any transaction in Company Securities without first obtaining pre-clearance of the transaction from the General Counsel.
The pre-clearance request should be submitted to the General Counsel, with a copy to the Chief Financial Officer, at least two business
days in advance of the proposed transaction, using the Company&rsquo;s Transaction Pre-Clearance Form, and must be effected within five
business days of receipt of pre-clearance, unless an exception is granted. You should also notify the General Counsel once the pre-cleared
transaction is completed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
General Counsel is not required to approve pre-clearance requests, and may determine not to permit a transaction. If you are denied permission
to engage in a transaction, then you should not initiate any transaction in Company Securities, and you should not inform any other person
of the restriction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
pre-clearance will serve only to confirm the status of the trading window. Even if you receive pre-clearance of an open trading window
from the General Counsel, you are still prohibited under this Policy from effecting the transaction if you possess material non-public
information or if it would violate any other provision of this Policy or any applicable securities law or regulation. Therefore, when
making a pre-clearance request, you should carefully consider whether you are aware of material non-public information that you have
obtained pursuant to your role with the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-clearance
is not a defense to a claim of insider trading and does not excuse you from otherwise complying with securities laws or this Policy.
For example, you should be prepared to comply with the SEC rules described below. You may want to consult outside counsel regarding the
proposed transaction. Transactions by the General Counsel must receive pre-clearance by the Chief Financial Officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
16: </B>Section 16 applies to directors, executive officers and more-than-10% stockholders of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Liability</U>.
In general, Section 16(b) provides that any profit realized on a purchase and a sale of Company stock within a six-month period is recoverable
by the Company. For this purpose, it does not matter whether the purchase or the sale occurs first. It is not necessary for the same
shares to be involved in each of the matched transactions. Losses cannot be offset against gains. Transactions are paired so as to match
the lowest purchase price and the highest sale price within a six-month period, resulting in the maximum amount of recoverable profit.
Good faith on the part of the insider is no defense. If the Company itself does not press a claim, a claim for recovery of the profit
may be asserted by any stockholder for the benefit of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are many types of transactions that constitute a &ldquo;purchase&rdquo; or a &ldquo;sale&rdquo; for Section 16 purposes, in addition
to normal open market transactions. The receipt of an option, warrant or other right to acquire common stock (a &ldquo;derivative security&rdquo;)
is generally a &ldquo;purchase&rdquo; unless received under certain employee plans and approved by independent directors. Many unusual
corporate reorganizations may be &ldquo;purchases&rdquo; or &ldquo;sales.&rdquo; &ldquo;Beneficial&rdquo; ownership for Section 16 purposes
may include indirect ownership, for example, through trusts or estates. In some circumstances, stock held by close relatives of a person
may be considered to be owned beneficially by such person, and a purchase (or sale) by one individual may be matched with a sale (or
purchase) by his or her close relative to produce a recoverable profit. The provisions also apply to stock held by a broker on your behalf
through a brokerage account (i.e., in &ldquo;street name&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Reports</U>.
As a supplement to the profit recapture provisions of Section 16(b), Section 16(a) includes beneficial ownership reporting provisions.
Each insider is responsible for filing Forms 3, 4 and 5 as required under Section 16(a).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Form
                                            3</I>. Within 10 days of a person becoming an officer, director or 10% stockholder of an
                                            Exchange Act reporting company, such person must file an Initial Statement of Beneficial
                                            Ownership of Securities, or a Form 3, as it is more commonly known, with the SEC. A Form
                                            3 is a statement by each reporting person of the amount of his or her beneficial ownership
                                            of each class of non-derivative securities (e.g., common stock) and derivative securities
                                            (e.g., options and warrants) of the Company. Generally, an individual is deemed a &#8220;beneficial
                                            owner&#8221; of a security if the individual has or shares the opportunity, directly or indirectly,
                                            to profit or share in any profit derived from a transaction in the securities. Special rules
                                            apply for the application of the beneficial ownership definition to trust holdings and transactions.
                                            In stating the amount of securities owned indirectly through a partnership, corporation,
                                            trust or other entity, the reporting person may report the entire amount owned by such entity
                                            or, alternatively, his or her proportionate interest in the securities beneficially owned
                                            by that entity.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Form
                                            4</I>. When there is a change in an insider&#8217;s beneficial ownership of Company Securities,
                                            a Form 4 must be filed with the SEC on or before the second business day following most transactions,
                                            including the following:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchases
                                            and sales;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
                                            option exercises;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
                                            option grants;</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
                                            stock grants;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
                                            grants, awards and any other acquisitions from the Company (including small acquisitions);</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gifts;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dispositions
                                            to the Company that satisfy the requirements of Rule 16b-3(e), which includes (i) shares
                                            delivered to pay tax withholding amounts or an option exercise price, (ii) surrender of an
                                            option in a repricing and (iii) sale of shares;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Discretionary
                                            transactions pursuant to employee benefit plans where the insider controls a trade date;
                                            and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
                                            in form of ownership (direct to indirect or indirect to direct), accompanied by a change
                                            in pecuniary interest.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Form
                                            5</I>. A Form 5 must be filed each year (within 45 days after the end of the Company&#8217;s
                                            fiscal year) by insiders to report any exempt transactions, unless voluntarily reported earlier
                                            on a Form 4, including the following:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acquisitions
                                            pursuant to stock allocations under ERISA profit sharing plans and employee stock ownership
                                            plans, purchases under 401(k) plans and employee stock purchase plans;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inheritances;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Small
                                            acquisitions (other than from the Company) that total $10,000 or less during a six-month
                                            period; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
                                            in form of ownership from indirect to direct or direct to indirect if no change in pecuniary
                                            interest.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Another
purpose of the Form 5 is to promote compliance with Section 16 by requiring insiders to report any transactions required to be reported
on a Form 4 but which had not been reported during the year. At year-end officers and directors who have no Form 5 items to report will
be required to provide the Company with a written representation that no Form 5 filing is due (i.e., there are no unreported transactions).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
events, like the acquisition of shares through an employee stock purchase plan or in connection with a stock dividend, are not reportable;
however, the holdings must be updated to reflect the change on the next Form 4 or 5 otherwise filed. In addition, officers and directors
(but not 10% owners) must report any changes which occur after they are no longer insiders if such change takes place within six months
of any opposite way transaction while an insider.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
changes in beneficial ownership (unless covered by a specific exemption) are reportable, not only transactions which are purchases or
sales, including sales pursuant to a Rule 10b5-1 trading plan. Reports may be due even though the reported change in beneficial ownership
is not a transaction of a type which can be &ldquo;matched&rdquo; for purposes of short-swing profit liability under Section 16(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Power
of Attorney</U>. It should be noted that the SEC will not excuse a late filing simply because the individual is unavailable. If an individual
is unable to personally sign a Form 4 or 5 (e.g., if you are out of town), the SEC permits the form to be signed on behalf of the individual
by another person pursuant to a power of attorney as long as a power is filed with the SEC as soon as practicable thereafter. We have
designed a standing power of attorney giving certain officers of the Company the authority to sign Forms 4 and 5 on your behalf in order
to facilitate timely filings in your absence. Please sign and return this if you have not done so already.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Short
Sales</U>. In addition to the foregoing, Section 16(c) prohibits the Company&rsquo;s directors, officers and more-than-10% stockholders
from making &ldquo;short sales&rdquo; of any equity security of the Company. A &ldquo;short sale&rdquo; is a sale of securities which
the seller does not own at the time or, if owned, securities that will not be delivered for a period longer than 20 days after the sale.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
13</B>: All more-than-5% stockholders of the Company are required to file initial reports under Section 13 of the Exchange Act. Follow-up
reports will be required if any material changes in their stockholdings occur. No filing is required where a change in the percentage
of shares owned by a reporting person is caused solely by a change in the number of outstanding shares. Material changes in stockholdings
in the interim will trigger additional Section 13 filing requirements, including potentially a Schedule 13D, which is a lengthier form
that requires amendments within two business days to report any material acquisitions or dispositions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Rule
144: </B>Rule 144 provides a safe harbor for sales of shares by Company affiliates that may otherwise be considered a &ldquo;distribution&rdquo;
that requires registration under securities laws. Company officers and directors are strongly encouraged to comply with Rule 144 in connection
with any transfers of Company securities &ndash; which include abiding by volume and manner-of-sale restrictions and filing a Form 144
if the securities to be sold during a three-month period exceed 5,000 shares or have an aggregate sale price in excess of $50,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Regulation
BTR: </B>Directors and executive officers may also be subject to trading blackouts pursuant to Regulation Blackout Trading Restriction,
or Regulation BTR, under U.S. federal securities laws. In general, Regulation BTR prohibits any director or executive officer from engaging
in certain transactions involving Company securities during periods when 401(k) plan participants are prevented from purchasing, selling
or otherwise acquiring or transferring an interest in certain securities held in individual account plans. Any profits realized from
a transaction that violates Regulation BTR are recoverable by the Company, regardless of the intentions of the director or officer effecting
the transaction. In addition, individuals who engage in such transactions are subject to sanctions by the SEC as well as potential criminal
liability. The Company has provided, or will provide, separate memoranda and other appropriate materials to its directors and executive
officers regarding compliance with Regulation BTR.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company will notify directors and officers if they are subject to a blackout trading restriction under Regulation BTR. Failure to comply
with an applicable trading blackout in accordance with Regulation BTR is a violation of law and our Policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Regulation
M:</B> Regulation M is a set of anti-market manipulation rules under the Exchange Act. Depending on the circumstances, this rule may
at times restrict directors and executive officers from bidding or purchasing Company Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Annual
Certification and Compliance: </B>Directors and executive officers may be required, on an annual basis, to certify compliance with the
attached Policy to Prohibit Insider Trading and the additional provisions of this Director and Executive Officer Addendum. In addition,
the Company&rsquo;s directors and executive officers are subject to the Company&rsquo;s other policies and procedures concerning confidential
information and securities in effect from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DO
NOT FORGET: ALL TRANSACTIONS IN COMPANY SECURITIES BY DIRECTORS AND EXECUTIVE OFFICERS MUST BE PRE-CLEARED BY CONTACTING OUR GENERAL
COUNSEL.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 14; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>ex23-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 23.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have issued our report dated March 31, 2025, with
respect to the financial statements included in the Annual Report of Celcuity Inc. on Form 10-K for the year ended December 31, 2024.
We hereby consent to the incorporation by reference in the Registration Statements of Celcuity Inc. on Form S-8 (Reg. Nos. 333-279556,
333-271976, 333-270238, 333-265328, 333-256500, 333-253940, 333-238787, and 333-221117) and on Form S-3 (Reg. No. 333-281887 and
333-275551).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; vertical-align: top; width: 50%; padding-right: 0pt; padding-left: 0pt">/s/ Boulay PLLP</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify; vertical-align: top; width: 50%; padding-right: 2pt; padding-left: 3pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">Minneapolis, Minnesota</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">March 31, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>ex31-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: right"><B>Exhibit 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>CERTIFICATION UNDER SECTION 302 OF THE SARBANES-OXLEY
ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">I, Brian F. Sullivan, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.5in">1.</TD><TD STYLE="text-align: justify">I have reviewed this annual report on Form 10-K of Celcuity Inc.;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 54.7pt; text-indent: -27.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.5in">2.</TD><TD STYLE="text-align: justify">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period
covered by this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 54.7pt; text-indent: -27.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.5in">3.</TD><TD STYLE="text-align: justify">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this
report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 54.7pt; text-indent: -27.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.5in">4.</TD><TD STYLE="text-align: justify">The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules
13a-15(f) and 15d-15(f)) for the registrant and have:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 54.7pt; text-indent: -27.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.25in">(a)</TD><TD STYLE="text-align: justify">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
within those entities, particularly during the period in which this report is being prepared;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 1in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.25in">(b)</TD><TD STYLE="text-align: justify">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with generally accepted accounting principles;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 1in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.25in">(c)</TD><TD STYLE="text-align: justify">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 1in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.25in">(d)</TD><TD STYLE="text-align: justify">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's
most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is
reasonably likely to materially affect, the registrant's internal control over financial reporting; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 54.7pt; text-indent: -27.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">5.</TD><TD STYLE="text-align: justify">The registrant&rsquo;s other certifying officer and I have disclosed,
based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee
of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 54.7pt; text-indent: -27.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.25in">(a)</TD><TD STYLE="text-align: justify">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which
are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 1in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.25in">(b)</TD><TD STYLE="text-align: justify">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 54.7pt; text-indent: -27.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="padding-right: 0pt; text-align: justify; vertical-align: top; width: 50%; padding-left: 0pt">Date: March 31, 2025&#9;</TD>
    <TD STYLE="text-align: justify; vertical-align: top; width: 3%; padding-right: 0pt; padding-left: 0pt">By</TD>
    <TD STYLE="padding-right: 0pt; text-align: justify; vertical-align: bottom; width: 1%; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; vertical-align: top; width: 46%; padding-right: 0pt; padding-left: 0pt"><I>/s/
    Brian F. Sullivan</I></TD></TR>
  <TR>
    <TD STYLE="padding-right: 0pt; text-align: justify; vertical-align: top; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0pt; text-align: justify; vertical-align: bottom; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0pt; text-align: justify; vertical-align: bottom; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt">Brian F. Sullivan</TD></TR>
  <TR>
    <TD STYLE="padding-right: 0pt; text-align: justify; vertical-align: top; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0pt; text-align: justify; vertical-align: bottom; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0pt; text-align: justify; vertical-align: bottom; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt">Chairman and Chief Executive Officer</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>ex31-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 23pt; text-align: justify; text-indent: -22pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 23pt; text-align: right; text-indent: -22pt"><B>Exhibit 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 23pt; text-align: justify; text-indent: -22pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>CERTIFICATION UNDER SECTION 302 OF THE SARBANES-OXLEY
ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">I, Vicky Hahne, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.5in">1.</TD><TD STYLE="text-align: justify">I have reviewed this annual report on Form 10-K of Celcuity Inc.;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 54.7pt; text-indent: -27.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.5in">2.</TD><TD STYLE="text-align: justify">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period
covered by this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 54.7pt; text-indent: -27.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.5in">3.</TD><TD STYLE="text-align: justify">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this
report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 54.7pt; text-indent: -27.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.5in">4.</TD><TD STYLE="text-align: justify">The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules
13a-15(f) and 15d-15(f)) for the registrant and have:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 54.7pt; text-indent: -27.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.25in">(a)</TD><TD STYLE="text-align: justify">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
within those entities, particularly during the period in which this report is being prepared;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 1in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.25in">(b)</TD><TD STYLE="text-align: justify">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with generally accepted accounting principles;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 1in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.25in">(c)</TD><TD STYLE="text-align: justify">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 1in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.25in">(d)</TD><TD STYLE="text-align: justify">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's
most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is
reasonably likely to materially affect, the registrant's internal control over financial reporting; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 54.7pt; text-indent: -27.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">5.</TD><TD STYLE="text-align: justify">The registrant&rsquo;s other certifying officer and I have disclosed,
based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee
of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 54.7pt; text-indent: -27.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.25in">(a)</TD><TD STYLE="text-align: justify">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which
are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 1in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.25in">(b)</TD><TD STYLE="text-align: justify">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 54.7pt; text-indent: -27.35pt">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="padding-right: 0pt; text-align: justify; vertical-align: top; width: 50%; padding-left: 0pt">Date: March 31, 2025&#9;</TD>
    <TD STYLE="text-align: justify; vertical-align: top; width: 3%; padding-right: 0pt; padding-left: 0pt">By</TD>
    <TD STYLE="padding-right: 0pt; text-align: justify; vertical-align: bottom; width: 1%; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; vertical-align: top; width: 46%; padding-right: 0pt; padding-left: 0pt"><I>/s/
    Vicky Hahne</I></TD></TR>
  <TR>
    <TD STYLE="padding-right: 0pt; text-align: justify; vertical-align: top; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0pt; text-align: justify; vertical-align: bottom; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0pt; text-align: justify; vertical-align: bottom; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt">Vicky Hahne</TD></TR>
  <TR>
    <TD STYLE="padding-right: 0pt; text-align: justify; vertical-align: top; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0pt; text-align: justify; vertical-align: bottom; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0pt; text-align: justify; vertical-align: bottom; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt">Chief Financial Officer</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>ex32-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: right"><B>Exhibit 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt inherit,serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED</B></P>

<P STYLE="font: 10pt inherit,serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">In connection with the filing of the Annual Report on Form 10-K for the
year ended December 31, 2024 (the &ldquo;Report&rdquo;) by Celcuity Inc. (the &ldquo;Registrant&rdquo;), I, Brian F. Sullivan, the Chief
Executive Officer of the Company, certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that to
the best of my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 24px">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 24px">1.</TD>
    <TD STYLE="text-align: justify">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 24px">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 24px">2.</TD>
    <TD STYLE="text-align: justify">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="text-align: justify; vertical-align: top; width: 50%">Date: March 31, 2025</TD>
    <TD STYLE="text-align: justify; vertical-align: top; width: 3%; padding-right: 2pt; padding-left: 3pt">By</TD>
    <TD STYLE="text-align: justify; vertical-align: bottom; width: 1%; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; vertical-align: top; width: 46%; padding-right: 2pt; padding-left: 3pt"><I>/s/
    Brian F. Sullivan</I></TD></TR>
  <TR>
    <TD STYLE="text-align: justify; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: justify; vertical-align: bottom; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; vertical-align: bottom; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; vertical-align: bottom; padding-right: 2pt; padding-left: 3pt">Brian F. Sullivan</TD></TR>
  <TR>
    <TD STYLE="text-align: justify; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: justify; vertical-align: bottom; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; vertical-align: bottom; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; vertical-align: bottom; padding-right: 2pt; padding-left: 3pt">Chairman and Chief Executive Officer</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>9
<FILENAME>ex32-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 32.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt inherit,serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED</B></P>

<P STYLE="font: 10pt inherit,serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">In connection with the filing of the Annual Report on Form 10-K for the
year ended December 31, 2024 (the &ldquo;Report&rdquo;) by Celcuity Inc. (the &ldquo;Registrant&rdquo;), I, Vicky Hahne, the Chief Financial
Officer of the Company, certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that to the best of
my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 24px">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 24px">1.</TD>
    <TD STYLE="text-align: justify">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 24px">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 24px">2.</TD>
    <TD STYLE="text-align: justify">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="padding-right: 0pt; text-align: justify; vertical-align: top; width: 50%; padding-left: 0pt">Date: March 31, 2025</TD>
    <TD STYLE="text-align: justify; vertical-align: top; width: 3%; padding-right: 0pt; padding-left: 0pt">By</TD>
    <TD STYLE="padding-right: 0pt; text-align: justify; vertical-align: bottom; width: 1%; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; vertical-align: top; width: 46%; padding-right: 0pt; padding-left: 0pt"><I>/s/
    Vicky Hahne</I></TD></TR>
  <TR>
    <TD STYLE="padding-right: 0pt; text-align: justify; vertical-align: top; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0pt; text-align: justify; vertical-align: bottom; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0pt; text-align: justify; vertical-align: bottom; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt">Vicky Hahne</TD></TR>
  <TR>
    <TD STYLE="padding-right: 0pt; text-align: justify; vertical-align: top; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0pt; text-align: justify; vertical-align: bottom; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0pt; text-align: justify; vertical-align: bottom; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt">Chief Financial Officer</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>image_001.jpg
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #, HH# 2(  A$! Q$!_\0
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M@RUN?!$WV'6/C'\(O R/X*U'5+K5(M9F\1:=>Z8EPEX(M5:.&U&G^SM^T?\
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M7="L?A9KFOP6'C"W_;&^&'A?QAX>^'OBZ77Y=4;1-:\%>*O$/]GZGXLTI_[
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MBPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *J?*'!R,MA3W/SG@_B>WXU;K!!G,W^KEVYM>?+D(_UK[^=O\
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M#R5C;:"P& 709RPRU'5BNR2(RAVW 8'S#8)<8..,X/7JH'/W?XB_A[_P4?\
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MMX?#21UC>5E7PI\6<B.-2SO_ ,D]Z*HR<=.!U(!_3']GO]HWX)_M6?!_P?\
M'W]GKX@Z3\4/@_X__P"$@_X0[QUH=OJMMI6N_P#"+>*-;\%^(/LD.LZ?IFI)
M_9GBCPYK>CS_ &FR@W7.GS/#YL#1325%J?-R-3Y>7FY6I<O,I./-RMVYE&3C
M>UU&5KV=E4IU:,*=2K2JTH5I3C1G5I5:4*LJ3A&I&G*K2IQG*G*K2C-1;<'4
M@I).<;^V453>_M(Y/*>8"3>B; LC'?(K,B_*I^\$;';*D9SQ31J5D45UN%96
M( VK(QR25^950LNU@RR%@!&RLLFTJP"YX)U$YQO2A3J5%S*].G64G1G-?9A5
M4)NG*5E449<CERNV;:5DVDVVE=K5J<*;2UU:J5:<&EJIU(1:O.*=ZBJ8O[0@
M$3 @YP0DA!(QE<A,;OF'RYW=>.#A[W=O&5#R;2Q;&5?&$C>5F)"D*@1&.]B$
M)P@8NRJ:>F^FV^F[LM^[T_RW!24DY1:<8\RE)--1Y$W.[6BY$FY7?NI-NUF6
M:*:KHZAE965E#*RG(*G!!!'!!!!!'4'(S3NM)-/5-/T=QA11UHI@%%%% !13
M#(@ZMCIV/?..W?!KRWXM_''X0_ 7P+K'Q,^,WQ%\*_#7P)H*P?VIXE\6ZK!I
M6GQ3WDGDV&GV_G$7&H:OJ=QBUTG1M/ANM6U:[>*UTZSNKB6.)\IUZ%/^)6I0
MTE+WZD(^["I2I3?O-:1JUZ-*3Z5*U*#]ZI",JC"<OAC*6_PQ;V3;V3V2;?9)
MMV2;/5:*^<_@]^UG^S]\>)]/L/AIX^;4=;U71?$?B73_  KXE\)^./AUXVNO
M#'A+6]"\-:_XH3P/\1_#7A/Q>OABRU_Q-H6DQ^(WT1-$OK[488-.OKMEF\OV
MOQ)XL\-^#_#VM>+/%&LV.A>&O#FF7^LZ[K>I2_9]/TO2]+@DN;^]N[AQLCAM
MH(9)'/+$+M169E4W4G&DY*K*--PG*G)5)*#C4@Z<9TY*35IP=6DI1=I1=2FF
MO?CS0FFE)--.G"JFFFG2J*;IU$TVG3J*E4<)IN,O9SY9/DE;H:*R;'7=)U/2
M]/UJPO8[K2]5M+._TZ\B25H[NSU"*&>SN(E,8D\J:&>*4,R+L1BT@0(^VU_:
M%GLW_:$V[2V?FR5 +$@;=Q!4$J0#N'W<Y%*=2%._/.$+2J0?/*,;3I1YZL'>
M2M.G'WJD7[T(ZS45J*,HRY>649<\83ARM/GA4FJ=.<;-\T9U)1A"2NI3:C%N
M32+E%<;X7^(7@KQK;ZI>>%/$FFZ]::+XDUGPAJ=SI\K2V]IXE\/7CZ=K6CM,
M46.2[T^^CDM9Q"TD?G(Z)(Y1L/UWQ]X.\,2^'8-?\0Z=I4_BWQ!I_A3PQ!=R
M.D^N^(]46[DLM'TR$(TMW>R0:??W4L<2,+6RLKN]NFAM+::9+VE3@_BJSC3I
M1^U4G.E.M"%..\YSHTZE6,8J4I4J<ZD4X0E*,^VI6O[6G;EJ2OSQMRT:T</6
ME>]K4L1.%"J]J=:4:4^6I)1?7T5Y5\,_C?\ "?XR:=XFU;X8^-]'\8Z;X,\:
M>(OAUXIN]*^UB+0_&WA*ZCLO$?AR_P#M5M;-%J&E74L<5PH5HB7#0RR(=U>I
MJZNH9"&4\@CH:2:DE*+4HRC"49)IIQJ4J5>G)-73C4H5Z-:#3:G2K4JL7*G4
MA.5*46W%2BY+F32:;3A.5.=U>ZY:D90EI[LXRB[230ZHS+&K,K.H955V7/S*
MC;PK$=0K>7)@]#L;T-25^5G_  4C_P""L_[*O_!+N\^$*?M.Q_%ZY3XZ_P#"
MPE\#1?"KX>R^/GC/PPM?!!\7+K?E:WHTFD"XC^(WA=]**"[^T-;:JYDMS$ U
M13G.G2@I3JU9<E*E",IU*L^64N2G3A&<ZD^6,I<L(2ERQD[63:<I1A&4YRC"
M$(\TYSE&$(132<ISG*$(13:3E*<8IM*^JO\ JG_G\NM)D>H_,5_,%'_P=G_\
M$JV&!H/[8!.6^4?LYWNY 22$81^,"I9 0K,,EB"Y)+$F4?\ !V5_P2P8D+X<
M_;%<CKM_9ONV(^N?%9;\R2?6M7A\0M\/B%OO0KK9V>]%;/1]GH[/0R^L8??Z
MQ0MIK[>A;5<RU]MUC[R[Q]Y7CJ?T\T5_,8/^#L+_ ()<-@CPK^V5@\ _\,V:
MG@^PV^+<?@H '0 <"K*_\'77_!,-\%/!O[:#9QC;^S1JISGD=/%OI1'#XB;:
MAA\1-QMS*%"O-QOMS*-&35[.UTKV=@>(P\;<V(P\;WMS5Z$;VWMS5HWMUM>W
M6Q_2+_9-MD*=-LE9Y9"_F:?#(H%U&;R_>&:+S7%Q<7A:6:[O6;SKHOA9'??*
M\:?')(BR6ZJJC#R;89)GB4M"D0<Z>CQQ,I,P6UNK>6S81);1K;*$/\W2_P#!
MUC_P3'8@)X(_;58D$@+^S+K+$@=<8\6$8'?/%/7_ (.K?^"9;<IX#_;9?_=_
M9>U5AV_N^)?<<@C!/!!IO#8F-W+#8F-MV\/B%;UO012K47:U:B[[6K47?TM5
M=]^ES^C]=+@5Y2=-M9OG1FS90QO))'#%;RW+*)$L&EDM52*.:-1)+&MI;3@#
M2E%2R6V#(4MA,]RJQR.88FEDA93&4NS<O&);:($%XWN[BYD3<D4(7BOYPA_P
M=2?\$U2>/AU^W"QQNX_9<U\DC&2?^1H/&,G/3'M4X_X.G?\ @FTW ^&G[<N>
MO'[*_B$G'K\OB7I^-9\E1?8FDMWR3LO5\EE\VGJ_,4HT:C3DXR=K*THWM?I:
M6NO;[S^C:.Q=)EFCCBB;.Q8UC:-0D<20)&RVKQB>V<@S*UX[_9H%6WCL48LR
M>"?&O]GH?&:[^%LL?Q8^-_PMT[X<^*9=>U/P]\)O$OAKP_X7^*VA7NG3:;J'
M@#XR>&/$W@SQ=HGC+P/J-LX=K/3].T+Q-I-XJ7.E>(-)F:29_P 1Q_P=+?\
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MY4X-3J13YH0:G)1B^8E3@VDIP;E!5(I2BW*FZJHJ:UU@ZS5%25XNJU33]HU
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M_E%_X.7V+?$#_@G[$PQ-%HW[6LTJ(IDV126_[/*+,5C#2,JO'()#&CF-51F
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MQC**=E**;;2:2=GJM;K5%KK12*"%4'J  ?KCFEJC4*0]#]#TZTM(P)5@.I!
M^N*'L_1_D"W*DK$*S>8JJ #DXP!AL]CUSG&.2. >M?SN?\%E/"/CO0?VC_\
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M.0Y/&-AZCX6\?Z9I<9N@;"P4;VQ_Q++0#&'Q@*S%=H!R3P#QGD&OT"^(MM<
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MNL/\%.*;FU?DBFVDDVOQRA_X-I/!-KQ;?\%/O^"FL/NGQ*^#W3TR/@R.?<X
M'' K5@_X-Q?#UL,0?\%4_P#@J!%_N?%+X0+C)['_ (4QD>O!'Z"OZ+](\10Z
MSH6D:]'I.MZ=;ZQI6FZM'8:YILVCZU90:E;072VNKZ3?B*\TK5;))Q%J6EW:
M1W=E=1SVL\8E@D5;POU6*69[.Y6**(RL[1C!4+N(0!LN>G(.W&6SCD92S+%O
MGY\;CJO[_P"KR7MZ\W&MSQIN#_>M_%.+YE&5-4VJKJ*C^]&\-E<*:K3PF#IT
MXTU5C.-"BDJ4J52OSR2H*48^RHU)WE"/PN-E-J$OYUH?^#=VSM]HA_X*P?\
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MGG+H2A[1SS"G@X8*Z4ER>QJT:4%B:%1.GB94L'*IK@H*:K4H5YJK.W/#"8C
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M2;XI_$JU2X^&?A&YNO#NGZU!XXN/V@_$ME;^,/#5U9Z9X?EU":ZF6TR_V_\
M_@G=^TI?_M#_ +?,7P*\$_&;4/#?Q,_9[^%G[=_PB\9>'/&OQ=N-%TG]JWX,
M>./%5K\6OV<_",=OXA;3;2#]HX^)+/Q!JW@&V,UE)IM[KVH:+]@N+6R@T_\
ML#33-@4+, %4(I$<B2*@D60JLT=PDB!F7+[6'FX4S>8P<NT:;,I=A<P[F8.#
M]AC4B7REC>5C'*A:63,BLX*L(#%$A5HY)9N3#4*V'P>78;VE>K4P6 QF!^NX
MB4:N.K5\8\%#^U<974U#$YA#%X7"YY7KTZ="C6Q^3Y76IX.C3H8G+\Q['#VE
M?$U)R25?,)8]+X::B\PR'&PPD:<(-T\*J>2RP$J-YVR_-\[HNI4J5J,W_*1^
MU5^R3XF\1_&S_@B[\:M9_9G^)^I:5?\ [0OC+XL?M.:!X0@^*OC&+X=>+?B=
M\,HM5\'Z3XFL;76KF]\$Z-IGC&RTC1H=3U230? GAC6();3Q9KFF:/>W7G?G
M[\&]$^/OPQ_:I@\>>#O@U^VMX2UGQ5_P<>_'GXL>(M2TG]F/]KC2?"&J?L,_
M%;P#I'A.Y\<>*3+\+M-^'T_P^\4>(IM+MKIM;N)M<M(]/.M6^GZ;I%BVHW']
MVTFC)*R.\RY170*MK;F-U<_*TOGK/*\L(,AB=9D0R32M<1W"N(Q8^P.$4+<N
MK*9#E3,B9F4++F-+A-^[,DB^:\@29_. WJ">S#R>'Q=+&*@O9QS;BO-9X.GR
MTX_5N(.),BXGI9+&#G.E2PF"J9%1RK"J$ZRIX>4)U93<'-\$L%6J9=4RZ>*J
M2B\LR#+:.)J2E/%0GE5+B.C4Q]23=G7JO/85ZRCI*>#HJG9I-?SF?\'"5MXM
MUSX%_LE>&O!'PV^-GQ-\2Z1^V]^SM\7=7T;X.? KXQ?&2YTKX?\ PJ\2IJGC
M/Q)K,WPR\$^*K718= L)C=6^G7\UIK&M#;!HNGZD\;E?R1_X*CK^T/XJ^.__
M  52\:_L]_#']OC5=0\8_L__ /!/SQ1^R5?_  __ &>OVWX=!UCXS^&/BS\-
MO$/Q7U+PC%IWP\M?#WA[Q;X?^%LDEIXKM-:E\/B!9O$&A:AIFH>)+#Q'I5O_
M '/?V8<D_:6 *%&"Q@;OEC4.SN[REQLR2) C9.]&YS&^E2,K 79#.0LDACD+
MM&K2%"'6Y25)HUFD:*02>7#<[+F*!'$BR\.$P;P:KUJ*E[2KQ#F&=2HU)1J<
M]7,</P-1YKN]/V&'Q/ N38V%%IRYJ>,C%-8N<*G<XMK!-ZSP& P&%A+FTK/
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M>'G"U*FX.67S<(M*G1]BL'4JTHQM?V-.K@YTO9QYKPS/.<6I588RGEV'\E^
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M_P"$O_S#T?\ #TK]NS_HMUM_X:_X2_\ S#TOZ_K1#3O_ %_PY_7YO/\ <?\
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MZM6:3NM5?6]]?D2W9M/=-IVLU=.V]T?U^;S_ ''_ "'_ ,51O/\ <?\ (?\
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M_#TK]NS_ *+=;?\ AK_A+_\ ,/1_P]*_;L_Z+=;?^&O^$O\ \P],9_7YO/\
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MT=?_  [^+WQ*3Q1X23X4>,_$L>G6_@WP)X=FCUG2]:\'Z=8W:ZAX<\-:5?\
M[BWUN^*QFX,9E,3LAV$-^^KSLK,H5"%8C)!)."1DG=R?6@"]16?'.\VYXY5*
MB3&Q3"65D\L-"9$::(J&2X$A!\P,2BE3&<W-TG_/-?\ OY_]A0!)14>Z7_GF
MO_?S_P"PHW2_\\U_[^?_ &% $E%1[I?^>:_]_/\ ["C=+_SS7_OY_P#84 24
M5'NE_P">:_\ ?S_["H9Y98HR^U5P0#\V[J<?W./R/6FDY-);MV7J-)MI+5R:
MBO5M+[M=?(G;[R_0_P#H<=?Y^FF_\>%C_P!>=K_Z26M?W[FYN 8V8DHUS' V
MV"21E$EQ&H.V*)RJG(1I'9(XE+S.P6(U_G_:/.LNDZ7,THC$NE:5(5=H@4EE
MTZVDD1I.$,AC:">6W\N.6S>X,$J#"!8JN-.<*<I1YIMN.JUY%S-:VUMZF<*D
M)T'B.:,*:E1A-U9QHJFZ_P!9]G[6I4M1IIO"U$N>JN:4J<8*4IV6NJ[I(US@
M-*HYXW#:Q,0/9W ^5@#C/0X%?HY\(O"WA[X8_L(>,_VHM#\-^%O&OQ9UWXN:
M7\,=*O?&>@:9XJ\/_#'P^\&BS7M_;>&O$$5WX<O?%]_-JHL+&77;&\M2UW8N
MMJRV\JM^;XEB4Y%S%G,;#,D!PT3ET(ST.XG)'+#Y6RHQ7K7PT^.GQ!^$UGXG
MTCPCKVD/X9\;01V_C#P5XGT30/%_@;Q*MNTKV4VL^#_$5EJ.@WMWI\LTLNGW
MDEG]ILI6\R"565"NOM8.DH77->/6*6F[OS+[B'B<+!<U7&8"E#;F>.PU75[+
MDPSQ%7WK/54W%6]Z44TW]F>%_P!EWX__ +1/B'X0>"_'WPG\%_"NT\7ZS?7D
M_P 9M*T'P1X;D\8^'8].N=0E\KPWX%NK+1-:N]/2)$2?3-&T:S2Y<V^JO;1L
M)ERY?V(?#UIXH\6WC_$_4Q\-? '[.FI?M!^)9(M,\%^(/B9X:ETC4KG3E\#W
M_A;3-<U?P6GBHZI9R31IJFKW-L= ,%JT1NUE2/YVNOVK_C=-XF^&?BFQ\;6'
MAZ[^#AE'PQTCPKH/AWPUX3\&I<J4O8-'\*:1IUKH45OJ$3/#J%L]G)%>PR21
M7".CL#5T7]I[XI^&_'7B/X@^'=4\&:!JWC'P_J_A7Q=H>C>!O!>G> _$V@:]
M//=ZQI^N> K72(O"VI)J&H7-UJEP]UIKR-J=W<WNX332%LI<CIUHQK4>>>%Q
M=.FO:Q3C6J4J4</.23;Y(U(5.>2]Z,9)Q3<K)TL9@9U*7)F&#=J]"<OWE6RA
M3G.<I-_5'RI*2L^5W;L[+5?HE^T1^SW\.?B]\6O@EIEC;:SX.T+5/V4/ WCN
M[NOAM\*O"5C?ZC<ZR+::;7O%ZZ;)X<\)^%K2**_BFU75[^^,4=TJ:9IMK>33
MJP_/']J/X(Q?L\?'/Q9\(+3Q.?%D.AG0)+37IK**QEN+?Q3I>CZMHQO+6">X
M@CN4M;V=;I()GA\QHO+?:F6[:3]NC]HB2[-Z/%WA&"X/P\L/A47M/A_X#MD7
MP+I5W;WNE:*L<>BJB_V5=6EM)I]X$%W:^1$L4JJN*\.^+/Q?\:_&[QK=?$/X
MCZY8:QXMOK/1[*\U.TT[1]%%S#H-G:6&EO-::5:V=L]Q!:V5O&URT/G2E&=V
M9G8GGQ:KU,53G1JT%AU6K2G'VB]I.E/,<VKT_=2:BXX/$X&FXW:]I"HN:T(R
MG>$QF6JGB*,L9A*M6%&%.'^TTJ<8U(8; 4.=3Q4<-&=.4L+42<).:C[-N%FW
M'SD.KJ)$R$==Z!B"55AE5)P,D!@">,D9[XI]5U,"JJ"XC"JJJH,T)PJ@ 9)R
M3PHSUS^-2L=F"[ !B<[56$QCLQ-U>!"".<X QT KHG.+G.5/WK\D:=&#4JU2
M3;YN2FG9J.C>JLFNIG&I&.%Q%=SI588*BL3BJF&KT,3"E2JXS X"ESO#SFJ<
MIU\=2Y?:^SC*,*SC*4H<DGTA+CF-S'("#'(HD9D<$;758BLK,K88+$RR$@"-
M@Y!#!)%T\U#V_P"/JP[#VO1C\>I![BC=%G/F(><X-UIY!]B/MO(H_?1J\M3"
MXJGRJ+O.C*TU*[]QIRORVM*]K-I:G15IRINI3;BW"K7HMQE%Q<J%65&;B[IN
M+E%N#:3<;-I/1?I+_P $YOA9X8\6>.KC6_B3X2TWQ)X0\92>(/@K8C7KKPXH
M\.Z]K&B75U?>)K2#Q!>+JFLS^%KR]\):#=7>F6[W%KJWBN3R(VET&1)^Y_9%
M^#]AX(\5?M[?"WXF>$=%\17OPE^#7CF:VDU[PQH^N:Q8WFAVFN&WU[0-5U*R
MNKK2]3ET*2*_LK?3KVU:;[1;J_RJP/P-_P +X\8+9_"2Q33OAK%!\$;L:AX"
M:+X=_#F.YBOFB@CNKOQ'=)9BX\77.I2VT-[J<WB&2_DU'4D&H73279\RO8;C
M]NW]H+5/$OB_Q->ZS\.TU_XF>'D\$>/=>M_A+\+&U/Q'X8N";6:UU00Z27U)
MXK:9TC:8&5XXXH7F2)%>/>#E/%.2I5ES8*I07-2FESNKSJ^FR6MUKTLTC.BN
M2%2,Y07-/F5Y1_EL^M_Z\SZ$^)G_  3[\"^%A\0/#O@SXJ>,O$'C_P !?LX>
M'_VGC9^(/".A:/X6U'P;/<7>DZGX=CU'2=9OM3AUTQV*WMK'-IB6_GQ*#,PF
M,D?F'QW_ &'I/@;\)X_%^I?$*VOO'6E^'OAUXA\1>&+P^'-.TW4H/'MG<3W,
M'@J)=<G\6ZC)X5E@ACUVXU+0K*R5=0A>SN)TC9CU7[5_[<=E\4TBL/@5JFN^
M'O"GBWX.>'OA1\0SXC^'7@7PIXIUGP]X2U&7[58Z7XVTSQ/XD\1MX6UR[OK-
M+WPN]SHNG?8;BX3RKD32QR_'_C_X^_$7XH^'_"_A[QUJ7A_78O!^@Z=X7T;6
MY?#W@ZW\7MX<TA0NF:+JOBZVCBU_6=.L5"K;VVI7UQ&@1.#M%<DXUFHQ5.?[
MJ/LW>G-+F4I2;B^1W3YE9NVJ:MU-:3IP34O>O)N\7&2M:*2UFK.Z=UYIWZ'C
MS*5<CH%+!@&W@AUC>(!L#E 7#X^\2N<8Y*CWQ <2(!OD?"W.GXW2[2V0+PY
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M$M$@\.VT&@Z7I^IZ]X>U34(M<NM0T]KJ2_>+1)M/LOLA6 1S_NF+KX?=?\%
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M5DD98XPGS-TP>,'9P/\ KO!GU../KR!@8Q7U9('XVE#R"=X)Q^X@XRN![?0
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M(?@5X)L9)+K5=(M"S+XT^)4QS'-;;R$>65ES($WO*\9B5L+^7/\ PICXB?\
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MG]JO;R1--T"ZL+2.>]NG2)9)I-W]9H^%WPS!R/AUX$!'0CPCX?!'X_V?3/\
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ME<[^0W3=SQZ9(K^M#_A5?PP_Z)QX"_\ "/\ #W?K_P P[O1_PJOX8?\ 1./
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MI5A!Q=6M5E5F^:<IOWI>_)WDW.K-^UQ%5RKUE&I)Q7XVZ'\3OV1/"WC7Q?\
M$OPQX>\$^&_B1\08=,MO'_Q$\/?".ST3QYX[M]&MA9Z-;^-/&.E^$K;Q'XJA
MTBS1;32XM=U*_CT^V5;>T6&)54=U_P -1?!; '_"5WV %4#_ (1O7,!5&% '
M]C8 4$A0. .!@5^K'_"J_AA_T3CP'_X2'A[_ .5U'_"K/AC_ -$X\!_^$AX>
M_P#E=41XCS-*WM*<;/2-.+C%+IHWOW?73L']DX7JG=ZOU^\_*J+]I[X*LR@^
M*[Y4,D".R^&]<+JK3QEF1/['7>?+5U;KA&8=&.?RZ_:(*_$+XS>-/&?A!FU+
MP]KR^%9;"^G^U64TQTGP7X=\-7@DM=3MK7RS]NT*ZE(MU;,T\[SXDD!D_J;'
MPM^&2D,OPY\"*R\AAX0\/@@^H(T_(_"D'PK^& X'PX\!@<\#P?X>[LSG_F'=
MW=V/JS,W5B3[&3<>9YDF)EBL*Z#J25G.=.\VK)-2>S5HI+=I+2VIY&=<'91G
M="C1Q/UB/LY-RY*EH25[KECO%VT=VTWJ?Q^GP;XD&1]B7'_7W:#MSP6/ZYZ@
M\D@EK>#/$3JZ/8QNDD;QR(]U9,DD4FWS(G4MM>-]B;T8%6*+N5MJX_L$_P"%
M6?#'_HG'@/\ \)#P]_\ *ZC_ (59\,?^B<> _P#PD/#W_P KJ^L_XCAQJKP2
MRJ5)[JIA'*;\Y2V;O?6VUET/GUX5<,1J<\5C%:SA^^UB[+KZIOIN?Q;P_LU>
M K?3?%VC6_P8^%D&C_$&YDO/'^D0>"? L6F>.[N6;[1+=>,]/CTE;3Q3=2W!
M-Q)/KD5_*\Q,KL9#FKG@/]GWPE\*[6]L?A;\)_AS\,;+4[C[9J=G\._"?@WP
M/:ZC=_9)M/\ M6H6OA?3=*@O;D6$TUB+BZ2646D\MJ&$$CHW]GG_  JSX8_]
M$Y\!_P#A(>'_ /Y74?\ "K/AC_T3CP'_ .$AX>_^5U<TO&/B.=:G.60<')4T
MTZ\,LQ$,=5YOBG5KQJ*/M*G_ "\<%",K*Z=CNCX=9%*C5HXBMF-6%249**Q=
M11O!<M-U(.HX5)06D92A*45I!P6A_&Y<_!VTO_#=[X.O? _A>]\'ZG;WMIJ?
MA.\TKP]<^&-1M=3N);O4;2_\/S6KZ1>V^HW<TUW?07-I)%>7,\D]PLDLKNU_
M2/AG=>'-*T[0?#WAO1] T+2+--/TC1-#ATC2-'TJPC*M'9:;IFGQVUE86<;*
MK):VEO# K*A5 :_L4_X59\,?^B<^ _\ PD/#_P#\KJ/^%6?#'_HG'@/_ ,)#
MP]_\KJZ'XU<51Q52O1PV44H3PT</"FL+S>S48J*]YZN*25DWS6W;=V^!^%7#
MLL-3P\L3FSC#%3Q"2Q;Y%&<W)046]'%-13VT730_C\/@[Q)S_H29SG(N[3\C
M\_/7_..-[PKX=U/2O%7A/5;]+:UM;'Q9H&I7KBX28Q6NC:W;7%R.6*HDRC]Z
MN=KCA\KT_KE_X59\,?\ HG'@/_PD/#W_ ,KJ#\*_A@00?AQX#(.<@^#_  ]@
M[B"<C^SN<D GU(!/2E/QLXOGA_8^RRE2T][ZI=:6Z;]._4N'A?P]"O[;FQ36
MUG5?-;97E>S=K7?5W?4_!X_%KP&22-8EP2<?\2S7QQVX&EX_*C_A;/@3_H,2
M\\?\@S7^_'?2\?G7[P?\*J^%_P#T3?P%_P"$?X>_^5U'_"JOA?\ ]$W\!?\
MA'^'O_E=7R[\0,_::DL$TTU+]QNFFI=.J<E\SZ'_ %0RA:J6,36J?MEHUJG\
MFD_D?SR_$6Y_9S^,'AEO!7Q>\&> OBQX+EOH-5?PA\3OAM;?$#PL^J6TLL]M
MJ;^'?%OA?5]&?4;:>>>:"]-E]IBEGEDCE1I7)H>([+]E[QAX0T#X>^+_ (<?
M"_Q7\/\ PM)I,OA;P%XE^$^EZ]X*\-2Z$D::#-X>\*ZKX2O- T.71%AB32'T
MS3[9]-6)!9-"$4#^BC_A5/PN_P"B;> ?_"/\/?7_ *!WKS1_PJGX7?\ 1-O
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M#XM> QUUB7./^@9K_/IUTKU/;GD8]_W@_P"%5?"__HF_@+_PC_#W_P KJ/\
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M5D$Y1@%=&)!("NI. PR?4L5NZ,U%[/EEJN^WY7#ZUA_^?L3TFBO.1\0?#?S
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M+3Q'J\G@SXD(/!T=IY9^U?\ \$K?V\?'7[;_ .S)\?\ X7?ML:QXK^%?A?\
M:^O/CAKO@G6_@Y\#_#MS^S/X.7PA'H%JO@SQ+K>LZAXG^+PNO#-C#\.8O#]Y
M!;V^BV^H77B"PT>RO"\K;4G6<L'!83%U(8C$RIUZKGAH*%!4Z3I8BE"4G*,<
M6I.O'#XCEKX6C)8;'1AF$:E-VZ5"K3Q%5T\1"="CSQBH0Y9KWVN9W<E>R2<5
MJ[+W5JOZ,WG61I'.=JM&\!=BTJV\\?E*TSNL+L;J2Q:>",P*(8U=05W[2@<'
MIDCUXQ]<YZ>](%B"GRHU1=RCA.9(EBB$#Q0G]WIQ9_M,EW8P9@$TL90@(,J
M2?EWG"EB-K'"J,LQP!P.K?B:[JD*D)SIPP6,J.-6<(M3P4%*G'EY*CYJUTY*
M3]UK3EMN].*,83HPJ?5\2ISBI<G+#E2=[:_$[V?];KN'H3],'^1-&[_9;\J:
MVX$C!R0K<J0-I&5X(XSG/K^M-^;^[_XZ/\*)4VG9SI479-TZU2#J1ND_>=&4
MJ>N\>5OW;7M*Z(4)-7=%P?\ +.34EZJW5:KR/$OVE_BKXP^!WP!^+OQG\$^
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MTV/4_M5\6CG\*:?#XE6TCO)X=/UOQ#JMK#)B')]D!R 6C"D@951D+@   GV
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MX,T70_A->W+_ !>^*D%WK#VNF>(=9TK2_!_A'3(C<KX=U#QO?0QZ5<_I,=C
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M>7Y'I_Y"?_"O3_A61_;6I8'_ #"Q_"5_Y>X?7K[?C7/F+_V'$_N<;']W\53
MUJ=->_3^*I*;C!>;35[+J;X.WUFC^XK0]_XI*/*O=GJ[:V_S1[K7$?$-V'A#
MQ.F!Y;^%O$N]@<RK_P 2BY5?+B 9I,EL'"D [02"P([>N&^(1QX6\0C.,^&O
M$./20_V=*/(/7:)<YW_P^7CO7Q-7E]AB7+X5A<2W;?2A5>GG=+76V[329]/A
MU_M>!E>2]GF&6U?=G2IM^SS/+7RN=:,J:C)2:E=7:TBU)IG\:%M@VUIAY/\
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M2G5R^MP[2S'$4ZU7B;+,TP<<$L=B:^#]IAL/2Q<E0PWLL=&<L7&?GFI_M(^
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MP_9^&_%-I>Z!X!N?CAHC:QI%GIESXS1-4FU/3_A/X:_L ?M@_P##KO\ 8T^
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M[-W^'W_JQ/B_7Y+MT/X?S%24]GZ/\F>]"]_97; 7PC^TLS$X 'Q0^$;$D9.
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M+[1=6OK?2K5]*U.V\!>/Y+^]BO[RUAOO[4FL+/4(I96\Z2,.K_Z/XKPV\/\
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MQMX+22%YC&Z1)*J/),IA53./+K^5S0OVSI&^&GQ_\<_%?X77?@6?X$^*M/\
M#MSH]CXWT?XEZ/XQU7Q1!86_AZWL-?A+>'_^$LO;C7='L]5M-$N=6\,Z2E^L
M%]#]I>*"32\9?MA1> ?"_CY_%'@6U@\??#;XB>#?A;XG\/Z%XVN;SP7I=_\
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MAVV=&4K*VFJZWW9\7Q)QQQ#@\92PN'Q480E"#<O9WFFXTV[/G4=Y/H?N(O\
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ML_N]Q9MQ;9C)/).2>:_F]_X)._\ )V-Y_P!D@\:_^I!X%K^EJ/\ U<?^XO\
MZ"*_F[Q1R+*^%^*,1E>6X92PM.CAYQ^LSE4J<U6G.<[SBZ5]8JUXZ+ON?LW
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M? =W>6SW,"1VL>IF)K[4 TCVB01N()R-E=!_PI[X;?\ 0M-_X4/BO_Y?4?\
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M>)R6F0*25=7)) 0B:-'38Q/SD ?/@?*<#)R#7<R?"#X;K'+(/#3!XX9&1O\
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MC6S,4F<--)IFBQ2S,<?O)A9Z;:PO*1A3+Y*NZHN]F*YJ/_A9OC7_ *"X_P#
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M5*-YR?,I4W8_&#3O ?BKX#:-XG\9_!WX3>%=+\0_%GQOX'NO$7P7M->U/_A
M_#$-I9_8O%FO>'-5T;04M(O%FJF2&'S5@L/#U[::5;/>V:O+(PO66E?M+:M\
M>[O6/%'PY^$.C_"6)-0\-:1XGC\;ZIK/Q%TKP9=6TK26^GZ/'H]GHMGK^OW2
MV\UW=L[R:9;QQVAENDM_G_9:\^"WPZLI&VZ-<2DCR@6UG6;?8&4?.@L;ZS59
M%W$JP'RD# XJJWPC^'8;:/#TH1@LK)_PD7BLJT@R-YW:ZS;B"<D,*Y\3XR\
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MK2S&G)4H2P]/DBU)QCS)2DY2D_//'>7TRSDC E4ZW,08SD%0F2W.T[>.N/\
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MGX4WOPW\10ZV-?\ #MC_ &=<GQ#!K%OY\-KIEC=Z')I6J[-3-S,KR1G]NO\
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M--1;BKWE9ZMO6R5DDD?/GFKZ-_WR:/-7T;_ODU]!_P#"NO"__/M<_P#@9/\
M_%4?\*Z\+_\ /M<_^!D__P 575_Q%S(?^A7F/_@V'_R)R_\ $.\T_P"@W"_<
M_P#Y$^>RZGUZC@J>G?\ K^!P1CIE:]%=7&B:U:Z?8Z3JE[=:9=)9:=X@-TVA
M7UZD3I;:;K<5OEFT/4A<S1ZN(8WN)%MK-<-&K*WTS_PKKPO_ ,^US_X&3_\
MQ5'_  KKPO\ \^US_P"!D_\ \565;Q7X>KTY4JF4YA*$DTU[6%]=[.VGW/4T
MI^'^;4IQJ0QV%4H.Z?O6^:MK]Z/Q5U_]B[_A:W@#XJ3:AX#\#_LU?$[XM?"*
M?X=^*[#X2ZRNJ>!M7UJTOK/5-'US4++2-&\-6$FF)=V:6CV,&D0:C_93SVUU
M>W+2EZ[KX*?LR:S_ ,)A\;?'?QW\.^$6MOC-\,_@]\(M=^&.D:G)XCT'5=&^
M$NB76AW'B#6M82QT83-XEBN+:YT>Q2T_M3PQ-I.F$ZG<7$ N1^N'_"NO"_\
MS[7/_@9/_P#%4?\ "NO"_P#S[7/_ (&3_P#Q5>+2XWX)I5Y5_P"P,PJ3E2=)
MJKB(R@X.-2+]U0A:3C6KKF33_?<RM.A@YX/V*W#W%-:BJ#S3"4XJK[92I0E&
MJIJ5*:M4E*I*T9X;!SBI<S4L%A[MKZPL3^2?Q"_97OM<^$.L>%/!MIH?AO58
M/%7A[4=!\%VVH31^$M3\#>&O%T/B35O OB/4=0MM6?4[GXGWUJ=>\7Z_K%OJ
M;W%]>IINHV]]9Z; \GM?[,_PR\0_"3X,>'O 7C&\M+S6K>]\67]S::;=37NE
M>'-/\0^(Y-9TGP=HU]/#!)=:3X8M'%C97/V>W4K&$AMX8=B+^@/_  KKPO\
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M $,OQG_\*WPO_P#,-5?\1SX-_P"@+B+_ ,)LN_\ FDI^%7$&J_M#+^VS[?\
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>form10-k_001.jpg
<TEXT>
begin 644 form10-k_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (Y!8H# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*1E#*58 J1@@]Z6B@#.TG0=)T)95TK3[>S64@R"%-NXCIFM&BB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *HZKHVFZW:K;:G90W<"L'"2KN ;IG]35ZB@".WMX;2V
MCM[>)8H8E"(B# 51P !4E%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M86?RG3#@ D8< ]&'YUKT44 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MN53LO^/O4?\ KX'_ **CH N4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU":SLY3%<WL-HSP1,#ALMW [D @5=U3Q9INF3VULJ75]=W,?G16]C"9G,?\
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ME?1OM?\ X'Z_<AV5UYV_X/Z?B:,'C&SF%M.UG?0Z?=2+';W\J((96;A<#=O
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M 4444 %%%% !1110 4444 %%%% &!XA_Y#?A3_L*O_Z17-;]8'B'_D-^%/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MK(\1Z_\ \([I\=W_ &3JNI[Y1%Y.F6WG2+D$[BN1A>,9]2/6N;TKXGPZO>V]
MO!X0\6HDUQ]G-Q+IH$43;]C%V#G 5@=WI@^E '=T444 %%%% !1110 4444
M8'B'_D-^%/\ L*O_ .D5S6_6!XA_Y#?A3_L*O_Z17-;] !1110 4444 %%%%
M !1110!@>!?^2?>&O^P5:_\ HI:WZP/ O_)/O#7_ &"K7_T4M;] !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MIN[TO;?;ST-3_A+_  Y_T'-/_P# A?\ &H_^$U\,_P#0;L_^_E6/^$7\/?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4 6**** "BBB@ HHHH **** ,#P+_P D^\-?]@JU_P#12UOU@>!?^2?>&O\
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M'_D-^%/^PJ__ *17-;]8'B'_ )#?A3_L*O\ ^D5S6_0(**** "BBB@ HHHH
M*Y#QSK/@?2?L'_"9Q6+^;YGV7[58FYQC;OQA&V]4],\>E=?6?J>A:1K7E?VK
MI5C?^3GR_M5NDNS.,XW XS@?D* /-?AGK_PYGA\.Z=IT.G#Q.+)$9DTTI+YJ
MP_O?WNP#. ^3NYYZYKUJN,^'_AO0K;PCX;U2#1=.BU Z;;N;M+5%E+-$-QW@
M9R<G)SSDUV= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MAK_L%6O_ **6M^@ HHHH **** ,"S_Y*#K/_ &"K#_T;=UOU@6?_ "4'6?\
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M7 _=QG_EA'V4>_\ GUKH: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M &%7_P#2*YK?H **** "L#QC_P @2V_["NG?^EL-;]8'C'_D"6W_ &%=._\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *R-;\3:'X=BW:QJ5O:[E)".V78>RCD_@*UZYS6_ OA_Q
M'K$&IZM9FZF@C$:(TA"8!)Y Z]3UI.XU;J>4^)?$W@SQ3<R6VA^")]7OF/\
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M2/3:***HYPK \'?\@2Y_["NH_P#I;-6_6!X._P"0)<_]A74?_2V:@#?HHHH
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M4I0;5DS3"XNC3JJ<Z:LNU_R;:/(?AWXAUFUU5K>&*^U2"*S*1V2W&$B4,@!
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M2[#3(_+L;*WME](HPN?KBK=%%;'BMMN["L#QC_R!+;_L*Z=_Z6PUOU@>,?\
MD"6W_85T[_TMAH$;]%%% !6!XQ_Y EM_V%=._P#2V&M^L#QC_P @2V_["NG?
M^EL- &_1110 4444 8'@7_DGWAK_ +!5K_Z*6M^L#P+_ ,D^\-?]@JU_]%+6
M_0 4444 %%%% &!9_P#)0=9_[!5A_P"C;NM^L"S_ .2@ZS_V"K#_ -&W=;]
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M<=G&?X[@Y;_OD=/QI/[!\_Y]4OY[KU3=L3\A6/MY2_AP;\WHOQU_ V]C&/\
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M@ ?NH^PK0JG9?\?>H_\ 7P/_ $5'4C+E%%% !1110 444UW6-&=V"HHRS,<
M#UH <3@9/2N5N]0NO$MU)IND2-%8H=MS>C^+_93U^O\ 3JV>XNO%MP]I9,\&
MCHV)KD<-.1_"OM_GVKIK2T@L;6.VMHQ'#&,*HH 98:?;:99I:VD0CB7\R?4G
MN:LT44 %%%% !1110 4444 %%%% !1110 4444 %%<#_ ,+K^'O_ $,'_DE<
M?_&ZZ[1-;T[Q%I$&JZ5<?:+*?=Y<NQDW;6*GA@".01TH T***KWUK]NT^YM/
M/GM_/B:+SK=]DD>X$;D;LPSD'L: +%%>6P?#^:7Q3?Z6WCGQIY%O96UPC#5C
MN+2/.K _+C&(EQQW/X>E6-K]AT^VM//GN/(B6+SKA]\DFT ;G;NQQDGN: *^
MMZ7_ &UI$^G_ &^^L/.V_P"DV$WE3)A@WRM@XSC!]B:\]TOX?S7VHZW;R^.?
M&@2PO5MXBNK')4V\,N6^7KND;IC@#ZUZ%KFL6^@://J=TDKP0;=RQ %CN8*,
M9('4CO7G6E_%#1+'4=;N);74"E_>K<1!8TR%%O#%AOGZ[HVZ9X(^E2YQ6[.F
MEA*]:/-3BVCU6O-?%O@F:$2:I!XR\6PO=:E;H8(M3*Q1K/<HC!%"\ +(=HSQ
M@=:]*K \8_\ ($MO^PKIW_I;#5',6/#F@?\ ".Z?):?VMJNI[Y3+YVIW/G2+
MD ;0V!A>,X]2?6M>J>I:K8Z/:&ZU"ZCMX1_$YZ^P'4GV%<M_PD>O^)#L\-:?
M]ELV_P"8E?+@$>J)W]CR/7%2Y)&].A.HN;9=WHOZ]+G3ZIK&GZ+:&YU&ZCMX
MAT+'EO8#J3]*^??&FIPZSXMOM0MXY4AF\O8)5VL0(U&<>AQD>Q%>T:7X(L;6
M[&H:I/+JVI?\_%UR%/\ LIT ].N*P?%'B7X5:?XBNK7Q);Z4VKIL\\SZ2TS\
MHI7+B,Y^4KWXZ5$H.:UT._"XNE@IN4$Y.UK[+Y+5_?\ <8WPWT&^U?P[<M'K
MU[86HNV4PVH"DML3+;^O0@8]J[)/ASH+,CWWVS49%.0]W=.Q_0@5:\%ZEX5U
M71II_"$=JFGK<,D@M;0VZ^;M4G*E5R=I7G'IZ5KZM'?3:-?1:7,D&H/;R+:R
MR#*I*5.QCP> V#T/T-.--)69A7Q]6I4E.+Y;]O\ .USS3_A2O_4P?^2?_P!L
MKT#3O#FG6.F6EH]G:SO!"D32M;J"Y50-QZ]<9ZUY;'8?&N76;G2U\7Z/Y]O;
MPW#L8$VE9&D50/\ 1\YS$V>.X_#VFG&$8[(BOCL172525[?+\CC?%OP^M?$O
MV/[-/#IOV??N\NU#>9NVXS@KTV^_6L_PU\*X= \0VFKRZL]R]H7:*-8!&"S(
MR?,=S9&UVX&.<<\8.GXYT_QQ?_8/^$,UFQT[9YGVK[4@;S,[=F,QOTP_IU'7
MMSG@&#XGWUUH^M:YXCTZZT*ZMQ</;)$JRE7B)0<0C!#%2<-V/6CDC>X?7:_L
MO8\WN_U\SU*BBBK.,**YSQI9^*K[1H8O"&IVNGZ@+A6DENE#*8MK9491^=Q4
M].QYKD/ L'Q/NM9@O]=\1Z==:+%<7-O<6\<2K([1M)%D8A7CS%!^\./RH ]2
MHHHH **YSQI9^*K[1H8O"&IVNGZ@+A6DENE#*8MK9491^=Q4].QYKD/ L'Q/
MNM9@O]=\1Z==:+%<7-O<6\<2K([1M)%D8A7CS%!^\./RH ]2HHHH **** /,
M=0T;XA6%]I-M_P +(W_VA=-;;O[#MQY>(99=V,\_ZK&./O9[8/?:)::C8Z1!
M;:KJ?]IWJ;O,N_LZP^9EB1\B\# ('OC/>J'B'_D-^%/^PJ__ *17-;] !111
M0 5@>,?^0);?]A73O_2V&M^N?\8E1HEON=5QJ5@YW,!\J743L>?158_A32;T
M0;'044 Y&1THI %8'C'_ ) EM_V%=._]+8:WZY_Q@0='M4W*&.IV# ,P&0MU
M$[=?158_A32OL!T%%%,EFB@3?-(D:^KL /UI /I&944LQ 4#))/ %8MUXNT*
MUX;4(Y&Z!809,_EQ7&^,/$UYJ$"P6]M<VVGOP9)8RIF/I]/:NBGAYSDE:QE.
MM&*ON==X'!7X?^&P001I=J"#V_=+6_7G/A#5O$<NGFUL[6*Y@A.U99V*A/\
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M444 %%%% !1110 53LO^/O4?^O@?^BHZN53LO^/O4?\ KX'_ **CH N4444
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MJ<_P1;]$_P#(Z>BN?AN/$%YR(8[93_$ZX_0Y/Z5+)HEW=C_3-3D8'JB+A?\
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M>C7M[>:?):1IILLEU)<(S&-MXCD=CG)X.#5O1K?2M9L-%MKCQ3?S7%H\$O\
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MEG!IG245S?\ 9/B?_H9D_P# )*4:;XI3@:_;R#U>T48_*E[./\R_'_(GG?\
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MY+>M8RA"<ES2;?F=5/,,323]C%0796O^*?YF9\//"/@_Q'9RZD-3EU4*[0&
MAK=$8;6SCARV#USMP<8R,UVR_#;P[$#]FBN[<GO%=..?7K61X(L[FXC%I<^
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M'X@ZMJVE(;3P[+?W$*A+B1;E8TW8Z\CC/6IYO%GBH@A='TVV?H!+=^;S_P
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/?'(]C7U'15JLTK#NUL<;_PK#PT.8H;J'UV7#<T?\*WTU<>3JNM0D?=,=WC
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M];6XMT%K)&$9 S-A@R-G.\_I775EZCXDT+1[A;?5-:TZQG9 ZQW5TD3%<D9
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M/?ZUYN%P&)IU93G4T=]GY^=T=U?&4)TU&,-5W]/*S,PS>(7^Y:V4?^^Y;^5
MA\0O]^ZLH_\ <0M_.MFBO3^K]YR^_P#R1P^W[17W?YLQO[-UAS^\UO:/1+=:
MYO7=(U)=0&6N+X% 1((3\O)^7C/U[=:[VBN?$9?3K0Y+M?-O\W8VHXV=*7-9
M?<E^2..\,Z*KM<MJ-BX*[?+\Y"!WSP>O:NMB@B@7;#$D:^B* /TJ2BML+A88
M:FH1U\[*YCB,1.O-R?W= HHHKK.<**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH ***R]1\2:%H]PMOJFM:=8SL@=8[JZ2)BN2,@,0<9!Y]C
M0!J45EZ=XDT+6+AK?2]:TZ^G5"[1VMTDK!<@9(4DXR1S[BM2@ HHHH ****
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M/_9ER]OKLDT2PN65L2;A@Y&<_K7$UY^-S2IAY)<F_=_Y'I87 4Z\6U/;LO\
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M*<N:K>WFM/PU*G@F)-!U"YO-2\3:_?;HO*CAO[MIXQD@E@N.&&T 'T)KN/\
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M&T_[_K_C1/=:7=VTD$\]G-!,A22.1U974C!!!X(([4<T>X^:/<S?^$Z\(?\
M0U:'_P"#"+_XJMN">&ZMXKBWE2:"5 \<D;!E=2,@@C@@CO7F5WHWA*W\9KY?
MA[1#9E8X9!]CB,?<[@,8!&_DCKM&<X%=]%JNB65O';P7=E%!$@2..)E"HH&
M !P !V%1&K%WUV,XUH2OKL:=%9+^)M&CSNOD./[JL?Y"H?\ A+=()PDTDA]%
MB;_"G[2'=%.K37VD;E%8?_"46Q_U=CJ$O^Y!_P#7H_X2&=_]7H>HG_>CVT>U
MAW%[:'?\_P#(W**PSK&KMQ'H$OU>=5_I0+WQ"_328(_]^X!_E1[1>?W,/:Q\
M_N9N5ROCKPYH^L>&]5GN]-T^6_-C)!;W=Q;J[Q,58)AB"1AFR,=":NE_$[GB
M/3(Q_M%R17*^*?$3VEW'X>U35+-=0NHQ/':10R9=-QY#[=H^XW!.>*F=5J+:
M3(G6:BVD_N.I\.:7X<CB&I:+HFGV,DBF-GM[2.)\9&5)4=,@''L*WJ\V\*ZA
M]KOIM"M-=-K?)&;HVHMB_P"[RJ[]QXZD#&<]\5UO]A7K_P"MUV]/^YA:4*DI
M13M^0J=6<H)\OY&Y16'_ ,(RC',NJ:G)ZAKC@_I1_P (GI;?ZT3R_P"_,35\
MT^WXFG-4_E_'_@&NUS GWYHU^K@5 ^KZ;']^_M0?3S5S_.JB>%]%CZ6*G_>=
MC_,U.FA:4G33[;\8P?YT?O/+\0O4[+\1C^(M(3K?P_@<_P JKMXMT4<"Z9CZ
M+$W^%:2:?91_ZNSMT_W8@/Z5.J*@PJA?H,46J=T%JG=?<_\ ,Q3XILS_ *JV
MOI?]R _UKD]%U&:#Q+<7$%K)*T[2%H4&"<DMSZ<UV/B/0/\ A(M/CM/[6U73
M-DHE\[3+GR9&P"-I;!RO.<>H'I6/:>!%MKRWE_MG4<6\D<BR+(!+,5()$K8^
M96Q\P &03652G4;B[]3"K2J2E%WV9I?VIKDI_=:%L'K)<*/TI3)XGE/RPZ="
M/]MF8_I6Y16O(^LF;^S?63_KY&']B\12CY]5MX?^N< ;^=']AZA)_K]>NF]?
M*41_RK<HH]FNM_O8>RCUO][,,>%[=O\ 7WVH3YZ^9/Q_*G1^%-&0Y-H7/JTC
M'^M;5%'LH=@]C3[%"/0]*C^[I]M^,8/\ZM1VT$7^KAC3']U *EHJU%+9%J,5
MLC"\0^'CK4ELZ2K&8R5<D=5/I[_XUN(H1%11@*,"EHI*"3<EU$H14G);L***
M*HL**** "BBB@ K$U[PKI7B*:TN;ZW+W=D)/LDPD9?*+@ G (#=!USTK;HI-
M75F)I-69RND>!=,LM0L]7NX1-J]IO$,ZR.!&&4J0%R >">2.]=5112C%15D*
M,5"*BM@K@+'PV-0^(GBFXU"WOTM)%M1"Z3S01S80AA\C 2 ="#G'XUW]%5UN
M7?2QS7B![W1[+3;71X)+;3Q)Y5Q)96OG26T04[?+C .><#[K8]*YW3K'4'D\
M;2O'JEPMW91BVFO+81R3_NG& JHHSG QM!Z9%>CT4FKII];_ (@G9JW2WX'F
MMM9ZCI]UX#NFTN\D2QTR1+L1Q$M"2D:X(]>OR]3@X!/%2W&@WWB>[\6W\,,U
MI!J&GI8V@N8VA:5E!)9D8!E&3CD XS7HM%5)\U[^?XB6GX?@>=ZHEYXB\&6/
MAJ'3+^VO_P#1TN#+;/'%;B-E+,)"-C?=X"DDY%:%NDWASQQKE[=6E[-9ZHD#
MPSVUN\^UT4J48("5[$$@#WKM**+N]^_ZB2LK'(75O=7GQ#T:]%G<QV_]F7".
M[1\1LS)A6(R ?;-0>"9)_#VAV_AV]T_4/MEM+(@=+9FBE0N2'$N-@&#T+ ^U
M=M126FG];W&]?Z\K'ENM:1J4OA_Q_''I]T[W5]&UNJPL3, L>2HQ\PX/(]#6
MW>K=6/Q&M-4;3[R:QCT@PRRP0L^QC)GH!ECQT7)YSC%=O10M+?UTL-N_]>:?
MZ')>$;"Y_MKQ%KDT$MM#J=Q&;>&9"C[$3;O93RI)SP<'CD4[QOX9;7-%NOLH
MO)+UA&$B2_ECC(#@G*;PF<9Y(S^E=711V\OT%W\RGIVFP:9$T<$ETX8[B;F[
MEG.?8R,Q ]A7/75G<Z'XUN-=CM);K3[^U2&Z$";Y(7CSM;8.64@D84$Y XKK
M:*.MPZ6/.]*T2&;Q]<W^CZ0^G:3)I+6SR?8C:;IB^<[&56)QWQVZU3\/^';&
M#P[#H&NZ;X@EO(@8I(8KB[-M, QP5*N(0",'!(^E>H44UI_7G?\ 4'KK_6UC
MBQ#-H'Q"U#49;.\GL=2M(8XY;>!YO+DCR-C!02H((.3QZFL_1QX@TGPWXCN+
M73)8[^;6))TBDCW,(G*;F49PY"D]#@D<9KT2BDMOZ[W#^OPL<!I,%[/\0K&^
M,NM7EHNG31_:=0LEMPKET^4 1H1T_B'/8GFGZ?IEP^F^*O#LT5S!<W]S=RPS
M&!_)*2#Y3YF-N>?NYSUXKO**&KJW];W&G9W]/P/-KN*^U7X<P>$8]+O8=5,$
M-K+YELZ0Q;2NY_-QL88&0%8D^E;$>GW4?Q'N[G[/,;;^Q$A$Y0[6<2-\N>A.
M.<5V-%.3O=OK?\582T27;_.YYQH>FP0_#W0+?6;#6+>YMU=HY;2"7S[=]Q[(
M"XR#W4@CK3[JVUZ]TWPFVHV]S-<P:T'D;RLNL(WA'D"C"G;MST&37HE%%];B
MMI;U.%T^XN-#\8>*KR[TS4&L[J:$PS06KR[RL0! 5021S][&,@@D5J> M)N]
M'\,+'?1^5<3W$MRT.<^5O<L%X]!C\:Z:BDM%\K#>OYA1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %4[+_C[U'_KX'_HJ.KE4[+_ (^]1_Z^!_Z*CH N4444 %%%
M% !1110 4444 -=%D1D=0R,,%6&015/3]%TO23(=.TZTLS*<O]GA5-Q]\#FK
MU%%P,#Q!X+T'Q* ^HV*&X7[EU$=DJ$="&'/YY%<]_9?CKPISI5_'XCTY/^72
M_;9<J/19>C'Z_E7H%%6IM:="7%/4\NUOXT6FCZ>F=#O%U83!)M.O"8&1,-EP
MVU@PR .V<Y[5F?#SXBZKK6H/I^G^$XYE>[:6[NAJ*(8(9)3@["@+B-"%^7KM
M[%JZ;XH^ [CQMIEFUA-%'?63L4$I(5U;&X9'0_*"/_KURW@KX+W5DMQ<ZYJ-
MQ:7#J$A73;DHZ#J2S8YY XY'%;<M%POLS%^TY]KH]GJM/I]G<_Z^T@D]WC!K
MCD^'E]:9^P^./$:>@N+@3 ?@12#PQX[MI,V_CU9D!X2YTR/I[D'/\JQ<(OJ:
MMM[K\C;U+PKIDMG.UO:!+@1L8]C$#=CCC..M<MH'A2R\013R:C&QCB8+'A5/
M/?J#[5C_ !"?XC:9X1NGNK_39K$E5FEL8Y(YU4G\@O0''KZ5P7PKU+Q5'XG:
M+05%UOA;SXKF1A"% X+'L0< ?E4_48S_ 'EUH<<X4_:KW3Z"_P"$8C_Z"NJ?
M^!'_ -:L'Q5HGV&QBN$NKRX42;6\^3>%R.HXXZ5)]N^)'_0%T'_P+D_PKR+X
MLZKXN.LV<&N*EG&(=T,5G*QB8Y.6R>K= ?08]>4L'&I[J:15:G#D=E^?^9[7
MI>@7:Z7;.FK7ENS(&\O.57/. .U7/[,UV,_N]=#CTDME_G7EGPS\2^-[?PKM
MMO#<VMV*S,L,\EZL)48&57<"64'//3J.W':3?$#5K*!Y;[P+KD:HNYC#MF &
M/;M0\+ROE7Y_\$N$8<JW7WG.W'A^;1;I=)^TS3,^-LCS.['<?[S'-=CHFB^(
MM"TB#3;>[LYXH=VV2YDDDD.6+<L1SU_+%>%GXM:_/XDBU6[6VFCCD#+;>4 J
M(#]T$<_B2>:]I'Q4\/;1YD.JQMW1K"3(_(5E'+W1DW;?M_PQ%-N3ES3=K]W_
M ,$V]GBC_GII?Y/_ (4;/%'_ #TTO\G_ ,*Y_P#X7%X)'#:G*K#JK6DN0?0_
M+4J_%WP*S #7 ">.;68?^R5K]7GY_P!?(UM#^=_><HWA6WTV<>&X[2".W<B+
MR4=V0B3D_,QW8.XYYKOK'1]:T_3[:PM;VT@MK6)888UC+;44849;DX '6O)=
M3^-$9\8+>VVBV\UE QC5W=A+(H/##L.^ 0?K7H8^,7@?RT;^UWW,,E/LLN5]
MC\N/RJ(X*I!MN^O]:F%*$$Y7EU[FU<Z1KDUK*DFN;PR,-BVRC=D=,CI7/^%-
M*GO3=.+JYM$3"$PG:6/IGV_K5'Q-\8M,MO#T\^A+<3WC86!YK5UB&3][) SQ
MG ]:XKP/\6O$S:V+*_ADUI;D-LAAB1)0X&<KM !'!R#_ /KKZBY>_P!ASA3]
MI%W?XGM \+V[?ZZ_U";UWS\?RJAK/A73X=)GEM4"3H PDEE('7G))Q5'_A)?
M'5W(5M/ Z6Z=I;S44_55&:\^^+">/9]"MYM;AT]-,68EH].,C;3CY3*6[=0"
M.,_A51PD)OE=M32<*?*_=/4_#^@:;)I$,L\5O<RODLZN' YZ9!QQ6LN@:2IR
M-/@_%,UX/\'[/QA(=0DT&Y@M;(A1(UY$SQ._^R!_$!U]L9[5ZA):_$^/'DZC
MX9FSU\V&9,?3&<TY8:$'RJVG]=ATXPY%[OX'5#1-+4Y&G6OXQ USGC./0]/T
MM%>;3=/N"X:,.\<)D X(&<9ZY_"JN?BK&<8\)2Y[_P"D<?RKQ[XE:'XRE\2_
M;]=LEFDG15C>P1W@4 8VKGD'J<'N2:J.%A4]UM"JJ/(UR_@?0>@Z5:1Z':AX
MK:=F3>9 %<-GG@]QS6C_ &?9?\^=O_WZ7_"O)_ FG_$S2?"=O;65MHT5LQ9X
MDU,RB9 QSC"G '?!YYKJ$MOB?(3YVH>&80.ABBF?/USBE[",=$UI_78TARJ*
M7+^!7U"+2!X\AM6U#3D#LA:V:= P('W-F<\XZ8[UULGAS2)<[K"(9_NY7^5?
M+.J>$O$Z>))["YTR\GU"28Y=(V82L3G<&Q@@YSG\Z]\M? WB.:QA34_'>K;_
M "P'6T5(MO'0,,DXZ9_&G+"4J>M[W,:48MR]T?XQCT#PAHO]I3V.H&)Y1"6L
MR7\LL#AGW,,+D8SZD#O7,:;JVFV^MV&GW4=_/+J4BPP+8@'&2,N_(.P Y)&>
M 3VK7UKX11:CHUS /$FN75XX!B;4+PRQA@<\J!T/XXZURGA?X(ZBVL++XID@
M?3X5*B&&=BTGH,C&U1UK/ZK0;4K[>6Y$Z%YQ:CH>M?\ "):03EX9)#ZM*W^-
M3)X8T:/&+%#_ +S,?YFN9_X4YX'_ .@5)_X%2_\ Q5'_  ISP/\ ] J3_P "
MI?\ XJCV5'^E_P $W]DE]E?U\B]XLO=!\&Z)_:=UH<ES!Y@B;[-;JYCW X9B
MQ 5<@#/JRCO7GWA7QYH2>(M/M'MWNSJ)6W7:H/DN[*%W!L#J>2.1COFNON/@
MQX+EMY(XK":"1E(65+F0E#Z@$D'\17-Z)\!8+/4Q<:EK4D\$?,:6T9A?=V;=
MDXQUX_.K5'#OWGNC.=*3G%I+0];_ +/LO^?.W_[]+_A1_9]E_P ^=O\ ]^E_
MPKC6^&4:/NM/%OBFV'9$U E1^8S^M/?P7XFC'^A>/]2C.>/M%K'-_/%+DAW_
M  .BW]W\B?Q]??\ "/>'/M-CX:?5&FE\B1;2/YX$*L3+\JG@;1Z=1R*X7P[X
MLWZY;6%CX2NM:M+N>**>_P#);R[0%MI)S&>@.3DCI^4_Q"\/^/8_!UPL_B(:
MQ:!U:>&*Q6&38._R]0#@D?X5POPIL?%<NORW?AD6Z;(BDTMX&\@@XPIV\ENA
M %5]4A)>TNM#GFH^UBW$^C6T'26&#I]O^" 5&WAK1GSFPCY]"1_(US'E?%7_
M )[^$ORN/\*/*^*O_/?PE^5Q_A4>PAY?U\C;EA_+^!T+>$M%/2T*_25_\:0>
M%--48C-Q'CIMF/'TKG_*^*O_ #W\)?E<?X4>5\5?^>_A+\KC_"E]7AY$\E/^
M3\#EYM2BO96N4TS7+-5P#;ZE;E+EL?W5R<YZ#'?BNYT32[/6](@U Q:Y8B;=
MFUOR8IDPQ7YEYQG&1ST(KYR\86'B*#Q??P:Q'*^H74VYO*#%)^?EV?WEZ >F
M,=J]MT2T^*MOH5A")O#JA($4+>&8S 8'#D#&[UIO PA[UT[G/2A'FE>)UY\*
M:81AOM!'<&9N:!X0T4'_ (]F/_;5O\:Y_P KXJ_\]_"7Y7'^%'E?%7_GOX2_
M*X_PI?5X>1T<E/\ D_ Z,>%-$!!%D./65S_6O,?&?B.ST/Q3)HL_AZ;3[-,-
M#JK,YCN"45BH&W'!8C(8\K[\=7Y7Q5_Y[^$ORN/\*\C^)^A>,WU^*^UVVBNC
M)$J1R:<CO"@&?EY&0>_/7/%5'"4Y^ZVEZ&=6$.1I1_ ]1^'E[#XIMKP7OA.:
MP@MA']GN[D-B]5MWSKE5QC:#P3]X?CV_]A:4!_R#[;_OV*\J^'VC_$K2O"D,
M5A_8]O:R.TL<.J"42H#[*. <9QUY/K74^5\5?^>_A+\KC_"AX>$79-?U\C2*
MARKW?P.N71=+4<:=:_C"I_I7 >/-7?1]4@TJU\'3RV4T*S2ZM:0,5@.Y@5(6
M,Y^Z"?F'#=/71\KXJ_\ /?PE^5Q_A7G?Q:B\>#2+)O$#Z>^G"0Y_LSS-@?C'
MF;A]<=NOM36&C/W;K7^NPJG+R/W?P.U\ :U+JFJW&DR^%KJ.PCB:>/5KF%E2
M9MRC8H9!ZD_>_A/%>A?V?9?\^=O_ -^E_P *\"^$</CC['?OX=:P2Q9EW'4O
M,\MGY^YM'7U_"O2L_%6/C;X2E]_](_\ K4WAXT_<36@Z7*H)<OX'9_V?9?\
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MQUST'/:M(4'--WV(G546E8^O**XG[=\2/^@+H/\ X%R?X4?;OB1_T!=!_P#
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M-CH<$'!]:YS0-:UGQ):QZQ9_8(M,DE98K>6-S+)&K%=_F!L*3@G;L/U],_\
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M@HHHI#"BBB@ HHHH RX-+LY+N_>>P@;=."K/"#D>6F2,CUW?CFK']D:9_P!
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M[\+_ (4?V1IG_0.M/^_"_P"%7** *?\ 9&F?] ZT_P"_"_X4?V1IG_0.M/\
MOPO^%7** *?]D:9_T#K3_OPO^%']D:9_T#K3_OPO^%7** *?]D:9_P! ZT_[
M\+_A1_9&F?\ 0.M/^_"_X5<HH I_V1IG_0.M/^_"_P"%5;K2+'[19>7IUOM\
MX^9M@7&WRWZ\=,X_'%:U% %/^R-,_P"@=:?]^%_PH_LC3/\ H'6G_?A?\*N4
M4 4_[(TS_H'6G_?A?\*/[(TS_H'6G_?A?\*N44 4_P"R-,_Z!UI_WX7_  H_
MLC3/^@=:?]^%_P *N44 4_[(TS_H'6G_ 'X7_"C^R-,_Z!UI_P!^%_PJY10!
M3_LC3/\ H'6G_?A?\*/[(TS_ *!UI_WX7_"KE% %/^R-,_Z!UI_WX7_"C^R-
M,_Z!UI_WX7_"KE% %/\ LC3/^@=:?]^%_P *JV&D6/V=_-TZWW>=+C? N=OF
M-M[=,8Q[8K6HH I_V1IG_0.M/^_"_P"%']D:9_T#K3_OPO\ A5RB@"G_ &1I
MG_0.M/\ OPO^%']D:9_T#K3_ +\+_A5RB@"G_9&F?] ZT_[\+_A1_9&F?] Z
MT_[\+_A5RB@"G_9&F?\ 0.M/^_"_X4?V1IG_ $#K3_OPO^%7** *?]D:9_T#
MK3_OPO\ A1_9&F?] ZT_[\+_ (5<HH I_P!D:9_T#K3_ +\+_A1_9&F?] ZT
M_P"_"_X5<HH R7TBQ_M2#&G6_E>3)NQ NW=N3&>.N-V/QJU_9&F?] ZT_P"_
M"_X5<HH I_V1IG_0.M/^_"_X4?V1IG_0.M/^_"_X5<HH I_V1IG_ $#K3_OP
MO^%']D:9_P! ZT_[\+_A5RB@"G_9&F?] ZT_[\+_ (4?V1IG_0.M/^_"_P"%
M7** *?\ 9&F?] ZT_P"_"_X4?V1IG_0.M/\ OPO^%7** *?]D:9_T#K3_OPO
M^%']D:9_T#K3_OPO^%7** *?]D:9_P! ZT_[\+_A1_9&F?\ 0.M/^_"_X5<H
MH R;#2+'[._FZ=;[O.EQO@7.WS&V]NF,8]L5:_LC3/\ H'6G_?A?\*N44 4_
M[(TS_H'6G_?A?\*/[(TS_H'6G_?A?\*N44 4_P"R-,_Z!UI_WX7_  H_LC3/
M^@=:?]^%_P *N44 4_[(TS_H'6G_ 'X7_"C^R-,_Z!UI_P!^%_PJY10!3_LC
M3/\ H'6G_?A?\*/[(TS_ *!UI_WX7_"KE% %/^R-,_Z!UI_WX7_"C^R-,_Z!
MUI_WX7_"KE% %/\ LC3/^@=:?]^%_P *JOI%C_:D&-.M_*\F3=B!=N[<F,\=
M<;L?C6M10!3_ +(TS_H'6G_?A?\ "C^R-,_Z!UI_WX7_  JY10!3_LC3/^@=
M:?\ ?A?\*/[(TS_H'6G_ 'X7_"KE% %/^R-,_P"@=:?]^%_PH_LC3/\ H'6G
M_?A?\*N44 4_[(TS_H'6G_?A?\*/[(TS_H'6G_?A?\*N44 4_P"R-,_Z!UI_
MWX7_  H_LC3/^@=:?]^%_P *N44 4_[(TS_H'6G_ 'X7_"C^R-,_Z!UI_P!^
M%_PJY10!3_LC3/\ H'6G_?A?\*JZ=I%C_9=IYVG6_F^2F_? N[=M&<Y'7-:U
M% %/^R-,_P"@=:?]^%_PH_LC3/\ H'6G_?A?\*N44 4_[(TS_H'6G_?A?\*/
M[(TS_H'6G_?A?\*N44 4_P"R-,_Z!UI_WX7_  H_LC3/^@=:?]^%_P *N44
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M0JYY("JHSWY.!G%7??Y_G_D3;IZ?EK^)L4445(PHHHH **** "BBB@ HHHH
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M57LCH<KN/M/FN)UA=RQB$>W:3@E0V_\ X#7;JH1%11A5& /:GI;^NW^8GO\
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M$4KF6Y\K!0,A4!.0I/S-G';/%JUU\ONN[DO^ONT_'J=C1114C"BBB@ HHHH
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M10 445'#<07 8P31RA&*,48-M8=0<=Z )**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "N1OM(LK7Q+H-JD"M'.UVTV\9,A9!DGUKK
MJSKS3#=:SIE^)0HLO-RFW._>N.O;%:TY\KW[_D1.-T6K.TBL;.*UAW>5$NU
MQR0.PJ>BBLV[ZLLYC4-*L[75-*B2%66XNY7FWC/F%HVSGVYK>T^QBTVR2T@+
M>5&6V!CD@$DXSZ#.!["HKW3S=WUA<"0*+61G*XSNRI7'MUJ]6DYMQ2N1&*3;
M"BL_5M/N-0BA2WOY;,QRAV:+JX'\/44#3[@:XU_]OE\@Q>6+7^ '^]UZ_A^-
M0DK7O_7_  1MN^QH45BQ:+>QZ-=63:S<O/,Y9+HYW1CC@<Y[>O>I7TJZ>73'
M&JW"K:#$JC_EXX'WN?;WZU7+'O\ U_6@7?;^OZU-6BLN/2[I+G493J<[+=+B
M)#G%OP1E>?Y8J!M$O6TFSLQK5R)H)0[W SNE&3\IYZ<]R>E)1CW_ *_X -OM
M_7_!-NBL\:?<#7&O_M\OD&+RQ:_P _WNO7\/QJK%HM['HUU9-K-R\\SEDNCG
M=&..!SGMZ]Z.5=_Z_P" %WV-JBLI]*NGETQQJMPJV@Q*H_Y>.!][GV]^M+'I
M=TESJ,IU.=ENEQ$ASBWX(RO/\L4<L>_]?UJ";[&I16(VB7K:39V8UJY$T$H=
M[@9W2C)^4\].>Y/2K8T^X&N-?_;Y?(,7EBU_@!_O=>OX?C0XQ[]_Z^8KOL:%
M%8:Z'?#1;BQ.MW)GEEWK='.Z,9'RCYLXX]>]69],N9;G3I4U.>-+7_6H.EQP
M/O<^WOUI\L>_]?UH.[[?U_6IIT5EQZ7=)<ZC*=3G9;I<1(<XM^",KS_+%0-H
MEZVDV=F-:N1-!*'>X&=THR?E//3GN3TI*,>_]?\  !M]OZ_X)M,-RE<XR,<5
MR)T33X_$UOI8MU-J=-<,IZL=XY)]?>NOK/?32WB"/4_-&$MS!Y>WKELYS54Y
M\M]13C>Q<@B$%O'"I)6-0H+=2 ,<U)11619S&H:59VNJ:5$D*LMQ=RO-O&?,
M+1MG/MS6]I]C%IMDEI 6\J,ML#') ))QGT&<#V%17NGF[OK"X$@46LC.5QG=
ME2N/;K5ZM9S;BE<B,4FV%<EXDEW>)-.M9M5N-/M'A=G>*X\KD=,D\5UM8FHZ
M%_:/B"RO9H[>6TAB='BE&XDGI@$8HI-*5WY_D*HFXV7]:HY9]4U!_"]Z%U"X
MDCBOEA@NU8J[IG^\.OU]ZUKN*^\,WVGRQ:G=WEI<3K!+%=OYA!;H0>U:GB#1
MI-1T46-@((621&0-E4 !SC@5571M6U*_M;C6[BT$5J_F1P6@;#-V)+<UT*I%
MJ^B6MU\O3_(Q<)+3RT^\Q9+C4K[2M3U^/5+J%[:=E@@C?$6Q2/O+W/-2>(M1
M06\=RVMWMM>30)+;6L!*)R!]XXP><]2*MR^&-56.\TZVO+5=+NYC*Y96\U,G
M)4=L<5=U/2]:FMY+"RFL#I\D8CQ<(V^-< <8X/KS3YX76J_X%EY=_P#A]1\L
MM;_UKIU[$&ISA-#TZ?5=:N;(-&!(;/K+(0#]Y0>.#TX-)X=74-7\,*L^J3)F
M8XGC=6D,?H6YP<]^M6TTO5M+TNSM-)N;1_)0I(MVC88DYR"O([\5G+X7U6U\
M/W-I9WL"7=Y-YD[<J@4CE5P#C\NE3>#BTFM]/O\ 3]6"4KIM=/T_K_,JZ9J6
MHVMIXA:&[FO;:S!%O-.=YW#.>>^/RJ.PU)[34M(>WUN74&O5(N8))0X1B,\#
M^'GM[5NZ1I^MV-D]G(FDPPK"5A^SK(?G]6W=1USWJ'3O#MT-3AO=0CTV'[.2
MT<-A"55F(QN8GDFJ<X7E>WX:Z6[=]=+"Y965OZU7F<Y_;5PNG1:S_;DIU$W.
M)+ RC8$W$8\OZ=_ZUO\ BA[ZVO--GCU"9(9;R.,01_(,'KN(Y;/Y>U#^&K^_
MO0=072H[<2B1WM8")9L'(#$]/?%2^(M)UO5;J 6KZ>MM;RK-%YI<.6'K@$8^
ME/G@YQVZ_=VV_P""'++EE_6IT<L@BB>0]%4L?PKS_P Z>'P&=02YEAN+V\\V
M26-RK<OCK]!7=Q1SRV CO/*\]DVR>5G9D]<9YQ7'6&F3ZKX._L=#$EQ9W920
M2D@<-GL#V-94;*]^Z^Z[+JW:5NS^^Q-I5Z]IXDDL[/5+G5; 6IFD+R"9E8=@
MP_#CWJ[I_B[[7K$6GS62PF;<(V2Z24@@9PRK]W\:UYM)MO[,N;*TBBM!/&R$
MPQA<$C&<"N<TOPIJ%IJ.G7$PTU$LR0?LZ,KR KC<Q(Y-4I4IW<NW^>N@FIQ^
M'^MC'F;9X8NVVEMNMDX4<GGM756WB8B_GM-2L)+!TA-PA:0/N0=3QT/MS5%_
M"M\^CSV8G@22343=!\DA5_+K[=/>IT\.W]_J%Q=ZS<6[%K9K:-;92 %.<L<]
M^>E5*5.2U?\ 5H_\$24T]/ZU?Z!%XME)MI[G2)K?3[IPD5R95.2>A*CH/QJQ
M_P )'/-J4UO9:5-=6UO*(I[A9 -K=\+U;%48O#NLS0V6GW]W9MIUHZLIB5O,
MD"_=#9X'X59@T;6-.U&Z_L^[M%L;J?SG\U"9(R>NWL?QJ6J72WXV_P"'L-.I
M;7]/P_ ABUZ+3FUJ>7[7+Y5T(DC>;?N8] @P-H]N:K>);Z\O/"UP+W39+&1)
MHL*T@<,"W8C^56+CPK<W":I_I$4<D]VMS;LN3M(SC=Q[]LU+J&D:YJVBS6U[
M<6/GN\918@P10IR22022?Z4XNFI1E?JOT_X-Q24[->OZ_P# *>M7.^?Q!;;[
MD[+ -M:;,8R!T3'!]\U-H_B&6WBTBSN]-E@M[B)(X+AI =[!1U4= >V:L7WA
MZ[NKW5YDDA"WEHL$89CD,/7CI^=0V_A[59+O3$U"[M7L].PT7E*0[L ,;L\<
M8[4)TW"S_K1_K8&IJ5U_6J_X)/HA^R>)]:T]>(BR7* =BP^;]<5'JD]YJ?B>
M/1(+N6SMT@\^:2$XD;G  /;M3]#!O/$VM:BO^J#+;(?4J/F_7%3:KHUZ^KQ:
MOI4\,=VD?E.DX)21<YYQR/\ ]51=*:OV_&Q5FXNW?]=?U*-O+>:+XE72GO[B
M[M;FW:2-KAMSHPS_ !>G%9NEV>I7'A4:S#KFHB\57?9)-OB.TGC:?85>2RUF
M'Q)%J&J6R77FQ>0CV>=EN2<9*GG'/)[9--L_#_B.'1AHS7>G0V9#*TL8=I=I
M))'.!WK6Z2W5]/UOT].Q%M=G;_@+S.ATNZ;5] M[B3,;7$/S&,X(/0D'M7(V
M^H:G/=Q^%FNIA<Q7)\V\67YFA'S=<YW'_/>NTAM#8:4MI8A=T,6R+S#QD#C)
M'O7.?\(C<Q:?;303Q?VS%<&X>X8D*[$_,I.,XQ[?SK.G*"E*^W3\;/T*E&?*
MEU_K\P\70W%E8RZBFLWL4JLJV\$;[4)XX('+'J>:L:X=3_X1);IKV6UGBM@\
MRQ*%9GP/XNPSGI4.HZ+KUUKZZBC:9+'" +>*Y:0B,X&3@#KGO5S6+'7M2T9;
M-&TU9)HRMR6+@ ]MG_UZ$U:*NM_Z6W],=O>;L]OZZFGI#O+HMC)(S.[6Z%F8
MY).T<DUS'BFQEL8Q+:ZQJWVR\G"00"Z(0$GG  Z#Z^E=%H=OJ%IID=MJ)MB\
M0"1FWW8*  #.>_6J\ND7%UXIBU*Y>(VEM$5MXP26#GJQ&,?KV%3&2C5;OIK\
M_(&FZ:5M3),-[JFMSZ3_ &K=P1:?;1@O!)M>60C[S'O]*33O%=S%HNF-/:R7
MES<2O 3&P#$KT.,8YX]/6K]_H^J1ZS-J6CW%JCW,0CF2Y#8&.C+CO]:BB\+R
MVL>B1PS1N+&9I9F?(+ENN!C^=:<U-I<W];W_ $)<9)OE_K:WZD?_  E]X4NT
M&@S_ &BSR;A//7;&N,YW8Y/L!5BX\5,1;+IVG/>2S6WVIE,JQA$^IZG/:I1H
MMR+G7I-\6-00+%R?E(0K\W'J>V:XS6[3^S[NQL[\6A%O9+&'N1,8F;))V&,9
MS]:<(4INR7Y]O\PE*<5=_P!:G91^(FE\*3:S-;"V^1C&GF!]W9><#J>U8,MJ
MFBP>&/M3A")WFG=NQ(R<_3I^%2"YEUJWT+2WLA:J\AEEB12%\J/I@'D GUK?
MUS16U>[TYCY1@MY&:9)"?F4C&!Q2TIRMM=O[E=(-9Q[V7XO_ (! ?$\BZ4M\
M=-D GG$-G&9 &FST8Y'R@_C4VB:Y=ZI>W=M<Z9]D:UP'/V@2?,>W ';O7,:[
MI]YI/A^&PNI(Y[)+P&&1MY58\'B3:,XY_AK4\#W6^.YMH;*V2V0AEN+99 DA
M/4?O/F)%$J</9N45_6@*<N=1?];G74445Q'2%%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !110>E)[ >4V/Q3\2ZO+>'2?!37L%K,T3O'=X.1[;>N
M*Z?P;\0;#Q=-<61M9]/U2V&9K.X^\!T)!XS@\'(!]JYGX)?\>GB/_L(G^55;
MY5B_:0L/L0 :2TS=;>Y\M^OX!/TJH[Q3ZK]+CE]IKH_UL>O$@8R0,]*6O#/$
MMCX$N[S5S-J.MZOJZ-(WG0!Y5MFY(4$#:%!X[]*C*:IXA^ UOJ7VN=[[2KAI
M4DWG<8U;!!/? .?^ U*>EWY?B%M;'N](2!U(%>,^*?$$OC:R\$Z/93,DFJNM
MQ=&)B"H7Y6''OO\ ^^:J^.X;>U^(4DOC.SU*Y\,F%$L6MV;RX6P 2<$<YW9[
M\CK5-6=GW:^[^M!+57\K_>>XT5C>%/[,'ABQ&CWDEYI^P^3-(Y9BN3P2>>.F
M#R,5LT-6=A)W04444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MKA@,#!YR><]:ZG1M!TOP]:-:Z391VL#.794R<MTR2>>PK1IO5)>0D[-M'/\
M@KPR/"/A:UTCS_/>,L\D@& 68Y.!Z5T%%%-N[NQ)6"BBBD,**** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#4-5O],6*5+FQ$?G;L;<NN1M.<G\0*5U>QHJ4W#GMI_PW^:-2BBBF9A1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
BHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>form10-k_002.jpg
<TEXT>
begin 644 form10-k_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &Y!0X# 2(  A$! Q$!_\0
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MR_\ A'-&_P"@=!_WS1_PCFC?] Z#_OFM2BCVD^[^\/9P[(R_^$<T;_H'0?\
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M'_?-'_".:-_T#H/^^:U**/:3[O[P]G#LC+_X1S1O^@=!_P!\T?\ ".:-_P!
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MR_\ A'-&_P"@=!_WS1_PCFC?] Z#_OFM2BCVD^[^\/9P[(R_^$<T;_H'0?\
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M'_?-'_".:-_T#H/^^:U**/:3[O[P]G#LC+_X1S1O^@=!_P!\T?\ ".:-_P!
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MU*R_#_\ R"S_ -=YO_1C5J5A4^-F]/X$%%%%9EA1110 4444 %%%% !1110
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M8[HJ6S&Z7_R"++_K@G_H(JW532_^019?]<$_]!%6Z)?$Q1^%!1114E!1110
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MX?\ ^06?^N\W_HQJU*R_#_\ R"S_ -=YO_1C5J5E4^-FM/X$%%%%9EA1110
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M4 %%%% !1110 4444 %%%% !1110 5E^(/\ D%?]MX?_ $8M:E9?B#_D%?\
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MKZ/X66STOPY>VMH=2,C+-//<71$-D>"V$! R.?Q%<M\4U(^(6H$@@,L1'O\
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M+"(JZA@?M"=#^-/T;P7:6&O7=MXQNH[**S@$[0K.N^;.<*I[]#TYZ5KPZMX
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M_(-M/^NQ_E785Q_Q!_Y!MI_UV/\ *NG"_P :)SXG^%(W/#__ ""S_P!=YO\
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M\0?\@K_MO#_Z,6M*?QHBI\#-2JVH_P#(,N_^N+_^@FK-5M1_Y!EW_P!<7_\
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M_P#"AM2_Z#=I_P!^FI?^%#ZE_P!!NT_[]-7N=%'UVMW_  #VDCPS_A0^I?\
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M_P#"DM0_Z#%K_P!^FKVBBCZ_7[_@'L8'B_\ PI/4/^@Q:_\ ?IJ7_A2FH?\
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M^@O:_P#?MJ/^%+:A_P!!>V_[]M7LM%'U^OW_  #ZM3['C?\ PI?4/^@O;?\
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MU?SIU% #<O\ W5_.C+_W5_.G44 -R_\ =7\Z,O\ W5_.G44 -R_]U?SHR_\
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MX?\ T8M:E9?B#_D%?]MX?_1BUI3^-$5/@9J56U'_ )!EW_UQ?_T$U9JMJ/\
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M^B8=3L+A2T%Y!* <$HX;'Y4DVJZ?;D">]MXBW3?(%S^=<)\'_P#D"ZC_ -?
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M'+<HLTGG2#?(-QQGU-<;\499+/Q5%':R-!&;1#MB.T9W-S@44\(YUW1OM?\
M =3&*%!5[;VT]3VFBO$_AC-+=^+3%<R/-']F<[)&+#.1V-=S\1XH[7P9<RV\
M:PR"2,!XQM(^8=Q15PCIUU1OO;\14L8JE!UK;7_ [.BOF#[?>_\ /W/_ -_#
M_C7TK%96AB0FUA^Z/^68IXO!O#6N[W#"8U8F]E:Q:HKYW\4W=S#XKU6.*XE2
M-;J0*JN0 -QX KN_A-_IMEJ9NOWY61 IE^;'!Z9JZV E3H^U<NWXF=',(U:W
ML5'O^!Z;17EGQ;)LAH_V0^1O\[=Y7R[L;,9Q]37(>#;JXG\8:7%-/+)&TP#(
M[D@C!Z@T4\!*I1]MS=_P%5S"-.O['E[?B?05%87B>VMX?"NJR101)(MI(594
M (.T\@U\^_;[W_G[G_[^'_&IPN"EB(N2=K%XO'1PTE%QO<^GZ*Y_PG;03>$M
M*EEACDD:V0LSH"2<=S7D'C>YN+?QEJ<4,\L<:R *B.0!\HZ 5-#".M4E33M;
M_.Q6(QBHTHU&KW_RN>_T5XY\*9'O/$-XET[3H+0D+*=P!WKSS73?%%$L_"D<
MELJP2&Z0;HAM.-K<9%$\(X5U0OO;7U'#&*>'=>VU]/0[VBOF>SOKQKV &ZG(
M,B@@R'UKZ4C@AA),44:$]=J@9HQ>$>&:3=[BPF,6)3:5K$E%%%<1W!7'_$'_
M )!MI_UV/\J["N/^(/\ R#;3_KL?Y5TX7^-$Y\3_  I&YX?_ .06?^N\W_HQ
MJU*R_#__ ""S_P!=YO\ T8U:E95/C9K3^!'CGQ9\->#=3U^WO=8\0O8ZL(%2
M*U6 W'F*"Q'[I1N.22,Y%<]X!TB_B\5V#0^ ;6:QCF!&JO;26KQC/WPKN02/
M3&:Z/XN:1X/GUNRN=5M-8U'7+B'RK:QTQ_G9%).XC!P,D\_I6)X$TGPC%XRL
M;6YTSQ-H6L(WG6D.HS_NY]O.!P,].E9EGOE%%% !1110 4444 %%%% %.U_Y
M"%[]4_E5RJ=K_P A"]^J?RJY0!'+#%.FR6-77.<,,C-1#3K($$6L((_V!5FB
MFFUL*R8V1!+&T;?=8$'Z&LS_ (1VP_NR?]]UJT4XSE'9B<8RW1%;P);0)#'G
M8O R:Y+7O^0S/_P'_P!!%=E7&Z]_R&9_^ _^@BNC#.\V88C2"+?AC_CZG_W!
M_.N7^,?_ ![:1_OR_P EKJ/#'_'U/_N#^=<O\8_^/;2/]^7^2UUX?_?(_P!=
M#CQ7^Y2_KJC@_!W_ ".6D?\ 7RG\Z]W\3?\ (J:Q_P!>,W_H!KPCP=_R.6D?
M]?*?SKW?Q-_R*FL?]>,W_H!K?,O]XI_+\T<V5_[O4^?Y,^;*^B/!'_(E:3_U
MP'\S7SO7T1X(_P"1*TG_ *X#^9K?-_X4?7]##)_XLO3]3P_Q9_R-VL?]?DO_
M *$:]#^#O_(/U3_KJG\C7GGBS_D;M8_Z_)?_ $(UZ'\'?^0?JG_75/Y&M,;_
M +E\E^AG@O\ ??G+]2O\9>NB_P#;?_VG7&>!O^1VTK_KM_0UV?QEZZ+_ -M_
M_:=<9X&_Y';2O^NW]#1A?]Q^3_4,5_O_ ,U^A[=XM_Y%#5_^O23_ -!-?.-?
M1WBW_D4-7_Z])/\ T$U\XUEE'\.7K^AKG/\ $CZ?J?3>D_\ (&L?^O>/_P!!
M%?._B3_D:=7_ .OV;_T,U]$:3_R!K'_KWC_]!%?._B3_ )&G5_\ K]F_]#-8
MY5_%G_75FV;?PJ?]=$>F_!__ ) NH_\ 7P/_ $$5F_&/_C[TC_<E_FM:7P?_
M .0+J/\ U\#_ -!%9OQC_P"/O2/]R7^:T0_Y&+^?Y!/_ )%J^7YG+?#_ /Y'
MK2_]]O\ T!J]6^)7_(AW_P#O1?\ HQ:\I^'_ /R/6E_[[?\ H#5ZM\2O^1#O
M_P#>B_\ 1BU>-_WRG\OS(P7^Y5/G^1X)7U!9?\>%M_UR7^0KY?KZ@LO^/"V_
MZY+_ "%&;[0^89-O/Y?J?-VM_P#(?U'_ *^I?_0C7JWP@_Y%N]_Z_#_Z M>4
MZW_R']1_Z^I?_0C7JWP@_P"1;O?^OP_^@+71F'^Z?<<^7?[Y]YROQ:_Y&^+_
M *\T_P#0GIGPH_Y'$_\ 7J_\UI_Q:_Y&^+_KS3_T)Z9\*/\ D<3_ ->K_P U
MH7_(O_[=!_\ (Q_[>.^^)_\ R(]S_P!=8_\ T(5X37NWQ/\ ^1'N?^NL?_H0
MKPFEE7\!^K_0,W_CKT7ZGU __'@W_7(_RKY?KZ@?_CP;_KD?Y5\OUAE'V_E^
MIT9S]CY_H>\?#+_D1K/_ *Z2?^AFO/OBK_R.9_Z]H_ZUZ#\,O^1&L_\ KI)_
MZ&:\^^*O_(YG_KVC_K487_?I_,O%_P"X0^1-\(_^1MN/^O)__0TKIOB__P B
M_8_]?7_LC5S/PC_Y&VX_Z\G_ /0TKIOB_P#\B_8_]?7_ +(U76_Y&,?E^3(H
M_P#(ME\_S1Y;H'_(QZ7_ -?<7_H8KZ-U'_D&7?\ UQ?_ -!-?.6@?\C'I?\
MU]Q?^ABOHW4?^09=_P#7%_\ T$U&:_Q(?UU1>4?PJG]=&?,->^_#?_D0M-_[
M:_\ HUZ\"KWWX;_\B%IO_;7_ -&O73FW\%>OZ,YLH_COT_5'FGQ0_P"1WN/^
MN4?_ *#6]\&_]?K'^[#_ #>L'XH?\CO<?]<H_P#T&M[X-_Z_6/\ =A_F]*K_
M ,B]>B'1_P"1B_5_D7OC#_R"=-_Z[M_Z#7FWAC_D;-'_ .OZ'_T,5Z3\8?\
MD$Z;_P!=V_\ 0:\V\,?\C9H__7]#_P"ABKP/^Y_?^I&._P!]_P# ?T/H36O^
M0%J'_7M)_P"@FOF:OIG6O^0%J'_7M)_Z":^9JPRCX9^J-\Y^*'HSZ!^'W_(B
MZ7_N/_Z&U>.^-O\ D=-6_P"NYKV+X??\B+I?^X__ *&U>.^-O^1TU;_KN:6!
M_P!ZJ?/\QX__ '2E\OR.V^#?W-9^L/\ [/4OQC_X\M)_ZZ2?R6HO@W]S6?K#
M_P"SU+\8_P#CRTG_ *Z2?R6H?_(R_KL6O^19_7<\_P#"/_(X:1_U]Q_SKVSQ
MU_R).J_]<?ZBO$_"/_(X:1_U]Q_SKVSQU_R).J_]<?ZBKS#_ 'FG\OS(R[_=
M:OS_ "/GFOI7P[_R+&D_]></_H KYJKZ5\._\BQI/_7G#_Z *K-_@AZO\B<F
M^.?HOS/!/%__ ".&K_\ 7W)_.O0/@Y_QY:M_UTC_ )-7G_B__D<-7_Z^Y/YU
MZ!\'/^/+5O\ KI'_ ":ML9_N7R7Z&."_W[YR_4ZCQ)_Q]P_[G]:K:'_R%H?H
MW\C5GQ)_Q]P_[G]:K:'_ ,A:'Z-_(U\%/_>?F?H,/]V^3.KDZ+_O"GTR3HO^
M\*?7K'CA1110 5E^(/\ D%?]MX?_ $8M:E9?B#_D%?\ ;>'_ -&+6E/XT14^
M!FI5;4?^09=_]<7_ /035FJVH_\ (,N_^N+_ /H)J8[HJ6S&Z7_R"++_ *X)
M_P"@BK=5-+_Y!%E_UP3_ -!%6Z)?$Q1^%'SEXKM/ )\1ZBV@7&HRZX9G-Q&M
MM'-")=QW B< =<]#^-=S\)8=?CN;PZOI^A6T7ECRWL1")F.?XQ$2,8_6N6\0
MZ/X?U7Q7JEMX:^'\FN7%O,3?W;7;Q1B5B25'/)S75_"B'PW%J&IP6?AR?0=?
MM46.\M9I6?*$Y!4D\CBI*/4J*** "BBB@ HHHH *H:9_R^?]?3_TJ_5#3/\
ME\_Z^G_I0!?HHHH **** "BBB@ HHHH *XW7_P#D,3?1?Y"NRJM-I]I<2F26
M!'<]2:UI34)79E5@YJR,#PQ_Q^3?]<_ZU>\3?\@V+_KL/_06K3@LK:U8M!"J
M$C!(J#5; ZC;+"L@0JX;)&>Q']:OVB=52Z$^S:IN)Q->AI]Q?I7.?\(O)_S]
M+_WQ_P#7KHP,*!Z"JQ$XRMRLFA"4;W. N/\ CYE_WS_.NG\,_P#(-D_Z['^0
MKFKA'^TR_*WWSV]ZZ7PT"-.DR"/WIZ_05M7_ (?W&5'^(4?$_P#Q^0?]<_ZU
M5T#_ )#$/T;^1JUXG_X_(/\ KG_6JN@?\AB'Z-_(T1_@_(4OXWS.BUO_ ) ]
MQ]!_,5Q5=KK?_('N/H/YBN*I8;X6/$?$CO[7_CSA_P"N:_RKCM9_Y"]Q_O#^
M0KL;7_CSA_ZYK_*N.UG_ )"]Q_O#^0K/#_&S2O\  C3\+??NOHO]:YGXP_\
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MT@-YW&?H:,+_ +C\G^H8K_?_ )K]#V_Q;_R*&K_]>DG_ *":^<:^B/%8N/\
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M%.>H]ZO,/]YI_+\R,N_W6K\_R/G^OI7P[_R+&D_]></_ * *^:J^CO#PN?\
MA&M*P\6/L<.,J?[@]ZK-_@AZO\B<F^.?HOS/"_%__(X:O_U]R?SKT#X.?\>6
MK?\ 72/^35Y]XMW?\)=JVX@M]JDSCZUWOP@$IL]5\MD'[R/.X9[-6V,_W+Y+
M]#'!?[]\Y?J=9XD_X^X?]S^M5M#_ .0M#]&_D:G\0"0747F,I.SC:,=ZK:-O
M.J1;" V&P2,CH:^"G_O/S/T&'^[?)G6R=%_WA3Z@Q.&7S&C*Y'W5(_K4]>L>
M.%%%% !67X@_Y!7_ &WA_P#1BUJ5E^(/^05_VWA_]&+6E/XT14^!FI5;4?\
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MC&Q^W^VU=&;?P5Z_H<V3_P :7I^IYY\6O^1NA_Z\T_\ 0GJ/X4_\CE_V[/\
MS%/^+.?^$MASC/V-.G^\]1_"K/\ PF)QC/V9^OU%6O\ D7_]NDO_ )&/_;QZ
M!\3O^1'NO^ND?_H0KPBO=?B;O_X0BZR1CS(^@_VA7A5+*OX#]7^@9O\ QUZ+
M]3ZDA_U$?^Z/Y5\S:I_R%KW_ *[O_P"A&OI:$/Y,?*_=';VKYIU3_D+7G_7=
M_P#T(URY1\4_D=><?##Y_H>O?"+_ )%.Y_Z_G_\ 0$KG/C!_R'=/_P"O8_\
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M_D9;W_KS/_H:UU7Q9_Y%"+_K[3_T%JY3X19_X22]P1_QZ'K_ +ZUU7Q8W?\
M"(Q9(Q]K3H/]EJ*__(PC\OU"A_R+I?/\T>-V7_'_ &__ %U7^8KZ@KY?LO\
MC^M_^NJ_SKZ?7=_$1^%&;[P^89-M/Y"T445X9[P5Q_Q!_P"0;:?]=C_*NPKC
M_B#_ ,@VT_Z['^5=.%_C1.?$_P *1N>'_P#D%G_KO-_Z,:M2LOP__P @L_\
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MHO\ T8M>3^ 6V^-M-;:S89SM'4_(W2O1/'6L27_@S4(7TC4K0#RV\RY1 O\
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M2!^M*JT\!;R0Z4&LPYNEW^1K_&'_ )!.F_\ 7=O_ $&O-O#'_(V:/_U_0_\
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MJA%J3RZ8]X=.O8V7/^C.B^:V/0;L<_6DTW4Y-1,@?3+ZSV8P;I%7=GTVL:+
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MYO\ 49\9>FB_]M__ &G7%>"/^1UTG_KN/Y&NG^*VH/>R:8C:?>6HB:8!KA5
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MK0!3M?\ D(7OU3^57*H02(FHWF]U7)3J<=JM^?#_ ,]8_P#OH4 245'Y\/\
MSUC_ .^A1Y\/_/6/_OH4 245'Y\/_/6/_OH4>?#_ ,]8_P#OH4 245'Y\/\
MSUC_ .^A1Y\/_/6/_OH4 25YA\8_^/;2/]^7^2UZ7Y\/_/6/_OH5RGC?PQ_P
MED5DD6H06_V=G)WC=G=CW]JZ\'4C3KQE)V7_  #CQM.52A*$%=O_ #/(_!W_
M ".6D?\ 7RG\Z]W\3?\ (J:Q_P!>,W_H!K@]$^&LFDZW9Z@^LVLBV\JR% N"
M<=NM=QXEGB/A75P)4)-E-QN']PUV8VM3JUX.#OM^:./ T*E&A-5%;?\ )GSA
M7T1X(_Y$K2?^N _F:^=Z^A?!,T2^#-*!D0$0#@L/4UV9O_"CZ_H<63_Q9>GZ
MGB7BS_D;M8_Z_)?_ $(UZ'\'?^0?JG_75/Y&O._%1!\6ZN000;R7D?[QKT+X
M/R(FGZIO=5S*G4X[&M,;_N7R7Z&>"_WWYR_4A^,O71?^V_\ [3KC/ W_ ".V
ME?\ 7;^AKL?C%(CG1=CJV//S@Y_YYUQW@@A?&FE%B !-U/T-&%_W'Y/]0Q7^
M_P#S7Z'MWBW_ )%#5_\ KTD_]!-?.-?1?BR:(^$=7 E0DVDG 8?W37SI664?
MPY>OZ&N<_P 2/I^I]-Z3_P @:Q_Z]X__ $$5\[^)/^1IU?\ Z_9O_0S7T)I,
M\(T:Q!E3_CWC_B']T5\]^(R#XHU8@Y!O9N?^!FL<J_BS_KJS;-OX5/\ KHCT
MWX/_ /(%U'_KX'_H(K-^,?\ Q]Z1_N2_S6M#X0R(FBZ@'=5/V@=3C^$5F_&&
M1'NM)V.K827H<]UHA_R,7\_R"?\ R+5\OS.8^'__ "/6E_[[?^@-7JWQ*_Y$
M._\ ]Z+_ -&+7E'@%@OCC2RQ  =N3_N-7JGQ(EC;P+?A9$)W1<!A_P ]%J\;
M_OE/Y?F1@O\ <JGS_(\'KZ@LO^/"V_ZY+_(5\OU].64\/V"W_>I_JE_B'H*,
MWVA\PR;>?R_4^<M;_P"0_J/_ %]2_P#H1KU;X0?\BW>_]?A_] 6O*-:(.O:B
M1R/M4G_H1KU3X1R1IX<O0[JI^UGJ<?P+71F'^Z?<<^7?[Y]YS'Q:_P"1OB_Z
M\T_]">F?"C_D<3_UZO\ S6G?%=U?Q=$58,/LB<@Y_B:F?"MU3Q@2S!1]F?DG
M'=:%_P B_P#[=!_\C'_MX[_XG_\ (CW/_76/_P!"%>$U[G\398W\$W(61"?-
MCX!_VA7AE+*OX#]7^@9O_'7HOU/J!_\ CP;_ *Y'^5?+]?3CSP_8&_>I_JC_
M !#TKYCK#*/M_+]3HSG['S_0]X^&7_(C6?\ UTD_]#->??%7_D<S_P!>T?\
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MFO\ ^@)7._%Y@VNV&#G_ $8_^A&BC_R,9?/\D%;_ )%L?E^;.9\$?\CKI/\
MUW'\C7N'BO\ Y%'6/^O.7_T$UX?X)('C32B?^>X_D:]N\5R*?".K@'_ESE_]
M!-&8_P"\T_E^899_NU3Y_D?.5?1?@[_D3=(_Z]D_E7SI7T3X.D4>#M)!/_+L
MG\JVS?\ AQ]?T,,G_BR]/U/&?'O_ "/&J_\ 70?^@BNM^#?^OUC_ '8?YO7)
M>/"#XWU0CIY@_P#0176?!U@LVL9./EA_F]:XC_<?DOT,\-_O_P W^I?^,/\
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M^#Z*VGZIN4']ZG4>QJAKGPQUS4M>O[V&>Q$5Q</(@>1@0"21GY:ZSP!X6O\
MPO:7L5\\#M.ZLODL3P >N0*O%8BE+"\D9)O3]",)AJT,7SRBTM?U.:^,:*IT
M7:H'^OZ#_KG7&^!P#XUTH$9'G=_H:[OXMV%Y?'1_LEI/<;/.W>5&7VYV8S@<
M=#7)>#-'U2W\8:9+-IMY'&LV6=X& '!ZDBM<-**P5K]'^IEBH2>.O;JOT/7O
M%D<8\(ZN0B@_9).W^R:^<Z^CO%O_ "*&K_\ 7I)_Z":^<:C*/X<O7]"\Y_B1
M]/U/IC28H_[&L?D7_CWC[?[(KYZ\1C'BC5P.GVV;_P!#-?1&D_\ (&L?^O>/
M_P!!%?._B3_D:=7_ .OV;_T,UCE7\6?]=6;9M_"I_P!=$>F?"!%;1=0W*#_I
M ZC_ &16;\855;O2=J@?)+T'NM:?P?\ ^0+J/_7P/_016;\8_P#C[TC_ ')?
MYK1#_D8OY_D$_P#D6KY?F<KX  /CG2P0"-[<'_<:O5?B3&B^!+\A%!W1<@?]
M-%KROX?_ /(]:7_OM_Z U>K?$K_D0[__ 'HO_1BU>-_WRG\OS(P7^Y5/G^1X
M)7T[911_8+?]VO\ JE[>PKYBKZ@LO^/"V_ZY+_(49OM#YADV\_E^I\VZWQKV
MH_\ 7U+_ .A&O5?A$B-X<O2R@G[6>H_V%KRO6_\ D/ZC_P!?4O\ Z$:]6^$'
M_(MWO_7X?_0%KHS#_=/N.?+O]\^\Y3XL*%\71!0 /LB=!_M-3/A4H;Q@0P!'
MV5^OU6I/BU_R-\7_ %YI_P"A/3/A1_R.)_Z]7_FM"_Y%_P#VZ#_Y&/\ V\=Y
M\3HT7P1<D(H/FQ\@?[0KPNO=OB?_ ,B/<_\ 76/_ -"%>$TLJ_@/U?Z!F_\
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M_P"0;:?]=C_*NG"_QHG/B?X4C<\/_P#(+/\ UWF_]&-6I67X?_Y!9_Z[S?\
MHQJU*RJ?&S6G\". \<_#CP]XFU*/7-:U*ZLS;1!%=9UC1 "3GD<'G]*X[1G\
M(0^---M-&\3>)M;NEN%R(9VEMUYZNV "OTS6_P#$?X=ZQXE\0VNM:?+8WD5O
M"(SI>H-((7().<J1R<C\JQ? EY?>$O'.J0:UX2GTA-:EMXK8642O;1,H*XW+
MP 2<UF6>UT444 %%%% !137=(XVD=@J*"69C@ #N:RM)\4Z%KKSII>JVMVT
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MUI_Q:_Y&^+_KS3_T)Z9\*/\ D<3_ ->K_P UH7_(O_[=!_\ (Q_[>.^^)_\
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M7_H8KZ-U'_D&7?\ UQ?_ -!-?.6@?\C'I?\ U]Q?^ABOHW4?^09=_P#7%_\
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MMC.&1@"..>10!J50TS_E\_Z^G_I5^J&F?\OG_7T_]* +]%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7RP>IKZGKY8/4U[N3_
M &_E^IX&<_8^?Z'N?PM_Y$J/_KO)_.N(^+7_ "-T/_7FG_H3UV_PM_Y$J/\
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M )$[2/\ KU3^5>+>//\ D>-5_P"NH_\ 017M/@[_ )$[2/\ KU3^5>+>//\
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M?QI72?%MY6T"QWQ!!]JZAL_PM7._"/\ Y&VX_P"O)_\ T-*Z;XO_ /(OV/\
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M:5IV^((//;HV?X:\Y\-$CQ5I! R?ML.!Z_.*]*^,/_()TW_KNW_H->;>&/\
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M_P"05_VWA_\ 1BUJ5E^(/^05_P!MX?\ T8M:4_C1%3X&:E5M1_Y!EW_UQ?\
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MS[XJ_P#(YG_KVC_K4X7_ 'Z?S*Q?^X0^1-\(_P#D;;C_ *\G_P#0TKIOB_\
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MJS?X(>K_ ")R;XY^B_,\$\7_ /(X:O\ ]?<G\Z] ^#G_ !Y:M_UTC_DU>?\
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M.#^X?^^C0!/14'V.#^X?^^C1]C@_N'_OHT 3T5!]C@_N'_OHT?8X/[A_[Z-
M$]%0?8X/[A_[Z-'V.#^X?^^C0!/14'V.#^X?^^C1]C@_N'_OHT 3T5!]C@_N
M'_OHT?8X/[A_[Z- $LB>9$Z9QN4C->4_\*<F_P"@W'_X#'_XJO4?L<']P_\
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M3_T%J*__ ",(_+]0H?\ (NE\_P T>-67_'];_P#75?YU]/JV[L1]17S!9?\
M'_;_ /75?YBOJ"C-]X?,,FVG\@HHHKPSW@KC_B#_ ,@VT_Z['^5=A7'_ !!_
MY!MI_P!=C_*NG"_QHG/B?X4C<\/_ /(+/_7>;_T8U:E9?A__ )!9_P"N\W_H
MQJU*RJ?&S6G\""BBBLRPHHHH **** "BBB@ HHHH IVO_(0O?JG\JN53M?\
MD(7OU3^57* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** /+/''@?7-<\3RWUC!$\#1HH+2A3D#!X-:WPY\+:IX<EU%M2B1!.L83;(&
MSC=GI]17>T5VRQM25'V+M8XHX&E&M[97N<+\3=%U'6M-L8].M7N'CF9G"D#
MQ[UPV@>"O$=IXCTRXGTJ5(8KN)W8LORJ'!)Z^E>YT55+'U*5+V22MK^)%;+Z
M=6K[5MWT_ HZU_R M0_Z]I/_ $$U\S5],ZU_R M0_P"O:3_T$U\S5Z.4?#/U
M1YN<_%#T9] _#[_D1=+_ -Q__0VKQWQM_P CIJW_ %W->Q?#[_D1=+_W'_\
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M=Z#=U^4CO0!U_DIZ'\S1Y*>A_,UY_8VSW/A*_NM0UK7$TFUFDGLKH7317$L
M3^)A@L"V[;GDC%/L8M5\-^#K'4[O4+Z>=KZ.>:*ZN&E*0RL$\HD]=H8'_>!]
M: .]\E/0_F:/)3T/YFGT4 ,\E/0_F:/)3T/YFGT4 ,\E/0_F:/)3T/YFGT4
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MO=:/=VVAHC2P11RIO\PX0[U((7VP: .ND\=:*FD0:DGVR6.:X-LL,5I(\PE
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MV%<?\0?^0;:?]=C_ "KIPO\ &B<^)_A2-SP__P @L_\ 7>;_ -&-6I67X?\
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M\0G\.ZV^GB/0V"HK9O-9%M)R/[GEMQ[YK=U+Q$VG^'K748[1;JYNS%'!;PS
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MYJRP/.J'Y@!@]05]^IK57QK&-.TV]FL_+BO+BYA?$F?+$(D);ISGRNG'7VH
MZNBN!\*?$^T\3:U#IQ@LX3<QM);^1?I.^%&<2( -AQSU/0C-=]0 4444 %%%
M% !1110 4R/[\O\ O?T%/ID?WY?][^@H ?1110 4444 %%%% !1110 4444
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M,;?X<,<\#'-.M/$=E#X5U;P^+2^NM5FN+V)+1;*7#EY7V_.5V8P0<YZ4 >I
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M1110 4444 %%%% !3(?]6/J?YT^F0_ZL?4_SH ?1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !7'_$'_D&VG_78_P J["N/^(/_ "#;3_KL
M?Y5TX7^-$Y\3_"D;GA__ )!9_P"N\W_HQJU*R_#_ /R"S_UWF_\ 1C5J5E4^
M-FM/X$%%%%9EA1110 444CLJ(SL<*HR3Z"@!:*YK1O&,.MSZRMOI]VL6G*C(
MS(0]P&4ME4(SSCCUS6?_ ,)W>Z=/%_PD7A]]+M[B"6:"5;H3-^[3>RNH4;&V
MCU([9H [6BN4T;Q;?WFJVECJVA-IGV^%IK)_M0E\P* 2K  ;&P<XY'7FNKH
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M90.E7+C2X+G5K+47:036:R+& 1M.\ '/'M5O$O\ ?3_O@_XT8E_OI_WP?\:
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M^> _(4 2;AZBC</45'M7_G@/R%&U?^> _(4 2;AZBC</45'M7_G@/R%&U?\
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MDP,*#@   =  *V** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M71-14/VRU_Y^8?\ OL4?;+7_ )^8?^^Q19A=$U%0_;+7_GYA_P"^Q1]LM?\
MGYA_[[%%F%T345#]LM?^?F'_ +[%'VRU_P"?F'_OL46871-14/VRU_Y^8?\
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MLQGAP%8$_P"L6KII\Z(J-<K-FJVH_P#(,N_^N+_^@FK-5M1_Y!EW_P!<7_\
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METZT$<J.1*<A6![5T85/VT3GQ+7LI'4-I&F.Y9].M&9CDDP*23^5-_L;2_\
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MD>Q1_L;2_P#H&V?_ 'X7_"C^QM+_ .@;9_\ ?A?\*O44<\NX<D>Q1_L;2_\
MH&V?_?A?\*/[&TO_ *!MG_WX7_"KU%'/+N')'L4?[&TO_H&V?_?A?\*/[&TO
M_H&V?_?A?\*O44<\NX<D>Q1_L;2_^@;9_P#?A?\ "C^QM+_Z!MG_ -^%_P *
MO44<\NX<D>Q1_L;2_P#H&V?_ 'X7_"C^QM+_ .@;9_\ ?A?\*O44<\NX<D>Q
M1_L;2_\ H&V?_?A?\*/[&TO_ *!MG_WX7_"KU%'/+N')'L4?[&TO_H&V?_?A
M?\*/[&TO_H&V?_?A?\*O44<\NX<D>Q1_L;2_^@;9_P#?A?\ "C^QM+_Z!MG_
M -^%_P *O44<\NX<D>Q1_L;2_P#H&V?_ 'X7_"C^QM+_ .@;9_\ ?A?\*O44
M<\NX<D>Q1_L;2_\ H&V?_?A?\*/[&TO_ *!MG_WX7_"KU%'/+N')'L4?[&TO
M_H&V?_?A?\*/[&TO_H&V?_?A?\*O44<\NX<D>Q1_L;2_^@;9_P#?A?\ "C^Q
MM+_Z!MG_ -^%_P *O44<\NX<D>Q1_L;2_P#H&V?_ 'X7_"C^QM+_ .@;9_\
M?A?\*O44<\NX<D>Q1_L;2_\ H&V?_?A?\*/[&TO_ *!MG_WX7_"KU%'/+N')
M'L4?[&TO_H&V?_?A?\*/[&TO_H&V?_?A?\*O44<\NX<D>Q1_L;2_^@;9_P#?
MA?\ "C^QM+_Z!MG_ -^%_P *O44<\NX<D>Q1_L;2_P#H&V?_ 'X7_"C^QM+_
M .@;9_\ ?A?\*O44<\NX<D>Q1_L;2_\ H&V?_?A?\*/[&TO_ *!MG_WX7_"K
MU%'/+N')'L4?[&TO_H&V?_?A?\*/[&TO_H&V?_?A?\*O44<\NX<D>Q1_L;2_
M^@;9_P#?A?\ "C^QM+_Z!MG_ -^%_P *O44<\NX<D>Q1_L;2_P#H&V?_ 'X7
M_"C^QM+_ .@;9_\ ?A?\*O44<\NX<D>Q1_L;2_\ H&V?_?A?\*/[&TO_ *!M
MG_WX7_"KU%'/+N')'L4?[&TO_H&V?_?A?\*/[&TO_H&V?_?A?\*O44<\NX<D
M>Q1_L;2_^@;9_P#?A?\ "C^QM+_Z!MG_ -^%_P *O44<\NX<D>Q1_L;2_P#H
M&V?_ 'X7_"C^QM+_ .@;9_\ ?A?\*O44<\NX<D>Q1_L;2_\ H&V?_?A?\*/[
M&TO_ *!MG_WX7_"KU%'/+N')'L4?[&TO_H&V?_?A?\*/[&TO_H&V?_?A?\*O
M44<\NX<D>Q1_L;2_^@;9_P#?A?\ "C^QM+_Z!MG_ -^%_P *O44<\NX<D>Q1
M_L;2_P#H&V?_ 'X7_"C^QM+_ .@;9_\ ?A?\*O44<\NX<D>Q1_L;2_\ H&V?
M_?A?\*/[&TO_ *!MG_WX7_"KU%'/+N')'L4?[&TO_H&V?_?A?\*/[&TO_H&V
M?_?A?\*O44<\NX<D>Q1_L;2_^@;9_P#?A?\ "C^QM+_Z!MG_ -^%_P *O44<
M\NX<D>Q1_L;2_P#H&V?_ 'X7_"G+I&F(P9=.M%8'((@4$'\JN44<\NX<D>P4
MC*&4JP!4C!!Z&EHJ2BC_ &-I?_0-L_\ OPO^%']C:7_T#;/_ +\+_A5ZBJYY
M=R>2/8H_V-I?_0-L_P#OPO\ A1_8VE_] VS_ ._"_P"%7J*.>7<.2/8H_P!C
M:7_T#;/_ +\+_A1_8VE_] VS_P"_"_X5>HHYY=PY(]BC_8VE_P#0-L_^_"_X
M4?V-I?\ T#;/_OPO^%7J*.>7<.2/8H_V-I?_ $#;/_OPO^%']C:7_P! VS_[
M\+_A5ZBCGEW#DCV*/]C:7_T#;/\ [\+_ (4?V-I?_0-L_P#OPO\ A5ZBCGEW
M#DCV*/\ 8VE_] VS_P"_"_X4?V-I?_0-L_\ OPO^%7J*.>7<.2/8H_V-I?\
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M_OPO^%']C:7_ - VS_[\+_A5ZBCGEW#DCV*/]C:7_P! VS_[\+_A1_8VE_\
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KY=PY(]BC_8VE_P#0-L_^_"_X4O\ 8VEC_F&V?_?A?\*NT4<\NX<D>Q__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>form10-k_003.jpg
<TEXT>
begin 644 form10-k_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &_!C # 2(  A$! Q$!_\0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 G##V/YU$RITR3[8[_ %XIR'@^@Y_G_A_.
MOB[]KC]N']F_]AWP'#\4_P!IKQ1XX\#> @LBZAX\\/\ P/\ CY\6O#/A-EGT
M98AXXU?X/?#GQQ'X#@N9M6TQ+4>,9/#"^(Y1)!:B>2*6).?$8C#X=J.(DKRL
MDN7F<FVE%)=VVDE?=V6Z35"B\1MS;MV6KZW_ "U^^Q]G[0$ &",G/4^OKV]<
M^M P@(QR>,>@[Y/O_@?2OR8\-?\ !;3_ ()K>(-(^%FO7/Q[\4> ?!'QLNQ8
M?"'XL?&[]G']JCX!_!7XDWZKED\&?&[XZ_!7P-\*]9:,Y&8?&,@4KR2!FOT\
MU3Q3X>\/^';[Q9K?B#1=(\-:?IG]K7>N:IJNFV'AZQTI85F_M275Y)4MH-**
M89;J>54*88?(RUK7E]4POUK&*T8ZNT=&WV;LM.NIST:RQ$_JV&O=.ST>FJ5K
M:N]VD]VF]KZ'6[5QG/'Y ?GG]:-VW@#(]<_7T^GM7YJ^%_\ @J[^PWXY@UO4
M_A]\3_B#\2/!7AN35+76OC/\.?V:?VI?B)^SCI[Z)IC:OK<A_:<\"_!?Q)\!
MRME;HK7>/BD\<3JD"L]PT$4_N-E^VW^RAJ'P(\1?M.Z?^T9\(=0_9X\,7NHV
MVM_'73_'>@ZE\)0= D-OK/\ 9/CN+4&\-ZZD5R@T-E\,W%V\GB-9;*&&6Y$D
M:37JK"83ZUB?=2=FHIZMM)*.]]UM?=))MI/?5XIX6VMNS]>_X7^?4^N]B^GZ
MG_&C8OI^I_QK\XOV-O\ @JO_ ,$_?^"@'B7Q5X2_9)_:;\+_ !6\7>"X7FU_
MPF= \:^!_$O]G;XMVLZ/H'Q%\,^#O$'B+04+(A\3>&(+SPN&E3%P6=0/T=WK
MZ_H?\*MT$MXO[O\ @"]LOYG]_P#P1U%%%46%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M898,X(#_ &?<BKF,#8TA8-\V"A#G'"U^''[$G_!07]KO4/VO_&__  3_ /\
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M/%;_  U\)W'B'4O%WCWQHOPL3Q9\0?&TGB7QHW@SPO:3^%/!?@_[>_X+F_\
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MQH^#WAB3]B?]BO\ 9DB\+_!32/$_[0^J_##X3:39ZVV@0(OA32M)T+QQXO\
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M#^(FB>(OA;"WAQFNF\%ZWX<,JQEXMOW_ /\ ! __ (*M>(?!&JZS_P $B?\
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M)^.-.G:-?B)JG@:^^'_@[2-'75[A5F7PYX8DN=3U^2TE0^>X\+7%QN-L@/\
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MHK_@H#9_#WPIX ^.G_!/7XC3_&70O#EMH.O_ !7\!_'O]EF\_9G\6Z_IVC&
M^+EUO6?C8O[1OA[1?$=U Q>&3]GSQ;J-G+)'$D%RGVF9/(O^"A,?_!:'P?\
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M _A=^P]^RW-^T%\<?VAO&^L>$[;X@>._#OQ/?]FS]GS2='TR*<_$O]H;Q?\
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M.M..'P^/Q%?GYXRK+E46ZDJG#]#AW$SIPDDU/]QQ+PY7]U-J'$,)-)71_3L
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M:'X@\:0^*V1/&MYH\/@ZZ/B/X>-XNM?&_P!U?\$N/B#_ ,%6/B7X6^*?B?\
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M5TS>&(?+T'8R  Q.8@B/M'W^/NM_P'^=?%W[ MS\<-0_9 ^!&H?M-Z(OA?\
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M2?LG_#C4_P!I6VU6#Q')XZNO^$I2PO/$D++)'XIUOP(OB&+X::]XXAG*S_\
M"6:_X/NO%KS10S27[&*.4X0RS"T84\FG+GR%0PO^LD5&,*LW1\45XIU=/:OW
MJBISX6@E-1I\ZXGJ>V48\,H53$/$TLRLO[1R3B:EB*4>6,HRE1\,\1X:IRJM
MZ*<\4^)[13E2C3_U;IR3G.O+\:_A?X,U/X-?\'"_[.4/Q$N(=!/B[_@C+X6^
M'_A@ZG+':Z9JOC7X:^,?#%UXW\-Z*90R2:MX=@T:;Q#.A ,=JTLBME0ZZ/\
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M_P#2RY^U]_X9CQG_ /1GUZG_ ,&MGQ^_:(_:+_82_:+\1?M*_'?XC_M ^/?
MW[>OQ?\ AGI7CGXF^(];\2:[%X5T'X.? *72M&CDUZ?[1#H:ZWKVO^(+?P^9
M@MM-K;N2LK;'_IQK^4#_ (- _P#DP?\ ;%_[2?\ [0__ *I?]F:MSV3^K^BB
MB@ HHHH **** "BBB@"BR1>8A)(V!STX(/7\>1C/7N>2*8RP*TLKG&\(6_V5
M&2I&0..#Z=:_%_\ :?\ VL_&'Q,_;S^&'_!+G]GCQSK/PW\3ZA\+-4_:'_:L
M^+WAV!I_&7P^^!NDZK;Z!H/PY^%DNKP7FA>'_B!\5?$>O06E[XVNH'G^'W@6
M.>\\%1OXXN/"M[X8_%7_ (+8W7Q/^!?_  54_P""4OPO^#_[3?[9_P /OAC^
MUQ\4]+\-_M!_#WPI^VK^UYH?A?Q9H]K\2/A1X/G71]&T3XRQIX#23P]KVJ(T
M/PSC\)(97:\5!=NT[>?EJIXW%\*8*"BI\4<1U\CX52B[5/JU#B:K5G)INSC'
MA'B9:*3?LHV33.;,,4\'A<WQE6ZADG"SXGF[<UZ,;R<(I.*YE!N24I)/X6XM
MZ?VC?9U5$52"J^2RGU$"\XP?[IR..@Z"FH@4!@,E#<'\&4L/P()/XGFOY!M=
M_:._:,_86_X."OV=/V#?A!\<?V@/CI^RE^TM\.])\4^.?@Q\=OBGXL_:*\0_
M"[6M='CNRN=5\%_$[XL^(/%WQIT/P_X5@\%:'XL$'BCQK=64=OJGB=1',GD/
M;>M_\%I?V<?$G[&?_!,#]J;]HWX7_M=?MZ2?M)Z1XP\+^(=(^*DG[>W[8/A[
M2-#/Q ^/'A>/6/#_ (4^%NB?&Z+X5Z%X<\-^%O$FM>%?!V@Q>$<65LL&V9G2
M)TC%9D\+E66Y]-J.4XCFA3DDV^=<4+A9WNEHIOVGNMKEE;XE)'9A\%B*^>4^
M'XV_M.K##5*6C^#B+AJIQ+3DXW<H)1I2@U447HJB4J;C)_U6N%VJ6(X!R,],
MG.3C_/\ 1N4(91P 2F#[#)S^!_7GW_G#_P""6_[+.J_'C]@O]@K]JG7OVKOV
MZ8_CU=:?\-OC%X_\4:[^W)^V#X_\%_%0:3XQ:X\1>"_&WP:^(7QN\4_">Y\-
M>+- MV\/7%M;^"X?+C=9PA9"LGY)?M"W/Q4\,?\ !RU\"/V(=*_:N_;JL?V3
M_B;X$LO&/C'X0V7[?O[9FFV-QJ^L?"_XL>)K]])\1)\:(?&&B:1)XB\-Z*R:
M#X;\60Q1PP?9+9XH&EMHO3J8-KB'+^&85(O-:M/BSEA.,VF^$.&)<48I.49)
M6E13</BM)>]RQDF>=1S"G6R:6>/3+X\]TWRN*C4=)M\RM95$X[_+9']S#P O
M'-Y9-QM;YP0%3SA&)0>/3=CI]X<\<H((1=37 BV32%-Y8?*WDB0QD=^2!G)_
MA)[X'XE_LM? "TUGX\?"/]K/]F;]I7]K#Q/\!-.\0_M*_ GXI?!WXH?ML?'W
M]ICX0>))? FO:]X$T?XN>';7XZ?$KQM-%KB>/O K1JMM<SF"'Q#/-$%2!W/X
MD_\ !97P=_P4H_8:_:-\4?MZ?L%?M-?M5>)_@/\ LRR_"/Q]\>/V5/B%^TK^
MT7\:OAG/I?CJX^(4FN^-;GP-X_\ B%XI@N?@[+;>'Y/#OC;PO&T;> WD;QKX
M(OO"ME;12>"?.684*&*RNAC,73RBIG<8J*JP=E"3PO)S\K:M*7$?#S3_ )ZU
MG91:>ZA5F\QP^&A)R@OW2;BO]8:BC5;5-W:A.V05$U)[:V=K/^X $9&!CL?3
M)R.^?Z_3U3'#9';'TY__ %^]?SJV'[17P _X+!?L=_LX?M4_!GXR_M-?!WQ
MGQU_9Z^&WQ.\&?L]_M>?'?X%ZYX'U/QQ\:/AQX=^+7PP^).C_"/XB^$?#&OB
M70]<FD\*>+O$WAF3Q;+X-EL[SP)<^$WOY$M?WW\*^';+PYH-AX>TZXUR?3]
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MO?IO!8K-<)&ZEDN(EPY-/_G[&23M_=7NM2LM_F?1"@ #^9XSGZ_3]*C?@\X
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MTC1- \3_ !6^*7BLPOKNL?V+X?<P^'O#%L$:+P=X3AN;R+PM;O)&EP[.4?\
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MX8^(NGZQK,2#0=*F\$Z[XHMO$R:QX@76-+2WMYK16NOM$#VPRY,GQ!X"\<_
MW_@JM\1/BC-!X'\5>%8_V$_VJ/@+J7PF\2_&'X':[\.OC#X7\>> 7\+?%_QY
M<Z+X*^+6@>%/BCX%T3XK^&]:_P"%8S_\)19^&9Y/",[3+X1CVL;WYW_X+@_\
M$PO!'_!4CQ1\(O@Y<ZA'X.^*?AW]FO\ :O\ B!\%?'T,9W:5\2/!GCO]E^+0
M])\;+=B&76_AYXACU_7=#N88P]QI[:Y+XML5N;BVACD\FO[?"4LNQ7]EU(SJ
MIS<TX\]'AMT%Q#[964DDHI.4%%SO;D;O:7K8*A'$8O-<+-QI4U!<TIJ+MQ'!
M2G*-2[T@D^&TI-Q4;R;T3/VZ^,/[0/[//[.7A/2_&WQ]^-OPD^!'@O4M8'A[
M2/$OQ@^(_@[X9>&]3\1/#/JJ:)8:WXZU_P .^'IM;FM]-U.XBMO-%Q(D+RX$
M4$ZOT'PG^,'PE^.?@ZQ^)OP1^*?@#XO_  ^UUM4M='\?_#'QCH?C_P %:Q/H
MVHR:-JZZ/XN\-:UX@\.7;6VL1/;2)#<S.DD,D$JM)$[1_P 7W_!.+_@J;XU\
M3_LJ?MN_\$>/^"D.GW^A_M>_L^?LW?M$>#_ =U\25&H:E\5_#'@KX7Z[(_@_
M4Y]=5'U_Q_X7T&)?$?@_7I'N8O&O@:VB\:)<S&TEN+W^VSP7INF:-X1\+Z7I
M-G;:9IVG>'])M+;3[.V%G96-E%ID0CACAP51(]H4C ()!?YMS'T\3A'3PT\?
MA5'-\L<HSX>JJ*C&K&-).,E.I%WO&46WS.5/FY&V^1RX\/5KQM#$\G]JP27$
M<?LI6DH..K:3235W*ZO[SU2\B^-O[7O[*O[,]YH.E_M&_M+_  !^!&H>++&_
MO_"NE_&CXQ_#KX67OB.RTB2&WU2;0D\>>)/#G]L10W$\4,LUONABEF02OP<>
M_P!G<VM]9QWMG/%=6]];I<VTT+ K<(5)4KC. P(P<D@M@XK^0#_@\NC$O["?
M[+L1YV_MF>#Q@\_ZSX:?%B$]>,8?L/8U^P7QW_X*2Z'^SK\5_P!C+]BSX5?#
MRU^-G[8?[4GAC2M0^''PVUOXAS?#'P+X8\!^'_"EQK?B;QK\5OB@GP_^*?B7
MPYX=2WT36FL8_#/PL\:^*?$MQH5R!8Q26P:3GP">(RJEC;IYK5XHJ\***C&S
M=+A?_6ERYFT[I\\>5)04:<I-WLCIS*+PN)RAI.4*W#%3B=NWP1I\4?ZKMMK:
M+;C>3=^::6K:1^Q0).21R8XQP>FXC(XZ]ZE 4ALX  *9]DQDX]SCG& .,5^1
M_P"S;_P5B^%GQIE_;-\$_$OP-JWP6^/?_!/X:S=?M,_#&TU8_$71;#PSHFE:
MIKX\;_#+QW#X9\+S>/\ P-XBT[0IWL#-X+\(>+7E2**[\(VLD]H\M/\ 83_X
M*3>-OVV_A_\  OXR>%OV>?#\_P (?C[XP\5:/I'C'X;?'J+XP:A\&_#_ (>\
M%>._$T8_:<T'_A6G@H?";XA:]XBT'1/"MMX3\,W7COPC;-KRFX^(PND\'>%O
M&G!A:/MN9T)QDEA\-Q&W.+BG1XFA*?#M6]I)PK1C*47=>["7VERC>*3Z-:[)
MW::=K6O=-/375.]UU/V$(4 '(P/Q!SUSZ].W]*<",9R,#T&/TK\2O@%_P5EO
MOVG_ !'\?Y_V?O@'I/Q3^'WP _:#C_9WUNT\,?';29?VEO[6B^)/A[P+XH^)
MNN_L\S?#I+7P[\%?#$.L:OXFC\3Q_%;Q1XS\76OARZ-MX"C#L]O^UD391O7C
M'L ?7Z]*[J$O;X:&)Y;<U]+6LUK:SL]FG>UM5:]S!UTL4\-U5K^K_73;Y 3@
MQ'MCCUZ\9KB_$WB_PMX.ATB?Q9XG\/>%8O$.O:9X5T>X\0:WIGA\:SXGUJ24
M:+H&BKJ_D1ZOXA\0/&([7P_"TEY-MF$$<LD67[0C)0=E!_'!_P#KU_&O_P '
M3FM_M'>-O@KIWQ$_9VU.VMOAU_P3G^./P.^,OQGEM!<7^K:C\7?&+-'\/U$>
ME(WE6WP?T.7P9XH\71>(V^S7-M\8/"]Y;.I\.NR\=;&X7#SRM8IV=:45':Z<
ME96OI>]M]-5<Z\/AL5B5F"PR5U'FN]E9)?-MM1BMV[VUO?\ L)U+6=)\/:5J
M&MZU>6.CZ1IME=WVIZMJ5Y%I]A9:=IBL7U+4]4EV+#$D,?FM)+(!'$7+$B-B
M/B!O^"K?_!+4[3_P\F_8(^7=G_C,3]G7"Y[L?^%BC:IZ@G'MG.*[+]@_]J3P
MW^VE^R)^SW^TYX9GM?L_Q4\ Z3J>MV%E*)8]#\;VTMQH7CKP^'8!_,\+^+=)
MUS0/,()D%NQ.T-7\@/P4^,GP%_9G_P"#M#]NSQQ\;?BC\(O@#\/YOA'+9?\
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M_>_]?U_5NVC65=<T?+SO<FHHHI&P4444 %%%% !1110 4444 %%%% !1110
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M+1->^/7@J&36H?&7@[Q!X6\0^ 9F'F2VWBSPSXG\,^+;7RWNK*\MY+:TE/\
M4[J__!,3_@FKK6LZCKOB+_@GK^P]KVN:O?W>H:OK>L_LH? ?4]5UC5M7G$NK
MZKJ>JW'P\>>?5;J=IIIYI9WDFF+$L=S-%?\ %'_!-7_@G+XZ\0:WXO\ &'[
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M=&\CPU'INM([8B\06Z#1C(D6Q72221\L,G]FZ "BBB@ HHHH **** "BBB@
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MZ-PUC9+^4S_@GQ^R=\?-!_;:_P""O/\ P5(\<_ ?XC:7\-_VA-$\7Z'^SS\
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MU'X3>+_"\>N^()=(7P'KNCRGQ-\7?B%XIBU/29/"?@[X5>#_ !5.+@NGCQ?
MT%M.)/=/B?\ "CX\:C_P:I^ ?V1M+_98_:ZO/VECXB\*^ [CX*1?LF_M&/\
M$G3M3T/]H4?%/5]7U30(_AA'+H_A0?#R)KP>,KA)?!<DLQ\"Q>++GQL7M8_[
MJVE@.T[<>7Y4@ XY<#RP>O '8]?UJ-HK<GDD[8YD],AMQ?(.>F3@GK@=@:\1
M8=5<JAE,E&I"WA3DCE#GC)_\0HPM+"X9I6<6JM*E&51-64H^ZO?;CV5).6;2
MSFHXJJ^*.+.*FM7'V_&"2XGM>4G%57'W6M81T7,E9_Y_/_!1KX3?M#_%G_@E
M?_P1.^$?PT_9)_;-\:_%7]GW_A![_P",/@G1_P!C3]JE/$WPR7P-X T?P-X@
MA\0M-\(4@1U\0:=.J[%:7QB6M_%O@I)?!TL#U^NO_!RI?2?'S_@G+^S?\$OA
MSIGB*;XC_M=_M4_L_P#@;X0>"_$G@C7_  OXSU/4_$%EXAU?&M>"_&WA[PQX
ML\!G0+=(U\6-XG\.>%O$GA%W,&K6UHPO()?ZDHA 6C'E@-)O(VGC)\O><<'[
MR *.@"CCDU\7WW['_A[Q?^U)I?[5'Q>\6ZU\2?%'PUT/4?#7[.W@&_TRPT[X
M;?L_Z?XCTR"U\<^,M"T2);AO$'QE\8R"2VU+XI^)[Z2;2_!)B\%>!/"7@^.;
MQA?>,/9KXQX_$T(8V/LJ>:>*U?Q;KQ:JN4ZE3%\)8V?"L'-M^P4^#^&H0C4D
MZJIOBAMN5>T.+#4UET88S \O]JY'PO4X8P\KW2C5?%%52<'%1<O;<53=O=@X
MQA%J_-?ZE\ >&$\$^"_"7A'SOM(\->%_#_AW[2<?Z4-&TJ'22Y&/XS )"".&
M<=#G/=@<-WX_J/\ )J,*)=KCMP1Z8_SU^I[<KO\ ]8>,=O0<_P N*Z*DO;UG
MB.:\VI\SZ<TI\VB>RU;MVM;0,/1P^$PV PN&5HQ45%?X5N_-V7],M4445D=8
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!_)[_ ,&IO_)+O^"G_P#VD\^,_P#Z8O#-?UA5_)[_ ,&IO_)+O^"G_P#V
MD\^,_P#Z8O#-?UA4 %%%% !1110 4444 8CP%EEDQP]M&@Y[AD'Y\ _XU_+M
M_P %Y/A_JGAW]M[_ ((A_M=:A@?"OX-_MLZ9\*?B+K1M_M5EX8/QUU/X>Q>$
M-=U=6.+;1(9? VNQSZZ"RVLSP YE>W0_U+C"KC^'R\XZC\.M> _'[X"_";]I
MSX4>-_@G\:_"-IXU^'/Q!T9M'\1:)=(FGL@1#+H^JZ5K48BUWP_XB\.Z]':Z
M]X3\2>'KJW\3^%?%<-CJ>GW=M=6D4D?/AZD8XO+,2U+DRKB"+?+:ZA.,Z;2O
MI=0KM*^B=GTURE1=7"YIA,0TEG?#=?AR:>]L1!J2ORMJTH1G=?R6:<6T?A;_
M ,'-]EX^^*__  3:\;_LO_!?X$_M+_';XR?%;Q-\+=<\-:!\"_V=/CI\8-'M
M-%\"_$C0];UW4_%_C/X?_#SQ7X1\.SQ0Z$[1^'/$GB6S\57GF036EK/#7Z-_
M\$FO%EUK_P"P%^RUX.UGX=_&KX4>./@W\!/@Q\(/B+X*^.'P(^+OP(\1Z)XU
M\#?"[PYX?UZ+2=#^+7A;PO)XBT5+JV8P^)/";^)_",AW0P7HFAN(K;[3^#7@
MKQ/\-_A[H_P^\8?$_7?BYJ/ANU.CV'C_ ,6Z5H]EXVUOPU"HBT23QG+X?6W\
M-:[XK5&:*_\ $UAX7\*VOB5X/._X1.UG,\L_LQ8!68 !E.">F=V>OY=L?UKH
MIP5'#YAA6M,TJ.KS7:Y9>SG!625FG"3OZ1::U4L:ZCB?[,Q#T_LCG^?/9R\N
MD;=+)W3O=?)G[77Q+L?A+^S[\2/$UWX-^+'CRYO?"FO>&=)\(?!SX/?%#X[>
M.M;\1:UHNJC2-+M/!?PC\+^+_$\<+2%XKCQ#<VD'A3PV\B->WMO&8U/\V/\
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M@E^V%^SW_P %1_!'Q&TOPU^SY\7_ -GSP'XO\0>#?VHY/#BZ!H>A:WX^\<>
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M3OK^UTO7/#NB/\,/ _ASPYXOT4^*/#^IRSI>WR(?#;1):WEJDLC1+\<^+_\
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M08YXOM0\,QC3G/BN_P!,EM(KFV=K&.Y^DOV"?VW? /[>W[.6@?'GPAX<\3^
M;H:[XF\"?$#X;^,X%C\6?#OXD>"KBXT;QMX,UU0R*]WX;U2W<>;$L<<L)ADC
M2+?M7CI5(5J3K4)U?9P7/*;Q%*,5".(GPU*<;S5X4^):4^&9RLHPXBI3H.]2
M$H$5\3AL-7P-"2I1]JTH2;LG*5%\1QBVU:+GPXGQ'%.RG23E3<DC[]K^4#_@
MT#_Y,'_;%_[2?_M#_P#JE_V9J_J_K^4#_@T#_P"3!_VQ?^TG_P"T/_ZI?]F:
MND[S^K^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/#?A/]J3X>Z9\:M5U71OV:/CY\8O@/K/P]_9[_:@U70Y-NKV'P2\<2ZW/?\
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M_IB\,U_6%4'2%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MWY^] V;>,XR/3/MCV_+VK\M_^"8?_!1O0?\ @I+^QS_PV OPQN/@QX;?QO\
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MI;16#:WIVIZ1:ZU;R:C!I1:UMM:@CD<77E+'DM"RGS6)?]-'>*.(LQ;:6Y/
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MVA^(?!>OP>'O#/\ 8/P^NXM"CT*T\*>'O#MOX5CP\OV::6!'A_)SP1++HO\
MP:??MDZ'XJD@N/%6E?M*_$+P]KEO>*=2U1?')_:Q\'S-&2NYO[?-P+9D9?G8
M(G>0J?ZKOV*?^"2/[.7[%?Q%\1_'/2_B/^TI^TY\?O$GA+3_ (9M\?OVOOBX
M_P :_BCX>^&.D1R&W^&WA#5SHOA/0-!\*+*0OE6WAM9V5%B:[-N76O(?&/\
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M[1C\*5]-VWMJ[O?Y66BBBI("BBB@ HHHH **** "BBB@"+Y6!V]AD=^G7O\
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M8T.*#PCNB\2SF3Q'X3L@((UDN[)3)/)\Q>,_@7\1_P#@B/\  _\ X)O?'O\
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M&IO_ "2[_@I__P!I//C/_P"F+PS7]85([ HHHH **** "BBB@ HHHH ****
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M +0__JE_V9J_J_K^4#_@T#_Y,'_;%_[2?_M#_P#JE_V9J /ZOZ*** "BBB@
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MBBB@ HHHH **** "BBB@ HHHH **** /Y/?^#4W_ ))=_P %/_\ M)Y\9_\
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MR>4)M99E"%[>"%?!R[L1^*O%"%HU_%S]H7XN:!\,_P!H-O#'PJ^'WA>QT?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MLO$>NV2BV;XS_$+3Y;K5+)XU*R.-?\0.YT&V<-N$/_"5^&0)>$\)2@(4]_\
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M;Z7:5NW;]M 5()XP>N?PS_3-!*@ \8'3'XX_KBOQ6_:E_P""Y7['/[)'QO\
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M_<^UE*T6I2C%^\I2N?FQ\6)9=+_X.7/@Q<>&X(TOM<_X)3?$U?&%A8[7BO\
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M9L94YKU;]FS4_%GB+_@H=_P;73^,C<ZI;C_@E?XZU^PGUF A3XD;X00G6]5
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MHMQ)_797\GO_  :F_P#)+O\ @I__ -I//C/_ .F+PS7]85=IZ@4444 %%%%
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M[ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=_P4_P#^TGGQG_\ 3%X9K^L*OY/?^#4W_DEW_!3_ /[2>?&?_P!,7AFOZPJ
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MX#1:_P")-8\,_&;XB_%VZ\/ZAX;TK2+CXD1:E\,]4TC6M<&OOJ4H\21R>)=
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\V;O]@/X]^/K5]0_:5_;Q^)6JZ1<C%_X3\)Q/X8\.' .T8?Q$OAEC@\9\'@
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M'_\ P2X_8S\&BVDN?A[J/C[4K;+"_P#'7BK7M0!XX#:!HD7AOPF!W_Y%@$]
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MC7-6T;3I!(A'+I=3@.)!O^38A3(*8 (/Y5?%7]MCQ)X7^,,WA/PK\</#>N^
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M2M]=TJY?RK?5M&FE49,4.H*V,'DX67)_+^6:^'/^';_[-G_/EXO_ /"JD_\
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MV>9:LZEE6&X>X=E"4EQ9QCQ9PIP;PW/D5Y^REQ37C5J\NC:IX:K)72LFU?\
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MQ#Y[1YVL@8A3_5#INCZ1X?TZ"PTG2-)TFUMQ_H]O965MIEFBK@!5C10OH#M
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M:][24;.,HS27:V^EJKAFEB>9-6OS72?+OHY.*U6WH]#TI2>05'UR_P#4 4K
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M#094GT7]]K&CEIB&W^<@C+^7*]>&']IG]NCQW$!\-_V1[3PDK*=W_"Q+[4Y
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MS(?<I(4LQ)/BOQ4_;@^!'PG6313XF@\:^,I@+6Q\)>!BFKW$VH/DK$=321=
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MU9./)2/PC+'<P7L/X$^#M,T[QQ_P:Z_MH?&G7=&@M?BGXD_;!\;_ !XU7QU
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M.W[1-+\?Q_P<2?M^C'_'.-_P4ZX]? _QG&?I_P 8H_KR/3TK._X,[[V?4_\
M@G7^U9JUSI\^DW.I?\%(_CG?7.EW'_'YIDMS\$?V8YVTF;/+2VC,]O)@X#(P
M4?-N'[&_\%7/B5XY^$W[-_A_Q%\.?$_B+P9XANOBUX=T,ZOX5UC6-!U1-,G\
M'^.;BXC$^AD3-%+_ &1"VS8(BL460FQ5K^<[]C7XP?$?]E/Q%;:%^SKH>FZ+
MHVN>+M5\?ZK\'/#V/#G@;QSX[U_1FT/7O&?C;0O /_")#7_$/_".Z+HC$8QG
M0?#)(Y-<+S"/+FD5'EY+/1MIVNEHTK6OM=WLKZGO]OO?S/[9(S,@R06'7Y3N
M_P#'65<G';_'C,U#4+>SAFNKH""WMUS-<3VTJI&HQ\S.LBJ!DCGIDXQS7\T'
MC/\ ;&_X*&^.9KB"]\8P_"_3[H*O]D?#_P #.R#;D IJY\.>+O$49.3DQ>+4
M!Z$8Q7R7XBL/$/CK4YI?C/\ %/XQ>/9K.["JFJ7FL>(E55  "C7_ !)@
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MM79:)^W)^Q1X>##2OV9OAQ/Y&<C4?'/AK6R,^G]J:1XEQC)PW4'TQ7KFE?\
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M@@@_YXKQ;XH_"3_A:6F0::?B#\0O 5H$U&VN?^$!U/0K)]8L]5C$31ZJVO\
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M<5AZUX@T708(I]9U33=)AF(MQ/J5]%IP9VYPKS,B!B>2=R!<]1T/YLI\8?\
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M*T4J*H72O).W=V2:5DY2DWHDE=Z=+*R4]%%%>^,**** "BBB@ HHHH ****
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M;BVF99CMEA:2+S8PZO(K0?@AX!_X)<_\%*_CW\2?V1=#_P""GG[4?[.7Q/\
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MWBH*GEWLV][G 3_@X@_;Z10/^(<G_@IN<-N_Y$GXS<Y_B'_&*6,#^(G('4X
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MK^'_ !S-N_MO1CHZ[C;'0YMEMY<;.,PJRL[.HKZ^89#*?1?S  _KG\*^$O\
M@G5X1\5>"/V)/V=/!WCOXE:7\8?''A?P!'H_C#XJZ!XFF\::3\3?%>C:KJT6
MM^.=(\2ZPQDUY?%&MB?Q FN7 /VEYD9F6(HR_=K' 9CZ+^9 /],?C7T..O\
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M#'\P*_7L/XP>*V%5H>)'&EEM;&5OSY)N_P V>C_;N;O;-:J_[>7Z['XQP?\
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MLX2\/[,'[+^K,1S!9>(!$Q]?WFK?M#PK^ ^F*_:#"GDLN?P/_LE(0.S<?[P
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M*E?](^_#7_AS=$_^:2OV%VG_ *9_DW_Q-&T_],_R;_XFM/\ 7_AG_HSW _\
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M$>6LPPR_YE-+_P #K_\ R;/Q6_X:?_X*_?\ 1CWPZ_\ "DL__GR5M1?M"_\
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MWN8I;6.\AFBN8H[B&8$30R!N5(((*EL!<#.,]ACI7IY%XSXO(,ZRS/,G\..
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M'$_7,7/%NZ<FW9]%9+7TM]]_(DHHHKP#B"BBB@ HHHH **** "BBB@ HHHH
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MZU'2]6MO.AU:-D,>UXW96!7K\@< ZFOY0/\ @T#_ .3!_P!L7_M)_P#M#_\
MJE_V9J_J_K^4#_@T#_Y,'_;%_P"TG_[0_P#ZI?\ 9FH _J_HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/2OS#_:$_9>^.GASXQ^,-%@\+_&;XR1VTWA\K\4)_!/BKQ)_PEN_PIHI$O\
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MN-+TA5'B%O%9\;>+=5P#+_8@T2+1O*T6[):()K!=V2&-1*A#/D[/SCQ7XO\
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M.A4I5(TX4URJ45X^%R#.,)CY8['YXW%\VD+W=WJDIQ<-[JT;K1^3/AA_#?\
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M7B_PGX\\=0W'A.U;P]KEX\WBR"ZE6>>RT>.*U1GD=;;Z8_X(^_L0_$C]C/\
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M<O@CQG\-_@_H.C)K-[KWQ#\)JNOKK/@75S)' MPIC>!OM$08QQ_Z1-?R@?\
M!H'_ ,F#_MB_]I/_ -H?_P!4O^S-78>B1_\ $8__ ,$E/^A=_:__ /#/>"?_
M )]-'_$8_P#\$E/^A=_:_P#_  SW@G_Y]-?UAT4 ?R>?\1C_ /P24_Z%W]K_
M /\ #/>"?_GTT?\ $8__ ,$E/^A=_:__ /#/>"?_ )]-?UAT4 ?R>?\ $8__
M ,$E/^A=_:__ /#/>"?_ )]-'_$8_P#\$E/^A=_:_P#_  SW@G_Y]-?UAT4
M?R>?\1C_ /P24_Z%W]K_ /\ #/>"?_GTT?\ $8__ ,$E/^A=_:__ /#/>"?_
M )]-?UAT4 ?R>?\ $8__ ,$E/^A=_:__ /#/>"?_ )]-'_$8_P#\$E/^A=_:
M_P#_  SW@G_Y]-?UAT4 ?R>?\1C_ /P24_Z%W]K_ /\ #/>"?_GTT?\ $8__
M ,$E/^A=_:__ /#/>"?_ )]-?UAT4 ?R>?\ $8__ ,$E/^A=_:__ /#/>"?_
M )]-'_$8_P#\$E/^A=_:_P#_  SW@G_Y]-?UAT4 ?R>?\1C_ /P24_Z%W]K_
M /\ #/>"?_GTT?\ $8__ ,$E/^A=_:__ /#/>"?_ )]-?UAU_*!_P:!_\F#_
M +8O_:3_ /:'_P#5+_LS4 1_\1C_ /P24_Z%W]K_ /\ #/>"?_GTT?\ $8__
M ,$E/^A=_:__ /#/>"?_ )]-?UAT4 ?R>?\ $8__ ,$E/^A=_:__ /#/>"?_
M )]-'_$8_P#\$E/^A=_:_P#_  SW@G_Y]-?UAT4 ?R>?\1C_ /P24_Z%W]K_
M /\ #/>"?_GTT?\ $8__ ,$E/^A=_:__ /#/>"?_ )]-?UAT4 ?R>?\ $8__
M ,$E/^A=_:__ /#/>"?_ )]-'_$8_P#\$E/^A=_:_P#_  SW@G_Y]-?UAT4
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M ))=_P %/_\ M)Y\9_\ TQ>&:_K"KM/5/Y0/^&U_^#M#_I#;^R!_XD=\(?\
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M[('_ (D=\(?_ *-2C_AM?_@[0_Z0V_L@?^)'?"'_ .C4K^K^B@#^4#_AM?\
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M7_@[H_X(SZ]<?:]=^&_[4.M7 M_LWVO5O@%\-M1<J#G87G^*,CX.>0#LQPJ
M'FQIG_!WW_P1VT-)(=!\!_M5:+'<$>?_ &1\"_ASIZDC_GI'#\4D67VWJ?SK
M^MLLN."1[ 8_I_A0&7'))]B,_P!/\:XOJ6 ^M_6O[,AS6M?G5_OM?^MAWE;_
M (&G^?EN?R?_ /$8_P#\$E/^A=_:_P#_  SW@G_Y]-'_ !&/_P#!)3_H7?VO
M_P#PSW@G_P"?37]8=%=HC^3S_B,?_P""2G_0N_M?_P#AGO!/_P ^FC_B,?\
M^"2G_0N_M?\ _AGO!/\ \^FOZPZ* /Y//^(Q_P#X)*?]"[^U_P#^&>\$_P#S
MZ:/^(Q__ ()*?]"[^U__ .&>\$__ #Z:_K#HH _D\_XC'_\ @DI_T+O[7_\
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MW@G_ .?31_Q&/_\ !)3_ *%W]K__ ,,]X)_^?37]8=% '\GG_$8__P $E/\
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M'Q]_ZNOXL4 ?N-1110 4444 %%%% !1110 4444 ?'?P@_8P^"GP'^,'Q?\
MC=\,H_B3X>\4?'?Q=J_CWXHZ'<?&#XGZK\./$'CC7PK:OXT3X5ZYXIN?AKH.
MO3B/$MSX:\,6A)"R'#$%?K\ E#]<_7M_GZ5+163@G06'OM!Q^\=W^-_F%%%%
M:B"BBB@ HHHH **** "BBB@# CBBCW,_)">=TQP8(UE''<B( =N?4<_+O[*O
M[(7[.W[%O@[Q'\//V9?ACIGPG\&^-_'VI?%?Q1X=TS5_$^JV^K>/O$.BZ%H6
ML>("_B37/$%TEW<Z%X1\/6\EO;W"VY72(BD,;R2R'\W_ /@X6_:'^(O[/?\
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M6O9Q;CQ/PU#B6&CO9I2Y7J_A37NRC?H:***Z3TPHHHH **** "BBB@ HHHH
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M]9\4Z390>)]%@UK1]%UE[CPSK?AK6S-:V^MZHL2K=BUD261W,@CA<<E^V_\
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MG[57C_\ X(8?\$UOA5\0?BI\7=/G_;:_X*$>%?V4D^+EYXEUFS^+6O?LL_\
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M4^&Y[C2EDC=#/;K)"9MZJ%E4Y /JRBOCKX6?MZ?L+?';Q19^!_@=^VK^R?\
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M9E*27,^#^%>)>9M<BXHCPU.7%5)\G,H*I6X;F_9OF_U;J5'*'-%.,?JCQ_\
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M1+3X1?$KX.Z[\+_V=?A%\5?"WBSX=?$_X_V7A[P#X&M-8N]2^%'C;PY'\1O
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M?\'"G[='[6WP+^*_[!7[+WP/T_X>:/\ "[]J;XZ>"9]?\0S^.O&EKXW\=?\
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MW7;6*75TG\6?%SQ+X/\ !]EH_B,?$'QGX3EMD,_NO_!+'_@KIH__  47U/\
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MX8U_P3XFC\/7'A3PM/8IXV\-V?C"+PSXSN)?"R?F)_P<5_LU_%>T\/?LH?\
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MWO\ QC^P?K_PMB^%V@>-] ,.J> _VB]0T3P;\(%U^;X:^())(?#OQ!T#PZ/
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M1G%<G[7?MB?\%J/@W^P7J?[.>G_M;?LN_M6?"9?VF+R?1?"FIW<O[*/B33_
MFN0:]#X=UO1?BAJW@C]JO7H]"D\/Z=K/A[Q?<Z]X67QEX07PEXCL1:^+K[QE
M9^,?"?A*GX-_X+N?L1^+?V@_C%^S)JOAS]ISX8_%GX6>$F\<>&?#_P 4/V?/
M&'AC5/C]X>EB6#0S^SWX(+7'Q0^(.O>*4U/23X&\'W7@/PEXN\?//"W@6Q\5
MVZM+7X/_ /!S?^T!\+?%WQ;_ ."-FICQ/8^%[J/XOZE\9M5\*>,YU\&^,_"7
MPUUOQG\'VT/X@>-?!NNI8>)/ GASQ&OA375MW\8Q>&[II_#_ (@B$:3>%?%(
ML=[QS\?/@=%_P=M?!KQ@_P 8OAH?"4?[-NE> 9O%<'C[PPWAV'QIK'PL\=0:
M#X+FU[^W!HDOB#Q-)XBT.WLM!\\3RSZ[H06 W$RYPR6E6QE/*\/F%&JIYOQ+
MXL\/-TXU&H4.$.$\-Q/PK4YE2J14<3B,1]43<H*:@U3YZL7!;9M-4,&\?@H\
M\)<(\,<5P;@TI5.).,(<,3BG))M0X6E[=6NXQY:C:A:H_P"B+_@G?_P5#_9>
M_P""CVG_ !C/P0TCXQ^ _%_P%\7VG@WXJ_"SX\^"K+X>?$KPMJ<4VOPV7]HZ
M)HWB#Q;8K'<2:'KED;=;R/Q)93Z#-9^*;*UO L;<;XH_X+1_L>^%+KXF>*VT
M[XI:]^SG\%OBYHWP$^-7[97A/P_X-U#]F?X:?&/7M8TK1H_!FM:T_P 0H?B?
MXC:TUSQ%X>C\4^)_AC\)_&W@7P?_ &O:-XP\66!DR/Y^O^" 'Q ^'/Q'_P""
ME'_!=KPWX&^+/@J[U/XZ?%#Q'XJ^$%YHWBW2]1;QSX6F^*/Q]1?&W@9[-Q)X
MA\,>&1XJ\)O/XAT+?;BW\2:%,08[B,U\+?\ !)GP!^RC\.])_:3_ ."2/_!5
M/X+_ +:6M_';4OB]J'C#X:_ /P7\3OV[-*^$/Q\T]AH<2PI\)?V?_B)X9^&-
MV]GXK\%#Q;%\:_BCX7@\&W&GFWOYO'5M#X12./2C0>-QO#MG.*SGPOX-XOIT
MI2E+$\0\48VE'_6WAB,*U"A./^J#4I5'.$IR=1RG:/#THF^-C_9;XH2DE3R/
MBN?#,J:@N>GPQ_JQ[7ANK/EJ24XNI>*J1_=U%2;=G*"7];'[:'_!;']FC]A'
M]HGX.?LY?&OX4_M)ZMJ'QYTK2-;^%?Q$^%G@[X>_$[X>^)M(U:>UTJ.71]%\
M%?$FZ^-=Q<PZW=Z7X?6U@^$5Q=ZG>ZIN\'+XELU$S][^PQ_P5^_9L_;W^(WQ
M\^"_PS\ _M&_#+XT_LXWWE?$CX1?M"_"O_A5OQ$&D[QI1UG3=%;Q+?IHD7]J
MA8+C0/%\OA'QM;2[WG\&VPF\V/\ GG_X*R^/O@C\+?\ @MY_P0O\+:MXT\!^
M M-^!>C^%-%^(FC:G\4]+O8O@YI?]J>&AX+TWQIKFN7)N;*%8K8M:^)/%,T<
MWB^",SO(K*9I+/\ P2J^,/PEUK_@YF_X*O3:;\4_ ^J6WQ(T#Q7H'P[U#3O%
M6D7-GX]UC0M7^'LFO:'X,83NWB37?#D>BZ\LL7AUIS#;:%XBE<30PB1(RNA3
MS&NL'[.I%NAXH8A24I*FGPKB>&J/"\)4O9RIM8BG.=1OVB_A2]FZD54E'AQ^
M-QF%H^T<&ZBI^%U246I-.7%&(E#BB*3A&<8TH*$E).3BZD6U&ZY_N;_@G5_P
M5K_:/_;4_P""I7[:GPJU;]FKXQZ-\)_V?5\!_ _3OAUH/BGX%7B?!+Q/H_Q(
M^)>D^//BE\:KGQ%\:O"\>NZ[KU[I']@&/X$I\88X?"_AR!+*&YS]N\4?U#7$
MBJ-H!^47 _$0S.?S+?3Z=*_B<_X(M:U>_ #_ (+H?\%>_A1\2? WC_3/B-\;
M_C'J'BSX<:/!X%\67L%]X"N?B[\2?&3^.M5\8RQ3^&O#W@8>%?$>D>)%\3>+
M/$UJOC,^78>#O^$G\:WD/A6Y_M@D59)9 .H*CZF6"56[],X_#IVJ<*YRX:X!
MQE)0?]K<'<+5ITY-RO7=!KB!Q<K2E&%7G@Y2M+FBT[RBVNO$.C#B;CG P2C3
MRGB=4X.$N:,H3PG#=6$DTY*TXM2CROE:O)6YW?;HHHK<ZPHHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'(XG\0_!_0?"WB74H'%SXO\ ^$8SLB: F988Q^A'_!:']FOX/67Q*\:_MW?
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M/VL?$5S\4DU[QI*LWV--<AL_%GBT^'KSQE%X6FCDL_$LW\[7[;7QP^#NL?\
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MUG]F_+&$8^C44451Z(4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MN\G97M=I=?S.+!8?#8"@L-AN\I/SE)N3?E>4I/?>3\A:***DZ@HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***^<OCO^U!\$
M?V;-,T^\^+_CNS\-R:HI&D:/;6>IZIXAU]D;8T>CZ-HL<MR[[MQW ;,#!(8
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M5K?U9?</J&;S/*E\C'G;?ESTW<8SGVZ=LU-15%G\P_\ P31_X)A_M]_L@_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MXW19HYBB[0QV\A0#N:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HKQ#XY?'?X<?L\^ ]4^)?Q+U?^S=!TS9:VEK9JU_
MJNMZFWF&+1M%TA'C-QK+LA"1H<A=P=QC:OPO\"/^"K7P%^-/Q#T_X<7FB>*O
MA[J&NW!L/"6K>+ETEM U'57?=I6B:O-I,]ROA[7I5"A+:7,8(56N H5D /U7
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O@#_@H9^T
M[X^_9.^#/A/XB_#W3_"6N:QK?Q/TOP3=6/C2PU;4=(>PU?PAXYUYY]NA^(?"
MTRO"_AZ)4)N7C*OEXV95>OO^OF+]I_\ 9=\"?M9> M$^'/Q%UKQ7H^A:'XMT
M_P :6UUX*N]%T_5SK&C:3KVBP,DNO>'?%,0A2+79PZ"W,CGRR)08R)0#\'?^
M'U7[4W_0@? #_P )KXE__/(K\[/V@OCYX_\ VFOB=JWQ2^(QTZW\0:G9Z7HE
MGI>@66L:;X;T/3-"(SH^B_V]XC\6+N8Y\4M@#YM?Z 5_0;_PY7_9<_Z'SX^_
M^%/\-_\ YV5?CI^W1^QAK'[*?Q%8^&;+Q;K7P:UFTTN[\*>,M8#7\NEZMG_B
M>:)X@UC0O#*>'(_$,GB$&2(R(C20LD@4!A0!\^_L[_M!>/\ ]F7XE:?\4OAS
M_9MQK-M9:IHMWI?B&SU?4_#6NZ9KN"NC:V-"\1^$URK >*AE6&?#X.#7Z)_\
M/JOVIO\ H0/@!_X37Q+_ /GD5\\?L'_L3ZW^U?X[GG\4V_BWP[\&]#L]3'B#
MQGI!_LW5=1U0O''H>D:'KGB#PT6&NQ&16GD"/Y4>7*G !_8'_ARO^RY_T/GQ
M]_\ "G^&_P#\[*@#Z&_X)Y_M.^/OVL?@SXL^(OQ"T_PEH>L:)\3]4\$VMCX+
ML-6T[2$L-(\(>!M>2?;KGB'Q3,SS/XAE5R+E(PJ92-69GK[_ *^8OV8/V7?
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!7&>*?">B>./"?B7P5XHLCJ/AKQAH&J>&O$&FM=/:?;-&UW2I=$UG2B^ELD@
M\RTDE@E='ROGO'"X5%QV=% 'Y^?\.M?V%?\ HAP_\.9\9/\ YXM?E5_P4O\
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M?%>M:'H<TS+:^?X4\+>,_$J.XE/A"XMP7;]"?V=?^"B_B#]H#X,?M8^([?\
M9U\2?\- _L<?$WQ[\%_BW^SOX$^(7@WQ@FN>/_ NE?VQ;1?#+XG^.1\(M"U[
MPUXJT:[MIK#Q#XF\/>"[O<MVI\+^;#&+OBK5X_V#3SA1<ZDN%^)N)I<TZ:]D
MN'.+>+.%%.2O3Y:3GA87G4Y5%U%S2Y$ZL>QRY<U>#5N51X5;E\*_XRKA2'%2
M2=FG\4HWC>SC9VE))_<OP"^/GPF_:8^%?A3XV_!'7G\8?#/QI_;+^&?$<F@>
M+O"[:E_8.I:MX?U<OH'C;0_#'B33)+?7]&U;39A=^'K9IWM9)84D@:&9O7KJ
M_P!.T^WNKZ\-O;65G;FYN;JXG6*S@M1:L[.TCE8U3RT* D 8Q\_*BOR@^!O_
M  5D^'GQ8_8(^#W[<FM?#+Q7X47X]>/F^&?PC^">CZOI/C+QUXM^).O_ !2\
M1?"SX>>#(-8\CP7X8.M>)FT1_$7BTW#IX8\"P?\ "1)>>*;A?"TM[-Z3\,_V
MX?B5/^UQ'^QY^TC^SOIWP?\ B'XS^$OB'XU?![QM\,/BEKOQR^$GCGP+X0UN
MVT+QGI&M^,?$'P8^#%UX'^)G@]]<\-3>*?"@\+^+/"_V?Q1X=-CXZNIYK:VN
M/0JT82Q4\)"K2>:1C4I."4&U4I<./B:HK*WN0HQ?$<E?W8IN[:2.&C6PKP_U
MN4K04I-WBHW@N)GPOHVK2<*S7#C:4K27O)*[/?\ ]FS]LS]F#]L33/'^O?LN
M_&'PM\9_#OPT\5-X!\8^)/!*ZKJ?A6T\6+H6D:^='TCQ";>/P[XB:#1M7TN1
M[OPQ<:Y9*]P(C/YQ=*^IO(=^5VG]R8P 1T9?EP/=LY/&,8R,X/\ .E_P2C^(
MG@3X,^(_^"Y7Q6\?:QI_A+X>> /^"BOQT^(7B_7;MS'IFB^'=&^&'P]\0^(-
M:F;!RD=LMU<.HP7,85<N55OK#QC_ ,%-OB'\'+S]G+XA_'_]F&U^&'[*G[6G
MQ'\$_"[X4?%G3_C;!XM^+7@#Q3\5-*EU?X5+^T3\$6^&OA?P_P##_2/%\<7V
M6XN?AG\9OC0/!TL+_P#":?V<LDBI4*4,:LII8%\D<[X<X2K0C2FH5W4XGX7I
M8F*]R*4J<Y3:X;44G4IVLFY13=7$JE'-)XN+]GE&?\314Y[*'#<(5)IRTCS0
MIU(N6RNUL^9+]EJ***Z3N"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ K/N[.RO[>:SO8(+FUN ?M-M<0
M!DD4C^)3P>@Y()[ANE:%% %"SL[:QMXK.S@@MK:V7_1K:W.U54 \ ''!+'/7
MKDFK]%% !1110!7R) /4'C)QT]??T]1[XKYC_;#_ &;_  E^UY^S'\;/V;?'
M42KX;^,_PW\2^"+ZYD4R-HM_K&FLNAZZJJ48W'A?7QI/B6W RHGT>,NCJ"C?
M3Z*IZ$\=,<?CWS3^N >?S&0/IG)[XX_"N/,<#A\QP[PN)4N6ZG%I\LX25G>+
M3NK-)Q::::33T+P]9X?$1Q6'?O1:DMOBCJGKOKT>]_,_F:_X):_M'^,/VO\
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M*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@#FM?T+0_$NBZEX?\1Z9IVMZ'JEB;'5
M-)U6S34M.OK!U#-%J6E3*L<B-LQM9" 0"=H4*OB_PV_96_9Y^#^N:CXG^'/P
M?\%^%/$-^CJVMZ7I^;^VC:)O,320X9= C8,4,7AQ;=6R0RL1BOHVB@ HHHH
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M6*-?&?B*#PEXJ\7R">6W\&>#KV<RO!ZOUA>7X?YG<?H5L7T_4_XT;%]/U/\
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M*YVT*+Q6)6%5KRLDVG:[VVU[;+OV9^L85,+R#@\'UQ@$9XQVZX]?HIV@GG+
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[4LWY7[6:=XR=W9Q]V.CT6D=6F5BD<[( <%-C@>H91(P/3H6 ![GIS7Y%_\
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MU/[8J\34:4U&$KOA?A.?%,N2,4Y<1MN"I0BO?_UIJQI^[*2B?V(?"?\ ;?\
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M6WUR[TF\LQ82:EI6INT4>E:#:-'*K:6@C9FD#K(R@*Q25/J%6W*25P/?J/\
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M9WCK"3XGJ<4R?^M,6WX)\??#GPH^(?B7_@G5\//B3JGB3]I&"3X!ZCK.E?\
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M/\*^%K:[\:>!)H)K:\@\(2627GS_ /MW_#?]GSQQ^UWX,\/?M8?\%&/VU/\
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M-.&U+_C&)J:_XQN49QXDXFBIVJ2AK3C;V:_:ZBBBO0/6"BBB@ HHHH ****
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M1TKP/K&@3>&$N+<D>3.EO'+"!Y<;IYDN[?T#X#?!'PGX\N/BOX4^#?PJ\/\
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M:^-%UJGB+7+OXQ:!^S_\)M,^*NI:UXPENAXDUBZ^(&D^%8?%,NJ^)UUG5?\
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M7A#+G;<021K(JX3Y>?E^V_X)O?\ !/2V\&ZE\,[7]A/]C>S^&VMZ_I?C35_
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MP1\9/"WC;QZ-%T6:2+Q'K?A_X6:)JR>'?%>OV%N\'AR*"VDEE)N;..X_M +
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M_:@TW]GS5?C)\(Y/AO\ M4? /P+^SZ_@7XW>+O!GB">::>/Q1\+/#NM>()O
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MX3>+;?QO?-!X\@O/"7C&X\72>//G?_@C#^QS^TC^PG^R5;_LR_M$0?!"_O\
MPQX]\<^,/"GBSX,?$WQ]XST_Q!I/Q0\>>*O&^K0^(-*\=?!CX5W/AJZ\+2>(
M5T.Q6UF\6IXEVO=SS>%MD<$F4^7B:/&<LU5.^=\-<*0:PSIN\GQ/-\3PX<]I
M&57#_NI)SG=.$)X:=*<.*.%I<[C4GE&&X9P67S][*N*WB91U4].&>*)\.SYD
ME%Q^LU(.33T3J14$IQ:UOV*/^";NC_#C]C;]BGP+\8)O%GA[]IW]GW]G#P[\
M.'^-'PT\<Z[X-^)?A)M9CAUWQ!\,H_$^AW/V3QS\./#7B$Q0VO@OQC%XF\#2
M2>'=$O3X.D$FT_5L5G^V=\(KBWMA?^#OVOO!-K=ES=ZLFC? 3]H*TT=2R+YT
M^AQ'X%_%OQ.^=Q6/PO\ LS>%=N'WJRY7[:V#Y!Z>WN1_@>?Y4;MV\'\!W.,C
M'Z]?I^/JUL0\1F>8YI44>:I=3C&_*GS2G)*[U4>:ROKI=N[9E0P6'P^%P&$L
MWRMMO;GD[RDVDDE=MO;R6EC^=3X-2^"O^":W_!13_@H<_P"T?XK\+?"'X!?M
MNZW\+_VA?V?OBAXNO-.\,>"?$7Q)BT37O"OQ=^#XUUYE2?XMCQ OA_Q/X2\(
MQR-XE\;VNMR?\(=:W<L-S#+>_P""8W@JS_9#_9__ ."@7_!0+]JN/6OA!X7_
M &G?VHOCY^UWJ<7BOP=XQ3QQX!_9VN'$/PS3QGX+@7Q-XK3Q$GA*";Q%/X;A
M\,CQ7&_B(6\ME=2".&+^A"94\G9)+M3R) 2.O$0W'CNA D ]">031 L9A")+
MN00( 3GC,)P1UP7.9#QD #))%>5A<''!49SP4Y0E6X<I<*U9<L'&7#E/B>/$
MZA3@W>G*4*5+A^UI^Y!3O>51.?JU/ZRZ;C_PF/B)<3.ES*_^L"@Z:6[?*I2E
MG]GI[1ZIQ21_/Y^WIX<BOOVH?^"6O_!5SX?37_B'X&? [5?&7ASXR:]I_AC6
M;B\T#]GK]K#X?6OA[1OC%J6D/#:>)M+\(^#/$L6A2^.YKCPQ/>^$/"WB6Y\:
MW,-E9>$O$VYOA?PIH/[<W_!7WX:_M=?"C5-&^(_[*'[)'[(WC[P#H7QL\/74
M7B/X;_$_XZ?''5[I==T7X4^,-#N[GPOXSM/"GPV58O&WBGPG<R6R7&OIX+N0
MY\UE_H(A6$"$Q\ QA4]UR/O=3P<_H/I746I:9@I!V-O! (V\A@#C/S97KQR>
MHS6U/#X>%*%",'_9$8<5I4+-4U#BMP@U"UE>BJO%$5=\E1<45TTFH-U7PM;$
M\M1RI^TE_JU#/Y)7]K'AV%TM;J/M/=NTFU&*M*[E)_R^?L2_$#P]_P $O?V0
M_P!J7]@7XPZA%X=^.7PN^*7[1^I?LI_"5%,WCS]JWX;_ !/;Q!\0OA9J?[.W
M@^"5-=^+<UU+KK>&?&$?A..=O!/BVTNX/'DWA4;K@>/'_@FA\7/V0?\ @G+_
M ,$A?%D7@F7Q1\5?^"<G[1'AK]H;]HOPKX9TH>*/$"> _BWK6KS?M)-H*0RO
M_P )#XA^%MOXD'B )H1?S8/ DLT5NQ$5R?ZYT1=P\Z2-\+"I7)XE?G<<#G<
M2IR1R,GK2B0R;=DR,")XP.1OD7H!V_=Y4L3@8Z=>71I8U.6,=6:S-KA=RDY.
M2DN&:<X2C&I*'-27%*?M.)E'F]^473:]E&[Q%&.*698;%N3RW$?ZS\T%:+YN
M*(RA55E*T5A_:/\ U;Y$G3DHRU<87_G?^*%MX2_X*4_\%/O^"=OQ1_9Q\:^'
M_C)^S5^Q%I7QG^./Q3^-/P^U*+QG\)[SXF^/]+\-^ ?A3\-/#_C_ $.=_#FO
M>/;>32==\5^,_#'ABYED\$1Z+'#XUC6::VLQ^B[?M_?L,?$+Q?\ &W]GNS^+
MWACQ?\7OAM>^*/ /Q)_9QN?#GBZ3XVZQ)'!!'JNF>'O@EK/AF+XC_%;P[<1:
MO"A\3>"_"OBOP7<IJSM'XB>'[7+%^C,(C,2%!\H P2 "-N<'CCC)P:B(A4QD
M;@=SE3@ Y)&3G\O<C\!4RPF'>6?V2VO[):XF2C=-I<3U)5*BNU:2O.S35I)6
M2C>YT.%7ZPL6KK,>3AM)QGRK_C'7*5[Q49)SE4G)2C-3A)J2E)I-?GO_ ,$X
M/V;=1_90_8P^"'P-\0VXT_5O!FAZS?ZAH,>J-KUEX)E\;>*M8\;/\.=+UR78
MU]H_PU76X?!=G/RDECX?M6B>2+86^._^"'OP\U2P^"O[6OQ5F(7PM^T3_P %
M%OVQ_C)\-[IM@_M3P#)\3Y_ .B:V,G.[Q!/X)U*X&<85_EY9J_3/X]>"OB1\
M2/"$?PO^'?C33_A;IGC :CHWQ$^(MM ^H?$/0?!UQ;)_;,?PJTQ[>3PY#X[\
M3K(;*S\8>*9KBS\#M*WB2/P=XSN4BL4]/^&?P[\#?!KX=^!?A1\.- TWPK\/
M_ASX9TGP?X.\-Z6GE:=H7AKP]I8TS1](B4L6V6\$2Q(!ECY9+Y?<3E.I/%8G
M-,3B)05:O1H\-4HTJE6$52CQ"N(JBA)J4I)2R'AM0E!)\JS_ )^5P][F]A3>
M"R[ Q3=/ZPN*:BT=J\?]9H)-:*U^*N)4HZ_%%**NE'U:BBBO4/0"BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH B7.PAL,/8C!YYY&>G^?2J;[(07
M54CSGYI6 X]LX&/7'<=:?$QB5(V;YCEF/H!D\_A^'(&*^*_VV?#^O>*/AIH4
M/AK1]9\07%MXTTVZO;'1-.U:^U 6,6E:VDLBKHNV0*"\2%R=@+JN S*6[L#A
M_K.+6%4E!2:7.U[FJERW3E&*3<79N27J>CP]ET,^SC*,GQ>:0R19S5C2E7JN
M/)04E)RJ3<I07+!)<WOQLFGS))M?96V ]+J%0.N/LQ]>H"#TZX/X5R7C7QCX
M=\!^%]8\6>(;J"/2M$L7OKLC[*TDRJK@6D:^6Q,CN41>V6!. &K\*_\ A4WQ
M7_Z)=X__ /"(\6__ #/5EZW\/O'/AJQ;4]?\&>,?#]DH%FVJ:]X?U;3].4'C
MYE5B5ST&<9["OM\-P1A9S4?]8,/*[MR1Y'-];*U=N^F_++9Z'[]A? KAF>+C
M!^)>#FFUI"CAVWU:27&$M;+>SLD^UU^_?AWQ!H?BO1-+\0:)>VTNEZQ9I>V5
MPJP9:&3&TE3$K;L[N#W7(^4UMA;?_GZA;'9DMP>O3.P\?C7\^.E?#GQ]X@LK
M?4] \#>,=7TJ[&ZSU33/">K7^FWX/&<,P.,@X(]#BK?_  J;XK#K\+_'P_[D
MCQ;_ /,]4RX)PT9-?ZPX>.K7+-KF7D^;$)WU5]%Z*YAB? K(H8MP_P"(DX*-
MFU:5+"IQUVDGQ?'WE=7T7IJ?T$ILF =E23&/FB8'CWQD8],]SUJXV=@"X4>Y
M&!SQR<=?\^E?$7[$WA_7O"_PTUV'Q+H^L^'[BY\::E=65CK>G:M8Z@;&72M$
M2*1EUK=(5)25 X.PE&7!96*_:DK&57C5OF&&4^H.#Q^'X<$8KXK'8?ZMBWA7
M)346USI>YHH\UDI2BTG)7:DUZ'X1Q#ET,ASC-\GPF:0SM9-5E2C7I./)745%
MQJ0<937+--\OORNDWS---VL* .>G(]S_ $Z8[8[FEPIW'(Y].W.??K50N0D9
MR>?\_E[5^0W[</[??[4'[(_[0/[,/P=\&_LL?!'XT^%?VO?BS;_ WX1?$'Q/
M^UOXT^$^L:'X\B\'7/BC7&^)_@C0?V-?BW#H7AE1I.K);>(_"7BKQE<7$<*-
MJ/AKPWNPWCRG'ZU@<(HIRS.55*[MK"DIO5NVL;_<WZ^;_P N/K'DG]\K?GJ?
ML/17YGZG^T/^WS\/O$_PPG^,_P"Q_P#LO:9\+/&GQ2\$?#/Q;XZ^#G[=/Q,^
M)?B?X=6_CS5O^$=T'Q=+X+^(7[ WP!T'Q!HB^)M8T#P])';^-[><RZW!S+B4
M/^F%=0PHHHH 8 N% .=N<>__ .KC_)IA5-K9/RDC/!]_0@\_YYJO')Q$<G+;
MN_?IS_+\*_(K_@H9^VK^T+^R/\6_V#O"7@#X:_!OQ/\ "W]J?]J?X?\ [-OQ
M!\;^-O$GB\^/?"FI>.=2_M=7\&^"-$T70/#\R2^'-!\1M%XGO_&TSKXND\.6
MS>";B$N\V*ES8S 8-)<V:S<%=V7-R*5VWHE;?T9SXBI'#83,,6[6RJ#G:^KB
MHINRZ[K1:^3LS]@Z**SKFZ@L[::]OI8;:WMK=KJYN+@J%M %RS$G "*%;OG(
MP,Y K8Z#1HKQKX*?%_P)^T!\-O#7QA^&FJ0^(/ 'C>WU&]\):]'L,>M:1!K>
MI:3'K.GLX=ETCQ"=)%U:?ZHM"R2!=S"1?9: "BBB@ HKP'XK']H/_A(?@K_P
MI/\ X4M_PA(^)!'[0?\ PM3_ (3G_A*/^%1?\(YKN[_A27_",?\ $B_X6-_P
MDO\ 8&W_ (3;_BE/^$7_ +?V_P"E_8Z]4UR37UTG4VT"QTF]UR*UOAH]GJFL
MSZ1IUQJ 6$Z6-2UR#0/$<^CJS,Y::/PKXD:'B1;>Y*F&XSYE]76)LM8MVZZ:
M?U^?0=OSL;S)D@#G=Y>#_N#!(_7OSVJ,H2)!UX8YX'WC]?<U^3G_  3 _;5^
M/?[86E_M>Q?'_P $?"7P'XR_9L_;%^('[,]KH?P;U?QEXE\-S:7\/O#_ ($;
M6M6_X2[Q]%X9U_Q)/)XEUS79K?71X-\#1/X6_P"$=>/PA'<R9N/UH+X+\=1)
M^.W!!/IVSC@X]*YZD*5%X&K+=TZ5116JY<]BJD&I:75FG>WSOM$E-SQV&>\&
MX_?&WIND6\C&<C'KVHR,9R,>O:H Q\K/N?T']3S7Y8:)_P %!/$=Q_P4AL/^
M">>N?LW^,/ 3:_\  OX@_M">&_C%XB^)7@K4=/U_PQX-\=:%X#T:RT/P5X#7
MQ2R_\)3</KGB4_\ "4^+]/U#PIX4@\(&_P#"PO/%]UX5\(]*:>(6'TUBW?R2
MOZ"O_L\L39>ZE?Y_B?JD AX&0?U_K_C^%25\+_M1_M>V?P)\9_!CX(>!O!+_
M !=_:6_:3USQ/H7P6^$[>(9O!OAS4+/P%HG_  DOCKQM\3?'S^'?%L?@+X9>
M#O#YM3XP\2VO@_QIXL#Z[HEOX,\!>,KIIHK:M^S/^UR/BW\0_C#^SG\1O!6G
M_!_]J#]GG_A$;KXJ?"[3O'J_$CP[>^%/'>E1Z_X+^)_PQ\:RZ%X+UOQ[\-_%
M#?VWX>7Q+XE\#^!_%]MXHT"]L_%O@73Y'M5F*'+B8MX5^ZM7=;?\ QKU_JR7
MUGJKIK6ZZ?UY[W9]XT4459TA1110!54!3&@Y'?C]/T]/Q-*#D2#/ ']?\\>O
M<\89,\4,;7#L%CC&6/4)COP/4X!]_6OP+^+W_!3;]J7X?^/_ /@G+<Z9\*?@
M!J?P%_;]_:@U+X5:)XWN_$/Q%?XCZ-\.]?\ &VM:S\*=;TWP4NAV?AS=XK^!
MNB:/XK?Q3)XSF7_A,/$<5H/ 4-GX:>7Q5R2K)8O+L(OBJJ[?9J-E?YZ?<<N(
MJ_5<)F&+Q&D(7?FU;_AWZ:Z'] %%%%=9U!117R7^T'^T+-\-O$/PY^$'P[\/
M6OCG]H/XTWGB.;X<_#^\U?\ X1_3K;PQX$:VF\=_$OQQJZQW$NB_#_PFFJZ)
M#YJ1"7Q?XN\2>%O ]D\=UXL6:WYP/K2BN4T%-:BTK2X]?NK"^UTVMG_:>H:/
M93Z=IU[?@1IJ+Z7H=UK?B:71=);:-D!\1WS0OA&GF;:\_5UT %%-WKZ_H?\
M"OBG]IS]LWX+_LV?""3XMW^I'XD&[^)'AGX%^"O!OPQO='\1^)O'OQW\<:Y!
MH'@CX6Z+))K@T#1?$4_B;4;6.5/%,T,'AB!9IYXU @BFYOK"\OP_S ^V,@=3
MBD;&.>G^>E?G3\+?VTO%$?[17AO]DS]J+X3>'/@#\=_B/\-]9^*_PB@\%_%H
M?&7X;_%'POX3UI-)\::'I'C+6OAM\'/$L'Q#\$QZQX?UKQCX:E\!R^&4MM>A
ME\'>._&"1WL]?>.O:YIN@:/>:WK-Y;Z=I&D65]JNJ:E<MLL[&PTM6EGEE<GY
M/*B1I#CG$4@7)V*=L0_JV'>)>FBE\F][^5G?:UM2*3]OB989*[[)-M]K+=MN
MR22;;:MUMOXC&>#S_N]UQV/]T_E^-&(SC@\?[O9<=S_='/M^%?BY9_\ !5J%
M/A'X6_;)\3? B7PI_P $\O&WC'2/#>C?M&ZK\5Q%\6-/TG7?%B_#W0/C-XQ_
M9Y7X>-HGAC]GOQ7XG.CW%MXJ?XT'Q[9>#M=C\;^,O@YX2B2YMX_J']HK]LFV
M^$OQ-^#/[//PF^'=I\;OVEOVA](\7>*?AEX"N_&TGPX\#Z?X(\":.FL>-_B5
M\3_B1_PC/C27P1X#LVU#P[H,5YX;\#^-O%?B?Q3XBM+33?!5W"+F:WY8/VCD
MH4Z$W"56$N63?+.CAY<258-\JM.GPU&?$,X.TX0A-3@I1DHRL3AWM.?V7\/\
M]E'2]WS)JUMVU;=-_H/L7T_4_P"-&Q?3]3_C7PQ^R_\ MEZ-\>M<^-_PH\8^
M&H_A)^TE^S-XDTCPS\?_ (1Q^)E\8:7X=_X271X/$'@[QQX)\=7'AOP?_P )
MS\-/%_A[-[X4\377A3PCJ1"W">,O!/A2ZV6[?(W_  ]@N)OA%J7[9NF_ QY_
M^"<VC^+9O#=U^TM=_%3['\7+[1M(\8-\.M4^-6F_LYM\-UT&3]G<>)8?-'BX
M?&N'Q])X12?QM'\&!;AXUZO:1[_D1[==U_7S/V7V\1 >AQ^9.*-H!F'L#GUP
M017RI^T/^T$WP8^"-Q\5/AUX*O?CYXX\1G2=$^!7PL\*>+=&\/:C\=?B#XRR
M/ ?A#0?'&O--X9T31/$NY];O_&-R[>%_!_@FU\1^,[B*6S\-OO\ GK]D;]H'
M_@HM\?M.^+EG^T[_ ,$^-"_8"U+1?#ZK\)=>U_\ :L^%_P"UAI_C/Q-JO]KQ
M^3K/A/X/:%X4ET?0/"[QZ5+<33>*+:?Q,L[P6GD-%]H:?;1_X4GRQ7]DZ33D
MHR=X<]E&34FTE9I)M:MI6ER[6E_L&ND[:]M-?5:W^_Y_IW17R-^SO^T)?_&:
M?XA_#[QWX.7X:?'SX)ZWH?AOXP_#2VUL:_I6G2ZM9-KO@WQIX%\2I#X;'CSX
M0_%#PUL\1^!/%*V]K=*8_$W@7QWX5\'?$'P9XR\(V'US6I04444 %%%% !11
M10 4444 %%%% !1110 4444 1;3MZ<D@_A@]?\YKGM>U[3_#.DZGK.IRI:Z7
MHNFZCJFHW3?=M;#2H7GGD*YR0D,<CX[[&'4C;T.X[>O(('X8/7_.:\_^(OAR
MZ\5^!O&GAFPF@@U'Q/X3\0Z);W-SG[$FH:QH\^DP%\$OL2216* $[<@Y)(.M
M%)UK3ORNW-T6ZO?TWZKK;0UH?5_K$/K%K7ZZ.W,N;7HTN9KS/'/^&N_V=^@\
M?,/IX4\5_P!?#55+O]K_ /9^AMYIK;QK=WLT%LTD%K;^&O%;-=D+D!"OAULD
MD8W;2%SG'.*^-?\ A@CXQG_F8/AU_P"#?Q</Y^'JS-7_ &'?C!I^FWFI#4O
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MEZ+\7/"_[??_  ;^>(-4^'OPW^!7@S29/CS\&OA7\/=!\0:S\2?BW9?""/\
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MX$\)_$CXJ>"_!7B3QM?G;$FF>#]"\3^(+6[U^=F=$D3PY%<L)F1<!WK\Z_\
M@FE\9+7XS:]\>-(^.7A"/P/_ ,%(O@[KDW@C]JC0-<"7^I6GAZ;6=:UKX2ZS
M\%=<8)+)^RKXJ\,W4MS\&5B:*7S(_$K^.9/%_P 06\8^-_&/Q4PD^&G[0?\
MP63^'_Q\^%?Q4_:G3]J+4?"VD?#;5_@O\$O&W[0VEGPMKO[/MOX>T/\ 9/\
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M47>,>&^&>%^)_:7O;EE0XIC*2:C[)1YI:3BE_0@R'C [>O?\30J'G([>O?\
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M\^'WASPMXB^(^HV5Z?%6B:KX<T)O'MSXZM;;0O#S1ZE:^*_#G@TS:5/XJM/
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M;:MXG\4%/!_B?PJ6>-I/!OB?Q3'+XGN_R#^"/_!.W]H_]K^#2?\ @H3\$/\
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M_"7/\:OVD[N\%O.50> X_A7H*^-S*AQN0V9A!SU"D  \5]W_ /!76V\6Q_\
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M'B3P_P##/PUK.W5=3T;P+H6O^%)[/P-H%U> W$^@^%HK2W+>3*;<A"T></\
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M &$?^#BG3]2U.QN=.TG]LS_@I.M[#J5SG3=/TS5/AO:2 2-CY(Y%CD+'(R5
M!!QG^@R+_@G9_P $_P"T\7WOQ$M_V&?V0H?B)K=_XDU/5O'D/[-7P>_X3;5-
M2\:'5G\1:AK/B5? 47B":?Q6FMZPOBN2YF=KDZS>)=22PR3RUGZ?_P $S/\
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MWPNTVXJ*_P!5N&JOLU%Q4?=Y.*9Q;D[N<.52?*T?J/1117:>B%%%% !1110
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M:S_1\C\*.,LUQBR_%934R)_$Y8F,X0O=)+W'>_71=-^A_9LDT:_>\E,>C@Y
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&'Q,<11496<6KNUI0:E&2]'%/73H]#6AB'AFL0M.6SUZ=?/JE_P5<_G%'_!
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M:4OB#3?"^G-_R A_8S_\(BNN^(/%/B /+)(WRQQ1R2-\JG'ZXC_@@9<X&_\
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M_P!D'X1WOBB_\"?![7]#\:^$O%GB31-(^+O_  CEOXM\<>)_A9XT\#>+Y_\
MA(M"N(IS-9"TE_5;X^^-T_:W_P""/GQ&^+FHZ!<>%=5^+G[$>H?&_0;%+R72
MM5\">.A\*F^*GAW6=(UHO,VF3^$O%&G:#XD\*WI*JLFC6[.J?.(O!&_X)X?M
M0^*_V7?!G_!-KQ1XW^#GAW]C#PCINF>"O$OQ;\$^)?B#JW[1_P :?V?-"UF.
MXT7X/S?"[6_AWX6^''P<\1Z_X8LM)\)>-OB?'\8OB^EY$NHS6/@+0Y/$J_8?
MK_\ X*#:A#\.?V*O'OP-^%-E91?$#XR>!T_97_9Z^'EKLC&O^*O'GAJ3P'HN
MB:>LA"P>&_!V@MK/C#QA?1MGPCX$\-^*/%<H6.Q+RQG-6<L!F&"RJG3C4A6R
M"EPGR-UIP<:?[F]10?L/:\3^QG7ERQC";XJXDFVY77LY+3=#-<HQF9U:<:7-
MQ+/B=-*K3]G+BNE-NI1A'GG#A?A:%54O?J-<+>RX9DU*+;]P_8)^->J_M'_L
M7_LP_'3Q#$MKXA^*_P #/A;XW\20]53Q-K_A#2;G7XT 4#9_;\MV(N%VQD \
M]/L@*HC )X&1^>/7TQGK^->"_LV_!3PY^SA\!/@Y\"?#3B;0?A#\,_!'PZT9
MV'S3V_@KP_9Z%_:!# ,9+G[.LS$@LK2 =2M>]94J<], @<GIG/KZD]>M=V;5
M\/6S/,\1A9)94ZU>5%/5J#K5'9VO\-*44U=K6*5K:<^08?$X7(\LPV+3YXPB
MI7=VEK**;=KNVE[:M-O?6>BBBN0]@**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BOGW]DWX[?\-0_LL_LU_M+?\ "+?\(-_PT-\ ?@W\<O\ A"O[<_X2
M;_A$/^%M?#WP]X\_X1?_ (2/^R/#_P#PD'_"/_V]_97]M_V#HG]J_9/MW]D:
M;Y_V.'Z"H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@#\_OVJ/^";O[(?[9GC#P5\1?VB?A
MQXF\4^-/AU#I]MX$\0>&/C'\<_A-J7A^71?$,/B30-7B;X/_ !*\'!]=\,^)
MC/K_ (4\331/J'A:XNGEM9K1HP]?8WACPY8>&_#FF^&=+?Q!+8:'8VVBV=WX
MB\3>(O&OB.[T_2$A@B?6_&?BC7_$?B?Q!J\BEO,U_P 3>(KOQ'<W'F75S-+<
M>?-)W>!C&!CT[48&,8&/3M4_\PRPM]EW[ZO3Y$6_VGZUIMW_ .!_3Z!1115%
MA1110 4444 %%%% !7DTWPM\ S?$R+XL77A2TU+XA6/AB+PGHWC'4OM^J:CX
M?\/27,DFLZ+X>^T22IX<'B=S#+XP'AN&#_A,6\.>$_\ A,VO/^$1\)+:>LT4
G %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>14
<FILENAME>celc-20241231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaGPCbP9z5Z8CekhvWB7bemaTy0hu6T30CSZF5g2YVIM -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:CELC="http://celcuity.com/20241231" elementFormDefault="qualified" targetNamespace="http://celcuity.com/20241231">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://celcuity.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/BalanceSheets" id="BalanceSheets">
          <link:definition>00000002 - Statement - Balance Sheets</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
          <link:definition>00000003 - Statement - Balance Sheets (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/StatementsOfOperations" id="StatementsOfOperations">
          <link:definition>00000004 - Statement - Statements of Operations</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/StatementsOfChangesInStockholdersEquity" id="StatementsOfChangesInStockholdersEquity">
          <link:definition>00000005 - Statement - Statements of Changes in Stockholders' Equity</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
          <link:definition>00000006 - Statement - Statements of Cash Flows</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/StatementsOfCashFlowsParenthetical" id="StatementsOfCashFlowsParenthetical">
          <link:definition>00000007 - Statement - Statements of Cash Flows (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/Organization" id="Organization">
          <link:definition>999015 - Disclosure - Organization</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncements" id="BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncements">
          <link:definition>999016 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/Liquidity" id="Liquidity">
          <link:definition>999017 - Disclosure - Liquidity</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/NetLossPerCommonShare" id="NetLossPerCommonShare">
          <link:definition>999018 - Disclosure - Net Loss Per Common Share</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/Investments" id="Investments">
          <link:definition>999019 - Disclosure - Investments</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/OtherCurrentAssets" id="OtherCurrentAssets">
          <link:definition>999020 - Disclosure - Other Current Assets</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/PropertyAndEquipment" id="PropertyAndEquipment">
          <link:definition>999021 - Disclosure - Property and Equipment</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/AccruedExpenses" id="AccruedExpenses">
          <link:definition>999022 - Disclosure - Accrued Expenses</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/Commitments" id="Commitments">
          <link:definition>999023 - Disclosure - Commitments</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/StockholdersEquity" id="StockholdersEquity">
          <link:definition>999024 - Disclosure - Stockholders&#8217; Equity</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/Stock-basedCompensation" id="Stock-basedCompensation">
          <link:definition>999025 - Disclosure - Stock-Based Compensation</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/Debt" id="Debt">
          <link:definition>999026 - Disclosure - Debt</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/IncomeTaxes" id="IncomeTaxes">
          <link:definition>999027 - Disclosure - Income Taxes</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/SubsequentEvent" id="SubsequentEvent">
          <link:definition>999028 - Disclosure - Subsequent Event</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies" id="BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies">
          <link:definition>999029 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsTables" id="BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsTables">
          <link:definition>999030 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/NetLossPerCommonShareTables" id="NetLossPerCommonShareTables">
          <link:definition>999031 - Disclosure - Net Loss Per Common Share (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/InvestmentsTables" id="InvestmentsTables">
          <link:definition>999032 - Disclosure - Investments (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/OtherCurrentAssetsTables" id="OtherCurrentAssetsTables">
          <link:definition>999033 - Disclosure - Other Current Assets (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/PropertyAndEquipmentTables" id="PropertyAndEquipmentTables">
          <link:definition>999034 - Disclosure - Property and Equipment (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/AccruedExpensesTables" id="AccruedExpensesTables">
          <link:definition>999035 - Disclosure - Accrued Expenses (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/CommitmentsTables" id="CommitmentsTables">
          <link:definition>999036 - Disclosure - Commitments (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/StockholdersEquityTables" id="StockholdersEquityTables">
          <link:definition>999037 - Disclosure - Stockholders&#8217; Equity (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/Stock-basedCompensationTables" id="Stock-basedCompensationTables">
          <link:definition>999038 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/DebtTables" id="DebtTables">
          <link:definition>999039 - Disclosure - Debt (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
          <link:definition>999040 - Disclosure - Income Taxes (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" id="ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails">
          <link:definition>999041 - Disclosure - Schedule of Estimated Useful Lives of Property and Equipment (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsDetailsNarrative" id="BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsDetailsNarrative">
          <link:definition>999042 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/LiquidityDetailsNarrative" id="LiquidityDetailsNarrative">
          <link:definition>999043 - Disclosure - Liquidity (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/ScheduleOfPotentially-dilutiveSharesExcludedFromDilutedWeighted-averageSharesOutstandingDetails" id="ScheduleOfPotentially-dilutiveSharesExcludedFromDilutedWeighted-averageSharesOutstandingDetails">
          <link:definition>999044 - Disclosure - Schedule of Potentially-Dilutive Shares Excluded from the Diluted Weighted-Average Shares Outstanding (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/NetLossPerCommonShareDetailsNarrative" id="NetLossPerCommonShareDetailsNarrative">
          <link:definition>999045 - Disclosure - Net Loss Per Common Share (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/ScheduleOfInvestmentDetails" id="ScheduleOfInvestmentDetails">
          <link:definition>999046 - Disclosure - Schedule of Investment (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/ScheduleOfOtherCurrentAssetsDetails" id="ScheduleOfOtherCurrentAssetsDetails">
          <link:definition>999047 - Disclosure - Schedule of Other Current Assets (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/SummaryOfPropertyAndEquipmentDetails" id="SummaryOfPropertyAndEquipmentDetails">
          <link:definition>999048 - Disclosure - Summary of Property and Equipment (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/PropertyAndEquipmentDetailsNarrative" id="PropertyAndEquipmentDetailsNarrative">
          <link:definition>999049 - Disclosure - Property and Equipment (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/ScheduleOfAccruedExpensesDetails" id="ScheduleOfAccruedExpensesDetails">
          <link:definition>999050 - Disclosure - Schedule of Accrued Expenses (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails" id="ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails">
          <link:definition>999051 - Disclosure - Schedule of Supplemental Balance Sheet Information Related to Leases (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/ScheduleOfMaturityAnalysisUnderLeaseAgreementsDetails" id="ScheduleOfMaturityAnalysisUnderLeaseAgreementsDetails">
          <link:definition>999052 - Disclosure - Schedule of Maturity Analysis Under Lease Agreements (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/ScheduleOfLeaseCostsDetails" id="ScheduleOfLeaseCostsDetails">
          <link:definition>999053 - Disclosure - Schedule of Lease Costs (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails" id="ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails">
          <link:definition>999054 - Disclosure - Schedule of Supplemental Cash Flow Information Related to Leases (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/CommitmentsDetailsNarrative" id="CommitmentsDetailsNarrative">
          <link:definition>999055 - Disclosure - Commitments (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/ScheduleOfWarrantsDetails" id="ScheduleOfWarrantsDetails">
          <link:definition>999056 - Disclosure - Schedule of Warrants (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
          <link:definition>999057 - Disclosure - Stockholders&#8217; Equity (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/ScheduleOfStockOptionsActivityDetails" id="ScheduleOfStockOptionsActivityDetails">
          <link:definition>999058 - Disclosure - Schedule of Stock Options Activity (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/ScheduleOfStockOptionsOutstandingAndExercisableDetails" id="ScheduleOfStockOptionsOutstandingAndExercisableDetails">
          <link:definition>999059 - Disclosure - Schedule of Stock Options Outstanding and Exercisable (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/ScheduleOfAssumptionsForFairValueOfEquity-basedAwardsDetails" id="ScheduleOfAssumptionsForFairValueOfEquity-basedAwardsDetails">
          <link:definition>999060 - Disclosure - Schedule of Assumptions for Fair Value of Equity-based Awards (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/ScheduleOfUnrecognizedCompensationCostDetails" id="ScheduleOfUnrecognizedCompensationCostDetails">
          <link:definition>999061 - Disclosure - Schedule of Unrecognized Compensation Cost (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/ScheduleOfStock-basedCompensationExpensesDetails" id="ScheduleOfStock-basedCompensationExpensesDetails">
          <link:definition>999062 - Disclosure - Schedule of Stock-based Compensation Expenses (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/Stock-basedCompensationDetailsNarrative" id="Stock-basedCompensationDetailsNarrative">
          <link:definition>999063 - Disclosure - Stock-Based Compensation (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/ScheduleOfLong-termDebtDetails" id="ScheduleOfLong-termDebtDetails">
          <link:definition>999064 - Disclosure - Schedule of Long-term Debt (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/ScheduleOfLongTermDebtFuturePrincipalPaymentsDetails" id="ScheduleOfLongTermDebtFuturePrincipalPaymentsDetails">
          <link:definition>999065 - Disclosure - Schedule of Long Term Debt Future Principal Payments (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/DebtDetailsNarrative" id="DebtDetailsNarrative">
          <link:definition>999066 - Disclosure - Debt (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" id="ScheduleOfEffectiveIncomeTaxRateReconciliationDetails">
          <link:definition>999067 - Disclosure - Schedule of Effective Income Tax Rate Reconciliation (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" id="ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
          <link:definition>999068 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
          <link:definition>999069 - Disclosure - Income Taxes (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/SubsequentEventDetailsNarrative" id="SubsequentEventDetailsNarrative">
          <link:definition>999070 - Disclosure - Subsequent Event (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="celc-20241231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="celc-20241231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="celc-20241231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="celc-20241231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://xbrl.sec.gov/cyd/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd" />
    <element id="CELC_PreferredStockOnAnAsIfConvertedToCommonStockMember" name="PreferredStockOnAnAsIfConvertedToCommonStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_OptionsToPurchaseCommonStockMember" name="OptionsToPurchaseCommonStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_WarrantsToPurchaseCommonStockMember" name="WarrantsToPurchaseCommonStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_SeriesAConvertiblePreferredStockMember" name="SeriesAConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_OpenMarketSaleAgreementMember" name="OpenMarketSaleAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_JefferiesLLCMember" name="JefferiesLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_UnderwritingAgreementMember" name="UnderwritingAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_LeerinkPartnersLLCMember" name="LeerinkPartnersLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_SecuritiesPurchaseAgreementMember" name="SecuritiesPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_InstitutionalAndOtherAccreditedInvestorsMember" name="InstitutionalAndOtherAccreditedInvestorsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_WarrantOneMember" name="WarrantOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_WarrantTwoMember" name="WarrantTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_WarrantThreeMember" name="WarrantThreeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_WarrantFourMember" name="WarrantFourMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_WarrantFiveMember" name="WarrantFiveMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_WarrantSixMember" name="WarrantSixMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_WarrantSevenMember" name="WarrantSevenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_WarrantEightMember" name="WarrantEightMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_WarrantNineMember" name="WarrantNineMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_WarrantTenMember" name="WarrantTenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_EquityIncentivePlanMember" name="EquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_StockIncentivePlanMember" name="StockIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_MayTwoThousandTwentyTwoExercisePriceModificationMember" name="MayTwoThousandTwentyTwoExercisePriceModificationMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_DecemberTwoThousandTwentyOneExercisePriceModificationMember" name="DecemberTwoThousandTwentyOneExercisePriceModificationMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_MayTwoThousandTwentyExercisePriceModificationMember" name="MayTwoThousandTwentyExercisePriceModificationMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_TwoThousandSeventeenPlanMember" name="TwoThousandSeventeenPlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_EmployeeStockPurchasePlanMember" name="EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_AmendedAndRestatedLoanAgreementMember" name="AmendedAndRestatedLoanAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_InnovatusLifeSciencesMember" name="InnovatusLifeSciencesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_TermALoanMember" name="TermALoanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_TermBLoanMember" name="TermBLoanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_TermCLoanMember" name="TermCLoanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_TermDLoanMember" name="TermDLoanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_TermELoanMember" name="TermELoanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_TermFLoanMember" name="TermFLoanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_PriorLoanAgreementMember" name="PriorLoanAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_StockIssuedDuringPeriodValueConversionOfPreferredToCommonStock" name="StockIssuedDuringPeriodValueConversionOfPreferredToCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_StockIssuedDuringPeriodSharesConversionOfPreferredToCommonStock" name="StockIssuedDuringPeriodSharesConversionOfPreferredToCommonStock" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_ExerciseOfCommonStockWarrants" name="ExerciseOfCommonStockWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_ExerciseOfCommonStockSharesWarrants" name="ExerciseOfCommonStockSharesWarrants" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsIssuanceWithPrivatePlacementOffering" name="AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsIssuanceWithPrivatePlacementOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_AdditionalPaidInCapitalPreFundedWarrantIssued" name="AdditionalPaidInCapitalPreFundedWarrantIssued" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_IssuanceCostsAssociatedWithPrefundedWarrants" name="IssuanceCostsAssociatedWithPrefundedWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_StockIssuedDuringPeriodValueStockWarrantsExercised" name="StockIssuedDuringPeriodValueStockWarrantsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_StockIssuedDuringPeriodSharesStockWarrantsExercised" name="StockIssuedDuringPeriodSharesStockWarrantsExercised" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_StockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts" name="StockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_StockIssuedDuringPeriodSharesIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts" name="StockIssuedDuringPeriodSharesIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_NoncashOperatingLeaseExpenseNet" name="NoncashOperatingLeaseExpenseNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_ChangeInAccruedInterestIncome" name="ChangeInAccruedInterestIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_ProceedsFromAtmOfferingNetOfIssuanceCosts" name="ProceedsFromAtmOfferingNetOfIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_PaymentsForSecondaryRegistrationStatementCosts" name="PaymentsForSecondaryRegistrationStatementCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_DeferredFinancingCostsAndOfferingAndRegistrationStatementCostsIncludedInAccountsPayable" name="DeferredFinancingCostsAndOfferingAndRegistrationStatementCostsIncludedInAccountsPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_PropertyAndEquipmentIncludedInAccountsPayable" name="PropertyAndEquipmentIncludedInAccountsPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_CommonStockWarrantsIssuedWithNotePayableTransaction" name="CommonStockWarrantsIssuedWithNotePayableTransaction" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" name="ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_PrefundedWarrantShares" name="PrefundedWarrantShares" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_PrepaidClinicalTrialCosts" name="PrepaidClinicalTrialCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_MiscellaneousReceivable" name="MiscellaneousReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_AccruedClinicalTrialExpense" name="AccruedClinicalTrialExpense" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_FinanceLeaseCostAbstract" name="FinanceLeaseCostAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_CashPaidForOperatingAndFinanceLeasesAbstract" name="CashPaidForOperatingAndFinanceLeasesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_CashPaidForOperatingAndFinanceLeases" name="CashPaidForOperatingAndFinanceLeases" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue" name="ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue" nillable="true" xbrli:periodType="duration" type="xbrli:dateItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_ProceedsFromIssuanceOfCommonStockNet" name="ProceedsFromIssuanceOfCommonStockNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_OfferingExpenses" name="OfferingExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOfWarrants" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOfWarrants" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostToBeRecognizedNextTwelveMonths" name="EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostToBeRecognizedNextTwelveMonths" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostToBeRecognizedWithinTwoYear" name="EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostToBeRecognizedWithinTwoYear" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostToBeRecognizedwithinThreeYears" name="EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostToBeRecognizedwithinThreeYears" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostToBeRecognizedWithinFourYears" name="EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostToBeRecognizedWithinFourYears" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostToBeRecognized" name="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostToBeRecognized" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_ChangeInCommonStockSharesReservedForIssuance" name="ChangeInCommonStockSharesReservedForIssuance" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_TotalCommonStockCapitalSharesReservedForFutureIssuance" name="TotalCommonStockCapitalSharesReservedForFutureIssuance" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_StockOptionAwardsSharesModified" name="StockOptionAwardsSharesModified" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_ModifiedStockOptionExercisePrice" name="ModifiedStockOptionExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_RemainingStockBasedCompensationExpenseRelatedToModification" name="RemainingStockBasedCompensationExpenseRelatedToModification" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_FinalFee" name="FinalFee" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_PaymentInKindInterestDebt" name="PaymentInKindInterestDebt" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_FinalFeePercentage" name="FinalFeePercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_NonUtilizationFee" name="NonUtilizationFee" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_WarrantOrRightToPurchasePercentage" name="WarrantOrRightToPurchasePercentage" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_DeferredTaxAssetsRightofuseAssets" name="DeferredTaxAssetsRightofuseAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_DeferredTaxAssetsLeaseLiability" name="DeferredTaxAssetsLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIRC174Expenditures" name="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIRC174Expenditures" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStartupExpenditures" name="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStartupExpenditures" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>15
<FILENAME>celc-20241231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://celcuity.com/role/Cover" xlink:href="celc-20241231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/BalanceSheets" xlink:href="celc-20241231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/BalanceSheetsParenthetical" xlink:href="celc-20241231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/StatementsOfOperations" xlink:href="celc-20241231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/StatementsOfChangesInStockholdersEquity" xlink:href="celc-20241231.xsd#StatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/StatementsOfCashFlows" xlink:href="celc-20241231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/StatementsOfCashFlowsParenthetical" xlink:href="celc-20241231.xsd#StatementsOfCashFlowsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#CybersecurityRiskManagementAndStrategyDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#MaterialCybersecurityIncidentDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/Organization" xlink:href="celc-20241231.xsd#Organization" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncements" xlink:href="celc-20241231.xsd#BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncements" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/Liquidity" xlink:href="celc-20241231.xsd#Liquidity" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/NetLossPerCommonShare" xlink:href="celc-20241231.xsd#NetLossPerCommonShare" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/Investments" xlink:href="celc-20241231.xsd#Investments" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/OtherCurrentAssets" xlink:href="celc-20241231.xsd#OtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/PropertyAndEquipment" xlink:href="celc-20241231.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/AccruedExpenses" xlink:href="celc-20241231.xsd#AccruedExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/Commitments" xlink:href="celc-20241231.xsd#Commitments" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/StockholdersEquity" xlink:href="celc-20241231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/Stock-basedCompensation" xlink:href="celc-20241231.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/Debt" xlink:href="celc-20241231.xsd#Debt" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/IncomeTaxes" xlink:href="celc-20241231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/SubsequentEvent" xlink:href="celc-20241231.xsd#SubsequentEvent" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies" xlink:href="celc-20241231.xsd#BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsTables" xlink:href="celc-20241231.xsd#BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/NetLossPerCommonShareTables" xlink:href="celc-20241231.xsd#NetLossPerCommonShareTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/InvestmentsTables" xlink:href="celc-20241231.xsd#InvestmentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/OtherCurrentAssetsTables" xlink:href="celc-20241231.xsd#OtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/PropertyAndEquipmentTables" xlink:href="celc-20241231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/AccruedExpensesTables" xlink:href="celc-20241231.xsd#AccruedExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/CommitmentsTables" xlink:href="celc-20241231.xsd#CommitmentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/StockholdersEquityTables" xlink:href="celc-20241231.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/Stock-basedCompensationTables" xlink:href="celc-20241231.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/DebtTables" xlink:href="celc-20241231.xsd#DebtTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/IncomeTaxesTables" xlink:href="celc-20241231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" xlink:href="celc-20241231.xsd#ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsDetailsNarrative" xlink:href="celc-20241231.xsd#BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/LiquidityDetailsNarrative" xlink:href="celc-20241231.xsd#LiquidityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/ScheduleOfPotentially-dilutiveSharesExcludedFromDilutedWeighted-averageSharesOutstandingDetails" xlink:href="celc-20241231.xsd#ScheduleOfPotentially-dilutiveSharesExcludedFromDilutedWeighted-averageSharesOutstandingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/NetLossPerCommonShareDetailsNarrative" xlink:href="celc-20241231.xsd#NetLossPerCommonShareDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/ScheduleOfInvestmentDetails" xlink:href="celc-20241231.xsd#ScheduleOfInvestmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/ScheduleOfOtherCurrentAssetsDetails" xlink:href="celc-20241231.xsd#ScheduleOfOtherCurrentAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/SummaryOfPropertyAndEquipmentDetails" xlink:href="celc-20241231.xsd#SummaryOfPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="celc-20241231.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/ScheduleOfAccruedExpensesDetails" xlink:href="celc-20241231.xsd#ScheduleOfAccruedExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails" xlink:href="celc-20241231.xsd#ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/ScheduleOfMaturityAnalysisUnderLeaseAgreementsDetails" xlink:href="celc-20241231.xsd#ScheduleOfMaturityAnalysisUnderLeaseAgreementsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/ScheduleOfLeaseCostsDetails" xlink:href="celc-20241231.xsd#ScheduleOfLeaseCostsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails" xlink:href="celc-20241231.xsd#ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/CommitmentsDetailsNarrative" xlink:href="celc-20241231.xsd#CommitmentsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/ScheduleOfWarrantsDetails" xlink:href="celc-20241231.xsd#ScheduleOfWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/StockholdersEquityDetailsNarrative" xlink:href="celc-20241231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/ScheduleOfStockOptionsActivityDetails" xlink:href="celc-20241231.xsd#ScheduleOfStockOptionsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/ScheduleOfStockOptionsOutstandingAndExercisableDetails" xlink:href="celc-20241231.xsd#ScheduleOfStockOptionsOutstandingAndExercisableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/ScheduleOfAssumptionsForFairValueOfEquity-basedAwardsDetails" xlink:href="celc-20241231.xsd#ScheduleOfAssumptionsForFairValueOfEquity-basedAwardsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/ScheduleOfUnrecognizedCompensationCostDetails" xlink:href="celc-20241231.xsd#ScheduleOfUnrecognizedCompensationCostDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/ScheduleOfStock-basedCompensationExpensesDetails" xlink:href="celc-20241231.xsd#ScheduleOfStock-basedCompensationExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="celc-20241231.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/ScheduleOfLong-termDebtDetails" xlink:href="celc-20241231.xsd#ScheduleOfLong-termDebtDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/ScheduleOfLongTermDebtFuturePrincipalPaymentsDetails" xlink:href="celc-20241231.xsd#ScheduleOfLongTermDebtFuturePrincipalPaymentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/DebtDetailsNarrative" xlink:href="celc-20241231.xsd#DebtDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:href="celc-20241231.xsd#ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="celc-20241231.xsd#ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/IncomeTaxesDetailsNarrative" xlink:href="celc-20241231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/SubsequentEventDetailsNarrative" xlink:href="celc-20241231.xsd#SubsequentEventDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/BalanceSheets" xlink:title="00000002 - Statement - Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaapShortTermInvestments" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapShortTermInvestments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaapOtherAssetsCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaapLongTermNotesPayable" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLongTermNotesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="loc_us-gaapInterestExpenseNonoperating" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestExpenseNonoperating" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaapInvestmentIncomeInterest" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInvestmentIncomeInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Statements of Changes in Stockholders&apos; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaidInKindInterest" xlink:label="loc_us-gaapPaidInKindInterest" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapPaidInKindInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_NoncashOperatingLeaseExpenseNet" xlink:label="loc_CELCNoncashOperatingLeaseExpenseNet" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_CELCNoncashOperatingLeaseExpenseNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_ChangeInAccruedInterestIncome" xlink:label="loc_CELCChangeInAccruedInterestIncome" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_CELCChangeInAccruedInterestIncome" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:label="loc_us-gaapProceedsFromSaleAndMaturityOfOtherInvestments" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapProceedsFromSaleAndMaturityOfOtherInvestments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaapPaymentsToAcquireInvestments" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireInvestments" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="loc_us-gaapProceedsFromStockPlans" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromStockPlans" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromOtherEquity" xlink:label="loc_us-gaapProceedsFromOtherEquity" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromOtherEquity" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="loc_us-gaapProceedsFromDebtNetOfIssuanceCosts" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromDebtNetOfIssuanceCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_ProceedsFromAtmOfferingNetOfIssuanceCosts" xlink:label="loc_CELCProceedsFromAtmOfferingNetOfIssuanceCosts" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_CELCProceedsFromAtmOfferingNetOfIssuanceCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_PaymentsForSecondaryRegistrationStatementCosts" xlink:label="loc_CELCPaymentsForSecondaryRegistrationStatementCosts" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_CELCPaymentsForSecondaryRegistrationStatementCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfDebtIssuanceCosts" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsOfDebtIssuanceCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaapFinanceLeasePrincipalPayments" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapFinanceLeasePrincipalPayments" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/StatementsOfCashFlowsParenthetical" xlink:title="00000007 - Statement - Statements of Cash Flows (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="00000013 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure" />
    <link:calculationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:title="00000014 - Disclosure - Material Cybersecurity Incident Disclosure" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/Organization" xlink:title="999015 - Disclosure - Organization" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncements" xlink:title="999016 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/Liquidity" xlink:title="999017 - Disclosure - Liquidity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/NetLossPerCommonShare" xlink:title="999018 - Disclosure - Net Loss Per Common Share" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/Investments" xlink:title="999019 - Disclosure - Investments" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/OtherCurrentAssets" xlink:title="999020 - Disclosure - Other Current Assets" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/PropertyAndEquipment" xlink:title="999021 - Disclosure - Property and Equipment" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/AccruedExpenses" xlink:title="999022 - Disclosure - Accrued Expenses" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/Commitments" xlink:title="999023 - Disclosure - Commitments" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/StockholdersEquity" xlink:title="999024 - Disclosure - Stockholders&#8217; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/Stock-basedCompensation" xlink:title="999025 - Disclosure - Stock-Based Compensation" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/Debt" xlink:title="999026 - Disclosure - Debt" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/IncomeTaxes" xlink:title="999027 - Disclosure - Income Taxes" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/SubsequentEvent" xlink:title="999028 - Disclosure - Subsequent Event" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies" xlink:title="999029 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsTables" xlink:title="999030 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/NetLossPerCommonShareTables" xlink:title="999031 - Disclosure - Net Loss Per Common Share (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/InvestmentsTables" xlink:title="999032 - Disclosure - Investments (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/OtherCurrentAssetsTables" xlink:title="999033 - Disclosure - Other Current Assets (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/PropertyAndEquipmentTables" xlink:title="999034 - Disclosure - Property and Equipment (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/AccruedExpensesTables" xlink:title="999035 - Disclosure - Accrued Expenses (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/CommitmentsTables" xlink:title="999036 - Disclosure - Commitments (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/StockholdersEquityTables" xlink:title="999037 - Disclosure - Stockholders&#8217; Equity (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/Stock-basedCompensationTables" xlink:title="999038 - Disclosure - Stock-Based Compensation (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/DebtTables" xlink:title="999039 - Disclosure - Debt (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/IncomeTaxesTables" xlink:title="999040 - Disclosure - Income Taxes (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" xlink:title="999041 - Disclosure - Schedule of Estimated Useful Lives of Property and Equipment (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsDetailsNarrative" xlink:title="999042 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/LiquidityDetailsNarrative" xlink:title="999043 - Disclosure - Liquidity (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfPotentially-dilutiveSharesExcludedFromDilutedWeighted-averageSharesOutstandingDetails" xlink:title="999044 - Disclosure - Schedule of Potentially-Dilutive Shares Excluded from the Diluted Weighted-Average Shares Outstanding (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/NetLossPerCommonShareDetailsNarrative" xlink:title="999045 - Disclosure - Net Loss Per Common Share (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfInvestmentDetails" xlink:title="999046 - Disclosure - Schedule of Investment (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfOtherCurrentAssetsDetails" xlink:title="999047 - Disclosure - Schedule of Other Current Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaapOtherAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_PrepaidClinicalTrialCosts" xlink:label="loc_CELCPrepaidClinicalTrialCosts" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAssetsCurrent" xlink:to="loc_CELCPrepaidClinicalTrialCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_MiscellaneousReceivable" xlink:label="loc_CELCMiscellaneousReceivable" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAssetsCurrent" xlink:to="loc_CELCMiscellaneousReceivable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaapPrepaidInsurance" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAssetsCurrent" xlink:to="loc_us-gaapPrepaidInsurance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAssetsCurrent" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/SummaryOfPropertyAndEquipmentDetails" xlink:title="999048 - Disclosure - Summary of Property and Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="999049 - Disclosure - Property and Equipment (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfAccruedExpensesDetails" xlink:title="999050 - Disclosure - Schedule of Accrued Expenses (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_AccruedClinicalTrialExpense" xlink:label="loc_CELCAccruedClinicalTrialExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_CELCAccruedClinicalTrialExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WorkersCompensationLiabilityCurrent" xlink:label="loc_us-gaapWorkersCompensationLiabilityCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapWorkersCompensationLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrentAndNoncurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="loc_us-gaapAccruedEmployeeBenefitsCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedEmployeeBenefitsCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails" xlink:title="999051 - Disclosure - Schedule of Supplemental Balance Sheet Information Related to Leases (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfMaturityAnalysisUnderLeaseAgreementsDetails" xlink:title="999052 - Disclosure - Schedule of Maturity Analysis Under Lease Agreements (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfLeaseCostsDetails" xlink:title="999053 - Disclosure - Schedule of Lease Costs (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaapLeaseCost" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaapOperatingLeaseCost" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLeaseCost" xlink:to="loc_us-gaapOperatingLeaseCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAssetAmortization" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLeaseCost" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="loc_us-gaapFinanceLeaseInterestExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLeaseCost" xlink:to="loc_us-gaapFinanceLeaseInterestExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaapVariableLeaseCost" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLeaseCost" xlink:to="loc_us-gaapVariableLeaseCost" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails" xlink:title="999054 - Disclosure - Schedule of Supplemental Cash Flow Information Related to Leases (Details)">
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_CashPaidForOperatingAndFinanceLeases" xlink:label="loc_CELCCashPaidForOperatingAndFinanceLeases" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_CELCCashPaidForOperatingAndFinanceLeases" xlink:to="loc_us-gaapOperatingLeasePayments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:label="loc_us-gaapFinanceLeaseInterestPaymentOnLiability" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_CELCCashPaidForOperatingAndFinanceLeases" xlink:to="loc_us-gaapFinanceLeaseInterestPaymentOnLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaapFinanceLeasePrincipalPayments" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_CELCCashPaidForOperatingAndFinanceLeases" xlink:to="loc_us-gaapFinanceLeasePrincipalPayments" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/CommitmentsDetailsNarrative" xlink:title="999055 - Disclosure - Commitments (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfWarrantsDetails" xlink:title="999056 - Disclosure - Schedule of Warrants (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/StockholdersEquityDetailsNarrative" xlink:title="999057 - Disclosure - Stockholders&#8217; Equity (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfStockOptionsActivityDetails" xlink:title="999058 - Disclosure - Schedule of Stock Options Activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfStockOptionsOutstandingAndExercisableDetails" xlink:title="999059 - Disclosure - Schedule of Stock Options Outstanding and Exercisable (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfAssumptionsForFairValueOfEquity-basedAwardsDetails" xlink:title="999060 - Disclosure - Schedule of Assumptions for Fair Value of Equity-based Awards (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfUnrecognizedCompensationCostDetails" xlink:title="999061 - Disclosure - Schedule of Unrecognized Compensation Cost (Details)">
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostToBeRecognized" xlink:label="loc_CELCEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostToBeRecognized" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostToBeRecognizedNextTwelveMonths" xlink:label="loc_CELCEmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostToBeRecognizedNextTwelveMonths" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_CELCEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostToBeRecognized" xlink:to="loc_CELCEmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostToBeRecognizedNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostToBeRecognizedWithinTwoYear" xlink:label="loc_CELCEmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostToBeRecognizedWithinTwoYear" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_CELCEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostToBeRecognized" xlink:to="loc_CELCEmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostToBeRecognizedWithinTwoYear" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostToBeRecognizedwithinThreeYears" xlink:label="loc_CELCEmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostToBeRecognizedwithinThreeYears" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_CELCEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostToBeRecognized" xlink:to="loc_CELCEmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostToBeRecognizedwithinThreeYears" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostToBeRecognizedWithinFourYears" xlink:label="loc_CELCEmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostToBeRecognizedWithinFourYears" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_CELCEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostToBeRecognized" xlink:to="loc_CELCEmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostToBeRecognizedWithinFourYears" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfStock-basedCompensationExpensesDetails" xlink:title="999062 - Disclosure - Schedule of Stock-based Compensation Expenses (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="999063 - Disclosure - Stock-Based Compensation (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfLong-termDebtDetails" xlink:title="999064 - Disclosure - Schedule of Long-term Debt (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaapLongTermNotesPayable" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLongTermNotesPayable" xlink:to="loc_us-gaapConvertibleNotesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_FinalFee" xlink:label="loc_CELCFinalFee" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLongTermNotesPayable" xlink:to="loc_CELCFinalFee" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_PaymentInKindInterestDebt" xlink:label="loc_CELCPaymentInKindInterestDebt" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLongTermNotesPayable" xlink:to="loc_CELCPaymentInKindInterestDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLongTermNotesPayable" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscount" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLongTermNotesPayable" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscount" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfLongTermDebtFuturePrincipalPaymentsDetails" xlink:title="999065 - Disclosure - Schedule of Long Term Debt Future Principal Payments (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaapLongTermDebt" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLongTermDebt" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLongTermDebt" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLongTermDebt" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/DebtDetailsNarrative" xlink:title="999066 - Disclosure - Debt (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:title="999067 - Disclosure - Schedule of Effective Income Tax Rate Reconciliation (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="loc_us-gaapIncomeTaxReconciliationTaxCreditsResearch" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationTaxCreditsResearch" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseOther" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseOther" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="999068 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaapDeferredTaxAssetsPropertyPlantAndEquipment" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaapDeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_DeferredTaxAssetsRightofuseAssets" xlink:label="loc_CELCDeferredTaxAssetsRightofuseAssets" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_CELCDeferredTaxAssetsRightofuseAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_DeferredTaxAssetsLeaseLiability" xlink:label="loc_CELCDeferredTaxAssetsLeaseLiability" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_CELCDeferredTaxAssetsLeaseLiability" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIRC174Expenditures" xlink:label="loc_CELCDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIRC174Expenditures" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_CELCDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIRC174Expenditures" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStartupExpenditures" xlink:label="loc_CELCDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStartupExpenditures" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_CELCDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStartupExpenditures" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/IncomeTaxesDetailsNarrative" xlink:title="999069 - Disclosure - Income Taxes (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/SubsequentEventDetailsNarrative" xlink:title="999070 - Disclosure - Subsequent Event (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>16
<FILENAME>celc-20241231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://celcuity.com/role/Cover" xlink:href="celc-20241231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/BalanceSheets" xlink:href="celc-20241231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/BalanceSheetsParenthetical" xlink:href="celc-20241231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/StatementsOfOperations" xlink:href="celc-20241231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/StatementsOfChangesInStockholdersEquity" xlink:href="celc-20241231.xsd#StatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/StatementsOfCashFlows" xlink:href="celc-20241231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/StatementsOfCashFlowsParenthetical" xlink:href="celc-20241231.xsd#StatementsOfCashFlowsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#CybersecurityRiskManagementAndStrategyDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#MaterialCybersecurityIncidentDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/Organization" xlink:href="celc-20241231.xsd#Organization" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncements" xlink:href="celc-20241231.xsd#BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncements" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/Liquidity" xlink:href="celc-20241231.xsd#Liquidity" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/NetLossPerCommonShare" xlink:href="celc-20241231.xsd#NetLossPerCommonShare" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/Investments" xlink:href="celc-20241231.xsd#Investments" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/OtherCurrentAssets" xlink:href="celc-20241231.xsd#OtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/PropertyAndEquipment" xlink:href="celc-20241231.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/AccruedExpenses" xlink:href="celc-20241231.xsd#AccruedExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/Commitments" xlink:href="celc-20241231.xsd#Commitments" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/StockholdersEquity" xlink:href="celc-20241231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/Stock-basedCompensation" xlink:href="celc-20241231.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/Debt" xlink:href="celc-20241231.xsd#Debt" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/IncomeTaxes" xlink:href="celc-20241231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/SubsequentEvent" xlink:href="celc-20241231.xsd#SubsequentEvent" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies" xlink:href="celc-20241231.xsd#BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsTables" xlink:href="celc-20241231.xsd#BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/NetLossPerCommonShareTables" xlink:href="celc-20241231.xsd#NetLossPerCommonShareTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/InvestmentsTables" xlink:href="celc-20241231.xsd#InvestmentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/OtherCurrentAssetsTables" xlink:href="celc-20241231.xsd#OtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/PropertyAndEquipmentTables" xlink:href="celc-20241231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/AccruedExpensesTables" xlink:href="celc-20241231.xsd#AccruedExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/CommitmentsTables" xlink:href="celc-20241231.xsd#CommitmentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/StockholdersEquityTables" xlink:href="celc-20241231.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/Stock-basedCompensationTables" xlink:href="celc-20241231.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/DebtTables" xlink:href="celc-20241231.xsd#DebtTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/IncomeTaxesTables" xlink:href="celc-20241231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" xlink:href="celc-20241231.xsd#ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsDetailsNarrative" xlink:href="celc-20241231.xsd#BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/LiquidityDetailsNarrative" xlink:href="celc-20241231.xsd#LiquidityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/ScheduleOfPotentially-dilutiveSharesExcludedFromDilutedWeighted-averageSharesOutstandingDetails" xlink:href="celc-20241231.xsd#ScheduleOfPotentially-dilutiveSharesExcludedFromDilutedWeighted-averageSharesOutstandingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/NetLossPerCommonShareDetailsNarrative" xlink:href="celc-20241231.xsd#NetLossPerCommonShareDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/ScheduleOfInvestmentDetails" xlink:href="celc-20241231.xsd#ScheduleOfInvestmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/ScheduleOfOtherCurrentAssetsDetails" xlink:href="celc-20241231.xsd#ScheduleOfOtherCurrentAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/SummaryOfPropertyAndEquipmentDetails" xlink:href="celc-20241231.xsd#SummaryOfPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="celc-20241231.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/ScheduleOfAccruedExpensesDetails" xlink:href="celc-20241231.xsd#ScheduleOfAccruedExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails" xlink:href="celc-20241231.xsd#ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/ScheduleOfMaturityAnalysisUnderLeaseAgreementsDetails" xlink:href="celc-20241231.xsd#ScheduleOfMaturityAnalysisUnderLeaseAgreementsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/ScheduleOfLeaseCostsDetails" xlink:href="celc-20241231.xsd#ScheduleOfLeaseCostsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails" xlink:href="celc-20241231.xsd#ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/CommitmentsDetailsNarrative" xlink:href="celc-20241231.xsd#CommitmentsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/ScheduleOfWarrantsDetails" xlink:href="celc-20241231.xsd#ScheduleOfWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/StockholdersEquityDetailsNarrative" xlink:href="celc-20241231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/ScheduleOfStockOptionsActivityDetails" xlink:href="celc-20241231.xsd#ScheduleOfStockOptionsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/ScheduleOfStockOptionsOutstandingAndExercisableDetails" xlink:href="celc-20241231.xsd#ScheduleOfStockOptionsOutstandingAndExercisableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/ScheduleOfAssumptionsForFairValueOfEquity-basedAwardsDetails" xlink:href="celc-20241231.xsd#ScheduleOfAssumptionsForFairValueOfEquity-basedAwardsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/ScheduleOfUnrecognizedCompensationCostDetails" xlink:href="celc-20241231.xsd#ScheduleOfUnrecognizedCompensationCostDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/ScheduleOfStock-basedCompensationExpensesDetails" xlink:href="celc-20241231.xsd#ScheduleOfStock-basedCompensationExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="celc-20241231.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/ScheduleOfLong-termDebtDetails" xlink:href="celc-20241231.xsd#ScheduleOfLong-termDebtDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/ScheduleOfLongTermDebtFuturePrincipalPaymentsDetails" xlink:href="celc-20241231.xsd#ScheduleOfLongTermDebtFuturePrincipalPaymentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/DebtDetailsNarrative" xlink:href="celc-20241231.xsd#DebtDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:href="celc-20241231.xsd#ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="celc-20241231.xsd#ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/IncomeTaxesDetailsNarrative" xlink:href="celc-20241231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/SubsequentEventDetailsNarrative" xlink:href="celc-20241231.xsd#SubsequentEventDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosureWithAdditionalMeasures" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosureWithAdditionalMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpTable" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsToCompensation" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpAdjustmentsToCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TabularListsByExecutiveCategory" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TabularListsByExecutiveCategory" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TabularListMeasures" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TabularListMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpMeasures" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpExecutiveCategoriesOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpAdjustmentsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#IndividualsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTypeOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TradingArrangmentsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ForgoneRecoveries" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ForgoneRecoveries" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/OutstandingRecoveries" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#OutstandingRecoveries" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardsCloseToMnpiDisc" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardsCloseToMnpiDisc" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsByInd" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangemenstByInd" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/Defaults" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#Defaults" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/BalanceSheets" xlink:title="00000002 - Statement - Balance Sheets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Balance Sheets (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Statements of Operations" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Statements of Changes in Stockholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensationGross_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensationGross_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensationGross_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensationGross_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_StockIssuedDuringPeriodValueConversionOfPreferredToCommonStock" xlink:label="loc_CELCStockIssuedDuringPeriodValueConversionOfPreferredToCommonStock_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELCStockIssuedDuringPeriodValueConversionOfPreferredToCommonStock_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_StockIssuedDuringPeriodSharesConversionOfPreferredToCommonStock" xlink:label="loc_CELCStockIssuedDuringPeriodSharesConversionOfPreferredToCommonStock_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELCStockIssuedDuringPeriodSharesConversionOfPreferredToCommonStock_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueEmployeeStockPurchasePlan_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueEmployeeStockPurchasePlan_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_ExerciseOfCommonStockWarrants" xlink:label="loc_CELCExerciseOfCommonStockWarrants_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELCExerciseOfCommonStockWarrants_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_ExerciseOfCommonStockSharesWarrants" xlink:label="loc_CELCExerciseOfCommonStockSharesWarrants_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELCExerciseOfCommonStockSharesWarrants_60" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsIssuanceWithPrivatePlacementOffering" xlink:label="loc_CELCAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsIssuanceWithPrivatePlacementOffering_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELCAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsIssuanceWithPrivatePlacementOffering_60" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_60" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_AdditionalPaidInCapitalPreFundedWarrantIssued" xlink:label="loc_CELCAdditionalPaidInCapitalPreFundedWarrantIssued_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELCAdditionalPaidInCapitalPreFundedWarrantIssued_60" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_IssuanceCostsAssociatedWithPrefundedWarrants" xlink:label="loc_CELCIssuanceCostsAssociatedWithPrefundedWarrants_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELCIssuanceCostsAssociatedWithPrefundedWarrants_60" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_60" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_StockIssuedDuringPeriodValueStockWarrantsExercised" xlink:label="loc_CELCStockIssuedDuringPeriodValueStockWarrantsExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELCStockIssuedDuringPeriodValueStockWarrantsExercised_60" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:label="loc_CELCStockIssuedDuringPeriodSharesStockWarrantsExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELCStockIssuedDuringPeriodSharesStockWarrantsExercised_60" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_StockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts" xlink:label="loc_CELCStockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELCStockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts_60" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_StockIssuedDuringPeriodSharesIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts" xlink:label="loc_CELCStockIssuedDuringPeriodSharesIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELCStockIssuedDuringPeriodSharesIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts_60" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued_60" xlink:type="arc" order="24" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Statements of Cash Flows" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/StatementsOfCashFlowsParenthetical" xlink:title="00000007 - Statement - Statements of Cash Flows (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="00000013 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:title="00000014 - Disclosure - Material Cybersecurity Incident Disclosure" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/Organization" xlink:title="999015 - Disclosure - Organization" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncements" xlink:title="999016 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/Liquidity" xlink:title="999017 - Disclosure - Liquidity" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/NetLossPerCommonShare" xlink:title="999018 - Disclosure - Net Loss Per Common Share" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/Investments" xlink:title="999019 - Disclosure - Investments" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/OtherCurrentAssets" xlink:title="999020 - Disclosure - Other Current Assets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/PropertyAndEquipment" xlink:title="999021 - Disclosure - Property and Equipment" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/AccruedExpenses" xlink:title="999022 - Disclosure - Accrued Expenses" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/Commitments" xlink:title="999023 - Disclosure - Commitments" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/StockholdersEquity" xlink:title="999024 - Disclosure - Stockholders&#8217; Equity" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/Stock-basedCompensation" xlink:title="999025 - Disclosure - Stock-Based Compensation" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/Debt" xlink:title="999026 - Disclosure - Debt" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/IncomeTaxes" xlink:title="999027 - Disclosure - Income Taxes" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/SubsequentEvent" xlink:title="999028 - Disclosure - Subsequent Event" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies" xlink:title="999029 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsTables" xlink:title="999030 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/NetLossPerCommonShareTables" xlink:title="999031 - Disclosure - Net Loss Per Common Share (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/InvestmentsTables" xlink:title="999032 - Disclosure - Investments (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/OtherCurrentAssetsTables" xlink:title="999033 - Disclosure - Other Current Assets (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/PropertyAndEquipmentTables" xlink:title="999034 - Disclosure - Property and Equipment (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/AccruedExpensesTables" xlink:title="999035 - Disclosure - Accrued Expenses (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/CommitmentsTables" xlink:title="999036 - Disclosure - Commitments (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/StockholdersEquityTables" xlink:title="999037 - Disclosure - Stockholders&#8217; Equity (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/Stock-basedCompensationTables" xlink:title="999038 - Disclosure - Stock-Based Compensation (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/DebtTables" xlink:title="999039 - Disclosure - Debt (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/IncomeTaxesTables" xlink:title="999040 - Disclosure - Income Taxes (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" xlink:title="999041 - Disclosure - Schedule of Estimated Useful Lives of Property and Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_50" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsDetailsNarrative" xlink:title="999042 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/LiquidityDetailsNarrative" xlink:title="999043 - Disclosure - Liquidity (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfPotentially-dilutiveSharesExcludedFromDilutedWeighted-averageSharesOutstandingDetails" xlink:title="999044 - Disclosure - Schedule of Potentially-Dilutive Shares Excluded from the Diluted Weighted-Average Shares Outstanding (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_PreferredStockOnAnAsIfConvertedToCommonStockMember" xlink:label="loc_CELCPreferredStockOnAnAsIfConvertedToCommonStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CELCPreferredStockOnAnAsIfConvertedToCommonStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_OptionsToPurchaseCommonStockMember" xlink:label="loc_CELCOptionsToPurchaseCommonStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_CELCOptionsToPurchaseCommonStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_WarrantsToPurchaseCommonStockMember" xlink:label="loc_CELCWarrantsToPurchaseCommonStockMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_CELCWarrantsToPurchaseCommonStockMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapRestrictedStockMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:label="loc_us-gaapEarningsPerShareDilutedOtherDisclosuresAbstract_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapEarningsPerShareDilutedOtherDisclosuresAbstract_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_110" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/NetLossPerCommonShareDetailsNarrative" xlink:title="999045 - Disclosure - Net Loss Per Common Share (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfInvestmentDetails" xlink:title="999046 - Disclosure - Schedule of Investment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:label="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:label="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaapUSTreasurySecuritiesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapUSTreasurySecuritiesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecurities" xlink:label="loc_us-gaapHeldToMaturitySecurities_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapHeldToMaturitySecurities_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:label="loc_us-gaapHeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapHeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:label="loc_us-gaapHeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapHeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesFairValue" xlink:label="loc_us-gaapHeldToMaturitySecuritiesFairValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapHeldToMaturitySecuritiesFairValue_50" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfOtherCurrentAssetsDetails" xlink:title="999047 - Disclosure - Schedule of Other Current Assets (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/SummaryOfPropertyAndEquipmentDetails" xlink:title="999048 - Disclosure - Summary of Property and Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_70" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="999049 - Disclosure - Property and Equipment (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfAccruedExpensesDetails" xlink:title="999050 - Disclosure - Schedule of Accrued Expenses (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails" xlink:title="999051 - Disclosure - Schedule of Supplemental Balance Sheet Information Related to Leases (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfMaturityAnalysisUnderLeaseAgreementsDetails" xlink:title="999052 - Disclosure - Schedule of Maturity Analysis Under Lease Agreements (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfLeaseCostsDetails" xlink:title="999053 - Disclosure - Schedule of Lease Costs (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails" xlink:title="999054 - Disclosure - Schedule of Supplemental Cash Flow Information Related to Leases (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/CommitmentsDetailsNarrative" xlink:title="999055 - Disclosure - Commitments (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfWarrantsDetails" xlink:title="999056 - Disclosure - Schedule of Warrants (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_WarrantOneMember" xlink:label="loc_CELCWarrantOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CELCWarrantOneMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_WarrantTwoMember" xlink:label="loc_CELCWarrantTwoMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CELCWarrantTwoMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_WarrantThreeMember" xlink:label="loc_CELCWarrantThreeMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CELCWarrantThreeMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_WarrantFourMember" xlink:label="loc_CELCWarrantFourMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CELCWarrantFourMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_WarrantFiveMember" xlink:label="loc_CELCWarrantFiveMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CELCWarrantFiveMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_WarrantSixMember" xlink:label="loc_CELCWarrantSixMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CELCWarrantSixMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_WarrantSevenMember" xlink:label="loc_CELCWarrantSevenMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CELCWarrantSevenMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_WarrantEightMember" xlink:label="loc_CELCWarrantEightMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CELCWarrantEightMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_WarrantNineMember" xlink:label="loc_CELCWarrantNineMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CELCWarrantNineMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_WarrantTenMember" xlink:label="loc_CELCWarrantTenMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CELCWarrantTenMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue" xlink:label="loc_CELCClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_CELCClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_220" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_220" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_220" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_220" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees" xlink:label="loc_us-gaapClassOfWarrantOrRightReasonForIssuingToNonemployees_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightReasonForIssuingToNonemployees_220" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/StockholdersEquityDetailsNarrative" xlink:title="999057 - Disclosure - Stockholders&#8217; Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapScheduleOfStockByClassTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_SeriesAConvertiblePreferredStockMember" xlink:label="loc_CELCSeriesAConvertiblePreferredStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_CELCSeriesAConvertiblePreferredStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_OpenMarketSaleAgreementMember" xlink:label="loc_CELCOpenMarketSaleAgreementMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CELCOpenMarketSaleAgreementMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_UnderwritingAgreementMember" xlink:label="loc_CELCUnderwritingAgreementMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CELCUnderwritingAgreementMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_SecuritiesPurchaseAgreementMember" xlink:label="loc_CELCSecuritiesPurchaseAgreementMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CELCSecuritiesPurchaseAgreementMember_170" xlink:type="arc" order="171" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_JefferiesLLCMember" xlink:label="loc_CELCJefferiesLLCMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_CELCJefferiesLLCMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_LeerinkPartnersLLCMember" xlink:label="loc_CELCLeerinkPartnersLLCMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CELCLeerinkPartnersLLCMember_140" xlink:type="arc" order="142" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_190" xlink:type="arc" order="192" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_InstitutionalAndOtherAccreditedInvestorsMember" xlink:label="loc_CELCInstitutionalAndOtherAccreditedInvestorsMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_CELCInstitutionalAndOtherAccreditedInvestorsMember_200" xlink:type="arc" order="201" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_260" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_260" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_260" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_260" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_260" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_260" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1_260" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaapConversionOfStockSharesIssued1_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockSharesIssued1_260" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="loc_us-gaapPreferredStockConvertibleConversionPrice_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockConvertibleConversionPrice_260" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_260" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_260" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises_260" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_260" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_260" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_260" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts_260" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_260" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_ProceedsFromIssuanceOfCommonStockNet" xlink:label="loc_CELCProceedsFromIssuanceOfCommonStockNet_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CELCProceedsFromIssuanceOfCommonStockNet_260" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_260" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharePrice_260" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement_260" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_OfferingExpenses" xlink:label="loc_CELCOfferingExpenses_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CELCOfferingExpenses_260" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_260" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOfWarrants" xlink:label="loc_CELCShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOfWarrants_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CELCShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOfWarrants_260" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_260" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_260" xlink:type="arc" order="25" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfStockOptionsActivityDetails" xlink:title="999058 - Disclosure - Schedule of Stock Options Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapOffsettingAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_60" xlink:type="arc" order="12" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfStockOptionsOutstandingAndExercisableDetails" xlink:title="999059 - Disclosure - Schedule of Stock Options Outstanding and Exercisable (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_30" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_30" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_30" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfAssumptionsForFairValueOfEquity-basedAwardsDetails" xlink:title="999060 - Disclosure - Schedule of Assumptions for Fair Value of Equity-based Awards (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_70" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfUnrecognizedCompensationCostDetails" xlink:title="999061 - Disclosure - Schedule of Unrecognized Compensation Cost (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfStock-basedCompensationExpensesDetails" xlink:title="999062 - Disclosure - Schedule of Stock-based Compensation Expenses (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="loc_us-gaapShareBasedCompensation_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="999063 - Disclosure - Stock-Based Compensation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_EquityIncentivePlanMember" xlink:label="loc_CELCEquityIncentivePlanMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CELCEquityIncentivePlanMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_StockIncentivePlanMember" xlink:label="loc_CELCStockIncentivePlanMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CELCStockIncentivePlanMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember_190" xlink:type="arc" order="191" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_EmployeeStockPurchasePlanMember" xlink:label="loc_CELCEmployeeStockPurchasePlanMember_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CELCEmployeeStockPurchasePlanMember_240" xlink:type="arc" order="241" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_MayTwoThousandTwentyTwoExercisePriceModificationMember" xlink:label="loc_CELCMayTwoThousandTwentyTwoExercisePriceModificationMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CELCMayTwoThousandTwentyTwoExercisePriceModificationMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_DecemberTwoThousandTwentyOneExercisePriceModificationMember" xlink:label="loc_CELCDecemberTwoThousandTwentyOneExercisePriceModificationMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CELCDecemberTwoThousandTwentyOneExercisePriceModificationMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_MayTwoThousandTwentyExercisePriceModificationMember" xlink:label="loc_CELCMayTwoThousandTwentyExercisePriceModificationMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CELCMayTwoThousandTwentyExercisePriceModificationMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_TwoThousandSeventeenPlanMember" xlink:label="loc_CELCTwoThousandSeventeenPlanMember_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CELCTwoThousandSeventeenPlanMember_230" xlink:type="arc" order="231" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_320" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_ChangeInCommonStockSharesReservedForIssuance" xlink:label="loc_CELCChangeInCommonStockSharesReservedForIssuance_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_CELCChangeInCommonStockSharesReservedForIssuance_320" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_TotalCommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_CELCTotalCommonStockCapitalSharesReservedForFutureIssuance_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_CELCTotalCommonStockCapitalSharesReservedForFutureIssuance_320" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_320" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_StockOptionAwardsSharesModified" xlink:label="loc_CELCStockOptionAwardsSharesModified_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_CELCStockOptionAwardsSharesModified_320" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_ModifiedStockOptionExercisePrice" xlink:label="loc_CELCModifiedStockOptionExercisePrice_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_CELCModifiedStockOptionExercisePrice_320" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_320" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_RemainingStockBasedCompensationExpenseRelatedToModification" xlink:label="loc_CELCRemainingStockBasedCompensationExpenseRelatedToModification_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_CELCRemainingStockBasedCompensationExpenseRelatedToModification_320" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_320" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_320" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_320" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_320" xlink:type="arc" order="11" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfLong-termDebtDetails" xlink:title="999064 - Disclosure - Schedule of Long-term Debt (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfLongTermDebtFuturePrincipalPaymentsDetails" xlink:title="999065 - Disclosure - Schedule of Long Term Debt Future Principal Payments (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/DebtDetailsNarrative" xlink:title="999066 - Disclosure - Debt (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_AmendedAndRestatedLoanAgreementMember" xlink:label="loc_CELCAmendedAndRestatedLoanAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CELCAmendedAndRestatedLoanAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_PriorLoanAgreementMember" xlink:label="loc_CELCPriorLoanAgreementMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CELCPriorLoanAgreementMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_InnovatusLifeSciencesMember" xlink:label="loc_CELCInnovatusLifeSciencesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CELCInnovatusLifeSciencesMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_TermALoanMember" xlink:label="loc_CELCTermALoanMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CELCTermALoanMember_20" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_TermBLoanMember" xlink:label="loc_CELCTermBLoanMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CELCTermBLoanMember_30" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_TermCLoanMember" xlink:label="loc_CELCTermCLoanMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CELCTermCLoanMember_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_TermDLoanMember" xlink:label="loc_CELCTermDLoanMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CELCTermDLoanMember_50" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_TermELoanMember" xlink:label="loc_CELCTermELoanMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CELCTermELoanMember_60" xlink:type="arc" order="63" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_TermFLoanMember" xlink:label="loc_CELCTermFLoanMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CELCTermFLoanMember_70" xlink:type="arc" order="73" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_AmendedAndRestatedLoanAgreementMember" xlink:label="loc_CELCAmendedAndRestatedLoanAgreementMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CELCAmendedAndRestatedLoanAgreementMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_120" xlink:type="arc" order="123" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_150" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount_150" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherBorrowings" xlink:label="loc_us-gaapOtherBorrowings_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapOtherBorrowings_150" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateTerms" xlink:label="loc_us-gaapDebtInstrumentInterestRateTerms_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateTerms_150" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_150" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_150" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_150" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_FinalFeePercentage" xlink:label="loc_CELCFinalFeePercentage_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_CELCFinalFeePercentage_150" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_NonUtilizationFee" xlink:label="loc_CELCNonUtilizationFee_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_CELCNonUtilizationFee_150" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_FinalFee" xlink:label="loc_CELCFinalFee_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_CELCFinalFee_150" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_WarrantOrRightToPurchasePercentage" xlink:label="loc_CELCWarrantOrRightToPurchasePercentage_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_CELCWarrantOrRightToPurchasePercentage_150" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_150" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_150" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_150" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:title="999067 - Disclosure - Schedule of Effective Income Tax Rate Reconciliation (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="999068 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/IncomeTaxesDetailsNarrative" xlink:title="999069 - Disclosure - Income Taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsDomestic_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsDomestic_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch_40" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/SubsequentEventDetailsNarrative" xlink:title="999070 - Disclosure - Subsequent Event (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionExercisePriceDecrease" xlink:label="loc_us-gaapStockOptionExercisePriceDecrease_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockOptionExercisePriceDecrease_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_30" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_30" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises_30" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_EquityIncentivePlanMember" xlink:label="loc_CELCEquityIncentivePlanMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CELCEquityIncentivePlanMember" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_StockIncentivePlanMember" xlink:label="loc_CELCStockIncentivePlanMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CELCStockIncentivePlanMember" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_EmployeeStockPurchasePlanMember" xlink:label="loc_CELCEmployeeStockPurchasePlanMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CELCEmployeeStockPurchasePlanMember" xlink:type="arc" order="20" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>17
<FILENAME>celc-20241231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_PreferredStockOnAnAsIfConvertedToCommonStockMember" xlink:label="CELC_PreferredStockOnAnAsIfConvertedToCommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_PreferredStockOnAnAsIfConvertedToCommonStockMember" xlink:to="CELC_PreferredStockOnAnAsIfConvertedToCommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_PreferredStockOnAnAsIfConvertedToCommonStockMember_lbl" xml:lang="en-US">Preferred Stock on an as-if-converted to Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_OptionsToPurchaseCommonStockMember" xlink:label="CELC_OptionsToPurchaseCommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_OptionsToPurchaseCommonStockMember" xlink:to="CELC_OptionsToPurchaseCommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_OptionsToPurchaseCommonStockMember_lbl" xml:lang="en-US">Options to Purchase Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_WarrantsToPurchaseCommonStockMember" xlink:label="CELC_WarrantsToPurchaseCommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_WarrantsToPurchaseCommonStockMember" xlink:to="CELC_WarrantsToPurchaseCommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_WarrantsToPurchaseCommonStockMember_lbl" xml:lang="en-US">Warrants to Purchase Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US">Restricted Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US">Financial Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xml:lang="en-US">US Treasury Securities [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_SeriesAConvertiblePreferredStockMember" xlink:label="CELC_SeriesAConvertiblePreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_SeriesAConvertiblePreferredStockMember" xlink:to="CELC_SeriesAConvertiblePreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_SeriesAConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series A Convertible Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_OpenMarketSaleAgreementMember" xlink:label="CELC_OpenMarketSaleAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_OpenMarketSaleAgreementMember" xlink:to="CELC_OpenMarketSaleAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_OpenMarketSaleAgreementMember_lbl" xml:lang="en-US">Open Market Sale Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_JefferiesLLCMember" xlink:label="CELC_JefferiesLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_JefferiesLLCMember" xlink:to="CELC_JefferiesLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_JefferiesLLCMember_lbl" xml:lang="en-US">Jefferies LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_UnderwritingAgreementMember" xlink:label="CELC_UnderwritingAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_UnderwritingAgreementMember" xlink:to="CELC_UnderwritingAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_UnderwritingAgreementMember_lbl" xml:lang="en-US">Underwriting Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_LeerinkPartnersLLCMember" xlink:label="CELC_LeerinkPartnersLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_LeerinkPartnersLLCMember" xlink:to="CELC_LeerinkPartnersLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_LeerinkPartnersLLCMember_lbl" xml:lang="en-US">Leerink Partners LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_SecuritiesPurchaseAgreementMember" xlink:label="CELC_SecuritiesPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_SecuritiesPurchaseAgreementMember" xlink:to="CELC_SecuritiesPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_SecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title and Position [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_InstitutionalAndOtherAccreditedInvestorsMember" xlink:label="CELC_InstitutionalAndOtherAccreditedInvestorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_InstitutionalAndOtherAccreditedInvestorsMember" xlink:to="CELC_InstitutionalAndOtherAccreditedInvestorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_InstitutionalAndOtherAccreditedInvestorsMember_lbl" xml:lang="en-US">Institutional and Other Accredited Investors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_WarrantOneMember" xlink:label="CELC_WarrantOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_WarrantOneMember" xlink:to="CELC_WarrantOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_WarrantOneMember_lbl" xml:lang="en-US">Warrant One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_WarrantTwoMember" xlink:label="CELC_WarrantTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_WarrantTwoMember" xlink:to="CELC_WarrantTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_WarrantTwoMember_lbl" xml:lang="en-US">Warrant Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_WarrantThreeMember" xlink:label="CELC_WarrantThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_WarrantThreeMember" xlink:to="CELC_WarrantThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_WarrantThreeMember_lbl" xml:lang="en-US">Warrant Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_WarrantFourMember" xlink:label="CELC_WarrantFourMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_WarrantFourMember" xlink:to="CELC_WarrantFourMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_WarrantFourMember_lbl" xml:lang="en-US">Warrant Four [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_WarrantFiveMember" xlink:label="CELC_WarrantFiveMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_WarrantFiveMember" xlink:to="CELC_WarrantFiveMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_WarrantFiveMember_lbl" xml:lang="en-US">Warrant Five [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_WarrantSixMember" xlink:label="CELC_WarrantSixMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_WarrantSixMember" xlink:to="CELC_WarrantSixMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_WarrantSixMember_lbl" xml:lang="en-US">Warrant Six [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_WarrantSevenMember" xlink:label="CELC_WarrantSevenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_WarrantSevenMember" xlink:to="CELC_WarrantSevenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_WarrantSevenMember_lbl" xml:lang="en-US">Warrant Seven [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_WarrantEightMember" xlink:label="CELC_WarrantEightMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_WarrantEightMember" xlink:to="CELC_WarrantEightMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_WarrantEightMember_lbl" xml:lang="en-US">Warrant Eight [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_WarrantNineMember" xlink:label="CELC_WarrantNineMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_WarrantNineMember" xlink:to="CELC_WarrantNineMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_WarrantNineMember_lbl" xml:lang="en-US">Warrant Nine [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_WarrantTenMember" xlink:label="CELC_WarrantTenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_WarrantTenMember" xlink:to="CELC_WarrantTenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_WarrantTenMember_lbl" xml:lang="en-US">Warrant Ten [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_EquityIncentivePlanMember" xlink:label="CELC_EquityIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_EquityIncentivePlanMember" xlink:to="CELC_EquityIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_EquityIncentivePlanMember_lbl" xml:lang="en-US">2012 Equity Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_StockIncentivePlanMember" xlink:label="CELC_StockIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_StockIncentivePlanMember" xlink:to="CELC_StockIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_StockIncentivePlanMember_lbl" xml:lang="en-US">2017 Stock Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_MayTwoThousandTwentyTwoExercisePriceModificationMember" xlink:label="CELC_MayTwoThousandTwentyTwoExercisePriceModificationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_MayTwoThousandTwentyTwoExercisePriceModificationMember" xlink:to="CELC_MayTwoThousandTwentyTwoExercisePriceModificationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_MayTwoThousandTwentyTwoExercisePriceModificationMember_lbl" xml:lang="en-US">May 2022 Exercise Price Modification [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_DecemberTwoThousandTwentyOneExercisePriceModificationMember" xlink:label="CELC_DecemberTwoThousandTwentyOneExercisePriceModificationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_DecemberTwoThousandTwentyOneExercisePriceModificationMember" xlink:to="CELC_DecemberTwoThousandTwentyOneExercisePriceModificationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_DecemberTwoThousandTwentyOneExercisePriceModificationMember_lbl" xml:lang="en-US">December 2021 Exercise Price Modification [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_MayTwoThousandTwentyExercisePriceModificationMember" xlink:label="CELC_MayTwoThousandTwentyExercisePriceModificationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_MayTwoThousandTwentyExercisePriceModificationMember" xlink:to="CELC_MayTwoThousandTwentyExercisePriceModificationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_MayTwoThousandTwentyExercisePriceModificationMember_lbl" xml:lang="en-US">May 2020 Exercise Price Modification [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_TwoThousandSeventeenPlanMember" xlink:label="CELC_TwoThousandSeventeenPlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_TwoThousandSeventeenPlanMember" xlink:to="CELC_TwoThousandSeventeenPlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_TwoThousandSeventeenPlanMember_lbl" xml:lang="en-US">2017 Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_EmployeeStockPurchasePlanMember" xlink:label="CELC_EmployeeStockPurchasePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_EmployeeStockPurchasePlanMember" xlink:to="CELC_EmployeeStockPurchasePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_EmployeeStockPurchasePlanMember_lbl" xml:lang="en-US">2017 Employee Stock Purchase Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_AmendedAndRestatedLoanAgreementMember" xlink:label="CELC_AmendedAndRestatedLoanAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_AmendedAndRestatedLoanAgreementMember" xlink:to="CELC_AmendedAndRestatedLoanAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_AmendedAndRestatedLoanAgreementMember_lbl" xml:lang="en-US">Amended and Restated Loan Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_InnovatusLifeSciencesMember" xlink:label="CELC_InnovatusLifeSciencesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_InnovatusLifeSciencesMember" xlink:to="CELC_InnovatusLifeSciencesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_InnovatusLifeSciencesMember_lbl" xml:lang="en-US">Innovatus Life Sciences [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_TermALoanMember" xlink:label="CELC_TermALoanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_TermALoanMember" xlink:to="CELC_TermALoanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_TermALoanMember_lbl" xml:lang="en-US">Term A Loan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_TermBLoanMember" xlink:label="CELC_TermBLoanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_TermBLoanMember" xlink:to="CELC_TermBLoanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_TermBLoanMember_lbl" xml:lang="en-US">Term B Loan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_TermCLoanMember" xlink:label="CELC_TermCLoanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_TermCLoanMember" xlink:to="CELC_TermCLoanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_TermCLoanMember_lbl" xml:lang="en-US">Term C Loan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_TermDLoanMember" xlink:label="CELC_TermDLoanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_TermDLoanMember" xlink:to="CELC_TermDLoanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_TermDLoanMember_lbl" xml:lang="en-US">Term D Loan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_TermELoanMember" xlink:label="CELC_TermELoanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_TermELoanMember" xlink:to="CELC_TermELoanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_TermELoanMember_lbl" xml:lang="en-US">Term E Loan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_TermFLoanMember" xlink:label="CELC_TermFLoanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_TermFLoanMember" xlink:to="CELC_TermFLoanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_TermFLoanMember_lbl" xml:lang="en-US">Term F Loan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_PriorLoanAgreementMember" xlink:label="CELC_PriorLoanAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_PriorLoanAgreementMember" xlink:to="CELC_PriorLoanAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_PriorLoanAgreementMember_lbl" xml:lang="en-US">Prior Loan Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US">Domestic Tax Jurisdiction [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorOpinionTextBlock" xlink:to="dei_AuditorOpinionTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorOpinionTextBlock_lbl" xml:lang="en-US">Auditor Opinion [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current Assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermInvestments_lbl" xml:lang="en-US">Investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right-of-use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermNotesPayable" xlink:to="us-gaap_LongTermNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermNotesPayable_lbl" xml:lang="en-US">Note payable, non-current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies (Note 9)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; Equity:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, $0.001 par value: 2,500,000 shares authorized; 317,577 and 854,134 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.001 par value: 95,000,000 and 65,000,000 shares authorized as of December 31, 2024 and December 31, 2023, respectively; 37,143,242 and 25,506,012 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total Liabilities and Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other (expense) income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpenseNonoperating_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Other income, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Net loss before income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax benefits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net loss per share, basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Net loss per share, diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average common shares outstanding, basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average common shares outstanding, diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_lbl" xml:lang="en-US">Stock-based compensation, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_StockIssuedDuringPeriodValueConversionOfPreferredToCommonStock" xlink:label="CELC_StockIssuedDuringPeriodValueConversionOfPreferredToCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_StockIssuedDuringPeriodValueConversionOfPreferredToCommonStock" xlink:to="CELC_StockIssuedDuringPeriodValueConversionOfPreferredToCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_StockIssuedDuringPeriodValueConversionOfPreferredToCommonStock_lbl" xml:lang="en-US">Conversion of preferred to common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_StockIssuedDuringPeriodSharesConversionOfPreferredToCommonStock" xlink:label="CELC_StockIssuedDuringPeriodSharesConversionOfPreferredToCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_StockIssuedDuringPeriodSharesConversionOfPreferredToCommonStock" xlink:to="CELC_StockIssuedDuringPeriodSharesConversionOfPreferredToCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_StockIssuedDuringPeriodSharesConversionOfPreferredToCommonStock_lbl" xml:lang="en-US">Conversion of preferred to common stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xml:lang="en-US">Employee stock purchases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US">Employee stock purchases, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Exercise of common stock options, net of shares withheld for exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercise of common stock options, net of shares withheld for exercise price, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_ExerciseOfCommonStockWarrants" xlink:label="CELC_ExerciseOfCommonStockWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_ExerciseOfCommonStockWarrants" xlink:to="CELC_ExerciseOfCommonStockWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="CELC_ExerciseOfCommonStockWarrants_lbl" xml:lang="en-US">Exercise of common stock warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_ExerciseOfCommonStockSharesWarrants" xlink:label="CELC_ExerciseOfCommonStockSharesWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_ExerciseOfCommonStockSharesWarrants" xlink:to="CELC_ExerciseOfCommonStockSharesWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_ExerciseOfCommonStockSharesWarrants_lbl" xml:lang="en-US">Exercise of common stock warrants, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsIssuanceWithPrivatePlacementOffering" xlink:label="CELC_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsIssuanceWithPrivatePlacementOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsIssuanceWithPrivatePlacementOffering" xlink:to="CELC_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsIssuanceWithPrivatePlacementOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="CELC_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsIssuanceWithPrivatePlacementOffering_lbl" xml:lang="en-US">Issuance costs associated with private placement offering</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of common stock in an ATM offering</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of common stock in an ATM offering, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US">Issuance costs associated with an ATM offering</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_AdditionalPaidInCapitalPreFundedWarrantIssued" xlink:label="CELC_AdditionalPaidInCapitalPreFundedWarrantIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_AdditionalPaidInCapitalPreFundedWarrantIssued" xlink:to="CELC_AdditionalPaidInCapitalPreFundedWarrantIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_AdditionalPaidInCapitalPreFundedWarrantIssued_lbl" xml:lang="en-US">Issuance of pre-funded warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_IssuanceCostsAssociatedWithPrefundedWarrants" xlink:label="CELC_IssuanceCostsAssociatedWithPrefundedWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_IssuanceCostsAssociatedWithPrefundedWarrants" xlink:to="CELC_IssuanceCostsAssociatedWithPrefundedWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_IssuanceCostsAssociatedWithPrefundedWarrants_lbl" xml:lang="en-US">Issuance costs associated with pre-funded warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_StockIssuedDuringPeriodValueStockWarrantsExercised" xlink:label="CELC_StockIssuedDuringPeriodValueStockWarrantsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_StockIssuedDuringPeriodValueStockWarrantsExercised" xlink:to="CELC_StockIssuedDuringPeriodValueStockWarrantsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_StockIssuedDuringPeriodValueStockWarrantsExercised_lbl" xml:lang="en-US">Exercise of common stock warrants, net of shares withheld for exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:label="CELC_StockIssuedDuringPeriodSharesStockWarrantsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:to="CELC_StockIssuedDuringPeriodSharesStockWarrantsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_StockIssuedDuringPeriodSharesStockWarrantsExercised_lbl" xml:lang="en-US">Exercise of common stock warrants, net of shares withheld for exercise price, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_StockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts" xlink:label="CELC_StockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_StockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts" xlink:to="CELC_StockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_StockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts_lbl" xml:lang="en-US">Issuance of common stock upon closing of follow-on offering, net of underwriting discounts and offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_StockIssuedDuringPeriodSharesIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts" xlink:label="CELC_StockIssuedDuringPeriodSharesIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_StockIssuedDuringPeriodSharesIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts" xlink:to="CELC_StockIssuedDuringPeriodSharesIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_StockIssuedDuringPeriodSharesIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts_lbl" xml:lang="en-US">Issuance of common stock upon closing of follow-on offering, net of underwriting discounts and offering costs, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US">Issuance of common stock warrants, note payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used for operations:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US">Amortization of debt issuance costs and discount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaidInKindInterest" xlink:to="us-gaap_PaidInKindInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaidInKindInterest_lbl" xml:lang="en-US">Payment-in-Kind interest</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_NoncashOperatingLeaseExpenseNet" xlink:label="CELC_NoncashOperatingLeaseExpenseNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_NoncashOperatingLeaseExpenseNet" xlink:to="CELC_NoncashOperatingLeaseExpenseNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_NoncashOperatingLeaseExpenseNet_lbl" xml:lang="en-US">Non-cash operating lease, net</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_ChangeInAccruedInterestIncome" xlink:label="CELC_ChangeInAccruedInterestIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_ChangeInAccruedInterestIncome" xlink:to="CELC_ChangeInAccruedInterestIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="CELC_ChangeInAccruedInterestIncome_lbl" xml:lang="en-US">Change in accrued interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xml:lang="en-US">Other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used for operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_lbl" xml:lang="en-US">Proceeds from maturities of investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInvestments" xlink:to="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xml:lang="en-US">Purchases of investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used for investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from exercise of common stock warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from exercise of employee stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockPlans" xlink:to="us-gaap_ProceedsFromStockPlans_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xml:lang="en-US">Proceeds from employee stock purchases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromOtherEquity" xlink:label="us-gaap_ProceedsFromOtherEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromOtherEquity" xlink:to="us-gaap_ProceedsFromOtherEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromOtherEquity_lbl" xml:lang="en-US">Proceeds from follow-on offering, net of underwriting discounts and offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl" xml:lang="en-US">Proceeds from note payable, net of debt issuance costs and discount of $2,437,644</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_ProceedsFromAtmOfferingNetOfIssuanceCosts" xlink:label="CELC_ProceedsFromAtmOfferingNetOfIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_ProceedsFromAtmOfferingNetOfIssuanceCosts" xlink:to="CELC_ProceedsFromAtmOfferingNetOfIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_ProceedsFromAtmOfferingNetOfIssuanceCosts_lbl" xml:lang="en-US">Proceeds from an ATM offering, net of issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US">Proceeds from pre-funded warrants, net of offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_PaymentsForSecondaryRegistrationStatementCosts" xlink:label="CELC_PaymentsForSecondaryRegistrationStatementCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_PaymentsForSecondaryRegistrationStatementCosts" xlink:to="CELC_PaymentsForSecondaryRegistrationStatementCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="CELC_PaymentsForSecondaryRegistrationStatementCosts_lbl" xml:lang="en-US">Payments for secondary registration statement costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xml:lang="en-US">Payments for debt issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xml:lang="en-US">Payments for finance leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl" xml:lang="en-US">Cash and cash equivalents:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xml:lang="en-US">End of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest paid</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Supplemental disclosures of non-cash investing and financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_DeferredFinancingCostsAndOfferingAndRegistrationStatementCostsIncludedInAccountsPayable" xlink:label="CELC_DeferredFinancingCostsAndOfferingAndRegistrationStatementCostsIncludedInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_DeferredFinancingCostsAndOfferingAndRegistrationStatementCostsIncludedInAccountsPayable" xlink:to="CELC_DeferredFinancingCostsAndOfferingAndRegistrationStatementCostsIncludedInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_DeferredFinancingCostsAndOfferingAndRegistrationStatementCostsIncludedInAccountsPayable_lbl" xml:lang="en-US">Deferred financing costs and offering and registration statement costs included in accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_PropertyAndEquipmentIncludedInAccountsPayable" xlink:label="CELC_PropertyAndEquipmentIncludedInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_PropertyAndEquipmentIncludedInAccountsPayable" xlink:to="CELC_PropertyAndEquipmentIncludedInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_PropertyAndEquipmentIncludedInAccountsPayable_lbl" xml:lang="en-US">Property and equipment included in accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_CommonStockWarrantsIssuedWithNotePayableTransaction" xlink:label="CELC_CommonStockWarrantsIssuedWithNotePayableTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_CommonStockWarrantsIssuedWithNotePayableTransaction" xlink:to="CELC_CommonStockWarrantsIssuedWithNotePayableTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_CommonStockWarrantsIssuedWithNotePayableTransaction_lbl" xml:lang="en-US">Common stock warrants issued with the note payable transaction</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_lbl" xml:lang="en-US">Debt issuance costs and discount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable" xlink:label="ecd_PvpTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTable" xlink:to="ecd_PvpTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTable_lbl" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis" xlink:label="ecd_ExecutiveCategoryAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ExecutiveCategoryAxis" xlink:to="ecd_ExecutiveCategoryAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ExecutiveCategoryAxis_lbl" xml:lang="en-US">Executive Category [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="ecd_IndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_IndividualAxis" xlink:to="ecd_IndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_IndividualAxis_lbl" xml:lang="en-US">Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis" xlink:label="ecd_AdjToCompAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAxis" xlink:to="ecd_AdjToCompAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAxis_lbl" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis" xlink:label="ecd_MeasureAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureAxis" xlink:to="ecd_MeasureAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureAxis_lbl" xml:lang="en-US">Measure [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock" xlink:label="ecd_PvpTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTableTextBlock" xlink:to="ecd_PvpTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTableTextBlock_lbl" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName" xlink:label="ecd_CoSelectedMeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureName" xlink:to="ecd_CoSelectedMeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureName_lbl" xml:lang="en-US">Company Selected Measure Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="ecd_PeerGroupIssuersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupIssuersFnTextBlock" xlink:to="ecd_PeerGroupIssuersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupIssuersFnTextBlock_lbl" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="ecd_ChangedPeerGroupFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ChangedPeerGroupFnTextBlock" xlink:to="ecd_ChangedPeerGroupFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ChangedPeerGroupFnTextBlock_lbl" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt" xlink:label="ecd_PeoTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoTotalCompAmt" xlink:to="ecd_PeoTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoTotalCompAmt_lbl" xml:lang="en-US">PEO Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="ecd_PeoActuallyPaidCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoActuallyPaidCompAmt" xlink:to="ecd_PeoActuallyPaidCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoActuallyPaidCompAmt_lbl" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="ecd_AdjToPeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToPeoCompFnTextBlock" xlink:to="ecd_AdjToPeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToPeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock" xlink:label="ecd_TabularListTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TabularListTableTextBlock" xlink:to="ecd_TabularListTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TabularListTableTextBlock_lbl" xml:lang="en-US">Tabular List, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt" xlink:label="ecd_TotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnAmt" xlink:to="ecd_TotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnAmt_lbl" xml:lang="en-US">Total Shareholder Return Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Net Income (Loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt" xlink:label="ecd_CoSelectedMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureAmt" xlink:to="ecd_CoSelectedMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureAmt_lbl" xml:lang="en-US">Company Selected Measure Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt" xlink:label="ecd_OtherPerfMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OtherPerfMeasureAmt" xlink:to="ecd_OtherPerfMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OtherPerfMeasureAmt_lbl" xml:lang="en-US">Other Performance Measure, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt" xlink:label="ecd_AdjToCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAmt" xlink:to="ecd_AdjToCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAmt_lbl" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName" xlink:label="ecd_PeoName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoName" xlink:to="ecd_PeoName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoName_lbl" xml:lang="en-US">PEO Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName" xlink:label="ecd_MeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureName" xlink:to="ecd_MeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xml:lang="en-US">Non-GAAP Measure Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="ecd_Additional402vDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Additional402vDisclosureTextBlock" xlink:to="ecd_Additional402vDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Additional402vDisclosureTextBlock_lbl" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="ecd_PnsnBnftsAdjFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PnsnBnftsAdjFnTextBlock" xlink:to="ecd_PnsnBnftsAdjFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PnsnBnftsAdjFnTextBlock_lbl" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable" xlink:label="ecd_ErrCompRecoveryTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompRecoveryTable" xlink:to="ecd_ErrCompRecoveryTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompRecoveryTable_lbl" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis" xlink:label="ecd_RestatementDateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDateAxis" xlink:to="ecd_RestatementDateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDateAxis_lbl" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate" xlink:label="ecd_RestatementDeterminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDeterminationDate" xlink:to="ecd_RestatementDeterminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDeterminationDate_lbl" xml:lang="en-US">Restatement Determination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt" xlink:label="ecd_AggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompAmt" xlink:to="ecd_AggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompAmt_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="ecd_ErrCompAnalysisTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompAnalysisTextBlock" xlink:to="ecd_ErrCompAnalysisTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompAnalysisTextBlock_lbl" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="ecd_OutstandingAggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingAggtErrCompAmt" xlink:to="ecd_OutstandingAggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingAggtErrCompAmt_lbl" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName" xlink:label="ecd_ForgoneRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_ForgoneRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName" xlink:label="ecd_OutstandingRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_OutstandingRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="ecd_OutstandingRecoveryCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryCompAmt" xlink:to="ecd_OutstandingRecoveryCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryCompAmt_lbl" xml:lang="en-US">Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xml:lang="en-US">Restatement does not require Recovery</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="ecd_AwardsCloseToMnpiDiscTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTable" xlink:to="ecd_AwardsCloseToMnpiDiscTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTable_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="ecd_AwardTmgMnpiDiscTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiDiscTextBlock" xlink:to="ecd_AwardTmgMnpiDiscTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiDiscTextBlock_lbl" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="ecd_AwardTmgMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMethodTextBlock" xlink:to="ecd_AwardTmgMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMethodTextBlock_lbl" xml:lang="en-US">Award Timing Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="ecd_AwardTmgPredtrmndFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgPredtrmndFlag" xlink:to="ecd_AwardTmgPredtrmndFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgPredtrmndFlag_lbl" xml:lang="en-US">Award Timing Predetermined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xml:lang="en-US">Award Timing MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="ecd_MnpiDiscTimedForCompValFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MnpiDiscTimedForCompValFlag" xlink:to="ecd_MnpiDiscTimedForCompValFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MnpiDiscTimedForCompValFlag_lbl" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="ecd_AwardsCloseToMnpiDiscIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="ecd_AwardUndrlygSecuritiesAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardUndrlygSecuritiesAmt" xlink:to="ecd_AwardUndrlygSecuritiesAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardUndrlygSecuritiesAmt_lbl" xml:lang="en-US">Underlying Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice" xlink:label="ecd_AwardExrcPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardExrcPrice" xlink:to="ecd_AwardExrcPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardExrcPrice_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue" xlink:label="ecd_AwardGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardGrantDateFairValue" xlink:to="ecd_AwardGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardGrantDateFairValue_lbl" xml:lang="en-US">Fair Value as of Grant Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="ecd_UndrlygSecurityMktPriceChngPct" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_UndrlygSecurityMktPriceChngPct" xlink:to="ecd_UndrlygSecurityMktPriceChngPct_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_UndrlygSecurityMktPriceChngPct_lbl" xml:lang="en-US">Underlying Security Market Price Change</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems" xlink:label="ecd_InsiderTradingArrLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_InsiderTradingArrLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingArrLineItems_lbl" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName" xlink:label="ecd_TrdArrIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_TrdArrIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle" xlink:label="ecd_TrdArrIndTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndTitle" xlink:to="ecd_TrdArrIndTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndTitle_lbl" xml:lang="en-US">Title</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrAdoptedFlag" xlink:to="ecd_Rule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Rule 10b51 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrAdoptedFlag" xlink:to="ecd_NonRule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Non-Rule 10b51 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate" xlink:label="ecd_TrdArrAdoptionDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrAdoptionDate" xlink:to="ecd_TrdArrAdoptionDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrAdoptionDate_lbl" xml:lang="en-US">Adoption Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrTrmntdFlag" xlink:to="ecd_Rule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Rule 10b51 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Non-Rule 10b51 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate" xlink:label="ecd_TrdArrTerminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrTerminationDate" xlink:to="ecd_TrdArrTerminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrTerminationDate_lbl" xml:lang="en-US">Termination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate" xlink:label="ecd_TrdArrExpirationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrExpirationDate" xlink:to="ecd_TrdArrExpirationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrExpirationDate_lbl" xml:lang="en-US">Expiration Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration" xlink:label="ecd_TrdArrDuration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrDuration" xlink:to="ecd_TrdArrDuration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrDuration_lbl" xml:lang="en-US">Arrangement Duration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="ecd_InsiderTradingPoliciesProcLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingPoliciesProcLineItems" xlink:to="ecd_InsiderTradingPoliciesProcLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingPoliciesProcLineItems_lbl" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xml:lang="en-US">Cybersecurity Risk Management, Strategy, and Governance [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Third Party Engaged [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xml:lang="en-US">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Board of Directors Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Role of Management [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentAbstract" xlink:label="cyd_MaterialCybersecurityIncidentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentAbstract" xlink:to="cyd_MaterialCybersecurityIncidentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentAbstract_lbl" xml:lang="en-US">Material Cybersecurity Incident [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentNatureTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentNatureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentNatureTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentNatureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentNatureTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Nature [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentScopeTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentScopeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentScopeTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentScopeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentScopeTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Scope [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentTimingTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentTimingTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentTimingTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentTimingTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentTimingTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Timing [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Information Not Available or Undetermined [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Organization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xml:lang="en-US">Liquidity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Net Loss Per Common Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="us-gaap_InvestmentsAllOtherInvestmentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="us-gaap_InvestmentsAllOtherInvestmentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsAllOtherInvestmentsAbstract_lbl" xml:lang="en-US">Investments, All Other Investments [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTextBlock" xlink:label="us-gaap_InvestmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTextBlock" xlink:to="us-gaap_InvestmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InvestmentTextBlock_lbl" xml:lang="en-US">Investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentAssetsTextBlock" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsTextBlock" xlink:to="us-gaap_OtherCurrentAssetsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl" xml:lang="en-US">Other Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">Accrued Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="us-gaap_CommitmentsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsDisclosureTextBlock" xlink:to="us-gaap_CommitmentsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsDisclosureTextBlock_lbl" xml:lang="en-US">Commitments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Event</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Accounting Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xml:lang="en-US">Investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Long-Lived Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xml:lang="en-US">Deferred Transaction Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtPolicyTextBlock" xlink:to="us-gaap_DebtPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xml:lang="en-US">Debt Issuance Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US">Comprehensive Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Risks and Uncertainties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:to="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl" xml:lang="en-US">Clinical Trial Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Data</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" xlink:label="CELC_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" xlink:to="CELC_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock_lbl" xml:lang="en-US">Schedule of Estimated Useful Lives of Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of Potentially-Dilutive Shares Excluded from the Diluted Weighted-Average Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTableTextBlock" xlink:label="us-gaap_InvestmentTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTableTextBlock" xlink:to="us-gaap_InvestmentTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentTableTextBlock_lbl" xml:lang="en-US">Schedule of Investment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of Other Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Summary of Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:label="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:to="srt_ScheduleOfCondensedBalanceSheetTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfCondensedBalanceSheetTableTextBlock_lbl" xml:lang="en-US">Schedule of Supplemental Balance Sheet Information Related to Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of Maturity Analysis Under Lease Agreements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Schedule of Lease Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl" xml:lang="en-US">Schedule of Supplemental Cash Flow Information Related to Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Stock Options Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_lbl" xml:lang="en-US">Schedule of Stock Options Outstanding and Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Assumptions for Fair Value of Equity-based Awards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_lbl" xml:lang="en-US">Schedule of Unrecognized Compensation Cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Schedule of Stock-based Compensation Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xml:lang="en-US">Schedule of Long-term Debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xml:lang="en-US">Schedule of Long Term Debt Future Principal Payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Estimated useful lives</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US">Cash equivalents FDIC insured, amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShortTermInvestments_2_lbl" xml:lang="en-US">Short-term investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCurrent" xlink:label="us-gaap_DeferredCostsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCurrent" xlink:to="us-gaap_DeferredCostsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCurrent_lbl" xml:lang="en-US">Deferred transaction costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xml:lang="en-US">Research and development expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:label="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:to="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_lbl" xml:lang="en-US">Potentially-dilutive shares excluded from diluted weighted-average shares outstanding:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Anti-dilutive securities excluded from diluted weighted- average shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_PrefundedWarrantShares" xlink:label="CELC_PrefundedWarrantShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_PrefundedWarrantShares" xlink:to="CELC_PrefundedWarrantShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_PrefundedWarrantShares_lbl" xml:lang="en-US">Pre-funded warrant shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:to="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable_lbl" xml:lang="en-US">Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:label="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_lbl" xml:lang="en-US">Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecurities" xlink:label="us-gaap_HeldToMaturitySecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HeldToMaturitySecurities" xlink:to="us-gaap_HeldToMaturitySecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_HeldToMaturitySecurities_lbl" xml:lang="en-US">Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:label="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:to="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_lbl" xml:lang="en-US">Debt Securities, Held-to-Maturity, Accumulated Unrecognized Gain</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:label="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:to="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_lbl" xml:lang="en-US">Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesFairValue" xlink:label="us-gaap_HeldToMaturitySecuritiesFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HeldToMaturitySecuritiesFairValue" xlink:to="us-gaap_HeldToMaturitySecuritiesFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_HeldToMaturitySecuritiesFairValue_lbl" xml:lang="en-US">Debt Securities, Held-to-Maturity, Fair Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" xml:lang="en-US">Current:</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_PrepaidClinicalTrialCosts" xlink:label="CELC_PrepaidClinicalTrialCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_PrepaidClinicalTrialCosts" xlink:to="CELC_PrepaidClinicalTrialCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_PrepaidClinicalTrialCosts_lbl" xml:lang="en-US">Prepaid clinical trial costs</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_MiscellaneousReceivable" xlink:label="CELC_MiscellaneousReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_MiscellaneousReceivable" xlink:to="CELC_MiscellaneousReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_MiscellaneousReceivable_lbl" xml:lang="en-US">Miscellaneous receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US">Directors &amp; officers&#8217; insurance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US">Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherAssetsCurrent_2_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property and equipment, Gross</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less: Accumulated depreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xml:lang="en-US">Total</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Depreciation_2_lbl" xml:lang="en-US">Depreciation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_AccruedClinicalTrialExpense" xlink:label="CELC_AccruedClinicalTrialExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_AccruedClinicalTrialExpense" xlink:to="CELC_AccruedClinicalTrialExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_AccruedClinicalTrialExpense_lbl" xml:lang="en-US">Clinical trial costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WorkersCompensationLiabilityCurrent" xlink:label="us-gaap_WorkersCompensationLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WorkersCompensationLiabilityCurrent" xlink:to="us-gaap_WorkersCompensationLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WorkersCompensationLiabilityCurrent_lbl" xml:lang="en-US">Accrued compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xml:lang="en-US">Employee stock purchase plan</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:label="us-gaap_LesseeOperatingLeaseDescriptionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:to="us-gaap_LesseeOperatingLeaseDescriptionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseDescriptionAbstract_lbl" xml:lang="en-US">Operating Lease</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xml:lang="en-US">Right-of-use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xml:lang="en-US">Less: short term portion</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xml:lang="en-US">Long term portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2026</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total minimum lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: Present value discount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiability_2_lbl" xml:lang="en-US">Present value of net minimum lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Operating leases, remaining lease term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Operating leases, discount rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating lease cost</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_FinanceLeaseCostAbstract" xlink:label="CELC_FinanceLeaseCostAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_FinanceLeaseCostAbstract" xlink:to="CELC_FinanceLeaseCostAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_FinanceLeaseCostAbstract_lbl" xml:lang="en-US">Finance lease cost:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xml:lang="en-US">Amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestExpense" xlink:to="us-gaap_FinanceLeaseInterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl" xml:lang="en-US">Interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableLeaseCost_lbl" xml:lang="en-US">Variable lease cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Lease costs</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_CashPaidForOperatingAndFinanceLeasesAbstract" xlink:label="CELC_CashPaidForOperatingAndFinanceLeasesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_CashPaidForOperatingAndFinanceLeasesAbstract" xlink:to="CELC_CashPaidForOperatingAndFinanceLeasesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_CashPaidForOperatingAndFinanceLeasesAbstract_lbl" xml:lang="en-US">Cash paid for amounts included in operating and finance leases:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating cash outflow from operating leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl" xml:lang="en-US">Operating cash outflow from finance leases</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeasePrincipalPayments_2_lbl" xml:lang="en-US">Financing cash outflow from finance leases</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_CashPaidForOperatingAndFinanceLeases" xlink:label="CELC_CashPaidForOperatingAndFinanceLeases" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_CashPaidForOperatingAndFinanceLeases" xlink:to="CELC_CashPaidForOperatingAndFinanceLeases_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="CELC_CashPaidForOperatingAndFinanceLeases_lbl" xml:lang="en-US">Total cash paid for amounts included in operating and finance leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligation_lbl" xml:lang="en-US">Non-cancelable contractual commitment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue" xlink:label="CELC_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue" xlink:to="CELC_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_lbl" xml:lang="en-US">Issue Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xml:lang="en-US">Expiration Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Number of Warrants Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees" xlink:label="us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees" xlink:to="us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees_lbl" xml:lang="en-US">Offering</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Class of Stock [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US">Number of shares converted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xml:lang="en-US">Number of shares issued in conversion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleConversionPrice" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice_lbl" xml:lang="en-US">Cost basis of shares transferred</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Additional warrants exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xml:lang="en-US">Exercise price of common stock warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_2_lbl" xml:lang="en-US">Proceeds from warant exercise</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Sale of stock number of shares issued in transaction</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Issuance of public offering price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US">Gross proceeds from public offering</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Commissions and other offering expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Gross proceeds from public offering</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_ProceedsFromIssuanceOfCommonStockNet" xlink:label="CELC_ProceedsFromIssuanceOfCommonStockNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_ProceedsFromIssuanceOfCommonStockNet" xlink:to="CELC_ProceedsFromIssuanceOfCommonStockNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_ProceedsFromIssuanceOfCommonStockNet_lbl" xml:lang="en-US">Net proceeds from public offering</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Pre-funded warrants sold to investors</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Warrant purchase price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US">Proceeds from issuance of private placement</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_OfferingExpenses" xlink:label="CELC_OfferingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_OfferingExpenses" xlink:to="CELC_OfferingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_OfferingExpenses_lbl" xml:lang="en-US">Offering expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOfWarrants" xlink:label="CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOfWarrants" xlink:to="CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOfWarrants_lbl" xml:lang="en-US">[custom:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOfWarrants-0]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Expirations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OffsettingAssetsTable" xlink:label="us-gaap_OffsettingAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OffsettingAssetsTable" xlink:to="us-gaap_OffsettingAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OffsettingAssetsTable_lbl" xml:lang="en-US">Offsetting Assets [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="us-gaap_OffsettingAssetsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OffsettingAssetsLineItems" xlink:to="us-gaap_OffsettingAssetsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OffsettingAssetsLineItems_lbl" xml:lang="en-US">Offsetting Assets [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Options outstanding at beginning of year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Options outstanding, weighted average exercise price at beginning of year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Shares, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Shares, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Shares, Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise, Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Options outstanding at end of year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Options outstanding, weighted average exercise price at end of year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Shares, options exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Options exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value for options granted during the period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Options outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Options outstanding, weighted average remaining contractual life</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Options outstanding, weighted average exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Options outstanding, aggregate intrinsic value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xml:lang="en-US">Options exercisable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Options exercisable, weighted average exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Options exercisable, aggregate intrinsic value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US">Risk-free interest rate, minimum</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US">Risk-free interest rate, maximum</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US">Expected volatility, minimum</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US">Expected volatility, maximum</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected life (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Expected dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostToBeRecognizedNextTwelveMonths" xlink:label="CELC_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostToBeRecognizedNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostToBeRecognizedNextTwelveMonths" xlink:to="CELC_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostToBeRecognizedNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CELC_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostToBeRecognizedNextTwelveMonths_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostToBeRecognizedWithinTwoYear" xlink:label="CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostToBeRecognizedWithinTwoYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostToBeRecognizedWithinTwoYear" xlink:to="CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostToBeRecognizedWithinTwoYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostToBeRecognizedWithinTwoYear_lbl" xml:lang="en-US">2026</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostToBeRecognizedwithinThreeYears" xlink:label="CELC_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostToBeRecognizedwithinThreeYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostToBeRecognizedwithinThreeYears" xlink:to="CELC_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostToBeRecognizedwithinThreeYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostToBeRecognizedwithinThreeYears_lbl" xml:lang="en-US">2027</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostToBeRecognizedWithinFourYears" xlink:label="CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostToBeRecognizedWithinFourYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostToBeRecognizedWithinFourYears" xlink:to="CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostToBeRecognizedWithinFourYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostToBeRecognizedWithinFourYears_lbl" xml:lang="en-US">2028</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostToBeRecognized" xlink:label="CELC_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostToBeRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostToBeRecognized" xlink:to="CELC_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostToBeRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="CELC_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostToBeRecognized_lbl" xml:lang="en-US">Total estimated compensation cost to be recognized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Common stock, shares reserved for issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_ChangeInCommonStockSharesReservedForIssuance" xlink:label="CELC_ChangeInCommonStockSharesReservedForIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_ChangeInCommonStockSharesReservedForIssuance" xlink:to="CELC_ChangeInCommonStockSharesReservedForIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_ChangeInCommonStockSharesReservedForIssuance_lbl" xml:lang="en-US">Change in common stock, shares reserved for issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_TotalCommonStockCapitalSharesReservedForFutureIssuance" xlink:label="CELC_TotalCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_TotalCommonStockCapitalSharesReservedForFutureIssuance" xlink:to="CELC_TotalCommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_TotalCommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Total common stock, shares reserved for issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Recognized stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_StockOptionAwardsSharesModified" xlink:label="CELC_StockOptionAwardsSharesModified" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_StockOptionAwardsSharesModified" xlink:to="CELC_StockOptionAwardsSharesModified_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_StockOptionAwardsSharesModified_lbl" xml:lang="en-US">Stock option awards shares modified</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_ModifiedStockOptionExercisePrice" xlink:label="CELC_ModifiedStockOptionExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_ModifiedStockOptionExercisePrice" xlink:to="CELC_ModifiedStockOptionExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_ModifiedStockOptionExercisePrice_lbl" xml:lang="en-US">Stock option exercise price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_lbl" xml:lang="en-US">Stock based compensation expense related to modification</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_RemainingStockBasedCompensationExpenseRelatedToModification" xlink:label="CELC_RemainingStockBasedCompensationExpenseRelatedToModification" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_RemainingStockBasedCompensationExpenseRelatedToModification" xlink:to="CELC_RemainingStockBasedCompensationExpenseRelatedToModification_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_RemainingStockBasedCompensationExpenseRelatedToModification_lbl" xml:lang="en-US">Remaining stock based compensation expense related to modification</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Restricted stock awards outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Restricted stock awards vested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Shares available for grant under the 2017 Plan</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xml:lang="en-US">Annual employee stock purchase plan description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="us-gaap_ConvertibleNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayable_lbl" xml:lang="en-US">Note payable</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_FinalFee" xlink:label="CELC_FinalFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_FinalFee" xlink:to="CELC_FinalFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_FinalFee_lbl" xml:lang="en-US">Add: Final fee</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_PaymentInKindInterestDebt" xlink:label="CELC_PaymentInKindInterestDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_PaymentInKindInterestDebt" xlink:to="CELC_PaymentInKindInterestDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_PaymentInKindInterestDebt_lbl" xml:lang="en-US">Add: PIK interest (added to principal)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xml:lang="en-US">Less: unamortized debt issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xml:lang="en-US">Less: unamortized debt discount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermNotesPayable" xlink:to="us-gaap_LongTermNotesPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LongTermNotesPayable_2_lbl" xml:lang="en-US">Total long-term debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xml:lang="en-US">2027</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xml:lang="en-US">2028</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl" xml:lang="en-US">2029</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Funded contingent loan, outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US">Funded loan amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherBorrowings" xlink:label="us-gaap_OtherBorrowings" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherBorrowings" xlink:to="us-gaap_OtherBorrowings_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherBorrowings_lbl" xml:lang="en-US">Costs associated with new borrowings</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateTerms" xlink:label="us-gaap_DebtInstrumentInterestRateTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateTerms" xlink:to="us-gaap_DebtInstrumentInterestRateTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateTerms_lbl" xml:lang="en-US">Debt instrument interest rate description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Loan conversion percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_2_lbl" xml:lang="en-US">Common stock price per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xml:lang="en-US">Common stock issued</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_FinalFeePercentage" xlink:label="CELC_FinalFeePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_FinalFeePercentage" xlink:to="CELC_FinalFeePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_FinalFeePercentage_lbl" xml:lang="en-US">Final fee percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_NonUtilizationFee" xlink:label="CELC_NonUtilizationFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_NonUtilizationFee" xlink:to="CELC_NonUtilizationFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_NonUtilizationFee_lbl" xml:lang="en-US">Non utilization fee</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_FinalFee" xlink:to="CELC_FinalFee_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CELC_FinalFee_2_lbl" xml:lang="en-US">Final fee</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_WarrantOrRightToPurchasePercentage" xlink:label="CELC_WarrantOrRightToPurchasePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_WarrantOrRightToPurchasePercentage" xlink:to="CELC_WarrantOrRightToPurchasePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_WarrantOrRightToPurchasePercentage_lbl" xml:lang="en-US">Warrant or right, reason for issuance, description</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_2_lbl" xml:lang="en-US">Warrants issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3_lbl" xml:lang="en-US">Warrants exercise price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Fair value of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Tax benefit at statutory federal rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State income tax benefit, net of federal tax effect</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance on deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xml:lang="en-US">Research &amp; Development Credits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl" xml:lang="en-US">Other permanent items</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Income tax benefits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Share-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xml:lang="en-US">Property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_DeferredTaxAssetsRightofuseAssets" xlink:label="CELC_DeferredTaxAssetsRightofuseAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_DeferredTaxAssetsRightofuseAssets" xlink:to="CELC_DeferredTaxAssetsRightofuseAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_DeferredTaxAssetsRightofuseAssets_lbl" xml:lang="en-US">Right-of-use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_DeferredTaxAssetsLeaseLiability" xlink:label="CELC_DeferredTaxAssetsLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_DeferredTaxAssetsLeaseLiability" xlink:to="CELC_DeferredTaxAssetsLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="CELC_DeferredTaxAssetsLeaseLiability_lbl" xml:lang="en-US">Lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIRC174Expenditures" xlink:label="CELC_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIRC174Expenditures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIRC174Expenditures" xlink:to="CELC_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIRC174Expenditures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIRC174Expenditures_lbl" xml:lang="en-US">IRC 174 Expenditures</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStartupExpenditures" xlink:label="CELC_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStartupExpenditures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStartupExpenditures" xlink:to="CELC_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStartupExpenditures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStartupExpenditures_lbl" xml:lang="en-US">Start-up expenditures</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating losses and tax credits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Net deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xml:lang="en-US">Federal net operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xml:lang="en-US">State net operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US">Tax credit carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionExercisePriceDecrease" xlink:label="us-gaap_StockOptionExercisePriceDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionExercisePriceDecrease" xlink:to="us-gaap_StockOptionExercisePriceDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionExercisePriceDecrease_lbl" xml:lang="en-US">Exercise price reduced</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xml:lang="en-US">Exercise price lower</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xml:lang="en-US">Exercise price upper</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xml:lang="en-US">Stock options held</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US">Warrants exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_3_lbl" xml:lang="en-US">Proceeds from warrants exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_ExerciseOfCommonStockWarrants" xlink:to="CELC_ExerciseOfCommonStockWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_ExerciseOfCommonStockWarrants_doc" xml:lang="en-US">Exercise of common stock warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsIssuanceWithPrivatePlacementOffering" xlink:to="CELC_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsIssuanceWithPrivatePlacementOffering_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsIssuanceWithPrivatePlacementOffering_doc" xml:lang="en-US">Issuance costs associated with private placement offering.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_AdditionalPaidInCapitalPreFundedWarrantIssued" xlink:to="CELC_AdditionalPaidInCapitalPreFundedWarrantIssued_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_AdditionalPaidInCapitalPreFundedWarrantIssued_doc" xml:lang="en-US">Additional paid in capital Pre-Funded Warrant issued.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_IssuanceCostsAssociatedWithPrefundedWarrants" xlink:to="CELC_IssuanceCostsAssociatedWithPrefundedWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_IssuanceCostsAssociatedWithPrefundedWarrants_doc" xml:lang="en-US">Issuance costs associated with pre-funded warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_StockIssuedDuringPeriodValueStockWarrantsExercised" xlink:to="CELC_StockIssuedDuringPeriodValueStockWarrantsExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_StockIssuedDuringPeriodValueStockWarrantsExercised_doc" xml:lang="en-US">Exercise of common stock warrants, net of shares withheld for exercise price, value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_StockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts" xlink:to="CELC_StockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_StockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts_doc" xml:lang="en-US">Stock issued during period value issuance upon closing of followon offering net of underwriting discounts and offering costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_ExerciseOfCommonStockSharesWarrants" xlink:to="CELC_ExerciseOfCommonStockSharesWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_ExerciseOfCommonStockSharesWarrants_doc" xml:lang="en-US">Exercise of common stock warrants , shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:to="CELC_StockIssuedDuringPeriodSharesStockWarrantsExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_StockIssuedDuringPeriodSharesStockWarrantsExercised_doc" xml:lang="en-US">Exercise of common stock warrants, net of shares withheld for exercise price, shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_StockIssuedDuringPeriodSharesIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts" xlink:to="CELC_StockIssuedDuringPeriodSharesIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_StockIssuedDuringPeriodSharesIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts_doc" xml:lang="en-US">Stock issued during period shares issuance upon closing of followon offering net of underwriting discounts and offering costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_NoncashOperatingLeaseExpenseNet" xlink:to="CELC_NoncashOperatingLeaseExpenseNet_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_NoncashOperatingLeaseExpenseNet_doc" xml:lang="en-US">Noncash operating lease expense net.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_ChangeInAccruedInterestIncome" xlink:to="CELC_ChangeInAccruedInterestIncome_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_ChangeInAccruedInterestIncome_doc" xml:lang="en-US">Change in accrued interest income.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_ProceedsFromAtmOfferingNetOfIssuanceCosts" xlink:to="CELC_ProceedsFromAtmOfferingNetOfIssuanceCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_ProceedsFromAtmOfferingNetOfIssuanceCosts_doc" xml:lang="en-US">Proceeds from atm offering net of issuance costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_PaymentsForSecondaryRegistrationStatementCosts" xlink:to="CELC_PaymentsForSecondaryRegistrationStatementCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_PaymentsForSecondaryRegistrationStatementCosts_doc" xml:lang="en-US">Payments for secondary registration statement costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_PropertyAndEquipmentIncludedInAccountsPayable" xlink:to="CELC_PropertyAndEquipmentIncludedInAccountsPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_PropertyAndEquipmentIncludedInAccountsPayable_doc" xml:lang="en-US">Property and equipment included in accounts payable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_DeferredFinancingCostsAndOfferingAndRegistrationStatementCostsIncludedInAccountsPayable" xlink:to="CELC_DeferredFinancingCostsAndOfferingAndRegistrationStatementCostsIncludedInAccountsPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_DeferredFinancingCostsAndOfferingAndRegistrationStatementCostsIncludedInAccountsPayable_doc" xml:lang="en-US">Deferred financing costs and offering and registration statement costs included in accounts payable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_CommonStockWarrantsIssuedWithNotePayableTransaction" xlink:to="CELC_CommonStockWarrantsIssuedWithNotePayableTransaction_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_CommonStockWarrantsIssuedWithNotePayableTransaction_doc" xml:lang="en-US">Common stock warrants issued with note payable transaction.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" xlink:to="CELC_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock_doc" xml:lang="en-US">Schedule of Estimated Useful Lives of Property and Equipment [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_WarrantsToPurchaseCommonStockMember" xlink:to="CELC_WarrantsToPurchaseCommonStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_WarrantsToPurchaseCommonStockMember_doc" xml:lang="en-US">Warrants to Purchase Common Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_PrefundedWarrantShares" xlink:to="CELC_PrefundedWarrantShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_PrefundedWarrantShares_doc" xml:lang="en-US">Prefunded warrant, shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_MiscellaneousReceivable" xlink:to="CELC_MiscellaneousReceivable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_MiscellaneousReceivable_doc" xml:lang="en-US">Miscellaneous receivable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_PrepaidClinicalTrialCosts" xlink:to="CELC_PrepaidClinicalTrialCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_PrepaidClinicalTrialCosts_doc" xml:lang="en-US">Prepaid clinical trial costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_AccruedClinicalTrialExpense" xlink:to="CELC_AccruedClinicalTrialExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_AccruedClinicalTrialExpense_doc" xml:lang="en-US">Accrued clinical trial, expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_SeriesAConvertiblePreferredStockMember" xlink:to="CELC_SeriesAConvertiblePreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_SeriesAConvertiblePreferredStockMember_doc" xml:lang="en-US">Series A Convertible Preferred Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_OpenMarketSaleAgreementMember" xlink:to="CELC_OpenMarketSaleAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_OpenMarketSaleAgreementMember_doc" xml:lang="en-US">Open Market Sale Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_JefferiesLLCMember" xlink:to="CELC_JefferiesLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_JefferiesLLCMember_doc" xml:lang="en-US">Jefferies LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_UnderwritingAgreementMember" xlink:to="CELC_UnderwritingAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_UnderwritingAgreementMember_doc" xml:lang="en-US">Underwriting Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_LeerinkPartnersLLCMember" xlink:to="CELC_LeerinkPartnersLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_LeerinkPartnersLLCMember_doc" xml:lang="en-US">Leerink Partners LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_ProceedsFromIssuanceOfCommonStockNet" xlink:to="CELC_ProceedsFromIssuanceOfCommonStockNet_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_ProceedsFromIssuanceOfCommonStockNet_doc" xml:lang="en-US">Proceeds from issuance of common stock net.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_SecuritiesPurchaseAgreementMember" xlink:to="CELC_SecuritiesPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_SecuritiesPurchaseAgreementMember_doc" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_InstitutionalAndOtherAccreditedInvestorsMember" xlink:to="CELC_InstitutionalAndOtherAccreditedInvestorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_InstitutionalAndOtherAccreditedInvestorsMember_doc" xml:lang="en-US">Institutional and Other Accredited Investors [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_OfferingExpenses" xlink:to="CELC_OfferingExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_OfferingExpenses_doc" xml:lang="en-US">Offering expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOfWarrants" xlink:to="CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOfWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOfWarrants_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non-option equity instruments weighted average exercise price of warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue" xlink:to="CELC_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_doc" xml:lang="en-US">Class of warrant or righst date from which warrants or rights issue.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_WarrantOneMember" xlink:to="CELC_WarrantOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_WarrantOneMember_doc" xml:lang="en-US">Warrant One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_WarrantTwoMember" xlink:to="CELC_WarrantTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_WarrantTwoMember_doc" xml:lang="en-US">Warrant Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_WarrantThreeMember" xlink:to="CELC_WarrantThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_WarrantThreeMember_doc" xml:lang="en-US">Warrant Three [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_WarrantFourMember" xlink:to="CELC_WarrantFourMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_WarrantFourMember_doc" xml:lang="en-US">Warrant Four [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_WarrantFiveMember" xlink:to="CELC_WarrantFiveMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_WarrantFiveMember_doc" xml:lang="en-US">Warrant Five [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_WarrantSixMember" xlink:to="CELC_WarrantSixMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_WarrantSixMember_doc" xml:lang="en-US">Warrant Six [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_WarrantSevenMember" xlink:to="CELC_WarrantSevenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_WarrantSevenMember_doc" xml:lang="en-US">Warrant Seven [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_WarrantEightMember" xlink:to="CELC_WarrantEightMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_WarrantEightMember_doc" xml:lang="en-US">Warrant Eight [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_WarrantNineMember" xlink:to="CELC_WarrantNineMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_WarrantNineMember_doc" xml:lang="en-US">Warrant Nine [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_WarrantTenMember" xlink:to="CELC_WarrantTenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_WarrantTenMember_doc" xml:lang="en-US">Warrant Ten [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_EquityIncentivePlanMember" xlink:to="CELC_EquityIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_EquityIncentivePlanMember_doc" xml:lang="en-US">2012 Equity Incentive Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_StockIncentivePlanMember" xlink:to="CELC_StockIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_StockIncentivePlanMember_doc" xml:lang="en-US">2017 Stock Incentive Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_ChangeInCommonStockSharesReservedForIssuance" xlink:to="CELC_ChangeInCommonStockSharesReservedForIssuance_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_ChangeInCommonStockSharesReservedForIssuance_doc" xml:lang="en-US">Change in common stock, shares reserved for issuance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_TotalCommonStockCapitalSharesReservedForFutureIssuance" xlink:to="CELC_TotalCommonStockCapitalSharesReservedForFutureIssuance_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_TotalCommonStockCapitalSharesReservedForFutureIssuance_doc" xml:lang="en-US">Total common stock capital shares reserved for future issuance.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_StockOptionAwardsSharesModified" xlink:to="CELC_StockOptionAwardsSharesModified_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_StockOptionAwardsSharesModified_doc" xml:lang="en-US">Stock option awards shares modified.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_MayTwoThousandTwentyTwoExercisePriceModificationMember" xlink:to="CELC_MayTwoThousandTwentyTwoExercisePriceModificationMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_MayTwoThousandTwentyTwoExercisePriceModificationMember_doc" xml:lang="en-US">May 2022 Exercise Price Modification [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_ModifiedStockOptionExercisePrice" xlink:to="CELC_ModifiedStockOptionExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_ModifiedStockOptionExercisePrice_doc" xml:lang="en-US">Modified stock option exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_RemainingStockBasedCompensationExpenseRelatedToModification" xlink:to="CELC_RemainingStockBasedCompensationExpenseRelatedToModification_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_RemainingStockBasedCompensationExpenseRelatedToModification_doc" xml:lang="en-US">Remaining stock based compensation expense related to modification.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_DecemberTwoThousandTwentyOneExercisePriceModificationMember" xlink:to="CELC_DecemberTwoThousandTwentyOneExercisePriceModificationMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_DecemberTwoThousandTwentyOneExercisePriceModificationMember_doc" xml:lang="en-US">December 2021 Exercise Price Modification [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_MayTwoThousandTwentyExercisePriceModificationMember" xlink:to="CELC_MayTwoThousandTwentyExercisePriceModificationMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_MayTwoThousandTwentyExercisePriceModificationMember_doc" xml:lang="en-US">May 2020 Exercise Price Modification [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_TwoThousandSeventeenPlanMember" xlink:to="CELC_TwoThousandSeventeenPlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_TwoThousandSeventeenPlanMember_doc" xml:lang="en-US">2017 Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostToBeRecognizedNextTwelveMonths" xlink:to="CELC_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostToBeRecognizedNextTwelveMonths_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostToBeRecognizedNextTwelveMonths_doc" xml:lang="en-US">Employee service share based compensation nonvested awards total compensation cost to be recognized next twelve months.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostToBeRecognizedWithinTwoYear" xlink:to="CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostToBeRecognizedWithinTwoYear_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostToBeRecognizedWithinTwoYear_doc" xml:lang="en-US">Employee service share based compensation nonvested awards total compensation cost to be recognized within two year.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostToBeRecognizedwithinThreeYears" xlink:to="CELC_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostToBeRecognizedwithinThreeYears_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostToBeRecognizedwithinThreeYears_doc" xml:lang="en-US">Employee service share based compensation nonvested awards total compensation cost to be recognized within three year.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostToBeRecognizedWithinFourYears" xlink:to="CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostToBeRecognizedWithinFourYears_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostToBeRecognizedWithinFourYears_doc" xml:lang="en-US">Employee service share based compensation nonvested awards total compensation cost to be recognized within four years.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostToBeRecognized" xlink:to="CELC_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostToBeRecognized_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostToBeRecognized_doc" xml:lang="en-US">Employee service share based compensation nonvested awards total compensation cost to be recognized.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_EmployeeStockPurchasePlanMember" xlink:to="CELC_EmployeeStockPurchasePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_EmployeeStockPurchasePlanMember_doc" xml:lang="en-US">2017 Employee Stock Purchase Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_AmendedAndRestatedLoanAgreementMember" xlink:to="CELC_AmendedAndRestatedLoanAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_AmendedAndRestatedLoanAgreementMember_doc" xml:lang="en-US">Amended and Restated Loan Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_InnovatusLifeSciencesMember" xlink:to="CELC_InnovatusLifeSciencesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_InnovatusLifeSciencesMember_doc" xml:lang="en-US">Innovatus Life Sciences [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_TermBLoanMember" xlink:to="CELC_TermBLoanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_TermBLoanMember_doc" xml:lang="en-US">Term B Loan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_TermALoanMember" xlink:to="CELC_TermALoanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_TermALoanMember_doc" xml:lang="en-US">Term A Loan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_TermCLoanMember" xlink:to="CELC_TermCLoanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_TermCLoanMember_doc" xml:lang="en-US">Term C Loan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_TermDLoanMember" xlink:to="CELC_TermDLoanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_TermDLoanMember_doc" xml:lang="en-US">Term D Loan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_TermELoanMember" xlink:to="CELC_TermELoanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_TermELoanMember_doc" xml:lang="en-US">Term E Loan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_TermFLoanMember" xlink:to="CELC_TermFLoanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_TermFLoanMember_doc" xml:lang="en-US">Term F Loan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_PriorLoanAgreementMember" xlink:to="CELC_PriorLoanAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_PriorLoanAgreementMember_doc" xml:lang="en-US">Prior Loan Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_FinalFeePercentage" xlink:to="CELC_FinalFeePercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_FinalFeePercentage_doc" xml:lang="en-US">Final fee percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_NonUtilizationFee" xlink:to="CELC_NonUtilizationFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_NonUtilizationFee_doc" xml:lang="en-US">Non utilization fee.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_FinalFee" xlink:to="CELC_FinalFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_FinalFee_doc" xml:lang="en-US">Final fee.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_PaymentInKindInterestDebt" xlink:to="CELC_PaymentInKindInterestDebt_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_PaymentInKindInterestDebt_doc" xml:lang="en-US">Payment in kind interest debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_DeferredTaxAssetsRightofuseAssets" xlink:to="CELC_DeferredTaxAssetsRightofuseAssets_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_DeferredTaxAssetsRightofuseAssets_doc" xml:lang="en-US">Deferred tax assets right of use assets.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_DeferredTaxAssetsLeaseLiability" xlink:to="CELC_DeferredTaxAssetsLeaseLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_DeferredTaxAssetsLeaseLiability_doc" xml:lang="en-US">Deferred tax assets lease liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIRC174Expenditures" xlink:to="CELC_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIRC174Expenditures_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIRC174Expenditures_doc" xml:lang="en-US">Deferred tax assets tax deferred expense compensation and benefits IRC 174 expenditures.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStartupExpenditures" xlink:to="CELC_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStartupExpenditures_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStartupExpenditures_doc" xml:lang="en-US">Start-up expenditures</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_FinanceLeaseCostAbstract" xlink:to="CELC_FinanceLeaseCostAbstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_FinanceLeaseCostAbstract_doc" xml:lang="en-US">Finance lease cost [Abstract]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_CashPaidForOperatingAndFinanceLeases" xlink:to="CELC_CashPaidForOperatingAndFinanceLeases_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_CashPaidForOperatingAndFinanceLeases_doc" xml:lang="en-US">Cash paid for operating and finance leases.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_OptionsToPurchaseCommonStockMember" xlink:to="CELC_OptionsToPurchaseCommonStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_OptionsToPurchaseCommonStockMember_doc" xml:lang="en-US">Options to Purchase Common Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_PreferredStockOnAnAsIfConvertedToCommonStockMember" xlink:to="CELC_PreferredStockOnAnAsIfConvertedToCommonStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_PreferredStockOnAnAsIfConvertedToCommonStockMember_doc" xml:lang="en-US">Preferred Stock on an as-if-converted to Common Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_StockIssuedDuringPeriodValueConversionOfPreferredToCommonStock" xlink:to="CELC_StockIssuedDuringPeriodValueConversionOfPreferredToCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_StockIssuedDuringPeriodValueConversionOfPreferredToCommonStock_doc" xml:lang="en-US">Conversion of preferred to common stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_StockIssuedDuringPeriodSharesConversionOfPreferredToCommonStock" xlink:to="CELC_StockIssuedDuringPeriodSharesConversionOfPreferredToCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_StockIssuedDuringPeriodSharesConversionOfPreferredToCommonStock_doc" xml:lang="en-US">Conversion of preferred to common stock, shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_WarrantOrRightToPurchasePercentage" xlink:to="CELC_WarrantOrRightToPurchasePercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_WarrantOrRightToPurchasePercentage_doc" xml:lang="en-US">Warrant or right, reason for issuance, description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseNonoperating_2_lbl" xml:lang="en-US">Interest Expense, Nonoperating</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_ExerciseOfCommonStockWarrants" xlink:to="CELC_ExerciseOfCommonStockWarrants_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_ExerciseOfCommonStockWarrants_3_lbl" xml:lang="en-US">ExerciseOfCommonStockWarrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsIssuanceWithPrivatePlacementOffering" xlink:to="CELC_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsIssuanceWithPrivatePlacementOffering_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsIssuanceWithPrivatePlacementOffering_3_lbl" xml:lang="en-US">AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsIssuanceWithPrivatePlacementOffering</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_2_lbl" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_ChangeInAccruedInterestIncome" xlink:to="CELC_ChangeInAccruedInterestIncome_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_ChangeInAccruedInterestIncome_3_lbl" xml:lang="en-US">ChangeInAccruedInterestIncome</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Current Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInvestments" xlink:to="us-gaap_PaymentsToAcquireInvestments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireInvestments_2_lbl" xml:lang="en-US">Payments to Acquire Investments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_PaymentsForSecondaryRegistrationStatementCosts" xlink:to="CELC_PaymentsForSecondaryRegistrationStatementCosts_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_PaymentsForSecondaryRegistrationStatementCosts_3_lbl" xml:lang="en-US">PaymentsForSecondaryRegistrationStatementCosts</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_2_lbl" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryIndName_2_lbl" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryIndName_2_lbl" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndName_2_lbl" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTextBlock" xlink:to="us-gaap_InvestmentTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentTextBlock_2_lbl" xml:lang="en-US">Investment [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentPolicyTextBlock_2_lbl" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2_lbl" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_2_lbl" xml:lang="en-US">Other Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_2_lbl" xml:lang="en-US">Lease, Cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_CashPaidForOperatingAndFinanceLeases" xlink:to="CELC_CashPaidForOperatingAndFinanceLeases_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_CashPaidForOperatingAndFinanceLeases_3_lbl" xml:lang="en-US">CashPaidForOperatingAndFinanceLeases</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_2_lbl" xml:lang="en-US">Warrants and Rights Outstanding, Maturity Date</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostToBeRecognizedNextTwelveMonths" xlink:to="CELC_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostToBeRecognizedNextTwelveMonths_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostToBeRecognizedNextTwelveMonths_3_lbl" xml:lang="en-US">EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostToBeRecognizedNextTwelveMonths</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostToBeRecognizedWithinTwoYear" xlink:to="CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostToBeRecognizedWithinTwoYear_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostToBeRecognizedWithinTwoYear_3_lbl" xml:lang="en-US">EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostToBeRecognizedWithinTwoYear</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostToBeRecognized" xlink:to="CELC_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostToBeRecognized_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostToBeRecognized_3_lbl" xml:lang="en-US">EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostToBeRecognized</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_2_lbl" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_2_lbl" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_2_lbl" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_2_lbl" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebt_2_lbl" xml:lang="en-US">Long-Term Debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_2_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_DeferredTaxAssetsLeaseLiability" xlink:to="CELC_DeferredTaxAssetsLeaseLiability_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_DeferredTaxAssetsLeaseLiability_3_lbl" xml:lang="en-US">DeferredTaxAssetsLeaseLiability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>18
<FILENAME>celc-20241231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://celcuity.com/role/Cover" xlink:href="celc-20241231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/BalanceSheets" xlink:href="celc-20241231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/BalanceSheetsParenthetical" xlink:href="celc-20241231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/StatementsOfOperations" xlink:href="celc-20241231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/StatementsOfChangesInStockholdersEquity" xlink:href="celc-20241231.xsd#StatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/StatementsOfCashFlows" xlink:href="celc-20241231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/StatementsOfCashFlowsParenthetical" xlink:href="celc-20241231.xsd#StatementsOfCashFlowsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#CybersecurityRiskManagementAndStrategyDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#MaterialCybersecurityIncidentDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/Organization" xlink:href="celc-20241231.xsd#Organization" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncements" xlink:href="celc-20241231.xsd#BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncements" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/Liquidity" xlink:href="celc-20241231.xsd#Liquidity" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/NetLossPerCommonShare" xlink:href="celc-20241231.xsd#NetLossPerCommonShare" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/Investments" xlink:href="celc-20241231.xsd#Investments" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/OtherCurrentAssets" xlink:href="celc-20241231.xsd#OtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/PropertyAndEquipment" xlink:href="celc-20241231.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/AccruedExpenses" xlink:href="celc-20241231.xsd#AccruedExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/Commitments" xlink:href="celc-20241231.xsd#Commitments" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/StockholdersEquity" xlink:href="celc-20241231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/Stock-basedCompensation" xlink:href="celc-20241231.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/Debt" xlink:href="celc-20241231.xsd#Debt" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/IncomeTaxes" xlink:href="celc-20241231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/SubsequentEvent" xlink:href="celc-20241231.xsd#SubsequentEvent" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies" xlink:href="celc-20241231.xsd#BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsTables" xlink:href="celc-20241231.xsd#BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/NetLossPerCommonShareTables" xlink:href="celc-20241231.xsd#NetLossPerCommonShareTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/InvestmentsTables" xlink:href="celc-20241231.xsd#InvestmentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/OtherCurrentAssetsTables" xlink:href="celc-20241231.xsd#OtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/PropertyAndEquipmentTables" xlink:href="celc-20241231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/AccruedExpensesTables" xlink:href="celc-20241231.xsd#AccruedExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/CommitmentsTables" xlink:href="celc-20241231.xsd#CommitmentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/StockholdersEquityTables" xlink:href="celc-20241231.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/Stock-basedCompensationTables" xlink:href="celc-20241231.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/DebtTables" xlink:href="celc-20241231.xsd#DebtTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/IncomeTaxesTables" xlink:href="celc-20241231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" xlink:href="celc-20241231.xsd#ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsDetailsNarrative" xlink:href="celc-20241231.xsd#BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/LiquidityDetailsNarrative" xlink:href="celc-20241231.xsd#LiquidityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/ScheduleOfPotentially-dilutiveSharesExcludedFromDilutedWeighted-averageSharesOutstandingDetails" xlink:href="celc-20241231.xsd#ScheduleOfPotentially-dilutiveSharesExcludedFromDilutedWeighted-averageSharesOutstandingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/NetLossPerCommonShareDetailsNarrative" xlink:href="celc-20241231.xsd#NetLossPerCommonShareDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/ScheduleOfInvestmentDetails" xlink:href="celc-20241231.xsd#ScheduleOfInvestmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/ScheduleOfOtherCurrentAssetsDetails" xlink:href="celc-20241231.xsd#ScheduleOfOtherCurrentAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/SummaryOfPropertyAndEquipmentDetails" xlink:href="celc-20241231.xsd#SummaryOfPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="celc-20241231.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/ScheduleOfAccruedExpensesDetails" xlink:href="celc-20241231.xsd#ScheduleOfAccruedExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails" xlink:href="celc-20241231.xsd#ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/ScheduleOfMaturityAnalysisUnderLeaseAgreementsDetails" xlink:href="celc-20241231.xsd#ScheduleOfMaturityAnalysisUnderLeaseAgreementsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/ScheduleOfLeaseCostsDetails" xlink:href="celc-20241231.xsd#ScheduleOfLeaseCostsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails" xlink:href="celc-20241231.xsd#ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/CommitmentsDetailsNarrative" xlink:href="celc-20241231.xsd#CommitmentsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/ScheduleOfWarrantsDetails" xlink:href="celc-20241231.xsd#ScheduleOfWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/StockholdersEquityDetailsNarrative" xlink:href="celc-20241231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/ScheduleOfStockOptionsActivityDetails" xlink:href="celc-20241231.xsd#ScheduleOfStockOptionsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/ScheduleOfStockOptionsOutstandingAndExercisableDetails" xlink:href="celc-20241231.xsd#ScheduleOfStockOptionsOutstandingAndExercisableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/ScheduleOfAssumptionsForFairValueOfEquity-basedAwardsDetails" xlink:href="celc-20241231.xsd#ScheduleOfAssumptionsForFairValueOfEquity-basedAwardsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/ScheduleOfUnrecognizedCompensationCostDetails" xlink:href="celc-20241231.xsd#ScheduleOfUnrecognizedCompensationCostDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/ScheduleOfStock-basedCompensationExpensesDetails" xlink:href="celc-20241231.xsd#ScheduleOfStock-basedCompensationExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="celc-20241231.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/ScheduleOfLong-termDebtDetails" xlink:href="celc-20241231.xsd#ScheduleOfLong-termDebtDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/ScheduleOfLongTermDebtFuturePrincipalPaymentsDetails" xlink:href="celc-20241231.xsd#ScheduleOfLongTermDebtFuturePrincipalPaymentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/DebtDetailsNarrative" xlink:href="celc-20241231.xsd#DebtDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:href="celc-20241231.xsd#ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="celc-20241231.xsd#ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/IncomeTaxesDetailsNarrative" xlink:href="celc-20241231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/SubsequentEventDetailsNarrative" xlink:href="celc-20241231.xsd#SubsequentEventDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_deiIcfrAuditorAttestationFlag" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiIcfrAuditorAttestationFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_deiDocumentFinStmtErrorCorrectionFlag" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFinStmtErrorCorrectionFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorOpinionTextBlock" xlink:label="loc_deiAuditorOpinionTextBlock" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorOpinionTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName" />
      <link:presentationArc order="610" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation" />
      <link:presentationArc order="620" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorLocation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId" />
      <link:presentationArc order="630" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorFirmId" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/BalanceSheets" xlink:title="00000002 - Statement - Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaapShortTermInvestments" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapShortTermInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaapOtherAssetsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaapLongTermNotesPayable" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLongTermNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="loc_us-gaapInterestExpenseNonoperating" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestExpenseNonoperating" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaapInvestmentIncomeInterest" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInvestmentIncomeInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Statements of Changes in Stockholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensationGross" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensationGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_StockIssuedDuringPeriodValueConversionOfPreferredToCommonStock" xlink:label="loc_CELCStockIssuedDuringPeriodValueConversionOfPreferredToCommonStock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELCStockIssuedDuringPeriodValueConversionOfPreferredToCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_StockIssuedDuringPeriodSharesConversionOfPreferredToCommonStock" xlink:label="loc_CELCStockIssuedDuringPeriodSharesConversionOfPreferredToCommonStock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELCStockIssuedDuringPeriodSharesConversionOfPreferredToCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_ExerciseOfCommonStockWarrants" xlink:label="loc_CELCExerciseOfCommonStockWarrants" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELCExerciseOfCommonStockWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_ExerciseOfCommonStockSharesWarrants" xlink:label="loc_CELCExerciseOfCommonStockSharesWarrants" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELCExerciseOfCommonStockSharesWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsIssuanceWithPrivatePlacementOffering" xlink:label="loc_CELCAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsIssuanceWithPrivatePlacementOffering" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELCAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsIssuanceWithPrivatePlacementOffering" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_AdditionalPaidInCapitalPreFundedWarrantIssued" xlink:label="loc_CELCAdditionalPaidInCapitalPreFundedWarrantIssued" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELCAdditionalPaidInCapitalPreFundedWarrantIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_IssuanceCostsAssociatedWithPrefundedWarrants" xlink:label="loc_CELCIssuanceCostsAssociatedWithPrefundedWarrants" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELCIssuanceCostsAssociatedWithPrefundedWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_StockIssuedDuringPeriodValueStockWarrantsExercised" xlink:label="loc_CELCStockIssuedDuringPeriodValueStockWarrantsExercised" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELCStockIssuedDuringPeriodValueStockWarrantsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:label="loc_CELCStockIssuedDuringPeriodSharesStockWarrantsExercised" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELCStockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_StockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts" xlink:label="loc_CELCStockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELCStockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_StockIssuedDuringPeriodSharesIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts" xlink:label="loc_CELCStockIssuedDuringPeriodSharesIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELCStockIssuedDuringPeriodSharesIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaidInKindInterest" xlink:label="loc_us-gaapPaidInKindInterest" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapPaidInKindInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_NoncashOperatingLeaseExpenseNet" xlink:label="loc_CELCNoncashOperatingLeaseExpenseNet" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_CELCNoncashOperatingLeaseExpenseNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_ChangeInAccruedInterestIncome" xlink:label="loc_CELCChangeInAccruedInterestIncome" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_CELCChangeInAccruedInterestIncome" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:label="loc_us-gaapProceedsFromSaleAndMaturityOfOtherInvestments" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromSaleAndMaturityOfOtherInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaapPaymentsToAcquireInvestments" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireInvestments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="loc_us-gaapProceedsFromStockPlans" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromStockPlans" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromOtherEquity" xlink:label="loc_us-gaapProceedsFromOtherEquity" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromOtherEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="loc_us-gaapProceedsFromDebtNetOfIssuanceCosts" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromDebtNetOfIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_ProceedsFromAtmOfferingNetOfIssuanceCosts" xlink:label="loc_CELCProceedsFromAtmOfferingNetOfIssuanceCosts" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_CELCProceedsFromAtmOfferingNetOfIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_PaymentsForSecondaryRegistrationStatementCosts" xlink:label="loc_CELCPaymentsForSecondaryRegistrationStatementCosts" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_CELCPaymentsForSecondaryRegistrationStatementCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfDebtIssuanceCosts" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsOfDebtIssuanceCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaapFinanceLeasePrincipalPayments" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapFinanceLeasePrincipalPayments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaapCashAndCashEquivalentsAbstract" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashAndCashEquivalentsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashAndCashEquivalentsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_DeferredFinancingCostsAndOfferingAndRegistrationStatementCostsIncludedInAccountsPayable" xlink:label="loc_CELCDeferredFinancingCostsAndOfferingAndRegistrationStatementCostsIncludedInAccountsPayable" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_CELCDeferredFinancingCostsAndOfferingAndRegistrationStatementCostsIncludedInAccountsPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_PropertyAndEquipmentIncludedInAccountsPayable" xlink:label="loc_CELCPropertyAndEquipmentIncludedInAccountsPayable" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_CELCPropertyAndEquipmentIncludedInAccountsPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_CommonStockWarrantsIssuedWithNotePayableTransaction" xlink:label="loc_CELCCommonStockWarrantsIssuedWithNotePayableTransaction" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_CELCCommonStockWarrantsIssuedWithNotePayableTransaction" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/StatementsOfCashFlowsParenthetical" xlink:title="00000007 - Statement - Statements of Cash Flows (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumNet" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:title="995410 - Disclosure - Pay vs Performance Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems" xlink:label="loc_ecdPayVsPerformanceDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable" xlink:label="loc_ecdPvpTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis" xlink:label="loc_ecdExecutiveCategoryAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdExecutiveCategoryAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember" xlink:label="loc_ecdAllExecutiveCategoriesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdExecutiveCategoryAxis" xlink:to="loc_ecdAllExecutiveCategoriesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis" xlink:label="loc_ecdAdjToCompAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdAdjToCompAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember" xlink:label="loc_ecdAllAdjToCompMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAdjToCompAxis" xlink:to="loc_ecdAllAdjToCompMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis" xlink:label="loc_ecdMeasureAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdMeasureAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock" xlink:label="loc_ecdPvpTableTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName" xlink:label="loc_ecdCoSelectedMeasureName" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdCoSelectedMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="loc_ecdNamedExecutiveOfficersFnTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdNamedExecutiveOfficersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="loc_ecdPeerGroupIssuersFnTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeerGroupIssuersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="loc_ecdChangedPeerGroupFnTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdChangedPeerGroupFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt" xlink:label="loc_ecdPeoTotalCompAmt" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="loc_ecdPeoActuallyPaidCompAmt" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoActuallyPaidCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="loc_ecdAdjToPeoCompFnTextBlock" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdAdjToPeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="loc_ecdNonPeoNeoAvgTotalCompAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="loc_ecdAdjToNonPeoNeoCompFnTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdAdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:presentationArc order="2140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" />
      <link:presentationArc order="2150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" />
      <link:presentationArc order="2160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock" xlink:label="loc_ecdTabularListTableTextBlock" />
      <link:presentationArc order="2170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTabularListTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt" xlink:label="loc_ecdTotalShareholderRtnAmt" />
      <link:presentationArc order="2180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="loc_ecdPeerGroupTotalShareholderRtnAmt" />
      <link:presentationArc order="2190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdPeerGroupTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="2200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt" xlink:label="loc_ecdCoSelectedMeasureAmt" />
      <link:presentationArc order="2210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdCoSelectedMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt" xlink:label="loc_ecdOtherPerfMeasureAmt" />
      <link:presentationArc order="2220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdOtherPerfMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt" xlink:label="loc_ecdAdjToCompAmt" />
      <link:presentationArc order="2230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdAdjToCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName" xlink:label="loc_ecdPeoName" />
      <link:presentationArc order="2240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdPeoName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName" xlink:label="loc_ecdMeasureName" />
      <link:presentationArc order="2250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="loc_ecdNonGaapMeasureDescriptionTextBlock" />
      <link:presentationArc order="2260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdMeasureName" xlink:to="loc_ecdNonGaapMeasureDescriptionTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="loc_ecdAdditional402vDisclosureTextBlock" />
      <link:presentationArc order="2270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdAdditional402vDisclosureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="loc_ecdPnsnBnftsAdjFnTextBlock" />
      <link:presentationArc order="2280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPnsnBnftsAdjFnTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:title="995440 - Disclosure - Recovery of Erroneously Awarded Compensation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems" xlink:label="loc_ecdRecoveryOfErrCompDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable" xlink:label="loc_ecdErrCompRecoveryTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdErrCompRecoveryTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis" xlink:label="loc_ecdRestatementDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdRestatementDateAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate" xlink:label="loc_ecdRestatementDeterminationDate" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdRestatementDeterminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt" xlink:label="loc_ecdAggtErrCompAmt" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="loc_ecdErrCompAnalysisTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdErrCompAnalysisTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="loc_ecdOutstandingAggtErrCompAmt" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdOutstandingAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="loc_ecdAggtErrCompNotYetDeterminedTextBlock" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdAggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName" xlink:label="loc_ecdForgoneRecoveryIndName" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName" xlink:label="loc_ecdOutstandingRecoveryIndName" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="loc_ecdOutstandingRecoveryCompAmt" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:title="995443 - Disclosure - Award Timing Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems" xlink:label="loc_ecdAwardTmgDiscLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="loc_ecdAwardsCloseToMnpiDiscTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_ecdIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="loc_ecdAwardTmgMnpiDiscTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiDiscTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="loc_ecdAwardTmgMethodTextBlock" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="loc_ecdAwardTmgPredtrmndFlag" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgPredtrmndFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="loc_ecdAwardTmgMnpiCnsdrdFlag" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiCnsdrdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="loc_ecdMnpiDiscTimedForCompValFlag" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdMnpiDiscTimedForCompValFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="loc_ecdAwardsCloseToMnpiDiscIndName" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="loc_ecdAwardUndrlygSecuritiesAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardUndrlygSecuritiesAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice" xlink:label="loc_ecdAwardExrcPrice" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardExrcPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue" xlink:label="loc_ecdAwardGrantDateFairValue" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="loc_ecdUndrlygSecurityMktPriceChngPct" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdUndrlygSecurityMktPriceChngPct" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="995445 - Disclosure - Insider Trading Arrangements">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems" xlink:label="loc_ecdInsiderTradingArrLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="loc_ecdMtrlTermsOfTrdArrTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdMtrlTermsOfTrdArrTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName" xlink:label="loc_ecdTrdArrIndName" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle" xlink:label="loc_ecdTrdArrIndTitle" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="loc_ecdRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="loc_ecdNonRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate" xlink:label="loc_ecdTrdArrAdoptionDate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrAdoptionDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="loc_ecdRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="loc_ecdNonRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate" xlink:label="loc_ecdTrdArrTerminationDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrTerminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate" xlink:label="loc_ecdTrdArrExpirationDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrExpirationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration" xlink:label="loc_ecdTrdArrDuration" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrDuration" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:title="995447 - Disclosure - Insider Trading Policies and Procedures">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="loc_ecdInsiderTradingPoliciesProcLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="00000013 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="loc_cydCybersecurityRiskManagementProcessesIntegratedFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementProcessesIntegratedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="loc_cydCybersecurityRiskManagementProcessesIntegratedTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="loc_cydCybersecurityRiskManagementThirdPartyEngagedFlag" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementThirdPartyEngagedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="loc_cydCybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="loc_cydCybersecurityRiskBoardOfDirectorsOversightTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="loc_cydCybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="loc_cydCybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="loc_cydCybersecurityRiskRoleOfManagementTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskRoleOfManagementTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="loc_cydCybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:title="00000014 - Disclosure - Material Cybersecurity Incident Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentAbstract" xlink:label="loc_cydMaterialCybersecurityIncidentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentNatureTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentNatureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentNatureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentScopeTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentScopeTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentScopeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentTimingTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentTimingTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentTimingTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/Organization" xlink:title="999015 - Disclosure - Organization">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncements" xlink:title="999016 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapBasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/Liquidity" xlink:title="999017 - Disclosure - Liquidity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="loc_us-gaapSubstantialDoubtAboutGoingConcernTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapSubstantialDoubtAboutGoingConcernTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/NetLossPerCommonShare" xlink:title="999018 - Disclosure - Net Loss Per Common Share">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaapEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/Investments" xlink:title="999019 - Disclosure - Investments">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTextBlock" xlink:label="loc_us-gaapInvestmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" xlink:to="loc_us-gaapInvestmentTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/OtherCurrentAssets" xlink:title="999020 - Disclosure - Other Current Assets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentAssetsTextBlock" xlink:label="loc_us-gaapOtherCurrentAssetsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapOtherCurrentAssetsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/PropertyAndEquipment" xlink:title="999021 - Disclosure - Property and Equipment">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/AccruedExpenses" xlink:title="999022 - Disclosure - Accrued Expenses">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/Commitments" xlink:title="999023 - Disclosure - Commitments">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/StockholdersEquity" xlink:title="999024 - Disclosure - Stockholders&#8217; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/Stock-basedCompensation" xlink:title="999025 - Disclosure - Stock-Based Compensation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/Debt" xlink:title="999026 - Disclosure - Debt">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/IncomeTaxes" xlink:title="999027 - Disclosure - Income Taxes">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/SubsequentEvent" xlink:title="999028 - Disclosure - Subsequent Event">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies" xlink:title="999029 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="loc_us-gaapInvestmentPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapInvestmentPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="loc_us-gaapDeferredChargesPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDeferredChargesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="loc_us-gaapDebtPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDebtPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaapComprehensiveIncomePolicyPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:label="loc_us-gaapInProcessResearchAndDevelopmentPolicy" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapInProcessResearchAndDevelopmentPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsTables" xlink:title="999030 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" xlink:label="loc_CELCScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_CELCScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/NetLossPerCommonShareTables" xlink:title="999031 - Disclosure - Net Loss Per Common Share (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/InvestmentsTables" xlink:title="999032 - Disclosure - Investments (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTableTextBlock" xlink:label="loc_us-gaapInvestmentTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" xlink:to="loc_us-gaapInvestmentTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/OtherCurrentAssetsTables" xlink:title="999033 - Disclosure - Other Current Assets (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="loc_us-gaapScheduleOfOtherCurrentAssetsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfOtherCurrentAssetsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/PropertyAndEquipmentTables" xlink:title="999034 - Disclosure - Property and Equipment (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/AccruedExpensesTables" xlink:title="999035 - Disclosure - Accrued Expenses (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/CommitmentsTables" xlink:title="999036 - Disclosure - Commitments (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:label="loc_srtScheduleOfCondensedBalanceSheetTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_srtScheduleOfCondensedBalanceSheetTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaapLeaseCostTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLeaseCostTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:label="loc_us-gaapScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/StockholdersEquityTables" xlink:title="999037 - Disclosure - Stockholders&#8217; Equity (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/Stock-basedCompensationTables" xlink:title="999038 - Disclosure - Stock-Based Compensation (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:label="loc_us-gaapScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/DebtTables" xlink:title="999039 - Disclosure - Debt (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="loc_us-gaapScheduleOfDebtInstrumentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="loc_us-gaapScheduleOfMaturitiesOfLongTermDebtTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/IncomeTaxesTables" xlink:title="999040 - Disclosure - Income Taxes (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" xlink:title="999041 - Disclosure - Schedule of Estimated Useful Lives of Property and Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsDetailsNarrative" xlink:title="999042 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashFDICInsuredAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaapShortTermInvestments" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShortTermInvestments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCurrent" xlink:label="loc_us-gaapDeferredCostsCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDeferredCostsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/LiquidityDetailsNarrative" xlink:title="999043 - Disclosure - Liquidity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaapShortTermInvestments" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapShortTermInvestments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfPotentially-dilutiveSharesExcludedFromDilutedWeighted-averageSharesOutstandingDetails" xlink:title="999044 - Disclosure - Schedule of Potentially-Dilutive Shares Excluded from the Diluted Weighted-Average Shares Outstanding (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_PreferredStockOnAnAsIfConvertedToCommonStockMember" xlink:label="loc_CELCPreferredStockOnAnAsIfConvertedToCommonStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CELCPreferredStockOnAnAsIfConvertedToCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_OptionsToPurchaseCommonStockMember" xlink:label="loc_CELCOptionsToPurchaseCommonStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_CELCOptionsToPurchaseCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_WarrantsToPurchaseCommonStockMember" xlink:label="loc_CELCWarrantsToPurchaseCommonStockMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_CELCWarrantsToPurchaseCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapRestrictedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:label="loc_us-gaapEarningsPerShareDilutedOtherDisclosuresAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapEarningsPerShareDilutedOtherDisclosuresAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/NetLossPerCommonShareDetailsNarrative" xlink:title="999045 - Disclosure - Net Loss Per Common Share (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_PrefundedWarrantShares" xlink:label="loc_CELCPrefundedWarrantShares" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_CELCPrefundedWarrantShares" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfInvestmentDetails" xlink:title="999046 - Disclosure - Schedule of Investment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:label="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" xlink:to="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:label="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:to="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaapUSTreasurySecuritiesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapUSTreasurySecuritiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecurities" xlink:label="loc_us-gaapHeldToMaturitySecurities" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapHeldToMaturitySecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:label="loc_us-gaapHeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapHeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:label="loc_us-gaapHeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapHeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesFairValue" xlink:label="loc_us-gaapHeldToMaturitySecuritiesFairValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapHeldToMaturitySecuritiesFairValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfOtherCurrentAssetsDetails" xlink:title="999047 - Disclosure - Schedule of Other Current Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrentAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_PrepaidClinicalTrialCosts" xlink:label="loc_CELCPrepaidClinicalTrialCosts" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_CELCPrepaidClinicalTrialCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_MiscellaneousReceivable" xlink:label="loc_CELCMiscellaneousReceivable" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_CELCMiscellaneousReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaapPrepaidInsurance" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapPrepaidInsurance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaapOtherAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapOtherAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/SummaryOfPropertyAndEquipmentDetails" xlink:title="999048 - Disclosure - Summary of Property and Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="999049 - Disclosure - Property and Equipment (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfAccruedExpensesDetails" xlink:title="999050 - Disclosure - Schedule of Accrued Expenses (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_AccruedClinicalTrialExpense" xlink:label="loc_CELCAccruedClinicalTrialExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_CELCAccruedClinicalTrialExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WorkersCompensationLiabilityCurrent" xlink:label="loc_us-gaapWorkersCompensationLiabilityCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapWorkersCompensationLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrentAndNoncurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="loc_us-gaapAccruedEmployeeBenefitsCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedEmployeeBenefitsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails" xlink:title="999051 - Disclosure - Schedule of Supplemental Balance Sheet Information Related to Leases (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:label="loc_us-gaapLesseeOperatingLeaseDescriptionAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseDescriptionAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfMaturityAnalysisUnderLeaseAgreementsDetails" xlink:title="999052 - Disclosure - Schedule of Maturity Analysis Under Lease Agreements (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfLeaseCostsDetails" xlink:title="999053 - Disclosure - Schedule of Lease Costs (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaapOperatingLeaseCost" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_FinanceLeaseCostAbstract" xlink:label="loc_CELCFinanceLeaseCostAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_CELCFinanceLeaseCostAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAssetAmortization" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CELCFinanceLeaseCostAbstract" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="loc_us-gaapFinanceLeaseInterestExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CELCFinanceLeaseCostAbstract" xlink:to="loc_us-gaapFinanceLeaseInterestExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaapVariableLeaseCost" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapVariableLeaseCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaapLeaseCost" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLeaseCost" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails" xlink:title="999054 - Disclosure - Schedule of Supplemental Cash Flow Information Related to Leases (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_CashPaidForOperatingAndFinanceLeasesAbstract" xlink:label="loc_CELCCashPaidForOperatingAndFinanceLeasesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_CELCCashPaidForOperatingAndFinanceLeasesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CELCCashPaidForOperatingAndFinanceLeasesAbstract" xlink:to="loc_us-gaapOperatingLeasePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:label="loc_us-gaapFinanceLeaseInterestPaymentOnLiability" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CELCCashPaidForOperatingAndFinanceLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseInterestPaymentOnLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaapFinanceLeasePrincipalPayments" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CELCCashPaidForOperatingAndFinanceLeasesAbstract" xlink:to="loc_us-gaapFinanceLeasePrincipalPayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_CashPaidForOperatingAndFinanceLeases" xlink:label="loc_CELCCashPaidForOperatingAndFinanceLeases" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CELCCashPaidForOperatingAndFinanceLeasesAbstract" xlink:to="loc_CELCCashPaidForOperatingAndFinanceLeases" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/CommitmentsDetailsNarrative" xlink:title="999055 - Disclosure - Commitments (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaapContractualObligation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapContractualObligation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfWarrantsDetails" xlink:title="999056 - Disclosure - Schedule of Warrants (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_WarrantOneMember" xlink:label="loc_CELCWarrantOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CELCWarrantOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_WarrantTwoMember" xlink:label="loc_CELCWarrantTwoMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CELCWarrantTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_WarrantThreeMember" xlink:label="loc_CELCWarrantThreeMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CELCWarrantThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_WarrantFourMember" xlink:label="loc_CELCWarrantFourMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CELCWarrantFourMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_WarrantFiveMember" xlink:label="loc_CELCWarrantFiveMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CELCWarrantFiveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_WarrantSixMember" xlink:label="loc_CELCWarrantSixMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CELCWarrantSixMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_WarrantSevenMember" xlink:label="loc_CELCWarrantSevenMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CELCWarrantSevenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_WarrantEightMember" xlink:label="loc_CELCWarrantEightMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CELCWarrantEightMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_WarrantNineMember" xlink:label="loc_CELCWarrantNineMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CELCWarrantNineMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_WarrantTenMember" xlink:label="loc_CELCWarrantTenMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CELCWarrantTenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue" xlink:label="loc_CELCClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_CELCClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees" xlink:label="loc_us-gaapClassOfWarrantOrRightReasonForIssuingToNonemployees" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightReasonForIssuingToNonemployees" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/StockholdersEquityDetailsNarrative" xlink:title="999057 - Disclosure - Stockholders&#8217; Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockByClassTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_SeriesAConvertiblePreferredStockMember" xlink:label="loc_CELCSeriesAConvertiblePreferredStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_CELCSeriesAConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_OpenMarketSaleAgreementMember" xlink:label="loc_CELCOpenMarketSaleAgreementMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CELCOpenMarketSaleAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_UnderwritingAgreementMember" xlink:label="loc_CELCUnderwritingAgreementMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CELCUnderwritingAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_SecuritiesPurchaseAgreementMember" xlink:label="loc_CELCSecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CELCSecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_deiLegalEntityAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_JefferiesLLCMember" xlink:label="loc_CELCJefferiesLLCMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_CELCJefferiesLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_LeerinkPartnersLLCMember" xlink:label="loc_CELCLeerinkPartnersLLCMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CELCLeerinkPartnersLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtTitleOfIndividualAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_InstitutionalAndOtherAccreditedInvestorsMember" xlink:label="loc_CELCInstitutionalAndOtherAccreditedInvestorsMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_CELCInstitutionalAndOtherAccreditedInvestorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaapConversionOfStockSharesIssued1" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockSharesIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="loc_us-gaapPreferredStockConvertibleConversionPrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockConvertibleConversionPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_ProceedsFromIssuanceOfCommonStockNet" xlink:label="loc_CELCProceedsFromIssuanceOfCommonStockNet" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CELCProceedsFromIssuanceOfCommonStockNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_OfferingExpenses" xlink:label="loc_CELCOfferingExpenses" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CELCOfferingExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOfWarrants" xlink:label="loc_CELCShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOfWarrants" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CELCShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfStockOptionsActivityDetails" xlink:title="999058 - Disclosure - Schedule of Stock Options Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapOffsettingAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapOffsettingAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfStockOptionsOutstandingAndExercisableDetails" xlink:title="999059 - Disclosure - Schedule of Stock Options Outstanding and Exercisable (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfAssumptionsForFairValueOfEquity-basedAwardsDetails" xlink:title="999060 - Disclosure - Schedule of Assumptions for Fair Value of Equity-based Awards (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfUnrecognizedCompensationCostDetails" xlink:title="999061 - Disclosure - Schedule of Unrecognized Compensation Cost (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostToBeRecognizedNextTwelveMonths" xlink:label="loc_CELCEmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostToBeRecognizedNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_CELCEmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostToBeRecognizedNextTwelveMonths" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostToBeRecognizedWithinTwoYear" xlink:label="loc_CELCEmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostToBeRecognizedWithinTwoYear" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_CELCEmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostToBeRecognizedWithinTwoYear" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostToBeRecognizedwithinThreeYears" xlink:label="loc_CELCEmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostToBeRecognizedwithinThreeYears" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_CELCEmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostToBeRecognizedwithinThreeYears" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostToBeRecognizedWithinFourYears" xlink:label="loc_CELCEmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostToBeRecognizedWithinFourYears" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_CELCEmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostToBeRecognizedWithinFourYears" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostToBeRecognized" xlink:label="loc_CELCEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostToBeRecognized" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_CELCEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostToBeRecognized" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfStock-basedCompensationExpensesDetails" xlink:title="999062 - Disclosure - Schedule of Stock-based Compensation Expenses (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="999063 - Disclosure - Stock-Based Compensation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_EquityIncentivePlanMember" xlink:label="loc_CELCEquityIncentivePlanMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CELCEquityIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_StockIncentivePlanMember" xlink:label="loc_CELCStockIncentivePlanMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CELCStockIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_EmployeeStockPurchasePlanMember" xlink:label="loc_CELCEmployeeStockPurchasePlanMember" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CELCEmployeeStockPurchasePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_MayTwoThousandTwentyTwoExercisePriceModificationMember" xlink:label="loc_CELCMayTwoThousandTwentyTwoExercisePriceModificationMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CELCMayTwoThousandTwentyTwoExercisePriceModificationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_DecemberTwoThousandTwentyOneExercisePriceModificationMember" xlink:label="loc_CELCDecemberTwoThousandTwentyOneExercisePriceModificationMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CELCDecemberTwoThousandTwentyOneExercisePriceModificationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_MayTwoThousandTwentyExercisePriceModificationMember" xlink:label="loc_CELCMayTwoThousandTwentyExercisePriceModificationMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CELCMayTwoThousandTwentyExercisePriceModificationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_TwoThousandSeventeenPlanMember" xlink:label="loc_CELCTwoThousandSeventeenPlanMember" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CELCTwoThousandSeventeenPlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_ChangeInCommonStockSharesReservedForIssuance" xlink:label="loc_CELCChangeInCommonStockSharesReservedForIssuance" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_CELCChangeInCommonStockSharesReservedForIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_TotalCommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_CELCTotalCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_CELCTotalCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_StockOptionAwardsSharesModified" xlink:label="loc_CELCStockOptionAwardsSharesModified" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_CELCStockOptionAwardsSharesModified" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_ModifiedStockOptionExercisePrice" xlink:label="loc_CELCModifiedStockOptionExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_CELCModifiedStockOptionExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_RemainingStockBasedCompensationExpenseRelatedToModification" xlink:label="loc_CELCRemainingStockBasedCompensationExpenseRelatedToModification" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_CELCRemainingStockBasedCompensationExpenseRelatedToModification" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfLong-termDebtDetails" xlink:title="999064 - Disclosure - Schedule of Long-term Debt (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapConvertibleNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_FinalFee" xlink:label="loc_CELCFinalFee" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_CELCFinalFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_PaymentInKindInterestDebt" xlink:label="loc_CELCPaymentInKindInterestDebt" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_CELCPaymentInKindInterestDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscount" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaapLongTermNotesPayable" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLongTermNotesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfLongTermDebtFuturePrincipalPaymentsDetails" xlink:title="999065 - Disclosure - Schedule of Long Term Debt Future Principal Payments (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaapLongTermDebt" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLongTermDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/DebtDetailsNarrative" xlink:title="999066 - Disclosure - Debt (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtInstrumentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapDebtInstrumentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_AmendedAndRestatedLoanAgreementMember" xlink:label="loc_CELCAmendedAndRestatedLoanAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CELCAmendedAndRestatedLoanAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_PriorLoanAgreementMember" xlink:label="loc_CELCPriorLoanAgreementMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CELCPriorLoanAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_InnovatusLifeSciencesMember" xlink:label="loc_CELCInnovatusLifeSciencesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CELCInnovatusLifeSciencesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_srtRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_TermALoanMember" xlink:label="loc_CELCTermALoanMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CELCTermALoanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_TermBLoanMember" xlink:label="loc_CELCTermBLoanMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CELCTermBLoanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_TermCLoanMember" xlink:label="loc_CELCTermCLoanMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CELCTermCLoanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_TermDLoanMember" xlink:label="loc_CELCTermDLoanMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CELCTermDLoanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_TermELoanMember" xlink:label="loc_CELCTermELoanMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CELCTermELoanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_TermFLoanMember" xlink:label="loc_CELCTermFLoanMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CELCTermFLoanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_AmendedAndRestatedLoanAgreementMember" xlink:label="loc_CELCAmendedAndRestatedLoanAgreementMember_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CELCAmendedAndRestatedLoanAgreementMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherBorrowings" xlink:label="loc_us-gaapOtherBorrowings" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapOtherBorrowings" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateTerms" xlink:label="loc_us-gaapDebtInstrumentInterestRateTerms" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateTerms" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_FinalFeePercentage" xlink:label="loc_CELCFinalFeePercentage" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_CELCFinalFeePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_NonUtilizationFee" xlink:label="loc_CELCNonUtilizationFee" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_CELCNonUtilizationFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_FinalFee" xlink:label="loc_CELCFinalFee" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_CELCFinalFee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_WarrantOrRightToPurchasePercentage" xlink:label="loc_CELCWarrantOrRightToPurchasePercentage" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_CELCWarrantOrRightToPurchasePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:title="999067 - Disclosure - Schedule of Effective Income Tax Rate Reconciliation (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="loc_us-gaapIncomeTaxReconciliationTaxCreditsResearch" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationTaxCreditsResearch" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseOther" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="999068 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaapDeferredTaxAssetsPropertyPlantAndEquipment" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_DeferredTaxAssetsRightofuseAssets" xlink:label="loc_CELCDeferredTaxAssetsRightofuseAssets" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_CELCDeferredTaxAssetsRightofuseAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_DeferredTaxAssetsLeaseLiability" xlink:label="loc_CELCDeferredTaxAssetsLeaseLiability" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_CELCDeferredTaxAssetsLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIRC174Expenditures" xlink:label="loc_CELCDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIRC174Expenditures" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_CELCDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIRC174Expenditures" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20241231.xsd#CELC_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStartupExpenditures" xlink:label="loc_CELCDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStartupExpenditures" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_CELCDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStartupExpenditures" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/IncomeTaxesDetailsNarrative" xlink:title="999069 - Disclosure - Income Taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/SubsequentEventDetailsNarrative" xlink:title="999070 - Disclosure - Subsequent Event (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionExercisePriceDecrease" xlink:label="loc_us-gaapStockOptionExercisePriceDecrease" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockOptionExercisePriceDecrease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 24, 2025</div></th>
<th class="th"><div>Jun. 28, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Celcuity Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001603454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-2863566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">16305
    36th<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Avenue North<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine3', window );">Entity Address, Address Line Three</a></td>
<td class="text">Suite 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Minneapolis<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">55446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(763)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">392-0767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CELC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 530,223,434<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,839,392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference [Text Block]</a></td>
<td class="text">Portions of the registrant&#8217;s definitive proxy statement relating
to its 2025 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual Report on Form 10-K.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorOpinionTextBlock', window );">Auditor Opinion [Text Block]</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying balance sheets of Celcuity Inc. (the Company) as of December 31, 2024 and 2023, and the related statements
of operations, changes in stockholders&#8217; equity, and cash flows for each of the years in the two-year period ended December 31,
2024, and the related notes (collectively referred to as the financial statements). In our opinion, the financial statements present
fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations
and its cash flows for each of the years in the two-year period ended December 31, 2024, in conformity with accounting principles generally
accepted in the United States of America.</span><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Boulay
LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Minneapolis,
Minnesota<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorOpinionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X<br> -Number 210<br> -Section 2<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorOpinionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 3 such as an Office Park</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 22,514,823<span></span>
</td>
<td class="nump">$ 30,662,774<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Investments</a></td>
<td class="nump">212,588,960<span></span>
</td>
<td class="nump">149,919,974<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">9,467,247<span></span>
</td>
<td class="nump">10,007,849<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">244,571,030<span></span>
</td>
<td class="nump">190,590,597<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">336,515<span></span>
</td>
<td class="nump">228,782<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">215,502<span></span>
</td>
<td class="nump">400,019<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">245,123,047<span></span>
</td>
<td class="nump">191,219,398<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">9,366,007<span></span>
</td>
<td class="nump">5,076,699<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">171,952<span></span>
</td>
<td class="nump">184,950<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">22,184,948<span></span>
</td>
<td class="nump">8,927,094<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">31,722,907<span></span>
</td>
<td class="nump">14,188,743<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">53,969<span></span>
</td>
<td class="nump">225,922<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Note payable, non-current</a></td>
<td class="nump">97,727,136<span></span>
</td>
<td class="nump">37,035,411<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">129,504,012<span></span>
</td>
<td class="nump">51,450,076<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Note 9)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value: 2,500,000 shares authorized; 317,577 and 854,134 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively</a></td>
<td class="nump">318<span></span>
</td>
<td class="nump">854<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value: 95,000,000 and 65,000,000 shares authorized as of December 31, 2024 and December 31, 2023, respectively; 37,143,242 and 25,506,012 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively</a></td>
<td class="nump">37,143<span></span>
</td>
<td class="nump">25,506<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">387,436,682<span></span>
</td>
<td class="nump">299,818,965<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(271,855,108)<span></span>
</td>
<td class="num">(160,076,003)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders&#8217; Equity</a></td>
<td class="nump">115,619,035<span></span>
</td>
<td class="nump">139,769,322<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders&#8217; Equity</a></td>
<td class="nump">$ 245,123,047<span></span>
</td>
<td class="nump">$ 191,219,398<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">2,500,000<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">317,577<span></span>
</td>
<td class="nump">854,134<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">317,577<span></span>
</td>
<td class="nump">854,134<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">95,000,000<span></span>
</td>
<td class="nump">65,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">37,143,242<span></span>
</td>
<td class="nump">25,506,012<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">37,143,242<span></span>
</td>
<td class="nump">25,506,012<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 104,203,230<span></span>
</td>
<td class="nump">$ 60,594,005<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">9,063,721<span></span>
</td>
<td class="nump">5,636,326<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">113,266,951<span></span>
</td>
<td class="nump">66,230,331<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(113,266,951)<span></span>
</td>
<td class="num">(66,230,331)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other (expense) income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="num">(10,280,445)<span></span>
</td>
<td class="num">(5,326,387)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">11,768,291<span></span>
</td>
<td class="nump">7,777,602<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">1,487,846<span></span>
</td>
<td class="nump">2,451,215<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before income taxes</a></td>
<td class="num">(111,779,105)<span></span>
</td>
<td class="num">(63,779,116)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefits</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (111,779,105)<span></span>
</td>
<td class="num">$ (63,779,116)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic</a></td>
<td class="num">$ (2.83)<span></span>
</td>
<td class="num">$ (2.69)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="num">$ (2.83)<span></span>
</td>
<td class="num">$ (2.69)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding, basic</a></td>
<td class="nump">39,449,393<span></span>
</td>
<td class="nump">23,679,472<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding, diluted</a></td>
<td class="nump">39,449,393<span></span>
</td>
<td class="nump">23,679,472<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Changes in Stockholders' Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Preferred Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 21,667<span></span>
</td>
<td class="nump">$ 1,121<span></span>
</td>
<td class="nump">$ 230,045,566<span></span>
</td>
<td class="num">$ (96,296,887)<span></span>
</td>
<td class="nump">$ 133,771,467<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2022</a></td>
<td class="nump">21,667,250<span></span>
</td>
<td class="nump">1,120,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Stock-based compensation</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,901,432<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,901,434<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross', window );">Stock-based compensation, shares</a></td>
<td class="nump">1,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_StockIssuedDuringPeriodValueConversionOfPreferredToCommonStock', window );">Conversion of preferred to common stock</a></td>
<td class="nump">$ 2,668<span></span>
</td>
<td class="num">$ (267)<span></span>
</td>
<td class="num">(2,401)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_StockIssuedDuringPeriodSharesConversionOfPreferredToCommonStock', window );">Conversion of preferred to common stock, shares</a></td>
<td class="nump">2,667,390<span></span>
</td>
<td class="num">(266,739)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Employee stock purchases</a></td>
<td class="nump">$ 33<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">202,812<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">202,845<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Employee stock purchases, shares</a></td>
<td class="nump">33,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of common stock options, net of shares withheld for exercise price</a></td>
<td class="nump">$ 99<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">388,423<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">388,522<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of common stock options, net of shares withheld for exercise price, shares</a></td>
<td class="nump">98,695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_ExerciseOfCommonStockWarrants', window );">Exercise of common stock warrants</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">22,503<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">22,505<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_ExerciseOfCommonStockSharesWarrants', window );">Exercise of common stock warrants, shares</a></td>
<td class="nump">2,369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsIssuanceWithPrivatePlacementOffering', window );">Issuance costs associated with private placement offering</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(7,486)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(7,486)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in an ATM offering</a></td>
<td class="nump">$ 1,035<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">14,999,216<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">15,000,251<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in an ATM offering, shares</a></td>
<td class="nump">1,034,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs associated with an ATM offering</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(614,205)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(614,205)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_AdditionalPaidInCapitalPreFundedWarrantIssued', window );">Issuance of pre-funded warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_IssuanceCostsAssociatedWithPrefundedWarrants', window );">Issuance costs associated with pre-funded warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(116,895)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(116,895)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(63,779,116)<span></span>
</td>
<td class="num">(63,779,116)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 25,506<span></span>
</td>
<td class="nump">$ 854<span></span>
</td>
<td class="nump">299,818,965<span></span>
</td>
<td class="num">(160,076,003)<span></span>
</td>
<td class="nump">139,769,322<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2023</a></td>
<td class="nump">25,506,012<span></span>
</td>
<td class="nump">854,134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Stock-based compensation</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,988,340<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,988,341<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross', window );">Stock-based compensation, shares</a></td>
<td class="nump">1,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_StockIssuedDuringPeriodValueConversionOfPreferredToCommonStock', window );">Conversion of preferred to common stock</a></td>
<td class="nump">$ 5,367<span></span>
</td>
<td class="num">$ (536)<span></span>
</td>
<td class="num">(4,831)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_StockIssuedDuringPeriodSharesConversionOfPreferredToCommonStock', window );">Conversion of preferred to common stock, shares</a></td>
<td class="nump">5,365,570<span></span>
</td>
<td class="num">(536,557)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Employee stock purchases</a></td>
<td class="nump">$ 33<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">275,568<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">275,601<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Employee stock purchases, shares</a></td>
<td class="nump">33,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of common stock options, net of shares withheld for exercise price</a></td>
<td class="nump">$ 104<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">769,463<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">769,567<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of common stock options, net of shares withheld for exercise price, shares</a></td>
<td class="nump">103,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in an ATM offering</a></td>
<td class="nump">$ 435<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,641,765<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,642,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in an ATM offering, shares</a></td>
<td class="nump">435,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs associated with an ATM offering</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(263,727)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(263,727)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(111,779,105)<span></span>
</td>
<td class="num">(111,779,105)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_StockIssuedDuringPeriodValueStockWarrantsExercised', window );">Exercise of common stock warrants, net of shares withheld for exercise price</a></td>
<td class="nump">$ 1,826<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">14,733,991<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">14,735,817<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_StockIssuedDuringPeriodSharesStockWarrantsExercised', window );">Exercise of common stock warrants, net of shares withheld for exercise price, shares</a></td>
<td class="nump">1,827,357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_StockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts', window );">Issuance of common stock upon closing of follow-on offering, net of underwriting discounts and offering costs</a></td>
<td class="nump">$ 3,871<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">56,248,237<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">56,252,108<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_StockIssuedDuringPeriodSharesIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts', window );">Issuance of common stock upon closing of follow-on offering, net of underwriting discounts and offering costs, shares</a></td>
<td class="nump">3,871,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of common stock warrants, note payable</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,228,911<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,228,911<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2024</a></td>
<td class="nump">$ 37,143<span></span>
</td>
<td class="nump">$ 318<span></span>
</td>
<td class="nump">$ 387,436,682<span></span>
</td>
<td class="num">$ (271,855,108)<span></span>
</td>
<td class="nump">$ 115,619,035<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2024</a></td>
<td class="nump">37,143,242<span></span>
</td>
<td class="nump">317,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_AdditionalPaidInCapitalPreFundedWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional paid in capital Pre-Funded Warrant issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_AdditionalPaidInCapitalPreFundedWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsIssuanceWithPrivatePlacementOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance costs associated with private placement offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsIssuanceWithPrivatePlacementOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_ExerciseOfCommonStockSharesWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise of common stock warrants , shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_ExerciseOfCommonStockSharesWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_ExerciseOfCommonStockWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise of common stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_ExerciseOfCommonStockWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_IssuanceCostsAssociatedWithPrefundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance costs associated with pre-funded warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_IssuanceCostsAssociatedWithPrefundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_StockIssuedDuringPeriodSharesConversionOfPreferredToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion of preferred to common stock, shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_StockIssuedDuringPeriodSharesConversionOfPreferredToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_StockIssuedDuringPeriodSharesIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares issuance upon closing of followon offering net of underwriting discounts and offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_StockIssuedDuringPeriodSharesIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_StockIssuedDuringPeriodSharesStockWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise of common stock warrants, net of shares withheld for exercise price, shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_StockIssuedDuringPeriodSharesStockWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_StockIssuedDuringPeriodValueConversionOfPreferredToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion of preferred to common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_StockIssuedDuringPeriodValueConversionOfPreferredToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_StockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value issuance upon closing of followon offering net of underwriting discounts and offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_StockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_StockIssuedDuringPeriodValueStockWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise of common stock warrants, net of shares withheld for exercise price, value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_StockIssuedDuringPeriodValueStockWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (111,779,105)<span></span>
</td>
<td class="num">$ (63,779,116)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used for operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">129,947<span></span>
</td>
<td class="nump">142,772<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">6,988,341<span></span>
</td>
<td class="nump">4,901,434<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt issuance costs and discount</a></td>
<td class="nump">1,330,652<span></span>
</td>
<td class="nump">241,752<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Payment-in-Kind interest</a></td>
<td class="nump">1,363,708<span></span>
</td>
<td class="nump">1,810,584<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_NoncashOperatingLeaseExpenseNet', window );">Non-cash operating lease, net</a></td>
<td class="num">(434)<span></span>
</td>
<td class="nump">4,368<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_ChangeInAccruedInterestIncome', window );">Change in accrued interest income</a></td>
<td class="nump">150,421<span></span>
</td>
<td class="num">(993,457)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other current assets</a></td>
<td class="nump">775,981<span></span>
</td>
<td class="num">(3,438,018)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">4,315,892<span></span>
</td>
<td class="nump">2,430,614<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">13,257,854<span></span>
</td>
<td class="nump">4,866,814<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used for operating activities</a></td>
<td class="num">(83,466,743)<span></span>
</td>
<td class="num">(53,812,253)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments', window );">Proceeds from maturities of investments</a></td>
<td class="nump">642,345,545<span></span>
</td>
<td class="nump">309,614,521<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="num">(705,164,950)<span></span>
</td>
<td class="num">(314,525,084)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(249,878)<span></span>
</td>
<td class="num">(97,644)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used for investing activities</a></td>
<td class="num">(63,069,283)<span></span>
</td>
<td class="num">(5,008,207)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of common stock warrants</a></td>
<td class="nump">14,735,817<span></span>
</td>
<td class="nump">22,505<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of employee stock options</a></td>
<td class="nump">769,571<span></span>
</td>
<td class="nump">388,522<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from employee stock purchases</a></td>
<td class="nump">275,601<span></span>
</td>
<td class="nump">202,845<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromOtherEquity', window );">Proceeds from follow-on offering, net of underwriting discounts and offering costs</a></td>
<td class="nump">56,252,108<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Proceeds from note payable, net of debt issuance costs and discount of $2,437,644</a></td>
<td class="nump">59,226,276<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_ProceedsFromAtmOfferingNetOfIssuanceCosts', window );">Proceeds from an ATM offering, net of issuance costs</a></td>
<td class="nump">7,356,107<span></span>
</td>
<td class="nump">14,431,186<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from pre-funded warrants, net of offering costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">49,917,589<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_PaymentsForSecondaryRegistrationStatementCosts', window );">Payments for secondary registration statement costs</a></td>
<td class="num">(227,405)<span></span>
</td>
<td class="num">(45,805)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments for debt issuance costs</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(2,716)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payments for finance leases</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(2,449)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">138,388,075<span></span>
</td>
<td class="nump">64,911,677<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="num">(8,147,951)<span></span>
</td>
<td class="nump">6,091,217<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Beginning of period</a></td>
<td class="nump">30,662,774<span></span>
</td>
<td class="nump">24,571,557<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">End of period</a></td>
<td class="nump">22,514,823<span></span>
</td>
<td class="nump">30,662,774<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">7,586,084<span></span>
</td>
<td class="nump">3,274,051<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosures of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_DeferredFinancingCostsAndOfferingAndRegistrationStatementCostsIncludedInAccountsPayable', window );">Deferred financing costs and offering and registration statement costs included in accounts payable</a></td>
<td class="nump">42,028<span></span>
</td>
<td class="nump">56,414<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_PropertyAndEquipmentIncludedInAccountsPayable', window );">Property and equipment included in accounts payable</a></td>
<td class="nump">1,417<span></span>
</td>
<td class="nump">13,615<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_CommonStockWarrantsIssuedWithNotePayableTransaction', window );">Common stock warrants issued with the note payable transaction</a></td>
<td class="nump">$ 1,228,911<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_ChangeInAccruedInterestIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in accrued interest income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_ChangeInAccruedInterestIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_CommonStockWarrantsIssuedWithNotePayableTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock warrants issued with note payable transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_CommonStockWarrantsIssuedWithNotePayableTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_DeferredFinancingCostsAndOfferingAndRegistrationStatementCostsIncludedInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred financing costs and offering and registration statement costs included in accounts payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_DeferredFinancingCostsAndOfferingAndRegistrationStatementCostsIncludedInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_NoncashOperatingLeaseExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash operating lease expense net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_NoncashOperatingLeaseExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_PaymentsForSecondaryRegistrationStatementCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments for secondary registration statement costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_PaymentsForSecondaryRegistrationStatementCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_ProceedsFromAtmOfferingNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from atm offering net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_ProceedsFromAtmOfferingNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_PropertyAndEquipmentIncludedInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Property and equipment included in accounts payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_PropertyAndEquipmentIncludedInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromOtherEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from the issuance of equity classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromOtherEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale and maturity (principal being due) of other investments, prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Cash Flows (Parenthetical)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Statement of Cash Flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet', window );">Debt issuance costs and discount</a></td>
<td class="nump">$ 2,437,644<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount (premium).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (111,779,105)<span></span>
</td>
<td class="num">$ (63,779,116)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingArrLineItems', window );"><strong>Insider Trading Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b51 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b51 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b51 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b51 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingArrLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingArrLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><b><span id="a_004a"></span>ITEM 1C. Cybersecurity</b><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Risk Management &amp; Strategy</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"><span><span><span>Our cybersecurity risk management process is a component
of our overall approach to managing material risks that could impact our operations, including cybersecurity threats. In general, we seek
to manage material internal and third-party cybersecurity risks through an approach that focuses on: (i) protecting information systems
and the information residing therein; (ii) identifying, preventing, and mitigating cybersecurity threats; and (iii) assessing and responding
to cybersecurity incidents when they occur. Maintaining, monitoring, and updating our information security program&#8212;in an effort
to ensure that it remains reasonable and appropriate in light of changes in the security threat landscape, available technology, and applicable
legal and contractual requirements&#8212;is an ongoing effort.</span></span></span></p>

<div><div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"><span><span><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_900_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20240101__20241231_zEEWnsACXBQg">We have implemented and maintain various processes,
procedures, and measures to support our overall risk management strategy and to manage and mitigate the material risks posed by cybersecurity
threats to our systems and data.</span> With respect to cybersecurity, these measures include conducting risk assessments of our operations and
using a risk register to assess identified risks; developing business continuity, disaster recovery and incident response plans; implementing
technical safeguards and tools; conducting ongoing cybersecurity awareness training; and using contractual protections where appropriate.
Our incident response plan outlines the procedures for reporting, investigating, and remediating cybersecurity incidents, including a
framework to facilitate the escalation to our management team and board of cybersecurity incidents, so that our management team is alerted
in a timely manner to material information that would be required to be disclosed or reported.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"><span><span>Our IT department maintains policies and procedures
regarding network security, data protection and incident response. Pursuant to those policies, IT engages with the Chief Financial Officer,
General Counsel and other experts when assessing cybersecurity threats, incident response, and making disclosure determinations following
a data or network breach. The Vice President, IT is accountable at the management level for our overall IT risk management program. Additionally,
our Chief Executive Officer and Audit Committee receives regular updates from the Chief Financial Officer, General Counsel and the Vice
President, IT about significant threats and incidents involving cybersecurity and data protection, as well as security enhancements made
to our IT infrastructure.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"><span><span>We use <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90E_ecyd--CybersecurityRiskManagementThirdPartyEngagedFlag_dbT_c20240101__20241231_zWJmelwkbqj">third-party</span> service providers for a variety
of services throughout our business, ranging from infrastructure support and maintenance, cybersecurity incident response, data protection
and privacy compliance. In addition, we engage with contract research organizations, contract manufacturing organizations, distributors,
and other supply chain resources.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"><span><span>We believe that the use of external service providers
improves our operational capabilities, and we have implemented a vendor qualification and management program that applies to our service
providers, including those that handle protected health information, personal information, or other information subject to protection
under applicable privacy and data protection regulations. This program is designed to identify, address and seek to mitigate potential
cybersecurity and data protection risks that arise from our use of external service providers. While we do not have full visibility into
the cybersecurity risk management processes of our vendors, we require new service providers to complete a vendor questionnaire that identifies
the vendor&#8217;s network and user protections, such as the use of multi-factor authentication, and other cybersecurity risk management
processes. Vendors that store or access our confidential information are required to certify that their information systems comply with
applicable industry guidelines for cybersecurity, backup, and system recovery. We rely on our third-party service providers to provide
notification of, and remediate, significant cybersecurity threats and cybersecurity incidents that jeopardize the confidentiality, integrity,
or availability of our information.</span></span></p>

</div></div>&#160;<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"><span><span>We periodically evaluate, test, and update our policies,
standards, and processes to mitigate cybersecurity threats and manage incidents effectively. These efforts include risk assessments, vulnerability
assessments and remediations, phishing tests and employee education, and external scans. Additionally, to enhance our capabilities, we
periodically engage third-party service providers, including cybersecurity consultants, to incorporate threat intelligence into our processes.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"><span>As of the date of this Form 10-K, we are <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_902_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbF_c20240101__20241231_z07C1xRxsPki">no</span>t aware
of any risks from cybersecurity threats, including those resulting from any previous cybersecurity incidents experienced by us or, to
our knowledge, by any of our third-party service providers, that have materially affected, or are reasonably likely to materially affect,
our business strategy, results of operations, or financial condition. For further discussion of cybersecurity and data privacy risks that
may materially affect the Company and how they may do so, see &#8220;Risk Factors&#8212;If our information technology systems or data,
or those of third parties upon which we rely, are or were compromised, we could face clinical trial delays; regulatory investigations
or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; and other adverse consequences,&#8221;
included in Item 1A of this Annual Report on Form 10-K.</span></p>

<span><b>&#160;</b></span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><b>Governance</b><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"><span><span><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90D_ecyd--CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_c20240101__20241231_z8aaMZ4bqBpa">Our Audit Committee oversees Celcuity&#8217;s management
of risks arising from cybersecurity threats. <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_901_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_c20240101__20241231_zLJMLFtcwxz5">Our CEO delivers periodic briefings to the Board and Audit Committee on material cybersecurity
risks that are pertinent to our business operations.</span> Additionally, we have processes to promptly notify the Audit Committee and Board
of a significant cybersecurity incident and to inform the Audit Committee and Board of remediation progress, as appropriate.</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"><span><span>The Vice President, IT has overall responsibility
for our information security program, with support from our management team and specialized partners in cybersecurity incident response
and privacy. <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90F_ecyd--CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_c20240101__20241231_zQDUHaxm1Nzl">The process includes managing our incident response strategy. If a cybersecurity incident meets certain criteria, however,
our CEO, CFO and General Counsel will become involved with the response strategy, including decisions about public disclosure and reporting.
Our Vice President, IT also coordinates with our CEO, CFO and General Counsel to determine strategic cybersecurity priorities and to establish
compliance procedures.</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"><span><span>We believe our business leaders have the appropriate
expertise, background and depth of experience to manage risks arising from cybersecurity threats. Our Vice President, IT has served in
various roles in information technology and information security for over three decades, which includes experience in the biotech, pharmaceutical
and healthcare industries and experience in cybersecurity risk management and data privacy compliance.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"><span>In the ordinary course of our business, we, and the
third parties upon which we rely, collect, process, receive, generate, use, transfer, disclose, make accessible, protect, secure, dispose
of, transmit, share and store (collectively, &#8220;process&#8221;) proprietary, confidential, and sensitive information, including protected
health information, personal information, credit card and other financial information, or other sensitive information owned or controlled
by ourselves or our customers, payors, and other parties.</span></p>

<span><b>&#160;</b></span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">Our Audit Committee oversees Celcuity&#8217;s management
of risks arising from cybersecurity threats. <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_901_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_c20240101__20241231_zLJMLFtcwxz5">Our CEO delivers periodic briefings to the Board and Audit Committee on material cybersecurity
risks that are pertinent to our business operations.</span> Additionally, we have processes to promptly notify the Audit Committee and Board
of a significant cybersecurity incident and to inform the Audit Committee and Board of remediation progress, as appropriate.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text">Our CEO delivers periodic briefings to the Board and Audit Committee on material cybersecurity
risks that are pertinent to our business operations.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text">The process includes managing our incident response strategy. If a cybersecurity incident meets certain criteria, however,
our CEO, CFO and General Counsel will become involved with the response strategy, including decisions about public disclosure and reporting.
Our Vice President, IT also coordinates with our CEO, CFO and General Counsel to determine strategic cybersecurity priorities and to establish
compliance procedures.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization</a></td>
<td class="text"><p id="xdx_80C_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zkK9dFmkB548" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"> <b>1.</b> <b><span id="xdx_829_znHvbdCz6Xc6">Organization</span></b></p>



<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><span style="text-decoration: underline">Nature of Business</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">Celcuity Inc., a Delaware corporation (the &#8220;Company&#8221;) is a
clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid tumor indications.
The Company&#8217;s lead therapeutic candidate is gedatolisib, a potent, well-tolerated, small molecule reversible inhibitor, administered
intravenously, that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (&#8220;PI3K&#8221;) and the two mechanistic
targets of rapamycin (&#8220;mTOR&#8221;) sub-complexes, mTORC1 and mTORC2. Gedatolisib&#8217;s mechanism of action and pharmacokinetic
properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together.
A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with
HR+/HER2- advanced breast cancer is currently enrolling patients. Site selection and activation activities for a Phase 3 clinical trial,
VIKTORIA-2, evaluating gedatolisib in combination with a CDK4/6 inhibitor and fulvestrant as first-line treatment for patients with HR+/HER2-
advanced breast cancer has commenced. The first patient is expected to be dosed in the second quarter of 2025. A Phase 1b/2 clinical trial,
CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer,
is currently underway. The Company was co-founded in 2012 by Brian F. Sullivan and Dr. Lance G. Laing and is based in Minnesota. The Company
has not generated any revenues to date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_800_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zlI0nJT6ysn7" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"> <b>2.</b> <b><span id="xdx_826_zryuu22buLa6">Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements</span></b></p>



<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>

<p id="xdx_846_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zqle3EpLCqti" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><span style="text-decoration: underline"><span id="xdx_86F_zfvrrS2Urjua">Basis of Presentation</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="background-color: white">The accompanying financial statements
have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;) and pursuant
to the rules and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;). Operating results for the year ended December
31, 2024 are not necessarily indicative of results to be expected for any future year.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_842_eus-gaap--UseOfEstimates_zqYd2kAzJWZ7" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_86E_zTnkypDHItge">Accounting Estimates</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 2.15pt 0 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 2.15pt 0 0">Management uses estimates and assumptions in preparing these
financial statements in accordance with U.S. GAAP. Those estimates and assumptions affect the reported amounts of assets and liabilities,
the disclosure of contingent assets and liabilities, and the reported revenues and expenses. Actual results could differ from those estimates
and the difference could be material. Significant items subject to such estimates and assumptions include the valuation of stock-based
compensation and prepaid or accrued clinical trial costs.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p id="xdx_84F_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zs41NFVAgjWa" style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="text-decoration: underline"><span id="xdx_862_zBSE7imawy8h">Cash and Cash Equivalents</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 2.15pt 0 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 2.15pt 0 0">The Company maintains its accounts at two financial institutions.
At times throughout the year, the Company&#8217;s cash balances may exceed amounts insured by the Federal Deposit Insurance Corporation.
At December 31, 2024 and December 31, 2023, the Company had $<span id="xdx_90D_eus-gaap--CashFDICInsuredAmount_iI_c20241231_zKYFJ5FLHDC3" title="Cash equivalents FDIC insured, amount">22,514,823</span> and $<span id="xdx_909_eus-gaap--CashFDICInsuredAmount_iI_c20231231_zdbbCz0ZDuN3" title="Cash equivalents FDIC insured, amount">30,662,774</span>, respectively, in business checking accounts and
money market funds that are considered cash equivalents and not insured by the Federal Deposit Insurance Corporation.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p id="xdx_84F_eus-gaap--InvestmentPolicyTextBlock_zZcCsrawuJQe" style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="text-decoration: underline"><span id="xdx_86C_zVP5ib2lPBri">Investments</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 2.15pt 0 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 2.15pt 0 0">The Company maintains its investments in U.S. governmental agency
securities and U.S. treasury bills and has classified them as held-to-maturity at the time of purchase. Held-to-maturity purchases are
those securities in which the Company has the ability and intent to hold until maturity. Held-to-maturity securities are recorded at amortized
cost, adjusted for the amortization or accretion of premiums and discounts. Premiums and discounts are amortized or accreted over the
life of the related held-to-maturity security using a straight-line method. The difference between the carrying value, which is based
on cost, and the aggregate fair value of the held-to-maturity securities, was immaterial as of December 31, 2024. At December 31, 2024
and December 31, 2023, the Company had $<span id="xdx_902_eus-gaap--ShortTermInvestments_iI_c20241231_zeScxzKuWOu3" title="Short-term investments">212,588,960</span> and $<span id="xdx_904_eus-gaap--ShortTermInvestments_iI_c20231231_zqV7aaEms22i" title="Short-term investments">149,919,974</span>, respectively, of short-term investments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;&#160;</p>

<p id="xdx_84A_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zErkpyNvmfA4" style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="text-decoration: underline"><span id="xdx_869_zcPUi34VFRg">Property and Equipment</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 2.15pt 0 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Property and equipment are stated at cost. Depreciation is provided
over estimated useful lives using the straight-line method. Maintenance and repairs are expensed as incurred; major improvements and betterments
are capitalized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p id="xdx_89B_ecustom--ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock_zbXmEHbRuoxi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Estimated useful lives of property and equipment are as follows for the
major classes of assets:</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.6in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B2_zvVaDreWGHl2" style="display: none">Schedule of Estimated Useful Lives of Property and Equipment</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 84%; margin-right: auto">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">Estimated</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; width: 85%; font-weight: bold; text-align: justify">Asset Description</td><td style="padding-bottom: 1pt; width: 1%; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 14%; font-weight: bold; text-align: center">Lives</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Furniture and Equipment</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_za2Cizkodqzb" title="Estimated useful lives">4</span>-<span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zoToZonzLH2l" title="Estimated useful lives">5</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Leasehold Improvements</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zwNRQRUPKqkj" title="Estimated useful lives">2</span>-<span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zjy5QdetKmE2" title="Estimated useful lives">3</span></td></tr>
  </table>

<p id="xdx_8AB_ziLDoGxeSjz5" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.6in">&#160;</p>

<p id="xdx_846_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zUrX149Fdpnj" style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="text-decoration: underline"><span id="xdx_862_zXjBiAbWKt3e">Long-Lived Assets</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">Long-lived assets, such as property and equipment, are reviewed for impairment
whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require
a long-lived asset or asset group be tested for possible impairment, the Company first compares undiscounted cash flows expected to be
generated by that asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group is not recoverable
on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying value exceeds its fair value. Fair value
is determined through various valuation techniques including discounted cash flow models, quoted market values, and third-party independent
appraisals, as considered necessary.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p id="xdx_845_eus-gaap--DeferredChargesPolicyTextBlock_zLw1ZX7RHbof" style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="text-decoration: underline"><span id="xdx_861_zc3C9lJETGe7">Deferred Transaction Costs</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">Deferred transaction costs primarily consist of legal fees that are capitalized
as incurred and will be offset against the proceeds from future equity financing arrangements. The deferred transaction costs will be
reviewed periodically to assess the probability that future securities will be offered. In the event that no future offering will occur,
any deferred transaction costs will be expensed. Total costs incurred, but not accounted for as a reduction in equity, were $<span id="xdx_902_eus-gaap--DeferredCostsCurrent_iI_c20241231_znLH97VNiqpa" title="Deferred transaction costs">235,379</span> and
$<span id="xdx_900_eus-gaap--DeferredCostsCurrent_iI_c20231231_zSoIRAfiqV2" title="Deferred transaction costs">0</span> as of December 31, 2024 and 2023, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>

<p id="xdx_845_eus-gaap--DebtPolicyTextBlock_zIQrsrmEItuc" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><span style="text-decoration: underline"><span id="xdx_862_zWjiikqHPfM1">Debt Issuance Costs</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">The Company recognizes debt issuance costs as deferred costs, which are
capitalized and amortized over the term of the related debt using the effective interest method. These costs primarily consist of fees,
commissions, legal, and other costs directly attributable to securing debt financing. Debt issuance costs are reported as a direct reduction
of the carrying amount of the related debt on the balance sheets. Amortization of these costs is recorded as interest expense in the statements
of operations over the life of the debt instrument.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>

<p id="xdx_840_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zFOlTBRBCjeh" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><span style="text-decoration: underline"><span id="xdx_865_zapig2q36X4b">Comprehensive Loss</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">Comprehensive loss includes net loss as well as other changes in stockholders&#8217;
equity that result from transactions and economic events other than those with stockholders. For all periods presented, there was no difference
between net loss and comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>

<p id="xdx_846_eus-gaap--ConcentrationRiskCreditRisk_zoGHHydaSJ1g" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><span style="text-decoration: underline"><span id="xdx_860_zimzFr8eXqGb">Risks and Uncertainties</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">The Company is subject to risks common to companies in the development
stage including, but not limited to, dependency on the clinical and commercial success of its initial drug product, gedatolisib, the ability
to obtain regulatory approval for gedatolisib, the need for substantial additional financing to achieve its goals, uncertainty of broad
adoption of its approved products, if any, by physicians and consumers, and significant competition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>

<p id="xdx_840_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zzWZPOiyddAl" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><span style="text-decoration: underline"><span id="xdx_860_zVnMYaSQNEed">Fair Value of Financial Instruments</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 5.75pt 0 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The Company&#8217;s accounting for fair value measurements of
assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring or nonrecurring basis
adheres to the Financial Accounting Standards Board (&#8220;FASB&#8221;) fair value hierarchy that prioritizes the inputs to valuation
techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical
assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level
3 measurements). The three levels of the fair value hierarchy are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 5.85pt 0 41pt; text-indent: -0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.5in; text-align: left">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Level
1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the Company at the measurement
date.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 5.95pt 0 41pt; text-indent: -0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.5in; text-align: left">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Level
2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly,
for substantially the full term of the asset or liability.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 5.8pt 0 41pt; text-indent: -0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.5in; text-align: left">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Level
3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available,
thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date.</span></td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The level in the fair value hierarchy within which a fair value
measurement in its entirety falls, is based on the lowest level input that is significant to the fair value measurement in its entirety.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 5.95pt 0 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The carrying values of cash equivalents, accounts payable, accrued
expenses and other financial working capital items approximate fair value at December 31, 2024 and December 31, 2023, due to the short
maturity nature of these items.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p id="xdx_845_eus-gaap--IncomeTaxPolicyTextBlock_z8vEUxHWNSgh" style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="text-decoration: underline"><span id="xdx_866_zgynWj3fZcYb">Income Taxes</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">The Company accounts for income taxes using the asset and liability method,
as required by the accounting standard for income taxes. Under this method, deferred tax assets and liabilities are recognized for the
future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities
and their respective tax bases, as well as net operating loss and tax credit carryforwards. Deferred taxes are measured using enacted
tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.
The effect on deferred taxes of a change in tax rates is recognized in results of operations in the period that includes the enactment
date. The effects of any future changes in tax laws or rates have not been considered. The Company regularly reviews deferred tax assets
to assess their potential realization and establish a valuation allowance for portions of such assets to reduce the carrying value if
the Company does not consider it to be more likely than not that the deferred tax assets will be realized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">The Company recognizes the impact of an uncertain tax position in its financial
statements if, in management&#8217;s judgment, the position is more-likely-than-not sustainable upon audit based on the position&#8217;s
technical merits. This involves the identification of potential uncertain tax positions, the evaluation of applicable tax laws and an
assessment of whether a liability for an uncertain tax position is necessary.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>

<p id="xdx_847_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zeKwV8b1dP64" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><span style="text-decoration: underline"><span id="xdx_866_zBXECk6Wy7Bj">Stock-Based Compensation</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 2.15pt 0 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 2.15pt 0 0">The Company&#8217;s stock-based compensation consists of stock
options and restricted stock issued to certain employees and non-employees of the Company and the Company&#8217;s 2017 Employee Stock
Purchase Plan. The Company recognizes compensation expense based on an estimated grant date fair value using the Black-Scholes option-pricing
method for equity-based awards and the Monte Carlo simulation model for performance-based awards. If the factors change and different
assumptions are used, the Company&#8217;s stock-based compensation expense could be materially different in the future. The Company recognizes
stock-based compensation expense for these options on a straight-line basis over the requisite service period. The Company has elected
to account for forfeitures as they occur.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p id="xdx_843_eus-gaap--ResearchAndDevelopmentExpensePolicy_zvGCg70bmtpj" style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="text-decoration: underline"><span id="xdx_864_z3XHAIp3vYBc">Research and Development</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">Research and development costs are expensed as incurred. Research and development
costs amounted to $<span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20241231_zxOzlJ7CAvLe" title="Research and development expense">104,203,230</span> for the year ended December 31, 2024 and $<span id="xdx_900_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231_zck4ehiBYfJ" title="Research and development expense">60,594,005</span> for the year ended December 31, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>

<p id="xdx_84E_eus-gaap--InProcessResearchAndDevelopmentPolicy_zKtIk5RQdI77" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><span style="text-decoration: underline"><span id="xdx_862_zcho2GdqM904">Clinical Trial Costs</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">The Company relies on third parties to conduct
certain aspects of clinical studies and to formulate and manufacture our drug product. While there are alternative vendors that can
perform these functions, any disruption or delay by the Company&#8217;s current third parties in carrying out their contractual
duties could delay the clinical trials. The Company records prepaid assets or accrued expenses for prepaid or estimated clinical
trial costs conducted by third-party service providers, which includes the conduct of preclinical studies and clinical trials. These
costs can be a significant component of the Company&#8217;s research and development expenses. The Company primarily relies on a
compilation of progress reports from third-party service providers, including the respective invoicing, to record actual expenses,
along with determining changes to prepaid assets and accrued liabilities. To date, the Company believes utilization of third-party
reports most accurately reflects expenses incurred. With the ongoing VIKTORIA-1 Phase 3 trial and the CELC-G-201 Phase 1b/2 trial,
and the commencement of the VIKTORIA-2 Phase 3 clinical trial site activation and patient enrollment anticipated in Q2 2025<span style="font-size: 10pt">,</span>
the Company&#8217;s estimated expenses in future periods and actual services performed may vary from these estimates, and these
estimates may become more significant. Changes in these estimates that result in material changes to the Company&#8217;s prepaid
assets or accrued expenses could materially affect the Company&#8217;s results of operations and financial position.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>

<p id="xdx_841_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zASjcBnZart7" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><span style="text-decoration: underline"><span id="xdx_867_zAWp6ew8cnbi">Segment Data</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">In November 2023, the FASB issued ASU 2023-07: Improvements to Reportable
Segment Disclosures. This ASU, which amends Topic 280: <i>Segment Reporting,</i> improves disclosure requirements for reportable segments
and enhances disclosures for companies with single reportable segments. The Company has a single reportable segment based on the nature
of its operations. The nature of business and the accounting policies of the segment are the same as described throughout Notes 1 and
2. The Company&#8217;s Chief Operating Decision Maker (&#8220;CODM&#8221;) is its executive team. The CODM assesses the reportable segment&#8217;s performance
and allocates resources for the reportable segment based on net income and total assets, which are the same amounts in all material respects
as those reported on the statements of operations and balance sheets. The Company adopted the standard on January 1, 2024. The adoption
did not have a material impact on the Company&#8217;s financial statements.</p>

<p id="xdx_856_z4iFfU2SxhT3" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock', window );">Liquidity</a></td>
<td class="text"><p id="xdx_80C_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_z0ZFGxAR4GLj" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"> <b>3.</b> <b><span id="xdx_822_zLpUqUXslu48">Liquidity</span></b></p>



<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">Based on the Company&#8217;s cash and cash equivalents and short-term investments
on hand at December 31, 2024 of $<span id="xdx_900_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20241231_zRw1Bj5a73Aj" title="Cash and cash equivalents">22,514,823</span> and $<span id="xdx_902_eus-gaap--ShortTermInvestments_iI_c20241231_zf8nTGzmfy1d" title="Short-term investments">212,588,960</span>, respectively, the Company believes that its cash and short-term investments
will be sufficient to fund the Company&#8217;s current operating plan through at least the next 12 months from the issuance date of this
Annual Report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205-40/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Common Share</a></td>
<td class="text"><p id="xdx_808_eus-gaap--EarningsPerShareTextBlock_ztLssPXQLrA5" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"> <b>4.</b> <b><span id="xdx_82C_zPsfjWKgtLxh">Net Loss Per Common Share</span></b></p>



<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">Basic and diluted net loss per common share is determined by dividing net
loss attributable to common stockholders by the weighted-average common shares outstanding during the period. For all periods presented,
the common shares underlying the preferred stock, options, warrants, and restricted stock have been excluded from the calculation because
their effect would be anti-dilutive. Therefore, the weighted-average shares outstanding used to calculate both basic and diluted loss
per common share are the same.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p id="xdx_895_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zCuI9maWij26" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes the potentially-dilutive shares excluded
from the diluted weighted-average shares outstanding:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B2_zsg6iauW7oD" style="display: none">Schedule of Potentially-Dilutive Shares Excluded from the Diluted Weighted-Average Shares Outstanding</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20240101__20241231_zofYC9DpIg31" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20230101__20231231_zPlGbIJe3Srk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--EarningsPerShareDilutedOtherDisclosuresAbstract_iB_zK5U31WUGCoh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Potentially-dilutive shares excluded from diluted weighted-average shares outstanding:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--StatementEquityComponentsAxis__custom--PreferredStockOnAnAsIfConvertedToCommonStockMember_zfg4f3aaJtE8" style="vertical-align: bottom; background-color: White">
    <td style="width: 68%; text-align: justify; text-indent: 0pt; padding-left: 20pt">Preferred stock on an as-if-converted to common stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">3,175,770</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">8,541,340</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsToPurchaseCommonStockMember_zvdpJd90xmai" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: 0pt; padding-left: 20pt">Options to purchase common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,306,977</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,815,392</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseCommonStockMember_zJErXOX8mBe3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: 0pt; padding-left: 20pt">Warrants to purchase common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,521,152</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,263,733</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_zQ1WuGg1Brne" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 0pt; text-indent: 0pt; padding-left: 20pt">Restricted common stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,079</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,958</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zxL8MHByRdU7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 0pt; text-indent: 0pt; padding-left: 10pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">13,004,978</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">18,622,423</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_z2UeiMuqyUJd" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 0pt; text-indent: 0pt; padding-left: 10pt">Anti-dilutive securities excluded from
    diluted weighted- average shares outstanding</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">13,004,978</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">18,622,423</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


<p id="xdx_8AC_zZQ7HsPeDVT2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">Pre-funded warrant shares of <span id="xdx_90C_ecustom--PrefundedWarrantShares_iI_c20241231_zJYxKIAPfTj6" title="Pre-funded warrant shares"><span id="xdx_907_ecustom--PrefundedWarrantShares_iI_c20231231_zpkA2iVop4qg" title="Pre-funded warrant shares">5,747,787</span></span> are included in the computation
of basic and diluted net loss per share for the years ended December 31, 2024 and 2023, as the pre-funded warrants are issuable for nominal
consideration.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTextBlock', window );">Investments</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--InvestmentTextBlock_zfn6QW5wgbd1" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"> <b>5.</b> <b><span id="xdx_822_zFpVbHn6lS2">Investments</span></b></p>



<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p id="xdx_89F_eus-gaap--InvestmentTableTextBlock_zCCqsRWlGsz4" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">The following table summarizes the Company&#8217;s held-to-maturity investment
securities at amortized cost as of December 31, 2024 and 2023:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B1_zjh6YZbQciIj" style="display: none">Schedule of Investment</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_48F_eus-gaap--HeldToMaturitySecurities_iI_zY95Wjuj9ZT9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amortized Cost, as Adjusted</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_489_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_iI_zDtVvdKS6E7j" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Gross Unrealized Holding Gains</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_48C_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_iI_zzFiqM32a51g" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Gross Unrealized Holding Losses</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_482_eus-gaap--HeldToMaturitySecuritiesFairValue_iI_zzI3b8XK0XTj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Estimated Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amortized Cost, as Adjusted</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Gross Unrealized Holding Gains</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Gross Unrealized Holding Losses</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Estimated Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_412_20241231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zLcyrLP42a6c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: justify; padding-bottom: 1pt; text-indent: 0pt">U.S. Treasury Bills</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">212,588,960</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">82,251</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0659">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">212,671,211</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_41D_20241231_zYVPzrbFP6sh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: 0pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">212,588,960</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">82,251</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0663">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">212,671,211</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_48F_eus-gaap--HeldToMaturitySecurities_iI_zQN0gpxq8gjk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amortized Cost, as Adjusted</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_48D_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_iI_zmcNOsJuEX0d" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Gross Unrealized Holding Gains</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_489_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_iI_zoua8HzmLeGd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Gross Unrealized Holding Losses</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_487_eus-gaap--HeldToMaturitySecuritiesFairValue_iI_zeXoWJsBIjm6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Estimated Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amortized Cost, as Adjusted</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Gross Unrealized Holding Gains</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Gross Unrealized Holding Losses</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Estimated Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_41D_20231231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zSaeWsAUrXNe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: justify; padding-bottom: 1pt; text-indent: 0pt">U.S. Treasury Bills</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">149,919,974</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">30,995</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0667">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">149,950,969</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_419_20231231_zbU8GJk04tyf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: 0pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">149,919,974</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">30,995</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0671">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">149,950,969</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A5_zwHyF3yoQHrc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">The fair value of the Company&#8217;s held-to-maturity debt securities
is determined based upon inputs, other than the quoted prices in active markets, that are observable either directly or indirectly, and
are classified as Level 2 fair value instruments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 321<br> -Publisher FASB<br> -URI https://asc.fasb.org/321/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 325<br> -Publisher FASB<br> -URI https://asc.fasb.org/325/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCurrentAssetsTextBlock', window );">Other Current Assets</a></td>
<td class="text"><p id="xdx_802_eus-gaap--OtherCurrentAssetsTextBlock_z90pEKHcg1m2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"> <b>6.</b> <b><span id="xdx_823_z5Xy4NBhlHo">Other Current Assets</span></b></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_894_eus-gaap--ScheduleOfOtherCurrentAssetsTableTextBlock_zL9Ky7RnXgpg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other current assets consisted of the following at
December 31:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B4_z25EpmOVAL45" style="display: none">Schedule of Other Current Assets</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20241231_zVoI33oyf2Qc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20231231_zzvMBVr3J0x9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PrepaidExpenseAndOtherAssetsCurrentAbstract_iB_zLjAY6e2KQIa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Current:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--PrepaidClinicalTrialCosts_iI_maOACz5EC_maOACzcDD_zrZR1MIwztZ7" style="vertical-align: bottom; background-color: White">
    <td style="width: 70%; text-align: justify">Prepaid clinical trial costs</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">6,768,668</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">8,763,150</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--MiscellaneousReceivable_iI_maOACz5EC_maOACzcDD_zgMqnqJOdguc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Miscellaneous receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,600,621</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">805,882</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--PrepaidInsurance_iI_maOACz5EC_maOACzcDD_ziST3dg7Mh91" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Directors &amp; officers&#8217; insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">256,629</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">157,453</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OtherPrepaidExpenseCurrent_iI_maOACz5EC_maOACzcDD_zCAHir9ln44e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">841,329</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">281,364</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OtherAssetsCurrent_iTI_mtOACz5EC_mtOACzcDD_zg52Bfkt2t9a" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: 10pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,467,247</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,007,849</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AA_zkFuD3XDj5sa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p id="xdx_802_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zM8LlpPMpLIi" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"> <b>7.</b> <b><span id="xdx_822_zwIPC0KzkEof">Property and Equipment</span></b></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_895_eus-gaap--PropertyPlantAndEquipmentTextBlock_zjOntXtkfmah" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Property and equipment consisted of the following
at December 31:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B2_zbRUXA1exdqi" style="display: none">Summary of Property and Equipment</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20241231_zWj4eYpg8fQg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20231231_zrJj7qrX1pE3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zQPkm78BcDr" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; text-align: justify">Furniture and equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,025,875</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1,788,195</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zfceKsZ0katd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Leasehold improvements</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">302,577</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">302,577</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzGp4_zUcwYof0nbwg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment, Gross</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,328,452</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,090,772</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzGp4_zxNtpWD73oi5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Less: Accumulated depreciation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,991,937</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,861,990</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzGp4_zSksBfWIeGEh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: 10pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">336,515</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">228,782</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AB_zeJmzC3fp6o5" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0in"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0in"><span style="font-weight: normal">Depreciation expense
was $<span id="xdx_901_eus-gaap--Depreciation_c20240101__20241231_zQhBxC99Wyy1" title="Depreciation expense">129,947</span> and $<span id="xdx_90F_eus-gaap--Depreciation_c20230101__20231231_zYqgbosfs3d5" title="Depreciation expense">142,772</span> for the years ended December 31, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0in"><span style="font-weight: normal">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_ziPJdj5s7qcg" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"> <b>8.</b> <b><span id="xdx_821_zucYWNR76scc">Accrued Expenses</span></b></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_896_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zErn4kMaNMrd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Accrued expenses consisted of the following at December
31:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B9_zyjmZEJcNGpa" style="display: none">Schedule of Accrued Expenses</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20241231_zl2ZIfBfvp8h" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20231231_zh5dZYKsqVf3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--AccruedClinicalTrialExpense_iI_maALCzp59_z7oRfzlBSGBa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; text-align: justify">Clinical trial costs</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">16,708,499</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">6,464,772</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--WorkersCompensationLiabilityCurrent_iI_maALCzp59_zkOBO8hhZ2P4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Accrued compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,987,786</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,763,316</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OtherAccruedLiabilitiesCurrentAndNoncurrent_iI_maALCzp59_z0cp9ECn6pQ2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,384,803</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">641,512</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AccruedEmployeeBenefitsCurrent_iI_maALCzp59_zb9wHpWbxTpj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Employee stock purchase plan</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">103,860</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">57,494</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCzp59_zHV3x8o5H9pg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: 10pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">22,184,948</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8,927,094</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AE_zsNaltowHbTk" style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0in">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;&#160;</b></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsDisclosureTextBlock', window );">Commitments</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--CommitmentsDisclosureTextBlock_zqHIgLYt2X65" style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"> 9. <span id="xdx_829_zwaUruN7uOv2">Commitments</span></p>



<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 19.8pt; text-indent: -19.8pt">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 19.8pt; text-indent: -19.8pt"><span style="text-decoration: underline">Operating and Finance Leases</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company leases its corporate space in Minneapolis,
Minnesota, with an operating lease in place through April 30, 2026. The lease provides for monthly rent, real estate taxes, and operating
expenses. Rent expense is recorded on a straight-line basis over the lease term. In March 2023, the Company signed the fourth amendment
to extend this lease through April 30, 2026. This amendment provides for monthly rent, real estate taxes and operating expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 2.15pt 0 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 2.15pt 0 0">In May 2018, the Company entered into a non-cancelable finance
lease agreement for office equipment with a five-year term. The underlying assets are included in furniture and equipment. The lease contains
a bargain purchase option at the end of the lease. The finance lease expired in May 2023 and the equipment was acquired for the bargain
purchase option price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 2.15pt 0 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 2.15pt 0 0">When an implicit rate is not provided, the Company uses its
incremental borrowing rate based on the information available at the lease commencement date in determining the present value of the lease
payments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p id="xdx_895_esrt--ScheduleOfCondensedBalanceSheetTableTextBlock_zuQPu1QXBhwi" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">Supplemental balance sheet information consisted of the following at December
31, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BE_zw3HBbzqg8w2" style="display: none">Schedule of Supplemental Balance Sheet Information Related to Leases</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" id="xdx_494_20241231_zT5RGc8NWm4i" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseDescriptionAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Operating Lease</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_zYQVceoYWCU9" style="vertical-align: bottom; background-color: White">
    <td style="width: 85%; text-align: justify; text-indent: 10pt">Right-of-use assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">215,502</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLeaseLiability_iI_pp0p0_zqUIZyHNsvma" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Operating lease liability</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">225,921</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_pp0p0_di_z5q7RAlD6Jv6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt; text-indent: 10pt">Less: short term portion</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(171,952</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: 10pt">Long term portion</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">53,969</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AF_zIoqi1yE0MD" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;&#160;</p>

<p id="xdx_890_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zzBGTQLd23i6" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">Maturity analysis under lease agreements consisted of the following as
of December 31, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B6_zXuYNHI4W3Af" style="display: none">Schedule of Maturity Analysis Under Lease Agreements</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20241231_zDYLnRejo5O3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Operating Leases</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzXrd_zrlJrxLp6Y" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 85%; text-align: justify">2025</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">220,389</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzXrd_zVnagI2JM905" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">2026</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">74,170</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzXrd_zobhmhwBJj9g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt; text-indent: 10pt">Total minimum lease payments</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">294,559</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zuqyqXxybD88" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt; text-indent: 10pt">Less: Present value discount</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(68,638</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingLeaseLiability_iI_zEXjJaN3t6Nh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: 10pt">Present value of net minimum lease payments</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">225,921</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: left">Weighted Average</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Remaining Lease Term</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Discount Rate</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 70%; text-align: justify">Operating lease</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;<span id="xdx_903_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20241231_zXNR8NJKHJM2" title="Operating leases, remaining lease term">1.3</span> years</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20241231_zYOM30IiwEf6" title="Operating leases, discount rate">10.5</span></td><td style="width: 1%; text-align: left">%</td></tr>
</table>

<p id="xdx_8AE_zAQnpZs3RsI9" style="margin: 0">&#160;</p>

<p id="xdx_89C_eus-gaap--LeaseCostTableTextBlock_zQqx8BBfFLxi" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Lease costs for the period ended December 31:</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>



<p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BE_ztIUpipt8P0d" style="display: none">Schedule of Lease Costs</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt; width: 70%">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left; width: 1%">&#160;</td><td id="xdx_498_20240101__20241231_z69Lp53vEyD4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; width: 12%">2024</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left; width: 1%">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left; width: 1%">&#160;</td><td id="xdx_49A_20230101__20231231_zXZfNMCMdLtg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; width: 12%">2023</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left; width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeaseCost_maLCzXSJ_maLCzphc_zWFKr6cRbmY7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: 10pt">Operating lease cost</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">213,104</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">212,238</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--FinanceLeaseCostAbstract_iB_zAH1tDujDzwa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: 10pt">Finance lease cost:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_i01_pp0p0_maLCzXSJ_maLCzphc_z20xoyVtRiyd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify; text-indent: 10pt">Amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0776">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,411</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--FinanceLeaseInterestExpense_i01_pp0p0_maLCzXSJ_maLCzphc_zmNVG91Je0i9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: justify; text-indent: 10pt">Interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0779">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--VariableLeaseCost_pp0p0_maLCzXSJ_maLCzphc_zPL8DHsVukc2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt; text-indent: 10pt">Variable lease cost</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">111,246</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">101,957</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--LeaseCost_iT_pp0p0_mtLCzphc_z3QzfXkEUPq4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif">Lease costs</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">324,350</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">316,610</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A9_zEDcf5xIIusl" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p id="xdx_89B_eus-gaap--ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_zB9UJmmc6PJc" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Supplemental cash flow information related to leases for the period ended December 31:</p>



<p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B8_zV76IQ6kDx15" style="display: none">Schedule of Supplemental Cash Flow Information Related to Leases</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20240101__20241231_zacNrvbFYyT" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20230101__20231231_zxZ1MztQsrH5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--CashPaidForOperatingAndFinanceLeasesAbstract_iB_z3T0lMG9DfWk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Cash paid for amounts included in operating and finance leases:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeasePayments_i01_pp0p0_maCPFOAzLxF_zT8id1pwmdac" style="vertical-align: bottom; background-color: White">
    <td style="width: 70%; text-align: justify; text-indent: 10pt">Operating cash outflow from operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">324,783</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">308,914</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--FinanceLeaseInterestPaymentOnLiability_i01_pp0p0_maCPFOAzLxF_zDLaW6oH5lYg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: 10pt">Operating cash outflow from finance leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0796">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--FinanceLeasePrincipalPayments_i01_pp0p0_maCPFOAzLxF_zhJwihAQWkdi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt; text-indent: 10pt">Financing cash outflow from finance leases</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0799">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,449</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--CashPaidForOperatingAndFinanceLeases_i01T_pp0p0_mtCPFOAzLxF_zodVNHNWeyx3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total cash paid for amounts
    included in operating and finance leases</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">324,783</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">311,367</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A9_zqcdOdtzXxkj" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><span style="text-decoration: underline">Clinical Research Studies</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">The Company enters into contracts in the normal course of business to conduct
research and development programs internally and through third parties that include, among others, arrangements with vendors, consultants,
CMOs, and CROs. The Company has a license agreement in place with Pfizer to research, develop, manufacture and commercialize gedatolisib.
In conjunction with the license agreement, the Company completed a Phase 1b clinical trial &#8211; B2151009 related to gedatolisib. These
patients subsequently transitioned to an Expanded Access study &#8211; CELC-G-001. Contracts related to the Expanded Access study are
generally based on time and material. In addition, contracts related to the Company&#8217;s Phase 3 clinical studies (VIKTORIA-1 and VIKTORIA-2)
and the Phase 1b/2 clinical trial (CELC-G-201) are generally cancelable with reasonable notice within 120 days and the Company&#8217;s
obligations under these contracts are primarily based on services performed through termination dates plus certain cancelation charges,
if any, as defined in each of the respective agreements. In addition, these agreements may, from time to time, be subjected to amendments
as a result of any change orders executed by the parties. As of December 31, 2024, the Company had five material non-cancelable contractual
commitments with respect to these arrangements, which totaled approximately $<span id="xdx_90F_eus-gaap--ContractualObligation_iI_pn5n6_c20241231_zShRqHtvWBG8" title="Non-cancelable contractual commitment">9.7</span> million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders&#8217; Equity</a></td>
<td class="text"><p id="xdx_807_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zoZ49RQScqt" style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"> 10. <span id="xdx_82C_zwjOQJ2kzy5i">Stockholders&#8217; Equity</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><span style="text-decoration: underline">Capital Stock</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At December 31, 2023, the Company&#8217;s authorized
capital stock consisted of <span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20231231_z58AORwDfBs2" title="Common stock, shares authorized">65,000,000</span> shares of $<span id="xdx_90F_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20231231_zJgTYDzfpAjg" title="Common stock, par value">.001</span> par value common stock, of which <span id="xdx_908_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20231231_zuH94DHujqf8" title="Common stock, shares outstanding">25,506,012</span> shares were outstanding, and <span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20231231_zNohAz6s1cH6" title="Preferred stock, shares authorized">2,500,000</span>
shares of $<span id="xdx_90B_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20231231_z4m7C5nD0oQb" title="Preferred stock, par value">.001</span> par value preferred stock, of which <span id="xdx_903_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20231231_zC5Hjt6xmnYb" title="Preferred stock, shares outstanding">854,134</span> shares were outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In 2024, several of the Company&#8217;s preferred
shareholders elected to convert <span id="xdx_900_eus-gaap--ConversionOfStockSharesConverted1_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zxGrOsknkA46" title="Number of shares converted">536,557</span> shares of Series A Convertible Preferred Stock into <span id="xdx_906_eus-gaap--ConversionOfStockSharesIssued1_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zfGlI0y7O6ge" title="Number of shares issued in conversion">5,365,570</span> shares of common stock, in accordance
with the Securities Purchase Agreement dated May 15, 2022. The cost basis of the shares transferred is $<span id="xdx_906_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zaMIf0ZK13X4" title="Cost basis of shares transferred">5.75</span> per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In 2024, several of the Company&#8217;s investors
exercised <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20241231_zHADFndXnH52" title="Additional warrants exercised">1,827,357</span> common stock warrants at exercise prices ranging between $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__srt--RangeAxis__srt--MinimumMember_zcaYVo5rE405" title="Class of warrant exercise price">8.05</span> and $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__srt--RangeAxis__srt--MaximumMember_z1c6oiZLr7F8" title="Class of warrant exercise price">9.50</span> per share, which generated approximately
$<span id="xdx_904_eus-gaap--ProceedsFromWarrantExercises_pn5n6_c20240101__20241231_zB5yUMl1KEBa" title="Proceeds from warant exercise">14.7</span> million in cash. The <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20241231_zfuggXWgi9Bj" title="Additional warrants exercised">1,827,357</span> common stock warrants were net of shares withheld for exercise price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify">At December 31, 2024, the Company&#8217;s
authorized capital stock consisted of <span id="xdx_903_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20241231_zwohx9jQHp8a" title="Common stock, shares authorized">95,000,000</span> shares of common stock, of which <span id="xdx_908_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20241231_zbgW50KgkuCj" title="Common stock, shares outstanding">37,143,242</span> shares were outstanding, and <span id="xdx_90E_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20241231_z1wnbw5zl0Tc" title="Preferred stock, shares authorized">2,500,000</span> shares
of preferred stock, including <span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z1ANVoyml8F5" title="Preferred stock, shares authorized">1,850,000</span> shares designated as Series A Preferred Stock, of which <span id="xdx_900_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20241231_zoFdcoiNvWJc" title="Preferred stock, shares outstanding">317,577</span> shares were outstanding. As of
December 31, 2024, no dividends have been declared on the Company&#8217;s capital stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><i>Sale and Issuance of Stock</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 22, 2024, pursuant to an Open Market Sale
Agreement<sup>SM</sup> with Jefferies LLC, as agent, the Company sold <span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240422__20240422__us-gaap--TypeOfArrangementAxis__custom--OpenMarketSaleAgreementMember__dei--LegalEntityAxis__custom--JefferiesLLCMember_zB8F5dHpHsJ4" title="Sale of stock">285,714</span> shares of common stock in a single transaction at a price
of $<span id="xdx_90F_eus-gaap--SaleOfStockPricePerShare_iI_c20240422__us-gaap--TypeOfArrangementAxis__custom--OpenMarketSaleAgreementMember__dei--LegalEntityAxis__custom--JefferiesLLCMember_zMSLcCZSIj85" title="Share price">17.50</span> per share, generating gross proceeds of $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20240422__20240422__us-gaap--TypeOfArrangementAxis__custom--OpenMarketSaleAgreementMember__dei--LegalEntityAxis__custom--JefferiesLLCMember_zVZfRImdr93h" title="Gross proceeds">5.0</span> million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify">On May 8, 2024, pursuant to an Open Market
Sale Agreement with Jefferies LLC, as agent, the Company sold <span id="xdx_90B_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240508__20240508__us-gaap--TypeOfArrangementAxis__custom--OpenMarketSaleAgreementMember__dei--LegalEntityAxis__custom--JefferiesLLCMember_zFgMBNFaayBa" title="Sale of stock number of shares issued in transaction">149,700</span> shares of common stock in a single transaction at a price of $<span id="xdx_90A_eus-gaap--SaleOfStockPricePerShare_iI_c20240508__us-gaap--TypeOfArrangementAxis__custom--OpenMarketSaleAgreementMember__dei--LegalEntityAxis__custom--JefferiesLLCMember_ziybsioOdUcl" title="Issuance of public offering price per share">17.65</span>
per share, generating gross proceeds of $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20240508__20240508__us-gaap--TypeOfArrangementAxis__custom--OpenMarketSaleAgreementMember__dei--LegalEntityAxis__custom--JefferiesLLCMember_zQMxRGkCOtN8" title="Gross proceeds from public offering">2.6</span> million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">Commissions and other offering expenses related to the Open Market Sale
Agreement transactions in April and May 2024 were $<span id="xdx_902_eus-gaap--PaymentsOfStockIssuanceCosts_pn5n6_c20240430__20240430__us-gaap--TypeOfArrangementAxis__custom--OpenMarketSaleAgreementMember_zWIGxvNR9XP3" title="Commissions and other offering expenses"><span id="xdx_90D_eus-gaap--PaymentsOfStockIssuanceCosts_pn5n6_c20240531__20240531__us-gaap--TypeOfArrangementAxis__custom--OpenMarketSaleAgreementMember_zqlqF4DntbM9" title="Commissions and other offering expenses">0.3</span></span> million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 30, 2024, the Company entered into an underwriting
agreement with Leerink Partners LLC, TD Securities (USA) LLC and Stifel, Nicolaus &amp; Company, Incorporated as representatives of the
several underwriters relating to the issuance and sale of <span id="xdx_903_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240530__20240530__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LeerinkPartnersLLCMember_zgi2coic5Ai3" title="Sale of stock number of shares issued in transaction">3,871,000</span> shares of common stock, at a price to the public of $<span id="xdx_901_eus-gaap--SaleOfStockPricePerShare_iI_c20240530__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LeerinkPartnersLLCMember_zhSUJT3GX9q2" title="Issuance of public offering price per share">15.50</span>, generating
gross proceeds of approximately $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20240530__20240530__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LeerinkPartnersLLCMember_zHKpZqZCKbF7" title="Gross proceeds from public offering">60.0</span> million. The offering closed on May 31, 2024 and resulted in net proceeds to the Company of approximately
$<span id="xdx_909_ecustom--ProceedsFromIssuanceOfCommonStockNet_pn5n6_c20240531__20240531__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LeerinkPartnersLLCMember_zeh8eaXyABs9" title="Net proceeds from public offering">56.3</span> million after deducting underwriting discounts and other offering expenses payable by the Company. The Company intends to use the
net proceeds from the offering for working capital and general corporate purposes, which may include capital expenditures, research and
development expenditures, clinical trial expenditures, expansion of business development activities and other general corporate purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline">Pre-Funded Warrants</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On October 18, 2023, the
Company entered into a securities purchase agreement (the &#8220;Securities Purchase Agreement&#8221;) with certain investors (the &#8220;Investors&#8221;)
pursuant to which the Company agreed to sell to the Investors in a private placement pre-funded warrants to purchase up to <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20231018__20231018__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zKSMTxN8oQMl" title="Pre-funded warrants sold to investors">5,747,787</span> shares
of the Company&#8217;s common stock, par value $<span id="xdx_902_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20231018__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z97C4UWFVdbh" title="Common stock, par value">0.001</span> per share. Each Warrant to purchase one share had a purchase price of $<span id="xdx_90F_eus-gaap--SharePrice_iI_pid_c20231018__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zeccBRVy2gef" title="Warrant purchase price">8.699</span> per
share, and an exercise price of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231018__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTLu4QIKk9Q8" title="Exercise price of common stock warrants">0.001</span> per share for the common stock issuable upon exercise of the Warrant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The closing of the Private
Placement occurred on October 20, 2023, and resulted in gross proceeds to the Company of approximately $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn5n6_c20231020__20231020__srt--TitleOfIndividualAxis__custom--InstitutionalAndOtherAccreditedInvestorsMember_zkxYRPpeIkJj" title="Proceeds from issuance of private placement">50.0</span> million, before deducting
offering expenses of approximately $<span id="xdx_90F_ecustom--OfferingExpenses_pn5n6_c20231020__20231020__srt--TitleOfIndividualAxis__custom--InstitutionalAndOtherAccreditedInvestorsMember_znvLnnmM5k9d" title="Offering expenses">0.1</span> million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Each Warrant is immediately
exercisable and will not expire. Under the terms of the Warrants, the Company may not effect the exercise of any such Warrant, and a holder
will not be entitled to exercise any portion of any Warrant, if, upon giving effect to such exercise, the aggregate number of shares of
common stock beneficially owned by the holder (together with its affiliates, other persons acting or who could be deemed to be acting
as a group together with the holder or any of the holder&#8217;s affiliates, and any other persons whose beneficial ownership of common
stock would or could be aggregated with the holder&#8217;s or any of the holder&#8217;s affiliates for purposes of Section 13(d) or Section
16 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)) would exceed 4.99% of the number of shares of
common stock outstanding immediately after giving effect to the exercise, as such percentage ownership is calculated in accordance with
Section 13(d) of the Exchange Act and the applicable regulations of the SEC (the &#8220;Maximum Percentage&#8221;). A holder may reset
the Maximum Percentage to a higher percentage (not to exceed 19.99%), effective 61 days after written notice to the Company, or a lower
percentage, effective immediately upon written notice to the Company. Any such increase or decrease will apply only to that holder and
not to any other holder of Warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Securities Purchase Agreement
contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations
of the Company, other obligations of the parties and termination provisions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><span style="text-decoration: underline">Warrants</span></b></p>

<p id="xdx_89E_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zsto21sRl4t3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BE_z2rn7RsYGXm4" style="display: none">Schedule of Warrants</span></span></b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>At December 31, 2024:</b></p></td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Issue Date</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Expiration <br/>
Date</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"># of Warrants <br/>
Outstanding</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise <br/>
Price</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Offering</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 14%; text-align: justify"><span id="xdx_90F_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantOneMember_zzy3QVehUMPk" title="Issue Date">1/21/2016</span></td><td style="width: 1%">&#160;</td>
    <td style="width: 12%; text-align: justify"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantOneMember_zm3MP6vzpn65" title="Expiration Date">1/14/2026</span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantOneMember_zbQLB19xUdXe" style="width: 12%; text-align: right" title="Number of Warrants Outstanding">33,719</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantOneMember_zRbGEXr1AZl4" style="width: 12%; text-align: right" title="Exercise Price">7.56</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 42%; text-align: justify"><span id="xdx_905_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantOneMember_zUP5W0NkT54d" title="Offering">private placement offering - issued to placement agent</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span id="xdx_909_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTwoMember_z1ejCN8TQZCl" title="Issue Date">5/2/2016</span></td><td>&#160;</td>
    <td style="text-align: justify"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTwoMember_zK2dMnFBPlWe" title="Expiration Date">5/2/2026</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTwoMember_zcrZXcNI65sg" style="text-align: right" title="Number of Warrants Outstanding">21,530</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTwoMember_zbZhsymVAKHh" style="text-align: right" title="Exercise Price">7.56</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTwoMember_zaMNtZcQeDf7" title="Offering">private placement offering - issued to placement agent</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span id="xdx_902_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantThreeMember_zpzw3gFg5DZd" title="Issue Date">4/28/2017</span></td><td>&#160;</td>
    <td style="text-align: justify"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantThreeMember_zNzbIHPWCVg7" title="Expiration Date">4/28/2027</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantThreeMember_zLssEEQmrMab" style="text-align: right" title="Number of Warrants Outstanding">33,250</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantThreeMember_zMkDOC743szj" style="text-align: right" title="Exercise Price">8.42</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify"><span id="xdx_901_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantThreeMember_zpmhmG59Rpw" title="Offering">private placement offering - issued to placement agent</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span id="xdx_909_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFourMember_zalzNQqwbrFg" title="Issue Date">5/17/2017</span></td><td>&#160;</td>
    <td style="text-align: justify"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFourMember_zAC3xvDT3uBh" title="Expiration Date">5/17/2027</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFourMember_zEOCCLNsGUaj" style="text-align: right" title="Number of Warrants Outstanding">15,365</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFourMember_zWOlYvSBfhO1" style="text-align: right" title="Exercise Price">8.42</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify"><span id="xdx_906_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFourMember_zrnfbCEu7dgl" title="Offering">private placement offering - issued to placement agent</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span id="xdx_90A_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFiveMember_zQhAPm6hIohg" title="Issue Date">9/22/2017</span></td><td>&#160;</td>
    <td style="text-align: justify"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFiveMember_zNI3eGRxNbO3" title="Expiration Date">9/19/2025</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFiveMember_z5ZtsHEZfpGh" style="text-align: right" title="Number of Warrants Outstanding">70,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFiveMember_zTABzIthnJkc" style="text-align: right" title="Exercise Price">10.45</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify"><span id="xdx_909_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFiveMember_zBu5zK2pk5v2" title="Offering">IPO - issued to underwriter</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span id="xdx_90F_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSixMember_zdKdLvwXNT5j" title="Issue Date">4/8/2021</span></td><td>&#160;</td>
    <td style="text-align: justify"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSixMember_zNZWWRgIdd82" title="Expiration Date">4/8/2031</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSixMember_z3G9nwBSAyp3" style="text-align: right" title="Number of Warrants Outstanding">26,042</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSixMember_zGWjh2pO9xnc" style="text-align: right" title="Exercise Price">14.40</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify"><span id="xdx_901_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSixMember_zZ1HBufNeQwg" title="Offering">debt financing - issued to lender</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span id="xdx_90D_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSevenMember_zJK8FAIwIrY6" title="Issue Date">5/30/2024</span></td><td>&#160;</td>
    <td style="text-align: justify"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSevenMember_zbQ5vZeVB7Wf" title="Expiration Date">5/30/2034</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSevenMember_z0LFPrsZBT1g" style="text-align: right" title="Number of Warrants Outstanding">84,227</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSevenMember_zf0PaICGlbRj" style="text-align: right" title="Exercise Price">14.84</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSevenMember_zblij2Twobbj" title="Offering">debt financing &#8211; issued to lender</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span id="xdx_90A_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantEightMember_zic20g9rc1ql" title="Issue Date">5/30/2024</span></td><td>&#160;</td>
    <td style="text-align: justify"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantEightMember_z7Sv8tviQRx6" title="Expiration Date">5/30/2034</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantEightMember_zFTIPLLSQhH" style="text-align: right" title="Number of Warrants Outstanding">19,649</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantEightMember_zZi0ytehV8Ya" style="text-align: right" title="Exercise Price">14.84</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify"><span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantEightMember_zYLtdPeigg8j" title="Offering">debt financing &#8211; issued to lender</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span id="xdx_90F_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantNineMember_zNmKUWPO56H8" title="Issue Date">12/9/2022</span></td><td>&#160;</td>
    <td style="text-align: justify">see below</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantNineMember_zXGAEV0ZyuAf" style="text-align: right" title="Number of Warrants Outstanding">5,217,370</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantNineMember_zev3Pr9tOfF7" style="text-align: right" title="Exercise Price">8.05</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantNineMember_zsYj2m7PJUt3" title="Offering">securities purchase agreement - issued to institutional and other accredited investors</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt"><span id="xdx_905_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTenMember_zQ2aRRiyhzKh" title="Issue Date">10/18/2023</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: justify; padding-bottom: 1pt">see above</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTenMember_zIHxFG7oVpml" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants Outstanding">5,747,787</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTenMember_z48GIU4yN60b" style="padding-bottom: 1pt; text-align: right" title="Exercise Price">0.001</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: justify; padding-bottom: 1pt"><span id="xdx_908_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTenMember_zbmOZ3d2wQE2" title="Offering">private placement offering - issued to investors</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Total Warrants Outstanding</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231_zOC3YLP8ubx8" style="font-weight: bold; text-align: right" title="Number of Warrants Outstanding">11,268,939</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  </table>

<p id="xdx_8AB_zxzmxtlf4sgd" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">At December 31, 2024 and 2023, the Company had warrants
to purchase <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4Jkj0ItTUN3">11,268,939
</span>and <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zKQ3kFlcT3t">13,011,520
</span>shares of common stock outstanding, at a weighted average exercise price of $<span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOfWarrants_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwqCFb5kt6e7">4.04
</span>and $<span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOfWarrants_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zO2YxejSqGT5">4.53</span>,
respectively. A total of <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z7O3Q99RMm4a">1,842,913
</span>and <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zT8cYO0TaCMl">2,369
</span>warrants were exercised in the years ended December 31, 2024 and 2023, respectively. There were <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPsKJxVdYTxd">3,544
</span>warrants that expired in 2024.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zl77xoio4Lj7" style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"> 11. <span id="xdx_823_z4h8In7A7UFf">Stock-Based Compensation</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><span style="text-decoration: underline">2012 Equity Incentive Plan</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">The 2012 Equity Incentive Plan, as amended, was adopted by the Company&#8217;s
board and approved by the members of Celcuity LLC on August 10, 2012. The Company reserved a maximum of <span id="xdx_905_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20120810__us-gaap--AwardTypeAxis__custom--EquityIncentivePlanMember_zvYAhqdRedX2" title="Common stock, shares reserved for issuance">625,000</span> shares of common stock
for issuance under the 2012 Equity Incentive Plan. The 2012 Equity Incentive Plan provides for options, restricted stock awards, performance
stock awards or stock bonuses. The exercise price of each option granted under the 2012 Equity Incentive Plan is not less than 100% of
the fair market value of one share on the date of grant. The maximum permitted term of options granted under the 2012 Equity Incentive
Plan is ten years. The Company&#8217;s board administers the 2012 Equity Incentive Plan and determines the provisions of incentive awards,
including eligible recipients, number of shares subject to an incentive award, exercise price, vesting schedule, duration of an incentive
award and other restrictions an incentive award may be subject to. The 2012 Equity Incentive Plan was frozen on September 6, 2017 and
new awards are issued under the terms of the 2017 Amended and Restated Stock Incentive Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><span style="text-decoration: underline">2017 Stock Incentive Plan</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">The 2017 Amended and Restated Stock Incentive Plan (the &#8220;2017 Plan&#8221;)
was adopted by the Company&#8217;s board on September 6, 2017, became effective following the corporate conversion on September 15, 2017,
and was approved by stockholders at the Company&#8217;s annual stockholder meeting on May 10, 2018. The 2017 Plan was amended and approved
by stockholders at the Company&#8217;s annual stockholder meeting on May 14, 2020. The Company initially reserved a maximum of <span id="xdx_90B_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20171025__us-gaap--AwardTypeAxis__custom--StockIncentivePlanMember_zy9mw031BNRd" title="Common stock, shares reserved for issuance">750,000</span>
shares of common stock for issuance under the 2017 Plan. The number of shares reserved for issuance was automatically increased by <span id="xdx_90F_ecustom--ChangeInCommonStockSharesReservedForIssuance_iI_pid_c20240101__us-gaap--AwardTypeAxis__custom--StockIncentivePlanMember_zj1lXpOBs0Sd" title="Change in common stock, shares reserved for issuance">255,060</span>
and <span id="xdx_907_ecustom--ChangeInCommonStockSharesReservedForIssuance_iI_pid_c20230101__us-gaap--AwardTypeAxis__custom--StockIncentivePlanMember_zjcWnIEgzKP7" title="Change in common stock, shares reserved for issuance">216,673</span> shares on January 1, 2024 and 2023, respectively, and will increase automatically on January 1 of each of 2025 through 2027
by the number of shares equal to 1.0% of the aggregate number of outstanding shares of Company common stock as of the immediately preceding
December 31. However, the Company&#8217;s board may reduce the amount of the increase in any particular year. At each of the Annual Meetings
held on May 12, 2021 and May 12, 2022, the stockholders approved a <span id="xdx_90A_ecustom--ChangeInCommonStockSharesReservedForIssuance_iI_pid_c20210512__us-gaap--AwardTypeAxis__custom--StockIncentivePlanMember_zdDMs0cGZwwi" title="Change in common stock, shares reserved for issuance"><span id="xdx_90D_ecustom--ChangeInCommonStockSharesReservedForIssuance_iI_pid_c20220512__us-gaap--AwardTypeAxis__custom--StockIncentivePlanMember_znRdBrTBdr27" title="Change in common stock, shares reserved for issuance">500,000</span></span> increase for a total of <span id="xdx_906_ecustom--TotalCommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20210512__us-gaap--AwardTypeAxis__custom--StockIncentivePlanMember_ztQYTaUZcTtl" title="Total common stock, shares reserved for issuance"><span id="xdx_907_ecustom--TotalCommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20220512__us-gaap--AwardTypeAxis__custom--StockIncentivePlanMember_zow5jheWFTJ4" title="Total common stock, shares reserved for issuance">1,000,000</span></span> increase, to the number of
shares reserved for issuance under the 2017 Plan. At each of the Annual Meetings held on May 11, 2023 and May 9, 2024, the stockholders
approved <span id="xdx_90F_ecustom--TotalCommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20230511__us-gaap--AwardTypeAxis__custom--StockIncentivePlanMember_z6TU2PbwJaR3" title="Total common stock, shares reserved for issuance">1,500,000</span> increases for a total increase of <span id="xdx_90E_ecustom--TotalCommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20240509__us-gaap--AwardTypeAxis__custom--StockIncentivePlanMember_zCBabljzE0E" title="Total common stock, shares reserved for issuance">3,000,000</span> to the number of shares reserved for issuance under the 2017 Plan. The
2017 Plan provides for options, restricted stock awards, stock appreciation rights, restricted stock units, performance awards and stock
bonuses. The exercise price of each option granted under the 2017 Plan is not less than 100% of the fair market value of one share on
the date of grant. The maximum permitted term of options granted under the 2017 Plan is ten years. The 2017 Plan is generally administered
by the compensation committee of the Company&#8217;s board, which has the authority to interpret the 2017 Plan, grant awards and make
all other determinations necessary for the administration of the 2017 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zOSgvTIVLrI" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">The following table summarizes the activity for all stock options outstanding
for the years ended December 31:</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B6_zl6OpamZLCef" style="display: none">Schedule of Stock Options Activity</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: justify">Options outstanding at beginning of year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zSPYsmp3gBwc" style="width: 12%; text-align: right" title="Options outstanding at beginning of year">2,815,392</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zmesmf88ipEf" style="width: 12%; text-align: right" title="Options outstanding, weighted average exercise price at beginning of year">7.95</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zmfBnJOTCI6a" style="width: 12%; text-align: right" title="Options outstanding at beginning of year">1,976,586</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zCBET0BdBjxa" style="width: 12%; text-align: right" title="Options outstanding, weighted average exercise price at beginning of year">6.34</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: justify">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_z9St0zHMEwu1" style="text-align: right" title="Shares, Granted">1,716,729</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zGD33vgHmzEg" style="text-align: right" title="Weighted Average Exercise Price, Granted">16.14</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zfISnnkWBnl1" style="text-align: right" title="Shares, Granted">1,003,298</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zjbip3FB4WRk" style="text-align: right" title="Weighted Average Exercise Price, Granted">10.69</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zHJlvZJj8Zm5" style="text-align: right" title="Shares, Exercised">(103,245</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zDuKZUDpU8J4" style="text-align: right" title="Weighted Average Exercise Price, Exercised">7.45</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_ze5YikrvvFd2" style="text-align: right" title="Shares, Exercised">(98,695</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zpugTMFU0Hn7" style="text-align: right" title="Weighted Average Exercise Price, Exercised">3.94</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: justify; padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zBIb2UJGk9f3" style="border-bottom: Black 1pt solid; text-align: right" title="Shares, Forfeited">(121,899</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zUV6nYVTuh13" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise, Forfeited">11.57</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zSbSduUjp7d7" style="border-bottom: Black 1pt solid; text-align: right" title="Shares, Forfeited">(65,797</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zxA7HOqB6AK4" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise, Forfeited">7.45</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify; padding-bottom: 1pt">Balance at December 31:</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_z9AKSp0QPPxe" style="border-bottom: Black 1pt solid; text-align: right" title="Options outstanding at end of year">4,306,977</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zrGgSswWkEri" style="border-bottom: Black 1pt solid; text-align: right" title="Options outstanding, weighted average exercise price at end of year">11.13</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zruFBhv5jPE2" style="border-bottom: Black 1pt solid; text-align: right" title="Options outstanding at end of year">2,815,392</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zLTfuTkJ2kz9" style="border-bottom: Black 1pt solid; text-align: right" title="Options outstanding, weighted average exercise price at end of year">7.95</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Options exercisable at December 31:</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zPa7Q8m6DZj" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares, options exercisable">2,011,474</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zTG5EMBmFq7i" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price, Options exercisable">7.35</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zOW35pU1Ftd1" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares, options exercisable">1,524,731</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_z3k2bDel1Ute" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price, Options exercisable">6.44</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Weighted Average Grant Date Fair Value for options granted during the year:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zkqfx8wCiia5" style="text-align: right" title="Weighted Average Grant Date Fair Value for options granted during the period">11.22</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zIgbZ80Sv321" style="text-align: right" title="Weighted Average Grant Date Fair Value for options granted during the period">7.48</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AB_zulv7JG4heh4" style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt; text-align: justify">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;&#160;</p>

<p id="xdx_89C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_z03Q5zIYvzg7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><span style="font-weight: normal">The
following table summarizes additional information about stock options outstanding and exercisable at December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><span style="font-weight: normal">&#160;&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BE_zbSIJPkNPEXi" style="display: none">Schedule
of Stock Options Outstanding and Exercisable</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options Outstanding</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options Exercisable</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options Outstanding</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options Exercisable</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zpuOPQ73lAua" style="width: 12%; text-align: right" title="Options outstanding">4,306,977</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zlB135Ixbs0g" title="Options outstanding, weighted average remaining contractual life">7.96</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z6s9z4Tfe23g" style="width: 12%; text-align: right" title="Options outstanding, weighted average exercise price">11.13</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pp0p0_c20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zaI6V7rIDWik" style="width: 12%; text-align: right" title="Options outstanding, aggregate intrinsic value">13,914,458</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zNs1vu03paZi" style="width: 12%; text-align: right" title="Options exercisable">2,011,474</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zYO9GUIJqj6l" style="width: 12%; text-align: right" title="Options exercisable, weighted average exercise price">7.35</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4NHWs1M5Klb" style="width: 12%; text-align: right" title="Options exercisable, aggregate intrinsic value">11,781,660</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AD_zM2nNZh2BdGk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">The Company recognized stock-based compensation expense for stock options
of $<span id="xdx_901_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z2Ij1CKZiohc" title="Recognized stock-based compensation expense">6,626,402</span> and $<span id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zthctUGcW1x1" title="Recognized stock-based compensation expense">4,716,475</span> for the years ended December 31, 2024 and 2023, respectively. In May 2022, the Company modified the exercise
price on <span id="xdx_900_ecustom--StockOptionAwardsSharesModified_iI_c20220531__us-gaap--PlanNameAxis__custom--MayTwoThousandTwentyTwoExercisePriceModificationMember_zMu9IcaD1gei" title="Stock option awards shares modified">776,324</span> stock option awards to $<span id="xdx_904_ecustom--ModifiedStockOptionExercisePrice_iI_c20220531__us-gaap--PlanNameAxis__custom--MayTwoThousandTwentyTwoExercisePriceModificationMember_zrI3NB8onBGd" title="Stock option exercise price per share">5.50</span>, the closing market price on the Nasdaq Capital Market on May 17,2022. The effect of this
modification on stock-based compensation was $<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_pp0p0_c20240101__20241231__us-gaap--PlanNameAxis__custom--MayTwoThousandTwentyTwoExercisePriceModificationMember_zK8zr4ymllGb" title="Stock based compensation expense related to modification">106,000</span> and $<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_pp0p0_c20230101__20231231__us-gaap--PlanNameAxis__custom--MayTwoThousandTwentyTwoExercisePriceModificationMember_z86b0ScheOb" title="Stock based compensation expense related to modification">134,000</span> for the years ended December 31, 2024 and 2023, respectively. The effect
of this modification on stock-based compensation over the remaining service period will be approximately $<span id="xdx_902_ecustom--RemainingStockBasedCompensationExpenseRelatedToModification_pdp0_c20240101__20241231__us-gaap--PlanNameAxis__custom--MayTwoThousandTwentyTwoExercisePriceModificationMember_zhOlYVakGVQk" title="Remaining stock based compensation expense related to modification">57,000</span>. In December 2021, the
Company modified the exercise price on <span id="xdx_903_ecustom--StockOptionAwardsSharesModified_iI_c20211231__us-gaap--PlanNameAxis__custom--DecemberTwoThousandTwentyOneExercisePriceModificationMember_zLWEK4WL3HE9" title="Stock option awards shares modified">311,000</span> stock option awards to $<span id="xdx_90C_ecustom--ModifiedStockOptionExercisePrice_iI_c20211231__us-gaap--PlanNameAxis__custom--DecemberTwoThousandTwentyOneExercisePriceModificationMember_zBR1hrTDyBL1" title="Stock option exercise price per share">13.44</span>, the closing market price on the Nasdaq Capital Market on
December 15, 2021. No director or officer awards were modified. The effect on stock-based compensation was $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_pp0p0_c20240101__20241231__us-gaap--PlanNameAxis__custom--DecemberTwoThousandTwentyOneExercisePriceModificationMember_zs7MfDLj4Je2" title="Stock based compensation expense related to modification">63,000</span> and $<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_pp0p0_c20230101__20231231__us-gaap--PlanNameAxis__custom--DecemberTwoThousandTwentyOneExercisePriceModificationMember_z9DvLiy1lnsh" title="Stock based compensation expense related to modification">65,000</span> for the
years ended December 31, 2024 and 2023, respectively. The effect on stock-based compensation over the remaining service period will be
approximately $<span id="xdx_903_ecustom--RemainingStockBasedCompensationExpenseRelatedToModification_c20240101__20241231__us-gaap--PlanNameAxis__custom--DecemberTwoThousandTwentyOneExercisePriceModificationMember_zHxFEnBStVxa" title="Remaining stock based compensation expense related to modification">35,000</span>. In May 2020, the Company modified the exercise price on <span id="xdx_909_ecustom--StockOptionAwardsSharesModified_iI_c20200531__us-gaap--PlanNameAxis__custom--MayTwoThousandTwentyExercisePriceModificationMember_zPmCcuOZAGuj" title="Stock option awards shares modified">203,750</span> stock option awards to $<span id="xdx_907_ecustom--ModifiedStockOptionExercisePrice_iI_c20200531__us-gaap--PlanNameAxis__custom--MayTwoThousandTwentyExercisePriceModificationMember_zEAhVaMiniV6" title="Stock option exercise price per share">5.10</span>, the closing market
price on the Nasdaq Capital Market on May 14, 2020. No director or officer awards were modified. The effect on stock-based compensation
was $<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_pp0p0_c20240101__20241231__us-gaap--PlanNameAxis__custom--MayTwoThousandTwentyExercisePriceModificationMember_zjCIyWfxx8kh" title="Stock based compensation expense related to modification">696</span> and $<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_pp0p0_c20230101__20231231__us-gaap--PlanNameAxis__custom--MayTwoThousandTwentyExercisePriceModificationMember_zIbRdVdy4F4k" title="Stock based compensation expense related to modification">19,000</span> for the years ended December 31, 2024 and 2023, respectively. There is no effect on stock-based compensation remaining.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 4.9pt 0 0">&#160;</p>

<p id="xdx_894_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zi73cEuSmWcd" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 4.9pt 0 0">The Black-Scholes option-pricing model was used to estimate the
fair value of equity-based awards and the Monte Carlo simulation model was used to estimate the fair value of the performance-based awards,
with the following weighted-average assumptions for the years ended December 31:</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 4.9pt 0 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BD_zHcfdfNr9DFl" style="display: none">Schedule
of Assumptions for Fair Value of Equity-based Awards</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 84%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Risk-free interest rate</td><td>&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20240101__20241231_z1XNMJkdpoic" title="Risk-free interest rate, minimum">3.48</span>% - <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20240101__20241231_zhikFLceRTj2" title="Risk-free interest rate, maximum">4.71</span>%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20230101__20231231_zoSbEHdl2yq3" title="Risk-free interest rate, minimum">3.41</span>% - <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20230101__20231231_zoIxufmX3D6j" title="Risk-free interest rate, maximum">4.86</span>%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Expected volatility</td><td>&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right">&#160;<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20240101__20241231_zuYuGglRn2gd" title="Expected volatility, minimum">71.2</span>% - <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20240101__20241231_zan1YJLKGjMl" title="Expected volatility, maximum">76.20</span>%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20230101__20231231_zTjU6ctWXmQh" title="Expected volatility, minimum">77.1</span>% - <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20230101__20231231_zNAdQkiZXBB2" title="Expected volatility, maximum">79.8</span>%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Expected life (years)</td><td>&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_ztcUXQwc3aKf" title="Expected life (years)">5.25</span> to <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_zLukX40oGYQi" title="Expected life (years)">10.00</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_ztrk0FdUILQj" title="Expected life (years)">5.25</span> to <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_zH5GuzyAtgvh" title="Expected life (years)">6.08</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 70%; text-align: justify">Expected dividend yield</td><td style="width: 1%">&#160;</td>
    <td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20241231_z6k1cfE1V3Ql" style="white-space: nowrap; width: 12%; text-align: right" title="Expected dividend yield">0</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20231231_ztVVj0EN6zzc" style="white-space: nowrap; width: 12%; text-align: right" title="Expected dividend yield">0</td><td style="width: 1%; text-align: left">%</td></tr>
  </table>

<p id="xdx_8A9_zJTc14J4s0Xa" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">The inputs for the Black-Scholes valuation model and the Monte Carlo simulation
model require management&#8217;s significant assumptions. Prior to the Company&#8217;s initial public offering, the price per share of
common stock was determined by the Company&#8217;s board based on recent prices of common stock sold in private offerings. Subsequent
to the initial public offering, the price per share of common stock is determined by using the closing market price on the Nasdaq Capital
Market on the grant date. The risk-free interest rates are based on the rate for U.S. Treasury securities at the date of grant with maturity
dates approximately equal to the expected life at the grant date. The expected life is based on the simplified method for the time-based
awards and the life of the option for the performance-based awards, in accordance with the SEC Staff Accounting Bulletin Nos. 107 and
110. The expected volatility is estimated based on historical volatility information of peer companies that are publicly available in
combination with the Company&#8217;s calculated volatility since being publicly traded for the time-based awards. For the performance-based
awards, the Company&#8217;s full historical volatility was used to value the options.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">All assumptions used to calculate the grant date fair value of non-employee
options are generally consistent with the assumptions used for options granted to employees. In the event the Company terminates any of
its consulting agreements, the unvested options issued in connection with the agreements would also be cancelled.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">The Company had <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_pid_c20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zyz9NJPipx76" title="Restricted stock awards outstanding">1,079</span> and <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_pid_c20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zC846HM4wu1e" title="Restricted stock awards outstanding">1,958</span> shares of restricted stock outstanding
at December 31, 2024 and 2023, respectively, and <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zhLZjZ9GRrL2" title="Restricted stock awards vested">2,308</span> and <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zYwuq1lotWr" title="Restricted stock awards vested">3,273</span> shares of restricted stock vested during the years ended December 31,
2024 and 2023, respectively. The Company recognized stock-based compensation expense for restricted stock of $<span id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zQClfC2rh6K6" title="Recognized stock-based compensation expense">22,220</span> and $<span id="xdx_908_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zHg1gQ7rcRhd" title="Recognized stock-based compensation expense">18,499</span> for the
years ended December 31, 2024 and 2023, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">The total remaining shares available for grant under the Company&#8217;s
2017 Plan as of December 31, 2024 was <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenPlanMember_zvVaB84mvc22" title="Shares available for grant under the 2017 Plan">1,177,450</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;&#160;</p>

<p id="xdx_89C_eus-gaap--ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_zFlXY2ZIJtIf" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">Total unrecognized compensation cost related to stock options and restricted
stock is estimated to be recognized at December 31:</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BF_zruehIE5AH0e" style="display: none">Schedule
of Unrecognized Compensation Cost</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_497_20241231_zDiqDKG6Yend" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td></tr>
<tr id="xdx_40D_ecustom--EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostToBeRecognizedNextTwelveMonths_iI_pp0p0_maESSBCzuFt_zL2GOdxD4VQ1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 85%; text-align: justify">2025</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">7,776,307</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostToBeRecognizedWithinTwoYear_iI_pp0p0_maESSBCzuFt_zcDSPaQcZ7Vf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,307,024</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostToBeRecognizedwithinThreeYears_iI_pp0p0_maESSBCzuFt_zUon9dbpcGAk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,165,880</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostToBeRecognizedWithinFourYears_iI_pp0p0_maESSBCzuFt_zShnqUzpWSag" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">2028</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,964,136</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostToBeRecognized_iTI_pp0p0_mtESSBCzuFt_zFTAbaTPyOAj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt; text-indent: 10.05pt">Total estimated compensation cost to be recognized</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">21,213,347</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A9_zcEaKapNqQVk" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><span style="text-decoration: underline">2017 Employee Stock Purchase Plan</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">The Company&#8217;s 2017 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;)
was adopted by the Company&#8217;s board on September 6, 2017 and approved by stockholders at the Company&#8217;s annual stockholder meeting
on May 10, 2018. The Company initially reserved a total of <span id="xdx_908_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20180510__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_zWkJLEboRYu8" title="Common stock, shares reserved for issuance">100,000</span> shares for issuance under the ESPP. The number of shares reserved for
issuance was automatically increased by <span id="xdx_90A_ecustom--ChangeInCommonStockSharesReservedForIssuance_iI_pid_c20240101__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_zplg5h83yCw1" title="Change in common stock, shares reserved for issuance">127,530</span> and <span id="xdx_90A_ecustom--ChangeInCommonStockSharesReservedForIssuance_iI_pid_c20230101__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_zgxHaixpYMVb" title="Change in common stock, shares reserved for issuance">108,337</span> shares on January 1, 2024 and 2023, respectively and will increase automatically
on each subsequent January 1 by <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_zjzjj9Oukk05" title="Annual employee stock purchase plan description">the number of shares equal to 0.5% of the total outstanding number of shares of Company common stock as
of the immediately preceding December 31.</span> However, the Company&#8217;s board may reduce the amount of the increase in any particular year.
The total remaining shares available for issuance under the employee stock purchase plan as of December 31, 2024 is <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_zAoN60aqUax5" title="Shares available for grant under the 2017 Plan">360,950</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">The ESPP provides participating employees with an opportunity to purchase
shares of the Company&#8217;s common stock at a discount through payroll deductions. The ESPP is available to all employees unless they
are employed for less than 20 hours per week or own 5% or more of the total combined voting power or value of the Company&#8217;s common
stock. The ESPP is administered using overlapping 24 month offering periods, referred to as an Offering Period. Each Offering Period has
four six-month purchase periods. A new Offering Period and purchase period begin every six months on May 1 and November 1 of each year.
Participating employees may purchase common stock, on a voluntary after tax-basis, at a price equal to 85% of the fair market value of
a share of common stock on either the offering date or the purchase date, whichever is lower. If the purchase date has a lower price,
the employee will automatically be placed in the Offering Period beginning immediately after the purchase date. The Company recognized
stock-based compensation expense related to the ESPP of $<span id="xdx_908_eus-gaap--AllocatedShareBasedCompensationExpense_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockIncentivePlanMember_zPgOedyf822b" title="Recognized stock-based compensation expense">339,719</span> and $<span id="xdx_90A_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockIncentivePlanMember_zgmMNiIojL2h" title="Recognized stock-based compensation expense">166,460</span> for the years ended December 31, 2024 and 2023, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_89A_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zqjQEPVij6Hl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognized total stock-based compensation
expense as follows for the years ended December 31:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BC_zjAZERWI5os" style="display: none">Schedule
of Stock-based Compensation Expenses</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20240101__20241231_z4pmCOqoASr7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20230101__20231231_zIZEONn9stw4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Years Ended</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31:</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Stock-based compensation expense in operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zE5iyqF5CJ8l" style="vertical-align: bottom; background-color: White">
    <td style="width: 70%; text-align: justify; text-indent: 10pt">Research and development</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">4,404,518</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,700,318</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zGtGu59uNYjh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt; text-indent: 10pt">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,583,823</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,201,116</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ShareBasedCompensation_zQia2ur1xLX7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: 10pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,988,341</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,901,434</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ShareBasedCompensation_zcZVzUBneNid" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: 10pt">Stock-based compensation expense</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,988,341</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,901,434</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8A1_zb28X9McXF7f" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text"><p id="xdx_807_eus-gaap--DebtDisclosureTextBlock_zMNrH3n0QoW1" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"> <b>12.</b> <b><span id="xdx_824_zR4RVYUpgQR3">Debt</span></b></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 30, 2024, the Company entered into an Amended
and Restated Loan and Security Agreement (the &#8220;A&amp;R Loan Agreement&#8221;) with Innovatus Life Sciences Lending Fund I, LP, a
Delaware limited partnership (&#8220;Innovatus&#8221;), as collateral agent, and the Lenders including Innovatus in its capacity as a
Lender and Oxford Finance LLC (&#8220;Oxford&#8221;), pursuant to which Innovatus and Oxford, as Lenders, have agreed to make certain
term loans (&#8220;Term Loans&#8221;) to the Company in the aggregate principal amount of up to $<span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_pn6n6_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__srt--RangeAxis__srt--MaximumMember_ztfxGLKU9yUi" title="Funded contingent loan, outstanding">180</span> million. The A&amp;R Loan Agreement
amends and restates, in its entirety, that certain Loan and Security Agreement, dated April 8, 2021, as amended, between the Company and
Innovatus, as collateral agent, and the Lenders named therein (the &#8220;Prior Loan Agreement&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Funding of the first $<span id="xdx_90A_eus-gaap--DebtInstrumentCarryingAmount_iI_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_zTSalFNX08oc" title="Funded loan amount">100</span> million under the A&amp;R
Loan Agreement occurred on May 30, 2024, including tranche payments of $<span id="xdx_904_eus-gaap--DebtInstrumentCarryingAmount_iI_pn5n6_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermALoanMember_zi3GRpUmejQ" title="Funded loan amount">16.8</span> million (the &#8220;Term A Loan&#8221;) and $<span id="xdx_90B_eus-gaap--DebtInstrumentCarryingAmount_iI_pn5n6_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermBLoanMember_zvbZPwsSfz59" title="Funded loan amount">21.5</span> million
(the &#8220;Term B Loan&#8221;) reflecting repayment of the principal amount of loans under the Prior Loan Agreement plus accrued payment-in-kind
interest, in addition to $<span id="xdx_90E_eus-gaap--DebtInstrumentCarryingAmount_iI_pn5n6_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermCLoanMember_zrqJkjMwWZa6" title="Funded loan amount">61.7</span> million of new borrowings (the &#8220;Term C Loan&#8221;). The Company will be eligible to draw on a fourth
tranche of $<span id="xdx_90D_eus-gaap--DebtInstrumentCarryingAmount_iI_pn6n6_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermDLoanMember_zc9qqqOg8Oje" title="Funded loan amount">30</span> million (the &#8220;Term D Loan&#8221;) and fifth tranche of $<span id="xdx_909_eus-gaap--DebtInstrumentCarryingAmount_iI_pn6n6_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermELoanMember_ztkNXOFDwlz5" title="Funded loan amount">50</span> million (the &#8220;Term E Loan&#8221;), in each case
upon achievement of certain clinical trial milestones and satisfaction of certain financial covenants determined on a pro forma as-funded
basis. The Lenders may, in their sole discretion upon the Company&#8217;s request, make additional term loans to the Company of $<span id="xdx_904_eus-gaap--DebtInstrumentCarryingAmount_iI_pn6n6_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermFLoanMember_z5LlJXBabZYf" title="Funded loan amount">45</span> million
(the &#8220;Term F Loan&#8221;). Funding of these additional tranches is also subject to other customary conditions and limits on when
the Company can request funding for such tranches. Costs associated with the new borrowings was approximately $<span id="xdx_908_eus-gaap--OtherBorrowings_iI_pn5n6_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_z0VgYGhNj4qa" title="Costs associated with new borrowings">2.4</span> million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the A&amp;R Loan Agreement, <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateTerms_pid_dp_c20240530__20240530__us-gaap--TypeOfArrangementAxis__custom--AmendedAndRestatedLoanAgreementMember_zUcTcz1HmJW8" title="Debt instrument interest rate description">the Company
is entitled to make interest-only payments for thirty-six months, or up to forty-eight months if certain conditions are met. The Term
Loans will mature on May 1, 2029 and will bear interest at a rate equal to the sum of (a) the greater of (i) the Prime Rate (as defined
in the A&amp;R Loan Agreement) or (ii) 7.75%, plus (b) 2.85%, provided that 1.0% of such interest will be payable in-kind by adding an
amount equal to such 1.0% of the outstanding principal amount to the then outstanding principal balance on a monthly basis through May
31, 2027.</span> The A&amp;R Loan Agreement is secured by all assets of the Company. Proceeds will be used for working capital purposes and to
fund the Company&#8217;s general business requirements, including the Phase 3 VIKTORIA-2 clinical trial. The A&amp;R Loan Agreement contains
customary representations and warranties and covenants, subject to customary carve-outs, and includes financial covenants related to liquidity
and other financial measures. Innovatus has the right, at its election and until August 9, 2025, to convert up to <span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermALoanMember_zn4oUIqq2pW4" title="Loan conversion percentage">20</span>% of the outstanding
principal of the Term A Loan into shares of the Company&#8217;s common stock at a price per share of $<span id="xdx_904_eus-gaap--SaleOfStockPricePerShare_iI_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermALoanMember_zj7cWUAWnNya" title="Common stock price per share">10.00</span> (the &#8220;Conversion Right&#8221;).
Innovatus will continue to have the right to exercise a previously disclosed warrant granted to it under the Prior Loan Agreement to purchase
<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240530__20240530__us-gaap--PlanNameAxis__custom--PriorLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_ziM1TP4R2dq1" title="Common stock issued">26,042</span> shares of common stock at a price per share of $<span id="xdx_90D_eus-gaap--SaleOfStockPricePerShare_iI_c20240530__us-gaap--PlanNameAxis__custom--PriorLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_zsPSU0AbrZni" title="Common stock price per share">14.40</span> through April 8, 2031.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The A&amp;R Loan Agreement contains a Final Fee, which
is equal to <span id="xdx_90C_ecustom--FinalFeePercentage_dp_uPure_c20240530__20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_zCEAWTy4P444" title="Final fee percentage">4.5</span>% of the initial funding of the agreement and is due on the earliest to occur of (a) the Maturity Date, (b) the acceleration
of any Term Loan, and (c) the prepayment of the Term Loans. There is also a contingent non-utilization fee for both the Term D and Term
E loans. If the Company achieves the Term D Milestone and (i) fails to draw the full amount of the Term D Loan during the Term D Draw
Period and (ii) fails to notify Collateral Agent, at any time before the date that is four weeks after the Company&#8217;s achievement
of the Term D Milestone, of the Company&#8217;s intent not to draw the full amount of the Term D Loan, a non-utilization fee of $<span id="xdx_909_ecustom--NonUtilizationFee_iI_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermDLoanMember_ziF0ZP2kePig" title="Non utilization fee">900,000</span>,
with respect to the Term D Loan shall become due and payable on the earliest of (i) the termination of the Term D Draw Period, (ii) the
Maturity Date, (iii) the acceleration of any Term Loan, and (iv) the prepayment in whole of the Term Loans. If the Company achieves the
Term E Milestone and (i) fails to draw the full amount of the Term E Loan during the Term E Draw Period and (ii) fails to notify Collateral
Agent, at any time before the date that is four weeks after the Company&#8217;s achievement of the Term E Milestone, of the Company&#8217;s
intent not to draw the full amount of the Term E Loan, a non-utilization fee of $<span id="xdx_90D_ecustom--NonUtilizationFee_iI_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermELoanMember_z3jgeNPV2N8g" title="Non utilization fee">1,500,000</span>, with respect to the Term E Loan shall become
due and payable on the earliest of (i) the termination of the Term E Draw Period, (ii) the Maturity Date, (iii) the acceleration of any
Term Loan, and (iv) the prepayment in whole of the Term Loans. After the 18-month anniversary of the Effective Date, the Company shall
have the option to prepay all, but not less than all, of the Term Loans advanced by the Lenders under the A&amp;R Loan Agreement, provided
the Company (i) provides written notice to Collateral Agent of its election to prepay the Term Loans at least seven Business Days prior
to such prepayment, and (ii) pays to Lenders on the date of such prepayment, payable to each Lender in accordance with its respective
Pro Rata Share, an amount equal to the sum of (A) all outstanding principal of the Term Loans plus accrued and unpaid interest thereon
through the prepayment date, (B) the Final Fee, (C) the Prepayment Fee, plus (D) all other outstanding Obligations that are due and payable,
including, without limitation, Lenders&#8217; Expenses and interest at the Default Rate with respect to any past due amounts. At May 30,
2024, the Company recognized the Final Fee of $<span id="xdx_90C_ecustom--FinalFee_iI_pn5n6_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_z1eqrYRN6cq7" title="Final fee">4.5</span> million as additional debt principal and a corresponding debt discount to be amortized
over the life of the loan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the funding of each of the Term
C Loan, the Term D Loan, the Term E Loan and the Term F Loan, the Company agreed to issue to Innovatus and Oxford warrants to purchase
that number of shares of the Company&#8217;s common stock equal to <span id="xdx_904_ecustom--WarrantOrRightToPurchasePercentage_iI_dp_uPure_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_zKnFu5iBraW4" title="Warrant or right, reason for issuance, description">2.5</span>% of the principal amount of the applicable Term Loan divided by
the exercise price, which shall, with respect to the Term C Loan, be equal to the lower of (i) the volume weighted average closing price
of the Company&#8217;s common stock for the five-trading day period ending on the last trading day immediately preceding the execution
of the A&amp;R Loan Agreement or (ii) the closing price on the last trading day immediately preceding the execution of the A&amp;R Loan
Agreement. Accordingly, on May 30, 2024, the Company issued <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zql8p3XMfkNb" title="Warrants issued">103,876</span> warrants with an exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zetOICOmbxl6" title="Warrants exercise price per share">14.84</span> per share. The relative
fair value of the warrants was approximately $<span id="xdx_909_eus-gaap--FairValueAdjustmentOfWarrants_pn5n6_c20240530__20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8m7nFWbi5Ol" title="Fair value of warrants">1.2</span> million. For the additional Term Loans, the exercise price will be based on the lower
of (i) the exercise price for the Warrants issued pursuant to the Term C Loan or (ii) the volume weighted average closing price of the
Company&#8217;s common stock for the five-trading day period ending on the last trading day immediately preceding the applicable Term
Loan funding. The Warrants may be exercised on a cashless basis and are exercisable through the tenth anniversary of the applicable funding
date. The number of shares of common stock for which each Warrant is exercisable and the associated exercise price are subject to certain
proportional adjustments as set forth in such Warrant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company evaluated the change of terms under ASC
470-50, &#8220;Debt &#8211; Modification and Extinguishment&#8221;, and concluded the change in terms did not result in significant and
consequential changes to the economic substance of the debt and thus resulted in a modification of the debt and not an extinguishment
of the debt.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p id="xdx_893_eus-gaap--ScheduleOfDebtInstrumentsTextBlock_z4FIW90rHuC5" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">Long-term debt consisted of the following at December 31, 2024 and 2023:</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B0_z8dSaWmxp0n4" style="display: none">Schedule
of Long-term Debt</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 84%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20241231_zKix3ZlY60Vk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20231231_zyyPM9XP68Be" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_maLTNPzDBl_zXqzR6wOdP28" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; text-align: justify">Note payable</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">100,000,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">35,000,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--FinalFee_iI_pp0p0_maLTNPzDBl_zy5rhZjOi9Yc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: 10pt">Add: Final fee</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,500,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1250">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--PaymentInKindInterestDebt_iI_pp0p0_maLTNPzDBl_z4bMaU1j59nf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: 10pt">Add: PIK interest (added to principal)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">593,288</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,565,660</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_pp0p0_di_msLTNPzDBl_zFCkF9UCglm2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: 10pt">Less: unamortized debt issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,613,734</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(480,810</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_pp0p0_di_msLTNPzDBl_zXHN7LV8JQd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt; text-indent: 10pt">Less: unamortized debt discount</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(5,752,418</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(49,439</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--LongTermNotesPayable_iTI_pp0p0_mtLTNPzDBl_zaFsIYSIvzXj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total long-term debt</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">97,727,136</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">37,035,411</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AD_zZXKhh9oIsed" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p id="xdx_89A_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_zouddcjRuUoj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Future principal payments, including the incurred PIK interest and Final
Fee, are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B1_zAZvIQEIocXl" style="display: none">Schedule
of Long Term Debt Future Principal Payments</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20241231_zCLwHSzl0jza" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Years Ending December 31,</td><td style="white-space: nowrap; text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_pp0p0_maLTDz4sG_zqGYNr5TbYpi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 85%; text-align: justify">2027</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">30,615,349</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_pp0p0_maLTDz4sG_zEDf33kGEZCk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">52,483,455</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_iI_pp0p0_maLTDz4sG_z1hIXAWYJFK" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">2029</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">21,994,484</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LongTermDebt_iTI_pp0p0_mtLTDz4sG_zu2R6m7Uw7ol" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">105,093,288</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AE_zvrM2ifobLvf" style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_807_eus-gaap--IncomeTaxDisclosureTextBlock_zVs5ZXjffgLk" style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"> 13. <span id="xdx_829_zCdWARHhC9p1">Income Taxes</span></p>



<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-weight: normal">Following the conversion of Celcuity
LLC to Celcuity Inc. on September 15, 2017, Celcuity Inc. began filing federal and state returns where required. No income tax benefit
was recorded for the years 2024 and 2023, due to net losses and recognition of a valuation allowance. The following table presents a reconciliation
of the tax expense computed at the statutory federal rate and the Company&#8217;s tax expense for the years ended December 31:</span></p>

<p id="xdx_89B_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zB5UX1r18GWb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span><span id="xdx_8B5_zEiyrQ6Thjgj" style="display: none">Schedule of Effective Income Tax Rate Reconciliation</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20240101__20241231_zd3FMT1mNz5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20230101__20231231_z8BoF2S3Hl7i" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBzqmi_zXiOhWKs6Rtj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; text-align: justify">Tax benefit at statutory federal rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(23,474,000</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(13,394,000</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBzqmi_z6hbwe6AMNp6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">State income tax benefit, net of federal tax effect</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(95,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(82,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzqmi_zM6obevT0q2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Change in valuation allowance on deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24,081,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,542,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_iN_di_msITEBzqmi_zww4MI5HDY4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Research &amp; Development Credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,236,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(550,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseOther_maITEBzqmi_zMmUTdfnRDg1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Other permanent items</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">724,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">484,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzqmi_zPQ1UHAjVfC2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: 10pt">Income tax benefits</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1293">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1294">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AC_zx3lRmetW93i" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">Deferred income taxes reflect the net effects of temporary differences
between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.
The Company&#8217;s deferred tax assets relate primarily to its net operating loss carryforwards and other balance sheet basis differences.
In accordance with ASC 740, &#8220;Income Taxes,&#8221; the Company recorded a valuation allowance to fully offset the net deferred tax
asset, because it is more likely than not that the Company will not realize future benefits associated with these deferred tax assets
at December 31, 2024. The tax effects of temporary differences and carryforwards that give rise to significant portions of the deferred
tax assets are at December 31:</p>

<p id="xdx_892_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zxB9MWb50gj5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B5_zbu4fytXjawc" style="display: none">Schedule of Deferred Tax Assets and Liabilities</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 84%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20241231_zvHguWFXE48f" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20231231_zdFXcPVIh0h7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Deferred tax assets (liabilities):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_iI_pp0p0_maDTALNzvdJ_zx0aXuA1qHg4" style="vertical-align: bottom; background-color: White">
    <td style="width: 70%; text-align: justify">Accrued expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">459,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">207,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pp0p0_maDTALNzvdJ_zVFZ3xyBdvE3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,861,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,141,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_pp0p0_maDTALNzvdJ_zTTjiupXCBl3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">420,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">393,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--DeferredTaxAssetsRightofuseAssets_iI_pp0p0_maDTALNzvdJ_zirTF1tRZYJl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(45,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(85,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_ecustom--DeferredTaxAssetsLeaseLiability_iNI_pp0p0_di_msDTALNzvdJ_zqCaJTda7Ey1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">87,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIRC174Expenditures_iI_pp0p0_maDTALNzvdJ_zgCv0dVYT3uc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">IRC 174 Expenditures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,133,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,900,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStartupExpenditures_iI_pp0p0_maDTALNzvdJ_zpUYiefYGzRg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Start-up expenditures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,998,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,029,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_maDTALNzvdJ_z4pNHArrA8fj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Net operating losses and tax credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,340,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,461,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_msDTALNzvdJ_zaxSpx68x7fh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(60,214,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(36,133,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pp0p0_mtDTALNzvdJ_zOBeSGoAa3xf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: 10pt">Net deferred tax assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1325">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1326">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A4_zFiEZ3lOBR6c" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At December 31, 2024, the Company had federal and
state net operating loss carryforwards of approximately $<span id="xdx_909_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_pn5n6_c20241231_zZBpufBRnsbe" title="Federal net operating loss carryforwards">43.2</span> million and $<span id="xdx_907_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_pn5n6_c20241231_zzH4SSSOB6Tf" title="State net operating loss carryforwards">0.8</span> million, respectively. The federal and state net operating
loss carryforwards for 2017 will begin to expire in the year ending December 31, 2037. The federal net operating loss carryforwards starting
in 2018 have no expiration. These deferred tax assets were subject to a full valuation allowance as of December 31, 2024 and December
31, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At December 31, 2024, the Company had federal and
state research and development tax credit carryforwards resulting in deferred tax assets of approximately $<span id="xdx_904_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pn5n6_c20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zd68bjXK0bbh" title="Tax credit carryforwards">2.9</span> million and $<span id="xdx_902_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pn5n6_c20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_z2KWtq0AfJC1" title="Tax credit carryforwards">1.6</span> million,
respectively. The federal and state credit carryforwards will begin to expire in the years ending December 31, 2038 and December 31, 2033,
respectively. These deferred tax assets were subject to a full valuation allowance as of December 31, 2024 and December 31, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under the provisions of Section&#160;382 of the Internal
Revenue Code of 1986, certain substantial changes in the Company&#8217;s ownership, including a sale of the Company, or significant changes
in ownership due to sales of equity, may limit in the future the amount of net operating loss carryforwards available to offset future
taxable income.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognizes uncertain tax positions in
accordance with ASC 740 on the basis of evaluating whether it is more-likely-than not that the tax positions will be sustained upon examination
by tax authorities. For those tax positions that meet the more-likely-than not recognition threshold, we recognize the largest amount
of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement. As of December 31, 2024, and 2023, the Company
has no significant uncertain tax positions. There are no unrecognized tax benefits included on the balance sheet that would, if recognized,
impact the effective tax rate. The Company does not anticipate there will be a significant change in unrecognized tax benefits within
the next 12 months.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Prior to the conversion, Celcuity was a limited liability
company and therefore was taxed as a partnership for income tax purposes. Accordingly, no benefit for income taxes was recorded prior
to the conversion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For years prior to 2021, the Company is no longer
subject to U.S. federal or state income tax examinations and remains open for the unutilized tax attributes as of December 31, 2024, carried
forward from these years. The Company&#8217;s policy is to recognize interest and penalties related to uncertain tax positions as a component
of general and administrative expenses.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Event<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Event</a></td>
<td class="text"><p id="xdx_803_eus-gaap--SubsequentEventsTextBlock_z5nkbanmoN2c" style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">14.
<span id="xdx_82A_zdjZSpiV6W98">Subsequent Event</span></p>



<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2025, the Board of Directors approved a repricing of certain outstanding stock options previously granted to employees. As of
the repricing date, the exercise prices of these options were reduced to $<span id="xdx_90F_eus-gaap--StockOptionExercisePriceDecrease_c20250102__20250131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zEvaBNA3zmjk" title="Exercise price reduced">11.92</span> per share, from their previous exercise prices ranging
from $<span id="xdx_909_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20250102__20250131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zP91PGC6ViA5" title="Exercise price lower">12.80</span> to $<span id="xdx_900_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250102__20250131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z0vWZ92OjNY9" title="Exercise price upper">18.73</span> per share. This adjustment was made in response to the decline in the company&#8217;s stock price, with the intent
of retaining and motivating key employees. As a result of this repricing, approximately <span id="xdx_908_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zF9SiEaWKlWa" title="Stock options held">837,000</span> stock options held by 44 employees were
affected. The repriced options will continue to vest according to their original schedule.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2025, an investor exercised <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20250131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zOjQRy4feQNd" title="Warrants exercised">695,650</span> warrants at an exercise price of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zcWNGZfE8Jg6" title="Warrants exercise price">8.05</span>, which generated approximately $<span id="xdx_909_eus-gaap--ProceedsFromWarrantExercises_pn5n6_c20250102__20250131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zv4arleANkt" title="Proceeds from warrants exercised">5.6</span> million in cash.
The warrants were issued pursuant to a private placement that closed and was funded on December 9, 2022.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p id="xdx_846_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zqle3EpLCqti" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><span style="text-decoration: underline"><span id="xdx_86F_zfvrrS2Urjua">Basis of Presentation</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="background-color: white">The accompanying financial statements
have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;) and pursuant
to the rules and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;). Operating results for the year ended December
31, 2024 are not necessarily indicative of results to be expected for any future year.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Accounting Estimates</a></td>
<td class="text"><p id="xdx_842_eus-gaap--UseOfEstimates_zqYd2kAzJWZ7" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_86E_zTnkypDHItge">Accounting Estimates</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 2.15pt 0 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 2.15pt 0 0">Management uses estimates and assumptions in preparing these
financial statements in accordance with U.S. GAAP. Those estimates and assumptions affect the reported amounts of assets and liabilities,
the disclosure of contingent assets and liabilities, and the reported revenues and expenses. Actual results could differ from those estimates
and the difference could be material. Significant items subject to such estimates and assumptions include the valuation of stock-based
compensation and prepaid or accrued clinical trial costs.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zs41NFVAgjWa" style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="text-decoration: underline"><span id="xdx_862_zBSE7imawy8h">Cash and Cash Equivalents</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 2.15pt 0 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 2.15pt 0 0">The Company maintains its accounts at two financial institutions.
At times throughout the year, the Company&#8217;s cash balances may exceed amounts insured by the Federal Deposit Insurance Corporation.
At December 31, 2024 and December 31, 2023, the Company had $<span id="xdx_90D_eus-gaap--CashFDICInsuredAmount_iI_c20241231_zKYFJ5FLHDC3" title="Cash equivalents FDIC insured, amount">22,514,823</span> and $<span id="xdx_909_eus-gaap--CashFDICInsuredAmount_iI_c20231231_zdbbCz0ZDuN3" title="Cash equivalents FDIC insured, amount">30,662,774</span>, respectively, in business checking accounts and
money market funds that are considered cash equivalents and not insured by the Federal Deposit Insurance Corporation.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--InvestmentPolicyTextBlock_zZcCsrawuJQe" style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="text-decoration: underline"><span id="xdx_86C_zVP5ib2lPBri">Investments</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 2.15pt 0 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 2.15pt 0 0">The Company maintains its investments in U.S. governmental agency
securities and U.S. treasury bills and has classified them as held-to-maturity at the time of purchase. Held-to-maturity purchases are
those securities in which the Company has the ability and intent to hold until maturity. Held-to-maturity securities are recorded at amortized
cost, adjusted for the amortization or accretion of premiums and discounts. Premiums and discounts are amortized or accreted over the
life of the related held-to-maturity security using a straight-line method. The difference between the carrying value, which is based
on cost, and the aggregate fair value of the held-to-maturity securities, was immaterial as of December 31, 2024. At December 31, 2024
and December 31, 2023, the Company had $<span id="xdx_902_eus-gaap--ShortTermInvestments_iI_c20241231_zeScxzKuWOu3" title="Short-term investments">212,588,960</span> and $<span id="xdx_904_eus-gaap--ShortTermInvestments_iI_c20231231_zqV7aaEms22i" title="Short-term investments">149,919,974</span>, respectively, of short-term investments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p id="xdx_84A_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zErkpyNvmfA4" style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="text-decoration: underline"><span id="xdx_869_zcPUi34VFRg">Property and Equipment</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 2.15pt 0 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Property and equipment are stated at cost. Depreciation is provided
over estimated useful lives using the straight-line method. Maintenance and repairs are expensed as incurred; major improvements and betterments
are capitalized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p id="xdx_89B_ecustom--ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock_zbXmEHbRuoxi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Estimated useful lives of property and equipment are as follows for the
major classes of assets:</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.6in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B2_zvVaDreWGHl2" style="display: none">Schedule of Estimated Useful Lives of Property and Equipment</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 84%; margin-right: auto">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">Estimated</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; width: 85%; font-weight: bold; text-align: justify">Asset Description</td><td style="padding-bottom: 1pt; width: 1%; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 14%; font-weight: bold; text-align: center">Lives</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Furniture and Equipment</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_za2Cizkodqzb" title="Estimated useful lives">4</span>-<span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zoToZonzLH2l" title="Estimated useful lives">5</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Leasehold Improvements</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zwNRQRUPKqkj" title="Estimated useful lives">2</span>-<span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zjy5QdetKmE2" title="Estimated useful lives">3</span></td></tr>
  </table>

<p id="xdx_8AB_ziLDoGxeSjz5" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.6in">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Long-Lived Assets</a></td>
<td class="text"><p id="xdx_846_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zUrX149Fdpnj" style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="text-decoration: underline"><span id="xdx_862_zXjBiAbWKt3e">Long-Lived Assets</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">Long-lived assets, such as property and equipment, are reviewed for impairment
whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require
a long-lived asset or asset group be tested for possible impairment, the Company first compares undiscounted cash flows expected to be
generated by that asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group is not recoverable
on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying value exceeds its fair value. Fair value
is determined through various valuation techniques including discounted cash flow models, quoted market values, and third-party independent
appraisals, as considered necessary.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Transaction Costs</a></td>
<td class="text"><p id="xdx_845_eus-gaap--DeferredChargesPolicyTextBlock_zLw1ZX7RHbof" style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="text-decoration: underline"><span id="xdx_861_zc3C9lJETGe7">Deferred Transaction Costs</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">Deferred transaction costs primarily consist of legal fees that are capitalized
as incurred and will be offset against the proceeds from future equity financing arrangements. The deferred transaction costs will be
reviewed periodically to assess the probability that future securities will be offered. In the event that no future offering will occur,
any deferred transaction costs will be expensed. Total costs incurred, but not accounted for as a reduction in equity, were $<span id="xdx_902_eus-gaap--DeferredCostsCurrent_iI_c20241231_znLH97VNiqpa" title="Deferred transaction costs">235,379</span> and
$<span id="xdx_900_eus-gaap--DeferredCostsCurrent_iI_c20231231_zSoIRAfiqV2" title="Deferred transaction costs">0</span> as of December 31, 2024 and 2023, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Debt Issuance Costs</a></td>
<td class="text"><p id="xdx_845_eus-gaap--DebtPolicyTextBlock_zIQrsrmEItuc" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><span style="text-decoration: underline"><span id="xdx_862_zWjiikqHPfM1">Debt Issuance Costs</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">The Company recognizes debt issuance costs as deferred costs, which are
capitalized and amortized over the term of the related debt using the effective interest method. These costs primarily consist of fees,
commissions, legal, and other costs directly attributable to securing debt financing. Debt issuance costs are reported as a direct reduction
of the carrying amount of the related debt on the balance sheets. Amortization of these costs is recorded as interest expense in the statements
of operations over the life of the debt instrument.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><p id="xdx_840_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zFOlTBRBCjeh" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><span style="text-decoration: underline"><span id="xdx_865_zapig2q36X4b">Comprehensive Loss</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">Comprehensive loss includes net loss as well as other changes in stockholders&#8217;
equity that result from transactions and economic events other than those with stockholders. For all periods presented, there was no difference
between net loss and comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Risks and Uncertainties</a></td>
<td class="text"><p id="xdx_846_eus-gaap--ConcentrationRiskCreditRisk_zoGHHydaSJ1g" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><span style="text-decoration: underline"><span id="xdx_860_zimzFr8eXqGb">Risks and Uncertainties</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">The Company is subject to risks common to companies in the development
stage including, but not limited to, dependency on the clinical and commercial success of its initial drug product, gedatolisib, the ability
to obtain regulatory approval for gedatolisib, the need for substantial additional financing to achieve its goals, uncertainty of broad
adoption of its approved products, if any, by physicians and consumers, and significant competition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p id="xdx_840_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zzWZPOiyddAl" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><span style="text-decoration: underline"><span id="xdx_860_zVnMYaSQNEed">Fair Value of Financial Instruments</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 5.75pt 0 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The Company&#8217;s accounting for fair value measurements of
assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring or nonrecurring basis
adheres to the Financial Accounting Standards Board (&#8220;FASB&#8221;) fair value hierarchy that prioritizes the inputs to valuation
techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical
assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level
3 measurements). The three levels of the fair value hierarchy are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 5.85pt 0 41pt; text-indent: -0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.5in; text-align: left">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Level
1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the Company at the measurement
date.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 5.95pt 0 41pt; text-indent: -0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.5in; text-align: left">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Level
2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly,
for substantially the full term of the asset or liability.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 5.8pt 0 41pt; text-indent: -0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.5in; text-align: left">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Level
3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available,
thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date.</span></td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The level in the fair value hierarchy within which a fair value
measurement in its entirety falls, is based on the lowest level input that is significant to the fair value measurement in its entirety.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 5.95pt 0 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The carrying values of cash equivalents, accounts payable, accrued
expenses and other financial working capital items approximate fair value at December 31, 2024 and December 31, 2023, due to the short
maturity nature of these items.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_845_eus-gaap--IncomeTaxPolicyTextBlock_z8vEUxHWNSgh" style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="text-decoration: underline"><span id="xdx_866_zgynWj3fZcYb">Income Taxes</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">The Company accounts for income taxes using the asset and liability method,
as required by the accounting standard for income taxes. Under this method, deferred tax assets and liabilities are recognized for the
future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities
and their respective tax bases, as well as net operating loss and tax credit carryforwards. Deferred taxes are measured using enacted
tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.
The effect on deferred taxes of a change in tax rates is recognized in results of operations in the period that includes the enactment
date. The effects of any future changes in tax laws or rates have not been considered. The Company regularly reviews deferred tax assets
to assess their potential realization and establish a valuation allowance for portions of such assets to reduce the carrying value if
the Company does not consider it to be more likely than not that the deferred tax assets will be realized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">The Company recognizes the impact of an uncertain tax position in its financial
statements if, in management&#8217;s judgment, the position is more-likely-than-not sustainable upon audit based on the position&#8217;s
technical merits. This involves the identification of potential uncertain tax positions, the evaluation of applicable tax laws and an
assessment of whether a liability for an uncertain tax position is necessary.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p id="xdx_847_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zeKwV8b1dP64" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><span style="text-decoration: underline"><span id="xdx_866_zBXECk6Wy7Bj">Stock-Based Compensation</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 2.15pt 0 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 2.15pt 0 0">The Company&#8217;s stock-based compensation consists of stock
options and restricted stock issued to certain employees and non-employees of the Company and the Company&#8217;s 2017 Employee Stock
Purchase Plan. The Company recognizes compensation expense based on an estimated grant date fair value using the Black-Scholes option-pricing
method for equity-based awards and the Monte Carlo simulation model for performance-based awards. If the factors change and different
assumptions are used, the Company&#8217;s stock-based compensation expense could be materially different in the future. The Company recognizes
stock-based compensation expense for these options on a straight-line basis over the requisite service period. The Company has elected
to account for forfeitures as they occur.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><p id="xdx_843_eus-gaap--ResearchAndDevelopmentExpensePolicy_zvGCg70bmtpj" style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="text-decoration: underline"><span id="xdx_864_z3XHAIp3vYBc">Research and Development</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">Research and development costs are expensed as incurred. Research and development
costs amounted to $<span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20241231_zxOzlJ7CAvLe" title="Research and development expense">104,203,230</span> for the year ended December 31, 2024 and $<span id="xdx_900_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231_zck4ehiBYfJ" title="Research and development expense">60,594,005</span> for the year ended December 31, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InProcessResearchAndDevelopmentPolicy', window );">Clinical Trial Costs</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--InProcessResearchAndDevelopmentPolicy_zKtIk5RQdI77" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><span style="text-decoration: underline"><span id="xdx_862_zcho2GdqM904">Clinical Trial Costs</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">The Company relies on third parties to conduct
certain aspects of clinical studies and to formulate and manufacture our drug product. While there are alternative vendors that can
perform these functions, any disruption or delay by the Company&#8217;s current third parties in carrying out their contractual
duties could delay the clinical trials. The Company records prepaid assets or accrued expenses for prepaid or estimated clinical
trial costs conducted by third-party service providers, which includes the conduct of preclinical studies and clinical trials. These
costs can be a significant component of the Company&#8217;s research and development expenses. The Company primarily relies on a
compilation of progress reports from third-party service providers, including the respective invoicing, to record actual expenses,
along with determining changes to prepaid assets and accrued liabilities. To date, the Company believes utilization of third-party
reports most accurately reflects expenses incurred. With the ongoing VIKTORIA-1 Phase 3 trial and the CELC-G-201 Phase 1b/2 trial,
and the commencement of the VIKTORIA-2 Phase 3 clinical trial site activation and patient enrollment anticipated in Q2 2025<span style="font-size: 10pt">,</span>
the Company&#8217;s estimated expenses in future periods and actual services performed may vary from these estimates, and these
estimates may become more significant. Changes in these estimates that result in material changes to the Company&#8217;s prepaid
assets or accrued expenses could materially affect the Company&#8217;s results of operations and financial position.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Data</a></td>
<td class="text"><p id="xdx_841_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zASjcBnZart7" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><span style="text-decoration: underline"><span id="xdx_867_zAWp6ew8cnbi">Segment Data</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">In November 2023, the FASB issued ASU 2023-07: Improvements to Reportable
Segment Disclosures. This ASU, which amends Topic 280: <i>Segment Reporting,</i> improves disclosure requirements for reportable segments
and enhances disclosures for companies with single reportable segments. The Company has a single reportable segment based on the nature
of its operations. The nature of business and the accounting policies of the segment are the same as described throughout Notes 1 and
2. The Company&#8217;s Chief Operating Decision Maker (&#8220;CODM&#8221;) is its executive team. The CODM assesses the reportable segment&#8217;s performance
and allocates resources for the reportable segment based on net income and total assets, which are the same amounts in all material respects
as those reported on the statements of operations and balance sheets. The Company adopted the standard on January 1, 2024. The adoption
did not have a material impact on the Company&#8217;s financial statements.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InProcessResearchAndDevelopmentPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InProcessResearchAndDevelopmentPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 12<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock', window );">Schedule of Estimated Useful Lives of Property and Equipment</a></td>
<td class="text"><p id="xdx_89B_ecustom--ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock_zbXmEHbRuoxi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Estimated useful lives of property and equipment are as follows for the
major classes of assets:</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.6in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B2_zvVaDreWGHl2" style="display: none">Schedule of Estimated Useful Lives of Property and Equipment</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 84%; margin-right: auto">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">Estimated</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; width: 85%; font-weight: bold; text-align: justify">Asset Description</td><td style="padding-bottom: 1pt; width: 1%; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 14%; font-weight: bold; text-align: center">Lives</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Furniture and Equipment</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_za2Cizkodqzb" title="Estimated useful lives">4</span>-<span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zoToZonzLH2l" title="Estimated useful lives">5</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Leasehold Improvements</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zwNRQRUPKqkj" title="Estimated useful lives">2</span>-<span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zjy5QdetKmE2" title="Estimated useful lives">3</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Estimated Useful Lives of Property and Equipment [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potentially-Dilutive Shares Excluded from the Diluted Weighted-Average Shares Outstanding</a></td>
<td class="text"><p id="xdx_895_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zCuI9maWij26" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes the potentially-dilutive shares excluded
from the diluted weighted-average shares outstanding:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B2_zsg6iauW7oD" style="display: none">Schedule of Potentially-Dilutive Shares Excluded from the Diluted Weighted-Average Shares Outstanding</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20240101__20241231_zofYC9DpIg31" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20230101__20231231_zPlGbIJe3Srk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--EarningsPerShareDilutedOtherDisclosuresAbstract_iB_zK5U31WUGCoh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Potentially-dilutive shares excluded from diluted weighted-average shares outstanding:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--StatementEquityComponentsAxis__custom--PreferredStockOnAnAsIfConvertedToCommonStockMember_zfg4f3aaJtE8" style="vertical-align: bottom; background-color: White">
    <td style="width: 68%; text-align: justify; text-indent: 0pt; padding-left: 20pt">Preferred stock on an as-if-converted to common stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">3,175,770</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">8,541,340</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsToPurchaseCommonStockMember_zvdpJd90xmai" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: 0pt; padding-left: 20pt">Options to purchase common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,306,977</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,815,392</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseCommonStockMember_zJErXOX8mBe3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: 0pt; padding-left: 20pt">Warrants to purchase common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,521,152</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,263,733</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_zQ1WuGg1Brne" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 0pt; text-indent: 0pt; padding-left: 20pt">Restricted common stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,079</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,958</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zxL8MHByRdU7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 0pt; text-indent: 0pt; padding-left: 10pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">13,004,978</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">18,622,423</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_z2UeiMuqyUJd" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 0pt; text-indent: 0pt; padding-left: 10pt">Anti-dilutive securities excluded from
    diluted weighted- average shares outstanding</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">13,004,978</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">18,622,423</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTableTextBlock', window );">Schedule of Investment</a></td>
<td class="text"><p id="xdx_89F_eus-gaap--InvestmentTableTextBlock_zCCqsRWlGsz4" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">The following table summarizes the Company&#8217;s held-to-maturity investment
securities at amortized cost as of December 31, 2024 and 2023:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B1_zjh6YZbQciIj" style="display: none">Schedule of Investment</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_48F_eus-gaap--HeldToMaturitySecurities_iI_zY95Wjuj9ZT9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amortized Cost, as Adjusted</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_489_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_iI_zDtVvdKS6E7j" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Gross Unrealized Holding Gains</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_48C_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_iI_zzFiqM32a51g" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Gross Unrealized Holding Losses</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_482_eus-gaap--HeldToMaturitySecuritiesFairValue_iI_zzI3b8XK0XTj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Estimated Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amortized Cost, as Adjusted</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Gross Unrealized Holding Gains</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Gross Unrealized Holding Losses</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Estimated Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_412_20241231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zLcyrLP42a6c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: justify; padding-bottom: 1pt; text-indent: 0pt">U.S. Treasury Bills</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">212,588,960</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">82,251</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0659">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">212,671,211</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_41D_20241231_zYVPzrbFP6sh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: 0pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">212,588,960</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">82,251</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0663">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">212,671,211</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_48F_eus-gaap--HeldToMaturitySecurities_iI_zQN0gpxq8gjk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amortized Cost, as Adjusted</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_48D_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_iI_zmcNOsJuEX0d" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Gross Unrealized Holding Gains</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_489_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_iI_zoua8HzmLeGd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Gross Unrealized Holding Losses</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_487_eus-gaap--HeldToMaturitySecuritiesFairValue_iI_zeXoWJsBIjm6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Estimated Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amortized Cost, as Adjusted</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Gross Unrealized Holding Gains</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Gross Unrealized Holding Losses</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Estimated Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_41D_20231231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zSaeWsAUrXNe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: justify; padding-bottom: 1pt; text-indent: 0pt">U.S. Treasury Bills</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">149,919,974</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">30,995</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0667">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">149,950,969</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_419_20231231_zbU8GJk04tyf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: 0pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">149,919,974</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">30,995</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0671">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">149,950,969</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 321<br> -Publisher FASB<br> -URI https://asc.fasb.org/321/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 325<br> -Publisher FASB<br> -URI https://asc.fasb.org/325/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock', window );">Schedule of Other Current Assets</a></td>
<td class="text"><p id="xdx_894_eus-gaap--ScheduleOfOtherCurrentAssetsTableTextBlock_zL9Ky7RnXgpg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other current assets consisted of the following at
December 31:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B4_z25EpmOVAL45" style="display: none">Schedule of Other Current Assets</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20241231_zVoI33oyf2Qc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20231231_zzvMBVr3J0x9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PrepaidExpenseAndOtherAssetsCurrentAbstract_iB_zLjAY6e2KQIa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Current:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--PrepaidClinicalTrialCosts_iI_maOACz5EC_maOACzcDD_zrZR1MIwztZ7" style="vertical-align: bottom; background-color: White">
    <td style="width: 70%; text-align: justify">Prepaid clinical trial costs</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">6,768,668</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">8,763,150</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--MiscellaneousReceivable_iI_maOACz5EC_maOACzcDD_zgMqnqJOdguc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Miscellaneous receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,600,621</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">805,882</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--PrepaidInsurance_iI_maOACz5EC_maOACzcDD_ziST3dg7Mh91" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Directors &amp; officers&#8217; insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">256,629</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">157,453</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OtherPrepaidExpenseCurrent_iI_maOACz5EC_maOACzcDD_zCAHir9ln44e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">841,329</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">281,364</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OtherAssetsCurrent_iTI_mtOACz5EC_mtOACzcDD_zg52Bfkt2t9a" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: 10pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,467,247</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,007,849</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of Property and Equipment</a></td>
<td class="text"><p id="xdx_895_eus-gaap--PropertyPlantAndEquipmentTextBlock_zjOntXtkfmah" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Property and equipment consisted of the following
at December 31:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B2_zbRUXA1exdqi" style="display: none">Summary of Property and Equipment</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20241231_zWj4eYpg8fQg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20231231_zrJj7qrX1pE3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zQPkm78BcDr" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; text-align: justify">Furniture and equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,025,875</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1,788,195</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zfceKsZ0katd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Leasehold improvements</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">302,577</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">302,577</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzGp4_zUcwYof0nbwg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment, Gross</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,328,452</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,090,772</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzGp4_zxNtpWD73oi5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Less: Accumulated depreciation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,991,937</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,861,990</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzGp4_zSksBfWIeGEh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: 10pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">336,515</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">228,782</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><p id="xdx_896_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zErn4kMaNMrd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Accrued expenses consisted of the following at December
31:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B9_zyjmZEJcNGpa" style="display: none">Schedule of Accrued Expenses</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20241231_zl2ZIfBfvp8h" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20231231_zh5dZYKsqVf3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--AccruedClinicalTrialExpense_iI_maALCzp59_z7oRfzlBSGBa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; text-align: justify">Clinical trial costs</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">16,708,499</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">6,464,772</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--WorkersCompensationLiabilityCurrent_iI_maALCzp59_zkOBO8hhZ2P4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Accrued compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,987,786</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,763,316</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OtherAccruedLiabilitiesCurrentAndNoncurrent_iI_maALCzp59_z0cp9ECn6pQ2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,384,803</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">641,512</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AccruedEmployeeBenefitsCurrent_iI_maALCzp59_zb9wHpWbxTpj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Employee stock purchase plan</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">103,860</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">57,494</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCzp59_zHV3x8o5H9pg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: 10pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">22,184,948</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8,927,094</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfCondensedBalanceSheetTableTextBlock', window );">Schedule of Supplemental Balance Sheet Information Related to Leases</a></td>
<td class="text"><p id="xdx_895_esrt--ScheduleOfCondensedBalanceSheetTableTextBlock_zuQPu1QXBhwi" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">Supplemental balance sheet information consisted of the following at December
31, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BE_zw3HBbzqg8w2" style="display: none">Schedule of Supplemental Balance Sheet Information Related to Leases</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" id="xdx_494_20241231_zT5RGc8NWm4i" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseDescriptionAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Operating Lease</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_zYQVceoYWCU9" style="vertical-align: bottom; background-color: White">
    <td style="width: 85%; text-align: justify; text-indent: 10pt">Right-of-use assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">215,502</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLeaseLiability_iI_pp0p0_zqUIZyHNsvma" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Operating lease liability</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">225,921</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_pp0p0_di_z5q7RAlD6Jv6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt; text-indent: 10pt">Less: short term portion</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(171,952</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: 10pt">Long term portion</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">53,969</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturity Analysis Under Lease Agreements</a></td>
<td class="text"><p id="xdx_890_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zzBGTQLd23i6" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">Maturity analysis under lease agreements consisted of the following as
of December 31, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B6_zXuYNHI4W3Af" style="display: none">Schedule of Maturity Analysis Under Lease Agreements</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20241231_zDYLnRejo5O3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Operating Leases</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzXrd_zrlJrxLp6Y" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 85%; text-align: justify">2025</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">220,389</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzXrd_zVnagI2JM905" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">2026</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">74,170</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzXrd_zobhmhwBJj9g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt; text-indent: 10pt">Total minimum lease payments</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">294,559</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zuqyqXxybD88" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt; text-indent: 10pt">Less: Present value discount</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(68,638</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingLeaseLiability_iI_zEXjJaN3t6Nh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: 10pt">Present value of net minimum lease payments</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">225,921</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: left">Weighted Average</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Remaining Lease Term</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Discount Rate</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 70%; text-align: justify">Operating lease</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;<span id="xdx_903_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20241231_zXNR8NJKHJM2" title="Operating leases, remaining lease term">1.3</span> years</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20241231_zYOM30IiwEf6" title="Operating leases, discount rate">10.5</span></td><td style="width: 1%; text-align: left">%</td></tr>
</table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Lease Costs</a></td>
<td class="text"><p id="xdx_89C_eus-gaap--LeaseCostTableTextBlock_zQqx8BBfFLxi" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Lease costs for the period ended December 31:</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>



<p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BE_ztIUpipt8P0d" style="display: none">Schedule of Lease Costs</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt; width: 70%">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left; width: 1%">&#160;</td><td id="xdx_498_20240101__20241231_z69Lp53vEyD4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; width: 12%">2024</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left; width: 1%">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left; width: 1%">&#160;</td><td id="xdx_49A_20230101__20231231_zXZfNMCMdLtg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; width: 12%">2023</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left; width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeaseCost_maLCzXSJ_maLCzphc_zWFKr6cRbmY7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: 10pt">Operating lease cost</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">213,104</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">212,238</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--FinanceLeaseCostAbstract_iB_zAH1tDujDzwa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: 10pt">Finance lease cost:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_i01_pp0p0_maLCzXSJ_maLCzphc_z20xoyVtRiyd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify; text-indent: 10pt">Amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0776">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,411</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--FinanceLeaseInterestExpense_i01_pp0p0_maLCzXSJ_maLCzphc_zmNVG91Je0i9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: justify; text-indent: 10pt">Interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0779">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--VariableLeaseCost_pp0p0_maLCzXSJ_maLCzphc_zPL8DHsVukc2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt; text-indent: 10pt">Variable lease cost</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">111,246</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">101,957</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--LeaseCost_iT_pp0p0_mtLCzphc_z3QzfXkEUPq4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif">Lease costs</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">324,350</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">316,610</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Schedule of Supplemental Cash Flow Information Related to Leases</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_zB9UJmmc6PJc" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Supplemental cash flow information related to leases for the period ended December 31:</p>



<p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B8_zV76IQ6kDx15" style="display: none">Schedule of Supplemental Cash Flow Information Related to Leases</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20240101__20241231_zacNrvbFYyT" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20230101__20231231_zxZ1MztQsrH5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--CashPaidForOperatingAndFinanceLeasesAbstract_iB_z3T0lMG9DfWk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Cash paid for amounts included in operating and finance leases:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeasePayments_i01_pp0p0_maCPFOAzLxF_zT8id1pwmdac" style="vertical-align: bottom; background-color: White">
    <td style="width: 70%; text-align: justify; text-indent: 10pt">Operating cash outflow from operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">324,783</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">308,914</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--FinanceLeaseInterestPaymentOnLiability_i01_pp0p0_maCPFOAzLxF_zDLaW6oH5lYg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: 10pt">Operating cash outflow from finance leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0796">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--FinanceLeasePrincipalPayments_i01_pp0p0_maCPFOAzLxF_zhJwihAQWkdi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt; text-indent: 10pt">Financing cash outflow from finance leases</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0799">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,449</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--CashPaidForOperatingAndFinanceLeases_i01T_pp0p0_mtCPFOAzLxF_zodVNHNWeyx3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total cash paid for amounts
    included in operating and finance leases</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">324,783</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">311,367</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfCondensedBalanceSheetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 04<br> -Paragraph a<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfCondensedBalanceSheetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Warrants</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zsto21sRl4t3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BE_z2rn7RsYGXm4" style="display: none">Schedule of Warrants</span></span></b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>At December 31, 2024:</b></p></td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Issue Date</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Expiration <br/>
Date</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"># of Warrants <br/>
Outstanding</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise <br/>
Price</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Offering</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 14%; text-align: justify"><span id="xdx_90F_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantOneMember_zzy3QVehUMPk" title="Issue Date">1/21/2016</span></td><td style="width: 1%">&#160;</td>
    <td style="width: 12%; text-align: justify"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantOneMember_zm3MP6vzpn65" title="Expiration Date">1/14/2026</span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantOneMember_zbQLB19xUdXe" style="width: 12%; text-align: right" title="Number of Warrants Outstanding">33,719</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantOneMember_zRbGEXr1AZl4" style="width: 12%; text-align: right" title="Exercise Price">7.56</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 42%; text-align: justify"><span id="xdx_905_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantOneMember_zUP5W0NkT54d" title="Offering">private placement offering - issued to placement agent</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span id="xdx_909_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTwoMember_z1ejCN8TQZCl" title="Issue Date">5/2/2016</span></td><td>&#160;</td>
    <td style="text-align: justify"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTwoMember_zK2dMnFBPlWe" title="Expiration Date">5/2/2026</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTwoMember_zcrZXcNI65sg" style="text-align: right" title="Number of Warrants Outstanding">21,530</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTwoMember_zbZhsymVAKHh" style="text-align: right" title="Exercise Price">7.56</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTwoMember_zaMNtZcQeDf7" title="Offering">private placement offering - issued to placement agent</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span id="xdx_902_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantThreeMember_zpzw3gFg5DZd" title="Issue Date">4/28/2017</span></td><td>&#160;</td>
    <td style="text-align: justify"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantThreeMember_zNzbIHPWCVg7" title="Expiration Date">4/28/2027</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantThreeMember_zLssEEQmrMab" style="text-align: right" title="Number of Warrants Outstanding">33,250</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantThreeMember_zMkDOC743szj" style="text-align: right" title="Exercise Price">8.42</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify"><span id="xdx_901_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantThreeMember_zpmhmG59Rpw" title="Offering">private placement offering - issued to placement agent</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span id="xdx_909_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFourMember_zalzNQqwbrFg" title="Issue Date">5/17/2017</span></td><td>&#160;</td>
    <td style="text-align: justify"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFourMember_zAC3xvDT3uBh" title="Expiration Date">5/17/2027</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFourMember_zEOCCLNsGUaj" style="text-align: right" title="Number of Warrants Outstanding">15,365</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFourMember_zWOlYvSBfhO1" style="text-align: right" title="Exercise Price">8.42</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify"><span id="xdx_906_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFourMember_zrnfbCEu7dgl" title="Offering">private placement offering - issued to placement agent</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span id="xdx_90A_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFiveMember_zQhAPm6hIohg" title="Issue Date">9/22/2017</span></td><td>&#160;</td>
    <td style="text-align: justify"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFiveMember_zNI3eGRxNbO3" title="Expiration Date">9/19/2025</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFiveMember_z5ZtsHEZfpGh" style="text-align: right" title="Number of Warrants Outstanding">70,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFiveMember_zTABzIthnJkc" style="text-align: right" title="Exercise Price">10.45</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify"><span id="xdx_909_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFiveMember_zBu5zK2pk5v2" title="Offering">IPO - issued to underwriter</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span id="xdx_90F_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSixMember_zdKdLvwXNT5j" title="Issue Date">4/8/2021</span></td><td>&#160;</td>
    <td style="text-align: justify"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSixMember_zNZWWRgIdd82" title="Expiration Date">4/8/2031</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSixMember_z3G9nwBSAyp3" style="text-align: right" title="Number of Warrants Outstanding">26,042</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSixMember_zGWjh2pO9xnc" style="text-align: right" title="Exercise Price">14.40</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify"><span id="xdx_901_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSixMember_zZ1HBufNeQwg" title="Offering">debt financing - issued to lender</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span id="xdx_90D_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSevenMember_zJK8FAIwIrY6" title="Issue Date">5/30/2024</span></td><td>&#160;</td>
    <td style="text-align: justify"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSevenMember_zbQ5vZeVB7Wf" title="Expiration Date">5/30/2034</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSevenMember_z0LFPrsZBT1g" style="text-align: right" title="Number of Warrants Outstanding">84,227</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSevenMember_zf0PaICGlbRj" style="text-align: right" title="Exercise Price">14.84</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSevenMember_zblij2Twobbj" title="Offering">debt financing &#8211; issued to lender</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span id="xdx_90A_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantEightMember_zic20g9rc1ql" title="Issue Date">5/30/2024</span></td><td>&#160;</td>
    <td style="text-align: justify"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantEightMember_z7Sv8tviQRx6" title="Expiration Date">5/30/2034</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantEightMember_zFTIPLLSQhH" style="text-align: right" title="Number of Warrants Outstanding">19,649</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantEightMember_zZi0ytehV8Ya" style="text-align: right" title="Exercise Price">14.84</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify"><span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantEightMember_zYLtdPeigg8j" title="Offering">debt financing &#8211; issued to lender</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span id="xdx_90F_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantNineMember_zNmKUWPO56H8" title="Issue Date">12/9/2022</span></td><td>&#160;</td>
    <td style="text-align: justify">see below</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantNineMember_zXGAEV0ZyuAf" style="text-align: right" title="Number of Warrants Outstanding">5,217,370</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantNineMember_zev3Pr9tOfF7" style="text-align: right" title="Exercise Price">8.05</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantNineMember_zsYj2m7PJUt3" title="Offering">securities purchase agreement - issued to institutional and other accredited investors</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt"><span id="xdx_905_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTenMember_zQ2aRRiyhzKh" title="Issue Date">10/18/2023</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: justify; padding-bottom: 1pt">see above</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTenMember_zIHxFG7oVpml" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants Outstanding">5,747,787</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTenMember_z48GIU4yN60b" style="padding-bottom: 1pt; text-align: right" title="Exercise Price">0.001</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: justify; padding-bottom: 1pt"><span id="xdx_908_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTenMember_zbmOZ3d2wQE2" title="Offering">private placement offering - issued to investors</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Total Warrants Outstanding</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231_zOC3YLP8ubx8" style="font-weight: bold; text-align: right" title="Number of Warrants Outstanding">11,268,939</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Options Activity</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zOSgvTIVLrI" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">The following table summarizes the activity for all stock options outstanding
for the years ended December 31:</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B6_zl6OpamZLCef" style="display: none">Schedule of Stock Options Activity</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: justify">Options outstanding at beginning of year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zSPYsmp3gBwc" style="width: 12%; text-align: right" title="Options outstanding at beginning of year">2,815,392</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zmesmf88ipEf" style="width: 12%; text-align: right" title="Options outstanding, weighted average exercise price at beginning of year">7.95</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zmfBnJOTCI6a" style="width: 12%; text-align: right" title="Options outstanding at beginning of year">1,976,586</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zCBET0BdBjxa" style="width: 12%; text-align: right" title="Options outstanding, weighted average exercise price at beginning of year">6.34</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: justify">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_z9St0zHMEwu1" style="text-align: right" title="Shares, Granted">1,716,729</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zGD33vgHmzEg" style="text-align: right" title="Weighted Average Exercise Price, Granted">16.14</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zfISnnkWBnl1" style="text-align: right" title="Shares, Granted">1,003,298</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zjbip3FB4WRk" style="text-align: right" title="Weighted Average Exercise Price, Granted">10.69</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zHJlvZJj8Zm5" style="text-align: right" title="Shares, Exercised">(103,245</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zDuKZUDpU8J4" style="text-align: right" title="Weighted Average Exercise Price, Exercised">7.45</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_ze5YikrvvFd2" style="text-align: right" title="Shares, Exercised">(98,695</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zpugTMFU0Hn7" style="text-align: right" title="Weighted Average Exercise Price, Exercised">3.94</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: justify; padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zBIb2UJGk9f3" style="border-bottom: Black 1pt solid; text-align: right" title="Shares, Forfeited">(121,899</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zUV6nYVTuh13" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise, Forfeited">11.57</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zSbSduUjp7d7" style="border-bottom: Black 1pt solid; text-align: right" title="Shares, Forfeited">(65,797</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zxA7HOqB6AK4" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise, Forfeited">7.45</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify; padding-bottom: 1pt">Balance at December 31:</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_z9AKSp0QPPxe" style="border-bottom: Black 1pt solid; text-align: right" title="Options outstanding at end of year">4,306,977</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zrGgSswWkEri" style="border-bottom: Black 1pt solid; text-align: right" title="Options outstanding, weighted average exercise price at end of year">11.13</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zruFBhv5jPE2" style="border-bottom: Black 1pt solid; text-align: right" title="Options outstanding at end of year">2,815,392</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zLTfuTkJ2kz9" style="border-bottom: Black 1pt solid; text-align: right" title="Options outstanding, weighted average exercise price at end of year">7.95</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Options exercisable at December 31:</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zPa7Q8m6DZj" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares, options exercisable">2,011,474</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zTG5EMBmFq7i" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price, Options exercisable">7.35</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zOW35pU1Ftd1" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares, options exercisable">1,524,731</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_z3k2bDel1Ute" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price, Options exercisable">6.44</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Weighted Average Grant Date Fair Value for options granted during the year:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zkqfx8wCiia5" style="text-align: right" title="Weighted Average Grant Date Fair Value for options granted during the period">11.22</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zIgbZ80Sv321" style="text-align: right" title="Weighted Average Grant Date Fair Value for options granted during the period">7.48</td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock', window );">Schedule of Stock Options Outstanding and Exercisable</a></td>
<td class="text"><p id="xdx_89C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_z03Q5zIYvzg7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><span style="font-weight: normal">The
following table summarizes additional information about stock options outstanding and exercisable at December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><span style="font-weight: normal">&#160;&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BE_zbSIJPkNPEXi" style="display: none">Schedule
of Stock Options Outstanding and Exercisable</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options Outstanding</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options Exercisable</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options Outstanding</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options Exercisable</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zpuOPQ73lAua" style="width: 12%; text-align: right" title="Options outstanding">4,306,977</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zlB135Ixbs0g" title="Options outstanding, weighted average remaining contractual life">7.96</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z6s9z4Tfe23g" style="width: 12%; text-align: right" title="Options outstanding, weighted average exercise price">11.13</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pp0p0_c20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zaI6V7rIDWik" style="width: 12%; text-align: right" title="Options outstanding, aggregate intrinsic value">13,914,458</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zNs1vu03paZi" style="width: 12%; text-align: right" title="Options exercisable">2,011,474</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zYO9GUIJqj6l" style="width: 12%; text-align: right" title="Options exercisable, weighted average exercise price">7.35</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4NHWs1M5Klb" style="width: 12%; text-align: right" title="Options exercisable, aggregate intrinsic value">11,781,660</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions for Fair Value of Equity-based Awards</a></td>
<td class="text"><p id="xdx_894_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zi73cEuSmWcd" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 4.9pt 0 0">The Black-Scholes option-pricing model was used to estimate the
fair value of equity-based awards and the Monte Carlo simulation model was used to estimate the fair value of the performance-based awards,
with the following weighted-average assumptions for the years ended December 31:</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 4.9pt 0 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BD_zHcfdfNr9DFl" style="display: none">Schedule
of Assumptions for Fair Value of Equity-based Awards</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 84%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Risk-free interest rate</td><td>&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20240101__20241231_z1XNMJkdpoic" title="Risk-free interest rate, minimum">3.48</span>% - <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20240101__20241231_zhikFLceRTj2" title="Risk-free interest rate, maximum">4.71</span>%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20230101__20231231_zoSbEHdl2yq3" title="Risk-free interest rate, minimum">3.41</span>% - <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20230101__20231231_zoIxufmX3D6j" title="Risk-free interest rate, maximum">4.86</span>%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Expected volatility</td><td>&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right">&#160;<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20240101__20241231_zuYuGglRn2gd" title="Expected volatility, minimum">71.2</span>% - <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20240101__20241231_zan1YJLKGjMl" title="Expected volatility, maximum">76.20</span>%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20230101__20231231_zTjU6ctWXmQh" title="Expected volatility, minimum">77.1</span>% - <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20230101__20231231_zNAdQkiZXBB2" title="Expected volatility, maximum">79.8</span>%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Expected life (years)</td><td>&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_ztcUXQwc3aKf" title="Expected life (years)">5.25</span> to <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_zLukX40oGYQi" title="Expected life (years)">10.00</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_ztrk0FdUILQj" title="Expected life (years)">5.25</span> to <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_zH5GuzyAtgvh" title="Expected life (years)">6.08</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 70%; text-align: justify">Expected dividend yield</td><td style="width: 1%">&#160;</td>
    <td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20241231_z6k1cfE1V3Ql" style="white-space: nowrap; width: 12%; text-align: right" title="Expected dividend yield">0</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20231231_ztVVj0EN6zzc" style="white-space: nowrap; width: 12%; text-align: right" title="Expected dividend yield">0</td><td style="width: 1%; text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock', window );">Schedule of Unrecognized Compensation Cost</a></td>
<td class="text"><p id="xdx_89C_eus-gaap--ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_zFlXY2ZIJtIf" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">Total unrecognized compensation cost related to stock options and restricted
stock is estimated to be recognized at December 31:</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BF_zruehIE5AH0e" style="display: none">Schedule
of Unrecognized Compensation Cost</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_497_20241231_zDiqDKG6Yend" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td></tr>
<tr id="xdx_40D_ecustom--EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostToBeRecognizedNextTwelveMonths_iI_pp0p0_maESSBCzuFt_zL2GOdxD4VQ1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 85%; text-align: justify">2025</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">7,776,307</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostToBeRecognizedWithinTwoYear_iI_pp0p0_maESSBCzuFt_zcDSPaQcZ7Vf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,307,024</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostToBeRecognizedwithinThreeYears_iI_pp0p0_maESSBCzuFt_zUon9dbpcGAk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,165,880</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostToBeRecognizedWithinFourYears_iI_pp0p0_maESSBCzuFt_zShnqUzpWSag" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">2028</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,964,136</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostToBeRecognized_iTI_pp0p0_mtESSBCzuFt_zFTAbaTPyOAj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt; text-indent: 10.05pt">Total estimated compensation cost to be recognized</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">21,213,347</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-based Compensation Expenses</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zqjQEPVij6Hl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognized total stock-based compensation
expense as follows for the years ended December 31:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BC_zjAZERWI5os" style="display: none">Schedule
of Stock-based Compensation Expenses</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20240101__20241231_z4pmCOqoASr7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20230101__20231231_zIZEONn9stw4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Years Ended</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31:</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Stock-based compensation expense in operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zE5iyqF5CJ8l" style="vertical-align: bottom; background-color: White">
    <td style="width: 70%; text-align: justify; text-indent: 10pt">Research and development</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">4,404,518</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,700,318</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zGtGu59uNYjh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt; text-indent: 10pt">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,583,823</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,201,116</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ShareBasedCompensation_zQia2ur1xLX7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: 10pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,988,341</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,901,434</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ShareBasedCompensation_zcZVzUBneNid" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: 10pt">Stock-based compensation expense</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,988,341</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,901,434</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost not yet recognized and weighted-average period over which cost is expected to be recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (i)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding and exercisable options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Long-term Debt</a></td>
<td class="text"><p id="xdx_893_eus-gaap--ScheduleOfDebtInstrumentsTextBlock_z4FIW90rHuC5" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">Long-term debt consisted of the following at December 31, 2024 and 2023:</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B0_z8dSaWmxp0n4" style="display: none">Schedule
of Long-term Debt</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 84%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20241231_zKix3ZlY60Vk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20231231_zyyPM9XP68Be" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_maLTNPzDBl_zXqzR6wOdP28" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; text-align: justify">Note payable</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">100,000,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">35,000,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--FinalFee_iI_pp0p0_maLTNPzDBl_zy5rhZjOi9Yc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: 10pt">Add: Final fee</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,500,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1250">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--PaymentInKindInterestDebt_iI_pp0p0_maLTNPzDBl_z4bMaU1j59nf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: 10pt">Add: PIK interest (added to principal)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">593,288</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,565,660</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_pp0p0_di_msLTNPzDBl_zFCkF9UCglm2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: 10pt">Less: unamortized debt issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,613,734</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(480,810</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_pp0p0_di_msLTNPzDBl_zXHN7LV8JQd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt; text-indent: 10pt">Less: unamortized debt discount</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(5,752,418</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(49,439</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--LongTermNotesPayable_iTI_pp0p0_mtLTNPzDBl_zaFsIYSIvzXj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total long-term debt</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">97,727,136</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">37,035,411</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Long Term Debt Future Principal Payments</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_zouddcjRuUoj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Future principal payments, including the incurred PIK interest and Final
Fee, are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B1_zAZvIQEIocXl" style="display: none">Schedule
of Long Term Debt Future Principal Payments</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20241231_zCLwHSzl0jza" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Years Ending December 31,</td><td style="white-space: nowrap; text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_pp0p0_maLTDz4sG_zqGYNr5TbYpi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 85%; text-align: justify">2027</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">30,615,349</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_pp0p0_maLTDz4sG_zEDf33kGEZCk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">52,483,455</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_iI_pp0p0_maLTDz4sG_z1hIXAWYJFK" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">2029</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">21,994,484</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LongTermDebt_iTI_pp0p0_mtLTDz4sG_zu2R6m7Uw7ol" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">105,093,288</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-8<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zB5UX1r18GWb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span><span id="xdx_8B5_zEiyrQ6Thjgj" style="display: none">Schedule of Effective Income Tax Rate Reconciliation</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20240101__20241231_zd3FMT1mNz5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20230101__20231231_z8BoF2S3Hl7i" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBzqmi_zXiOhWKs6Rtj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; text-align: justify">Tax benefit at statutory federal rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(23,474,000</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(13,394,000</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBzqmi_z6hbwe6AMNp6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">State income tax benefit, net of federal tax effect</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(95,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(82,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzqmi_zM6obevT0q2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Change in valuation allowance on deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24,081,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,542,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_iN_di_msITEBzqmi_zww4MI5HDY4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Research &amp; Development Credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,236,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(550,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseOther_maITEBzqmi_zMmUTdfnRDg1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Other permanent items</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">724,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">484,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzqmi_zPQ1UHAjVfC2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: 10pt">Income tax benefits</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1293">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1294">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><p id="xdx_892_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zxB9MWb50gj5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B5_zbu4fytXjawc" style="display: none">Schedule of Deferred Tax Assets and Liabilities</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 84%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20241231_zvHguWFXE48f" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20231231_zdFXcPVIh0h7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Deferred tax assets (liabilities):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_iI_pp0p0_maDTALNzvdJ_zx0aXuA1qHg4" style="vertical-align: bottom; background-color: White">
    <td style="width: 70%; text-align: justify">Accrued expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">459,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">207,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pp0p0_maDTALNzvdJ_zVFZ3xyBdvE3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,861,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,141,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_pp0p0_maDTALNzvdJ_zTTjiupXCBl3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">420,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">393,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--DeferredTaxAssetsRightofuseAssets_iI_pp0p0_maDTALNzvdJ_zirTF1tRZYJl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(45,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(85,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_ecustom--DeferredTaxAssetsLeaseLiability_iNI_pp0p0_di_msDTALNzvdJ_zqCaJTda7Ey1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">87,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIRC174Expenditures_iI_pp0p0_maDTALNzvdJ_zgCv0dVYT3uc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">IRC 174 Expenditures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,133,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,900,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStartupExpenditures_iI_pp0p0_maDTALNzvdJ_zpUYiefYGzRg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Start-up expenditures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,998,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,029,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_maDTALNzvdJ_z4pNHArrA8fj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Net operating losses and tax credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,340,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,461,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_msDTALNzvdJ_zaxSpx68x7fh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(60,214,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(36,133,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pp0p0_mtDTALNzvdJ_zOBeSGoAa3xf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: 10pt">Net deferred tax assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1325">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1326">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Estimated Useful Lives of Property and Equipment (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Cash equivalents FDIC insured, amount</a></td>
<td class="nump">$ 22,514,823<span></span>
</td>
<td class="nump">$ 30,662,774<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">212,588,960<span></span>
</td>
<td class="nump">149,919,974<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCurrent', window );">Deferred transaction costs</a></td>
<td class="nump">235,379<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">$ 104,203,230<span></span>
</td>
<td class="nump">$ 60,594,005<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Liquidity (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 22,514,823<span></span>
</td>
<td class="nump">$ 30,662,774<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">$ 212,588,960<span></span>
</td>
<td class="nump">$ 149,919,974<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Potentially-Dilutive Shares Excluded from the Diluted Weighted-Average Shares Outstanding (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract', window );"><strong>Potentially-dilutive shares excluded from diluted weighted-average shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from diluted weighted- average shares outstanding</a></td>
<td class="nump">13,004,978<span></span>
</td>
<td class="nump">18,622,423<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=CELC_OptionsToPurchaseCommonStockMember', window );">Options to Purchase Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract', window );"><strong>Potentially-dilutive shares excluded from diluted weighted-average shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from diluted weighted- average shares outstanding</a></td>
<td class="nump">4,306,977<span></span>
</td>
<td class="nump">2,815,392<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=CELC_WarrantsToPurchaseCommonStockMember', window );">Warrants to Purchase Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract', window );"><strong>Potentially-dilutive shares excluded from diluted weighted-average shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from diluted weighted- average shares outstanding</a></td>
<td class="nump">5,521,152<span></span>
</td>
<td class="nump">7,263,733<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract', window );"><strong>Potentially-dilutive shares excluded from diluted weighted-average shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from diluted weighted- average shares outstanding</a></td>
<td class="nump">1,079<span></span>
</td>
<td class="nump">1,958<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=CELC_PreferredStockOnAnAsIfConvertedToCommonStockMember', window );">Preferred Stock on an as-if-converted to Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract', window );"><strong>Potentially-dilutive shares excluded from diluted weighted-average shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from diluted weighted- average shares outstanding</a></td>
<td class="nump">3,175,770<span></span>
</td>
<td class="nump">8,541,340<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=CELC_OptionsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=CELC_OptionsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=CELC_WarrantsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=CELC_WarrantsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=CELC_PreferredStockOnAnAsIfConvertedToCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=CELC_PreferredStockOnAnAsIfConvertedToCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Net Loss Per Common Share (Details Narrative) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_PrefundedWarrantShares', window );">Pre-funded warrant shares</a></td>
<td class="nump">5,747,787<span></span>
</td>
<td class="nump">5,747,787<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_PrefundedWarrantShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prefunded warrant, shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_PrefundedWarrantShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Investment (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems', window );"><strong>Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss</a></td>
<td class="nump">$ 212,588,960<span></span>
</td>
<td class="nump">$ 149,919,974<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain', window );">Debt Securities, Held-to-Maturity, Accumulated Unrecognized Gain</a></td>
<td class="nump">82,251<span></span>
</td>
<td class="nump">30,995<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Debt Securities, Held-to-Maturity, Fair Value</a></td>
<td class="nump">212,671,211<span></span>
</td>
<td class="nump">149,950,969<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">US Treasury Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems', window );"><strong>Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss</a></td>
<td class="nump">212,588,960<span></span>
</td>
<td class="nump">149,919,974<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain', window );">Debt Securities, Held-to-Maturity, Accumulated Unrecognized Gain</a></td>
<td class="nump">82,251<span></span>
</td>
<td class="nump">30,995<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Debt Securities, Held-to-Maturity, Fair Value</a></td>
<td class="nump">$ 212,671,211<span></span>
</td>
<td class="nump">$ 149,950,969<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-7A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrecognized gain on investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Other Current Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_PrepaidClinicalTrialCosts', window );">Prepaid clinical trial costs</a></td>
<td class="nump">$ 6,768,668<span></span>
</td>
<td class="nump">$ 8,763,150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_MiscellaneousReceivable', window );">Miscellaneous receivable</a></td>
<td class="nump">1,600,621<span></span>
</td>
<td class="nump">805,882<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Directors &amp; officers&#8217; insurance</a></td>
<td class="nump">256,629<span></span>
</td>
<td class="nump">157,453<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other</a></td>
<td class="nump">841,329<span></span>
</td>
<td class="nump">281,364<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Total</a></td>
<td class="nump">$ 9,467,247<span></span>
</td>
<td class="nump">$ 10,007,849<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_MiscellaneousReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Miscellaneous receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_MiscellaneousReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_PrepaidClinicalTrialCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid clinical trial costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_PrepaidClinicalTrialCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Property and Equipment (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, Gross</a></td>
<td class="nump">$ 2,328,452<span></span>
</td>
<td class="nump">$ 2,090,772<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation</a></td>
<td class="num">(1,991,937)<span></span>
</td>
<td class="num">(1,861,990)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total</a></td>
<td class="nump">336,515<span></span>
</td>
<td class="nump">228,782<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, Gross</a></td>
<td class="nump">2,025,875<span></span>
</td>
<td class="nump">1,788,195<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, Gross</a></td>
<td class="nump">$ 302,577<span></span>
</td>
<td class="nump">$ 302,577<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 129,947<span></span>
</td>
<td class="nump">$ 142,772<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Accrued Expenses (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_AccruedClinicalTrialExpense', window );">Clinical trial costs</a></td>
<td class="nump">$ 16,708,499<span></span>
</td>
<td class="nump">$ 6,464,772<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WorkersCompensationLiabilityCurrent', window );">Accrued compensation</a></td>
<td class="nump">3,987,786<span></span>
</td>
<td class="nump">1,763,316<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent', window );">Other</a></td>
<td class="nump">1,384,803<span></span>
</td>
<td class="nump">641,512<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Employee stock purchase plan</a></td>
<td class="nump">103,860<span></span>
</td>
<td class="nump">57,494<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 22,184,948<span></span>
</td>
<td class="nump">$ 8,927,094<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_AccruedClinicalTrialExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued clinical trial, expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_AccruedClinicalTrialExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WorkersCompensationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations and payables pertaining to claims incurred of a workers compensation nature. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WorkersCompensationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Supplemental Balance Sheet Information Related to Leases (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescriptionAbstract', window );"><strong>Operating Lease</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">$ 215,502<span></span>
</td>
<td class="nump">$ 400,019<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="nump">225,921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: short term portion</a></td>
<td class="num">(171,952)<span></span>
</td>
<td class="num">(184,950)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long term portion</a></td>
<td class="nump">$ 53,969<span></span>
</td>
<td class="nump">$ 225,922<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescriptionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescriptionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Maturity Analysis Under Lease Agreements (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 220,389<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">74,170<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">294,559<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Present value discount</a></td>
<td class="num">(68,638)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of net minimum lease payments</a></td>
<td class="nump">$ 225,921<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating leases, remaining lease term</a></td>
<td class="text">1 year 3 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating leases, discount rate</a></td>
<td class="nump">10.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Lease Costs (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 213,104<span></span>
</td>
<td class="nump">$ 212,238<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_FinanceLeaseCostAbstract', window );"><strong>Finance lease cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,411<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">111,246<span></span>
</td>
<td class="nump">101,957<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Lease costs</a></td>
<td class="nump">$ 324,350<span></span>
</td>
<td class="nump">$ 316,610<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_FinanceLeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance lease cost [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_FinanceLeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Supplemental Cash Flow Information Related to Leases (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_CashPaidForOperatingAndFinanceLeasesAbstract', window );"><strong>Cash paid for amounts included in operating and finance leases:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash outflow from operating leases</a></td>
<td class="nump">$ 324,783<span></span>
</td>
<td class="nump">$ 308,914<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Operating cash outflow from finance leases</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Financing cash outflow from finance leases</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,449<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_CashPaidForOperatingAndFinanceLeases', window );">Total cash paid for amounts included in operating and finance leases</a></td>
<td class="nump">$ 324,783<span></span>
</td>
<td class="nump">$ 311,367<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_CashPaidForOperatingAndFinanceLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash paid for operating and finance leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_CashPaidForOperatingAndFinanceLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_CashPaidForOperatingAndFinanceLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_CashPaidForOperatingAndFinanceLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments (Details Narrative)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Non-cancelable contractual commitment</a></td>
<td class="nump">$ 9.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Warrants (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants Outstanding</a></td>
<td class="nump">11,268,939<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CELC_WarrantOneMember', window );">Warrant One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue', window );">Issue Date</a></td>
<td class="text">Jan. 21,  2016<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration Date</a></td>
<td class="text">Jan. 14,  2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants Outstanding</a></td>
<td class="nump">33,719<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 7.56<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees', window );">Offering</a></td>
<td class="text">private placement offering - issued to placement agent<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CELC_WarrantTwoMember', window );">Warrant Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue', window );">Issue Date</a></td>
<td class="text">May  02,  2016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration Date</a></td>
<td class="text">May  02,  2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants Outstanding</a></td>
<td class="nump">21,530<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 7.56<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees', window );">Offering</a></td>
<td class="text">private placement offering - issued to placement agent<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CELC_WarrantThreeMember', window );">Warrant Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue', window );">Issue Date</a></td>
<td class="text">Apr. 28,  2017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration Date</a></td>
<td class="text">Apr. 28,  2027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants Outstanding</a></td>
<td class="nump">33,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 8.42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees', window );">Offering</a></td>
<td class="text">private placement offering - issued to placement agent<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CELC_WarrantFourMember', window );">Warrant Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue', window );">Issue Date</a></td>
<td class="text">May 17,  2017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration Date</a></td>
<td class="text">May 17,  2027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants Outstanding</a></td>
<td class="nump">15,365<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 8.42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees', window );">Offering</a></td>
<td class="text">private placement offering - issued to placement agent<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CELC_WarrantFiveMember', window );">Warrant Five [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue', window );">Issue Date</a></td>
<td class="text">Sep. 22,  2017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration Date</a></td>
<td class="text">Sep. 19,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants Outstanding</a></td>
<td class="nump">70,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 10.45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees', window );">Offering</a></td>
<td class="text">IPO - issued to underwriter<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CELC_WarrantSixMember', window );">Warrant Six [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue', window );">Issue Date</a></td>
<td class="text">Apr.  08,  2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration Date</a></td>
<td class="text">Apr.  08,  2031<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants Outstanding</a></td>
<td class="nump">26,042<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 14.40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees', window );">Offering</a></td>
<td class="text">debt financing - issued to lender<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CELC_WarrantSevenMember', window );">Warrant Seven [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue', window );">Issue Date</a></td>
<td class="text">May 30,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration Date</a></td>
<td class="text">May 30,  2034<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants Outstanding</a></td>
<td class="nump">84,227<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 14.84<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees', window );">Offering</a></td>
<td class="text">debt financing &#8211; issued to lender<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CELC_WarrantEightMember', window );">Warrant Eight [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue', window );">Issue Date</a></td>
<td class="text">May 30,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration Date</a></td>
<td class="text">May 30,  2034<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants Outstanding</a></td>
<td class="nump">19,649<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 14.84<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees', window );">Offering</a></td>
<td class="text">debt financing &#8211; issued to lender<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CELC_WarrantNineMember', window );">Warrant Nine [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue', window );">Issue Date</a></td>
<td class="text">Dec.  09,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants Outstanding</a></td>
<td class="nump">5,217,370<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 8.05<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees', window );">Offering</a></td>
<td class="text">securities purchase agreement - issued to institutional and other accredited investors<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CELC_WarrantTenMember', window );">Warrant Ten [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue', window );">Issue Date</a></td>
<td class="text">Oct. 18,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants Outstanding</a></td>
<td class="nump">5,747,787<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees', window );">Offering</a></td>
<td class="text">private placement offering - issued to investors<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or righst date from which warrants or rights issue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of reason for issuing warrant or right.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CELC_WarrantOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CELC_WarrantOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CELC_WarrantTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CELC_WarrantTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CELC_WarrantThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CELC_WarrantThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CELC_WarrantFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CELC_WarrantFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CELC_WarrantFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CELC_WarrantFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CELC_WarrantSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CELC_WarrantSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CELC_WarrantSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CELC_WarrantSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CELC_WarrantEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CELC_WarrantEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CELC_WarrantNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CELC_WarrantNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CELC_WarrantTenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CELC_WarrantTenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2024</div></th>
<th class="th"><div>May 30, 2024</div></th>
<th class="th"><div>May 08, 2024</div></th>
<th class="th"><div>Apr. 30, 2024</div></th>
<th class="th"><div>Apr. 22, 2024</div></th>
<th class="th"><div>Oct. 20, 2023</div></th>
<th class="th"><div>Oct. 18, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,000,000<span></span>
</td>
<td class="nump">65,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,143,242<span></span>
</td>
<td class="nump">25,506,012<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">317,577<span></span>
</td>
<td class="nump">854,134<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Additional warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,827,357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from warant exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,735,817<span></span>
</td>
<td class="nump">$ 22,505<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=CELC_InstitutionalAndOtherAccreditedInvestorsMember', window );">Institutional and Other Accredited Investors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_OfferingExpenses', window );">Offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,268,939<span></span>
</td>
<td class="nump">13,011,520<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOfWarrants', window );">[custom:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOfWarrants-0]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.04<span></span>
</td>
<td class="nump">$ 4.53<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,842,913<span></span>
</td>
<td class="nump">2,369<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Expirations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CELC_OpenMarketSaleAgreementMember', window );">Open Market Sale Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Commissions and other offering expenses</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CELC_OpenMarketSaleAgreementMember', window );">Open Market Sale Agreement [Member] | Jefferies LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock number of shares issued in transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">285,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Issuance of public offering price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Gross proceeds from public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CELC_UnderwritingAgreementMember', window );">Underwriting Agreement [Member] | Leerink Partners LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock number of shares issued in transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,871,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Issuance of public offering price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_ProceedsFromIssuanceOfCommonStockNet', window );">Net proceeds from public offering</a></td>
<td class="nump">$ 56,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CELC_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Pre-funded warrants sold to investors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,747,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CELC_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Warrant purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=CELC_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">536,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Number of shares issued in conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,365,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Cost basis of shares transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,850,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_OfferingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Offering expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_OfferingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_ProceedsFromIssuanceOfCommonStockNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_ProceedsFromIssuanceOfCommonStockNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non-option equity instruments weighted average exercise price of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share conversion price of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=CELC_InstitutionalAndOtherAccreditedInvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=CELC_InstitutionalAndOtherAccreditedInvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CELC_OpenMarketSaleAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CELC_OpenMarketSaleAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=CELC_JefferiesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=CELC_JefferiesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CELC_UnderwritingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CELC_UnderwritingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CELC_LeerinkPartnersLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CELC_LeerinkPartnersLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CELC_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CELC_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=CELC_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=CELC_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Stock Options Activity (Details) - Share-Based Payment Arrangement, Option [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding at beginning of year</a></td>
<td class="nump">2,815,392<span></span>
</td>
<td class="nump">1,976,586<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, weighted average exercise price at beginning of year</a></td>
<td class="nump">$ 7.95<span></span>
</td>
<td class="nump">$ 6.34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Shares, Granted</a></td>
<td class="nump">1,716,729<span></span>
</td>
<td class="nump">1,003,298<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="nump">$ 16.14<span></span>
</td>
<td class="nump">$ 10.69<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares, Exercised</a></td>
<td class="num">(103,245)<span></span>
</td>
<td class="num">(98,695)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="nump">$ 7.45<span></span>
</td>
<td class="nump">$ 3.94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Shares, Forfeited</a></td>
<td class="num">(121,899)<span></span>
</td>
<td class="num">(65,797)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise, Forfeited</a></td>
<td class="nump">$ 11.57<span></span>
</td>
<td class="nump">$ 7.45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding at end of year</a></td>
<td class="nump">4,306,977<span></span>
</td>
<td class="nump">2,815,392<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, weighted average exercise price at end of year</a></td>
<td class="nump">$ 11.13<span></span>
</td>
<td class="nump">$ 7.95<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Shares, options exercisable</a></td>
<td class="nump">2,011,474<span></span>
</td>
<td class="nump">1,524,731<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options exercisable</a></td>
<td class="nump">$ 7.35<span></span>
</td>
<td class="nump">$ 6.44<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value for options granted during the period</a></td>
<td class="nump">$ 11.22<span></span>
</td>
<td class="nump">$ 7.48<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OffsettingAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OffsettingAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Stock Options Outstanding and Exercisable (Details) - Share-Based Payment Arrangement, Option [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding | shares</a></td>
<td class="nump">4,306,977<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding, weighted average remaining contractual life</a></td>
<td class="text">7 years 11 months 15 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, weighted average exercise price | $ / shares</a></td>
<td class="nump">$ 11.13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, aggregate intrinsic value | $</a></td>
<td class="nump">$ 13,914,458<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable | shares</a></td>
<td class="nump">2,011,474<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable, weighted average exercise price | $ / shares</a></td>
<td class="nump">$ 7.35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options exercisable, aggregate intrinsic value | $</a></td>
<td class="nump">$ 11,781,660<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Assumptions for Fair Value of Equity-based Awards (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">3.48%<span></span>
</td>
<td class="nump">3.41%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">4.71%<span></span>
</td>
<td class="nump">4.86%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">71.20%<span></span>
</td>
<td class="nump">77.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">76.20%<span></span>
</td>
<td class="nump">79.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
<td class="text">5 years 3 months<span></span>
</td>
<td class="text">5 years 3 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">6 years 29 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Unrecognized Compensation Cost (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostToBeRecognizedNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 7,776,307<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostToBeRecognizedWithinTwoYear', window );">2026</a></td>
<td class="nump">6,307,024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostToBeRecognizedwithinThreeYears', window );">2027</a></td>
<td class="nump">5,165,880<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostToBeRecognizedWithinFourYears', window );">2028</a></td>
<td class="nump">1,964,136<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostToBeRecognized', window );">Total estimated compensation cost to be recognized</a></td>
<td class="nump">$ 21,213,347<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostToBeRecognizedWithinFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee service share based compensation nonvested awards total compensation cost to be recognized within four years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostToBeRecognizedWithinFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostToBeRecognizedWithinTwoYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee service share based compensation nonvested awards total compensation cost to be recognized within two year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostToBeRecognizedWithinTwoYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostToBeRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee service share based compensation nonvested awards total compensation cost to be recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostToBeRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostToBeRecognizedNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee service share based compensation nonvested awards total compensation cost to be recognized next twelve months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostToBeRecognizedNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostToBeRecognizedwithinThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee service share based compensation nonvested awards total compensation cost to be recognized within three year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostToBeRecognizedwithinThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Stock-based Compensation Expenses (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 6,988,341<span></span>
</td>
<td class="nump">$ 4,901,434<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">4,404,518<span></span>
</td>
<td class="nump">2,700,318<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 2,583,823<span></span>
</td>
<td class="nump">$ 2,201,116<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>May 09, 2024</div></th>
<th class="th"><div>Jan. 01, 2024</div></th>
<th class="th"><div>May 11, 2023</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>May 12, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>May 12, 2021</div></th>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>May 10, 2018</div></th>
<th class="th"><div>Oct. 25, 2017</div></th>
<th class="th"><div>Aug. 10, 2012</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=CELC_MayTwoThousandTwentyTwoExercisePriceModificationMember', window );">May 2022 Exercise Price Modification [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_StockOptionAwardsSharesModified', window );">Stock option awards shares modified</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">776,324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_ModifiedStockOptionExercisePrice', window );">Stock option exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost', window );">Stock based compensation expense related to modification</a></td>
<td class="nump">$ 106,000<span></span>
</td>
<td class="nump">$ 134,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_RemainingStockBasedCompensationExpenseRelatedToModification', window );">Remaining stock based compensation expense related to modification</a></td>
<td class="nump">57,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=CELC_DecemberTwoThousandTwentyOneExercisePriceModificationMember', window );">December 2021 Exercise Price Modification [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_StockOptionAwardsSharesModified', window );">Stock option awards shares modified</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">311,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_ModifiedStockOptionExercisePrice', window );">Stock option exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost', window );">Stock based compensation expense related to modification</a></td>
<td class="nump">63,000<span></span>
</td>
<td class="nump">65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_RemainingStockBasedCompensationExpenseRelatedToModification', window );">Remaining stock based compensation expense related to modification</a></td>
<td class="nump">35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=CELC_MayTwoThousandTwentyExercisePriceModificationMember', window );">May 2020 Exercise Price Modification [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_StockOptionAwardsSharesModified', window );">Stock option awards shares modified</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">203,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_ModifiedStockOptionExercisePrice', window );">Stock option exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost', window );">Stock based compensation expense related to modification</a></td>
<td class="nump">$ 696<span></span>
</td>
<td class="nump">19,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=CELC_TwoThousandSeventeenPlanMember', window );">2017 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant under the 2017 Plan</a></td>
<td class="nump">1,177,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=CELC_EquityIncentivePlanMember', window );">2012 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">625,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=CELC_StockIncentivePlanMember', window );">2017 Stock Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_ChangeInCommonStockSharesReservedForIssuance', window );">Change in common stock, shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">255,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">216,673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_TotalCommonStockCapitalSharesReservedForFutureIssuance', window );">Total common stock, shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Recognized stock-based compensation expense</a></td>
<td class="nump">$ 339,719<span></span>
</td>
<td class="nump">166,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Recognized stock-based compensation expense</a></td>
<td class="nump">6,626,402<span></span>
</td>
<td class="nump">4,716,475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Recognized stock-based compensation expense</a></td>
<td class="nump">$ 22,220<span></span>
</td>
<td class="nump">$ 18,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Restricted stock awards outstanding</a></td>
<td class="nump">1,079<span></span>
</td>
<td class="nump">1,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Restricted stock awards vested</a></td>
<td class="nump">2,308<span></span>
</td>
<td class="nump">3,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=CELC_EmployeeStockPurchasePlanMember', window );">2017 Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_ChangeInCommonStockSharesReservedForIssuance', window );">Change in common stock, shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108,337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant under the 2017 Plan</a></td>
<td class="nump">360,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Annual employee stock purchase plan description</a></td>
<td class="text">the number of shares equal to 0.5% of the total outstanding number of shares of Company common stock as
of the immediately preceding December 31.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_ChangeInCommonStockSharesReservedForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in common stock, shares reserved for issuance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_ChangeInCommonStockSharesReservedForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_ModifiedStockOptionExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Modified stock option exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_ModifiedStockOptionExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_RemainingStockBasedCompensationExpenseRelatedToModification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining stock based compensation expense related to modification.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_RemainingStockBasedCompensationExpenseRelatedToModification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_StockOptionAwardsSharesModified">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock option awards shares modified.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_StockOptionAwardsSharesModified</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_TotalCommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total common stock capital shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_TotalCommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>An excess of the fair value of the modified award over the fair value of the award immediately before the modification.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=CELC_MayTwoThousandTwentyTwoExercisePriceModificationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=CELC_MayTwoThousandTwentyTwoExercisePriceModificationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=CELC_DecemberTwoThousandTwentyOneExercisePriceModificationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=CELC_DecemberTwoThousandTwentyOneExercisePriceModificationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=CELC_MayTwoThousandTwentyExercisePriceModificationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=CELC_MayTwoThousandTwentyExercisePriceModificationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=CELC_TwoThousandSeventeenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=CELC_TwoThousandSeventeenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=CELC_EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=CELC_EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=CELC_StockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=CELC_StockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=CELC_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=CELC_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Long-term Debt (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Note payable</a></td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="nump">$ 35,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_FinalFee', window );">Add: Final fee</a></td>
<td class="nump">4,500,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_PaymentInKindInterestDebt', window );">Add: PIK interest (added to principal)</a></td>
<td class="nump">593,288<span></span>
</td>
<td class="nump">2,565,660<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Less: unamortized debt issuance costs</a></td>
<td class="num">(1,613,734)<span></span>
</td>
<td class="num">(480,810)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: unamortized debt discount</a></td>
<td class="num">(5,752,418)<span></span>
</td>
<td class="num">(49,439)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Total long-term debt</a></td>
<td class="nump">$ 97,727,136<span></span>
</td>
<td class="nump">$ 37,035,411<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_FinalFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Final fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_FinalFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_PaymentInKindInterestDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment in kind interest debt</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_PaymentInKindInterestDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Long Term Debt Future Principal Payments (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2027</a></td>
<td class="nump">$ 30,615,349<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2028</a></td>
<td class="nump">52,483,455<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2029</a></td>
<td class="nump">21,994,484<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 105,093,288<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>May 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_FinalFee', window );">Final fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,268,939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CELC_AmendedAndRestatedLoanAgreementMember', window );">Amended and Restated Loan Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateTerms', window );">Debt instrument interest rate description</a></td>
<td class="text">the Company
is entitled to make interest-only payments for thirty-six months, or up to forty-eight months if certain conditions are met. The Term
Loans will mature on May 1, 2029 and will bear interest at a rate equal to the sum of (a) the greater of (i) the Prime Rate (as defined
in the A&R Loan Agreement) or (ii) 7.75%, plus (b) 2.85%, provided that 1.0% of such interest will be payable in-kind by adding an
amount equal to such 1.0% of the outstanding principal amount to the then outstanding principal balance on a monthly basis through May
31, 2027.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=CELC_AmendedAndRestatedLoanAgreementMember', window );">Amended and Restated Loan Agreement [Member] | Innovatus Life Sciences [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Funded loan amount</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherBorrowings', window );">Costs associated with new borrowings</a></td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_FinalFeePercentage', window );">Final fee percentage</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_FinalFee', window );">Final fee</a></td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_WarrantOrRightToPurchasePercentage', window );">Warrant or right, reason for issuance, description</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=CELC_AmendedAndRestatedLoanAgreementMember', window );">Amended and Restated Loan Agreement [Member] | Innovatus Life Sciences [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued</a></td>
<td class="nump">103,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price per share</a></td>
<td class="nump">$ 14.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants</a></td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=CELC_AmendedAndRestatedLoanAgreementMember', window );">Amended and Restated Loan Agreement [Member] | Innovatus Life Sciences [Member] | Term A Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Funded loan amount</a></td>
<td class="nump">$ 16,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Loan conversion percentage</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Common stock price per share</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=CELC_AmendedAndRestatedLoanAgreementMember', window );">Amended and Restated Loan Agreement [Member] | Innovatus Life Sciences [Member] | Term B Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Funded loan amount</a></td>
<td class="nump">$ 21,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=CELC_AmendedAndRestatedLoanAgreementMember', window );">Amended and Restated Loan Agreement [Member] | Innovatus Life Sciences [Member] | Term C Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Funded loan amount</a></td>
<td class="nump">61,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=CELC_AmendedAndRestatedLoanAgreementMember', window );">Amended and Restated Loan Agreement [Member] | Innovatus Life Sciences [Member] | Term D Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Funded loan amount</a></td>
<td class="nump">30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_NonUtilizationFee', window );">Non utilization fee</a></td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=CELC_AmendedAndRestatedLoanAgreementMember', window );">Amended and Restated Loan Agreement [Member] | Innovatus Life Sciences [Member] | Term E Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Funded loan amount</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_NonUtilizationFee', window );">Non utilization fee</a></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=CELC_AmendedAndRestatedLoanAgreementMember', window );">Amended and Restated Loan Agreement [Member] | Innovatus Life Sciences [Member] | Term F Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Funded loan amount</a></td>
<td class="nump">45,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=CELC_AmendedAndRestatedLoanAgreementMember', window );">Amended and Restated Loan Agreement [Member] | Innovatus Life Sciences [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Funded contingent loan, outstanding</a></td>
<td class="nump">$ 180,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=CELC_PriorLoanAgreementMember', window );">Prior Loan Agreement [Member] | Innovatus Life Sciences [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Common stock price per share</a></td>
<td class="nump">$ 14.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued</a></td>
<td class="nump">26,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_FinalFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Final fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_FinalFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_FinalFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Final fee percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_FinalFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_NonUtilizationFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non utilization fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_NonUtilizationFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_WarrantOrRightToPurchasePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant or right, reason for issuance, description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_WarrantOrRightToPurchasePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the interest rate as being fixed or variable, and, if variable, identification of the index or rate on which the interest rate is based and the number of points or percentage added to that index or rate to set the rate, and other pertinent information, such as frequency of rate resets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying amount as of the balance sheet date for the aggregate of other miscellaneous borrowings owed by the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CELC_AmendedAndRestatedLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CELC_AmendedAndRestatedLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=CELC_AmendedAndRestatedLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=CELC_AmendedAndRestatedLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CELC_InnovatusLifeSciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CELC_InnovatusLifeSciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=CELC_TermALoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=CELC_TermALoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=CELC_TermBLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=CELC_TermBLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=CELC_TermCLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=CELC_TermCLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=CELC_TermDLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=CELC_TermDLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=CELC_TermELoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=CELC_TermELoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=CELC_TermFLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=CELC_TermFLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=CELC_PriorLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=CELC_PriorLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Effective Income Tax Rate Reconciliation (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Tax benefit at statutory federal rate</a></td>
<td class="num">$ (23,474,000)<span></span>
</td>
<td class="num">$ (13,394,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income tax benefit, net of federal tax effect</a></td>
<td class="num">(95,000)<span></span>
</td>
<td class="num">(82,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance on deferred tax assets</a></td>
<td class="nump">24,081,000<span></span>
</td>
<td class="nump">13,542,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research &amp; Development Credits</a></td>
<td class="num">(1,236,000)<span></span>
</td>
<td class="num">(550,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther', window );">Other permanent items</a></td>
<td class="nump">724,000<span></span>
</td>
<td class="nump">484,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefits</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">$ 459,000<span></span>
</td>
<td class="nump">$ 207,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Share-based compensation</a></td>
<td class="nump">2,861,000<span></span>
</td>
<td class="nump">2,141,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">420,000<span></span>
</td>
<td class="nump">393,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_DeferredTaxAssetsRightofuseAssets', window );">Right-of-use assets</a></td>
<td class="num">(45,000)<span></span>
</td>
<td class="num">(85,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_DeferredTaxAssetsLeaseLiability', window );">Lease liability</a></td>
<td class="nump">48,000<span></span>
</td>
<td class="nump">87,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIRC174Expenditures', window );">IRC 174 Expenditures</a></td>
<td class="nump">30,133,000<span></span>
</td>
<td class="nump">13,900,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStartupExpenditures', window );">Start-up expenditures</a></td>
<td class="nump">12,998,000<span></span>
</td>
<td class="nump">11,029,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating losses and tax credits</a></td>
<td class="nump">13,340,000<span></span>
</td>
<td class="nump">8,461,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(60,214,000)<span></span>
</td>
<td class="num">(36,133,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_DeferredTaxAssetsLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_DeferredTaxAssetsLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_DeferredTaxAssetsRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets right of use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_DeferredTaxAssetsRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIRC174Expenditures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets tax deferred expense compensation and benefits IRC 174 expenditures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIRC174Expenditures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStartupExpenditures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Start-up expenditures</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStartupExpenditures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details Narrative)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Federal net operating loss carryforwards</a></td>
<td class="nump">$ 43.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">State net operating loss carryforwards</a></td>
<td class="nump">0.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Tax credit carryforwards</a></td>
<td class="nump">2.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Tax credit carryforwards</a></td>
<td class="nump">$ 1.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Event (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,735,817<span></span>
</td>
<td class="nump">$ 22,505<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionExercisePriceDecrease', window );">Exercise price reduced</a></td>
<td class="nump">$ 11.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price lower</a></td>
<td class="nump">12.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price upper</a></td>
<td class="nump">$ 18.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Stock options held</a></td>
<td class="nump">837,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrants exercised</a></td>
<td class="nump">695,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of common stock warrants</a></td>
<td class="nump">$ 8.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from warrants exercised</a></td>
<td class="nump">$ 5,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionExercisePriceDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share decrease in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionExercisePriceDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>86
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    (  Z(?UI&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    (  Z(?UK7"A_8\0   "L"   1
M9&]C4')O<',O8V]R92YX;6S-DE%+PS 0Q[^*Y+V]M,4AH<N+8T\*@@/%MY#<
MMF#3A.2DW;<WK5NGZ ?P,7?__.YW<*T.0ON(3]$'C&0QW8RNZY/08<V.1$$
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M,XTPS7&MMP\?PMT$E;L)S%YDT_J^I# 02%P[QIP=<M](9XEA-,%2%@8 .>Y
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M,,G)"^#[!85IIW@C?Z \67KQ7U!+ P04    "  .B']:4]!^V* %   Y%@
M&    'AL+W=O<FMS:&5E=',O<VAE970R+GAM;+U8;6_;-A#^*X17%!W@Q"(I
MBF*:&$C=#2O0;4&S;I\9F8Z%2J(K4DFS7[^C[%BV2"DI&@R(8[W<G9\['N^Y
MX_F]KK^8M5(6?2N+REQ,UM9NSF8SDZU5*<VIWJ@*WJQT74H+M_7MS&QJ)9>M
M4EG,2!0ELU+FU61^WCZ[JN?GNK%%7JFK&IFF+&7]\$X5^OYB@B>/#S[EMVOK
M'LSFYQMYJZZ5_;RYJN%NMK>RS$M5F5Q7J%:KB\DE/EL0YA1:B;]S=6\.KI%S
MY4;K+^[FP_)B$CE$JE"9=28D?-VIA2H*9PEP?-T9G>Q_TRD>7C]:_[5U'IRY
MD48M=/%/OK3KBTDZ04NUDDUA/^G[W]3.H19@I@O3_D?W.]EH@K+&6%WNE %!
MF5?;;_EM%X@#!1P/*)"= GFN MTIT-;1+;+6K??2ROEYK>]1[:3!FKMH8]-J
M@S=YY9;QVM;P-@<].W\G"UEE"ET["P:=H,_7[]&;5S^?SRQ8=S*S;&?IW=82
M&;#T7F6GB.(I(A&) ^J+YZO38_49^+1WC.P=(ZT].F!OT=2UJBRZ- 8<.POY
MLS40APVX_7-F-C)3%Q/8($;5=VHR?_T33J*W(>]>R-B1KW3O*QVS/E](LT:R
M6J+,7:BO37XG"W#>A+S>FF*M*;?)[^:$,!RG+NIWAQ[Y@C1*$L)YO!<\0AOO
MT<:C:#]4=\K8<@C?5CDYQ(<)2U.11#V OB2.A<!"#"%D>X1L%.&?=JUJV'W;
M#))M!H6@,@^ B!-.8MX#ZLOA*(IX&HLPSF2/,QG%^9>VLG@&SL0/:1PSCB/:
M#ZDOB47$W!\/0^5[J'P4ZE4-S%/;AS9-789N7 ),4:5L"#'W<%":,,QZ<'TQ
M0E*>DC#6=(\U'5]^0"IM7MVB0@%#H-I1P8E>G31P,QSE-)"XC$6DA]D7BR$9
M\$ JB#UF\8Q4N!P$)P(IP#"AD9>LOB06F&!!11J&B*..:Z)GU>2/N;S)B]SF
M*ER8=V9>J#*_E+5CIP\(%H^NS&66Z09J'=K(!WE3J*##V*\D-$F@1O06)R#(
M(IXD8B!]<$>7>)2AO*0ONC4*(B9^FG L6#_;0W)0]U@T@+>C/#S.>1#6NE%0
M2[Y!1VL&0-) ?7 _'Z=]F+YD*@B/Q "3X([L\#C;'=?HIZ+J4QK%G!#A)T*(
M_'":\I@.(.[(#S_!?M^9"3Z[,2H2T0?LBT'?(<A K<8=!^)Q$OQ#6_6XMX!/
M='6R"W80K$]P@G/",4WZ>'U)RB/*8HP'$'=4B,>Y<)L2'Y\(J\]MF,"^B2/L
M[3%?%!HZ!M4C&8#:,2$>I\*%+LM\VZNUS+W0E<L,564 &[UI8R_"P\*HX7#5
M1<'R_>.&CIWO*!6+4;JZMCK[LM;%4M7F]4\IP?PM^@5:%_L09JU1AOYNUGHA
M:\?#4T?59)05H5]3*P7;:(F,B\(4O8I.H4N!C58C&"X:=8;(%%)L"KT+,FL)
M&)!L[%K7^;]J^18F.3YEG+=)D[)XBFG\*)8;XPJW>Z,;:RQ<N&(C#=(K!&.@
M*F^@^WZ<)%NY_E,Z16!IH]HS@.(A.-Q%@5+:+_L!(0 ;WC2D8WPRSOANT^AJ
M.'""N:BUD7/.)=VM%\@?B0HL I_BF$Y)3%IYPF#%DBD4D/]Y*?RFA7(<]^?-
M@!B!_GF@AI&#@X#QSN9RN<S=D1'4W(W,ER=Y!7/R)H<:' 3K-RS4L6J2I/VZ
M&Q E0J081E4V +IK;\B3[4U3-H6TL#Q+M<JS/,AGQ.];3H#-4L9PY"5[0!:[
M'A,^ TT#Z=H<\IPV9[AB!L$'>AC,$I@X:7_0"XE2P1-!AQH(TO4[9+S?\>BX
MS?/O=(7YIRH#\U5 =&C FAV<Z[E#U=]E?9M7!OJR%>A&IQR,U-MSRNV-U9OV
MJ.]&6ZO+]G*M)+C@!.#]2@-A[V[<Z>'^M'C^'U!+ P04    "  .B']:JXO!
M*.,"  #D"0  &    'AL+W=O<FMS:&5E=',O<VAE970S+GAM;*V676_:,!2&
M_XJ53=,F=<3YA@XBM533=C$)%6V[F'9AD@.QZL29;:#;KY^=I!F04* :%XGM
MG/?-<\QQ[/&6BP>9 2CTF+-"3JQ,J?+:MF6204[D@)=0Z"=++G*B=%>L;%D*
M(&DERIGM8AS:.:&%%8^KL9F(QWRM&"U@)I!<YSD1OV^!\>W$<JRG@7NZRI09
ML.-Q258P!_6UG G=LUN7E.902,H+)& YL6Z<ZZF#C:"*^$9A*W?:R*2RX/S!
M=#ZG$PL;(F"0*&-!]&T#4V#,.&F.7XVIU;[3"'?;3^X?J^1U,@LB8<K9=YJJ
M;&(-+93"DJR9NN?;3] D%!B_A#-97=&VCO5]"R5KJ7C>B#5!3HOZ3AZ;B=@1
M.,<$;B-PSQ5XC<"K$JW)JK3NB"+Q6/ M$B9:NYE&-3>56F=#"_,WSI703ZG6
MJ?B6,%(D@.;&0:*W,R*@4!DHFA#V#KU'KY&-9*9'Y=A6^H5&9B>-^6UM[AXQ
MOX-D@#SG"KG8]7ODT_/EWK[<UFFVN;IMKF[EYQWQFRNB0)>@0GR)/M)")TX)
M0S,N:552/VX64@E=6#_[4JV]_7YOL]JN94D2F%AZ.4D0&[#B-Z^<$'_H2_P_
MF>U-@]=.@_><>SS3"P6$@!3IZDH>KE!)!-H0MH:^M&NOJ/(RWX1-C <8.V-[
MLYO/J:@]4+\%]2\#K>L0D;7*N*!_(.T#KCW#'10WP.9W@'PZ;@\Z:*&#%T%3
M*=?]P$$'Q'.B((H.>+MAP\!W/+\?-VQQPQ?AZB^^5*1(:;'J8P[/8^Z&/<<<
MM<S1L\Q3GN=ZN9Y3O=%9U7LJ:H]RV%(.+Z \JW2'G>D:U25Y6+O=P/ P<(]Y
MU#*/+F<^7KFC;A5$CN^YOGO VPUT@P"'V''[>1W\;_O"EQ.?*-[&\@SNGL@C
MX/;.%FS./U^(6-%"(@9++<6#2"]?41\IZH[B9;4K+[C2>WS5S/0Q#(0)T,^7
MG*NGCMGHVX-=_!=02P,$%     @ #HA_6@FR74TP!   N \  !@   !X;"]W
M;W)K<VAE971S+W-H965T-"YX;6RMEVUSHS80Q[^*AG8Z=S-W 0D0D-J>N22]
M]F9Z;2;I]5XK(!OF +F2;*??OBO V 9!TT[R(N9A]>>WVI56NS@(^4WEG&OT
M7)6U6CJYUMMKUU5ISBNFKL26U_!F+63%--S*C:NVDK.L&525+O$\ZE:LJ)W5
MHGEV+U<+L=-E4?-[B=2NJIC\^X:7XK!TL'-\\%!L<FT>N*O%EFWX(]=?MO<2
M[MQ>)2LJ7JM"U$CR]=+Y@*]O<6P&-!9_%OR@SJZ1<>5)B&_FYE.V=#Q#Q$N>
M:B/!X&?/;WE9&B7@^*L3=?IOFH'GUT?UCXWSX,P34_Q6E%^+3.=+)W90QM=L
M5^H'<?B%=PZ%1B\5I6K^HT-K&Q('I3NE1=4-!H*JJ-M?]MQ-Q-D 3"<&D&X
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MF(68: D66I^@KMJG<+4_9JNXA>K5&3HC5]2[]H7#%!+\* P9U_,JEL5DT.)
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M*</K6T*8H3.' '7KNV&OD7K+#RMZS&!< JV76N,I< TV_3UD_P!02P,$%
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M#<^&>N@Y;P,7R3 :\=S9_%3 $$,+G%JN#BAE?<-S:/B0I]:P;Z@'L#8"4I$
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MR560_9#"G)J+O^U_&5\Y2D&%=^^,&?!\N]5PT*E:'/_M VS'G$%H"D#X\];
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M-S_TTUESHRM2$5DL9M**JMQZJ%$($(+!+,3F8</\*-F#.7=X6(#\:;U_A/I
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MH_^X+4!FD29\K0RM3$";O"6U/:B.2GR1=WO@)DG&V<%_U?-7([#W?I$7NEU
M]C/J%L/((TWCLQ+J0N&Y1WV.0*HX/<""@5;69LF[!\YP]BMKG(2%#HX6$D(
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M;?MWWN[QN&QGYF]X^_+<<;L4VH'$A8=F_;.3!&P[S>V"3!,G:&[(SV,T:_\
MH@T!?G]A#.T6X8#N22W^ %!+ P04    "  .B']:JX[FGA$$  "U"0  &0
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M'!BZ @  U@4  !D   !X;"]W;W)K<VAE971S+W-H965T,3@N>&ULC91-;YM
M$(;O_A4C&O6$S*<!N[8E.TG5'J):23\.50]K& S*PM+=)4[^?6?!IF[D6+W
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M-'A1F@#:SX701\,<,(SRY1]02P,$%     @ #HA_6J^#A+]C"   !!0  !D
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MC\TBMN*/NF60"IY!+X!MLA#?I#W?NAC#51;I8SADC#:VB<T/3P)"P2Y'R:K
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MSD +,+^N:],]T ']9][+_P%02P,$%     @ #HA_6L6B02NM"P  $Q\  !D
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MDT+2?19$;A+Z6O<H<H[,K(W!/E#8?L]ES7[C12<T5WJ&K*RY\J[N0YT,_<9
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MTI3$_;XN@1# >.FG_#!NY[3V+6KS8:/8:CK'4$$_(AS= 9SG,%[2IP^?PMT
M-6;[OEQ,!E^5*@&>H&]G(&EBBO"!J7_:?YZ[#E^EMLO#M[W?03/DY%(4$)V.
M3XY&&#?]][)PXW3MOU$MM7.Z\I<KP1%&6H#WA=:NNZ$-^H^65_\#4$L#!!0
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M:9]3^5_<TV6=_M0[Y!5)O%8HI<^N?8+!2TZ[[ZZM8#G=5_"N1$B@Q"?Y]4C
M^ T-!7V:@R@QBIQARXUJ>%279#J%[7O@O<\R9U19\57,>&':\^VU]XB/J,]A
MX1GC%E3+T^J5).37(YT ARX_U-U]M8,F4J@%CA176 \3UBXAJ =W4".!P6$6
MRCJKOB)YYF>C[(5V F@;1%_YU)RX(C-S-;N015$B8F(K3$Q)> L0@O8,8(</
M%%/,>T4Q/A^2A#>[S!^6*B65<Q.B8;D9H5_AA4&X<A->>_#C _'H0C?F UBC
MW NBH"MN1-Q]R86[EZYV'"JW+@J#:("$V3SY%$L4A##9< -4,O=9)/,0F1[6
M<3GP=^T<PW3<\^UR0(]3(6UER"=I=!Y4=,RXM;N6H%XJ2USD\H$]MN.&.[-<
M.5^5O8KK_* 41+F)S??^OJ$>T^9D4.O35,@GKZ2Y8X5J05W_!V 89Z2I<:)7
M8F9GQ/4.=PU@8U.6OPEAI:1TCTHJ:JS@K3=)/][(C'*E][ Q0)D_TL)8*G5\
M4>S0$5_0L%A''S/64#ATFWDLHE@MX_ 63]-P<1(S+B;'C1:^>,B%^6"=2;]Y
M:3.C]T7LBHK)Q>]MMNWN1#IB-6_IU&WIE+9T2ENJ$==A93:)MB(IMV1] \<8
MB(0U?"!.$1ZR.NV*P#J$KV&'' 5NN$/-W]''\Q[?<#WSE=Q^GQ#9+6@P@@7M
MY(IAF3AE8K3"P(>=8L\H>SCMFM^.RK?^N_<&72_1<KJ9Z(Z[FEZS\&Y[74VC
MGNP;FHF.T1]-,WLM5F+08N7+H'7LPTI,U96DJ"J(()K0C5]R)=-!71 C<#$W
M>^4C$B2,I]T3'^]&%^M3GT/F5HOEE7CC9PG>5_+!=Z6(#[DLCYK/8"NA>AGU
M%<?=W;5OK?0!93\(ZGS[ZUQ"0G?ISE"WIQ/"*640&) XQ\PZY,IY7I22/5+<
M&#4H@T^@GT&86/A>47?+Y8!*66ZAAQ(.*,1+PPV0P,#[>&_@.E6<OVF20<^A
M51SLC[=V'3WN(*-'K7UYY]B:&&:S4S@F_.0O%_$Q"3X%G>(*P["]8>UZA4-%
MF6,H&"5=]-A[Y&_>K0VYH/XC;NDG'V]"H.4J*,9N%'< <*D6-/?NMF?:K+LV
MLN5T']E'[(<2#A\JQUKAJ%E_0U?9,?IB\*)7I.Q=*HRU@<R/3DS\Q,+?64&0
M_Q#+Q<5LM3B?K<X7XLEB=GE],5LL+B=%US7M+*>[=FY#6?03MQT=OZ'ZAJ:=
M,=H'BIM3V,QN3",0IRME[>I8P$"J6R8!TB0'K"XU"V3K!K[0@QRFD!63>3L3
MA4&W9+F<";5V4-"=B]]V.E<^.^8R2PZ3*UVS]KTJ,[)WCB:04B8>(;S=;."N
MO#OD&$77MJU"TQM 1>Y#KO&HN9,.G_/\_F:IGR-$0;Y!5%MN.Z;?*+2(*[*6
M!_I^85YA4-'FEMOZ,298=_G K;I=J2=T[,:LE4&PZ^CMX#DLD/1Z>L/!A(RJ
MZP2(V. :JVR\4!S$O7ZZ[PD</<JQ?=7*6P;.@R!2/JI2FU)UEW&'DK?'[+1K
MSNX+K[N1[#14<ANTSKMPR9JMI6C971O6H85[4B)=[X4#UIB&46S&?FWF(F0Z
M/>'./S*)A)9:5=R=4^CZX-J"3Q$P\^"\.13S!]Y+!>G2G/WNL#-G3;OEOK=&
MYX-[RKBI).RVP'$0Z982$9;4)F<+C7K5H=UOQ# M!.X-,?SKNW]_^N7CNYO3
MI?C $<6Y[QN/X<B;][>G_SQ%%.('+-=G*S=F%MOB^1;'_Y IG'RDO(J4#UK3
MV9%QW:O7T(Z/K ZE-7GN>NBH1JHKZ7^P\I\5E5TNQ6P2=KN^M.5T8]J=XB1
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M_>-/)Q&89OHT"ZNKT/$K;=W\"&;A!C8:[^#.<ZWM=N$#='\!Z0M02P,$%
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MP:'?+4N\94%9 WQ?2"RK86,#C/?VX@=02P,$%     @ #HA_6IA%JUK_ @
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M 57>1:5@Y+*8_S-IZ#8IE@E=WZBL ]GG4IJU8#>H/PA&/P!02P,$%     @
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MSE]*@W.DW18XN$%9![Q?26EVADW0_Q6D?P%02P,$%     @ #HA_6D'88"W
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M[+*BP8O2.-#Y6@B]-\P%AU&>_P%02P,$%     @ #HA_6M\$'WM\!   D P
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MSGJBMQVXRN<+PP.#T>E*SO$:S9?5I:+>H+62Y4LL=5Z5H'!VUAN+D_.4Y:W
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MVUR@S%"Q ,W/JLIL.[Q ^TO'Z']02P,$%     @ #HA_6DWT451R P  Y <
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M*''+V\I^4(=?L,_'$RQ49?P_'#K?/ V@:(U5=1],#&HANR__W)_#DX!I]$)
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M0M-=:H<E?;R@- :T7@BAAXG98/\YM/P;4$L#!!0    (  Z(?UKLJ?D,O0(
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MV0VX/I/2K">V^VJ:Y^0_4$L#!!0    (  Z(?UJM4-0S%P,  !0(   9
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M7;11NQ^J?O#")%@+.&>;9._?UP9"0D*XVPJ=(JTVV,P\S//88X:9[!E_%3&
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M@43 M8&ZOV9J4U8#_8"ZY37[#U!+ P04    "  .B']:<,UI3"$"   )!0
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M1%VW@.L ]7W$F'QNZ -]>8'K_ %02P,$%     @ #HA_6I-BY &_ @  B <
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M>'L"YAZ=D_8?]4CEQKPMQ&%MI-Y-;#QD<^XW'2W*^NA<"FT.XKJY-;]*D+;
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M:EJ]]+<B'>O(8WDR56J6D<<T69357Q3_IO9;2]_H=2Y]I.9#-0K5&%3C4$U
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MO2$KJ=Z0E9P2)-K[D:W3$F%=F^]!YQZ 1N(G_@X,.BN':@*J2:@6H#2]NIM
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M:&5E=#4X+GAM;,56;6^;,!#^*Q:;IE9JRVL(Z1*DO'1;I56*&G7[4.V# Y>
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M%R&JG=(?GI+)8Y2><%)]-W[NOAQ4TU!-1S4#U4Q4LU#-1C4'U5Q4\U#-1[4
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M* JMA!Q?.U&GGU,[7CZ_JO]F@L=@]E3"AA=_LER=UD[BD!P.M"G4(S__#EU
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MTO4JJM99310O;+M:<J6;GQVN]><&"'- [V><J_N)Z8#-!TS\&U!+ P04
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M9G-!C-8G^KK 25&=<3>$BQ-S=;D'' .5#<3]+2'\5) =M.]5@G\!4$L#!!0
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M _4. KT#]0X"O0/U#@*] _4. KT#]0X"O6/RL9) [T"]@T#O0+V#0.] O8-
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MLAH460V*K 9%5H,BJ_E/6>^=6_]Q_/@L.]OT;_EL_"/:X@502P$"% ,4
M"  .B']:1L=-2)4   #-    $               @ $     9&]C4')O<',O
M87!P+GAM;%!+ 0(4 Q0    (  Z(?UK7"A_8\0   "L"   1
M  "  <,   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    (  Z(?UJ97)PC
M$ 8  )PG   3              "  >,!  !X;"]T:&5M92]T:&5M93$N>&UL
M4$L! A0#%     @ #HA_6GTF#4&G"0  93H  !@              ("!) @
M 'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    (  Z(?UI3T'[8
MH 4  #D6   8              " @0$2  !X;"]W;W)K<VAE971S+W-H965T
M,BYX;6Q02P$"% ,4    "  .B']:JXO!*.,"  #D"0  &
M@('7%P  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ #HA_
M6@FR74TP!   N \  !@              ("!\!H  'AL+W=O<FMS:&5E=',O
M<VAE970T+GAM;%!+ 0(4 Q0    (  Z(?UI"[-TW6@D  !=%   8
M      " @58?  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4
M"  .B']:I!@QPD\(  !T)0  &               @('F*   >&PO=V]R:W-H
M965T<R]S:&5E=#8N>&UL4$L! A0#%     @ #HA_6HE$ AT& @  *@0  !@
M             ("!:S$  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4
M Q0    (  Z(?UI78:D&3@(  *0%   8              " @:<S  !X;"]W
M;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    "  .B']:>P<JBD("  ",
M!@  &               @($K-@  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL
M4$L! A0#%     @ #HA_6J?L00!B"P  GR,  !D              ("!HS@
M 'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    "  .B']:(J8I
MB#0%  !/"P  &0              @($\1   >&PO=V]R:W-H965T<R]S:&5E
M=#$Q+GAM;%!+ 0(4 Q0    (  Z(?UH_'P>'[!$  -0P   9
M  " @:=)  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @
M#HA_6@@#YUIT @  7@4  !D              ("!REL  'AL+W=O<FMS:&5E
M=',O<VAE970Q,RYX;6Q02P$"% ,4    "  .B']:JX[FGA$$  "U"0  &0
M            @(%U7@  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4
M Q0    (  Z(?UH#GK^7= ,  !D)   9              " @;UB  !X;"]W
M;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ #HA_6J&$_\GK @
M- 8  !D              ("!:&8  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX
M;6Q02P$"% ,4    "  .B']:#+(DDM$"  !(!@  &0              @(&*
M:0  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    (  Z(?UJA
M-!P8N@(  -8%   9              " @9)L  !X;"]W;W)K<VAE971S+W-H
M965T,3@N>&UL4$L! A0#%     @ #HA_6J^#A+]C"   !!0  !D
M     ("!@V\  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  Z(?UI>HU4@J0(  ,,%   9              "
M@9F<  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ #HA_
M6D4;=Z<K$P  =CD  !D              ("!>9\  'AL+W=O<FMS:&5E=',O
M<VAE970R-2YX;6Q02P$"% ,4    "  .B']:\XA..JD"   .!@  &0
M        @(';L@  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0
M   (  Z(?UIEM!6A/@,  ,,'   9              " @;NU  !X;"]W;W)K
M<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ #HA_6IA%JUK_ @  ' @
M !D              ("!,+D  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q0
M2P$"% ,4    "  .B']:R-"^,/$"   P!@  &0              @(%FO
M>&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    (  Z(?UJ\2 0)
MOP(  !8&   9              " @8Z_  !X;"]W;W)K<VAE971S+W-H965T
M,S N>&UL4$L! A0#%     @ #HA_6D'88"W  @  U@4  !D
M ("!A,(  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    "  .
MB']:WP0?>WP$  "0#   &0              @(%[Q0  >&PO=V]R:W-H965T
M<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    (  Z(?UJC";]/CP,  (((   9
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M970S-RYX;6Q02P$"% ,4    "  .B']:K5#4,Q<#   4"   &0
M    @('SW@  >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    (
M  Z(?UH(RIUT;P(  -L%   9              " @4'B  !X;"]W;W)K<VAE
M971S+W-H965T,SDN>&UL4$L! A0#%     @ #HA_6GV-$5+> P  _A(  !D
M             ("!Y^0  'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"
M% ,4    "  .B']:<,UI3"$"   )!0  &0              @('\Z   >&PO
M=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    (  Z(?UJ:S""R/P,
M ,P-   9              " @53K  !X;"]W;W)K<VAE971S+W-H965T-#(N
M>&UL4$L! A0#%     @ #HA_6I-BY &_ @  B <  !D              ("!
MRNX  'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    "  .B']:
MT)SBAQ4#  #/"P  &0              @(' \0  >&PO=V]R:W-H965T<R]S
M:&5E=#0T+GAM;%!+ 0(4 Q0    (  Z(?UIOSO.,7P(  + %   9
M      " @0SU  !X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%
M  @ #HA_6OCJ+5*_ @  A0<  !D              ("!HO<  'AL+W=O<FMS
M:&5E=',O<VAE970T-BYX;6Q02P$"% ,4    "  .B']:INZ4")T"   Q!P
M&0              @(&8^@  >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+
M 0(4 Q0    (  Z(?UI!$J(_W0(  'P'   9              " @6S]  !X
M;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @ #HA_6D%]CP<
M P  4PD  !D              ("!@  ! 'AL+W=O<FMS:&5E=',O<VAE970T
M.2YX;6Q02P$"% ,4    "  .B']:E8U-EML"  "%"   &0
M@(&W P$ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    (  Z(
M?UH,S_AH'0(  % $   9              " @<D& 0!X;"]W;W)K<VAE971S
M+W-H965T-3$N>&UL4$L! A0#%     @ #HA_6D [QQX#!P  5RX  !D
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M=#4V+GAM;%!+ 0(4 Q0    (  Z(?UK_%#94=0(   T&   9
M  " @9 I 0!X;"]W;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%     @
M#HA_6LI#3C0R P  P L  !D              ("!/"P! 'AL+W=O<FMS:&5E
M=',O<VAE970U."YX;6Q02P$"% ,4    "  .B']:-Q'V)XP-  #VS@  &0
M            @(&E+P$ >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4
M Q0    (  Z(?UJ6"=FB\0(  ($(   9              " @6@] 0!X;"]W
M;W)K<VAE971S+W-H965T-C N>&UL4$L! A0#%     @ #HA_6H8B\ ]/ @
M;P4  !D              ("!D$ ! 'AL+W=O<FMS:&5E=',O<VAE970V,2YX
M;6Q02P$"% ,4    "  .B']:,>GT[I@(  #P1   &0              @($6
M0P$ >&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4 Q0    (  Z(?UI_
M80EA3@,  *()   9              " @>5+ 0!X;"]W;W)K<VAE971S+W-H
M965T-C,N>&UL4$L! A0#%     @ #HA_6@F4F&1\ P  3@L  !D
M     ("!:D\! 'AL+W=O<FMS:&5E=',O<VAE970V-"YX;6Q02P$"% ,4
M"  .B']:%("'C[8"  #,"   &0              @($=4P$ >&PO=V]R:W-H
M965T<R]S:&5E=#8U+GAM;%!+ 0(4 Q0    (  Z(?UKL@P[\J0,  &,1   9
M              " @0I6 0!X;"]W;W)K<VAE971S+W-H965T-C8N>&UL4$L!
M A0#%     @ #HA_6M(J),9' P  RA0   T              ( !ZED! 'AL
M+W-T>6QE<RYX;6Q02P$"% ,4    "  .B']:EXJ[',     3 @  "P
M        @ %<70$ 7W)E;',O+G)E;'-02P$"% ,4    "  .B']:^Q=/?6L%
M  !%*P  #P              @ %%7@$ >&PO=V]R:V)O;VLN>&UL4$L! A0#
M%     @ #HA_6A[?F5X< @  /2<  !H              ( !W6,! 'AL+U]R
M96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ #HA_6J5_#G'N 0
MD"8  !,              ( !,68! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
2     $H 2@ ]%   4&@!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>151</ContextCount>
  <ElementCount>334</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>57</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/BalanceSheets</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/StatementsOfOperations</Role>
      <ShortName>Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Statements of Changes in Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/StatementsOfChangesInStockholdersEquity</Role>
      <ShortName>Statements of Changes in Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/StatementsOfCashFlows</Role>
      <ShortName>Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Statement - Statements of Cash Flows (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/StatementsOfCashFlowsParenthetical</Role>
      <ShortName>Statements of Cash Flows (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>999015 - Disclosure - Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/Organization</Role>
      <ShortName>Organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>999016 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncements</Role>
      <ShortName>Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>999017 - Disclosure - Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/Liquidity</Role>
      <ShortName>Liquidity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>999018 - Disclosure - Net Loss Per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/NetLossPerCommonShare</Role>
      <ShortName>Net Loss Per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>999019 - Disclosure - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/Investments</Role>
      <ShortName>Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>999020 - Disclosure - Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/OtherCurrentAssets</Role>
      <ShortName>Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>999021 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/PropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>999022 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/AccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>999023 - Disclosure - Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/Commitments</Role>
      <ShortName>Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>999024 - Disclosure - Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders??? Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>999025 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/Stock-basedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>999026 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>999027 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>999028 - Disclosure - Subsequent Event</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/SubsequentEvent</Role>
      <ShortName>Subsequent Event</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>999029 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies</Role>
      <ShortName>Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncements</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>999030 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsTables</Role>
      <ShortName>Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncements</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>999031 - Disclosure - Net Loss Per Common Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/NetLossPerCommonShareTables</Role>
      <ShortName>Net Loss Per Common Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://celcuity.com/role/NetLossPerCommonShare</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>999032 - Disclosure - Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/InvestmentsTables</Role>
      <ShortName>Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://celcuity.com/role/Investments</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>999033 - Disclosure - Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/OtherCurrentAssetsTables</Role>
      <ShortName>Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://celcuity.com/role/OtherCurrentAssets</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>999034 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/PropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://celcuity.com/role/PropertyAndEquipment</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>999035 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/AccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://celcuity.com/role/AccruedExpenses</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>999036 - Disclosure - Commitments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/CommitmentsTables</Role>
      <ShortName>Commitments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://celcuity.com/role/Commitments</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>999037 - Disclosure - Stockholders??? Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders??? Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://celcuity.com/role/StockholdersEquity</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>999038 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/Stock-basedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://celcuity.com/role/Stock-basedCompensation</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>999039 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/DebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://celcuity.com/role/Debt</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>999040 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://celcuity.com/role/IncomeTaxes</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>999041 - Disclosure - Schedule of Estimated Useful Lives of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails</Role>
      <ShortName>Schedule of Estimated Useful Lives of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>999042 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsDetailsNarrative</Role>
      <ShortName>Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>999043 - Disclosure - Liquidity (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/LiquidityDetailsNarrative</Role>
      <ShortName>Liquidity (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://celcuity.com/role/Liquidity</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>999044 - Disclosure - Schedule of Potentially-Dilutive Shares Excluded from the Diluted Weighted-Average Shares Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/ScheduleOfPotentially-dilutiveSharesExcludedFromDilutedWeighted-averageSharesOutstandingDetails</Role>
      <ShortName>Schedule of Potentially-Dilutive Shares Excluded from the Diluted Weighted-Average Shares Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>999045 - Disclosure - Net Loss Per Common Share (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/NetLossPerCommonShareDetailsNarrative</Role>
      <ShortName>Net Loss Per Common Share (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://celcuity.com/role/NetLossPerCommonShareTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>999046 - Disclosure - Schedule of Investment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/ScheduleOfInvestmentDetails</Role>
      <ShortName>Schedule of Investment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>999047 - Disclosure - Schedule of Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/ScheduleOfOtherCurrentAssetsDetails</Role>
      <ShortName>Schedule of Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>999048 - Disclosure - Summary of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/SummaryOfPropertyAndEquipmentDetails</Role>
      <ShortName>Summary of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>999049 - Disclosure - Property and Equipment (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/PropertyAndEquipmentDetailsNarrative</Role>
      <ShortName>Property and Equipment (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://celcuity.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>999050 - Disclosure - Schedule of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/ScheduleOfAccruedExpensesDetails</Role>
      <ShortName>Schedule of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>999051 - Disclosure - Schedule of Supplemental Balance Sheet Information Related to Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails</Role>
      <ShortName>Schedule of Supplemental Balance Sheet Information Related to Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>999052 - Disclosure - Schedule of Maturity Analysis Under Lease Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/ScheduleOfMaturityAnalysisUnderLeaseAgreementsDetails</Role>
      <ShortName>Schedule of Maturity Analysis Under Lease Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>999053 - Disclosure - Schedule of Lease Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/ScheduleOfLeaseCostsDetails</Role>
      <ShortName>Schedule of Lease Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>999054 - Disclosure - Schedule of Supplemental Cash Flow Information Related to Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails</Role>
      <ShortName>Schedule of Supplemental Cash Flow Information Related to Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>999055 - Disclosure - Commitments (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/CommitmentsDetailsNarrative</Role>
      <ShortName>Commitments (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://celcuity.com/role/CommitmentsTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>999056 - Disclosure - Schedule of Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/ScheduleOfWarrantsDetails</Role>
      <ShortName>Schedule of Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>999057 - Disclosure - Stockholders??? Equity (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>Stockholders??? Equity (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://celcuity.com/role/StockholdersEquityTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>999058 - Disclosure - Schedule of Stock Options Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/ScheduleOfStockOptionsActivityDetails</Role>
      <ShortName>Schedule of Stock Options Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>999059 - Disclosure - Schedule of Stock Options Outstanding and Exercisable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/ScheduleOfStockOptionsOutstandingAndExercisableDetails</Role>
      <ShortName>Schedule of Stock Options Outstanding and Exercisable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>999060 - Disclosure - Schedule of Assumptions for Fair Value of Equity-based Awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/ScheduleOfAssumptionsForFairValueOfEquity-basedAwardsDetails</Role>
      <ShortName>Schedule of Assumptions for Fair Value of Equity-based Awards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>999061 - Disclosure - Schedule of Unrecognized Compensation Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/ScheduleOfUnrecognizedCompensationCostDetails</Role>
      <ShortName>Schedule of Unrecognized Compensation Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>999062 - Disclosure - Schedule of Stock-based Compensation Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/ScheduleOfStock-basedCompensationExpensesDetails</Role>
      <ShortName>Schedule of Stock-based Compensation Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>999063 - Disclosure - Stock-Based Compensation (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/Stock-basedCompensationDetailsNarrative</Role>
      <ShortName>Stock-Based Compensation (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://celcuity.com/role/Stock-basedCompensationTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>999064 - Disclosure - Schedule of Long-term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/ScheduleOfLong-termDebtDetails</Role>
      <ShortName>Schedule of Long-term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>999065 - Disclosure - Schedule of Long Term Debt Future Principal Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/ScheduleOfLongTermDebtFuturePrincipalPaymentsDetails</Role>
      <ShortName>Schedule of Long Term Debt Future Principal Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>999066 - Disclosure - Debt (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/DebtDetailsNarrative</Role>
      <ShortName>Debt (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://celcuity.com/role/DebtTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>999067 - Disclosure - Schedule of Effective Income Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails</Role>
      <ShortName>Schedule of Effective Income Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>999068 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Schedule of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>999069 - Disclosure - Income Taxes (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>Income Taxes (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://celcuity.com/role/IncomeTaxesTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>999070 - Disclosure - Subsequent Event (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/SubsequentEventDetailsNarrative</Role>
      <ShortName>Subsequent Event (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://celcuity.com/role/SubsequentEvent</ParentRole>
      <Position>66</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>celc-20241231.xsd</File>
    <File>celc-20241231_cal.xml</File>
    <File>celc-20241231_def.xml</File>
    <File>celc-20241231_lab.xml</File>
    <File>celc-20241231_pre.xml</File>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="form10-k.htm">form10-k.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>form10-k_001.jpg</File>
    <File>form10-k_002.jpg</File>
    <File>form10-k_003.jpg</File>
    <File>image_001.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2024</BaseTaxonomy>
    <BaseTaxonomy items="610">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="8">http://xbrl.sec.gov/cyd/2024</BaseTaxonomy>
    <BaseTaxonomy items="41">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>92
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form10-k.htm": {
   "nsprefix": "CELC",
   "nsuri": "http://celcuity.com/20241231",
   "dts": {
    "schema": {
     "local": [
      "celc-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "celc-20241231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "celc-20241231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "celc-20241231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "celc-20241231_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "form10-k.htm"
     ]
    }
   },
   "keyStandard": 287,
   "keyCustom": 47,
   "axisStandard": 18,
   "axisCustom": 0,
   "memberStandard": 18,
   "memberCustom": 36,
   "hidden": {
    "total": 75,
    "http://fasb.org/us-gaap/2024": 51,
    "http://celcuity.com/20241231": 21,
    "http://xbrl.sec.gov/dei/2024": 3
   },
   "contextCount": 151,
   "entityCount": 1,
   "segmentCount": 57,
   "elementCount": 601,
   "unitCount": 4,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 610,
    "http://xbrl.sec.gov/dei/2024": 41,
    "http://xbrl.sec.gov/cyd/2024": 8,
    "http://xbrl.sec.gov/ecd/2024": 4,
    "http://fasb.org/srt/2024": 1
   },
   "report": {
    "R1": {
     "role": "http://celcuity.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://celcuity.com/role/BalanceSheets",
     "longName": "00000002 - Statement - Balance Sheets",
     "shortName": "Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:AssetsCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://celcuity.com/role/BalanceSheetsParenthetical",
     "longName": "00000003 - Statement - Balance Sheets (Parenthetical)",
     "shortName": "Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:PreferredStockSharesIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://celcuity.com/role/StatementsOfOperations",
     "longName": "00000004 - Statement - Statements of Operations",
     "shortName": "Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity",
     "longName": "00000005 - Statement - Statements of Changes in Stockholders' Equity",
     "shortName": "Statements of Changes in Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://celcuity.com/role/StatementsOfCashFlows",
     "longName": "00000006 - Statement - Statements of Cash Flows",
     "shortName": "Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:AmortizationOfFinancingCostsAndDiscounts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://celcuity.com/role/StatementsOfCashFlowsParenthetical",
     "longName": "00000007 - Statement - Statements of Cash Flows (Parenthetical)",
     "shortName": "Statements of Cash Flows (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R9": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2024-10-012024-12-31",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-012024-12-31",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://celcuity.com/role/Organization",
     "longName": "999015 - Disclosure - Organization",
     "shortName": "Organization",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncements",
     "longName": "999016 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements",
     "shortName": "Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://celcuity.com/role/Liquidity",
     "longName": "999017 - Disclosure - Liquidity",
     "shortName": "Liquidity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://celcuity.com/role/NetLossPerCommonShare",
     "longName": "999018 - Disclosure - Net Loss Per Common Share",
     "shortName": "Net Loss Per Common Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://celcuity.com/role/Investments",
     "longName": "999019 - Disclosure - Investments",
     "shortName": "Investments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:InvestmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:InvestmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://celcuity.com/role/OtherCurrentAssets",
     "longName": "999020 - Disclosure - Other Current Assets",
     "shortName": "Other Current Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://celcuity.com/role/PropertyAndEquipment",
     "longName": "999021 - Disclosure - Property and Equipment",
     "shortName": "Property and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://celcuity.com/role/AccruedExpenses",
     "longName": "999022 - Disclosure - Accrued Expenses",
     "shortName": "Accrued Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://celcuity.com/role/Commitments",
     "longName": "999023 - Disclosure - Commitments",
     "shortName": "Commitments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://celcuity.com/role/StockholdersEquity",
     "longName": "999024 - Disclosure - Stockholders\u2019 Equity",
     "shortName": "Stockholders\u2019 Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://celcuity.com/role/Stock-basedCompensation",
     "longName": "999025 - Disclosure - Stock-Based Compensation",
     "shortName": "Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://celcuity.com/role/Debt",
     "longName": "999026 - Disclosure - Debt",
     "shortName": "Debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://celcuity.com/role/IncomeTaxes",
     "longName": "999027 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://celcuity.com/role/SubsequentEvent",
     "longName": "999028 - Disclosure - Subsequent Event",
     "shortName": "Subsequent Event",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies",
     "longName": "999029 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Policies)",
     "shortName": "Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "25",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsTables",
     "longName": "999030 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Tables)",
     "shortName": "Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "CELC:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "CELC:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://celcuity.com/role/NetLossPerCommonShareTables",
     "longName": "999031 - Disclosure - Net Loss Per Common Share (Tables)",
     "shortName": "Net Loss Per Common Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://celcuity.com/role/InvestmentsTables",
     "longName": "999032 - Disclosure - Investments (Tables)",
     "shortName": "Investments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:InvestmentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InvestmentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:InvestmentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InvestmentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://celcuity.com/role/OtherCurrentAssetsTables",
     "longName": "999033 - Disclosure - Other Current Assets (Tables)",
     "shortName": "Other Current Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://celcuity.com/role/PropertyAndEquipmentTables",
     "longName": "999034 - Disclosure - Property and Equipment (Tables)",
     "shortName": "Property and Equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://celcuity.com/role/AccruedExpensesTables",
     "longName": "999035 - Disclosure - Accrued Expenses (Tables)",
     "shortName": "Accrued Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://celcuity.com/role/CommitmentsTables",
     "longName": "999036 - Disclosure - Commitments (Tables)",
     "shortName": "Commitments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "srt:ScheduleOfCondensedBalanceSheetTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "srt:ScheduleOfCondensedBalanceSheetTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://celcuity.com/role/StockholdersEquityTables",
     "longName": "999037 - Disclosure - Stockholders\u2019 Equity (Tables)",
     "shortName": "Stockholders\u2019 Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://celcuity.com/role/Stock-basedCompensationTables",
     "longName": "999038 - Disclosure - Stock-Based Compensation (Tables)",
     "shortName": "Stock-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://celcuity.com/role/DebtTables",
     "longName": "999039 - Disclosure - Debt (Tables)",
     "shortName": "Debt (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://celcuity.com/role/IncomeTaxesTables",
     "longName": "999040 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://celcuity.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails",
     "longName": "999041 - Disclosure - Schedule of Estimated Useful Lives of Property and Equipment (Details)",
     "shortName": "Schedule of Estimated Useful Lives of Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31_srt_MinimumMember_us-gaap_FurnitureAndFixturesMember",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "CELC:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31_srt_MinimumMember_us-gaap_FurnitureAndFixturesMember",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "CELC:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsDetailsNarrative",
     "longName": "999042 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Details Narrative)",
     "shortName": "Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:CashFDICInsuredAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:CashFDICInsuredAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://celcuity.com/role/LiquidityDetailsNarrative",
     "longName": "999043 - Disclosure - Liquidity (Details Narrative)",
     "shortName": "Liquidity (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R40": {
     "role": "http://celcuity.com/role/ScheduleOfPotentially-dilutiveSharesExcludedFromDilutedWeighted-averageSharesOutstandingDetails",
     "longName": "999044 - Disclosure - Schedule of Potentially-Dilutive Shares Excluded from the Diluted Weighted-Average Shares Outstanding (Details)",
     "shortName": "Schedule of Potentially-Dilutive Shares Excluded from the Diluted Weighted-Average Shares Outstanding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://celcuity.com/role/NetLossPerCommonShareDetailsNarrative",
     "longName": "999045 - Disclosure - Net Loss Per Common Share (Details Narrative)",
     "shortName": "Net Loss Per Common Share (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "CELC:PrefundedWarrantShares",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "CELC:PrefundedWarrantShares",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://celcuity.com/role/ScheduleOfInvestmentDetails",
     "longName": "999046 - Disclosure - Schedule of Investment (Details)",
     "shortName": "Schedule of Investment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:HeldToMaturitySecurities",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentTableTextBlock",
       "us-gaap:InvestmentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:HeldToMaturitySecurities",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentTableTextBlock",
       "us-gaap:InvestmentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://celcuity.com/role/ScheduleOfOtherCurrentAssetsDetails",
     "longName": "999047 - Disclosure - Schedule of Other Current Assets (Details)",
     "shortName": "Schedule of Other Current Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "CELC:PrepaidClinicalTrialCosts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "CELC:PrepaidClinicalTrialCosts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://celcuity.com/role/SummaryOfPropertyAndEquipmentDetails",
     "longName": "999048 - Disclosure - Summary of Property and Equipment (Details)",
     "shortName": "Summary of Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://celcuity.com/role/PropertyAndEquipmentDetailsNarrative",
     "longName": "999049 - Disclosure - Property and Equipment (Details Narrative)",
     "shortName": "Property and Equipment (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:Depreciation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R46": {
     "role": "http://celcuity.com/role/ScheduleOfAccruedExpensesDetails",
     "longName": "999050 - Disclosure - Schedule of Accrued Expenses (Details)",
     "shortName": "Schedule of Accrued Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "CELC:AccruedClinicalTrialExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "CELC:AccruedClinicalTrialExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://celcuity.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails",
     "longName": "999051 - Disclosure - Schedule of Supplemental Balance Sheet Information Related to Leases (Details)",
     "shortName": "Schedule of Supplemental Balance Sheet Information Related to Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R48": {
     "role": "http://celcuity.com/role/ScheduleOfMaturityAnalysisUnderLeaseAgreementsDetails",
     "longName": "999052 - Disclosure - Schedule of Maturity Analysis Under Lease Agreements (Details)",
     "shortName": "Schedule of Maturity Analysis Under Lease Agreements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://celcuity.com/role/ScheduleOfLeaseCostsDetails",
     "longName": "999053 - Disclosure - Schedule of Lease Costs (Details)",
     "shortName": "Schedule of Lease Costs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://celcuity.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails",
     "longName": "999054 - Disclosure - Schedule of Supplemental Cash Flow Information Related to Leases (Details)",
     "shortName": "Schedule of Supplemental Cash Flow Information Related to Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://celcuity.com/role/CommitmentsDetailsNarrative",
     "longName": "999055 - Disclosure - Commitments (Details Narrative)",
     "shortName": "Commitments (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:ContractualObligation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:ContractualObligation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://celcuity.com/role/ScheduleOfWarrantsDetails",
     "longName": "999056 - Disclosure - Schedule of Warrants (Details)",
     "shortName": "Schedule of Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31_custom_WarrantOneMember",
      "name": "CELC:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://celcuity.com/role/StockholdersEquityDetailsNarrative",
     "longName": "999057 - Disclosure - Stockholders\u2019 Equity (Details Narrative)",
     "shortName": "Stockholders\u2019 Equity (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://celcuity.com/role/ScheduleOfStockOptionsActivityDetails",
     "longName": "999058 - Disclosure - Schedule of Stock Options Activity (Details)",
     "shortName": "Schedule of Stock Options Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_EmployeeStockOptionMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31_us-gaap_EmployeeStockOptionMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://celcuity.com/role/ScheduleOfStockOptionsOutstandingAndExercisableDetails",
     "longName": "999059 - Disclosure - Schedule of Stock Options Outstanding and Exercisable (Details)",
     "shortName": "Schedule of Stock Options Outstanding and Exercisable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31_us-gaap_EmployeeStockOptionMember1617134453",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31_us-gaap_EmployeeStockOptionMember1617134453",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://celcuity.com/role/ScheduleOfAssumptionsForFairValueOfEquity-basedAwardsDetails",
     "longName": "999060 - Disclosure - Schedule of Assumptions for Fair Value of Equity-based Awards (Details)",
     "shortName": "Schedule of Assumptions for Fair Value of Equity-based Awards (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://celcuity.com/role/ScheduleOfUnrecognizedCompensationCostDetails",
     "longName": "999061 - Disclosure - Schedule of Unrecognized Compensation Cost (Details)",
     "shortName": "Schedule of Unrecognized Compensation Cost (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "CELC:EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostToBeRecognizedNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "CELC:EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostToBeRecognizedNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://celcuity.com/role/ScheduleOfStock-basedCompensationExpensesDetails",
     "longName": "999062 - Disclosure - Schedule of Stock-based Compensation Expenses (Details)",
     "shortName": "Schedule of Stock-based Compensation Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31_us-gaap_ResearchAndDevelopmentExpenseMember",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative",
     "longName": "999063 - Disclosure - Stock-Based Compensation (Details Narrative)",
     "shortName": "Stock-Based Compensation (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "AsOf2022-05-31_custom_MayTwoThousandTwentyTwoExercisePriceModificationMember",
      "name": "CELC:StockOptionAwardsSharesModified",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-05-31_custom_MayTwoThousandTwentyTwoExercisePriceModificationMember",
      "name": "CELC:StockOptionAwardsSharesModified",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://celcuity.com/role/ScheduleOfLong-termDebtDetails",
     "longName": "999064 - Disclosure - Schedule of Long-term Debt (Details)",
     "shortName": "Schedule of Long-term Debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:ConvertibleNotesPayable",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:ConvertibleNotesPayable",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://celcuity.com/role/ScheduleOfLongTermDebtFuturePrincipalPaymentsDetails",
     "longName": "999065 - Disclosure - Schedule of Long Term Debt Future Principal Payments (Details)",
     "shortName": "Schedule of Long Term Debt Future Principal Payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://celcuity.com/role/DebtDetailsNarrative",
     "longName": "999066 - Disclosure - Debt (Details Narrative)",
     "shortName": "Debt (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "CELC:FinalFee",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-05-302024-05-30_custom_AmendedAndRestatedLoanAgreementMember",
      "name": "us-gaap:DebtInstrumentInterestRateTerms",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R63": {
     "role": "http://celcuity.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails",
     "longName": "999067 - Disclosure - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "shortName": "Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://celcuity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails",
     "longName": "999068 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "shortName": "Schedule of Deferred Tax Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://celcuity.com/role/IncomeTaxesDetailsNarrative",
     "longName": "999069 - Disclosure - Income Taxes (Details Narrative)",
     "shortName": "Income Taxes (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://celcuity.com/role/SubsequentEventDetailsNarrative",
     "longName": "999070 - Disclosure - Subsequent Event (Details Narrative)",
     "shortName": "Subsequent Event (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ProceedsFromWarrantExercises",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-022025-01-31_us-gaap_SubsequentEventMember",
      "name": "us-gaap:StockOptionExercisePriceDecrease",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://celcuity.com/role/AccruedExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Expenses",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r50",
      "r54",
      "r875"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r669"
     ]
    },
    "CELC_AccruedClinicalTrialExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "AccruedClinicalTrialExpense",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical trial costs",
        "documentation": "Accrued clinical trial, expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedEmployeeBenefitsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee stock purchase plan",
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://celcuity.com/role/ScheduleOfAccruedExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://celcuity.com/role/BalanceSheets",
      "http://celcuity.com/role/ScheduleOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses",
        "totalLabel": "Total",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/SummaryOfPropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/SummaryOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r136",
      "r511"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r743"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r669",
      "r918"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r543",
      "r820",
      "r821",
      "r822",
      "r823",
      "r881",
      "r919"
     ]
    },
    "CELC_AdditionalPaidInCapitalPreFundedWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "AdditionalPaidInCapitalPreFundedWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of pre-funded warrants",
        "documentation": "Additional paid in capital Pre-Funded Warrant issued."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Issuance costs associated with an ATM offering",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r86"
     ]
    },
    "CELC_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsIssuanceWithPrivatePlacementOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsIssuanceWithPrivatePlacementOffering",
     "crdr": "debit",
     "presentation": [
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Issuance costs associated with private placement offering",
        "documentation": "Issuance costs associated with private placement offering.",
        "label": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsIssuanceWithPrivatePlacementOffering"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock warrants, note payable",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r29",
      "r86"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used for operations:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r710",
      "r721",
      "r735",
      "r761"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r713",
      "r724",
      "r738",
      "r764"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r749"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r756"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r714",
      "r725",
      "r739",
      "r756",
      "r765",
      "r769",
      "r777"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recognized stock-based compensation expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r360",
      "r369"
     ]
    },
    "CELC_AmendedAndRestatedLoanAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "AmendedAndRestatedLoanAgreementMember",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amended and Restated Loan Agreement [Member]",
        "documentation": "Amended and Restated Loan Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of debt issuance costs and discount",
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r297",
      "r649",
      "r650",
      "r814",
      "r899"
     ]
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfPotentially-dilutiveSharesExcludedFromDilutedWeighted-averageSharesOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Anti-dilutive securities excluded from diluted weighted- average shares outstanding",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r186"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfPotentially-dilutiveSharesExcludedFromDilutedWeighted-averageSharesOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfPotentially-dilutiveSharesExcludedFromDilutedWeighted-averageSharesOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfPotentially-dilutiveSharesExcludedFromDilutedWeighted-averageSharesOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative",
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r407"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://celcuity.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Assets",
        "label": "Assets [Default Label]",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r107",
      "r138",
      "r160",
      "r190",
      "r194",
      "r205",
      "r206",
      "r240",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r408",
      "r410",
      "r430",
      "r502",
      "r578",
      "r640",
      "r641",
      "r669",
      "r682",
      "r844",
      "r845",
      "r905"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://celcuity.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r143",
      "r160",
      "r240",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r408",
      "r410",
      "r430",
      "r669",
      "r844",
      "r845",
      "r905"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://celcuity.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Assets:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r694",
      "r696",
      "r717"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r694",
      "r696",
      "r717"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r694",
      "r696",
      "r717"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Opinion [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r772"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r773"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "auth_ref": [
      "r768"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfStockOptionsOutstandingAndExercisableDetails",
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r332",
      "r333",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r771"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r770"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r769"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r769"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAbstract",
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/BalanceSheets",
      "http://celcuity.com/role/LiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r134",
      "r631"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning of period",
        "periodEndLabel": "End of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r72",
      "r157"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/StatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net change in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r72"
     ]
    },
    "us-gaap_CashFDICInsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFDICInsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash equivalents FDIC insured, amount",
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosures of non-cash investing and financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "CELC_CashPaidForOperatingAndFinanceLeases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "CashPaidForOperatingAndFinanceLeases",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total cash paid for amounts included in operating and finance leases",
        "documentation": "Cash paid for operating and finance leases.",
        "label": "CashPaidForOperatingAndFinanceLeases"
       }
      }
     },
     "auth_ref": []
    },
    "CELC_CashPaidForOperatingAndFinanceLeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "CashPaidForOperatingAndFinanceLeasesAbstract",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for amounts included in operating and finance leases:"
       }
      }
     },
     "auth_ref": []
    },
    "CELC_ChangeInAccruedInterestIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "ChangeInAccruedInterestIncome",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in accrued interest income",
        "documentation": "Change in accrued interest income.",
        "label": "ChangeInAccruedInterestIncome"
       }
      }
     },
     "auth_ref": []
    },
    "CELC_ChangeInCommonStockSharesReservedForIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "ChangeInCommonStockSharesReservedForIssuance",
     "presentation": [
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in common stock, shares reserved for issuance",
        "documentation": "Change in common stock, shares reserved for issuance"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r139",
      "r140",
      "r141",
      "r160",
      "r180",
      "r181",
      "r183",
      "r185",
      "r192",
      "r193",
      "r240",
      "r266",
      "r268",
      "r269",
      "r270",
      "r273",
      "r274",
      "r306",
      "r307",
      "r311",
      "r314",
      "r321",
      "r430",
      "r537",
      "r538",
      "r539",
      "r540",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r566",
      "r587",
      "r605",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r795",
      "r815",
      "r824"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r140",
      "r141",
      "r192",
      "r306",
      "r307",
      "r309",
      "r311",
      "r314",
      "r319",
      "r321",
      "r537",
      "r538",
      "r539",
      "r540",
      "r651",
      "r795",
      "r815"
     ]
    },
    "CELC_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue": {
     "xbrltype": "dateItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issue Date",
        "documentation": "Class of warrant or righst date from which warrants or rights issue."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative",
      "http://celcuity.com/role/ScheduleOfWarrantsDetails",
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative",
      "http://celcuity.com/role/SubsequentEventDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Exercise Price",
        "label": "Exercise price of common stock warrants",
        "terseLabel": "Warrants exercise price per share",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r322"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "presentation": [
      "http://celcuity.com/role/SubsequentEventDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants exercised",
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional warrants exercised",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r322"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative",
      "http://celcuity.com/role/ScheduleOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Warrants Outstanding",
        "verboseLabel": "Warrants issued",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightReasonForIssuingToNonemployees",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering",
        "documentation": "Description of reason for issuing warrant or right."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightTable",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Table]",
        "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies (Note 9)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r100",
      "r504",
      "r565"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsDisclosureTextBlock",
     "presentation": [
      "http://celcuity.com/role/Commitments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments",
        "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares reserved for issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r672",
      "r673",
      "r674",
      "r676",
      "r677",
      "r678",
      "r679",
      "r820",
      "r821",
      "r823",
      "r881",
      "r917",
      "r919"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://celcuity.com/role/BalanceSheetsParenthetical",
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://celcuity.com/role/BalanceSheetsParenthetical",
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r566"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://celcuity.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://celcuity.com/role/BalanceSheetsParenthetical",
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r58",
      "r566",
      "r584",
      "r919",
      "r920"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, $0.001 par value: 95,000,000 and 65,000,000 shares authorized as of December 31, 2024 and December 31, 2023, respectively; 37,143,242 and 25,506,012 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r506",
      "r669"
     ]
    },
    "CELC_CommonStockWarrantsIssuedWithNotePayableTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "CommonStockWarrantsIssuedWithNotePayableTransaction",
     "crdr": "credit",
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock warrants issued with the note payable transaction",
        "documentation": "Common stock warrants issued with note payable transaction."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r751"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Loss",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risks and Uncertainties",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r115"
     ]
    },
    "us-gaap_ContractualObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractualObligation",
     "crdr": "credit",
     "presentation": [
      "http://celcuity.com/role/CommitmentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cancelable contractual commitment",
        "documentation": "Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments."
       }
      }
     },
     "auth_ref": [
      "r818"
     ]
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockSharesConverted1",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares converted",
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21",
      "r22"
     ]
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockSharesIssued1",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares issued in conversion",
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21",
      "r22"
     ]
    },
    "us-gaap_ConvertibleNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfLong-termDebtDetails": {
       "parentTag": "us-gaap_LongTermNotesPayable",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfLong-termDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note payable",
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r99",
      "r915"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r704",
      "r787"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r704",
      "r787"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r706",
      "r789"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r706",
      "r789"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r706",
      "r789"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r699",
      "r782"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r700",
      "r783"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r700",
      "r783"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r698",
      "r781"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r701",
      "r784"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r703",
      "r786"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r703",
      "r786"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r704",
      "r787"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r705",
      "r788"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r702",
      "r785"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://celcuity.com/role/Debt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r158",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r264",
      "r265",
      "r275",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r291",
      "r298",
      "r299",
      "r301",
      "r439"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r49",
      "r50",
      "r97",
      "r99",
      "r162",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r282",
      "r287",
      "r288",
      "r289",
      "r290",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r667",
      "r816",
      "r840",
      "r841",
      "r842",
      "r898",
      "r900"
     ]
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Funded loan amount",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r99",
      "r302"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Funded contingent loan, outstanding",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r276",
      "r439",
      "r440",
      "r647",
      "r648",
      "r667"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan conversion percentage",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r277"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateTerms": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateTerms",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt instrument interest rate description",
        "documentation": "Description of the interest rate as being fixed or variable, and, if variable, identification of the index or rate on which the interest rate is based and the number of points or percentage added to that index or rate to set the rate, and other pertinent information, such as frequency of rate resets."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r282",
      "r287",
      "r288",
      "r289",
      "r290",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r300",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r667",
      "r816",
      "r898",
      "r900"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r162",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r282",
      "r287",
      "r288",
      "r289",
      "r290",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r667",
      "r816",
      "r840",
      "r841",
      "r842",
      "r898",
      "r900"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r32",
      "r35",
      "r44",
      "r84",
      "r85",
      "r162",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r282",
      "r287",
      "r288",
      "r289",
      "r290",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r300",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r667",
      "r816",
      "r898",
      "r900"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentUnamortizedDiscount",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfLong-termDebtDetails": {
       "parentTag": "us-gaap_LongTermNotesPayable",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfLong-termDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: unamortized debt discount",
        "label": "Debt Instrument, Unamortized Discount",
        "documentation": "Amount, after accumulated amortization, of debt discount."
       }
      }
     },
     "auth_ref": [
      "r847",
      "r897",
      "r898",
      "r900"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfLong-termDebtDetails": {
       "parentTag": "us-gaap_LongTermNotesPayable",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfLong-termDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: unamortized debt issuance costs",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r303",
      "r438",
      "r439",
      "r440",
      "r647",
      "r648",
      "r667"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentUnamortizedDiscountPremiumNet",
     "crdr": "debit",
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt issuance costs and discount",
        "documentation": "Amount, after accumulated amortization, of debt discount (premium)."
       }
      }
     },
     "auth_ref": [
      "r847",
      "r897",
      "r898",
      "r900"
     ]
    },
    "us-gaap_DebtPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtPolicyTextBlock",
     "presentation": [
      "http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Issuance Costs",
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfInvestmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Table]",
        "documentation": "Disclosure of information about allowance for credit loss on investment in debt security measured at amortized cost (held-to-maturity)."
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfInvestmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "CELC_DecemberTwoThousandTwentyOneExercisePriceModificationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "DecemberTwoThousandTwentyOneExercisePriceModificationMember",
     "presentation": [
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "December 2021 Exercise Price Modification [Member]",
        "documentation": "December 2021 Exercise Price Modification [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredChargesPolicyTextBlock",
     "presentation": [
      "http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Transaction Costs",
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges."
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCostsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCostsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred transaction costs",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "CELC_DeferredFinancingCostsAndOfferingAndRegistrationStatementCostsIncludedInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "DeferredFinancingCostsAndOfferingAndRegistrationStatementCostsIncludedInAccountsPayable",
     "crdr": "credit",
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred financing costs and offering and registration statement costs included in accounts payable",
        "documentation": "Deferred financing costs and offering and registration statement costs included in accounts payable."
       }
      }
     },
     "auth_ref": []
    },
    "CELC_DeferredTaxAssetsLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "DeferredTaxAssetsLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Lease liability",
        "documentation": "Deferred tax assets lease liability.",
        "label": "DeferredTaxAssetsLeaseLiability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax assets",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating losses and tax credits",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
     "crdr": "debit",
     "presentation": [
      "http://celcuity.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal net operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "crdr": "debit",
     "presentation": [
      "http://celcuity.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State net operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "CELC_DeferredTaxAssetsRightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "DeferredTaxAssetsRightofuseAssets",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-use assets",
        "documentation": "Deferred tax assets right of use assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "presentation": [
      "http://celcuity.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax credit carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "CELC_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIRC174Expenditures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIRC174Expenditures",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IRC 174 Expenditures",
        "documentation": "Deferred tax assets tax deferred expense compensation and benefits IRC 174 expenditures."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based compensation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "CELC_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStartupExpenditures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStartupExpenditures",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Start-up expenditures",
        "documentation": "Start-up expenditures"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued expenses",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities."
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r388"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/PropertyAndEquipmentDetailsNarrative",
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "verboseLabel": "Depreciation expense",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r27"
     ]
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeContractTypeDomain",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "auth_ref": [
      "r555",
      "r557",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r579",
      "r580",
      "r581",
      "r582",
      "r593",
      "r594",
      "r595",
      "r596",
      "r599",
      "r600",
      "r601",
      "r602",
      "r617",
      "r618",
      "r619",
      "r620",
      "r672",
      "r674",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r893",
      "r894"
     ]
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeInstrumentRiskAxis",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instrument [Axis]",
        "documentation": "Information by type of derivative contract."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r42",
      "r43",
      "r95",
      "r555",
      "r557",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r579",
      "r580",
      "r581",
      "r582",
      "r593",
      "r594",
      "r595",
      "r596",
      "r599",
      "r600",
      "r601",
      "r602",
      "r617",
      "r618",
      "r619",
      "r620",
      "r633",
      "r672",
      "r674",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r893",
      "r894"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://celcuity.com/role/Stock-basedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r327",
      "r330",
      "r361",
      "r362",
      "r364",
      "r655"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r696"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r694",
      "r696",
      "r717"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r694",
      "r696",
      "r717",
      "r757"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r695"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r683"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r696"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r696"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r686"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://celcuity.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Jurisdiction [Member]",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://celcuity.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per share, basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r178",
      "r180",
      "r183",
      "r184",
      "r185",
      "r189",
      "r403",
      "r406",
      "r421",
      "r422",
      "r498",
      "r517",
      "r635"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://celcuity.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per share, diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r180",
      "r183",
      "r184",
      "r185",
      "r189",
      "r403",
      "r406",
      "r421",
      "r422",
      "r498",
      "r517",
      "r635"
     ]
    },
    "us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDilutedOtherDisclosuresAbstract",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfPotentially-dilutiveSharesExcludedFromDilutedWeighted-averageSharesOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Potentially-dilutive shares excluded from diluted weighted-average shares outstanding:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://celcuity.com/role/NetLossPerCommonShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Common Share",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r186",
      "r187",
      "r188"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationLineItems",
     "presentation": [
      "http://celcuity.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r377",
      "r378",
      "r656"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTable",
     "presentation": [
      "http://celcuity.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation [Table]",
        "documentation": "Disclosure of information about income tax rate reconciliation between amount of reported income tax expense (benefit) attributable to continuing operation to amount of income tax expense(benefit) that would result from applying statutory federal (national) tax rate to pretax income (loss) from continuing operation."
       }
      }
     },
     "auth_ref": [
      "r377",
      "r378",
      "r656"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfStock-basedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostToBeRecognizedWithinFourYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostToBeRecognizedWithinFourYears",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfUnrecognizedCompensationCostDetails": {
       "parentTag": "CELC_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostToBeRecognized",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfUnrecognizedCompensationCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2028",
        "documentation": "Employee service share based compensation nonvested awards total compensation cost to be recognized within four years."
       }
      }
     },
     "auth_ref": []
    },
    "CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostToBeRecognizedWithinTwoYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostToBeRecognizedWithinTwoYear",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfUnrecognizedCompensationCostDetails": {
       "parentTag": "CELC_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostToBeRecognized",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfUnrecognizedCompensationCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2026",
        "documentation": "Employee service share based compensation nonvested awards total compensation cost to be recognized within two year.",
        "label": "EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostToBeRecognizedWithinTwoYear"
       }
      }
     },
     "auth_ref": []
    },
    "CELC_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostToBeRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostToBeRecognized",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfUnrecognizedCompensationCostDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfUnrecognizedCompensationCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total estimated compensation cost to be recognized",
        "documentation": "Employee service share based compensation nonvested awards total compensation cost to be recognized.",
        "label": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostToBeRecognized"
       }
      }
     },
     "auth_ref": []
    },
    "CELC_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostToBeRecognizedNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostToBeRecognizedNextTwelveMonths",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfUnrecognizedCompensationCostDetails": {
       "parentTag": "CELC_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostToBeRecognized",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfUnrecognizedCompensationCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2025",
        "documentation": "Employee service share based compensation nonvested awards total compensation cost to be recognized next twelve months.",
        "label": "EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostToBeRecognizedNextTwelveMonths"
       }
      }
     },
     "auth_ref": []
    },
    "CELC_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostToBeRecognizedwithinThreeYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostToBeRecognizedwithinThreeYears",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfUnrecognizedCompensationCostDetails": {
       "parentTag": "CELC_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostToBeRecognized",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfUnrecognizedCompensationCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2027",
        "documentation": "Employee service share based compensation nonvested awards total compensation cost to be recognized within three year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfStockOptionsActivityDetails",
      "http://celcuity.com/role/ScheduleOfStockOptionsOutstandingAndExercisableDetails",
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "CELC_EmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "EmployeeStockPurchasePlanMember",
     "presentation": [
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2017 Employee Stock Purchase Plan [Member]",
        "documentation": "2017 Employee Stock Purchase Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r689"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r685"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r685"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r685"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r685"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r685"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r685"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r685"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative",
      "http://celcuity.com/role/ScheduleOfPotentially-dilutiveSharesExcludedFromDilutedWeighted-averageSharesOutstandingDetails",
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity",
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r130",
      "r147",
      "r148",
      "r149",
      "r163",
      "r164",
      "r165",
      "r167",
      "r172",
      "r174",
      "r176",
      "r191",
      "r241",
      "r242",
      "r251",
      "r323",
      "r393",
      "r394",
      "r400",
      "r401",
      "r402",
      "r404",
      "r405",
      "r406",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r420",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r441",
      "r442",
      "r458",
      "r515",
      "r524",
      "r525",
      "r526",
      "r543",
      "r605"
     ]
    },
    "CELC_EquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "EquityIncentivePlanMember",
     "presentation": [
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2012 Equity Incentive Plan [Member]",
        "documentation": "2012 Equity Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r750"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r710",
      "r721",
      "r735",
      "r761"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r707",
      "r718",
      "r732",
      "r758"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "CELC_ExerciseOfCommonStockSharesWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "ExerciseOfCommonStockSharesWarrants",
     "presentation": [
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of common stock warrants, shares",
        "documentation": "Exercise of common stock warrants , shares."
       }
      }
     },
     "auth_ref": []
    },
    "CELC_ExerciseOfCommonStockWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "ExerciseOfCommonStockWarrants",
     "crdr": "credit",
     "presentation": [
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Exercise of common stock warrants",
        "documentation": "Exercise of common stock warrants.",
        "label": "ExerciseOfCommonStockWarrants"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of warrants",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r5"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "CELC_FinalFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "FinalFee",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfLong-termDebtDetails": {
       "parentTag": "us-gaap_LongTermNotesPayable",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative",
      "http://celcuity.com/role/ScheduleOfLong-termDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Add: Final fee",
        "verboseLabel": "Final fee",
        "documentation": "Final fee."
       }
      }
     },
     "auth_ref": []
    },
    "CELC_FinalFeePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "FinalFeePercentage",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Final fee percentage",
        "documentation": "Final fee percentage."
       }
      }
     },
     "auth_ref": []
    },
    "CELC_FinanceLeaseCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "FinanceLeaseCostAbstract",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance lease cost:",
        "documentation": "Finance lease cost [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseInterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfLeaseCostsDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest",
        "documentation": "Amount of interest expense on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r445",
      "r450",
      "r668"
     ]
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails": {
       "parentTag": "CELC_CashPaidForOperatingAndFinanceLeases",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating cash outflow from finance leases",
        "documentation": "Amount of interest paid on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r447",
      "r453"
     ]
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeasePrincipalPayments",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails": {
       "parentTag": "CELC_CashPaidForOperatingAndFinanceLeases",
       "weight": 1.0,
       "order": 3.0
      },
      "http://celcuity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails",
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments for finance leases",
        "label": "Financing cash outflow from finance leases",
        "documentation": "Amount of cash outflow for principal payment on finance lease."
       }
      }
     },
     "auth_ref": [
      "r446",
      "r453"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfLeaseCostsDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization",
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r445",
      "r450",
      "r668"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfInvestmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r300",
      "r319",
      "r418",
      "r429",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r516",
      "r644",
      "r657",
      "r658",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r670",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r832",
      "r833",
      "r834",
      "r835",
      "r882",
      "r883",
      "r884",
      "r885",
      "r892",
      "r895"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r714",
      "r725",
      "r739",
      "r765"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r714",
      "r725",
      "r739",
      "r765"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r714",
      "r725",
      "r739",
      "r765"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r714",
      "r725",
      "r739",
      "r765"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r714",
      "r725",
      "r739",
      "r765"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails",
      "http://celcuity.com/role/SummaryOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r589"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfStock-basedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "us-gaap_HeldToMaturitySecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "HeldToMaturitySecurities",
     "crdr": "debit",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfInvestmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss",
        "documentation": "Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity)."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r223",
      "r245",
      "r837"
     ]
    },
    "us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain",
     "crdr": "credit",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfInvestmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Held-to-Maturity, Accumulated Unrecognized Gain",
        "documentation": "Amount of accumulated unrecognized gain on investment in debt security measured at amortized cost (held-to-maturity)."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r233"
     ]
    },
    "us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss",
     "crdr": "debit",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfInvestmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at amortized cost (held-to-maturity)."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r234"
     ]
    },
    "us-gaap_HeldToMaturitySecuritiesFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "HeldToMaturitySecuritiesFairValue",
     "crdr": "debit",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfInvestmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Held-to-Maturity, Fair Value",
        "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity)."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r232",
      "r423",
      "r427",
      "r497",
      "r501"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r694",
      "r696",
      "r717"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Assets",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r79"
     ]
    },
    "us-gaap_InProcessResearchAndDevelopmentPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InProcessResearchAndDevelopmentPolicy",
     "presentation": [
      "http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical Trial Costs",
        "documentation": "Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r104",
      "r106",
      "r499",
      "r513",
      "r637",
      "r640",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfStock-basedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r258",
      "r259",
      "r425",
      "r426",
      "r428",
      "r521",
      "r523",
      "r590",
      "r630",
      "r659",
      "r916"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfStock-basedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r258",
      "r259",
      "r425",
      "r426",
      "r428",
      "r521",
      "r523",
      "r590",
      "r630",
      "r659",
      "r916"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://celcuity.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r377",
      "r378",
      "r385",
      "r391",
      "r656",
      "r879"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://celcuity.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r377",
      "r378",
      "r385",
      "r391",
      "r656",
      "r879"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://celcuity.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r373",
      "r377",
      "r382",
      "r383",
      "r384",
      "r386",
      "r390",
      "r395",
      "r397",
      "r398",
      "r399",
      "r542",
      "r656"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://celcuity.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails",
      "http://celcuity.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income tax benefits",
        "totalLabel": "Income tax benefits",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r121",
      "r175",
      "r176",
      "r190",
      "r197",
      "r206",
      "r376",
      "r377",
      "r396",
      "r519",
      "r656"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r374",
      "r375",
      "r386",
      "r387",
      "r389",
      "r392",
      "r536"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in valuation allowance on deferred tax assets",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r381",
      "r656",
      "r876"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax benefit at statutory federal rate",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r377",
      "r656"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseOther",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other permanent items",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r656",
      "r876",
      "r877"
     ]
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State income tax benefit, net of federal tax effect",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r380",
      "r656",
      "r876"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Research &amp; Development Credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r656",
      "r876",
      "r877"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued expenses",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherCurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other current assets",
        "label": "Increase (Decrease) in Other Current Assets",
        "documentation": "Amount of increase (decrease) in current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r714",
      "r725",
      "r739",
      "r756",
      "r765",
      "r769",
      "r777"
     ]
    },
    "CELC_InnovatusLifeSciencesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "InnovatusLifeSciencesMember",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Innovatus Life Sciences [Member]",
        "documentation": "Innovatus Life Sciences [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r697",
      "r780"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r697",
      "r780"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r697",
      "r780"
     ]
    },
    "CELC_InstitutionalAndOtherAccreditedInvestorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "InstitutionalAndOtherAccreditedInvestorsMember",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Institutional and Other Accredited Investors [Member]",
        "documentation": "Institutional and Other Accredited Investors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "Interest Expense, Nonoperating",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r811"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest paid",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r154",
      "r155"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r195",
      "r206",
      "r640",
      "r810"
     ]
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentPolicyTextBlock",
     "presentation": [
      "http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Investments",
        "label": "Investment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment in financial asset."
       }
      }
     },
     "auth_ref": [
      "r518",
      "r532",
      "r533",
      "r534",
      "r535",
      "r612",
      "r613"
     ]
    },
    "us-gaap_InvestmentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentTableTextBlock",
     "presentation": [
      "http://celcuity.com/role/InvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Investment",
        "documentation": "Tabular disclosure of investment."
       }
      }
     },
     "auth_ref": [
      "r796",
      "r797",
      "r831"
     ]
    },
    "us-gaap_InvestmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentTextBlock",
     "presentation": [
      "http://celcuity.com/role/Investments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Investments",
        "label": "Investment [Text Block]",
        "documentation": "The entire disclosure for investment."
       }
      }
     },
     "auth_ref": [
      "r796",
      "r797",
      "r831"
     ]
    },
    "us-gaap_InvestmentsAllOtherInvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsAllOtherInvestmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, All Other Investments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "CELC_IssuanceCostsAssociatedWithPrefundedWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "IssuanceCostsAssociatedWithPrefundedWarrants",
     "crdr": "debit",
     "presentation": [
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance costs associated with pre-funded warrants",
        "documentation": "Issuance costs associated with pre-funded warrants."
       }
      }
     },
     "auth_ref": []
    },
    "CELC_JefferiesLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "JefferiesLLCMember",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Jefferies LLC [Member]",
        "documentation": "Jefferies LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfLeaseCostsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Lease costs",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r449",
      "r668"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://celcuity.com/role/CommitmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Lease Costs",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r901"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails",
      "http://celcuity.com/role/SummaryOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r457"
     ]
    },
    "CELC_LeerinkPartnersLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "LeerinkPartnersLLCMember",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leerink Partners LLC [Member]",
        "documentation": "Leerink Partners LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseDescriptionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseDescriptionAbstract",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://celcuity.com/role/CommitmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Maturity Analysis Under Lease Agreements",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r902"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfMaturityAnalysisUnderLeaseAgreementsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfMaturityAnalysisUnderLeaseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total minimum lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r456"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfMaturityAnalysisUnderLeaseAgreementsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfMaturityAnalysisUnderLeaseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r456"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfMaturityAnalysisUnderLeaseAgreementsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfMaturityAnalysisUnderLeaseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r456"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfMaturityAnalysisUnderLeaseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Present value discount",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r456"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r49",
      "r50",
      "r51",
      "r53",
      "r54",
      "r55",
      "r56",
      "r160",
      "r240",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r409",
      "r410",
      "r411",
      "r430",
      "r564",
      "r636",
      "r682",
      "r844",
      "r905",
      "r906"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://celcuity.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Liabilities and Stockholders\u2019 Equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r101",
      "r508",
      "r669",
      "r817",
      "r836",
      "r896"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://celcuity.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Stockholders\u2019 Equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r133",
      "r160",
      "r240",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r409",
      "r410",
      "r411",
      "r430",
      "r669",
      "r844",
      "r905",
      "r906"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://celcuity.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfLongTermDebtFuturePrincipalPaymentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfLongTermDebtFuturePrincipalPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Long-Term Debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r99",
      "r288",
      "r304",
      "r647",
      "r648",
      "r667",
      "r915"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfLongTermDebtFuturePrincipalPaymentsDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfLongTermDebtFuturePrincipalPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2029",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r162",
      "r293"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfLongTermDebtFuturePrincipalPaymentsDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfLongTermDebtFuturePrincipalPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2028",
        "label": "Long-Term Debt, Maturity, Year Three",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r162",
      "r293"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfLongTermDebtFuturePrincipalPaymentsDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfLongTermDebtFuturePrincipalPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2027",
        "label": "Long-Term Debt, Maturity, Year Two",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r162",
      "r293"
     ]
    },
    "us-gaap_LongTermNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      },
      "http://celcuity.com/role/ScheduleOfLong-termDebtDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://celcuity.com/role/BalanceSheets",
      "http://celcuity.com/role/ScheduleOfLong-termDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note payable, non-current",
        "totalLabel": "Total long-term debt",
        "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "cyd_MaterialCybersecurityIncidentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r728",
      "r729"
     ]
    },
    "cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Information Not Available or Undetermined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r728",
      "r730"
     ]
    },
    "cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r728",
      "r731"
     ]
    },
    "cyd_MaterialCybersecurityIncidentNatureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentNatureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Nature [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r728",
      "r731"
     ]
    },
    "cyd_MaterialCybersecurityIncidentScopeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentScopeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Scope [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r728",
      "r731"
     ]
    },
    "cyd_MaterialCybersecurityIncidentTimingTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentTimingTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Timing [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r728",
      "r731"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative",
      "http://celcuity.com/role/ScheduleOfAssumptionsForFairValueOfEquity-basedAwardsDetails",
      "http://celcuity.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails",
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "documentation": "Upper limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r124",
      "r125",
      "r126",
      "r127",
      "r128",
      "r129",
      "r260",
      "r261",
      "r262",
      "r263",
      "r326",
      "r370",
      "r424",
      "r495",
      "r520",
      "r522",
      "r529",
      "r556",
      "r557",
      "r611",
      "r614",
      "r615",
      "r616",
      "r621",
      "r628",
      "r629",
      "r643",
      "r651",
      "r654",
      "r660",
      "r661",
      "r665",
      "r666",
      "r671",
      "r846",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912"
     ]
    },
    "CELC_MayTwoThousandTwentyExercisePriceModificationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "MayTwoThousandTwentyExercisePriceModificationMember",
     "presentation": [
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "May 2020 Exercise Price Modification [Member]",
        "documentation": "May 2020 Exercise Price Modification [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELC_MayTwoThousandTwentyTwoExercisePriceModificationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "MayTwoThousandTwentyTwoExercisePriceModificationMember",
     "presentation": [
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "May 2022 Exercise Price Modification [Member]",
        "documentation": "May 2022 Exercise Price Modification [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name"
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfAssumptionsForFairValueOfEquity-basedAwardsDetails",
      "http://celcuity.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails",
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "documentation": "Lower limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r124",
      "r125",
      "r126",
      "r127",
      "r128",
      "r129",
      "r260",
      "r261",
      "r262",
      "r263",
      "r326",
      "r370",
      "r424",
      "r495",
      "r520",
      "r522",
      "r529",
      "r556",
      "r557",
      "r611",
      "r614",
      "r615",
      "r616",
      "r621",
      "r628",
      "r629",
      "r643",
      "r651",
      "r654",
      "r660",
      "r661",
      "r665",
      "r671",
      "r846",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912"
     ]
    },
    "CELC_MiscellaneousReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "MiscellaneousReceivable",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Miscellaneous receivable",
        "documentation": "Miscellaneous receivable."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "CELC_ModifiedStockOptionExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "ModifiedStockOptionExercisePrice",
     "presentation": [
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock option exercise price per share",
        "documentation": "Modified stock option exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r153"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used for investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r153"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://celcuity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used for operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r73",
      "r74"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://celcuity.com/role/StatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows",
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity",
      "http://celcuity.com/role/StatementsOfOperations",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "label": "Net loss",
        "verboseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r74",
      "r105",
      "r131",
      "r144",
      "r145",
      "r149",
      "r160",
      "r166",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r175",
      "r176",
      "r182",
      "r240",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r403",
      "r406",
      "r422",
      "r430",
      "r514",
      "r586",
      "r603",
      "r604",
      "r680",
      "r844"
     ]
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b51 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b51 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "CELC_NonUtilizationFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "NonUtilizationFee",
     "crdr": "credit",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non utilization fee",
        "documentation": "Non utilization fee."
       }
      }
     },
     "auth_ref": []
    },
    "CELC_NoncashOperatingLeaseExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "NoncashOperatingLeaseExpenseNet",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash operating lease, net",
        "documentation": "Noncash operating lease expense net."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other income, net",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://celcuity.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other (expense) income"
       }
      }
     },
     "auth_ref": []
    },
    "CELC_OfferingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "OfferingExpenses",
     "crdr": "debit",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering expenses",
        "documentation": "Offering expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OffsettingAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OffsettingAssetsLineItems",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offsetting Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OffsettingAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OffsettingAssetsTable",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offsetting Assets [Table]",
        "documentation": "Disclosure of information about derivative and financial assets that are subject to offsetting, including enforceable master netting arrangements."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r65"
     ]
    },
    "CELC_OpenMarketSaleAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "OpenMarketSaleAgreementMember",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Open Market Sale Agreement [Member]",
        "documentation": "Open Market Sale Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://celcuity.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r637",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfLeaseCostsDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r451",
      "r668"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfMaturityAnalysisUnderLeaseAgreementsDetails",
      "http://celcuity.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liability",
        "verboseLabel": "Present value of net minimum lease payments",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r444"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/BalanceSheets",
      "http://celcuity.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liabilities",
        "negatedLabel": "Less: short term portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r444"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/BalanceSheets",
      "http://celcuity.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating lease liabilities",
        "label": "Long term portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r444"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails": {
       "parentTag": "CELC_CashPaidForOperatingAndFinanceLeases",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating cash outflow from operating leases",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r448",
      "r453"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/BalanceSheets",
      "http://celcuity.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease right-of-use assets",
        "verboseLabel": "Right-of-use assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r443"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfMaturityAnalysisUnderLeaseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating leases, discount rate",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r455",
      "r668"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfMaturityAnalysisUnderLeaseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating leases, remaining lease term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r454",
      "r668"
     ]
    },
    "CELC_OptionsToPurchaseCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "OptionsToPurchaseCommonStockMember",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfPotentially-dilutiveSharesExcludedFromDilutedWeighted-averageSharesOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options to Purchase Common Stock [Member]",
        "documentation": "Options to Purchase Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://celcuity.com/role/Organization"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r94",
      "r530",
      "r531"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrentAndNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other",
        "label": "Other Accrued Liabilities",
        "documentation": "Amount of expenses incurred but not yet paid classified as other."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://celcuity.com/role/ScheduleOfOtherCurrentAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://celcuity.com/role/BalanceSheets",
      "http://celcuity.com/role/ScheduleOfOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other current assets",
        "totalLabel": "Total",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r669"
     ]
    },
    "us-gaap_OtherBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherBorrowings",
     "crdr": "credit",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs associated with new borrowings",
        "documentation": "The carrying amount as of the balance sheet date for the aggregate of other miscellaneous borrowings owed by the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r99"
     ]
    },
    "us-gaap_OtherCurrentAssetsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCurrentAssetsTextBlock",
     "presentation": [
      "http://celcuity.com/role/OtherCurrentAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Current Assets",
        "documentation": "The entire disclosure for other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherPrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other",
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r808",
      "r839"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r696"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r712",
      "r723",
      "r737",
      "r763"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r715",
      "r726",
      "r740",
      "r766"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r715",
      "r726",
      "r740",
      "r766"
     ]
    },
    "us-gaap_PaidInKindInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaidInKindInterest",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment-in-Kind interest",
        "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "auth_ref": [
      "r744"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "CELC_PaymentInKindInterestDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "PaymentInKindInterestDebt",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfLong-termDebtDetails": {
       "parentTag": "us-gaap_LongTermNotesPayable",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfLong-termDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Add: PIK interest (added to principal)",
        "documentation": "Payment in kind interest debt"
       }
      }
     },
     "auth_ref": []
    },
    "CELC_PaymentsForSecondaryRegistrationStatementCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "PaymentsForSecondaryRegistrationStatementCosts",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments for secondary registration statement costs",
        "documentation": "Payments for secondary registration statement costs.",
        "label": "PaymentsForSecondaryRegistrationStatementCosts"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfDebtIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments for debt issuance costs",
        "label": "Payments of Debt Issuance Costs",
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commissions and other offering expenses",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireInvestments",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of investments",
        "label": "Payments to Acquire Investments",
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative",
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative",
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r690"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r692"
     ]
    },
    "us-gaap_PreferredStockConvertibleConversionPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockConvertibleConversionPrice",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost basis of shares transferred",
        "documentation": "Per share conversion price of preferred stock."
       }
      }
     },
     "auth_ref": [
      "r308"
     ]
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r672",
      "r673",
      "r676",
      "r677",
      "r678",
      "r679",
      "r917",
      "r919"
     ]
    },
    "CELC_PreferredStockOnAnAsIfConvertedToCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "PreferredStockOnAnAsIfConvertedToCommonStockMember",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfPotentially-dilutiveSharesExcludedFromDilutedWeighted-averageSharesOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock on an as-if-converted to Common Stock [Member]",
        "documentation": "Preferred Stock on an as-if-converted to Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://celcuity.com/role/BalanceSheetsParenthetical",
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r306"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://celcuity.com/role/BalanceSheetsParenthetical",
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r566"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://celcuity.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r306"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://celcuity.com/role/BalanceSheetsParenthetical",
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r566",
      "r584",
      "r919",
      "r920"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, $0.001 par value: 2,500,000 shares authorized; 317,577 and 854,134 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r505",
      "r669"
     ]
    },
    "CELC_PrefundedWarrantShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "PrefundedWarrantShares",
     "presentation": [
      "http://celcuity.com/role/NetLossPerCommonShareDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-funded warrant shares",
        "documentation": "Prefunded warrant, shares."
       }
      }
     },
     "auth_ref": []
    },
    "CELC_PrepaidClinicalTrialCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "PrepaidClinicalTrialCosts",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid clinical trial costs",
        "documentation": "Prepaid clinical trial costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidInsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidInsurance",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Directors &amp; officers\u2019 insurance",
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r632",
      "r645",
      "r839"
     ]
    },
    "CELC_PriorLoanAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "PriorLoanAgreementMember",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Loan Agreement [Member]",
        "documentation": "Prior Loan Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELC_ProceedsFromAtmOfferingNetOfIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "ProceedsFromAtmOfferingNetOfIssuanceCosts",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from an ATM offering, net of issuance costs",
        "documentation": "Proceeds from atm offering net of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromDebtNetOfIssuanceCosts",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from note payable, net of debt issuance costs and discount of $2,437,644",
        "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination."
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Gross proceeds from public offering",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "CELC_ProceedsFromIssuanceOfCommonStockNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "ProceedsFromIssuanceOfCommonStockNet",
     "crdr": "debit",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net proceeds from public offering",
        "documentation": "Proceeds from issuance of common stock net."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of private placement",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from pre-funded warrants, net of offering costs",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "crdr": "debit",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross proceeds from public offering",
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r537"
     ]
    },
    "us-gaap_ProceedsFromOtherEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromOtherEquity",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from follow-on offering, net of underwriting discounts and offering costs",
        "documentation": "Amount of cash inflow from the issuance of equity classified as other."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleAndMaturityOfOtherInvestments",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from maturities of investments",
        "documentation": "The cash inflow associated with the sale and maturity (principal being due) of other investments, prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from exercise of employee stock options",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r13"
     ]
    },
    "us-gaap_ProceedsFromStockPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockPlans",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from employee stock purchases",
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows",
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative",
      "http://celcuity.com/role/SubsequentEventDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from exercise of common stock warrants",
        "verboseLabel": "Proceeds from warant exercise",
        "terseLabel": "Proceeds from warrants exercised",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "CELC_PropertyAndEquipmentIncludedInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "PropertyAndEquipmentIncludedInAccountsPayable",
     "crdr": "credit",
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment included in accounts payable",
        "documentation": "Property and equipment included in accounts payable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails",
      "http://celcuity.com/role/SummaryOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r457"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://celcuity.com/role/PropertyAndEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r116",
      "r119",
      "r120"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/SummaryOfPropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/SummaryOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r135",
      "r512"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails",
      "http://celcuity.com/role/SummaryOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r457"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://celcuity.com/role/SummaryOfPropertyAndEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://celcuity.com/role/BalanceSheets",
      "http://celcuity.com/role/SummaryOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net",
        "totalLabel": "Total",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r457",
      "r500",
      "r512",
      "r669"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r116",
      "r119",
      "r510"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://celcuity.com/role/PropertyAndEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Property and Equipment",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails",
      "http://celcuity.com/role/SummaryOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r457"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Estimated useful lives",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative",
      "http://celcuity.com/role/ScheduleOfAssumptionsForFairValueOfEquity-basedAwardsDetails",
      "http://celcuity.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails",
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r124",
      "r125",
      "r126",
      "r127",
      "r128",
      "r129",
      "r260",
      "r261",
      "r262",
      "r263",
      "r324",
      "r326",
      "r356",
      "r357",
      "r358",
      "r370",
      "r424",
      "r470",
      "r479",
      "r495",
      "r520",
      "r522",
      "r529",
      "r556",
      "r557",
      "r611",
      "r614",
      "r615",
      "r616",
      "r621",
      "r628",
      "r629",
      "r643",
      "r651",
      "r654",
      "r660",
      "r661",
      "r665",
      "r666",
      "r671",
      "r674",
      "r843",
      "r846",
      "r884",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative",
      "http://celcuity.com/role/ScheduleOfAssumptionsForFairValueOfEquity-basedAwardsDetails",
      "http://celcuity.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails",
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r124",
      "r125",
      "r126",
      "r127",
      "r128",
      "r129",
      "r260",
      "r261",
      "r262",
      "r263",
      "r324",
      "r326",
      "r356",
      "r357",
      "r358",
      "r370",
      "r424",
      "r470",
      "r479",
      "r495",
      "r520",
      "r522",
      "r529",
      "r556",
      "r557",
      "r611",
      "r614",
      "r615",
      "r616",
      "r621",
      "r628",
      "r629",
      "r643",
      "r651",
      "r654",
      "r660",
      "r661",
      "r665",
      "r666",
      "r671",
      "r674",
      "r843",
      "r846",
      "r884",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "auth_ref": [
      "r707",
      "r718",
      "r732",
      "r758"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative",
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r325",
      "r459",
      "r460",
      "r503",
      "r509",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r583",
      "r585",
      "r610"
     ]
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative",
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r325",
      "r459",
      "r460",
      "r503",
      "r509",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r583",
      "r585",
      "r610",
      "r904"
     ]
    },
    "CELC_RemainingStockBasedCompensationExpenseRelatedToModification": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "RemainingStockBasedCompensationExpenseRelatedToModification",
     "crdr": "credit",
     "presentation": [
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Remaining stock based compensation expense related to modification",
        "documentation": "Remaining stock based compensation expense related to modification."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsDetailsNarrative",
      "http://celcuity.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "verboseLabel": "Research and development expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r372",
      "r630",
      "r640",
      "r913"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfStock-basedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r371"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r708",
      "r719",
      "r733",
      "r759"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r709",
      "r720",
      "r734",
      "r760"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r716",
      "r727",
      "r741",
      "r767"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfPotentially-dilutiveSharesExcludedFromDilutedWeighted-averageSharesOutstandingDetails",
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r86",
      "r507",
      "r527",
      "r528",
      "r541",
      "r567",
      "r669"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r163",
      "r164",
      "r165",
      "r167",
      "r172",
      "r174",
      "r176",
      "r241",
      "r242",
      "r251",
      "r393",
      "r394",
      "r400",
      "r401",
      "r402",
      "r404",
      "r405",
      "r406",
      "r412",
      "r414",
      "r415",
      "r417",
      "r420",
      "r441",
      "r442",
      "r524",
      "r526",
      "r543",
      "r919"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b51 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b51 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of stock number of shares issued in transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative",
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of public offering price per share",
        "verboseLabel": "Common stock price per share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://celcuity.com/role/AccruedExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accrued Expenses",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfPotentially-dilutiveSharesExcludedFromDilutedWeighted-averageSharesOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://celcuity.com/role/NetLossPerCommonShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Potentially-Dilutive Shares Excluded from the Diluted Weighted-Average Shares Outstanding",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
     "presentation": [
      "http://celcuity.com/role/CommitmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Supplemental Cash Flow Information Related to Leases",
        "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScheduleOfCondensedBalanceSheetTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScheduleOfCondensedBalanceSheetTableTextBlock",
     "presentation": [
      "http://celcuity.com/role/CommitmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Supplemental Balance Sheet Information Related to Leases",
        "documentation": "Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations."
       }
      }
     },
     "auth_ref": [
      "r805",
      "r819"
     ]
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "presentation": [
      "http://celcuity.com/role/DebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-term Debt",
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r32",
      "r35",
      "r44",
      "r84",
      "r85",
      "r647",
      "r649",
      "r819",
      "r898"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://celcuity.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://celcuity.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r379",
      "r656",
      "r876"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfStock-basedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://celcuity.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock-based Compensation Expenses",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "CELC_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock",
     "presentation": [
      "http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Estimated Useful Lives of Property and Equipment",
        "documentation": "Schedule of Estimated Useful Lives of Property and Equipment [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "presentation": [
      "http://celcuity.com/role/DebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long Term Debt Future Principal Payments",
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock",
     "presentation": [
      "http://celcuity.com/role/OtherCurrentAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Other Current Assets",
        "documentation": "Tabular disclosure of the carrying amounts of other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails",
      "http://celcuity.com/role/SummaryOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r457"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfAssumptionsForFairValueOfEquity-basedAwardsDetails",
      "http://celcuity.com/role/ScheduleOfStockOptionsOutstandingAndExercisableDetails",
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r328",
      "r329",
      "r331",
      "r332",
      "r333",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://celcuity.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock Options Activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r12",
      "r87"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://celcuity.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Assumptions for Fair Value of Equity-based Awards",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r32",
      "r33",
      "r34",
      "r35",
      "r82",
      "r84",
      "r85",
      "r86",
      "r139",
      "r140",
      "r141",
      "r192",
      "r306",
      "r307",
      "r309",
      "r311",
      "r314",
      "r319",
      "r321",
      "r537",
      "r538",
      "r539",
      "r540",
      "r651",
      "r795",
      "r815"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Warrants",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock",
     "presentation": [
      "http://celcuity.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Unrecognized Compensation Cost",
        "documentation": "Tabular disclosure of cost not yet recognized and weighted-average period over which cost is expected to be recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "CELC_SecuritiesPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "SecuritiesPurchaseAgreementMember",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Purchase Agreement [Member]",
        "documentation": "Securities Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r684"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r688"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r693"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Data",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r207",
      "r208",
      "r638",
      "r639",
      "r642"
     ]
    },
    "CELC_SeriesAConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "SeriesAConvertiblePreferredStockMember",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Convertible Preferred Stock [Member]",
        "documentation": "Series A Convertible Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeriesAPreferredStockMember",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Preferred Stock [Member]",
        "documentation": "Series A preferred stock."
       }
      }
     },
     "auth_ref": [
      "r806",
      "r807",
      "r848"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfStock-basedCompensationExpensesDetails",
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation",
        "label": "Stock-based compensation expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription",
     "presentation": [
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual employee stock purchase plan description",
        "documentation": "Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r38"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted stock awards outstanding",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r344"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted stock awards vested",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r347"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfAssumptionsForFairValueOfEquity-basedAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r357"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfAssumptionsForFairValueOfEquity-basedAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected volatility, maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfAssumptionsForFairValueOfEquity-basedAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected volatility, minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfAssumptionsForFairValueOfEquity-basedAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk-free interest rate, maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfAssumptionsForFairValueOfEquity-basedAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk-free interest rate, minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfAssumptionsForFairValueOfEquity-basedAwardsDetails",
      "http://celcuity.com/role/ScheduleOfStockOptionsOutstandingAndExercisableDetails",
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r328",
      "r329",
      "r331",
      "r332",
      "r333",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised",
        "documentation": "Number of non-option equity instruments exercised by participants."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Expirations",
        "documentation": "Number of shares under non-option equity instrument agreements for which rights to exercise lapsed."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number",
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r89"
     ]
    },
    "CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOfWarrants": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOfWarrants",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOfWarrants-0]",
        "documentation": "Share based compensation arrangement by share based payment award non-option equity instruments weighted average exercise price of warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares available for grant under the 2017 Plan",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfStockOptionsActivityDetails",
      "http://celcuity.com/role/ScheduleOfStockOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, options exercisable",
        "verboseLabel": "Options exercisable",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r337"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfStockOptionsActivityDetails",
      "http://celcuity.com/role/ScheduleOfStockOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Options exercisable",
        "verboseLabel": "Options exercisable, weighted average exercise price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r337"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Shares, Forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r341"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r339"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Grant Date Fair Value for options granted during the period",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r349"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfStockOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options outstanding, aggregate intrinsic value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfStockOptionsActivityDetails",
      "http://celcuity.com/role/ScheduleOfStockOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Options outstanding at beginning of year",
        "periodEndLabel": "Options outstanding at end of year",
        "label": "Options outstanding",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r335",
      "r336"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfStockOptionsActivityDetails",
      "http://celcuity.com/role/ScheduleOfStockOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Options outstanding, weighted average exercise price at beginning of year",
        "periodEndLabel": "Options outstanding, weighted average exercise price at end of year",
        "label": "Options outstanding, weighted average exercise price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r335",
      "r336"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
     "presentation": [
      "http://celcuity.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock Options Outstanding and Exercisable",
        "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding and exercisable options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost",
     "crdr": "debit",
     "presentation": [
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock based compensation expense related to modification",
        "documentation": "An excess of the fair value of the modified award over the fair value of the award immediately before the modification."
       }
      }
     },
     "auth_ref": [
      "r363"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfStockOptionsOutstandingAndExercisableDetails",
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r332",
      "r333",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r340"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise, Forfeited",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r341"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r339"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r327",
      "r334",
      "r353",
      "r354",
      "r355",
      "r356",
      "r359",
      "r365",
      "r366",
      "r367",
      "r368"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "presentation": [
      "http://celcuity.com/role/SubsequentEventDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price lower",
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "presentation": [
      "http://celcuity.com/role/SubsequentEventDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock options held",
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r89"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "presentation": [
      "http://celcuity.com/role/SubsequentEventDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price upper",
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharePrice",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant purchase price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfAssumptionsForFairValueOfEquity-basedAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected life (years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r355"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfStockOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options exercisable, aggregate intrinsic value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfStockOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options outstanding, weighted average remaining contractual life",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, shares",
        "periodEndLabel": "Balance, shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/BalanceSheets",
      "http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsDetailsNarrative",
      "http://celcuity.com/role/LiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments",
        "verboseLabel": "Short-term investments",
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r103",
      "r809"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r691"
     ]
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://celcuity.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r139",
      "r140",
      "r141",
      "r160",
      "r180",
      "r181",
      "r183",
      "r185",
      "r192",
      "r193",
      "r240",
      "r266",
      "r268",
      "r269",
      "r270",
      "r273",
      "r274",
      "r306",
      "r307",
      "r311",
      "r314",
      "r321",
      "r430",
      "r537",
      "r538",
      "r539",
      "r540",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r566",
      "r587",
      "r605",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r795",
      "r815",
      "r824"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative",
      "http://celcuity.com/role/ScheduleOfPotentially-dilutiveSharesExcludedFromDilutedWeighted-averageSharesOutstandingDetails",
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity",
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r58",
      "r61",
      "r62",
      "r130",
      "r147",
      "r148",
      "r149",
      "r163",
      "r164",
      "r165",
      "r167",
      "r172",
      "r174",
      "r176",
      "r191",
      "r241",
      "r242",
      "r251",
      "r323",
      "r393",
      "r394",
      "r400",
      "r401",
      "r402",
      "r404",
      "r405",
      "r406",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r420",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r441",
      "r442",
      "r458",
      "r515",
      "r524",
      "r525",
      "r526",
      "r543",
      "r605"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r164",
      "r165",
      "r191",
      "r442",
      "r496",
      "r532",
      "r554",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r566",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r585",
      "r588",
      "r589",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r605",
      "r675"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r164",
      "r165",
      "r191",
      "r209",
      "r442",
      "r496",
      "r532",
      "r554",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r566",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r585",
      "r588",
      "r589",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r605",
      "r675"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r711",
      "r722",
      "r736",
      "r762"
     ]
    },
    "CELC_StockIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "StockIncentivePlanMember",
     "presentation": [
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2017 Stock Incentive Plan [Member]",
        "documentation": "2017 Stock Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELC_StockIssuedDuringPeriodSharesConversionOfPreferredToCommonStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesConversionOfPreferredToCommonStock",
     "presentation": [
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of preferred to common stock, shares",
        "documentation": "Conversion of preferred to common stock, shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee stock purchases, shares",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r57",
      "r58",
      "r86"
     ]
    },
    "CELC_StockIssuedDuringPeriodSharesIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts",
     "presentation": [
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock upon closing of follow-on offering, net of underwriting discounts and offering costs, shares",
        "documentation": "Stock issued during period shares issuance upon closing of followon offering net of underwriting discounts and offering costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative",
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity",
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock in an ATM offering, shares",
        "verboseLabel": "Pre-funded warrants sold to investors",
        "terseLabel": "Common stock issued",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r57",
      "r58",
      "r86",
      "r537",
      "r605",
      "r623"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationGross",
     "presentation": [
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation, shares",
        "documentation": "Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfStockOptionsActivityDetails",
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of common stock options, net of shares withheld for exercise price, shares",
        "negatedLabel": "Shares, Exercised",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r57",
      "r58",
      "r86",
      "r340"
     ]
    },
    "CELC_StockIssuedDuringPeriodSharesStockWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesStockWarrantsExercised",
     "presentation": [
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of common stock warrants, net of shares withheld for exercise price, shares",
        "documentation": "Exercise of common stock warrants, net of shares withheld for exercise price, shares."
       }
      }
     },
     "auth_ref": []
    },
    "CELC_StockIssuedDuringPeriodValueConversionOfPreferredToCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "StockIssuedDuringPeriodValueConversionOfPreferredToCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of preferred to common stock",
        "documentation": "Conversion of preferred to common stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "crdr": "credit",
     "presentation": [
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee stock purchases",
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r57",
      "r58",
      "r86"
     ]
    },
    "CELC_StockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "StockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts",
     "crdr": "credit",
     "presentation": [
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock upon closing of follow-on offering, net of underwriting discounts and offering costs",
        "documentation": "Stock issued during period value issuance upon closing of followon offering net of underwriting discounts and offering costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock in an ATM offering",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r57",
      "r58",
      "r86",
      "r543",
      "r605",
      "r623",
      "r681"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensationGross",
     "crdr": "credit",
     "presentation": [
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation",
        "documentation": "Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of common stock options, net of shares withheld for exercise price",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r58",
      "r61",
      "r62",
      "r86"
     ]
    },
    "CELC_StockIssuedDuringPeriodValueStockWarrantsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "StockIssuedDuringPeriodValueStockWarrantsExercised",
     "crdr": "credit",
     "presentation": [
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of common stock warrants, net of shares withheld for exercise price",
        "documentation": "Exercise of common stock warrants, net of shares withheld for exercise price, value."
       }
      }
     },
     "auth_ref": []
    },
    "CELC_StockOptionAwardsSharesModified": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "StockOptionAwardsSharesModified",
     "presentation": [
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock option awards shares modified",
        "documentation": "Stock option awards shares modified."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockOptionExercisePriceDecrease": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockOptionExercisePriceDecrease",
     "presentation": [
      "http://celcuity.com/role/SubsequentEventDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price reduced",
        "documentation": "Per share decrease in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r322"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/BalanceSheets",
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Stockholders\u2019 Equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r61",
      "r62",
      "r76",
      "r568",
      "r584",
      "r606",
      "r607",
      "r669",
      "r682",
      "r817",
      "r836",
      "r896",
      "r919"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://celcuity.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r159",
      "r305",
      "r307",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r320",
      "r323",
      "r419",
      "r608",
      "r609",
      "r627"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://celcuity.com/role/SubsequentEventDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r437",
      "r462"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://celcuity.com/role/SubsequentEventDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r437",
      "r462"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://celcuity.com/role/SubsequentEventDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r437",
      "r462"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://celcuity.com/role/SubsequentEventDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r437",
      "r462"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://celcuity.com/role/SubsequentEventDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r437",
      "r462"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://celcuity.com/role/SubsequentEvent"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r461",
      "r463"
     ]
    },
    "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubstantialDoubtAboutGoingConcernTextBlock",
     "presentation": [
      "http://celcuity.com/role/Liquidity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liquidity",
        "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r755"
     ]
    },
    "CELC_TermALoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "TermALoanMember",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term A Loan [Member]",
        "documentation": "Term A Loan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELC_TermBLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "TermBLoanMember",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term B Loan [Member]",
        "documentation": "Term B Loan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELC_TermCLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "TermCLoanMember",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term C Loan [Member]",
        "documentation": "Term C Loan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELC_TermDLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "TermDLoanMember",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term D Loan [Member]",
        "documentation": "Term D Loan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELC_TermELoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "TermELoanMember",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term E Loan [Member]",
        "documentation": "Term E Loan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELC_TermFLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "TermFLoanMember",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term F Loan [Member]",
        "documentation": "Term F Loan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]",
        "documentation": "Information by title and position of individual or group within organization."
       }
      }
     },
     "auth_ref": [
      "r830",
      "r903"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title and position of individual or group within organization."
       }
      }
     },
     "auth_ref": []
    },
    "CELC_TotalCommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "TotalCommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total common stock, shares reserved for issuance",
        "documentation": "Total common stock capital shares reserved for future issuance."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfInvestmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r300",
      "r319",
      "r418",
      "r429",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r516",
      "r657",
      "r658",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r670",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r832",
      "r833",
      "r834",
      "r835",
      "r882",
      "r883",
      "r884",
      "r885",
      "r892",
      "r895"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title"
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "CELC_TwoThousandSeventeenPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "TwoThousandSeventeenPlanMember",
     "presentation": [
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2017 Plan [Member]",
        "documentation": "2017 Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative",
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r407"
     ]
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfInvestmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Treasury Securities [Member]",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r634",
      "r652",
      "r653",
      "r657",
      "r914"
     ]
    },
    "CELC_UnderwritingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "UnderwritingAgreementMember",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underwriting Agreement [Member]",
        "documentation": "Underwriting Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r774"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r25",
      "r26",
      "r113",
      "r114",
      "r117",
      "r118"
     ]
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfLeaseCostsDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable lease cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r452",
      "r668"
     ]
    },
    "CELC_WarrantEightMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "WarrantEightMember",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Eight [Member]",
        "documentation": "Warrant Eight [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELC_WarrantFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "WarrantFiveMember",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Five [Member]",
        "documentation": "Warrant Five [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELC_WarrantFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "WarrantFourMember",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Four [Member]",
        "documentation": "Warrant Four [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative",
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r672",
      "r673",
      "r676",
      "r677",
      "r678",
      "r679"
     ]
    },
    "CELC_WarrantNineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "WarrantNineMember",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Nine [Member]",
        "documentation": "Warrant Nine [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELC_WarrantOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "WarrantOneMember",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant One [Member]",
        "documentation": "Warrant One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELC_WarrantOrRightToPurchasePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "WarrantOrRightToPurchasePercentage",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant or right, reason for issuance, description",
        "documentation": "Warrant or right, reason for issuance, description."
       }
      }
     },
     "auth_ref": []
    },
    "CELC_WarrantSevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "WarrantSevenMember",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Seven [Member]",
        "documentation": "Warrant Seven [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELC_WarrantSixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "WarrantSixMember",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Six [Member]",
        "documentation": "Warrant Six [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELC_WarrantTenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "WarrantTenMember",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Ten [Member]",
        "documentation": "Warrant Ten [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELC_WarrantThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "WarrantThreeMember",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Three [Member]",
        "documentation": "Warrant Three [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELC_WarrantTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "WarrantTwoMember",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Two [Member]",
        "documentation": "Warrant Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsOutstandingMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingMaturityDate",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Expiration Date",
        "label": "Warrants and Rights Outstanding, Maturity Date",
        "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r883",
      "r884",
      "r885"
     ]
    },
    "CELC_WarrantsToPurchaseCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20241231",
     "localname": "WarrantsToPurchaseCommonStockMember",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfPotentially-dilutiveSharesExcludedFromDilutedWeighted-averageSharesOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants to Purchase Common Stock [Member]",
        "documentation": "Warrants to Purchase Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://celcuity.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average common shares outstanding, diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r185"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://celcuity.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average common shares outstanding, basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r185"
     ]
    },
    "us-gaap_WorkersCompensationLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WorkersCompensationLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued compensation",
        "documentation": "Carrying value as of the balance sheet date of obligations and payables pertaining to claims incurred of a workers compensation nature. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "13",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481766/480-10-25-13"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-2"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205-40/tableOfContent"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-4"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-7A"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(a)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(b)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 4",
   "Publisher": "SEC"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "12",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-12"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 6-K",
   "Section": "General Instruction",
   "Subsection": "B"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05",
   "Subsection": "Instruction",
   "Paragraph": "2"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05",
   "Subsection": "a"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Topic": "321",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/321/tableOfContent"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Topic": "325",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/325/tableOfContent"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "04",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>93
<FILENAME>0001641172-25-001826-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001641172-25-001826-xbrl.zip
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M%/<6;J0.L6"EF"I>:+0]2?V>9/TBHJ07L D<4+-2468+7G-LFYP[4/9[CA+
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M) U7,#9>GSTQS^\E-)RM'',-HGCYM*XK9OKBOOMPH Y@XS__!U!+ P04
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M5383C,PT7>WFRX(JZO_. "+?09RSRVW<NHHKCM-G0"+-]_917[ZRF2*@J7#
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MZ>Y<K<=[:^5 +^B:@@(G\T;9;F)TEM%#OT6$D8L)SLPM>-@+73=50*"ZYHX
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MUWN9%,"0S 6EU*<U.BAC2H@PK=-B<;JF_P$DG(DX; S2(3HU?6\&L1LS]E]
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MY.YC5'0\'+4FPK_CV1LGW6/&D#3#O0V9>;$?ZA_F4\'&U'LN+.VP>T_? =/
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M=@7Y;YC$:<F+S*F%!085_JBS[PJPGYKVA0A.5(!0#.X1I6-7; YL+8</,HH
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M8;(3QBMBC5'4>:V'V45]PX!:1I,;D"(5)\%G^0ZG7D=:"S4^F>"R;M RPA3
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MW2<"4.UR_T4[JKWN[_/'TX[W[K-TX+#I;&N==LU=)#AT:OBA3A3S'^N",.\
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M67''GEG=[BO7(LT.<Q!6-/[GV+SAUPK JD4-.LU6'J)R00<$-8[Y:V$N[58
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M6561]'%=\2?0V70X@L'N69ZX58A-!V8[,$,U-([V[?IJ$ZB2VF4RU4-*6B%
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M8/^ ";:$0R2\F4_(G,/BQ$4/>+<U$/$_H3H>$AZ1(+]_)%'$=VY>#-+ROO9
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MJC[8.=LC2ZP)A9/24E_M5_ VY&Z_Q4W&J'*S?>W_R%B*^9('ZHR="7Z$$ W
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M1$P@)-#EU;[=KA.4K#UVPLH0":EY1Q?-1+?Y[:\V'2_?_B7^K7@IGE% ,]2
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MDK%D?TH9/_U%AL0]_R$C@<L/G9)\C\"T1\I.%..\%5@^DBSTO6A/;*,RYX_
MRIRS?VD,]J]OE3J/K=[VP*P'HR'GA'V.O:)H$=F7)[JE9!/F&Z4/;C3(Z=7F
M'(#1Y#-1()(2_^MU\O0-\8-B-MX^;0]&IS7Q?OKIA^_??\NFVJ$%^P<S+K.G
M='9+J-BPQ#ZI_?WXR5:GL-!./S@H)?L'SQWX):U]_O#UZW:-XYHBLIZ@CL=/
M,@ '3]NEQ(?A9.[_JIL('4T:=SY (6M.B08']4(A4R![\4+\G*VFY(S-X75"
M=_.74*(-DJ8.8-[2CAJP$IIKE7"G 'D>16U"F._RB6P>".W'6MT#'W*EVM3P
M5_-Q6)>FD,)5'#"O,<B]2*[C[3;X2"N4NTULK7CO1%I]H$"GS3TM\;'MUXBF
M^O80/JW:SH/_6B:\0*I<:UM-\(%5*&V+UEI9XHET=D^ 1F,[[?!A[56%IKIV
MJ)Y663\13VS&I:K::("/J$)1&Y36JBY/Z>\NV0;E(QOP=[7C6VL&ORHZ^F[P
M:.^WP^VH)S1ZU,^2>Q(1?OY;RO[&ZZTERMI*FH+1'S\338ECHB,<!6_^Z8,G
MN5BM0I_0]#+6:#V@&U@.XR=U:3%.3!A!D<LM(51D.(@@*4 BR@Y@68R?$64@
M"P#/4ULCD<)Y($PK!64'L!3&3]LQD * Y\GG0K+DJ:_"Z]KT!6R%\K0:@=$>
M/Y_%2.=[>9L>X;F?L?U5M.,)&CJ@>]N"\1X_0\4,;P6G$\,N-@J,(DZ%UK1(
M&X.!'S]/Q !X#:]3NSU)S&BY8<KPM-;;%GEK,/;C9V( G4T=IXC "TIJDQ&$
M?V\GL!C&3XD8( 8%WQ@&:$\:W S)N\ KZ]B0!!3E!,H.BE2*FB+\N?("-N8-
M;T15G_.09T(1MJG7BLET#+#<K.R:S>4V#*/)@QE-5GY)A046;VX53P_?9=H=
MA>$88$%:V7:;"W(81NB"W#_L82R^OIY@H5G9GX\A-#D>Z*+J>*C&(E.- !:=
ME4W]&*+3XS.Q"'L, (]HE_$(C?3 G<&"LQ(?,!><(2KHTTZ41QLZXR2=P3*S
M$F,88[(I49EZGGD/>>31ZS#-("==BN9@N5@)00R82SK.\2V>=#,L:PN6@950
MQ"CV##, 6ME1 TEH.X%%8B4L82X2( KHE_9ZWZ;OK;93;P8O'(L2).HGNH,X
M[KM. P[PI=.GOR582C9K,_=(0'%\CV>VA#?!<SUT6/<V!$-MLY2R$FH%?QB1
M4N4A0;,%&%N;-8^5V/9Q-/VQHSR]9_]',)0VBPXKH6SQ,3&*VD2I0>E1%HH!
MDZ'):0ZD227QSTP12D+.2>K34(2;=7E2@'Y@B5C9U&K2H\!\3VZ/@Y#3X47?
M?_OAZ:!&VM,K;3>P.*SL98=-$# :4QOX.(T_QJLL98N-/H--UA@L$3N'[,/R
M:=6<.W*1\H)2[@$H+U-^W[E,R5\W9QN+';_"S$9(8I+D:;2;S9\])HE@QH<D
M<2JHG.)N947/8M7AIR.BILK!>DYRYEM\OR)(<=.ROR5^&K^)%.H'N;WL3'T%
MDY<=*R]0G[/_RN].]#;$!U^E/C6P>ZF?^"+F:5X!! +\=AWP2[@.6)]&)"-T
M$\8"(CZG]&:CVP/WPM! PPT!8>I-P7J=E3S(PS2M-KC7A4 @)E+B45"N"&"[
MC5T:IKI$-&EKW M"$B@[CHF4S8E1O\]^OZ7^@BY3>I%F85%T\1/)'I- (P%8
M3]PK0EIIF+ _=1 ^S]@DCGEM6H@!4C3'O2"DE8&643QS?Y-D_TGV)I3HI@2L
M)^X-(JTX3-B?6#*7C-TD)I5GP1PV>71:UA;W/I$6?36+)W1@VV+D/"?+Y.*%
M!W (\PAY@5]?^"=2@V8T .YE)5.I0L# G5J"PE_")!((+E9_3S;DC!=OH[MK
M[]E(9NI1<&\Z&?K)0T%R0)9L\_4/MK,-5Z%?4KOT7CZ2F*S"+#62IWXDW&M3
M(\@4"A:N7)D!B;RX)/!JL^4U&1G!#V$49CN-IS)P*-QK6$>)2BIQ,QCQ-@$@
MKT?5'O<NUDC"TP-R0CY2#S/0/5ZG/>X%+7O2Q=T+UA>3A*1L0W1'_I&'=,^I
MQLZ:],>]K362!,T!<^3,6IPR+\--\120XMSZN_:YM>@Y*[I.7/ZW('HC*+Y6
MGTE+FDX24.&?3L\8+$RG/L7;D-.@.(I6M<<_2E)B7H^C*+B8^ASZ- ]']7JC
M/R*=L [PVQ$IQJ6-8CJR#T@TNVS7:H8/-URY^SD8-05@T*L._![/1R\E03TQ
M:\[?X%@7;U%\W!W:E&]V"R8.G,3!+=M[<>_]/-EX8=]S)]5#!%:^AJP&_9+M
ME;X=_B<N=URNG'MMUYRFR)OC9C88>0 J?J<^V*KH@1SO2AOC9C888^_$66Y%
MS2TE048W<7 9>6LU[JVFR%D-AJCW\HFE[6SVG<5I0 &@M]LB9R\,L#-=3I%@
M_WOR?* ':&MD?9 3& S%H.9\ZEM<U=H3;@B/\7#OX1<ODD\%90?DU 6@(  \
M8TR*7F<?,C-T'9%3&HZ.AV#/D5[*E,<LZA[(R0C'R.-TSU($.Y_C@$:[]3WQ
M<RH>D93GZ\J;XZ8D&(E/Q2_&)+IXH?XM#7W5M*FUP4T4,$*ZPQD&O#_S]TUY
M'L.E%U)>I%*%<U]CW/-[(\#EO$Z,?'..[3[]G@D].'N,U[>][Y>R3KH^N$?Q
M4#G .'?D_.XJ3D,&VI)Z(I&X%ACK.\3[H7V(5W:?E?UGC0$F.:%ID=\13/NT
M1MY^DGU%1J,EH9MTL5K2@'U?X\BJV@-G@XVIH(>]OJ_0\CQU?3=!A=)3;34!
M0FW%[!AAW<O:";FC>_J7W.IH9%.V ;M#S@BGP=S4J3EY1-Y_^_##>T;*/$BV
M&5$$^*2-@9A;B>\98:YA=_K"-4;XJ]H#16 EMF<D CW3*/9?T*&\)MS7#HBZ
ME4#> &/3QR2BP5G239P![4V]+1!U*X&ZP>:FRRRNM=&!KV@.Q-]*8.X86X,N
M@LKA!10ED#0%0F\EJ#; X$A818']XF4;4A#J[99 T*W$UP: WL\H"N;G>4&(
M"NU#&_"^RA&@V]PY&<2Y3:+0#TEZ2Y-]ZE4]B/.C+HA3#3#SXF#&1R$!:X@0
MSZES8A38D72<)F>X)"2H$Z'U] '=G(GW*,72R"T&0C&QI>JGZR;)2M(T,3F#
M[N[$C8Z3F0(;7!/H[TH3>+9[(#0M0^YW8?K[)R_VBD#T/ [N,V:WR7HGO:+R
MK?B_]YU+*HUA9WS<V6%@81^KH:U<8>'L"1UF/QQTF/WC-P6_%46,[Y_YW:&8
MU\F</Z09OZ+9H])LN.&CC3=?!_$J5J<T)>EE0N?\ORG3]:N _25<[?BJ'@>B
M,?MQR;[M9<H"26HDCOH6EO$^2KA-ZV 1'8O+P'%J=14S>#A&LJ4;"$I['+2%
MP;X0S;2E'V"G-6$$"]([&-HYAKLZX;")6#Z&S$?R:+:[B-?L=\,,A&04M.,5
M1U1!"2ZV#AR(6[ E,PW7C]S%+&$HKWP?D()KQ8!QT<Z 4/5DL "P-><3LVDT
MY*]^S5<K\6;1@MX1+TUB[R':78>_DVBW3-JM[L@ZY!Y9G!F9F#$^A7;:A6R'
MQA/3J:N<N;,SVO?0#OU.6OF<<YD^)AX-%JOSD#(Z$YKN;;:I:D$&0CNH1-49
M.,1.*,-9LMF$64;(@M[G#W[UKSN2;I,X#1\BPF Z3DT&?P+MN!5?@8X4"[9J
ME1 Q&J]X95!>5F@";1O]JVA'SZ@*:$EXV#IYQV!?K&K[6D/M4O3'.SI'510M
MHM@BKR&1I.(9N'1!]VJ<UC5W4$09-"A4.5YO?-D ^]/1F",BS_"1H;KS>N/0
MIE)P1X%X<72:A6G#1(ZB0 8C0Q5HZNCUB(>=QC@[DB51A0T:K%W%?LBGD2XY
MXOMV<D0U6BM+HAIOXHP()6_J] =@URDFMY*4&R_3/*JK8Z8S F)>@I' :O-R
M"$03FV@EB?=^LCU*B.T!,),)K BQ'R&79%B4+3Y&B)T1,(__K4A1@I%+8JS^
M>+79,@:[@?;FWX\1]^ O8:8"6%&+(S%W27V*6)40!<^0??+"B!=F6M#/S"^#
M/'ZFP\KT YCY %:491C"DWO;/HG\G)']M9]L"D][0==>'/[1O"U27<+XZ=OW
MG4H:C0XHE8GK%)RQC4P2A4&A.7%P6X-FL;H,^=Z)R>R^>K0@53C8Y?@C#8]3
MM?DHX@]R5MF",6#J_1*6BS^NW)MVPQI8SAB0CUX:IHM5G8O[?+/Q^,O0]^$Z
M%IE.S+#Z/G\ZK7;#@[%^1WS2^!--8O:C+RGLP\S1G]KF2'Q^EJQF=0+^YZPD
M@?^A1L3L\*GFY;&"D,:?FZ3@U+[O8J:U7JH^.":I1T'X31>5:@#,SW&C(IL:
MO6!;]F,,#!VP%=?A/_(P8+_JF]J=ZYZ'UJ>WE+YR-^,^?^ />66,J/,D?V!N
M<Y)G/R=,_1@K/J$Q8 :;C/&*70-S*!V8R#<DNT[2]):(DR>VXO.G*?HF]9_;
MDYKUG/&N,]9W5G2>%;U1%/G"HS&#FG,BJ-#/6WD/G*G8I@<P\Q1=D">:3ARM
MN:/EW8&I<A4_D323.K0_=8L<'-JC*%2-@'D4+;)'0NN_TDX0:'^<Z7(@!3!1
M>ALC3Q$S\;0FC(+[D8LO3A['XD"<Y90CR+,N>F?;AV\[T2S>;5;VFY4=413S
MO,3\+$FS],S;AID7A7\0[E]LO3!@GH:@M2#QP(-^/AX],%(DJR-02%!*U0EY
MXHXDX'9D20^3 XO@+4UX(@I/:;E@F[HMMT!]\_-]>WY6'464YM 512,K6O@K
M:UF=$_T<!'3%F652PHQBP6:C(,]#L!A;,VT(5 Y,O;GOTYP$/!,L3DGOJOBA
M\^1QT6>V[X2CF]Z.GZ'Q0+$@R(L WJ>R$](3ID5L+BU)JRAC[E7H/821>-C#
M:+H-'A![YND%VGX4]3CH')A^16:N;/OWH5O(J=8>15MK!#"XSQ(15":QWT!:
M/P\-A\&9F34BC2:@KA_R/!LDPM;,@T'CP 2[SQ@]CTG$$$WYDMQ[N/"ADQ-<
M[_;/__3G#^]__.NL[(X3QA/?!H0?6^V0XO\=T&^2C!C-(8,AL(.2O:)IA_%-
M$7%EZKQ[:+\ZW3=_.FE 15_Q&O6LT1DG>+(G;;&J4W-'(EZ>26RY183XH?9\
M-L";/'9<G-D)IKK^F#@DO'+TP-@AF%'4I#7S1T+; 7MP3AYZHS*=I!O1$"E*
M^I"9!3_[VR--S 8UD DGZX ]D91B:$\0-=<.*/Y5S'XD2^^E/S[24XB<MY\5
M'9".L4J*32:#LA/6<5R')-"YG*H7^@&=5C2=4SD]" [,$IZI0OZ1L^$NGB3Q
M^TZZQZ'/K.B$EJY4HQS@^,E[X"5<U>D!YE=)NB#/$)TX>C*DE+P[,#?L94%7
M#?NF6R=Y9)ILZ-F_5,W_]2TQ^NC$Z!9AN^)_X2G0VOXGFNP,Q&74>W9#Q/B9
M5U>X2+-PP[9[?:^^E W;[=!N0P^52S^CZ/B?>>DC#W.S__# VY,7[<TF9!8!
MNZ/=>AXJ+2-8T(5X2$P#"T[1!>TN\E!A:=D?.3O/D203L*SA(Z#=+!XJ>E-P
M3EH3^%WYD'+N%I0YKMLD]:+%ZCJ)U]?A$PF*!#:X!1@T&EJM\,'&X0C0T W[
M/NOQT:-K I>MKA]:T>VA4H0!X8"\'N!FN;<Q6FGKX9*1LHPN#GZ@1,DCB5,V
MU8LXH>$N$3X"6DGIP2ZN(3@.2#/FD97B;59>J>^,&80PXS^I!*CHA%:%>;C,
MM!"@B^F2+;>_>%%.:O<YKV+&5GZ(R.WD @-VQRN,/%1V1KB@2W%_JF*PHY3U
MP*M3/'Q'J>;^I+<1AW2*>L+%8EM>R;X2)H:M"7Q/I9VN@P;#*SX\5"&.P.RD
M=>6."8:1SF-AY^2)1,FV*HP;IT2G&Z#.>'6$A^J" 28.F/&RH'8_T3H) KM#
M9>A.W,@(%W0IWI-U47IZF] !1UW [E INA/;,<+E59]S+\75H)Y3[N\ZE[:G
M.N4N2/J2S[BY @C2WG_X[KT@[^SB^NRW>_^1!'E4.PX,/J=DE4<\("G4HWO=
M5X"IFNI\Y#$&/IGC[K$8=L8X]%8%DL_KSF5O:6T@Y*EX^D6"#FHV9ZH9A%'.
M7?W[HH@M4]&+%S_*F: OF3;S[4%>U;,:4%W(QK>P;P"9E26RA[8#D[Q6;$8^
MM3LWRFN]D"?S%U/>2+?>=OAQ;"$=J]"1JZME3^46Z7SJ7!/OJUN$/+'>"AC)
MUER)I(W64OT8Z%>";)0W,@?1@9DM==I[YW;G:GI_S2/DV?U%%3\Z)B/-G1DY
M>J$C%^=:J[R1?)IU;K"WBQQA3[!74NVHMOGIE.HQ7_;T8V!/,N.:1N8 .3#-
M:N5@Y%.L<T^\U@MY=IU\5:.49C4^V;\./+)_U&8=(RK@]BSXZ$7\X=#[1T+T
MFT$VAN$0IUSCR)Q;1X[1KOG#PF3!EF>/\WM-O)14YH,_2";>I():V4&#8=]:
M&J.VU1$H.J !C%B^QX)+6=(!^T;3.))4HH$NK9J5\=+'RRAYOL^WVT@<,'K1
M@<T!GI'A@-A7HL:0]I%H.N!&=:N$R;VI3M41><DZ[/.QTZI=M]>B_IIMOWJ4
MLHUONJ!WX?H15FIA^)#8)UN@VG;'(N;*S.O6NI-/OVXI$TG%.^RP^UOIN_[)
MW9OO*H18)+VF<S\+GPS\Y3'&Q@[2VRB -Q[F^/Y:+P-S;M[6PLWXN.N4\IL_
M>S0HV?N%I Q&'C-]V1*?_;A,^*\6><;?^ J8RR/^1J@?I@(!J.HATX6]Z[.C
MMTX(&U_G>Z9OG=OZ].6W?PJ4TC3?%+\[QGP>\QWL_>MDMO1X83BD8Y]C2OQD
M'?.CX3IJ'*Z;1&1ML#G%61V@6$<,CKT_MJQ-1\/ND I=;+91LB/DGM"GD,=K
M>\UX),@0:75W>]9O"0V3 DPCQ1K]D]AE2BRKFR41.;"/Y,4"Y)O&3D$^WAQ[
M@WC2)9,/.L7IJMTV-IJ_\K[8&S*30LIP+!RRUN5Y2LAO,_":-4M"-_M)9"1$
MZ$CHFY5A,C4#R@%36*N:+;6(WW<N;]5K9Z.G@K^.(MJU=7>U(CS"0O94WK'E
MG"^NL1]&X2'D:>;]#!@5/7G<M CW&" Z9':K=%Q&?9$M.X^/R\0R'!#;"!^C
M (.P<\ @#[E,>$XR+XQZ37?G?EXU/K]AN__"K/C$3'RCN)3;G[Y<?NE+ODX[
MXOR6)^ER[81,:-T(NAG<47LK\]C\1CV8P7J!)<<2T)DE(%<9V2C*24/ZNB%"
M4Z6%IJ/7&-W'>L<5I2;I\HX?%,Q?PCXIL;_7_GS:@FCR4ENY)X;Z$]D\$*H
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M^M%+2<#3>!EM)7C[JY@?=X<FI5L[?_8HO["YV/*VQ=Z#I[W1O'!Z#T>811!
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M;41]>]!S]J#GK+7COR-\(K+?5S<D<B]:$KKYH-'(J8EQWOP=I;0XHG5#K;^
M8T'\#.U3L+E?1*2\QN\5FY5AG(:^Y9BXXI/8J=NGH);]8CIY13R)8VAK^>#.
M*A[DN/I$BVN^'75/D$E^"HIM]5:A,^I^A$]?PZJY^B@>I+'Y3>RL=6<W7WI!
M.75N/D_3?+//:=Z?\5</%KP3; K^4OGI^9^^59V>USXQ6R5TQC\R$U_A?ZU_
M9U9\Z.T4_>T4_>T4_>T4_>T4_0L^14]I5M,C]J^##K%__';'*92<FK._U_[\
MRB799-;.*3E$%M)SS(I Z*FE97DT\>K'LB+5RG&Q!LQ/81QN\HT*SE83M(A=
M&ZX.F+V\V F3Z5#U7K2H-IN@A:/TJ/;Q<KK!Q_V>H[9/X 7S+BGA.RC"<&>
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MB*8DPX"D8($D%+AQ/=.DB#'XA#283/Y.Z'CY&704X'#Q3!D]P@4I+E'!B9T
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MKN1PP,F2$D+Y] V27!G)$I ?9!7<7;+;KS9K&164C:HQ?VHQ2^(HS6/2JEP
MIA-A6B14A>,Z+_Z,IBKFC'9XNKT[U-LV#H(7TKSP-OP%-C O=8I9GE/YP(_$
M]#!,506ZAXV9DA.WGB4V8DI!*K"Z8;C]2&OXH#P#ME!J]MG"*&;+<9& 85@4
M.!HD'Z+>C3>;Z+[U*-C=O0@8#Y QC1=L_^& SW_IYNZG&M;!*10"9 MV,XW3
MI:=L6>K0MW#+"C?/4RL]A\NJH&BZS.F,-)> L+B8;3O6G'V>VN-E@ ^3BSU(
MV75<:)H4I@PJSS15-<>.X-%P AR9 #LSY-&VB;P^@\<^!JO49!-#KQ;>'(S
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M$$O&+?JLRU+%,X;"<H9:+5L @7$IJXJF1[G?XSFYHRX7I_EP<&9-3PQ,8U/
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M'_\U[QH'!_05#IACX&QHLF524U;T+,Y9SN @@B60-?4OI6I>9IJ\<1F9J_Y
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M^SZ!<,LV+8QPQEY"W1*7/W"Z\64:7U;];;SW?FU=J>X-^?;P<"$V;UG#-=S
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MC>LEM;2JZIH01Z&6J47S>H(/]Z9OH+$PT@C[/3>11H#@$FD5G0\D<CVRRG"
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MX?G)/9_ Z<FKXT.Z-^<GP>G9R6_'SX_/@^/7;XY?T!Z=GQU Y-SS&7X%$#3
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MHW&IEXS)@ \U;[R $6L)O])&2\P099RN@#B,'6:RA*\E;HK'-3ABD7$%32&
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ML(/XK0+0N@Y9BGLE653VA\R8?;=@),+$M6#VC%$:,,HJ6EE#8K_&.'B=>KY
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M>#(S+3$N:'1MU591C]HX$'Y'XC],(UUUE0@AI %V22,!R;;H6(@@O5,?36+
MUV#G;-,M__XF)-YM;]N3*FVK-@_.C#TSW^>Q/7;P)KU=A.U6\":>1/B'Z@O2
M>;J(P\"I_SCJ-,/!=!6]@TWZ;A&_LG:"ZVMP>Z6&E!VI@B6]@[4X$MZI.SJP
MH9+M+'1$U^1;_<9P)'+/^#7TQJ#I1VV3@NU1_?ND--N=K? YWZIR'#C)4R-(
MMC]H*PRF8?SQP+9,0]_KNH$S#;\#V)-/Q]:BO* TZE9H+8Z/<#/*-956.%LM
M-_$RA=4-S)=1G,38H+J.7\\W:;R.(TC>3A?S&4QFL]7;93I?OFZW;N;KVU\A
M%U]'^(O"@7R@P)0ZT1S$28*DI9 :<J*QXY;([ ">VX%^K^]WX([I0[LEJ2II
MID$+T <*.\8)SQ@I0&GT.F)*%3">%:<<0S!^,9IP?D*+=1U=[&!&B^S$]!GF
M/.N"X' CY!$G9?\!.R$O/F=*)%!>18EH1H];*@V7E]UVJR)/)=V>(1-<(:HA
MA-A"(@[1#./BN*0[-.09-6S6=,^4;@PV#ZR_RFMCC^!W].K"4J@N>)YG]X=7
MOC_HM%NUXEX-!YUFH-?W1HT\\+V^D?V!W^L9V;MZ:61O-!P-.T!X7NM]UW6'
M+R[Z [YWC]_ C]S1:%@9&0:^[[LONC]P0Z:3Z2*&6;Q8;)+)#(_$*ZMG7?1D
M$D5&_V86=RS7A\JT]]L8MD+F5-J9* I2*HHGMI&L2Z4.TG53L8,T,E"-CSGR
MTX)D[\%%8"4*EG]Q;F/X0*5F&2G, -:/>RI^Q:0D><[XWK[41<Q1J1_Z"KJK
MNZS040Y,Q:D@9T@P$7B!1(\9&C]#T:V"/0FM_F-:7D7++!VRP:9.&@K5"H8_
M:_7Z8D+N8:WPEG%.28F+BCX710E-OBOB9_7PQQTUQ'AFVW##:)%?0T+V=(R!
M_CE5-0WQQK JJU*FKF%!E ;;-ELNFO]IN/WG(AQ4&^7_3PI>_LGGWLT>?R 7
M.(A@P#ZAZ%0<:QX-?Z=Z-M7OJ.JY]2]02P,$%     @ #HA_6KQ6)L+E!P
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MH (H*&: S44R&^6EE66\<$L!AUIP*/+W '_5 />WS <..H\Q2"=#F>:V3XI
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ME9"U8C3<WW/6U,\ENZ$P"4/FHQ]5&%82IX1O-(1>J$1HD.8BRU$[R 035N9
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MCXBYO$>U1N2??3#_Q)!X^'EQ44])7(@>!Y*-$TG/,!G@D0D$F715WT/R]'O
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MP'1RP];<44,8">$N#O/OBD:!7Q 7:!FR4JPH/D'.BDPE6WQ%U?K0FFY3-IT
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ML\(!&F<&%('EP\T*\)CPDTNP(@.=[5#T7@E#+2DJ3\&S"I4$KNRQ@&0W6?E
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MJ%0QV^DO:%BNQ<N.)<*,Q^49I=D:?AS!+TR5UT(J-1+U\GWT(KMH*IZ(NQ8
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M6#0(=*0O4.FI'BO+HE.(0R J8JE9X2+W>)J_J*&'87*&'EX^0<)5(14/9%<
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M@[<Z5%P<WK@X_=1HMT"'Y"4?*?<G#@5+H5*Q*E.5CK-BM+I=7]1/I[@QN$1
M^2D#E71^*3/2T3B$2DV(^,+I BC,_@ 3BK2K2MZ4QR/F@)%L Y4$)=M\4RJ
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MTXT2Q*4)8E-:&96LZUF -UL%8!> G0#VX0S %I8K66GZ=DX8%X&=%+0L@5)
M<TE% -%(RO@EK!-C1 P]B.V*NB"6:7IL!7@_&F@8E"27%?#^RN#=?P2DMY\5
MTKG<"C(VE18R1#OA%+@_'=BS-+\ ]0+423@O0+VP3*R%94+VCDU9*%(6N\'#
MJQCQC*L<HT"J5.[YI4I#QCAKJP\HTL<'K*$_T<.;&P?)&RP2!D#IW&G\4H#A
MJP##0ZP*+,$D),^"J %,WFK-+% B]S=6#/0D>"K2AR7+ NY2()W1W*S]&L:C
M@S "&@[_4NE5!5@\P8C(M;E9IP<]FS_XKD$? _'12+U'B5+*Y"(KHMD^F3T
MA.&6O"T1W02W <^X/%E4U(47U=7BR._U1#=HGAZ5V,XNT'8F&]53P9=&]1=#
MU55,HA:03O/^TCQO@9SUHK[7<^#% R)2]XJ(U&>,2-TK(E)7("*5W^ \M#HO
MM:2^U-221Z[S&5(K5BRAI.#]R^7]5]+5RYM_O"]TZ-74H96-<TZU JOLD!-3
M%^Y+]'5>'5.JXDP11:@:?PPPJ;Z&"BK_LY[8T<MLR((^SY[7:K)RD8L_W: 0
M]>U[WPEY:G(@2CRK)=2KZ7JKY+/U6!P%_HAYCF5N@NX!,EH88;2@$SDAB)"[
MOW"1,K#" 7RL_K)5,<ZT=Z@$PP\/)5?>"6U:KC$5M[E*AD9=!^L%!*$C&@GP
M.F@I#0ES4%G@.S8&%/LQ=NUP0)@D]ZC1QU/A97O4B>07ME7E;]!CFZHL2V<@
MD[JI!ED]=4@?Y-GCI6UG7Z8M\'=1V]M-O9JJQLC]B7K56E5\6Y2TU=\LJ,7K
MH!:4/"(!VE$^[I2NE9@<E+X5=@>@%;E 5R3P/0;QC8<@_BXBOLOB'_(;P(,M
MT1=>)P?P+8]-F!_YC <@W\X#D"_[\CW89V2Q;[O N=<F=9'%11;#4Y8'GA:
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M8#<B$&  HEOTKS]KS->:"P!;[9U86Q)5J8I;W22PGO,YYIB\,H6N3*8B"N?
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MI9^OJJ @D@.'JL'92YC'9Q[RQ>NFO:G+-2(2*)SNR"IG[H :5VPH:N#=PE_
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M6IPHS(SU!<8#) 8O6:L)Q )U7Y2\83SW)+O#@]JJ^9'92;-U.1'IVW$FI!>
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M4QMEC]IK3A#XXPW<5Z&P0ZI, I?@53 K%/^8Q$HSQ,([G-QM6?2@ :0LP^4
M,G,%M6VK/K["%8E[6\@?(') 7/')1Y$H^RY"(EXP#B%,]3=_ZT@'_O9ONU ^
MA[#'WXURI<_HM#U$PD!LN/ZW'M;[I##="0@W[*KM.%.<1&C8]MJ4P,+6><9$
MG%@[ZAPB@%36#(:>0V&W^C=)U&:</7_T4ZZN/R%GE6<YP1?CZC67PI%K]"99
M@A4U0&A2HZY-($F]M'5N.)E\07AAR3"A)HM^[(,"*H#S!@M1MSY[798[P9X*
MVC;G)I5[X@G.8PT7_H1<8=@#/6YA @#41-@5D1'Q& 5UJL!8ZO['*3;\*.5
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MV7=]!M)ZJ/"35#5V^C/5TE.UO=+'956O-'%KUYY@3-:FQQ1T:YS8#!\<E+V
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MCT1HZ="?6 KTC==%0]G9E_?.UN'3-P43-0G>,GXG>JLX)(2!D<>8^&;2>=D
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M?)O Z?"D2 X;OO&"S?1OVZ);6\>\)R^^C=D% _(Y5EE@36.SH=$@J*IGZ<\
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M0!5+<HRYI/U"1QA(7'+L*]7>OEF!GN.+KT2U$4+30)ZG<"L>M[%%+W?" +A
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M1("Q8//]:E :G*- J)E@<C8\LL;*]BFK>03U&WGG%'@[Z]1E$Y2*3U[&0#*
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M:W<)3A[7-8W-&.DI^ZG)^)SB</&XG?:-83QH\D+&VEZ5-8>4Y/CY4.2X@I%
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MP&"*G;6;,WHJWFBP UYVM]?B?V7\46M-7:6=Q.FO5A8*9R0<AR$]UXXGY+V
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M$;C;>?VP@WO51<&MVIP1*P'BTJ*-B ^!\+TXMHTFNN0KP5[I7B/"I1\GC+,
MOL5>X7M$^Z")(..)['-.M/ [I4N!IC$C]RNKTDS/C+_/KE8G_ME.=P)'+.=O
M2KQ3X5/.<0ZZ7U0/P[0IE\8>*:37%FVEMT2NDXLJ:CR^"/; 35#M\&47#I'
M7?0X(-X(';O3QM)I#_V/V803:+>:. 36)D6?N07F(!G30/1R)13,Q^%5J<_C
MI>:Z[8F0MMT\7WP;K$37Z/7XQ[/P<0\,(9A$6$A;:JME!%Q34FY=+*9V2%B3
MUS1J>UV8[5."VG.9H.IH]%V 4TC.,S8\4V$1W>0C&V[G[21$P2L*??@@C=+T
MNJ(XK _2L<P'F8'H*>8X+'IC<2 &=Q*@CC/5E'JMT"[2/?5,NST@)]LH&7%,
MT/+G79[./H?^2<&8) *:!,G)ESKF?0&*_'FF--\=)NHH&C-!K8<06:*<DW#5
M3DHQ3?ELVB \,S4-Q6Q<2SCI710'OF<GR72(5! _ =J:3M#S-HAM;@I.VWRQ
MHH2=]@F_8$3$%U]__8=88_SD>6PYL5A1P]>U/P]F]2FQ@5CU8K^H $P=8C/=
MCOB]6?F&N!'$Z"J"?-ON]F)W\=^(W8\STPQ>)N-HT3H$=0XAMRT+#NW/&;/D
M=35$[6W,V'H&Z41OJYX:A@?9%H9?'N370>"#1.^&FZ'0&&.QN4('H"?#MK5K
MN/'L_#M_4]EM#-V1H-2N&08SB21GQP(%4'*__%*+&][O@?"#%\ZV_FWO=<&&
M91 3@$)1L91M:$)#2VYZYIZ'"$4C\>=C@\/2A]-+VTF\<H4.E)0_?AYV'E>R
M(50)B@*X<@O++W^3QY4@\5C!P&^'/DMWE;20 HC#^YIR5"BV+NLJO)=RZVV7
M*.+I2O7YU,">M'D+OA/:RD^".[_*(5[\6QSBS+3R20B\Q(IFN\4B*P5%R"CB
M7S9K[J[*$+=U%G,'DL[S24LP#RC.DGJF0ENE^1HU@2<Y%_&[.DMA$0^.F9FQ
MB2L1%*C5*7&G"^"KUV0T/<##")'HC/F+!X[UD5WI];%88\/$J-IH+"GJ<VVD
M%\]U8MESG?/+ ?F=AM^_T7M*B!$?7/*N@*T7)BBCI43+1J"/%/XR%Z05_6RK
M=;YX7%0UR-KWK;9& N  9GVQ"D8(=_ RHH"2_NGHF=8)1009U<@4RK#RQ70P
M;"O9SK3=[,8(^D5Q9!R4@#+8(U!F-LQ)7#8QXT:-.DG_'LN<92D68-F*#-;[
MYPP]!?OU:=\X7T#D3=WS!1DGU""EV#*YGCB19OG8@<A>:2,39I(T4E6BM5".
M#/F>QP%__^35HP??IW0S?*>EPA=PJ03!GF8(Z8ZZ9B+)->1D*ILU4B*!!<QC
MWI%>AY,;+)%>1%.,<R'PO&8&/I(95E\7+P)1[2T/=H,U*I;%B43?H>_;%4IR
MT%9U1J;P6K!$-,.0*IMLO%1B3M"'N1Z689JRK(85C>^T^(2VF2N(\8/J'MD5
M0JGTBIHTXW9?TA)26^=T:H(A)%M5DR3A!RM1(H886E(R@_849,EFUF[&?(B$
M-(6E),@' XUBN!-71;V1/H9^5!!B-5+90>96U%EC:*C4F<?J2N$S5_U6C%<K
M[I"NE23O&XP9:%5@N[2&PU\4VCBZMZ8"V5@E<98RDZE(RPPIL"Q5V5BP=;SH
M^=PQTFIM]$DX:.4:V4BB'2^I.H03^ONPL\'$[A5VR5U[!"=T@%K85+6->.5
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M B+J-((_,HU46<R$0N-R-8/IM!2^ S1L9GBA%'XXTZ5FE*>2XH2G0TL@6%U
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M8_WK7/G%2N*]EOV35M'<- D5ZMA%-FVT?9R+HOBH5A:C.2=<8BK\#[*MD8]
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MK-M3F%AKF.Q2$\[2&:+2Y1E?<YVA$L4A]"&YAS.KOWT$V9\^88:NM8W&:6$
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M+J(%&[TTH!+SK&(IZ@ FWLR%7Q;$W!SY8ML9"ZN#QA/#]3[\BVH+KQ#F!RC
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ML*+LG,\K:*X2CLC04'\$MV0L,F,^V1?RY8L235JZME%$&1\_ OIF?K "QJ!
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MCG@K9J_+,_S8AZ^&(Z9@@J0U5#2*&*2$#U!81;\D8Q/\B;W75;5BJ?C(_SA
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M4K6+DSKD^YN29-V!-KL@YIQS-UR.P2B;A 1-)S5GY8K/PEK:X+I*J7R:EDD
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MY5/E.L4>1CH8PSTH,&^4CHN@1)<N$W]'=>T3$IRZ';:GIX1A87@H7L7MK32
MA:=-0!)>L1 SHL+U.3$&XNS@=59BS?E= %_3'O J>@G%!P]Z^?R$##W5\) $
M2\BT4].=9S'!;HC#$V*^<"SQ\I$YQ12;IJ9WX/X8<ZZ3@2L<49WOK![QKT4:
M-,\M/ZR_>Q[&%#<\"20J!J5] $3[ONHB_AI^V""!'4S]2=DS'>K(AQZF=L0Q
M=FD.W_C Q^16H*G!OKE$1!SMMK,,PJ;G2%[*R]4\V]'Z& =I5'>^ JLG&!P<
MEOH,QIQ)GZOLV;K]_&M;C)DBNBWP1+H>J7W-2[.7QN-Y([S4Y]I!N3,%KX13
M"H(G"!M+(524LZ+=NF)M>O7RUFY-LM/8E"$\NJ!*3-W R2U%-01M+YO&-8CM
M\!I]#P5BV2%39K\FX+OS7X2?JQLY,M/)Y!&5QU2.G.\,QW'3*5T"H/Z3*:8I
MCA#;_HEAZ=>]IPT^I5B2Y46$2*1TIB#RQ%Z&6G<=L(-^ JT>1'"QMK@(BZ=U
MD\1^4%/]$8\YJCP;)?^F<_V"633?!D><SARYEAM[2(.Y-RG:9MAFPZ!ULDQ)
M0<HZ1;)=S1TV+O]F>T=L1K^TO>,'F8',JHZ)R!>5)C:@2I_3^%CSSW#%"B;+
MO(KT'.*!OA'6:JA39M/(&V91J_R5%3PS*WCZ Z>BC\E?N#-D'>:WJ;91AJLR
MC<!D0^*0$] DJAJ\/^?HG::M'=P5HT1F'*B=TU+YTEAWLR/02KQ19BJ=5<P:
M+>NCE_!@1U=;:BT=;X!"MK+8?/90:]J1.H.PH X%/)<F- =)]&"P=@0<&SBW
M:9RBQE>5T#,JN,VL8=$%)A]3'$GH.\JN;NHP0$S)P^(\B1NW$]XA79!3C@L%
MW=7B#3MA$R!)K>2(KI8F]0<XR5F,,&/E]$8%AP\XJDBPKE*=DD!IFPN/!\X0
M7]#FO( R?HG_>D'4>R'J0"YTG,6-22/9Q[$M__(T?X@56P:1XA/.NK#,0()+
MW]51B,K81 AAEH-[!<;%H'Q0#)):OD Q8%MP.L&G$HU#@65$\(A1)-7!#I A
M 8' BB+?V*-U#!%)&*>+2J,>==/#I2![-[>7Z-3.4+ZK?5UETM2LW0JM7D*&
M+@V9P(TX3-_8E/*3RGP-8,_P+,3Y2P8TQL1%5LHY3S,QKV8L28^BEGR3UT#/
M*XQY$S";5_O%,W"(;X1"'%<S[U#>D9WO!;QV*+94YB\CW<31%AP]YSC3G[SO
MNN8%K"SG9RAW]#$:U.4L_<$,^1Y<)#SUOS:49&V;_>RXL5R5 UPW27XC#J+.
M[H:."@P!RO5)#AR%0@)@ X[/V>HTW#"FPO!/'1;K<D?E!$C]01?.B FE3]HC
M^VJ]-F*+R<"<2UO4Q$@D D9E!1YT[NK4-V8& @MO)^[, '4&%;)/L*+?&!5^
MY#> "^,*66D/VZ K1;(J4JG('.[*Y=!C5<B,"=H#PJ:>"?A@O:L3W+TC>]G<
M58OIXM8>Y]1X;R.;;,L@^QL6:]US WQ$L_\>D.>W#CXASS\@\OS6P2?D^>\7
M>3X2)J!BY(M(AY)SD>4YG]0?I3Z!M<RF#":MJ6%;62>MPH>32NONF1<;'W#:
M('/$_DYZ!SF+4S!D./:(:7(M;HW"T,E8SS<,>5Y6%6J53$LXK\KY@J(R(A_Q
M#%H[94HO3?1,R!E3B%L,4W7HV=JZA-DD/>+-B5"BS@55IL9K21L 4!/67 "E
M!1>E(DW>9<'ELN"&Y9<++[>Q2TK#MP "8]?C\"?D0^:>HAWS,Q6J_SIH/?:U
MFL(*7N2[U^N-9#VL*S9X6E79$4ES=U8VP@'!&=R'+YZ%'ZS4DEG/=A0^9[B$
M(VR:JL)(=77 J LL&K8*-[4+<HA=FOX]TIG]SA8JDCT*.1.]]EPB@LA68K8M
M62&BV,'?):$]R?%K"VRP6?-R&P[8O7FY=0QW?OE-\"37W8C=;NVE^^QA*(7?
M!F]I/PP+>4#G(23HV:A1)M B54DT IYK82-Z8=2)'3"/<74WDNU%;<'D<5P"
M'<]1"-0@1:5,B&X#U$'>?6[ZV\A "\AL=#KPV\2D@#?M7SU\GMIT857B[T1T
M(.A8-L%5YU4O\>K<"[ :2TZGR5G@[?PQP#D+/-1I.P4E0IBA$^0VW'YP)"8O
MHYDP?N_AVUCW^XI:VX,I(4.RJE3-\W0P=3EF'+ M^T.R9+/QH1Q"+8"2C"\V
MH11+)V**G=(Q+X[F@A.R!LBC_G!5**-RZ^3BDR30G(PJ5=Q@W@#\$P@B316?
MP&\Y4^- E#5Q*=#.$K),>F%^"FXA@D!70FTS.G6F1,<%-<4[5A/EB6BEH=@<
M&"Q+DN0R#))X6&PC^7)]>MD422(OS%5%X(R%:-:M26"OW##+97DB3!"GX6FU
MB&R@VFS FWE>A8#]? ;QTJY^4\XX.6OT /2]&W%<0 EI4#" E<2D7NT02_/'
M<+4@\2T>Z*CYLJ!J=A5>Z!0Y,7(G!@Q>$3R-4I[C'!YX)MF@6EI+<YVT2^CA
MIRT2;<>H<0)5!$/6@D7*$'G3M&X[/+,D%,B4CP-8HM'ZM?P63N9$)4$XEO%T
M#AY%9\GP6!V40POI(.%D+D BF?*7N3D<SHQ'>,#.)_1=[CSW52QQN"05RS9$
MW3/L\.J\7)S&2"C[-2(A/*KG%.YVA4:%M,]%3D5DW%F6.(O==?_:E"P."4:6
M35?.3 K$S["W?K#ON+2"W/LD^Q4YTW"0H%>(B,B18XM8*O@2/>> IYV(5E3O
M,#=<:>^+W2ZN7QB3Z'#W2=E4T%"95_,B<T*,=E3,+VDO,<JUM!VZN"RH))O1
M7=$)."%S$0*>(<3V-#Q?@UW!OXW ?;=A"/+/QFIWHV6$<E(IMK+FR! :9(-N
M@XFF1CWD38'4LJ%N.+&,-F&0L8,I\_"1U5(O#\ZHN!5, Z3%M0"U(=3]1IKP
MJ4G09AV'!*G4]^K#,'^+G008V#%2?&JY7::FPJV)>E?L05I'Y*P16-_90@T3
M;U9>@ZWS/"Q7:,/'&40S_R43&+L]02"KW+1D9E*]6^6JB%>#5DLYLX+C#](E
M8UD$/A==L<D]2<<:WN[1X+QM5N3 #R?<^N9P?3B)D?[8K]Q5.7M=GE$_R+J5
M2Z*T6I]08@>7Q"TT4/)^3^9R@:,5%\:5RJ4]!V2R8@M[),U/^I=- G5'5<&M
M]LEKNV<DD^KO?",\V*%%*BU]T6R6)^3TI5RSR3HJ,N=?-0@&E@3Q\!]2%\&X
M6<^HX8Z.P*3'F0U9/[)D!97PZ/*ZZIJS"=6:S'>&I4M]@D<^(N^L=$A/&%\X
MYFW3:T'Y@4?'AY[+,-B:C,D8"QB)B^E>,5STU[O/&,M=@RMM-PE_^=7'@[:&
M9V_:Q48<\C;UWWS>!"YA$H(()9YS#L@K%%+P9GM?:YQL9P9/K'T[&B?W3!@Y
M5V(3;LY:NG;'B2L!7JA!KS8[I2U0"-C-7HW2L%R93F2,>$_O,D\#UM2(VKQO
MOLPEKSR5 SEKV_G@G905S8E^<(.JJ+^EF:E9VW&Z#KM+\QDN._98TG5KQ]VF
M]!1T\$^.3$P;!AN:\906@S82[_/%7)CBZ7?["5,B#NHMY-%;X*93=(I2\J B
MR'^RYZ+AAZ?XL>'IT,>>MK,,B+@O*NVBX+6DQV64B@?H.N$12BAL^,BD=;.C
M8,4G+"$]9RX\E,N-5+XD_1R>,!&1ID9S;G66B#)^R.'#+;:_27[A3I)N#SI*
M>W"LF#.:;8;8CVB]+R])HM_33S"%V=0-Y;.SJ_ W[KQ<J>W)$@S@:&5-H+OK
M+JZ)$'^ZTQHVJ9AX65DIV\@ZK&L/YU'J%H98<+Z"'.$ZC#JH4%F,08&$;@1B
M AZK4'08[%ABKH-) S9<X'A2'"6 2"8YX;I+LE!2Y/M=R(S?.OR$WOF0Z)W#
M3^B=:W'H/G=95]9V9EM1T[\E;=6KC"EM:C0)49:U-GAN-JR\)*C_PO)KY Y9
M/P.W>%H.CE++@KZE/Q@/;8@8-BQ!+>482YQI#[QW4;/6D<><E'U]LT[7Q\'A
MF%,45N16"K0Y(QZ@OA=74E+(3C0I>WD.'WEZGN.A0E5AH$57XY7#7)(]N@L+
MI19G(J!UM[$.NI*:K%:$?L87VAEW_0HM<J;?&\_^HBKGW";!"Y,\^B76D7*5
M5]V;6A5%=/DRG8NCCK8,>NR82>#?0.I&4&UFZ5OBV=&AZ>#'2QUC:OW+V!)/
M(Z9-67@F]L)^_I([: B+0['7:UH)/2$5J.^MI).WR,(IN^G08]B7_;KR307R
MW@R%[C8KWF$GVSA;-C(7+$-UL?O!W1Z3%),70L_4-^(YY#Q"NN64HH>B[X:N
MG9\RQP;MUX[?'?Q#%,8S_=L%X//!$^R)[,*>MM!TPK33F.U2=C'^Q$3G%^Z(
M>XPIV5]3^'J_P96:A_=LX$<PS8<#-Y6R7,_%>'Y\*$WM'DVR&.7LO*Z,U?Q-
M-<1XN&I0AKP*@3XLA.!4P39);^@5N:) >1U:XJ((*DN,K&38CZP?4)<-]PK5
M"OV(J:Y5N6T3Y%H.[<_(!T%>^J:A#1I;QT[3Q)2$)C?J['O*4 \K EEQ1Z>G
M'\]X-IKQF%1/,"B:6M=Z/YD\SC@M*+T+LR<=/&$:3FHV:KX(;Y&@R= UU,S*
M.#13FJ;&)0\=^!774#ZYAO;S)U'4H\B,6 )ID)C1D)PR4295X#A&-<%\#/!K
M)F+ 3[7\/2Z6QHF1RHYN'R*A%OF>;$$?@:]@KYX@D*UJZO7SAOFQ<>F9F5"Z
M]K2&T<=)==F6S=IT5=E[\$&A,,/A]BO)M\&9%%&UI4NC&V&850G^]+YV"__?
M_;!%!OMF;W*WOE- .XI:W^Z!?3AV, JL#ZZ*=S_[2^:BQ\FWEP>3-_S\+^_V
M^3 B][ZX>V\4)T]\];._5+17%><54[6F@M<+^(Z/7Z]IZ6+:[#J],3+ECO21
M5.N3$S;9&PPGHAV1HV?-L[V1AW==1R'$J\'(U$AJ(+(HN<^NG$-";MUI:UN<
M?#D(*-<(?_2ZOCHM #)NP1HTPK6%0A22D!.I4\ZP;I%XC4<*Z(0T&=YK.2Z>
M;:(%V,^Z^D2Z8X6D3:%@<J7K/(QAG53-&4L_.X?#U^!J:/&N*"RZSF\ZIHGU
M",D$EA#>!W@)=QKW0N@A[D$XX>OE"9$DT$9"*?(:#PU1AP3[J)8$83_@A$*)
M1:$Q$_^11S_,@]X OSYE\FNS'4YC?JG32*/Z:[F-'U>4S-T,:7%STNGM"Y]K
MB7I#F;'M:S4^EN\17KD"/@4 X?MESP#Y=<7!"HOK.+QV _P7YZ$%;MT;69>6
M9AL[;=A(9 .60="G&%J,'8[PE1JM+ YBH+!H*9.Q!.( \"D=9(:_4/B#L!1J
M#&G,4!/="$0-!8+MGE509N=^;&Y4M.YXO728K6=O)#S#!P:QE4\%Y=/LG[2
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M*!?H)_Q3Y(-2L6S(_6RWY8_6OFVFS5,4IR0(%R)/5"LB;;)D\8IPTJTY!NM
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MFE?J9#H+D!PT:%LO>W/U615)LC>@FR!Q2PHY.7:+ 7 268D*E<16.)3:8'Y
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MTM><'"TB K/P>9=+)NK#3FZ815?(!ZV"JP<J*A4HYFA[#!(F8A.4=FDWIQO
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MUD?[Q%Z&0Z!ZKVP(OR<CE+"6+,!/BD4YFVU6VX$2S^$719C:K/_7AK;Y*5'
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M"G4HHAEGE5)'+/Z0Y8@R&;:H'-EOER?MPF2O'W_]4%)3(? D$_VR6JU5)*Z
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ME0X5HQ'1,#P>3)3(1.<D425(A9OB)5(_,6POGI*O+*"M8RQ+ISS1M* E,HK
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MLK-.X&$/=/*YJ<86_#3-O)*FF%?3Y 'C>!-UCI%Q12O $7&;K*SS2XZ,$ZA
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MX":!6ZOO\'U(&[81<J=SR*V>#;(/@S3QUG5\UB6ZL5N+I^HZ'E%_F[D38J<
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M$<R//PL"5$;%C&4@5IAG&I(_(BNXOM?OPV,FE:D8WE0DID'3&"V2(($"+"W
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M7.G:H[1G0DQ01=6>T^ %W4$M7:H\@N[Y7G!Q],T_7$Y8N9BM.ZE:]%V3XI:
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MN?N<&&[LTIK1J"LPI<'0C+EO[BI,$6@H6H%4>,%#G9C7\*K/,W%@\Q?M+^W
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MQ]MVY::WC"G<*Q["7=J\,.>#YC,5HVHJ9FU]U?-*1S^7-[)+([G "909NKU
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M?(?RCIRUVS>S;[&8SGG#(["SQ$PG0Z/\(@4=A"*5=M#L9X[;M=U10O#BBJ%
MI#6S)HUL$QCG?V_TZ!@J#?TZ)3#Q=-?K6O\<W%Y^@OZT@K=!RMK2>+I(V1+6
M=DT\;W5$:0(IC) H!B7*S>5/]^3N=_"KV5D"48Q%$$7('$PM5)MDU'L([>^
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M%Z;6-CHJS$3>'<)K)&$5?\\<7?Y__QSM7PH[0#FOF*<H<RBB69BW!M],I,\
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MY4\YX!"@&'2\4*FVTI$<"WN*HU/&#1E_\X*54!S;(= &;DC419.(S-EXL,3
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M2;M3WFJ-*[GA_J^C3H\?K+CD4XIR)\7$<B=B:URX'^7/:GWMR/CVD^R <[?
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MD8@);X:!9('XX:Z[0G^!C(T$#KN0\\1$_$2*%5SC&3OO-G227.-(6OC(-W0
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MGIGTP>38L@?+-9I/$"-[),@B"74"0C!>".-C A2HF&.K=1P:^!FJ'$@@GHF
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MC-3\Z]]J,G8RZ9;_*%M3<<I<YLUFII#VD)$!AL;M_F%//[NXJ61@ /;8IV<
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MG(4+CE^:%/KLV9'V5* 84(@33(\8KOR)\45'OP1DBBP46')LLG[$D>X-[7[
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M(R@R"=US*C['B0#_:Z5\L:N95+M#EBH=%<*+H74:0.\!\0L<)*B9BO697KR
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MRPT/ $_B- 28+\VHNI!=[9U0EIRAE _\[;"NC^E>5M3I4\:"JG #Q8!_T1]
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MY,(&L@I;5RRM%>G-* CIG9[BP]%:6S)RPV0V Z661KK;;S5\=2H/('_$SJC
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M,9%[<+P"JG ]E+OM6/6#<@V\;*V4_RT\Q<K"4]/L7S-R[+__#U!+ P04
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MC?<%%L^I+G(SY,K-U!"0;F/&2>9:N%\@<[#H8-=8G_R'F2>Z.\-3C?0//-!
MUW3ZLXC.UN<CJ'XG/K%NOI[1+:O^Y3@*[R!]".BT4. HU(U8+IRE>4&\',3A
M_DB*X;Z["A5_2=5SB^O<:/FQ%,/RN7@_"Q</<S1 =@-V7_6^994=X[!/QEY7
M6'O'[#Y3*J=*UY@!\BA8)2A8%;'[\^!9TM/[-C;)?J<H4-(D,I5YA@;[*!8@
M#59;BXIL[!CGPLK-?EG7KS?TDAZT4B%C5XY(=T-5QS;JP0&4\8]?:=M1#$M%
MO9&D:#FE03VM$Y'0767M2C$R/E^<[I@[6$T;8T7]3H,^^X#19TLG%M[=@AQ:
M:^$SCU ?+2TS=VK07/W];I!0'3?\"G_!3,[]R5LY18E@GY-<>V0*(NTH]_[I
MG/S)2PGQPM^/(.TI(+K-+SY*4A[KDZDQF67FGF5/$K5GF7I*![<5UG5 ,>(O
M??B7A^0UY;KVZ)- MR[V)"C*X14C%D_0 8;7*!*B5(7W,GDCEVG:9@T-?"PJ
M/#VC%2QOP:\($H)V_@S5G. ZM&=I_9Z&=UQ]('LIQ^?]M?>X7$DM'"7<AI#+
MRMWVD@T>-QABS/U ;CE3%AG?[*U;XB$T\@[)+0O%I.;('IXH9#T3/-D*]=&U
M7EX*@_44>&.=O+:HC[ 568AG;:!+R$4#$8.C)G!&J<Y-5*V$5*<?*S+)<Y5:
MS->RT^W\RB4F;..=GA(7H2B7]UJM#C(,P6T"GXY8'A4 BSUO[C,SW9+[]6N_
M"^#I'-%! T&H9SO&_%/T*E55+8':GX<:WS<Y/J18SM _D8H0UM#S>3]NO\4L
MB^4V)HK)_.R3VG'1M89:X95B"CF$Q(\!Z3Y8CP %EZU5FT$=PQ6.?84/WQ-.
MZ!9[@+O.Z5CA-U3=)9Z._0GF7_W-G"95/$VZN,.NN,-N^+D"LJ1=O=T]MC&.
M'^*&@ (FXB,=V0OAA/X?@E;FO>3#.!*UG$0;O2W-KJL<26CH"$![*C9I/V<%
M7-*I$:_VH%3-JE\[;!T6Q\05,WBX>):BP=D5HO"83@GN-Q.U[(.W5"1Q$HIY
MXQE#G%5$@7]TNHGN#7D)TCZ2F-U8Y$5&E7I 5KG25JX5.)+'UOH6QW+(+^>#
M BD(TB=W!4^@W7O=XRC.=XN-Y 8>91ML+[Z6JTHI[:"!E<R:BBN,1<C29%%$
ML_@935*SC0?NZM.*50CU;K+@*9FUG4U<C1T.#R3Q90YS)2UAGADR8S4F?/_&
MUWUEB%"ULIZWCRF8CM6:9A_/2X2N-A2NNF[LHS!YF*!4.E751W+^J]#I:LK]
MBV"?N#!B\42W(5S1M*YAOI].F*8+1+G6(N:#?3Y!#X/Z$L ZN]M(\R8X<QKA
MM54&-<55/P)"2&+C,_C':EK9?%Y-^I ZY?_,^VG]I%'>'?SY8\]# (_GK*A9
M&!$JAQ!J ^<:6%\@5#Z]8^\CMNI(W,)3LUF3LI*ZQ-XV.>LQN<6V2IH],:5=
MRK+96M7M*F.<=,77ZC@??,]CU-WL#W@?$CB=,;;0MZ,$JQ%U7Z:G$ +$K^=8
M Z+=A/A_'A*:&=)_07$A/^W]A%(9IT.%W9.$\F?5.]YJ5QWTLU:L)(\CGZ_X
MRKP<<> 6?&:\J'PA%TV)@4<D_9.I4E0J0=/D\4$EMU5K/ED60JNGL:Q[$&G9
MJ6K+\-%$8$Z1GX;FDQQP]<GF+OFV14S[/9EF&A4<?&=6G\*(O:R9^8,2-J!X
M*AXST**SNSFN-)[?D!:':^#"=3#"%JWB@X##.AR(;_12]*&?>RWO=T&CG3H.
M.6O]<C-&)CI7-WS#,SK68W*?E3LUD^9#OZ !*'Y/UGF%@'+U@<J&Y;CE&V]=
M>7EI5_&,NVC4XMUIS 7]DTBBD5]S"$4IOZ?]X?^ P@MGH %9ME9!H$R2S@*O
MX87US>!5-NM)!D3P#->:WV@EBDCR6VN]V:/1*"L1JVQ79V:.\V7/1S:MJ1&8
M>+#9\?5JUK8UU<?B<#8'J@2\>]P5#<*DCU)R"TPR0.7I'T-C1Y 1JX3Q\''4
MXQ;L#U^;&(L-GS]1M"NEN"=*<U%BC(WPG6I9)D,\R,-[976SNF./$T@L@<&:
MZCW]AV2:<P'J-Q]U@KFPL/4+=K=7NQ@W3AD]34N!J3?"4#10$08Y91LM^YB4
MU/?Y-,+/4E JQH_51J?*QLLD>&Q)!6AT^-R4<+81X/ 3#%E)ZMKQL1"_LL^S
M(WGQF?>R&+[.')%*ARW"Q-2B@R#L.6!2;)P0V!88W*FPR_60=HR@=&6V% OK
M\2W!7;8,#9T[$I?AW"@9&/TC#O9<YH4]0Z*CY)$J:.H;Q]R!Z9 >N&4(#5#<
MR$V)2R'(5>&WN60JUD[K#M8:$3>'TC_Q0&HVVWZ,'JO<6-N2/A]$72E_#UJ9
M9$G,!/P&(7&.V\*K<2&1R8:_R@>IYD0?-IB%82^["Z33OT56(UYY+^B_5::6
M/6&J<CX1L'$LBBD:]+7YT)"=5':+DY ]=WK]NT0+P1KN@,*U>;&9M[%S\:G&
MSF;*>]6)R)52BI=)'$7JW:Z3+'YQ[JZ3+C)9J[P./;&H3$8#OUXJK535[QN<
M=-O=J(\?.J!H=G6\?'.AQ$1T?>\CJQ\Q:W7$F.JA\*?*$I79'S83EEI/OYJ7
M9UF'O0_&UNX?/%N/^16>.[GAL">GK);@@P8$G/PH[<3>N?D:K-)56!36KH=S
M/LC4<*3?H+FZ!8_Z.!4MBE3!IV+$NHMVHX($S$.@ 9Z>?"]H'"6&G-)YF^L1
M^3&WP05(XK>U$^O?U6!<960B*S\OO\2WT;CU"8XN>& :O5@Z;TU;W:RL%W+2
M_R&$+0H+YP_YN*W 6N"54>VPYW!"C4Q!W?D$4\IHK9WZ#?94!;U6<]PQI<7K
M!L^9ODR^:&I16A6P!\Z27-+;VH8:Q&9!L3&'6'K/ZH57G&[&MV.GC(YB'_'J
M:7'NY2BY/<W*MM;(>=I&A6K<9Y>MU@\\;8-2(=7=S#H7DES(B"P;F$.(0PU8
M0MC9<-YX[@N5X:DZR'@-(0A>/8,.OK* MSU% U)[*(HL-(#=C8I:Y:;4ZW86
M7,QQ\J4M3P S!P>*V5,"J8#(+;M[5SK%I,O19W>>NFJ(9)F-Y!QG?\,GO5"N
MS*W#X-^@.C ]ZI%!"T0'T9<\YFT0TAR]]J8QCL^_KZF/K;=0%(C=,]H*/JJE
M?X3DS9X6V$L10U#/&>9UR8IW1CH81DN#H)1#']% \);%K>_U312W3;HNI& '
M^BL+GM,5YQ'3?G[@Q*[H;M4#^V@6-[.A*'&<Z[R7?,C>*0D8B>M>':;^<CN(
M5I=XR*)V0GKH6GKF?FB>4$$^\BP[/# P_%GFO?_;T.J"3,(?_HSBDE[%H!;@
MZR>=MZRV:W<=KJ!'PBNR]]A-X)L)J[XB,[M3$4X$[L]_4Q(6Q_8)U*HHNM!%
MB;3FB='3(,W4QW6N.#_]9&1O^%Q=S.?-%_\5_ O%O4<FR0Y7J<O+4;6WW:\E
MQAJ[SV _.V$)9;!<K+U+SM)(\/#";4ZQI^?O(<3IZ>^!0UL?VLR=1>KXEX$_
M"5*>29JK*CNP%C&?I(,D?O"^CK-BW!_F@H=V.N C8SK)]#_[,4WJR(7Y(',:
M7S(Z2EKTS >D?S\P:O-OIEXYPC6T87T]:=&:J!([#_K.?-S7C[F!"4H_"W""
M$W=^FN?OA!3)4(H>=^:8S3QNN#DQ@GZ^H<[SX.LP4.%X\_H7G=Y3WU_K> 3^
M&$B<IL6C#W;CSOW_DP(3/-XL##]2@+=]X79-88_HY^+J9.?XG4?"_T $0WI7
M+)D31;M#MB@*(<OK7FEU^W@\6/$-VZ@@JF'G2(E*Q"0;NJQ=NWEB:60B?J,7
MRXALR^]G*F:4M_WURQ$@^*18D542CG#HN,7M>5%EH__Y C[/\8K[U)I(!E"D
MQ"M(MW'5U-RG$JFY2G%"MG7R*\7*KG(^6?]$JN%@QA*V#2ST5] BEFZ2#JA1
MC3#(MNNTO@\NO"5OG?RY=TFU#&,?Z68,5E JC?Q8([[!RF)LJ4?'=-<T\2+G
M1F54HH K45PH^U==J3)MVP)*-TAF1B?+ ITUX@(E1XN+JI="A;"/MS)"^@6G
M[O9A! TH.42@Z*PE!5JJ&R?LN1F]U=_*-A7B80^+:NT8-/Z.=2BW2M)7&52H
MN^#](RV'@8>N*Y ?J2UX#:6#6I@LJ?4=T]_35_&%DW>1G>_JZX*CBE^D,J;Z
M)?SVX8&'A*X.XM8?N99<BVU;] 4NNK[L>]GYOJC_M_0-^X(XZXH8/6B[5_E'
MXNJ[-U'/P2'WPQ@P1S"BV>.G);&19KJM<<>@IO'%5WIK4(OC8^]@AC6X2(G#
MDD.C20 1TFZS9UL*7YPS$]GX^YC6[7!-.\*YUT'BE^UOH>6X+)E'&.4E)HBV
MT!M^B)U%B8DG\3Q^7ZN!,&6/(F9 AHG2 #RF8P'T\RKT/#@WR9T\18DCOKXC
M:!KC)7VZC0.9C\AHLUDQS(8J$FK-V?CPO&.9O=PYZ*NOVAO7G*J="7")Y7L"
M.7FE8RD8)DK6EQW5IH;RG]RSN5>HS@.TE[OW2.*--X,+I"T*AYP?RW G1]D/
M$#C*BX*B;9@K?JP>-'0BDUZA8$CL?(6P[_NV[QMCM@N%(6NYJ+>;R?C=%S%W
M%,-!^FW;UXU/#TJ<4+#\D:'V[?[-?5]NLUS]&2MUJVTJY7=VW?6/'RDS4'O>
ML*? DSHY"7_"2J^B,SCGJP=">,]#=1[F!CH%TP65@5T/:!J-T8"$XC6VZ]SZ
ML.1MYDN#-D* Y]X;@%Z[/&>-+DJR!'[('N'"=?Z8>3_3?!_V-F8E%44Z@NQ=
M026L67/D3A0T?X'9SYZ[O^VSM135VF8O/([O/U8*46E2,$V-3IURNQ#U6MQ8
M'%,;Z(V_84!L?O5A?Q!6N/33VO.CGM;!8ZS'3Y@CB7OD%'IKW2N1XYWC>W4P
MP;JB^T-G/0=%]HOOJ:59G0E ]QI43)9C@EW%ZNJAX!;QRD%YV[UJR9\!O<M.
M!_J+Q$C3E:.'1A%SLO7U+4#QL.-R J@<  @'!=TWW<WU!_J.I3!VW*C:>F@U
MIS5J0G:7?C4Z<)GC-1#^_%GA.>[#G;E]\71+98RCC)5-O1^/K2QHCFGG72-]
MIR]U)XJM 8&?>U'AZFC^5-1(B>LDWI^$_M>TJ69-I*ZY<&F*^/4:85C;#W%R
MSAKNNB.-IXOB=*\@E#?U:"  IPBNU@F9I7OT(K4_(DVQ^6=LWQ?'',0ZBK'N
MQ@2^I(3(S['S+#(V*9@=_]"-%4Y,V2_"IJHV_:.\"K;(KORN+//EUZX (OF7
MF>]QF+(=2FX"]6<YDS:5C?FOI=N'\K:3, ^9QYY<505*G1(;#QE*=:=AUPX#
MQE_B7<X_&\D!6QO72\@=F[ #O^Y.;UKRX *##&RKDPKYJL]H8"VPF7]EH3NA
MH@?_H_)EV6JHL(S+?G'#"<BY!SS62@#&+;Z1K/W<^K'2#>JTC3& ^NSW5DL#
M2;\2I:S9T!IW]#;JD,5:CRE9(K.ROT<]U?QJ:GRL)*EBU0+76])D3P9:.^GR
MW)Z,74)&U3,C6.'CJZ%]0%1P!0V0K$9#(F':_(S])!$VY9%\%)0/&6*4CD[5
M@B1I1EQ+5'1@)]IQWKHG1!:)?+G7*QBW8%TCI',.,JA;*)VA,?V,ZZ#.3B'M
ME5#//!]._/3(1(FS[#E[;E+LSYOW<,&0A%P#9(1T=72'@>+;CV0E&U&Y-^7
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M2L8UT+P,QY:<[&Q-*,P(_3&'+[EW@&E\\L98V1[[/'NN,G*-9BM?M&R&S($
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M(V'5QM88]^_"WVB$WL4. FI8!/(VO[GRSB3>:/-MCT;D'YZV0.>&9;10C]$
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M!H[(Q(8IE)C_4 1G%0WTCA[Z#F>C@0RGB6X'O$>YO*_#2,P>^CNV*7E@O 0
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MLC-UII./-K,4])MFS=XFPA3?_$H'MQKZ8P_&>3V[*3'VQVE'Q-P$<+;MLQ=
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MUW]V@;_V3W_\M<.Z_=>703#_^K#@'=W]N[WR7:FXOJ^/!K;S_L9M_L^#K;R
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M(*#AU>D5R;TSST7&G32U%)W1,IDJUNK#CS^*NNGJ++B"J6:(6"(8O"9+]3V
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M,OB8/3\2OF^Q@I>ZSD? 'O*T=XG$5L[0BQ]S;R^[W-+UR@ LXT<.Q*5;3YQ
M)N;7&-=QD!4W#9L+XZ;4I\5@#63/>7E^D%O;*QE^@"AS>GP2_610J=U1DS%3
ME7<3<+6RX9)WC^5<U=QMI@QPW"DZ9:M3;SR3Z/4;GKECZN,D2Q,$1K2H:P5,
M!L]X.6_U;8B7['P+;F9 W;Q IU<;5Q"2^)B4KTMY^;OXQ^2Y.6CD34H%@BYP
MT<<2JBJ"QHJGVE%(6D\>]2#8^<L/%:COQ<KG71.G=&/[UD@MD5!/RA0K^A&F
M2"L]<O%\JGNTU'C(VI)[0QJ-^R01"?U:W@3&KRBLLY0^03C\3C"*<ZD DMK2
MN%:O[3EF3$EZME-8(G>]6. #GJ./.='F$2,&.=C$)9&&X__1!/U/%:YB2X<[
MJ^&B<T'.Z)BPV.QTX/.[K$C#CPDM>P%O=*IJQ_<RE](9]D=]>$=0[29,?\I>
M)QR*A2T!A =SUL5$ATPRH.T4",SQ'E9IV1?418:NM#D1><G:>)>]727"9P[+
M:Y*Z##.WOH!VRM BI2MR-@WLH!\.^#L?Q&1N^ Y'PUE<2N=;O=RC/I?NIG0F
M-Z4=/:1Z5 RP-)2,^VHR;P#SGC-$'3W7@25,7KWK"V,O^,<I !ID<K%W@'DE
MW.2W5I E765V%Y9SV8MI:J[WTYSN6I@)%7'<KV51":UJ.WTJ*Q':!<K!#(P@
M;1GXG^P^=4%<JKXHOC.53(X$BG;W*7HY@,K3)^;6^P\7PDPY.F+.0VC-HR($
M_D0;E'AGH0WB.T2>("W3QC!T[2\P7-5697W*/5CVC<GC4>R7DAN8A5CS7/=?
MK!]U+;E->S4<'DU">KL6=7@73M&=K_-.JJGH%\9+8#.=O5'N84E7OD\"/>UG
MY0@E[%WEBR_&Q)F_;"Y@\&D8+2VH1P#*N<0:X[P5C*^%::>HYGA RJ+.A P)
MH]#R HAKFUZ<S\A;U02B;QO)T^43R_5D!OMZ%B9_YI,5SB3GRW$L:6G+\B?<
MS=[FDOMG1:\&___GJ] TGA"T<KL7QO^[&T!B ' 4I9;BBF\8XVE4=7V>DJ,\
MK)>)<O:2";_Z<7QQ#7A7DKZTU0DGL;$8NA,5&5JJ]%",L:UY?AU9#U)5?@$V
MKZF)4'I@?B_+G]HL#V638 .R>13%BNT]9JLK$OQ?&#DH6JX!;5MG-_!.GA"G
M8@39K]^J5K-_MT\9<Z<HU\@WJ\]WSJB!6@3\,2\8$"5+SXXG%\;9=%R&JKY,
M 4I[0Z2?AP_"?6.5:DGK:*L>K#!T_>4E,R1L/\_=5\,ES(GMY\786X(=(H3,
M:ZNCQ<ME>/A"$NG<9;[EZB&OO@%KJ@_7:P^>Z35N?9MG27E%F]90T:6R:WV[
M&7X3,,$VC]'7 /OF\L.::T#.E-KJVY\?YKD^+(NVGCQO/%4]@PB=9)>@^I>A
M-/CE388>89O=K&J-_*O-)@TY=C\72$J\*.N*#3=H)"_21MY@9.%.';?,ZP(C
M+ +&HH[7#4P['Y)UJT_LLL+&[IG.E73(FK\-HL1T!I]?[$;66P5*Q_,X&E;]
M2B!KLC[4#+<^-C@TI3Q[;OTZ.8>!?_\SKVN!868@]]MB]>)3]@A2.<SM'K>(
M_8"))LZ_D4GUWWJ8M8!K -$NE#7OI*:H8.]'_[JMN[1+^/<[?Z:H3 2B-7Q!
M)@6;!B51T=9VL/OY.XN,'>MEY?0J)Q3]D#:ELK/OVY@)Z(FA\#7@9_S! NEF
MZ/S4@92CQDI,D_CC_+H:X[GPBZ.ZT<WD+F@6DC9-<5/"XYM<=\()7H',F_/3
MKN14\:%P>]A]CU7E3P<G=W5!CYC54[WH++Q)389SSYYU36S;TN0<;"(3L5AC
M)_)K0&4:X&@KK'5?*=2/P@;WK!ZVS]K\ UG_^?#WA>I;;%9\?\B@GT;3&5J=
M7:S$10)36Z_'42<K)F%PR1L[?G4-<(S$S,LVCV,EG(:W)FLHLW9^M-O>CD4]
MYD:4R=V1*JH$?A._SR]UBA*B)E^1FAVMN"*B +5Z)0:Y&M/88)_2%]IL.?0R
MP:J%M]9V-)QR==EL3!S1:(.+:O=1Z\EA&V<6FB^HGIK*'OX"#LV*:$+_*2F2
M/Z.1@O%)03Z^!O&LHLV&)]< ":-#X)D&XO@E9 5Z#?A<]FJT42Q/#YV0$&T%
MDFB]]WH$5A^XJO6PN\S(JL3SLQLCS>J$G0MLWR]Z'85J=]C^H)9K84/QZAJ@
M-.C\V"IJ&7.2[/C5O/)9LP2I,:N&+KS_0'2>$BL-V^>=P@U(BMM/G^X>[,A[
MIM0LBW*-VB,,AC"3;;4N)(^0M@>;0TXG04CVB5M4+WIZ#^D'8F"H@"C'(2IQ
M/[%1K"/DA.1,7BB%7L(JZ:0,QF0O(.%FSH=X*Y.G/@D76Z"29ILWMKZ8J%N2
M$M^2JX<_(?D<P]FGO<1*^"CB4:=*NYN4]4KD+J-QV793M$C#E<^01E88Y^#+
MK+HA&OVSPDO%8%XB6[=ZOPP>BIP$M#Q'.,A24?U\1NMHV[-4OJ7<!U@_\0$Q
MZ:.49VQ=862$FC'L)BN.&JZ.L?A(L?S[O1]F^2"#1./?QN?^W[YA&#O>;]>'
MM$L402=QX&O ?6;(2="HH1VN'<Y@\C3!>&I(9K,B2OK$^\,IDO57MGF.++AP
M$X)T+VCXW7 IWKYF&<KX#/.2B.%LR"OS;P['?]<K=^->)<R?4(PBCFIHYDLA
M7:R*H?9UXXX%>F(S+3X%KH\KUH>UHQ?5GA_)5OQ1?R5&3<^><^MOI2+X%G0_
M@% )IM9'M>GV .\E]7W7QW!3!1V9(,&;S?F7YCV9_;'/" MH<QMP90.X4+14
M>-%!@,<2UT(1[KJT<V\R>(PYII[@*[7 N:.1?82DFF?^JW)#E!'*9J\U5J\O
M*3IO%%G/L;@NQ@JB?E?]L:QNTH..X@RR6"Z+;^.6\05UJFIXO"[]:+Q1B2<=
M_'GG8UW@8YAE6MC7:X"5U#4@;]68TL>2%\Q >A,D[^*JWWWYF@SV78K49G5)
M&E$W6BS?UT)X&U1_P]6A[N!<H%/B*]"M1B#?2=2TYL68M^AQ+!;24^H^G<;*
MS)^5\)'B52_+PBVC14S."./\V3==>TNH-;9">>[NJ*5<U:SMXQ77V 5H=RY=
M]44_AMCF!/O60]+X%UL4SZZ[R'0I.+-: %K_P)[K3G?FH?)0>6DRA'Q#IYVW
MT!!ZL8:Z!AS131(2!N1"R%5_";6E>)BKS+WRL^?N)U@>^V&&/D@^,E1[\K9"
MP1!$ZX($S##31H\="S59_XFLL_M=4%^*[5+9+X6R83V1\W/0"[._Y-N$)A.[
M,LM#[9H+UP"*CGX&&3QCIK]&+!:++=1$SUT#%B,]+<=3Y[$Z3]A^)7Z"8MC,
MKMAQK9,\,LM['54 2/ <131C2&ELF%311NPYI/U;E;'AY: ][E&)M.D9MF&,
M5V!RJ);%[V?1=P]=.7C7 /_,-6!2%G$-D!OXK*XRGK(I](XKDUSXCV&$[ -'
MDM?O$7U)ON;V^=.](%>J6.H[1#*_O6@J]!B>8^!8%H3E-2#TI"[7%PK!!I9)
M1@NX25\#"$51W;^ )0JSN]H);1[TSZX!7YD5ZI1C11HJ@]>,OQ35<_%A!UPH
M^CQT6\K/WBU((4*$+C<HY[?WD:9S=\U"G6HY U[A$[0<X8=M;H#A;G=9B@/#
MV'->_KOX\9_5^7]YKO?.;QM= Z9TU:\!(]/Y>'[_Z!>%@7YR)[H<=E,=N]VN
MRMU_GD3[6>7WT/1'N6E<_(\MS;S]7MZD' XM:#OE@"U76DKGPY[@UM9KP*\#
MHAL8<OQVRZ!INH. G/'\-"@UNG27@[,4TOXU]\#M<O9[+E7[F[BP\]FKONVM
MPKM[8#!B<J:3L4J4XC?D$TBW<8"[BP1[E&(+/2,J6,!\QSNM[,@XUHIVWQS;
M,3Y2/W;'/H.N :NS1Y--POKWXDQC @I!(KKB66]X\'+3^@>L6Y7ZWC1^.%I?
M<:-;+RNQF3Z+.MD=M4)]7K:>RJF,I6_=B@S_LQ!%M"&[IU)T9F&H0@H[7#U4
M>9A*)[+ E3TJJ$K/\_ [JGN-;Y8E]XEW#:"7R;D%;X/ \Z<1):>0T?YCGZB3
MZL9K ,GOO;*(3$Z?'\_JQLL\T/"^:T!,8(6LB[P1O9*F70:8@W$5">.>?!\I
M/(UVJPGS;K Z[!:"*W@=H8=S]HBX3MWM]ZQ2Q'0+<C8EW'24^RXI"T0NKI05
M91H>0"9+\&1A=G:LM;4R1R/R5UPZ82CDT*_T8%/=O)/X*T-+O6H4NUC4!).O
MVPK.%91+K@.&-PA%F-,_*Z9H\7E[#0@*N@:0(<YD9=!E*)GE^:M(Z!9DP5>&
M87Q^6#F[ T<ETZGORGW/V#C\3$?5]_(GBFSXITI$K(R'"BLQ4+II"\7U+QZ>
MSQ2AO\Z\+V4Z:09A)V4"E\IRDE!>!M.$7+\3ST%? O#P*Y>*\")K9Q/;&B]8
MT)+!/#*[@T;O;46C?401NZ64UB-9QLA/>8%3>F>QA.,,^D*=YZL>BA^?2WU=
M>$1T1.?8+04JSHJO+M\K&;37P62;GD& HSME [GC_K($"^&.1D\5SYW$"YC+
M#@J.@?<-;&G4@GZ0"66C1Y2X?U3D2VLRM2Q@%$6?P:T+P4U^%KF6]C$I-C9%
M1"N7;@7DL?P4\B#0*F?<</GOE9CC;ICFEU<-<<8UXS U1:ZDS\NQ$B[PFI?^
MC-2\B>!N@$O+2<DFAV=TS_K1/#'PEU(^4@%":S-I+UA "I>VL'_:;WFZF,BR
M "9,KY[R82,[>RC)+303255]*6"DV$ 5X=H%7!UPT5(?F9_XT@P7"_'A\[MH
MCH;X%K;RGNC%F <C^WL5==0:5Z<"I:*DOAE4Y9Z!+H7IG61@YU!DHL;,>G]W
M?-.K;A/'J$:=8W(I;>BQ([<PKMB9L(T*TQR9J^1#N:YB;0&OLW;*7:;J?[[X
M75;2;F^BGLLUB7O9,(E,)1"[1T.N(YVI(LHP+6.0$ :&.^IE7+PE _W9(EBY
M?"V\9U=(-*6=I!?+E[JJY-78[A2SR:>JP#W^;>WC&;#]&H )/W.;5[G41?HD
MN!WZ-"7-=-9;7"R7R#LO;E4LB1VGR:B'S:G^)+L[X6TO&J2A?#"X.N4I)?]@
M.6R#/7-SMV7E(^9E='NR=)0KI5F>:<EZJAEU(JAJI\OC<FH(_J821]WTI<,@
M'9YGVTO0>: 8+%;2.-6BT,TD'NNU$,@7]QV4FQ6]=6":1;*UCUAS^M)28Y.)
MTNMVY9Q%F?@V\;H%=BW$JL9OR/92'6$W=_*^K?O:<IOK-H4='! ET[H&SK23
MOYF:<4MPTEMXL(M&PO.S+ZYDF' (S90121'?S(+*\O$8P1B!-]^E2M'F#U!A
M+U(JX"S'<J^D;$4PVK!.1$A)Z:Z!LFM!1\<SL+6R-AXA&PL%H2B6*_^OA[H&
ML#S9NH(8_)RH_U1RHL\->VA"^^-E]9N/U0>A/5WKK"C'"S##>)K]0JN]Y6*X
M&:3A\F&[W0%D$AL$:3HX'O+:S,^^X9QE6^]K$L2LL=SYTZ:;I\EVU=^E\V12
MGO7;K+TPMU:OMF<4(8SKEG$/F_I3#3(EL:ZI-T[?>S[K0!W]NR,U07HE%J08
M1AG6\E_N/?>F=N+'<B9RY@9&G=%S'$7<U;C5VGTG#B5;,D2 ^12Y#'V$G-\R
MH(399"&-9R5HM0;_+)<^L4%=@4:P]%D>B#>-=7$=?DSA&@'+]\FM:Y'36Z=*
MMBL[?A1G-8.[N]ZFM+#,^N_]['#_##>IOF \H8DS^78&IC]E=L\G)-6ER\AC
M@I17-&[3K4M6%)IFY")^;VW\;QX[8L*]U"^HYG6X;?)BW\.MEI=3H>ASL&2S
M@>@8&^!!_GJ4J.@*WO2O9 D/$YLT#4':I)\W,*4 !*4:"N*]\S6R][+,2>G
M]'#R%^-700Z8H0HS5'>\3#!D5V1GS Y[GN-;=)  ,+MS"V\,:G#D\CI,*$I(
M2X'J'T,PA8F>P0*8 H6B6/YQK?)7P^\F:X\WRN=>)5X2MC.B_#[=,(DK:0E[
M-BK4:>ML:GJ:\.4$Y$NCYA(CV;FN^+<;)%99W1^N[FSO?I5-A_NTDZO[X5:P
M=F@O.L(]@[CYGV0D/?N,88+V=VWVY[<2H98UL>KW$#_V$IF^O_1/#X-P=@]+
MLWM(=!@TTNC$%_MFG=S0;=-/22)@C>Z$5X2 ].I;DY-X)6>C7>(*8Y=^C.<G
MJBXU?VXR^N>V9K=S?,>:V9S2I?Y6=+J7KJ^)ZS*"SB8AKB:4Y<FG->1)W^*L
MNAN%2M9/?W<K":V ;E,[&S'6.A@G!9=J0G*#^!ZQK?A@7EZO<%TFQ-RH.)=R
M?L?&L>XED6_/2WX5JI/3$J]5EZ$0/[JQ8I.=,IT>EB#)HAKM[PMXWS-BE42'
M*G[)=/@23,=V[]1'A#EHC(S_Q-7F#C&L034[C$N5\A*/$&11#0M#]^6+/2R?
M82:B0H5ST)PE$:_$KV(7R^=YF9T*6G=O[1BGQ4>F)UG1YP;E4-8,KUN\5"1]
MPA(71/<@%KAL*J2R1&]G%;HZ(43H8>KS=I+GC?!(G8F'A'ZPTD<EKV,@T8S'
MLB9F_$?-I)?[=(H?C_V#V,&;57/=:5WPOC<H]".MV'W)*71Q<8BCK!.2A!;2
MU&K"#8SPVF,1 MM_)%$BYF[C;-0[(W6MBV6/C2E%YEZF<N#NJVJ%,RINZ?NQ
M8'2@9HMJYN\;QUS!<JH@CCS3ZEG*U4?ERQ$'$N-PGI"E(,Y[JNEYX#CLD5B^
M']>YR=/&<4B%\TF*'G=C&<QWGF,-/#T]Z+-M3@?>2Y=P7MXH\S,F5!ISU7 .
M)6.FTS]U0Y_K_H9BXO6N 4-<T9>KD*YFQ(@0D1"8LEL#IJ3JW>^Q^TP)P%^4
M_X$(W]_!FV:081BKY">Q27YN3#" T#U+]UW&6]I1:DLL*W@>DSOEM]VH893O
M?%@JHMS!M$[?Y>5>]CQJF-53W96;C@IJ;C=>\N-QM4C?VY]FP701$2NN^"39
M6/6L_B5&8F.TPTPKF.62[\6)C4LX;+PN%*>#CO*RDE+P? ?%5&DBFL=+$/!J
M0=Q0O2%X'A,ZS2CPLI-GVSSZN/8FIDEA.+5^P#[W!8-UOGK:='%XR1Q*+"_.
M4[1-P_;C*J,7TCMI92(]":.8F\.[1/8W-;NEI@Y.^\G .E?(Y:B9C\U190_W
MN[_@GJH6S-DJ:6$N]8$%<@FM)<P"G$UM+$]1/;UX3G<(HK0>N1/?2Y.VM)"D
MM-SF%'LG,H)D@:Z L1R8M<1\&TW;Q(0B1V>*427&E,-G@'RG)[^<O"[O'?O%
M]_E(#POMX,FF3W:(T'P^M7<98;;!%*N'].4#@B+O; >OT_,-Y>GJ$AT4T7G\
M5NW0<;W!<5-<$?O=P4=<1:)[NX+&XJ!>5VXIEMK8<1HE3==[C_0BONNN=N?1
M<U7]S36AXT3CY1;W:^-DQSX7?5+S4B#1>L=,[\<-RKP'& 2L3VGWL6<\^&?A
M_@0!%/N#W@K7JL-X(;P+WP#\B\+@;Q[L?Q\0TCI_@%]W#2@OS;X&Y%;I7/U]
MXNE_@PK</-3?V\W+/JIEZ&&/N-=!:V+EC:#0:46YM;L?[_E> [SCCDJ\AR@W
M)B(>&=]/ LY&37E&0'AD#":GM4;5>DYB=L%_WMT!OEDC+EA2 T;*O%&EBL;6
M--FGX,[IHB=2);F$3F@-QTO+I,PBSM7]Y,O0P.G<?0D_F<DY'C<<N6'SODGT
MASE#X^)1%])7DEULHU$"QT+K#%Q-XZ[WQ^N: Y?NZ[!M5_2EO#+-*W/&495I
M5XRX7 FY32/E23X78KLWO9(3=ON0.%**L;N"9E\('&-B_DQ4%\G]*(WO*7BG
MJ?-YJ9%_CL>8DK<J-\7P&M#/6V,W#Z_A0XW*]%-4(+H@A_T*V)5K  T:T-*"
M5K#BG!EHUCZEH''3:1!KP@E< ](->-?9SB8)E@DG4K35BPDTX:=R+\[U]N 7
MZ]"1IN",^DI8$VEX/O-/Q<51K_4'$N,C'>QO=MF3?WAF@ZJB_KCX0M1'LD!7
M'W='YJU)%1CP@WQ571FF!T"="TW41BJ.=*>Q),MU23^A_;?K:3A93< UU4<<
M&F$&FSJPT>+B;Q?<.3?+-"G:!AT)OY)&:5;%CNSRL;P3HV\]9@@N'M8[E)B[
M2-8WZ'H2"!W \ 3P:>NF  -UD2_O"]K^AI"IE"#_Y42/V6/S*?9_9.Z;:/=8
M) CF"H_=%!OXT292)7?(]5F4+Y\I<4@V)BY* :#U+V<-^931EX5!:NRT7:&A
MSQSM[[H;<VKR&8^ B1'6/:_<P6)BK&=4ZVC@P]#$-J3<C(HKRU(?*?/<4Y6D
MF@=)Y+'RZ_F]K4//_87^R94YX,=^9F[<!&_:ITQ<IE=2^?)NU!C9-59?/$#E
MWLOUS%_YJ?.7/ZYHDWA]!JZ:)\VD$R\B F5@^OUV=!$[/$&RW6.C*G"+YV/:
MT]$+]D2V.(I+R$E9."_L&E!][F>*_();M]M>=H8;MX_N1L$FQXVESWFW)Q9U
M[9SNQ:62:JBX@Y]<](?$7:W?3@E_-S$6+UI;8*JHIO#>%_0N>L\X\QK@SHTM
MY-VY%+X&:,4-7 .,EI\7:*1LR)>I^.;8JNMS%P^45]HDTBIY.GPY%$IC"_MT
M*%E;LL3CQ5D7)W,Z\'H'N!QK4@))>E\PA%% O+[9<>B-4C_:Z$<F3D^CIH'[
MXLM'8C*YJL]#W=UD1H7$J!CRPV^X'LE(LKKMINK^-8#).=;- ?+M/.8L6E_8
M+:1&U[%DZ"<>Y\[')X050SZZ7+_.PGRILJB?;(\825!-!3U\,4+F]]DQB64H
M3W1!5YWMZ^=DLBS]4U<JSCL0SKX126X0A%DX&S^2CBR[^+/#_>P[U-U&_ 7=
M\O/,SQIMSR3!;Y6JO^X0@*91DTJ(32\7QY]ZZB?.WYKW0$57.Y\-XDS&?H$K
MFJJ5+BNRE:\!BVJ7PA7>IRO-#KYZKV1XCB>4R!UYIH;?>[%W2F3TEJE.J5^J
M]$\ #W242&!EP_D7"GYVVZN9F.J<74B5(E#SR]-K0'=M"56CA%U1Z*=D!=R"
MA.X!^>4\V4:RX[,][:K0;UK\@?.G/6L5IDO",1Q<OPQMQ;._1!@85. \2M"=
MFCAR+5\RTVCL8S%-5YF0F29#2/!\P'![KIYL-,^$9%10\/)Y<@T #P"0(G!B
M1#7S-K/H>9A(:#&O)ERL^.77"D+,ST;?X^TT/X.5F^Q/H>QNGB8%7UL"$1I/
MXQ@5RN*ZXG^7#>#ZO-*^43L#7??$"Y;U<C/PU<TOX!.1W,5(?+05:*@]YFK\
M-OW-S"P]PI\*YUIFN2B%]PYONUXMZR45L3EQ.PY_6D@:;4#'&R+-V<I0D7<-
M,*]2,W^\5\]Z[SQCOQKO2PO+E2/:F,Z4]*C 3"4HN)C9\F'#]E=_*2>2@T(!
M+,N?7:M8S[)CI03%%]N6T;&>;+NZVAG6#F?>JL;BR*4U:])08#5_Q7O/EA8Z
M*[;]HKB@:HZ#(S[#)> W<^H$U=K$7^LP!YGX^_L";6JIFY\1AIXR69/&:M;#
M@\84%9L"ZAXG;/(IP! 3\A@\GHI'A)?#]=">$CU3FC/+$#S#JO6)MSI5>M-5
ME""]NU*_/Q8U!V7W!#&^J;"4DC?,)#S*GGUX;VMIB+BN95)PKVN5\%!(TH]I
M^)/&L.T),2%^21_CUGN1($GQY;3[:ECN]Y"GZB)?) 77V5Y78I_AG:OO!@<G
M;^KPW#)$?2+,)"L8V@(FGTS,W65+6!**$N39UG/(L(#VE:>T2%-^=,Z6'<I^
MB5.LA=+X"#E+?<>4?F^E,-TAW&%^H&*,V&*4-*N'>!_8*#08V3QW@Y+8,S5@
M*"/I^.\()\08]$DQ"-Z#)/A]U54S45L $GL,M2.QM[VMOKR)Z6V(4+T??$[%
ML:G<3B'#*^E>II]EPY:17'5OW6*B[)C;[O#-,.6T= >YL8E1MG(HLQ.SED9N
ME!B;0Y>2P491<*6UI$"91QA*/[Y$\.H=!-;J,R+HB.VC^-Y#--42)4:8+J[E
M2OQ-V_PJ[UZ/D$IQKC:U?LFR=<!6:K: .9US[2E:NQBKF3UOU$G0-!K']XR:
MYBZ96,@Z:4\?Q05C/?#-XH?@:X#VMVX=+Z&=G34H:X[-KW[6L42BW^;@)3'Z
M*"</42%[1?@(+.4A)7*Y4^30R$"2[!KP"0S79XKG"[+0>QUV:R%6B?YRU #1
M</QX].+H&B!0WKS/$Y\W)Y5Z^AI(XQF+'SIKIOFGI^]>E]146!_&/92E"<,=
M7%8T<QXW:$$0*UG]50) \<@BE=C?*NSW,&])-2_I6>FDS@\E5T_WDW!+!W>C
M#G, 4?=^3.!+?MOH8->4:!(?_C\U"@\4#9.X5VOKAN*L)7NE/5\J ?S% ^+&
M- Q-1P_-O5$#."5K2;4\M5]SLRC) Z&,CO*K6%,QJB@1!;C'D$F:&%K;AVWI
MQV2CP)U<MQ)[=KB^G?[.2C!%#TN\%=4'OK''QZ60=O?'IF?]':7V8/N(9-_F
MWATFZZRXJP^T3CL-HPX?93B'II^78!2J(_EEA7-M0#1&R-?3\??*N6G95\@H
M@DD,Q'WG4V1!?Y7\7KN[^7$,[Y5FU02OR;*<'SR8.'A=M0^=K<HGZ9;AD-3!
M3[[Z?XA[ZZBXOJY-L!(L! L$]P1+<'>H\"-X@ #!+00(4KA[)1#<(4 @% 37
MHH([%=S=0N'N;@445</;W6OF>WO-K)ZON]?,'_N_<\^]YQ[9SW/.V?LY1K2
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M89BYB>D_)79@_M3W(>RB3XKIEC<5\'9[<UC"2E@1QMAE__!P967_=^?X^1C
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M.$M]@?.3,8]YQX41[;*1)"/&K]L*&(#,<_0MN>\X>/0! K2%6H [2%:7;_'
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M"<X4X$BPQ6K+;8PG#I ^J?]6B\]W(<-W4"_XUL+F[BWL.RL9_X&2+E.*QP5
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MY!QD[JH'-'X!)'IRT2R1)C\AW1-*W=J=H^+V(7!3NLPOKE<D?^<5XO@4)[*
M+_AX'(C$Z9=E];&V$FCWY9D*03+7>W'L_B%O7T\_TN"6YJG0W)EX\U('F00R
MXW(T8YMCN@I0VZ4EO?V4?R:2/'.V"%Z,%\EF]8?!T0!_IS'P[% 7[6BL4_6&
MCQEBS M4-K:<NS+[ UFM=<H4@5)WS3&#-ION1M$J\[A55IQ0BQJ<*;/ +V&V
M=Y3EBYZZ-!=??<HA01-'=+;Y#:UB!'" KX6+Z^$%U+:'U\XTB%VW4J<([U6G
MTQ4&(!1Z@ENV-I\(SK'3^1N27Q6I?6-,>KSPAK U:)>E^'K7M&K1!\UTV104
MZ0+<C:D(?^ L4 8IC19'25Q318.4M!>/@P$BH#O!:W3P)'CY<:Z]]*CNM>"Z
M67[NSS!T]I8%!-SS/E-M9>,[V(]'#@ ,PR\GH?'9.@*2+-JEM3%E#1@CS2C.
M-_2T8T3A&BW/;Z*.,(!J/O .C]C]"=?W4YM@Y@>:$0DY/)P>*J:4)@/H7J$T
M]]^^P&.M@).UPCG=,FG5)E%]-4P1DG70@A<U)P?UU\^*U2(I-RW5_^[WK<O8
M^[88KN4^,652KPOZHN:]=8X! $H"7J^H\_8\\B/JM_M*1*=R1II%#!C=7VJF
MYCZ$AA]]C)7I.+\9Y[.AG-0G]AT9R5"1O8;_:XMH-;<%&0J^IE*OUQE/HL0
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M;C('G[):<9:?4F!)>^;OM7,M:-20M0[*XFG_2\/D]XLTM3ILTKZ7;'W0O<T
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M[^T]^2+-L[LP)V](\[;OO%JV"RQG)%J]QRUD48JP?P4,-D_Y@Y) [2)(8@.
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M *3RI+(YU^ 9L/I;2,7A?'WR3D-OJQ?%MBQA0_T,3,38F$'#ULGAW3^>L<J
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M[_LL4<1&V=#FM>QK5X3W."]V!TWF;L(Z-6-O? [??@IA+^G34^#\:, EG%:
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M4+HSA._5HXZZ&-HZ:-@:B^J+\M//IXY,_'\=]A\Z2OZ.&UK,(>";\A!X[OK
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MN\JDRO3<&KEDE@1=S?8J@Z-S'Z7!X$V4U9B-3.#R(^!9?J,;R[#N+W9HPB-
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M6\D711/#C&%L,>?:_]9-'@'B'C[8KEB-233A"^/"2F"GLN&-BM^Z[J3.PR;
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M\(!TNA9! V\"GZ32:!$\D?*"#>,8G& 7HJ">ZTQ XVI!Q.2UCLJ31AQKAA[
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M^VF#Z'Q;=+]Y/Y+RN[_/\:;FZ=DO$TS_$@0#8&W JCU\D8RU :W$$73:$<N
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M;2+]BHRO&Q&HB;K\!<U7YTQG^T"SM_K.@K]IX54/#@]2:$N?E2A'!F?+-T2
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MW*B[4-A50[1C[H4GJ+?AZE]W7DS%S1?OK[9C@*M*J]C\OD0#V6R</Q,LU*Y
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M!3H>%N;A&DU' ]>Z(B$8+.5VF'O1?-@[<E$"$4P$@SZX*N>XC7R&9=_>X<,
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MW(B\3.8W+@MYX/J.]"WX>5M8UA%<'LOVT=->?6_;<>-L=N ,>+^XW!-4EMJ
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MEQ5Y#K'I-&5:?53Z@IU+0ENB&C<Q4/&4>Y#ER:0PG"(V8,HR4S@.8-P105Z
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M #WQ+R=54?0K@)F.N]IB.F#&L[S7<Z$:H.[/(ZQ#2)1D7K:K?&T$1W]F;,>
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M(=$;FG"#UG3(E*=B:(;5.-))""BGH$XB-IG^I^^BN8"/ )8D?)PR-8V3^JR
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MU64>5AK=!N+A"<[U;L*N].,>YAU;W <LIQ]40=J+CIGEQJYMP&(8K'9+=O1
M7AS#XZ=TJ*MXMG03ZG!/-0P&EB+7A=Y A<=X4(?^C"LSY<+@A1[F@#'D-J:
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M4VV FN9>HX/0SUOW/Q-?39,*RW+%[=CZH56?U,NR( BA=;.)!6*@0F-%\C.
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M5]4^\SS\J$3?8FS!ZZ:H@+MT^M'+>GDJ^!['XS']6WB49]B.RI^'I<TQ]KK
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M-X71JBM"/.]\4V9YZE:4>+@HZ^E-I3Q4_YW#7;>-;\[@]*Z9'B-S2UR:^I?
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MN."I_(OJI<V":]SAX#8")TZW32*5\#P7LEAVX,=+[$,"$)RY8MC[ /,UQBH
M;O5]QQX"0O2.:/<P :;G"N!IC1L.3M%)X'*"GC#TL2-&'U8V26)<?6%%3.+
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M7(CD=YE2OE:[UHB&LW^CK0+.K]/QE""9TY"SX'4)<\V@.@U]\[6"Q6/[(HS
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M1?=9;^/[8YY7^<Y%FHZM-F *72F"CLM<ZU,YF=HASMSFSOUOQ0 BJ[=#-?4
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M:=U$(E9T1P29!=F55L&$$*6 *YGG7M<'< >GP&(>C*B ''#H.'BEG'X'E6P
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MR*2A4W=4,1U=7A8^\%\EE>5"?M5MYR</KO0GTA0R_R(&UM?4A1BEP_\/U<4
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MYDJ99ALQ U<OOFT1K79413I6;)>)J-8E.\!Q6V9K.;VZS.N?[K:<;F!==KB
M?U#BAYWP>Q_YP^\"+26)RA .+SJ_PN)W.X<&B6(BB  <E=Y7JU8@<F&.6M;"
M-_80@'DF:P+@R[C'O:_&LTGGTE;VJU*ATH\ 4O>CT>KBGS@ <P#F ,P!F+\F
MF/-M:;:AM419K MB"Z6C\>,I_WLW.MBKF!S@!HS&\Y0ASU5N F!AZ_>%LH@
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M[32(H<G]W.O6"JW=87ZJV3Q39&(2EY?DDA21O3(,77X6 V/U1]F@%TV=-!Y
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M&MNF(I90C?]:(I'_@20W5IP!1-$^L'GNW>34*>TB@:D8D>,1>SNPH/]>"+>
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M BZB4\!_"+U[1SKD.+ED0Q=CTD[X4A('/6_6$1ZK\)9K<R/JF-"<PFSM[K2
ME84.1'4$#SB@J_<\("?R!FNY2]/S<\* F76QE 9JMBB4:X#!#W6N(U"Z.\\M
M9O#@<_5S-V:):CQE-&]C-@^;_J0U4Z?^=M=%=J92K0ZA1?RGGZY"(W/6$3*[
M=.L;D:-LY"A[%B1N%S\&(A;5=B,4*5O+#PU;4R?9""?XQ,;&J7'?MM"<YA(>
MP\\9+0TS )AVZE"" 4$70/<\N%T[<<&;_1CH&L0_G<Z6;)/\BT!6BHI-2!TI
MN2:Z),Z6&$=)G-XO_M1SEZ+2K@I?.HY0[[KPM@_L2RE[Q34@8=; +P)WJ7SX
M6BK<\*M>HWV6_Z1-:?IRX\5SY<F,#V5V2J<K>.G[S^%&ZK5YCENX.4X17-W7
MAPA%$REK-Y5Q>S<=L@A(PR5O:OU2G5E]\QBA=3VS/017=HCHP?R'^_7=0;##
MEOFMDK=)85-2WC'Z3<I2P@WO&?M#R=<?5+F2LB3O@2=]\U7"4TBE[.Y8S</E
MX&2<M0B_IP5[05(^7XK2)[0> 0,RERP3NBDJ(L*Y@[ %R.@.^FK$TEW.(&G#
M"2Y0";-7BLJ8LA &I!I3>')TX;UHZ\9@#WA2BI(+AVF"-MA!N%5D"T4R@'%^
MMV0EO /"\&W)7;1U1&7X''<.L\KJ>76LL^SHTC"E&Z_1].)21P#/M2@4W%^?
MS[5GTSO74AAA1D*;*?7G%+K?QTG D_*D[X\[+Y>#9;@X-6+R[?T=XDJ)C3K,
M$KKB9\X_'9M9@%RZ?Q_.5^K$7'%Z98S<O^2,GSYHHAF8:O-&+HVH7)W:N6_T
M^UOD"K.) &Q4+WF#Q"T;!6AUZLQ1])Q,A'X$'Y;S9GCW P*;/E["!!3A1)*6
M:,_W<X@U,MP9!9-WO:\/'VW"-X3 5T>TXTO"KAX)8;3\S3^27 +)R86?OAYS
M@)P3LOG1]_&ZBK928,ZXHK#LD%FWW2&C*/K:;8>,"*])/>CCQVZ* :>.LG#Z
MDHF&J</#FM.,&L:9O*HW]RZ\M8U<;6[_L-;5#'&9BK1/NT&L.(>$:)S!**HW
M9K9(_(KV,Y3($F*)T; WU,=IO=P!@,&\@,L2"\+6GY=,W1)4B?;0X7P^#FW5
M6!GXX4%C1>\C^ )U?6I(OT'YCGQY4>X'K_EG3>DWUY#N_+?Y+AY9_*7-Q\WQ
M19&!U5^'BD('?0X.DN36NO9DGHEZ9?_J=(]2C9M'MV\A][%3N(Z;IY5U;JY?
M;EZX9NGUXX.>"^J^(9'M_\D:Y59/#A\R%5T\7K;&H7LG) &"OB_F .I$>="?
M2RMPMA3Y0)JW.8N9>&61Y6.XM\?9?-CX^]DZ-$-7]M9V:MV<ZA:_OP\P\X(_
M)__3\[W6>27)7?(: ,. #S\$CV &R.9TYH-\!(?F #32<Y FOB6Z)'0C]?VF
M,A+2\<VRE'M-M/'?E)>+.BPJX4Z':T*"^L;($N9AB>X*NYS-S3_$MQHKIHS6
M@1_"W_9JF;ZNGR\J:I@[>?N7M45S!KWCL.G?=VXW- OQL;--/WYAVE UJZ#4
M45P&\"#*9)=<WMJ;HD1Q(CX;T^0CTLH48,6ESDXP@Y.0BX#,F\#8![OS<(HP
M7I OOMNI+5(9%D4+;26]4QN@QFCYN]%( 7::;7R6@,V\WZ;+5'I/.$&78*-:
MFS;:/[BZES*+G3@A4=@M=):P#.5@7UZ"]ICH /P<:3+DBVW]G2BBCOBV2,'9
MDG@*?E73F=<^0,GH5"S@O3U'.-'_Y<J#.]_N7@;B)AZ]:HDH='K1:<"]L356
M*\YR,?2%ICBYLS2VI7)T#G^HI66NFI\2//V%E*O\0A:WT@NO0F)B6N5>2E$3
MTQP11=MYS23A$7V"(=D\(L$0EKF+3#P:E]JY460&W^(^V,W#9N)413I&WJ:9
M'1[<&N.6P+_L[-8<*N8^*RZ>E'SLTW&^+#DW%D0>_E;:&/S@\>#,9-"[Y2#M
M8Y#BNG(*>#'&4MWWP-G_U>*@AL?K*PNM4I3K48F]I',81GRPW H(X?9SXG8]
M(4V^$K?+*9);?V'Q'>[WL'##8M/*P6(^-;2,5$[+)SD"7?'.NI(!O*$4=12+
MZ/M&K?D^H1UACK_,Q!9,*0&RX[/.&*CU)8 B1';Y]=03@"#)*-1=!V7RY1AZ
M#PK.-@^MKJ*E$BWXFJ6<4^T)2O>T3+\DO7$V52OB@W!LZ! C?F YFF\?<Z;Q
M3(Y$?=,,4!3?4U7<[&+3^]1[8FS(+VZ^,&1<Q/[\8@!W<]*MCP<L( '(+DA8
M?W9FQMP%D>)*TE;B)>@*G)Q8 X_ZBN]T8D4.8HI$>V9J+9Q+C764HG)/(AQH
M20CNHJRV[3=IDJ+ /".B'522=[]DP7!C?L55>Z5X&A@6NYC/7H&+9,-&?2)5
M#%.*4CVGXV3))Z]!9"U[P92?[W@^G[0AIERV$P8X"T;NH6'<P^'@=(;QLZ&E
M7Y8F+M-M8#.KFW\*,:_[*: K5H;4CU^!.TJ]BFNT6S 7VL,3 B*<"5K06PTU
MGL<!/7@9$<"E8ER2'\>V@Z-$G4=$ [@8TN69U;F^.3T93.CLI2>QDJQM'T+J
M4<L6G]A@,!DVWDD6:?AS^JZ<!'$%2"1IM*;IE\KX0U!)%UIW=EUH'_<Y__%F
MQ7J"1??HN),RSQ*]&]K2;Q/\4.3*;2H5TB5_#:QO+YA@0D9!7DL?9C_LPZKX
MLT;N^>!> 3R+TVPMZ&_5] !3ADI>].%,V^*:[BW%]RJ2\B:*JE9CKK^:":@K
M.L3X\?BV#5D1(BN"S1YCSCH\TJ8;&RS6?1JUL[A>F=7>Y)<07-,LW I.<Q&O
MHT&T!S/I9%24+I#1L9J#48X.0X/UZ0_H+2T7DS-M0BW/OK5Z;7O@T1Z&Z@.H
MW0.]&-*1/MD)P%Y"*T0;E1'E^( 2<1-H>G5)F\UC,]ED -UA4'?$ZRXAB3[E
M#-=NIU%G@\*N41F5A(=PT!1>-;9S8]Y<IS98?8M+48CMBXSCFE?F2C9B[(AK
MQ!4TSMWM )IHSD$74$ ??-:@*/Q]AT/<W3DI2D,D!RT* CL0 @RFSHQOO0P_
M._<BDG]<TM]IV$]T/[=2*\-G[ >K/;^LP5UU]QE*]"VG7(F"&D:DF=F%X)&$
M(BP+E/!7,*H2.X(/+Z.:AQXWXC0/E:_K)SI IMSZCL]G\1D2>8C*Z@8ODUW
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MY@.$:XC'!TEFQ-/B)Y*5(@Q<$U<AVC2T^5Q?%J#;H<$%M%KIE'2)6O^YNH1
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MSA*^O9X^!.*9B[G.?T')W7?0#(E&:E<0)G>5H1E4-WS]_._J["%WZPOHN#D
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M(0X%CO;ZFQ.M/R]/:PO?NIF_\\TY$W>_\(QW:Y-_RL;SG"@OM>P"5<?M ^2
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M[%C3)29'VY_Q=G +N!Y?I5ER>$,%_<OI7I-HQS('K^SXHK"%F.:C]=24:L^
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MEXKY^C\-%1]>^NY5&[].2$*K4(+H\;"W*^VP\1;&3$HEC?F+W0];5-\"2&?
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M(VT&PA&D7-MN">&!D.H76"(W2]B+2D"_I2R[,/O5P8M*>"C?+%,HOX5929(
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M2$.S=Z[\OI[RBG#-K:9):^MY^3-A8KO$C6%JY ^;Y ]<21;-N==ZW[#JTZ;
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M_RS?:B7UR,=]V/#YW(I7M5NT:;O;/O_'6DN_%/)';%3F3$@+'RR&.9JDV?X
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M:_6D1 0UC# AVD&2XTH \]:0 N[DL_U47LX,81M4I-MZ$BSH1*D,_#.F83*
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M<THG\A^G2X6+2EQ=C.UD=/#OM;]N@<]2L_YGZ;Z=XB(:[G.?7NZ]44:R@Z+
M>XV^)#4^R_XP3%&TYUA!VR:9WAF 5+<*J8LJ FEWKF48WPW'7:/(COZ1T',"
MR^)$'R"MM\4IU$8:JFS]S@#:WMRSB0BY>;>JF//$-SW@GN6VP_TKHNA$\]$8
M7KI93N'W!UQ:9!A[6;+=ZVQ14<'=^<F5Y97;"-D<?ZRGYM6* Z'155T5;RB7
M\X,JNVW-CSMFC=?]>3IX228DS_3&$#OZIS#TKJ&SX)#Q;W5) K2;U/E6M).J
MT&H$(&CN:VGH$+)D,%VYU36R1(B_T,G2D$9W?IIQYFIO/7$7UM<B56K[[[3.
MVCRD%<-\]^Z,RRTUCEK+N"X6^BY!6A@A0F$ILG'DG:XA@%VVAW0W3IL7,S"9
M%#1.FT?BV@)1WN!2?+T -J['%$K"\-2:$)7A>0&LEDY3WS;6A5<'Q*>O-(TM
MXNQ#61AEZ.'U^[^9X/P_EQ-GU__E$0DS>:3:@ 4,9S>4Q-8&VL'P+L)=BD$3
ME!'%G$*SJF;C6R]4S$^$=_EJ8OLM1X39!Z<WLR31]^1#6-AN&S_@W>&2_J9O
M*R)26=2 )6AWU((K!X5SAD+ O9-,^&( &-XA?/T;559=U-K&A;]@,3MNK)7
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M$MW\@-O-R0PEIE",HSO4N..(D\STM,/)Y\<7@#)R-<%Q$A:(Z-U4Q]1\;QV
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MCM!F3E91V(DOOV\O)NH=5M2)6/DA,2 LYRKS5UTN1.![83SI 'L74$AFS4F
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M')26:A)V]WV9MBO30M90'O95/:_#0](^B.^[I9J-/YI]L!\,L26SXUG36NA
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MOA5(VXM$\" /E_O+W-AL3@)A_B420L*@I]/M.=5<*5@2&P9$6O)%=.I?OYS
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M2=,_4EDQH!Z>2:=;^:A7_/XW44'ER=*!:V$/IPJ"/D= ^?*M_W3 TV9CE?!
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MS2E#:."G^.[8W/.G(F*C8#>:<I#>O.;)A))YD 8TF8\.PET$.2YL!LRR!'T
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MNAU;_1XBH5)!UE@%[L*#Q/PS:W"YKHKJA,.!?#&[1P!\"ZPXY/;.F0&H@HR
M.X:GB'R._5C>T&XUVS4F@)-;TE>O7GI6J@I\=?FM58C\8# /\@:S"O,N!X-1
M8 :S J7=FR?#398 7!ZNAT39V1U7RPYEXM\I%:@^D<U7>(0-NIXIC_?)'NJ2
M3KU6K%#QO.9NZL*1W][K,+_@(Z4O[]E0TW5*V:-AI_.\% %1JTP;?09:4FOQ
MK?-Y^'4&39MV1\>IS%GJ.=8<GHROO&Q;=<UT./D8&^X2JW7>6K)Z;4I[V\61
MT\(.8,JR""+XCSR(0)L-8V7%VX@ / $?J;T"@VT>'W'Z.B[S<E]QQ@(VJZ=
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M48]7>5;YN:)9DQ9H3Z3TIW<_RY]$/@J:V"RJJ'MPKI7NZ;%QL[[)H0X;TH1
M"@HR"#$W"KN)BC=HT-^YL[L@.[3"F[+%[#:G9* 2)E*L_,#!/&:>:9G29WY5
M"JN!D&J1**HO%__ E]KB25=?<9PS\POI1 @K>[=<HE7>YJRX*&<@F%HYDG)Y
M+=:T+ZEF:C,8,J:;4M.P<E7B(T%H81=T%*,-F%/'R'G8&\01>H3ACJ+UF+:
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M&Z>8&/,Y>6Y63DA_%P3#<YLR4$<Z/WSLF0F2(_6OS_VAT(U71JC(*(SA"/1
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MJN"[]75,C_?RY:7]58N.K=$YL=EO4)!_&"N$>/95>L3=\!OIJY-7&-EQ4(O
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MM-E9TS;3JR6^Z[,;^6#A:3F?O'7?"*0OI1D19_M'B'6=T[@+NM__&%$W1J8
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MZ-RQ-=) YH9NI:,]8J*\[[[-_EMTK0#VU[LLP^O"T0FFNPE\;+WD$7*F^N&
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MPJX3@:8V]6WY)*7<H"#"8MB*(EW5$;T?= LAG$!=)B* [\LY61,^#BVIY.N
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M^1D;V2+)N 0Z4@7$0>G_6!-VYDV?X?Q@ !O2IO<T))./4CBS=>XFRK*R CG
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M4UMWSQU'QJU\*3G\[5PH[ZMWFAAZ#3+NA^MFCV+WM4ZT+CV,P:&[9TF,4#
M'0',DW>^CJU@CBZZR &FWG"^-3_N^$(:*8-W.4VT&)!GF(5(BV1P)YA]4+H
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M@M2^]%6I6,IKP!Y'K=@,;,$#C.2=]2\JC*:.W9)8^<T+6H;OG.,J*&Z:;>&
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M5,AU*YAUE!OA6N!GIPG"$4&VO9PNC&2W=9L%V_U3@;Z,VS>ZK@,YG"LZ-#!
M%5:E_-*H;_ ),I<<M5CSHC]\^OM:21=[#CEG2!HMLB.0_(S *6AY]$SN[V4I
MO#QV9M^TW(^Z'A>K<T":ECRBK+WRC6]$3*>VB>T2'DP_W!3+F(BY[Z*:WBCW
MN6=;@96.5V3W1C2V:3AVYK(/#)':96&QJZ$ZY.0I1]N/U;F7V*.RKRSU<622
ML(@FN:H8D:0VV]$^?"$V8&#8[,C=S+%\P:AX$^&RHNEBF3=E]BIQX>>,5EON
M*>*"U@>39KZRD_$B@9W@N6E%VKR9W?&^,YXJ@R5QN%.!W06+W3&S'X*OWBC1
MNVXU6* V+F93<+-,NEM-(,-3^IIOYX4"#]M=_;GNG-WSD94&D4M1[N7Z[J^2
MU'9-MIXDG7JQ]W\RB70'Q+&/ ?F,T&5HW2@1.BXU8]#R$.IA+8"$T1=:Y&4G
M'.BP).1M*B'U-U.-_FH">!(@!4@TJ_G-K(E\0=/2%^.)&X@'Z,.(]T#Y9O*S
MA;CI@5O%V.&Z=> $CBDF=ZT98SM F"D@O8_+1=^C6!JSC+<O CQERP[?;Z;V
M]_ 2O\ZG?NW[)B_C\BIN%JT&DT+/9&%I3NOCA.U45B5>#]4&I=UT@V_#@3UO
MV<.$.OU<\GJT/J'><<V31F"+!ASVAHDQSQ<CNBU,Y&DX8B;@:,ZM2]IX@$1U
MX[WG@VVB5H'OVI7R<S'L@P)<L% +.*_,E!)H1\&<QM#^UA.3F>D95R#2-V9Q
M=!U-PX6\W\%)J7.&E]7&[>)\-*7)Y?8IBL[=MB7@1!6T5)'M=F:\Q@[5WUY&
M[LZ;DJ1O[WN]=_P>- 19G2AS66R<WEU&A[I+Y!/7BL?:R:75?L)]J-22]K(:
MC=37SJ=DSP_Z;?O;IPUOCCXZ!=;*KCZS-V?I)^WR#[3F3ZHI*P+EZM@"HUEQ
M0'$P,0@?NPU<"VM93QD=E<6TP^)@PIO<Y8*T&%8>TBN\"\1WRNYG%Y? IX_Z
MH=OV-)]_BQ5;P0<D#+H_UPE5=LF^>]F/ XK4MW;H>-AA?7'B)<Y13N;V2J^*
M2?=@AAU&L]N:Y-K=@Z6,NOV:7O_64RT@$9=26 F/>EW("(,9N]0/9PW9F.G\
M9W M^R;:^V_CAJSW?V_C38@GU>+6%&>@?$@?0)[&P^8C4F#)^$. %=V N&N>
MPI;%)A49 B62T>\0!$<:+,'OEPFT$GX&$:5[4-%' ];CMM=0"M[R+)];IANK
MI%F#<0+5 J;9]@0H=%(*'6>DF&*9VUVL&J3QS 18)(XNDKB)>PS9DX7XS#SV
MPD=V/8&_2RO.;/JC7N4[O++:T7L.A=>LU3F@*VP2N(8#6LNDE;'YQ6AOV?SA
M##[F?AIFS8<J!QXCM8-K%CK08X-.P"<R[#'^V*B)<CE0ARAN<=>B83$F84*=
M,6LNQ/$Y:B_EJV:)TT)-/S5I6&8VK&'7@WV0P3C$O,)*X8"\P+*XSH<F)Z'>
MV'$H%=<.&P^AEF ?K\MR0$1GD324&A"SPM.:IUEV+'Q$HUGGU?B2T:%F\]^:
M)Y*<_)PJQPU/4+N& I_;ZQ;[!I&+%%^>D-TH+6ZWI;LWBAEEEDF7V/?$W"OX
MD#MM_XK:FF/)A]@9JW-0UD:F!R=1KA_*/OOY""(8&PNDR5)6]&>SX'275]37
MA?/+X[T?V+<YH#8N9:196.]*H>$<$%-GFH\#6AB$Q4-IY[6 L^!MZ?]XYMZ#
M5F"+HOIEP9U<*2O%O,&J9JLPT;0%IAII+\*R+2(84.Q "[%%%HW.P V:_K1!
M^2I65MX!4HYGS/=.JJ3.!-1=DNX$[UX:_?V8 SK 35W1[)^$[4P.:!S, =TD
MK/:ZQ;\RYX!$,5S_= *ZZ,;"<6O5AU#F@+!68#JW$LS#=NQ8TC@'Q $)_GF"
MWMD<W8HW Z&5L?^8V?\O1:%OA=[@_?WPOPW]5PR%,5^@6UZ@?__% 35HL5YS
M0-OQ'-"P%D/GQC[T_UOK_-^&_L,0K/,/4X;* 9W$,2+18VR ^]$>]\B;!\\!
M)71RX3D#NZG)'N6  *]F,0ZHKQ0#I*#9?"H<T(7U-337MT2V0)F[\%WBJT?0
MS+Y_RO/^EX(([XQ.\>R8_+>9?\S;=F'S57) ^R%_"\=R#D@ <A1YF_6\CI2X
M&QX#D0=8;!G$8\A) ':%UE&!O-&D$$LYKNN]J24.U*C4.?2'51YCKOVX79#Q
M,<U";K.!D$D"] S8%N%,<0Z(/?"0CN6 KKG+O!!9X?\' B>HG)!(07VY0'CT
M>5JD49H5R<_V1\,3] 3Z@+-4-I]]V?(-OF9C+\9IU%#3]\?S$]A-M&A9+(XR
M<E>H1;FKCD;G!9QN>NV396=[JMY,+X@5A,XH;^XT;3/WHUS1+>>Y_5.HQ;@+
M1,](=6!C876\2="[?>.#V^ZCS7:5R(.L5TB5&6M>YG6KO6#Y1;47B)Y6_!G
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M@!:'BMER,+;P#P[HM3[[*QA()QU$[^JI[1*XB^V_;_C/&W"Y4'@ H/Z'>22
M<9!Y' \P& [H%BT"E_/%<D '=4FB/A"YS_3SP*=7B!_F%4#LK*QPSCCT$=3W
M[YUOLRR"JD<#:<3+$CQ6LW>KV3_?[B"Y\[R9,">LH,,!U3X&1#F@LE[_1R:$
MJZQ/T)F5RH!K[T=TL8 B:14=7N;KT(1Z>SL86^=%E,_->U IG:'B<1@U'M2T
MDV3_XVK%'5>="R\>C6-I7%=%>Q#/.M:X?8Y+1]. BQQ0?SELL+,5MW,")H1>
MO4S38C_3C=B, +%O0,GUW$FY)K)[,6"52R,3Y6E<#E)LB_G'QB^SD_[[EG^Y
M!6_!]?U/QM$M[<[A:X^+V:U2!-JU@#%AD7%"&UA I$-#D6P(U!8'X($ \?$V
M*XH$_0VK8H*,ZPZU\HR/([4O44HMO<(P=U0R&6&X.8%VPN]&#JB5P+A\H)@[
M)[ )62#2_T?6R/\.-^#ZH< Q<Z9X,J6,*6&]K39"\,$FX_<!D;25]MV 3A%Y
MIJ:L"%&L$A<[847[E3AC%2'DEMMF]"?)?VYDJMGJ6):5D;E,G+8X?.'[&L,)
MULW+E.$.YZDLNCFKD /J@+(NH$1O\&ZAS<1O[/F'=.",KG=Z-_6DQ[VD [S?
M/5(/86X(%AK=?8";=V'SPUX@M+:YI3P9^_L$+@[HKG6J@G@-D$SCM00<&=>0
M:+I4Z[J$\U*1(A! [9-?*I)G=]#.TW.?;'W]Q8121  S:(U;Y2"L(4]9EEE]
M^5EV#FSIY36S2\&A<98W\)]:%=^8(KZYLD*&',E>3''2M@VK K9=RTI&S[R"
M53L2M?B0D4 /X]1/I U-.>GO#40EF9?[4:+@%)@@7AE 31^PYD=>H\M:DK$B
MB.36IJGFF@G,X8Z&7)5W/4<I$DD+G14+YE!RWL\RB6Q-Q?R*/W,I@&-RMLS5
M[N5):W:EA:FK_9Q$:4&V#U7-\WD#F.<L43M7^(-=)K*ATFA2M[1$K;0 " LR
M.;I3_+!;=/ZZ!5;][[UO38+(?V_0SLN4<B3+UZ?^2F3HH-IA=>%)$$,$^ M;
M9O ;;D9K'Z*,7/J1[M+I?HCF$"]0H?F8=WL/!Q2C14R_4EX_GRI_K8(8!Z8A
M,,S#M^63$?!M?%O-NV(P;[.PA;3:(%M*BS=(6H89L;#IQ>;38"@RT8 LMIZP
M!F8X+RH<IL'6U!@AR,@AMB&"1"9$(R^8>+Y&*M!R\DO-R.OQ:($%>DW7MK48
M$-VZ*SC>%B[[)ZZ0J7U\LE,^)M:#.^E\0*U?][ 51%BU?3M;5;MGR@7+X@-_
M?E3=:; ANNH(NMT:"K'7OOGA7HY"4U:)Y(*!0U:Q;7%P2*&A1?>KS(*:5H.M
M@KY#T[A$1.J4TQ342R'R;6G)V>_OG%&_\_PG1V +W(;NXWJ":"YFW0X E',?
M$^ZO\5!'HNG;'- -+E-C>##/ :P9;Q08D&N%**7UM,ANI[[H++Y8U8M#GJ<]
MM4+('UV_0BV\5I52TQ"(#N: *-I<KJY4QA(@<!&1+;.^CP/:6"KYUUBEUYLB
MLQML13!WYEY%__C$@'% Y"(:]U>0/.@_%H5;$>8"[N4P&&!<S#[8AW.-PKD!
M 8P;*XY[2:LD^#!^#U)_R/6-X4]W=-(9B/!#T&HG_R.%^SY86CB)*3IQT>+8
M#R0OP]Z[>E)T@;M,D ) 2%FY(CO"7*1=R2FJL9RYLCNA_F$F??4 M RX(1/4
MI?PSA0.RIE=IE?\%:=S"K7X-<1Y=<&2LH5=N3SMP0(_+=G;\T5QA^+^J,!V]
M,?^5EEO_<V;Q/Y?$?K_XXK_4P?^K9E;^XR^37="YPT527-)"  PYH#?6[>,@
MS/\V3?S?R\S*#H25A)Z[3P+4T:P\WM4E#J@B<EOYQ8%_>5AISKS,E0W[LCB@
ME^';! Z(:#J#94?IL6[WGP-W+?QCIB[ZGQ][CLB+[V$6_7/F_^_-Z+$$49VP
M>FNN<IZ(W X";C/LD3+Q[=K,,P"AQ->($/V27IHM^9B"6>V5<AM%&IX=U<WW
M"V@+;%?>GD]\^UI#8K)7Z;B*N 2H:Y9$<X#NF&&9XF7L;R+;G1S0"!*(A2EP
MX:B1]#L6_%..W08&HY=7@.ISX ]#_[ E-S*<%KU]&E"A@:F\[1Q0*DFP&,@D
MKXLCP^D/<%12DI%\9X=(XBZ.B#F$H,+XQPFI8F3WCY1\;%R3\.>SF,.3 )PH
M&?.TYHCV?A0!E 5U946BL2669G=G"O?'XW\$,3K# =(\UY+OT?\QO'7OV5>8
M$*B2<N'@$6E%)W/YKPE[)K V?3V$&MQJ+,,8U8X7IH.)?6.YY+3G-&P+WH"^
M74*'M2O(#^JAQ98;=ALQS1=?+3I+5E/VLI5&3<Z'YH8;2<4@30-.?/[<.I$]
M<%Q%,$"I!MS+73)G7;;C@62&*;=?])O##%JQTKXD82:<'DWQ:D4_:G WH+7/
MYGDEF.B\1EK1"W/2J?*6%T<JF8FZ;G[-)F&?;E4-W,V8-,[*=II5H<6O#M*4
MOT!I5[GEJA-6!QD:J)Z(,DQHP-CH]C0K W("D4O!$&$2R'/T,LPFG(2!\2M9
MB[HB[SU&!E&T1'M>(7+;I^6?:S3;CGS+&=2T/=B<Z" Z[PET>50?)AH-WK!?
M(-IDD:&^'S)R^7N2O:[:9A5+M]"&'MXL"- \[IOA6CZ$.6 L=J0BQ;'.^@]L
M17=):3Q7V(Y28,!GE&;YW$#A)"4I,$6]+F#:]@?[[Y=(F]]I_Q9@K))U\(:"
MP,-3Q9,:3:S@!P4HU]$>6,V?U<>,LZAVR$&Z-9$TEDF.RZ65M:",Z.Q:NGD;
M6WY@"RNV/,+M_?HUD4LT=C7%(+,M;R%!<V!Y_3PM/G[->9IO8#+UI);FV3SS
M+*8<!\2[A^GV&3#FKH-45EW]U,EI]HH#'4LT PQ*6DJ<\WNHD73"K7Z(N&JG
MK/^=O4!Y3XU0IV^%&F08^A1&,[..!].NB,2AZZQ;<+Q(758*VA<S)L;FUWB%
M%+#,&D7#H4+L'R3!>BV,LWK1P4%=:!):#"(!&'>@I4Q<:"M.M(5DO7VC 4=)
M9.N#;BZMM5:E"-N!D1_F!YS\8&O..Y4GKMJRV]]]_'A\3@6ZY<6ZEUE/10R4
MB2\'-YXR,_S=/5DF[.'(T.%[U+'BTW%5LR='V]62Z&I@>-5U%*-W=5G;S^EJ
M5U<(>,Q*W,:YL.5?:#VOJ<[K#/4XB&),RJ//7BGWW0N5>*5!V"R&QQQZS&Y;
MG?6<< <M @RV@FO66Z>4R0;Q[..(#B[1LDX)K51SI.N_E:RF%EI;-/0OT/?5
M !A7NF!_;Q#\]43QA;2&]'>G/!K,'7AW3K#>L$]R9_A%_''NU0\ZDZT 954B
M)<BXQU 0CN"KA9E68&5">'V<V_(XH"21.(C\&/HV'":#5^D8=:B8/@K@%.K)
M.R:2I?,G:?'1U/U(L+]748 LZ@FZY7(H6 !%PM(<U\>TV'R9] E[>MI+QHE;
MJ%[T8:@/+IEPT$2;"I5&@,V!/DKN4!A!"! [1R^JG]$Z#'BT);\"KD:!@)R1
MLU4WHMYDI9GES?1)"2N4:DE%DRM^^O:_J=U%6COHEBA8>UK&EN.5LLI4D>^Q
M4*'RH<P_)ZZ_SC: ."/-59$_"ZX%K][S/'(G*,>>: )-*G?0]HM4.$XY2YLJ
MJM03/KY]HZG.?UV<-1VP]$M 6]Q'S2-R_*)?H\F<M$+1,_ ;"NZ@13B5[7R-
M6!1X9Z*H\.PL*S!B=(.+#_OXZ0NIH00AU!2I1BH)Z4;1DD>X;,NP&O!J2#'
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MKK/[3RWKE]0&FT5]*)3/%*M6#!!4:?U$>*?LP%*6G@.<![QP$# 6AAZMO2:
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M5%^BAE@-/)\'X+7(VPKYY5>@"AYCX)7(B3(TM6"?SZPD7=@/7KC:;> )"H#
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MV]J$P]YH\:&@$OTC_KJ_FMM9<_6$RI!'\WY\&TU*.86%!WTQVL@T!HVL$Y\
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MSM:JL?2>NN^CCK_46D4%W6@'# &GNC]'RR(,*W;:]4J>/*+VQI$O @38F#!
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M+"Z"-APF^/M0&K>!NM#)3]87UDL8W19(/U..&6EF*B1+RAE4();L#U9E=Q%
M)JM\ V3^&,+V=LL05>$,X& &$'5B#'F%[^\%HDH\3C9LG'")(&A@YWY5#FG\
MW#TB<DE@;L1IKS32;<:H8X^T^R]YN5("^VF;VG)NV5[RCD8>3Y&7.V;9D8YK
MOH6NHB)64;7B(VVW1_W."(E98/WMHA<BZP#6/*;K%;6V_$/5#!5T^U5%"9.&
MV%-[=VR3M*VB3@_I?@Q7'$5DPDDT8'D1+: N"$M&_"&;-!V79(V@YN%SE\Y=
MZW(1H-&QB.HM1TM@.O@(08V4LC!^/BI<L_@S>KU4[O])C0QE3DT Q0O>D"G
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M *-\J60!&WO*]TK*A_*[M\&,_@2Q[?@Y0FXWMG2 JRW6 L>QO\Z/OFS7193
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MTW&DBO-$/*PK>1BPK=SKO=51_>\?*L^5^0UPKKM?N/7P#ZOO<)6..&*Y^PV
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MU[)ZKGU=R'<WV@KOYFS\.XQ(NH 8#!)CE5,"6D>9O%%JWO^UZ[$RJE+$CF7
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MZX4%Q$FAEJ*?LIP=X=T+#3NQHYJ'')Q$M*FE]%6--9@!B@29DQ![JG-7KA>
MX?HD?1_$F=^4. 0= )@O9U,]K"2,I5 \]T)3!H,92; >+$_]3ATTE<&0-Z N
MF>9@!_H%;11MLKNBAVY\\6X\#K">' ?0O%:!T@T[+8/B0A,HJ)BYJG8*"G:
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M5V0-J$04PM8FF4!N%=^57\O#;46^!&-T0CF>(1W#ME!]"M#9YB-VN#3?%BC
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MBY!>/%[Q;_F4QJ6?>BHO_@<J^/Q_;\P]4AJ/DHFJYU_YC<VFZ/RF3'Y1/32
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MG[1SF84IN(#@X Q@A_[?_!RRI4E0>L1'6FL1<'CNYZ!2J:E_*;D\-:WXP+*
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M^5%97/,RPH'.?1"&!)L[,=P,SL8FJ@J<% !W8O#8,62W@ \L61?)YW$8!IM
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M?:ZKFO@R*+[NSLZKJO K+FG<-C26I DOG6FX!#_MZY:N!=EY8O\X?M_E]@U
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M[$]+$7W\U<O2,2)1[]P'*J8FEH32LT+:"DFIU/D;J9'] I6!0XEMJF:"K"]
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M^=@ LY[N7<T^SAQ10 X<5EBMW7^$XJ#BFJU79U:S)VS=MGAJAZE9'R?7<VX
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MXW"!%^_-J<D^V76?+/0>DNEW,:ZE:."R4=;\?Y)KG7:N-]430V(@V)1Y->K
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M\GN&MNS7\L0_C7QL!D:#K17Z+XDN<L\A8T#I_F;6B][(.+H)B7$8O'LKX:G
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M4/)N3GV\(F8HUI_DAH@Y**\M?=W11KVYB-*6ZU"Z&*O)>Z!E_R2W8337]ES
M\-DV>AZ=PM=:K<Z10H;J6,F46,-OU]P)@W-!.N8%'D#&OUEFVL.B'#W S;)4
MO\(S*:91]WBI_LNQ$_W6GZ)YU/H#NZHVF>,R.%K'"J?+[5-$%$L@W>'RCZ_'
MWX)M1[(/R3]8;]HY'"-OU7YT(J'#0)[<^-/DVJ958VZ74!U$IB+5IJ3;8$MA
M!R]J:![ 7%>([MX]3KWXY21_8#YM&J_]'QSD_8F\#_@/0<ON:85&%$\MU'_]
M\:K*?V])SZE]50'=>_O?;R_)?=^W0_P-F\T 3W 4?P.EH)0DXHN03)P)-.X!
MMTGW<456G*4".$@XFX6EF 18TOZ>A5/@>5S\.1R-)B6VH=6N>A<^_,!1+X.*
M24X>@\@>#)V>LB6JZWW@G<,Q(DI5U4B$5T1\G__>G7_P)<?YW*]TV^:O7[]]
M__VZ<;INR%?6,;'6;6]2Y$3'N(QPZJ,'_6S!U>@_BRCW0;L_B4(JO(F>3%F'
M>, 34H>3\BY&O;NBO(03KJ\.N_^M2KHGPE0//B3? 8VG(OL>3Q:M!QG9+'5H
MV3ZX1X09>B?@!EHD'WU55P-A^9RL,>6ZY+8VG,YFGCALW8O,'OGR113W "&$
MD(.IS6^+&KX0CK>"783HZW@SN%3(&5;AB>2%Q:1$/G$YRPMTB+5L<T6W3RDL
MR&H2AU<5#6P_^69,!W+/F+DHWH.SBB9]6?DSTGTR4Z?3OLLQ>OG9?+N)^M('
M"06<UOMN,Z41=8P0W%W+R=>1%#:[T#M_DOX1_7D15=C?"=/XIH9@6G:B"*,]
M==4IC4PH]2LH].<;RBO/E$[LU-6D<RHG%_AOC;?FOIJO.5S9-!.V9 _]:_\X
MHM,GI"6S]H&=A^!N<(?D#8P] _W\/+N(.A^E.<6HO5L+Y<H-C2UNVGU+;BE:
M*<N-$PSKB=UIR'[R3G2F?ZM #Z]+MH#.!6K?*2*J.EJSH .SA+I7_H@71)]^
M*\4MM_>+YW>G[R0:X<W"'%+\ZE,7$(RLL& _G/)N^.C=GJ;D /BCPKNPUHF8
M:-*#@U5E<#[_EOORW']*KVD</3+D1"1.R?7'%_A7B0N_0_K8AG EV-F!7PLY
MI2$&BBJVG/0J$+3K3^7D_%V]8CI#IO7"SP>\?/N<DMNO'DJ/C2;0RIL,W:KO
M]I"2]H3YVJ8;KNDRGD(_>1P9ID$=.+WP<V7T(/O:PN]OG+MHV"+M-=@A<925
M*8S#Z_OS212]B04TKSN-:"Q7BZ"8PDX@]2"HET3TN"?75,[E4C5^JX<001HO
MD:I)XO"O]CH!ZAI1:V!/4F7;?: >O7Q^TRI91=\B*G)&J951R^&CAQ,E_\(8
M2"#!PU'"C9<+W<8/PXNH,V#F,6B@MHQ$G^[Y7GP()$XK&"-9_.TEYF9]5:QO
M+WECD2:TAQ3?H46J":VB KK.AO^,[KIP*MJ XI71TSR*;1UUK<S(QVH=]PH*
MK0@<S)MSKL[^K+#Z3O7\;]J>Q,VBP/7 &]>AG3#ECO+/NL(_8C?6[D\>?K^L
M]I6QX76'WP*']OYTYRPK__,M+W*?_.T')[-;=&:#PX+/URX.HH,%\,E05"MA
M"64764E6K="(O[OC=.JJ7/B$%8B)B#,TR\?HUQ,R355[#(?LN@V_;Y._->R>
MT2=O4\2YRMO*"6NQ$34SAFP%T5/6]T]_A9@I+"OC-$?9UD_U5B98MY>?F-76
M,\^FK<=^2+[%Z%@_N^/"RFDQMEA_EOKY.TFI[%6.GKKQT5'O@.G1ZKL/&OO;
M!"<K*ZOL0H(-)]GF0/'[X?"!_H;/M^L;K_HG<GAH+TBA+X1K0)75R<'?D58>
MT-TGM@3ED^'-#85G*DATO\:>ZOJ*ND+=3?\KC/ .T-H_$,=;49&PHB'7EJ9[
MRV7[E:6$?YFN;6^F1M%^R!D93;XMC*C'7D5V4QB*,K+[1]P9L94@?0;RGA<6
M%0KIRTE,$3.;M4)J#FNU^PG2R"N$]!3Y<A!+.P]Y==]D;Z:VKM-KPYA8IME*
M&6O@P7:V&?W#_V K+ENE#BREJU*Y8?AEI%F);[ZD#W1J<1^>;Z/68F@L)_&,
MD0C+_XP!B"D7NA6\JX;@!^,8Z B&%OF,L(LJLD^3KX^@HB5A/J9F!7(=8@HK
M5DQ0#8,,<'$ 5NGPX\^UDF,1\T\E=S9\U;U_0J3ZT^-JAW^YNWN:<]7TK2[S
M/U6S98U38^/3(SI?5E^+V7OM)2)K4_&YOF3N[=S\^,]YNU]NC5(/2O>8@0)J
MV!93##VR9BGL(6K//?,,L7E9X)<Y(]#:$E>H3TH^0%P2&KVAR!QB-^+3UC?3
M_@$_Z<5W+Z\.'%I%-TU M\\.8T3%+9QE[*5$Q $L;!N<Q6^1]ZL^(QD[EQF@
M'+J3."&%ZSA 7$3O=;S"6 ;D2R*:AQ\^>QE54#8[1?#L11H''7]]K^^IG*U^
MQ:*\H"TT#F+C/EMQ7.=EZ!<EGL>4KS=H?E"J_$?WJ.S2ZJN1W60/O1]?UX[<
M2<_[]6_G\BS./$^=MAMH/L\I(B;9X]44\YBO$&U'CK#8(60&#42A$:*,03WK
M&@*@IZ6@$>"4]<Q?868T+A/2[1UVOA+-9E+U&;QF5A"O0R2"TV9Y<FTP/VN-
MEHBS;(ATC9:*M4;^V* 5J,XUIH;2#6'./ED-(9B3CM\TB(M\)F_EU ^V,89F
M6RG;((TJFQ<BZR#A3$I%-7E+)M^O2W"3[%(]-;9680+'%U$I5\1\/X03^BK3
ML6'?EMQ]I'4_:U[R- ^=R-;O?=ITUMCWO5B?.1=3KLG:$G+$L[_24AEH2G-]
M8A-HEK).5VP11-1S4??]<()%&+#C78PT7T2I_BR>\8@)G[1F3IM&V!O4C>6,
MSXQLWIUYJV%[39#E;>X5]+'H7]=VMUGTIX^>0[WOS8&'R]^;CL9V1/DABJ\G
MW4/"!W ^TA JUYX@+#1T'7A5CA!DE92UY*/P':DC@6;W2J9W G+G<H:D+6$B
M(NQUG]]LIGX)=A'1;MK4C409MM;Z<45TU>_V@4JWA4ZBBH\_BTP&6+NE2E1N
M %[K[R82)80 <-(X-3XS-Z369'=HK  DM#K@\P%FFN(!\'OD'ZZV#7"J21P@
M*OFW92/(2;Z A("_/,^(Z:JP?VM#YQ.X_% C5-5]OWWRD$#U9NH%VVWU%J]3
MOD->1^QT2@^5D(X4.K <-[J:6YEK6!9<:7P!A'\8[?5F!6[>%7[G-&"^I5)V
M*J\A*O?FZ"/=_MY3+VJ]7^7ON.K7\7ME3LFAWI+#VW0/:7@?AKGM:(/6*]QQ
M7-]=7?J*=>DZK/$O129IVEE%]':H3RFG'V')>:9*8#FBXRXY+BOG7&3D&#HA
M&S@&\HWDT[(26^S0'E'J'R^H?+H4Y %U@Q@T6W<1Q=L%IUW)EJ\A^A-HQ1 Q
MA^P"6( 1I/%VGQU=XOI7P0%%#@+08Q&51:WO_KL135D)2(,HY0 Z"P,>$PQ[
M\ 2U(3-+Q.@5DXNH_P(W1RU%+ ?JNY3$9?4/";3'ZL 4,\-[P?1VJGAU!Z"/
M7UL7?+)C:8^CSVU2H'>M0T1:@O"39Y"\IMUKG:6>:030OYOZ[*+>I=OS-J.:
MA5<[U66EZ7G!6QIH"Q]*3R@GSJ:*-WE&YWKG133%@./6I2=.9$2?>B<80,(C
MASPCWV0LI3&[UC@MD_PH/3+_/=KQG2I]NX[*RZ1@W(W<S<YK?HWFC;J[G[BZ
M!)E'_/YV!W'M",(R#*B05A2ERU0%'&Q%#XU(QE_ /5("X@UCP4642Q\+"\Y0
M-OQ]"Y01--O*R78@) '-C>"'=/$?FSBF)AS27K3I!3@:N!DJ9;]8"HNHNJ?\
MX%TC2.[?(^3H #V3&A:I*%6@)Q6VP,SL@*;DRN6@!T^NW\<VD/=05\EW3-&X
M#.4YZFK<3[(OW"6>3:(NP6]0:%TBZ<J>NQ]9=D](Y>WQ[I:I+&OASGRNZ<H$
M7, .4HV9_WW?_;P3N?+A193O)/>GQZD7@'>%=][#;Q7-N9('>^7,5GNOXH"-
MN\V9)[*B_G<:LGG@Z64Y/5WP@'3#;H51E_WL@9M:=R=.G C;5$GULA_; +8S
M*L,<-!Y5AQE>>5G-+FDVS;Y6,2'Q:WAED7\ANV(1=7:BIMFUHH TMOOB02NS
M?<85&Q[;K1T\(<+^>YL"="C=D6Y/'C31^E-TY\\$V"DY)?L7%RQ%(^8P5KIW
MPC"0)MT]#&-:QS;)'K"<P'F??CMK]Y;S+@GU@J6(%QPL=E\=$ @7=7=03!G'
M<OD#IE:YQQ2"Q JP982^3/AR=^DL;"&8V5M%Z6?4R&^)NHU'P[3(I^ @,3U=
M4#O;@8&=_NTH&45.P^M$,_' ?+9=MLWHFV176EM,:*6HDD2[^R^/R;^5XG5H
M;\T=Q_3WE\:&HWWW9/]Y] 8P\"+O-O=UMC2PV9 "SMAM.A0X/?WIMOC1S6^\
MX/\5.!4X^/1;E S'K>USFY)OXY?]>>F?M^'./+'X\G''"U?W.6H?6_+_<:TX
M'_ETU2GZQ?)%U+.5N^3U/^?;F$/)+0*#>BE6EY3K"1UB5(0-'_G>X_\]_JIK
MX;WG]!/]<;9A0?V7C1IN>T<>YV=5Z3MF>Z:=_LGY='ICH 8PJCE".!6W2UQ$
MJ4ON5/IW'X)_< [=9_?UO,%YWP*@R,BNT\R[@*HF*LGW#U0G]LP\ZD[GG8D^
M&9+2YNAFTU5>VS"8&2Z9>(H/@%VD6TE&P@^<1%&W^F31QD]VUD[.D8;^UV)F
MG5FUNFO"_;S+9K2O>B>']KRK*GV8?:]$HV;[]6<G/!=2_6-N^RP3/%&87,TB
M0M6FGV^%:Q)^+\1>IYXZ\6]IPAZGTTH79-&?@HI("\?SO]X[?SSMY(7*+=F;
MPY"M&1G7(A,:HQS9C])X9RXU!:>TMNW?/&->PY9D7!R<JK1\G&'5[Z 1\VWT
M=>O6B9LTILN;+Q,=?XP-Y><HNP+"B2H$X3?ZD$L'1L]F[0LX!&)*,% \ESGT
MZ]0G+*'V=R8Q\ZI3MDW]7XOC>+3KJPLSXNZYO"&#Q$<B@KK_IK 3N[KG5K4=
MN+.6_'CG\O'KAX5!#S^@=7XR9]RE9I1N3D,(+P^.E/X#JPC:#7<65DW(-X(Y
M+R+BG\")[8J:S(HM5L[]!^+P,$;PU4F,%DFU V\:9C"C$,V(3O\[I]^^GGD/
M#C+<+K5^>WDHS.+33Z^,8NT[?XK;C.W\4[](KD1G1Y0]Z[MZL>>NI>K<@UK[
M=WZ9Y46'4BR&6;G%_%$L'_H2[\V"SZJ$U1MP?[J$UO^D(SJ\-H()14_.8]19
M=C"'QB5)T")J6@IA)8GP/H4%R?"S6T2EL@Q RW:Y,71GD/;;M_YD791Q*$>?
MK8%XWJK3N;]N%UZ+J@1G-<7?71!9:';^V2'B#&,DM5#4]-\=;.=!]RR\N:O4
M$<Z4JZP0%]IW4 WJ,=E%>) V72YD&K&HM9)RR(/'J&TO%E.'.)*$!]\YZC@/
M45-\>6HNH)2-<X<N[MWN3I/;0A?D*M#>_CI.E>DV1?F.=(62@?ETO#H2*FNB
M7B1D8E#D &"J&TUB")F99&?ISK %]YNX;546$RS,,\0-M)]^!6"'G7Q[[JN^
MM+X=&2'>VY$^MDODDGV(?#'*!_ZEN-NIOX>RAW*&_%NI+\9SY*:?3R*Z<'20
M,-$];2O)*:#_-\: ;/,)MT(K#*\\2%860=8=-R\')/*BT]<U#'Q-3#=/\LWN
M_5S9]4#.-#8Y>O7U%M$)T47]V\G%JUR!L#Z1(_]?<F],65-2"7R^W'R4N-#8
M:>-B;W.5J9/AZT_;H 7\L":EB?6?,M._7^JRT<^ZG1'+4/4\Y>[;]<ZZ>L,Q
M5I6I^]M99;*6[#E5^(!MJT"Q"(X*65]VB[*4TKE5WL9830XH5DQFK5)[=_HB
M2KLNTD=R#_8I(=$Z' A\^C*2O;\L]^_JLPK)0#%6 Z8&$#6-O G([LU,='46
M/WC^D^TDJR"<5VBC0),J%&"-*".&7PL;;Q+"9Q6^Z,5X*MZ6["(KOSADA\X.
MW XYT6<0>R8\R&6OA9-MQ?Q.\$9U7&$(;T"P[-8Z^)JP,O1RA/LJ&-N:"SNY
M11 $G"&L7%D&CDB.@&6<TE'R>5D%-7QV#9SKR '[%U%\PL@!<=%+Z3ZX7<"-
M5 LF*Y>HG[GLKD**;56K71+]$/9I#31Q7W/0>K"M-_#4, ]GJFR):#8*33I:
MB)G$FG,88T*$-5;B!!<$4R/#I/8GR4?!O, EL->9ZDF:?_]E0NJ8.36M"VH\
M N:=>+N5#@QFX+>0."VK&NTWD]>M7YV>9J]2GO;^.Y WOM$3.'EI^ND[EKD7
MT%0*V3D?*0T3&=^_X^6-U3E1,FZCOXCR?AH+?FDZZ\*T*<3AL=9,4ENU95S9
MPZIPZF1KR8.\A',C>2&D*66\947;=NK447^*,C3/8ZC@U\'Y<N5^\)?(K4+D
M/GQ(&;]DTN'#'47P?>R5FY*6M0=JP#_0*7CC[W<Q^NR=Y7R!)NP/$&D4#'G%
M??_*RMWRC9L/RK="KGE$]!TD<KDI&J*.VT\/"J>HNE3N]K_V'E/;W8ZAL=78
M\#4I%KDHJ[;&JY,-!WXHM1-IBO^S,A7TZ^PP505IK3/$P+]':VW(Y'%4R<[K
M<EO2 <5\N1%6[A3 ^XE=)RV(GQT5J782T?I(CI/N)/O B1!=4@C'041),.B4
M+C<B18BLR]L*":+R'/9Z\F8HISB2J8 U-<KF"$8=/8V"M4]'MC9_9<7 #OI:
MO!A8K20:P1>TWMTZU!'9]_=WSZ1@>3=C5:Z$VUM'7T,^#X4D+:(B9U>3YO]O
M/S1IMF.GW!SLRJF"=G"OVE]G7243["7+33>2$/?'W_]MI0);H)#,X+J-5$ K
MXO#)]1.%4AS%B#XA'/[6+6[;D75FU;M+HB8H7@T*4?GTI33XT*16N4J5>>L<
M9H,'P/SLGID*=FZ@*6_Q_.SX+Y6_>?[KB6>C^6J7.H&<+8WUA;[8Z(K]6C%D
M#^6?D*-S].8LAG@G_9IP$36T1ZZLIQC*!G"0BZ4U*[6\QDB&X%O2)60K607>
M'-$&);E@,;]QS 0N+_WN(N88PN)V.0H<AA_ F:)S5XVI:B7P[5YFYMVH-=PK
MN#,F+1E?V<]E]7@E!"]+QMO*6SAU>M..0G<-LB9$;W,?V0,PIJ>@3H#3&N%J
MWV*J(7O,-D2B>W$^>NESW>D4M9X9G]8Q/)PJ3+A\'J8'0]@V[T446. 4"72O
M48)N9L1EL/_T$(0/.,N"9#EK96EXLPB,-GXO6;T&/'\#G'?,%W7?9.VUS%38
M%>KRL6=C*'G+(,64% %<IF#ZV8:.D<6+J%8]D4 =IG2WO[EO3[O(Q 6(=D>*
M[MKD U'3QQ_"3GSY$LB'3Z<+ZK S+L_(1M?<J,FNT@.3 M6X96#9KU,@"/8,
M_$Z%7<!$8",TFY[[3W/_933L2] M@RO%\+,Y@38/D]4(,]O:I0/O(9UHWV^1
M!;^&2YJJ.9K[RWE*O.UQ)C8&=_3=-//6?GH,[#Y L^9'W3I$WJ%L&JRF89/F
MDM1Z]GSIS*YPID9UF.6F:'-GKSS2HT2DJ%>SPG5GKDB?K5_^MJ1<Z]="^XBB
M,B73R7$H8X5%*65M=(]18]3KW30SD*R[CKA?\.GB/-?C836_%^U4?.Z&7!VQ
MAAN?(7AH!:.M"LLEJN&MD)-PNAA]TX>A'O>:*C3>$6HX]EJ,-8'S^90-S?36
M0+.!X<N)3*U3+L:7-D2O8C4]9O9OI KO&VIC&MD*5%NA3I,TR:H&19)*H1WL
M'"^,:Y85& G_P/8:M7]?2%D(<G&[.+67H"/P-9SS*_XV.(O4QHJ39-&@6P<C
M1YU:H^ -(3Q"V@[Y?S6*/%M$S41"23S)KX8!C"3G(V7#%*:6G1DDPJR>&D8C
M9NXBF:H'O%OJ@&R$+)/BIJ@:CT!9*3.%=2!"^#Y@3Q>@_%ZW;*2#%WP\54U'
M[=3OJE:6,T]G37/C J]-9U?17J/PS2=\,IUMYWN8WJQMA!&T44K>%IB10KJW
M/^R(S:E-/$T@9=3\QTO;^W7]#_PSO4/&QZ>=Q405Q$Y6P0DA#M6*!Z=]%33'
MW;.("K_<B]\8^+V1J#YKBS:DO,4TZE87K3;$9LHM0PE:>,PDQ2B93S L^UCG
M 1E44W:0_D'.]>)TGI(R6_4"MS1':9]2K20\CTI^)L?(_VZW#9Q=%KK R*PG
MHD-O4[H'_7"$OTW[BZCTJW?R$0L&BAP'8?QZ@@:06!%!&Z9)-11<U1'PDK8O
M/Z;E?M/A_L%W1V2A"A;9+?QL*9J_@=]&$HL8'>XY#AQNIVL &T6*%6/3\7I3
M8QAX]9C91PY@.#!+-G\&NP#C*6P+6'!R -EC1;I"U$&N0AWM1"W]K[</8Q\G
ME-UW0TO^-FB'D3PDB3)%]H12A\]CAHF2!W"MJ'NX4FHOUV,D*>1Q>B(![&N+
M !CH3B!*:50=TT*LS><1-+^?4/C_#W),/5&=5#,\)E'H:%BDJ#&YVXW<FF/O
MP TY$A?&#2%C1$35#RXCS9H,;;810\/1N:L]V\%&)\"19V?&LZ5>:;KXX.R?
MH+=WSQ2G/IG\_K"IL?7#IB^94<,V6DP#:*^3]V.O\"//M,V4^+T5_#CC$OBN
M1]:9XW)M^3MB#;.%:$KE-E+5J:&*00MR_<BV)^O)[K"W(Q$P0>K(?3JY0&CC
M)+&W@8<>06B^W\H*<%"4EQTO$BPE)5Q$=C]Z*\:HDO;[4U>2WF TK4@VL:(P
MQ^[?"L):CL!W($LQ9MI=NIGL#W>>O:Q 3>H:"HJ\"6JDSPP+ILWD:QAK8$O'
M@;C*[G69^BF-.XRJ'LZ\[WBL,_*+>)TCO,U!D96%R^$EI61?67$<X3_ [DS5
MA. %-H.5 $1IDE?T92WPK\Y*T)*Y;MZ<K,2NFQ8]%7A!#! S.(JG(9OG=I%^
MD$VB55KN+J(JKNA^/.G/BPB]Y3_,7?YQQ+_UZ9KAO:EF!UM:/#TU;XQ<3+!D
M)(@K1-#NMO#_<:*V_.2H#R0][?^^GX[VR@)6;"+\P33WI/PY6]AT,>^Q3!)V
M8.GSY^^>3U2?*H1V.&^R"?/..\>(:!AE!$1>+B H<X3 KIURWACZ)>&*^_"\
M!+][IH ^K ?\OA[W]T#5B3$Z8GP'<$WD$\'#[HJ9WN#3%X;7@A@M' QIUKVW
M2O>GV -$T_"V"'Z %5BVHV?+V>,B9R-]RX-OK9H,I73)G"+LR"0/N8HJP%F)
M[%4$_3YY#T.%O Q ZY*".ER%@J1XPM(ZV0X^Q0$\_R*BFH1I<QBK@CPD5)@I
MRF>T+KQ^&*?  AKB"LRJG(JRY,L-!@V$_UX[QUGU^[4/H-[![<[T^U$)]1T8
M0/0J2)8=AO0V=3.NU1/D2&_<7M-K5OZFMCW("H"Z@KPW2&3D.W31FK5#*% 9
MNA!SR^^0GQ?>24*QN$N\6;CIT.Y"O!40:)42'&_@DOH4+ V/\K=, %G#5P8+
M8]B1"]_-#^SFGBV=#8Y*FP+G#A:<^,;DL_;M+JWA8%=_.C)CT?OZ\0^*)I7;
MTB"1$Q2/?8F, O.OKY/W#E)L*0/4%]04O(YU]B/V)^Q<9%3'@M/-RTX]/@]>
MA5X]6.UO%+#5R"@3\WT[%=U6 5]UU5UP/>ATK?3SR5/=Q9/#G+1Z3-'0\1&W
M?F1/7'!UV)J&KIZNQZ,';$]-1S<RTN4*UMHMUR+C(<M6]0@^80W> ;D$=D\+
M^^RG&\%!,34=AQ%1E\H_M'R? =X8<3,!YA*2>QL>-XC; _2[+N/BM\@>XGRA
MS/8BE;H0!6^[M#7L<-ER9_YN8_G8I$/ U]2TJ@KXQ.3D\(_>$;[#B>_,IZ'3
M7B<GA_VF%BPS<+MZ.^J>A3%ARN2R7P;67UR?R.*VPB<[=MSY5%P 65,LY/-V
M%XU+>:<:PFR+W50K7X7YQI0ATXTKB.I$JQQ+K]Q+;7C#*_%NSGT/[L</-1T:
MZ+$:$1%NN\.6G.E2T%+$F&Y3U*@G\!G(ASM,;\>L@HF2;[)GE]&K_D-.05%9
M;*L(/(;&9:#)1F'"JJ@# Y2UI-PVT[5$$_B(D>MZK#+Y6!@'P!TO]O]CBFTB
M;G7Z16N7)KHPX9V=DE 9R^Y\+E_0@.%%H2E=@58*2#T"T[T'<8Y09<M"!:P0
M]6YN7QA;#2X6.5]$O(34OPWM=]T!JCX<R\-& D3=JGYN4]IX=X8BTA,HZE3N
MNCK,]3%U63FB*<2.E$O$M7W4"*(N7"Y2:HL\^U,L.?J)M5]!1]<E,?!4N^EJ
MAMQ@:2BRJ8*4N>^Y8NB]=YG5%?"N>,_?'H4/\"B&4 I>&_)FO)TB@@?<4YIG
MI[&/J-Q=<]01*\G0:UD^>7=B24/FHX! ^9M*44HOCO#,CU3 &U,AFCA)USHR
MV;2'I-I#Q-55+00P5^351^3/ AOHO&/]QH<VY_W,J*O<W:[#6DZZ&>/\J=(E
MF=J?00[,TWE09):V]5?)G>(9_R-U9J:A!WI+4QX9]Y^M57YZ[X2(JA6,C>.R
M#41/;7![7#>YW%WC9?'5?-.1K7UW/;Z<&N4@VG3^&@:= [I5S@Z'$]0[%0H[
M *F0 XC#5] FRD'P@00H/"I-M[F;NT%6;/O-DN=!QGC3.B[HB6(9R<_AJ@MT
MOH[S()<>J(C$Y>] IS3$4GJ8RMW')I!QD%/V#$%8A-$@.P)W9'0[C J9!//*
MY&_]J*D$P'WG:^E!!1K>@BV!112&,53+QZPDVXLFUE%7D5W!\63+ALRV9>VK
M88N9TR^<5[HCVEI" ;<!KI=N1'1E3SE1Z)%$"0[L;J'>*-K<3]ZD"#L54-#A
M:BD)_L2V)B5W!%I_Q.G9<P6&2#@8Q6.H4=[+C2%,FJV[6JA\ W0)(J0@)HIR
MK\<5850P2YUMG<4\[&-Y)^8Y/>T;9-V+:"M4X9'\,[&1.OT:B@6^O7R(7*1)
MTF6/6<I2?[+Y8)UW,_CCA7 *F\K1U@,0O/''.88V5M)^0]P#^"+$N&BA2;R_
MLU)RO3-.3Y32@4TY5;NE>XD#LPCG^L/9RW.=J;FHHLL]/6S79L))X'_@ES!P
M- ^P/V1;T18+;7=/:] 1@O<"M0R\BV-HJCP?I4UX?5B@NB<0F_Z)*MYXMZKN
MSX^'3 &ECZT]\$QAW12FO5$OAQP2$EVFR ,Q;;I1ZD;Y6&3;-W>AHP)./ Z7
M"J/6D+IY;+6!6R_#Y-HDE5DN0Z7QT-+ZQJ3(CRNWFQ&X!/!H(F8H1/(3M)^N
MD&ZCC#!JQY/C.":4M]07W=. 6&%>BA4.IIVY G9JDQO!7+"O@[J2C>FHHO05
MF0[8%?AR@+W@%'RG%#Z[B%+7W42V%+[];16E#R-P1SM^,W@ P<N3%U$1F*%D
M%]ESRG)DOZR(? #R$)6W4I7(;CW5+"-QEP>PG*KZ",+7"P."#C(.#^(,:Y
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M/_ZJ9/ZA4";WBK!#&AN:=PB+I1LH'\5,WEV%RVEL)2(??5Y0NHFUY>WN*Y%
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MHJF F*]59B]?KEX'=PCI,U@TSQ4CUS"%E)+82TBUDEQH@T"7=08*:A4HL<Z
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M>%%4S0A'3*S!EJG@C%")O/P.J"]_A-\BB4=S)8A3HF(4IRQXYS!22V( G6V
MD+V1N"-\'X3CL\F^3-O/)!D33:[%;Y0J36V/:8[A[=GIL%^;ON[:_C+$NC7Q
M?K1)A4&LX8_GZ@35L-?[&*\?F&_T@[7+NW,>4 \>M)YD[[[MW9"4LS,FM^-T
M]?;%+X<5F4\.R $1,5X%0-5KZ&&@F5WS[EBRB54WD.\2F)$"W6GYOCO:_,ZH
M^J&0,]DGW2M"NH'&+]B"Y)H8!V?CJ4+DN.A\3I4'J?<0,[LX[!AU_R5,/UFH
MK+9<!<65X27)0UJ:W922+I87#U+4E]A9#!FQF3 <LN3!U?'HKI_";4!O*Q#6
M8ZO36@TENH.R(U;_B;6FH%(N;4\.OO!XB+/CI.;==J"2SUI:R";N%MJ)\AF<
M%\'6T.JJ,]1W%/H'0/"&A$J-W%8F)H6D+39Z)9:%_I:N\E?K)2O@R7Z !4G#
M\J5 K!T^O9/,Q*FE<@!&FKVO[-B7=E;L!3A%D_*M=>#HP5LQR]%V_ &[9+LE
MJ8_G;KPO>+WIRN_P#:+MY\*J'OR:"VKL\BI%S;WP]UN#*<_DWJ2T#[!LM+?=
MC4DLK-;OWZU<>"FOF%=!Z3!\HW-A'\24TM(=+4B!@@OV?QI(FOJ27_XJY_$4
M+:KJQ53NUTM"W[]C^<*=H%,:(WH-!AE)"3X7$MNX[$1VTZ,&0(U;T+5Q[$ES
MAX$'5,"E3 QTCI=JC]/W9R%\D:&,9'L,3S8:+0=M%NQLQ:CA79DDH%#/I=1H
M&[M.QP:DW"2JX+U8* 6D/M37S9 CK.,(5*_'LHA68%_J$GD;/J1[Q;LLY "U
M'DH,?IYR9/CRO:[UKAG]JO(+\I?W!,$?Z/=^/?UA_9OVQ+@=NP]_&*IZ0S)W
M<WUX>H-P-[ET#;;_!%PK9W.G]&R?_TC>GXL?MIFJNGCT ^^@N ,Y7\I=BO]M
M:?X875KWZ=7 D6O/OMPUWL<Z:S48:?1\.;+$\%)5U0<N9/>MOB4>58R"K)SX
M85T+Z8A&DL"$BUY/\(1B^2B52>+4&JPYI0=+W0HEL*X=*^=A4>OQ"WR#M#BT
M1$KX )QB*-<%8*?KREHE_9JKQ>S^;=[DV6^Q[PBES)\LF%A5$$:U0 ( ?EAR
M[Q8R,$J$?:4H" TJ+?LE,H,-45K-@T?C-CR<>Z%,VD [^N ;1N$758KM6#LY
M:-#SV'X?4LF):^)'B$C@G[974!E/-UF#N?.R-V65^*Y[O\_IQ*8L;R=B6N8,
M(M^Z(OC?._@X\HWO3YP=S,GW9NXL]+EP>[Y8VP=O";6^Y[IJ<G%01^WD<D-[
ME6/2<TQ21)N5G)^-)_?Q&P^7 WE_0@X\O)^D$1?N>_=,RD@%5-^JXA#GU0/Z
M*L4$'>_U.(G]7>QJV!L327CJ'KP807"41.Y%4:G0;74WL8?2Z#2_P#=Q=_-B
ML;<B%2!4MUC_\EC5V)XET7D'VTFW@",CENC[GX&9Y%TY&%G(Y^#3@M$F;*!6
M]#WB?@DZ>I B41.C7))0U4HL_:F,< 3B @5=*U1F%FZYC@9EG.&1M&8U @CV
MHT0CH<K;)3/8]U+KG*MGR9TXWN#5D)2N.E[5S2G6,ZET&T7#1/)LQ\3!0OWM
M4XIACS_G.: 0(8*3+=J50V! ]4HQ? T6[+1(]5(%U<GRH1,_#HP9,]- +0_K
MT8)G&;7!6NY?R^.0IZU87C'IT<['%+X^HUAZ5OTZ047D^S6;ZERVJ?@QFA=X
MO?Q3?]LQ=]^(_G[ZN0EAN]! ] QU[@.#P\%-[9J7\.-ZDR=%RSJ0$\?:TI61
M$;PMT;$#E/  145X=)P0QWE).[;R'4_$*4&ZATOMAK9#$<J1.AKAEN_:LQ6X
M ZW49,997!KB&;F/\<%*+"</>?%P:2F]TQJ@KP"[&BH\_Z[);$(\<PC*^+OR
MLO<YP9XN"Y4! UV3^XVAF8/(G<,/L23%WCI.V_U3@?@W=IA]/Q&"IT'' EN^
M["@BW%6WB_X'9>7.3T'T7#2?I'N)&HA2A&.B!\0-^!0NI9N=ZA_&1"A&:K!O
MQLW&!<4S%:'6;J+1"$V)+^GAY<%0$#]J/5P>?PD[!"/X ^*D6&"@S\/Q(D8L
M/Z0 W;2.^GKU)$+1VL]I3W523IYVM$I9M\FI6M41<AK &V<I9IZE&K8Y7S)X
ME>?M6JU7^CQ^VP%+OE*U1[TA,R;HP5A=M]#85+.*B25=JMA3W%2:;=O5Q,C%
M)%$ ']P'Q'(=Q)3XW5? 2:"]>I'XNG1+BRB#=IU+5L/K!D+>7,14<)\_- ->
M(-@_AS!E"$TT6+2,AER! 8FJC\>:ML7P$*IZ%%6Z>0#T[)"R%&MZ:Z-?%>Y[
M O<P0ILX@FBRZ@N8>DK0Y> M*!.MW.;OP;,+Y<YG.)>+^A":M*#*C^V;;M03
M=:$'!#/P\B5KUGBGM/#!D+S!_A/ @B .Y'<B32"'51^"MBB?L 58@_6*U7&;
M(*8GA *G>.B^#/)V*"QH)"YK0Y]M8+ <N# _MXKRAS:[/G[DMT>?I"X\A52/
M*%1_""8<.8]NM_ADYSYZH<YB2@:;X&HL<R8T# O;>O>]JT9OZH.<PX*##G)P
MO9OHCLS GRLC18F7>&G6!I?92NY*U774A4'_B%?NKXPN?5@T"LU[K)_TY4JF
M]7GY]@P/LFQ+Q]0Q(Z2O)M);;=>GG'PR9ZB3C;B<@)["B;<R5C'$ 9($VCLI
MJ9-_%ZV?E.2VQQ;LB45OJ!_(1B=+XJ!3)VJ]>(C*P61-FP)AJ0:%$7S0J7M(
M;BYX1U$G0TEHMV<:#E R"M%2QT>IF87'1/=$#,8%] <[\58EB>V($!?,Z$9H
M,KAZ4'Q9.$):;!"I4=6=M1.=09$GA0VE%6*R[5%\:@H5+.*&W?#'*>)#C@"]
M'=QOT?:D*%[J/)?<]0*=;I"<0&EDVC.&S^:W=+[H<$(O136\2FL[F'3V(.S*
MY.AK5_!ML9'Q78E5/[ WB\T)6 !]HXXN)3P"D&X)O3GPC."M4%T<%Y-*1[P3
M.@%3O/?W.<Z,9ETHC$^&G,[IZ+]=LB&XX<JA^B$64MNU=Y3@Q\U:]X-@Q,-7
MWOT(/>MVA-_YW!9Y,X?[[6)%^'N7\F?<JQ[M@4V<FMC>PN+ZCZ?R^1JWL<E5
M$RE,,X']D/ER=G%C08]BL<DQ'T]FI49@FI7T9''UH:ZC;J#>N$*KNU'?GTY(
M80VVZ93H)@EG!AF2YX- *PE%"^ZL6D(A/,P\^(C@ 44!<.[O;@1</.YX AJ4
M &7+'>X:; .:MZ E=!$]()U;F/C-9&PU"7U[V:C.7ATX;*8$C2CP!(1RH2,8
MQ?[PH&#E)53%Q3+4"9;0'<Z4>EDK#8R_2<-PI^RJH:,=XQ99CLY.H=^]MSWN
M-'QCI>4[J$%*)$60R6*%HDY2,Z.+.D'I1,JWCUE$" ^5"_6A"5!S.:L)?%]2
M-D?4'D\N'/H[8:1].49GW;ZY0MM^O=HUV);.].FIERUIIC]T04PR?3ZJKDLK
M?S>\E?BIKR/NO-]Y^+[^W:$%E(7J& >;H\WS7+E=WH%?-I:KJ1GX5U04E=Y)
M*FPU!#QZSNSWSK[I<C)P7_5B0O] <HY'9LM7WZ0#T\4C7R/'?801$OVB?WC%
M2:@8NQP.1#]L8/)(2:4*T T@H<_6IH=<CE_EIO2PM2&UWA7'IR<=^WC:<LNZ
M-V[69-W)J85R)9Y9(GI""J-N(G4ITEP!1(\8];89GBVVHRP/ !@F>V(*+5,C
MC((&>!@UZ#=//SOM(<$8PE)="(? P#<K8W65TPQNT56A"?=>I0=_5Y.J1GX/
M:9B12MQ$. >9\*GI2*0HQP2I/+>"ZA4XG0)Q/4/_(=2%7CQ&"E*FB*]:63'U
MC<_[_1]=_V_%7)5'@.S?T@+/_B5E(A5SN58944(<X2W^I\S0%GPOGS6"7YPA
M0;KP^=C5X^)NTC-OQOS ZI%#P&&QA))U',"A3'LCWE B0HEPG>^ ZM% L^ Z
M^-K>E2;DCA%:'!#"#1I*KJ>9&*3Z.C8$^-'\2_4G?\<.<J/N=.WR^L(+!XL;
MO=W_L&4O5F@P;:-_$M!6/0!W*$+=FRG^[OPFWEV^5.-RE9PA-R+V^;M2CV1N
ML2H&E;";UYJ6%^<UFHQ_2+!#GLL+)#9ZRKDY*%6K;*Q2;6:<)4.[?I !_O(!
M43I!!KR)4\4G+)>(**0PN)S0FI2%D+6/K8>L>)A;17[9VO$]B&WE(#(E=AFM
M);0&QE-/G)R$S'K-\46=(\[<3XI+D.VA7:._+OB06N*[C3,2SI X"Y.K70=:
M0P>GGQ1:=:(GMXXZ>;ZD7U[1<N)@6 PE>KS*W]IOC59)5[B_:TU]!76)GW5*
MIS^3;LS\\6B_ I#6?>3K(JB8*O[W]SWVQ\+N?<U7OEH3Y&[.V$T8*<YI'W,J
M?+4R>^7'1/XV500\J?/,'K9Q5$?;YP6C SG.02W+/_U/B^.0LJX<*K2K5:CL
M)=ZJM09K(J4+38 4CIJ@O4YH)BHCA2VDZYC21FGF'(H"P3GCR#C-&(SG0./!
MH<YB$[*\68H0S363[M/%%_0NO_A( 5+\/PW(OMXW+7'N$/SNH65'$>7OI!@,
M<-)LLMX!RY5*DN M>S*#/R.(KV;Q&%)XEGT,!S$QR>U!;1OM)<K<(+CQFD!%
MO,L6VE%4,A=X"0;B>/_@3/+?W;0^*[ZUZ]3/*\ZF[W[J;<RF';'2L2M;?]!A
MRV>E(S+JMW:ZMFV47F?#WUNL,+[IS3G[<[!]SBI?SER,Z?(H!KSR] -2C"[6
M^5WJZ@VT0:?Q>[XK<S[-OCI9Z9HBB%B][=7QQ<-FI1GUY$4T"K@'I<7LKWQ-
M%3\UM(V(9N_.JZ1,S ITJEEZ)!2EM2IE)UWTF,2YRP"\AU)&,5 *)ZQ3X-L;
MK 7U4R/$V]]'FUG )^:6GT+7L5R!YM^>8G^@=->(4)<SI,@J<^6WU=N;.RS<
MLC?A!5 T/C)#0[EF2M&X)*'1 _%'-N#+3F8TCW=G>1V#R*N&Q'[$,RLR;4,9
MX0+PZUVP+H0#4?RJ/NW@V;A/:EQTIH5=.T4&>C/:39'-/PNVIA,,8O6?!6)G
M.>VW9P9#Q3?_.7WP5E^G>1(Z[N7J)[04ZL&*KT>D__FMASY,=<&R:,DP/NJ
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MQX7:?+N\=)8#BDMA,C80-*!X#B8)(6<A:]7-@(NUH#!G@)1(LZJLRJ\*#]8
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M%O7^&:$X>.R/[.I%,9O4+#5/7CTH?HV2(FBN[B$H0*-<S.1OWB"CDWT+(T]
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MM(&_STF)QH3C(%JH/"3>>A]8]!=5T_6)HQ0I>R6)SWUH[6%OBJ-LAUJ[2G<
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M$V2VZD6X #JEV1MS,W"R>,VN07#7E!_$!W-9I0A1<1,I2V/FQC]>H%0 Y/&
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M!S&0H>]\G547-9&A?8$6PS?!=B&:5.\5+G2YZ79+D!IIAV_G+;""C/B+%&_
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M@?$;=4HEV+^2+A0!%*$R9?D@^*8*]&42=: LW@ YE;*A.6]8$F74W]&EA?'
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M&<G(#J9O#-D5<>T8LX,\:B[AM'%R>4 @![+ =I#3MDYVNKAMEV!7(H-.W*U
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MFWIT&H6E0E.BJ& >T\#IPHV4R0G*XI^LL1P1)^,A*M<\4Q2_+Y71A)[*3+?
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M@P7[Q3<I2R+X:GI0;?_!_[ZL-;YP\VZ5LNK&0X>[P_BT)U?#C>W#^9IL;>_
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M6'2^*/@Z9>UYH["G2?=FY7\IKSBR55$96%JAL&.\3N"J0U;T>$[*Q+*GT&H
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M.IMV3S82G+WE4*7:F6?1O;J'RJ\5IYQ:-^3-:\=!MLZ=N%0"5LGEB=(FK,$
M 37#3.O/T<Q;Z &@1R;L+<$;T4C\";TW],VU=*/@I$6APXXUT1VQGX/L,R1W
MUYBM;"X-UU^_=VQ<U<C"K!<(\QN B?.8)>-HA&9'&PT"4Z-)DU\3%(9=80EG
MJXV^J(2"Y XA]C-_W]'G\;N&Z=M/M^C87S*655%/7BE8<TV9!/1]+5/@(?5]
M@#M+Q!X9%GFDU'/2G8W2:X">/0"GG9@Q:EK(+PD[Y#00-5J9?/:Y^5]-#<#S
M;[<=>JV/'('.N ;GW.N7^8\+ZMU;DG:*V.W>9(E/'EAP&/('IOVA-O'SS4>
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MU>(S?@99IACA$B?&+*+,;[D5Y:-R>(XDAINH9IO79*Y6;')HY'SG%1LJ]LG
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MS?S#"%F^6VQZ4W>>(Y \""W;2JW;,4@R5[5 9HFY@ST)<<&A?B'.(!\C %F
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M-1&E,_7^'FG@I6^;4\R?1->+_L'ZC<\LLT[RQC7R[ ;0]<*;D30P0I1B?5(
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M(&\L&RUDHG8AR^TDWTO/U*%J^JFG3K_ZHG*LGAR#GI?5JR_!O FYB5GF=UP
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M7?(K"I\:AZ1]_:WVS%OR"*H5W9\61MJY3WCMWZ>J,4;)'AA+1G/1H R1)LH
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M8JO4%OB"84,K?;P"Y=YD'0#-J834F6BTT6S5990^V0.'$JX(>KSAOI,2FKN
M#!UEJ-.;&_\X4P(/YO^=[/V;V4\H_XJ6:VZ<;4:B+GC[U$K#^PK]<"^06)M6
M0B;^^\L655'W].U"M4HAW*'H6.OISF;Z+N_[J@MW.#\E*-IDQ7ZN3.VYD7?E
MX8M('^'DR-T,?%+CGUNJWU8/)P]M6-8?:8BTQ(M2:7:YM2K: :C7/98E5QJT
MJ];M\WT]=.H5Y+_1$"YCC2B[Q$IW)=6.TW#-7ONR[)J**G*.[],CYI]N-)XM
MH/HS-*'$(K8-%>CR$QU6M+K^6-V^'9ZOL>9]"%[D'OTZMMOK/$VW'Y&^#X%U
M2-<'+8O\4D^^NO67*]M(M-X5Y=P%/J#>\S #GP0'^ '&3V*Q1[6P,F#(K8'4
MZS2,&,J'1OB6O'>9]6&YZ7>"T6%@W1W,#":/S:WWP@2,!9$->WVLT[1PT(IF
M2G%GZ-,(1/R<S+#U#$-7E=X)Q)-93RC96?"6ZNUT:A3-/Z%9\KP<L93K'4#*
M+\('I):CVT$'>C<H3\7.#U#\O_F_6 *[U.<YR+;$$F4*-KTYQ*H[MC^;_*?C
M &6K*$3W,HWS 97?U(I%HAT2-6!K[:_E;E-VJA'QR?/"/>XX\6/&/O0T9@<:
MPAJ:U^U?/LIP>P,658,8.A+@>F"L@O*8[C@'9/>SSDQJL3,*<MDCC']#@E3:
M6!8@ZBQSHF.B>J*R@"2!SHR\6P-Z_+=G_*[N4G7@LE^[M';P)0J\1<EIM=NY
MG]+$XW3L2;F*UEFGW90QU\G<FDD26>EZC)->M8IRXK3XL+CU/>>[B+E7](D/
MMS_QJ?$T!YD<ZWOI2,O5M'$C_3")K".'Y])JIY4\;Y0/ZCO:5<KP4A2V[]:B
M1^'\'>$T7CH+6/]6LF<(2NSTM>LF&0N,5;%FQY$_S, VBG34YE]K4=-9;6PF
M 0+W@QYF:,1<*FDMDRIPWTEK-E35_[4/$=R26&,K';ME1V"T@IVUJ$.O6IE/
MT'#497 ;L*'27< _>Z'(+7H=LPYM_)6E/1Y"\.MT&&"'/DMXB[@BVKNM2?']
MK$B&2B+-9DGS-KFEQZ8JI]1\P7(J)EGB.O#E=^&7&0D4HM-8%J2M('@80F'S
ML*O)?2Y8: 6(*4?9:H!Q/2S9F0X/W<26>IXQN]:.20:,O,>[([09.[PQ.6<>
M4^WF856S8')LRDQB+F-\$84"/?WKS<GDA@\HCVC@X18U#@Q=&O!\2[N"X(]X
M%[4/29TIKR =G<FGD]=#C(F6!/8OB:O;]:3ZSJ;/<^_31]++K;A5W <N>=/T
MX_#FHF:=I[KP'H?O#U!ICVLJ.<DN_(G#07Z1N*T@AGSN1ZRJD790Y*;V5S^M
MV\B774TD;]IXM0MO*M'=CN3=J-GK?<;F(>Z21>^[L5=/Q2PK%''>8+JXG5<E
MCP#\PTY"1]P]X!VE[=OZGA-K7J>-P(.&HOR9S^$K+Y8!._QA!AQ,?K[5)3T=
MUJ7[>0/&R>+$]!@;'S)=:4X\/8L)M!5&?YA!RX)O5PCQ=]S!9$I4/;5H.Y1J
M!:AF9S!4.3:\9@$\7;*C"W38@V]@113 =/7M<%H!<>DD&UF2H',^9@76DT;'
MV/EM@1X_!0_8@09BFTO?PI)_$210ZJ /L##0)J&);!CH9BF#&!PCF&:<&@G4
M+BTXO;&VAT(QIAAN] D00UDF8@^AG !=.@7I0C%/UL)*(D-5HXF%L_$MS1,H
MAVKWS7%2/1+AW#*I?4_479W>/QV1&36VYS=@_\Z_P[7X3_!B?>5DN\C%B,5C
MKYQR/.S37%N'8T[I/!Z5,3W;>7;P3BMMD"^-)EW>I1<TY6N?>-E\?O(YT))G
M^=HABP=[LL>^XH]CD)]0L*_4>0]QM]VAT*23@KE.<8YI5KS.69*?JC9LPO$F
M=NF%KM\\^>B_JA4M[[)&ZA]^H(U!+2M\)>Q(JWFK@Q)J]5 2;(Y(+Z=]8]N>
M(,X:*71.7(&FN$2QSM*P#^$!_%Z[T*->K(E2WDEC:=3)CUVRKNB/+ ,K:V^4
M])X1ZP-+#<RF(#@91_X]F_(OB>[EI^"S#-3*&UB3QCQ@_#TR0@"9;=[%7+$Q
M^>(CS7ENBVDN,UVP.GC.WJVC(L"U]XKZD1Q.B_@*^Q[- 8WA8[*.>;)9G#^V
MASPA6R]R!%<S8,]>V9A#.&9+UQ_/8M$M5E?.&_#<S:V1MZF,48@9U;!^JQMX
M5VO*X[:+]7D/?R>E\$K/7A$4D%M>OR/M$5CQY%?(,"*GZ9*0<_5__Z=C8_YO
MS2F:SWSX/DE E^_^[=N7Q4[=YK[V,/:F1*-=@AQ,]\(#=J1[585:*!R.4>Q9
MN/1]:6)ZHV7YRS.-:S/I7M^W_]3;_1EA)T=#YL/F?RNOON'PJ"/8_FQ@A_17
M-X,AR69T"GVG)T?Q@2MC:7#^ED8\TM9N^F?$F^9['O\];:$GUL]=B R,/)V,
MNR9I^%3[R/,2M#$-^FV,+=+@'_L+&)O;AU"XLEGJ7JSW^Q ^8XD@D9V]_T"'
M%>BV-1OQR;"S==YD<YV\I]HD<1\"#3468)RWC6_:-/AL'^1UHNL)":W]=BI"
MWRQ>H4@EI.8:ZYO6Q;J:D'</UL-,S#2)'%OO97],1=:(?&RX7#+J*F,V ='O
M"2@\?<=0J\IT,?['TQ=UY%K;3]-IQ(ZATCM?+67&Q\Y6QR?Q;%C<B9-H#KQP
M(\#1IO2TXZL[N 8>GJ"6,RZ%=89WB=PIW3UU_99)&DOS=CFV^?7GO63J;)!H
ME'T%/KUF=M>3@@?E$-L^M'>4L>UM6GS_DA H""A0LTGX>5WRSG;RWE'T!/H
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M,72J^5C4<1A 5TNG'OQW&7NX=P+XEN.#W1M [*R< %[<8WOV;#N5%H ^IIX
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MA RQ9J_3?)?L!&:P)#-L_X6IY'0N"#QL"71<F(7,T W#/#GCL\2;B,EA[2>
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M5DW$@8^U2$CY6IH"G/.G3["GL?FN3'[-K^>H02VNQZUFHT-M.[]1[2@V]N[
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MCW0%!M/G#?B>?:O#*VYPZA;0NQ59VV@)38C?+OYL4PMQHQA0+7ZJFQ' ?-#
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M[Y6H+?K:5_$KV[AR\/:S1?<@B=%JO<0#USS"SO==JW&EXQ6>-VM.IZ9H1+9
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MC=787<1U5HS\V;FXIE]H)YJ9M,[K'_$J]6F=WXV9/OV]K:>*^YN]SZMK3(K
M0Y=9.=/ZY] M6"YUH"<7E8/U #CLKA IXQNL__\0]MYA37W=MG LB%*D]Q(1
M$.G2>Z(B(" @($5:I!NJ- D2B=*E*E6I(@2D2^\$"$5 0+IT E*D)M0 (;GQ
M]Y[SGGO/.=_S\1?/2&"OM>:<8XPY WMCZ+K[T]\M5HR*2Y:O?>-T,_6RFGOW
M)6['U7S'@R]X?D==,&WV8>WW;BNS 7=<XA(HYTQ]&JXW*5:-X.BE)#!3:YQ'
MBQ&I8*D=G*8U)3#)-@401<4$@0^GT$8G]PU'&4ZP] H$OH/;R<T(M53AN%EE
MGDIW\2;E(Q#4J4[L8>&^^W"K%%'1K.?+8GJRZ_<S+9A?AXXD)FWJF$=.C1J%
M/A%1;JXP_'0BX=E%D/E@.G1G*I7JQ9&MUKEWAX.B U9)MR \)Q(3Z25HU??D
MZXN]3M."T X[7A[,G:Q)GICN^_E T9RXSD!N5J$C*3-,YVG7SEM'RC>2?N=2
M?/5C<!6W+/:&B>KO5<1,B=)\RYGSQHGI=@[UZ.^^^6;HWA<YG2)GHL"++J*%
MF3+Z6*="B?BUGJ)[^;_P@4:-HX=RWRP_5A=OJNA>8,D8O=]M"2OS>UAN<<([
M]=GQBC+A_GEFZ61'=K5!V^9,8"T.TC$4M\!"%K9,XT6MSC-QV79<:;.E0.-\
MQ!+P.MRM/BIP>"G[TO/4E%<M$V^]Q'_5CP[+!O@UB<K>^84^4&C;?8MB0SCO
MTL-6U=1M1AQP5QJP58]&=W:"N P*-U^5[H:"N%V)$CA$9*N*2YI301XT$L7>
M;,ARGOVF^0(&-M,YF>!2:^PJ?VS#%WCUP&*C-,7^A8M^K5=4C.-]%JC>$O]9
MC]+>U[P"V("KT%!E;$JM9S3?,DWNG607<\3U/1IFZ:T1F"H)P!$<KO4.F8(1
M>A,09QW?V5= )P@1'KRCS_ZC@"7D**&K)CHW$NU8W]S$]29BXX$%9>A.BKKG
M%Y@^QG M9O;7\VF-E0\IX]-*2]#E*E'7FN'D+\GY"=P!'CM]/_I:N;&]SPPB
M5%6"<]X0VT8X-%],71?;"U"E.9OL0E68;0,1N)"[XZIRDN@A.IBH 3:B8S=X
M@4E5O  /6NY4CLLLP-,MLX8$OL9(4N$3UBS'Y%S#<8@(,5_3:--)I_I1=[@6
M15=9J41Z?NEBG4&C[3X89EW5''%7*I3B@H,AA_";J>X1X\8$*9LK-Y7*K-]U
M:0;D*[^(8_1^''=3(6-#6#,M../ -R\C?ZYZ1.)/[L$.$ [LG+H_*+V5>J,X
MN%N_#!)>*'9%7;\%VOC+3<XEZ2;>+U"0+1(I7#21&!+?)&RS8!#4G4T'XL+'
M+]%%;1\.1<Q?F'3;;J;EBUHPQSJ'UU@^GZ>UUZJY?Z-U9"U:F';L3WW9ZKZ"
ME$24V8$ED=F@+?N4#T6!H@O-IO/"([KD802#B5;V\PCOH%NP.2I 2%M"LNCP
MQ\T@H#/X>-*X?4V5QOE@S957_<4K[U=F!Y-A3Y#$/$<_J=%2")MI_BT35SMN
M5Q^-08DDV]ZAVWN:IMEJY:+>Q1I5A/139Z.G!G&?LJ@IC62_26&"F$LC.A;$
M8U55NAP/*UCX]3E>4E]C%X()!YH8]G;I)"5QH5* ;R$7Z5D]WY)EZ.?M7F@0
M QS\?')N7%6%JS)DW' \_B[ZZUI-? 2D<C="3HU? R>$CI\J0"M/1MI80NC6
M;?BPX/9SR:<3DMM+#+-/H:S*R5GI?N6S7?Y<<IW*>KFU665\2;-5.?%S=YXP
MMBD"5JY*L/M.FU$JG3)L7"U?2252Y3A>B3B[3QQ' 9NE!" LJDQ8?W+[6+P(
MG"YHFQ<+GP=&0FA5%9:R(UDY"T):;Q#1\])[-<*J8!QH;UJ6.'_/EO53F=KP
MJ.^ 1CEQL.+UW"/3Z^&BU*%9P&M*=@DO2B/C!94- \*-4P?]N/)F7XPYIS\N
MC>J\76^+V<J]/9BO0-M+0(<@+7F+:FR:K=GSB>5&##%E>6.<29_GH'O]4UK0
M;A9/98_L77 N!Y&5." _SQ?2,4H0/\\4:]8KA!XK5_-RUF.%T%R># 9?VGG&
M!W.+UZ?YGS^&Q5E+].NG"#:V*+L?93^S/W,?+/"B,6--I4)=0S@U',[, >"W
MS[-6</*I!3/S+IQ4!&6\=> 2#YM.BU.@FO[9 [V+:KKZ%8U-*;][>:KOM/NN
M+EU=?K<5$T_X3?R9344$F0?].IYG'_%]#8'@5\YT@A90E93;]\ZXX0XC<KL4
M\W_O5KQ5@"4!.J8](X+ ,& /B*<9YUC>3>X':;%"83)TG4J'"Q3DU^-Q+1.%
MKHXEL%Y"X%(L$_JT8)KN[";Q)_@:RM/:\RBD J<5+/<5=(-@AO][\X>05V'Y
M527].+9N9?^N^' B'5:CO(/<]MCP-ORT_S;<RD <%,?,H(!ZKXMAW43YU^IG
M"D2&.3:C^C$_L]MV=^JCY#9UJ;F!XYNCZ+Y0['Z!@G*26G-#;K^$SB\HY%IL
MCB2".CH$K>_GR&:XHF2"C$1C<MXEM5:$Q4G(B0Z8K(06Z62\WH#.LS!SK_=:
M3K?KP),.HL]?QB\6;)W[R,W*DP 4011Z@KEY"H86!&F\IY]<YK"$S?SI/)B6
M0TQP+U0_9;0Y,0>:8CK[^1H*\P!^C03XPH6%D "T0/0"T:EX[_B([[S6KYPK
M:/A5_-9D(5RN;EA5:2DZ>SK;]"?<%GRT!63YC3/;PN!RT8AKQ)NPZ&6YE(*O
M>@64^.0E.E;T$H(BEE\=.[VN;((D%PR[GVO3I>*YH+YBUHMZZ:8/2_L+*8]]
M;CZ,(UL3.[> $L2[5+7KE+XOWF?8*S_),674+M2\)HD]&];?U#T8]VN(P?EA
MA#7&0ZI>Y6]M3V^<3]1.G:)$$&\6+F30D@ 7B52M$S0YK8QP-<P;NP(@-HYF
M[\J%R]R\=#H$G_-" L_B+EW03S"#+^HZ7J4CB&=4W+(#ZIF_SLLQ+&O)GK#<
M;L,[EC\#S3>W:&O?/13=C*GV^.YAHSC%Q] #W.75I*/,5V8@2 3&_=IMZU6-
MF<0<;[]!+ N ;JTI[:MRRXSM8S<[>)?WUV(N19TM7+_#$22ITF5;\8N&QT0G
MP]%ES"I_MK##L.DQ=$H^U]G=SPRD$EMA_MWQET6UU,<BQHS\O#\FH<^G] V/
M[0?S,E-;8,5--?DD@$2FI,XRIU-6BT\TEP?*0)*WA:Z&;^1@*!E1);OG(/9-
M8<J=3^,#FR_*/<7<P8"_7^H\2Y%%@A=Q1Z:2V>3G[].,#)JXGC(E0L/V)$L7
M00MW/1=#%T%4Q)E&Y\]N<DZ&-P.7Z!C7IS6*\BI=7F5'B%GL35S-K>_*.Q;W
M4:M)1L:$\MQW?_BH\];'')1=UTHS.!P96;(70QU+/9_0,>;'D[S-MM7 ]5IN
M.ZA@E:%SE45T^$M5AEWRRX3L"?[>*ULMNT%G1V<#_B1 J!./GNRGH?!)8U>E
M&L7J+XUZK;D2V1<3!0DI"@K00-Y,SXJ!KC'68\,O\$GI7V$TO06HL)K7\M9F
MV@BJC4;X_0VS"3<)V7=P-0^Q\32BZ+;.R&M-+E=KWFG16 .S,<8 8KN+.\5*
M2TUUQ&/$]_@IR<XZY=THWVW*I;A"C&2D#0L><R:1/0WL0;'X4=.JW!\G\/B7
M;"3T+&=3;<ZK?!MS+TMOJQWY[EM<[#HS(+&L%Z+=-)+5.\Z G,8[GX$)BKC4
MMMT9(*9GJQSGBCE*=<0%=C5"8N ,BY K^#4R V.S.Q9HI^>AE]!$EHGM:CT$
MQ).ZKOM<M[TQ/'%)NR1+SUAS1-)-S./ @%Z#NQ&>K6 @W;8D[+/2K)"\+(9T
MDYS8VY*7EM?N9D1&]:XF':]%EQOVI+%EE&T?R$EG:'#HL&?Q#^;(+F;JF'S!
M1ADEY0@.;4OJ"7%X"\]DIT!=^Q$37#X8RSEI'ALTD6%FX":L<\)B#/*,^+VY
M*D7#\C4YA/PS&HXO:$2OY]#+)PSY_^Y($-$2?<IIDW!7M&"*137XB#4]$M1D
M9P+ZP7S%Z@[WY,IP8O?"!1 C/JI[7VO$;T U:+BQ>!YFK-G0.A[$"3/N7N!4
M1=A*A@5Q"<X6=%@0R['+&.LF"52IWF?+YR_-B#<;4M$O/9']]D7K$V _XA"8
MM1PD"Q<=(2 "/C]=/\V94#7XO*'LE[$WMSZ9-O26H"T?5FB]GLJDYR5+Y)QX
MY [*VK/2W^2]$;"2(/3R\)MO)8V)@3U$L TCY4IKP!2)-*;;-N%,+. 8S]E^
M<6"OD_='K^\Z\K9FS&Q X=?V+DE1CHC!%V,M+6)#=SHQ*^\*PW,5E[X6)?-?
M4^PH2=H0A'[=]QQX.5?SZ!"#A#H\@Z;PQ.DEEX-0>T,+&;R@>I:6Q7@ZV,NU
M'E[:\#7T-,4/;SP*7:&3N)[F4"QBO6EZ-$E].U!+0K#.*29U]C'/=Y,VET$3
MJ3"] >&8JS]B@T>8N?P38U9:]WD_V>,/>2^2^]?C=BO$CQ6,U?4,1(>Z:USN
MUS6>>*#%5OD;S)!#$0G@[)A1G&RYD5R.3!P?=LT](-1_M:_Z.N&+J/'JTS^;
MC$MIC1M7,*URK:I+_:.-OX<-% )?;65R1A$L#2Z1 'M1:4%T!."-4#P86_@K
MF(4/;[\(=7)2I8B2_SFF+<K+?[^/Y[M1WW6M+UD%*=Q9\@<D0 \TILODHQ3%
MO6=/FY$4 11Y-ZZV\0OV=KQ>;BOOW+#])OMGK/ \\ZU+IG*RV-<G34\P1LCD
M/SOGF<FG-4$%F[)K,9DZ+TY7GS5L&(?-O3*U.N2C;GHRY3,W9=,[8\FK5PH'
MXRDP[O*;5CBS-ZT7\:X:E6="TS6HOP^D[7Z'F7GHX2@_/&NS<=J2DOK\_<(&
MA7AU\0<_EL$<1NN>_/7&)&Q)*<]""-AY@/IA!8YG-X1X\0^GVNZ1T7J68"MV
MLF,.K#U6)N?L-YHVU EQ_%913QQS#CE3*GFIK2I +3L&&G&JQ8L2J>P76XR7
M0*@S=H(*/K#TN3"N=?/H#<Z_4S)TGAK_"?,.KG<&AFMZ1@"OP W*84U:^.&\
M'WI14'JX\O!:)58O;-H*'Z7GO6I #PL:(C+@=\K8]B8Q!M';K6)XR)%230,6
MN9J-?43L)P&PQK3VG5F,N.2)3Z7XZ_U';[ M/9$2Y:5PVJ\N7K<27V,6KNC>
M*B$!J-<>VKM3WXWC&A!Y*.%;. >?KB<(BFDJT*H67P(7&3#H#68*RT%^V1<M
M"FT9Y^<U;!CYW2BR.%BYLK63BN26OPD3NR7GI%A=\:30Q'?%5 2&<'\;#F(H
M.CD16-8OJ$K,6V$Q98H;;B(F>A*N814TFT:8S,AF-%9DV:RY?N3@HQR$"JXZ
MNBN7><\]?WS'K3ITS&TK;RQ?V3TEQZ?08FK("\$2W",TC0PVJZEO$.I A0Q;
MY7]20-.%DKL\^='DBNPV$(6V1VF)Y -&EY1I^*F.=;-3 "/EIV?U87?[^D)6
MP6\Y>[9:SM2)P^!*Q-9;7%47"<!0#:2&RB,JG-^J<N&T.HEJK9/;<$\LT&*T
M59H Q ]YG3T@R W;#OL%#K$2+,?A?-BE8\P"@;\Q>3)4XO":7\O-_@?D+K!9
MJ<R5EW6<6(C//7/!DP"+V=OR$_,B>"UG_Z)-7B#>H Q?),FL6X**;);#CBX+
M==6W<N)%,:B.F7,F0^O+>'1'ZC9E=.OMFL'L)5&U5R2 L;7"@];1ZA85G<94
M9'.K=,ZU%7-S_5;EVHM2*3SS<K=MA9=6E 2!F'J3F)NI+8/IKBD_5CN'>VQ7
M'#_:BY95(6VX"UV+US)/7^_NG#\F <+N8?V)[]@Z/ GRK90DP H+$/L51.<+
M)%=IS"E<%@L&+>Q=D%NOE!#\\*26/^41YHZ.ZHL\5VG  ^D> 9E$3E::D8>#
M]ZBJ%WZ<.J^LC7Y>RU?>_V.=;=*_7/KH.L,]6:2([ZW\LC'CZ"3&1F^]!>1I
MADQY3*A5B@Q[AI%_J05C7@V$V]9PH'3\2SI*=$J^I>I(&H]8I*,E.-:/P>46
MP9?Q+N<$VB4NK5;L0FBSVF?K7G?Y DPO[S4/W]?*?5!;YW?<6J*-Q;=]J3H3
M3UM8)Z+DG;P'.%E5?G,(WE,5IE(: @!4 *+[,D=ZRTN=]<N\=).:, XAPY\&
MK5KL[4<\L4$?T76]T2JH\8*"8XT@A1Y&9/C@QDBN:;)B=Z:H$ ?2\9I-?ZJN
MDH0[RUQ6+5@3,[W?]<Q>N']:L38CH='=TL-5+1LRN+8/)KO55_B 93J6H/%Y
MKK%JR]L2XGQXEL5T#H'&<=_H^S]:9?')4C]\+#WY>)\^];FAMRO:;6?:0;0B
MV_:/^'<DP-T!!1* "G@=L;>*JL^T;P?1X%BF%_ A'2#V2<F$>94'S1.RM*+&
M3;KF#FGF[BE+1R,!*?/"'D()BNJ1(]JK?H]'&MQ0>!,4#6H]$\9$ EP#TI'Y
MM;75]]A@293(W--I<'H%BL(_QON0 *DLOV!::$2U)/K$3R7^ JRJ<_YRMD45
M9U -.)@H)!3F-"%VX;+YQL@Z[^UOB495!]7-T,_?@4WEVVQ$%D^TY*F0S67R
MLK70) "A//=_@7ZZ3)J1OZPG3?:U<%U?7!9JUL(.5#QI8,[+E%V>M'BGT6V[
M4700$+]9^GR>M^;,[_=IV)_:8=D%+HL_[U_7/6YL1#7NE3Z9G9^=M>YO#5CY
M4+IIPW]>"=?.AZP'\>-G<"&=RK>*/=QJ]+AL\.?EFYSZA4[:]JZ%T,;X.(^2
M\E)=[O.LC6M?9OW=AN3.WR$Z2O&.),"#S;9L_$,\@@1(/OA?()7^N4PDFY]@
M6>%.C>GV:2(S1FE 125H$S'7G[M?M8ZZA(\$4A#Y ("1@Y]77L;C'\(5 7-U
M+RF/>KB.;B!VW1Y/3=\I6.SI!)TZ96['T^-?[ _9ECC@LCT-![6.MLFAK<.D
MGC.57T1@^#$D -%L^'^!O@P+]C./L>W-2^ON-,Y4[<@UNO?*3ZJ$K"2:'9<<
MFYE9'+P$1_KCI7 7U%E'JU<><$U%1,)5ZD4&+@A2'M4+!7M34@)HF-*.4?@'
M<ET2ETVW^OF>7DZ+#<WAUJ#K"T<_SGS"G?&.*H$%_NTN' &)P#BCF28Q0V^&
M+OM@Z.BRKDN#?_/\7'3P;SM@+L#XHV^16X'FJ[.)0Z%P4,"-BP&CI^\!0C_I
M[D$4LEYT0[)'VXV[R;E4V9>'O-VDM*_Q]2M"/'TR/6UCT]_GR."JJO>R)#DE
M)AZ^"&?C*U>/M$>[(&F6+T%8KO;?[' R=ZDLP>(S!"WB&<1\18:/_/Z<"6D4
MM8YK/R#>16$8)DF M?DA$N 2XBP_2Y6O='FMMEI@[3+DF1^WCZA/._'&=2UN
M!P0$C"T&L9, PXI8()&1EY?,7G[ _PG!CPGJ(. Z3A2UJ^QGK0!V+#U8PZ74
M4!UD&6/.%4R3,%1)WFX33*%YBV5SCS:9V"@IC&2BD ."<M".@7[\$ [5!KX*
MUZNL'6F]16Y#O7"BVE7U"7L]VOBWF'@:V)!>95.6XF+*SD1_9PHGLII-^A[W
M"VU5*2W9;U\>C##?I90J)/:BKO@-R*"G;[6<@0A4D[Z>5Y]:08,81N2RP^<!
M8P?95% S!6^; 23>6:_E9YG; 2W(LI#VQ\2K)_(I^U:I#0GRR=&31^7DA*G"
MQ)\SQ5\@ 3!\F%VBF>'_A,S<)0"]SQNEPJS@4,/B[5Q]]D_M(AD)^6L4'-UW
MDG*%./I$I#->3REIS=D$@?]D+NG;1_4L55@!,6$N]01>2.IDJ65$\43G1-NB
MH.J3.S4;X\D&[KIG.C5N?K<-LF2=;_=EV)HH1^!V\PEJ#</5YRJ:/P_<@0^&
M90.Y]"2UAZL3G0N@%C:?;#UY\K/S_S3Z?0P>-1C=<K>+FA[I&V0O+7T6I7CC
MW4V->[YX+>O>&4]HW%1++^%A/2#;"B #F5P@B R%@P_TX60A"HV(( %.K+7^
M)V2%P-%*LV[J^'3IF[CV%7GD%TGK>=?NS.C-KQ4 "[1B9 N'<]5O8G>2N=78
MAY%T6U:]7SODM05U9=J_%@LZI,>EW0,'_+T[=^0F";"_ZTP"O"T@ 1(T7M5U
MP,PZ_$$W$BV3W:\@>=./3.N2!:4?"OCRAZ\]#]"\9AOQ'L'E?$KN;,.>8GN(
M[X;>D/W3>^S?1]Z+?OT7N$("1/LL@I."4;B',,2*B#<2L63=3ODAYMF>4GE@
M&-Y, J-Z=JE3R:I8+,AJ0_?ZAD%:MIP&2T!/D57AS Z(J7,("7X7)((%T[\
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MB:^,-[,LZWK2$11&,3A(: VT5%QPC"!7CB1&?]5V]12<2QJ@T4!\EOR7Z<[
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M43>'$ JDWA0J+2T\7?"*(YS4'RR/U+L'+H+?$HR7,IEZ0&)X0^QDEXTLMLT
MK]5L6XYW17.B8N!@;B/5?F $W*P(>OQJ(K1#6P &T6^IHQ_@?_19R@Y118<W
M0= H(SKJL:QJ8 P=]IAL+ JU.H;" ;_ABECV&[\9R#;]XG6?#!+ V>\[)>A+
M2UJK+"Z<K\LL-_%) 4>'"V,[9#YT6;%_WDC',,DX6EM.("\-*H?61;NE1,CD
M0#CT?6(PPMW57V9%-!]G&,=\.5_7A^9/N^AIRTXCNO(_G<GB)1]-@$1=?6!T
M;:=E5;@B7260N&[A\]8K=?'=+R>< F1GZ.C7.3TB6).7J9\/S$U.'QK0:P44
MJZ8J&)UT:/]V_I6^*!0LH<H$1(O&AX%I/$!D0RP/Q:XBJ/!VGA<$D=6;?NYN
M6=<3#3ROE]:T](G_H*>5LPOW??K!5(,.,O413V9-&KH(T"7 [_>J?!CL-24!
M7(&_P-JDD&PVMJB5C>SK%;!L1 ;B/[[>&<A>G\6,DXIC$_+IG#2Q6@F.K@XX
M6:'<F6L('&C)R%L1F)L!+W$Z>#+=KZZ8&JK*N3<2IKA<="N_\$S9Q^@HQ690
MWK &R8YDU[DF@(JE]5S4"E'5PX@" ;!4LHH8,."I'W$^'X53E\,@:(NAD.KA
M7$V^86([QEW+H.'GEF;B509HMF-%]!GH1L7TR<.+<1/@:QO?>K@?__JESBRE
MX4ES9Z[$"^WIR=EUF4&+*S3NJEWLS2@!J@_=D9$Y)N1T1?U-5S(_>"U**".Z
M@/_IYXLQB',FQ 4$YA_$3$.2LSX_;$6+.LGXZXB^Z]6:VLEA^42/OIW)(']O
M[%#$VO6G2S(N40J^RZKVR8J],V9LOJ.5JY7ZIMJU"75[="3 U<$:$@!4NX#G
M1N!7@I D0+O00?0Y>%FKL] #$RZ;B G6S%?)5DPERU>YAAN+V"_VRSO+&=</
MSRS_QV),!Z,7ARCQ'DNNJ.MX8_0KBO%.L'/6FL;/ZA:1)=?7FT(?9"?DOVD+
M@.P$LHRK;AV:S33<X^98B&XVRUY1W$H'<M<\VZ<"H>G7,0$B>X$6<J][%^92
MU:ZZ3F\6#B?C$0DK2N%L4FA=^DV,R)F%CI\DKX=.TJ&U25$_5EGGMZK7/LP9
MHOXVF\XU7U[R6\#"U*C <WU-]1W/?)F?G)L;PI_#,9Q*F*CG<T]YE7*U&8;?
MFIIJT924Y(4;7;WQ_MX5E'B2O>(@T^I*H3Y221'T5-"(,<3K-:<1XM:D\2YS
MAB!'-W.!B _2E*$$*6)U4&Q82BEW)6\DF7D\S;]J2H5LJ'_^,5MPJMV;8*:E
M\6BHC[%]6=A-;7_YD)]2=3%C56NDYM99[$7:=3R31OC>GCV-@D_%I[EK@&*I
M;O+//EW %A'9G]'AS7@OMK%?(M*3??JS"S\OG&>V\89$&?PM>_!Z!HR:'"WR
M*Z\1ZSR; W @0;TD6#^]^+"P1J0,6917)%(^;^H_Z1FU61J_N7+P"V<7=[/D
MVXGD)5UJ[@=%SPJ7]GZ\=L&_DBX(^U*H7^TE992 U"RQ6OR276N9-TI4D"N?
M0BV6OX,;L\4UZY']<OP[53^*@=(#7OE)(@>>\BDNMF4N)EH\>18D-'8@FNDA
M6LR1+%!5KXN3:_Y:>7]](\^W"GX;&]JJA(BB; L"@!D=1R5\5<HC$V"6:",\
M<?=!DTJ9[%.XRP1E9X%VUF.!A@KE1(O!-@X^MV<D )EX_YX XI^VG%R^IR3
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M5#Z>B*W#?-C$KK5%K$&5L!$1Q+,*?\0)Y?GQ2V>GC1^ZC-JWTO\G8:]SR]G
MQ9-^]NUM/@E3TC<1BM(I\D<T/4G!ZDCH^'M^VJNI(,PM:;&M!@E[Z=F(+XG=
M,@G_L;D2(&_]=,57=#C,.?E94(%(HDF1P6SZ\?I]>=_/*QP-VODHX:'M>]A'
MP6",2 M?^%5/FDT'>MB-^"TX0UQ/O(UH+\%S"?S+<\DS%BZ*DUPR0\>' 1E
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MWWN'HXQ;WSEE,??>LE32MYUF)+NF4=A,C%6V^.^&!%W3VL;1HE,)ML56V>4
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M!'TA 2)9EEW@"=CR.'NS)4.X:)9WHX&&G(0U1"Y15V/V7.R?77N3 ##RON7
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MVI*\O2ILA\5!1:*TJ].G!*;--@L@'_ZO?$K+CFQEN^J@H'!13C,Y3W[DZH2
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MKS('E=S2:0=D:@]WP/#<W6K[K+6))S=1;RR(CZ@K+L.:S^*?/^'XC6#NI$0
MQT[@@IV[H@KI$D0!X#OQRHB:/WN'U>_LQ_NL:,HJH6$H1,\JPB9SR7!D\^1G
ME?Q3J<X^ZQ]C;$=EZS/I#^J=HNL3B]DB='@01GN[ ;#<\F_?;2\EXW7.><:^
MOK03,5+N6'(-V[P98?QP$]_X%UKQ$$SXKRE-IC*Y#_B1T'NY0(SP5,0QY&G
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M42,N5"1@D]QII8"6261Q:M-K_@&]@+.H>\R$;5(,E,"[[D(/M >M#[19_7/
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MH6(V7J:6&3+I>,4W)>I,.)XA.-)2 QEFG*(75D?I%F- QUFI;-M06Z?2HE!
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M4I]GO(OZ$J76"XCT./P48K,CVY3F/@+_,R@9_V2SJ2B2=.?WF'-&F8KCF_2
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M(9+V4* GA<F8#6X-%!*/!HJN ^IA>)XFR"5ORGFB<2)NZ@!R9ADVZ,N]->4
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M<M") R_'-;'[D)[]5D7*6)TW.+%(&OPB04A9JR&V)J*^[&7A?2$[=NL4^[6
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M6YRVUE IK+9;NG;0_N7S/>Q5!;HW"8R@N#-':?0:>XOJ+\D:Q%;1J+SUV'2
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MXKB:@7'B)/:H3S8,E_8&-8R_Q6 YW<7V.\=.<.BE<HV+3+#+#5BV=+)WH="
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M?=C;)G*CU5?JM_\%4$L! A0#%     @ #HA_6C;<(H6W$0  *LD  !$
M         ( !     &-E;&,M,C R-#$R,S$N>'-D4$L! A0#%     @ #HA_
M6N"NG0XW%P  '"0! !4              ( !YA$  &-E;&,M,C R-#$R,S%?
M8V%L+GAM;%!+ 0(4 Q0    (  Z(?UJGX&$B-RH  &JC @ 5
M  "  5 I  !C96QC+3(P,C0Q,C,Q7V1E9BYX;6Q02P$"% ,4    "  .B']:
MF%B#\85Z   /"P< %0              @ &Z4P  8V5L8RTR,#(T,3(S,5]L
M86(N>&UL4$L! A0#%     @ #HA_6J]8T7NE4@  IE0% !4
M ( !<LX  &-E;&,M,C R-#$R,S%?<')E+GAM;%!+ 0(4 Q0    (  Z(?UI_
M7E24*3,  "5. 0 +              "  4HA 0!E>#$P+3,U+FAT;5!+ 0(4
M Q0    (  Z(?UJD%\B\>TT  '<T @ (              "  9Q4 0!E>#$Y
M+FAT;5!+ 0(4 Q0    (  Z(?UJ9XTPN"P,  '4)   *              "
M 3VB 0!E>#(S+3$N:'1M4$L! A0#%     @ #HA_6KQ6)L+E!P  Y2L   H
M             ( !<*4! &5X,S$M,2YH=&U02P$"% ,4    "  .B']:%9?X
M+><'  !D+   "@              @ %]K0$ 97@S,2TR+FAT;5!+ 0(4 Q0
M   (  Z(?UH(.K:\%00  .40   *              "  8RU 0!E>#,R+3$N
M:'1M4$L! A0#%     @ #HA_6HVE =8-!   KQ$   H              ( !
MR;D! &5X,S(M,BYH=&U02P$"% ,4    "  .B']: &5ISC<D  "A_@  "0
M            @ '^O0$ 97@T+3(N:'1M4$L! A0#%     @ #HA_6@%!$G@,
MNP( #) 3  P              ( !7.(! &9O<FTQ,"UK+FAT;5!+ 0(4 Q0
M   (  Z(?UH?-FS.,2L! !57 0 0              "  9*=! !F;W)M,3 M
M:U\P,#$N:G!G4$L! A0#%     @ #HA_6E6I4&/0W0  [3P! !
M     ( !\<@% &9O<FTQ,"UK7S P,BYJ<&=02P$"% ,4    "  .B']:Z'=6
M]2A_ P#'M@, $               @ 'OI@8 9F]R;3$P+6M?,# S+FIP9U!+
M 0(4 Q0    (  Z(?UJ$B7E2>G<! />  0 -              "  44F"@!I
B;6%G95\P,#$N:G!G4$L%!@     2 !( . 0  .J="P    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>form10-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:CELC="http://celcuity.com/20241231"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="celc-20241231.xsd" xlink:type="simple"/>
    <context id="From2024-01-01to2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
        </entity>
        <period>
            <instant>2024-06-28</instant>
        </period>
    </context>
    <context id="AsOf2025-03-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
        </entity>
        <period>
            <instant>2025-03-24</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_srt_MinimumMember_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_srt_MaximumMember_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_srt_MinimumMember_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_srt_MaximumMember_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_PreferredStockOnAnAsIfConvertedToCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELC:PreferredStockOnAnAsIfConvertedToCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_PreferredStockOnAnAsIfConvertedToCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELC:PreferredStockOnAnAsIfConvertedToCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_OptionsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CELC:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_OptionsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CELC:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_WarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CELC:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_WarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CELC:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CELC:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CELC:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-04-222024-04-22_custom_OpenMarketSaleAgreementMember_custom_JefferiesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:OpenMarketSaleAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CELC:JefferiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-22</startDate>
            <endDate>2024-04-22</endDate>
        </period>
    </context>
    <context id="AsOf2024-04-22_custom_OpenMarketSaleAgreementMember_custom_JefferiesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:OpenMarketSaleAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CELC:JefferiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-22</instant>
        </period>
    </context>
    <context id="From2024-05-082024-05-08_custom_OpenMarketSaleAgreementMember_custom_JefferiesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:OpenMarketSaleAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CELC:JefferiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-08</startDate>
            <endDate>2024-05-08</endDate>
        </period>
    </context>
    <context id="AsOf2024-05-08_custom_OpenMarketSaleAgreementMember_custom_JefferiesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:OpenMarketSaleAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CELC:JefferiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-08</instant>
        </period>
    </context>
    <context id="From2024-04-302024-04-30_custom_OpenMarketSaleAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:OpenMarketSaleAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-30</startDate>
            <endDate>2024-04-30</endDate>
        </period>
    </context>
    <context id="From2024-05-312024-05-31_custom_OpenMarketSaleAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:OpenMarketSaleAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-31</startDate>
            <endDate>2024-05-31</endDate>
        </period>
    </context>
    <context id="From2024-05-302024-05-30_custom_UnderwritingAgreementMember_custom_LeerinkPartnersLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:LeerinkPartnersLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:UnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-30</startDate>
            <endDate>2024-05-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-05-30_custom_UnderwritingAgreementMember_custom_LeerinkPartnersLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:LeerinkPartnersLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:UnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-30</instant>
        </period>
    </context>
    <context id="From2024-05-312024-05-31_custom_UnderwritingAgreementMember_custom_LeerinkPartnersLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:LeerinkPartnersLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:UnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-31</startDate>
            <endDate>2024-05-31</endDate>
        </period>
    </context>
    <context id="From2023-10-182023-10-18_custom_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-18</startDate>
            <endDate>2023-10-18</endDate>
        </period>
    </context>
    <context id="AsOf2023-10-18_custom_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-18</instant>
        </period>
    </context>
    <context id="AsOf2023-10-18_custom_SecuritiesPurchaseAgreementMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-18</instant>
        </period>
    </context>
    <context id="From2023-10-202023-10-20_custom_InstitutionalAndOtherAccreditedInvestorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">CELC:InstitutionalAndOtherAccreditedInvestorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-20</startDate>
            <endDate>2023-10-20</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_WarrantOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_WarrantOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_WarrantTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_WarrantTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_WarrantThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_WarrantThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_WarrantFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_WarrantFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_WarrantFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_WarrantFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_WarrantSixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_WarrantSixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_WarrantSevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_WarrantSevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_WarrantEightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_WarrantEightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_WarrantNineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_WarrantNineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_WarrantTenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_WarrantTenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2012-08-10_custom_EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELC:EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2012-08-10</instant>
        </period>
    </context>
    <context id="AsOf2017-10-25_custom_StockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELC:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-25</instant>
        </period>
    </context>
    <context id="AsOf2024-01-01_custom_StockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELC:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-01</instant>
        </period>
    </context>
    <context id="AsOf2023-01-01_custom_StockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELC:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="AsOf2021-05-12_custom_StockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELC:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-12</instant>
        </period>
    </context>
    <context id="AsOf2022-05-12_custom_StockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELC:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-12</instant>
        </period>
    </context>
    <context id="AsOf2023-05-11_custom_StockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELC:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-11</instant>
        </period>
    </context>
    <context id="AsOf2024-05-09_custom_StockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELC:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-09</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-05-31_custom_MayTwoThousandTwentyTwoExercisePriceModificationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:MayTwoThousandTwentyTwoExercisePriceModificationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_MayTwoThousandTwentyTwoExercisePriceModificationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:MayTwoThousandTwentyTwoExercisePriceModificationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_MayTwoThousandTwentyTwoExercisePriceModificationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:MayTwoThousandTwentyTwoExercisePriceModificationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_DecemberTwoThousandTwentyOneExercisePriceModificationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:DecemberTwoThousandTwentyOneExercisePriceModificationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_DecemberTwoThousandTwentyOneExercisePriceModificationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:DecemberTwoThousandTwentyOneExercisePriceModificationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_DecemberTwoThousandTwentyOneExercisePriceModificationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:DecemberTwoThousandTwentyOneExercisePriceModificationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-05-31_custom_MayTwoThousandTwentyExercisePriceModificationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:MayTwoThousandTwentyExercisePriceModificationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_MayTwoThousandTwentyExercisePriceModificationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:MayTwoThousandTwentyExercisePriceModificationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_MayTwoThousandTwentyExercisePriceModificationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:MayTwoThousandTwentyExercisePriceModificationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RestrictedStockMember1617133937">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RestrictedStockMember1617133937">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TwoThousandSeventeenPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:TwoThousandSeventeenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2018-05-10_custom_EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELC:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-10</instant>
        </period>
    </context>
    <context id="AsOf2024-01-01_custom_EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELC:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-01</instant>
        </period>
    </context>
    <context id="AsOf2023-01-01_custom_EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELC:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELC:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELC:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_StockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELC:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_StockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELC:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember1617134281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember1617134281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember1617134453">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:AmendedAndRestatedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-30</instant>
        </period>
    </context>
    <context id="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:AmendedAndRestatedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-30</instant>
        </period>
    </context>
    <context id="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermALoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELC:TermALoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:AmendedAndRestatedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-30</instant>
        </period>
    </context>
    <context id="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermBLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELC:TermBLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:AmendedAndRestatedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-30</instant>
        </period>
    </context>
    <context id="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermCLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELC:TermCLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:AmendedAndRestatedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-30</instant>
        </period>
    </context>
    <context id="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermDLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELC:TermDLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:AmendedAndRestatedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-30</instant>
        </period>
    </context>
    <context id="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermELoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELC:TermELoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:AmendedAndRestatedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-30</instant>
        </period>
    </context>
    <context id="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermFLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELC:TermFLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:AmendedAndRestatedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-30</instant>
        </period>
    </context>
    <context id="From2024-05-302024-05-30_custom_AmendedAndRestatedLoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:AmendedAndRestatedLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-30</startDate>
            <endDate>2024-05-30</endDate>
        </period>
    </context>
    <context id="From2024-05-302024-05-30_custom_PriorLoanAgreementMember_custom_InnovatusLifeSciencesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:PriorLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-30</startDate>
            <endDate>2024-05-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-05-30_custom_PriorLoanAgreementMember_custom_InnovatusLifeSciencesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:PriorLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-30</instant>
        </period>
    </context>
    <context id="From2024-05-302024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:AmendedAndRestatedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-30</startDate>
            <endDate>2024-05-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:AmendedAndRestatedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-30</instant>
        </period>
    </context>
    <context id="From2024-05-302024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:AmendedAndRestatedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-30</startDate>
            <endDate>2024-05-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_StateAndLocalJurisdictionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-022025-01-31_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-02</startDate>
            <endDate>2025-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-01-31_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-31</instant>
        </period>
    </context>
    <context id="From2024-10-012024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2024-01-01to2024-12-31" id="Fact000003">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2024-01-01to2024-12-31" id="Fact000004">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="From2024-01-01to2024-12-31" id="Fact000005">0001603454</dei:EntityCentralIndexKey>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0118"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0119"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0204"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0205"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0237"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0239"
      unitRef="USD"
      xsi:nil="true"/>
    <CELC:StockIssuedDuringPeriodValueConversionOfPreferredToCommonStock
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0247"
      unitRef="USD"
      xsi:nil="true"/>
    <CELC:StockIssuedDuringPeriodValueConversionOfPreferredToCommonStock
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0248"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0255"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0257"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0263"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0265"
      unitRef="USD"
      xsi:nil="true"/>
    <CELC:ExerciseOfCommonStockWarrants
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0271"
      unitRef="USD"
      xsi:nil="true"/>
    <CELC:ExerciseOfCommonStockWarrants
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0273"
      unitRef="USD"
      xsi:nil="true"/>
    <CELC:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsIssuanceWithPrivatePlacementOffering
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0278"
      unitRef="USD"
      xsi:nil="true"/>
    <CELC:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsIssuanceWithPrivatePlacementOffering
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0279"
      unitRef="USD"
      xsi:nil="true"/>
    <CELC:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsIssuanceWithPrivatePlacementOffering
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0281"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0285"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0287"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0292"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0293"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0295"
      unitRef="USD"
      xsi:nil="true"/>
    <CELC:AdditionalPaidInCapitalPreFundedWarrantIssued
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0298"
      unitRef="USD"
      xsi:nil="true"/>
    <CELC:AdditionalPaidInCapitalPreFundedWarrantIssued
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0299"
      unitRef="USD"
      xsi:nil="true"/>
    <CELC:AdditionalPaidInCapitalPreFundedWarrantIssued
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0301"
      unitRef="USD"
      xsi:nil="true"/>
    <CELC:IssuanceCostsAssociatedWithPrefundedWarrants
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0304"
      unitRef="USD"
      xsi:nil="true"/>
    <CELC:IssuanceCostsAssociatedWithPrefundedWarrants
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0305"
      unitRef="USD"
      xsi:nil="true"/>
    <CELC:IssuanceCostsAssociatedWithPrefundedWarrants
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0307"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0310"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0311"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0337"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0339"
      unitRef="USD"
      xsi:nil="true"/>
    <CELC:StockIssuedDuringPeriodValueConversionOfPreferredToCommonStock
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0347"
      unitRef="USD"
      xsi:nil="true"/>
    <CELC:StockIssuedDuringPeriodValueConversionOfPreferredToCommonStock
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0348"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0355"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0357"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0363"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0365"
      unitRef="USD"
      xsi:nil="true"/>
    <CELC:StockIssuedDuringPeriodValueStockWarrantsExercised
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0371"
      unitRef="USD"
      xsi:nil="true"/>
    <CELC:StockIssuedDuringPeriodValueStockWarrantsExercised
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0373"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0379"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0381"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0386"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0387"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0389"
      unitRef="USD"
      xsi:nil="true"/>
    <CELC:StockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0393"
      unitRef="USD"
      xsi:nil="true"/>
    <CELC:StockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0395"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0400"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0401"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0403"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0406"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0407"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0408"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromOtherEquity
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0502"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0505"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0512"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0518"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0521"
      unitRef="USD"
      xsi:nil="true"/>
    <CELC:CommonStockWarrantsIssuedWithNotePayableTransaction
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0555"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="AsOf2024-12-31_us-gaap_USTreasurySecuritiesMember"
      id="xdx2ixbrl0659"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0663"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="AsOf2023-12-31_us-gaap_USTreasurySecuritiesMember"
      id="xdx2ixbrl0667"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0671"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0776"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0779"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0796"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0799"
      unitRef="USD"
      xsi:nil="true"/>
    <CELC:FinalFee
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1250"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl1293"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1294"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl1325"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1326"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2024-01-01to2024-12-31" id="Fact000011">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="From2024-01-01to2024-12-31" id="Fact000012">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2024-01-01to2024-12-31" id="Fact000013">2024-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="From2024-01-01to2024-12-31" id="Fact000014">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2024-01-01to2024-12-31" id="Fact000015">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="From2024-01-01to2024-12-31" id="Fact000016">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2024-01-01to2024-12-31" id="Fact000017">001-38207</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2024-01-01to2024-12-31" id="Fact000018">Celcuity Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2024-01-01to2024-12-31" id="Fact000019">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2024-01-01to2024-12-31" id="Fact000020">82-2863566</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2024-01-01to2024-12-31" id="Fact000021">16305     36th</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2024-01-01to2024-12-31" id="Fact000022">Avenue North</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine3 contextRef="From2024-01-01to2024-12-31" id="Fact000023">Suite 100</dei:EntityAddressAddressLine3>
    <dei:EntityAddressCityOrTown contextRef="From2024-01-01to2024-12-31" id="Fact000024">Minneapolis</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2024-01-01to2024-12-31" id="Fact000025">MN</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2024-01-01to2024-12-31" id="Fact000026">55446</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2024-01-01to2024-12-31" id="Fact000027">(763)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2024-01-01to2024-12-31" id="Fact000028">392-0767</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2024-01-01to2024-12-31" id="Fact000029">Common Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2024-01-01to2024-12-31" id="Fact000030">CELC</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2024-01-01to2024-12-31" id="Fact000031">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2024-01-01to2024-12-31" id="Fact000032">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2024-01-01to2024-12-31" id="Fact000033">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2024-01-01to2024-12-31" id="Fact000034">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2024-01-01to2024-12-31" id="Fact000035">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2024-01-01to2024-12-31" id="Fact000036">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2024-01-01to2024-12-31" id="Fact000037">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2024-01-01to2024-12-31" id="Fact000038">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="From2024-01-01to2024-12-31" id="Fact000039">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="From2024-01-01to2024-12-31" id="Fact000040">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="From2024-01-01to2024-12-31" id="Fact000041">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="AsOf2024-06-28"
      decimals="0"
      id="Fact000042"
      unitRef="USD">530223434</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2025-03-24"
      decimals="INF"
      id="Fact000043"
      unitRef="Shares">37839392</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000044">Portions of the registrant&#x2019;s definitive proxy statement relating
to its 2025 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual Report on Form 10-K.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000049">&lt;b&gt;&lt;span id="a_004a"&gt;&lt;/span&gt;ITEM 1C. Cybersecurity&lt;/b&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Risk Management &amp;amp; Strategy&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Our cybersecurity risk management process is a component
of our overall approach to managing material risks that could impact our operations, including cybersecurity threats. In general, we seek
to manage material internal and third-party cybersecurity risks through an approach that focuses on: (i) protecting information systems
and the information residing therein; (ii) identifying, preventing, and mitigating cybersecurity threats; and (iii) assessing and responding
to cybersecurity incidents when they occur. Maintaining, monitoring, and updating our information security program&#x2014;in an effort
to ensure that it remains reasonable and appropriate in light of changes in the security threat landscape, available technology, and applicable
legal and contractual requirements&#x2014;is an ongoing effort.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;div&gt;&lt;div&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"&gt;&lt;span&gt;&lt;span&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_900_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20240101__20241231_zEEWnsACXBQg"&gt;We have implemented and maintain various processes,
procedures, and measures to support our overall risk management strategy and to manage and mitigate the material risks posed by cybersecurity
threats to our systems and data.&lt;/span&gt; With respect to cybersecurity, these measures include conducting risk assessments of our operations and
using a risk register to assess identified risks; developing business continuity, disaster recovery and incident response plans; implementing
technical safeguards and tools; conducting ongoing cybersecurity awareness training; and using contractual protections where appropriate.
Our incident response plan outlines the procedures for reporting, investigating, and remediating cybersecurity incidents, including a
framework to facilitate the escalation to our management team and board of cybersecurity incidents, so that our management team is alerted
in a timely manner to material information that would be required to be disclosed or reported.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"&gt;&lt;span&gt;&lt;span&gt;Our IT department maintains policies and procedures
regarding network security, data protection and incident response. Pursuant to those policies, IT engages with the Chief Financial Officer,
General Counsel and other experts when assessing cybersecurity threats, incident response, and making disclosure determinations following
a data or network breach. The Vice President, IT is accountable at the management level for our overall IT risk management program. Additionally,
our Chief Executive Officer and Audit Committee receives regular updates from the Chief Financial Officer, General Counsel and the Vice
President, IT about significant threats and incidents involving cybersecurity and data protection, as well as security enhancements made
to our IT infrastructure.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"&gt;&lt;span&gt;&lt;span&gt;We use &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90E_ecyd--CybersecurityRiskManagementThirdPartyEngagedFlag_dbT_c20240101__20241231_zWJmelwkbqj"&gt;third-party&lt;/span&gt; service providers for a variety
of services throughout our business, ranging from infrastructure support and maintenance, cybersecurity incident response, data protection
and privacy compliance. In addition, we engage with contract research organizations, contract manufacturing organizations, distributors,
and other supply chain resources.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"&gt;&lt;span&gt;&lt;span&gt;We believe that the use of external service providers
improves our operational capabilities, and we have implemented a vendor qualification and management program that applies to our service
providers, including those that handle protected health information, personal information, or other information subject to protection
under applicable privacy and data protection regulations. This program is designed to identify, address and seek to mitigate potential
cybersecurity and data protection risks that arise from our use of external service providers. While we do not have full visibility into
the cybersecurity risk management processes of our vendors, we require new service providers to complete a vendor questionnaire that identifies
the vendor&#x2019;s network and user protections, such as the use of multi-factor authentication, and other cybersecurity risk management
processes. Vendors that store or access our confidential information are required to certify that their information systems comply with
applicable industry guidelines for cybersecurity, backup, and system recovery. We rely on our third-party service providers to provide
notification of, and remediate, significant cybersecurity threats and cybersecurity incidents that jeopardize the confidentiality, integrity,
or availability of our information.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;/div&gt;&lt;/div&gt;&#160;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"&gt;&lt;span&gt;&lt;span&gt;We periodically evaluate, test, and update our policies,
standards, and processes to mitigate cybersecurity threats and manage incidents effectively. These efforts include risk assessments, vulnerability
assessments and remediations, phishing tests and employee education, and external scans. Additionally, to enhance our capabilities, we
periodically engage third-party service providers, including cybersecurity consultants, to incorporate threat intelligence into our processes.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"&gt;&lt;span&gt;As of the date of this Form 10-K, we are &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_902_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbF_c20240101__20241231_z07C1xRxsPki"&gt;no&lt;/span&gt;t aware
of any risks from cybersecurity threats, including those resulting from any previous cybersecurity incidents experienced by us or, to
our knowledge, by any of our third-party service providers, that have materially affected, or are reasonably likely to materially affect,
our business strategy, results of operations, or financial condition. For further discussion of cybersecurity and data privacy risks that
may materially affect the Company and how they may do so, see &#x201c;Risk Factors&#x2014;If our information technology systems or data,
or those of third parties upon which we rely, are or were compromised, we could face clinical trial delays; regulatory investigations
or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; and other adverse consequences,&#x201d;
included in Item 1A of this Annual Report on Form 10-K.&lt;/span&gt;&lt;/p&gt;

&lt;span&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag contextRef="From2024-01-01to2024-12-31" id="Fact000050">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag contextRef="From2024-01-01to2024-12-31" id="Fact000051">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag contextRef="From2024-01-01to2024-12-31" id="Fact000052">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000055">&lt;b&gt;Governance&lt;/b&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"&gt;&lt;span&gt;&lt;span&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90D_ecyd--CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_c20240101__20241231_z8aaMZ4bqBpa"&gt;Our Audit Committee oversees Celcuity&#x2019;s management
of risks arising from cybersecurity threats. &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_901_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_c20240101__20241231_zLJMLFtcwxz5"&gt;Our CEO delivers periodic briefings to the Board and Audit Committee on material cybersecurity
risks that are pertinent to our business operations.&lt;/span&gt; Additionally, we have processes to promptly notify the Audit Committee and Board
of a significant cybersecurity incident and to inform the Audit Committee and Board of remediation progress, as appropriate.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"&gt;&lt;span&gt;&lt;span&gt;The Vice President, IT has overall responsibility
for our information security program, with support from our management team and specialized partners in cybersecurity incident response
and privacy. &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90F_ecyd--CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_c20240101__20241231_zQDUHaxm1Nzl"&gt;The process includes managing our incident response strategy. If a cybersecurity incident meets certain criteria, however,
our CEO, CFO and General Counsel will become involved with the response strategy, including decisions about public disclosure and reporting.
Our Vice President, IT also coordinates with our CEO, CFO and General Counsel to determine strategic cybersecurity priorities and to establish
compliance procedures.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"&gt;&lt;span&gt;&lt;span&gt;We believe our business leaders have the appropriate
expertise, background and depth of experience to manage risks arising from cybersecurity threats. Our Vice President, IT has served in
various roles in information technology and information security for over three decades, which includes experience in the biotech, pharmaceutical
and healthcare industries and experience in cybersecurity risk management and data privacy compliance.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"&gt;&lt;span&gt;In the ordinary course of our business, we, and the
third parties upon which we rely, collect, process, receive, generate, use, transfer, disclose, make accessible, protect, secure, dispose
of, transmit, share and store (collectively, &#x201c;process&#x201d;) proprietary, confidential, and sensitive information, including protected
health information, personal information, credit card and other financial information, or other sensitive information owned or controlled
by ourselves or our customers, payors, and other parties.&lt;/span&gt;&lt;/p&gt;

&lt;span&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000056">Our Audit Committee oversees Celcuity&#x2019;s management
of risks arising from cybersecurity threats. &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_901_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_c20240101__20241231_zLJMLFtcwxz5"&gt;Our CEO delivers periodic briefings to the Board and Audit Committee on material cybersecurity
risks that are pertinent to our business operations.&lt;/span&gt; Additionally, we have processes to promptly notify the Audit Committee and Board
of a significant cybersecurity incident and to inform the Audit Committee and Board of remediation progress, as appropriate.</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000057">Our CEO delivers periodic briefings to the Board and Audit Committee on material cybersecurity
risks that are pertinent to our business operations.</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000058">The process includes managing our incident response strategy. If a cybersecurity incident meets certain criteria, however,
our CEO, CFO and General Counsel will become involved with the response strategy, including decisions about public disclosure and reporting.
Our Vice President, IT also coordinates with our CEO, CFO and General Counsel to determine strategic cybersecurity priorities and to establish
compliance procedures.</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <dei:AuditorOpinionTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000059">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
have audited the accompanying balance sheets of Celcuity Inc. (the Company) as of December 31, 2024 and 2023, and the related statements
of operations, changes in stockholders&#x2019; equity, and cash flows for each of the years in the two-year period ended December 31,
2024, and the related notes (collectively referred to as the financial statements). In our opinion, the financial statements present
fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations
and its cash flows for each of the years in the two-year period ended December 31, 2024, in conformity with accounting principles generally
accepted in the United States of America.&lt;/span&gt;</dei:AuditorOpinionTextBlock>
    <dei:AuditorName contextRef="From2024-01-01to2024-12-31" id="Fact000060">Boulay LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="From2024-01-01to2024-12-31" id="Fact000061">Minneapolis, Minnesota</dei:AuditorLocation>
    <dei:AuditorFirmId contextRef="From2024-01-01to2024-12-31" id="Fact000062">542</dei:AuditorFirmId>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000070"
      unitRef="USD">22514823</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000071"
      unitRef="USD">30662774</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000073"
      unitRef="USD">212588960</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000074"
      unitRef="USD">149919974</us-gaap:ShortTermInvestments>
    <us-gaap:OtherAssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000076"
      unitRef="USD">9467247</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000077"
      unitRef="USD">10007849</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000079"
      unitRef="USD">244571030</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000080"
      unitRef="USD">190590597</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000082"
      unitRef="USD">336515</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000083"
      unitRef="USD">228782</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000085"
      unitRef="USD">215502</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000086"
      unitRef="USD">400019</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Assets
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000088"
      unitRef="USD">245123047</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000089"
      unitRef="USD">191219398</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000097"
      unitRef="USD">9366007</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000098"
      unitRef="USD">5076699</us-gaap:AccountsPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000100"
      unitRef="USD">171952</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000101"
      unitRef="USD">184950</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000103"
      unitRef="USD">22184948</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000104"
      unitRef="USD">8927094</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000106"
      unitRef="USD">31722907</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000107"
      unitRef="USD">14188743</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000109"
      unitRef="USD">53969</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000110"
      unitRef="USD">225922</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LongTermNotesPayable
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000112"
      unitRef="USD">97727136</us-gaap:LongTermNotesPayable>
    <us-gaap:LongTermNotesPayable
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000113"
      unitRef="USD">37035411</us-gaap:LongTermNotesPayable>
    <us-gaap:Liabilities
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000115"
      unitRef="USD">129504012</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000116"
      unitRef="USD">51450076</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000127"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000129"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000131"
      unitRef="Shares">2500000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000133"
      unitRef="Shares">2500000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000135"
      unitRef="Shares">317577</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000137"
      unitRef="Shares">317577</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000139"
      unitRef="Shares">854134</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000141"
      unitRef="Shares">854134</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000124"
      unitRef="USD">318</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000125"
      unitRef="USD">854</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000146"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000148"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000150"
      unitRef="Shares">95000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000152"
      unitRef="Shares">65000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000154"
      unitRef="Shares">37143242</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000156"
      unitRef="Shares">37143242</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000158"
      unitRef="Shares">25506012</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000160"
      unitRef="Shares">25506012</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000143"
      unitRef="USD">37143</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000144"
      unitRef="USD">25506</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000162"
      unitRef="USD">387436682</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000163"
      unitRef="USD">299818965</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000165"
      unitRef="USD">-271855108</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000166"
      unitRef="USD">-160076003</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000168"
      unitRef="USD">115619035</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000169"
      unitRef="USD">139769322</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000171"
      unitRef="USD">245123047</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000172"
      unitRef="USD">191219398</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000177"
      unitRef="USD">104203230</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000178"
      unitRef="USD">60594005</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000180"
      unitRef="USD">9063721</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000181"
      unitRef="USD">5636326</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000183"
      unitRef="USD">113266951</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000184"
      unitRef="USD">66230331</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000186"
      unitRef="USD">-113266951</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000187"
      unitRef="USD">-66230331</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000192"
      unitRef="USD">10280445</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000193"
      unitRef="USD">5326387</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InvestmentIncomeInterest
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000195"
      unitRef="USD">11768291</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000196"
      unitRef="USD">7777602</us-gaap:InvestmentIncomeInterest>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000198"
      unitRef="USD">1487846</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000199"
      unitRef="USD">2451215</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000201"
      unitRef="USD">-111779105</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000202"
      unitRef="USD">-63779116</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000207"
      unitRef="USD">-111779105</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000208"
      unitRef="USD">-63779116</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000210"
      unitRef="USDPShares">-2.83</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000212"
      unitRef="USDPShares">-2.83</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000214"
      unitRef="USDPShares">-2.69</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000216"
      unitRef="USDPShares">-2.69</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000218"
      unitRef="Shares">39449393</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000220"
      unitRef="Shares">39449393</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000222"
      unitRef="Shares">23679472</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000224"
      unitRef="Shares">23679472</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000232"
      unitRef="Shares">21667250</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000226"
      unitRef="USD">21667</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact000234"
      unitRef="Shares">1120873</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember"
      decimals="0"
      id="Fact000227"
      unitRef="USD">1121</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000228"
      unitRef="USD">230045566</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000229"
      unitRef="USD">-96296887</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000230"
      unitRef="USD">133771467</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000242"
      unitRef="Shares">1958</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000236"
      unitRef="USD">2</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000238"
      unitRef="USD">4901432</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000240"
      unitRef="USD">4901434</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <CELC:StockIssuedDuringPeriodSharesConversionOfPreferredToCommonStock
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000250"
      unitRef="Shares">2667390</CELC:StockIssuedDuringPeriodSharesConversionOfPreferredToCommonStock>
    <CELC:StockIssuedDuringPeriodValueConversionOfPreferredToCommonStock
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000244"
      unitRef="USD">2668</CELC:StockIssuedDuringPeriodValueConversionOfPreferredToCommonStock>
    <CELC:StockIssuedDuringPeriodSharesConversionOfPreferredToCommonStock
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact000252"
      unitRef="Shares">-266739</CELC:StockIssuedDuringPeriodSharesConversionOfPreferredToCommonStock>
    <CELC:StockIssuedDuringPeriodValueConversionOfPreferredToCommonStock
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember"
      decimals="0"
      id="Fact000245"
      unitRef="USD">-267</CELC:StockIssuedDuringPeriodValueConversionOfPreferredToCommonStock>
    <CELC:StockIssuedDuringPeriodValueConversionOfPreferredToCommonStock
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000246"
      unitRef="USD">-2401</CELC:StockIssuedDuringPeriodValueConversionOfPreferredToCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000260"
      unitRef="Shares">33850</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000254"
      unitRef="USD">33</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000256"
      unitRef="USD">202812</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000258"
      unitRef="USD">202845</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000268"
      unitRef="Shares">98695</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000262"
      unitRef="USD">99</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000264"
      unitRef="USD">388423</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000266"
      unitRef="USD">388522</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <CELC:ExerciseOfCommonStockSharesWarrants
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000276"
      unitRef="Shares">2369</CELC:ExerciseOfCommonStockSharesWarrants>
    <CELC:ExerciseOfCommonStockWarrants
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000270"
      unitRef="USD">-2</CELC:ExerciseOfCommonStockWarrants>
    <CELC:ExerciseOfCommonStockWarrants
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000272"
      unitRef="USD">-22503</CELC:ExerciseOfCommonStockWarrants>
    <CELC:ExerciseOfCommonStockWarrants
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000274"
      unitRef="USD">-22505</CELC:ExerciseOfCommonStockWarrants>
    <CELC:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsIssuanceWithPrivatePlacementOffering
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000280"
      unitRef="USD">7486</CELC:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsIssuanceWithPrivatePlacementOffering>
    <CELC:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsIssuanceWithPrivatePlacementOffering
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000282"
      unitRef="USD">7486</CELC:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsIssuanceWithPrivatePlacementOffering>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000290"
      unitRef="Shares">1034500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000284"
      unitRef="USD">1035</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000286"
      unitRef="USD">14999216</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000288"
      unitRef="USD">15000251</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000294"
      unitRef="USD">614205</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000296"
      unitRef="USD">614205</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <CELC:AdditionalPaidInCapitalPreFundedWarrantIssued
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000300"
      unitRef="USD">50000000</CELC:AdditionalPaidInCapitalPreFundedWarrantIssued>
    <CELC:AdditionalPaidInCapitalPreFundedWarrantIssued
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000302"
      unitRef="USD">50000000</CELC:AdditionalPaidInCapitalPreFundedWarrantIssued>
    <CELC:IssuanceCostsAssociatedWithPrefundedWarrants
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000306"
      unitRef="USD">-116895</CELC:IssuanceCostsAssociatedWithPrefundedWarrants>
    <CELC:IssuanceCostsAssociatedWithPrefundedWarrants
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000308"
      unitRef="USD">-116895</CELC:IssuanceCostsAssociatedWithPrefundedWarrants>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000313"
      unitRef="USD">-63779116</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000314"
      unitRef="USD">-63779116</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000322"
      unitRef="Shares">25506012</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000316"
      unitRef="USD">25506</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact000324"
      unitRef="Shares">854134</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember"
      decimals="0"
      id="Fact000317"
      unitRef="USD">854</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000318"
      unitRef="USD">299818965</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000319"
      unitRef="USD">-160076003</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000320"
      unitRef="USD">139769322</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000332"
      unitRef="Shares">25506012</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000326"
      unitRef="USD">25506</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact000334"
      unitRef="Shares">854134</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember"
      decimals="0"
      id="Fact000327"
      unitRef="USD">854</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000328"
      unitRef="USD">299818965</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000329"
      unitRef="USD">-160076003</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000330"
      unitRef="USD">139769322</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000342"
      unitRef="Shares">1429</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000336"
      unitRef="USD">1</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000338"
      unitRef="USD">6988340</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000340"
      unitRef="USD">6988341</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <CELC:StockIssuedDuringPeriodSharesConversionOfPreferredToCommonStock
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000350"
      unitRef="Shares">5365570</CELC:StockIssuedDuringPeriodSharesConversionOfPreferredToCommonStock>
    <CELC:StockIssuedDuringPeriodValueConversionOfPreferredToCommonStock
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000344"
      unitRef="USD">5367</CELC:StockIssuedDuringPeriodValueConversionOfPreferredToCommonStock>
    <CELC:StockIssuedDuringPeriodSharesConversionOfPreferredToCommonStock
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact000352"
      unitRef="Shares">-536557</CELC:StockIssuedDuringPeriodSharesConversionOfPreferredToCommonStock>
    <CELC:StockIssuedDuringPeriodValueConversionOfPreferredToCommonStock
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember"
      decimals="0"
      id="Fact000345"
      unitRef="USD">-536</CELC:StockIssuedDuringPeriodValueConversionOfPreferredToCommonStock>
    <CELC:StockIssuedDuringPeriodValueConversionOfPreferredToCommonStock
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000346"
      unitRef="USD">-4831</CELC:StockIssuedDuringPeriodValueConversionOfPreferredToCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000360"
      unitRef="Shares">33215</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000354"
      unitRef="USD">33</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000356"
      unitRef="USD">275568</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000358"
      unitRef="USD">275601</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000368"
      unitRef="Shares">103245</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000362"
      unitRef="USD">104</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000364"
      unitRef="USD">769463</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000366"
      unitRef="USD">769567</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <CELC:StockIssuedDuringPeriodSharesStockWarrantsExercised
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000376"
      unitRef="Shares">1827357</CELC:StockIssuedDuringPeriodSharesStockWarrantsExercised>
    <CELC:StockIssuedDuringPeriodValueStockWarrantsExercised
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000370"
      unitRef="USD">1826</CELC:StockIssuedDuringPeriodValueStockWarrantsExercised>
    <CELC:StockIssuedDuringPeriodValueStockWarrantsExercised
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000372"
      unitRef="USD">14733991</CELC:StockIssuedDuringPeriodValueStockWarrantsExercised>
    <CELC:StockIssuedDuringPeriodValueStockWarrantsExercised
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000374"
      unitRef="USD">14735817</CELC:StockIssuedDuringPeriodValueStockWarrantsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000384"
      unitRef="Shares">435414</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000378"
      unitRef="USD">435</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000380"
      unitRef="USD">7641765</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000382"
      unitRef="USD">7642200</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000388"
      unitRef="USD">263727</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000390"
      unitRef="USD">263727</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <CELC:StockIssuedDuringPeriodSharesIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000398"
      unitRef="Shares">3871000</CELC:StockIssuedDuringPeriodSharesIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts>
    <CELC:StockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000392"
      unitRef="USD">3871</CELC:StockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts>
    <CELC:StockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000394"
      unitRef="USD">56248237</CELC:StockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts>
    <CELC:StockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000396"
      unitRef="USD">56252108</CELC:StockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000402"
      unitRef="USD">1228911</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000404"
      unitRef="USD">1228911</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000409"
      unitRef="USD">-111779105</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000410"
      unitRef="USD">-111779105</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000418"
      unitRef="Shares">37143242</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000412"
      unitRef="USD">37143</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact000420"
      unitRef="Shares">317577</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember"
      decimals="0"
      id="Fact000413"
      unitRef="USD">318</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000414"
      unitRef="USD">387436682</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000415"
      unitRef="USD">-271855108</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000416"
      unitRef="USD">115619035</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000428"
      unitRef="Shares">37143242</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000422"
      unitRef="USD">37143</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact000430"
      unitRef="Shares">317577</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember"
      decimals="0"
      id="Fact000423"
      unitRef="USD">318</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000424"
      unitRef="USD">387436682</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000425"
      unitRef="USD">-271855108</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000426"
      unitRef="USD">115619035</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000435"
      unitRef="USD">-111779105</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000436"
      unitRef="USD">-63779116</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000441"
      unitRef="USD">129947</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000442"
      unitRef="USD">142772</us-gaap:Depreciation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000444"
      unitRef="USD">6988341</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000445"
      unitRef="USD">4901434</us-gaap:ShareBasedCompensation>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000447"
      unitRef="USD">1330652</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000448"
      unitRef="USD">241752</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:PaidInKindInterest
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000450"
      unitRef="USD">1363708</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000451"
      unitRef="USD">1810584</us-gaap:PaidInKindInterest>
    <CELC:NoncashOperatingLeaseExpenseNet
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000453"
      unitRef="USD">-434</CELC:NoncashOperatingLeaseExpenseNet>
    <CELC:NoncashOperatingLeaseExpenseNet
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000454"
      unitRef="USD">4368</CELC:NoncashOperatingLeaseExpenseNet>
    <CELC:ChangeInAccruedInterestIncome
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000456"
      unitRef="USD">-150421</CELC:ChangeInAccruedInterestIncome>
    <CELC:ChangeInAccruedInterestIncome
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000457"
      unitRef="USD">993457</CELC:ChangeInAccruedInterestIncome>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000462"
      unitRef="USD">-775981</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000463"
      unitRef="USD">3438018</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000465"
      unitRef="USD">4315892</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000466"
      unitRef="USD">2430614</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000468"
      unitRef="USD">13257854</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000469"
      unitRef="USD">4866814</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000471"
      unitRef="USD">-83466743</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000472"
      unitRef="USD">-53812253</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000477"
      unitRef="USD">642345545</us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments>
    <us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000478"
      unitRef="USD">309614521</us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000480"
      unitRef="USD">705164950</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000481"
      unitRef="USD">314525084</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000483"
      unitRef="USD">249878</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000484"
      unitRef="USD">97644</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000486"
      unitRef="USD">-63069283</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000487"
      unitRef="USD">-5008207</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000492"
      unitRef="USD">14735817</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000493"
      unitRef="USD">22505</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000495"
      unitRef="USD">769571</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000496"
      unitRef="USD">388522</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockPlans
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000498"
      unitRef="USD">275601</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000499"
      unitRef="USD">202845</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromOtherEquity
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000501"
      unitRef="USD">56252108</us-gaap:ProceedsFromOtherEquity>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000507"
      unitRef="USD">2437644</us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000504"
      unitRef="USD">59226276</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <CELC:ProceedsFromAtmOfferingNetOfIssuanceCosts
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000509"
      unitRef="USD">7356107</CELC:ProceedsFromAtmOfferingNetOfIssuanceCosts>
    <CELC:ProceedsFromAtmOfferingNetOfIssuanceCosts
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000510"
      unitRef="USD">14431186</CELC:ProceedsFromAtmOfferingNetOfIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000513"
      unitRef="USD">49917589</us-gaap:ProceedsFromIssuanceOfWarrants>
    <CELC:PaymentsForSecondaryRegistrationStatementCosts
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000515"
      unitRef="USD">227405</CELC:PaymentsForSecondaryRegistrationStatementCosts>
    <CELC:PaymentsForSecondaryRegistrationStatementCosts
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000516"
      unitRef="USD">45805</CELC:PaymentsForSecondaryRegistrationStatementCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000519"
      unitRef="USD">2716</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000522"
      unitRef="USD">2449</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000524"
      unitRef="USD">138388075</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000525"
      unitRef="USD">64911677</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000527"
      unitRef="USD">-8147951</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000528"
      unitRef="USD">6091217</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000533"
      unitRef="USD">30662774</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000534"
      unitRef="USD">24571557</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000536"
      unitRef="USD">22514823</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000537"
      unitRef="USD">30662774</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:InterestPaidNet
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000542"
      unitRef="USD">7586084</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000543"
      unitRef="USD">3274051</us-gaap:InterestPaidNet>
    <CELC:DeferredFinancingCostsAndOfferingAndRegistrationStatementCostsIncludedInAccountsPayable
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000548"
      unitRef="USD">42028</CELC:DeferredFinancingCostsAndOfferingAndRegistrationStatementCostsIncludedInAccountsPayable>
    <CELC:DeferredFinancingCostsAndOfferingAndRegistrationStatementCostsIncludedInAccountsPayable
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000549"
      unitRef="USD">56414</CELC:DeferredFinancingCostsAndOfferingAndRegistrationStatementCostsIncludedInAccountsPayable>
    <CELC:PropertyAndEquipmentIncludedInAccountsPayable
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000551"
      unitRef="USD">1417</CELC:PropertyAndEquipmentIncludedInAccountsPayable>
    <CELC:PropertyAndEquipmentIncludedInAccountsPayable
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000552"
      unitRef="USD">13615</CELC:PropertyAndEquipmentIncludedInAccountsPayable>
    <CELC:CommonStockWarrantsIssuedWithNotePayableTransaction
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000554"
      unitRef="USD">1228911</CELC:CommonStockWarrantsIssuedWithNotePayableTransaction>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000557">&lt;p id="xdx_80C_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zkK9dFmkB548" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt; &lt;b&gt;1.&lt;/b&gt; &lt;b&gt;&lt;span id="xdx_829_znHvbdCz6Xc6"&gt;Organization&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Nature of Business&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;Celcuity Inc., a Delaware corporation (the &#x201c;Company&#x201d;) is a
clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid tumor indications.
The Company&#x2019;s lead therapeutic candidate is gedatolisib, a potent, well-tolerated, small molecule reversible inhibitor, administered
intravenously, that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (&#x201c;PI3K&#x201d;) and the two mechanistic
targets of rapamycin (&#x201c;mTOR&#x201d;) sub-complexes, mTORC1 and mTORC2. Gedatolisib&#x2019;s mechanism of action and pharmacokinetic
properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together.
A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with
HR+/HER2- advanced breast cancer is currently enrolling patients. Site selection and activation activities for a Phase 3 clinical trial,
VIKTORIA-2, evaluating gedatolisib in combination with a CDK4/6 inhibitor and fulvestrant as first-line treatment for patients with HR+/HER2-
advanced breast cancer has commenced. The first patient is expected to be dosed in the second quarter of 2025. A Phase 1b/2 clinical trial,
CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer,
is currently underway. The Company was co-founded in 2012 by Brian F. Sullivan and Dr. Lance G. Laing and is based in Minnesota. The Company
has not generated any revenues to date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000559">&lt;p id="xdx_800_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zlI0nJT6ysn7" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt; &lt;b&gt;2.&lt;/b&gt; &lt;b&gt;&lt;span id="xdx_826_zryuu22buLa6"&gt;Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zqle3EpLCqti" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86F_zfvrrS2Urjua"&gt;Basis of Presentation&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;span style="background-color: white"&gt;The accompanying financial statements
have been prepared in accordance with accounting principles generally accepted in the United States (&#x201c;U.S. GAAP&#x201d;) and pursuant
to the rules and regulations of the Securities and Exchange Commission (the &#x201c;SEC&#x201d;). Operating results for the year ended December
31, 2024 are not necessarily indicative of results to be expected for any future year.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--UseOfEstimates_zqYd2kAzJWZ7" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86E_zTnkypDHItge"&gt;Accounting Estimates&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 2.15pt 0 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 2.15pt 0 0"&gt;Management uses estimates and assumptions in preparing these
financial statements in accordance with U.S. GAAP. Those estimates and assumptions affect the reported amounts of assets and liabilities,
the disclosure of contingent assets and liabilities, and the reported revenues and expenses. Actual results could differ from those estimates
and the difference could be material. Significant items subject to such estimates and assumptions include the valuation of stock-based
compensation and prepaid or accrued clinical trial costs.&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zs41NFVAgjWa" style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_862_zBSE7imawy8h"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 2.15pt 0 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 2.15pt 0 0"&gt;The Company maintains its accounts at two financial institutions.
At times throughout the year, the Company&#x2019;s cash balances may exceed amounts insured by the Federal Deposit Insurance Corporation.
At December 31, 2024 and December 31, 2023, the Company had $&lt;span id="xdx_90D_eus-gaap--CashFDICInsuredAmount_iI_c20241231_zKYFJ5FLHDC3" title="Cash equivalents FDIC insured, amount"&gt;22,514,823&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--CashFDICInsuredAmount_iI_c20231231_zdbbCz0ZDuN3" title="Cash equivalents FDIC insured, amount"&gt;30,662,774&lt;/span&gt;, respectively, in business checking accounts and
money market funds that are considered cash equivalents and not insured by the Federal Deposit Insurance Corporation.&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--InvestmentPolicyTextBlock_zZcCsrawuJQe" style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86C_zVP5ib2lPBri"&gt;Investments&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 2.15pt 0 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 2.15pt 0 0"&gt;The Company maintains its investments in U.S. governmental agency
securities and U.S. treasury bills and has classified them as held-to-maturity at the time of purchase. Held-to-maturity purchases are
those securities in which the Company has the ability and intent to hold until maturity. Held-to-maturity securities are recorded at amortized
cost, adjusted for the amortization or accretion of premiums and discounts. Premiums and discounts are amortized or accreted over the
life of the related held-to-maturity security using a straight-line method. The difference between the carrying value, which is based
on cost, and the aggregate fair value of the held-to-maturity securities, was immaterial as of December 31, 2024. At December 31, 2024
and December 31, 2023, the Company had $&lt;span id="xdx_902_eus-gaap--ShortTermInvestments_iI_c20241231_zeScxzKuWOu3" title="Short-term investments"&gt;212,588,960&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--ShortTermInvestments_iI_c20231231_zqV7aaEms22i" title="Short-term investments"&gt;149,919,974&lt;/span&gt;, respectively, of short-term investments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&#160;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zErkpyNvmfA4" style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_869_zcPUi34VFRg"&gt;Property and Equipment&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 2.15pt 0 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;Property and equipment are stated at cost. Depreciation is provided
over estimated useful lives using the straight-line method. Maintenance and repairs are expensed as incurred; major improvements and betterments
are capitalized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89B_ecustom--ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock_zbXmEHbRuoxi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Estimated useful lives of property and equipment are as follows for the
major classes of assets:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.6in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B2_zvVaDreWGHl2" style="display: none"&gt;Schedule of Estimated Useful Lives of Property and Equipment&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 84%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;Estimated&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 85%; font-weight: bold; text-align: justify"&gt;Asset Description&lt;/td&gt;&lt;td style="padding-bottom: 1pt; width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 14%; font-weight: bold; text-align: center"&gt;Lives&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Furniture and Equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_za2Cizkodqzb" title="Estimated useful lives"&gt;4&lt;/span&gt;-&lt;span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zoToZonzLH2l" title="Estimated useful lives"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Leasehold Improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zwNRQRUPKqkj" title="Estimated useful lives"&gt;2&lt;/span&gt;-&lt;span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zjy5QdetKmE2" title="Estimated useful lives"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_ziLDoGxeSjz5" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.6in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zUrX149Fdpnj" style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_862_zXjBiAbWKt3e"&gt;Long-Lived Assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;Long-lived assets, such as property and equipment, are reviewed for impairment
whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require
a long-lived asset or asset group be tested for possible impairment, the Company first compares undiscounted cash flows expected to be
generated by that asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group is not recoverable
on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying value exceeds its fair value. Fair value
is determined through various valuation techniques including discounted cash flow models, quoted market values, and third-party independent
appraisals, as considered necessary.&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--DeferredChargesPolicyTextBlock_zLw1ZX7RHbof" style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_861_zc3C9lJETGe7"&gt;Deferred Transaction Costs&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;Deferred transaction costs primarily consist of legal fees that are capitalized
as incurred and will be offset against the proceeds from future equity financing arrangements. The deferred transaction costs will be
reviewed periodically to assess the probability that future securities will be offered. In the event that no future offering will occur,
any deferred transaction costs will be expensed. Total costs incurred, but not accounted for as a reduction in equity, were $&lt;span id="xdx_902_eus-gaap--DeferredCostsCurrent_iI_c20241231_znLH97VNiqpa" title="Deferred transaction costs"&gt;235,379&lt;/span&gt; and
$&lt;span id="xdx_900_eus-gaap--DeferredCostsCurrent_iI_c20231231_zSoIRAfiqV2" title="Deferred transaction costs"&gt;0&lt;/span&gt; as of December 31, 2024 and 2023, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--DebtPolicyTextBlock_zIQrsrmEItuc" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_862_zWjiikqHPfM1"&gt;Debt Issuance Costs&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;The Company recognizes debt issuance costs as deferred costs, which are
capitalized and amortized over the term of the related debt using the effective interest method. These costs primarily consist of fees,
commissions, legal, and other costs directly attributable to securing debt financing. Debt issuance costs are reported as a direct reduction
of the carrying amount of the related debt on the balance sheets. Amortization of these costs is recorded as interest expense in the statements
of operations over the life of the debt instrument.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zFOlTBRBCjeh" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_865_zapig2q36X4b"&gt;Comprehensive Loss&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;Comprehensive loss includes net loss as well as other changes in stockholders&#x2019;
equity that result from transactions and economic events other than those with stockholders. For all periods presented, there was no difference
between net loss and comprehensive loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--ConcentrationRiskCreditRisk_zoGHHydaSJ1g" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_860_zimzFr8eXqGb"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;The Company is subject to risks common to companies in the development
stage including, but not limited to, dependency on the clinical and commercial success of its initial drug product, gedatolisib, the ability
to obtain regulatory approval for gedatolisib, the need for substantial additional financing to achieve its goals, uncertainty of broad
adoption of its approved products, if any, by physicians and consumers, and significant competition.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zzWZPOiyddAl" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_860_zVnMYaSQNEed"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 5.75pt 0 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;The Company&#x2019;s accounting for fair value measurements of
assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring or nonrecurring basis
adheres to the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) fair value hierarchy that prioritizes the inputs to valuation
techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical
assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level
3 measurements). The three levels of the fair value hierarchy are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 5.85pt 0 41pt; text-indent: -0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.5in; text-align: left"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level
1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the Company at the measurement
date.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 5.95pt 0 41pt; text-indent: -0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.5in; text-align: left"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level
2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly,
for substantially the full term of the asset or liability.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 5.8pt 0 41pt; text-indent: -0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.5in; text-align: left"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level
3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available,
thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;The level in the fair value hierarchy within which a fair value
measurement in its entirety falls, is based on the lowest level input that is significant to the fair value measurement in its entirety.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 5.95pt 0 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;The carrying values of cash equivalents, accounts payable, accrued
expenses and other financial working capital items approximate fair value at December 31, 2024 and December 31, 2023, due to the short
maturity nature of these items.&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--IncomeTaxPolicyTextBlock_z8vEUxHWNSgh" style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_866_zgynWj3fZcYb"&gt;Income Taxes&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;The Company accounts for income taxes using the asset and liability method,
as required by the accounting standard for income taxes. Under this method, deferred tax assets and liabilities are recognized for the
future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities
and their respective tax bases, as well as net operating loss and tax credit carryforwards. Deferred taxes are measured using enacted
tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.
The effect on deferred taxes of a change in tax rates is recognized in results of operations in the period that includes the enactment
date. The effects of any future changes in tax laws or rates have not been considered. The Company regularly reviews deferred tax assets
to assess their potential realization and establish a valuation allowance for portions of such assets to reduce the carrying value if
the Company does not consider it to be more likely than not that the deferred tax assets will be realized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;The Company recognizes the impact of an uncertain tax position in its financial
statements if, in management&#x2019;s judgment, the position is more-likely-than-not sustainable upon audit based on the position&#x2019;s
technical merits. This involves the identification of potential uncertain tax positions, the evaluation of applicable tax laws and an
assessment of whether a liability for an uncertain tax position is necessary.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zeKwV8b1dP64" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_866_zBXECk6Wy7Bj"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 2.15pt 0 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 2.15pt 0 0"&gt;The Company&#x2019;s stock-based compensation consists of stock
options and restricted stock issued to certain employees and non-employees of the Company and the Company&#x2019;s 2017 Employee Stock
Purchase Plan. The Company recognizes compensation expense based on an estimated grant date fair value using the Black-Scholes option-pricing
method for equity-based awards and the Monte Carlo simulation model for performance-based awards. If the factors change and different
assumptions are used, the Company&#x2019;s stock-based compensation expense could be materially different in the future. The Company recognizes
stock-based compensation expense for these options on a straight-line basis over the requisite service period. The Company has elected
to account for forfeitures as they occur.&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--ResearchAndDevelopmentExpensePolicy_zvGCg70bmtpj" style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_864_z3XHAIp3vYBc"&gt;Research and Development&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;Research and development costs are expensed as incurred. Research and development
costs amounted to $&lt;span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20241231_zxOzlJ7CAvLe" title="Research and development expense"&gt;104,203,230&lt;/span&gt; for the year ended December 31, 2024 and $&lt;span id="xdx_900_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231_zck4ehiBYfJ" title="Research and development expense"&gt;60,594,005&lt;/span&gt; for the year ended December 31, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--InProcessResearchAndDevelopmentPolicy_zKtIk5RQdI77" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_862_zcho2GdqM904"&gt;Clinical Trial Costs&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;The Company relies on third parties to conduct
certain aspects of clinical studies and to formulate and manufacture our drug product. While there are alternative vendors that can
perform these functions, any disruption or delay by the Company&#x2019;s current third parties in carrying out their contractual
duties could delay the clinical trials. The Company records prepaid assets or accrued expenses for prepaid or estimated clinical
trial costs conducted by third-party service providers, which includes the conduct of preclinical studies and clinical trials. These
costs can be a significant component of the Company&#x2019;s research and development expenses. The Company primarily relies on a
compilation of progress reports from third-party service providers, including the respective invoicing, to record actual expenses,
along with determining changes to prepaid assets and accrued liabilities. To date, the Company believes utilization of third-party
reports most accurately reflects expenses incurred. With the ongoing VIKTORIA-1 Phase 3 trial and the CELC-G-201 Phase 1b/2 trial,
and the commencement of the VIKTORIA-2 Phase 3 clinical trial site activation and patient enrollment anticipated in Q2 2025&lt;span style="font-size: 10pt"&gt;,&lt;/span&gt;
the Company&#x2019;s estimated expenses in future periods and actual services performed may vary from these estimates, and these
estimates may become more significant. Changes in these estimates that result in material changes to the Company&#x2019;s prepaid
assets or accrued expenses could materially affect the Company&#x2019;s results of operations and financial position.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zASjcBnZart7" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_867_zAWp6ew8cnbi"&gt;Segment Data&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;In November 2023, the FASB issued ASU 2023-07: Improvements to Reportable
Segment Disclosures. This ASU, which amends Topic 280: &lt;i&gt;Segment Reporting,&lt;/i&gt; improves disclosure requirements for reportable segments
and enhances disclosures for companies with single reportable segments. The Company has a single reportable segment based on the nature
of its operations. The nature of business and the accounting policies of the segment are the same as described throughout Notes 1 and
2. The Company&#x2019;s Chief Operating Decision Maker (&#x201c;CODM&#x201d;) is its executive team. The CODM assesses the reportable segment&#x2019;s performance
and allocates resources for the reportable segment based on net income and total assets, which are the same amounts in all material respects
as those reported on the statements of operations and balance sheets. The Company adopted the standard on January 1, 2024. The adoption
did not have a material impact on the Company&#x2019;s financial statements.&lt;/p&gt;

&lt;p id="xdx_856_z4iFfU2SxhT3" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000561">&lt;p id="xdx_846_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zqle3EpLCqti" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86F_zfvrrS2Urjua"&gt;Basis of Presentation&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;span style="background-color: white"&gt;The accompanying financial statements
have been prepared in accordance with accounting principles generally accepted in the United States (&#x201c;U.S. GAAP&#x201d;) and pursuant
to the rules and regulations of the Securities and Exchange Commission (the &#x201c;SEC&#x201d;). Operating results for the year ended December
31, 2024 are not necessarily indicative of results to be expected for any future year.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2024-01-01to2024-12-31" id="Fact000563">&lt;p id="xdx_842_eus-gaap--UseOfEstimates_zqYd2kAzJWZ7" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86E_zTnkypDHItge"&gt;Accounting Estimates&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 2.15pt 0 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 2.15pt 0 0"&gt;Management uses estimates and assumptions in preparing these
financial statements in accordance with U.S. GAAP. Those estimates and assumptions affect the reported amounts of assets and liabilities,
the disclosure of contingent assets and liabilities, and the reported revenues and expenses. Actual results could differ from those estimates
and the difference could be material. Significant items subject to such estimates and assumptions include the valuation of stock-based
compensation and prepaid or accrued clinical trial costs.&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000565">&lt;p id="xdx_84F_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zs41NFVAgjWa" style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_862_zBSE7imawy8h"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 2.15pt 0 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 2.15pt 0 0"&gt;The Company maintains its accounts at two financial institutions.
At times throughout the year, the Company&#x2019;s cash balances may exceed amounts insured by the Federal Deposit Insurance Corporation.
At December 31, 2024 and December 31, 2023, the Company had $&lt;span id="xdx_90D_eus-gaap--CashFDICInsuredAmount_iI_c20241231_zKYFJ5FLHDC3" title="Cash equivalents FDIC insured, amount"&gt;22,514,823&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--CashFDICInsuredAmount_iI_c20231231_zdbbCz0ZDuN3" title="Cash equivalents FDIC insured, amount"&gt;30,662,774&lt;/span&gt;, respectively, in business checking accounts and
money market funds that are considered cash equivalents and not insured by the Federal Deposit Insurance Corporation.&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashFDICInsuredAmount
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000567"
      unitRef="USD">22514823</us-gaap:CashFDICInsuredAmount>
    <us-gaap:CashFDICInsuredAmount
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000569"
      unitRef="USD">30662774</us-gaap:CashFDICInsuredAmount>
    <us-gaap:InvestmentPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000571">&lt;p id="xdx_84F_eus-gaap--InvestmentPolicyTextBlock_zZcCsrawuJQe" style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86C_zVP5ib2lPBri"&gt;Investments&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 2.15pt 0 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 2.15pt 0 0"&gt;The Company maintains its investments in U.S. governmental agency
securities and U.S. treasury bills and has classified them as held-to-maturity at the time of purchase. Held-to-maturity purchases are
those securities in which the Company has the ability and intent to hold until maturity. Held-to-maturity securities are recorded at amortized
cost, adjusted for the amortization or accretion of premiums and discounts. Premiums and discounts are amortized or accreted over the
life of the related held-to-maturity security using a straight-line method. The difference between the carrying value, which is based
on cost, and the aggregate fair value of the held-to-maturity securities, was immaterial as of December 31, 2024. At December 31, 2024
and December 31, 2023, the Company had $&lt;span id="xdx_902_eus-gaap--ShortTermInvestments_iI_c20241231_zeScxzKuWOu3" title="Short-term investments"&gt;212,588,960&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--ShortTermInvestments_iI_c20231231_zqV7aaEms22i" title="Short-term investments"&gt;149,919,974&lt;/span&gt;, respectively, of short-term investments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&#160;&lt;/p&gt;

</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:ShortTermInvestments
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000573"
      unitRef="USD">212588960</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000575"
      unitRef="USD">149919974</us-gaap:ShortTermInvestments>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000577">&lt;p id="xdx_84A_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zErkpyNvmfA4" style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_869_zcPUi34VFRg"&gt;Property and Equipment&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 2.15pt 0 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;Property and equipment are stated at cost. Depreciation is provided
over estimated useful lives using the straight-line method. Maintenance and repairs are expensed as incurred; major improvements and betterments
are capitalized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89B_ecustom--ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock_zbXmEHbRuoxi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Estimated useful lives of property and equipment are as follows for the
major classes of assets:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.6in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B2_zvVaDreWGHl2" style="display: none"&gt;Schedule of Estimated Useful Lives of Property and Equipment&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 84%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;Estimated&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 85%; font-weight: bold; text-align: justify"&gt;Asset Description&lt;/td&gt;&lt;td style="padding-bottom: 1pt; width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 14%; font-weight: bold; text-align: center"&gt;Lives&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Furniture and Equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_za2Cizkodqzb" title="Estimated useful lives"&gt;4&lt;/span&gt;-&lt;span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zoToZonzLH2l" title="Estimated useful lives"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Leasehold Improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zwNRQRUPKqkj" title="Estimated useful lives"&gt;2&lt;/span&gt;-&lt;span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zjy5QdetKmE2" title="Estimated useful lives"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_ziLDoGxeSjz5" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.6in"&gt;&#160;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <CELC:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000579">&lt;p id="xdx_89B_ecustom--ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock_zbXmEHbRuoxi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Estimated useful lives of property and equipment are as follows for the
major classes of assets:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.6in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B2_zvVaDreWGHl2" style="display: none"&gt;Schedule of Estimated Useful Lives of Property and Equipment&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 84%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;Estimated&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 85%; font-weight: bold; text-align: justify"&gt;Asset Description&lt;/td&gt;&lt;td style="padding-bottom: 1pt; width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 14%; font-weight: bold; text-align: center"&gt;Lives&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Furniture and Equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_za2Cizkodqzb" title="Estimated useful lives"&gt;4&lt;/span&gt;-&lt;span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zoToZonzLH2l" title="Estimated useful lives"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Leasehold Improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zwNRQRUPKqkj" title="Estimated useful lives"&gt;2&lt;/span&gt;-&lt;span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zjy5QdetKmE2" title="Estimated useful lives"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</CELC:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_srt_MinimumMember_us-gaap_FurnitureAndFixturesMember"
      id="Fact000581">P4Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_srt_MaximumMember_us-gaap_FurnitureAndFixturesMember"
      id="Fact000583">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_srt_MinimumMember_us-gaap_LeaseholdImprovementsMember"
      id="Fact000585">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_srt_MaximumMember_us-gaap_LeaseholdImprovementsMember"
      id="Fact000587">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000589">&lt;p id="xdx_846_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zUrX149Fdpnj" style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_862_zXjBiAbWKt3e"&gt;Long-Lived Assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;Long-lived assets, such as property and equipment, are reviewed for impairment
whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require
a long-lived asset or asset group be tested for possible impairment, the Company first compares undiscounted cash flows expected to be
generated by that asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group is not recoverable
on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying value exceeds its fair value. Fair value
is determined through various valuation techniques including discounted cash flow models, quoted market values, and third-party independent
appraisals, as considered necessary.&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:DeferredChargesPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000591">&lt;p id="xdx_845_eus-gaap--DeferredChargesPolicyTextBlock_zLw1ZX7RHbof" style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_861_zc3C9lJETGe7"&gt;Deferred Transaction Costs&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;Deferred transaction costs primarily consist of legal fees that are capitalized
as incurred and will be offset against the proceeds from future equity financing arrangements. The deferred transaction costs will be
reviewed periodically to assess the probability that future securities will be offered. In the event that no future offering will occur,
any deferred transaction costs will be expensed. Total costs incurred, but not accounted for as a reduction in equity, were $&lt;span id="xdx_902_eus-gaap--DeferredCostsCurrent_iI_c20241231_znLH97VNiqpa" title="Deferred transaction costs"&gt;235,379&lt;/span&gt; and
$&lt;span id="xdx_900_eus-gaap--DeferredCostsCurrent_iI_c20231231_zSoIRAfiqV2" title="Deferred transaction costs"&gt;0&lt;/span&gt; as of December 31, 2024 and 2023, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

</us-gaap:DeferredChargesPolicyTextBlock>
    <us-gaap:DeferredCostsCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000593"
      unitRef="USD">235379</us-gaap:DeferredCostsCurrent>
    <us-gaap:DeferredCostsCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000595"
      unitRef="USD">0</us-gaap:DeferredCostsCurrent>
    <us-gaap:DebtPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000597">&lt;p id="xdx_845_eus-gaap--DebtPolicyTextBlock_zIQrsrmEItuc" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_862_zWjiikqHPfM1"&gt;Debt Issuance Costs&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;The Company recognizes debt issuance costs as deferred costs, which are
capitalized and amortized over the term of the related debt using the effective interest method. These costs primarily consist of fees,
commissions, legal, and other costs directly attributable to securing debt financing. Debt issuance costs are reported as a direct reduction
of the carrying amount of the related debt on the balance sheets. Amortization of these costs is recorded as interest expense in the statements
of operations over the life of the debt instrument.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

</us-gaap:DebtPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000599">&lt;p id="xdx_840_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zFOlTBRBCjeh" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_865_zapig2q36X4b"&gt;Comprehensive Loss&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;Comprehensive loss includes net loss as well as other changes in stockholders&#x2019;
equity that result from transactions and economic events other than those with stockholders. For all periods presented, there was no difference
between net loss and comprehensive loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2024-01-01to2024-12-31" id="Fact000601">&lt;p id="xdx_846_eus-gaap--ConcentrationRiskCreditRisk_zoGHHydaSJ1g" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_860_zimzFr8eXqGb"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;The Company is subject to risks common to companies in the development
stage including, but not limited to, dependency on the clinical and commercial success of its initial drug product, gedatolisib, the ability
to obtain regulatory approval for gedatolisib, the need for substantial additional financing to achieve its goals, uncertainty of broad
adoption of its approved products, if any, by physicians and consumers, and significant competition.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2024-01-01to2024-12-31" id="Fact000603">&lt;p id="xdx_840_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zzWZPOiyddAl" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_860_zVnMYaSQNEed"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 5.75pt 0 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;The Company&#x2019;s accounting for fair value measurements of
assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring or nonrecurring basis
adheres to the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) fair value hierarchy that prioritizes the inputs to valuation
techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical
assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level
3 measurements). The three levels of the fair value hierarchy are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 5.85pt 0 41pt; text-indent: -0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.5in; text-align: left"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level
1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the Company at the measurement
date.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 5.95pt 0 41pt; text-indent: -0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.5in; text-align: left"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level
2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly,
for substantially the full term of the asset or liability.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 5.8pt 0 41pt; text-indent: -0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.5in; text-align: left"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level
3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available,
thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;The level in the fair value hierarchy within which a fair value
measurement in its entirety falls, is based on the lowest level input that is significant to the fair value measurement in its entirety.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 5.95pt 0 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;The carrying values of cash equivalents, accounts payable, accrued
expenses and other financial working capital items approximate fair value at December 31, 2024 and December 31, 2023, due to the short
maturity nature of these items.&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000605">&lt;p id="xdx_845_eus-gaap--IncomeTaxPolicyTextBlock_z8vEUxHWNSgh" style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_866_zgynWj3fZcYb"&gt;Income Taxes&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;The Company accounts for income taxes using the asset and liability method,
as required by the accounting standard for income taxes. Under this method, deferred tax assets and liabilities are recognized for the
future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities
and their respective tax bases, as well as net operating loss and tax credit carryforwards. Deferred taxes are measured using enacted
tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.
The effect on deferred taxes of a change in tax rates is recognized in results of operations in the period that includes the enactment
date. The effects of any future changes in tax laws or rates have not been considered. The Company regularly reviews deferred tax assets
to assess their potential realization and establish a valuation allowance for portions of such assets to reduce the carrying value if
the Company does not consider it to be more likely than not that the deferred tax assets will be realized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;The Company recognizes the impact of an uncertain tax position in its financial
statements if, in management&#x2019;s judgment, the position is more-likely-than-not sustainable upon audit based on the position&#x2019;s
technical merits. This involves the identification of potential uncertain tax positions, the evaluation of applicable tax laws and an
assessment of whether a liability for an uncertain tax position is necessary.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2024-01-01to2024-12-31" id="Fact000607">&lt;p id="xdx_847_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zeKwV8b1dP64" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_866_zBXECk6Wy7Bj"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 2.15pt 0 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 2.15pt 0 0"&gt;The Company&#x2019;s stock-based compensation consists of stock
options and restricted stock issued to certain employees and non-employees of the Company and the Company&#x2019;s 2017 Employee Stock
Purchase Plan. The Company recognizes compensation expense based on an estimated grant date fair value using the Black-Scholes option-pricing
method for equity-based awards and the Monte Carlo simulation model for performance-based awards. If the factors change and different
assumptions are used, the Company&#x2019;s stock-based compensation expense could be materially different in the future. The Company recognizes
stock-based compensation expense for these options on a straight-line basis over the requisite service period. The Company has elected
to account for forfeitures as they occur.&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2024-01-01to2024-12-31" id="Fact000609">&lt;p id="xdx_843_eus-gaap--ResearchAndDevelopmentExpensePolicy_zvGCg70bmtpj" style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_864_z3XHAIp3vYBc"&gt;Research and Development&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;Research and development costs are expensed as incurred. Research and development
costs amounted to $&lt;span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20241231_zxOzlJ7CAvLe" title="Research and development expense"&gt;104,203,230&lt;/span&gt; for the year ended December 31, 2024 and $&lt;span id="xdx_900_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231_zck4ehiBYfJ" title="Research and development expense"&gt;60,594,005&lt;/span&gt; for the year ended December 31, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000611"
      unitRef="USD">104203230</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000613"
      unitRef="USD">60594005</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:InProcessResearchAndDevelopmentPolicy contextRef="From2024-01-01to2024-12-31" id="Fact000615">&lt;p id="xdx_84E_eus-gaap--InProcessResearchAndDevelopmentPolicy_zKtIk5RQdI77" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_862_zcho2GdqM904"&gt;Clinical Trial Costs&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;The Company relies on third parties to conduct
certain aspects of clinical studies and to formulate and manufacture our drug product. While there are alternative vendors that can
perform these functions, any disruption or delay by the Company&#x2019;s current third parties in carrying out their contractual
duties could delay the clinical trials. The Company records prepaid assets or accrued expenses for prepaid or estimated clinical
trial costs conducted by third-party service providers, which includes the conduct of preclinical studies and clinical trials. These
costs can be a significant component of the Company&#x2019;s research and development expenses. The Company primarily relies on a
compilation of progress reports from third-party service providers, including the respective invoicing, to record actual expenses,
along with determining changes to prepaid assets and accrued liabilities. To date, the Company believes utilization of third-party
reports most accurately reflects expenses incurred. With the ongoing VIKTORIA-1 Phase 3 trial and the CELC-G-201 Phase 1b/2 trial,
and the commencement of the VIKTORIA-2 Phase 3 clinical trial site activation and patient enrollment anticipated in Q2 2025&lt;span style="font-size: 10pt"&gt;,&lt;/span&gt;
the Company&#x2019;s estimated expenses in future periods and actual services performed may vary from these estimates, and these
estimates may become more significant. Changes in these estimates that result in material changes to the Company&#x2019;s prepaid
assets or accrued expenses could materially affect the Company&#x2019;s results of operations and financial position.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

</us-gaap:InProcessResearchAndDevelopmentPolicy>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000617">&lt;p id="xdx_841_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zASjcBnZart7" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_867_zAWp6ew8cnbi"&gt;Segment Data&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;In November 2023, the FASB issued ASU 2023-07: Improvements to Reportable
Segment Disclosures. This ASU, which amends Topic 280: &lt;i&gt;Segment Reporting,&lt;/i&gt; improves disclosure requirements for reportable segments
and enhances disclosures for companies with single reportable segments. The Company has a single reportable segment based on the nature
of its operations. The nature of business and the accounting policies of the segment are the same as described throughout Notes 1 and
2. The Company&#x2019;s Chief Operating Decision Maker (&#x201c;CODM&#x201d;) is its executive team. The CODM assesses the reportable segment&#x2019;s performance
and allocates resources for the reportable segment based on net income and total assets, which are the same amounts in all material respects
as those reported on the statements of operations and balance sheets. The Company adopted the standard on January 1, 2024. The adoption
did not have a material impact on the Company&#x2019;s financial statements.&lt;/p&gt;

</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000619">&lt;p id="xdx_80C_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_z0ZFGxAR4GLj" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt; &lt;b&gt;3.&lt;/b&gt; &lt;b&gt;&lt;span id="xdx_822_zLpUqUXslu48"&gt;Liquidity&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;Based on the Company&#x2019;s cash and cash equivalents and short-term investments
on hand at December 31, 2024 of $&lt;span id="xdx_900_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20241231_zRw1Bj5a73Aj" title="Cash and cash equivalents"&gt;22,514,823&lt;/span&gt; and $&lt;span id="xdx_902_eus-gaap--ShortTermInvestments_iI_c20241231_zf8nTGzmfy1d" title="Short-term investments"&gt;212,588,960&lt;/span&gt;, respectively, the Company believes that its cash and short-term investments
will be sufficient to fund the Company&#x2019;s current operating plan through at least the next 12 months from the issuance date of this
Annual Report.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000621"
      unitRef="USD">22514823</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000623"
      unitRef="USD">212588960</us-gaap:ShortTermInvestments>
    <us-gaap:EarningsPerShareTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000625">&lt;p id="xdx_808_eus-gaap--EarningsPerShareTextBlock_ztLssPXQLrA5" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt; &lt;b&gt;4.&lt;/b&gt; &lt;b&gt;&lt;span id="xdx_82C_zPsfjWKgtLxh"&gt;Net Loss Per Common Share&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;Basic and diluted net loss per common share is determined by dividing net
loss attributable to common stockholders by the weighted-average common shares outstanding during the period. For all periods presented,
the common shares underlying the preferred stock, options, warrants, and restricted stock have been excluded from the calculation because
their effect would be anti-dilutive. Therefore, the weighted-average shares outstanding used to calculate both basic and diluted loss
per common share are the same.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zCuI9maWij26" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table summarizes the potentially-dilutive shares excluded
from the diluted weighted-average shares outstanding:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B2_zsg6iauW7oD" style="display: none"&gt;Schedule of Potentially-Dilutive Shares Excluded from the Diluted Weighted-Average Shares Outstanding&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20240101__20241231_zofYC9DpIg31" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20230101__20231231_zPlGbIJe3Srk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--EarningsPerShareDilutedOtherDisclosuresAbstract_iB_zK5U31WUGCoh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Potentially-dilutive shares excluded from diluted weighted-average shares outstanding:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--StatementEquityComponentsAxis__custom--PreferredStockOnAnAsIfConvertedToCommonStockMember_zfg4f3aaJtE8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 68%; text-align: justify; text-indent: 0pt; padding-left: 20pt"&gt;Preferred stock on an as-if-converted to common stock&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;3,175,770&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;8,541,340&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsToPurchaseCommonStockMember_zvdpJd90xmai" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: 0pt; padding-left: 20pt"&gt;Options to purchase common stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,306,977&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,815,392&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseCommonStockMember_zJErXOX8mBe3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; text-indent: 0pt; padding-left: 20pt"&gt;Warrants to purchase common stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,521,152&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,263,733&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_zQ1WuGg1Brne" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 0pt; text-indent: 0pt; padding-left: 20pt"&gt;Restricted common stock&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,079&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,958&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zxL8MHByRdU7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 0pt; text-indent: 0pt; padding-left: 10pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;13,004,978&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;18,622,423&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_z2UeiMuqyUJd" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 0pt; text-indent: 0pt; padding-left: 10pt"&gt;Anti-dilutive securities excluded from
    diluted weighted- average shares outstanding&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;13,004,978&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;18,622,423&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p id="xdx_8AC_zZQ7HsPeDVT2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;Pre-funded warrant shares of &lt;span id="xdx_90C_ecustom--PrefundedWarrantShares_iI_c20241231_zJYxKIAPfTj6" title="Pre-funded warrant shares"&gt;&lt;span id="xdx_907_ecustom--PrefundedWarrantShares_iI_c20231231_zpkA2iVop4qg" title="Pre-funded warrant shares"&gt;5,747,787&lt;/span&gt;&lt;/span&gt; are included in the computation
of basic and diluted net loss per share for the years ended December 31, 2024 and 2023, as the pre-funded warrants are issuable for nominal
consideration.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000627">&lt;p id="xdx_895_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zCuI9maWij26" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table summarizes the potentially-dilutive shares excluded
from the diluted weighted-average shares outstanding:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B2_zsg6iauW7oD" style="display: none"&gt;Schedule of Potentially-Dilutive Shares Excluded from the Diluted Weighted-Average Shares Outstanding&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20240101__20241231_zofYC9DpIg31" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20230101__20231231_zPlGbIJe3Srk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--EarningsPerShareDilutedOtherDisclosuresAbstract_iB_zK5U31WUGCoh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Potentially-dilutive shares excluded from diluted weighted-average shares outstanding:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--StatementEquityComponentsAxis__custom--PreferredStockOnAnAsIfConvertedToCommonStockMember_zfg4f3aaJtE8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 68%; text-align: justify; text-indent: 0pt; padding-left: 20pt"&gt;Preferred stock on an as-if-converted to common stock&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;3,175,770&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;8,541,340&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsToPurchaseCommonStockMember_zvdpJd90xmai" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: 0pt; padding-left: 20pt"&gt;Options to purchase common stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,306,977&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,815,392&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseCommonStockMember_zJErXOX8mBe3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; text-indent: 0pt; padding-left: 20pt"&gt;Warrants to purchase common stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,521,152&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,263,733&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_zQ1WuGg1Brne" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 0pt; text-indent: 0pt; padding-left: 20pt"&gt;Restricted common stock&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,079&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,958&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zxL8MHByRdU7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 0pt; text-indent: 0pt; padding-left: 10pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;13,004,978&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;18,622,423&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_z2UeiMuqyUJd" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 0pt; text-indent: 0pt; padding-left: 10pt"&gt;Anti-dilutive securities excluded from
    diluted weighted- average shares outstanding&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;13,004,978&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;18,622,423&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_custom_PreferredStockOnAnAsIfConvertedToCommonStockMember"
      decimals="INF"
      id="Fact000632"
      unitRef="Shares">3175770</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_custom_PreferredStockOnAnAsIfConvertedToCommonStockMember"
      decimals="INF"
      id="Fact000633"
      unitRef="Shares">8541340</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_custom_OptionsToPurchaseCommonStockMember"
      decimals="INF"
      id="Fact000635"
      unitRef="Shares">4306977</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_custom_OptionsToPurchaseCommonStockMember"
      decimals="INF"
      id="Fact000636"
      unitRef="Shares">2815392</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_custom_WarrantsToPurchaseCommonStockMember"
      decimals="INF"
      id="Fact000638"
      unitRef="Shares">5521152</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_custom_WarrantsToPurchaseCommonStockMember"
      decimals="INF"
      id="Fact000639"
      unitRef="Shares">7263733</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="Fact000641"
      unitRef="Shares">1079</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="Fact000642"
      unitRef="Shares">1958</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000644"
      unitRef="Shares">13004978</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000645"
      unitRef="Shares">18622423</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000647"
      unitRef="Shares">13004978</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000648"
      unitRef="Shares">18622423</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <CELC:PrefundedWarrantShares
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000650"
      unitRef="Shares">5747787</CELC:PrefundedWarrantShares>
    <CELC:PrefundedWarrantShares
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000652"
      unitRef="Shares">5747787</CELC:PrefundedWarrantShares>
    <us-gaap:InvestmentTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000654">&lt;p id="xdx_80F_eus-gaap--InvestmentTextBlock_zfn6QW5wgbd1" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt; &lt;b&gt;5.&lt;/b&gt; &lt;b&gt;&lt;span id="xdx_822_zFpVbHn6lS2"&gt;Investments&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--InvestmentTableTextBlock_zCCqsRWlGsz4" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;The following table summarizes the Company&#x2019;s held-to-maturity investment
securities at amortized cost as of December 31, 2024 and 2023:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B1_zjh6YZbQciIj" style="display: none"&gt;Schedule of Investment&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_48F_eus-gaap--HeldToMaturitySecurities_iI_zY95Wjuj9ZT9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Amortized Cost, as Adjusted&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_489_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_iI_zDtVvdKS6E7j" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Gross Unrealized Holding Gains&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_48C_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_iI_zzFiqM32a51g" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Gross Unrealized Holding Losses&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_482_eus-gaap--HeldToMaturitySecuritiesFairValue_iI_zzI3b8XK0XTj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Estimated Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Amortized Cost, as Adjusted&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Gross Unrealized Holding Gains&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Gross Unrealized Holding Losses&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Estimated Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_412_20241231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zLcyrLP42a6c" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: justify; padding-bottom: 1pt; text-indent: 0pt"&gt;U.S. Treasury Bills&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;212,588,960&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;82,251&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0659"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;212,671,211&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41D_20241231_zYVPzrbFP6sh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt; text-indent: 0pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;212,588,960&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;82,251&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0663"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;212,671,211&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_48F_eus-gaap--HeldToMaturitySecurities_iI_zQN0gpxq8gjk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Amortized Cost, as Adjusted&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_48D_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_iI_zmcNOsJuEX0d" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Gross Unrealized Holding Gains&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_489_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_iI_zoua8HzmLeGd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Gross Unrealized Holding Losses&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_487_eus-gaap--HeldToMaturitySecuritiesFairValue_iI_zeXoWJsBIjm6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Estimated Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Amortized Cost, as Adjusted&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Gross Unrealized Holding Gains&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Gross Unrealized Holding Losses&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Estimated Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41D_20231231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zSaeWsAUrXNe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: justify; padding-bottom: 1pt; text-indent: 0pt"&gt;U.S. Treasury Bills&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;149,919,974&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;30,995&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0667"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;149,950,969&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_419_20231231_zbU8GJk04tyf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt; text-indent: 0pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;149,919,974&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;30,995&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0671"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;149,950,969&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zwHyF3yoQHrc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;The fair value of the Company&#x2019;s held-to-maturity debt securities
is determined based upon inputs, other than the quoted prices in active markets, that are observable either directly or indirectly, and
are classified as Level 2 fair value instruments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

</us-gaap:InvestmentTextBlock>
    <us-gaap:InvestmentTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000656">&lt;p id="xdx_89F_eus-gaap--InvestmentTableTextBlock_zCCqsRWlGsz4" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;The following table summarizes the Company&#x2019;s held-to-maturity investment
securities at amortized cost as of December 31, 2024 and 2023:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B1_zjh6YZbQciIj" style="display: none"&gt;Schedule of Investment&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_48F_eus-gaap--HeldToMaturitySecurities_iI_zY95Wjuj9ZT9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Amortized Cost, as Adjusted&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_489_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_iI_zDtVvdKS6E7j" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Gross Unrealized Holding Gains&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_48C_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_iI_zzFiqM32a51g" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Gross Unrealized Holding Losses&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_482_eus-gaap--HeldToMaturitySecuritiesFairValue_iI_zzI3b8XK0XTj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Estimated Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Amortized Cost, as Adjusted&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Gross Unrealized Holding Gains&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Gross Unrealized Holding Losses&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Estimated Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_412_20241231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zLcyrLP42a6c" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: justify; padding-bottom: 1pt; text-indent: 0pt"&gt;U.S. Treasury Bills&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;212,588,960&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;82,251&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0659"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;212,671,211&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41D_20241231_zYVPzrbFP6sh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt; text-indent: 0pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;212,588,960&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;82,251&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0663"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;212,671,211&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_48F_eus-gaap--HeldToMaturitySecurities_iI_zQN0gpxq8gjk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Amortized Cost, as Adjusted&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_48D_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_iI_zmcNOsJuEX0d" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Gross Unrealized Holding Gains&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_489_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_iI_zoua8HzmLeGd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Gross Unrealized Holding Losses&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_487_eus-gaap--HeldToMaturitySecuritiesFairValue_iI_zeXoWJsBIjm6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Estimated Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Amortized Cost, as Adjusted&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Gross Unrealized Holding Gains&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Gross Unrealized Holding Losses&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Estimated Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41D_20231231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zSaeWsAUrXNe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: justify; padding-bottom: 1pt; text-indent: 0pt"&gt;U.S. Treasury Bills&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;149,919,974&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;30,995&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0667"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;149,950,969&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_419_20231231_zbU8GJk04tyf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt; text-indent: 0pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;149,919,974&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;30,995&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0671"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;149,950,969&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:InvestmentTableTextBlock>
    <us-gaap:HeldToMaturitySecurities
      contextRef="AsOf2024-12-31_us-gaap_USTreasurySecuritiesMember"
      decimals="0"
      id="Fact000657"
      unitRef="USD">212588960</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="AsOf2024-12-31_us-gaap_USTreasurySecuritiesMember"
      decimals="0"
      id="Fact000658"
      unitRef="USD">82251</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="AsOf2024-12-31_us-gaap_USTreasurySecuritiesMember"
      decimals="0"
      id="Fact000660"
      unitRef="USD">212671211</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecurities
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000661"
      unitRef="USD">212588960</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000662"
      unitRef="USD">82251</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000664"
      unitRef="USD">212671211</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecurities
      contextRef="AsOf2023-12-31_us-gaap_USTreasurySecuritiesMember"
      decimals="0"
      id="Fact000665"
      unitRef="USD">149919974</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="AsOf2023-12-31_us-gaap_USTreasurySecuritiesMember"
      decimals="0"
      id="Fact000666"
      unitRef="USD">30995</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="AsOf2023-12-31_us-gaap_USTreasurySecuritiesMember"
      decimals="0"
      id="Fact000668"
      unitRef="USD">149950969</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecurities
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000669"
      unitRef="USD">149919974</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000670"
      unitRef="USD">30995</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000672"
      unitRef="USD">149950969</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:OtherCurrentAssetsTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000674">&lt;p id="xdx_802_eus-gaap--OtherCurrentAssetsTextBlock_z90pEKHcg1m2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt; &lt;b&gt;6.&lt;/b&gt; &lt;b&gt;&lt;span id="xdx_823_z5Xy4NBhlHo"&gt;Other Current Assets&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--ScheduleOfOtherCurrentAssetsTableTextBlock_zL9Ky7RnXgpg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Other current assets consisted of the following at
December 31:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B4_z25EpmOVAL45" style="display: none"&gt;Schedule of Other Current Assets&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20241231_zVoI33oyf2Qc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20231231_zzvMBVr3J0x9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--PrepaidExpenseAndOtherAssetsCurrentAbstract_iB_zLjAY6e2KQIa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Current:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--PrepaidClinicalTrialCosts_iI_maOACz5EC_maOACzcDD_zrZR1MIwztZ7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 70%; text-align: justify"&gt;Prepaid clinical trial costs&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;6,768,668&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;8,763,150&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--MiscellaneousReceivable_iI_maOACz5EC_maOACzcDD_zgMqnqJOdguc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Miscellaneous receivable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,600,621&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;805,882&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--PrepaidInsurance_iI_maOACz5EC_maOACzcDD_ziST3dg7Mh91" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Directors &amp;amp; officers&#x2019; insurance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;256,629&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;157,453&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--OtherPrepaidExpenseCurrent_iI_maOACz5EC_maOACzcDD_zCAHir9ln44e" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;841,329&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;281,364&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OtherAssetsCurrent_iTI_mtOACz5EC_mtOACzcDD_zg52Bfkt2t9a" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt; text-indent: 10pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;9,467,247&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;10,007,849&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_zkFuD3XDj5sa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

</us-gaap:OtherCurrentAssetsTextBlock>
    <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000676">&lt;p id="xdx_894_eus-gaap--ScheduleOfOtherCurrentAssetsTableTextBlock_zL9Ky7RnXgpg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Other current assets consisted of the following at
December 31:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B4_z25EpmOVAL45" style="display: none"&gt;Schedule of Other Current Assets&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20241231_zVoI33oyf2Qc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20231231_zzvMBVr3J0x9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--PrepaidExpenseAndOtherAssetsCurrentAbstract_iB_zLjAY6e2KQIa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Current:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--PrepaidClinicalTrialCosts_iI_maOACz5EC_maOACzcDD_zrZR1MIwztZ7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 70%; text-align: justify"&gt;Prepaid clinical trial costs&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;6,768,668&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;8,763,150&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--MiscellaneousReceivable_iI_maOACz5EC_maOACzcDD_zgMqnqJOdguc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Miscellaneous receivable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,600,621&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;805,882&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--PrepaidInsurance_iI_maOACz5EC_maOACzcDD_ziST3dg7Mh91" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Directors &amp;amp; officers&#x2019; insurance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;256,629&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;157,453&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--OtherPrepaidExpenseCurrent_iI_maOACz5EC_maOACzcDD_zCAHir9ln44e" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;841,329&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;281,364&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OtherAssetsCurrent_iTI_mtOACz5EC_mtOACzcDD_zg52Bfkt2t9a" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt; text-indent: 10pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;9,467,247&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;10,007,849&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
    <CELC:PrepaidClinicalTrialCosts
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000681"
      unitRef="USD">6768668</CELC:PrepaidClinicalTrialCosts>
    <CELC:PrepaidClinicalTrialCosts
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000682"
      unitRef="USD">8763150</CELC:PrepaidClinicalTrialCosts>
    <CELC:MiscellaneousReceivable
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000684"
      unitRef="USD">1600621</CELC:MiscellaneousReceivable>
    <CELC:MiscellaneousReceivable
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000685"
      unitRef="USD">805882</CELC:MiscellaneousReceivable>
    <us-gaap:PrepaidInsurance
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000687"
      unitRef="USD">256629</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000688"
      unitRef="USD">157453</us-gaap:PrepaidInsurance>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000690"
      unitRef="USD">841329</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000691"
      unitRef="USD">281364</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000693"
      unitRef="USD">9467247</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000694"
      unitRef="USD">10007849</us-gaap:OtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000696">&lt;p id="xdx_802_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zM8LlpPMpLIi" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt; &lt;b&gt;7.&lt;/b&gt; &lt;b&gt;&lt;span id="xdx_822_zwIPC0KzkEof"&gt;Property and Equipment&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--PropertyPlantAndEquipmentTextBlock_zjOntXtkfmah" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Property and equipment consisted of the following
at December 31:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B2_zbRUXA1exdqi" style="display: none"&gt;Summary of Property and Equipment&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20241231_zWj4eYpg8fQg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20231231_zrJj7qrX1pE3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zQPkm78BcDr" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%; text-align: justify"&gt;Furniture and equipment&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;2,025,875&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;1,788,195&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zfceKsZ0katd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;302,577&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;302,577&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzGp4_zUcwYof0nbwg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property and equipment, Gross&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,328,452&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,090,772&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzGp4_zxNtpWD73oi5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Less: Accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,991,937&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,861,990&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzGp4_zSksBfWIeGEh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt; text-indent: 10pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;336,515&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;228,782&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zeJmzC3fp6o5" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0in"&gt;&lt;span style="font-weight: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0in"&gt;&lt;span style="font-weight: normal"&gt;Depreciation expense
was $&lt;span id="xdx_901_eus-gaap--Depreciation_c20240101__20241231_zQhBxC99Wyy1" title="Depreciation expense"&gt;129,947&lt;/span&gt; and $&lt;span id="xdx_90F_eus-gaap--Depreciation_c20230101__20231231_zYqgbosfs3d5" title="Depreciation expense"&gt;142,772&lt;/span&gt; for the years ended December 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0in"&gt;&lt;span style="font-weight: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000698">&lt;p id="xdx_895_eus-gaap--PropertyPlantAndEquipmentTextBlock_zjOntXtkfmah" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Property and equipment consisted of the following
at December 31:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B2_zbRUXA1exdqi" style="display: none"&gt;Summary of Property and Equipment&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20241231_zWj4eYpg8fQg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20231231_zrJj7qrX1pE3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zQPkm78BcDr" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%; text-align: justify"&gt;Furniture and equipment&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;2,025,875&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;1,788,195&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zfceKsZ0katd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;302,577&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;302,577&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzGp4_zUcwYof0nbwg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property and equipment, Gross&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,328,452&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,090,772&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzGp4_zxNtpWD73oi5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Less: Accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,991,937&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,861,990&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzGp4_zSksBfWIeGEh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt; text-indent: 10pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;336,515&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;228,782&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31_us-gaap_FurnitureAndFixturesMember"
      decimals="0"
      id="Fact000700"
      unitRef="USD">2025875</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31_us-gaap_FurnitureAndFixturesMember"
      decimals="0"
      id="Fact000701"
      unitRef="USD">1788195</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember"
      decimals="0"
      id="Fact000703"
      unitRef="USD">302577</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31_us-gaap_LeaseholdImprovementsMember"
      decimals="0"
      id="Fact000704"
      unitRef="USD">302577</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000706"
      unitRef="USD">2328452</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000707"
      unitRef="USD">2090772</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000709"
      unitRef="USD">1991937</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000710"
      unitRef="USD">1861990</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000712"
      unitRef="USD">336515</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000713"
      unitRef="USD">228782</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000715"
      unitRef="USD">129947</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000717"
      unitRef="USD">142772</us-gaap:Depreciation>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000719">&lt;p id="xdx_80A_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_ziPJdj5s7qcg" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt; &lt;b&gt;8.&lt;/b&gt; &lt;b&gt;&lt;span id="xdx_821_zucYWNR76scc"&gt;Accrued Expenses&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zErn4kMaNMrd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Accrued expenses consisted of the following at December
31:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B9_zyjmZEJcNGpa" style="display: none"&gt;Schedule of Accrued Expenses&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20241231_zl2ZIfBfvp8h" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20231231_zh5dZYKsqVf3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--AccruedClinicalTrialExpense_iI_maALCzp59_z7oRfzlBSGBa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%; text-align: justify"&gt;Clinical trial costs&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;16,708,499&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;6,464,772&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--WorkersCompensationLiabilityCurrent_iI_maALCzp59_zkOBO8hhZ2P4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Accrued compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,987,786&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,763,316&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--OtherAccruedLiabilitiesCurrentAndNoncurrent_iI_maALCzp59_z0cp9ECn6pQ2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,384,803&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;641,512&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AccruedEmployeeBenefitsCurrent_iI_maALCzp59_zb9wHpWbxTpj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Employee stock purchase plan&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;103,860&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;57,494&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCzp59_zHV3x8o5H9pg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt; text-indent: 10pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;22,184,948&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;8,927,094&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zsNaltowHbTk" style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0in"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;b&gt;&#160;&#160;&lt;/b&gt;&lt;/p&gt;

</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000721">&lt;p id="xdx_896_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zErn4kMaNMrd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Accrued expenses consisted of the following at December
31:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B9_zyjmZEJcNGpa" style="display: none"&gt;Schedule of Accrued Expenses&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20241231_zl2ZIfBfvp8h" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20231231_zh5dZYKsqVf3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--AccruedClinicalTrialExpense_iI_maALCzp59_z7oRfzlBSGBa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%; text-align: justify"&gt;Clinical trial costs&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;16,708,499&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;6,464,772&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--WorkersCompensationLiabilityCurrent_iI_maALCzp59_zkOBO8hhZ2P4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Accrued compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,987,786&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,763,316&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--OtherAccruedLiabilitiesCurrentAndNoncurrent_iI_maALCzp59_z0cp9ECn6pQ2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,384,803&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;641,512&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AccruedEmployeeBenefitsCurrent_iI_maALCzp59_zb9wHpWbxTpj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Employee stock purchase plan&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;103,860&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;57,494&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCzp59_zHV3x8o5H9pg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt; text-indent: 10pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;22,184,948&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;8,927,094&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <CELC:AccruedClinicalTrialExpense
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000723"
      unitRef="USD">16708499</CELC:AccruedClinicalTrialExpense>
    <CELC:AccruedClinicalTrialExpense
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000724"
      unitRef="USD">6464772</CELC:AccruedClinicalTrialExpense>
    <us-gaap:WorkersCompensationLiabilityCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000726"
      unitRef="USD">3987786</us-gaap:WorkersCompensationLiabilityCurrent>
    <us-gaap:WorkersCompensationLiabilityCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000727"
      unitRef="USD">1763316</us-gaap:WorkersCompensationLiabilityCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000729"
      unitRef="USD">1384803</us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000730"
      unitRef="USD">641512</us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000732"
      unitRef="USD">103860</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000733"
      unitRef="USD">57494</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000735"
      unitRef="USD">22184948</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000736"
      unitRef="USD">8927094</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:CommitmentsDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000738">&lt;p id="xdx_80A_eus-gaap--CommitmentsDisclosureTextBlock_zqHIgLYt2X65" style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt; 9. &lt;span id="xdx_829_zwaUruN7uOv2"&gt;Commitments&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 19.8pt; text-indent: -19.8pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 19.8pt; text-indent: -19.8pt"&gt;&lt;span style="text-decoration: underline"&gt;Operating and Finance Leases&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company leases its corporate space in Minneapolis,
Minnesota, with an operating lease in place through April 30, 2026. The lease provides for monthly rent, real estate taxes, and operating
expenses. Rent expense is recorded on a straight-line basis over the lease term. In March 2023, the Company signed the fourth amendment
to extend this lease through April 30, 2026. This amendment provides for monthly rent, real estate taxes and operating expenses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 2.15pt 0 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 2.15pt 0 0"&gt;In May 2018, the Company entered into a non-cancelable finance
lease agreement for office equipment with a five-year term. The underlying assets are included in furniture and equipment. The lease contains
a bargain purchase option at the end of the lease. The finance lease expired in May 2023 and the equipment was acquired for the bargain
purchase option price.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 2.15pt 0 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 2.15pt 0 0"&gt;When an implicit rate is not provided, the Company uses its
incremental borrowing rate based on the information available at the lease commencement date in determining the present value of the lease
payments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_895_esrt--ScheduleOfCondensedBalanceSheetTableTextBlock_zuQPu1QXBhwi" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;Supplemental balance sheet information consisted of the following at December
31, 2024:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BE_zw3HBbzqg8w2" style="display: none"&gt;Schedule of Supplemental Balance Sheet Information Related to Leases&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20241231_zT5RGc8NWm4i" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--LesseeOperatingLeaseDescriptionAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Operating Lease&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_zYQVceoYWCU9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 85%; text-align: justify; text-indent: 10pt"&gt;Right-of-use assets&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;215,502&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--OperatingLeaseLiability_iI_pp0p0_zqUIZyHNsvma" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Operating lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;225,921&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_pp0p0_di_z5q7RAlD6Jv6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt; text-indent: 10pt"&gt;Less: short term portion&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(171,952&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt; text-indent: 10pt"&gt;Long term portion&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;53,969&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_zIoqi1yE0MD" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&#160;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zzBGTQLd23i6" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;Maturity analysis under lease agreements consisted of the following as
of December 31, 2024:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B6_zXuYNHI4W3Af" style="display: none"&gt;Schedule of Maturity Analysis Under Lease Agreements&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20241231_zDYLnRejo5O3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Operating Leases&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzXrd_zrlJrxLp6Y" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 85%; text-align: justify"&gt;2025&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;220,389&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzXrd_zVnagI2JM905" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;74,170&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzXrd_zobhmhwBJj9g" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt; text-indent: 10pt"&gt;Total minimum lease payments&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;294,559&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zuqyqXxybD88" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt; text-indent: 10pt"&gt;Less: Present value discount&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(68,638&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--OperatingLeaseLiability_iI_zEXjJaN3t6Nh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt; text-indent: 10pt"&gt;Present value of net minimum lease payments&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;225,921&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;Weighted Average&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Remaining Lease Term&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Discount Rate&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; width: 70%; text-align: justify"&gt;Operating lease&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&#160;&lt;span id="xdx_903_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20241231_zXNR8NJKHJM2" title="Operating leases, remaining lease term"&gt;1.3&lt;/span&gt; years&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20241231_zYOM30IiwEf6" title="Operating leases, discount rate"&gt;10.5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8AE_zAQnpZs3RsI9" style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--LeaseCostTableTextBlock_zQqx8BBfFLxi" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;Lease costs for the period ended December 31:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;



&lt;p style="margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BE_ztIUpipt8P0d" style="display: none"&gt;Schedule of Lease Costs&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt; width: 70%"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_498_20240101__20241231_z69Lp53vEyD4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; width: 12%"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49A_20230101__20231231_zXZfNMCMdLtg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; width: 12%"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--OperatingLeaseCost_maLCzXSJ_maLCzphc_zWFKr6cRbmY7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: 10pt"&gt;Operating lease cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;213,104&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;212,238&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--FinanceLeaseCostAbstract_iB_zAH1tDujDzwa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; text-indent: 10pt"&gt;Finance lease cost:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_i01_pp0p0_maLCzXSJ_maLCzphc_z20xoyVtRiyd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify; text-indent: 10pt"&gt;Amortization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0776"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,411&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--FinanceLeaseInterestExpense_i01_pp0p0_maLCzXSJ_maLCzphc_zmNVG91Je0i9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify; text-indent: 10pt"&gt;Interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0779"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--VariableLeaseCost_pp0p0_maLCzXSJ_maLCzphc_zPL8DHsVukc2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt; text-indent: 10pt"&gt;Variable lease cost&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;111,246&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;101,957&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--LeaseCost_iT_pp0p0_mtLCzphc_z3QzfXkEUPq4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;Lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;324,350&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;316,610&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_zEDcf5xIIusl" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_zB9UJmmc6PJc" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;Supplemental cash flow information related to leases for the period ended December 31:&lt;/p&gt;



&lt;p style="margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B8_zV76IQ6kDx15" style="display: none"&gt;Schedule of Supplemental Cash Flow Information Related to Leases&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20240101__20241231_zacNrvbFYyT" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20230101__20231231_zxZ1MztQsrH5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--CashPaidForOperatingAndFinanceLeasesAbstract_iB_z3T0lMG9DfWk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Cash paid for amounts included in operating and finance leases:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--OperatingLeasePayments_i01_pp0p0_maCPFOAzLxF_zT8id1pwmdac" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 70%; text-align: justify; text-indent: 10pt"&gt;Operating cash outflow from operating leases&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;324,783&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;308,914&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--FinanceLeaseInterestPaymentOnLiability_i01_pp0p0_maCPFOAzLxF_zDLaW6oH5lYg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: 10pt"&gt;Operating cash outflow from finance leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0796"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--FinanceLeasePrincipalPayments_i01_pp0p0_maCPFOAzLxF_zhJwihAQWkdi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt; text-indent: 10pt"&gt;Financing cash outflow from finance leases&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0799"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,449&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--CashPaidForOperatingAndFinanceLeases_i01T_pp0p0_mtCPFOAzLxF_zodVNHNWeyx3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total cash paid for amounts
    included in operating and finance leases&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;324,783&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;311,367&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_zqcdOdtzXxkj" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;b&gt;&#160;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Clinical Research Studies&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;The Company enters into contracts in the normal course of business to conduct
research and development programs internally and through third parties that include, among others, arrangements with vendors, consultants,
CMOs, and CROs. The Company has a license agreement in place with Pfizer to research, develop, manufacture and commercialize gedatolisib.
In conjunction with the license agreement, the Company completed a Phase 1b clinical trial &#x2013; B2151009 related to gedatolisib. These
patients subsequently transitioned to an Expanded Access study &#x2013; CELC-G-001. Contracts related to the Expanded Access study are
generally based on time and material. In addition, contracts related to the Company&#x2019;s Phase 3 clinical studies (VIKTORIA-1 and VIKTORIA-2)
and the Phase 1b/2 clinical trial (CELC-G-201) are generally cancelable with reasonable notice within 120 days and the Company&#x2019;s
obligations under these contracts are primarily based on services performed through termination dates plus certain cancelation charges,
if any, as defined in each of the respective agreements. In addition, these agreements may, from time to time, be subjected to amendments
as a result of any change orders executed by the parties. As of December 31, 2024, the Company had five material non-cancelable contractual
commitments with respect to these arrangements, which totaled approximately $&lt;span id="xdx_90F_eus-gaap--ContractualObligation_iI_pn5n6_c20241231_zShRqHtvWBG8" title="Non-cancelable contractual commitment"&gt;9.7&lt;/span&gt; million.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:CommitmentsDisclosureTextBlock>
    <srt:ScheduleOfCondensedBalanceSheetTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000740">&lt;p id="xdx_895_esrt--ScheduleOfCondensedBalanceSheetTableTextBlock_zuQPu1QXBhwi" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;Supplemental balance sheet information consisted of the following at December
31, 2024:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BE_zw3HBbzqg8w2" style="display: none"&gt;Schedule of Supplemental Balance Sheet Information Related to Leases&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20241231_zT5RGc8NWm4i" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--LesseeOperatingLeaseDescriptionAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Operating Lease&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_zYQVceoYWCU9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 85%; text-align: justify; text-indent: 10pt"&gt;Right-of-use assets&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;215,502&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--OperatingLeaseLiability_iI_pp0p0_zqUIZyHNsvma" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Operating lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;225,921&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_pp0p0_di_z5q7RAlD6Jv6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt; text-indent: 10pt"&gt;Less: short term portion&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(171,952&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt; text-indent: 10pt"&gt;Long term portion&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;53,969&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</srt:ScheduleOfCondensedBalanceSheetTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000744"
      unitRef="USD">215502</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000746"
      unitRef="USD">225921</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000748"
      unitRef="USD">171952</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000750"
      unitRef="USD">53969</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000752">&lt;p id="xdx_890_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zzBGTQLd23i6" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;Maturity analysis under lease agreements consisted of the following as
of December 31, 2024:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B6_zXuYNHI4W3Af" style="display: none"&gt;Schedule of Maturity Analysis Under Lease Agreements&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20241231_zDYLnRejo5O3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Operating Leases&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzXrd_zrlJrxLp6Y" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 85%; text-align: justify"&gt;2025&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;220,389&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzXrd_zVnagI2JM905" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;74,170&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzXrd_zobhmhwBJj9g" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt; text-indent: 10pt"&gt;Total minimum lease payments&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;294,559&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zuqyqXxybD88" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt; text-indent: 10pt"&gt;Less: Present value discount&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(68,638&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--OperatingLeaseLiability_iI_zEXjJaN3t6Nh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt; text-indent: 10pt"&gt;Present value of net minimum lease payments&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;225,921&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;Weighted Average&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Remaining Lease Term&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Discount Rate&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; width: 70%; text-align: justify"&gt;Operating lease&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&#160;&lt;span id="xdx_903_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20241231_zXNR8NJKHJM2" title="Operating leases, remaining lease term"&gt;1.3&lt;/span&gt; years&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20241231_zYOM30IiwEf6" title="Operating leases, discount rate"&gt;10.5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000754"
      unitRef="USD">220389</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000756"
      unitRef="USD">74170</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000758"
      unitRef="USD">294559</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000760"
      unitRef="USD">68638</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000762"
      unitRef="USD">225921</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2024-12-31" id="Fact000764">P1Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000766"
      unitRef="Pure">0.105</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LeaseCostTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000768">&lt;p id="xdx_89C_eus-gaap--LeaseCostTableTextBlock_zQqx8BBfFLxi" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;Lease costs for the period ended December 31:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;



&lt;p style="margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BE_ztIUpipt8P0d" style="display: none"&gt;Schedule of Lease Costs&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt; width: 70%"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_498_20240101__20241231_z69Lp53vEyD4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; width: 12%"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49A_20230101__20231231_zXZfNMCMdLtg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; width: 12%"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--OperatingLeaseCost_maLCzXSJ_maLCzphc_zWFKr6cRbmY7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: 10pt"&gt;Operating lease cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;213,104&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;212,238&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--FinanceLeaseCostAbstract_iB_zAH1tDujDzwa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; text-indent: 10pt"&gt;Finance lease cost:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_i01_pp0p0_maLCzXSJ_maLCzphc_z20xoyVtRiyd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify; text-indent: 10pt"&gt;Amortization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0776"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,411&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--FinanceLeaseInterestExpense_i01_pp0p0_maLCzXSJ_maLCzphc_zmNVG91Je0i9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify; text-indent: 10pt"&gt;Interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0779"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--VariableLeaseCost_pp0p0_maLCzXSJ_maLCzphc_zPL8DHsVukc2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt; text-indent: 10pt"&gt;Variable lease cost&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;111,246&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;101,957&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--LeaseCost_iT_pp0p0_mtLCzphc_z3QzfXkEUPq4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;Lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;324,350&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;316,610&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000770"
      unitRef="USD">213104</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000771"
      unitRef="USD">212238</us-gaap:OperatingLeaseCost>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000777"
      unitRef="USD">2411</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000780"
      unitRef="USD">4</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:VariableLeaseCost
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000782"
      unitRef="USD">111246</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000783"
      unitRef="USD">101957</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000785"
      unitRef="USD">324350</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000786"
      unitRef="USD">316610</us-gaap:LeaseCost>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000788">&lt;p id="xdx_89B_eus-gaap--ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_zB9UJmmc6PJc" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;Supplemental cash flow information related to leases for the period ended December 31:&lt;/p&gt;



&lt;p style="margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B8_zV76IQ6kDx15" style="display: none"&gt;Schedule of Supplemental Cash Flow Information Related to Leases&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20240101__20241231_zacNrvbFYyT" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20230101__20231231_zxZ1MztQsrH5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--CashPaidForOperatingAndFinanceLeasesAbstract_iB_z3T0lMG9DfWk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Cash paid for amounts included in operating and finance leases:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--OperatingLeasePayments_i01_pp0p0_maCPFOAzLxF_zT8id1pwmdac" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 70%; text-align: justify; text-indent: 10pt"&gt;Operating cash outflow from operating leases&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;324,783&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;308,914&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--FinanceLeaseInterestPaymentOnLiability_i01_pp0p0_maCPFOAzLxF_zDLaW6oH5lYg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: 10pt"&gt;Operating cash outflow from finance leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0796"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--FinanceLeasePrincipalPayments_i01_pp0p0_maCPFOAzLxF_zhJwihAQWkdi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt; text-indent: 10pt"&gt;Financing cash outflow from finance leases&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0799"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,449&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--CashPaidForOperatingAndFinanceLeases_i01T_pp0p0_mtCPFOAzLxF_zodVNHNWeyx3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total cash paid for amounts
    included in operating and finance leases&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;324,783&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;311,367&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000793"
      unitRef="USD">324783</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000794"
      unitRef="USD">308914</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000797"
      unitRef="USD">4</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000800"
      unitRef="USD">2449</us-gaap:FinanceLeasePrincipalPayments>
    <CELC:CashPaidForOperatingAndFinanceLeases
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000802"
      unitRef="USD">324783</CELC:CashPaidForOperatingAndFinanceLeases>
    <CELC:CashPaidForOperatingAndFinanceLeases
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000803"
      unitRef="USD">311367</CELC:CashPaidForOperatingAndFinanceLeases>
    <us-gaap:ContractualObligation
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact000805"
      unitRef="USD">9700000</us-gaap:ContractualObligation>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000807">&lt;p id="xdx_807_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zoZ49RQScqt" style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt; 10. &lt;span id="xdx_82C_zwjOQJ2kzy5i"&gt;Stockholders&#x2019; Equity&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Capital Stock&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At December 31, 2023, the Company&#x2019;s authorized
capital stock consisted of &lt;span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20231231_z58AORwDfBs2" title="Common stock, shares authorized"&gt;65,000,000&lt;/span&gt; shares of $&lt;span id="xdx_90F_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20231231_zJgTYDzfpAjg" title="Common stock, par value"&gt;.001&lt;/span&gt; par value common stock, of which &lt;span id="xdx_908_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20231231_zuH94DHujqf8" title="Common stock, shares outstanding"&gt;25,506,012&lt;/span&gt; shares were outstanding, and &lt;span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20231231_zNohAz6s1cH6" title="Preferred stock, shares authorized"&gt;2,500,000&lt;/span&gt;
shares of $&lt;span id="xdx_90B_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20231231_z4m7C5nD0oQb" title="Preferred stock, par value"&gt;.001&lt;/span&gt; par value preferred stock, of which &lt;span id="xdx_903_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20231231_zC5Hjt6xmnYb" title="Preferred stock, shares outstanding"&gt;854,134&lt;/span&gt; shares were outstanding.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In 2024, several of the Company&#x2019;s preferred
shareholders elected to convert &lt;span id="xdx_900_eus-gaap--ConversionOfStockSharesConverted1_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zxGrOsknkA46" title="Number of shares converted"&gt;536,557&lt;/span&gt; shares of Series A Convertible Preferred Stock into &lt;span id="xdx_906_eus-gaap--ConversionOfStockSharesIssued1_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zfGlI0y7O6ge" title="Number of shares issued in conversion"&gt;5,365,570&lt;/span&gt; shares of common stock, in accordance
with the Securities Purchase Agreement dated May 15, 2022. The cost basis of the shares transferred is $&lt;span id="xdx_906_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zaMIf0ZK13X4" title="Cost basis of shares transferred"&gt;5.75&lt;/span&gt; per share.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In 2024, several of the Company&#x2019;s investors
exercised &lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20241231_zHADFndXnH52" title="Additional warrants exercised"&gt;1,827,357&lt;/span&gt; common stock warrants at exercise prices ranging between $&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__srt--RangeAxis__srt--MinimumMember_zcaYVo5rE405" title="Class of warrant exercise price"&gt;8.05&lt;/span&gt; and $&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__srt--RangeAxis__srt--MaximumMember_z1c6oiZLr7F8" title="Class of warrant exercise price"&gt;9.50&lt;/span&gt; per share, which generated approximately
$&lt;span id="xdx_904_eus-gaap--ProceedsFromWarrantExercises_pn5n6_c20240101__20241231_zB5yUMl1KEBa" title="Proceeds from warant exercise"&gt;14.7&lt;/span&gt; million in cash. The &lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20241231_zfuggXWgi9Bj" title="Additional warrants exercised"&gt;1,827,357&lt;/span&gt; common stock warrants were net of shares withheld for exercise price.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify"&gt;At December 31, 2024, the Company&#x2019;s
authorized capital stock consisted of &lt;span id="xdx_903_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20241231_zwohx9jQHp8a" title="Common stock, shares authorized"&gt;95,000,000&lt;/span&gt; shares of common stock, of which &lt;span id="xdx_908_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20241231_zbgW50KgkuCj" title="Common stock, shares outstanding"&gt;37,143,242&lt;/span&gt; shares were outstanding, and &lt;span id="xdx_90E_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20241231_z1wnbw5zl0Tc" title="Preferred stock, shares authorized"&gt;2,500,000&lt;/span&gt; shares
of preferred stock, including &lt;span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z1ANVoyml8F5" title="Preferred stock, shares authorized"&gt;1,850,000&lt;/span&gt; shares designated as Series A Preferred Stock, of which &lt;span id="xdx_900_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20241231_zoFdcoiNvWJc" title="Preferred stock, shares outstanding"&gt;317,577&lt;/span&gt; shares were outstanding. As of
December 31, 2024, no dividends have been declared on the Company&#x2019;s capital stock.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;i&gt;Sale and Issuance of Stock&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On April 22, 2024, pursuant to an Open Market Sale
Agreement&lt;sup&gt;SM&lt;/sup&gt; with Jefferies LLC, as agent, the Company sold &lt;span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240422__20240422__us-gaap--TypeOfArrangementAxis__custom--OpenMarketSaleAgreementMember__dei--LegalEntityAxis__custom--JefferiesLLCMember_zB8F5dHpHsJ4" title="Sale of stock"&gt;285,714&lt;/span&gt; shares of common stock in a single transaction at a price
of $&lt;span id="xdx_90F_eus-gaap--SaleOfStockPricePerShare_iI_c20240422__us-gaap--TypeOfArrangementAxis__custom--OpenMarketSaleAgreementMember__dei--LegalEntityAxis__custom--JefferiesLLCMember_zMSLcCZSIj85" title="Share price"&gt;17.50&lt;/span&gt; per share, generating gross proceeds of $&lt;span id="xdx_901_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20240422__20240422__us-gaap--TypeOfArrangementAxis__custom--OpenMarketSaleAgreementMember__dei--LegalEntityAxis__custom--JefferiesLLCMember_zVZfRImdr93h" title="Gross proceeds"&gt;5.0&lt;/span&gt; million.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify"&gt;On May 8, 2024, pursuant to an Open Market
Sale Agreement with Jefferies LLC, as agent, the Company sold &lt;span id="xdx_90B_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240508__20240508__us-gaap--TypeOfArrangementAxis__custom--OpenMarketSaleAgreementMember__dei--LegalEntityAxis__custom--JefferiesLLCMember_zFgMBNFaayBa" title="Sale of stock number of shares issued in transaction"&gt;149,700&lt;/span&gt; shares of common stock in a single transaction at a price of $&lt;span id="xdx_90A_eus-gaap--SaleOfStockPricePerShare_iI_c20240508__us-gaap--TypeOfArrangementAxis__custom--OpenMarketSaleAgreementMember__dei--LegalEntityAxis__custom--JefferiesLLCMember_ziybsioOdUcl" title="Issuance of public offering price per share"&gt;17.65&lt;/span&gt;
per share, generating gross proceeds of $&lt;span id="xdx_906_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20240508__20240508__us-gaap--TypeOfArrangementAxis__custom--OpenMarketSaleAgreementMember__dei--LegalEntityAxis__custom--JefferiesLLCMember_zQMxRGkCOtN8" title="Gross proceeds from public offering"&gt;2.6&lt;/span&gt; million.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;Commissions and other offering expenses related to the Open Market Sale
Agreement transactions in April and May 2024 were $&lt;span id="xdx_902_eus-gaap--PaymentsOfStockIssuanceCosts_pn5n6_c20240430__20240430__us-gaap--TypeOfArrangementAxis__custom--OpenMarketSaleAgreementMember_zWIGxvNR9XP3" title="Commissions and other offering expenses"&gt;&lt;span id="xdx_90D_eus-gaap--PaymentsOfStockIssuanceCosts_pn5n6_c20240531__20240531__us-gaap--TypeOfArrangementAxis__custom--OpenMarketSaleAgreementMember_zqlqF4DntbM9" title="Commissions and other offering expenses"&gt;0.3&lt;/span&gt;&lt;/span&gt; million.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On May 30, 2024, the Company entered into an underwriting
agreement with Leerink Partners LLC, TD Securities (USA) LLC and Stifel, Nicolaus &amp;amp; Company, Incorporated as representatives of the
several underwriters relating to the issuance and sale of &lt;span id="xdx_903_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240530__20240530__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LeerinkPartnersLLCMember_zgi2coic5Ai3" title="Sale of stock number of shares issued in transaction"&gt;3,871,000&lt;/span&gt; shares of common stock, at a price to the public of $&lt;span id="xdx_901_eus-gaap--SaleOfStockPricePerShare_iI_c20240530__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LeerinkPartnersLLCMember_zhSUJT3GX9q2" title="Issuance of public offering price per share"&gt;15.50&lt;/span&gt;, generating
gross proceeds of approximately $&lt;span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20240530__20240530__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LeerinkPartnersLLCMember_zHKpZqZCKbF7" title="Gross proceeds from public offering"&gt;60.0&lt;/span&gt; million. The offering closed on May 31, 2024 and resulted in net proceeds to the Company of approximately
$&lt;span id="xdx_909_ecustom--ProceedsFromIssuanceOfCommonStockNet_pn5n6_c20240531__20240531__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LeerinkPartnersLLCMember_zeh8eaXyABs9" title="Net proceeds from public offering"&gt;56.3&lt;/span&gt; million after deducting underwriting discounts and other offering expenses payable by the Company. The Company intends to use the
net proceeds from the offering for working capital and general corporate purposes, which may include capital expenditures, research and
development expenditures, clinical trial expenditures, expansion of business development activities and other general corporate purposes.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Pre-Funded Warrants&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;On October 18, 2023, the
Company entered into a securities purchase agreement (the &#x201c;Securities Purchase Agreement&#x201d;) with certain investors (the &#x201c;Investors&#x201d;)
pursuant to which the Company agreed to sell to the Investors in a private placement pre-funded warrants to purchase up to &lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20231018__20231018__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zKSMTxN8oQMl" title="Pre-funded warrants sold to investors"&gt;5,747,787&lt;/span&gt; shares
of the Company&#x2019;s common stock, par value $&lt;span id="xdx_902_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20231018__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z97C4UWFVdbh" title="Common stock, par value"&gt;0.001&lt;/span&gt; per share. Each Warrant to purchase one share had a purchase price of $&lt;span id="xdx_90F_eus-gaap--SharePrice_iI_pid_c20231018__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zeccBRVy2gef" title="Warrant purchase price"&gt;8.699&lt;/span&gt; per
share, and an exercise price of $&lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231018__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTLu4QIKk9Q8" title="Exercise price of common stock warrants"&gt;0.001&lt;/span&gt; per share for the common stock issuable upon exercise of the Warrant.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;The closing of the Private
Placement occurred on October 20, 2023, and resulted in gross proceeds to the Company of approximately $&lt;span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn5n6_c20231020__20231020__srt--TitleOfIndividualAxis__custom--InstitutionalAndOtherAccreditedInvestorsMember_zkxYRPpeIkJj" title="Proceeds from issuance of private placement"&gt;50.0&lt;/span&gt; million, before deducting
offering expenses of approximately $&lt;span id="xdx_90F_ecustom--OfferingExpenses_pn5n6_c20231020__20231020__srt--TitleOfIndividualAxis__custom--InstitutionalAndOtherAccreditedInvestorsMember_znvLnnmM5k9d" title="Offering expenses"&gt;0.1&lt;/span&gt; million.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;Each Warrant is immediately
exercisable and will not expire. Under the terms of the Warrants, the Company may not effect the exercise of any such Warrant, and a holder
will not be entitled to exercise any portion of any Warrant, if, upon giving effect to such exercise, the aggregate number of shares of
common stock beneficially owned by the holder (together with its affiliates, other persons acting or who could be deemed to be acting
as a group together with the holder or any of the holder&#x2019;s affiliates, and any other persons whose beneficial ownership of common
stock would or could be aggregated with the holder&#x2019;s or any of the holder&#x2019;s affiliates for purposes of Section 13(d) or Section
16 of the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;)) would exceed 4.99% of the number of shares of
common stock outstanding immediately after giving effect to the exercise, as such percentage ownership is calculated in accordance with
Section 13(d) of the Exchange Act and the applicable regulations of the SEC (the &#x201c;Maximum Percentage&#x201d;). A holder may reset
the Maximum Percentage to a higher percentage (not to exceed 19.99%), effective 61 days after written notice to the Company, or a lower
percentage, effective immediately upon written notice to the Company. Any such increase or decrease will apply only to that holder and
not to any other holder of Warrants.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;The Securities Purchase Agreement
contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations
of the Company, other obligations of the parties and termination provisions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Warrants&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zsto21sRl4t3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BE_z2rn7RsYGXm4" style="display: none"&gt;Schedule of Warrants&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;b&gt;At December 31, 2024:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Issue Date&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Expiration &lt;br/&gt;
Date&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;# of Warrants &lt;br/&gt;
Outstanding&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Exercise &lt;br/&gt;
Price&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Offering&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 14%; text-align: justify"&gt;&lt;span id="xdx_90F_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantOneMember_zzy3QVehUMPk" title="Issue Date"&gt;1/21/2016&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; text-align: justify"&gt;&lt;span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantOneMember_zm3MP6vzpn65" title="Expiration Date"&gt;1/14/2026&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantOneMember_zbQLB19xUdXe" style="width: 12%; text-align: right" title="Number of Warrants Outstanding"&gt;33,719&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantOneMember_zRbGEXr1AZl4" style="width: 12%; text-align: right" title="Exercise Price"&gt;7.56&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 42%; text-align: justify"&gt;&lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantOneMember_zUP5W0NkT54d" title="Offering"&gt;private placement offering - issued to placement agent&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_909_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTwoMember_z1ejCN8TQZCl" title="Issue Date"&gt;5/2/2016&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTwoMember_zK2dMnFBPlWe" title="Expiration Date"&gt;5/2/2026&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTwoMember_zcrZXcNI65sg" style="text-align: right" title="Number of Warrants Outstanding"&gt;21,530&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTwoMember_zbZhsymVAKHh" style="text-align: right" title="Exercise Price"&gt;7.56&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTwoMember_zaMNtZcQeDf7" title="Offering"&gt;private placement offering - issued to placement agent&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_902_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantThreeMember_zpzw3gFg5DZd" title="Issue Date"&gt;4/28/2017&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantThreeMember_zNzbIHPWCVg7" title="Expiration Date"&gt;4/28/2027&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantThreeMember_zLssEEQmrMab" style="text-align: right" title="Number of Warrants Outstanding"&gt;33,250&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantThreeMember_zMkDOC743szj" style="text-align: right" title="Exercise Price"&gt;8.42&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantThreeMember_zpmhmG59Rpw" title="Offering"&gt;private placement offering - issued to placement agent&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_909_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFourMember_zalzNQqwbrFg" title="Issue Date"&gt;5/17/2017&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFourMember_zAC3xvDT3uBh" title="Expiration Date"&gt;5/17/2027&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFourMember_zEOCCLNsGUaj" style="text-align: right" title="Number of Warrants Outstanding"&gt;15,365&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFourMember_zWOlYvSBfhO1" style="text-align: right" title="Exercise Price"&gt;8.42&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFourMember_zrnfbCEu7dgl" title="Offering"&gt;private placement offering - issued to placement agent&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_90A_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFiveMember_zQhAPm6hIohg" title="Issue Date"&gt;9/22/2017&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFiveMember_zNI3eGRxNbO3" title="Expiration Date"&gt;9/19/2025&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFiveMember_z5ZtsHEZfpGh" style="text-align: right" title="Number of Warrants Outstanding"&gt;70,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFiveMember_zTABzIthnJkc" style="text-align: right" title="Exercise Price"&gt;10.45&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFiveMember_zBu5zK2pk5v2" title="Offering"&gt;IPO - issued to underwriter&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_90F_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSixMember_zdKdLvwXNT5j" title="Issue Date"&gt;4/8/2021&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSixMember_zNZWWRgIdd82" title="Expiration Date"&gt;4/8/2031&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSixMember_z3G9nwBSAyp3" style="text-align: right" title="Number of Warrants Outstanding"&gt;26,042&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSixMember_zGWjh2pO9xnc" style="text-align: right" title="Exercise Price"&gt;14.40&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSixMember_zZ1HBufNeQwg" title="Offering"&gt;debt financing - issued to lender&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_90D_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSevenMember_zJK8FAIwIrY6" title="Issue Date"&gt;5/30/2024&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSevenMember_zbQ5vZeVB7Wf" title="Expiration Date"&gt;5/30/2034&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSevenMember_z0LFPrsZBT1g" style="text-align: right" title="Number of Warrants Outstanding"&gt;84,227&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSevenMember_zf0PaICGlbRj" style="text-align: right" title="Exercise Price"&gt;14.84&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSevenMember_zblij2Twobbj" title="Offering"&gt;debt financing &#x2013; issued to lender&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_90A_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantEightMember_zic20g9rc1ql" title="Issue Date"&gt;5/30/2024&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantEightMember_z7Sv8tviQRx6" title="Expiration Date"&gt;5/30/2034&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantEightMember_zFTIPLLSQhH" style="text-align: right" title="Number of Warrants Outstanding"&gt;19,649&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantEightMember_zZi0ytehV8Ya" style="text-align: right" title="Exercise Price"&gt;14.84&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantEightMember_zYLtdPeigg8j" title="Offering"&gt;debt financing &#x2013; issued to lender&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_90F_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantNineMember_zNmKUWPO56H8" title="Issue Date"&gt;12/9/2022&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;see below&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantNineMember_zXGAEV0ZyuAf" style="text-align: right" title="Number of Warrants Outstanding"&gt;5,217,370&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantNineMember_zev3Pr9tOfF7" style="text-align: right" title="Exercise Price"&gt;8.05&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantNineMember_zsYj2m7PJUt3" title="Offering"&gt;securities purchase agreement - issued to institutional and other accredited investors&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;&lt;span id="xdx_905_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTenMember_zQ2aRRiyhzKh" title="Issue Date"&gt;10/18/2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;see above&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTenMember_zIHxFG7oVpml" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants Outstanding"&gt;5,747,787&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTenMember_z48GIU4yN60b" style="padding-bottom: 1pt; text-align: right" title="Exercise Price"&gt;0.001&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTenMember_zbmOZ3d2wQE2" title="Offering"&gt;private placement offering - issued to investors&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Total Warrants Outstanding&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231_zOC3YLP8ubx8" style="font-weight: bold; text-align: right" title="Number of Warrants Outstanding"&gt;11,268,939&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zxzmxtlf4sgd" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;At December 31, 2024 and 2023, the Company had warrants
to purchase &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4Jkj0ItTUN3"&gt;11,268,939
&lt;/span&gt;and &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zKQ3kFlcT3t"&gt;13,011,520
&lt;/span&gt;shares of common stock outstanding, at a weighted average exercise price of $&lt;span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOfWarrants_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwqCFb5kt6e7"&gt;4.04
&lt;/span&gt;and $&lt;span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOfWarrants_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zO2YxejSqGT5"&gt;4.53&lt;/span&gt;,
respectively. A total of &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z7O3Q99RMm4a"&gt;1,842,913
&lt;/span&gt;and &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zT8cYO0TaCMl"&gt;2,369
&lt;/span&gt;warrants were exercised in the years ended December 31, 2024 and 2023, respectively. There were &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPsKJxVdYTxd"&gt;3,544
&lt;/span&gt;warrants that expired in 2024.&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000809"
      unitRef="Shares">65000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000811"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000813"
      unitRef="Shares">25506012</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000815"
      unitRef="Shares">2500000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000817"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000819"
      unitRef="Shares">854134</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2024-01-012024-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000821"
      unitRef="Shares">536557</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="From2024-01-012024-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000823"
      unitRef="Shares">5365570</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="AsOf2024-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000825"
      unitRef="USDPShares">5.75</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000827"
      unitRef="Shares">1827357</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_srt_MinimumMember"
      decimals="INF"
      id="Fact000829"
      unitRef="USDPShares">8.05</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_srt_MaximumMember"
      decimals="INF"
      id="Fact000831"
      unitRef="USDPShares">9.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2024-01-01to2024-12-31"
      decimals="-5"
      id="Fact000833"
      unitRef="USD">14700000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000835"
      unitRef="Shares">1827357</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000837"
      unitRef="Shares">95000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000839"
      unitRef="Shares">37143242</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000841"
      unitRef="Shares">2500000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000843"
      unitRef="Shares">1850000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000845"
      unitRef="Shares">317577</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2024-04-222024-04-22_custom_OpenMarketSaleAgreementMember_custom_JefferiesLLCMember"
      decimals="INF"
      id="Fact000847"
      unitRef="Shares">285714</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2024-04-22_custom_OpenMarketSaleAgreementMember_custom_JefferiesLLCMember"
      decimals="INF"
      id="Fact000849"
      unitRef="USDPShares">17.50</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2024-04-222024-04-22_custom_OpenMarketSaleAgreementMember_custom_JefferiesLLCMember"
      decimals="-5"
      id="Fact000851"
      unitRef="USD">5000000.0</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2024-05-082024-05-08_custom_OpenMarketSaleAgreementMember_custom_JefferiesLLCMember"
      decimals="INF"
      id="Fact000853"
      unitRef="Shares">149700</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2024-05-08_custom_OpenMarketSaleAgreementMember_custom_JefferiesLLCMember"
      decimals="INF"
      id="Fact000855"
      unitRef="USDPShares">17.65</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2024-05-082024-05-08_custom_OpenMarketSaleAgreementMember_custom_JefferiesLLCMember"
      decimals="-5"
      id="Fact000857"
      unitRef="USD">2600000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2024-04-302024-04-30_custom_OpenMarketSaleAgreementMember"
      decimals="-5"
      id="Fact000859"
      unitRef="USD">300000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2024-05-312024-05-31_custom_OpenMarketSaleAgreementMember"
      decimals="-5"
      id="Fact000861"
      unitRef="USD">300000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2024-05-302024-05-30_custom_UnderwritingAgreementMember_custom_LeerinkPartnersLLCMember"
      decimals="INF"
      id="Fact000863"
      unitRef="Shares">3871000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2024-05-30_custom_UnderwritingAgreementMember_custom_LeerinkPartnersLLCMember"
      decimals="INF"
      id="Fact000865"
      unitRef="USDPShares">15.50</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-05-302024-05-30_custom_UnderwritingAgreementMember_custom_LeerinkPartnersLLCMember"
      decimals="-5"
      id="Fact000867"
      unitRef="USD">60000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <CELC:ProceedsFromIssuanceOfCommonStockNet
      contextRef="From2024-05-312024-05-31_custom_UnderwritingAgreementMember_custom_LeerinkPartnersLLCMember"
      decimals="-5"
      id="Fact000869"
      unitRef="USD">56300000</CELC:ProceedsFromIssuanceOfCommonStockNet>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-10-182023-10-18_custom_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact000871"
      unitRef="Shares">5747787</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-10-18_custom_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact000873"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SharePrice
      contextRef="AsOf2023-10-18_custom_SecuritiesPurchaseAgreementMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000875"
      unitRef="USDPShares">8.699</us-gaap:SharePrice>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-10-18_custom_SecuritiesPurchaseAgreementMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000877"
      unitRef="USDPShares">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2023-10-202023-10-20_custom_InstitutionalAndOtherAccreditedInvestorsMember"
      decimals="-5"
      id="Fact000879"
      unitRef="USD">50000000.0</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <CELC:OfferingExpenses
      contextRef="From2023-10-202023-10-20_custom_InstitutionalAndOtherAccreditedInvestorsMember"
      decimals="-5"
      id="Fact000881"
      unitRef="USD">100000</CELC:OfferingExpenses>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000883">&lt;p id="xdx_89E_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zsto21sRl4t3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BE_z2rn7RsYGXm4" style="display: none"&gt;Schedule of Warrants&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;b&gt;At December 31, 2024:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Issue Date&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Expiration &lt;br/&gt;
Date&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;# of Warrants &lt;br/&gt;
Outstanding&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Exercise &lt;br/&gt;
Price&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Offering&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 14%; text-align: justify"&gt;&lt;span id="xdx_90F_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantOneMember_zzy3QVehUMPk" title="Issue Date"&gt;1/21/2016&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; text-align: justify"&gt;&lt;span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantOneMember_zm3MP6vzpn65" title="Expiration Date"&gt;1/14/2026&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantOneMember_zbQLB19xUdXe" style="width: 12%; text-align: right" title="Number of Warrants Outstanding"&gt;33,719&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantOneMember_zRbGEXr1AZl4" style="width: 12%; text-align: right" title="Exercise Price"&gt;7.56&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 42%; text-align: justify"&gt;&lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantOneMember_zUP5W0NkT54d" title="Offering"&gt;private placement offering - issued to placement agent&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_909_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTwoMember_z1ejCN8TQZCl" title="Issue Date"&gt;5/2/2016&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTwoMember_zK2dMnFBPlWe" title="Expiration Date"&gt;5/2/2026&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTwoMember_zcrZXcNI65sg" style="text-align: right" title="Number of Warrants Outstanding"&gt;21,530&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTwoMember_zbZhsymVAKHh" style="text-align: right" title="Exercise Price"&gt;7.56&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTwoMember_zaMNtZcQeDf7" title="Offering"&gt;private placement offering - issued to placement agent&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_902_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantThreeMember_zpzw3gFg5DZd" title="Issue Date"&gt;4/28/2017&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantThreeMember_zNzbIHPWCVg7" title="Expiration Date"&gt;4/28/2027&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantThreeMember_zLssEEQmrMab" style="text-align: right" title="Number of Warrants Outstanding"&gt;33,250&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantThreeMember_zMkDOC743szj" style="text-align: right" title="Exercise Price"&gt;8.42&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantThreeMember_zpmhmG59Rpw" title="Offering"&gt;private placement offering - issued to placement agent&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_909_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFourMember_zalzNQqwbrFg" title="Issue Date"&gt;5/17/2017&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFourMember_zAC3xvDT3uBh" title="Expiration Date"&gt;5/17/2027&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFourMember_zEOCCLNsGUaj" style="text-align: right" title="Number of Warrants Outstanding"&gt;15,365&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFourMember_zWOlYvSBfhO1" style="text-align: right" title="Exercise Price"&gt;8.42&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFourMember_zrnfbCEu7dgl" title="Offering"&gt;private placement offering - issued to placement agent&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_90A_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFiveMember_zQhAPm6hIohg" title="Issue Date"&gt;9/22/2017&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFiveMember_zNI3eGRxNbO3" title="Expiration Date"&gt;9/19/2025&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFiveMember_z5ZtsHEZfpGh" style="text-align: right" title="Number of Warrants Outstanding"&gt;70,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFiveMember_zTABzIthnJkc" style="text-align: right" title="Exercise Price"&gt;10.45&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFiveMember_zBu5zK2pk5v2" title="Offering"&gt;IPO - issued to underwriter&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_90F_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSixMember_zdKdLvwXNT5j" title="Issue Date"&gt;4/8/2021&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSixMember_zNZWWRgIdd82" title="Expiration Date"&gt;4/8/2031&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSixMember_z3G9nwBSAyp3" style="text-align: right" title="Number of Warrants Outstanding"&gt;26,042&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSixMember_zGWjh2pO9xnc" style="text-align: right" title="Exercise Price"&gt;14.40&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSixMember_zZ1HBufNeQwg" title="Offering"&gt;debt financing - issued to lender&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_90D_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSevenMember_zJK8FAIwIrY6" title="Issue Date"&gt;5/30/2024&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSevenMember_zbQ5vZeVB7Wf" title="Expiration Date"&gt;5/30/2034&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSevenMember_z0LFPrsZBT1g" style="text-align: right" title="Number of Warrants Outstanding"&gt;84,227&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSevenMember_zf0PaICGlbRj" style="text-align: right" title="Exercise Price"&gt;14.84&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSevenMember_zblij2Twobbj" title="Offering"&gt;debt financing &#x2013; issued to lender&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_90A_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantEightMember_zic20g9rc1ql" title="Issue Date"&gt;5/30/2024&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantEightMember_z7Sv8tviQRx6" title="Expiration Date"&gt;5/30/2034&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantEightMember_zFTIPLLSQhH" style="text-align: right" title="Number of Warrants Outstanding"&gt;19,649&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantEightMember_zZi0ytehV8Ya" style="text-align: right" title="Exercise Price"&gt;14.84&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantEightMember_zYLtdPeigg8j" title="Offering"&gt;debt financing &#x2013; issued to lender&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_90F_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantNineMember_zNmKUWPO56H8" title="Issue Date"&gt;12/9/2022&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;see below&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantNineMember_zXGAEV0ZyuAf" style="text-align: right" title="Number of Warrants Outstanding"&gt;5,217,370&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantNineMember_zev3Pr9tOfF7" style="text-align: right" title="Exercise Price"&gt;8.05&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantNineMember_zsYj2m7PJUt3" title="Offering"&gt;securities purchase agreement - issued to institutional and other accredited investors&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;&lt;span id="xdx_905_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTenMember_zQ2aRRiyhzKh" title="Issue Date"&gt;10/18/2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;see above&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTenMember_zIHxFG7oVpml" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants Outstanding"&gt;5,747,787&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTenMember_z48GIU4yN60b" style="padding-bottom: 1pt; text-align: right" title="Exercise Price"&gt;0.001&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTenMember_zbmOZ3d2wQE2" title="Offering"&gt;private placement offering - issued to investors&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Total Warrants Outstanding&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231_zOC3YLP8ubx8" style="font-weight: bold; text-align: right" title="Number of Warrants Outstanding"&gt;11,268,939&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <CELC:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue
      contextRef="From2024-01-012024-12-31_custom_WarrantOneMember"
      id="Fact000885">2016-01-21</CELC:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2024-12-31_custom_WarrantOneMember"
      id="Fact000887">2026-01-14</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_WarrantOneMember"
      decimals="INF"
      id="Fact000889"
      unitRef="Shares">33719</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_WarrantOneMember"
      decimals="INF"
      id="Fact000891"
      unitRef="USDPShares">7.56</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees
      contextRef="From2024-01-012024-12-31_custom_WarrantOneMember"
      id="Fact000893">private placement offering - issued to placement agent</us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees>
    <CELC:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue
      contextRef="From2024-01-012024-12-31_custom_WarrantTwoMember"
      id="Fact000895">2016-05-02</CELC:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2024-12-31_custom_WarrantTwoMember"
      id="Fact000897">2026-05-02</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_WarrantTwoMember"
      decimals="INF"
      id="Fact000899"
      unitRef="Shares">21530</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_WarrantTwoMember"
      decimals="INF"
      id="Fact000901"
      unitRef="USDPShares">7.56</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees
      contextRef="From2024-01-012024-12-31_custom_WarrantTwoMember"
      id="Fact000903">private placement offering - issued to placement agent</us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees>
    <CELC:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue
      contextRef="From2024-01-012024-12-31_custom_WarrantThreeMember"
      id="Fact000905">2017-04-28</CELC:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2024-12-31_custom_WarrantThreeMember"
      id="Fact000907">2027-04-28</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_WarrantThreeMember"
      decimals="INF"
      id="Fact000909"
      unitRef="Shares">33250</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_WarrantThreeMember"
      decimals="INF"
      id="Fact000911"
      unitRef="USDPShares">8.42</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees
      contextRef="From2024-01-012024-12-31_custom_WarrantThreeMember"
      id="Fact000913">private placement offering - issued to placement agent</us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees>
    <CELC:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue
      contextRef="From2024-01-012024-12-31_custom_WarrantFourMember"
      id="Fact000915">2017-05-17</CELC:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2024-12-31_custom_WarrantFourMember"
      id="Fact000917">2027-05-17</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_WarrantFourMember"
      decimals="INF"
      id="Fact000919"
      unitRef="Shares">15365</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_WarrantFourMember"
      decimals="INF"
      id="Fact000921"
      unitRef="USDPShares">8.42</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees
      contextRef="From2024-01-012024-12-31_custom_WarrantFourMember"
      id="Fact000923">private placement offering - issued to placement agent</us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees>
    <CELC:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue
      contextRef="From2024-01-012024-12-31_custom_WarrantFiveMember"
      id="Fact000925">2017-09-22</CELC:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2024-12-31_custom_WarrantFiveMember"
      id="Fact000927">2025-09-19</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_WarrantFiveMember"
      decimals="INF"
      id="Fact000929"
      unitRef="Shares">70000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_WarrantFiveMember"
      decimals="INF"
      id="Fact000931"
      unitRef="USDPShares">10.45</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees
      contextRef="From2024-01-012024-12-31_custom_WarrantFiveMember"
      id="Fact000933">IPO - issued to underwriter</us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees>
    <CELC:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue
      contextRef="From2024-01-012024-12-31_custom_WarrantSixMember"
      id="Fact000935">2021-04-08</CELC:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2024-12-31_custom_WarrantSixMember"
      id="Fact000937">2031-04-08</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_WarrantSixMember"
      decimals="INF"
      id="Fact000939"
      unitRef="Shares">26042</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_WarrantSixMember"
      decimals="INF"
      id="Fact000941"
      unitRef="USDPShares">14.40</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees
      contextRef="From2024-01-012024-12-31_custom_WarrantSixMember"
      id="Fact000943">debt financing - issued to lender</us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees>
    <CELC:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue
      contextRef="From2024-01-012024-12-31_custom_WarrantSevenMember"
      id="Fact000945">2024-05-30</CELC:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2024-12-31_custom_WarrantSevenMember"
      id="Fact000947">2034-05-30</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_WarrantSevenMember"
      decimals="INF"
      id="Fact000949"
      unitRef="Shares">84227</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_WarrantSevenMember"
      decimals="INF"
      id="Fact000951"
      unitRef="USDPShares">14.84</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees
      contextRef="From2024-01-012024-12-31_custom_WarrantSevenMember"
      id="Fact000953">debt financing &#x2013; issued to lender</us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees>
    <CELC:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue
      contextRef="From2024-01-012024-12-31_custom_WarrantEightMember"
      id="Fact000955">2024-05-30</CELC:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2024-12-31_custom_WarrantEightMember"
      id="Fact000957">2034-05-30</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_WarrantEightMember"
      decimals="INF"
      id="Fact000959"
      unitRef="Shares">19649</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_WarrantEightMember"
      decimals="INF"
      id="Fact000961"
      unitRef="USDPShares">14.84</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees
      contextRef="From2024-01-012024-12-31_custom_WarrantEightMember"
      id="Fact000963">debt financing &#x2013; issued to lender</us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees>
    <CELC:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue
      contextRef="From2024-01-012024-12-31_custom_WarrantNineMember"
      id="Fact000965">2022-12-09</CELC:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_WarrantNineMember"
      decimals="INF"
      id="Fact000967"
      unitRef="Shares">5217370</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_WarrantNineMember"
      decimals="INF"
      id="Fact000969"
      unitRef="USDPShares">8.05</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees
      contextRef="From2024-01-012024-12-31_custom_WarrantNineMember"
      id="Fact000971">securities purchase agreement - issued to institutional and other accredited investors</us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees>
    <CELC:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue
      contextRef="From2024-01-012024-12-31_custom_WarrantTenMember"
      id="Fact000973">2023-10-18</CELC:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_WarrantTenMember"
      decimals="INF"
      id="Fact000975"
      unitRef="Shares">5747787</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_WarrantTenMember"
      decimals="INF"
      id="Fact000977"
      unitRef="USDPShares">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees
      contextRef="From2024-01-012024-12-31_custom_WarrantTenMember"
      id="Fact000979">private placement offering - issued to investors</us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000981"
      unitRef="Shares">11268939</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2024-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000982"
      unitRef="Shares">11268939</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000983"
      unitRef="Shares">13011520</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <CELC:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOfWarrants
      contextRef="AsOf2024-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000984"
      unitRef="USDPShares">4.04</CELC:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOfWarrants>
    <CELC:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOfWarrants
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000985"
      unitRef="USDPShares">4.53</CELC:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOfWarrants>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000986"
      unitRef="Shares">1842913</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000987"
      unitRef="Shares">2369</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000988"
      unitRef="Shares">3544</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000990">&lt;p id="xdx_80F_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zl77xoio4Lj7" style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt; 11. &lt;span id="xdx_823_z4h8In7A7UFf"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;2012 Equity Incentive Plan&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;The 2012 Equity Incentive Plan, as amended, was adopted by the Company&#x2019;s
board and approved by the members of Celcuity LLC on August 10, 2012. The Company reserved a maximum of &lt;span id="xdx_905_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20120810__us-gaap--AwardTypeAxis__custom--EquityIncentivePlanMember_zvYAhqdRedX2" title="Common stock, shares reserved for issuance"&gt;625,000&lt;/span&gt; shares of common stock
for issuance under the 2012 Equity Incentive Plan. The 2012 Equity Incentive Plan provides for options, restricted stock awards, performance
stock awards or stock bonuses. The exercise price of each option granted under the 2012 Equity Incentive Plan is not less than 100% of
the fair market value of one share on the date of grant. The maximum permitted term of options granted under the 2012 Equity Incentive
Plan is ten years. The Company&#x2019;s board administers the 2012 Equity Incentive Plan and determines the provisions of incentive awards,
including eligible recipients, number of shares subject to an incentive award, exercise price, vesting schedule, duration of an incentive
award and other restrictions an incentive award may be subject to. The 2012 Equity Incentive Plan was frozen on September 6, 2017 and
new awards are issued under the terms of the 2017 Amended and Restated Stock Incentive Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;2017 Stock Incentive Plan&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;The 2017 Amended and Restated Stock Incentive Plan (the &#x201c;2017 Plan&#x201d;)
was adopted by the Company&#x2019;s board on September 6, 2017, became effective following the corporate conversion on September 15, 2017,
and was approved by stockholders at the Company&#x2019;s annual stockholder meeting on May 10, 2018. The 2017 Plan was amended and approved
by stockholders at the Company&#x2019;s annual stockholder meeting on May 14, 2020. The Company initially reserved a maximum of &lt;span id="xdx_90B_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20171025__us-gaap--AwardTypeAxis__custom--StockIncentivePlanMember_zy9mw031BNRd" title="Common stock, shares reserved for issuance"&gt;750,000&lt;/span&gt;
shares of common stock for issuance under the 2017 Plan. The number of shares reserved for issuance was automatically increased by &lt;span id="xdx_90F_ecustom--ChangeInCommonStockSharesReservedForIssuance_iI_pid_c20240101__us-gaap--AwardTypeAxis__custom--StockIncentivePlanMember_zj1lXpOBs0Sd" title="Change in common stock, shares reserved for issuance"&gt;255,060&lt;/span&gt;
and &lt;span id="xdx_907_ecustom--ChangeInCommonStockSharesReservedForIssuance_iI_pid_c20230101__us-gaap--AwardTypeAxis__custom--StockIncentivePlanMember_zjcWnIEgzKP7" title="Change in common stock, shares reserved for issuance"&gt;216,673&lt;/span&gt; shares on January 1, 2024 and 2023, respectively, and will increase automatically on January 1 of each of 2025 through 2027
by the number of shares equal to 1.0% of the aggregate number of outstanding shares of Company common stock as of the immediately preceding
December 31. However, the Company&#x2019;s board may reduce the amount of the increase in any particular year. At each of the Annual Meetings
held on May 12, 2021 and May 12, 2022, the stockholders approved a &lt;span id="xdx_90A_ecustom--ChangeInCommonStockSharesReservedForIssuance_iI_pid_c20210512__us-gaap--AwardTypeAxis__custom--StockIncentivePlanMember_zdDMs0cGZwwi" title="Change in common stock, shares reserved for issuance"&gt;&lt;span id="xdx_90D_ecustom--ChangeInCommonStockSharesReservedForIssuance_iI_pid_c20220512__us-gaap--AwardTypeAxis__custom--StockIncentivePlanMember_znRdBrTBdr27" title="Change in common stock, shares reserved for issuance"&gt;500,000&lt;/span&gt;&lt;/span&gt; increase for a total of &lt;span id="xdx_906_ecustom--TotalCommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20210512__us-gaap--AwardTypeAxis__custom--StockIncentivePlanMember_ztQYTaUZcTtl" title="Total common stock, shares reserved for issuance"&gt;&lt;span id="xdx_907_ecustom--TotalCommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20220512__us-gaap--AwardTypeAxis__custom--StockIncentivePlanMember_zow5jheWFTJ4" title="Total common stock, shares reserved for issuance"&gt;1,000,000&lt;/span&gt;&lt;/span&gt; increase, to the number of
shares reserved for issuance under the 2017 Plan. At each of the Annual Meetings held on May 11, 2023 and May 9, 2024, the stockholders
approved &lt;span id="xdx_90F_ecustom--TotalCommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20230511__us-gaap--AwardTypeAxis__custom--StockIncentivePlanMember_z6TU2PbwJaR3" title="Total common stock, shares reserved for issuance"&gt;1,500,000&lt;/span&gt; increases for a total increase of &lt;span id="xdx_90E_ecustom--TotalCommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20240509__us-gaap--AwardTypeAxis__custom--StockIncentivePlanMember_zCBabljzE0E" title="Total common stock, shares reserved for issuance"&gt;3,000,000&lt;/span&gt; to the number of shares reserved for issuance under the 2017 Plan. The
2017 Plan provides for options, restricted stock awards, stock appreciation rights, restricted stock units, performance awards and stock
bonuses. The exercise price of each option granted under the 2017 Plan is not less than 100% of the fair market value of one share on
the date of grant. The maximum permitted term of options granted under the 2017 Plan is ten years. The 2017 Plan is generally administered
by the compensation committee of the Company&#x2019;s board, which has the authority to interpret the 2017 Plan, grant awards and make
all other determinations necessary for the administration of the 2017 Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zOSgvTIVLrI" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;The following table summarizes the activity for all stock options outstanding
for the years ended December 31:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B6_zl6OpamZLCef" style="display: none"&gt;Schedule of Stock Options Activity&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: justify"&gt;Options outstanding at beginning of year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zSPYsmp3gBwc" style="width: 12%; text-align: right" title="Options outstanding at beginning of year"&gt;2,815,392&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zmesmf88ipEf" style="width: 12%; text-align: right" title="Options outstanding, weighted average exercise price at beginning of year"&gt;7.95&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zmfBnJOTCI6a" style="width: 12%; text-align: right" title="Options outstanding at beginning of year"&gt;1,976,586&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zCBET0BdBjxa" style="width: 12%; text-align: right" title="Options outstanding, weighted average exercise price at beginning of year"&gt;6.34&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_z9St0zHMEwu1" style="text-align: right" title="Shares, Granted"&gt;1,716,729&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zGD33vgHmzEg" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;16.14&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zfISnnkWBnl1" style="text-align: right" title="Shares, Granted"&gt;1,003,298&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zjbip3FB4WRk" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;10.69&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zHJlvZJj8Zm5" style="text-align: right" title="Shares, Exercised"&gt;(103,245&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zDuKZUDpU8J4" style="text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;7.45&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_ze5YikrvvFd2" style="text-align: right" title="Shares, Exercised"&gt;(98,695&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zpugTMFU0Hn7" style="text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;3.94&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify; padding-bottom: 1pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zBIb2UJGk9f3" style="border-bottom: Black 1pt solid; text-align: right" title="Shares, Forfeited"&gt;(121,899&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zUV6nYVTuh13" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise, Forfeited"&gt;11.57&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zSbSduUjp7d7" style="border-bottom: Black 1pt solid; text-align: right" title="Shares, Forfeited"&gt;(65,797&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zxA7HOqB6AK4" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise, Forfeited"&gt;7.45&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify; padding-bottom: 1pt"&gt;Balance at December 31:&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_z9AKSp0QPPxe" style="border-bottom: Black 1pt solid; text-align: right" title="Options outstanding at end of year"&gt;4,306,977&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zrGgSswWkEri" style="border-bottom: Black 1pt solid; text-align: right" title="Options outstanding, weighted average exercise price at end of year"&gt;11.13&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zruFBhv5jPE2" style="border-bottom: Black 1pt solid; text-align: right" title="Options outstanding at end of year"&gt;2,815,392&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zLTfuTkJ2kz9" style="border-bottom: Black 1pt solid; text-align: right" title="Options outstanding, weighted average exercise price at end of year"&gt;7.95&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Options exercisable at December 31:&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zPa7Q8m6DZj" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares, options exercisable"&gt;2,011,474&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zTG5EMBmFq7i" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price, Options exercisable"&gt;7.35&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zOW35pU1Ftd1" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares, options exercisable"&gt;1,524,731&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_z3k2bDel1Ute" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price, Options exercisable"&gt;6.44&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Weighted Average Grant Date Fair Value for options granted during the year:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zkqfx8wCiia5" style="text-align: right" title="Weighted Average Grant Date Fair Value for options granted during the period"&gt;11.22&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zIgbZ80Sv321" style="text-align: right" title="Weighted Average Grant Date Fair Value for options granted during the period"&gt;7.48&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zulv7JG4heh4" style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt; text-align: justify"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&#160;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_z03Q5zIYvzg7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-weight: normal"&gt;The
following table summarizes additional information about stock options outstanding and exercisable at December 31, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-weight: normal"&gt;&#160;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BE_zbSIJPkNPEXi" style="display: none"&gt;Schedule
of Stock Options Outstanding and Exercisable&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Options Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Options Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Options Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Remaining Contractual Life&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Aggregate Intrinsic Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Options Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Aggregate Intrinsic Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zpuOPQ73lAua" style="width: 12%; text-align: right" title="Options outstanding"&gt;4,306,977&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zlB135Ixbs0g" title="Options outstanding, weighted average remaining contractual life"&gt;7.96&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z6s9z4Tfe23g" style="width: 12%; text-align: right" title="Options outstanding, weighted average exercise price"&gt;11.13&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pp0p0_c20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zaI6V7rIDWik" style="width: 12%; text-align: right" title="Options outstanding, aggregate intrinsic value"&gt;13,914,458&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zNs1vu03paZi" style="width: 12%; text-align: right" title="Options exercisable"&gt;2,011,474&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zYO9GUIJqj6l" style="width: 12%; text-align: right" title="Options exercisable, weighted average exercise price"&gt;7.35&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4NHWs1M5Klb" style="width: 12%; text-align: right" title="Options exercisable, aggregate intrinsic value"&gt;11,781,660&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_zM2nNZh2BdGk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;The Company recognized stock-based compensation expense for stock options
of $&lt;span id="xdx_901_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z2Ij1CKZiohc" title="Recognized stock-based compensation expense"&gt;6,626,402&lt;/span&gt; and $&lt;span id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zthctUGcW1x1" title="Recognized stock-based compensation expense"&gt;4,716,475&lt;/span&gt; for the years ended December 31, 2024 and 2023, respectively. In May 2022, the Company modified the exercise
price on &lt;span id="xdx_900_ecustom--StockOptionAwardsSharesModified_iI_c20220531__us-gaap--PlanNameAxis__custom--MayTwoThousandTwentyTwoExercisePriceModificationMember_zMu9IcaD1gei" title="Stock option awards shares modified"&gt;776,324&lt;/span&gt; stock option awards to $&lt;span id="xdx_904_ecustom--ModifiedStockOptionExercisePrice_iI_c20220531__us-gaap--PlanNameAxis__custom--MayTwoThousandTwentyTwoExercisePriceModificationMember_zrI3NB8onBGd" title="Stock option exercise price per share"&gt;5.50&lt;/span&gt;, the closing market price on the Nasdaq Capital Market on May 17,2022. The effect of this
modification on stock-based compensation was $&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_pp0p0_c20240101__20241231__us-gaap--PlanNameAxis__custom--MayTwoThousandTwentyTwoExercisePriceModificationMember_zK8zr4ymllGb" title="Stock based compensation expense related to modification"&gt;106,000&lt;/span&gt; and $&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_pp0p0_c20230101__20231231__us-gaap--PlanNameAxis__custom--MayTwoThousandTwentyTwoExercisePriceModificationMember_z86b0ScheOb" title="Stock based compensation expense related to modification"&gt;134,000&lt;/span&gt; for the years ended December 31, 2024 and 2023, respectively. The effect
of this modification on stock-based compensation over the remaining service period will be approximately $&lt;span id="xdx_902_ecustom--RemainingStockBasedCompensationExpenseRelatedToModification_pdp0_c20240101__20241231__us-gaap--PlanNameAxis__custom--MayTwoThousandTwentyTwoExercisePriceModificationMember_zhOlYVakGVQk" title="Remaining stock based compensation expense related to modification"&gt;57,000&lt;/span&gt;. In December 2021, the
Company modified the exercise price on &lt;span id="xdx_903_ecustom--StockOptionAwardsSharesModified_iI_c20211231__us-gaap--PlanNameAxis__custom--DecemberTwoThousandTwentyOneExercisePriceModificationMember_zLWEK4WL3HE9" title="Stock option awards shares modified"&gt;311,000&lt;/span&gt; stock option awards to $&lt;span id="xdx_90C_ecustom--ModifiedStockOptionExercisePrice_iI_c20211231__us-gaap--PlanNameAxis__custom--DecemberTwoThousandTwentyOneExercisePriceModificationMember_zBR1hrTDyBL1" title="Stock option exercise price per share"&gt;13.44&lt;/span&gt;, the closing market price on the Nasdaq Capital Market on
December 15, 2021. No director or officer awards were modified. The effect on stock-based compensation was $&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_pp0p0_c20240101__20241231__us-gaap--PlanNameAxis__custom--DecemberTwoThousandTwentyOneExercisePriceModificationMember_zs7MfDLj4Je2" title="Stock based compensation expense related to modification"&gt;63,000&lt;/span&gt; and $&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_pp0p0_c20230101__20231231__us-gaap--PlanNameAxis__custom--DecemberTwoThousandTwentyOneExercisePriceModificationMember_z9DvLiy1lnsh" title="Stock based compensation expense related to modification"&gt;65,000&lt;/span&gt; for the
years ended December 31, 2024 and 2023, respectively. The effect on stock-based compensation over the remaining service period will be
approximately $&lt;span id="xdx_903_ecustom--RemainingStockBasedCompensationExpenseRelatedToModification_c20240101__20241231__us-gaap--PlanNameAxis__custom--DecemberTwoThousandTwentyOneExercisePriceModificationMember_zHxFEnBStVxa" title="Remaining stock based compensation expense related to modification"&gt;35,000&lt;/span&gt;. In May 2020, the Company modified the exercise price on &lt;span id="xdx_909_ecustom--StockOptionAwardsSharesModified_iI_c20200531__us-gaap--PlanNameAxis__custom--MayTwoThousandTwentyExercisePriceModificationMember_zPmCcuOZAGuj" title="Stock option awards shares modified"&gt;203,750&lt;/span&gt; stock option awards to $&lt;span id="xdx_907_ecustom--ModifiedStockOptionExercisePrice_iI_c20200531__us-gaap--PlanNameAxis__custom--MayTwoThousandTwentyExercisePriceModificationMember_zEAhVaMiniV6" title="Stock option exercise price per share"&gt;5.10&lt;/span&gt;, the closing market
price on the Nasdaq Capital Market on May 14, 2020. No director or officer awards were modified. The effect on stock-based compensation
was $&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_pp0p0_c20240101__20241231__us-gaap--PlanNameAxis__custom--MayTwoThousandTwentyExercisePriceModificationMember_zjCIyWfxx8kh" title="Stock based compensation expense related to modification"&gt;696&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_pp0p0_c20230101__20231231__us-gaap--PlanNameAxis__custom--MayTwoThousandTwentyExercisePriceModificationMember_zIbRdVdy4F4k" title="Stock based compensation expense related to modification"&gt;19,000&lt;/span&gt; for the years ended December 31, 2024 and 2023, respectively. There is no effect on stock-based compensation remaining.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 4.9pt 0 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zi73cEuSmWcd" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 4.9pt 0 0"&gt;The Black-Scholes option-pricing model was used to estimate the
fair value of equity-based awards and the Monte Carlo simulation model was used to estimate the fair value of the performance-based awards,
with the following weighted-average assumptions for the years ended December 31:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 4.9pt 0 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BD_zHcfdfNr9DFl" style="display: none"&gt;Schedule
of Assumptions for Fair Value of Equity-based Awards&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 84%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20240101__20241231_z1XNMJkdpoic" title="Risk-free interest rate, minimum"&gt;3.48&lt;/span&gt;% - &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20240101__20241231_zhikFLceRTj2" title="Risk-free interest rate, maximum"&gt;4.71&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20230101__20231231_zoSbEHdl2yq3" title="Risk-free interest rate, minimum"&gt;3.41&lt;/span&gt;% - &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20230101__20231231_zoIxufmX3D6j" title="Risk-free interest rate, maximum"&gt;4.86&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;&#160;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20240101__20241231_zuYuGglRn2gd" title="Expected volatility, minimum"&gt;71.2&lt;/span&gt;% - &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20240101__20241231_zan1YJLKGjMl" title="Expected volatility, maximum"&gt;76.20&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20230101__20231231_zTjU6ctWXmQh" title="Expected volatility, minimum"&gt;77.1&lt;/span&gt;% - &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20230101__20231231_zNAdQkiZXBB2" title="Expected volatility, maximum"&gt;79.8&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Expected life (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_ztcUXQwc3aKf" title="Expected life (years)"&gt;5.25&lt;/span&gt; to &lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_zLukX40oGYQi" title="Expected life (years)"&gt;10.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_ztrk0FdUILQj" title="Expected life (years)"&gt;5.25&lt;/span&gt; to &lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_zH5GuzyAtgvh" title="Expected life (years)"&gt;6.08&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 70%; text-align: justify"&gt;Expected dividend yield&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20241231_z6k1cfE1V3Ql" style="white-space: nowrap; width: 12%; text-align: right" title="Expected dividend yield"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20231231_ztVVj0EN6zzc" style="white-space: nowrap; width: 12%; text-align: right" title="Expected dividend yield"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_zJTc14J4s0Xa" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;The inputs for the Black-Scholes valuation model and the Monte Carlo simulation
model require management&#x2019;s significant assumptions. Prior to the Company&#x2019;s initial public offering, the price per share of
common stock was determined by the Company&#x2019;s board based on recent prices of common stock sold in private offerings. Subsequent
to the initial public offering, the price per share of common stock is determined by using the closing market price on the Nasdaq Capital
Market on the grant date. The risk-free interest rates are based on the rate for U.S. Treasury securities at the date of grant with maturity
dates approximately equal to the expected life at the grant date. The expected life is based on the simplified method for the time-based
awards and the life of the option for the performance-based awards, in accordance with the SEC Staff Accounting Bulletin Nos. 107 and
110. The expected volatility is estimated based on historical volatility information of peer companies that are publicly available in
combination with the Company&#x2019;s calculated volatility since being publicly traded for the time-based awards. For the performance-based
awards, the Company&#x2019;s full historical volatility was used to value the options.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;All assumptions used to calculate the grant date fair value of non-employee
options are generally consistent with the assumptions used for options granted to employees. In the event the Company terminates any of
its consulting agreements, the unvested options issued in connection with the agreements would also be cancelled.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;The Company had &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_pid_c20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zyz9NJPipx76" title="Restricted stock awards outstanding"&gt;1,079&lt;/span&gt; and &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_pid_c20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zC846HM4wu1e" title="Restricted stock awards outstanding"&gt;1,958&lt;/span&gt; shares of restricted stock outstanding
at December 31, 2024 and 2023, respectively, and &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zhLZjZ9GRrL2" title="Restricted stock awards vested"&gt;2,308&lt;/span&gt; and &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zYwuq1lotWr" title="Restricted stock awards vested"&gt;3,273&lt;/span&gt; shares of restricted stock vested during the years ended December 31,
2024 and 2023, respectively. The Company recognized stock-based compensation expense for restricted stock of $&lt;span id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zQClfC2rh6K6" title="Recognized stock-based compensation expense"&gt;22,220&lt;/span&gt; and $&lt;span id="xdx_908_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zHg1gQ7rcRhd" title="Recognized stock-based compensation expense"&gt;18,499&lt;/span&gt; for the
years ended December 31, 2024 and 2023, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;The total remaining shares available for grant under the Company&#x2019;s
2017 Plan as of December 31, 2024 was &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenPlanMember_zvVaB84mvc22" title="Shares available for grant under the 2017 Plan"&gt;1,177,450&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&#160;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_zFlXY2ZIJtIf" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;Total unrecognized compensation cost related to stock options and restricted
stock is estimated to be recognized at December 31:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BF_zruehIE5AH0e" style="display: none"&gt;Schedule
of Unrecognized Compensation Cost&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_497_20241231_zDiqDKG6Yend" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_ecustom--EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostToBeRecognizedNextTwelveMonths_iI_pp0p0_maESSBCzuFt_zL2GOdxD4VQ1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 85%; text-align: justify"&gt;2025&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;7,776,307&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostToBeRecognizedWithinTwoYear_iI_pp0p0_maESSBCzuFt_zcDSPaQcZ7Vf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,307,024&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostToBeRecognizedwithinThreeYears_iI_pp0p0_maESSBCzuFt_zUon9dbpcGAk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,165,880&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostToBeRecognizedWithinFourYears_iI_pp0p0_maESSBCzuFt_zShnqUzpWSag" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;2028&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,964,136&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostToBeRecognized_iTI_pp0p0_mtESSBCzuFt_zFTAbaTPyOAj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt; text-indent: 10.05pt"&gt;Total estimated compensation cost to be recognized&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;21,213,347&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_zcEaKapNqQVk" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;2017 Employee Stock Purchase Plan&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;The Company&#x2019;s 2017 Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;)
was adopted by the Company&#x2019;s board on September 6, 2017 and approved by stockholders at the Company&#x2019;s annual stockholder meeting
on May 10, 2018. The Company initially reserved a total of &lt;span id="xdx_908_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20180510__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_zWkJLEboRYu8" title="Common stock, shares reserved for issuance"&gt;100,000&lt;/span&gt; shares for issuance under the ESPP. The number of shares reserved for
issuance was automatically increased by &lt;span id="xdx_90A_ecustom--ChangeInCommonStockSharesReservedForIssuance_iI_pid_c20240101__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_zplg5h83yCw1" title="Change in common stock, shares reserved for issuance"&gt;127,530&lt;/span&gt; and &lt;span id="xdx_90A_ecustom--ChangeInCommonStockSharesReservedForIssuance_iI_pid_c20230101__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_zgxHaixpYMVb" title="Change in common stock, shares reserved for issuance"&gt;108,337&lt;/span&gt; shares on January 1, 2024 and 2023, respectively and will increase automatically
on each subsequent January 1 by &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_zjzjj9Oukk05" title="Annual employee stock purchase plan description"&gt;the number of shares equal to 0.5% of the total outstanding number of shares of Company common stock as
of the immediately preceding December 31.&lt;/span&gt; However, the Company&#x2019;s board may reduce the amount of the increase in any particular year.
The total remaining shares available for issuance under the employee stock purchase plan as of December 31, 2024 is &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_zAoN60aqUax5" title="Shares available for grant under the 2017 Plan"&gt;360,950&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;The ESPP provides participating employees with an opportunity to purchase
shares of the Company&#x2019;s common stock at a discount through payroll deductions. The ESPP is available to all employees unless they
are employed for less than 20 hours per week or own 5% or more of the total combined voting power or value of the Company&#x2019;s common
stock. The ESPP is administered using overlapping 24 month offering periods, referred to as an Offering Period. Each Offering Period has
four six-month purchase periods. A new Offering Period and purchase period begin every six months on May 1 and November 1 of each year.
Participating employees may purchase common stock, on a voluntary after tax-basis, at a price equal to 85% of the fair market value of
a share of common stock on either the offering date or the purchase date, whichever is lower. If the purchase date has a lower price,
the employee will automatically be placed in the Offering Period beginning immediately after the purchase date. The Company recognized
stock-based compensation expense related to the ESPP of $&lt;span id="xdx_908_eus-gaap--AllocatedShareBasedCompensationExpense_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockIncentivePlanMember_zPgOedyf822b" title="Recognized stock-based compensation expense"&gt;339,719&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockIncentivePlanMember_zgmMNiIojL2h" title="Recognized stock-based compensation expense"&gt;166,460&lt;/span&gt; for the years ended December 31, 2024 and 2023, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zqjQEPVij6Hl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company recognized total stock-based compensation
expense as follows for the years ended December 31:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BC_zjAZERWI5os" style="display: none"&gt;Schedule
of Stock-based Compensation Expenses&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20240101__20241231_z4pmCOqoASr7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20230101__20231231_zIZEONn9stw4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Years Ended&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31:&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Stock-based compensation expense in operating expenses:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zE5iyqF5CJ8l" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 70%; text-align: justify; text-indent: 10pt"&gt;Research and development&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;4,404,518&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;2,700,318&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zGtGu59uNYjh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt; text-indent: 10pt"&gt;General and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,583,823&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,201,116&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--ShareBasedCompensation_zQia2ur1xLX7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt; text-indent: 10pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;6,988,341&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;4,901,434&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--ShareBasedCompensation_zcZVzUBneNid" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt; text-indent: 10pt"&gt;Stock-based compensation expense&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;6,988,341&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;4,901,434&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A1_zb28X9McXF7f" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2012-08-10_custom_EquityIncentivePlanMember"
      decimals="INF"
      id="Fact000992"
      unitRef="Shares">625000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2017-10-25_custom_StockIncentivePlanMember"
      decimals="INF"
      id="Fact000994"
      unitRef="Shares">750000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <CELC:ChangeInCommonStockSharesReservedForIssuance
      contextRef="AsOf2024-01-01_custom_StockIncentivePlanMember"
      decimals="INF"
      id="Fact000996"
      unitRef="Shares">255060</CELC:ChangeInCommonStockSharesReservedForIssuance>
    <CELC:ChangeInCommonStockSharesReservedForIssuance
      contextRef="AsOf2023-01-01_custom_StockIncentivePlanMember"
      decimals="INF"
      id="Fact000998"
      unitRef="Shares">216673</CELC:ChangeInCommonStockSharesReservedForIssuance>
    <CELC:ChangeInCommonStockSharesReservedForIssuance
      contextRef="AsOf2021-05-12_custom_StockIncentivePlanMember"
      decimals="INF"
      id="Fact001000"
      unitRef="Shares">500000</CELC:ChangeInCommonStockSharesReservedForIssuance>
    <CELC:ChangeInCommonStockSharesReservedForIssuance
      contextRef="AsOf2022-05-12_custom_StockIncentivePlanMember"
      decimals="INF"
      id="Fact001002"
      unitRef="Shares">500000</CELC:ChangeInCommonStockSharesReservedForIssuance>
    <CELC:TotalCommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2021-05-12_custom_StockIncentivePlanMember"
      decimals="INF"
      id="Fact001004"
      unitRef="Shares">1000000</CELC:TotalCommonStockCapitalSharesReservedForFutureIssuance>
    <CELC:TotalCommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2022-05-12_custom_StockIncentivePlanMember"
      decimals="INF"
      id="Fact001006"
      unitRef="Shares">1000000</CELC:TotalCommonStockCapitalSharesReservedForFutureIssuance>
    <CELC:TotalCommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2023-05-11_custom_StockIncentivePlanMember"
      decimals="INF"
      id="Fact001008"
      unitRef="Shares">1500000</CELC:TotalCommonStockCapitalSharesReservedForFutureIssuance>
    <CELC:TotalCommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2024-05-09_custom_StockIncentivePlanMember"
      decimals="INF"
      id="Fact001010"
      unitRef="Shares">3000000</CELC:TotalCommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001012">&lt;p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zOSgvTIVLrI" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;The following table summarizes the activity for all stock options outstanding
for the years ended December 31:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B6_zl6OpamZLCef" style="display: none"&gt;Schedule of Stock Options Activity&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: justify"&gt;Options outstanding at beginning of year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zSPYsmp3gBwc" style="width: 12%; text-align: right" title="Options outstanding at beginning of year"&gt;2,815,392&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zmesmf88ipEf" style="width: 12%; text-align: right" title="Options outstanding, weighted average exercise price at beginning of year"&gt;7.95&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zmfBnJOTCI6a" style="width: 12%; text-align: right" title="Options outstanding at beginning of year"&gt;1,976,586&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zCBET0BdBjxa" style="width: 12%; text-align: right" title="Options outstanding, weighted average exercise price at beginning of year"&gt;6.34&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_z9St0zHMEwu1" style="text-align: right" title="Shares, Granted"&gt;1,716,729&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zGD33vgHmzEg" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;16.14&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zfISnnkWBnl1" style="text-align: right" title="Shares, Granted"&gt;1,003,298&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zjbip3FB4WRk" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;10.69&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zHJlvZJj8Zm5" style="text-align: right" title="Shares, Exercised"&gt;(103,245&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zDuKZUDpU8J4" style="text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;7.45&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_ze5YikrvvFd2" style="text-align: right" title="Shares, Exercised"&gt;(98,695&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zpugTMFU0Hn7" style="text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;3.94&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify; padding-bottom: 1pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zBIb2UJGk9f3" style="border-bottom: Black 1pt solid; text-align: right" title="Shares, Forfeited"&gt;(121,899&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zUV6nYVTuh13" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise, Forfeited"&gt;11.57&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zSbSduUjp7d7" style="border-bottom: Black 1pt solid; text-align: right" title="Shares, Forfeited"&gt;(65,797&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zxA7HOqB6AK4" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise, Forfeited"&gt;7.45&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify; padding-bottom: 1pt"&gt;Balance at December 31:&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_z9AKSp0QPPxe" style="border-bottom: Black 1pt solid; text-align: right" title="Options outstanding at end of year"&gt;4,306,977&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zrGgSswWkEri" style="border-bottom: Black 1pt solid; text-align: right" title="Options outstanding, weighted average exercise price at end of year"&gt;11.13&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zruFBhv5jPE2" style="border-bottom: Black 1pt solid; text-align: right" title="Options outstanding at end of year"&gt;2,815,392&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zLTfuTkJ2kz9" style="border-bottom: Black 1pt solid; text-align: right" title="Options outstanding, weighted average exercise price at end of year"&gt;7.95&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Options exercisable at December 31:&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zPa7Q8m6DZj" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares, options exercisable"&gt;2,011,474&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zTG5EMBmFq7i" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price, Options exercisable"&gt;7.35&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zOW35pU1Ftd1" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares, options exercisable"&gt;1,524,731&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_z3k2bDel1Ute" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price, Options exercisable"&gt;6.44&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Weighted Average Grant Date Fair Value for options granted during the year:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zkqfx8wCiia5" style="text-align: right" title="Weighted Average Grant Date Fair Value for options granted during the period"&gt;11.22&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmployeeStockOptionMember_zIgbZ80Sv321" style="text-align: right" title="Weighted Average Grant Date Fair Value for options granted during the period"&gt;7.48&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001014"
      unitRef="Shares">2815392</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001016"
      unitRef="USDPShares">7.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001018"
      unitRef="Shares">1976586</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001020"
      unitRef="USDPShares">6.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember1617134281"
      decimals="INF"
      id="Fact001022"
      unitRef="Shares">1716729</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember1617134281"
      decimals="INF"
      id="Fact001024"
      unitRef="USDPShares">16.14</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember1617134281"
      decimals="INF"
      id="Fact001026"
      unitRef="Shares">1003298</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember1617134281"
      decimals="INF"
      id="Fact001028"
      unitRef="USDPShares">10.69</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember1617134281"
      decimals="INF"
      id="Fact001030"
      unitRef="Shares">103245</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember1617134281"
      decimals="INF"
      id="Fact001032"
      unitRef="USDPShares">7.45</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember1617134281"
      decimals="INF"
      id="Fact001034"
      unitRef="Shares">98695</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember1617134281"
      decimals="INF"
      id="Fact001036"
      unitRef="USDPShares">3.94</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember1617134281"
      decimals="INF"
      id="Fact001038"
      unitRef="Shares">121899</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember1617134281"
      decimals="INF"
      id="Fact001040"
      unitRef="USDPShares">11.57</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember1617134281"
      decimals="INF"
      id="Fact001042"
      unitRef="Shares">65797</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember1617134281"
      decimals="INF"
      id="Fact001044"
      unitRef="USDPShares">7.45</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001046"
      unitRef="Shares">4306977</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001048"
      unitRef="USDPShares">11.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001050"
      unitRef="Shares">2815392</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001052"
      unitRef="USDPShares">7.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001054"
      unitRef="Shares">2011474</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001056"
      unitRef="USDPShares">7.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001058"
      unitRef="Shares">1524731</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001060"
      unitRef="USDPShares">6.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember1617134281"
      decimals="INF"
      id="Fact001062"
      unitRef="USDPShares">11.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember1617134281"
      decimals="INF"
      id="Fact001064"
      unitRef="USDPShares">7.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001066">&lt;p id="xdx_89C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_z03Q5zIYvzg7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-weight: normal"&gt;The
following table summarizes additional information about stock options outstanding and exercisable at December 31, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-weight: normal"&gt;&#160;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BE_zbSIJPkNPEXi" style="display: none"&gt;Schedule
of Stock Options Outstanding and Exercisable&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Options Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Options Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Options Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Remaining Contractual Life&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Aggregate Intrinsic Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Options Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Aggregate Intrinsic Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zpuOPQ73lAua" style="width: 12%; text-align: right" title="Options outstanding"&gt;4,306,977&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zlB135Ixbs0g" title="Options outstanding, weighted average remaining contractual life"&gt;7.96&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z6s9z4Tfe23g" style="width: 12%; text-align: right" title="Options outstanding, weighted average exercise price"&gt;11.13&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pp0p0_c20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zaI6V7rIDWik" style="width: 12%; text-align: right" title="Options outstanding, aggregate intrinsic value"&gt;13,914,458&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zNs1vu03paZi" style="width: 12%; text-align: right" title="Options exercisable"&gt;2,011,474&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zYO9GUIJqj6l" style="width: 12%; text-align: right" title="Options exercisable, weighted average exercise price"&gt;7.35&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4NHWs1M5Klb" style="width: 12%; text-align: right" title="Options exercisable, aggregate intrinsic value"&gt;11,781,660&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember1617134453"
      decimals="INF"
      id="Fact001068"
      unitRef="Shares">4306977</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember"
      id="Fact001070">P7Y11M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember1617134453"
      decimals="INF"
      id="Fact001072"
      unitRef="USDPShares">11.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember1617134453"
      decimals="0"
      id="Fact001074"
      unitRef="USD">13914458</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember1617134453"
      decimals="INF"
      id="Fact001076"
      unitRef="Shares">2011474</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember1617134453"
      decimals="INF"
      id="Fact001078"
      unitRef="USDPShares">7.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember1617134453"
      decimals="0"
      id="Fact001080"
      unitRef="USD">11781660</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      id="Fact001082"
      unitRef="USD">6626402</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      id="Fact001084"
      unitRef="USD">4716475</us-gaap:AllocatedShareBasedCompensationExpense>
    <CELC:StockOptionAwardsSharesModified
      contextRef="AsOf2022-05-31_custom_MayTwoThousandTwentyTwoExercisePriceModificationMember"
      decimals="INF"
      id="Fact001086"
      unitRef="Shares">776324</CELC:StockOptionAwardsSharesModified>
    <CELC:ModifiedStockOptionExercisePrice
      contextRef="AsOf2022-05-31_custom_MayTwoThousandTwentyTwoExercisePriceModificationMember"
      decimals="INF"
      id="Fact001088"
      unitRef="USDPShares">5.50</CELC:ModifiedStockOptionExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
      contextRef="From2024-01-012024-12-31_custom_MayTwoThousandTwentyTwoExercisePriceModificationMember"
      decimals="0"
      id="Fact001090"
      unitRef="USD">106000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
      contextRef="From2023-01-012023-12-31_custom_MayTwoThousandTwentyTwoExercisePriceModificationMember"
      decimals="0"
      id="Fact001092"
      unitRef="USD">134000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <CELC:RemainingStockBasedCompensationExpenseRelatedToModification
      contextRef="From2024-01-012024-12-31_custom_MayTwoThousandTwentyTwoExercisePriceModificationMember"
      decimals="0"
      id="Fact001094"
      unitRef="USD">57000</CELC:RemainingStockBasedCompensationExpenseRelatedToModification>
    <CELC:StockOptionAwardsSharesModified
      contextRef="AsOf2021-12-31_custom_DecemberTwoThousandTwentyOneExercisePriceModificationMember"
      decimals="INF"
      id="Fact001096"
      unitRef="Shares">311000</CELC:StockOptionAwardsSharesModified>
    <CELC:ModifiedStockOptionExercisePrice
      contextRef="AsOf2021-12-31_custom_DecemberTwoThousandTwentyOneExercisePriceModificationMember"
      decimals="INF"
      id="Fact001098"
      unitRef="USDPShares">13.44</CELC:ModifiedStockOptionExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
      contextRef="From2024-01-012024-12-31_custom_DecemberTwoThousandTwentyOneExercisePriceModificationMember"
      decimals="0"
      id="Fact001100"
      unitRef="USD">63000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
      contextRef="From2023-01-012023-12-31_custom_DecemberTwoThousandTwentyOneExercisePriceModificationMember"
      decimals="0"
      id="Fact001102"
      unitRef="USD">65000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <CELC:RemainingStockBasedCompensationExpenseRelatedToModification
      contextRef="From2024-01-012024-12-31_custom_DecemberTwoThousandTwentyOneExercisePriceModificationMember"
      decimals="0"
      id="Fact001104"
      unitRef="USD">35000</CELC:RemainingStockBasedCompensationExpenseRelatedToModification>
    <CELC:StockOptionAwardsSharesModified
      contextRef="AsOf2020-05-31_custom_MayTwoThousandTwentyExercisePriceModificationMember"
      decimals="INF"
      id="Fact001106"
      unitRef="Shares">203750</CELC:StockOptionAwardsSharesModified>
    <CELC:ModifiedStockOptionExercisePrice
      contextRef="AsOf2020-05-31_custom_MayTwoThousandTwentyExercisePriceModificationMember"
      decimals="INF"
      id="Fact001108"
      unitRef="USDPShares">5.10</CELC:ModifiedStockOptionExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
      contextRef="From2024-01-012024-12-31_custom_MayTwoThousandTwentyExercisePriceModificationMember"
      decimals="0"
      id="Fact001110"
      unitRef="USD">696</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
      contextRef="From2023-01-012023-12-31_custom_MayTwoThousandTwentyExercisePriceModificationMember"
      decimals="0"
      id="Fact001112"
      unitRef="USD">19000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001114">&lt;p id="xdx_894_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zi73cEuSmWcd" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 4.9pt 0 0"&gt;The Black-Scholes option-pricing model was used to estimate the
fair value of equity-based awards and the Monte Carlo simulation model was used to estimate the fair value of the performance-based awards,
with the following weighted-average assumptions for the years ended December 31:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 4.9pt 0 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BD_zHcfdfNr9DFl" style="display: none"&gt;Schedule
of Assumptions for Fair Value of Equity-based Awards&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 84%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20240101__20241231_z1XNMJkdpoic" title="Risk-free interest rate, minimum"&gt;3.48&lt;/span&gt;% - &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20240101__20241231_zhikFLceRTj2" title="Risk-free interest rate, maximum"&gt;4.71&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20230101__20231231_zoSbEHdl2yq3" title="Risk-free interest rate, minimum"&gt;3.41&lt;/span&gt;% - &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20230101__20231231_zoIxufmX3D6j" title="Risk-free interest rate, maximum"&gt;4.86&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;&#160;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20240101__20241231_zuYuGglRn2gd" title="Expected volatility, minimum"&gt;71.2&lt;/span&gt;% - &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20240101__20241231_zan1YJLKGjMl" title="Expected volatility, maximum"&gt;76.20&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20230101__20231231_zTjU6ctWXmQh" title="Expected volatility, minimum"&gt;77.1&lt;/span&gt;% - &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20230101__20231231_zNAdQkiZXBB2" title="Expected volatility, maximum"&gt;79.8&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Expected life (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_ztcUXQwc3aKf" title="Expected life (years)"&gt;5.25&lt;/span&gt; to &lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_zLukX40oGYQi" title="Expected life (years)"&gt;10.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_ztrk0FdUILQj" title="Expected life (years)"&gt;5.25&lt;/span&gt; to &lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_zH5GuzyAtgvh" title="Expected life (years)"&gt;6.08&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 70%; text-align: justify"&gt;Expected dividend yield&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20241231_z6k1cfE1V3Ql" style="white-space: nowrap; width: 12%; text-align: right" title="Expected dividend yield"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20231231_ztVVj0EN6zzc" style="white-space: nowrap; width: 12%; text-align: right" title="Expected dividend yield"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001116"
      unitRef="Pure">0.0348</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001118"
      unitRef="Pure">0.0471</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001120"
      unitRef="Pure">0.0341</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001122"
      unitRef="Pure">0.0486</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001124"
      unitRef="Pure">0.712</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001126"
      unitRef="Pure">0.7620</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001128"
      unitRef="Pure">0.771</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001130"
      unitRef="Pure">0.798</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2024-01-012024-12-31_srt_MinimumMember"
      id="Fact001132">P5Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2024-01-012024-12-31_srt_MaximumMember"
      id="Fact001134">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2023-01-012023-12-31_srt_MinimumMember"
      id="Fact001136">P5Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2023-01-012023-12-31_srt_MaximumMember"
      id="Fact001138">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001140"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001142"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2024-12-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="Fact001144"
      unitRef="Shares">1079</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2023-12-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="Fact001146"
      unitRef="Shares">1958</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockMember1617133937"
      decimals="INF"
      id="Fact001148"
      unitRef="Shares">2308</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockMember1617133937"
      decimals="INF"
      id="Fact001150"
      unitRef="Shares">3273</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockMember1617133937"
      decimals="0"
      id="Fact001152"
      unitRef="USD">22220</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockMember1617133937"
      decimals="0"
      id="Fact001154"
      unitRef="USD">18499</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2024-12-31_custom_TwoThousandSeventeenPlanMember"
      decimals="INF"
      id="Fact001156"
      unitRef="Shares">1177450</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001158">&lt;p id="xdx_89C_eus-gaap--ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_zFlXY2ZIJtIf" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;Total unrecognized compensation cost related to stock options and restricted
stock is estimated to be recognized at December 31:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BF_zruehIE5AH0e" style="display: none"&gt;Schedule
of Unrecognized Compensation Cost&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_497_20241231_zDiqDKG6Yend" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_ecustom--EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostToBeRecognizedNextTwelveMonths_iI_pp0p0_maESSBCzuFt_zL2GOdxD4VQ1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 85%; text-align: justify"&gt;2025&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;7,776,307&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostToBeRecognizedWithinTwoYear_iI_pp0p0_maESSBCzuFt_zcDSPaQcZ7Vf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,307,024&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostToBeRecognizedwithinThreeYears_iI_pp0p0_maESSBCzuFt_zUon9dbpcGAk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,165,880&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostToBeRecognizedWithinFourYears_iI_pp0p0_maESSBCzuFt_zShnqUzpWSag" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;2028&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,964,136&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostToBeRecognized_iTI_pp0p0_mtESSBCzuFt_zFTAbaTPyOAj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt; text-indent: 10.05pt"&gt;Total estimated compensation cost to be recognized&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;21,213,347&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock>
    <CELC:EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostToBeRecognizedNextTwelveMonths
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001160"
      unitRef="USD">7776307</CELC:EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostToBeRecognizedNextTwelveMonths>
    <CELC:EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostToBeRecognizedWithinTwoYear
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001162"
      unitRef="USD">6307024</CELC:EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostToBeRecognizedWithinTwoYear>
    <CELC:EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostToBeRecognizedwithinThreeYears
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001164"
      unitRef="USD">5165880</CELC:EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostToBeRecognizedwithinThreeYears>
    <CELC:EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostToBeRecognizedWithinFourYears
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001166"
      unitRef="USD">1964136</CELC:EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostToBeRecognizedWithinFourYears>
    <CELC:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostToBeRecognized
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001168"
      unitRef="USD">21213347</CELC:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostToBeRecognized>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2018-05-10_custom_EmployeeStockPurchasePlanMember"
      decimals="INF"
      id="Fact001170"
      unitRef="Shares">100000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <CELC:ChangeInCommonStockSharesReservedForIssuance
      contextRef="AsOf2024-01-01_custom_EmployeeStockPurchasePlanMember"
      decimals="INF"
      id="Fact001172"
      unitRef="Shares">127530</CELC:ChangeInCommonStockSharesReservedForIssuance>
    <CELC:ChangeInCommonStockSharesReservedForIssuance
      contextRef="AsOf2023-01-01_custom_EmployeeStockPurchasePlanMember"
      decimals="INF"
      id="Fact001174"
      unitRef="Shares">108337</CELC:ChangeInCommonStockSharesReservedForIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription
      contextRef="From2024-01-012024-12-31_custom_EmployeeStockPurchasePlanMember"
      id="Fact001176">the number of shares equal to 0.5% of the total outstanding number of shares of Company common stock as
of the immediately preceding December 31.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2024-12-31_custom_EmployeeStockPurchasePlanMember"
      decimals="INF"
      id="Fact001178"
      unitRef="Shares">360950</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-12-31_custom_StockIncentivePlanMember"
      decimals="0"
      id="Fact001180"
      unitRef="USD">339719</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31_custom_StockIncentivePlanMember"
      decimals="0"
      id="Fact001182"
      unitRef="USD">166460</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001184">&lt;p id="xdx_89A_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zqjQEPVij6Hl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company recognized total stock-based compensation
expense as follows for the years ended December 31:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BC_zjAZERWI5os" style="display: none"&gt;Schedule
of Stock-based Compensation Expenses&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20240101__20241231_z4pmCOqoASr7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20230101__20231231_zIZEONn9stw4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Years Ended&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31:&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Stock-based compensation expense in operating expenses:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zE5iyqF5CJ8l" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 70%; text-align: justify; text-indent: 10pt"&gt;Research and development&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;4,404,518&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;2,700,318&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zGtGu59uNYjh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt; text-indent: 10pt"&gt;General and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,583,823&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,201,116&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--ShareBasedCompensation_zQia2ur1xLX7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt; text-indent: 10pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;6,988,341&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;4,901,434&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--ShareBasedCompensation_zcZVzUBneNid" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt; text-indent: 10pt"&gt;Stock-based compensation expense&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;6,988,341&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;4,901,434&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-12-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      id="Fact001186"
      unitRef="USD">4404518</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-12-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      id="Fact001187"
      unitRef="USD">2700318</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact001189"
      unitRef="USD">2583823</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact001190"
      unitRef="USD">2201116</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001192"
      unitRef="USD">6988341</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001193"
      unitRef="USD">4901434</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001195"
      unitRef="USD">6988341</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001196"
      unitRef="USD">4901434</us-gaap:ShareBasedCompensation>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001198">&lt;p id="xdx_807_eus-gaap--DebtDisclosureTextBlock_zMNrH3n0QoW1" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt; &lt;b&gt;12.&lt;/b&gt; &lt;b&gt;&lt;span id="xdx_824_zR4RVYUpgQR3"&gt;Debt&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On May 30, 2024, the Company entered into an Amended
and Restated Loan and Security Agreement (the &#x201c;A&amp;amp;R Loan Agreement&#x201d;) with Innovatus Life Sciences Lending Fund I, LP, a
Delaware limited partnership (&#x201c;Innovatus&#x201d;), as collateral agent, and the Lenders including Innovatus in its capacity as a
Lender and Oxford Finance LLC (&#x201c;Oxford&#x201d;), pursuant to which Innovatus and Oxford, as Lenders, have agreed to make certain
term loans (&#x201c;Term Loans&#x201d;) to the Company in the aggregate principal amount of up to $&lt;span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_pn6n6_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__srt--RangeAxis__srt--MaximumMember_ztfxGLKU9yUi" title="Funded contingent loan, outstanding"&gt;180&lt;/span&gt; million. The A&amp;amp;R Loan Agreement
amends and restates, in its entirety, that certain Loan and Security Agreement, dated April 8, 2021, as amended, between the Company and
Innovatus, as collateral agent, and the Lenders named therein (the &#x201c;Prior Loan Agreement&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Funding of the first $&lt;span id="xdx_90A_eus-gaap--DebtInstrumentCarryingAmount_iI_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_zTSalFNX08oc" title="Funded loan amount"&gt;100&lt;/span&gt; million under the A&amp;amp;R
Loan Agreement occurred on May 30, 2024, including tranche payments of $&lt;span id="xdx_904_eus-gaap--DebtInstrumentCarryingAmount_iI_pn5n6_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermALoanMember_zi3GRpUmejQ" title="Funded loan amount"&gt;16.8&lt;/span&gt; million (the &#x201c;Term A Loan&#x201d;) and $&lt;span id="xdx_90B_eus-gaap--DebtInstrumentCarryingAmount_iI_pn5n6_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermBLoanMember_zvbZPwsSfz59" title="Funded loan amount"&gt;21.5&lt;/span&gt; million
(the &#x201c;Term B Loan&#x201d;) reflecting repayment of the principal amount of loans under the Prior Loan Agreement plus accrued payment-in-kind
interest, in addition to $&lt;span id="xdx_90E_eus-gaap--DebtInstrumentCarryingAmount_iI_pn5n6_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermCLoanMember_zrqJkjMwWZa6" title="Funded loan amount"&gt;61.7&lt;/span&gt; million of new borrowings (the &#x201c;Term C Loan&#x201d;). The Company will be eligible to draw on a fourth
tranche of $&lt;span id="xdx_90D_eus-gaap--DebtInstrumentCarryingAmount_iI_pn6n6_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermDLoanMember_zc9qqqOg8Oje" title="Funded loan amount"&gt;30&lt;/span&gt; million (the &#x201c;Term D Loan&#x201d;) and fifth tranche of $&lt;span id="xdx_909_eus-gaap--DebtInstrumentCarryingAmount_iI_pn6n6_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermELoanMember_ztkNXOFDwlz5" title="Funded loan amount"&gt;50&lt;/span&gt; million (the &#x201c;Term E Loan&#x201d;), in each case
upon achievement of certain clinical trial milestones and satisfaction of certain financial covenants determined on a pro forma as-funded
basis. The Lenders may, in their sole discretion upon the Company&#x2019;s request, make additional term loans to the Company of $&lt;span id="xdx_904_eus-gaap--DebtInstrumentCarryingAmount_iI_pn6n6_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermFLoanMember_z5LlJXBabZYf" title="Funded loan amount"&gt;45&lt;/span&gt; million
(the &#x201c;Term F Loan&#x201d;). Funding of these additional tranches is also subject to other customary conditions and limits on when
the Company can request funding for such tranches. Costs associated with the new borrowings was approximately $&lt;span id="xdx_908_eus-gaap--OtherBorrowings_iI_pn5n6_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_z0VgYGhNj4qa" title="Costs associated with new borrowings"&gt;2.4&lt;/span&gt; million.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Pursuant to the A&amp;amp;R Loan Agreement, &lt;span id="xdx_909_eus-gaap--DebtInstrumentInterestRateTerms_pid_dp_c20240530__20240530__us-gaap--TypeOfArrangementAxis__custom--AmendedAndRestatedLoanAgreementMember_zUcTcz1HmJW8" title="Debt instrument interest rate description"&gt;the Company
is entitled to make interest-only payments for thirty-six months, or up to forty-eight months if certain conditions are met. The Term
Loans will mature on May 1, 2029 and will bear interest at a rate equal to the sum of (a) the greater of (i) the Prime Rate (as defined
in the A&amp;amp;R Loan Agreement) or (ii) 7.75%, plus (b) 2.85%, provided that 1.0% of such interest will be payable in-kind by adding an
amount equal to such 1.0% of the outstanding principal amount to the then outstanding principal balance on a monthly basis through May
31, 2027.&lt;/span&gt; The A&amp;amp;R Loan Agreement is secured by all assets of the Company. Proceeds will be used for working capital purposes and to
fund the Company&#x2019;s general business requirements, including the Phase 3 VIKTORIA-2 clinical trial. The A&amp;amp;R Loan Agreement contains
customary representations and warranties and covenants, subject to customary carve-outs, and includes financial covenants related to liquidity
and other financial measures. Innovatus has the right, at its election and until August 9, 2025, to convert up to &lt;span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermALoanMember_zn4oUIqq2pW4" title="Loan conversion percentage"&gt;20&lt;/span&gt;% of the outstanding
principal of the Term A Loan into shares of the Company&#x2019;s common stock at a price per share of $&lt;span id="xdx_904_eus-gaap--SaleOfStockPricePerShare_iI_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermALoanMember_zj7cWUAWnNya" title="Common stock price per share"&gt;10.00&lt;/span&gt; (the &#x201c;Conversion Right&#x201d;).
Innovatus will continue to have the right to exercise a previously disclosed warrant granted to it under the Prior Loan Agreement to purchase
&lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240530__20240530__us-gaap--PlanNameAxis__custom--PriorLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_ziM1TP4R2dq1" title="Common stock issued"&gt;26,042&lt;/span&gt; shares of common stock at a price per share of $&lt;span id="xdx_90D_eus-gaap--SaleOfStockPricePerShare_iI_c20240530__us-gaap--PlanNameAxis__custom--PriorLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_zsPSU0AbrZni" title="Common stock price per share"&gt;14.40&lt;/span&gt; through April 8, 2031.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The A&amp;amp;R Loan Agreement contains a Final Fee, which
is equal to &lt;span id="xdx_90C_ecustom--FinalFeePercentage_dp_uPure_c20240530__20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_zCEAWTy4P444" title="Final fee percentage"&gt;4.5&lt;/span&gt;% of the initial funding of the agreement and is due on the earliest to occur of (a) the Maturity Date, (b) the acceleration
of any Term Loan, and (c) the prepayment of the Term Loans. There is also a contingent non-utilization fee for both the Term D and Term
E loans. If the Company achieves the Term D Milestone and (i) fails to draw the full amount of the Term D Loan during the Term D Draw
Period and (ii) fails to notify Collateral Agent, at any time before the date that is four weeks after the Company&#x2019;s achievement
of the Term D Milestone, of the Company&#x2019;s intent not to draw the full amount of the Term D Loan, a non-utilization fee of $&lt;span id="xdx_909_ecustom--NonUtilizationFee_iI_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermDLoanMember_ziF0ZP2kePig" title="Non utilization fee"&gt;900,000&lt;/span&gt;,
with respect to the Term D Loan shall become due and payable on the earliest of (i) the termination of the Term D Draw Period, (ii) the
Maturity Date, (iii) the acceleration of any Term Loan, and (iv) the prepayment in whole of the Term Loans. If the Company achieves the
Term E Milestone and (i) fails to draw the full amount of the Term E Loan during the Term E Draw Period and (ii) fails to notify Collateral
Agent, at any time before the date that is four weeks after the Company&#x2019;s achievement of the Term E Milestone, of the Company&#x2019;s
intent not to draw the full amount of the Term E Loan, a non-utilization fee of $&lt;span id="xdx_90D_ecustom--NonUtilizationFee_iI_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermELoanMember_z3jgeNPV2N8g" title="Non utilization fee"&gt;1,500,000&lt;/span&gt;, with respect to the Term E Loan shall become
due and payable on the earliest of (i) the termination of the Term E Draw Period, (ii) the Maturity Date, (iii) the acceleration of any
Term Loan, and (iv) the prepayment in whole of the Term Loans. After the 18-month anniversary of the Effective Date, the Company shall
have the option to prepay all, but not less than all, of the Term Loans advanced by the Lenders under the A&amp;amp;R Loan Agreement, provided
the Company (i) provides written notice to Collateral Agent of its election to prepay the Term Loans at least seven Business Days prior
to such prepayment, and (ii) pays to Lenders on the date of such prepayment, payable to each Lender in accordance with its respective
Pro Rata Share, an amount equal to the sum of (A) all outstanding principal of the Term Loans plus accrued and unpaid interest thereon
through the prepayment date, (B) the Final Fee, (C) the Prepayment Fee, plus (D) all other outstanding Obligations that are due and payable,
including, without limitation, Lenders&#x2019; Expenses and interest at the Default Rate with respect to any past due amounts. At May 30,
2024, the Company recognized the Final Fee of $&lt;span id="xdx_90C_ecustom--FinalFee_iI_pn5n6_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_z1eqrYRN6cq7" title="Final fee"&gt;4.5&lt;/span&gt; million as additional debt principal and a corresponding debt discount to be amortized
over the life of the loan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In connection with the funding of each of the Term
C Loan, the Term D Loan, the Term E Loan and the Term F Loan, the Company agreed to issue to Innovatus and Oxford warrants to purchase
that number of shares of the Company&#x2019;s common stock equal to &lt;span id="xdx_904_ecustom--WarrantOrRightToPurchasePercentage_iI_dp_uPure_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_zKnFu5iBraW4" title="Warrant or right, reason for issuance, description"&gt;2.5&lt;/span&gt;% of the principal amount of the applicable Term Loan divided by
the exercise price, which shall, with respect to the Term C Loan, be equal to the lower of (i) the volume weighted average closing price
of the Company&#x2019;s common stock for the five-trading day period ending on the last trading day immediately preceding the execution
of the A&amp;amp;R Loan Agreement or (ii) the closing price on the last trading day immediately preceding the execution of the A&amp;amp;R Loan
Agreement. Accordingly, on May 30, 2024, the Company issued &lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zql8p3XMfkNb" title="Warrants issued"&gt;103,876&lt;/span&gt; warrants with an exercise price of $&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zetOICOmbxl6" title="Warrants exercise price per share"&gt;14.84&lt;/span&gt; per share. The relative
fair value of the warrants was approximately $&lt;span id="xdx_909_eus-gaap--FairValueAdjustmentOfWarrants_pn5n6_c20240530__20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8m7nFWbi5Ol" title="Fair value of warrants"&gt;1.2&lt;/span&gt; million. For the additional Term Loans, the exercise price will be based on the lower
of (i) the exercise price for the Warrants issued pursuant to the Term C Loan or (ii) the volume weighted average closing price of the
Company&#x2019;s common stock for the five-trading day period ending on the last trading day immediately preceding the applicable Term
Loan funding. The Warrants may be exercised on a cashless basis and are exercisable through the tenth anniversary of the applicable funding
date. The number of shares of common stock for which each Warrant is exercisable and the associated exercise price are subject to certain
proportional adjustments as set forth in such Warrant.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company evaluated the change of terms under ASC
470-50, &#x201c;Debt &#x2013; Modification and Extinguishment&#x201d;, and concluded the change in terms did not result in significant and
consequential changes to the economic substance of the debt and thus resulted in a modification of the debt and not an extinguishment
of the debt.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--ScheduleOfDebtInstrumentsTextBlock_z4FIW90rHuC5" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;Long-term debt consisted of the following at December 31, 2024 and 2023:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B0_z8dSaWmxp0n4" style="display: none"&gt;Schedule
of Long-term Debt&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 84%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20241231_zKix3ZlY60Vk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20231231_zyyPM9XP68Be" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_maLTNPzDBl_zXqzR6wOdP28" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%; text-align: justify"&gt;Note payable&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;100,000,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;35,000,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--FinalFee_iI_pp0p0_maLTNPzDBl_zy5rhZjOi9Yc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; text-indent: 10pt"&gt;Add: Final fee&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,500,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1250"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--PaymentInKindInterestDebt_iI_pp0p0_maLTNPzDBl_z4bMaU1j59nf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: 10pt"&gt;Add: PIK interest (added to principal)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;593,288&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,565,660&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_pp0p0_di_msLTNPzDBl_zFCkF9UCglm2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; text-indent: 10pt"&gt;Less: unamortized debt issuance costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,613,734&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(480,810&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_pp0p0_di_msLTNPzDBl_zXHN7LV8JQd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt; text-indent: 10pt"&gt;Less: unamortized debt discount&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(5,752,418&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(49,439&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--LongTermNotesPayable_iTI_pp0p0_mtLTNPzDBl_zaFsIYSIvzXj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total long-term debt&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;97,727,136&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;37,035,411&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_zZXKhh9oIsed" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_zouddcjRuUoj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Future principal payments, including the incurred PIK interest and Final
Fee, are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B1_zAZvIQEIocXl" style="display: none"&gt;Schedule
of Long Term Debt Future Principal Payments&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20241231_zCLwHSzl0jza" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Years Ending December 31,&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_pp0p0_maLTDz4sG_zqGYNr5TbYpi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 85%; text-align: justify"&gt;2027&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;30,615,349&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_pp0p0_maLTDz4sG_zEDf33kGEZCk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;2028&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;52,483,455&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_iI_pp0p0_maLTDz4sG_z1hIXAWYJFK" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;2029&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;21,994,484&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--LongTermDebt_iTI_pp0p0_mtLTDz4sG_zu2R6m7Uw7ol" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;105,093,288&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zvrM2ifobLvf" style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_srt_MaximumMember"
      decimals="-6"
      id="Fact001200"
      unitRef="USD">180000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember"
      decimals="0"
      id="Fact001202"
      unitRef="USD">100</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermALoanMember"
      decimals="-5"
      id="Fact001204"
      unitRef="USD">16800000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermBLoanMember"
      decimals="-5"
      id="Fact001206"
      unitRef="USD">21500000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermCLoanMember"
      decimals="-5"
      id="Fact001208"
      unitRef="USD">61700000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermDLoanMember"
      decimals="-6"
      id="Fact001210"
      unitRef="USD">30000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermELoanMember"
      decimals="-6"
      id="Fact001212"
      unitRef="USD">50000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermFLoanMember"
      decimals="-6"
      id="Fact001214"
      unitRef="USD">45000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:OtherBorrowings
      contextRef="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember"
      decimals="-5"
      id="Fact001216"
      unitRef="USD">2400000</us-gaap:OtherBorrowings>
    <us-gaap:DebtInstrumentInterestRateTerms
      contextRef="From2024-05-302024-05-30_custom_AmendedAndRestatedLoanAgreementMember"
      id="Fact001218">the Company
is entitled to make interest-only payments for thirty-six months, or up to forty-eight months if certain conditions are met. The Term
Loans will mature on May 1, 2029 and will bear interest at a rate equal to the sum of (a) the greater of (i) the Prime Rate (as defined
in the A&amp;R Loan Agreement) or (ii) 7.75%, plus (b) 2.85%, provided that 1.0% of such interest will be payable in-kind by adding an
amount equal to such 1.0% of the outstanding principal amount to the then outstanding principal balance on a monthly basis through May
31, 2027.</us-gaap:DebtInstrumentInterestRateTerms>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermALoanMember"
      decimals="INF"
      id="Fact001220"
      unitRef="Pure">0.20</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermALoanMember"
      decimals="INF"
      id="Fact001222"
      unitRef="USDPShares">10.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-05-302024-05-30_custom_PriorLoanAgreementMember_custom_InnovatusLifeSciencesMember"
      decimals="INF"
      id="Fact001224"
      unitRef="Shares">26042</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2024-05-30_custom_PriorLoanAgreementMember_custom_InnovatusLifeSciencesMember"
      decimals="INF"
      id="Fact001226"
      unitRef="USDPShares">14.40</us-gaap:SaleOfStockPricePerShare>
    <CELC:FinalFeePercentage
      contextRef="From2024-05-302024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember"
      decimals="INF"
      id="Fact001228"
      unitRef="Pure">0.045</CELC:FinalFeePercentage>
    <CELC:NonUtilizationFee
      contextRef="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermDLoanMember"
      decimals="0"
      id="Fact001230"
      unitRef="USD">900000</CELC:NonUtilizationFee>
    <CELC:NonUtilizationFee
      contextRef="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermELoanMember"
      decimals="0"
      id="Fact001232"
      unitRef="USD">1500000</CELC:NonUtilizationFee>
    <CELC:FinalFee
      contextRef="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember"
      decimals="-5"
      id="Fact001234"
      unitRef="USD">4500000</CELC:FinalFee>
    <CELC:WarrantOrRightToPurchasePercentage
      contextRef="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember"
      decimals="INF"
      id="Fact001236"
      unitRef="Pure">0.025</CELC:WarrantOrRightToPurchasePercentage>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001238"
      unitRef="Shares">103876</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001240"
      unitRef="USDPShares">14.84</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-05-302024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_us-gaap_WarrantMember"
      decimals="-5"
      id="Fact001242"
      unitRef="USD">1200000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001244">&lt;p id="xdx_893_eus-gaap--ScheduleOfDebtInstrumentsTextBlock_z4FIW90rHuC5" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;Long-term debt consisted of the following at December 31, 2024 and 2023:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B0_z8dSaWmxp0n4" style="display: none"&gt;Schedule
of Long-term Debt&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 84%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20241231_zKix3ZlY60Vk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20231231_zyyPM9XP68Be" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_maLTNPzDBl_zXqzR6wOdP28" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%; text-align: justify"&gt;Note payable&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;100,000,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;35,000,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--FinalFee_iI_pp0p0_maLTNPzDBl_zy5rhZjOi9Yc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; text-indent: 10pt"&gt;Add: Final fee&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,500,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1250"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--PaymentInKindInterestDebt_iI_pp0p0_maLTNPzDBl_z4bMaU1j59nf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: 10pt"&gt;Add: PIK interest (added to principal)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;593,288&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,565,660&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_pp0p0_di_msLTNPzDBl_zFCkF9UCglm2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; text-indent: 10pt"&gt;Less: unamortized debt issuance costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,613,734&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(480,810&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_pp0p0_di_msLTNPzDBl_zXHN7LV8JQd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt; text-indent: 10pt"&gt;Less: unamortized debt discount&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(5,752,418&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(49,439&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--LongTermNotesPayable_iTI_pp0p0_mtLTNPzDBl_zaFsIYSIvzXj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total long-term debt&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;97,727,136&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;37,035,411&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001246"
      unitRef="USD">100000000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001247"
      unitRef="USD">35000000</us-gaap:ConvertibleNotesPayable>
    <CELC:FinalFee
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001249"
      unitRef="USD">4500000</CELC:FinalFee>
    <CELC:PaymentInKindInterestDebt
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001252"
      unitRef="USD">593288</CELC:PaymentInKindInterestDebt>
    <CELC:PaymentInKindInterestDebt
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001253"
      unitRef="USD">2565660</CELC:PaymentInKindInterestDebt>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001255"
      unitRef="USD">1613734</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001256"
      unitRef="USD">480810</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001258"
      unitRef="USD">5752418</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001259"
      unitRef="USD">49439</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:LongTermNotesPayable
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001261"
      unitRef="USD">97727136</us-gaap:LongTermNotesPayable>
    <us-gaap:LongTermNotesPayable
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001262"
      unitRef="USD">37035411</us-gaap:LongTermNotesPayable>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001264">&lt;p id="xdx_89A_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_zouddcjRuUoj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Future principal payments, including the incurred PIK interest and Final
Fee, are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B1_zAZvIQEIocXl" style="display: none"&gt;Schedule
of Long Term Debt Future Principal Payments&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20241231_zCLwHSzl0jza" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Years Ending December 31,&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_pp0p0_maLTDz4sG_zqGYNr5TbYpi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 85%; text-align: justify"&gt;2027&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;30,615,349&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_pp0p0_maLTDz4sG_zEDf33kGEZCk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;2028&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;52,483,455&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_iI_pp0p0_maLTDz4sG_z1hIXAWYJFK" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;2029&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;21,994,484&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--LongTermDebt_iTI_pp0p0_mtLTDz4sG_zu2R6m7Uw7ol" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;105,093,288&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001266"
      unitRef="USD">30615349</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001268"
      unitRef="USD">52483455</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001270"
      unitRef="USD">21994484</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebt
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001272"
      unitRef="USD">105093288</us-gaap:LongTermDebt>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001274">&lt;p id="xdx_807_eus-gaap--IncomeTaxDisclosureTextBlock_zVs5ZXjffgLk" style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt; 13. &lt;span id="xdx_829_zCdWARHhC9p1"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;span style="font-weight: normal"&gt;Following the conversion of Celcuity
LLC to Celcuity Inc. on September 15, 2017, Celcuity Inc. began filing federal and state returns where required. No income tax benefit
was recorded for the years 2024 and 2023, due to net losses and recognition of a valuation allowance. The following table presents a reconciliation
of the tax expense computed at the statutory federal rate and the Company&#x2019;s tax expense for the years ended December 31:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zB5UX1r18GWb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-weight: normal"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B5_zEiyrQ6Thjgj" style="display: none"&gt;Schedule of Effective Income Tax Rate Reconciliation&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20240101__20241231_zd3FMT1mNz5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20230101__20231231_z8BoF2S3Hl7i" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBzqmi_zXiOhWKs6Rtj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%; text-align: justify"&gt;Tax benefit at statutory federal rate&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;(23,474,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;(13,394,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBzqmi_z6hbwe6AMNp6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;State income tax benefit, net of federal tax effect&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(95,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(82,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzqmi_zM6obevT0q2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Change in valuation allowance on deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24,081,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,542,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_iN_di_msITEBzqmi_zww4MI5HDY4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Research &amp;amp; Development Credits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,236,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(550,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseOther_maITEBzqmi_zMmUTdfnRDg1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Other permanent items&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;724,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;484,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzqmi_zPQ1UHAjVfC2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt; text-indent: 10pt"&gt;Income tax benefits&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1293"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1294"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zx3lRmetW93i" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;Deferred income taxes reflect the net effects of temporary differences
between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.
The Company&#x2019;s deferred tax assets relate primarily to its net operating loss carryforwards and other balance sheet basis differences.
In accordance with ASC 740, &#x201c;Income Taxes,&#x201d; the Company recorded a valuation allowance to fully offset the net deferred tax
asset, because it is more likely than not that the Company will not realize future benefits associated with these deferred tax assets
at December 31, 2024. The tax effects of temporary differences and carryforwards that give rise to significant portions of the deferred
tax assets are at December 31:&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zxB9MWb50gj5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B5_zbu4fytXjawc" style="display: none"&gt;Schedule of Deferred Tax Assets and Liabilities&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 84%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20241231_zvHguWFXE48f" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20231231_zdFXcPVIh0h7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Deferred tax assets (liabilities):&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_iI_pp0p0_maDTALNzvdJ_zx0aXuA1qHg4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 70%; text-align: justify"&gt;Accrued expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;459,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;207,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pp0p0_maDTALNzvdJ_zVFZ3xyBdvE3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Share-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,861,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,141,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_pp0p0_maDTALNzvdJ_zTTjiupXCBl3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Property and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;420,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;393,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--DeferredTaxAssetsRightofuseAssets_iI_pp0p0_maDTALNzvdJ_zirTF1tRZYJl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Right-of-use assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(45,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(85,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--DeferredTaxAssetsLeaseLiability_iNI_pp0p0_di_msDTALNzvdJ_zqCaJTda7Ey1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;48,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;87,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIRC174Expenditures_iI_pp0p0_maDTALNzvdJ_zgCv0dVYT3uc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;IRC 174 Expenditures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30,133,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,900,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStartupExpenditures_iI_pp0p0_maDTALNzvdJ_zpUYiefYGzRg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Start-up expenditures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12,998,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,029,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_maDTALNzvdJ_z4pNHArrA8fj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Net operating losses and tax credits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,340,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,461,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_msDTALNzvdJ_zaxSpx68x7fh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(60,214,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(36,133,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pp0p0_mtDTALNzvdJ_zOBeSGoAa3xf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt; text-indent: 10pt"&gt;Net deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1325"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1326"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zFiEZ3lOBR6c" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At December 31, 2024, the Company had federal and
state net operating loss carryforwards of approximately $&lt;span id="xdx_909_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_pn5n6_c20241231_zZBpufBRnsbe" title="Federal net operating loss carryforwards"&gt;43.2&lt;/span&gt; million and $&lt;span id="xdx_907_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_pn5n6_c20241231_zzH4SSSOB6Tf" title="State net operating loss carryforwards"&gt;0.8&lt;/span&gt; million, respectively. The federal and state net operating
loss carryforwards for 2017 will begin to expire in the year ending December 31, 2037. The federal net operating loss carryforwards starting
in 2018 have no expiration. These deferred tax assets were subject to a full valuation allowance as of December 31, 2024 and December
31, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At December 31, 2024, the Company had federal and
state research and development tax credit carryforwards resulting in deferred tax assets of approximately $&lt;span id="xdx_904_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pn5n6_c20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zd68bjXK0bbh" title="Tax credit carryforwards"&gt;2.9&lt;/span&gt; million and $&lt;span id="xdx_902_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pn5n6_c20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_z2KWtq0AfJC1" title="Tax credit carryforwards"&gt;1.6&lt;/span&gt; million,
respectively. The federal and state credit carryforwards will begin to expire in the years ending December 31, 2038 and December 31, 2033,
respectively. These deferred tax assets were subject to a full valuation allowance as of December 31, 2024 and December 31, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Under the provisions of Section&#160;382 of the Internal
Revenue Code of 1986, certain substantial changes in the Company&#x2019;s ownership, including a sale of the Company, or significant changes
in ownership due to sales of equity, may limit in the future the amount of net operating loss carryforwards available to offset future
taxable income.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company recognizes uncertain tax positions in
accordance with ASC 740 on the basis of evaluating whether it is more-likely-than not that the tax positions will be sustained upon examination
by tax authorities. For those tax positions that meet the more-likely-than not recognition threshold, we recognize the largest amount
of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement. As of December 31, 2024, and 2023, the Company
has no significant uncertain tax positions. There are no unrecognized tax benefits included on the balance sheet that would, if recognized,
impact the effective tax rate. The Company does not anticipate there will be a significant change in unrecognized tax benefits within
the next 12 months.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Prior to the conversion, Celcuity was a limited liability
company and therefore was taxed as a partnership for income tax purposes. Accordingly, no benefit for income taxes was recorded prior
to the conversion.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;For years prior to 2021, the Company is no longer
subject to U.S. federal or state income tax examinations and remains open for the unutilized tax attributes as of December 31, 2024, carried
forward from these years. The Company&#x2019;s policy is to recognize interest and penalties related to uncertain tax positions as a component
of general and administrative expenses.&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001276">&lt;p id="xdx_89B_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zB5UX1r18GWb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-weight: normal"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B5_zEiyrQ6Thjgj" style="display: none"&gt;Schedule of Effective Income Tax Rate Reconciliation&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20240101__20241231_zd3FMT1mNz5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20230101__20231231_z8BoF2S3Hl7i" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBzqmi_zXiOhWKs6Rtj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%; text-align: justify"&gt;Tax benefit at statutory federal rate&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;(23,474,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;(13,394,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBzqmi_z6hbwe6AMNp6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;State income tax benefit, net of federal tax effect&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(95,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(82,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzqmi_zM6obevT0q2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Change in valuation allowance on deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24,081,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,542,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_iN_di_msITEBzqmi_zww4MI5HDY4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Research &amp;amp; Development Credits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,236,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(550,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseOther_maITEBzqmi_zMmUTdfnRDg1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Other permanent items&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;724,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;484,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzqmi_zPQ1UHAjVfC2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt; text-indent: 10pt"&gt;Income tax benefits&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1293"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1294"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001278"
      unitRef="USD">-23474000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001279"
      unitRef="USD">-13394000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001281"
      unitRef="USD">-95000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001282"
      unitRef="USD">-82000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001284"
      unitRef="USD">24081000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001285"
      unitRef="USD">13542000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001287"
      unitRef="USD">1236000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001288"
      unitRef="USD">550000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001290"
      unitRef="USD">724000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001291"
      unitRef="USD">484000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001296">&lt;p id="xdx_892_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zxB9MWb50gj5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B5_zbu4fytXjawc" style="display: none"&gt;Schedule of Deferred Tax Assets and Liabilities&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 84%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20241231_zvHguWFXE48f" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20231231_zdFXcPVIh0h7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Deferred tax assets (liabilities):&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_iI_pp0p0_maDTALNzvdJ_zx0aXuA1qHg4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 70%; text-align: justify"&gt;Accrued expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;459,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;207,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pp0p0_maDTALNzvdJ_zVFZ3xyBdvE3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Share-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,861,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,141,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_pp0p0_maDTALNzvdJ_zTTjiupXCBl3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Property and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;420,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;393,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--DeferredTaxAssetsRightofuseAssets_iI_pp0p0_maDTALNzvdJ_zirTF1tRZYJl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Right-of-use assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(45,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(85,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--DeferredTaxAssetsLeaseLiability_iNI_pp0p0_di_msDTALNzvdJ_zqCaJTda7Ey1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;48,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;87,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIRC174Expenditures_iI_pp0p0_maDTALNzvdJ_zgCv0dVYT3uc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;IRC 174 Expenditures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30,133,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,900,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStartupExpenditures_iI_pp0p0_maDTALNzvdJ_zpUYiefYGzRg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Start-up expenditures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12,998,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,029,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_maDTALNzvdJ_z4pNHArrA8fj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Net operating losses and tax credits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,340,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,461,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_msDTALNzvdJ_zaxSpx68x7fh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(60,214,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(36,133,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pp0p0_mtDTALNzvdJ_zOBeSGoAa3xf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt; text-indent: 10pt"&gt;Net deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1325"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1326"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001298"
      unitRef="USD">459000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001299"
      unitRef="USD">207000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001301"
      unitRef="USD">2861000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001302"
      unitRef="USD">2141000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001304"
      unitRef="USD">420000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001305"
      unitRef="USD">393000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <CELC:DeferredTaxAssetsRightofuseAssets
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001307"
      unitRef="USD">-45000</CELC:DeferredTaxAssetsRightofuseAssets>
    <CELC:DeferredTaxAssetsRightofuseAssets
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001308"
      unitRef="USD">-85000</CELC:DeferredTaxAssetsRightofuseAssets>
    <CELC:DeferredTaxAssetsLeaseLiability
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001310"
      unitRef="USD">-48000</CELC:DeferredTaxAssetsLeaseLiability>
    <CELC:DeferredTaxAssetsLeaseLiability
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001311"
      unitRef="USD">-87000</CELC:DeferredTaxAssetsLeaseLiability>
    <CELC:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIRC174Expenditures
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001313"
      unitRef="USD">30133000</CELC:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIRC174Expenditures>
    <CELC:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIRC174Expenditures
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001314"
      unitRef="USD">13900000</CELC:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIRC174Expenditures>
    <CELC:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStartupExpenditures
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001316"
      unitRef="USD">12998000</CELC:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStartupExpenditures>
    <CELC:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStartupExpenditures
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001317"
      unitRef="USD">11029000</CELC:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStartupExpenditures>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001319"
      unitRef="USD">13340000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001320"
      unitRef="USD">8461000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001322"
      unitRef="USD">60214000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001323"
      unitRef="USD">36133000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact001328"
      unitRef="USD">43200000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact001330"
      unitRef="USD">800000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="AsOf2024-12-31_us-gaap_DomesticCountryMember"
      decimals="-5"
      id="Fact001332"
      unitRef="USD">2900000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="AsOf2024-12-31_us-gaap_StateAndLocalJurisdictionMember"
      decimals="-5"
      id="Fact001334"
      unitRef="USD">1600000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001336">&lt;p id="xdx_803_eus-gaap--SubsequentEventsTextBlock_z5nkbanmoN2c" style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;14.
&lt;span id="xdx_82A_zdjZSpiV6W98"&gt;Subsequent Event&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.5in"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
January 2025, the Board of Directors approved a repricing of certain outstanding stock options previously granted to employees. As of
the repricing date, the exercise prices of these options were reduced to $&lt;span id="xdx_90F_eus-gaap--StockOptionExercisePriceDecrease_c20250102__20250131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zEvaBNA3zmjk" title="Exercise price reduced"&gt;11.92&lt;/span&gt; per share, from their previous exercise prices ranging
from $&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20250102__20250131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zP91PGC6ViA5" title="Exercise price lower"&gt;12.80&lt;/span&gt; to $&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250102__20250131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z0vWZ92OjNY9" title="Exercise price upper"&gt;18.73&lt;/span&gt; per share. This adjustment was made in response to the decline in the company&#x2019;s stock price, with the intent
of retaining and motivating key employees. As a result of this repricing, approximately &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zF9SiEaWKlWa" title="Stock options held"&gt;837,000&lt;/span&gt; stock options held by 44 employees were
affected. The repriced options will continue to vest according to their original schedule.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
March 2025, an investor exercised &lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20250131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zOjQRy4feQNd" title="Warrants exercised"&gt;695,650&lt;/span&gt; warrants at an exercise price of $&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zcWNGZfE8Jg6" title="Warrants exercise price"&gt;8.05&lt;/span&gt;, which generated approximately $&lt;span id="xdx_909_eus-gaap--ProceedsFromWarrantExercises_pn5n6_c20250102__20250131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zv4arleANkt" title="Proceeds from warrants exercised"&gt;5.6&lt;/span&gt; million in cash.
The warrants were issued pursuant to a private placement that closed and was funded on December 9, 2022.&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockOptionExercisePriceDecrease
      contextRef="From2025-01-022025-01-31_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001338"
      unitRef="USDPShares">11.92</us-gaap:StockOptionExercisePriceDecrease>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2025-01-022025-01-31_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001340"
      unitRef="USDPShares">12.80</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2025-01-022025-01-31_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001342"
      unitRef="USDPShares">18.73</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2025-01-31_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001344"
      unitRef="Shares">837000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2025-01-31_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001346"
      unitRef="Shares">695650</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-01-31_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001348"
      unitRef="USDPShares">8.05</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2025-01-022025-01-31_us-gaap_SubsequentEventMember"
      decimals="-5"
      id="Fact001350"
      unitRef="USD">5600000</us-gaap:ProceedsFromWarrantExercises>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="From2024-10-012024-12-31" id="Fact001352">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="From2024-10-012024-12-31" id="Fact001354">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="From2024-10-012024-12-31" id="Fact001356">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="From2024-10-012024-12-31" id="Fact001358">false</ecd:NonRule10b51ArrTrmntdFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
